Publication Type;Authors;Book Authors;Book Editors;Book Group Authors;Author Full Names;Book Author Full Names;Group Authors;Article Title;Source Title;Book Series Title;Book Series Subtitle;Language;Document Type;Conference Title;Conference Date;Conference Location;Conference Sponsor;Conference Host;Author Keywords;Keywords Plus;Abstract;Addresses;Affiliations;Reprint Addresses;Email Addresses;Researcher Ids;ORCIDs;Funding Orgs;Funding Name Preferred;Funding Text;Cited References;Cited Reference Count;Times Cited, WoS Core;Times Cited, All Databases;180 Day Usage Count;Since 2013 Usage Count;Publisher;Publisher City;Publisher Address;ISSN;eISSN;ISBN;Journal Abbreviation;Journal ISO Abbreviation;Publication Date;Publication Year;Volume;Issue;Part Number;Supplement;Special Issue;Meeting Abstract;Start Page;End Page;Article Number;DOI;DOI Link;Book DOI;Early Access Date;Number of Pages;WoS Categories;Web of Science Index;Research Areas;IDS Number;Pubmed Id;Open Access Designations;Highly Cited Status;Hot Paper Status;Date of Export;UT (Unique WOS ID);Web of Science Record
J;"Marini, S; D'Agostino, L; Ciamarra, C; De Berardis, D; Gentile, A";;;;"Marini, Stefano; D'Agostino, Lucia; Ciamarra, Carla; De Berardis, Domenico; Gentile, Alessandro";;;Gabapentin treatment for challenging behaviors in autism spectrum disorder and coexisting intellectual disability: a case report;ADVANCES IN MENTAL HEALTH AND INTELLECTUAL DISABILITIES;;;English;Article;;;;;;"Autism; Challenging behavior; Treatment; Intellectual disability; Psychopharmacology; Gabapentin";"SELF-INJURIOUS-BEHAVIOR; GAMMA-AMINOBUTYRIC-ACID; CHILDREN; PREVALENCE; ADULTS; PEOPLE; INDIVIDUALS; PHARMACOLOGY; ADOLESCENTS; DYSFUNCTION";PurposeThe purpose of this case report is to report the clinical experience of the use of gabapentin in the management of problem behaviors in a person with autism spectrum disorder and comorbid intellectual disability. Autism spectrum disorder is a neurodevelopmental disorder with a high prevalence of intellectual disability. Challenging behaviors in autism spectrum disorder are very common. In recent years, the hypothesis that the symptoms of autism derive from a deficiency of the inhibitory neurotransmission of gamma-aminobutyric acid is gaining considerable weight.Design/methodology/approachExploring behavioral symptoms improvement in an adult man with ASD and severe intellectual disability taking gabapentin.FindingsThe rating scales used show improvement in challenging behaviors and aggressions. No side effects were observed.Originality/valueCurrently, there are no authorized drugs for the treatment of the symptomatic features of autism spectrum disorder, but drugs are used for comorbid psychopathological aspects. The authors want to speculate on a hypothetical function of gabapentin in remodeling the expression of alpha-2-delta subunits in people with autism and the processing of neural information.;"[Marini, Stefano; D'Agostino, Lucia; Ciamarra, Carla; De Berardis, Domenico; Gentile, Alessandro] Natl Hlth Serv, Dept Mental Hlth, Termoli, Italy";;Marini, S (corresponding author), Natl Hlth Serv, Dept Mental Hlth, Termoli, Italy.;sfnmarini@gmail.com;"Marini, Stefano/GLU-8690-2022; De Berardis, Domenico/HII-7444-2022";Marini, Stefano/0000-0002-1771-6940;;;;"American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Banks R., 2016, CLIN SERVICE GUIDELI; Baron-Cohen S, 2005, ANNU REV NEUROSCI, V28, P109, DOI 10.1146/annurev.neuro.27.070203.144137; Belmonte MK, 2004, MOL PSYCHIATR, V9, P646, DOI 10.1038/sj.mp.4001499; Bölte S, 2019, CELL MOL LIFE SCI, V76, P1275, DOI 10.1007/s00018-018-2988-4; Braat S, 2015, NEURON, V86, P1119, DOI 10.1016/j.neuron.2015.03.042; Branford D, 2019, ADV MENT HEALTH INTE, V13, P31, DOI 10.1108/AMHID-02-2018-0004; Breau LM, 2003, J PEDIATR-US, V142, P498, DOI 10.1067/mpd.2003.163; Bruinsma E, 2020, J INTELL DISABIL RES, V64, P561, DOI 10.1111/jir.12736; Bryson SE, 2008, CAN J PSYCHIAT, V53, P449, DOI 10.1177/070674370805300710; Calandre EP, 2016, EXPERT REV NEUROTHER, V16, P1263, DOI 10.1080/14737175.2016.1202764; Carrasco M, 2012, PEDIATRICS, V129, pE1301, DOI 10.1542/peds.2011-3285; Casanova MF, 2003, NEUROSCIENTIST, V9, P496, DOI 10.1177/1073858403253552; Cochran DM, 2015, J CHILD ADOL PSYCHOP, V25, P314, DOI 10.1089/cap.2014.0112; Contestabile A, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00054; Cooper SA, 2009, J INTELL DISABIL RES, V53, P217, DOI 10.1111/j.1365-2788.2008.01127.x; Courchesne E, 2005, INT J DEV NEUROSCI, V23, P153, DOI 10.1016/j.ijdevneu.2005.01.003; Deb S, 2015, J INTELL DISABIL RES, V59, P11, DOI 10.1111/jir.12119; Donovan APA, 2017, J ANAT, V230, P4, DOI 10.1111/joa.12542; Dufour BD, 2023, AUTISM, V27, P1730, DOI 10.1177/13623613231154053; Edelson SM, 2021, PEDIATRIC REP, V13, P558, DOI 10.3390/pediatric13040066; Emerson E, 2001, RES DEV DISABIL, V22, P77, DOI 10.1016/S0891-4222(00)00061-5; EMERSON E, 1995, J INTELL DISABIL RES, V39, P388, DOI 10.1111/j.1365-2788.1995.tb00543.x; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Forsberg SL, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-017-0062-x; Fung LK, 2015, CNS DRUGS, V29, P453, DOI 10.1007/s40263-015-0252-0; Gaetz W, 2014, NEUROIMAGE, V86, P1, DOI 10.1016/j.neuroimage.2013.05.068; Galasso C, 2008, J CHILD NEUROL, V23, P802, DOI 10.1177/0883073808314150; Gössler A, 2007, J PEDIATR SURG, V42, P1486, DOI 10.1016/j.jpedsurg.2007.04.009; Groves L, 2023, LANCET PSYCHIAT, V10, P682, DOI 10.1016/S2215-0366(23)00197-9; Guglielmo R, 2013, J CLIN PSYCHOPHARM, V33, P273, DOI 10.1097/JCP.0b013e318285680c; Handen BL, 2006, J CHILD PSYCHOL PSYC, V47, P871, DOI 10.1111/j.1469-7610.2006.01588.x; Harada M, 2011, J AUTISM DEV DISORD, V41, P447, DOI 10.1007/s10803-010-1065-0; Hemmings CP, 2006, J INTELL DISABIL RES, V50, P269, DOI 10.1111/j.1365-2788.2006.00827.x; Henninger NA, 2013, AUTISM, V17, P103, DOI 10.1177/1362361312441266; Heyvaert M, 2012, RES DEV DISABIL, V33, P766, DOI 10.1016/j.ridd.2011.10.010; Holden B, 2006, RES DEV DISABIL, V27, P456, DOI 10.1016/j.ridd.2005.06.001; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Jensen AA, 2002, MOL PHARMACOL, V61, P1377, DOI 10.1124/mol.61.6.1377; Kaufman L., 2011, COMMON GENETIC ETIOL; Khachadourian V, 2023, TRANSL PSYCHIAT, V13, DOI 10.1038/s41398-023-02374-w; Kroon T, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00075; Kurzius-Spencer M, 2018, RES AUTISM SPECT DIS, V56, P61, DOI 10.1016/j.rasd.2018.09.002; La Malfa G, 2004, J INTELL DISABIL RES, V48, P262, DOI 10.1111/j.1365-2788.2003.00567.x; Lanneau C, 2001, NEUROPHARMACOLOGY, V41, P965, DOI 10.1016/S0028-3908(01)00140-X; Laumonnier F, 2006, AM J PSYCHIAT, V163, P1622, DOI 10.1176/appi.ajp.163.9.1622; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Lundqvist LO, 2013, RES DEV DISABIL, V34, P1346, DOI 10.1016/j.ridd.2013.01.010; Lydon S, 2013, RES DEV DISABIL, V34, P3148, DOI 10.1016/j.ridd.2013.06.010; Matson J.L., 1995, The Diagnostic Assessment for the Severely Handicapped revised (DASH-II); Matson JL, 2010, RES DEV DISABIL, V31, P1570, DOI 10.1016/j.ridd.2010.05.005; Mazzone L, 2006, BRAIN DEV-JPN, V28, P668, DOI 10.1016/j.braindev.2006.05.004; Murphy GH, 2005, J AUTISM DEV DISORD, V35, P405, DOI 10.1007/s10803-005-5030-2; Murphy O, 2009, RES AUTISM SPECT DIS, V3, P474, DOI 10.1016/j.rasd.2008.09.008; Murray ML, 2014, PSYCHOPHARMACOLOGY, V231, P1011, DOI 10.1007/s00213-013-3140-7; Nelson SB, 2015, NEURON, V87, P684, DOI 10.1016/j.neuron.2015.07.033; NICE, 2019, ASSESSING BEHAVIOUR; NICE, 2017, NO NICE KEY THERAPEU; Noterdaeme M., 2009, Neuroscience and Behavioral Reviews, V46, P161, DOI DOI 10.1016/J.NEUBIOREV.2014.02.015; O'Brien G, 2004, AUTISM, V8, P125, DOI 10.1177/1362361304042718; Onore C, 2012, BRAIN BEHAV IMMUN, V26, P383, DOI 10.1016/j.bbi.2011.08.007; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; Rojas DC, 2014, NEUROIMAGE, V86, P28, DOI 10.1016/j.neuroimage.2013.01.045; Rubenstein J L R, 2003, Genes Brain Behav, V2, P255; Sanders S.J., 2015, INSIGHTS AUTISM SPEC, V87, P1215; Satterstrom FK, 2020, CELL, V180, P568, DOI 10.1016/j.cell.2019.12.036; SHAH A, 1982, APPL RES MENT RETARD, V3, P303, DOI 10.1016/0270-3092(82)90022-4; Sharma A, 2012, J PEDIATR HEALTH CAR, V26, P291, DOI 10.1016/j.pedhc.2011.02.008; Sills GJ, 2006, CURR OPIN PHARMACOL, V6, P108, DOI 10.1016/j.coph.2005.11.003; Song M, 2020, J INTELL DISABIL RES, V64, P45, DOI 10.1111/jir.12685; Srivastava AK, 2014, NEUROSCI BIOBEHAV R, V46, P161, DOI 10.1016/j.neubiorev.2014.02.015; Sullivan WF, 2018, CAN FAM PHYSICIAN, V64, P254; Tang X, 2021, NAT REV NEUROSCI, V22, P290, DOI 10.1038/s41583-021-00443-x; Taylor CP, 2007, EPILEPSY RES, V73, P137, DOI 10.1016/j.eplepsyres.2006.09.008; Thurm A, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00526; Tonhajzerova I, 2015, ADV EXP MED BIOL, V861, P93, DOI 10.1007/5584_2015_145; Turner M, 1999, J CHILD PSYCHOL PSYC, V40, P839, DOI 10.1017/S0021963099004278; Ullmann R, 2007, HUM MUTAT, V28, P674, DOI 10.1002/humu.20546; Vilela J, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.932305; Willsey AJ, 2015, CURR OPIN NEUROBIOL, V30, P92, DOI 10.1016/j.conb.2014.10.015; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; Yang JX, 2022, FEBS J, V289, P2318, DOI 10.1111/febs.15872";82;0;0;0;0;EMERALD GROUP PUBLISHING LTD;Leeds;Floor 5, Northspring 21-23 Wellington Street, Leeds, W YORKSHIRE, ENGLAND;2044-1282;2044-1290;;ADV MENT HEALTH INTE;Adv. Ment. Health Intellet. Disabil.;sept-05;2024;18;3;;;;;101;109;;10.1108/AMHID-06-2023-0021;http://dx.doi.org/10.1108/AMHID-06-2023-0021;;juin-24;9;Psychiatry;Emerging Sources Citation Index (ESCI);Psychiatry;E5J7F;;;;;24/11/2024;WOS:001246108800001;View Full Record in Web of Science
J;"Matson, JL; Hess, JA";;;;"Matson, Johnny L.; Hess, Julie A.";;;Psychotropic drug efficacy and side effects for persons with autism spectrum disorders;RESEARCH IN AUTISM SPECTRUM DISORDERS;;;English;Article;;;;;;"Autism; Psychotropic drugs; Side effects";"AGGRESSIVE CHALLENGING BEHAVIOR; INTELLECTUAL DISABILITY; PHARMACOLOGICAL-TREATMENT; DIFFERENTIAL-DIAGNOSIS; PSYCHOACTIVE MEDICINES; RISPERIDONE TREATMENT; TARDIVE-DYSKINESIA; MOVEMENT-DISORDERS; ADVERSE EVENTS; YOUNG-CHILDREN";Pharmacotherapy is a frequently employed treatment option in the area of autism spectrum disorders (ASD). A considerable literature base has developed indicating when these medications should or could be administered. However, research on the potential side effects and cost benefit analysis of these treatments is not well understood at this time. The purpose of this review is to assess current prescription practices, to determine what is needed with respect to better understanding the cost and benefits of these prescription practices, and notions about future trends in research to better aid in our understanding of psychotropic drug side effects. Future research of this sort should further establish best practices with respect to pharmacotherapy and ASD. (C) 2011 Elsevier Ltd. All rights reserved.;[Matson, Johnny L.] Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA;"Louisiana State University System; Louisiana State University";Matson, JL (corresponding author), Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA.;johnmatson@aol.com;Matson, Johnny/B-1284-2013;;;;;"Alacqua M, 2008, PHARM WORLD SCI, V30, P44, DOI 10.1007/s11096-007-9139-6; Aman MG, 2003, J AUTISM DEV DISORD, V33, P527, DOI 10.1023/A:1025883612879; AMAN MG, 1994, J CHILD FAM STUD, V3, P241; AMAN MG, 2008, CHILD ADOL PSYCH CL, V12, P23; [Anonymous], ACTA PSYCHIAT SCAND; [Anonymous], 1976, ECDEU ASSESSMENT MAN; Applegate H, 1999, RES DEV DISABIL, V20, P229, DOI 10.1016/S0891-4222(99)00005-0; Armand-Branger S, 2009, ENCEPHALE, V35, P370, DOI 10.1016/j.encep.2008.04.008; Armstrong C, 2008, AM FAM PHYSICIAN, V78, P1399; Baghdadli A, 2005, ENCEPHALE, V31, P302; Brasic JR, 1997, PSYCHOL REP, V81, P755, DOI 10.2466/pr0.1997.81.3.755; Calles JL, 2008, PEDIATR CLIN N AM, V55, P1227, DOI 10.1016/j.pcl.2008.07.002; Campbell M, 1996, J AM ACAD CHILD PSY, V35, P134, DOI 10.1097/00004583-199602000-00005; Campbell M, 1997, J AM ACAD CHILD PSY, V36, P835, DOI 10.1097/00004583-199706000-00022; Chiang HM, 2008, J INTELL DISABIL RES, V52, P966, DOI 10.1111/j.1365-2788.2008.01042.x; Cohen IL, 2010, J AUTISM DEV DISORD, V40, P599, DOI 10.1007/s10803-009-0908-z; Conrad P, 2004, ARCH PEDIAT ADOL MED, V158, P829, DOI 10.1001/archpedi.158.8.829; CRANE GE, 1973, SCIENCE, V181, P124, DOI 10.1126/science.181.4095.124; Dawson JE, 1998, RES DEV DISABIL, V19, P439, DOI 10.1016/S0891-4222(98)00016-X; Desjardins S, 2009, ENCEPHALE, V35, P168, DOI 10.1016/j.encep.2008.01.004; Durukan I, 2009, KLIN PSIKOFARMAKOL B, V19, P285; Eikeseth S, 2009, RES DEV DISABIL, V30, P158, DOI 10.1016/j.ridd.2008.02.003; Ellis CR, 1996, J DEV PHYS DISABIL, V8, P391, DOI 10.1007/BF02578403; Farmer CA, 2009, RES DEV DISABIL, V30, P1155, DOI 10.1016/j.ridd.2009.03.001; Feroz-Nainar C, 2006, AUTISM, V10, P302, DOI 10.1177/1362361306063297; Fido A, 2008, MED PRIN PRACT, V17, P415, DOI 10.1159/000141508; Findling RL, 2005, J CLIN PSYCHIAT, V66, P26; Garcia MJ, 2008, J INTELLECT DEV DIS, V33, P171, DOI 10.1080/13668250802065190; Gilbert DL, 2008, ANN NY ACAD SCI, V1142, P72, DOI 10.1196/annals.1444.005; Hartley SL, 2008, J INTELL DISABIL RES, V52, P819, DOI 10.1111/j.1365-2788.2008.01065.x; Hasnain M, 2008, SOUTH MED J, V101, P367, DOI 10.1097/SMJ.0b013e3181683f8e; Hellings JA, 2001, J CHILD ADOL PSYCHOP, V11, P229, DOI 10.1089/10445460152595559; Hughes JR, 2009, EPILEPSY BEHAV, V16, P569, DOI 10.1016/j.yebeh.2009.09.023; Jerrell JM, 2008, HUM PSYCHOPHARM CLIN, V23, P283, DOI 10.1002/hup.932; Jerrell JM, 2008, J CHILD NEUROL, V23, P1392, DOI 10.1177/0883073808319070; Kolevzon A, 2006, J CLIN PSYCHIAT, V67, P407, DOI 10.4088/JCP.v67n0311; Kwon H, 2004, AM J PSYCHIAT, V161, P757, DOI 10.1176/appi.ajp.161.4.757-a; Lakhan Shaheen E, 2007, Clin Pract Epidemiol Ment Health, V3, P21, DOI 10.1186/1745-0179-3-21; Langworthy-Lam KS, 2002, J CHILD ADOL PSYCHOP, V12, P311, DOI 10.1089/104454602762599853; Leskovec TJ, 2008, HARVARD REV PSYCHIAT, V16, P97, DOI 10.1080/10673220802075852; Malone RP, 2009, DRUGS, V69, P535, DOI 10.2165/00003495-200969050-00003; Malone RP, 2002, J AM ACAD CHILD PSY, V41, P140, DOI 10.1097/00004583-200202000-00007; Matson JL, 1996, RES DEV DISABIL, V17, P135, DOI 10.1016/0891-4222(95)00044-5; Matson JL, 1997, RES DEV DISABIL, V18, P221, DOI 10.1016/S0891-4222(97)00005-X; Matson JL, 1998, RES DEV DISABIL, V19, P493, DOI 10.1016/S0891-4222(98)00020-1; Matson JL, 2008, RES DEV DISABIL, V29, P363, DOI 10.1016/j.ridd.2007.06.001; Matson JL, 2008, RES DEV DISABIL, V29, P341, DOI 10.1016/j.ridd.2007.06.006; Matson JL, 2007, RES AUTISM SPECT DIS, V1, P75, DOI 10.1016/j.rasd.2006.09.001; Matson JL, 2007, RES DEV DISABIL, V28, P567, DOI 10.1016/j.ridd.2006.08.001; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Matson JL, 2007, RES DEV DISABIL, V28, P207, DOI 10.1016/j.ridd.2005.07.006; Matson JL, 2007, RES DEV DISABIL, V28, P109, DOI 10.1016/j.ridd.2005.07.005; Matson JL, 2009, RES DEV DISABIL, V30, P1107, DOI 10.1016/j.ridd.2009.06.003; Matson JL, 2009, RES DEV DISABIL, V30, P961, DOI 10.1016/j.ridd.2009.01.009; Matson JL, 2009, RES DEV DISABIL, V30, P572, DOI 10.1016/j.ridd.2008.08.007; Matson JL, 2009, RES DEV DISABIL, V30, P249, DOI 10.1016/j.ridd.2008.04.002; Matson JL, 2009, RES DEV DISABIL, V30, P240, DOI 10.1016/j.ridd.2008.04.001; Matson JL, 1998, J INTELLECT DEV DIS, V23, P137, DOI 10.1080/13668259800033641; MATTILA ML, 2008, NASCER CRECER, V17, P85; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2006, CLIN NEUROSCI RES, V6, P179, DOI 10.1016/j.cnr.2006.06.012; Meltzer HY, 2009, LANCET, V373, P1007, DOI 10.1016/S0140-6736(09)60606-1; Mohammadi MR, 2007, CURR DRUG THER, V2, P97, DOI 10.2174/157488507780619095; Myers SM, 2007, EXPERT OPIN PHARMACO, V8, P1579, DOI 10.1517/14656566.8.11.1579; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Oliver-Africano P, 2010, J INTELL DISABIL RES, V54, P17, DOI 10.1111/j.1365-2788.2009.01195.x; Oliver-Africano P, 2009, CNS DRUGS, V23, P903, DOI 10.2165/11310930-000000000-00000; Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041; PAULSON GW, 1975, CLIN PEDIATR, V14, P953, DOI 10.1177/000992287501401013; Perry R, 1997, J CHILD ADOL PSYCHOP, V7, P167, DOI 10.1089/cap.1997.7.167; Petscher ES, 2009, RES DEV DISABIL, V30, P409, DOI 10.1016/j.ridd.2008.08.008; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; Poustka L, 2007, Z KINDER JUG-PSYCH, V35, P87, DOI 10.1024/1422-4917.35.2.87; Provenzano G, 2008, ACTA MEDICA MEDITERR, V24, P109; Santosh Paramala Janardhanan, 2001, Indian Journal of Pediatrics, V68, P427, DOI 10.1007/BF02723022; SANTOSH PJ, 2008, PSYCHIATRY, V7, P384; Schlaggar BL, 2003, PEDIATR REV, V24, P39, DOI 10.1542/pir.24-2-39; Scott Lesley J, 2007, Paediatr Drugs, V9, P343; Shattuck PT, 2006, PEDIATRICS, V117, P1028, DOI 10.1542/peds.2005-1516; Shin L, 2008, HARVARD REV PSYCHIAT, V16, P69, DOI 10.1080/10673220802073915; Soorya L, 2008, CHILD ADOL PSYCH CL, V17, P753, DOI 10.1016/j.chc.2008.06.003; Sparks JA, 2008, J FAM PSYCHOTHER, V19, P1, DOI 10.1080/08975350801904072; Stachnik JM, 2007, ANN PHARMACOTHER, V41, P626, DOI 10.1345/aph.1H527; Stigler KA, 2008, CHILD ADOL PSYCH CL, V17, P739, DOI 10.1016/j.chc.2008.06.002; Stigler Kimberly A, 2004, Paediatr Drugs, V6, P33, DOI 10.2165/00148581-200406010-00003; Towbin KE, 2003, CHILD ADOL PSYCH CL, V12, P23, DOI 10.1016/S1056-4993(02)00049-4; Tyrer P, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13210; Tyrer P, 2009, LANCET, V373, P4, DOI 10.1016/S0140-6736(08)61765-1; Volkmar Fred, 1999, Journal of the American Academy of Child and Adolescent Psychiatry, V38, p32S; Wisniewski T, 2007, J PEDIATR NEUROL, V5, P189; Witwer A, 2005, J CHILD ADOL PSYCHOP, V15, P671, DOI 10.1089/cap.2005.15.671";91;27;34;2;18;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;1750-9467;1878-0237;;RES AUTISM SPECT DIS;Res. Autism Spectr. Disord.;JAN-MAR;2011;5;1;;;;;230;236;;10.1016/j.rasd.2010.04.004;http://dx.doi.org/10.1016/j.rasd.2010.04.004;;;7;"Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychology; Psychiatry; Rehabilitation";676XX;;;;;24/11/2024;WOS:000283953800024;View Full Record in Web of Science
J;"Malow, BA; Findling, RL; Schroder, CM; Maras, A; Breddy, J; Nir, T; Zisapel, N; Gringras, P";;;;"Malow, Beth A.; Findling, Robert L.; Schroder, Carmen M.; Maras, Athanasios; Breddy, John; Nir, Tali; Zisapel, Nava; Gringras, Paul";;;Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"autism; melatonin; sleep";"MENTAL-HEALTH; INSOMNIA; ADOLESCENTS; CONSEQUENCES; SYMPTOMS; EFFICACY; QUALITY; SAFETY; INDEX";"Objective: A recent 3-month double-blind, placebo-controlled study demonstrated efficacy and safety of pediatric prolonged-release melatonin (PedPRM) for insomnia in children with autism spectrum disorder. This study examined the long-term effects of PedPRM treatment on sleep, growth, body mass index, and pubertal development. Method: Eighty children and adolescents (2-17.5 years of age; 96% with autism spectrum disorder) who completed the double-blind, placebo-controlled trial were given 2 mg, 5 mg, or 10 mg PedPRM nightly up to 104 weeks, followed by a 2-week placebo period to assess withdrawal effects. Results: Improvements in child sleep disturbance and caregiver satisfaction with child sleep patterns, quality of sleep, and quality of life were maintained throughout the 104-week treatment period (p < .001 versus baseline for all). During the 2-week withdrawal placebo period, measures declined compared with the treatment period but were still improved compared with baseline. PedPRM was generally safe; the most frequent treatment-related adverse events were fatigue (6.3%), somnolence (6.3%), and mood swings (4.2%). Changes in mean weight, height, body mass index, and pubertal status (Tanner staging done by a physician) were within normal ranges for age with no evidence of delay in body mass index or pubertal development. Conclusion: Nightly PedPRM at optimal dose (2, 5, or 10 mg nightly) is safe and effective for long-term treatment in children and adolescents with autism spectrum disorder and insomnia. There were no observed detrimental effects on children's growth and pubertal development and no withdrawal or safety issues related to the use or discontinuation of the drug.";"[Malow, Beth A.] Vanderbilt Univ, Med Ctr, Sleep Div, Nashville, TN 37232 USA; [Findling, Robert L.] Johns Hopkins Univ, Kennedy Kreger Inst, Baltimore, MD USA; [Schroder, Carmen M.] Strasbourg Univ, Strasbourg, France; [Schroder, Carmen M.] CNRS UMR 3212, Inst Cellular & Integrat Neurosci, Strasbourg, France; [Maras, Athanasios] Yulius Acad, Yulius Mental Hlth Org, Dordrecht, Netherlands; [Breddy, John] Pharmastat Consulting Ltd, Canterbury, Kent, England; [Nir, Tali; Zisapel, Nava] Neurim Pharmaceut Ltd, Tel Aviv, Israel; [Gringras, Paul] Guys & St Thomas, Evelina London Childrens Hosp, Childrens Sleep Med, London, England";"Vanderbilt University; Johns Hopkins University; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg";Malow, BA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol, Sleep Div, 1161 21st Ave South,Room A-0116, Nashville, TN 37232 USA.;beth.malow@vumc.org;"Zisapel, Nava/GRO-1677-2022; Malow, Beth/KPA-4500-2024";"Malow, Beth/0000-0002-1624-7636; Findling, Robert L./0000-0002-7654-5782";"Neurim Pharmaceuticals; Clinical and Translational Sciences Awards (CTSA) Program award from the National Center for Advancing Translational Sciences [UL1 TR002243]";"Neurim Pharmaceuticals; Clinical and Translational Sciences Awards (CTSA) Program award from the National Center for Advancing Translational Sciences";This project was supported by Neurim Pharmaceuticals. The project described was also supported by Clinical and Translational Sciences Awards (CTSA) Program award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. The medication used in the trial (Slenyto [PedPRM]) is a product of Neurim Pharmaceuticals.;"Anderson G, 2018, PROG NEURO-PSYCHOPH, V80, P255, DOI 10.1016/j.pnpbp.2017.04.022; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Backhaus J, 2002, J PSYCHOSOM RES, V53, P737, DOI 10.1016/S0022-3999(02)00330-6; Badin E, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0687-0; Bech P, 2003, INT J METH PSYCH RES, V12, P85, DOI 10.1002/mpr.145; Buysse DJ, 2006, SLEEP, V29, P1155, DOI 10.1093/sleep/29.9.1155; Center for Drug Evaluation and Research; US Food and Drug Administration, VOIC PAT SER REP US; Crowley SJ, 2012, DEV PSYCHOBIOL, V54, P468, DOI 10.1002/dev.20605; Cuomo BM, 2017, PHARMACOTHERAPY, V37, P555, DOI 10.1002/phar.1920; De Leersnyder H, 2006, TRENDS ENDOCRIN MET, V17, P291, DOI 10.1016/j.tem.2006.07.007; Devnani PA, 2015, J PEDIATR NEUROSCI, V10, P304, DOI 10.4103/1817-1745.174438; Elrod MG, 2015, J DEV BEHAV PEDIATR, V36, P166, DOI 10.1097/DBP.0000000000000140; Feliciano EMC, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4085; Gringas P, 2017, J AM ACAD CHILD PSY, V56, P948, DOI 10.1016/j.jaac.2017.09.414; Gringras P, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6664; KITAY JI, 1954, J CLIN ENDOCR METAB, V14, P622, DOI 10.1210/jcem-14-6-622; Kotagal S, 2012, PEDIATR NEUROL, V47, P242, DOI 10.1016/j.pediatrneurol.2012.05.007; Krakowiak P, 2008, J SLEEP RES, V17, P197, DOI 10.1111/j.1365-2869.2008.00650.x; Lemoine P, 2007, J SLEEP RES, V16, P372, DOI 10.1111/j.1365-2869.2007.00613.x; Luthringer R, 2009, INT CLIN PSYCHOPHARM, V24, P239, DOI 10.1097/YIC.0b013e32832e9b08; Malow B, 2012, J AUTISM DEV DISORD, V42, P1729, DOI 10.1007/s10803-011-1418-3; Maras A, 2018, J CHILD ADOL PSYCHOP, V28, P699, DOI 10.1089/cap.2018.0020; McConachie H, 2018, J AUTISM DEV DISORD, V48, P1041, DOI 10.1007/s10803-017-3282-2; Millman RP, 2005, PEDIATRICS, V115, P1774, DOI 10.1542/peds.2005-0772; Mindell JA, 2006, PEDIATRICS, V117, pE1223, DOI 10.1542/peds.2005-1693; Must A, 2006, INT J OBESITY, V30, P590, DOI 10.1038/sj.ijo.0803300; Nilsson ME, 2001, DRUG INF J, V35, P1289, DOI 10.1177/009286150103500425; QUINE L, 1991, J MENT DEFIC RES, V35, P269; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Schroder CM, 2019, J AUTISM DEV DISORD, V49, P3218, DOI 10.1007/s10803-019-04046-5; Sheldon SH, 1998, LANCET, V351, P1254, DOI 10.1016/S0140-6736(05)79321-1; SILMAN RE, 1979, NATURE, V282, P301, DOI 10.1038/282301a0; Srinivasan V, 2009, GYNECOL ENDOCRINOL, V25, P779, DOI 10.3109/09513590903159649; Taira M, 1998, PSYCHIAT CLIN NEUROS, V52, P182, DOI 10.1111/j.1440-1819.1998.tb01018.x; Thomson SA, 2009, PEDIATRICS, V123, pE235, DOI 10.1542/peds.2008-2059; van Buuren S., PUBERTY PLOT WEB APP; van Geijlswijk IM, 2011, PSYCHOPHARMACOLOGY, V216, P111, DOI 10.1007/s00213-011-2202-y; Wade AG, 2011, CURR MED RES OPIN, V27, P87, DOI 10.1185/03007995.2010.537317; Zwart TC, 2018, HEALTHCARE-BASEL, V6, DOI 10.3390/healthcare6010023";39;69;76;5;52;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;FEB;2021;60;2;;;;;252;+;;10.1016/j.jaac.2019.12.007;http://dx.doi.org/10.1016/j.jaac.2019.12.007;;janv-21;13;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";QA3HZ;31982581;Green Accepted, hybrid;;;24/11/2024;WOS:000613339700012;View Full Record in Web of Science
J;"Sheppard, KW; Boone, KM; Gracious, B; Klebanoff, MA; Rogers, LK; Rausch, J; Bartlett, C; Coury, DL; Keim, SA";;;;"Sheppard, Kelly W.; Boone, Kelly M.; Gracious, Barbara; Klebanoff, Mark A.; Rogers, Lynette K.; Rausch, Joseph; Bartlett, Christopher; Coury, Daniel L.; Keim, Sarah A.";;;Effect of Omega-3 and-6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Children born preterm; Autism spectrum disorder; Language development; MacArthur Bates communicative development inventory; Omega-3 fatty acids; Omega-6 fatty acids";"POLYUNSATURATED FATTY-ACIDS; FISH-OIL SUPPLEMENTATION; LONG-TERM POTENTIATION; ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID; ARACHIDONIC-ACID; CONTROLLED-TRIAL; TRANSPORTER BINDING; CHILDREN; INFANTS";Delayed language development may be an early indicator of autism spectrum disorder (ASD). Early intervention is critical for children with ASD, and the present study presents pilot data on a clinical trial of omega-3 and -6 fatty acid supplementation and language development, a secondary trial outcome, in children at risk for ASD. We randomized 31 children to receive an omega-3 and -6 supplement or a placebo for 3 months, and measured their language abilities at baseline and after supplementation. Gesture use, but not word production, increased for children in the treatment group more than children in the placebo group. These results suggest possible effectiveness of omega-3 and -6 supplementation for language development in children at risk for ASD.;"[Sheppard, Kelly W.; Boone, Kelly M.; Rausch, Joseph; Coury, Daniel L.; Keim, Sarah A.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA; [Gracious, Barbara] Nationwide Childrens Hosp, Res Inst, Ctr Innovat Pediat Practice, 700 Childrens Dr, Columbus, OH 43205 USA; [Klebanoff, Mark A.; Rogers, Lynette K.] Nationwide Childrens Hosp, Res Inst, Ctr Perinatal Res, 700 Childrens Dr, Columbus, OH 43205 USA; [Bartlett, Christopher] Nationwide Childrens Hosp, Res Inst, Battelle Ctr Math Med, 700 Childrens Dr, Columbus, OH 43205 USA; [Coury, Daniel L.] Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA; [Sheppard, Kelly W.; Klebanoff, Mark A.; Rogers, Lynette K.; Bartlett, Christopher; Keim, Sarah A.] Ohio State Univ, Dept Pediat, Coll Med, 700 Childrens Dr, Columbus, OH 43205 USA; [Gracious, Barbara] Ohio State Univ, Dept Psychiat & Behav Hlth, Coll Med, 1670 Upham Dr,Suite 130, Columbus, OH 43210 USA";"University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University";"Sheppard, KW (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.;Sheppard, KW (corresponding author), Ohio State Univ, Dept Pediat, Coll Med, 700 Childrens Dr, Columbus, OH 43205 USA.";kelly.sheppard@nationwidechildrens.org;"Rausch, Joseph/E-8107-2018; Bartlett, Christopher/AAD-8813-2022; Coury, Daniel/L-6556-2019; Rogers, Lynette/V-6802-2019; Keim, Sarah/F-8929-2013; Bartlett, Christopher/B-4958-2009";"Keim, Sarah/0000-0003-3490-3649; Coury, Daniel/0000-0001-9754-3914; Sheppard, Kelly/0000-0002-3412-8649; Boone, Kelly M./0000-0003-2986-1077; Bartlett, Christopher/0000-0001-7837-6348";"Marci and Bill Ingram Fund for Autism Spectrum Disorders Research; Cures Within Reach; National Center for Advancing Translational Sciences/NIH [UL1TR001070]; Research Institute at Nationwide Children's Hospital";"Marci and Bill Ingram Fund for Autism Spectrum Disorders Research; Cures Within Reach; National Center for Advancing Translational Sciences/NIH; Research Institute at Nationwide Children's Hospital(Ohio State University)";This study was funded by The Marci and Bill Ingram Fund for Autism Spectrum Disorders Research (no grant number), Cures Within Reach (no grant number), the National Center for Advancing Translational Sciences/NIH (UL1TR001070), and internal support from the Research Institute at Nationwide Children's Hospital.;"Ahmad A, 2002, PEDIATR NEUROL, V26, P210, DOI 10.1016/S0887-8994(01)00383-6; Ahmad A, 2002, NUTR NEUROSCI, V5, P103, DOI 10.1080/10284150290018973; Aïd S, 2003, J LIPID RES, V44, P1545, DOI 10.1194/jlr.M300079-JLR200; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; [Anonymous], PLOS ONE; [Anonymous], COCHRANE DATABASE SY; [Anonymous], J NUTR; Arriaga RI, 1998, APPL PSYCHOLINGUIST, V19, P209, DOI 10.1017/S0142716400010043; Auestad N, 2001, PEDIATRICS, V108, P372, DOI 10.1542/peds.108.2.372; Barden AE, 2016, CURR OPIN LIPIDOL, V27, P26, DOI 10.1097/MOL.0000000000000262; Bent S, 2014, J AM ACAD CHILD PSY, V53, P658, DOI 10.1016/j.jaac.2014.01.018; BOURRE JM, 1993, PROSTAG LEUKOTR ESS, V48, P5, DOI 10.1016/0952-3278(93)90003-F; BOURRE JM, 1989, J NUTR, V119, P1880, DOI 10.1093/jn/119.12.1880; Bowen Kate J, 2016, Curr Treat Options Cardiovasc Med, V18, P69; BRECKENRIDGE WC, 1973, BIOCHIM BIOPHYS ACTA, V320, P681, DOI 10.1016/0304-4165(73)90148-7; Bruckner C, 2007, J SPEECH LANG HEAR R, V50, P1631, DOI 10.1044/1092-4388(2007/110); Catalan J, 2002, BEHAV NEUROSCI, V116, P1022, DOI 10.1037//0735-7044.116.6.1022; Cattani A, 2010, INT J LANG COMM DIS, V45, P162, DOI 10.3109/13682820902818870; Chalon S, 1998, J NUTR, V128, P2512, DOI 10.1093/jn/128.12.2512; Clandinin MT, 2005, J PEDIATR-US, V146, P461, DOI 10.1016/j.jpeds.2004.11.030; CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101; Coderre EL, 2017, J AUTISM DEV DISORD, V47, P795, DOI 10.1007/s10803-016-2985-0; DALE PS, 1991, J SPEECH HEAR RES, V34, P565, DOI 10.1044/jshr.3403.565; DELION S, 1994, J NUTR, V124, P2466, DOI 10.1093/jn/124.12.2466; Du Bois TM, 2006, NEUROSCIENCE, V139, P1397, DOI 10.1016/j.neuroscience.2006.02.068; Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z; Fang YJ, 2011, BIOCHEM J, V438, P203, DOI 10.1042/BJ20110569; Farvid MS, 2014, CIRCULATION, V130, P1568, DOI 10.1161/CIRCULATIONAHA.114.010236; Fenson L, 2000, APPL PSYCHOLINGUIST, V21, P95, DOI 10.1017/S0142716400001053; Fewtrell MS, 2004, J PEDIATR-US, V144, P471, DOI 10.1016/j.jpeds.2004.01.034; Foster-Cohen S, 2007, J CHILD LANG, V34, P655, DOI 10.1017/S0305000907008070; Frank MC, 2017, J CHILD LANG, V44, P677, DOI 10.1017/S0305000916000209; Garton Alison., 1985, FL, V6, P29; Gibson RA, 2013, PROSTAG LEUKOTR ESS, V88, P139, DOI 10.1016/j.plefa.2012.04.003; Gordon RG, 2015, J AUTISM DEV DISORD, V45, P2267, DOI 10.1007/s10803-015-2390-0; Groen WB, 2008, NEUROSCI BIOBEHAV R, V32, P1416, DOI 10.1016/j.neubiorev.2008.05.008; Harnack K, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-8; Harris William S, 2006, Curr Atheroscler Rep, V8, P453, DOI 10.1007/s11883-006-0019-7; Henriksen C, 2008, PEDIATRICS, V121, P1137, DOI 10.1542/peds.2007-1511; Ikemoto A, 1997, NEUROCHEM RES, V22, P671, DOI 10.1023/A:1027393724676; Innis SM, 2014, MIL MED, V179, P82, DOI 10.7205/MILMED-D-14-00147; Johnson M, 2017, J CHILD PSYCHOL PSYC, V58, P83, DOI 10.1111/jcpp.12614; Johnson S, 2010, J PEDIATR-US, V156, P525, DOI 10.1016/j.jpeds.2009.10.041; Jucaite A, 2005, BIOL PSYCHIAT, V57, P229, DOI 10.1016/j.biopsych.2004.11.009; Jumpsen J, 1997, J NUTR, V127, P724, DOI 10.1093/jn/127.5.724; Jumpsen JA, 1997, BBA-LIPID LIPID MET, V1347, P40, DOI 10.1016/S0005-2760(97)00046-5; KATO K, 1991, BRAIN RES, V563, P94, DOI 10.1016/0006-8993(91)91519-7; Koletzko B, 2008, J PERINAT MED, V36, P5, DOI 10.1515/JPM.2008.001; Kris-Etherton P, 2010, J AM DIET ASSOC, V110, P201, DOI 10.1016/j.jada.2009.12.006; Kuzniewicz MW, 2014, J PEDIATR-US, V164, P20, DOI 10.1016/j.jpeds.2013.09.021; Lapillonne A, 2016, ANN NUTR METAB, V69, P36, DOI 10.1159/000448265; Lauritzen L, 2005, REPROD NUTR DEV, V45, P535, DOI 10.1051/rnd:2005044; LeBarton ES, 2016, INT J LANG COMM DIS, V51, P18, DOI 10.1111/1460-6984.12180; LeBarton ES, 2015, J COGN DEV, V16, P199, DOI 10.1080/15248372.2013.858041; Lee JM, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010023; LYNCH MA, 1994, EUR J NEUROSCI, V6, P1008, DOI 10.1111/j.1460-9568.1994.tb00595.x; Mankad D, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0010-7; Martínez M, 1998, J NEUROCHEM, V71, P2528; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; McNamara RK, 2007, BIOL PSYCHIAT, V62, P17, DOI 10.1016/j.biopsych.2006.08.026; McNamara RK, 2011, J AFFECT DISORDERS, V129, P359, DOI 10.1016/j.jad.2010.08.021; McNamara RK, 2010, J AFFECT DISORDERS, V126, P303, DOI 10.1016/j.jad.2010.03.015; McNamara RK, 2010, J NUTR, V140, P864, DOI 10.3945/jn.109.113233; Meldrum SJ, 2012, BRIT J NUTR, V108, P1443, DOI 10.1017/S0007114511006878; Mody M, 2017, J AUTISM DEV DISORD, V47, P155, DOI 10.1007/s10803-016-2934-y; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; MUNDY P, 1987, J AUTISM DEV DISORD, V17, P349, DOI 10.1007/BF01487065; Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211; Özçaliskan S, 2016, AUTISM, V20, P754, DOI 10.1177/1362361315605921; Pan BA, 2004, J CHILD LANG, V31, P587, DOI 10.1017/S0305000904006270; Parladé MV, 2015, J AUTISM DEV DISORD, V45, P2218, DOI 10.1007/s10803-015-2391-z; Patrick RP, 2015, FASEB J, V29, P2207, DOI 10.1096/fj.14-268342; Pritchard MA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1949; RESCORLA L, 1991, TOP LANG DISORD, V11, P14, DOI 10.1097/00011363-199111040-00004; Richardson AJ, 2005, PEDIATRICS, V115, P1360, DOI 10.1542/peds.2004-2164; Ring E.D., 2000, FIRST LANG, V20, P141, DOI DOI 10.1177/014272370002005902; Sansavini A, 2011, NEUROPSYCHOLOGIA, V49, P3677, DOI 10.1016/j.neuropsychologia.2011.09.023; SCHAECHTER JD, 1993, J NEUROSCI, V13, P4361; Schneider MR, 2012, BIPOLAR DISORD, V14, P356, DOI 10.1111/j.1399-5618.2012.01024.x; Scott DT, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e59; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Sheppard KW, 2017, AM J CLIN NUTR, V105, P32, DOI 10.3945/ajcn.116.141390; Spencer TJ, 2007, BIOL PSYCHIAT, V62, P1059, DOI 10.1016/j.biopsych.2006.12.008; Spittle AJ, 2017, DEV MED CHILD NEUROL, V59, P207, DOI 10.1111/dmcn.13297; Verhaeghe L, 2016, CHILD PSYCHIAT HUM D, V47, P729, DOI 10.1007/s10578-015-0606-3; Voigt RG, 2014, J PEDIATR GASTR NUTR, V58, P715, DOI 10.1097/MPG.0000000000000260; Wainwright PE, 1997, J NUTR, V127, P184, DOI 10.1093/jn/127.1.184; Wainwright PE, 1999, PHYSIOL BEHAV, V66, P833, DOI 10.1016/S0031-9384(99)00028-1; Weiser MJ, 2015, J LIPID RES, V56, P151, DOI 10.1194/jlr.M055558; Willatts P, 2000, PROSTAG LEUKOTR ESS, V63, P95, DOI 10.1054/plef.2000.0198; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Winkens B, 2007, CONTEMP CLIN TRIALS, V28, P713, DOI 10.1016/j.cct.2007.04.002; Zimmer L, 2000, NEUROSCI LETT, V284, P25, DOI 10.1016/S0304-3940(00)00950-2";93;19;20;3;29;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;NOV;2017;47;11;;;;;3358;3369;;10.1007/s10803-017-3249-3;http://dx.doi.org/10.1007/s10803-017-3249-3;;;12;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;FJ3YD;28748334;Green Accepted;;;24/11/2024;WOS:000412668100004;View Full Record in Web of Science
J;"Kollárovics, N; Nagy, P; Balázs, J";;;;"Kollarovics Nora; Nagy Peter; Balazs Judit";;;Possible association between methylphenidate treatment in a child with autism spectrum disorder and subsequent gynecomastia;ORVOSI HETILAP;;;Hungarian;Article;;;;;;"attention deficit/hyperactivity disorder; autism spectrum disorder; methylphenidate; gynecomastia";"INTERNATIONAL CONSENSUS STATEMENT; UNILATERAL GYNECOMASTIA; ADHD";Although gynecomastia associated with methylphenidate monotherapy in the treatment of attention deficit hyperactivity disorder has already been reported in some adverse event databases, based on a review of the literature it appears that only five case reports have been published. In our study, we present the case of a child diagnosed with both autism spectrum disorder and attention deficit/hyperactivity disorder, who developed bilateral gynecomastia in association with continuous methylphenidate monotherapy for 6 months. With immediate cessation of methylphenidate therapy, clomiphene treatment was given for 10 days. A total of 14 days after cessation of methylphenidate treatment gynecomastia receded on both sides. After a methylphenidate drug-free period of 3 months, methylphenidate therapy was restarted, but 1 month later the side effect reappeared. The relationship between methylphenidate and the development of gynecomastia raises questions about a number of mechanisms. From a child psychiatrist point of view, it is an interesting question whether the presence of comorbid autism spectrum disorder and attention deficit/hyperactivity disorder may be relevant in the onset of adverse events by medication. The phenomenon may also be caused by altered regulation of the neuroendocrine-immune system. Our case report draws the attention of practicing physicians to monitoring of potential gynecomastia during methylphenidate therapy.;"[Kollarovics Nora] Semmelweis Egyet, Maltalis Egeszsegtud Doktori Iskola, Pszichiatria Program, Gyermekpszichiatriai Korkepek Vizsgalata Munkacso, Budapest, Hungary; [Kollarovics Nora] Nemzetkozi Cseperedo Alapitvany, Budapest, Hungary; [Nagy Peter] Bethesda Gyermekkorhaz, Figyelemhianyos Hiperaktivitas Zavar ADHD Ambulan, Budapest, Hungary; [Balazs Judit] Eotvos Lorand Univ, Pedagogiai & Pszichologiai Kar, Pszicholegiai Int, Fejlodes & Klinikai Gyermekpszichologia Tanszek, Budapest, Hungary; [Balazs Judit] Bjorknes Univ Coll, Oslo, Norway";"Semmelweis University; Eotvos Lorand University";Raoul Wallenberg U 2,1 Em 2, H-1136 Budapest, Hungary.;norakollarovics@gmail.com;Nagy, peter/KMY-7425-2024;;;;;"Adriani W, 2006, ANN NY ACAD SCI, V1074, P52, DOI 10.1196/annals.1369.005; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Balazs J., 1998, Psychiat Hung, V13, P160; Barkley R., 1996, AUST EDUC DEV PSYCHO, V13, P2; Barkley RA, 2002, CLIN CHILD FAM PSYCH, V5, P89; Bowman JD, 2012, PHARMACOTHERAPY, V32, P1123, DOI 10.1002/phar.1138; Braunstein G D, 1997, Curr Ther Endocrinol Metab, V6, P401; Brown RT, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e43; Coskun M, 2014, J CLIN PSYCHOPHARM, V34, P537, DOI 10.1097/JCP.0000000000000141; DuPaul G. J., 1998, ADHD rating Scale-IV: Checklists, norms, and clinical interpretation; Ensat F, 2012, EUR J PEDIATR, V171, P197, DOI 10.1007/s00431-011-1546-y; Food and Drug Administration, 2017, LAB METH; Goldman RD, 2010, CAN FAM PHYSICIAN, V56, P344; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Groenman AP, 2017, EXPERT OPIN DRUG SAF, V16, P455, DOI 10.1080/14740338.2017.1301928; Han Almis B, 2016, ANADOLU PSIKIYATR DE, V17, P74, DOI 10.5455/apd.177010; Hoevenaren IA, 2011, EUR J PLAST SURG, V34, P395, DOI 10.1007/s00238-010-0469-6; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Ismail AAA, 2001, ANN CLIN BIOCHEM, V38, P596, DOI 10.1258/0004563011900993; Johnson RE, 2009, MAYO CLIN PROC, V84, P1010, DOI 10.1016/S0025-6196(11)60671-X; Karayagmurlu A, 2020, CLIN PSYCHOPHARM NEU, V18, P337, DOI 10.9758/cpn.2020.18.2.337; Kutcher S, 2004, EUR NEUROPSYCHOPHARM, V14, P11, DOI 10.1016/S0924-977X(03)00045-2; Maciejewski M, 2016, POWERS PERILS POSTMA; Nordt CA, 2008, CURR OPIN PEDIATR, V20, P375, DOI 10.1097/MOP.0b013e328306a07c; Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028; Reichow B, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001572; Santosh PJ, 2000, EUR CHILD ADOLES PSY, V9, P27; Sheehan DV, 2010, J CLIN PSYCHIAT, V71, P313, DOI 10.4088/JCP.09m05305whi; Turi Eszter, 2013, Psychiatr Hung, V28, P165";29;0;0;0;4;AKADEMIAI KIADO ZRT;BUDAPEST;BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY;0030-6002;1788-6120;;ORVOSI HETILAP;Orvosi Hetilap;OCT;2021;162;42;;;;;1703;1708;;10.1556/650.2021.32198;http://dx.doi.org/10.1556/650.2021.32198;;;6;Medicine, General & Internal;Science Citation Index Expanded (SCI-EXPANDED);General & Internal Medicine;WI9ZY;34657003;Green Accepted, hybrid;;;24/11/2024;WOS:000708712300006;View Full Record in Web of Science
J;"Hegvik, TA; Klungsoyr, K; Kuja-Halkola, R; Remes, H; Haavik, J; D'Onofrio, BM; Metsä-Simola, N; Engeland, A; Fazel, S; Lichtenstein, P; Martikainen, P; Larsson, H; Sariaslan, A";;;;"Hegvik, Tor-Arne; Klungsoyr, Kari; Kuja-Halkola, Ralf; Remes, Hanna; Haavik, Jan; D'Onofrio, Brian M.; Metsa-Simola, Niina; Engeland, Anders; Fazel, Seena; Lichtenstein, Paul; Martikainen, Pekka; Larsson, Henrik; Sariaslan, Amir";;;Labor epidural analgesia and subsequent risk of offspring autism spectrum disorder and attention-deficit/hyperactivity disorder: a cross-national cohort study of 4.5 million individuals and their siblings;AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY;;;English;Article;;;;;;"attention-deficit; hyperactivity disorder; autism spectrum disorder; causal inference; family-based designs; labor epidural analgesia";"DEFICIT HYPERACTIVITY DISORDER; PREGNANCY; REGISTRY; SCHIZOPHRENIA; ASSOCIATION; INFECTION; CHILDREN; ADHD";"BACKGROUND: A recent study has suggested that labor epidural analgesia may be associated with increased rates of offspring autism spectrum disorder. Subsequent replication attempts have lacked sufficient power to confidently exclude the possibility of a small effect, and the causal nature of this association remains unknown. OBJECTIVE: This study aimed to investigate the extent to which exposure to labor epidural analgesia is associated with offspring autism spectrum disorder and attention-deficit/hyperactivity disorder following adjustments for unmeasured familial confounding.STUDY DESIGN: We identified 4,498,462 singletons and their parents using the Medical Birth Registers in Finland (cohorts born from 1987-2005), Norway (1999-2015), and Sweden (1987-2011) linked with population and patient registries. These cohorts were followed from birth until they either had the outcomes of interest, emigrated, died, or reached the end of the follow-up (at mean ages 13.6-16.8 years), whichever occurred first. Cox regression models were used to estimate country-specific associations between labor epidural analgesia recorded at birth and outcomes (eg, at least 1 secondary care diagnosis of autism spectrum disorder and attention-deficit/hyperactivity disorder or at least 1 dispensed prescription of medication used for the treatment of attention-deficit/hyperactivity disorder). The models were adjusted for sex, birth year, birth order, and unmeasured familial confounders via sibling comparisons. Pooled estimates across all the 3 countries were estimated using inverse variance weighted fixed-effects meta-analysis models.RESULTS: A total of 4,498,462 individuals (48.7% female) were included, 1,091,846 (24.3%) of which were exposed to labor epidural analgesia. Of these, 1.2% were diagnosed with autism spectrum disorder and 4.0% with attention-deficit/hyperactivity disorder. On the population level, pooled estimates showed that labor epidural analgesia was asso-ciated with increased risk of offspring autism spectrum disorder (adjusted hazard ratio, 1.12; 95% confidence interval, 1.10-1.14, absolute risks, 1.20% vs 1.07%) and attention-deficit/hyperactivity disorder (adjusted hazard ratio, 1.20; 95% confidence interval, 1.19-1.21; absolute risks, 3.95% vs 3.32%). However, when comparing full siblings who were differentially exposed to labor epidural analgesia, the associations were fully attenuated for both conditions with narrow confidence intervals (adjusted hazard ratio [autism spectrum disorder], 0.98; 95% confidence interval, 0.93-1.03; adjusted hazard ratio attention-deficit/hyperactivity disorder, 0.99; 95% confidence interval, 0.96-1.02).CONCLUSION: In this large cross-national study, we found no support for the hypothesis that exposure to labor epidural analgesia causes either offspring autism spectrum disorder or attention-deficit/hyperactivity disorder.";"[Hegvik, Tor-Arne; Haavik, Jan] Univ Bergen, Dept Biomed, Bergen, Norway; [Hegvik, Tor-Arne] Haukeland Hosp, Dept Heart Dis, Bergen, Norway; [Klungsoyr, Kari; Engeland, Anders] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway; [Klungsoyr, Kari; Engeland, Anders] Norwegian Inst Publ Hlth, Div Mental & Phys Hlth, Bergen, Norway; [Kuja-Halkola, Ralf; Lichtenstein, Paul; Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Remes, Hanna; Metsa-Simola, Niina; Martikainen, Pekka] Univ Helsinki, Fac Social Sci, Populat Res Unit, Helsinki, Finland; [Haavik, Jan] Haukeland Hosp, Bergen Ctr Brain Plast, Div Psychiat, Bergen, Norway; [D'Onofrio, Brian M.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Fazel, Seena; Sariaslan, Amir] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; [Martikainen, Pekka] Stockholm Univ, Ctr Hlth Equ Studies CHESS, Stockholm, Sweden; [Martikainen, Pekka] Karolinska Inst, Stockholm, Sweden; [Martikainen, Pekka] Max Planck Inst Demog Res, Rostock, Germany; [Larsson, Henrik] Orebro Univ, Sch Med Sci, Orebro, Sweden";"University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; Norwegian Institute of Public Health (NIPH); Karolinska Institutet; University of Helsinki; University of Bergen; Haukeland University Hospital; Indiana University System; Indiana University Bloomington; University of Oxford; Stockholm University; Karolinska Institutet; Max Planck Society; Orebro University";Sariaslan, A (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England.;amir.sariaslan@psych.ox.ac.uk;"Klungsøyr, Kari/ABC-6147-2020; Haavik, Jan/ABE-1535-2020; Metsä-Simola, Niina/AAI-7689-2020; Kuja-Halkola, Ralf/ABA-5061-2020; Fazel, Seena/B-5307-2008; Larsson, Henrik/GYD-5161-2022";"Metsa-Simola, Niina/0000-0001-8813-3980; Fazel, Seena/0000-0002-5383-5365; Remes, Hanna/0000-0002-9291-703X; Kuja-Halkola, Ralf/0000-0002-3765-2067; Larsson, Henrik/0000-0002-6851-3297; Martikainen, Pekka/0000-0001-9374-1438";"Academy of Finland [308247, 294861]; University of Bergen; Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) [340-2013-5867]; Swedish Research Council [2014-3831]; National Institute on Drug Abuse [R01DA048042]; National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre [BRC-1215-20005]; Wellcome Trust [202836/Z/16/Z]; European Research Council [101019329]; NordForsk [83540]; Nev SomeOslo University Hospital; European Research Council (ERC) [101019329] Funding Source: European Research Council (ERC)";"Academy of Finland(Research Council of Finland); University of Bergen; Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM); Swedish Research Council(Swedish Research Council); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre(National Institutes of Health Research (NIHR)); Wellcome Trust(Wellcome Trust); European Research Council(European Research Council (ERC)); NordForsk(NordForsk); Nev SomeOslo University Hospital; European Research Council (ERC)(European Research Council (ERC))";The study was supported by the Academy of Finland (#308247, #294861) , University of Bergen, Nev SomeOslo University Hospital, the Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) framework (#340-2013-5867) , the Swedish Research Council (#2014-3831) , and the National Institute on Drug Abuse (R01DA048042) . A.S. and S.F. are supported by the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (grant BRC-1215-20005) . S.F. is further funded by the Wellcome Trust as part of a Senior Research Fellowship in Clinical Science (#202836/Z/16/Z) . P.M. has received funding from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agree-ment No 101019329) and the NordForsk grant for the project WELLIFE (#83540) .;"Alder J, 2007, J MATERN-FETAL NEO M, V20, P189, DOI 10.1080/14767050701209560; Amer Soc Anesthesiologists Task Fo, 2016, ANESTHESIOLOGY, V124, P270, DOI 10.1097/ALN.0000000000000935; American College of Obstetricians and Gynecologists' Committee on Practice BulletinsObstetrics, 2019, Obstet Gynecol, V133, pe208, DOI 10.1097/AOG.0000000000003132; American Society of Anesthesiologists, 2020, LAB EP CAUS AUT SAF; Anim-Somuah M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub4; Anorson N, 2021, EUR J PUBLIC HEALTH, P31; Arrhenius B, 2021, ACTA PAEDIATR, V110, P3275, DOI 10.1111/apa.16062; Bai D, 2019, JAMA PSYCHIAT, V76, P1035, DOI 10.1001/jamapsychiatry.2019.1411; Bakken IJ, 2020, SCAND J PUBLIC HEALT, V48, P49, DOI 10.1177/1403494819859737; Carrier FM, 2021, CAN J ANESTH, V68, P277, DOI 10.1007/s12630-020-01880-5; D'Onofrio BM, 2020, ANNU REV CLIN PSYCHO, V16, P25, DOI 10.1146/annurev-clinpsy-032816-045030; D'Onofrio BM, 2013, AM J PUBLIC HEALTH, V103, P46, DOI 10.2105/AJPH.2013.301252; Faraone SV, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.20; Finnish Institute for Health and Welfare, 2015, TRENDS ACC SPEC HLTH; Furu K, 2010, BASIC CLIN PHARMACOL, V106, P86, DOI 10.1111/j.1742-7843.2009.00494.x; Ghirardi L, 2018, MOL PSYCHIATR, V23, P257, DOI 10.1038/mp.2017.17; Ghirardi L, 2021, J CHILD PSYCHOL PSYC, V62, P1274, DOI 10.1111/jcpp.13508; Ginsberg Y, 2019, J CHILD PSYCHOL PSYC, V60, P160, DOI 10.1111/jcpp.12959; Grove J, 2019, NAT GENET, V51, P431, DOI 10.1038/s41588-019-0344-8; Hammad IA, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.07.024; Hanley GE, 2021, JAMA-J AM MED ASSOC, V326, P1178, DOI 10.1001/jama.2021.14986; Hillyard SG, 2011, BRIT J ANAESTH, V107, P668, DOI 10.1093/bja/aer300; Idring S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041280; Joelsson P, 2016, CHILD PSYCHIAT HUM D, V47, P574, DOI 10.1007/s10578-015-0591-6; Kalkbrenner AE, 2020, AUTISM RES, V13, P134, DOI 10.1002/aur.2196; Kern-Goldberger Adina R, 2021, JAMA Pediatr, V175, P536, DOI 10.1001/jamapediatrics.2020.6692; Lampi KM, 2010, ACTA PAEDIATR, V99, P1425, DOI 10.1111/j.1651-2227.2010.01835.x; Langhoff-Roos J, 2014, ACTA OBSTET GYN SCAN, V93, P132, DOI 10.1111/aogs.12302; Larsson H, 2014, J CHILD PSYCHOL PSYC, V55, P428, DOI 10.1111/jcpp.12140; Larsson H, 2013, BRIT J PSYCHIAT, V203, P103, DOI 10.1192/bjp.bp.112.120808; Lee A, 2021, JAMA PEDIATR, V175, P536, DOI 10.1001/jamapediatrics.2020.6686; Lichtenstein P, 2010, AM J PSYCHIAT, V167, P1357, DOI 10.1176/appi.ajp.2010.10020223; Lim G, 2018, ANESTHESIOLOGY, V129, P192, DOI [10.1097/ALN.0000000000002182, 10.1097/aln.0000000000002182]; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Maret-Ouda J, 2017, SCAND J PUBLIC HEALT, V45, P14, DOI 10.1177/1403494817702336; McIntosh AM, 2019, NEURON, V102, P91, DOI 10.1016/j.neuron.2019.03.022; McKeen DM, 2021, CAN J ANESTH, V68, P180, DOI 10.1007/s12630-020-01840-z; Meier SM, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1002-7; Mikkelsen AP, 2021, JAMA-J AM MED ASSOC, V326, P1170, DOI 10.1001/jama.2021.12655; National Institute for Health and Care Excellence (NICE), 2019, INTR CAR HLTH WOM BA; Oberg AS, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0965; Pitkänen MT, 2013, ACTA ANAESTH SCAND, V57, P553, DOI 10.1111/aas.12064; Polanczyk GV, 2015, J CHILD PSYCHOL PSYC, V56, P345, DOI 10.1111/jcpp.12381; Qiu CY, 2020, JAMA PEDIATR, V174, P1168, DOI 10.1001/jamapediatrics.2020.3231; Ren T, 2022, BRIT J ANAESTH, V128, P513, DOI 10.1016/j.bja.2021.10.042; Royal College of Anaesthetists, 2020, EV LAB EP CAUS AUT; Ruppen W, 2006, ANESTHESIOLOGY, V105, P394, DOI 10.1097/00000542-200608000-00023; Sandin S, 2017, JAMA-J AM MED ASSOC, V318, P1182, DOI 10.1001/jama.2017.12141; Sariaslan A, 2021, INT J EPIDEMIOL, V50, P1628, DOI 10.1093/ije/dyab099; Sariaslan A, 2015, SCHIZOPHRENIA BULL, V41, P494, DOI 10.1093/schbul/sbu105; Seijmonsbergen-Schermers AE, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003103; Sjölander A, 2022, ANNU REV STAT APPL, V9, P71, DOI 10.1146/annurev-statistics-040120-024521; Skoglund C, 2014, J CHILD PSYCHOL PSYC, V55, P61, DOI 10.1111/jcpp.12124; Smorti M, 2019, J OBSTET GYNAECOL, V39, P492, DOI 10.1080/01443615.2018.1536697; Surén P, 2019, TIDSSKR NORSKE LAEGE, V139, P1372, DOI 10.4045/tidsskr.18.0960; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wall-Wieler E, 2021, JAMA PEDIATR, V175, P698, DOI 10.1001/jamapediatrics.2021.0376; Wang K, 2017, NAT GENET, V49, P1319, DOI 10.1038/ng.3931; Wiggs KK, 2017, BEHAV GENET, V47, P383, DOI 10.1007/s10519-017-9852-4; Wu CS, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.046; Zhang TY, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0837";61;9;10;2;15;MOSBY-ELSEVIER;NEW YORK;360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA;0002-9378;1097-6868;;AM J OBSTET GYNECOL;Am. J. Obstet. Gynecol.;FEB;2023;228;2;;;;;;;;10.1016/j.ajog.2022.08.016;http://dx.doi.org/10.1016/j.ajog.2022.08.016;;janv-23;12;Obstetrics & Gynecology;Science Citation Index Expanded (SCI-EXPANDED);Obstetrics & Gynecology;8P6XM;35973476;;;;24/11/2024;WOS:000926665200001;View Full Record in Web of Science
J;"Bearss, K; Johnson, C; Smith, T; Lecavalier, L; Swiezy, N; Aman, M; McAdam, DB; Butter, E; Stillitano, C; Minshawi, N; Sukhodolsky, DG; Mruzek, DW; Turner, K; Neal, T; Hallett, V; Mulick, JA; Green, B; Handen, B; Deng, YH; Dziura, J; Scahill, L";;;;"Bearss, Karen; Johnson, Cynthia; Smith, Tristram; Lecavalier, Luc; Swiezy, Naomi; Aman, Michael; McAdam, David B.; Butter, Eric; Stillitano, Charmaine; Minshawi, Noha; Sukhodolsky, Denis G.; Mruzek, Daniel W.; Turner, Kylan; Neal, Tiffany; Hallett, Victoria; Mulick, James A.; Green, Bryson; Handen, Benjamin; Deng, Yanhong; Dziura, James; Scahill, Lawrence";;;Effect of Parent Training vs Parent Education on Behavioral Problems in Children With Autism Spectrum Disorder A Randomized Clinical Trial;JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; YOUNG-CHILDREN; PROGRAM";"IMPORTANCE Disruptive behavior is common in children with autism spectrum disorder. Behavioral interventions are used to treat disruptive behavior but have not been evaluated in large-scale randomized trials. OBJECTIVE To evaluate the efficacy of parent training for children with autism spectrum disorder and disruptive behavior. DESIGN, SETTING, AND PARTICIPANTS This 24-week randomized trial compared parent training (n = 89) to parent education (n = 91) at 6 centers (Emory University, Indiana University, Ohio State University, University of Pittsburgh, University of Rochester, Yale University). We screened 267 children; 180 children (aged 3-7 years) with autism spectrum disorder and disruptive behaviors were randomly assigned (86% white, 88% male) between September 2010 and February 2014. INTERVENTIONS Parent training (11 core, 2 optional sessions; 2 telephone boosters; 2 home visits) provided specific strategies to manage disruptive behavior. Parent education (12 core sessions, 1 home visit) provided information about autism but no behavior management strategies. MAIN OUTCOMES AND MEASURES Parents rated disruptive behavior and noncompliance on co-primary outcomes: the Aberrant Behavior Checklist-Irritability subscale (range, 0-45) and the Home Situations Questionnaire-Autism Spectrum Disorder (range, 0-9). On both measures, higher scores indicate greater severity and a 25% reduction indicates clinical improvement. A clinician blind to treatment assignment rated the Improvement scale of the Clinical Global Impression (range, 1-7), a secondary outcome, with a positive response less than 3. RESULTS At week 24, the Aberrant Behavior Checklist-Irritability subscale declined 47.7% in parent training (from 23.7 to 12.4) compared with 31.8% for parent education (23.9 to 16.3) (treatment effect, -3.9; 95% CI, -6.2 to -1.7; P < .001, standardized effect size = 0.62). The Home Situations Questionnaire-Autism Spectrum Disorder declined 55% (from 4.0 to 1.8) compared with 34.2% in parent education (3.8 to 2.5) (treatment effect, -0.7; 95% CI, -1.1 to -0.3; P < .001, standardized effect size = 0.45). Neither measure met the prespecified minimal clinically important difference. The proportions with a positive response on the Clinical Global Impression-Improvement scale were 68.5% for parent training vs 39.6% for parent education (P < .001). CONCLUSIONS AND RELEVANCE For children with autism spectrum disorder, a 24-week parent training program was superior to parent education for reducing disruptive behavior on parent-reported outcomes, although the clinical significance of the improvement is unclear. The rate of positive response judged by a blinded clinician was greater for parent training vs parent education.";"[Bearss, Karen; Green, Bryson; Scahill, Lawrence] Childrens Healthcare Atlanta, Marcus Autism Ctr, Dept Pediat, Atlanta, GA 30329 USA; [Bearss, Karen; Green, Bryson; Scahill, Lawrence] Emory Univ, Atlanta, GA 30329 USA; [Johnson, Cynthia; Stillitano, Charmaine] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Smith, Tristram; McAdam, David B.; Mruzek, Daniel W.] Univ Rochester, Dept Pediat, Rochester, NY USA; [Lecavalier, Luc; Aman, Michael] Ohio State Univ, Nisonger Ctr, UCEDD, Dept Psychol, Columbus, OH 43210 USA; [Lecavalier, Luc; Aman, Michael] Ohio State Univ, Nisonger Ctr, UCEDD, Dept Psychiat, Columbus, OH 43210 USA; [Swiezy, Naomi; Minshawi, Noha; Neal, Tiffany] Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA; [Butter, Eric; Mulick, James A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Butter, Eric; Mulick, James A.] Natl Childrens Hosp, Columbus, OH USA; [Sukhodolsky, Denis G.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Turner, Kylan] Arizona State Univ, Mary Lou Fulton Teachers Coll, Div Educ Leadership & Innovat, Tempe, AZ USA; [Hallett, Victoria] Kings Coll London, Dept Psychol, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England; [Handen, Benjamin] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Deng, Yanhong] Yale Univ, Sch Publ Hlth, New Haven, CT USA; [Dziura, James] Yale Univ, Dept Emergency Med, New Haven, CT USA";"Children's Healthcare of Atlanta (CHOA); Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Rochester; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Indiana University System; Indiana University Indianapolis; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Yale University; Arizona State University; Arizona State University-Tempe; University of London; King's College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Yale University";Scahill, L (corresponding author), Childrens Healthcare Atlanta, Marcus Autism Ctr, 1920 Briarcliff NE, Atlanta, GA 30329 USA.;lawrence.scahill@emory.edu;"Swiezy, Naomi/AAZ-5697-2021; Sukhodolsky, Denis/Z-3532-2019; Handen, Benjamin/GRY-0095-2022; deng, yan/KCK-8563-2024; Butter, Eric/AAS-8595-2021";"Sukhodolsky, Denis/0000-0002-5401-792X; Turner, Kylan/0000-0002-9511-5059";"National Institute of Mental Health [MH081148, MH080965, MH081105, MH081221, MH080906]; University of Rochester from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [UL1 TR000042]; National Center for Research Resources (NCRR), a component of the NIH [UL1 RR024139, 5KL2RR024138]; NIH Roadmap for Medical Research; Public Health Service grant from the CTSA program of the NIH NCRR at Emory University School of Medicine [UL1 RR025008]; Marcus Foundation; Joseph B. Whitehead Foundation; Children's Healthcare of Atlanta Foundation; Cox Foundation; [MH079130]";"National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); University of Rochester from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); National Center for Research Resources (NCRR), a component of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Public Health Service grant from the CTSA program of the NIH NCRR at Emory University School of Medicine; Marcus Foundation; Joseph B. Whitehead Foundation; Children's Healthcare of Atlanta Foundation; Cox Foundation;";"This work was funded by the National Institute of Mental Health by grants to Yale University/Emory University (MH081148; principal investigator: Dr Scahill), the University of Pittsburgh (MH080965; principal investigator: Dr Johnson), Ohio State University (MH081105; principal investigator: Dr Lecavalier), Indiana University (MH081221; principal investigator: Dr Swiezy), and the University of Rochester (MH080906; principal investigator: Dr Smith). The project described in this publication also was supported by MH079130 (principal investigator: Dr Sukhodolsky); a University of Rochester Clinical and Translational Scholar Award (CTSA) (UL1 TR000042) from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); a CTSA (UL1 RR024139) and grant from the National Center for Research Resources (NCRR) (5KL2RR024138), a component of the NIH; and the NIH Roadmap for Medical Research. This work was supported in part by a Public Health Service grant (UL1 RR025008) from the CTSA program of the NIH NCRR at Emory University School of Medicine and also supported by the Marcus Foundation, Joseph B. Whitehead Foundation, Children's Healthcare of Atlanta Foundation, and Cox Foundation.";"AMAN MG, 1985, AM J MENT DEF, V89, P492; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Bearss K, 2013, NEUROPSYCHIATRY-LOND, V3, P169, DOI 10.2217/NPY.13.14; Carter MJ, 2014, THER RECREAT J, V48, P275; Chowdhury M, 2010, J INTELL DISABIL RES, V54, P281, DOI 10.1111/j.1365-2788.2010.01259.x; Dretzke Janine, 2009, Child Adolesc Psychiatry Ment Health, V3, P7, DOI 10.1186/1753-2000-3-7; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Gadow K.D., 2002, Childhood Symptom Inventory-4 screening and norms manual; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Guy W., 1976, Clinical global impression. ECDEU assessment manual for psychopharmacology, P218; Handen BL, 2013, J DEV PHYS DISABIL, V25, P355, DOI 10.1007/s10882-012-9316-y; Hartley SL, 2008, J INTELL DISABIL RES, V52, P819, DOI 10.1111/j.1365-2788.2008.01065.x; Hayes SA, 2013, J AUTISM DEV DISORD, V43, P629, DOI 10.1007/s10803-012-1604-y; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Kraemer HC, 2006, ARCH GEN PSYCHIAT, V63, P484, DOI 10.1001/archpsyc.63.5.484; Lecavalier L, 2006, J INTELL DISABIL RES, V50, P172, DOI 10.1111/j.1365-2788.2005.00732.x; Maskey M, 2013, J AUTISM DEV DISORD, V43, P851, DOI 10.1007/s10803-012-1622-9; Mazurek MO, 2013, RES AUTISM SPECT DIS, V7, P455, DOI 10.1016/j.rasd.2012.11.004; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Oono IP, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009774.pub2; Scahill L, 2012, J AM ACAD CHILD PSY, V51, P136, DOI 10.1016/j.jaac.2011.11.010; Sofronoff K, 2004, AUTISM, V8, P301, DOI 10.1177/1362361304045215; Sparrow Sparrow SS. SS., VINELAND 2 VINELAND; Tonge B, 2014, AUTISM, V18, P166, DOI 10.1177/1362361312458186; Whittingham K, 2009, J ABNORM CHILD PSYCH, V37, P469, DOI 10.1007/s10802-008-9285-x";27;262;323;10;74;AMER MEDICAL ASSOC;CHICAGO;330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA;0098-7484;1538-3598;;JAMA-J AM MED ASSOC;JAMA-J. Am. Med. Assoc.;APR 21;2015;313;15;;;;;1524;1533;;10.1001/jama.2015.3150;http://dx.doi.org/10.1001/jama.2015.3150;;;10;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;CG3SA;25898050;Green Accepted;Y;N;24/11/2024;WOS:000353198700017;View Full Record in Web of Science
J;"Stachon, M; Sierocka, M; Poniewierski, P; Kostiukow, A; Samborski, W";;;;"Stachon, Malgorzata; Sierocka, Milena; Poniewierski, Piotr; Kostiukow, Anna; Samborski, Wlodzimierz";;;Cannabinoids in the treatment of children with autism spectrum disorder;AKTUALNOSCI NEUROLOGICZNE;;;Polish;Article;;;;;;"cannabinoids; marijuana; autism; paediatrics";"SOCIAL DEFICITS; CANNABIDIOL; SEIZURES";Introduction: Isolation of two compounds, tetrahydrocannabinol (THC) and cannabidiol (CBD), contributed to an increased interest in the use of marijuana for medicinal purposes. It was then that research on the effects of marijuana on the course of different diseases began. Aim: The aim of this paper was to analyse the use of cannabinoids in the treatment of children with autism spectrum disorder. Results: There are different methods for cannabinoid administration. Researchers use various preparations with doses ranging between 0.04 mg to 900 mg. Preliminary studies are conducted on animal models, usually in genetically modified mice. Cannabinoids have been found to have a positive effect on social and emotional behaviours of children, as well as to show anxiolytic and antipsychotic effects. Cannabidiol plays an important role in the secretion of vasopressin and oxytocin. Some patients experience adverse effects. Antidepressant and anticonvulsant effects have been observed in patients with neurological and mental disorders. Conclusions: Cannabinoid therapy is not the standard of care in children with autism spectrum disorders, and the doses used vary significantly. There is evidence for the positive effects of cannabinoids in patients with comorbidities. It is possible that cannabinoids have an anxiolytic effect and allow for a reduced use of antipsychotics in the analysed group of patients. Antidepressant and anticonvulsant effects have also been observed. Furthermore, it was shown that CBDs administered in mice with Dravet syndrome improve social behaviour, dysfunction of which is one of the central symptoms of autism spectrum disorder.;"[Stachon, Malgorzata; Sierocka, Milena; Poniewierski, Piotr] Uniwersytet Med Poznaniu, Neurorozwojowe Studenckie Kolo Naukowe, Poznan, Poland; [Poniewierski, Piotr; Kostiukow, Anna; Samborski, Wlodzimierz] Uniwersytet Med Poznaniu, Katedra & Klin Reumatol & Rehabilitacji, Poznan, Poland";"Poznan University of Medical Sciences; Poznan University of Medical Sciences";Stachon, M (corresponding author), Ortopedyczno Rehabilitacyjny Szpital Klini, Ul 28 Czerwca 1956 R 135-147, PL-61545 Poznan, Poland.;malgosiastachon@gmail.com;;;;;;"Abbot Patrick., 2008, Psychiatric Times, V25, P43; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; [Anonymous], JEDNOLITA KONWENCJA; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Araujo DJ, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00424; Campos AC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00269; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Devinsky O, 2015, NEUROTHERAPEUTICS, V12, P689, DOI 10.1007/s13311-015-0388-0; Esposito G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028668; Gu B., 2017, Glob Drugs Therap, V2, P1, DOI DOI 10.15761/GDT.1000134; Hadland SE, 2015, J DEV BEHAV PEDIATR, V36, P115, DOI 10.1097/DBP.0000000000000129; Kaplan JS, 2017, P NATL ACAD SCI USA, V114, P11229, DOI 10.1073/pnas.1711351114; Karhson DS, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0203-y; Klimkiewicz A., 2018, Psychiatria, V15, P88, DOI [DOI 10.17226/24625, 10.17226/24625]; Kurz R., 2010, Can Underwrit, V5, P4; Lee JLC, 2017, BRIT J PHARMACOL, V174, P3242, DOI 10.1111/bph.13724; Lorenz R, 2004, NEUROENDOCRINOL LETT, V25, P40; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; Mastinu A, 2018, NEUROPHARMACOLOGY, V133, P366, DOI 10.1016/j.neuropharm.2018.02.007; More SV, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0012-0; Oberbarnscheidt T., 2016, J. Addict. Res. Ther, VS11, P012, DOI [10.4172/2155- 6105.1000S11-012, 10.4172/2155-6105.S11-012, DOI 10.4172/2155-6105.S11-012]; Premoli M, 2019, LIFE SCI, V224, P120, DOI 10.1016/j.lfs.2019.03.053; Reece AS., 2019, CLIN PEDIAT OA, V4, P154; Schleider LBL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37570-y; Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3; Ustawa z dnia 7 lipca, 2017, ZMIANIE USTAWY PRZEC; Verrotti A, 2016, CLIN DRUG INVEST, V36, P331, DOI 10.1007/s40261-016-0379-x; Wei D, 2016, CANNABIS CANNABINOID, V1, P81, DOI 10.1089/can.2015.0008";29;0;0;4;19;MEDICAL COMMUNICATIONS;WARSZAWA;UL POWSINSKA 34, WARSZAWA, 02903, POLAND;1641-9227;;;AKTUAL NEUROL;Aktual. Neurol.;;2020;20;3;;;;;119;124;;10.15557/AN.2020.0015;http://dx.doi.org/10.15557/AN.2020.0015;;;6;Clinical Neurology;Emerging Sources Citation Index (ESCI);Neurosciences & Neurology;RH7EA;;gold;;;24/11/2024;WOS:000636375900003;View Full Record in Web of Science
J;"McLaughlin, CS; Grosman, HE; Guillory, SB; Isenstein, EL; Wilkinson, E; Trelles, MD; Halpern, DB; Siper, PM; Kolevzon, A; Buxbaum, JD; Wang, AT; Foss-Feig, JH";;;;"McLaughlin, Christopher S.; Grosman, Hannah E.; Guillory, Sylvia B.; Isenstein, Emily L.; Wilkinson, Emma; Trelles, Maria Del Pilar; Halpern, Danielle B.; Siper, Paige M.; Kolevzon, Alexander; Buxbaum, Joseph D.; Wang, A. Ting; Foss-Feig, Jennifer H.";;;Reduced engagement of visual attention in children with autism spectrum disorder;AUTISM;;;English;Article;;;;;;"autism spectrum disorders; eye-tracking; gap effect; saccade; social; visual attention";"JOINT ATTENTION; YOUNG-CHILDREN; EYE-MOVEMENTS; GAP; DISENGAGEMENT; STIMULI; INFANTS; FACES; INDIVIDUALS; FIXATION";"A common example of social differences in autism spectrum disorder is poor modulation of reciprocal gaze, including reduced duration of eye contact and difficulty detecting the aim of another's gaze. It remains unclear, however, whether such differences are specific to the social domain, or are instead indicative of broader alterations in processes of visual engagement and disengagement in autism spectrum disorder. To assess whether children with autism spectrum disorder experience altered engagement of visual attention, and whether such processes are specific to social stimuli, we implemented a gap-overlap eye-tracking paradigm consisting of both social and nonsocial images with children with autism spectrum disorder (n = 35) and typical development (n = 32). Children with autism spectrum disorder demonstrated a significantly reduced overall gap effect (i.e. difference in saccade latency to peripheral stimuli between overlap and gap trials) compared with the controls. This reduction spanned both social and nonsocial conditions. Our findings suggest that children with autism spectrum disorder experience alterations in general processes of engagement of visual attention, and that these alterations are not specific to the social domain, but do associate with cognitive functioning. Affected processes of visual engagement in autism spectrum disorder may contribute to features like poor reciprocal gaze, but social-specific symptoms of autism spectrum disorder likely originate from other subcortical processes or higher order cognition. Lay abstract Limited eye contact and difficulty tracking where others are looking are common in people with autism spectrum disorder. It is unclear, however, whether these are specifically social differences; it is possible that they are a result of broader alterations in engaging and disengaging visual attention. We used eye-tracking technology with children with autism spectrum disorder (n = 35) and typical development (n = 32), showing them both social and nonsocial imaging to test their visual attention. Children with autism spectrum disorder had a significant difference in how long it took them to look from an image in the middle to one on the side, depending on whether the middle image stayed on the screen or flashed off before the one on the side appeared. This difference was present for both social and nonsocial images, and was related to cognitive ability for only the children with autism spectrum disorder. Our findings suggest that children with autism spectrum disorder have differences in general processes of engaging visual attention that are not specifically social in nature, and that these processes may relate to cognitive ability in autism spectrum disorder. Affected processes of visual engagement in autism spectrum disorder may contribute to symptoms like reduced eye contact, but social-specific symptoms of autism spectrum disorder likely do not stem from reduced visual engagement alone.";"[McLaughlin, Christopher S.; Grosman, Hannah E.; Guillory, Sylvia B.; Trelles, Maria Del Pilar; Halpern, Danielle B.; Siper, Paige M.; Kolevzon, Alexander; Buxbaum, Joseph D.; Wang, A. Ting; Foss-Feig, Jennifer H.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Isenstein, Emily L.] Univ Rochester, Rochester, NY 14627 USA; [Wilkinson, Emma] SUNY Albany, Albany, NY 12222 USA";"Icahn School of Medicine at Mount Sinai; University of Rochester; State University of New York (SUNY) System; University at Albany, SUNY";Foss-Feig, JH (corresponding author), Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, Dept Psychiat, 1 GustaveL Levy Pl,Box 1230, New York, NY 10029 USA.;jennifer.foss-feig@mssm.edu;;"Isenstein, Emily/0000-0002-2486-6162; Wilkinson, Emma/0000-0003-2529-9144; Buxbaum, Joseph/0000-0001-8898-8313; Grosman, Hannah/0000-0002-0096-5553";"National Institute of Mental Health [R21MH1152901]; National Institute of Neurological Disorders and Stroke [R01NS105845]; Seaver Foundation";"National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Seaver Foundation";"The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the National Institute of Mental Health [R21MH1152901]; the National Institute of Neurological Disorders and Stroke [R01NS105845]; and the Seaver Foundation.";"Achenbach T. M., 2001, -Age Forms Profiles; Adamson LB, 2009, J AUTISM DEV DISORD, V39, P84, DOI 10.1007/s10803-008-0601-7; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Bacon EC, 2020, AUTISM, V24, P658, DOI 10.1177/1362361319878578; Campbell R, 2006, DEV PSYCHOPATHOL, V18, P99, DOI 10.1017/S0954579406060068; Chawarska K, 2012, J CHILD PSYCHOL PSYC, V53, P903, DOI 10.1111/j.1469-7610.2012.02538.x; Chawarska K, 2010, ARCH GEN PSYCHIAT, V67, P178, DOI 10.1001/archgenpsychiatry.2009.194; Chernenok M, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01567; Christensen DL, 2019, MMWR SURVEILL SUMM, V68, P1, DOI 10.15585/mmwr.ss6802a1; Clifford S, 2007, J AUTISM DEV DISORD, V37, P301, DOI 10.1007/s10803-006-0160-8; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Csibra G, 1998, INT J PSYCHOPHYSIOL, V29, P201, DOI 10.1016/S0167-8760(98)00016-6; d'Arc BF, 2017, AUTISM, V21, P100, DOI 10.1177/1362361316630880; Dawson G, 2002, CHILD DEV, V73, P700, DOI 10.1111/1467-8624.00433; Dawson G, 2004, DEV PSYCHOL, V40, P271, DOI 10.1037/0012-1649.40.2.271; Desai A, 2019, BRAIN COGNITION, V137, DOI 10.1016/j.bandc.2019.103616; Wilson CE, 2019, AUTISM, V23, P677, DOI 10.1177/1362361318768025; Elliot C.D., 2007, Differential Abilities Scales, V2nd; Farroni T, 1999, DEVELOPMENTAL SCI, V2, P174, DOI 10.1111/1467-7687.00066; FISCHER B, 1993, BEHAV BRAIN SCI, V16, P553, DOI 10.1017/S0140525X00031575; Fischer J, 2014, CLIN PSYCHOL SCI, V2, P214, DOI 10.1177/2167702613496242; Goldberg MC, 2002, NEUROPSYCHOLOGIA, V40, P2039, DOI 10.1016/S0028-3932(02)00059-3; HOOD BM, 1993, INFANT BEHAV DEV, V16, P405, DOI 10.1016/0163-6383(93)80001-O; Howard MA, 2000, NEUROREPORT, V11, P2931, DOI 10.1097/00001756-200009110-00020; Iao LS, 2014, J EXP CHILD PSYCHOL, V122, P1, DOI 10.1016/j.jecp.2013.11.017; Jones W, 2013, NATURE, V504, P427, DOI 10.1038/nature12715; Karlsson MF, 2019, J CLIN EXP NEUROPSYC, V41, P1024, DOI 10.1080/13803395.2019.1646214; Kikuchi Y, 2011, J AUTISM DEV DISORD, V41, P629, DOI 10.1007/s10803-010-1082-z; Klin A, 2002, ARCH GEN PSYCHIAT, V59, P809, DOI 10.1001/archpsyc.59.9.809; Klin A, 2003, PHILOS T R SOC B, V358, P345, DOI 10.1098/rstb.2002.1202; Król ME, 2020, AUTISM, V24, P374, DOI 10.1177/1362361319865809; Landry R, 2004, J CHILD PSYCHOL PSYC, V45, P1115, DOI 10.1111/j.1469-7610.2004.00304.x; Lewis JD, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.24; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C., 2012, AUTISM DIAGNOSTIC OB; Madipakkam AR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13945-5; Matsuzawa M, 1997, INFANT BEHAV DEV, V20, P449, DOI 10.1016/S0163-6383(97)90035-7; Mo SL, 2019, RES AUTISM SPECT DIS, V65, P56, DOI 10.1016/j.rasd.2019.05.006; Mottron L, 2006, J AUTISM DEV DISORD, V36, P27, DOI 10.1007/s10803-005-0040-7; Mullen EM., 1995, MULLEN SCALES EARLY; MUNDY P, 1995, DEV PSYCHOPATHOL, V7, P63, DOI 10.1017/S0954579400006349; Pelphrey KA, 2002, J AUTISM DEV DISORD, V32, P249, DOI 10.1023/A:1016374617369; Richard AE, 2015, J CLIN EXP NEUROPSYC, V37, P671, DOI 10.1080/13803395.2015.1042838; Roid G. H., 2003, The Stanford-Binet intelligence scales; Sabatos-DeVito M, 2016, J AUTISM DEV DISORD, V46, P1319, DOI 10.1007/s10803-015-2681-5; Sadria M, 2019, COMPUT BIOL MED, V111, DOI 10.1016/j.compbiomed.2019.103332; SASLOW MG, 1967, J OPT SOC AM, V57, P1024, DOI 10.1364/JOSA.57.001024; Schmitt LM, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-47; Shic F, 2020, J CHILD PSYCHOL PSYC, V61, P459, DOI 10.1111/jcpp.13118; Todd J, 2009, J MOTOR BEHAV, V41, P419, DOI 10.3200/35-08-042; Ueda H, 2014, EXP BRAIN RES, V232, P329, DOI 10.1007/s00221-013-3743-6; van der Geest JN, 2001, BIOL PSYCHIAT, V50, P614, DOI 10.1016/S0006-3223(01)01070-8; Wang QD, 2020, DEVELOPMENTAL SCI, V23, DOI 10.1111/desc.12856; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 2014, Psychological Corporation; Werner E, 2005, J AUTISM DEV DISORD, V35, P337, DOI 10.1007/s10803-005-3301-6";56;5;7;6;63;SAGE PUBLICATIONS LTD;LONDON;1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND;1362-3613;1461-7005;;AUTISM;Autism;OCT;2021;25;7;;;;;2064;2073;1,36E+16;10.1177/13623613211010072;http://dx.doi.org/10.1177/13623613211010072;;MAY 2021;10;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;UL7CW;33966481;Green Accepted;;;24/11/2024;WOS:000650132100001;View Full Record in Web of Science
J;"Tanir, Y; Turkmen, G";;;;"Tanir, Yasar; Turkmen, Gaye";;;Atomoxetine-Induced Mania in a 6-year-old Child with Autism Spectrum Disorder;PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"atomoxetine; mania; autism spectrum disorder; child";;Atomoxetine, a selective norepinephrine (noradrenaline) reuptake inhibitor, is an effective and safe medication in the treatment of attention-deficit hyperactivity disorder (ADHD) with or without autism spectrum disorder (ASD) in children. However, unusual side effects may occur during the course of the treatment. In this case study, we present a 6-year-old child diagnosed with ASD comorbid with ADHD who developed atomoxetine induced mania during his treatment for ADHD.;"[Tanir, Yasar; Turkmen, Gaye] Istanbul Univ, Istanbul Med Fac, Child & Adolescent Psychiat Dept, Istanbul, Turkey";Istanbul University;Tanir, Y (corresponding author), Istanbul Univ, Istanbul Med Fac, Child & Adolescent Psychiat Dept, Istanbul, Turkey.;yasar.tanir@istanbul.edu.tr;"Tan?r, Ya?ar/AAS-9237-2020; Turkmen Noyan, Gaye/KOC-1817-2024";Turkmen Noyan, Gaye/0000-0001-7806-6630;;;;"Axelson D, 2006, ARCH GEN PSYCHIAT, V63, P1139, DOI 10.1001/archpsyc.63.10.1139; Bahali K, 2013, ACTAS ESP PSIQUIATRI, V41, P137; Espluga-Frigola Nuria, 2017, Actas Esp Psiquiatr, V45, P79; Guney E., 2014, J CHILD ADOLESC PSYC; Henderson TA, 2004, J CLIN PSYCHOPHARM, V24, P567, DOI 10.1097/01.jcp.0000139760.11458.aa; Kose S, 2017, PSYCHIAT CLIN PSYCH, V27, P210, DOI 10.1080/24750573.2017.1332512; Liu CC, 2014, J CHILD ADOL PSYCHOP, V24, P466, DOI 10.1089/cap.2014.0038; Mukaddes NM, 2010, WORLD J BIOL PSYCHIA, V11, P486, DOI [10.1080/15622970902789130, 10.3109/15622970902789130]; PIVEN J, 1991, J AM ACAD CHILD PSY, V30, P471, DOI 10.1097/00004583-199105000-00019; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P599, DOI 10.1089/cap.2006.16.599; STEINBERG S, 1985, AM J PSYCHIAT, V142, P1517";11;0;0;0;0;TURKISH ASSOC PSYCHOPHARMACOLOGY;ISTANBUL;FENERBAHCE MAH KISMET SOK KISMET APT NO 3 D 2, KADIKOY, ISTANBUL, TURKEY;2475-0573;2475-0581;;PSYCHIAT CLIN PSYCH;Psychiatry Clin. Psychopharmacol.;;2020;30;4;;;;;464;466;;10.5455/PCP.20201009072139;http://dx.doi.org/10.5455/PCP.20201009072139;;;3;"Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pharmacology & Pharmacy; Psychiatry";PO1LE;;gold;;;24/11/2024;WOS:000604931500018;View Full Record in Web of Science
J;"Halbur, M; Kodak, T; McKee, M; Reidy, J; Preas, E; Carroll, R";;;;"Halbur, Mary; Kodak, Tiffany; McKee, Marisa; Reidy, Jessi; Preas, Elizabeth; Carroll, Regina";;;Decreasing face touching for children with autism spectrum disorder;BEHAVIORAL INTERVENTIONS;;;English;Article;;;;;;"autism spectrum disorder; differential reinforcement of other behavior; face touching; M-DRO";STEREOTYPY;Face touching is a prevalent behavior for individuals of all ages. However, frequent face touching has potential negative side effects such as the transmission of viruses, bacterial infections, and skin infections. The present investigation extended previous research by evaluating a reinforcement-based intervention package on the reduction of face touching for children with autism spectrum disorder who tolerated face coverings (i.e., masks, face shields). The treatment package included an unsignaled, momentary differential reinforcement of other behavior procedure with prompts. Results indicated that rates of face touching decreased from baseline levels for all three children during 5-min treatment sessions. Furthermore, low levels of face touching were observed during follow-up sessions that were longer in duration (i.e., 15 min) across participants. Results support the utility of behavioral interventions on the reduction of potentially unsafe behaviors related to medical routines.;"[Halbur, Mary; Preas, Elizabeth; Carroll, Regina] Univ Nebraska Med Ctr, Integrated Ctr Autism Spectrum Disorders, Munroe Meyer Inst, 9012 Q St, Omaha, NE 68127 USA; [Kodak, Tiffany; McKee, Marisa; Reidy, Jessi] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA";"University of Nebraska System; University of Nebraska Medical Center; Marquette University";Halbur, M (corresponding author), Univ Nebraska Med Ctr, Integrated Ctr Autism Spectrum Disorders, Munroe Meyer Inst, 9012 Q St, Omaha, NE 68127 USA.;mary.halbur@unmc.edu;;;;;;"Ahearn WH, 2007, J APPL BEHAV ANAL, V40, P263, DOI 10.1901/jaba.2007.30-06; American Academy of Dermatology, 2021, SUN PROTECTION; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Association for Professionals in Infection Control and Epidemiology, 2020, APIC DONT TOUCH YOUR; AZRIN NH, 1977, AM PSYCHOL, V32, P140, DOI 10.1037/0003-066X.32.2.140; BARTON LE, 1986, J APPL BEHAV ANAL, V19, P277, DOI 10.1901/jaba.1986.19-277; Carr JE, 2000, J APPL BEHAV ANAL, V33, P353, DOI 10.1901/jaba.2000.33-353; Centers for Disease Control and Prevention, 2020, SEL WEAR CLEAN YOUR; Chen YJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.16924; Cox AD, 2017, J APPL BEHAV ANAL, V50, P8, DOI 10.1002/jaba.351; Derwas H., 1993, BEHAV INTERVENT, V8, P45, DOI [10.1002/bin.2360080106, DOI 10.1002/BIN.2360080106]; Desai Angel N, 2020, JAMA, V323, P2103, DOI 10.1001/jama.2020.6437; Elder NC, 2014, J AM BOARD FAM MED, V27, P339, DOI 10.3122/jabfm.2014.03.130242; FISHER WW, 1994, J APPL BEHAV ANAL, V27, P447, DOI 10.1901/jaba.1994.27-447; Halbur M, 2021, J APPL BEHAV ANAL, V54, P600, DOI 10.1002/jaba.833; Hammond JL, 2011, J APPL BEHAV ANAL, V44, P69, DOI 10.1901/jaba.2011.44-69; Heinicke MR, 2020, J APPL BEHAV ANAL, V53, P1225, DOI 10.1002/jaba.745; Jess RL, 2020, J APPL BEHAV ANAL, V53, P1219, DOI 10.1002/jaba.732; Kwok YLA, 2015, AM J INFECT CONTROL, V43, P112, DOI 10.1016/j.ajic.2014.10.015; Lazzarino AI, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2003; Liao YH, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-041364; Loftin RL, 2008, J AUTISM DEV DISORD, V38, P1124, DOI 10.1007/s10803-007-0499-5; Nicas M, 2008, J OCCUP ENVIRON HYG, V5, P347, DOI 10.1080/15459620802003896; Piazza CC, 2003, J APPL BEHAV ANAL, V36, P309, DOI 10.1901/jaba.2003.36-309; Reid D.H., 1995, MOTIVATING HUMAN SER; Sivaraman M, 2021, J APPL BEHAV ANAL, V54, P70, DOI 10.1002/jaba.802; Tarbox J., 2017, Treating feeding challenges in autism: Turning the tables on mealtime; Ward-Horner J, 2010, J APPL BEHAV ANAL, V43, P685, DOI 10.1901/jaba.2010.43-685; Wilke AE, 2012, RES AUTISM SPECT DIS, V6, P824, DOI 10.1016/j.rasd.2011.11.003; Winborn L, 2002, J APPL BEHAV ANAL, V35, P295, DOI 10.1901/jaba.2002.35-295";30;2;2;0;1;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1072-0847;1099-078X;;BEHAV INTERVENT;Behav. Intervent.;APR;2022;37;2;;;;;248;258;;10.1002/bin.1854;http://dx.doi.org/10.1002/bin.1854;;DEC 2021;11;Psychology, Clinical;Social Science Citation Index (SSCI);Psychology;0M6NT;;;;;24/11/2024;WOS:000733153500001;View Full Record in Web of Science
J;Hervás, A;;;;Hervas, Amaia;;;Emotional dysregulation and autism spectrum disorders;REVISTA DE NEUROLOGIA;;;Spanish;Article;;;;;;"Autism spectrum disorders; Autism; Comorbidity; Emotional dysregulation; Emotional regulation; Treatment";"MATERNAL MENTAL-HEALTH; PSYCHIATRIC-DISORDERS; EXECUTIVE FUNCTIONS; CHILDREN; ALEXITHYMIA; ADOLESCENTS; MANAGEMENT; SYMPTOMS; BEHAVIOR; ADULTS";Introduction. Autism spectrum disorders (ASD) are neurodevelopmental disorders that affect social communication and present stereotyped behaviours. They exhibit a wide range of phenotypic variability related with the capacity to use language for expression, cognitive skills and psychiatric comorbidities, among others. Psychiatric comorbidity is very frequent in ASD and in many cases it is multiple. Emotional dysregulation is related with ASD and with other psychiatric and neurodevelopmental disorders. Multiple comorbidity associated with ASD is the group that presents a high degree of functional inability, multiple pharmacology and hospital admissions. Emotional dysregulation could be the basis of the multiple comorbidity that exists in ASD and will require its own particular considerations in the diagnostic evaluation and treatment. Aims. To review emotional dysregulation, the currently held concept of it and its relationship with ASD. Development. This work offers a review of the different definitions of emotional dysregulation, the associated cognitive and neurobiological mechanisms, the clinical presentation when associated to ASD, its role in psychiatric comorbidity and further considerations regarding psychological and pharmacological interventions. Conclusions. Emotional dysregulation could be associated to the multiple comorbidity present in persons with ASD, as well as being related with high rates of morbidity, hospital admissions and use of psychopharmaceuticals. Failure to identify and diagnose emotional dysregulation could be linked with low effectiveness and a large number of side effects in the case of comorbidity associated to ASD.;[Hervas, Amaia] Hosp Univ Mutua Terrassa, IGAIN, Psiquiatria Infantil & Juvenil, Barcelona, Spain;Hospital Universitario Mutua Terrassa;Hervás, A (corresponding author), Hosp Univ Mutua Terrassa, Psiquiatria Infantil & Juvenil, Pl Doctor Robert 5, E-08221 Terrassa, Barcelona, Spain.;ahervas@mutuaterrassa.es;;;;;;"[Anonymous], 2007, HDB EMOTION REGULATI; [Anonymous], GUIA ESENCIAL PSICOF; [Anonymous], PEDIAT INTE IN PRESS; Bird G, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.61; Bird G, 2010, BRAIN, V133, P1515, DOI 10.1093/brain/awq060; Carter MJ, 2014, THER RECREAT J, V48, P275; Cassidy S, 2014, LANCET PSYCHIAT, V1, P142, DOI 10.1016/S2215-0366(14)70248-2; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cole P.M., 1994, MONOGR SOC RES CHILD, V59, P250, DOI DOI 10.2307/1166139; Cole P. M., 2008, CHILD ADOLESCENT PSY, P265; Eisenberg N, 2004, CHILD DEV, V75, P334, DOI 10.1111/j.1467-8624.2004.00674.x; Freeman RD, 2010, DEV MED CHILD NEUROL, V52, P733, DOI 10.1111/j.1469-8749.2010.03627.x; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gal E, 2009, RES DEV DISABIL, V30, P342, DOI 10.1016/j.ridd.2008.06.003; Garon N, 2009, J ABNORM CHILD PSYCH, V37, P59, DOI 10.1007/s10802-008-9258-0; Gjevik E, 2011, J AUTISM DEV DISORD, V41, P761, DOI 10.1007/s10803-010-1095-7; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Graziano PA, 2007, J SCHOOL PSYCHOL, V45, P3, DOI 10.1016/j.jsp.2006.09.002; Grossman RB, 2015, AUTISM RES, V8, P307, DOI 10.1002/aur.1447; Herrington JD, 2016, SOC COGN AFFECT NEUR, V11, P907, DOI 10.1093/scan/nsw015; Hervás A, 2016, REV NEUROLOGIA, V62, pS9; Hervas A, 2014, EUR NEUROPSYCHOPHARM, V24, P1861, DOI 10.1016/j.euroneuro.2014.09.014; Howe FEJ, 2016, J AUTISM DEV DISORD, V46, P1656, DOI 10.1007/s10803-015-2693-1; Jahromi LB, 2008, MERRILL PALMER QUART, V54, P125, DOI 10.1353/mpq.2008.0007; Kennedy DP, 2012, NEUROPSYCHOLOGIA, V50, P3313, DOI 10.1016/j.neuropsychologia.2012.09.038; Kumar B, 2012, PHARMACOL REP, V64, P1291, DOI 10.1016/S1734-1140(12)70927-1; Leung RC, 2016, CHILD NEUROPSYCHOL, V22, P336, DOI 10.1080/09297049.2015.1005066; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Marcus RN, 2011, J CHILD ADOL PSYCHOP, V21, P229, DOI 10.1089/cap.2009.0121; Mazefsky CA, 2015, J AUTISM DEV DISORD, V45, P3405, DOI 10.1007/s10803-015-2602-7; Mazefsky CA, 2013, J AM ACAD CHILD PSY, V52, P679, DOI 10.1016/j.jaac.2013.05.006; Mazzone L, 2012, ANN GEN PSYCHIATR, V11, DOI 10.1186/1744-859X-11-16; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Myles BS, 2003, CHILD ADOL PSYCH CL, V12, P123, DOI 10.1016/S1056-4993(02)00048-2; Nazeer A, 2011, PEDIATR CLIN N AM, V58, P85, DOI 10.1016/j.pcl.2010.10.011; OZONOFF S, 1994, DEV PSYCHOPATHOL, V6, P415, DOI 10.1017/S0954579400006027; Perlman SB, 2010, SOC NEUROSCI-UK, V5, P533, DOI 10.1080/17470911003683219; Prizant BM, 2003, INFANT YOUNG CHILD, V16, P296, DOI 10.1097/00001163-200310000-00004; Samson AC, 2012, EMOTION, V12, P659, DOI 10.1037/a0027975; Sasayama D, 2010, PSYCHIAT CLIN NEUROS, V64, P394, DOI 10.1111/j.1440-1819.2010.02102.x; Scarpa A, 2011, BEHAV COGN PSYCHOTH, V39, P495, DOI 10.1017/S1352465811000063; Schwenck Christina, 2012, J Child Psychol Psychiatry, V53, P651, DOI 10.1111/j.1469-7610.2011.02499.x; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Sofronoff K, 2007, J AUTISM DEV DISORD, V37, P1203, DOI 10.1007/s10803-006-0262-3; Totsika V, 2011, J ABNORM CHILD PSYCH, V39, P1137, DOI 10.1007/s10802-011-9534-2; Totsika V, 2011, J CHILD PSYCHOL PSYC, V52, P91, DOI 10.1111/j.1469-7610.2010.02295.x; Uljarevic M, 2013, J AUTISM DEV DISORD, V43, P1517, DOI 10.1007/s10803-012-1695-5; Wilson B.J., 2007, EARLY EDUC DEV, V18, P201";48;10;12;5;42;REVISTA DE NEUROLOGIA;BARCELONA;C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN;0210-0010;1576-6578;;REV NEUROLOGIA;Rev. Neurologia;;2017;64;;;1;;;S17;S25;;10.33588/rn.64S01.2017030;http://dx.doi.org/10.33588/rn.64S01.2017030;;;9;Clinical Neurology;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;EY0ZW;28256682;;;;24/11/2024;WOS:000403691600004;View Full Record in Web of Science
J;"Hongkaew, Y; Ngamsamut, N; Puangpetch, A; Vanwong, N; Srisawasdi, P; Bhunnada, MC; Chamkrachchangpada, B; Tan-Kam, T; Limsila, P; Sukasem, C";;;;"Hongkaew, Yaowaluck; Ngamsamut, Nattawat; Puangpetch, Apichaya; Vanwong, Natchaya; Srisawasdi, Pornpen; Chamnanphon, Montri; Chamkrachchangpada, Bhunnada; Tan-Kam, Teerarat; Limsila, Penkhae; Sukasem, Chonlaphat";;;Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone;NEUROPSYCHIATRIC DISEASE AND TREATMENT;;;English;Article;;;;;;"prolactin level; risperidone; autism spectrum disorders; Thai; hyperprolactinemia";"DOPAMINE-D-2 RECEPTOR GENE; PROLACTIN LEVELS; ELEVATION; CYP2D6";Hyperprolactinemia is a common adverse effect observed in children with autism spectrum disorder (ASD) during pharmacotherapy with risperidone. The main aim of this study was to investigate important clinical factors influencing the prolactin response in risperidone-treated Thai ASD. A total of 147 children and adolescents (127 males and 20 females) aged 3-19 years with ASD received risperidone treatment (0.10-6.00 mg/day) for up to 158 weeks. Prolactin levels were measured by chemiluminescence immunoassay. The clinical data of patients collected from medical records - age, weight, height, body mass index, dose of risperidone, duration of treatment, and drug-use pattern - were recorded. Hyperprolactinemia was observed in 66 of 147 (44.90%) subjects. Median prolactin level at the high doses (24.00, interquartile range [IQR] 14.30-29.20) of risperidone was significantly found to be higher than at the recommended (16.20, IQR 10.65-22.30) and low (11.70, IQR 7.51-16.50) doses of risperidone. There was no relationship between prolactin levels and duration of risperidone treatment. Dose-dependence is identified as a main factor associated with hyperprolactinemia in Thai children and adolescents with ASD treated with risperidone. This study suggests that risperidone treatment causes prolactin elevations and the effects of risperidone on prolactin are probably dose-related in pediatric patients.;"[Hongkaew, Yaowaluck; Puangpetch, Apichaya; Vanwong, Natchaya; Chamnanphon, Montri; Sukasem, Chonlaphat] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol,Div Pharmacogen & Personalized Med, Bangkok 10400, Thailand; [Hongkaew, Yaowaluck; Puangpetch, Apichaya; Vanwong, Natchaya; Chamnanphon, Montri; Sukasem, Chonlaphat] Mahidol Univ, Ramathibodi Hosp, Somdech Phra Debaratana Med Ctr SDMC, Lab Pharmacogen, Bangkok 10400, Thailand; [Ngamsamut, Nattawat; Chamkrachchangpada, Bhunnada; Tan-Kam, Teerarat; Limsila, Penkhae] Mahidol Univ, Yuwaprasart Waithayopathum Child & Adolescent Ps, Dept Mental Hlth Serv, Minist Publ Hlth, Bangkok 10400, Thailand; [Srisawasdi, Pornpen] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol,Div Clin Chem, Bangkok 10400, Thailand";"Mahidol University; Mahidol University; Ministry of Public Health - Thailand; Mahidol University; Mahidol University";Sukasem, C (corresponding author), Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol,Div Pharmacogen & Personalized Med, Bangkok 10400, Thailand.;chonlaphat.suk@mahidol.ac.th;"Chamnanphon, Monpat/GNP-8714-2022; Vanwong, Natchaya/ABA-4512-2021; Srisawasdi, Pornpen/AAV-6237-2021";Chamnanphon, Monpat/0000-0003-3917-6567;"Mahidol University; Khun Poom Foundation; National Research Council of Thailand; Faculty of Medicine, Ramathibodi Hospital";"Mahidol University; Khun Poom Foundation; National Research Council of Thailand(National Research Council of Thailand (NRCT)); Faculty of Medicine, Ramathibodi Hospital";This research project was supported by 1) Mahidol University, 2) Khun Poom Foundation, a project under Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee, 3) the National Research Council of Thailand, and 4) the Faculty of Medicine, Ramathibodi Hospital. The authors would specially like to thank the staff at Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital for their assistance. We are also grateful to all the children and adolescents with ASD who contributed to the study.;"Aklillu E, 2007, PHARMACOGENET GENOM, V17, P989, DOI 10.1097/FPC.0b013e3282f01aa3; Anderson GM, 2007, BIOL PSYCHIAT, V61, P545, DOI 10.1016/j.biopsych.2006.02.032; [Anonymous], PSYCHIAT DANUB; [Anonymous], GER J PSYCHIAT; [Anonymous], THER CHILDR AUT SPEC; Bishop JR, 2012, THER ADV PSYCHOPHARM, V2, P95, DOI 10.1177/2045125312442080; Calarge CA, 2009, PHARMACOGENET GENOM, V19, P373, DOI 10.1097/FPC.0b013e328329a60f; Carter MJ, 2014, THER RECREAT J, V48, P275; Douglas-Hall P, 2011, J CENT NERV SYST DIS, V3, P143, DOI 10.4137/JCNSD.S4140; Elmlinger MW, 2002, CLIN CHEM LAB MED, V40, P1151, DOI 10.1515/CCLM.2002.202; Gagliano A, 2004, J CHILD ADOL PSYCHOP, V14, P39, DOI 10.1089/104454604773840472; Hellings JA, 2005, J CHILD ADOL PSYCHOP, V15, P885, DOI 10.1089/cap.2005.15.885; Kent JM, 2013, J AUTISM DEV DISORD, V43, P1773, DOI 10.1007/s10803-012-1723-5; Kinon BJ, 2003, PSYCHONEUROENDOCRINO, V28, P55, DOI 10.1016/S0306-4530(02)00127-0; Kleinberg DL, 1999, J CLIN PSYCHOPHARM, V19, P57, DOI 10.1097/00004714-199902000-00011; Lemmon ME, 2011, J CHILD NEUROL, V26, P428, DOI 10.1177/0883073810382143; Masi G, 2001, J CHILD ADOL PSYCHOP, V11, P389, DOI 10.1089/104454601317261564; Migliardi G, 2009, PROG NEURO-PSYCHOPH, V33, P1496, DOI 10.1016/j.pnpbp.2009.08.009; Roke Y, 2013, PHARMACOGENET GENOM, V23, P487, DOI 10.1097/FPC.0b013e3283647c33; Roke Y, 2012, J CHILD ADOL PSYCHOP, V22, P432, DOI 10.1089/cap.2011.0109; Roke Y, 2012, HORM RES PAEDIAT, V77, P235, DOI 10.1159/000337910; Stevens JR, 2005, J CHILD ADOL PSYCHOP, V15, P893, DOI 10.1089/cap.2005.15.893; Turrone P, 2002, AM J PSYCHIAT, V159, P133, DOI 10.1176/appi.ajp.159.1.133; Wingate M, 2014, MMWR SURVEILL SUMM, V63; Yasui-Furukori N, 2008, PROG NEURO-PSYCHOPH, V32, P1491, DOI 10.1016/j.pnpbp.2008.05.006; Young RM, 2004, BRIT J PSYCHIAT, V185, P147, DOI 10.1192/bjp.185.2.147";26;17;21;0;7;DOVE MEDICAL PRESS LTD;ALBANY;PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND;;1178-2021;;NEUROPSYCH DIS TREAT;Neuropsychiatr. Dis. Treat.;;2015;11;;;;;;191;196;;10.2147/NDT.S76276;http://dx.doi.org/10.2147/NDT.S76276;;;6;"Clinical Neurology; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Psychiatry";AZ4MD;25653528;Green Submitted, Green Published, gold;;;24/11/2024;WOS:000348194400001;View Full Record in Web of Science
J;Turner, M;;;;Turner, Melanie;;;The role of drugs in the treatment of autism;AUSTRALIAN PRESCRIBER;;;English;Article;;;;;;"antipsychotic drugs; autism spectrum disorder; selective serotonin reuptake inhibitors";"SPECTRUM DISORDERS; CHILDREN; ANXIETY";The prevalence of autism spectrum disorder is increasing. It usually presents in childhood with abnormal behaviour and development. The diagnosis can be difficult. There are often comorbidities which can cause confusion. Non-drug treatments are first line. Drug treatment is not effective for the core symptoms of autism spectrum disorder. However, drugs may have a role in managing comorbidities and related symptoms, such as irritability and aggression. Anxiety is a common comorbidity. Cognitive behaviour therapy can be effective, but in some cases selective serotonin reuptake inhibitors may have a role. Most patients have problems sleeping, but drugs are not usually used to treat sleep disorders in children. Antipsychotics, such as risperidone, may be considered for irritability and aggression. Clonidine is first line for children with Tourette syndrome. Patients need regular monitoring because of the adverse effects of these drugs.;"[Turner, Melanie] MyChild Psychiat & Psychol, Norwood, SA, Australia; [Turner, Melanie] Univ Adelaide, Adelaide, SA, Australia";University of Adelaide;"Turner, M (corresponding author), MyChild Psychiat & Psychol, Norwood, SA, Australia.;Turner, M (corresponding author), Univ Adelaide, Adelaide, SA, Australia.";;;;;;;"Abdelgadir IS, 2018, ARCH DIS CHILD, V103, P1155, DOI 10.1136/archdischild-2017-314181; AMH Children's Dosing Companion, 2020, AMH CHILDRENS DOSING; [Anonymous], 2016, BJPSYCH ADV; Antshel KM, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1020-5; Australian Bureau of Statistics, 2018, DIS AG CAR AUSTR AUT; CAMPBELL M, 1995, J AM ACAD CHILD PSY, V34, P1124, DOI 10.1097/00004583-199509000-00008; Eissa N, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00304; FARETRA G, 1970, AM J PSYCHIAT, V126, P1670, DOI 10.1176/ajp.126.11.1670; Fitzpatrick SE, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S84585; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Hollander E, 2003, LANCET, V362, P732, DOI 10.1016/S0140-6736(03)14236-5; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; Hollis C, 2016, HEALTH TECHNOL ASSES, V20, pI, DOI 10.3310/hta20040; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Joshi G, 2010, J AUTISM DEV DISORD, V40, P1361, DOI 10.1007/s10803-010-0996-9; King M, 2009, INT J EPIDEMIOL, V38, P1224, DOI 10.1093/ije/dyp261; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Lake JK, 2017, J AUTISM DEV DISORD, V47, P1391, DOI 10.1007/s10803-017-3058-8; Murray ML, 2014, PSYCHOPHARMACOLOGY, V231, P1011, DOI 10.1007/s00213-013-3140-7; Nadeau J, 2011, NEUROPSYCHIATRY-LOND, V1, P567, DOI 10.2217/NPY.11.62; National Institute for Health and Care Excellence (NICE), 2013, CLIN GUID CG170; Patra S, 2019, AUTISM RES, V12, P542, DOI 10.1002/aur.2059; Paval D, 2017, DEV NEUROSCI-BASEL, V39, P355, DOI 10.1159/000478725; Quezada J, 2018, CNS DRUGS, V32, P33, DOI 10.1007/s40263-017-0486-0; Reinblatt SP, 2009, J CHILD ADOL PSYCHOP, V19, P119, DOI 10.1089/cap.2008.040; Shann F., 2017, DRUG DOSES; Stahl Online, 2020, PRESCR GUID; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x";28;11;13;5;17;NATL PRESCRIBING SERVICE LTD;DEAKIN;STE 8, 8 PHIPPS CLOSE, DEAKIN, ACT 2600, AUSTRALIA;0312-8008;1839-3942;;AUST PRESCR;Aust. Prescr.;DEC;2020;43;6;;;;;185;190;;10.18773/austprescr.2020.054;http://dx.doi.org/10.18773/austprescr.2020.054;;;6;Pharmacology & Pharmacy;Emerging Sources Citation Index (ESCI);Pharmacology & Pharmacy;PA0LA;33363299;Green Published, gold;;;24/11/2024;WOS:000595307100004;View Full Record in Web of Science
J;"Napoli, E; Dueñas, N; Giulivi, C";;;;"Napoli, Eleonora; Duenas, Nadia; Giulivi, Cecilia";;;Potential therapeutic use of the ketogenic diet in autism spectrum disorders;FRONTIERS IN PEDIATRICS;;;English;Article;;;;;;"epilepsy; autism spectrum disorders; dietary intervention; mitochondria; bioenergetics; ketogenic diet; oxidative stress";"PYRUVATE-DEHYDROGENASE DEFICIENCY; SUCCINIC SEMIALDEHYDE REDUCTASE; FATTY-ACID OXIDATION; MITOCHONDRIAL-DNA; KETONE-BODIES; MAMMALIAN TARGET; COPY NUMBER; AMINO-ACIDS; HUMAN BRAIN; RAT MODEL";The ketogenic diet (KGD) has been recognized as an effective treatment for individuals with glucose transporter 1 (GLUT1) and pyruvate dehydrogenase (PDH) deficiencies as well as with epilepsy. More recently, its use has been advocated in a number of neurological disorders prompting a newfound interest in its possible therapeutic use in autism spectrum disorders (ASD). One study and one case report indicated that children with ASD treated with a KGD showed decreased seizure frequencies and exhibited behavioral improvements (i.e., improved learning abilities and social skills). The KGD could benefit individuals with ASD affected with epileptic episodes as well as those with either PDH or mild respiratory chain (RC) complex deficiencies. Given that the mechanism of action of the KGD is not fully understood, caution should be exercised in ASD cases lacking a careful biochemical and metabolic characterization to avoid deleterious side effects or refractory outcomes.;"[Napoli, Eleonora; Duenas, Nadia; Giulivi, Cecilia] Univ Calif Davis, Dept Mol Biosci, One Shields Ave, Davis, CA 95616 USA; [Giulivi, Cecilia] Med Invest Neurodev Disorders MIND Inst, Sacramento, CA USA";"University of California System; University of California Davis";Napoli, E (corresponding author), Univ Calif Davis, Dept Mol Biosci, One Shields Ave, Davis, CA 95616 USA.;enapoli@ucdavis.edu;"Napoli, Eleonora/AAQ-6079-2021; Giulivi, Cecilia/AAV-6774-2021; Giulivi, Cecilia/C-4015-2012";"Napoli, Eleonora/0000-0001-8808-4242; Giulivi, Cecilia/0000-0003-1033-7435";Simons Foundation (SFARI) [271406, R01-ES011269, R01-ES015359, R01-ES020392];Simons Foundation (SFARI);This work was supported by Simons Foundation (SFARI #271406 to Cecilia Giulivi), R01-ES011269, R01-ES015359, and R01-ES020392.;"Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076; AlMudallal AS, 1996, EPILEPSIA, V37, P258, DOI 10.1111/j.1528-1157.1996.tb00022.x; Andriamampandry C, 1998, BIOCHEM J, V334, P43, DOI 10.1042/bj3340043; Banerjee A, 2013, INT J NEUROPSYCHOPH, V16, P1309, DOI 10.1017/S1461145712001216; Baranano Kristin W, 2008, Curr Treat Options Neurol, V10, P410, DOI 10.1007/s11940-008-0043-8; Barnerias C, 2010, DEV MED CHILD NEUROL, V52, pe1, DOI 10.1111/j.1469-8749.2009.03541.x; Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00; Boltor PF, 2011, BRIT J PSYCHIAT, V198, P289, DOI 10.1192/bjp.bp.109.076877; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Breitkreuz KE, 2003, J BIOL CHEM, V278, P41552, DOI 10.1074/jbc.M305717200; Bujas-Petkovic Z, 1989, Lijec Vjesn, V111, P458; Çakir T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100085; Carro E, 2003, MOL NEUROBIOL, V27, P153, DOI 10.1385/MN:27:2:153; Celestino-Soper PBS, 2012, P NATL ACAD SCI USA, V109, P7974, DOI 10.1073/pnas.1120210109; Chattopadhyaya Bidisha, 2012, Front Psychiatry, V3, P51, DOI 10.3389/fpsyt.2012.00051; Chen JL, 2014, INT J DEV NEUROSCI, V35, P35, DOI 10.1016/j.ijdevneu.2014.03.006; Cheng CM, 2003, ENDOCRINOLOGY, V144, P2676, DOI 10.1210/en.2002-0057; Clark-Taylor T, 2004, MED HYPOTHESES, V62, P970, DOI 10.1016/j.mehy.2004.01.011; Coleman ST, 2001, J BIOL CHEM, V276, P244, DOI 10.1074/jbc.M007103200; Collins AL, 2006, NEUROGENETICS, V7, P167, DOI 10.1007/s10048-006-0045-1; Coppola G, 2010, EUR J PAEDIATR NEURO, V14, P229, DOI 10.1016/j.ejpn.2009.06.006; Dahlin M, 2005, EPILEPSY RES, V64, P115, DOI 10.1016/j.eplepsyres.2005.03.008; Deutsch SI, 2010, CLIN NEUROPHARMACOL, V33, P114, DOI 10.1097/WNF.0b013e3181d6f7ad; DEVIVO DC, 1978, ANN NEUROL, V3, P331, DOI 10.1002/ana.410030410; Di Pisa V, 2012, J CHILD NEUROL, V27, P1593, DOI 10.1177/0883073812436424; Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602; El-Gharbawy AH, 2011, MOL GENET METAB, V102, P214, DOI 10.1016/j.ymgme.2010.11.001; Ellenbroek JH, 2014, AM J PHYSIOL-ENDOC M, V306, pE552, DOI 10.1152/ajpendo.00453.2013; Erasmus DJ, 2003, FEMS YEAST RES, V3, P375, DOI 10.1016/S1567-1356(02)00203-9; Evangeliou A, 2003, J CHILD NEUROL, V18, P113, DOI 10.1177/08830738030180020501; Fatemi SH, 2009, J AUTISM DEV DISORD, V39, P223, DOI 10.1007/s10803-008-0646-7; Fatemi SH, 2002, BIOL PSYCHIAT, V52, P805, DOI 10.1016/S0006-3223(02)01430-0; Finsterer J, 2012, SEIZURE-EUR J EPILEP, V21, P316, DOI 10.1016/j.seizure.2012.03.003; Fisman S, 1996, J AM ACAD CHILD PSY, V35, P937, DOI 10.1097/00004583-199607000-00021; Frazier TW, 2014, J AUTISM DEV DISORD, V44, P2013, DOI 10.1007/s10803-014-2081-2; Freeman J, 2006, EPILEPSY RES, V68, P145, DOI 10.1016/j.eplepsyres.2005.10.003; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.143; Fukao T, 2014, J INHERIT METAB DIS, V37, P541, DOI 10.1007/s10545-014-9704-9; Gano LB, 2014, J LIPID RES, V55, P2211, DOI 10.1194/jlr.R048975; Gasparini L, 2003, TRENDS NEUROSCI, V26, P404, DOI 10.1016/S0166-2236(03)00163-2; Ghaleiha A, 2014, J PSYCHOPHARMACOL, V28, P677, DOI 10.1177/0269881113508830; Giulivi C, 2010, JAMA-J AM MED ASSOC, V304, P2389, DOI 10.1001/jama.2010.1706; Gkogkas CG, 2013, NATURE, V493, P371, DOI 10.1038/nature11628; Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010; Gu F, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.68; Halestrap AP, 2013, COMPR PHYSIOL, V3, P1611, DOI 10.1002/cphy.c130008; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; Han S, 2012, NATURE, V489, P385, DOI 10.1038/nature11356; Hartman AL, 2007, PEDIATR NEUROL, V36, P281, DOI 10.1016/j.pediatrneurol.2007.02.008; Herbert MR, 2013, J CHILD NEUROL, V28, P975, DOI 10.1177/0883073813488668; Holmboe K, 2014, J AM ACAD CHILD PSY, V53, P221, DOI 10.1016/j.jaac.2013.11.001; Hughes SD, 2014, J NEUROCHEM, V129, P426, DOI 10.1111/jnc.12646; Imahori K, 1997, J BIOCHEM, V121, P179; James SJ, 2009, FASEB J, V23, P2374, DOI 10.1096/fj.08-128926; James SJ, 2009, AM J CLIN NUTR, V89, P425, DOI 10.3945/ajcn.2008.26615; Jarrett SG, 2008, J NEUROCHEM, V106, P1044, DOI 10.1111/j.1471-4159.2008.05460.x; Johnston CS, 2006, AM J CLIN NUTR, V83, P1055, DOI 10.1093/ajcn/83.5.1055; Józwiak S, 2011, NEUROL NEUROCHIR POL, V45, P370; Kang HC, 2004, EPILEPSIA, V45, P1116, DOI 10.1111/j.0013-9580.2004.10004.x; Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x; Karvat G, 2014, NEUROPSYCHOPHARMACOL, V39, P831, DOI 10.1038/npp.2013.274; Kelleher RJ, 2008, CELL, V135, P401, DOI 10.1016/j.cell.2008.10.017; Kemper TL, 1998, J NEUROPATH EXP NEUR, V57, P645, DOI 10.1097/00005072-199807000-00001; Kim DY, 2010, J NEUROCHEM, V114, P130, DOI 10.1111/j.1471-4159.2010.06728.x; Kim YM, 2012, BRAIN DEV-JPN, V34, P570, DOI 10.1016/j.braindev.2011.09.013; Knerr I, 2008, EXP NEUROL, V211, P11, DOI 10.1016/j.expneurol.2008.01.015; Kossoff EH, 2007, EPILEPSY BEHAV, V10, P432, DOI 10.1016/j.yebeh.2007.01.012; Kossoff EH, 2009, J CHILD NEUROL, V24, P979, DOI 10.1177/0883073809337162; Kossoff Eric H, 2013, Biomed J, V36, P2, DOI 10.4103/2319-4170.107152; Kwiterovich PO, 2003, JAMA-J AM MED ASSOC, V290, P912, DOI 10.1001/jama.290.7.912; Latif A, 2002, AUTISM, V6, P103, DOI 10.1177/1362361302006001008; Li BM, 2011, EPILEPSY BEHAV, V21, P291, DOI 10.1016/j.yebeh.2011.04.060; Liebhaber G, 2006, KLIN PADIATR, V218, P260, DOI 10.1055/s-2005-836811; Liebhaber GM, 2003, J CHILD NEUROL, V18, P74, DOI 10.1177/08830738030180011801; Liu Yeou-mei Christiana, 2013, Biomed J, V36, P9, DOI 10.4103/2319-4170.107154; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Mantis JG, 2009, EPILEPSY BEHAV, V15, P133, DOI 10.1016/j.yebeh.2009.02.038; Marsh EB, 2006, EPILEPSIA, V47, P425, DOI 10.1111/j.1528-1167.2006.00439.x; Maurer CM, 2010, J NEUROSCI, V30, P11962, DOI 10.1523/JNEUROSCI.2848-10.2010; McDaniel SS, 2011, EPILEPSIA, V52, pe7, DOI 10.1111/j.1528-1167.2011.02981.x; Mendu SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042959; Milder J, 2012, EPILEPSY RES, V100, P295, DOI 10.1016/j.eplepsyres.2011.09.021; Milder JB, 2010, NEUROBIOL DIS, V40, P238, DOI 10.1016/j.nbd.2010.05.030; Morris AAM, 1996, J INHERIT METAB DIS, V19, P573, DOI 10.1007/BF01799117; Musa-Veloso K, 2006, NUTRITION, V22, P1, DOI 10.1016/j.nut.2005.04.008; Napoli E, 2014, PEDIATRICS, V133, pE1405, DOI 10.1542/peds.2013-1545; Napoli E, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-2; Napoli E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042504; NGUYEN Q, 1995, SYNAPSE, V19, P77, DOI 10.1002/syn.890190203; Nicolson R, 2006, J CHILD ADOL PSYCHOP, V16, P621, DOI 10.1089/cap.2006.16.621; Niederhofer H, 2002, BRIT MED J, V325, P1422; Nizamuddin J, 2008, J CHILD NEUROL, V23, P758, DOI 10.1177/0883073808318061; Noh HS, 2004, MOL BRAIN RES, V129, P80, DOI 10.1016/j.molbrainres.2004.06.020; Nordli DR, 1997, EPILEPSIA, V38, P743, DOI 10.1111/j.1528-1157.1997.tb01460.x; Nylen K, 2008, EXP NEUROL, V210, P449, DOI 10.1016/j.expneurol.2007.11.015; Olpin SE, 2004, PROSTAG LEUKOTR ESS, V70, P293, DOI 10.1016/j.plefa.2003.06.003; Parikh S, 2009, CURR TREAT OPTION N, V11, P414, DOI 10.1007/s11940-009-0046-0; Park S, 2011, EXP BIOL MED, V236, P194, DOI 10.1258/ebm.2010.010186; Prasad C, 2011, BRAIN DEV-JPN, V33, P856, DOI 10.1016/j.braindev.2011.08.003; RAMOS F, 1985, EUR J BIOCHEM, V149, P401, DOI 10.1111/j.1432-1033.1985.tb08939.x; REICHARD GA, 1979, J CLIN INVEST, V63, P619, DOI 10.1172/JCI109344; Rogovik AL, 2010, CAN FAM PHYSICIAN, V56, P540; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol DA, 2012, MOL PSYCHIATR, V17, P290, DOI 10.1038/mp.2010.136; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Ruskin DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065021; Sankar R, 1999, EPILEPSY RES, V37, P191, DOI 10.1016/S0920-1211(99)00071-6; Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Sawicka K, 2012, NEUROPSYCHOPHARMACOL, V37, P305, DOI 10.1038/npp.2011.210; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Schönfeld P, 2010, BBA-BIOENERGETICS, V1797, P929, DOI 10.1016/j.bbabio.2010.01.010; Sobanski E, 1999, EUR CHILD ADOLES PSY, V8, P312, DOI 10.1007/s007870050106; Sokol DK, 2002, J CHILD NEUROL, V17, P245, DOI 10.1177/088307380201700401; Stafstrom CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00059; Steffenburg U, 2001, ACTA PAEDIATR, V90, P34; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tuchman R, 2010, BRAIN DEV-JPN, V32, P709, DOI 10.1016/j.braindev.2010.04.008; Veech RL, 2001, IUBMB LIFE, V51, P241; Veggiotti P, 2010, BRAIN DEV-JPN, V32, P404, DOI 10.1016/j.braindev.2009.04.013; Weber S, 2009, SEIZURE-EUR J EPILEP, V18, P237, DOI 10.1016/j.seizure.2008.10.004; Weissman JR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003815; Werther GA, 1998, HORM RES, V49, P37, DOI 10.1159/000053066; Weston MC, 2012, J NEUROSCI, V32, P11441, DOI 10.1523/JNEUROSCI.1283-12.2012; Wexler ID, 1997, NEUROLOGY, V49, P1655, DOI 10.1212/WNL.49.6.1655; WIJBURG FA, 1992, NEUROPEDIATRICS, V23, P147, DOI 10.1055/s-2008-1071331; Wong Michael, 2013, Biomed J, V36, P40, DOI 10.4103/2319-4170.110365; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164; Yudkoff M, 2005, NEUROCHEM INT, V47, P119, DOI 10.1016/j.neuint.2005.04.014; Yudkoff M, 2007, ANNU REV NUTR, V27, P415, DOI 10.1146/annurev.nutr.27.061406.093722; Zecavati N, 2009, CURR NEUROL NEUROSCI, V9, P129, DOI 10.1007/s11910-009-0021-x; Zhao Y, 2010, MOL PSYCHIATR, V15, P286, DOI 10.1038/mp.2009.51; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399";136;52;61;2;15;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;2296-2360;;;FRONT PEDIATR;Front. Pediatr.;;2014;2;;;;;;;;69;10.3389/fped.2014.00069;http://dx.doi.org/10.3389/fped.2014.00069;;;9;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;V46PX;25072037;Green Published, gold;;;24/11/2024;WOS:000209897200068;View Full Record in Web of Science
J;"Lemmon, ME; Gregas, M; Jeste, SS";;;;"Lemmon, Monica E.; Gregas, Matt; Jeste, Shafali S.";;;Risperidone Use in Autism Spectrum Disorders: A Retrospective Review of a Clinic-Referred Patient Population;JOURNAL OF CHILD NEUROLOGY;;;English;Article;;;;;;"autism spectrum disorders; risperidone; weight gain; somnolence; receptors; serotonin; dopamine";"PERVASIVE DEVELOPMENTAL DISORDERS; YOUNG-CHILDREN; SYMPTOMS; DISCONTINUATION; ADOLESCENTS; TRIAL";Risperidone is widely used in children with autism spectrum disorders for behavioral modification. In this study, the authors aimed to (1) describe a clinic-referred sample of patients with an autism spectrum disorder on risperidone, (2) identify differences between the success and nonsuccess groups, and (3) describe our experience with young children (< age 5 years) on risperidone. Eighty patients were initiated on risperidone. Indications included aggression (66%), impulsivity (14%), and stereotypies (4%). Sixty-six percent met criteria for success at 6 months and 53% at 1 year. Sixty-seven percent of the nonsuccess group reported side effects, compared to 47% of the success group. Weight gain was the most common side effect in both groups, followed by somnolence. Somnolence was the most robust predictor of nonsuccess. In our clinic-referred sample, the short-term success rate of risperidone was more than 50%, and side effects limited its use. Although weight gain was common, somnolence more significantly influenced treatment discontinuation.;"[Lemmon, Monica E.] Johns Hopkins Univ Hosp, Dept Pediat, Baltimore, MD 21287 USA; [Lemmon, Monica E.; Gregas, Matt] Harvard Univ, Sch Med, Boston, MA USA; [Gregas, Matt] Childrens Hosp Boston, Dept Clin Res, Boston, MA USA; [Jeste, Shafali S.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA";"Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of California System; University of California Los Angeles";Lemmon, ME (corresponding author), Johns Hopkins Univ Hosp, Dept Pediat, 600 N Wolfe St, Baltimore, MD 21287 USA.;mlemmon2@jhmi.edu;"Gregas, Matt/AFU-8094-2022; Jeste, Shafali/N-2350-2017";Jeste, Shafali/0000-0003-2955-6902;;;;"Aman MG, 2004, CNS SPECTRUMS, V9, P36, DOI 10.1017/S1092852900008348; [Anonymous], PEDIAT NEUROL; Arnold LE, 2010, J CHILD ADOL PSYCHOP, V20, P83, DOI 10.1089/cap.2009.0022; Campbell M, 1997, J AM ACAD CHILD PSY, V36, P835, DOI 10.1097/00004583-199706000-00022; Estes AM, 2007, AM J MENT RETARD, V112, P439, DOI 10.1352/0895-8017(2007)112[439:LOIFPP]2.0.CO;2; Findling RL, 1997, PSYCHOPHARMACOL BULL, V33, P155; Hartley SL, 2008, J INTELL DISABIL RES, V52, P819, DOI 10.1111/j.1365-2788.2008.01065.x; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 1997, J AM ACAD CHILD PSY, V36, P685, DOI 10.1097/00004583-199705000-00020; Ming X, 2008, J CHILD NEUROL, V23, P6, DOI 10.1177/0883073807307102; Nicolson R, 1998, J AM ACAD CHILD PSY, V37, P372, DOI 10.1097/00004583-199804000-00014; Posey DJ, 2000, HARVARD REV PSYCHIAT, V8, P45, DOI 10.1093/hrp/8.2.45; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Simeon J, 2002, PROG NEURO-PSYCHOPH, V26, P267, DOI 10.1016/S0278-5846(01)00264-0; Troost PW, 2005, J AM ACAD CHILD PSY, V44, P1137, DOI 10.1097/01.chi.0000177055.11229.76; Zuddas A, 2000, J CHILD ADOL PSYCHOP, V10, P79, DOI 10.1089/cap.2000.10.79";16;25;29;0;6;SAGE PUBLICATIONS INC;THOUSAND OAKS;2455 TELLER RD, THOUSAND OAKS, CA 91320 USA;0883-0738;;;J CHILD NEUROL;J. Child Neurol.;APR;2011;26;4;;;;;428;432;;10.1177/0883073810382143;http://dx.doi.org/10.1177/0883073810382143;;;5;"Clinical Neurology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics";751OO;20929907;Green Submitted;;;24/11/2024;WOS:000289627600003;View Full Record in Web of Science
J;"Agarwal, R; Burke, SL; Maddux, M";;;;"Agarwal, Rumi; Burke, Shanna L.; Maddux, Marlaina";;;Current state of evidence of cannabis utilization for treatment of autism spectrum disorders;BMC PSYCHIATRY;;;English;Article;;;;;;"Autism spectrum disorders; Autism; Cannabis; Cannabinoids";"ENDOCANNABINOID SYSTEM; MEDICINAL PROPERTIES; VALPROIC ACID; MOUSE MODEL; CNR1 GENE; EPILEPSY; CHILDREN; BEHAVIOR; SLEEP; PHARMACOLOGY";The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of evidence regarding cannabis use for the ASD population. Systematic reviews, reports, and experimental studies were assessed to understand the current extent and nature of the evidence on the risks and benefits of cannabis use for ASD. At this time, three large-scale clinical trials are currently at varying stages of progress and publication of results. Only five small studies were identified that have specifically examined cannabis use in ASD. Given the sparse state of evidence directly assessed in this population, studies which examined effects of cannabis on shared pathological symptoms of ASD such as hyperactivity, sleep disorders, self-injury, anxiety, behavioral problems, and communication were also reviewed. Studies revealed mixed and inconclusive findings of cannabis effects for all conditions, except epilepsy. Adverse outcomes were also reported, which included severe psychosis, increased agitation, somnolence, decreased appetite, and irritability. In addition, a wide range of cannabis compositions and dosage were identified within the studies, which impact generalizability. There is currently insufficient evidence for cannabis use in ASD, which creates an urgent need for additional large-scale controlled studies to increase understanding of risks and benefits and also to examine the impact of entourage effects. This will support discussions of treatment options between health care providers and ASD patients and their families. Evidence may lead to a desired new line of treatment or prevent adverse outcomes from unsubstantiated use amongst families aiming for symptom reduction.;"[Agarwal, Rumi; Maddux, Marlaina] Florida Int Univ, FIU Embrace, 11200 SW 8th St, Miami, FL 33199 USA; [Agarwal, Rumi; Burke, Shanna L.; Maddux, Marlaina] Florida Int Univ, Sch Social Work, BRAINN Lab, 11200 SW 8th St, Miami, FL 33199 USA; [Agarwal, Rumi] Florida Int Univ, Sch Publ Hlth, Robert Stempel Coll Publ Hlth & Social Work Hlth, 11200 SW 8th St, Miami, FL 33199 USA; [Burke, Shanna L.] Florida Int Univ, Sch Social Work, Robert Stempel Coll Publ Hlth & Social Work, 11200 SW 8th St,AHC5 585, Miami, FL 33199 USA; [Maddux, Marlaina] Easterseals Blake Fdn, 750 E Broadway Blvd, Tucson, AZ 85710 USA";"State University System of Florida; Florida International University; State University System of Florida; Florida International University; State University System of Florida; Florida International University; State University System of Florida; Florida International University";"Burke, SL (corresponding author), Florida Int Univ, Sch Social Work, BRAINN Lab, 11200 SW 8th St, Miami, FL 33199 USA.;Burke, SL (corresponding author), Florida Int Univ, Sch Social Work, Robert Stempel Coll Publ Hlth & Social Work, 11200 SW 8th St,AHC5 585, Miami, FL 33199 USA.";sburke@fiu.edu;;;FIU Embrace;FIU Embrace;Thank you to FIU Embrace for generously funding the time of all the graduate research assistants on this project. The funding body did not have any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.;"Abrams DI, 2018, EUR J INTERN MED, V49, P7, DOI 10.1016/j.ejim.2018.01.003; AMAN MG, 1985, AM J MENT DEF, V89, P485; Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005; Anderson CL, 2017, J PEDIATR NEUROL, V15, P143, DOI 10.1055/s-0037-1598109; [Anonymous], HLTH EFF CANN CUNN C; [Anonymous], 2018, DAT STAT AUT SPECTR; [Anonymous], 1976, ECDEU: Assessment Manual for Psychopharmacology (revised); [Anonymous], 2018, CANN BEH PROBL CHILD; [Anonymous], 2018, SHIFT BRAIN EXC INH; [Anonymous], 2018, MAR CANN; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Arditi L., 2018, MORNING EDITION; Arora M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15493; Barchel D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01521; Baron EP, 2018, HEADACHE, V58, P1139, DOI 10.1111/head.13345; Benno R, 2009, BEHAV BRAIN RES, V197, P462, DOI 10.1016/j.bbr.2008.09.041; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6; Blanco C, 2016, JAMA PSYCHIAT, V73, P388, DOI 10.1001/jamapsychiatry.2015.3229; Borgelt LM, 2013, PHARMACOTHERAPY, V33, P195, DOI 10.1002/phar.1187; Bridgeman Mary Barna, 2017, P T, V42, P180; Busquets-Garcia A, 2013, NAT MED, V19, P603, DOI 10.1038/nm.3127; Chakrabarti B, 2006, EUR J NEUROSCI, V23, P1944, DOI 10.1111/j.1460-9568.2006.04697.x; Chakrabarti B, 2015, NEUROTHERAPEUTICS, V12, P837, DOI 10.1007/s13311-015-0371-9; Chen DJ, 2017, ACTA PHARMACOL SIN, V38, P312, DOI 10.1038/aps.2016.149; Chowdhury M, 2016, AUTISM, V20, P528, DOI 10.1177/1362361315593941; Cooper RE, 2017, EUR NEUROPSYCHOPHARM, V27, P795, DOI 10.1016/j.euroneuro.2017.05.005; Crippa JA, 2018, SCHIZOPHRENIA BULL, V44, pS28, DOI 10.1093/schbul/sby014.068; D'Souza DC, 2015, JAMA-J AM MED ASSOC, V313, P2431, DOI 10.1001/jama.2015.6407; De Alwis D, 2014, J STUD ALCOHOL DRUGS, V75, P211, DOI 10.15288/jsad.2014.75.211; Devnani PA, 2015, J PEDIATR NEUROSCI, V10, P304, DOI 10.4103/1817-1745.174438; Di Marzo V, 2011, NAT NEUROSCI, V14, P9, DOI 10.1038/nn.2720; Domschke K, 2008, EUR NEUROPSYCHOPHARM, V18, P751, DOI 10.1016/j.euroneuro.2008.05.003; Dryburgh LM, 2018, BRIT J CLIN PHARMACO, V84, P2468, DOI 10.1111/bcp.13695; Duvall SW, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-0558; Feingold D, 2016, EUR NEUROPSYCHOPHARM, V26, P493, DOI 10.1016/j.euroneuro.2015.12.037; Fernández-Ruiz J, 2010, CNS NEUROSCI THER, V16, pe72, DOI 10.1111/j.1755-5949.2010.00144.x; Földy C, 2013, NEURON, V78, P498, DOI 10.1016/j.neuron.2013.02.036; Gaston TE, 2017, EPILEPSY BEHAV, V70, P313, DOI 10.1016/j.yebeh.2016.11.016; Gates PJ, 2014, SLEEP MED REV, V18, P477, DOI 10.1016/j.smrv.2014.02.005; Good CB, 2019, ANN INTERN MED, V170, P123, DOI 10.7326/M18-3237; Gregorio Joseph, 2014, Virtual Mentor, V16, P732, DOI 10.1001/virtualmentor.2014.16.09.hlaw1-1409; Gu B., 2017, Glob Drugs Therap, V2, P1, DOI DOI 10.15761/GDT.1000134; Harrison KL, 2017, SCI AUTISM TREAT, V14, P12; Jung KM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2045; Kerr DM, 2013, BEHAV BRAIN RES, V249, P124, DOI 10.1016/j.bbr.2013.04.043; Kidd VD, 2018, PEDIATR NEUROL, V88, P10, DOI 10.1016/j.pediatrneurol.2018.08.023; King BH, 2013, JAMA PEDIATR, V167, P1045, DOI 10.1001/jamapediatrics.2013.2698; Kuester G, 2017, J NEUROL SCI, V381, P932, DOI 10.1016/j.jns.2017.08.2623; Kurz R., 2010, Can Underwrit, V5, P4; Li C, 2011, PHARMACOL THERAPEUT, V129, P307, DOI 10.1016/j.pharmthera.2010.10.006; Little B., 2017, History; MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004; Maccarrone M, 2010, NEUROPSYCHOPHARMACOL, V35, P1500, DOI 10.1038/npp.2010.19; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; McGuire P, 2018, AM J PSYCHIAT, V175, P225, DOI 10.1176/appi.ajp.2017.17030325; McTighe SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062189; Nicholson AN, 2004, J CLIN PSYCHOPHARM, V24, P305, DOI 10.1097/01.jcp.0000125688.05091.8f; NIDA, 2017, MARIJUANA MED; Nuutinen T, 2018, EUR J MED CHEM, V157, P198, DOI 10.1016/j.ejmech.2018.07.076; Onaivi ES, 2011, CURR NEUROPHARMACOL, V9, P209, DOI 10.2174/157015911795017047; Pacher P, 2013, FEBS J, V280, P1918, DOI 10.1111/febs.12260; Pietropaolo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017073; Poleg S, 2019, PROG NEURO-PSYCHOPH, V89, P90, DOI 10.1016/j.pnpbp.2018.08.030; Premoli M, 2019, LIFE SCI, V224, P120, DOI 10.1016/j.lfs.2019.03.053; Pretzsch CM, 2019, NEUROPSYCHOPHARMACOL, V44, P1398, DOI 10.1038/s41386-019-0333-8; Richards C, 2016, J NEURODEV DISORD, V8, DOI 10.1186/s11689-016-9153-x; Rodriguez O, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00420; Roullet FI, 2013, NEUROTOXICOL TERATOL, V36, P47, DOI 10.1016/j.ntt.2013.01.004; Rubino T, 2016, BIOL PSYCHIAT, V79, P578, DOI 10.1016/j.biopsych.2015.07.024; Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064-005-6978-1; Russo EB, 2017, EPILEPSY BEHAV, V70, P292, DOI 10.1016/j.yebeh.2016.09.040; Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI 10.1111/j.1476-5381.2011.01238.x; Sagar A, 2013, AM J MED GENET A, V161A, P845, DOI 10.1002/ajmg.a.35754; Salgado CA, 2018, GLOB PEDIAT HLTH, V5, P1; Schleider LBL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37570-y; Schultz S, 2019, AIMS MOL SCI, V6, P27, DOI 10.3934/molsci.2019.1.27; Silva LMT, 2012, J AUTISM DEV DISORD, V42, P566, DOI 10.1007/s10803-011-1274-1; Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201; Siniscalco D., 2013, AUTISM, V10, P2165; Siniscalco D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-78; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Sulak D, 2017, EPILEPSY BEHAV, V70, P328, DOI 10.1016/j.yebeh.2016.12.032; Suraev AS, 2017, EPILEPSY BEHAV, V70, P334, DOI 10.1016/j.yebeh.2017.02.005; van der Stelt M, 2003, EUR J PHARMACOL, V480, P133, DOI 10.1016/j.ejphar.2003.08.101; Wang J, 2009, PROSTAG OTH LIPID M, V89, P112, DOI 10.1016/j.prostaglandins.2008.12.002; Wei D, 2016, CANNABIS CANNABINOID, V1, P81, DOI 10.1089/can.2015.0008; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Zhang LH, 2010, J NEUROSCI, V30, P5724, DOI 10.1523/JNEUROSCI.0795-10.2010";88;17;18;0;13;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;oct-29;2019;19;1;;;;;;;328;10.1186/s12888-019-2259-4;http://dx.doi.org/10.1186/s12888-019-2259-4;;;10;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;JP6RR;31664964;gold, Green Published;;;24/11/2024;WOS:000498391000004;View Full Record in Web of Science
J;"Barchel, D; Stolar, O; De-Haan, T; Ziv-Baran, T; Saban, N; Fuchs, DO; Koren, G; Berkovitch, M";;;;"Barchel, Dana; Stolar, Orit; De-Haan, Tal; Ziv-Baran, Tomer; Saban, Naama; Fuchs, Danny Or; Koren, Gideon; Berkovitch, Matitiahu";;;Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities;FRONTIERS IN PHARMACOLOGY;;;English;Article;;;;;;"cannabidiol; autism spectrum disorder; ASD comorbid symptoms; ASD treatment; pediatrics; clinical research trial; THC - tetrahydrocannabinol";"DRUG-INTERACTIONS; ARIPIPRAZOLE; EFFICACY; ANXIETY; CBD";"Objective: Children with autism spectrum disorder (ASD) commonly exhibit comorbid symptoms such as aggression, hyperactivity and anxiety. Several studies are being conducted worldwide on cannabidiol use in ASD; however, these studies are still ongoing, and data on the effects of its use is very limited. In this study we aimed to report the experience of parents who administer, under supervision, oral cannabinoids to their children with ASD. Methods: After obtaining a license from the Israeli Ministry of Health, parents of children with ASD were instructed by a nurse practitioner how to administer oral drops of cannabidiol oil. Information on comorbid symptoms and safety was prospectively recorded biweekly during follow-up interviews. An independent group of specialists analyzed these data for changes in ASD symptoms and drug safety. Results: 53 children at a median age of 11 (4-22) year received cannabidiol for a median duration of 66 days (30-588). Self-injury and rage attacks (n = 34) improved in 67.6% and worsened in 8.8%. Hyperactivity symptoms (n = 38) improved in 68.4%, did not change in 28.9% and worsened in 2.6%. Sleep problems (n = 21) improved in 71.4% and worsened in 4.7%. Anxiety (n = 17) improved in 47.1% and worsened in 23.5%. Adverse effects, mostly somnolence and change in appetite were mild. Conclusion: Parents' reports suggest that cannabidiol may improve ASD comorbidity symptoms; however, the long-term effects should be evaluated in large scale studies.";"[Barchel, Dana; De-Haan, Tal; Fuchs, Danny Or; Koren, Gideon; Berkovitch, Matitiahu] Assaf Harofeh Med Ctr, Clin Pharmacol & Toxicol Unit, Tel Aviv, Israel; [Stolar, Orit] Assaf Harofeh Med Ctr, Autist Spectrum Disorder Clin, Tel Aviv, Israel; [Ziv-Baran, Tomer] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Tel Aviv, Israel; [Saban, Naama] Tikun Olam, Tel Aviv, Israel; [Koren, Gideon] Maccabi Inst Hlth Serv Res, Tel Aviv, Israel";"Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University";Berkovitch, M (corresponding author), Assaf Harofeh Med Ctr, Clin Pharmacol & Toxicol Unit, Tel Aviv, Israel.;mberkovitch@asaf.health.gov.il;"Ziv-Baran, Tomer/AAA-8408-2022; koren, gideon/AAG-7726-2019";koren, gideon/0000-0002-9234-0875;;;;"[Anonymous], 2013, Substance-related and addictive disorders in diagnostic and statistical manual of mental disorders, V5th, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Brzozowska NI, 2017, NEUROPSYCHOPHARMACOL, V42, P2222, DOI 10.1038/npp.2017.50; Canitano Roberto, 2008, Neuropsychiatr Dis Treat, V4, P723; Degenhardt L, 2018, ADDICTION, V113, P924, DOI 10.1111/add.14145; Detyniecki K, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0586-5; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Devnani PA, 2015, J PEDIATR NEUROSCI, V10, P304, DOI 10.4103/1817-1745.174438; Földy C, 2013, NEURON, V78, P498, DOI 10.1016/j.neuron.2013.02.036; Food and Drug Administration, 2004, MEDDRA MED DICT REG; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Hurwitz R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008372.pub2; Kuester G, 2017, J NEUROL SCI, V381, P932, DOI 10.1016/j.jns.2017.08.2623; Kurz R., 2010, Can Underwrit, V5, P4; Lindsey WT, 2012, AM J DRUG ALCOHOL AB, V38, P334, DOI 10.3109/00952990.2011.643997; Mannion A, 2013, RES AUTISM SPECT DIS, V7, P1595, DOI 10.1016/j.rasd.2013.09.006; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Moore ML, 2004, ANN PHARMACOTHER, V38, P1515, DOI 10.1345/aph.1D543; Murray MJ, 2010, CURR PSYCHIAT REP, V12, P382, DOI 10.1007/s11920-010-0145-3; Palmieri B, 2017, ISR MED ASSOC J, V19, P79; Poleg S, 2019, PROG NEURO-PSYCHOPH, V89, P90, DOI 10.1016/j.pnpbp.2018.08.030; Porter BE, 2013, EPILEPSY BEHAV, V29, P574, DOI 10.1016/j.yebeh.2013.08.037; Richards C, 2016, J NEURODEV DISORD, V8, DOI 10.1186/s11689-016-9153-x; Rong C, 2018, EXPERT OPIN DRUG SAF, V17, P51, DOI 10.1080/14740338.2017.1397128; Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI 10.1111/j.1476-5381.2011.01238.x; Shah D, 2017, ASIAN J PSYCHIATR, V30, P180, DOI 10.1016/j.ajp.2017.10.003; South M, 2017, J AUTISM DEV DISORD, V47, P3679, DOI 10.1007/s10803-017-3322-y; Stachnik J, 2010, ADOLESC HEALTH MED T, V1, P105, DOI 10.2147/AHMT.S9819; Stout SM, 2014, DRUG METAB REV, V46, P86, DOI 10.3109/03602532.2013.849268; Sturm H, 2004, DEV MED CHILD NEUROL, V46, P444, DOI 10.1017/S0012162204000738; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; Wei D, 2015, P NATL ACAD SCI USA, V112, P14084, DOI 10.1073/pnas.1509795112; Wilkinson Samuel T, 2014, Curr Addict Rep, V1, P115; Wink LK, 2010, EXPERT OPIN EMERG DR, V15, P481, DOI 10.1517/14728214.2010.487860";34;99;104;2;36;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1663-9812;;;FRONT PHARMACOL;Front. Pharmacol.;janv-09;2019;9;;;;;;;;1521;10.3389/fphar.2018.01521;http://dx.doi.org/10.3389/fphar.2018.01521;;;5;Pharmacology & Pharmacy;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pharmacology & Pharmacy;HG9HI;30687090;Green Published, gold;;;24/11/2024;WOS:000455317700001;View Full Record in Web of Science
J;"Frye, RE; Lane, A; Worner, A; Werner, BA; McCarty, PJ; Scheck, AC; Collins, HL; Adelman, SJ; Quadros, EV; Rossignol, DA";;;;"Frye, Richard E.; Lane, Alison; Worner, Ashley; Werner, Brianna A.; McCarty, Patrick J.; Scheck, Adrienne C.; Collins, Heidi L.; Adelman, Steven J.; Quadros, Edward V.; Rossignol, Daniel A.";;;The Soluble Folate Receptor in Autism Spectrum Disorder: Relation to Autism Severity and Leucovorin Treatment;JOURNAL OF PERSONALIZED MEDICINE;;;English;Article;;;;;;"autism spectrum disorder; soluble folate receptor; folinic acid; leucovorin";"OXIDATIVE STRESS; CHILDREN; GENE; POLYMORPHISM; NETWORK";Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with life-long consequences that affects up to 1 in 44 children. Treatment with leucovorin (folinic acid), a reduced form of folate, has been shown to improve symptoms in those with ASD and folate pathway abnormalities in controlled clinical trials. Although soluble folate binding proteins (sFBPs) have been observed in the serum of some patients with ASD, the significance of this finding has not been studied. Here, we present a cohort of ASD patients with sFBPs. These patients had severe ASD and were medically complex. Using baseline controlled open-label methodology and standardized assessments, these patients were found to improve in both core and associated ASD symptoms with leucovorin treatment. No adverse effects were related to leucovorin treatment. This is the first report of the sFBPs in ASD. This study complements ongoing controlled clinical trials and suggests that leucovorin may be effective for children with ASD who are positive for sFBPs. Further, sFBPs might be important biomarkers for treatment response to leucovorin in children with ASD. This study paves the way for further controlled studies for patients with sFBPs.;"[Frye, Richard E.] Rossignol Med Ctr, Phoenix, AZ 85050 USA; [Frye, Richard E.; Rossignol, Daniel A.] Autism Discovery & Treatment Fdn, Phoenix, AZ 85050 USA; [Lane, Alison; Worner, Ashley; Scheck, Adrienne C.] Univ Arizona Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ 85004 USA; [Lane, Alison; Worner, Ashley; Scheck, Adrienne C.] Phoenix Childrens Hosp, Phoenix, AZ 85016 USA; [Werner, Brianna A.] Creighton Univ Sch Med, Phoenix, AZ 85012 USA; [McCarty, Patrick J.] Tulane Univ Med Sch, New Orleans, LA 70112 USA; [Collins, Heidi L.; Adelman, Steven J.] VascularStrategies LLC, Plymouth Meeting, PA 19462 USA; [Quadros, Edward V.] State Univ New York Downstate, Brooklyn, NY 11203 USA; [Rossignol, Daniel A.] Rossignol Med Ctr, Aliso Viejo, CA 92656 USA";"Phoenix Children's Hospital; Creighton University; Tulane University; State University of New York (SUNY) System; SUNY Downstate Health Sciences University";"Frye, RE (corresponding author), Rossignol Med Ctr, Phoenix, AZ 85050 USA.;Frye, RE (corresponding author), Autism Discovery & Treatment Fdn, Phoenix, AZ 85050 USA.";drfrye@rossignolmedicalcenter.com;"Scheck, Adrienne/AAH-5040-2020; Rose, Shannon/JZE-1449-2024; Rossignol, Daniel/I-5947-2019";"Scheck, Adrienne/0000-0003-3497-1895; McCarty, Patrick/0000-0001-7111-9576; Frye, Richard/0000-0003-4442-2937; Rossignol, Daniel/0000-0002-4405-8664";Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01HD088528] Funding Source: NIH RePORTER;Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD));;"Al Mahmuda N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050772; Almekkawi AK, 2022, J PERS MED, V12, DOI 10.3390/jpm12101609; Bakulski KM, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.775390; Ciernia AV, 2016, NAT REV NEUROSCI, V17, P411, DOI 10.1038/nrn.2016.41; Connery K, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0214-7; Duvekot J, 2015, J AUTISM DEV DISORD, V45, P1658, DOI 10.1007/s10803-014-2323-3; Fallah MS, 2019, J CHILD ADOL PSYCHOP, V29, P168, DOI 10.1089/cap.2018.0115; Franco CN, 2022, METABOLITES, V12, DOI 10.3390/metabo12100961; Frustaci A, 2012, FREE RADICAL BIO MED, V52, P2128, DOI 10.1016/j.freeradbiomed.2012.03.011; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Frye RE, 2013, MOL PSYCHIATR, V18, P369, DOI 10.1038/mp.2011.175; Frye RE, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00066; Garrido N, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-020-00995-2; Guo BQ, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113283; Guo BQ, 2020, ACTA PSYCHIAT SCAND, V141, P492, DOI 10.1111/acps.13170; Haghiri R, 2016, ACTA NEUROBIOL EXP, V76, P318, DOI 10.21307/ane-2017-030; Holm J, 2020, BBA-PROTEINS PROTEOM, V1868, DOI 10.1016/j.bbapap.2020.140466; Howsmon DP, 2018, BIOENG TRANSL MED, V3, P156, DOI 10.1002/btm2.10095; Howsmon DP, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005385; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2010, AM J MED GENET B, V153B, P1209, DOI 10.1002/ajmg.b.31094; Jensen AR, 2022, MOL DIAGN THER, V26, P483, DOI 10.1007/s40291-022-00600-7; Kovalev IS, 2022, MOLECULES, V27, DOI 10.3390/molecules27196229; Maenner MJ, 2020, MMWR SURVEILL SUMM, V69, P1, DOI 10.15585/mmwr.ss6904a1; Murray MJ, 2011, J AUTISM DEV DISORD, V41, P1586, DOI 10.1007/s10803-011-1178-0; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol DA, 2021, J PERS MED, V11, DOI 10.3390/jpm11111141; Sequeira JM, 2013, CLIN CHEM LAB MED, V51, P545, DOI 10.1515/cclm-2012-0577";28;2;2;0;2;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2075-4426;;J PERS MED;J. Pers. Med.;DEC;2022;12;12;;;;;;;2033;10.3390/jpm12122033;http://dx.doi.org/10.3390/jpm12122033;;;8;"Health Care Sciences & Services; Medicine, General & Internal";Science Citation Index Expanded (SCI-EXPANDED);"Health Care Sciences & Services; General & Internal Medicine";7E4NN;36556254;gold, Green Published;;;24/11/2024;WOS:000901147000001;View Full Record in Web of Science
J;"Lee, BR; Park, S; Kwon, HJ; Hwang, GS; Kim, M";;;;"Lee, Boram; Park, Serin; Kwon, Hyun Jeong; Hwang, Gwi Seo; Kim, Moonju";;;Integrative treatment program for the treatment of children with autism spectrum disorder: A prospective observational case series;FRONTIERS IN NEUROLOGY;;;English;Article;;;;;;"integrative medicine; autism spectrum disorder; herbal medicine; Floortime; sensory enrichment therapy; case series";"ENVIRONMENTAL ENRICHMENT; ALTERNATIVE MEDICINE; COMPLEMENTARY; INTERVENTION; INFANTS; TRIAL; RISK";BackgroundIn a situation where conventional treatments for autism spectrum disorder (ASD) are labor-intensive and there are concerns about the side effects of conventional medications, a 6-month integrative treatment program, including herbal medicine (HM), Floortime, and sensory enrichment therapy (SET) has been used on children with ASD in Korean medicine clinical settings. MethodsWe observed the treatment responses of 18 children with ASD (66.7% male, mean age 3.9 +/- 0.9 years) to the integrative treatment program as part of a prospective, single-center, observational case series. Individualized HMs were administered according to the patient's symptoms, and parents were instructed to perform Floortime and SET with their children at home for 2 h and 20 min a day, 5 days a week, respectively. The Childhood Autism Rating Scale (CARS) and Autism Behavior Checklist (ABC) were used to evaluate the core symptoms of ASD. A linear mixed model for repeated measures was used for analyzing the effect of the program over time, and logistic regression used to explore the predictors of treatment response. ResultsThe CARS and ABC scores were significantly improved from 34.58 +/- 6.27 and 69.28 +/- 15.73 at baseline to 28.56 +/- 6.05 and 39.67 +/- 20.36 after 6 months (p < 0.0001, respectively). No serious adverse events (AEs) were reported, and compliance with HM, Floortime, and SET was high at >90%. ConclusionThis 6-month integrative treatment program appears to be a potentially effective, safe, and feasible option for children with ASD. Low baseline CARS scores may be predictors of higher treatment response.;"[Lee, Boram] Korea Inst Oriental Med, KM Sci Res Div, Daejeon, South Korea; [Park, Serin; Kwon, Hyun Jeong] Floortime Ctr Korea, Seoul, South Korea; [Hwang, Gwi Seo] Gachon Univ, Coll Korean Med, Seongnam, South Korea; [Kim, Moonju] ITomato Korean Med Clin, Seoul, South Korea";"Korea Institute of Oriental Medicine (KIOM); Gachon University";Kim, M (corresponding author), ITomato Korean Med Clin, Seoul, South Korea.;moonju-kim@hanmail.net;"Kim, Jeongwon/GQR-2443-2022; Lee, Bo Ram/AAQ-9275-2021";Lee, Boram/0000-0003-1679-0644;Korea Institute of Oriental Medicine [KSN2022210];Korea Institute of Oriental Medicine;This work was supported by the Korea Institute of Oriental Medicine (KSN2022210).;"Amaral DG, 2008, TRENDS NEUROSCI, V31, P137, DOI 10.1016/j.tins.2007.12.005; [Anonymous], 1995, SOCIAL MATURITY SCAL; APA. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorder, V5, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596.744053]; Aronoff E, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2734915; Bang M, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8614680; Baroncelli L, 2010, CELL DEATH DIFFER, V17, P1092, DOI 10.1038/cdd.2009.193; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Ben-Sasson A, 2009, J AUTISM DEV DISORD, V39, P1, DOI 10.1007/s10803-008-0593-3; Briones T L, 2000, Biol Res Nurs, V1, P299, DOI 10.1177/109980040000100406; Casenhiser DM, 2013, AUTISM, V17, P220, DOI 10.1177/1362361311422052; Ding L., 2015, CHIN PEDIAT INTEGR T, V7, P502, DOI [10.3969/j.issn.1674-3865.2015.05.034, DOI 10.3969/J.ISSN.1674-3865.2015.05.034]; Gonzales ELT, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.29245; Green J, 2013, J AUTISM DEV DISORD, V43, P2502, DOI 10.1007/s10803-013-1797-8; Greenspan SI, 1999, J ASSOC PERS SEVERE, V24, P147, DOI 10.2511/rpsd.24.3.147; Hanson E, 2007, J AUTISM DEV DISORD, V37, P628, DOI 10.1007/s10803-006-0192-0; Hazlett HC, 2017, NATURE, V542, P348, DOI 10.1038/nature21369; Jang S, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/4089019; Jiang H, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110679; Jurek L, 2022, EUR CHILD ADOLES PSY, V31, P1285, DOI 10.1007/s00787-021-01772-z; Kasari C, 2010, J AUTISM DEV DISORD, V40, P1045, DOI 10.1007/s10803-010-0955-5; Klein N, 2016, CURR PROB PEDIATR AD, V46, P195, DOI 10.1016/j.cppeds.2015.12.004; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; KRUG DA, 1980, J CHILD PSYCHOL PSYC, V21, P221, DOI 10.1111/j.1469-7610.1980.tb01797.x; Lee JY, 2016, PHYTOTHER RES, V30, P1412, DOI 10.1002/ptr.5647; Lee J, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/3410213; Li Y., 2011, CHIN MED MOD DIST ED, V9, P57, DOI [10.3969/j.issn.1672-2779.2011.22.039, DOI 10.3969/J.ISSN.1672-2779.2011.22.039]; Maenner MJ, 2021, MMWR SURVEILL SUMM, V70, DOI [10.15585/mmwr.ss7011a1, 10.15585/mmwr.ss7010a1]; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P1811, DOI 10.2147/NDT.S151802; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; Mering S, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00106; Owen-Smith AA, 2015, RES AUTISM SPECT DIS, V17, P40, DOI 10.1016/j.rasd.2015.05.002; Pajareya K, 2011, AUTISM, V15, P563, DOI 10.1177/1362361310386502; Sanchack KE, 2016, AM FAM PHYSICIAN, V94, P972; Sandbank M, 2020, PSYCHOL BULL, V146, P1, DOI 10.1037/bul0000215; Schertz H.H., 2017, Young Exceptional Children, V20, P16, DOI [10.1177/1096250615576808, DOI 10.1177/1096250615576808]; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Shin M.S., 1998, Korean Journal of Clinical Psychology, V17, P1; Stieben J, 2007, DEV PSYCHOPATHOL, V19, P455, DOI 10.1017/S0954579407070228; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wang G., 1994, J TRADIT CHIN MED, V35, P544; Woo CC, 2015, BEHAV NEUROSCI, V129, P412, DOI 10.1037/bne0000068; Woo CC, 2013, BEHAV NEUROSCI, V127, P487, DOI 10.1037/a0033010; Xiang H., 2008, GUANGXI J TRADIT CHI, V31, P45; Zhu E., 2018, INNER MONG J TRADIT, V37, P27, DOI [10.16040/j.cnki.cn15-1101.2018.02.021, DOI 10.16040/J.CNKI.CN15-1101.2018.02.021]";44;0;1;2;7;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-2295;;;FRONT NEUROL;Front. Neurol.;janv-04;2023;13;;;;;;;;1017005;10.3389/fneur.2022.1017005;http://dx.doi.org/10.3389/fneur.2022.1017005;;;9;"Clinical Neurology; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;8A3LG;36686506;Green Published, gold;;;24/11/2024;WOS:000916142600001;View Full Record in Web of Science
J;"Ozsahin, I; Mustapha, MT; Albarwary, S; Sanlidag, B; Ozsahin, DU; Butler, TA";;;;"Ozsahin, Ilker; Mustapha, Mubarak T.; Albarwary, Safa; Sanlidag, Burcin; Ozsahin, Dilber Uzun; Butler, Tracy A.";;;An investigation to choose the proper therapy technique in the management of autism spectrum disorder;JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH;;;English;Article;;;;;;"autism spectrum disorder; decision-making; fuzzy; PROMETHEE; therapy; TOPSIS";"CHILDREN; PROMETHEE; IRRITABILITY; ADOLESCENTS; PREVALENCE; RISK";Aim: Autism spectrum disorder is a class of neurological disorders that affect the development of brain functions. This study aims to evaluate, compare and rank the therapy techniques used in the management of autism spectrum disorder using multicriteria decision-making approaches. Materials & methods: Fuzzy PROMETHEE and fuzzy TOPSIS approaches were used. Fuzzy PROMETHEE utilizes a pair-wise comparison of alternatives under the fuzzy environment while fuzzy TOPSIS utilizes geometric distance from the positive ideal solution under the fuzzy environment for the evaluation of the effectiveness of the alternatives.The techniques selected for evaluation are applied behavioral analysis, cognitive behavioral therapy, speech therapy and pharmacological therapy such as Risperidone and Aripiprazole. Criteria used in this study include efficacy, cost and side effects, and their weights are assigned based on specific patient conditions. Results: The results indicate that applied behavioral analysis, cognitive behavioral therapy and speech therapy are the most preferred techniques, followed by Aripiprazole and Risperidone. Conclusion: More criteria could be considered and the weights could be assigned according to the patient profile. Lay abstract Autism spectrum disorder is a neurodevelopmental disorder (affecting the development of the brain) that usually presents during childhood. Because autism spectrum disorder has no cure, selecting the best therapy to manage the disorder is important for therapists, parents, health institutions and researchers with an interest in these types of disorders. This study focuses on comparing specific therapy techniques by using multicriteria decision-making methods. The result obtained by a decision-maker is not always the same, as different decision-makers may come up with different solutions depending on things like the cost and how well a therapy works on different aspects of the disorder. The outcome of the study indicates that applied behavioral analysis, cognitive behavioral therapy and speech therapy are preferred treatment alternatives, followed by treatment with Risperidone and Aripiprazole. Further analyses are needed to obtain more accurate patient-specific results that will incorporate specific patient demographics and data, as well as looking at the combination of two or three techniques.;"[Ozsahin, Ilker; Mustapha, Mubarak T.; Albarwary, Safa; Ozsahin, Dilber Uzun] Near East Univ, Fac Engn, Dept Biomed Engn, TR-99138 Nicosia, Northern Cyprus, Turkey; [Ozsahin, Ilker; Mustapha, Mubarak T.; Albarwary, Safa; Ozsahin, Dilber Uzun] Near East Univ, DESAM Inst, TR-99138 Nicosia, Northern Cyprus, Turkey; [Ozsahin, Ilker; Butler, Tracy A.] Weill Cornell Med, Brain Hlth Imaging Inst, Dept Radiol, New York, NY 10065 USA; [Sanlidag, Burcin] Near East Univ, Fac Med, TR-99138 Nicosia, Northern Cyprus, Turkey; [Ozsahin, Dilber Uzun] Univ Sharjah, Coll Hlth Sci, Dept Med Diagnost Imaging, Sharjah 27272, U Arab Emirates";"Near East University; Near East University; Cornell University; Weill Cornell Medicine; Near East University; University of Sharjah";"Ozsahin, I (corresponding author), Near East Univ, Fac Engn, Dept Biomed Engn, TR-99138 Nicosia, Northern Cyprus, Turkey.;Ozsahin, I (corresponding author), Near East Univ, DESAM Inst, TR-99138 Nicosia, Northern Cyprus, Turkey.;Ozsahin, I (corresponding author), Weill Cornell Med, Brain Hlth Imaging Inst, Dept Radiol, New York, NY 10065 USA.";ilkerozsahin@windowslive.com;"Mustapha, Mubarak/HII-4840-2022; Uzun Ozsahin, Dilber/GLT-9806-2022; Ozsahin, Ilker/AAR-6410-2020; Sanlidag, Burcin/ADG-9205-2022";"Ozsahin, Ilker/0000-0002-3141-6805; Butler, Tracy/0000-0003-0130-8122";;;;"American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Chandler S, 2016, DEV MED CHILD NEUROL, V58, P202, DOI 10.1111/dmcn.12830; Christensen DL, 2019, MMWR SURVEILL SUMM, V68, P1, DOI 10.15585/mmwr.ss6802a1; de Schipper E, 2015, AUTISM RES, V8, P782, DOI 10.1002/aur.1485; Gaugler T, 2014, NAT GENET, V46, P881, DOI 10.1038/ng.3039; Geldermann J, 2000, FUZZY SET SYST, V115, P45, DOI 10.1016/S0165-0114(99)00021-4; Gokcekus H, 2020, DESALIN WATER TREAT, V177, P431, DOI 10.5004/dwt.2020.25115; Goumas M, 2000, EUR J OPER RES, V123, P606, DOI 10.1016/S0377-2217(99)00093-4; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Hasnain M, 2012, POSTGRAD MED, V124, P154, DOI 10.3810/pgm.2012.07.2577; Havdahl A, 2019, LANCET PSYCHIAT, V6, P794, DOI 10.1016/S2215-0366(19)30326-8; Hill AP, 2014, RES AUTISM SPECT DIS, V8, P1121, DOI 10.1016/j.rasd.2014.05.006; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Kirino E, 2014, CLIN MED INSIGHTS-PE, V8, P17, DOI 10.4137/CMPed.S8304; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Lee SH, 2013, NAT GENET, V45, P984, DOI 10.1038/ng.2711; Leigh JP, 2015, J AUTISM DEV DISORD, V45, P4135, DOI 10.1007/s10803-015-2521-7; Lequia J, 2012, RES AUTISM SPECT DIS, V6, P480, DOI 10.1016/j.rasd.2011.07.008; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Macharis C, 2004, EUR J OPER RES, V153, P307, DOI 10.1016/S0377-2217(03)00153-X; Mannion A, 2013, RES AUTISM SPECT DIS, V7, P35, DOI 10.1016/j.rasd.2012.05.002; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Modabbernia A, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0121-4; National Institute for Mental Health (NIMH), 2020, AUTISM SPECTRUM DISO; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Ozsahin D, 2018, 2018 ADV SCI ENG TEC; Ozsahin DU, 2018, INT J MED RES HEALTH, V7, P29; Ozsahin DU, 2017, PROCEDIA COMPUT SCI, V120, P699, DOI 10.1016/j.procs.2017.11.298; Ozsahin DU, 2017, INT J ADV COMPUT SC, V8, P177, DOI 10.14569/IJACSA.2017.081024; Ozsahin I, 2019, WORLD CANCER RES J, V6; Ozsahin I, 2020, HEALTHC INFORM RES, V26, P201; Ozsahin I, 2020, ARCH PSYCHIATR PSYCH, V22, P52, DOI 10.12740/APP/111624; Palczewski K, 2019, PROCEDIA COMPUT SCI, V159, P2294, DOI 10.1016/j.procs.2019.09.404; Pezzimenti F, 2019, CHILD ADOL PSYCH CL, V28, P397, DOI 10.1016/j.chc.2019.02.009; Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e; Rogers SJ, 2008, J CLIN CHILD ADOLESC, V37, P8, DOI 10.1080/15374410701817808; Sanders SJ, 2015, NEURON, V87, P1215, DOI 10.1016/j.neuron.2015.09.016; Satterstrom FK, 2020, CELL, V180, P568, DOI 10.1016/j.cell.2019.12.036; Schey C, 2014, VALUE HEALTH, V17, pA556, DOI 10.1016/j.jval.2014.08.1830; Soke GN, 2018, J AUTISM DEV DISORD, V48, P2663, DOI 10.1007/s10803-018-3521-1; Son, 2020, INTRO HDB LIFE COURS, P1; Stahmer AC, 2011, BRAIN RES, V1380, P229, DOI 10.1016/j.brainres.2010.09.043; Tromans Samuel, 2018, Clin Pract Epidemiol Ment Health, V14, P177, DOI 10.2174/1745017901814010177; Tzeng GH, 2011, MULTIPLE ATTRIBUTE DECISION MAKING: METHODS AND APPLICATIONS, P1; Ülengin F, 2001, EUR J OPER RES, V134, P179, DOI 10.1016/S0377-2217(00)00247-2; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2; Wu S, 2017, ACTA PSYCHIAT SCAND, V135, P29, DOI 10.1111/acps.12666; Yin X., 2020, J PSYCHOL RES, V2, DOI [10.30564/jpr.v2i4.2236, DOI 10.30564/JPR.V2I4.2236]";50;5;6;1;14;Becaris Publishing;Royston;43 Kneesworth Street, Royston, UNITED KINGDOM;2042-6305;2042-6313;;J COMP EFFECT RES;J. Comparative Effectiveness Res.;APR;2021;10;5;;;;;423;437;;10.2217/cer-2020-0162;http://dx.doi.org/10.2217/cer-2020-0162;;mars-21;15;Health Care Sciences & Services;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Health Care Sciences & Services;QZ1FR;33709772;;;;24/11/2024;WOS:000627899800001;View Full Record in Web of Science
J;"Downs, JM; Lechler, S; Dean, H; Sears, N; Patel, R; Shetty, H; Simonoff, E; Hotopf, M; Ford, TJ; Diaz-Caneja, CM; Arango, C; MacCabe, JH; Hayes, RD; Pina-Camacho, L";;;;"Downs, Johnny M.; Lechler, Suzannah; Dean, Harry; Sears, Nicola; Patel, Rashmi; Shetty, Hitesh; Simonoff, Emily; Hotopf, Matthew; Ford, Tamsin J.; Diaz-Caneja, Covadonga M.; Arango, Celso; MacCabe, James H.; Hayes, Richard D.; Pina-Camacho, Laura";;;The Association Between Comorbid Autism Spectrum Disorders and Antipsychotic Treatment Failure in Early-Onset Psychosis: A Historical Cohort Study Using Electronic Health Records;JOURNAL OF CLINICAL PSYCHIATRY;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; TREATMENT-RESISTANT; ADULT-ONSET; ADOLESCENT SCHIZOPHRENIA; TREATMENT RESPONSE; CHILDREN; CHILDHOOD; ILLNESS; TRIAL; PRETREATMENT";"Objective: In a sample of children and adolescents with first-episode psychosis, we investigated whether multiple treatment failure (MTF, defined as the initiation of a third trial of novel antipsychotic due to nonadherence, adverse effects, or insufficient response) was associated with comorbid autism spectrum disorders. Methods: Data were from the electronic health records of 638 children (51% male) aged from 10 to 17 years with first-episode psychosis (per ICD-10 criteria) from January 1, 2008, to November 1, 2014, referred to mental health services in South London, United Kingdom; data were extracted using the Clinical Record Interactive Search (CRIS) system. The effect of autism spectrum disorder comorbidity on the development of MTF during a 5-year period was modeled using Cox regression. Results: There were 124 cases of MTF prior to the age of 18 (19.4% of the sample). Comorbid autism spectrum disorders were significantly associated with MTF (adjusted hazard ratio = 1.99; 95% CI, 1.19-3.31; P = .008) after controlling for a range of potential confounders. Other factors significantly associated with MTF included higher age at first presentation (P = .001), black ethnicity (P = .03), and frequency of clinical contact (P < .001). No significant association between other comorbid neurodevelopmental disorders (hyperkinetic disorder or intellectual disability) and MTF was found. Conclusions: Children with first-episode psychosis and comorbid autism spectrum disorders at first presentation are less likely to have a beneficial response to antipsychotics. (C) Copyright 2017 Physicians Postgraduate Press, Inc.";"[Downs, Johnny M.; Lechler, Suzannah; Dean, Harry; Sears, Nicola; Patel, Rashmi; Simonoff, Emily; Hotopf, Matthew; MacCabe, James H.; Hayes, Richard D.; Pina-Camacho, Laura] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England; [Downs, Johnny M.; Lechler, Suzannah; Dean, Harry; Sears, Nicola; Patel, Rashmi; Shetty, Hitesh; Simonoff, Emily; Hotopf, Matthew; MacCabe, James H.; Hayes, Richard D.; Pina-Camacho, Laura] NIHR South London & Maudsley NHS Fdn Trust, Biomed Res Ctr, London, England; [Ford, Tamsin J.] Univ Exeter, Med Sch, Exeter, Devon, England; [Diaz-Caneja, Covadonga M.; Arango, Celso; Pina-Camacho, Laura] Univ Complutense, Hosp Gen Univ Gregorio Maranon, Dept Child & Adolescent Psychiat, IiSGM,Sch Med,CIBERSAM, Madrid, Spain";"University of London; King's College London; University of Exeter; General University Gregorio Maranon Hospital; Complutense University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM";Downs, JM (corresponding author), Kings Coll London, IOPPN Biomed Res Ctr Nucleus, Dept Psychol Med, Ground Floor,Mapother House,POB 92, London SE5 8AF, England.;johnny.downs@kcl.ac.uk;"Dean, Harry/IAR-5656-2023; Downs, Johnny/AAC-8287-2021; Hotopf, Matthew/E-4971-2010; Hayes, Richard/D-2382-2010; Arango, Celso/AAZ-8314-2021; Ford, Tamsin/V-5908-2019; Simonoff, Emily/B-7593-2011; Sears, Nicola/HKE-7307-2023; Pina-Camacho, Laura/AAH-2770-2021; Arango, Celso/H-6433-2015; Martinez Diaz-Caneja, Covadonga/X-8877-2018; Patel, Rashmi/O-1327-2013; MacCabe, James/E-5210-2010; Pina-Camacho, Laura/E-8873-2019";"Simonoff, Emily/0000-0002-5450-0823; Arango, Celso/0000-0003-3382-4754; Hayes, Richard/0000-0003-4453-244X; Martinez Diaz-Caneja, Covadonga/0000-0001-8538-3175; Hotopf, Matthew/0000-0002-3980-4466; Ford, Tamsin/0000-0001-5295-4904; Patel, Rashmi/0000-0002-9259-8788; MacCabe, James/0000-0002-6754-1018; Pina-Camacho, Laura/0000-0003-1960-6443; Downs, Johnny/0000-0002-8061-295X";"National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London; Medical Research Council (MRC) Clinical Research Training Fellowship [MR/L017105/1]; Foundation of Professional Services to Adolescents, UK; MRC Population Health Scientist Fellowship [MR/J01219X/1]; MRC CRTF [MR/K002813/1]; Instituto de Salud Carlos III; ERDF; European Commission; CIBERSAM; Madrid Regional Government; EU Structural Funds and Seventh Framework Program; Fundacion Alicia Koplowitz; Fundacion Mutua Madrilena; Guy's and St Thomas' Charity; Maudsley Charity [BRC-2011-10035]; MRC [MR/J01219X/1, MR/K002813/1, MR/L011794/1, MR/L017105/1] Funding Source: UKRI";"National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London; Medical Research Council (MRC) Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Foundation of Professional Services to Adolescents, UK; MRC Population Health Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC CRTF(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Instituto de Salud Carlos III(Instituto de Salud Carlos IIISpanish Government); ERDF(European Union (EU)); European Commission(European Union (EU)European Commission Joint Research Centre); CIBERSAM; Madrid Regional Government; EU Structural Funds and Seventh Framework Program; Fundacion Alicia Koplowitz; Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Guy's and St Thomas' Charity; Maudsley Charity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))";This article represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Dr Downs is supported by a Medical Research Council (MRC) Clinical Research Training Fellowship (MR/L017105/1). Mr Dean and Ms Lechler received salary support from the Foundation of Professional Services to Adolescents, UK. Dr Hayes was funded by an MRC Population Health Scientist Fellowship (MR/J01219X/1). Dr Patel was funded by an MRC CRTF (MR/K002813/1). Professors Hotopf and Simonoff are NIHR Senior Investigators. Professor Arrango, Dr Pina-Camacho, and Dr Diaz-Caneja received honoraria or grants from Instituto de Salud Carlos III, co-financed by funds from the ERDF, European Commission, CIBERSAM, Madrid Regional Government, EU Structural Funds and Seventh Framework Program, Fundacion Alicia Koplowitz, and Fundacion Mutua Madrilena. Other funders include Guy's and St Thomas' Charity and the Maudsley Charity (BRC-2011-10035).;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; [Anonymous], 2011, The English indices of deprivation 2010 for the Department for Communities and Local Government, DOI DOI 10.21704/AC.V77I2.483; Baird G, 2006, LANCET, V368, P210, DOI 10.1016/S0140-6736(06)69041-7; Ballageer T, 2005, J AM ACAD CHILD PSY, V44, P782, DOI 10.1097/01.chi.0000164591.55942.ea; Buitelaar JK, 1998, J CHILD PSYCHOL PSYC, V39, P911, DOI 10.1017/S0021963098002820; CANNONSPOOR HE, 1982, SCHIZOPHRENIA BULL, V8, P470, DOI 10.1093/schbul/8.3.470; Correll CU, 2011, CLIN THER, V33, pB16, DOI 10.1016/j.clinthera.2011.11.016; Cunningham H, 2002, COMPUT HUMANITIES, V36, P223, DOI 10.1023/A:1014348124664; Del Rey-Mejías A, 2015, EUR CHILD ADOLES PSY, V24, P1447, DOI 10.1007/s00787-015-0693-5; Demjaha A, 2014, BIOL PSYCHIAT, V75, pE11, DOI 10.1016/j.biopsych.2013.06.011; Díaz-Caneja CM, 2015, NPJ SCHIZOPHR, V1, DOI 10.1038/npjschz.2014.5; Downs J, 2016, EUR CHILD ADOLES PSY, V25, P649, DOI 10.1007/s00787-015-0780-7; Findling RL, 2010, J AM ACAD CHILD PSY, V49, P583, DOI 10.1016/j.jaac.2010.03.013; Fleischhaker C, 2005, SCHIZOPHRENIA BULL, V31, P769, DOI 10.1093/schbul/sbi014; Frank J, 2015, MOL PSYCHIATR, V20, P150, DOI 10.1038/mp.2014.56; Hassan GAM, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-28; Hayes RD, 2015, SCHIZOPHRENIA BULL, V41, P644, DOI 10.1093/schbul/sbu120; Hui CLM, 2014, PSYCHIAT RES, V220, P797, DOI 10.1016/j.psychres.2014.08.046; Kästner A, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0494-x; Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9; Kane JM, 2010, J CLIN PSYCHIAT, V71, P1115, DOI 10.4088/JCP.10r06264yel; Khandaker GM, 2014, PSYCHOL MED, V44, P3229, DOI 10.1017/S0033291714000750; Kumra S, 1998, J AM ACAD CHILD PSY, V37, P91, DOI 10.1097/00004583-199801000-00022; Kyriakopoulos M, 2015, EUR CHILD ADOLES PSY, V24, P301, DOI 10.1007/s00787-014-0576-1; Larson FV, 2017, BRIT J PSYCHIAT, V210, P269, DOI 10.1192/bjp.bp.116.187682; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Lin K-M, 2000, PSYCHOPHARMACOLOGY 4, P1907; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C., AUTISM DIAGNOSTIC OB, VSecond; McCutcheon R, 2015, J PSYCHOPHARMACOL, V29, P892, DOI 10.1177/0269881115576688; Meng H, 2006, ACTA PSYCHIAT SCAND, V114, P249, DOI 10.1111/j.1600-0447.2006.00773.x; National Collaborating Centre for Mental prohibited Health (UK), PSYCH SCHIZ CHILDR Y; Patel R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009888; Perera G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008721; Pina-Camacho L., 2016, BJPSYCH ADV, V22, P316, DOI [10.1192/apt.bp.115.014720, DOI 10.1192/APT.BP.115.014720]; Politte LC, 2014, HARVARD REV PSYCHIAT, V22, P76, DOI 10.1097/HRP.0000000000000030; Rabinowitz J, 2006, BRIT J PSYCHIAT, V189, P31, DOI 10.1192/bjp.bp.105.013276; Rabinowitz J, 2011, J CLIN PSYCHOPHARM, V31, P75, DOI 10.1097/JCP.0b013e31820568c6; Rajji TK, 2009, BRIT J PSYCHIAT, V195, P286, DOI 10.1192/bjp.bp.108.060723; Rapoport J, 2009, J AM ACAD CHILD PSY, V48, P10, DOI 10.1097/CHI.0b013e31818b1c63; Remschmidt H, 2012, NEUROPSYCHOBIOLOGY, V66, P63, DOI 10.1159/000338548; Schimmelmann BG, 2007, SCHIZOPHR RES, V95, P1, DOI 10.1016/j.schres.2007.06.004; Schneider C, 2015, EUR NEUROPSYCHOPHARM, V25, P857, DOI 10.1016/j.euroneuro.2015.02.003; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Sheitman BB, 2004, SCHIZOPHR RES, V69, P119, DOI 10.1016/S0920-9964(03)00177-4; Sporn AL, 2004, BIOL PSYCHIAT, V55, P989, DOI 10.1016/j.biopsych.2004.01.019; Starling J, 2009, CURR PSYCHIAT REP, V11, P190, DOI 10.1007/s11920-009-0030-0; Stentebjerg-Olesen M, 2016, J CHILD ADOL PSYCHOP, V26, P410, DOI 10.1089/cap.2015.0097; Suzuki T, 2012, PSYCHIAT RES, V197, P1, DOI 10.1016/j.psychres.2012.02.013; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013; Weiden PJ, 2007, J CLIN PSYCHIAT, V68, P12; Wimberley T, 2016, LANCET PSYCHIAT, V3, P358, DOI 10.1016/S2215-0366(15)00575-1";52;41;41;1;9;PHYSICIANS POSTGRADUATE PRESS;MEMPHIS;P O BOX 752870, MEMPHIS, TN 38175-2870 USA;0160-6689;1555-2101;;J CLIN PSYCHIAT;J. Clin. Psychiatry;NOV-DEC;2017;78;9;;;;;E1233;+;;10.4088/JCP.16m11422;http://dx.doi.org/10.4088/JCP.16m11422;;;11;"Psychology, Clinical; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";FR0YZ;29125721;Green Accepted;;;24/11/2024;WOS:000418792500011;View Full Record in Web of Science
J;"Douglas, JF; Sanders, KB; Benneyworth, MH; Smith, JL; DeJean, VM; McGrew, SG; Veenstra-VanderWeele, J";;;;"Douglas, Jessica F.; Sanders, Kevin B.; Benneyworth, M. Hannah; Smith, Jessica L.; DeJean, Virginia M.; McGrew, Susan G.; Veenstra-VanderWeele, Jeremy";;;Brief Report: Retrospective Case Series of Oxcarbazepine for Irritability/Agitation Symptoms in Autism Spectrum Disorder;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Antiepileptic; Anticonvulsant; Mood stabilizer; Sodium channel; Pervasive developmental disorder";"PERVASIVE DEVELOPMENTAL DISORDERS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; PSYCHOACTIVE MEDICINES; PSYCHIATRIC-DISORDERS; ANTIEPILEPTIC DRUGS; BIPOLAR DISORDER; CHILDREN; ADOLESCENTS; CARBAMAZEPINE";We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5-21) and taking two other psychotropic medications (range 0-4). Fourteen patients (47 %) had a clinical global impression of improvement score of 'much improved' during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution.;"[Douglas, Jessica F.; Sanders, Kevin B.; Benneyworth, M. Hannah; Smith, Jessica L.; DeJean, Virginia M.; Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Sanders, Kevin B.; McGrew, Susan G.; Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA";"Vanderbilt University; Vanderbilt University";Veenstra-VanderWeele, J (corresponding author), 7158 MRB 3,465 21st Ave S, Nashville, TN 37232 USA.;j.vvw@vanderbilt.edu;Veenstra-VanderWeele, Jeremy/K-1935-2015;Veenstra-VanderWeele, Jeremy/0000-0002-6349-1076;;;;"Aman MG, 2003, J AUTISM DEV DISORD, V33, P527, DOI 10.1023/A:1025883612879; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Barry JJ, 2004, CLIN EEG NEUROSCI, V35, P4, DOI 10.1177/155005940403500107; Belsito KM, 2001, J AUTISM DEV DISORD, V31, P175, DOI 10.1023/A:1010799115457; Cueva JE, 1996, J AM ACAD CHILD PSY, V35, P480, DOI 10.1097/00004583-199604000-00014; Danielsson S, 2005, EPILEPSIA, V46, P918, DOI 10.1111/j.1528-1167.2005.57504.x; Di Martino A, 2001, PEDIATR NEUROL, V25, P199, DOI 10.1016/S0887-8994(01)00276-4; Gayatri NA, 2006, DEV MED CHILD NEUROL, V48, P394, DOI 10.1017/S0012162206000843; Gjevik E, 2011, J AUTISM DEV DISORD, V41, P761, DOI 10.1007/s10803-010-1095-7; Grunze Heinz C R, 2008, Dialogues Clin Neurosci, V10, P77; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Hirschfeld RMA, 2004, INT J NEUROPSYCHOPH, V7, P507, DOI 10.1017/S1461145704004651; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; Joshi G, 2010, J AUTISM DEV DISORD, V40, P1361, DOI 10.1007/s10803-010-0996-9; Kakkar AK, 2009, EUR PSYCHIAT, V24, P178, DOI 10.1016/j.eurpsy.2008.12.014; Kapetanovic S, 2007, AM J PSYCHIAT, V164, P832, DOI 10.1176/appi.ajp.164.5.832; Langworthy-Lam KS, 2002, J CHILD ADOL PSYCHOP, V12, P311, DOI 10.1089/104454602762599853; Levy SE, 2010, J DEV BEHAV PEDIATR, V31, P267, DOI 10.1097/DBP.0b013e3181d5d03b; Lopez-Larson M, 2006, HARVARD REV PSYCHIAT, V14, P285, DOI 10.1080/10673220601082869; Mandell DS, 2008, J AUTISM DEV DISORD, V38, P1059, DOI 10.1007/s10803-007-0481-2; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Monji A, 2004, EUR PSYCHIAT, V19, P322, DOI 10.1016/j.eurpsy.2004.06.001; Oswald DP, 2007, J CHILD ADOL PSYCHOP, V17, P348, DOI 10.1089/cap.2006.17303; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041; Pedrini M, 2009, BRIT J CLIN PHARMACO, V67, P579, DOI 10.1111/j.1365-2125.2009.03398.x; Rice Catherine, 2007, Morbidity and Mortality Weekly Report, V56, P12; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Stigler KA, 2008, CHILD ADOL PSYCH CL, V17, P739, DOI 10.1016/j.chc.2008.06.002; Tuchman R, 2002, LANCET NEUROL, V1, P352, DOI 10.1016/S1474-4422(02)00160-6; Vasudev A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005171.pub2; Wagner KD, 2006, AM J PSYCHIAT, V163, P1179, DOI 10.1176/appi.ajp.163.7.1179; Yildiz A, 2011, NEUROPSYCHOPHARMACOL, V36, P375, DOI 10.1038/npp.2010.192";37;19;19;1;8;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;MAY;2013;43;5;;;;;1243;1247;;10.1007/s10803-012-1661-2;http://dx.doi.org/10.1007/s10803-012-1661-2;;;5;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;122YX;22976374;;;;24/11/2024;WOS:000317355800023;View Full Record in Web of Science
J;"Minshawi, NF; Wink, LK; Shaffer, R; Plawecki, MH; Posey, DJ; Liu, H; Hurwitz, S; McDougle, CJ; Swiezy, NB; Erickson, CA";;;;"Minshawi, Noha F.; Wink, Logan K.; Shaffer, Rebecca; Plawecki, Martin H.; Posey, David J.; Liu, Hai; Hurwitz, Sarah; McDougle, Christopher J.; Swiezy, Naomi B.; Erickson, Craig A.";;;A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders;MOLECULAR AUTISM;;;English;Article;;;;;;"D-cycloserine; Autism spectrum disorders; Social skills training; Social deficits";"DIAGNOSTIC OBSERVATION SCHEDULE; ADAPTIVE-BEHAVIOR; NEGATIVE SYMPTOMS; CHILDREN; ANXIETY; ANTIPSYCHOTICS; SCHIZOPHRENIA; INDIVIDUALS; RISPERIDONE; EXTINCTION";Background: Researchers have demonstrated that D-cycloserine (DCS) can enhance the effects of behavioral interventions in adults with anxiety and enhances prosocial behavior in animal models of autism spectrum disorders (ASD). This study extended upon this background by combining DCS with behavioral social skills therapy in youth with ASD to assess its impact on the core social deficits of ASD. We hypothesized that DCS used in combination with social skills training would enhance the acquisition of social skills in children with ASD. Methods: A 10-week, double-blind, placebo-controlled trial of DCS (50 mg) given 30 min prior to weekly group social skills training was conducted at two sites. Children with ASD were randomized to receive 10 weeks (10 doses) of DCS or placebo in a 1: 1 ratio. Results: No statistically significant difference attributable to drug treatment was observed in the change scores for the primary outcome measure, the Social Responsiveness Scale (SRS), total score (p = 0.45), or on secondary outcome measures. Conclusions: The results of this trial demonstrated no drug-related short-term improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with ASD. This suggests a need to further study the efficacy of the social skills training protocol. Limitations to the current study and areas for future research are discussed.;"[Minshawi, Noha F.; Plawecki, Martin H.; Swiezy, Naomi B.] Indiana Univ Sch Med, Riley Hosp Children, Indiana Univ Hlth, Christian Sarkine Autism Treatment Ctr,Dept Psych, Indianapolis, IN 46202 USA; [Wink, Logan K.; Shaffer, Rebecca; Erickson, Craig A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Posey, David J.] David J Posey MD LLC, Indianapolis, IN USA; [Liu, Hai] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Hurwitz, Sarah] Indiana Univ, Sch Educ, Bloomington, IN 47405 USA; [McDougle, Christopher J.] Harvard Univ, Sch Med, Dept Psychiat, Lurie Ctr Autism,Massachusetts Gen Hosp, Boston, MA 02115 USA; [McDougle, Christopher J.] Harvard Univ, Sch Med, Dept Pediat, Lurie Ctr Autism,Massachusetts Gen Hosp, Boston, MA 02115 USA; [McDougle, Christopher J.] Harvard Univ, Sch Med, MassGen Hosp Children, Boston, MA USA";"Indiana University Health; IU Health University Hospital; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital";Erickson, CA (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.;craig.erickson@cchmc.org;"Erickson, Craig/M-8933-2017; Hurwitz, Sarah/AAF-8438-2020; Swiezy, Naomi/AAZ-5697-2021; PLAWECKI, MARTIN/T-2467-2018";"PLAWECKI, MARTIN/0000-0003-0708-9514; Hurwitz, Sarah/0000-0003-3219-4041";United States Department of Defense [W81XWH-09-1-0091];United States Department of Defense(United States Department of Defense);Funding for this study was provided by the United States Department of Defense Award Number W81XWH-09-1-0091. Statistical support was provided by Hai Liu, Ph.D., Indiana University School of Medicine Department of Biostatistics. We would like to acknowledge the contributions of Stacie Pozdol, M.A., Carrie McGinnis, B.S., CCRP, and Lyndsi Moser, B. S., CCRP at Indiana University, and Katherine Friedmann, RN, Lauren Mathieu-Frasier, MA, and Tori Schaefer, PhD at Cincinnati Children's Hospital Medical Center.;"Aman M., 1986, Aberrant Behavior Checklist Manual; [Anonymous], 2 CDC; [Anonymous], AM COLL NEUR 46 ANN; [Anonymous], 2008, VINELAND ADAPTIVE BE; [Anonymous], CHILD SYMPTOM INVENT; [Anonymous], AUTISM SPECTRUM DISO; [Anonymous], 2000, Diagnostic and statistical manual of mental disorders, V4th; [Anonymous], ANN CONV ASS BEH AN; Carter MJ, 2014, THER RECREAT J, V48, P275; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Cortese BM, 2005, CNS SPECTRUMS, V10, P820, DOI 10.1017/S1092852900010427; Duncan EJ, 2004, SCHIZOPHR RES, V71, P239, DOI 10.1016/j.schres.2004.03.013; Erickson CA, 2014, J AUTISM DEV DISORD, V44, P958, DOI 10.1007/s10803-013-1963-z; Fisch GS, 2001, J AUTISM DEV DISORD, V31, P249, DOI 10.1023/A:1010719720000; Foxx RM, 2008, CHILD ADOL PSYCH CL, V17, P821, DOI 10.1016/j.chc.2008.06.007; Freeman BJ, 1999, J AUTISM DEV DISORD, V29, P379, DOI 10.1023/A:1023078827457; Goff DC, 1999, ARCH GEN PSYCHIAT, V56, P21, DOI 10.1001/archpsyc.56.1.21; Goff DC, 2005, PSYCHOPHARMACOLOGY, V179, P144, DOI 10.1007/s00213-004-2032-2; Goff DC, 2008, SCHIZOPHR RES, V106, P320, DOI 10.1016/j.schres.2008.08.012; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; Gresham FM., 2008, SOCIAL SKILLS IMPROV; Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Hofmann SG, 2006, ARCH GEN PSYCHIAT, V63, P298, DOI 10.1001/archpsyc.63.3.298; Kanner L, 1943, NERV CHILD, V2, P217; Koegel LK, 2012, J POSIT BEHAV INTERV, V14, P220, DOI 10.1177/1098300712437042; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; Lord C, 1997, J AUTISM DEV DISORD, V27, P501, DOI 10.1023/A:1025873925661; Lyall K, 2014, JAMA PSYCHIAT, V71, P936, DOI 10.1001/jamapsychiatry.2014.476; Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002; Marrus N, 2014, J CHILD ADOL PSYCHOP, V24, P513, DOI 10.1089/cap.2014.0055; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, J CLIN PSYCHIAT, V66, P9; Modi ME, 2011, BIOL PSYCHIAT, V70, P298, DOI 10.1016/j.biopsych.2011.01.026; Murray DS, 2009, LANG SPEECH HEAR SER, V40, P109, DOI 10.1044/0161-1461(2008/07-0089); Norberg MM, 2008, BIOL PSYCHIAT, V63, P1118, DOI 10.1016/j.biopsych.2008.01.012; Posey DJ, 2008, CHILD ADOL PSYCH CL, V17, P787, DOI 10.1016/j.chc.2008.06.010; Posey DJ, 2004, AM J PSYCHIAT, V161, P2115, DOI 10.1176/appi.ajp.161.11.2115; Reichow B, 2010, J AUTISM DEV DISORD, V40, P149, DOI 10.1007/s10803-009-0842-0; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Rodrigues H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093519; Roid G.H., 2005, STANFORD BINET INTEL, VFifth; Ruble L., 2007, CLIN CASE STUD, V7, P287; Scattone D., 2006, Focus on Autism and Other Developmental Disabilities, V21, P211, DOI DOI 10.1177/10883576060210040201; Schneider N, 2010, J POSIT BEHAV INTERV, V12, P149, DOI 10.1177/1098300709334198; Stone W., 2003, TRIAD Social Skills Assessment Manual; Swanson CJ, 2005, NAT REV DRUG DISCOV, V4, P131, DOI 10.1038/nrd1630; van Berckel BNM, 1999, NEUROPSYCHOPHARMACOL, V21, P203, DOI 10.1016/S0893-133X(99)00014-7; Wink LK, 2010, CURR TREAT OPTION NE, V12, P529, DOI 10.1007/s11940-010-0091-8";49;47;50;2;12;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;janv-14;2016;7;;;;;;;;2;10.1186/s13229-015-0062-8;http://dx.doi.org/10.1186/s13229-015-0062-8;;;10;"Genetics & Heredity; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Genetics & Heredity; Neurosciences & Neurology";DB1AV;26770664;Green Published, gold;;;24/11/2024;WOS:000368241300001;View Full Record in Web of Science
J;"Gupta, M; Hoover, G";;;;"Gupta, Mayank; Hoover, Gary, Jr.";;;Lurasidone an Effective Alternative for the Treatment of Irritability Associated With Autism Spectrum Disorder;CUREUS JOURNAL OF MEDICAL SCIENCE;;;English;Article;;;;;;"lurasidone; autism";"ATYPICAL ANTIPSYCHOTICS; DOUBLE-BLIND; OPEN-LABEL; SCHIZOPHRENIA; CHILDREN; PLACEBO; OLANZAPINE; SAFETY";The key objective to demonstrate the use of Lurasidone in children or adolescents with autism spectrum disorders (ASD) and add further insights into its use in clinical practice with youth. We present four cases treated in the inpatient settings with unique challenges and their treatment course to address the unique clinical practice challenges. There is a dearth of psychopharmacologic options to treat irritability and affective symptoms in children and/or adolescents with autism spectrum disorders. Although recent research has yielded mixed results, there is still a not clear consensus on its effectiveness. Based on our experience, we found Lurasidone was an effective alternative due to its unique psychopharmacologic profile. It was well tolerated without any side effects, and its efficacy was more observed at higher doses.;"[Gupta, Mayank] Lake Erie Coll Osteopath Med, Psychiat, Erie, PA 16509 USA; [Gupta, Mayank] Clarion Psychiat Ctr, Psychiat & Behav Sci, Clarion, PA 16214 USA; [Hoover, Gary, Jr.] Allegheny Hlth Network, Phys Med & Rehabil, Pittsburgh, PA USA";;"Gupta, M (corresponding author), Lake Erie Coll Osteopath Med, Psychiat, Erie, PA 16509 USA.;Gupta, M (corresponding author), Clarion Psychiat Ctr, Psychiat & Behav Sci, Clarion, PA 16214 USA.";mayank6nov@gmail.com;;;;;;"Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Caccia S, 2013, PEDIATR DRUGS, V15, P217, DOI 10.1007/s40272-013-0024-6; Correll CU, 2016, CNS SPECTRUMS, V21, P393, DOI 10.1017/S1092852915000917; Curran MP, 2011, PEDIATR DRUGS, V13, P197, DOI 10.2165/11207230-000000000-00000; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Ishibashi T, 2010, J PHARMACOL EXP THER, V334, P171, DOI 10.1124/jpet.110.167346; Jesner OS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005040.pub2; Loebel A, 2016, J AUTISM DEV DISORD, V46, P1153, DOI 10.1007/s10803-015-2628-x; Loebel A, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0629-0; Loebel A, 2014, AM J PSYCHIAT, V171, P160, DOI 10.1176/appi.ajp.2013.13070984; Maayan L, 2011, J CHILD ADOL PSYCHOP, V21, P517, DOI 10.1089/cap.2011.0015; McClellan L, 2017, EXPERT OPIN INV DRUG, V26, P985, DOI 10.1080/13543784.2017.1353600; Meltzer HY, 2011, AM J PSYCHIAT, V168, P957, DOI 10.1176/appi.ajp.2011.10060907; Meyer JM, 2009, EXPERT OPIN INV DRUG, V18, P1715, DOI 10.1517/13543780903286388; Millard H, 2014, J CHILD ADOL PSYCHOP, V24, P354, DOI 10.1089/cap.2014.2462; Politte LC, 2014, PSYCHOPHARMACOLOGY, V231, P1023, DOI 10.1007/s00213-013-3068-y; Stahl SM, 2013, J CLIN PSYCHIAT, V74, P507, DOI 10.4088/JCP.12m08084; Youngster I, 2014, DEV MED CHILD NEUROL, V56, P990, DOI 10.1111/dmcn.12470";18;2;2;0;1;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;;2168-8184;;CUREUS J MED SCIENCE;Cureus J Med Sci;DEC 29;2020;12;12;;;;;;;e12360;10.7759/cureus.12360;http://dx.doi.org/10.7759/cureus.12360;;;4;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;PN1QO;33520554;gold, Green Published;;;24/11/2024;WOS:000604261600010;View Full Record in Web of Science
J;"Rotem, RS; Chodick, G; Shalev, V; Davidovitch, M; Koren, G; Hauser, R; Coull, BA; Seely, EW; Nguyen, VT; Weisskopf, MG";;;;"Rotem, Ran S.; Chodick, Gabriel; Shalev, Varda; Davidovitch, Michael; Koren, Gideon; Hauser, Russ; Coull, Brent A.; Seely, Ellen W.; Nguyen, Vy T.; Weisskopf, Marc G.";;;Maternal Thyroid Disorders and Risk of Autism Spectrum Disorder in Progeny;EPIDEMIOLOGY;;;English;Article;;;;;;"Autism spectrum disorders; Endocrine disruptors; Hyperthyroidism; Hypothyroidism; Neurodevelopment; Thyroid";"EARLY-PREGNANCY; HORMONE-LEVELS; CLUSTER-SIZE; HYPOTHYROXINEMIA; ASSOCIATION; POPULATION; HYPERTHYROIDISM; GUIDELINES; MANAGEMENT; CHILDHOOD";Background: Maternal thyroid dysfunction is suspected of causing adverse neurodevelopmental effects, but current evidence is inconclusive. Epidemiologic investigations generally suggest an association between maternal thyroid dysfunction and neurodevelopment impairments in progeny, but clinical trials of thyroid treatment during pregnancy reported null effects. To better understand these discrepant findings, we evaluated the association between maternal thyroid conditions and autism spectrum disorder (ASD), including examining the role of gestational thyroid-related hormone concentrations and thyroid medications use. Methods: Analyses considered 437,222 singleton live births occurring in a large Israeli health fund in 1999-2013, followed through 2016. Thyroid conditions and ASD cases were identified through International Classification of Diseases-9 codes with subsequent validation through review of medical records. Laboratory gestational thyroid hormone measurements were also considered. Results: Children of mothers who ever experienced hypothyroidism had a higher risk of ASD compared with children of mothers without hypothyroidism (adjusted odds ratio [aOR] = 1.26, 95% confidence interval [CI] = 1.12, 1.42). The association with hyperthyroidism was less consistent, but elevated in main analyses (aOR = 1.42, 95% CI = 1.04, 1.94). These associations were not explained by maternal gestational thyroid hormones levels nor mitigated by gestational use of thyroid medications. Conclusions: Results indicate that maternal thyroid conditions are associated with increased ASD risk in progeny, but suggestively not due to direct effects of thyroid hormones. Instead, factors that influence maternal thyroid function could have etiologic roles in ASD through pathways independent of maternal gestational thyroid hormones and thus be unaffected by medication treatment. Factors known to disrupt thyroid function should be examined for possible involvement in ASD etiology.;"[Rotem, Ran S.; Hauser, Russ; Coull, Brent A.; Nguyen, Vy T.; Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA; [Rotem, Ran S.; Chodick, Gabriel; Shalev, Varda; Davidovitch, Michael; Koren, Gideon] Maccabi Healthcare Serv, Kahn Sagol Maccabi Res & Innovat Inst, Tel Aviv, Israel; [Chodick, Gabriel; Shalev, Varda] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Tel Aviv, Israel; [Davidovitch, Michael] Maccabi Healthcare Serv, Child Dev Dept, Tel Aviv, Israel; [Hauser, Russ; Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Coull, Brent A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Seely, Ellen W.] Brigham & Womens Hosp, Endocrinol Diabet & Hypertens Div, 75 Francis St, Boston, MA 02115 USA; [Seely, Ellen W.] Harvard Med Sch, Boston, MA 02115 USA";"Harvard University; Harvard T.H. Chan School of Public Health; Tel Aviv University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School";Rotem, RS (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.;ran.rotem@mail.harvard.edu;chodick, gabby/AFP-0827-2022;/0000-0002-5189-8995;National Institutes of Health/National Institute of Environmental Health Sciences [R21-ES028900];National Institutes of Health/National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS));The results reported herein correspond to specific aims of grant R21-ES028900 from the National Institutes of Health/National Institute of Environmental Health Sciences. This work was (also) supported by Mr. James Crystal, in honor of Mrs. Lilian Yaros.;"Alexander EK, 2017, THYROID, V27, P315, DOI 10.1089/thy.2016.0457; Andersen SL, 2014, BJOG-INT J OBSTET GY, V121, P1365, DOI 10.1111/1471-0528.12681; Andersen SL, 2018, THYROID, V28, P537, DOI 10.1089/thy.2017.0425; Andersen SL, 2015, CLIN ENDOCRINOL, V83, P751, DOI 10.1111/cen.12744; [Anonymous], 2004, EUR J ENDOCRINOL S3; Atkins P, 2000, DRUG SAFETY, V23, P229, DOI 10.2165/00002018-200023030-00005; Brown AS, 2015, PROG NEURO-PSYCHOPH, V57, P86, DOI 10.1016/j.pnpbp.2014.10.010; Casey BM, 2017, NEW ENGL J MED, V376, P815, DOI 10.1056/NEJMoa1606205; Chen CH, 2011, NEUROTOX RES, V20, P15, DOI 10.1007/s12640-010-9214-y; Chevrier J, 2014, AM J EPIDEMIOL, V180, P490, DOI 10.1093/aje/kwu160; de Escobar GM, 2000, J CLIN ENDOCR METAB, V85, P3975, DOI 10.1210/jc.85.11.3975; Dong BJ, 2000, WESTERN J MED, V172, P102, DOI 10.1136/ewjm.172.2.102; Engel SM, 2018, ENVIRON HEALTH PERSP, V126, DOI [10.1289/ehp2358, 10.1289/EHP2358]; Evans IM, 2002, J ENDOCRINOL, V175, P597, DOI 10.1677/joe.0.1750597; Guo ZL, 2018, ENVIRON INT, V121, P906, DOI 10.1016/j.envint.2018.10.028; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Haugen BR, 2009, BEST PRACT RES CL EN, V23, P793, DOI 10.1016/j.beem.2009.08.003; Janssen BG, 2017, ENVIRON HEALTH PERSP, V125, P699, DOI 10.1289/EHP508; Johns LE, 2016, ENVIRON HEALTH PERSP, V124, P1808, DOI 10.1289/EHP170; Julvez J, 2013, EPIDEMIOLOGY, V24, P150, DOI 10.1097/EDE.0b013e318276ccd3; Kardas F, 2016, J CHILD NEUROL, V31, P629, DOI 10.1177/0883073815609150; Kooistra L, 2006, PEDIATRICS, V117, P161, DOI 10.1542/peds.2005-0227; Korevaar TIM, 2016, LANCET DIABETES ENDO, V4, P35, DOI 10.1016/S2213-8587(15)00327-7; Kuo FC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123884; Lavado-Autric R, 2003, J CLIN INVEST, V111, P1073, DOI 10.1172/JCI200316262; Lazarus JH, 2012, NEW ENGL J MED, V366, P493, DOI 10.1056/NEJMoa1106104; Lyall K, 2017, ENVIRON HEALTH PERSP, V125, P474, DOI 10.1289/EHP277; Moog NK, 2017, NEUROSCIENCE, V342, P68, DOI 10.1016/j.neuroscience.2015.09.070; Noten AME, 2015, EUR J ENDOCRINOL, V173, P563, DOI 10.1530/EJE-15-0397; Ornoy A, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00316; Park C, 2017, SCI TOTAL ENVIRON, V584, P950, DOI 10.1016/j.scitotenv.2017.01.144; Pop VJ, 2005, LANCET, V365, P1604, DOI 10.1016/S0140-6736(05)66489-6; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; Raz R, 2015, J AUTISM DEV DISORD, V45, P1062, DOI 10.1007/s10803-014-2262-z; Román GC, 2013, ANN NEUROL, V74, P733, DOI 10.1002/ana.23976; Seaman SR, 2014, BIOMETRICS, V70, P449, DOI 10.1111/biom.12151; Stagnaro-Green A, 2011, THYROID, V21, P1081, DOI 10.1089/thy.2011.0087; Statistics ICBo, 2008, CHAR CLASS GEOGR UN; Turyk ME, 2007, ENVIRON HEALTH PERSP, V115, P1197, DOI 10.1289/ehp.10179; Williamson JM, 2003, BIOMETRICS, V59, P36, DOI 10.1111/1541-0420.00005; Wood SN, 2011, J ROY STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x; Yau VM, 2015, J AUTISM DEV DISORD, V45, P719, DOI 10.1007/s10803-014-2227-2; Yelland LN, 2015, PAEDIATR PERINAT EP, V29, P567, DOI 10.1111/ppe.12228";43;16;19;1;17;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;1044-3983;1531-5487;;EPIDEMIOLOGY;Epidemiology;MAY;2020;31;3;;;;;409;417;;10.1097/EDE.0000000000001174;http://dx.doi.org/10.1097/EDE.0000000000001174;;;9;Public, Environmental & Occupational Health;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Public, Environmental & Occupational Health;LH5AN;32251066;;;;24/11/2024;WOS:000528798000019;View Full Record in Web of Science
J;"Ghanizadeh, A; Sahraeizadeh, A; Berk, M";;;;"Ghanizadeh, Ahmad; Sahraeizadeh, Aliakbar; Berk, Michael";;;A Head-to-Head Comparison of Aripiprazole and Risperidone for Safety and Treating Autistic Disorders, a Randomized Double Blind Clinical Trial;CHILD PSYCHIATRY & HUMAN DEVELOPMENT;;;English;Article;;;;;;"Autism; Treatment; Aripiprazole; Risperidone; Clinical trial; Randomized";"PLACEBO-CONTROLLED TRIAL; ABERRANT BEHAVIOR; CHILDREN; IRRITABILITY";Aripiprazole and risperidone are the only FDA approved medications for treating irritability in autistic disorder, however there are no head-to-head data comparing these agents. This is the first prospective randomized clinical trial comparing the safety and efficacy of these two medications in patients with autism spectrum disorders. Fifty nine children and adolescents with autism spectrum disorders were randomized to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was change in Aberrant Behavior Checklist (ABC) scores. Adverse events were assessed. Aripiprazole as well as risperidone lowered ABC scores during 2 months. The rates of adverse effects were not significantly different between the two groups. The safety and efficacy of aripiprazole (mean dose 5.5 mg/day) and risperidone (mean dose 1.12 mg/day) were comparable. The choice between these two medications should be on the basis of clinical equipoise considering the patient's preference and clinical profile.;"[Ghanizadeh, Ahmad; Sahraeizadeh, Aliakbar] Shiraz Univ Med Sci, Sch Med, Res Ctr Psychiat & Behav Sci, Shiraz, Iran; [Ghanizadeh, Ahmad; Sahraeizadeh, Aliakbar] Shiraz Univ Med Sci, Sch Med, Dept Psychiat, Shiraz, Iran; [Berk, Michael] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia; [Berk, Michael] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Orygen Res Ctr, Dept Psychiat, Melbourne, Vic, Australia";"Shiraz University of Medical Science; Shiraz University of Medical Science; Deakin University; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Orygen, The National Centre of Excellence in Youth Mental Health";Ghanizadeh, A (corresponding author), Shiraz Univ Med Sci, Sch Med, Res Ctr Psychiat & Behav Sci, Shiraz, Iran.;ghanizadeha@hotmail.com;"Berk, Michael/AGH-9427-2022; Berk, Michael/M-7891-2013";Berk, Michael/0000-0002-5554-6946;;;;"Akhondzadeh S, 2010, PROG NEURO-PSYCHOPH, V34, P32, DOI 10.1016/j.pnpbp.2009.09.012; Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P869, DOI 10.1089/cap.2005.15.869; AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD003380.pub3; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Asadabadi M, 2012, PSYCHOPHARMACOLOGY B; Curran MP, 2011, PEDIATR DRUGS, V13, P197, DOI 10.2165/11207230-000000000-00000; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Farmer CA, 2011, EXPERT OPIN PHARMACO, V12, P635, DOI 10.1517/14656566.2011.557661; Fombonne E, 2012, EVID BASED MENT HLTH, V13, P32; Ghanizadeh A, 2012, CURR MED CHEM, V19, P4000, DOI 10.2174/092986712802002572; Ghanizadeh A, 2012, MITOCHONDRION; Ghanizadeh A, 2013, J ATTEN DISORD, V17, P635, DOI 10.1177/1087054712443154; Ghanizadeh A, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-13; Hasanzadeh E, 2012, CHILD PSYCHIAT HUM D, V43, P674, DOI 10.1007/s10578-012-0292-3; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Maayan L, 2011, J CHILD ADOL PSYCHOP, V21, P517, DOI 10.1089/cap.2011.0015; Marcus RN, 2011, J CHILD ADOL PSYCHOP, V21, P229, DOI 10.1089/cap.2009.0121; McKinney C, 2011, CLIN PSYCHOL REV, V31, P465, DOI 10.1016/j.cpr.2010.11.005; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Rezaei V, 2010, PROG NEURO-PSYCHOPH, V34, P1269, DOI 10.1016/j.pnpbp.2010.07.005; Robb Adelaide S, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10m01008gry; Scott Lesley J, 2007, Paediatr Drugs, V9, P343; Varni JW, 2012, CLIN THER, V34, P980, DOI 10.1016/j.clinthera.2012.02.023";24;80;86;1;18;SPRINGER;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0009-398X;1573-3327;;CHILD PSYCHIAT HUM D;Child Psychiat. Hum. Dev.;APR;2014;45;2;;;;;185;192;;10.1007/s10578-013-0390-x;http://dx.doi.org/10.1007/s10578-013-0390-x;;;8;"Psychology, Developmental; Pediatrics; Psychiatry";Social Science Citation Index (SSCI);"Psychology; Pediatrics; Psychiatry";AB8YS;23801256;;;;24/11/2024;WOS:000332076700006;View Full Record in Web of Science
J;"Akman, OA; Girgeç, SK; Çelik, S; Kardes, VC; Atasoy, N";;;;"Akman, Oznur Adiguzel; Girgec, Sibel Kahraman; Celik, Samet; Kardes, Vildan Cakir; Atasoy, Nuray";;;Maintenance Electroconvulsive Therapy for Agitation and Self- Injurious Behaviors in Autism Spectrum Disorder;TURK PSIKIYATRI DERGISI;;;English;Article;;;;;;"Autism spectrum disorder; self-injurious behavior; maintenance electroconvulsive therapy";"CATATONIA; CHILDREN; ECT; ADOLESCENTS; PREVALENCE; SYMPTOMS";"Self-injurious behaviors (SIBs) in autism spectrum disorder (ASD) are destructive symptoms that can lead to dangerous injuries and life-threatening risks. Agitation and SIBs may not respond to psychopharmacological and behavioral interventions. There are reports in the literature on improvement after electroconvulsive therapy (ECT) in cases not responding pharmacotherapy. However, data on the efficacy of the therapy on the benefiting patients, the course of the treatment and on the use of maintenance ECT (m-ECT) are very limited. This report presents the clinical features and the course of m-ECT on two cases under follow up for pharmacotherapy resistant ASD with significant agitation, mood disorder and SIGs that could cause severe head traumas. The initial stage of therapy consisted of 7 sessions of ECT patients showed improvement after the 5th session. m-ECT were started since the agitation repeated one week after discharge despite ongoing pharmacotherapy. In the first case, m-ECT was continued once every two weeks for a total of 46 sessions; and in the second case a total of 18 weekly sessions were conducted. No significant side effects or complications were observed and the general state of well-being was preserved. Our paper is among the few that reported succesful treatment of agitation with m-ECT. m-ECT should be considered in treatment resistant cases.";"[Akman, Oznur Adiguzel] Ordu Univ, Dept Child & Adolescent Psychiat, Fac Med, Ordu, Turkey; [Girgec, Sibel Kahraman; Kardes, Vildan Cakir; Atasoy, Nuray] Bulent Ecevit Univ, Fac Med, Dept Psychiat, Zonguldak, Turkey; [Celik, Samet] BEU Hlth Applicat & Res Ctr, Psychol, Zonguldak, Turkey";"Ordu University; Zonguldak Bulent Ecevit University";Akman, OA (corresponding author), Ordu Univ, Dept Child & Adolescent Psychiat, Fac Med, Ordu, Turkey.;oznuradiguzel58@gmail.com;"Çelik, Samet/AAD-7092-2021; ÇAKIR KARDE?, V?LDAN/JQJ-2743-2023";;;;;"Ak I, 2018, TURKIYE KLINIKLERI J, V11, P71; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2008, The practice of electroconvulsive therapy: Recommendations for treatment, training, and privileging: A task force report of the American Psychiatric Association; Bilgi MM, 2010, CURRENT APPROACHES P, V2, P421; Bilici R, 2013, DUNSEN ADAM, V26, P190, DOI 10.5350/DAJPN2013260209; Breen J, 2017, J INTELL DISABIL RES, V61, P580, DOI 10.1111/jir.12362; Dhossche DM, 2006, INT REV NEUROBIOL, V72, P267, DOI 10.1016/S0074-7742(05)72016-X; Dominick KC, 2007, RES DEV DISABIL, V28, P145, DOI 10.1016/j.ridd.2006.02.003; Duerden EG, 2012, J AUTISM DEV DISORD, V42, P2460, DOI 10.1007/s10803-012-1497-9; Ellawala TI, 2015, SCHOLARLY UNDERGRADU, V1, P18; Ghaziuddin N, 2010, J ECT, V26, P274, DOI 10.1097/YCT.0b013e3181de332e; Glass OM, 2017, INT PSYCHOGERIATR, V29, P717, DOI 10.1017/S1041610216002258; Haq AU, 2014, J NEUROPSYCH CLIN N, V26, P64, DOI 10.1176/appi.neuropsych.12110284; Hare DJ, 2004, AUTISM, V8, P183, DOI 10.1177/1362361304042722; Matson JL, 2007, BEHAV MODIF, V31, P682, DOI 10.1177/0145445507301650; Mazzone L, 2014, CNS DRUGS, V28, P205, DOI 10.1007/s40263-014-0143-9; Sajith SG, 2017, J ECT, V33, P63, DOI 10.1097/YCT.0000000000000338; South M, 2005, J AUTISM DEV DISORD, V35, P145, DOI 10.1007/s10803-004-1992-8; Wachtel LE, 2008, AM J PSYCHIAT, V165, P329, DOI 10.1176/appi.ajp.2007.07081246; Wachtel LE, 2010, MED HYPOTHESES, V75, P111, DOI 10.1016/j.mehy.2010.02.001; Wachtel LE, 2009, EUR CHILD ADOLES PSY, V18, P458, DOI 10.1007/s00787-009-0754-8; Wachtel LE, 2018, CURR OPIN PSYCHIATR, V31, P116, DOI 10.1097/YCO.0000000000000393; Wachtel LE, 2010, J ECT, V26, P70, DOI 10.1097/YCT.0b013e3181a744ec; Wing L, 2000, BRIT J PSYCHIAT, V176, P357, DOI 10.1192/bjp.176.4.357; Wing L, 2006, INT REV NEUROBIOL, V72, P21, DOI 10.1016/S0074-7742(05)72002-X; Yildiz Aysegul, 2003, Turk Psikiyatri Derg, V14, P134";26;2;2;0;5;TURKIYE SINIR VE RUH SAGLIGI DERNEGI;YENISEHIR;PK 401, YENISEHIR, 06442, TURKEY;1300-2163;;;TURK PSIKIYATR DERG;Turk. Psikiyatr. Derg.;SPR;2021;32;1;;;;;65;69;;10.5080/u23768;http://dx.doi.org/10.5080/u23768;;;5;Psychiatry;Social Science Citation Index (SSCI);Psychiatry;US1IZ;34181747;gold;;;24/11/2024;WOS:000697191100010;View Full Record in Web of Science
J;"Higuchi, Y; Motoki, T; Ishida, H; Kanamitsu, K; Washio, K; Oyama, T; Noda, T; Tsurumaru, Y; Okada, A; Tsukahara, H; Shimada, A";;;;"Higuchi, Yousuke; Motoki, Takayuki; Ishida, Hisashi; Kanamitsu, Kiichiro; Washio, Kana; Oyama, Takanori; Noda, Takuo; Tsurumaru, Yasuko; Okada, Ayumi; Tsukahara, Hirokazu; Shimada, Akira";;;Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report;BMC CANCER;;;English;Article;;;;;;"Sorafenib; Pediatrics; Papillary thyroid carcinoma; Lung metastases; Autism spectrum disorder";"REFRACTORY SOLID TUMORS; PHASE-II TRIAL; CANCER; MANAGEMENT; GROWTH";"Background: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. Case presentation: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases. Total thyroidectomy and adjuvant RAI therapy is the standard treatment; however, the latter therapy was impractical because of his respiratory status and challenging behaviors. He was therefore started on sorafenib 200 mg/day (150 mg/m(2)/day) and this dosage was increased to 400 mg/day (300 mg/m(2)/day). The adverse effects were mild and tolerable. After administration of medication, his dyspnea improved and surgery was performed. We attempted to administer RAI therapy after surgery; however, we abandoned it because he had difficulty taking care of himself according to isolation room rules. Thyrotropin suppression therapy was therefore started and sorafenib treatment (400 mg/day) resumed. Follow-up imaging showed regression of pulmonary metastases. The metastases have remained stable for over 24 months on continuous sorafenib treatment without serious adverse events. Conclusion: We inevitably used sorafenib as an alternative to standard therapy because of the patient's specific circumstances. Individualized strategies for pediatric cancer patients with autism spectrum disorder are needed.";"[Higuchi, Yousuke; Ishida, Hisashi; Kanamitsu, Kiichiro; Washio, Kana; Tsurumaru, Yasuko; Shimada, Akira] Okayama Univ Hosp, Dept Pediat, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan; [Motoki, Takayuki] Okayama Univ Hosp, Dept Gen Thorac Surg & Breast & Endocrine Surg, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan; [Oyama, Takanori; Noda, Takuo] Okayama Univ Hosp, Dept Pediat Surg, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan; [Okada, Ayumi; Tsukahara, Hirokazu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan";"Okayama University; Okayama University; Okayama University; Okayama University";Shimada, A (corresponding author), Okayama Univ Hosp, Dept Pediat, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.;pajj236e@okayama-u.ac.jp;"Kanamitsu, Kiichiro/Q-9895-2019; Oyama, Takanori/K-3905-2013; Higuchi, Yousuke/ABE-7200-2020";"Washio, Kana/0000-0001-6126-0189; Ishida, Hisashi/0000-0002-3391-8403; SHIMADA, Akira/0000-0001-5207-3779; Higuchi, Yousuke/0000-0001-5253-6569";Ministry of Health, Labor and Welfare of Japan;Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan);This study was supported in part by a Grant-in-Aid for Cancer Research and a grant for Clinical Cancer Research and Research on Children and Families from the Ministry of Health, Labor and Welfare of Japan. The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing this manuscript.;"Ballester LY, 2016, PEDIATR DEVEL PATHOL, V19, P94, DOI 10.2350/15-05-1638-OA.1; Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9; Brose Marcia S, 2014, Semin Oncol, V41 Suppl 2, pS1, DOI 10.1053/j.seminoncol.2014.01.001; Carter MJ, 2014, THER RECREAT J, V48, P275; Chaukar DA, 2005, J SURG ONCOL, V92, P130, DOI 10.1002/jso.20339; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Francis GL, 2015, THYROID, V25, P716, DOI 10.1089/thy.2014.0460; Gupta-Abramson V, 2008, J CLIN ONCOL, V26, P4714, DOI 10.1200/JCO.2008.16.3279; Howlader N., 2021, SEER Cancer Statistics Review 19752018; Iyer P, 2014, THYROID, V24, P169, DOI 10.1089/thy.2012.0468; Jarzab B, 2000, EUR J NUCL MED, V27, P833, DOI 10.1007/s002590000271; Johnson Norah L, 2013, Pediatr Nurs, V39, P131; Kim A, 2015, PEDIATR BLOOD CANCER, V62, P1562, DOI 10.1002/pbc.25548; Kloos RT, 2009, J CLIN ONCOL, V27, P1675, DOI 10.1200/JCO.2008.18.2717; Murphy DA, 2006, AM J PATHOL, V169, P1875, DOI 10.2353/ajpath.2006.050711; National Cancer Institute, COMM TERM CRIT ADV E; Picarsic JL, 2016, PEDIATR DEVEL PATHOL, V19, P115, DOI 10.2350/15-07-1667-OA.1; Rivkees SA, 2011, ENDOCR REV, V32, P798, DOI 10.1210/er.2011-0011; Vaisman F, 2011, J THROID RES, V2011, DOI 10.4061/2011/845362; Voss SD, 2015, PEDIATR BLOOD CANCER, V62, P45, DOI 10.1002/pbc.25229; Waguespack SG, 2009, THYROID, V19, P407, DOI 10.1089/thy.2008.0429; Widemann BC, 2012, CLIN CANCER RES, V18, P6011, DOI 10.1158/1078-0432.CCR-11-3284; Woyach JA, 2009, ENDOCR-RELAT CANCER, V16, P715, DOI 10.1677/ERC-08-0335; Yu XM, 2013, THYROID, V23, P1263, DOI 10.1089/thy.2012.0453";25;7;10;0;4;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-2407;;BMC CANCER;BMC Cancer;nov-21;2017;17;;;;;;;;775;10.1186/s12885-017-3782-7;http://dx.doi.org/10.1186/s12885-017-3782-7;;;5;Oncology;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Oncology;FN5MN;29162036;Green Published, gold;;;24/11/2024;WOS:000416051800002;View Full Record in Web of Science
J;"Hull, MM; Madhavan, D; Zaroff, CM";;;;"Hull, Mariam Mettry; Madhavan, Deepak; Zaroff, Charles M.";;;Autistic spectrum disorder, epilepsy, and vagus nerve stimulation;CHILDS NERVOUS SYSTEM;;;English;Article;;;;;;"Autism; Vagus nerve stimulation; Epilepsy; Stereotypy";"DRUG-RESISTANT EPILEPSY; EPILEPTIFORM EEG; LONG-TERM; BEHAVIOR; THERAPY; ABNORMALITIES; CHILDREN; BASES";In individuals with a comorbid autistic spectrum disorder and medically refractory epilepsy, vagus nerve stimulation may offer the potential of seizure control and a positive behavioral side effect profile. We aimed to examine the behavioral side effect profile using longitudinal and quantitative data and review the potential mechanisms behind behavioral changes. We present a case report of a 10-year-old boy with autistic spectrum disorder and epilepsy, who underwent vagus nerve stimulation subsequent to unsuccessful treatment with antiepileptic medication. Following vagus nerve stimulation implantation, initial, if temporary, improvement was observed in seizure control. Modest improvements were also observed in behavior and development, improvements which were observed independent of seizure control. Vagus nerve stimulation in autistic spectrum disorder is associated with modest behavioral improvement, with unidentified etiology, although several candidates for this improvement are evident.;"[Hull, Mariam Mettry; Madhavan, Deepak] Nebraska Med Ctr, Nebraska Comprehens Epilepsy Program, Omaha, NE USA; [Zaroff, Charles M.] Univ Macau, Dept Psychol, Fss, Taipa, Peoples R China";"University of Nebraska System; University of Nebraska Medical Center; University of Macau";Zaroff, CM (corresponding author), Univ Macau, Dept Psychol, Ave Univ,E21-3053, Fss, Taipa, Peoples R China.;charleszaroff@umac.mo;;Hull, Mariam/0000-0002-7340-1660;;;;"Abu-Akel A, 2011, NEUROPSYCHOLOGIA, V49, P2971, DOI 10.1016/j.neuropsychologia.2011.07.012; Aldenkamp AP, 2001, EPILEPSY BEHAV, V2, P343, DOI 10.1006/ebeh.2001.0218; Aoki Y, 2015, WORLD J BIOL PSYCHIA, V16, P291, DOI 10.3109/15622975.2014.957719; Ballaban-Gil K, 2000, MENT RETARD DEV D R, V6, P300, DOI 10.1002/1098-2779(2000)6:4<300::AID-MRDD9>3.0.CO;2-R; Blackwell J, 2001, J Am Acad Nurse Pract, V13, P534; Buescher AVS, 2014, JAMA PEDIATR, V168, P721, DOI 10.1001/jamapediatrics.2014.210; Calkins SD, 2004, DEV PSYCHOBIOL, V45, P101, DOI 10.1002/dev.20020; Casanova MF, 2006, ACTA NEUROPATHOL, V112, P287, DOI 10.1007/s00401-006-0085-5; Cheshire WP, 2012, AUTON NEUROSCI-BASIC, V171, P4, DOI 10.1016/j.autneu.2012.08.003; Chez MG, 2006, EPILEPSY BEHAV, V8, P267, DOI 10.1016/j.yebeh.2005.11.001; Cohen S, 2015, J CLIN CHILD ADOLESC, V44, P250, DOI 10.1080/15374416.2013.843462; Danielsson S, 2008, EPILEPSY BEHAV, V12, P298, DOI 10.1016/j.yebeh.2007.10.007; Field T, 2008, INFANT BEHAV DEV, V31, P361, DOI 10.1016/j.infbeh.2007.12.008; Helmstaedter C, 2014, EPILEPSY BEHAV, V31, P43, DOI 10.1016/j.yebeh.2013.11.010; Kushki A, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-39; LAINHART JE, 1994, J AUTISM DEV DISORD, V24, P587, DOI 10.1007/BF02172140; Levy ML, 2010, J NEUROSURG-PEDIATR, V5, P595, DOI 10.3171/2010.3.PEDS09153; Morris GL, 1999, NEUROLOGY, V53, P1731, DOI 10.1212/WNL.53.8.1731; Murphy JV, 2000, PEDIATR NEUROL, V23, P167, DOI 10.1016/S0887-8994(00)00170-3; Nagarajan L, 2002, ACTA NEUROL SCAND, V105, P13, DOI 10.1034/j.1600-0404.2002.00129.x; Nass R, 1999, PEDIATR NEUROL, V21, P464, DOI 10.1016/S0887-8994(99)00029-6; Orosz I, 2014, EPILEPSIA, V55, P1576, DOI 10.1111/epi.12762; Parain D, 2001, PEDIATR NEUROL, V25, P213, DOI 10.1016/S0887-8994(01)00312-5; Park YD, 2003, EPILEPSY BEHAV, V4, P286, DOI 10.1016/S1525-5050(03)00080-5; Parker APJ, 1999, PEDIATRICS, V103, P778, DOI 10.1542/peds.103.4.778; Porges SW, 1996, DEV PSYCHOBIOL, V29, P697, DOI 10.1002/(SICI)1098-2302(199612)29:8<697::AID-DEV5>3.0.CO;2-O; Roberts JE, 2012, AJIDD-AM J INTELLECT, V117, P90, DOI 10.1352/1944-7558-117.2.90";27;15;17;1;29;SPRINGER;NEW YORK;ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES;0256-7040;1433-0350;;CHILD NERV SYST;Childs Nerv. Syst.;AUG;2015;31;8;;;;;1377;1385;;10.1007/s00381-015-2720-8;http://dx.doi.org/10.1007/s00381-015-2720-8;;;9;"Clinical Neurology; Pediatrics; Surgery";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics; Surgery";CN4EG;25922052;;;;24/11/2024;WOS:000358382400027;View Full Record in Web of Science
J;"Leekam, SR; Prior, MR; Uljarevic, M";;;;"Leekam, Susan R.; Prior, Margot R.; Uljarevic, Mirko";;;Restricted and Repetitive Behaviors in Autism Spectrum Disorders: A Review of Research in the Last Decade;PSYCHOLOGICAL BULLETIN;;;English;Article;;;;;;"restricted and repetitive behaviors (RRBs); autism spectrum disorders (ASDs)";"YOUNG-CHILDREN; STEREOTYPED BEHAVIORS; DIAGNOSTIC INTERVIEW; DEVELOPMENTAL TRAJECTORIES; COMMUNICATION DISORDERS; NALTREXONE TREATMENT; SOCIAL-INTERACTION; INTERESTS DOMAIN; BASAL GANGLIA; INTERVENTION";Restricted and repetitive behaviors (RRBs) are a core feature of autism spectrum disorders. They constitute a major barrier to learning and social adaptation, but research on their definition, cause, and capacity for change has been relatively neglected. The last decade of research has brought new measurement techniques that have improved the description of RRBs. Research has also identified distinctive subtypes of RRBs in autism spectrum disorders. Research on potential causal origins and immediate triggers for RRBs is still at an early stage. However, promising new ideas and evidence are emerging from neurobiology and developmental psychology that identify neural adaptation, lack of environmental stimulation, arousal, and adaptive functions as key factors for the onset and maintenance of RRBs. Further research is needed to understand how these factors interact with each other to create and sustain atypical levels of RRB. The literature indicates that RRBs have the potential to spontaneously reduce across time, and this is enhanced for those with increased age and cognitive and language ability. Research on interventions is sparse. Pharmacological treatments can be helpful in some children but have adverse side effects. Behavioral intervention methods provide the better intervention option with positive effects, but a more systematic and targeted approach is urgently needed. Evidence suggests that we will learn best from the last decade of research by taking a developmental perspective, by directing future research toward subtypes of RRBs, and by implementing early intervention targeted to improve RRBs before these behaviors become entrenched.;"[Leekam, Susan R.; Uljarevic, Mirko] Cardiff Univ, Sch Psychol, Wales Autism Res Ctr, Cardiff, S Glam, Wales; [Prior, Margot R.] Univ Melbourne, Melbourne, Vic, Australia";"Cardiff University; University of Melbourne";Leekam, SR (corresponding author), Cardiff Univ, Sch Psychol, Wales Autism Res Ctr, Tower Bldg,Pk Pl, Cardiff, S Glam, Wales.;LeekamSR@cardiff.ac.uk;;Uljarevic, Mirko/0000-0002-7481-3923;"Economic and Social Research Council, United Kingdom [RES-000-2771]; Welsh Assembly Government [SCS/09/0212]; ESRC [ES/F037821/1] Funding Source: UKRI";"Economic and Social Research Council, United Kingdom(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Welsh Assembly Government; ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))";This research was supported in part by Economic and Social Research Council, United Kingdom, Grant RES-000-2771 to Susan R. Leekam to study the development of repetitive behaviors in young children and by Welsh Assembly Government Ph.D. Grant SCS/09/0212 to Mirko Uljarevic. We thank Dale Hay for helpful comments and Anastasia Kourkoulou, Beverley Winn, and Chris Ramsden for help with preparation of the article.;"Alarcón M, 2002, AM J HUM GENET, V70, P60, DOI 10.1086/338241; Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P116, DOI 10.1089/cap.2005.15.116; [Anonymous], 2009, NAT STAND REP ADDR N; [Anonymous], THESIS FLORIDA STATE; [Anonymous], 2010, AUTISM DIAGNOSTIC OB; Arnold PD, 2006, ARCH GEN PSYCHIAT, V63, P769, DOI 10.1001/archpsyc.63.7.769; Arnott B, 2010, J DEV BEHAV PEDIATR, V31, P223, DOI 10.1097/DBP.0b013e3181d5a2ad; Asperger H, 1944, ARCH PSYCHIAT NERVEN, V117, P76, DOI 10.1007/BF01837709; Asperger H., 1991, AUTISM ASPERGER SYND, P37; Attwood T, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P126; Barrett S, 2004, AUTISM, V8, P61, DOI 10.1177/1362361304040640; Ben Itzchak E, 2008, RES DEV DISABIL, V29, P447, DOI 10.1016/j.ridd.2007.08.003; Ben Itzchak E, 2009, RES AUTISM SPECT DIS, V3, P967, DOI 10.1016/j.rasd.2009.05.001; Ben-Itzchak E, 2007, RES DEV DISABIL, V28, P287, DOI 10.1016/j.ridd.2006.03.002; BENJAMIN S, 1995, J AM ACAD CHILD PSY, V34, P238, DOI 10.1097/00004583-199502000-00020; Berkson G, 2000, J EARLY INTERVENTION, V23, P1, DOI 10.1177/10538151000230010401; Bishop S., 2010, 242 SOC RES CHILD DE; Bishop SL, 2006, CHILD NEUROPSYCHOL, V12, P247, DOI 10.1080/09297040600630288; Bodfish J.W., 1999, REPETITIVE BEHAV SCA, DOI DOI 10.1037/T17338-000; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Boyd BA, 2010, AUTISM RES, V3, P78, DOI 10.1002/aur.124; Boyd BA, 2009, RES AUTISM SPECT DIS, V3, P959, DOI 10.1016/j.rasd.2009.05.003; Brian JA, 2003, J CHILD PSYCHOL PSYC, V44, P552, DOI 10.1111/1469-7610.00144; Brodkin ES, 1997, J CHILD ADOL PSYCHOP, V7, P109, DOI 10.1089/cap.1997.7.109; Bryson SE, 2008, J AUTISM DEV DISORD, V38, P731, DOI 10.1007/s10803-007-0440-y; Carcani-Rathwell I, 2006, J CHILD PSYCHOL PSYC, V47, P573, DOI 10.1111/j.1469-7610.2005.01565.x; Charman T, 2005, J CHILD PSYCHOL PSYC, V46, P500, DOI 10.1111/j.1469-7610.2004.00377.x; Chen YH, 2009, J AUTISM DEV DISORD, V39, P635, DOI 10.1007/s10803-008-0663-6; Clark C, 2002, J CHILD PSYCHOL PSYC, V43, P785, DOI 10.1111/1469-7610.00084; Cohen SA, 2004, J CLIN PSYCHIAT, V65, P110; Constantino JN, 2004, J CHILD PSYCHOL PSYC, V45, P719, DOI 10.1111/j.1469-7610.2004.00266.x; Cox A, 1999, J CHILD PSYCHOL PSYC, V40, P719, DOI 10.1111/1469-7610.00488; Cuccaro ML, 2007, CHILD PSYCHIAT HUM D, V37, P347, DOI 10.1007/s10578-007-0052-y; Cuccaro ML, 2003, CHILD PSYCHIAT HUM D, V34, P3, DOI 10.1023/A:1025321707947; Dawson G, 2008, DEV PSYCHOPATHOL, V20, P775, DOI 10.1017/S0954579408000370; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; Di Giovanni G, 2006, CURR MED CHEM, V13, P3069, DOI 10.2174/092986706778521805; DILAVORE PC, 1995, J AUTISM DEV DISORD, V25, P355, DOI 10.1007/BF02179373; Durand V.M., 1988, The Motivation Assessment Scale (MAS) administrative guide; ElChaar GM, 2006, ANN PHARMACOTHER, V40, P1086, DOI 10.1345/aph.1G499; Eldevik S, 2006, J AUTISM DEV DISORD, V36, P211, DOI 10.1007/s10803-005-0058-x; Esbensen AJ, 2009, J AUTISM DEV DISORD, V39, P57, DOI 10.1007/s10803-008-0599-x; Evans DW, 1997, CHILD DEV, V68, P58, DOI 10.2307/1131925; Evans DW, 2004, BRAIN COGNITION, V55, P220, DOI 10.1016/s0278-2626(03)00274-4; Evans DW, 1999, CHILD PSYCHIAT HUM D, V29, P261, DOI 10.1023/A:1021392931450; Fecteau S, 2003, AUTISM, V7, P255, DOI 10.1177/13623613030073003; Findling RL, 2002, J CLIN PSYCHIAT, V63, P27; Frith U., 2003, Autism: Explaining the enigma, V1st and 2nd; Gabriels RL, 2005, RES DEV DISABIL, V26, P169, DOI 10.1016/j.ridd.2004.05.003; Gabriels RL, 2008, RES AUTISM SPECT DIS, V2, P660, DOI 10.1016/j.rasd.2008.02.002; Gardenier NC, 2004, RES DEV DISABIL, V25, P99, DOI 10.1016/j.ridd.2003.05.004; Gesell A., 1974, INFANT CHILD CULTURE; Gillott A, 2001, AUTISM, V5, P277, DOI 10.1177/1362361301005003005; Goldman S, 2009, DEV MED CHILD NEUROL, V51, P30, DOI 10.1111/j.1469-8749.2008.03178.x; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Gottlieb G, 2007, DEVELOPMENTAL SCI, V10, P1, DOI 10.1111/j.1467-7687.2007.00556.x; Greaves N, 2006, J INTELL DISABIL RES, V50, P92, DOI 10.1111/j.1365-2788.2005.00726.x; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Happe F., 1994, Autism: An introduction to psychological theory; Happé F, 2006, NAT NEUROSCI, V9, P1218, DOI 10.1038/nn1770; Happe Francesca, 2008, Neuropsychol Rev, V18, P287, DOI 10.1007/s11065-008-9076-8; HAY D, 1993, PRECURSORS CAUSES DE; Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627; HONEY E, AUTISM INT IN PRESS; Honey E, 2008, J AUTISM DEV DISORD, V38, P1439, DOI 10.1007/s10803-006-0191-1; Honey E, 2007, J AUTISM DEV DISORD, V37, P1107, DOI 10.1007/s10803-006-0253-4; Horner RH, 2002, J AUTISM DEV DISORD, V32, P423, DOI 10.1023/A:1020593922901; Howlin P, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P269; Howlin P, 2009, AJIDD-AM J INTELLECT, V114, P23, DOI 10.1352/2009.114:23;nd41; Hus V, 2007, BIOL PSYCHIAT, V61, P438, DOI 10.1016/j.biopsych.2006.08.044; HUTT C, 1965, ANIM BEHAV, V13, P1, DOI 10.1016/0003-3472(65)90064-3; Iverson JM, 2007, J AUTISM DEV DISORD, V37, P158, DOI 10.1007/s10803-006-0339-z; Joosten AV, 2009, J AUTISM DEV DISORD, V39, P521, DOI 10.1007/s10803-008-0654-7; Kamp-Becker I, 2009, J AUTISM DEV DISORD, V39, P557, DOI 10.1007/s10803-008-0656-5; KANNER L, 1968, ACTA PAEDOPSYCHIATR, V35, P100; Kanner L., 1973, Childhood psychosis: Initial studies and new insights. Wiley; Kim SH, 2010, AUTISM RES, V3, P162, DOI 10.1002/aur.142; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lam KSL, 2008, J CHILD PSYCHOL PSYC, V49, P1193, DOI 10.1111/j.1469-7610.2008.01944.x; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Langen M, 2011, NEUROSCI BIOBEHAV R, V35, P356, DOI 10.1016/j.neubiorev.2010.02.005; Langen M, 2011, NEUROSCI BIOBEHAV R, V35, P345, DOI 10.1016/j.neubiorev.2010.02.004; Langen M, 2009, BIOL PSYCHIAT, V66, P327, DOI 10.1016/j.biopsych.2009.03.017; Lee S, 2007, J POSIT BEHAV INTERV, V9, P67, DOI 10.1177/10983007070090020401; LEEKAM SR, 2009, M SOC RES CHILD DEV; Leekam S, 2007, J CHILD PSYCHOL PSYC, V48, P1131, DOI 10.1111/j.1469-7610.2007.01778.x; Lewis M, 2009, J NEURODEV DISORD, V1, P114, DOI 10.1007/s11689-009-9019-6; Lewis MH, 2007, BEHAV BRAIN RES, V176, P66, DOI 10.1016/j.bbr.2006.08.023; Liss M, 2001, J AUTISM DEV DISORD, V31, P219, DOI 10.1023/A:1010707417274; Loftin RL, 2008, J AUTISM DEV DISORD, V38, P1124, DOI 10.1007/s10803-007-0499-5; Logan LR, 2008, DEV MED CHILD NEUROL, V50, P99, DOI 10.1111/j.1469-8749.2007.02005.x; Loh A, 2007, J AUTISM DEV DISORD, V37, P25, DOI 10.1007/s10803-006-0333-5; Lord C, 2006, ARCH GEN PSYCHIAT, V63, P694, DOI 10.1001/archpsyc.63.6.694; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 2006, CLIN NEUROSCI RES, V6, P189, DOI 10.1016/j.cnr.2006.06.005; LOVAAS I, 1987, J APPL BEHAV ANAL, V20, P45, DOI 10.1901/jaba.1987.20-45; MacDonald R, 2007, RES DEV DISABIL, V28, P266, DOI 10.1016/j.ridd.2006.01.004; Mandy WPL, 2008, J CHILD PSYCHOL PSYC, V49, P795, DOI 10.1111/j.1469-7610.2008.01911.x; Martin A, 1999, J CHILD ADOL PSYCHOP, V9, P99, DOI 10.1089/cap.1999.9.99; Matson JL, 2009, DEV NEUROREHABIL, V12, P122, DOI 10.1080/17518420902936730; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Mccracken JT, 2005, AM J PSYCHIAT, V162, P1361; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Militerni R, 2002, EUR CHILD ADOLES PSY, V11, P210, DOI 10.1007/s00787-002-0279-x; Miller LJ, 2007, AM J OCCUP THER, V61, P135, DOI 10.5014/ajot.61.2.135; Mirenda P, 2010, J AUTISM DEV DISORD, V40, P1521, DOI 10.1007/s10803-010-1012-0; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Mooney EL, 2009, J AUTISM DEV DISORD, V39, P765, DOI 10.1007/s10803-008-0680-5; Moore V, 2003, AUTISM, V7, P47, DOI 10.1177/1362361303007001018; Morgan LW, 2008, J AVIAN BIOL, V39, P584, DOI 10.1111/j.0908-8857.2008.04269.x; Moss J., 2008, REPETITIVE BEHAV SCA; MOSS J, 2005, THESIS U BIRMINGHAM; Moss J, 2009, J AUTISM DEV DISORD, V39, P572, DOI 10.1007/s10803-008-0655-6; Mullen EM., 1995, MULLEN SCALES EARLY; Murphy GH, 2005, J AUTISM DEV DISORD, V35, P405, DOI 10.1007/s10803-005-5030-2; ORNITZ EM, 1968, ARCH GEN PSYCHIAT, V18, P76; Ozonoff S., 2000, AUTISM, V4, P29; Ozonoff S, 2008, AUTISM, V12, P457, DOI 10.1177/1362361308096402; Papageorgiou V, 2008, J AUTISM DEV DISORD, V38, P558, DOI 10.1007/s10803-007-0409-x; Patterson SY, 2010, DEV MED CHILD NEUROL, V52, P318, DOI 10.1111/j.1469-8749.2009.03597.x; Piaget J., 1952, ORIGINS INTELLIGENCE, DOI [10.1037/11494-000, DOI 10.1037/11494-000]; PRIOR M, 1973, J AUTISM CHILD SCHIZ, V3, P154, DOI 10.1007/BF01537990; Prior M, 2007, CA CH AD PS, P69, DOI 10.1017/CBO9780511544446.004; Rapp JT, 2005, RES DEV DISABIL, V26, P548, DOI 10.1016/j.ridd.2004.11.006; Richler J, 2007, J AUTISM DEV DISORD, V37, P73, DOI 10.1007/s10803-006-0332-6; Richler J, 2010, DEV PSYCHOPATHOL, V22, P55, DOI 10.1017/S0954579409990265; Robins DL, 2001, J AUTISM DEV DISORD, V31, P131, DOI 10.1023/A:1010738829569; Rogers S.J., 2009, EARLY START DENVER M; Rogers SJ, 2009, AUTISM RES, V2, P125, DOI 10.1002/aur.81; Rojas DC, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-56; Ronald A, 2005, DEVELOPMENTAL SCI, V8, P444, DOI 10.1111/j.1467-7687.2005.00433.x; Ronald A, 2006, J AM ACAD CHILD PSY, V45, P1206, DOI 10.1097/01.chi.0000230165.54117.41; Ronald A, 2010, BEHAV GENET, V40, P31, DOI 10.1007/s10519-009-9308-6; Russell J. E., 1997, Autism as an executive disorder; Rutter M, 1999, J CHILD PSYCHOL PSYC, V40, P537, DOI 10.1111/1469-7610.00472; Rutter M, 2007, J CHILD PSYCHOL PSYC, V48, P1200, DOI 10.1111/j.1469-7610.2007.01792.x; Sallows GO, 2005, AM J MENT RETARD, V110, P417, DOI 10.1352/0895-8017(2005)110[417:IBTFCW]2.0.CO;2; Sanchez LE, 1996, J AM ACAD CHILD PSY, V35, P537, DOI 10.1097/00004583-199604000-00021; Schneider T, 2006, NEUROPSYCHOPHARMACOL, V31, P36, DOI 10.1038/sj.npp.1300767; Schoen SA, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.029.2009; Sears LL, 1999, PROG NEURO-PSYCHOPH, V23, P613, DOI 10.1016/S0278-5846(99)00020-2; Shao YJ, 2003, AM J HUM GENET, V72, P539, DOI 10.1086/367846; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Sofronoff K, 2007, J AUTISM DEV DISORD, V37, P1203, DOI 10.1007/s10803-006-0262-3; Soorya L, 2008, CHILD ADOL PSYCH CL, V17, P753, DOI 10.1016/j.chc.2008.06.003; South M, 2005, J AUTISM DEV DISORD, V35, P145, DOI 10.1007/s10803-004-1992-8; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Spence S.H., 1995, SOCIAL SKILLS TRAINI; Spence SH, 1998, BEHAV RES THER, V36, P545, DOI 10.1016/S0005-7967(98)00034-5; Stone WL, 1999, J CHILD PSYCHOL PSYC, V40, P219, DOI 10.1111/1469-7610.00435; Sutcliffe JS, 2005, AM J HUM GENET, V77, P265, DOI 10.1086/432648; Symons FJ, 2004, MENT RETARD DEV D R, V10, P193, DOI 10.1002/mrdd.20031; Szatmari P, 2000, AM J PSYCHIAT, V157, P1980, DOI 10.1176/appi.ajp.157.12.1980; Szatmari P, 2006, J CHILD PSYCHOL PSYC, V47, P582, DOI 10.1111/j.1469-7610.2005.01537.x; Thakkar KN, 2008, BRAIN, V131, P2464, DOI 10.1093/brain/awn099; THELEN E, 1981, DEV PSYCHOL, V17, P237, DOI 10.1037/0012-1649.17.3.237; THELEN E, 1979, ANIM BEHAV, V27, P699, DOI 10.1016/0003-3472(79)90006-X; TINBERGEN N., 1951, STUDY INSTINCT; Tonge B., 1999, Autism, V3, P117; Tregay J, 2009, BRIT J DEV PSYCHOL, V27, P283, DOI 10.1348/026151008X299737; Turner M, 1999, J CHILD PSYCHOL PSYC, V40, P839, DOI 10.1017/S0021963099004278; Turner M., 1997, Autism as an executive disorder, P57, DOI DOI 10.1111/1469-7610.00502; Turner M, 1995, Repetitive behavior and cognitive functioning in autism; Ventola PE, 2006, J AUTISM DEV DISORD, V36, P839, DOI 10.1007/s10803-006-0128-8; Vollmer TR, 1996, RES DEV DISABIL, V17, P229, DOI 10.1016/0891-4222(96)00006-6; Watt N, 2008, J AUTISM DEV DISORD, V38, P1518, DOI 10.1007/s10803-007-0532-8; Weeden M, 2009, RES AUTISM SPECT DIS, V3, P905, DOI 10.1016/j.rasd.2009.06.004; Werner E, 2005, ARCH GEN PSYCHIAT, V62, P889, DOI 10.1001/archpsyc.62.8.889; Wetherby A. M., 2002, Communication and symbolic behavior scales: Developmental profile; White SW, 2009, J AUTISM DEV DISORD, V39, P1006, DOI 10.1007/s10803-009-0713-8; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; Wing L, 2002, J CHILD PSYCHOL PSYC, V43, P307, DOI 10.1111/1469-7610.00023; WING L, 1996, CLIN DEV MED, V139, P268; Wink LK, 2010, CURR TREAT OPTION NE, V12, P529, DOI 10.1007/s11940-010-0091-8; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x; World Health Organization, 1993, INT CLASS MENT BEH D; Yerys BE, 2009, AUTISM, V13, P523, DOI 10.1177/1362361309335716; Yirmiya N, 2010, J CHILD PSYCHOL PSYC, V51, P432, DOI 10.1111/j.1469-7610.2010.02214.x; Zandt F, 2007, J AUTISM DEV DISORD, V37, P251, DOI 10.1007/s10803-006-0158-2; Zandt F, 2009, AUTISM, V13, P43, DOI 10.1177/1362361308097120";182;334;458;2;157;AMER PSYCHOLOGICAL ASSOC;WASHINGTON;750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA;0033-2909;1939-1455;;PSYCHOL BULL;Psychol. Bull.;JUL;2011;137;4;;;;;562;593;;10.1037/a0023341;http://dx.doi.org/10.1037/a0023341;;;32;"Psychology; Psychology, Multidisciplinary";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychology;787WP;21574682;Green Accepted;;;24/11/2024;WOS:000292407700003;View Full Record in Web of Science
J;"Klaiman, C; Huffman, L; Masaki, L; Elliott, GR";;;;"Klaiman, Cheryl; Huffman, Lynne; Masaki, Lauren; Elliott, Glen R.";;;Tetrahydrobiopterin as a Treatment for Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled Trial;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"ABERRANT BEHAVIOR CHECKLIST; CHILDREN";"Objective: The purpose of this study was to determine if tetrahydrobiopterin (BH4) reduced core symptoms of autism spectrum disorder (ASD). Method: In this study, 46 children, 3-7 years of age diagnosed with an ASD were randomly assigned to double-blind treatment with 20mg/kg/day BH4 or placebo for 16 weeks. The primary outcome measure was the Clinical Global Impressions Improvement and Severity Scales (CGI-I and CGI-S); secondary outcomes were the Preschool Language Scale-4 (PLS-4), Social Responsiveness Scale (SRS), Aberrant Behavior Checklist (ABC), and Vineland Adaptive Behavior Scales (Vineland). Results: Overall, no differences were found on global improvement as measured with the CGI-I or CGI-S. Secondary measures indicated significant improvements for BH4 relative to placebo with regard to social awareness, autism mannerisms, hyperactivity, and inappropriate speech. Side effects were minimal and similar between both active medication and placebo. Conclusions: These results indicate that BH4 offers promise in reducing symptoms of ASD. Clinical Trials.gov Identifier: NCT00850070.";"[Klaiman, Cheryl] Emory Univ, Sch Med, Marcus Autism Ctr, Childrens Healthcare Atlanta, Atlanta, GA USA; [Klaiman, Cheryl] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Huffman, Lynne; Masaki, Lauren; Elliott, Glen R.] Stanford Univ, Sch Med, Stanford, CA USA; [Elliott, Glen R.] Childrens Hlth Council, Palo Alto, CA USA";"Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Stanford University";Klaiman, C (corresponding author), Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA.;cheryl.klaiman@emory.edu;;;BioMarin Pharmaceutical, Inc. [CHC0901];BioMarin Pharmaceutical, Inc.;This research was funded by BioMarin Pharmaceutical, Inc. as an investigator initiated study (#CHC0901).;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 1990, KISO RINSHOU; [Anonymous], 2017, Statistical Issues in Drug Research and Development, DOI DOI 10.1201/9780203738610; [Anonymous], 2010, AUTISM DIAGNOSTIC OB; [Anonymous], 1990, Rinsho Iyaku; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; [Anonymous], BRAIN DEV; Boyle CA, 2011, PEDIATRICS, V127, P1034, DOI 10.1542/peds.2010-2989; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Constantino J., 2002, SOCIAL RESPONSIVENES; Danfors T, 2005, J CLIN PSYCHOPHARM, V25, P485, DOI 10.1097/01.jcp.0000177667.35016.e9; Fernell E, 1997, DEV MED CHILD NEUROL, V39, P313; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.14; Frye RE, 2010, NEUROTHERAPEUTICS, V7, P241, DOI 10.1016/j.nurt.2010.05.004; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Huffman LC, 2011, J DEV BEHAV PEDIATR, V32, P56, DOI 10.1097/DBP.0b013e3182040acf; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Moshfegh Alanna J., 2012, Morbidity and Mortality Weekly Report, V61, P92; NARUSE H, 1987, P JPN ACAD B-PHYS, V63, P231, DOI 10.2183/pjab.63.231; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Vismara LA, 2010, ANNU REV CLIN PSYCHO, V6, P447, DOI 10.1146/annurev.clinpsy.121208.131151; Warren Z, 2011, PEDIATRICS, V127, pE1303, DOI 10.1542/peds.2011-0426; Zimmerman I.L., 2002, PRESCHOOL LANGUAGE S, VFourth";28;45;54;0;12;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;JUN;2013;23;5;;;;;320;328;;10.1089/cap.2012.0127;http://dx.doi.org/10.1089/cap.2012.0127;;;9;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";168LJ;23782126;;;;24/11/2024;WOS:000320707000004;View Full Record in Web of Science
J;"Alaghband-Rad, J; Nikvarz, N; Tehrani-Doost, M; Ghaeli, P";;;;"Alaghband-Rad, Javad; Nikvarz, Naemeh; Tehrani-Doost, Mehdi; Ghaeli, Padideh";;;Memantine-induced speech problems in two patients with autistic disorder;DARU-JOURNAL OF PHARMACEUTICAL SCIENCES;;;English;Article;;;;;;"Stuttering; Autism spectrum disorder; Memantine";"ADOLESCENTS; TOPIRAMATE; CHILDREN; THERAPY; APHASIA";Stuttering is a complex speech disorder. There are two forms of stuttering: developmental stuttering and acquired stuttering. Developmental stuttering is a disorder of early childhood but acquired stuttering can develop at any age. Some medications can induce or deteriorate stuttering as an adverse effect. There are several reports of stuttering due to psychotropic drugs. Memantine, a glutamate antagonist used in the treatment of Alzheimer's disease, has also been studied for the treatment of autism spectrum disorders. This report presents deterioration of stuttering and speech problem in two children with autistic disorder who were receiving memantine. Based on our knowledge, this is the first time these adverse drug reactions have been attributed to memantine. In conclusion clinicians should consider that speech problems including stuttering may be due to the consumption of memantine, especially, in children may be a side effect of memantine especially in children.;"[Alaghband-Rad, Javad; Tehrani-Doost, Mehdi] Univ Tehran Med Sci, Roozbeh Hosp, Fac Med, Dept Psychiat, Tehran, Iran; [Nikvarz, Naemeh] Kerman Univ Med Sci, Fac Pharm, Dept Pharmacotherapy, Kerman, Iran; [Ghaeli, Padideh] Univ Tehran Med Sci, Fac Pharm, Res Ctr Rat Use Drugs, Tehran, Iran; [Ghaeli, Padideh] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran";"Tehran University of Medical Sciences; Kerman University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences";Ghaeli, P (corresponding author), Univ Tehran Med Sci, Fac Pharm, Res Ctr Rat Use Drugs, Tehran, Iran.;mmppg@yahoo.com;"Alaghband-rad, Javad/AAV-8517-2020; Tehrani-Doost, Mehdi/J-9596-2012; Nikvarz, Naemeh/AAB-4105-2019; Alaghband Rad, Javad/S-7846-2017";"Nikvarz, Naemeh/0000-0002-0144-3415; Alaghband Rad, Javad/0000-0002-1488-8456";;;;"Aukst-Margetic B, 2008, PSYCHIAT CLIN NEUROS, V62, P748, DOI 10.1111/j.1440-1819.2008.01878.x; Bär KJ, 2004, PHARMACOPSYCHIATRY, V37, P131, DOI 10.1055/s-2004-818992; Berthier ML, 2009, ANN NEUROL, V65, P577, DOI 10.1002/ana.21597; Brady JP, 1998, J CLIN PSYCHOPHARM, V18, P50, DOI 10.1097/00004714-199802000-00008; BURD L, 1991, J CLIN PSYCHOPHARM, V11, P72, DOI 10.1097/00004714-199102000-00020; Chez MG, 2007, J CHILD NEUROL, V22, P574, DOI 10.1177/0883073807302611; Costa D, 2000, CAN MED ASSOC J, V162, P1849; Demouy J, 2011, RES AUTISM SPECT DIS, V5, P1402, DOI 10.1016/j.rasd.2011.01.026; Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9; Fetterolf F, 2012, GEN HOSP PSYCHIAT, DOI DOI 10.1016/J.GENH0SPPSYCH.2012.07.003; FISH CH, 1965, CALIF MED, V103, P337; Gross-Tsur V, 2004, NEUROLOGY, V62, P299, DOI 10.1212/01.WNL.0000103285.85821.B3; Grover S, 2012, GEN HOSP PSYCHIAT, V34; Gulack Brian C, 2011, Ann Pharmacother, V45, pe57, DOI 10.1345/aph.1Q140; Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3; Kaplan PW, 2011, EPILEPSY BEHAV, V21, P191, DOI 10.1016/j.yebeh.2011.03.028; Lavid N, 1999, Ann Clin Psychiatry, V11, P233, DOI 10.1023/A:1022365513865; Maguire G.A., 2012, Journal of Experimental and Clinical Medicine, V4, P92, DOI [DOI 10.1016/J.JECM.2012.02.001, 10.1016/j.jecm.2012.02.001]; Maguire Gerald A, 2004, Ann Clin Psychiatry, V16, P63, DOI 10.1080/10401230490452834; Makino KM, 2011, AGING HLTH, V7, P342; Niederhofer H, 2007, J CLIN PSYCHOPHARM, V27, P317, DOI 10.1097/01.jcp.0000270082.30500.69; Owley T, 2006, J CHILD ADOL PSYCHOP, V16, P517, DOI 10.1089/cap.2006.16.517; Paul R, 2005, J AUTISM DEV DISORD, V35, P861, DOI 10.1007/s10803-005-0031-8; Shriberg LD, 2001, J SPEECH LANG HEAR R, V44, P1097, DOI 10.1044/1092-4388(2001/087); Whitehouse AJO, 2008, J COMMUN DISORD, V41, P319, DOI 10.1016/j.jcomdis.2008.01.002; Yadav DS, 2010, GEN HOSP PSYCHIAT, V32; Yairi E, 2013, J FLUENCY DISORD, V38, P66, DOI 10.1016/j.jfludis.2012.11.002";27;7;8;0;15;SPRINGER INTERNATIONAL PUBLISHING AG;CHAM;GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND;;2008-2231;;DARU;DARU;juil-02;2013;21;;;;;;;;54;10.1186/2008-2231-21-54;http://dx.doi.org/10.1186/2008-2231-21-54;;;3;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;183SD;23819879;Green Published;;;24/11/2024;WOS:000321836600001;View Full Record in Web of Science
J;"Häge, A; Banaschewski, T; Buitelaar, JK; Dijkhuizen, RM; Franke, B; Lythgoe, DJ; Mechler, K; Williams, SCR; Dittmann, RW";;;;"Haege, Alexander; Banaschewski, Tobias; Buitelaar, Jan K.; Dijkhuizen, Rick M.; Franke, Barbara; Lythgoe, David J.; Mechler, Konstantin; Williams, Steven C. R.; Dittmann, Ralf W.";;TACTICS Consortium;Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial;TRIALS;;;English;Article;;;;;;"Glutamate; Memantine; Obsessive-compulsive disorder; Autism; Pilot trial; Psychopharmacology; Child and adolescent psychiatry";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ABERRANT BEHAVIOR CHECKLIST; MEMANTINE AUGMENTATION; DIAGNOSTIC INTERVIEW; SOCIAL-BEHAVIOR; SERUM-LEVELS; CHILDREN; RELIABILITY; DYSFUNCTION; SCALE";Background: Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence. Despite the effectiveness of serotonergic compounds in the treatment of obsessive-compulsive disorder, treatment-resistant symptoms remaining in 40 to 60 % of patients present a pressing clinical problem. There are currently no medications that effectively treat the core impairments of autism spectrum disorder. There is an urgent need for the development of conceptually novel pharmacological strategies. Agents targeting glutamate neurotransmission, such as memantine, represent promising candidates. This proof-of-concept clinical study will allow pilot-testing of memantine for both clinical effectiveness and tolerability/safety. Memantine is an N-methyl-D-aspartate receptor antagonist, approved for the treatment of Alzheimer's dementia in a number of countries. Methods/Design: This 12-week study has an add-on, randomised, double-blind, placebo-controlled design of treatment with memantine, including an up-titration phase (forced flexible dose design, 5-15 mg/day), in patients aged 6-17 years and 9 months with obsessive-compulsive disorder or autism spectrum disorder. It is planned to include patients with obsessive-compulsive disorder (N = 50) or autism spectrum disorder (N = 50) across four centres in three European countries. Patients will be randomly assigned to memantine or placebo in a 1:1 ratio. Primary objectives are the investigation of the effectiveness of memantine in paediatric patients for improving symptoms of compulsivity (primary outcome measure: total score on the Children's Yale-Brown Obsessive-Compulsive Scale) and to explore its tolerability and safety. Secondary objectives are to explore the effects of memantine at the level of structure, function and biochemistry of the fronto-striatal circuits, and to collect blood for genetic analyses and biomarkers. Tertiary objectives are to explore the role of new candidate genes and pathways for compulsivity by linking genes to clinical phenotypes, response to treatment, neurocognitive test performance, and key structural and functional neuroimaging measures of the fronto-striatal circuits and to explore biomarkers/proteomics for compulsivity traits. Discussion: This study is part of the large, translational project TACTICS (http://www.tactics-project.eu/) that is funded by the European Union and investigates the neural, genetic and molecular factors involved in the pathogenesis of compulsivity. Its results will provide clinically relevant solid information on potential new mechanisms and medication treatment in obsessive-compulsive and autism spectrum disorders.;"[Haege, Alexander; Mechler, Konstantin; Dittmann, Ralf W.] Heidelberg Univ, Paediat Psychopharmacol, Dept Child & Adolescent Psychiat & Psychotherapy, Cent Inst Mental Hlth,Med Fac Mannheim, POB 12 21 20, D-68072 Mannheim, Germany; [Banaschewski, Tobias] Heidelberg Univ, Dept Child & Adolescent Psychiat & Psychotherapy, Cent Inst Mental Hlth, Med Fac Mannheim, D-68072 Mannheim, Germany; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Dept Cognit Neurosci, Donders Inst Brain Cognit & Behav, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Dijkhuizen, Rick M.] Univ Med Ctr Utrecht, Biomed MR Imaging & Spect Grp, Ctr Image Sci, Utrecht, Netherlands; [Franke, Barbara] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Franke, Barbara] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Psychiat, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Lythgoe, David J.; Williams, Steven C. R.] Kings Coll London, Dept Neuroimaging, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England";"Ruprecht Karls University Heidelberg; Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Central Institute of Mental Health; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; Radboud University Nijmegen; University of London; King's College London";Häge, A (corresponding author), Heidelberg Univ, Paediat Psychopharmacol, Dept Child & Adolescent Psychiat & Psychotherapy, Cent Inst Mental Hlth,Med Fac Mannheim, POB 12 21 20, D-68072 Mannheim, Germany.;alexander.haege@zi-mannheim.de;"Banaschewski, Tobias/ABE-5985-2020; Buitelaar, Jan/AAY-7522-2020; Mechler, Konstantin/AAH-4678-2020; Lythgoe, David/E-5275-2010; Williams, Steve/D-6979-2011; Franke, Barbara/D-4836-2009";"Banaschewski, Tobias/0000-0003-4595-1144; Donner, Nina/0000-0003-0548-1408; Williams, Steve/0000-0003-4299-1941; Lythgoe, David/0000-0002-5078-9025; Dijkhuizen, Rick/0000-0002-4623-4078; Bruchhage, Muriel/0000-0001-9637-0951; Franke, Barbara/0000-0003-4375-6572";European Community's Seventh Framework Programme (FP7) [278948];European Community's Seventh Framework Programme (FP7)(European Union (EU));The research leading to this study protocol has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number 278948 (TACTICS project). This manuscript reflects only the authors' views and the European Union is not liable for any use that may be made of the information contained therein.;"Aboujaoude E, 2009, J CLIN PSYCHOPHARM, V29, P51, DOI 10.1097/JCP.0b013e318192e9a4; Achenbach T., 2001, MANUAL ASEBA SCH AGE; Achenbach TM., 1991, Manual for the Youth Self-Report and 1991 profile; AMAN MG, 1995, AM J MENT RETARD, V100, P283; AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; Andersen SL, 2010, BIOL PSYCHIAT, V68, P741, DOI 10.1016/j.biopsych.2010.05.011; Anholt GE, 2014, PSYCHOL MED, V44, P185, DOI 10.1017/S0033291713000470; [Anonymous], 2002, VRAGENLIJST INVENTAR; [Anonymous], VISK HERZIENE HANDLE; [Anonymous], 1985, PSYCHOPHARMACOL BULL, V21, P839; [Anonymous], CPMPICH37795 EUR MED; [Anonymous], 2007, SCI P 2007 ANN M AM; [Anonymous], 2015, Current Medicinal Chemistry; [Anonymous], 1976, ECDEU ASSESSMENT MAN; Arnold PD, 2009, PSYCHIAT RES-NEUROIM, V172, P136, DOI 10.1016/j.pscychresns.2009.02.005; Barnby G, 2005, AM J HUM GENET, V76, P950, DOI 10.1086/430454; Behl A, 2010, NEUROPSYCHOBIOLOGY, V61, P210, DOI 10.1159/000306591; Bethea TC, 2007, BIOL PSYCHIAT, V61, P521, DOI 10.1016/j.biopsych.2006.09.021; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Bralten J, 2011, AM J PSYCHIAT, V168, P1083, DOI 10.1176/appi.ajp.2011.10101509; Britton JC, 2010, J AM ACAD CHILD PSY, V49, P944, DOI 10.1016/j.jaac.2010.05.006; Carlsson ML, 1998, J NEURAL TRANSM, V105, P525, DOI 10.1007/s007020050076; Carter MJ, 2014, THER RECREAT J, V48, P275; Chakrabarty K, 2005, NEUROPSYCHOPHARMACOL, V30, P1735, DOI 10.1038/sj.npp.1300733; Chamberlain SR, 2006, AM J PSYCHIAT, V163, P1282, DOI 10.1176/appi.ajp.163.7.1282; Chez MG, 2007, J CHILD NEUROL, V22, P574, DOI 10.1177/0883073807302611; Coric V, 2005, BIOL PSYCHIAT, V58, P424, DOI 10.1016/j.biopsych.2005.04.043; Coric V, 2003, PSYCHOPHARMACOLOGY, V167, P219, DOI 10.1007/s00213-003-1396-z; Crawford JR, 2010, BRIT J CLIN PSYCHOL, V49, P235, DOI 10.1348/014466509X455470; Emanuele E, 2010, CLIN BIOCHEM, V43, P317, DOI 10.1016/j.clinbiochem.2009.10.005; Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9; Feusner JD, 2009, PSYCHOPHARMACOL BULL, V42, P81; Findling RL, 2007, J CHILD ADOL PSYCHOP, V17, P19, DOI 10.1089/cap.2006.0044; Fineberg NA, 2010, NEUROPSYCHOPHARMACOL, V35, P591, DOI 10.1038/npp.2009.185; Ghanizadeh A, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/536521; Glennon J, 2014, EUR CHILD ADOLES PSY, V23, P1149, DOI 10.1007/s00787-013-0498-3; Goodman Wayne K, 2007, J Clin Psychiatry, V68, pe30; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Grant JE, 2007, J CLIN PSYCHIAT, V68, P1384, DOI 10.4088/JCP.v68n0909; Hartman CA, 2006, J AUTISM DEV DISORD, V36, P325, DOI 10.1007/s10803-005-0072-z; Kolevzon A, 2006, J CLIN PSYCHIAT, V67, P407, DOI 10.4088/JCP.v67n0311; Langen M, 2007, BIOL PSYCHIAT, V62, P262, DOI 10.1016/j.biopsych.2006.09.040; Langen M, 2009, BIOL PSYCHIAT, V66, P327, DOI 10.1016/j.biopsych.2009.03.017; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; MacMaster FP, 2008, J AM ACAD CHILD PSY, V47, P1262, DOI 10.1097/CHI.0b013e318185d2be; Maina G, 2010, J AFFECT DISORDERS, V122, P174, DOI 10.1016/j.jad.2009.07.009; Mancuso E, 2010, J CHILD ADOL PSYCHOP, V20, P299, DOI 10.1089/cap.2010.0040; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; Marin JCM, 2008, EPILEPSY BEHAV, V13, P43, DOI 10.1016/j.yebeh.2008.03.004; McDougle CJ, 2002, J AM ACAD CHILD PSY, V41, P921, DOI 10.1097/00004583-200208000-00010; Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; Moy SS, 2008, MOL PSYCHIATR, V13, P4, DOI 10.1038/sj.mp.4002082; Munafò MR, 2008, BIOL PSYCHIAT, V63, P852, DOI 10.1016/j.biopsych.2007.08.016; Naaijen J, 2015, NEUROSCI BIOBEHAV R, V52, P74, DOI 10.1016/j.neubiorev.2015.02.009; Owley T, 2006, J CHILD ADOL PSYCHOP, V16, P517, DOI 10.1089/cap.2006.16.517; Palmieri L, 2010, BBA-BIOENERGETICS, V1797, P1130, DOI 10.1016/j.bbabio.2010.04.018; Pasquini M, 2006, PROG NEURO-PSYCHOPH, V30, P1173, DOI 10.1016/j.pnpbp.2006.04.013; Riley AW, 2004, MED CARE, V42, P221, DOI 10.1097/01.mlr.0000114910.46921.73; Rommelse NNJ, 2008, AM J HUM GENET, V83, P99, DOI 10.1016/j.ajhg.2008.06.006; Rommelse NNJ, 2010, EUR CHILD ADOLES PSY, V19, P281, DOI 10.1007/s00787-010-0092-x; Rosenberg DR, 2000, J AM ACAD CHILD PSY, V39, P1096, DOI 10.1097/00004583-200009000-00008; Rotge JY, 2010, NEUROSCIENCE, V165, P408, DOI 10.1016/j.neuroscience.2009.10.043; Russell VA., 2011, Current Protocols in Neuroscience, DOI 10.1002/; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Stewart SE, 2010, J CLIN PSYCHOPHARM, V30, P34, DOI 10.1097/JCP.0b013e3181c856de; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P335; van der Kooij MA, 2007, NEUROSCI BIOBEHAV R, V31, P597, DOI 10.1016/j.neubiorev.2006.12.002; Wechsler D., 1991, WISC 3 MANUAL; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2";73;21;22;2;23;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1745-6215;;TRIALS;Trials;mars-17;2016;17;;;;;;;;141;10.1186/s13063-016-1266-8;http://dx.doi.org/10.1186/s13063-016-1266-8;;;16;Medicine, Research & Experimental;Science Citation Index Expanded (SCI-EXPANDED);Research & Experimental Medicine;DH2HF;26983548;Green Published, gold;;;24/11/2024;WOS:000372604700001;View Full Record in Web of Science
J;"Lin, XF; Wang, ZY; Feng, WJ";;;;"Lin, Xiao-Fei; Wang, Zheng-Yan; Feng, Wei-Jing";;;Influence of Drug-Metabolizing Enzymes by Autism Treatment Drug Haloperidol;LATIN AMERICAN JOURNAL OF PHARMACY;;;English;Article;;;;;;"adverse effects; autism; haloperidol; lipidomics";"ATHEROGENIC LIPOPROTEINS; CHILDREN; LYSOPHOSPHATIDYLCHOLINE; CLOPIDOGREL; RISPERIDONE; ADOLESCENTS; COMPONENT; DISORDER; SAFETY";Autism spectrum disorders (ASD) is a heterogeneous group of severe neurodevelopment disorders, and haloperidol is a potential therapeutic drug for autism. The present study aims to find the key biomarkers of ASD and evaluate the potential adverse effect of haloperidol. Lipidomics was used to compare the lipid profile between healthy volunteers and patients with ASD. The inhibition of haloperidol towards human carboxylesterase 1 (hCES1)-catalyzed hydrolysis of clopidogrel and UDP-glucuronosyl-transferase (UGT) 1A9-catalyzed propofol glucuronidation reaction was determined. The results showed that Lysophosphatidylcholine (LPC) 16:0 and 18:0 significantly increased in serum from patients with ASD. Haloperidol exhibited strong inhibition towards recombinant hCES1 and human liver microsomes (HLMs)-catalyzed hydrolysis of clopidogrel. Human liver microsomes (HLMs) glucuronidation of propofol was also inhibited by haloperidol. In conclusion, lipidomics was used to discover the important role of LPC16:0 and LPC 18:0 in the pathogenesis of autism. Additionally, the potential adverse effect of haloperidol was demonstrated in the present study through investigating the inhibition of haloperidol towards hCES1-catalyzed hydrolysis of clopidogrel.;"[Lin, Xiao-Fei] Yangzhou Univ, Huaian Matern & Child Hlth Hosp, Dept Paediat, Intens Care Units, Huaian 223002, Jiangsu, Peoples R China; [Wang, Zheng-Yan] Xuzhou Med Coll, Huaian Hosp, Dept Pediat, Huaian 223002, Peoples R China; [Wang, Zheng-Yan] Huaian Second Peoples Hosp, Huaian 223002, Peoples R China; [Feng, Wei-Jing] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Pediat, Huaian 223300, Jiangsu, Peoples R China";"Yangzhou University; Xuzhou Medical University; Nanjing Medical University";Feng, WJ (corresponding author), Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Pediat, 6 Beijing Rd West, Huaian 223300, Jiangsu, Peoples R China.;fengweijinghuaian@163.com;"Lin, XiaoFei/HSG-5138-2023; zhou, han/JUV-0193-2023";;;;;"Brockmöller J, 2002, CLIN PHARMACOL THER, V72, P438, DOI 10.1067/mcp.2002.127494; Gencer O, 2008, EUR CHILD ADOLES PSY, V17, P217, DOI 10.1007/s00787-007-0656-6; Goepfert E, 2015, CHILD ADOL PSYCH CL, V24, P571, DOI 10.1016/j.chc.2015.02.009; Kato Y, 2012, DRUG METAB DISPOS, V40, P240, DOI 10.1124/dmd.111.042150; Kohno M, 1998, CIRCULATION, V98, P353, DOI 10.1161/01.CIR.98.4.353; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LaSalle JM, 2013, J HUM GENET, V58, P396, DOI 10.1038/jhg.2013.49; Li F, 2014, J PROTEOME RES, V13, P2679, DOI 10.1021/pr500145n; Loke YJ, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00107; Matsubara T, 2011, HEPATOLOGY, V53, P1282, DOI 10.1002/hep.24193; Mikeska T, 2014, GENES-BASEL, V5, P821, DOI 10.3390/genes5030821; Miral S, 2008, EUR CHILD ADOLES PSY, V17, P1, DOI 10.1007/s00787-007-0620-5; Pisula E, 2015, INT J MOL SCI, V16, P13217, DOI 10.3390/ijms160613217; Qi YP, 2015, BBA-MOL CELL BIOL L, V1851, P19, DOI 10.1016/j.bbalip.2014.04.008; Schaevitz LR, 2012, ILAR J, V53, P322, DOI 10.1093/ilar.53.3-4.322; Sun XZ, 2015, LAT AM J PHARM, V34, P619; Tang M, 2006, J PHARMACOL EXP THER, V319, P1467, DOI 10.1124/jpet.106.110577; Zhang AH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/354671; Zhu HJ, 2013, J PHARMACOL EXP THER, V344, P665, DOI 10.1124/jpet.112.201640";19;1;1;0;6;COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES;LA PLATA;DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA;0326-2383;;;LAT AM J PHARM;Lat. Am. J. Pharm.;;2015;34;8;;;;;1693;1696;;;;;;4;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;CW9YZ;;;;;24/11/2024;WOS:000365355400032;View Full Record in Web of Science
J;"Brehm, B; Schill, J; Rauh, R; Fleischhaker, C; Biscaldi, M";;;;"Brehm, Bettina; Schill, Judith; Rauh, Reinhold; Fleischhaker, Christian; Biscaldi, Monica";;;Preliminary Evaluation of the FETASS Training for Parents of Children With Autism Spectrum Disorder: A Pilot Study;FRONTIERS IN PSYCHOLOGY;;;English;Article;;;;;;"parent training; Autism Spectrum Disorder; Freiburg Parent Training for Autism Spectrum Disorder; quality of life; preliminary evaluation; parental stress; children";"PSYCHOSOCIAL INTERVENTIONS; EDUCATION; BEHAVIOR; STRESS; ADOLESCENTS; FAMILIES; PROGRAM; PSYCHOTHERAPY; ADAPTABILITY; CAREGIVERS";"While several recent evaluation studies have shown the efficacy of parent training programs for children with neurodevelopmental disorders, manual-based training in German is still scarce. To address this gap, we developed a specific modularized training program for parents of children from preschool to pre-adolescent age with Autism Spectrum Disorder (FETASS). The overarching purpose of the FETASS intervention is to enhance social communication behavior and quality of life of the child by coaching parents. As a proximal target, the FETASS training aims to provide families with behavior management and communication strategies. The development of the training was influenced by published behavioral parent trainings and autism-specific interventions. The training comprises eight weekly sessions and targets families whose children have a diagnosis of Autism Spectrum Disorder (ASD) without intellectual and language impairments. As a preliminary pilot study, the purpose was to evaluate the acceptability of the training. Furthermore, the study aimed at initially evaluating social communication behavior, quality of life of the child, parental stress level, and parenting after training in comparison to a treatment as usual (TAU) group. Exploratively, long-term effects were investigated after 6 months of training as well. In total, 57 families participated (n[TAU] = 29, n[FETASS] = 28). Questionnaires about social communication behavior and quality of life of the child, parental stress, and parenting were administered at three time points (t1: baseline TAU/FETASS, t2: post TAU/FETASS; and t3: 6-month follow-up after FETASS). Primary outcome measures were the social communication behavior of the child and the parent's proxy report on quality of life of the child. Secondary outcome measures were changes in parental stress and parenting behavior. Acceptability of the training was very high and we had almost no dropouts during training. Results for the primary outcome measure of social communication behavior, overall quality of life of the child, and long-term effects on social communication behavior were not significant. While long-term findings for parent stress reduction and for the quality of life of the child are promising, further research has to be done in a future randomized controlled trial.";"[Brehm, Bettina; Schill, Judith; Rauh, Reinhold; Fleischhaker, Christian; Biscaldi, Monica] Univ Freiburg, Dept Child & Adolescent Psychiat Psychotherapy &, Med Ctr, Fac Med, Freiburg, Germany";University of Freiburg;Biscaldi, M (corresponding author), Univ Freiburg, Dept Child & Adolescent Psychiat Psychotherapy &, Med Ctr, Fac Med, Freiburg, Germany.;monica.biscaldi-schaefer@uniklinik-freiburg.de;Rauh, Reinhold/S-6361-2019;;"Baden-Wuerttemberg Ministry of Science, Research and Art; University of Freiburg";"Baden-Wuerttemberg Ministry of Science, Research and Art; University of Freiburg";The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding program Open Access Publishing.;"[Anonymous], 2004, Diagnostische Beobachtungsskala fur Autistische Storungen. ADOS.; Manual; Deutsche Fassung der Autism Diagnostic Observation Schedule von Catherine Lord; [Anonymous], 2002, TEACCH APPROACH AUTI; [Anonymous], 2013, Diagnostic and statistical manual of mental disorders; Arnold D.S., 1993, PSYCHOL ASSESSMENT, V5, P137, DOI [10.1037/1040-3590.5.2.137, DOI 10.1037/1040-3590.5.2.137]; Baker JK, 2011, J FAM PSYCHOL, V25, P601, DOI 10.1037/a0024409; Baker JK, 2011, J ABNORM PSYCHOL, V120, P465, DOI 10.1037/a0021900; Baker JK, 2010, J AUTISM DEV DISORD, V40, P988, DOI 10.1007/s10803-010-0948-4; Baker-Ericzén MJ, 2005, RES PRACT PERS SEV D, V30, P194, DOI 10.2511/rpsd.30.4.194; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Bolte S., 2006, DIAGNOSTISCHES INTER; BOLTE S, 2008, SKALA ERFASSUNG SOZI; Borenstein M., 2021, INTRO META ANAL; Brereton A., 2005, PRESCHOOLERS AUTISM; Brookman-Frazee L, 2006, CLIN CHILD FAM PSYCH, V9, P181, DOI 10.1007/s10567-006-0010-4; Chiang HM, 2014, FOCUS AUTISM DEV DIS, V29, P88, DOI 10.1177/1088357613504990; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Cox MJ, 2003, CURR DIR PSYCHOL SCI, V12, P193, DOI 10.1111/1467-8721.01259; Crank JE, 2021, AUTISM RES, V14, P817, DOI 10.1002/aur.2471; Crowell JA, 2019, COMPR PSYCHIAT, V90, P21, DOI 10.1016/j.comppsych.2018.11.007; Cutress AL, 2014, AUTISM, V18, P651, DOI 10.1177/1362361313495718; Davis NO, 2008, J AUTISM DEV DISORD, V38, P1278, DOI 10.1007/s10803-007-0512-z; Domsch H., 2010, ESF: Elternstressfragebogen. Hogrefe, Vfirst; Edwards GS, 2019, RES AUTISM SPECT DIS, V66, DOI 10.1016/j.rasd.2019.101409; Eldridge Sandra M, 2016, Pilot Feasibility Stud, V2, P64, DOI 10.1136/bmj.i5239; Estes A, 2009, AUTISM, V13, P375, DOI 10.1177/1362361309105658; Farmer J, 2013, AUST J RURAL HEALTH, V21, P20, DOI 10.1111/ajr.12004; Fleischhaker C, 2015, FREIBURGER ELTERNTRA; Fombonne E, 2012, AUTISM RES, V5, P180, DOI 10.1002/aur.1235; Freitag CM, 2016, J CHILD PSYCHOL PSYC, V57, P596, DOI 10.1111/jcpp.12509; Frohlich U., 2014, ELTERNTRAINING ANBAH; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Green J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2881-3; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Greenberg JS, 2006, AM J MENT RETARD, V111, P229, DOI 10.1352/0895-8017(2006)111[229:BEOEEA]2.0.CO;2; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Harrop C, 2016, J AUTISM DEV DISORD, V46, P1773, DOI 10.1007/s10803-016-2707-7; Hayes SA, 2013, J AUTISM DEV DISORD, V43, P629, DOI 10.1007/s10803-012-1604-y; Howlin P, 2017, CURR OPIN PSYCHIATR, V30, P69, DOI 10.1097/YCO.0000000000000308; Iida N, 2018, NEUROPSYCH DIS TREAT, V14, P3355, DOI 10.2147/NDT.S188387; Ilg J, 2018, PSYCHOL FR, V63, P181, DOI 10.1016/j.psfr.2016.12.004; Ingersoll B, 2006, J POSIT BEHAV INTERV, V8, P79, DOI 10.1177/10983007060080020601; Ji BB, 2014, ARCH PSYCHIAT NURS, V28, P319, DOI 10.1016/j.apnu.2014.06.003; Karst JS, 2012, CLIN CHILD FAM PSYCH, V15, P247, DOI 10.1007/s10567-012-0119-6; Keen D, 2010, RES AUTISM SPECT DIS, V4, P229, DOI 10.1016/j.rasd.2009.09.009; Lecavalier L, 2006, J INTELL DISABIL RES, V50, P172, DOI 10.1111/j.1365-2788.2005.00732.x; Lee PC, 2012, RES DEV DISABIL, V33, P2040, DOI 10.1016/j.ridd.2012.05.011; Lord C, 2005, J AUTISM DEV DISORD, V35, P695, DOI 10.1007/s10803-005-0017-6; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; Mandy W, 2016, J CHILD PSYCHOL PSYC, V57, P271, DOI 10.1111/jcpp.12501; Matson ML, 2009, RES AUTISM SPECT DIS, V3, P868, DOI 10.1016/j.rasd.2009.02.003; Mattejat F., 2006, ILK ERFASSUNG LEBENS; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; Meyer T, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-52; Milton D.E. M., 2014, Good Autism Practice, V15, P6; Naumann S, 2010, DIAGNOSTICA, V56, P144, DOI 10.1026/0012-1924/a000018; Oono IP, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009774.pub2; Patterson J., 2017, Deep learning: A practitioner's approach; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Preece D., 2017, Hrvatska revija za rehabilitacijska istrazivanja, P128, DOI [DOI 10.31299/HRRI.53.1.10, 10.31299/hrri.53.1.10]; Reichow Brian, 2013, Evid Based Child Health, V8, P266, DOI 10.1002/ebch.1903; Sanders MR, 2006, TRAINER MANUAL TRIPL; Schlitt S, 2015, FRANKFURTER AUTISMUS; Schutte C, 2018, J AUTISM DEV DISORD, V48, P751, DOI 10.1007/s10803-017-3453-1; Serketich WJ, 1996, BEHAV THER, V27, P171, DOI 10.1016/S0005-7894(96)80013-X; Smith T, 2007, J AUTISM DEV DISORD, V37, P354, DOI 10.1007/s10803-006-0173-3; Spence SJ, 2010, LANCET, V375, P2124, DOI 10.1016/S0140-6736(10)60757-X; Strauss E., 2006, A compendium of neuropsychological tests: Administration, norms, and commentary, V3rd, P554; Tellegen CL, 2014, J CONSULT CLIN PSYCH, V82, P1193, DOI 10.1037/a0037246; Turner-Brown L, 2019, J AUTISM DEV DISORD, V49, P2685, DOI 10.1007/s10803-016-2812-7; Vasilopoulou E, 2016, RES AUTISM SPECT DIS, V23, P36, DOI 10.1016/j.rasd.2015.11.008; Virués-Ortega J, 2010, CLIN PSYCHOL REV, V30, P387, DOI 10.1016/j.cpr.2010.01.008; WEBSTERSTRATTON C, 1989, J CONSULT CLIN PSYCH, V57, P550, DOI 10.1037/0022-006X.57.4.550; Weisz J. R., 2017, Evidence-Based Psychotherapies for Children and Adolescents; WEISZ JR, 1995, PSYCHOL BULL, V117, P450, DOI 10.1037/0033-2909.117.3.450; Whitehead AL, 2016, STAT METHODS MED RES, V25, P1057, DOI 10.1177/0962280215588241; Whittingham K, 2009, J ABNORM CHILD PSYCH, V37, P469, DOI 10.1007/s10802-008-9285-x";77;1;3;2;14;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-1078;;;FRONT PSYCHOL;Front. Psychol.;APR 30;2021;12;;;;;;;;604851;10.3389/fpsyg.2021.604851;http://dx.doi.org/10.3389/fpsyg.2021.604851;;;12;Psychology, Multidisciplinary;Social Science Citation Index (SSCI);Psychology;SB7MV;33995174;Green Published, gold;;;24/11/2024;WOS:000650174200001;View Full Record in Web of Science
J;"Masiran, R; Ilias, MNA; Yubbu, P";;;;"Masiran, Ruziana; Ilias, Mohamad Nizam Adha; Yubbu, Putri";;;Methylphenidate-associated chest pain in a child;BMJ CASE REPORTS;;;English;Article;;;;;;"Psychiatry (drugs and medicines); Developmental paediatrics; Child and adolescent psychiatry (paediatrics); Unwanted effects / adverse reactions; Child and adolescent psychiatry";"ADOLESCENTS; ADHD";A young child was diagnosed with autism spectrum disorder with comorbid attention-deficit/hyperactivity disorder. His hyperactivity, impulsivity and absence of awareness towards danger increased his risk of harm and hence methylphenidate was indicated. Unfortunately, he developed chest pain eight months after the treatment initiation. We then stopped the stimulant and changed his treatment to atomoxetine, after which he no longer had chest pain. In the following illustrated case, we will discuss the cardiac side effect of methylphenidate.;"[Masiran, Ruziana; Yubbu, Putri] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Psychiat, Serdang, Selangor, Malaysia; [Masiran, Ruziana; Ilias, Mohamad Nizam Adha] Hosp Sultan Abdul Aziz Shah, Dept Psychiat, Serdang, Selangor, Malaysia; [Yubbu, Putri] Hosp Serdang, Pediat Cardiol Unit, Serdang, Selangor, Malaysia";Universiti Putra Malaysia;"Masiran, R (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Psychiat, Serdang, Selangor, Malaysia.;Masiran, R (corresponding author), Hosp Sultan Abdul Aziz Shah, Dept Psychiat, Serdang, Selangor, Malaysia.";ruziana_m@upm.edu.my;;"Masiran, Ruziana/0000-0002-9987-4255; yubbu, putri/0000-0001-5477-9847";;;;"Baumeister Timo-Benjamin, 2016, Drug Saf Case Rep, V3, P10; Bjorgvinsdottir EB., 2023, Effect of methylphenidate treatment as an intervention for children diagnosed with ASD showing ADHD symptoms: Systematic Review; Buchhorn R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238139; Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4; Dadfarmay S, 2009, CARDIOVASC TOXICOL, V9, P49, DOI 10.1007/s12012-009-9033-7; Dhillon R., 2018, Paediatrics and Child Health, V28, P566, DOI [10.1016/j.paed.2018.10.009, DOI 10.1016/J.PAED.2018.10.009]; Gonzalez VJ, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-1693; Hennissen L, 2017, CNS DRUGS, V31, P199, DOI 10.1007/s40263-017-0410-7; Hole Lisa Drange, 2014, BMC Res Notes, V7, P480, DOI 10.1186/1756-0500-7-480; Houghton R, 2020, CNS DRUGS, V34, P93, DOI 10.1007/s40263-019-00686-4; Idrees I, 2023, NEUROSCI BIOBEHAV R, V144, DOI 10.1016/j.neubiorev.2022.104968; Kohn MR, 2012, CLIN MED INSIGHTS-PE, V6, P95, DOI 10.4137/CMPed.S7868; Kurt R, 2013, J AM COLL CARDIOL, V62, pC129, DOI 10.1016/j.jacc.2013.08.385; Lilja MM, 2022, J NEURODEV DISORD, V14, DOI 10.1186/s11689-022-09424-2; Munk K, 2015, CASE REP PEDIAT, V2015, DOI 10.1155/2015/905097; Omidi N, 2021, IJC HEART VASC, V34, DOI 10.1016/j.ijcha.2021.100805; Roest AM, 2023, J CHILD PSYCHOL PSYC, V64, P464, DOI 10.1111/jcpp.13677; Savill Nicola, 2012, Child Adolesc Psychiatry Ment Health, V6, P2, DOI 10.1186/1753-2000-6-2; Schelleman H, 2012, AM J PSYCHIAT, V169, P178, DOI 10.1176/appi.ajp.2011.11010125; Shin JY, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2550; Stahl SM, 2010, J CLIN PSYCHIAT, V71, P12, DOI 10.4088/JCP.09bs05890pur; Stammschulte T, 2022, EUR CHILD ADOLES PSY, V31, P939, DOI 10.1007/s00787-021-01729-2; Storebo OJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012069.pub2; Topriceanu CC, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.1020961; Torres-Acosta N, 2020, J AM COLL CARDIOL, V76, P858, DOI 10.1016/j.jacc.2020.05.081; Vertessen K, 2022, J AM ACAD CHILD PSY, V61, P626, DOI 10.1016/j.jaac.2021.08.023; Zhang L, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.43597";27;0;0;0;0;BMJ PUBLISHING GROUP;LONDON;BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND;;1757-790X;;BMJ CASE REP;BMJ Case Rep.;NOV;2023;16;11;;;;;;;e255187;10.1136/bcr-2023-255187;http://dx.doi.org/10.1136/bcr-2023-255187;;;4;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;CG5K7;38011950;;;;24/11/2024;WOS:001124112200022;View Full Record in Web of Science
J;"Srisawasdi, P; Vanwong, N; Hongkaew, Y; Puangpetch, A; Vanavanan, S; Intachak, B; Ngamsamut, N; Limsila, P; Sukasem, C; Kroll, MH";;;;"Srisawasdi, Pornpen; Vanwong, Natchaya; Hongkaew, Yaowaluck; Puangpetch, Apichaya; Vanavanan, Somlak; Intachak, Boontarika; Ngamsamut, Nattawat; Limsila, Penkhae; Sukasem, Chonlaphat; Kroll, Martin H.";;;Impact of risperidone on leptin and insulin in children and adolescents with autistic spectrum disorders;CLINICAL BIOCHEMISTRY;;;English;Article;;;;;;"Autistic spectrum disorders; Risperidone; Metabolic risk factors; Diabetes; Children; Adolescent";"ENERGY HOMEOSTASIS; METABOLIC SYNDROME; GLUCOSE; RESISTANCE; ANTIPSYCHOTICS; OBESITY; WEIGHT; ONSET; BOYS; AGE";Objective: To evaluate the influence of dose and duration of risperidone treatment on cardiovascular and diabetes risk biomarkers in children and adolescents with autistic spectrum disorders (ASDs). Design and methods: In this cross-sectional analysis, a total of 168 ASDs patients (89% male) treated with a risperidone-based regimen for >= 12 months were included. Blood samples were analyzed for glucose and lipid metabolic markers, adiponectin, leptin, prolactin, cortisol and high sensitive C-reactive protein. Results: The mean concentrations of glucose, insulin, prolactin and leptin and HOMA-IR significantly rose with risperidone dosage (all P < 0.025), but those of adiponectin and cortisol did not. Using regression analysis, insulin, leptin, prolactin and glucose concentrations and HOMA-IR show significant association with dosage. None of the markers except adiponectin showed dependence on duration of treatment. However, insulin and leptin concentrations and HOMA-IR clearly increased with increasing both dosage and duration. Dosage and duration of treatment had minimal effect on standard lipid profile and lipoprotein subclasses. Conclusions: Risperidone treatment disturbed glucose homeostasis and endocrine regulation (particularly leptin) in children and adolescents with ASDs, in a dose- and duration-dependent manner, being suggestive of leptin and insulin resistance mechanisms. Metabolic adverse effects, especially development of type 2 diabetes mellitus should be closely monitored, particularly in individuals receiving high doses and/or long-term risperidone treatment. (C) 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.;"[Srisawasdi, Pornpen; Vanavanan, Somlak; Intachak, Boontarika] Mahidol Univ, Ramathibodi Hosp, Div Clin Chem, Dept Pathol,Fac Med, Rama IV Rd, Bangkok 10400, Thailand; [Vanwong, Natchaya; Hongkaew, Yaowaluck; Puangpetch, Apichaya; Sukasem, Chonlaphat] Fac Med, Dept Pathol, Div Pharmacogen & Personalized Med, Bangkok 10400, Thailand; [Ngamsamut, Nattawat; Limsila, Penkhae] Yuwaprasart Waithayopathum Child & Adolescent Psy, Dept Mental Hlth Serv, Minist Publ Hlth, Samut Prakan 10270, Thailand; [Kroll, Martin H.] Quest Diagnost, 3 Giralda Farms, Madison, NJ 07940 USA";Mahidol University;Srisawasdi, P (corresponding author), Mahidol Univ, Ramathibodi Hosp, Div Clin Chem, Dept Pathol,Fac Med, Rama IV Rd, Bangkok 10400, Thailand.;srisawasdip@yahoo.com;"Srisawasdi, Pornpen/AAV-6237-2021; Vanwong, Natchaya/ABA-4512-2021";;"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand [56076]; Khun Poom Foundation, a project under Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee; National Research Council of Thailand [92/2558]";"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand; Khun Poom Foundation, a project under Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee; National Research Council of Thailand(National Research Council of Thailand (NRCT))";This study was supported by research grants of 1) the Faculty of Medicine, Ramathibodi Hospital, Mahidol University (56076), Thailand, 2) Khun Poom Foundation, a project under Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee and 3) the National Research Council of Thailand (92/2558).;"Alikasifoglu Ayfer, 2009, J Clin Res Pediatr Endocrinol, V1, P233, DOI 10.4274/jcrpe.v1i5.233; Allard P, 2003, CLIN CHEM, V49, P644, DOI 10.1373/49.4.644; [Anonymous], 2000, DIAGN STAT MAN MENT, P70; [Anonymous], FDA APPR 1 DRUG TREA; [Anonymous], MED GES FORSCH HERST; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Carton L, 2015, CURR PHARM DESIGN, V21, P3280, DOI 10.2174/1381612821666150619092903; Cheng LC, 2015, MOL CELL ENDOCRINOL, V412, P12, DOI 10.1016/j.mce.2015.04.025; Cheng LC, 2015, J NUTR BIOCHEM, V26, P541, DOI 10.1016/j.jnutbio.2014.12.011; Cnop M, 2002, DIABETES, V51, P1005, DOI 10.2337/diabetes.51.4.1005; Covey SD, 2006, CELL METAB, V4, P291, DOI 10.1016/j.cmet.2006.09.005; De Hert M, 2011, EUR PSYCHIAT, V26, P144, DOI 10.1016/j.eurpsy.2010.09.011; Hert M, 2012, NAT REV ENDOCRINOL, V8, P114, DOI 10.1038/nrendo.2011.156; Esen-Danac A, 2008, PROG NEURO-PSYCHOPH, V32, P1434, DOI 10.1016/j.pnpbp.2008.03.015; Gagliano A, 2004, J CHILD ADOL PSYCHOP, V14, P39, DOI 10.1089/104454604773840472; GarciaMayor RV, 1997, J CLIN ENDOCR METAB, V82, P2849, DOI 10.1210/jc.82.9.2849; Khalil RB, 2012, CLIN NEUROPHARMACOL, V35, P141, DOI 10.1097/WNF.0b013e31824d5288; Kiatsopit N, 2015, ASIAN BIOMED, V9, P225, DOI 10.5372/1905-7415.0902.391; Kursungoz C, 2015, BRAIN RES, V1596, P146, DOI 10.1016/j.brainres.2014.10.070; Maayan LA, 2010, HUM PSYCHOPHARM CLIN, V25, P133, DOI 10.1002/hup.1097; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Matsuzawa Y, 2010, P JPN ACAD B-PHYS, V86, P131, DOI 10.2183/pjab.86.131; Mccracken JT, 2005, AM J PSYCHIAT, V162, P1361; Meigs JB, 2003, DIABETES, V52, P1475, DOI 10.2337/diabetes.52.6.1475; Moon HS, 2013, ENDOCR REV, V34, P377, DOI 10.1210/er.2012-1053; Moshfegh Alanna J., 2012, Morbidity and Mortality Weekly Report, V61, P92; Niswender KD, 2004, TRENDS ENDOCRIN MET, V15, P362, DOI 10.1016/j.tem.2004.07.009; Panagiotopoulos C, 2009, CAN J PSYCHIAT, V54, P743, DOI 10.1177/070674370905401104; Park HK, 2015, METABOLISM, V64, P24, DOI 10.1016/j.metabol.2014.08.004; Penfold RB, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0426-8; Piao L, 2014, INT J MOL MED, V33, P1364, DOI 10.3892/ijmm.2014.1693; Roke Y, 2009, J CHILD ADOL PSYCHOP, V19, P403, DOI 10.1089/cap.2008.0120; Ronsley R, 2015, CAN J PSYCHIAT, V60, P441, DOI 10.1177/070674371506001005; Rubin DM, 2015, JAMA PEDIATR, V169, DOI 10.1001/jamapediatrics.2015.0285; Teff KL, 2015, J CLIN PSYCHOPHARM, V35, P579, DOI 10.1097/JCP.0000000000000393; Teff KL, 2013, DIABETES, V62, P3232, DOI 10.2337/db13-0430; van der Weide J, 2005, THER DRUG MONIT, V27, P478, DOI 10.1097/01.ftd.0000162868.84596.c3; Zhang ZJ, 2004, BRIT J PSYCHIAT, V184, P58, DOI 10.1192/bjp.184.1.58; Zimmet P, 2007, PEDIATR DIABETES, V8, P299, DOI 10.1111/j.1399-5448.2007.00271.x; Zuo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054615";40;30;31;0;7;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0009-9120;1873-2933;;CLIN BIOCHEM;Clin. Biochem.;AUG;2017;50;12;;;;;678;685;;10.1016/j.clinbiochem.2017.02.003;http://dx.doi.org/10.1016/j.clinbiochem.2017.02.003;;;8;Medical Laboratory Technology;Science Citation Index Expanded (SCI-EXPANDED);Medical Laboratory Technology;FB4BN;28167244;;;;24/11/2024;WOS:000406086600008;View Full Record in Web of Science
J;"Hesapcioglu, ST; Ceylan, MF; Kasak, M; Sen, CP";;;;"Hesapcioglu, Selma Tural; Ceylan, Mehmet Fatih; Kasak, Meryem; Sen, Cansu Pinar";;;Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders;RESEARCH IN AUTISM SPECTRUM DISORDERS;;;English;Article;;;;;;"Antipsychotic; Aripiprazole; Autism Spectrum Disorders; Irritability; Olanzapine; Risperidone";"PERVASIVE DEVELOPMENTAL DISORDERS; ABERRANT BEHAVIOR CHECKLIST; OPEN-LABEL; ANTIPSYCHOTIC MEDICATIONS; ATYPICAL ANTIPSYCHOTICS; RATING-SCALE; WEIGHT-GAIN; EFFICACY; SAFETY; TRIAL";"Background: The aim of this study is to examine the use of olanzapine, risperidone and aripiprazole in autism spectrum disorders (ASD) in terms of their effects and side effects. Methods: ASD patients that had been initiated to be treated with one of the three antipsychotics that continued for a minimum of eight weeks were included in the study, retrospectively. The participants were recruited with 20 olanzapine using patients (2.5-10 mg/day) in comparison with 42 risperidone (1 4 mg/day) and 40 aripiprazole (3-15 mg/day) using patients that are using the matched equivalent chlorpromazine doses of the antipsychotics between the same time period. Results: All three antipsychotics significantly decreased all of the ABC subscales scores in eight weeks. Sleepiness/sedation, increased duration of sleep, and weight gain were the most common side effects of the three antipsychotics and they were more frequent with olanzapine than with the others (X-2 = 26.9, p < 0.0001; X-2 = 20.8, p < 0.0001; X-2 = 8.4, p = 0.01, respectively). Discussion: Our results reveal that risperidone, aripiprazole, and olanzapine are effective in treatment of irritability, hyperactivity, social withdrawal, stereotypy, and inappropriate speech in ASD. But the side effects are more frequent with olanzapine and it should be considered when choosing antipsychotics for ASD.";"[Hesapcioglu, Selma Tural; Ceylan, Mehmet Fatih; Kasak, Meryem; Sen, Cansu Pinar] Ankara Yildirim Beyazit Univ, Fac Med Child & Adolescent Psychiat, Ankara, Turkey";Ankara Yildirim Beyazit University;Hesapcioglu, ST (corresponding author), Ankara Yildirim Beyazit Univ, Fac Med Child & Adolescent Psychiat, Ankara, Turkey.;shesapcioglu@ybu.edu.tr;"Ka?ak, Meryem/HGF-0390-2022; Tural Hesapcioglu, Selma/V-9119-2017";Tural Hesapcioglu, Selma/0000-0002-4816-0228;;;;"Adler BA, 2015, AUTISM, V19, P102, DOI 10.1177/1362361314524641; AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman M, 2015, J CHILD ADOL PSYCHOP, V25, P482, DOI 10.1089/cap.2015.0005; [Anonymous], 2013, DIAGNOSTIC STAT MANU, VFifth, P1000, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], 1993, ANKARA GELISIM TARAM; [Anonymous], LEWIS CHILD ADOLESCE; [Anonymous], AR AB US FULL PRESCR; [Anonymous], RISP RISP US FULL PR; [Anonymous], 2005, AM J PSYCHIAT; Arnold LE, 2010, J CHILD ADOL PSYCHOP, V20, P83, DOI 10.1089/cap.2009.0022; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Carbon M, 2015, J AM ACAD CHILD PSY, V54, P718, DOI 10.1016/j.jaac.2015.06.015; Chakrabarti S, 2001, JAMA-J AM MED ASSOC, V285, P3093, DOI 10.1001/jama.285.24.3093; Chavez Benjamin, 2007, Paediatr Drugs, V9, P249, DOI 10.2165/00148581-200709040-00006; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; De Hert M, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-17; Dinnissen M, 2015, EXPERT OPIN DRUG MET, V11, P111, DOI 10.1517/17425255.2015.981151; Fido A, 2008, MED PRIN PRACT, V17, P415, DOI 10.1159/000141508; Findling RL, 2014, J CLIN PSYCHIAT, V75, P22, DOI 10.4088/JCP.13m08500; Fontaine KR, 2001, PSYCHIAT RES, V101, P277, DOI 10.1016/S0165-1781(01)00234-7; Frenchman IB, 2005, DRUG AGING, V22, P257, DOI 10.2165/00002512-200522030-00006; [Gay W. Health P.R.B.N.I.o.M. Health P.R.B.N.I.o.M.], 1976, ECDEU Assessment Manual for Psychopharmacology, Revised, US Dept Health, Education, and Welfare publication (ADM), P534; Ghanizadeh A, 2014, CHILD PSYCHIAT HUM D, V45, P185, DOI 10.1007/s10578-013-0390-x; Hollander E, 2006, J CHILD ADOL PSYCHOP, V16, P541, DOI 10.1089/cap.2006.16.541; Karabekiroglu K, 2009, CHILD PSYCHIAT HUM D, V40, P99, DOI 10.1007/s10578-008-0108-7; Kemner C, 2002, J CLIN PSYCHOPHARM, V22, P455, DOI 10.1097/00004714-200210000-00003; Kim YS, 2011, AM J PSYCHIAT, V168, P904, DOI 10.1176/appi.ajp.2011.10101532; Lemmon ME, 2011, J CHILD NEUROL, V26, P428, DOI 10.1177/0883073810382143; Leskovec TJ, 2008, HARVARD REV PSYCHIAT, V16, P97, DOI 10.1080/10673220802075852; Levine SZ, 2016, EUR PSYCHIAT, V32, P16, DOI 10.1016/j.eurpsy.2015.11.004; LINGJAERDE O, 1987, ACTA PSYCHIAT SCAND, V76, P7; Malone RP, 2001, J AM ACAD CHILD PSY, V40, P887, DOI 10.1097/00004583-200108000-00009; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Olfson M, 2015, JAMA PSYCHIAT, V72, P867, DOI 10.1001/jamapsychiatry.2015.0500; Penfold RB, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0426-8; Potenza MN, 1999, J CLIN PSYCHOPHARM, V19, P37, DOI 10.1097/00004714-199902000-00008; Savasir I., 1995, Wechsler Cocuklar Icin Zeka Olcegi (WISCR) El Kitabi; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Stentebjerg-Olesen M, 2013, J CHILD ADOL PSYCHOP, V23, P665, DOI 10.1089/cap.2013.0007; Volkmar FR, 2007, LEWISS CHILD ADOLESC; Volkmar Fred, 1999, Journal of the American Academy of Child and Adolescent Psychiatry, V38, p32S; Wechsler D., 1949, Wechsler Intelligence Scale for ChildrenFifth Edition; Wingate M, 2014, MMWR SURVEILL SUMM, V63; Wink LK, 2014, J CHILD ADOL PSYCHOP, V24, P78, DOI 10.1089/cap.2013.0099; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663, DOI 10.4088/JCP.v64n0607; Xia L, 2018, J CHILD ADOL PSYCHOP, V28, P244, DOI 10.1089/cap.2017.0120; Yoon Y, 2016, J CHILD ADOL PSYCHOP, V26, P822, DOI 10.1089/cap.2016.0049";49;19;20;3;20;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;1750-9467;1878-0237;;RES AUTISM SPECT DIS;Res. Autism Spectr. Disord.;APR;2020;72;;;;;;;;101520;10.1016/j.rasd.2020.101520;http://dx.doi.org/10.1016/j.rasd.2020.101520;;;11;"Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychology; Psychiatry; Rehabilitation";KW9OF;;;;;24/11/2024;WOS:000521512300009;View Full Record in Web of Science
J;"Scahill, L; Hallett, V; Aman, MG; McDougle, CJ; Arnold, LE; McCracken, JT; Tierney, E; Deng, YH; Dziura, J; Vitiello, B";;;;"Scahill, Lawrence; Hallett, Victoria; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Tierney, Elaine; Deng, Yanhong; Dziura, James; Vitiello, Benedetto";;Res Units Pediatric;Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Social disability; Autism; Research Units on Pediatric Psychopharmacology (RUPP) Autism Network; Social withdrawal; Risperidone; Aberrant Behavior Checklist";"PERVASIVE DEVELOPMENTAL DISORDERS; ABERRANT BEHAVIOR CHECKLIST; YOUNG-PEOPLE; CHILDREN; RISPERIDONE; SYMPTOMS; IRRITABILITY; ARIPIPRAZOLE; INDIVIDUALS; ADOLESCENTS";There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.;"[Scahill, Lawrence; Hallett, Victoria] Yale Univ, Sch Nursing, New Haven, CT 06536 USA; [Scahill, Lawrence; Hallett, Victoria] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Aman, Michael G.; Arnold, L. Eugene] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [McDougle, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lurie Ctr Autism, Boston, MA USA; [McDougle, Christopher J.] Indiana Univ, Indinapolis, IN USA; [McCracken, James T.] Univ Calif Los Angeles, Div Child Psychiat, Los Angeles, CA USA; [Tierney, Elaine] Johns Hopkins Univ, Baltimore, MD USA; [Tierney, Elaine] Kennedy Krieger Inst, Baltimore, MD USA; [Deng, Yanhong] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Dziura, James] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA; [Vitiello, Benedetto] NIMH, Bethesda, MD 20892 USA";"Yale University; Yale University; University System of Ohio; Ohio State University; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California Los Angeles; Johns Hopkins University; Kennedy Krieger Institute; Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)";Scahill, L (corresponding author), Emory Univ, Dept Pediat, 1920 Briarcliff Rd, Atlanta, GA 30329 USA.;lawrence.scahill@emory.edu;"Vitiello, Benedetto/AAC-1758-2022; deng, yan/KCK-8563-2024";Scahill, Lawrence/0000-0001-5073-1707;"NCATS NIH HHS [UL1 TR001108] Funding Source: Medline; NCRR NIH HHS [UL1 RR024139, UL1 RR025755, UL1 RR025761] Funding Source: Medline; NIMH NIH HHS [U01 MH070010, U10MH66768, U10 MH066766, N01MH70009, U10MH66764, U10 MH066768, U10 MH066764, K24 MH001805, N01MH70010, N01MH70001, U10MH66766, U01 MH070009, N01MH80011] Funding Source: Medline";"NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))";;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P492; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; [Anonymous], 2012, MMWR, V61, P2; [Anonymous], 2006, FED REG; [Anonymous], IACC STRAT PLAN AUT; Autism Speaks, 2011, AUT SPEAKS ANN MAJ E; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Carter AS, 1998, J AUTISM DEV DISORD, V28, P287, DOI 10.1023/A:1026056518470; Dölen G, 2010, PHARMACOL THERAPEUT, V127, P78, DOI 10.1016/j.pharmthera.2010.02.008; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Jacquemont S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001708; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Levy SE, 2011, LANCET, V378, P1546; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; O'Roak BJ, 2008, AUTISM RES, V1, P4, DOI 10.1002/aur.3; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Posey DJ, 2008, CHILD ADOL PSYCH CL, V17, P787, DOI 10.1016/j.chc.2008.06.010; Robinson EB, 2011, ARCH GEN PSYCHIAT, V68, P1113, DOI 10.1001/archgenpsychiatry.2011.119; Scahill L, 2012, J AM ACAD CHILD PSY, V51, P136, DOI 10.1016/j.jaac.2011.11.010; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; Veenstra-VanderWeele J., 2011, NCDEU SPRING";28;38;38;1;22;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;MAR;2013;43;3;;;;;739;746;;10.1007/s10803-012-1689-3;http://dx.doi.org/10.1007/s10803-012-1689-3;;;8;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;095LU;23104617;Green Accepted;;;24/11/2024;WOS:000315336800020;View Full Record in Web of Science
J;"Koch, E; Demontis, D";;;;"Koch, Elise; Demontis, Ditte";;;Drug repurposing candidates to treat core symptoms in autism spectrum disorder;FRONTIERS IN PHARMACOLOGY;;;English;Article;;;;;;"autism spectrum disorder; drug repurposing; protein-protein interactome; network medicine; genetics";"GROWTH-HORMONE RESPONSE; SUMATRIPTAN CHALLENGE; MULTITARGET DRUGS; INFANTILE-AUTISM; CONNECTIVITY MAP; GENE-EXPRESSION; CHILDREN; TESTOSTERONE; ANTIPSYCHOTICS; CATECHOLAMINES";Autism spectrum disorder (ASD) is characterized by high heritability and clinical heterogeneity. The main core symptoms are social communication deficits. There are no medications approved for the treatment of these symptoms, and medications used to treat non-specific symptoms have serious side effects. To identify potential drugs for repurposing to effectively treat ASD core symptoms, we studied ASD risk genes within networks of protein-protein interactions of gene products. We first defined an ASD network from network-based analyses, and identified approved drugs known to interact with proteins within this network. Thereafter, we evaluated if these drugs can change ASD-associated gene expression perturbations in genes in the ASD network. This was done by analyses of drug-induced versus ASD-associated gene expression, where opposite gene expression perturbations in drug versus ASD indicate that the drug could counteract ASD-associated perturbations. Four drugs showing significant (p < 0.05) opposite gene expression perturbations in drug versus ASD were identified: Loperamide, bromocriptine, drospirenone, and progesterone. These drugs act on ASD-related biological systems, indicating that these drugs could effectively treat ASD core symptoms. Based on our bioinformatics analyses of ASD genetics, we shortlist potential drug repurposing candidates that warrant clinical translation to treat core symptoms in ASD.;"[Koch, Elise] Univ Oslo, Norwegian Ctr Mental Disorders Res NORMENT, Oslo, Norway; [Koch, Elise] Oslo Univ Hosp, Oslo, Norway; [Demontis, Ditte] IPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark; [Demontis, Ditte] Aarhus Univ, Dept Biomed Human Genet, Aarhus, Denmark; [Demontis, Ditte] Aarhus Univ, Ctr Integrat Sequencing, Aarhus, Denmark; [Demontis, Ditte] Ctr Genom & Personalized Med, Aarhus, Denmark";"University of Oslo; University of Oslo; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH); Aarhus University; Aarhus University";"Koch, E (corresponding author), Univ Oslo, Norwegian Ctr Mental Disorders Res NORMENT, Oslo, Norway.;Koch, E (corresponding author), Oslo Univ Hosp, Oslo, Norway.";e.m.koch@medisin.uio.no;Demontis, Ditte/M-4515-2013;"Demontis, Ditte/0000-0001-9124-2766; Koch, Elise/0000-0003-3727-4470";iPSYCH grants from the Lundbeck Foundation [R102-A9118, R155-2014-1724, R248-2017-2003];iPSYCH grants from the Lundbeck Foundation;The study was supported by iPSYCH grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724 and R248-2017-2003).;"Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Aman MG, 2018, J CHILD ADOL PSYCHOP, V28, P266, DOI 10.1089/cap.2017.0072; Barabási AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Baranova J, 2021, CELL MOL NEUROBIOL, V41, P619, DOI 10.1007/s10571-020-00882-7; Barbeira AN, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-020-02252-4; Barbeira AN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03621-1; Baron-Cohen S, 2015, MOL PSYCHIATR, V20, P369, DOI 10.1038/mp.2014.48; Baron-Cohen S, 2020, MOL PSYCHIATR, V25, P2970, DOI 10.1038/s41380-019-0454-9; Barton BB, 2020, EXPERT OPIN DRUG SAF, V19, P295, DOI 10.1080/14740338.2020.1713091; Borron SW, 2017, J EMERG MED, V53, P73, DOI 10.1016/j.jemermed.2017.03.018; Bowers K, 2015, PEDIATR DRUGS, V17, P115, DOI 10.1007/s40272-014-0106-0; Bowker A, 2011, J AUTISM DEV DISORD, V41, P1373, DOI 10.1007/s10803-010-1164-y; Carlin DE, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005598; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5; Cohen D, 2012, J CLIN PSYCHOPHARM, V32, P309, DOI 10.1097/JCP.0b013e3182549259; Coleman DM, 2019, J CHILD ADOL PSYCHOP, V29, P107, DOI 10.1089/cap.2018.0121; Crespi BJ, 2016, BIOL REV, V91, P390, DOI 10.1111/brv.12175; Crider A, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-46; Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007; DOLLFUS S, 1992, J AUTISM DEV DISORD, V22, P47, DOI 10.1007/BF01046402; DOLLFUS S, 1993, J CHILD ADOL PSYCHOP, V3, P145, DOI 10.1089/cap.1993.3.145; Dudley JT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002648; Enache OM, 2019, BIOINFORMATICS, V35, P1427, DOI 10.1093/bioinformatics/bty784; Fang JS, 2021, NATURE AGING, V1, P1175, DOI 10.1038/s43587-021-00138-z; Freshour SL, 2021, NUCLEIC ACIDS RES, V49, pD1144, DOI 10.1093/nar/gkaa1084; Gogos A, 2019, BRIT J PHARMACOL, V176, P4119, DOI 10.1111/bph.14584; Grove J, 2019, NAT GENET, V51, P431, DOI 10.1038/s41588-019-0344-8; Guney E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10331; Gysi DM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025581118; Henderson VW, 2018, CLIMACTERIC, V21, P333, DOI 10.1080/13697137.2018.1476484; Hollander E, 2000, NEUROPSYCHOPHARMACOL, V22, P163, DOI 10.1016/S0893-133X(99)00121-9; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Jobski K, 2017, ACTA PSYCHIAT SCAND, V135, P8, DOI 10.1111/acps.12644; Knickmeyer RC, 2006, J CHILD NEUROL, V21, P825, DOI 10.1177/08830738060210101601; Köhler S, 2008, AM J HUM GENET, V82, P949, DOI 10.1016/j.ajhg.2008.02.013; Korcsmáros T, 2007, EXPERT OPIN DRUG DIS, V2, P799, DOI 10.1517/17460441.2.6.799; Korsen M, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.559; Kvernmo T, 2006, CLIN THER, V28, P1065, DOI 10.1016/j.clinthera.2006.08.004; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lamy M, 2020, PEDIATR DRUGS, V22, P473, DOI 10.1007/s40272-020-00408-0; Lamy M, 2018, CURR PROB PEDIATR AD, V48, P250, DOI 10.1016/j.cppeds.2018.08.015; Lasoff DR, 2017, PHARMACOTHERAPY, V37, P249, DOI 10.1002/phar.1885; LAUNAY JM, 1987, J AUTISM DEV DISORD, V17, P333, DOI 10.1007/BF01487064; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Madden JM, 2017, J AUTISM DEV DISORD, V47, P144, DOI 10.1007/s10803-016-2946-7; Madra M, 2020, CHILD ADOL PSYCH CL, V29, P501, DOI 10.1016/j.chc.2020.02.005; Malinky CA, 2021, ACS CHEM NEUROSCI, V12, P2964, DOI 10.1021/acschemneuro.1c00382; Mandic-Maravic V, 2022, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.787097; McGregor C, 2017, FRONT NEUROENDOCRIN, V47, P19, DOI 10.1016/j.yfrne.2017.06.003; Meier IM, 2021, NEUROSCI BIOBEHAV R, V121, P250, DOI 10.1016/j.neubiorev.2020.12.013; Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601; Muhammad J, 2018, CURR TOP MED CHEM, V18, P949, DOI 10.2174/1568026618666180330141351; Nabirotchkin S, 2020, CURR OPIN PHARMACOL, V51, P78, DOI 10.1016/j.coph.2019.12.004; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Novotny S, 2000, PSYCHIAT RES, V94, P173, DOI 10.1016/S0165-1781(00)00134-7; Ostatníková D, 2020, PHYSIOL RES, V69, pS403, DOI 10.33549/physiolres.934592; Paval D, 2021, DEV NEUROSCI-BASEL, V43, P73, DOI 10.1159/000515751; Pellissier LP, 2018, BRIT J PHARMACOL, V175, P2750, DOI 10.1111/bph.13808; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478; Reay WR, 2021, NAT REV GENET, V22, P658, DOI 10.1038/s41576-021-00387-z; Satterstrom FK, 2020, CELL, V180, P568, DOI 10.1016/j.cell.2019.12.036; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stepanova E, 2017, DIALOGUES CLIN NEURO, V19, P395; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Tfelt-Hansen P, 2013, EXPERT OPIN DRUG MET, V9, P91, DOI 10.1517/17425255.2013.744394; Tfelt-Hansen PC, 2010, J HEADACHE PAIN, V11, P5, DOI 10.1007/s10194-009-0170-y; Tick B, 2016, J CHILD PSYCHOL PSYC, V57, P585, DOI 10.1111/jcpp.12499; Vanunu O, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000641; Vohra Rini, 2016, Drugs Real World Outcomes, V3, P409; Voineagu I, 2012, NEUROBIOL DIS, V45, P69, DOI 10.1016/j.nbd.2011.07.017; Watanabe K, 2019, NAT GENET, V51, P1339, DOI 10.1038/s41588-019-0481-0; Weickert TW, 2015, MOL PSYCHIATR, V20, P685, DOI 10.1038/mp.2015.11; Whitaker-Azmitia PM, 2014, MED HYPOTHESES, V82, P313, DOI 10.1016/j.mehy.2013.12.018; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037; Yadav BS, 2018, CURR TOP MED CHEM, V18, P1737, DOI 10.2174/1568026618666181025112344; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338; Ying MA, 2014, CNS NEUROL DISORD-DR, V13, P1836";80;6;7;0;6;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;;1663-9812;;FRONT PHARMACOL;Front. Pharmacol.;sept-12;2022;13;;;;;;;;995439;10.3389/fphar.2022.995439;http://dx.doi.org/10.3389/fphar.2022.995439;;;9;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;M1AH2;36172193;Green Published, gold;;;24/11/2024;WOS:001027537100001;View Full Record in Web of Science
J;"Holdman, R; Vigil, D; Robinson, K; Shah, PJ; Contreras, AE";;;;"Holdman, Richard; Vigil, Daniel; Robinson, Kelsey; Shah, Puja; Contreras, Alexandra Elyse";;;Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications;CANNABIS AND CANNABINOID RESEARCH;;;English;Article;;;;;;"cannabinol; medical marijuana; pharmaceuticals; tetrahydrocannabinol; psychopharmacology; autism spectrum disorder";"DOUBLE-BLIND; ENDOCANNABINOID SYSTEM; REPETITIVE BEHAVIORS; ALTERNATIVE MEDICINE; CHILDREN; PLACEBO; SYMPTOMS; HYPERACTIVITY; RISPERIDONE; PSYCHOSIS";"Objective: The objective of this study was to evaluate the safety and efficacy of medications commonly used in autism spectrum disorder (ASD) and compare this to what current research has shown regarding medical cannabis use in this population. Methods: Searches were performed to collect information surrounding currently used medications and their safety and efficacy profiles, biologic plausibility of cannabis use for symptoms of ASD, and studies detailing cannabis' safety and efficacy profile for use in the ASD population. Results were used to compare medications to cannabis as a proposed treatment. Results: The heterogeneity of ASD produces great difficulties in finding appropriate treatment, leading to many medication changes or treatment trials throughout a patient's life. Commonly prescribed medications display varying levels of efficacy, safety, and tolerability between patients and symptoms targeted. Some of the most common side effects cited are also considered the most troubling symptoms associated with ASD; aggression, anxiety, irritability, and a negative effect on cognition, leading many patients to discontinue use as the side effects outweigh benefits. Recent case reports and retrospective studies have displayed the potential efficacy, safety, and tolerability of cannabidiol (CBD)-rich medical cannabis use for treating both core symptoms of ASD and many comorbid symptoms such as irritability and sleep problems. Studies have also identified circulating endocannabinoids as a possible biomarker for ASD, providing another possible method of diagnosis. Conclusions: Currently, there are no approved medications for the core symptoms of ASD and only two medications Food and Drug Administration approved for associated irritability. Prescribed medications for symptoms associated with ASD display varying levels of efficacy, safety, and tolerability among the heterogeneous ASD population. At the time of this study there are no published placebo-controlled trials of medical cannabis for ASD and the observational studies have limitations. CBD-rich medical cannabis seems to be an effective, tolerable, and relatively safe option for many symptoms associated with ASD, however, the long-term safety is unknown at this time.";"[Holdman, Richard; Vigil, Daniel; Robinson, Kelsey; Shah, Puja; Contreras, Alexandra Elyse] Marijuana Hlth Monitoring & Res, Colorado Dept Publ Hlth & Environm, 4300 Cherry Creek South Dr, Denver, CO 80246 USA";Colorado Department of Public Health & Environment;Holdman, R (corresponding author), Marijuana Hlth Monitoring & Res, Colorado Dept Publ Hlth & Environm, 4300 Cherry Creek South Dr, Denver, CO 80246 USA.;richard.holdman@state.co.us;Holdman, Richard/KVY-0873-2024;Holdman, Richard/0000-0003-3108-625X;Colorado Department of Public Health and Environment (CDPHE);Colorado Department of Public Health and Environment (CDPHE);Funding was provided by Colorado Department of Public Health and Environment (CDPHE).;"Abd-Elsalam S., 2021, ROLE BUMETANIDE TREA; Aman MG, 2017, J CHILD ADOL PSYCHOP, V27, P403, DOI 10.1089/cap.2015.0146; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Ammerman S, 2015, PEDIATRICS, V135, pE769, DOI [10.1542/peds.2014-4147, 10.1542/peds.2014-4146]; Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16; Andersen IM, 2008, J CHILD NEUROL, V23, P482, DOI 10.1177/0883073807309783; [Anonymous], 2019, State Medical Marijuana Laws; Aran A, 2021, MOL AUTISM, V12, DOI 10.1186/s13229-021-00420-2; Aran A, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-019-0256-6; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110; Autism Research Institute, 2009, PAR RAT BEH EFF BIOM; Barchel D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01521; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6; Bestard JA, 2011, PAIN PRACT, V11, P353, DOI 10.1111/j.1533-2500.2010.00427.x; Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI 10.1212/01.WNL.0000031422.66442.49; Bolognani F, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat7838; Campbell DB, 2011, J NEURODEV DISORD, V3, P101, DOI 10.1007/s11689-010-9071-2; Campos AC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00269; Chaste Pauline, 2012, Dialogues Clin Neurosci, V14, P281; Cifelli P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030723; Coleman DM, 2019, J CHILD ADOL PSYCHOP, V29, P107, DOI 10.1089/cap.2018.0121; D'Souza DC, 2004, NEUROPSYCHOPHARMACOL, V29, P1558, DOI 10.1038/sj.npp.1300496; Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3; Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631; Devnani PA, 2015, J PEDIATR NEUROSCI, V10, P304, DOI 10.4103/1817-1745.174438; Di Forti M, 2015, LANCET PSYCHIAT, V2, P233, DOI 10.1016/S2215-0366(14)00117-5; Di Marzo V, 2015, NEUROTHERAPEUTICS, V12, P692, DOI 10.1007/s13311-015-0374-6; Dijkers M., 2013, Introducing GRADE: a systematic approach to rating evidence in systematic reviews and to guideline development; Douglas JF, 2013, J AUTISM DEV DISORD, V43, P1243, DOI 10.1007/s10803-012-1661-2; Duvall SW, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-0558; Evanoff AB, 2017, DRUG ALCOHOL DEPEN, V180, P151, DOI 10.1016/j.drugalcdep.2017.08.010; Farmer C, 2013, DRUGS, V73, P303, DOI 10.1007/s40265-013-0021-7; FDA,, 2018, FDA APPR 1 DRUG COMP; Fergusson DM, 2005, ADDICTION, V100, P354, DOI 10.1111/j.1360-0443.2005.01001.x; Fleury-Teixeira P, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01145; Frye Richard E, 2013, Front Public Health, V1, P31, DOI 10.3389/fpubh.2013.00031; Fusar-Poli L, 2019, PSYCHIAT RES, V276, P203, DOI 10.1016/j.psychres.2019.04.013; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Hanssen Pharmaceuticals., 2012, RISPERDAL PRESCRIBIN; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627; Hollander E, 2012, AM J PSYCHIAT, V169, P292, DOI 10.1176/appi.ajp.2011.10050764; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; Iannotti FA, 2014, ACS CHEM NEUROSCI, V5, P1131, DOI 10.1021/cn5000524; Jenabi Ensiyeh, 2019, Korean J Pediatr, V62, P405, DOI 10.3345/kjp.2019.00668; Karahmadi Mojgan, 2018, Adv Biomed Res, V7, P131, DOI 10.4103/abr.abr_100_18; Karhson DS, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.169; Karhson DS, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0203-y; Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173; Kent JM, 2013, J AUTISM DEV DISORD, V43, P1773, DOI 10.1007/s10803-012-1723-5; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Laughren T., 2009, RECOMMENDATION APPRO; Lee BH, 2015, EPILEPSY BEHAV, V47, P191, DOI 10.1016/j.yebeh.2015.03.017; Levy SE, 2015, CHILD ADOL PSYCH CL, V24, P117, DOI 10.1016/j.chc.2014.09.004; MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615; Madden JM, 2017, J AUTISM DEV DISORD, V47, P144, DOI 10.1007/s10803-016-2946-7; Marconi A, 2016, SCHIZOPHRENIA BULL, V42, P1262, DOI 10.1093/schbul/sbw003; Marcus RN, 2011, J CHILD ADOL PSYCHOP, V21, P229, DOI 10.1089/cap.2009.0121; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Mechoulam R, 2013, ANNU REV PSYCHOL, V64, P21, DOI 10.1146/annurev-psych-113011-143739; Medina KL, 2007, J INT NEUROPSYCH SOC, V13, P807, DOI 10.1017/S1355617707071032; Moher D, 2010, INT J SURG, V8, P658, DOI [10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2700]; Morrison PD, 2009, PSYCHOL MED, V39, P1607, DOI 10.1017/S0033291709005522; Mustonen A, 2018, BRIT J PSYCHIAT, V212, P227, DOI 10.1192/bjp.2017.52; Narang S, 2008, J PAIN, V9, P254, DOI 10.1016/j.jpain.2007.10.018; Nicholson AN, 2004, J CLIN PSYCHOPHARM, V24, P305, DOI 10.1097/01.jcp.0000125688.05091.8f; Poleg S, 2019, PROG NEURO-PSYCHOPH, V89, P90, DOI 10.1016/j.pnpbp.2018.08.030; Pope HG, 2003, DRUG ALCOHOL DEPEN, V69, P303, DOI 10.1016/S0376-8716(02)00334-4; Pretzsch CM, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0654-8; Pretzsch CM, 2019, J PSYCHOPHARMACOL, V33, P1141, DOI 10.1177/0269881119858306; Pretzsch CM, 2019, NEUROPSYCHOPHARMACOL, V44, P1398, DOI 10.1038/s41386-019-0333-8; Robb Adelaide S, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10m01008gry; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Rouche H-L., 2021, STUDY BALOVAPTAN ADU; Rubino T, 2008, NEUROPHARMACOLOGY, V54, P151, DOI 10.1016/j.neuropharm.2007.06.024; Scahill L, 2017, J CHILD ADOL PSYCHOP, V27, P125, DOI 10.1089/cap.2016.0107; Scahill L, 2016, J AM ACAD CHILD PSY, V55, P415, DOI 10.1016/j.jaac.2016.02.016; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Schleider LBL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37570-y; Schreiner AM, 2012, EXP CLIN PSYCHOPHARM, V20, P420, DOI 10.1037/a0029117; Scott JC, 2018, JAMA PSYCHIAT, V75, P585, DOI 10.1001/jamapsychiatry.2018.0335; Sprengers JJ, 2021, J AM ACAD CHILD PSY, V60, P865, DOI 10.1016/j.jaac.2020.07.888; Stepanova E, 2017, DIALOGUES CLIN NEURO, V19, P395; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Thorkelson G, 2019, J CHILD ADOL PSYCHOP, V29, P705, DOI 10.1089/cap.2019.0001; van Os J, 2002, AM J EPIDEMIOL, V156, P319, DOI 10.1093/aje/kwf043; Vaughn LK, 2010, BRIT J PHARMACOL, V160, P530, DOI 10.1111/j.1476-5381.2010.00790.x; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Volkmar FR, 2003, LANCET, V362, P1133, DOI 10.1016/S0140-6736(03)14471-6; Ware MA, 2010, ANESTH ANALG, V110, P604, DOI 10.1213/ANE.0b013e3181c76f70; Wei D, 2016, CANNABIS CANNABINOID, V1, P81, DOI 10.1089/can.2015.0008; Wilkinson Samuel T, 2014, Curr Addict Rep, V1, P115; Zamberletti E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091916";97;8;8;0;26;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;2578-5125;2378-8763;;CANNABIS CANNABINOID;Cannabis Cannabinoid Res.;AUG;2022;7;4;;;;;451;463;;10.1089/can.2020.0154;http://dx.doi.org/10.1089/can.2020.0154;;AUG 2021;13;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;4D8GH;34432543;Green Published;;;24/11/2024;WOS:000690235600001;View Full Record in Web of Science
J;"Surapaty, IA; Simadibrata, C; Rejeki, ES; Mangunatmadja, I";;;;"Surapaty, Imtiaz Amrinusantara; Simadibrata, Christina; Rejeki, Ekky Sri; Mangunatmadja, Irawan";;;Laser Acupuncture Effects on Speech and Social Interaction in Patients with Autism Spectrum Disorder;MEDICAL ACUPUNCTURE;;;English;Article;;;;;;"speech ability; social interaction; autism spectrum disorder; laser acupuncture";"KNEE OSTEOARTHRITIS; NEUROTROPHIC FACTOR; CHILDREN; EFFICACY; SEROTONIN; PROTEIN; MODEL";"Objective: Disorders of speech ability and social interaction are the most-common symptoms in children with autism spectrum disorder (ASD). Acupuncture, as an adjunctive therapy, is known to help improve speech ability and social interaction in children with this condition. One of the acupuncture modalities with minimal side-effects, and that is safe for children, is laser acupuncture orlaserpuncture. This study's aim was to determine laserpuncture's effects on speech ability and social interactions in patients with ASD. Materials and Methods: This randomized, double-blinded clinical trial involved 46 patients in 2 groups. All respondents qualified, and none dropped out. The treatment group (n = 23) received sensory-occupational integrative therapy and verum laserpuncture therapy and the control group (n = 23) received sensory-occupational integrative therapy and placebo laserpuncture. The groups' speech ability and social interaction were evaluated with a WeeFIM(R)questionnaire; parental reports were collected, using sensory profiles before and after treatment. Results: There were improvements in speech ability and social interaction in the verum laserpuncture group more than in the placebo group after treatment. Perception score wasP < 0.001; odds ratio (OR): 18.8; 95% confidence interval (CI): 4.09-87.17. Expression score wasP < 0.001;OR:50.2; 95% CI: 5.61-450.2. Social interaction score wasP = 0.005;OR:7.2; 95% CI: 1.68-31.42. Parental report score wasP = 0.765. Conclusions: Verum laserpuncture in this clinical trial improved speech ability and social interaction scores more effectively than placebo laserpuncture did in patients with ASD.";"[Surapaty, Imtiaz Amrinusantara; Simadibrata, Christina] Univ Indonesia, RSUPN Dr Cipto Mangunkusumo Natl Gen Hosp, Fac Med, Dept Med Acupuncture, Cent Jakarta, Indonesia; [Rejeki, Ekky Sri] RSPAD Gatot Soebroto, Cent Jakarta, Indonesia; [Mangunatmadja, Irawan] Univ Indonesia, RSUPN Dr Cipto Mangunkusumo, Fac Med, Div Pediat Neurol,Dept Pediat, Cent Jakarta, Indonesia";"University of Indonesia; University of Indonesia";Surapaty, IA (corresponding author), Univ Indonesia, Dr Cipto Mangunkusumo Natl Gen Hosp, Fac Med, Dept Med Acupuncture, Jl Pangeran Diponegoro 71, Cent Jakarta 10430, Indonesia.;amrinusantara@gmail.com;;Mangunatmadja, Irawan/0000-0002-6766-8633;;;;"Al Rashoud AS, 2014, PHYSIOTHERAPY, V100, P242, DOI 10.1016/j.physio.2013.09.007; Al-Ayadhi LY, 2012, NEUROCHEM RES, V37, P394, DOI 10.1007/s11064-011-0624-x; Allam H, 2008, J ALTERN COMPLEM MED, V14, P109, DOI 10.1089/acm.2007.0508; Amjad A, 2015, J MOL GENETIC MED, V9, P1; [Anonymous], 2016, J PEDIAT TRADITIONAL; Anwar S, 2020, LASER ACUPUNCTURE AU; APA, 2013, DIAGN STAT MAN MENT, Vfifth; Autism Society of America, 2020, LIV AUT; Bauman M.L., 1994, NEUROBIOLOGY AUTISM; Boat TF, 2015, MENTAL DISORDERS AND DISABILITIES AMONG LOW-INCOME CHILDREN, P1; Carlon S, 2014, AUSTRALAS J SPEC EDU, V38, P63, DOI 10.1017/jse.2014.4; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Ciptomangunkusumo General Hospital Outpatient Installation, 2015, REP NUMB CHILDR POL; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; Goin-Kochel RP, 2009, RES AUTISM SPECT DIS, V3, P528, DOI 10.1016/j.rasd.2008.11.001; Griffiths KK, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4314025; Guthrie W, 2013, J CHILD PSYCHOL PSYC, V54, P582, DOI 10.1111/jcpp.12008; Helianthi DR, 2016, ACTA MED INDONES, V48, P114; Hwang IK, 2010, J VET MED SCI, V72, P1431, DOI 10.1292/jvms.09-0527; Kanner L, 1995, PSYCHIAT ENFANT, V38, P421; Kasran S., 2003, J KEDOKTER TRISAKTI, V22, P24; Khongrum J, 2017, J ACUPUNCT MERIDIAN, V10, P231, DOI 10.1016/j.jams.2017.06.006; KIM SY, 2016, EVID-BASED COMPL ALT, V2016; Kreisel V, 2012, PRACTICAL HDB LASER; Li LY, 2014, ACUPUNCT MED, V32, P503, DOI 10.1136/acupmed-2014-010602; Li QQ, 2015, PHYSIOL BEHAV, V139, P482, DOI 10.1016/j.physbeh.2014.12.001; LITSCHER G, 2012, EVID BASED COMPL ALT; Lu YJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-178; Rossignol DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00150; Salomone E, 2016, AUTISM, V20, P233, DOI 10.1177/1362361315577218; Shan Y, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/103491; Sujudi Y, 2004, Effects of Laserpuncture on Children with Autism; Toma C, 2013, WORLD J BIOL PSYCHIA, V14, P516, DOI 10.3109/15622975.2011.602719; Wattanathorn J, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/937601; Whitaker-Azmitia PM, 2001, BRAIN RES BULL, V56, P479, DOI 10.1016/S0361-9230(01)00615-3; Won H, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00019; Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91; Yun YC, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/7181637; Zhang D, 2012, PHYSIOL RES, V61, P113, DOI 10.33549/physiolres.932053";39;11;13;0;9;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1933-6586;1933-6594;;MED ACUPUNCT;Med. Acupunct.;oct-01;2020;32;5;;;;;300;309;;10.1089/acu.2020.1417;http://dx.doi.org/10.1089/acu.2020.1417;;sept-20;10;Integrative & Complementary Medicine;Emerging Sources Citation Index (ESCI);Integrative & Complementary Medicine;OF1BJ;33101575;Green Published;;;24/11/2024;WOS:000582008200001;View Full Record in Web of Science
J;"Kasari, C; Dean, M; Kretzmann, M; Shih, W; Orlich, F; Whitney, R; Landa, R; Lord, C; King, B";;;;"Kasari, Connie; Dean, Michelle; Kretzmann, Mark; Shih, Wendy; Orlich, Felice; Whitney, Rondalyn; Landa, Rebecca; Lord, Catherine; King, Bryan";;;Children with autism spectrum disorder and social skills groups at school: a randomized trial comparing intervention approach and peer composition;JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY;;;English;Article;;;;;;"Social skills groups; autism spectrum disorders; inclusion; peer relationships; teacher child relationship; social networks";;BackgroundPeer relationships improve for children with autism spectrum disorder (ASD) in clinic-based social skills groups but rarely generalize to real world contexts. This study compares child outcomes of two social skills interventions conducted in schools with children in Kindergarten through fifth grade. MethodChildren with ASD were randomized to one of two interventions that varied on group composition (mixed typical and ASD vs. all ASD or social difficulties) and intervention approach (didactic SKILLS based vs. activity-based ENGAGE groups). Interventions were implemented at school for 8 weeks (16 sessions) with an 8-week follow-up. Innovative measures of peer nomination and playground peer engagement, as well as teacher reports of child behavior problems and teacher-child relationship were analyzed for 137 children with ASD across four sites. ResultsOn the primary outcome of social network connections from the peer nomination measure, there was no main effect of treatment, but there were moderator effects. Children with low teacher-child closeness or high conflict improved more in their social connections if they received the SKILLS intervention, whereas children with higher teacher-child closeness improved more if they received the ENGAGE intervention. Only two secondary outcome measures yielded significant effects of treatment. Children in the SKILLS groups increased peer engagement and decreased isolation during recess. Child behavior problems and teacher-child closeness moderated peer engagement such that children with higher behavior problems and lower closeness benefitted more from SKILLS groups. ConclusionsThese findings suggest that social skills groups conducted at school can affect both peer engagement during recess as well as peer acceptability. Child characteristics and teacher-child relationship prior to intervention yield important information on who might benefit from a specific social skills intervention.;"[Kasari, Connie] Univ Calif Los Angeles, Ctr Autism Res & Treatment, Los Angeles, CA 90024 USA; [Dean, Michelle] Calif State Univ, Dept Special Educ, Channel Isl, CA USA; [Kretzmann, Mark; Shih, Wendy; King, Bryan] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA; [Orlich, Felice] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA; [Whitney, Rondalyn] Clarkson Univ, Dept Occupat Therapy, Potsdam, NY USA; [Landa, Rebecca] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA; [Lord, Catherine] Weill Cornell Med Coll, Ctr Autism & Developing Brain, White Plains, NY USA";"University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Clarkson University; Kennedy Krieger Institute; Johns Hopkins University; Cornell University; Weill Cornell Medicine";Kasari, C (corresponding author), Univ Calif Los Angeles, Semel Inst 68 268, Los Angeles, CA 90024 USA.;Kasari@gseis.ucla.edu;"Whitney, Rondalyn/AAS-1870-2021; Dean, Michelle/AAA-4528-2022";;"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [UA3MC11055]; Autism Intervention Research Network on Behavioral Health";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS); Autism Intervention Research Network on Behavioral Health";This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number UA3MC11055, Autism Intervention Research Network on Behavioral Health. The information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.;"[Anonymous], STUDENT TEACHE UNPUB; [Anonymous], 2005, The development of the playground observation of peer engagement (POPE) Measure, DOI DOI 10.1080/13803610802337657; [Anonymous], 1994, Lifelines and risks: Pathways of youth in our time; Bauminger N, 2003, J AUTISM DEV DISORD, V33, P489, DOI 10.1023/A:1025827427901; Beaumont R, 2015, PSYCHOL SCHOOLS, V52, P390, DOI 10.1002/pits.21831; Bellini S, 2007, REM SPEC EDUC, V28, P153, DOI 10.1177/07419325070280030401; Berndt TJ, 2002, CURR DIR PSYCHOL SCI, V11, P7, DOI 10.1111/1467-8721.00157; Dean M, 2013, DISCOURSE STUD, V15, P147, DOI 10.1177/1461445612471472; Gresham FM., 2008, SOCIAL SKILLS IMPROV; Hallinan M.T., 1980, FRIENDSHIP SOCIAL RE, P321; Kasari C, 2013, AUTISM, V17, P254, DOI 10.1177/1362361312470496; Kasari C, 2012, J CHILD PSYCHOL PSYC, V53, P431, DOI 10.1111/j.1469-7610.2011.02493.x; Kasari C, 2011, J AUTISM DEV DISORD, V41, P533, DOI 10.1007/s10803-010-1076-x; Kenworthy L, 2014, J CHILD PSYCHOL PSYC, V55, P374, DOI 10.1111/jcpp.12161; Koegel LK, 2012, J POSIT BEHAV INTERV, V14, P220, DOI 10.1177/1098300712437042; Kretzmann M., 2008, ENGAGE SOCIAL UNPUB; Laugeson EA, 2012, J AUTISM DEV DISORD, V42, P1025, DOI 10.1007/s10803-011-1339-1; Lord C., 2002, AUTISM DIAGNOSTIC OB; Reichow Brian, 2013, Evid Based Child Health, V8, P266, DOI 10.1002/ebch.1903; Robertson K, 2003, J AUTISM DEV DISORD, V33, P123, DOI 10.1023/A:1022979108096; Rutter M., 2003, SOCIAL COMMUNICATION; Wolfberg P, 2015, J AUTISM DEV DISORD, V45, P830, DOI 10.1007/s10803-014-2245-0";22;103;132;6;99;WILEY-BLACKWELL;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0021-9630;1469-7610;;J CHILD PSYCHOL PSYC;J. Child Psychol. Psychiatry;FEB;2016;57;2;;;;;171;179;;10.1111/jcpp.12460;http://dx.doi.org/10.1111/jcpp.12460;;;9;"Psychology, Developmental; Psychiatry; Psychology";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";DB8YO;26391889;;;;24/11/2024;WOS:000368803300008;View Full Record in Web of Science
J;"Frye, RE; Sequeira, JM; Quadros, EV; James, SJ; Rossignol, DA";;;;"Frye, R. E.; Sequeira, J. M.; Quadros, E. V.; James, S. J.; Rossignol, D. A.";;;Cerebral folate receptor autoantibodies in autism spectrum disorder;MOLECULAR PSYCHIATRY;;;English;Article;;;;;;"autism spectrum disorders; cerebral folate deficiency; folate receptor autoantibody; folinic acid; leucovorin calcium";"CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; PROPIONIC-ACID; CHILDREN; DEFICIENCY; POLYMORPHISM; ASSOCIATION; 5-METHYLTETRAHYDROFOLATE; AUTOIMMUNITY; RETARDATION";"Cerebral folate deficiency (CFD) syndrome is a neurodevelopmental disorder typically caused by folate receptor autoantibodies (FRAs) that interfere with folate transport across the blood-brain barrier. Autism spectrum disorders (ASDs) and improvements in ASD symptoms with leucovorin (folinic acid) treatment have been reported in some children with CFD. In children with ASD, the prevalence of FRAs and the response to leucovorin in FRA-positive children has not been systematically investigated. In this study, serum FRA concentrations were measured in 93 children with ASD and a high prevalence (75.3%) of FRAs was found. In 16 children, the concentration of blocking FRA significantly correlated with cerebrospinal fluid 5-methyltetrahydrofolate concentrations, which were below the normative mean in every case. Children with FRAs were treated with oral leucovorin calcium (2mgkg(-1) per day; maximum 50mg per day). Treatment response was measured and compared with a wait-list control group. Compared with controls, significantly higher improvement ratings were observed in treated children over a mean period of 4 months in verbal communication, receptive and expressive language, attention and stereotypical behavior. Approximately one-third of treated children demonstrated moderate to much improvement. The incidence of adverse effects was low. This study suggests that FRAs may be important in ASD and that FRA-positive children with ASD may benefit from leucovorin calcium treatment. Given these results, empirical treatment with leucovorin calcium may be a reasonable and non-invasive approach in FRA-positive children with ASD. Additional studies of folate receptor autoimmunity and leucovorin calcium treatment in children with ASD are warranted. Molecular Psychiatry (2013) 18, 369-381; doi:10.1038/mp.2011.175; published online 10 January 2012";"[Frye, R. E.; James, S. J.] Univ Arkansas Med Sci, Dept Pediat, Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72202 USA; [Sequeira, J. M.; Quadros, E. V.] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; [Rossignol, D. A.] Int Child Dev Resource Ctr, Melbourne, FL USA";"University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; State University of New York (SUNY) System; SUNY Downstate Health Sciences University";Frye, RE (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72202 USA.;REFrye@uams.edu;"Frye, Richard/AAB-5543-2020; Rossignol, Daniel/I-5947-2019";Rossignol, Daniel/0000-0002-4405-8664;"Autism Research Institute; Jane Botsford Johnson Foundation";"Autism Research Institute; Jane Botsford Johnson Foundation";We thank Michelle R Christie and Jamie Chu for their technical assistance. This study was supported, in part, by funding from the Autism Research Institute and the Jane Botsford Johnson Foundation.;"Adams M, 2007, NEUROSCI LETT, V422, P24, DOI 10.1016/j.neulet.2007.05.025; Ahn MS, 2005, J CHILD ADOL PSYCHOP, V15, P520, DOI 10.1089/cap.2005.15.520; [Anonymous], 1976, ECDEU ASSESSMENT MAN; APA, 1994, AM PSYCHIATR ASSOC, V4th; Berrocal-Zaragoza MI, 2009, FERTIL STERIL, V91, P1518, DOI 10.1016/j.fertnstert.2008.08.104; Boris M., 2004, J AM PHYS SURG, V9, P106; Braunschweig D, 2008, NEUROTOXICOLOGY, V29, P226, DOI 10.1016/j.neuro.2007.10.010; Chauhan Abha, 2006, Pathophysiology, V13, P171, DOI 10.1016/j.pathophys.2006.05.007; Chauhan A, 2011, J NEUROCHEM, V117, P209, DOI 10.1111/j.1471-4159.2011.07189.x; Croen LA, 2008, BIOL PSYCHIAT, V64, P583, DOI 10.1016/j.biopsych.2008.05.006; Crott JW, 2001, CANCER EPIDEM BIOMAR, V10, P1089; Duthie SJ, 1998, FASEB J, V12, P1491, DOI 10.1096/fasebj.12.14.1491; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Filipek PA, 2004, J AUTISM DEV DISORD, V34, P615, DOI 10.1007/s10803-004-5283-1; Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914; Finegold SM, ANAEROBE; Frye RE, 2011, PEDIATR RES, V69, p41R, DOI 10.1203/PDR.0b013e318212f16b; Garcia-Cazorla A, 2008, NEUROLOGY, V70, P1360, DOI 10.1212/01.wnl.0000309223.98616.e4; Goin-Kochel RP, 2009, AUTISM RES, V2, P98, DOI 10.1002/aur.70; Hansen FJ, 2005, MOL GENET METAB, V84, P371, DOI 10.1016/j.ymgme.2004.12.001; Hou ZJ, 2009, J BIOL CHEM, V284, P3285, DOI 10.1074/jbc.M807206200; Hulley S.B., 2006, Designing Clinical Research, V3rd; Hyland K, 2010, J INHERIT METAB DIS, V33, P563, DOI 10.1007/s10545-010-9159-6; Berrocal-Zaragoza MI, 2009, J NUTR, V139, P1037, DOI 10.3945/jn.108.102475; Iskandar BJ, 2010, J CLIN INVEST, V120, P1603, DOI 10.1172/JCI40000; James SJ, 2008, J AUTISM DEV DISORD, V38, P1966, DOI [10.1007/s10803-008-0591-5, 10.1007/s10803-008-0614-2]; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2009, AM J CLIN NUTR, V89, P425, DOI 10.3945/ajcn.2008.26615; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Koenig MK, 2008, J CHILD NEUROL, V23, P106, DOI 10.1177/0883073807307986; MacFabe DF, 2007, BEHAV BRAIN RES, V176, P149, DOI 10.1016/j.bbr.2006.07.025; MacFabe DF., 2008, American Journal of Biochemistry and Biotechnology, V4, P146, DOI DOI 10.3844/AJBBSP.2008.146.166; Matherly LH, 2007, CANCER METAST REV, V26, P111, DOI 10.1007/s10555-007-9046-2; Melnyk S, J AUTISM DEV DISORD; Miller AL, 2008, ALTERN MED REV, V13, P216; Mohammad NS, 2009, PSYCHIAT GENET, V19, P171, DOI 10.1097/YPG.0b013e32832cebd2; Molloy AM, 2009, NEW ENGL J MED, V361, P152, DOI 10.1056/NEJMoa0803783; Moretti P, 2005, NEUROLOGY, V64, P1088, DOI 10.1212/01.WNL.0000154641.08211.B7; Moretti P, 2008, J AUTISM DEV DISORD, V38, P1170, DOI 10.1007/s10803-007-0492-z; Nagarajan RP, 2006, EPIGENETICS-US, V1, P172, DOI 10.4161/epi.1.4.3514; Neustadt J, 2008, MOL NUTR FOOD RES, V52, P780, DOI 10.1002/mnfr.200700075; Nikolov RN, 2009, J AUTISM DEV DISORD, V39, P405, DOI 10.1007/s10803-008-0637-8; O'Byrne MR, 2010, BIRTH DEFECTS RES A, V88, P689, DOI 10.1002/bdra.20706; Pogribny IP, 2008, BRAIN RES, V1237, P25, DOI 10.1016/j.brainres.2008.07.077; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P276, DOI 10.1055/s-2008-1065354; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P184, DOI 10.1055/s-2007-991150; Ramaekers VT, 2008, DEV MED CHILD NEUROL, V50, P346, DOI 10.1111/j.1469-8749.2008.02053.x; Ramaekers VT, 2005, NEW ENGL J MED, V352, P1985, DOI 10.1056/NEJMoa043160; Ramaekers VT, 2002, NEUROPEDIATRICS, V33, P301, DOI 10.1055/s-2002-37082; Ramaekers VT, 2003, NEUROLOGY, V61, P506, DOI 10.1212/01.WNL.0000078939.64774.1B; Ramaekers VT, 2004, DEV MED CHILD NEUROL, V46, P843, DOI 10.1017/S0012162204001471; Rice Catherine, 2009, Morbidity and Mortality Weekly Report, V58, P1; Rossignol DA, MOL PSYCHIAT; Sajdel-Sulkowska EM, 2011, CEREBELLUM, V10, P43, DOI 10.1007/s12311-010-0223-4; Sajdel-Sulkowska EM, 2009, CEREBELLUM, V8, P366, DOI 10.1007/s12311-009-0105-9; Salojin KV, 2011, BLOOD, V117, P4895, DOI 10.1182/blood-2010-04-279653; Solanky N, 2010, PLACENTA, V31, P134, DOI 10.1016/j.placenta.2009.11.017; Thomas RH, 2010, J NEUROCHEM, V113, P515, DOI 10.1111/j.1471-4159.2010.06614.x; WEITMAN SD, 1992, CANCER RES, V52, P6708; Whiteley P, 2010, NUTR NEUROSCI, V13, P87, DOI 10.1179/147683010X12611460763922; Williams BL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024585; Wills S, 2007, ANN NY ACAD SCI, V1107, P79, DOI 10.1196/annals.1381.009; Wills S, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-5; Wills S, 2009, BRAIN BEHAV IMMUN, V23, P64, DOI 10.1016/j.bbi.2008.07.007; Wollack JB, 2008, J NEUROCHEM, V104, P1494, DOI 10.1111/j.1471-4159.2007.05095.x; Yuasa H, 2009, J PHARM SCI-US, V98, P1608, DOI 10.1002/jps.21515";66;144;160;0;4;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;1359-4184;1476-5578;;MOL PSYCHIATR;Mol. Psychiatr.;MAR;2013;18;3;;;;;369;381;;10.1038/mp.2011.175;http://dx.doi.org/10.1038/mp.2011.175;;;13;"Biochemistry & Molecular Biology; Neurosciences; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry";112BZ;22230883;hybrid, Green Published;;;24/11/2024;WOS:000316568100014;View Full Record in Web of Science
J;"Nasiri, M; Parmoon, Z; Farahmand, Y; Moradi, A; Farahmand, K; Moradi, K; Basti, FA; Mohammadi, MR; Akhondzadeh, S";;;;"Nasiri, Mehry; Parmoon, Zohal; Farahmand, Yalda; Moradi, Ali; Farahmand, Kimia; Moradi, Kamyar; Basti, Fatemeh A.; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin";;;L-carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial;INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"adjunctive therapy; autism spectrum disorder; clinical trial; L-carnitine; risperidone";"ACETYL-L-CARNITINE; ALPHA-LIPOIC ACID; RATING-SCALE; CHILDREN; VALIDITY; ADULTS; SUPPLEMENTATION; SCHIZOPHRENIA; ADOLESCENTS; RELIABILITY";The present study was designed to evaluate the efficacy and safety of L-carnitine as an adjuvant agent to risperidone in the treatment of autism spectrum disorder (ASD)-associated behaviors. In this study, 68 children with confirmed ASD were randomly allocated to receive either L-carnitine (150 mg/day) or matched placebo in addition to risperidone. We utilized the Aberrant Behavior Checklist-Community Edition scale (ABC-C) and a checklist of potential adverse effects to assess changes in behavioral status and safety profile at weeks 0, 5 and 10 of the trial. The primary outcome was defined as a change in the irritability subscale score. Sixty patients with similar baseline characteristics completed the trial period. Although scores of ABC-C subscales significantly decreased in both groups over the trial period, the combination of L-carnitine and risperidone resulted in more reduction on the irritability and hyperactivity subscales compared to the combination of risperidone and placebo (P = 0.033 and P < 0.001, respectively). However, changes in lethargy, stereotypic behavior and inappropriate speech subscales were similar between groups. In conclusion, L-carnitine adjuvant to risperidone could improve irritability and hyperactivity features in children with ASD. Results of this study should be considered preliminary and further clinical trials with larger sample sizes and longer follow-up periods are warranted.;"[Nasiri, Mehry; Parmoon, Zohal; Moradi, Ali; Farahmand, Kimia; Moradi, Kamyar; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin] Roozbeh Psychiat Hosp, Psychiat Res Ctr, Tehran, Iran; [Farahmand, Yalda] Univ Tehran Med Sci, Sch Med, Tehran, Iran; [Basti, Fatemeh A.] Islamic Azad Univ, Tehran Med Branch, Tehran, Iran; [Akhondzadeh, Shahin] Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, Dept Psychiat, South Kargar St, Tehran 13337, Iran";"Tehran University of Medical Sciences; Islamic Azad University; Tehran University of Medical Sciences";Akhondzadeh, S (corresponding author), Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, Dept Psychiat, South Kargar St, Tehran 13337, Iran.;s.akhond@neda.net;"Mohammadi, Mohammad Reza/ABD-9550-2021; Moradi, Kamyar/KXQ-6495-2024; Moradi, Ali/AAV-9313-2021; Akhondzadeh, Shahin/F-2914-2018";Parmoon, Zohal/0000-0001-9462-0750;Tehran University of Medical Sciences [50830];Tehran University of Medical Sciences(Tehran University of Medical SciencesGolestan University of Medical Sciences);This study was supported by a grant from Tehran University of Medical Sciences to Prof. Shahin Akhondzadeh (grant number 50830).;"Abbasi SH, 2010, SCHIZOPHR RES, V116, P101, DOI 10.1016/j.schres.2009.11.008; Akhondzadeh S, 2000, J CLIN PHARM THER, V25, P347, DOI 10.1046/j.1365-2710.2000.00295.x; AMAN MG, 1995, AM J MENT RETARD, V100, P283; AMAN MG, 1985, AM J MENT DEF, V89, P485; Anderson M.P., 2008, Am J Biochem Biotechnol, P167, DOI [10.3844/ajbbsp.2008.167.176, DOI 10.3844/AJBBSP.2008.167.176]; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053; Bankaitis VA, 2019, J BIOL CHEM, V294, P19424, DOI 10.1074/jbc.AW119.008137; BARONCOHEN S, 1988, J AUTISM DEV DISORD, V18, P379, DOI 10.1007/BF02212194; Bauman ML, 2010, NEUROTHERAPEUTICS, V7, P320, DOI 10.1016/j.nurt.2010.06.001; Bölte S, 2019, CELL MOL LIFE SCI, V76, P1275, DOI 10.1007/s00018-018-2988-4; Brennan BP, 2013, J CLIN PSYCHOPHARM, V33, P627, DOI 10.1097/JCP.0b013e31829a83f5; Chen FL, 2020, NAT PROD RES, V34, P2816, DOI 10.1080/14786419.2019.1596092; Chouinard G, 2005, SCHIZOPHR RES, V76, P247, DOI 10.1016/j.schres.2005.02.013; Fahmy SF, 2013, VALUE HEALTH, V16, pA15, DOI 10.1016/j.jval.2013.03.092; Fahmy SF, 2013, RES AUTISM SPECT DIS, V7, P159, DOI 10.1016/j.rasd.2012.07.006; Ferreira GC, 2017, NEUROCHEM RES, V42, P1661, DOI 10.1007/s11064-017-2288-7; Foxx RM, 2008, CHILD ADOL PSYCH CL, V17, P821, DOI 10.1016/j.chc.2008.06.007; GARFIN DG, 1988, J AUTISM DEV DISORD, V18, P367, DOI 10.1007/BF02212193; Gargus J.J., 2008, Am J Biochem Biotechnol, V4, P198, DOI [10.3844/ajbbsp.2008.198.207, DOI 10.3844/AJBBSP.2008.198.207]; Geier DA, 2011, MED SCI MONITOR, V17, pPI15, DOI 10.12659/MSM.881792; Goin-Kochel Robin P, 2019, Glob Pediatr Health, V6, p2333794X19830696, DOI 10.1177/2333794X19830696; Hellings JA, 2006, J AUTISM DEV DISORD, V36, P401, DOI 10.1007/s10803-006-0078-1; Hirvikoski T, 2016, BRIT J PSYCHIAT, V208, P232, DOI 10.1192/bjp.bp.114.160192; Jonsson U, 2017, J CHILD PSYCHOL PSYC, V58, P439, DOI 10.1111/jcpp.12645; Kashani L, 2017, PHARMACOPSYCHIATRY, V50, P64, DOI 10.1055/s-0042-115306; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kepka A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061202; Kern JK, 2011, RES AUTISM SPECT DIS, V5, P1011, DOI 10.1016/j.rasd.2010.11.002; Kodak T, 2020, PEDIATR CLIN N AM, V67, P525, DOI 10.1016/j.pcl.2020.02.007; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Malaguarnera M, 2007, AM J CLIN NUTR, V86, P1738; McDougle CJ, 1998, ARCH GEN PSYCHIAT, V55, P633, DOI 10.1001/archpsyc.55.7.633; Nasca D ZG, 1989, New Trends Clin Neuropharmacol, V3, P225; Negin Y., 2015, Iran J Psychiatry, V10, P144; Palmieri L, 2010, BBA-BIOENERGETICS, V1797, P1130, DOI 10.1016/j.bbabio.2010.04.018; Pettegrew JW, 2002, BIPOLAR DISORD, V4, P61, DOI 10.1034/j.1399-5618.2002.01180.x; Robb AS, 2010, DEV DISABIL RES REV, V16, P258, DOI 10.1002/ddrr.118; Rossignol D.A., 2008, Am. J. Biochem. Biotechnol, V4, P208, DOI [10.3844/AJBBSP.2008.208.217, DOI 10.3844/AJBBSP.2008.208.217]; Sanchack KE, 2016, AM FAM PHYSICIAN, V94, P972; Shakibaei F, 2023, CLIN NEUROPHARMACOL, V46, P55, DOI 10.1097/WNF.0000000000000544; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Suchy J, 2009, NUTR RES, V29, P70, DOI 10.1016/j.nutres.2008.11.004; Vahia VN, 2013, INDIAN J PSYCHIAT, V55, P220, DOI 10.4103/0019-5545.117131; Wang R, 2019, MOL MED REP, V19, P743, DOI 10.3892/mmr.2018.9647; Zaitone SA, 2012, PHARMACOL BIOCHEM BE, V100, P347, DOI 10.1016/j.pbb.2011.09.002";45;4;4;1;1;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0268-1315;1473-5857;;INT CLIN PSYCHOPHARM;Int. Clin. Psychopharmacol.;JUL;2024;39;4;;;;;232;239;;10.1097/YIC.0000000000000496;http://dx.doi.org/10.1097/YIC.0000000000000496;;;8;"Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pharmacology & Pharmacy; Psychiatry";SO1H7;37551601;;;;24/11/2024;WOS:001235296500006;View Full Record in Web of Science
J;"Mizuguchi, M; Ikeda, H; Kagitani-Shimono, K; Yoshinaga, H; Suzuki, Y; Aoki, M; Endo, M; Yonemura, M; Kubota, M";;;;"Mizuguchi, Masashi; Ikeda, Hiroko; Kagitani-Shimono, Kuriko; Yoshinaga, Harumi; Suzuki, Yasuhiro; Aoki, Makoto; Endo, Masae; Yonemura, Masataka; Kubota, Masaya";;;Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan;BRAIN & DEVELOPMENT;;;English;Article;;;;;;"Tuberous sclerosis complex; Epilepsy; Autism spectrum disorder; Everolimus; Refractory seizures; EXIST-3";"GIANT-CELL ASTROCYTOMAS; MAMMALIAN TARGET; SPORADIC LYMPHANGIOLEIOMYOMATOSIS; DOUBLE-BLIND; MTOR; ANGIOMYOLIPOMA; THERAPY; MULTICENTER; INHIBITORS; PHASE-3";"Background: Epilepsy and autism spectrum disorder (ASD) are the common neurological manifestations of tuberous sclerosis complex (TSC). EXIST-3 study has recently demonstrated that everolimus reduces seizures in patients with TSC and refractory epilepsy. Here we report the efficacy and safety of everolimus for treatment-refractory seizures in Japanese patients of EXIST-3, along with the exploratory analysis evaluating the everolimus effect on comorbid ASD symptoms in these patients. Methods: Primary end point was change in seizure frequency from baseline defined as response rate (>= 50% reduction) and median percentage reduction in the seizure frequency. Pervasive Developmental Disorders Autism Society Japan Rating Scale (PARS) scores were assessed at baseline and at week-18 for ASD symptoms. Results: Overall, 35 Japanese patients were randomized to everolimus low-exposure (LE; n = 10), everolimus high-exposure (HE; n = 14), or placebo (n = 11). The response rate was 30.0% and 28.6% versus 0% with the everolimus LE and HE versus placebo arm, respectively. Similarly, the median percentage reduction in seizure frequency was 6.88% and 38.06% versus -6.67%. Stomatitis was the most frequently reported adverse event (everolimus LE, 100%; HE, 78.6%; placebo, 9.1%). Four of 11 patients with ASD in the everolimus arms and 1 of 8 patients with ASD in the placebo arm showed >= 5 point decrease in PARS scores. Conclusions: Adjunctive everolimus treatment improved seizure frequency with a tolerable safety relative to placebo among 35 Japanese patients with TSC-associated refractory seizures, consistent with the results of overall EXIST-3 study involving 366 patients. A favorable trend towards the improvement of ASD symptoms was observed. (C) 2018 The Authors. Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.";"[Mizuguchi, Masashi] Univ Tokyo, Grad Sch Med, Dept Dev Med Sci, Tokyo, Japan; [Ikeda, Hiroko] NHO, Dept Pediat, Shizuoka Inst Epilepsy & Neurol Disorders, Shizuoka, Japan; [Kagitani-Shimono, Kuriko] Osaka Univ, United Grad Sch Child Dev, Osaka, Japan; [Yoshinaga, Harumi] Okayama Univ Hosp, Dept Child Neurol, Okayama, Japan; [Yoshinaga, Harumi] Minami Okayama Med Ctr, Dept Severely Disabled, Children Ctr, Okayama, Japan; [Suzuki, Yasuhiro] Osaka Womens & Childrens Hosp, Dept Pediat Neurol, Osaka, Japan; [Aoki, Makoto; Endo, Masae; Yonemura, Masataka] Novatis Pharma KK, Tokyo, Japan; [Kubota, Masaya] Natl Ctr Child Hlth & Dev, Div Neurol, Tokyo, Japan";"University of Tokyo; Osaka University; Okayama University; National Center for Child Health & Development - Japan";Mizuguchi, M (corresponding author), Univ Tokyo, Dept Dev Med Sci, Tokyo, Japan.;mizuguchi-tky@umin.net;"; Kagitani-Shimono, Kuriko/IWL-8088-2023";"Kubota, Masaya/0000-0002-8299-4867; Kagitani-Shimono, Kuriko/0000-0001-9649-9499";;;;"[Anonymous], 2006, SEISHINIGAKU; Bissler JJ, 2013, LANCET, V381, P817, DOI 10.1016/S0140-6736(12)61767-X; Cardamone M, 2014, J PEDIATR-US, V164, P1195, DOI 10.1016/j.jpeds.2013.12.053; Crino PB, 2010, NEUROLOGY, V74, P1716, DOI 10.1212/WNL.0b013e3181e04325; Curatolo P, 2016, EUR J PAEDIATR NEURO, V20, P203, DOI 10.1016/j.ejpn.2015.12.005; Curatolo P, 2015, LANCET NEUROL, V14, P733, DOI 10.1016/S1474-4422(15)00069-1; Curatolo P, 2010, J CHILD NEUROL, V25, P873, DOI 10.1177/0883073810361789; Davies DM, 2011, CLIN CANCER RES, V17, P4071, DOI 10.1158/1078-0432.CCR-11-0445; Davies M, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0581-9; de Vries PJ, 2009, INT TSC RES C DNA HU; DeFilippis Melissa, 2016, Psychopharmacol Bull, V46, P18; Franz DN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158476; Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9; French JA, 2016, LANCET, V388, P2153, DOI 10.1016/S0140-6736(16)31419-2; Hatano T, 2016, INT J UROL, V23, P833, DOI 10.1111/iju.13168; Ishii R, 2015, Neuropsychiatr Electrophysiol, V1, P6, DOI DOI 10.1186/S40810-015-0004-X; Ito H, 2012, RES AUTISM SPECT DIS, V6, P1265, DOI 10.1016/j.rasd.2012.04.002; Kilincaslan A, 2017, J CHILD ADOL PSYCHOP, V27, P383, DOI 10.1089/cap.2016.0100; Krueger DA, 2013, ANN NEUROL, V74, P679, DOI 10.1002/ana.23960; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Meng XF, 2013, J NEUROL SCI, V332, P4, DOI 10.1016/j.jns.2013.05.029; Muncy J, 2009, J CHILD NEUROL, V24, P477, DOI 10.1177/0883073808324535; National Cancer Institute, 2010, COMM TERM CRIT ADV E; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Sato A, 2016, CNS NEUROL DISORD-DR, V15, P533, DOI 10.2174/1871527315666160413120638; Sato A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2295; Song DK, 2015, AM J MED GENET A, V167, P64, DOI 10.1002/ajmg.a.36787; Stafstrom C.E., 2012, Jasper's Basic Mechanisms of the Epilepsies, V4th; Sumi SMT, 2014, AUTISM OPEN ACCESS, V4, P6; Vignoli A, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0371-1; Wang S, 2014, NEUROPSYCH DIS TREAT, V10, P2021, DOI 10.2147/NDT.S51789; Wong M, 2010, EPILEPSIA, V51, P27, DOI 10.1111/j.1528-1167.2009.02341.x; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331";34;57;63;0;6;ELSEVIER SCIENCE BV;AMSTERDAM;PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS;0387-7604;1872-7131;;BRAIN DEV-JPN;Brain Dev.;JAN;2019;41;1;;;;;1;10;;10.1016/j.braindev.2018.07.003;http://dx.doi.org/10.1016/j.braindev.2018.07.003;;;10;"Clinical Neurology; Pediatrics";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Neurosciences & Neurology; Pediatrics";HH4KM;30060984;hybrid;;;24/11/2024;WOS:000455691300001;View Full Record in Web of Science
J;"Thabrew, H; Viswanathan, A; Eggleston, M; Moor, S; Chinn, D";;;;"Thabrew, Hiran; Viswanathan, Anisha; Eggleston, Matthew; Moor, Stephanie; Chinn, David";;;Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder;RESEARCH IN AUTISM SPECTRUM DISORDERS;;;English;Article;;;;;;"Autism spectrum disorder; Autism; Children; Adolescents; Pharmacotherapy; Guidelines";"RISPERIDONE; PEOPLE; TRIAL; ASD";Background: There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method: Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results: Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions: Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful.;"[Thabrew, Hiran; Viswanathan, Anisha] Univ Auckland, Dept Psychol Med, Sch Med, Auckland Hosp, Bldg 599,Level 12,Room 12007,2 Pk Rd, Auckland, New Zealand; [Eggleston, Matthew] Child & Family Specialty Serv, Christchurch, New Zealand; [Moor, Stephanie] Univ Otago, Christchurch Dept Psychol Med, Christchurch, New Zealand; [Chinn, David] ICAFS, Hutt Valley DHB, 638 High St, Lower Hutt 5010, New Zealand";"University of Auckland; Auckland City Hospital; University of Otago";Thabrew, H (corresponding author), Univ Auckland, Sch Med, Dept Psychol Med, Bldg 507,22-30 Pk Ave, Auckland, New Zealand.;"h.thabrew@auckland.ac.nz; apal754@aucklanduni.ac.nz; Matt.Eggleston@cdhb.health.nz; stephanie.moor@otago.ac.nz; David.Chinn@huttvalleydhb.org.nz";;Thabrew, Hiran/0000-0002-8755-6217;"Rotary Club of Downtown Auckland; University of Auckland";"Rotary Club of Downtown Auckland; University of Auckland";This study was generously funded by the Rotary Club of Downtown Auckland. Anisha Palanivelu Viswanathan's time also was funded by a University of Auckland summer student scholarship. Neither funder was involved in the design of the study, data collection, analysis or interpretation of data, writing of the report of the decision to submit the article for publication.;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; [Anonymous], TREATMENT COMORBID A; [Anonymous], 2013, Autism spectrum disorder in under 19s: support and management; Baribeau DA, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-014-0437-0; Broadstock M., 2011, NZ AUTISM SPECTRUM D; Chakrabarti A., 2007, COCHRANE DATABASE SY; Chandrasekhar T, 2015, DIALOGUES CLIN NEURO, V17, P219; Doyle Carolyn A, 2012, Dialogues Clin Neurosci, V14, P263; Geller B, 2012, ARCH GEN PSYCHIAT, V69, P515, DOI 10.1001/archgenpsychiatry.2011.1508; Gibson AP, 2006, ANN PHARMACOTHER, V40, P1134, DOI 10.1345/aph.1G582; Hirsch LE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009043.pub3; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Hsia YF, 2014, PSYCHOPHARMACOLOGY, V231, P999, DOI 10.1007/s00213-013-3263-x; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Ministry of Health New Zealand (NZ), 2016, NZ AUT SPECTR DIS GU; Murray ML, 2014, PSYCHOPHARMACOLOGY, V231, P1011, DOI 10.1007/s00213-013-3140-7; Postorino V, 2017, CLIN CHILD FAM PSYCH, V20, P391, DOI 10.1007/s10567-017-0237-2; Scottish Intercollegiate Guidelines Network (SIGN), 2016, SIGN 145 ASS DIAGN I; Vasa RA, 2016, PEDIATRICS, V137, pS115, DOI 10.1542/peds.2015-2851J; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013";21;7;7;1;9;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;1750-9467;1878-0237;;RES AUTISM SPECT DIS;Res. Autism Spectr. Disord.;JUN;2020;74;;;;;;;;101553;10.1016/j.rasd.2020.101553;http://dx.doi.org/10.1016/j.rasd.2020.101553;;;7;"Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychology; Psychiatry; Rehabilitation";LK4ZL;;;;;24/11/2024;WOS:000530875200001;View Full Record in Web of Science
J;"Sugimoto, Y; Yamamura, K; Takayama, T; Fukuta, Y; Aoki, K; Mikami, K; Tomoda, A";;;;"Sugimoto, Yuna; Yamamura, Kayo; Takayama, Tomoyo; Fukuta, Yasuhiko; Aoki, Kazuo; Mikami, Katsunaka; Tomoda, Akemi";;;Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance;BMC PSYCHIATRY;;;English;Article;;;;;;"Aripiprazole; Autism spectrum disorder; Children and adolescents; Irritability; Post-marketing surveillance";"DIFFICULTIES QUESTIONNAIRE; PEDIATRIC-PATIENTS; OPEN-LABEL; SAFETY; RECEPTORS; COMMUNITY; STRENGTHS";Background The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6-17 years) with autism spectrum disorder (ASD) in actual clinical sites of Japan. Methods In this post-marketing surveillance, patients were enrolled into the multicenter, prospective, non-interventional, observational study for 52 weeks, and were dosed with aripiprazole (1-15 mg/day) under daily clinical settings in Japan. Results In 510 patients, the continuation rate of aripiprazole treatment was 84.6% at day 168 (week 24) and 78.1% at day 364 (week 52). Adverse drug reactions (ADRs) occurred in 22.7% of patients (n = 116), and the most common ADRs were somnolence (9.4%), followed by weight increased (3.3%). At week 4, the mean change from baseline in the irritability subscale score for the Aberrant Behavior Checklist Japanese version (ABC-J) was - 5.7 +/- 6.8 (n = 288). Based on multiple regression analysis, comorbid attention deficit and hyperactivity did not affect the ABC-J irritability subscale score at endpoint. At week 24, the mean change from baseline for the Strengths and Difficulties Questionnaire was - 3.3 +/- 4.9 (n = 215) for the total difficulties score and 0.6 +/- 1.7 (n = 217) for the prosocial behavior subscale score. Conclusions Aripiprazole was well tolerated and effective in the long-term treatment of irritability associated with ASD in Japanese pediatric patients in the real-world clinical practice.;"[Sugimoto, Yuna; Yamamura, Kayo; Takayama, Tomoyo; Fukuta, Yasuhiko] Otsuka Pharmaceut Co Ltd, Pharmacovigilance Dept, Tokyo, Japan; [Aoki, Kazuo] Otsuka Pharmaceut Co Ltd, Med Affairs Dept, Tokyo, Japan; [Mikami, Katsunaka] Tokai Univ, Sch Med, Dept Psychiat, Hiratsuka, Kanagawa, Japan; [Tomoda, Akemi] Univ Fukui, Res Ctr Child Mental Dev, Fukui, Japan";"Otsuka Pharmaceutical; Otsuka Pharmaceutical; Tokai University; University of Fukui";Sugimoto, Y (corresponding author), Otsuka Pharmaceut Co Ltd, Pharmacovigilance Dept, Tokyo, Japan.;Sugimoto.Yuna@otsuka.jp;Tomoda, Akemi/IUO-2950-2023;;Otsuka Pharmaceutical Co., Ltd.;Otsuka Pharmaceutical Co., Ltd.(Otsuka Pharmaceutical);This surveillance was funded by Otsuka Pharmaceutical Co., Ltd.;"American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2016, JPN J CLIN PSYCHOPHA; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Caccia S, 2013, PEDIATR DRUGS, V15, P217, DOI 10.1007/s40272-013-0024-6; Coustals N, 2021, J CHILD ADOL PSYCHOP, V31, P4, DOI 10.1089/cap.2020.0014; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Hirsch LE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009043.pub3; Hirshkowitz M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/j.sleh.2014.12.010; Ichikawa H, 2018, PSYCHIAT CLIN NEUROS, V72, P84, DOI 10.1111/pcn.12607; Ichikawa H, 2017, CHILD PSYCHIAT HUM D, V48, P796, DOI 10.1007/s10578-016-0704-x; Iizuka C, 2010, BRAIN DEV-JPN, V32, P609, DOI 10.1016/j.braindev.2009.09.009; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P3063, DOI 10.2147/NDT.S174622; Mankoski R, 2013, J CHILD ADOL PSYCHOP, V23, P572, DOI 10.1089/cap.2012.0075; Marcus RN, 2011, J CLIN PSYCHIAT, V72, P1270, DOI 10.4088/JCP.09m05933; Marcus RN, 2011, J CHILD ADOL PSYCHOP, V21, P229, DOI 10.1089/cap.2009.0121; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Matsuishi T, 2008, BRAIN DEV-JPN, V30, P410, DOI 10.1016/j.braindev.2007.12.003; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Ono Y, 1996, RES DEV DISABIL, V17, P303, DOI 10.1016/0891-4222(96)00015-7; Otsuka America Pharmaceutical Inc, 2020, AR; Otsuka Pharmaceutical Co. Ltd., 2018, AR; Otsuka Pharmaceutical Netherlands B.V, 2020, AR SUMM PROD CHAR; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Robb Adelaide S, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10m01008gry; Russell G, 2011, SOC PSYCH PSYCH EPID, V46, P1283, DOI 10.1007/s00127-010-0294-z; Stark AD, 2007, PSYCHOPHARMACOLOGY, V190, P373, DOI 10.1007/s00213-006-0621-y; Tadori Y, 2007, EUR J PHARMACOL, V574, P103, DOI 10.1016/j.ejphar.2007.07.031; Volkmar Fred, 1999, Journal of the American Academy of Child and Adolescent Psychiatry, V38, p32S";29;5;6;0;6;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;APR 22;2021;21;1;;;;;;;204;10.1186/s12888-021-03201-6;http://dx.doi.org/10.1186/s12888-021-03201-6;;;12;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;RS9EX;33888067;Green Published, gold;;;24/11/2024;WOS:000644075200001;View Full Record in Web of Science
J;"Alsayouf, HA; Talo, H; Biddappa, ML";;;;"Alsayouf, Hamza A.; Talo, Haitham; Biddappa, Marisa L.";;;Core Signs and Symptoms in Children with Autism Spectrum Disorder Improved after Starting Risperidone and Aripiprazole in Combination with Standard Supportive Therapies: A Large, Single-Center, Retrospective Case Series;BRAIN SCIENCES;;;English;Article;;;;;;"autism spectrum disorder; risperidone; aripiprazole; antipsychotic agents; case study";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; DOUBLE-BLIND; CLINICAL CHARACTERISTICS; REPETITIVE BEHAVIORS; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; ADOLESCENTS; IRRITABILITY; CLONIDINE";"Background: There are a number of medications prescribed to address comorbid challenging behaviors in children with autism spectrum disorder (ASD), including risperidone and aripiprazole. This retrospective case series reports the use of these drugs in children aged 2 to 13 years. Methodology: A total of 82 children (mean age, 5 years; 79% male) with ASD treated at the Kids Neuro Clinic and Rehab Center in Dubai between January 2020 and September 2021 were included in this retrospective case series. All patients had comorbid challenging behaviors that were resistant to standard supportive therapies alone and warranted pharmacological intervention. The Childhood Autism Rating Scale-2nd Edition Standard form (CARS2-ST) and the Clinical Global Impression (CGI)-Severity (CGI-S) and CGI-Improvement (CGI-I) scales were used to assess the severity of ASD at baseline and to monitor response to treatment with risperidone or aripiprazole. Results: Besides the expected improvement in comorbid challenging behaviors, 79/82 patients (96%) attained a CGI-I score of 2 or 1 following treatment, and 35/82 patients (43%) achieved both a CGI-I score of 1 and minimal-to-no symptoms as per the CARS2-ST test, with complete resolution of their ASD signs and symptoms. The differences in the overall mean CARS2-ST and CGI-S scores preand post-treatment were statistically significant (Z = -7.86, p < 0.0001 for both), with pre- and posttreatment mean values of 42 and 23 for CARS2-ST, respectively, and 6 and 2 for CGI-S, respectively. The main side effects were asymptomatic elevated prolactin (n = 12) and excessive weight gain (n = 2). Conclusions: ASD core symptoms and comorbid behaviors in young children improved following chronic treatment with antipsychotic medications, either with or without medications for attention deficit hyperactivity disorder, when combined with standard supportive therapies. Double-blind, placebo-controlled clinical trials are needed to verify these findings.";"[Alsayouf, Hamza A.; Talo, Haitham; Biddappa, Marisa L.] Kids Neuro Clin & Rehab Ctr, Al Razi Med Complex, Dubai Healthcare City 1015, Dubai, U Arab Emirates";;Alsayouf, HA (corresponding author), Kids Neuro Clin & Rehab Ctr, Al Razi Med Complex, Dubai Healthcare City 1015, Dubai, U Arab Emirates.;"leeamra1000@gmail.com; htalo@yahoo.com; marisa.lobobiddappa@gmail.com";;"alsayouf, hamza/0000-0002-3646-7599; Lobo Biddappa, Marisa/0000-0001-5086-012X";;;;"Alsayouf HA, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8050318; Alsayouf HA, 2020, NEUROPSYCH DIS TREAT, V16, P2779, DOI 10.2147/NDT.S277294; Aman MG, 2008, J CHILD ADOL PSYCHOP, V18, P227, DOI 10.1089/cap.2007.0133; Amer Diabet Assoc, 2004, DIABETES CARE, V27, P596, DOI 10.2337/diacare.27.2.596; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Anagnostou E, 2018, CURR OPIN NEUROL, V31, P119, DOI 10.1097/WCO.0000000000000542; [Anonymous], 2009, BRIST MYERS SQUIBB U; Asakawa T, 2018, CNS NEUROSCI THER, V24, P863, DOI 10.1111/cns.13036; Bal VH, 2019, AUTISM RES, V12, P89, DOI 10.1002/aur.2004; Banas K, 2020, J CAN ACAD CHILD ADO, V29, P110; Boon-Yasidhi Vitharon, 2002, Journal of the Medical Association of Thailand, V85, pS784; Brian JA, 2019, PAED CHILD HEALT-CAN, V24, P444, DOI 10.1093/pch/pxz117; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Carbone PS, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-2314; Cicala G, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00152; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Dawkins T, 2016, J AUTISM DEV DISORD, V46, P3361, DOI 10.1007/s10803-016-2860-z; Diler RS, 2002, CURR THER RES CLIN E, V63, P91, DOI 10.1016/S0011-393X(02)80009-1; Esbensen AJ, 2009, J AUTISM DEV DISORD, V39, P57, DOI 10.1007/s10803-008-0599-x; FANKHAUSER MP, 1992, J CLIN PSYCHIAT, V53, P77; Fayyazi Afshin, 2014, Iran J Child Neurol, V8, P33; Findling RL, 2014, J CLIN PSYCHIAT, V75, P22, DOI 10.4088/JCP.13m08500; Food and Drug Administration, 2006, APPR RISP RISP RISP; Guthrie W, 2013, J CHILD PSYCHOL PSYC, V54, P582, DOI 10.1111/jcpp.12008; Haddad PM, 2004, DRUGS, V64, P2291, DOI 10.2165/00003495-200464200-00003; Handen BL, 2015, J AM ACAD CHILD PSY, V54, P905, DOI 10.1016/j.jaac.2015.08.013; Harfterkamp M, 2013, J CHILD ADOL PSYCHOP, V23, P194, DOI 10.1089/cap.2012.0012; Hergüner MÖ, 2008, PEDIATR NEUROL, V38, P411, DOI 10.1016/j.pediatrneurol.2008.02.007; Ho J, 2011, PAED CHILD HEALT-CAN, V16, P575, DOI 10.1093/pch/16.9.575; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447; Ichikawa H, 2017, CHILD PSYCHIAT HUM D, V48, P796, DOI 10.1007/s10578-016-0704-x; Jahromi LB, 2009, J AUTISM DEV DISORD, V39, P395, DOI 10.1007/s10803-008-0636-9; James SN, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100827; JASELSKIS CA, 1992, J CLIN PSYCHOPHARM, V12, P322; Jensen KG, 2015, J AM ACAD CHILD PSY, V54, P25, DOI 10.1016/j.jaac.2014.10.002; Kent JM, 2013, J AUTISM DEV DISORD, V43, P1773, DOI 10.1007/s10803-012-1723-5; Kimura G, 2015, INT J MED SCI, V12, P135, DOI 10.7150/ijms.10453; Kloosterboer SM, 2021, BRIT J CLIN PHARMACO, V87, P1069, DOI 10.1111/bcp.14465; Lamy M, 2020, PEDIATR DRUGS, V22, P473, DOI 10.1007/s40272-020-00408-0; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Masi G, 2003, J CLIN PSYCHIAT, V64, P1039, DOI 10.4088/JCP.v64n0909; Masi G, 2001, J CHILD NEUROL, V16, P395, DOI 10.1177/088307380101600602; Masi G, 2001, J AM ACAD CHILD PSY, V40, P1206, DOI 10.1097/00004583-200110000-00015; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; McDougle CJ, 1998, ARCH GEN PSYCHIAT, V55, P633, DOI 10.1001/archpsyc.55.7.633; Militerni R, 2002, EUR CHILD ADOLES PSY, V11, P210, DOI 10.1007/s00787-002-0279-x; Nachshen J., 2008, SCREENING ASSESSMENT; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Nash K, 2016, INT J PSYCHIAT MED, V51, P201, DOI 10.1177/0091217416636600; Ng QX, 2017, J CHILD ADOL PSYCHOP, V27, P112, DOI 10.1089/cap.2016.0124; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; Pearson DA, 2013, J CHILD ADOL PSYCHOP, V23, P337, DOI 10.1089/cap.2012.0096; Politte LC, 2014, PSYCHOPHARMACOLOGY, V231, P1023, DOI 10.1007/s00213-013-3068-y; Posey DJ, 1999, J CHILD ADOL PSYCHOP, V9, P273, DOI 10.1089/cap.1999.9.273; Rizzo R, 2013, EUR CHILD ADOLES PSY, V22, P577, DOI 10.1007/s00787-013-0413-y; Roke Y, 2009, J CHILD ADOL PSYCHOP, V19, P403, DOI 10.1089/cap.2008.0120; Santosh PJ, 2006, CHILD CARE HLTH DEV, V32, P575, DOI 10.1111/j.1365-2214.2006.00631.x; Schopler E., 2010, CHILDHOOD AUTISM RAT; Schopler E., 1988, The childhood autism rating scale (CARS); Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Thorkelson G, 2019, J CHILD ADOL PSYCHOP, V29, P705, DOI 10.1089/cap.2019.0001; Vasa RA, 2014, J AUTISM DEV DISORD, V44, P3215, DOI 10.1007/s10803-014-2184-9; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013; Yilmaz S, 2014, J PEDIATR NEUROSCI, V9, P105, DOI 10.4103/1817-1745.139266; Zwaigenbaum L, 2015, PEDIATRICS, V136, pS60, DOI 10.1542/peds.2014-3667E";69;6;7;1;7;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2076-3425;;BRAIN SCI;Brain Sci.;MAY;2022;12;5;;;;;;;618;10.3390/brainsci12050618;http://dx.doi.org/10.3390/brainsci12050618;;;11;Neurosciences;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;1O4QO;35625005;gold, Green Published;;;24/11/2024;WOS:000801319200001;View Full Record in Web of Science
J;"Wolf, K; Widjaja, F; 'Keefe, W; Chen, YT; Breard, M; Parenteau, C; Keys, J; Riemer, R; Hendren, RL";;;;"Wolf, Kimberly; Widjaja, Felicia; 'Keefe, Whitney; Chen, Yingtong; Breard, Michael; Parenteau, China; Keys, Jordan; Riemer, Richard; Hendren, Robert L.";;;Osteopathic manipulative treatment for autism spectrum disorder: Three case reports;INTERNATIONAL JOURNAL OF OSTEOPATHIC MEDICINE;;;English;Article;;;;;;;"OF-THE-LITERATURE; GASTROINTESTINAL SYMPTOMS; THORACIC-DUCT; CHILDREN; THERAPY; COMPLEMENTARY; MEDICINE; NETWORK; TISSUE";Context: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with a prevalence that is on the rise. Despite a growing body of research, definitive etiology or universally beneficial treatments have not been identified. Patients and providers try therapeutic modalities beyond the conventional interventions, including osteopathic manipulative treatment or OMT. Reports on OMT as therapy for patients with ASD are few. These case reports seek to add to the small body of evidence supporting the use of OMT in patients with ASD. Objective: To determine whether OMT can be a safe and effective therapeutic intervention for patients with ASD. Methods: Three students with ASD at a non-public school for youths with ASD and neurodevelopmental disorders received a series of adjunctive OMT sessions and their clinical progress was monitored. These students received a specified series of OMT for at least eight weeks from a pediatrician trained in OMT. Symptoms, including communication, anxiety, classroom behavior, peer interaction and sleep were monitored by the OMT provider, the patient's primary psychiatrist, their parents, and their teachers. Results: Patients receiving the OMT were observed by parents, teachers, and clinicians to demonstrate improvement in posture, gait, awareness, eye contact, communication, and an overall more relaxed state. All patients tolerated the OMT well with no adverse events reported. Conclusion: OMT was well -tolerated and improvements were observed in the clinical cases. This series of three cases informs the development of a protocol to demonstrate the potential benefits of OMT for the treatment of ASD. Implications for practice: center dot OMT was well -tolerated in pediatric patients with autism spectrum disorder (ASD). center dot No adverse events/effects were reported in the case series of applying OMT for pediatric patients with ASD. center dot Pediatric patients with ASD who received OMT showed improved mood, concentration, posture, and other benefits as reported by clinicians, teachers, school administrators, and families.;"['Keefe, Whitney; Breard, Michael] Oak Hill Sch, San Anselmo, CA USA; [Wolf, Kimberly; Keys, Jordan; Riemer, Richard] Touro Univ Calif, Coll Osteopath Med, 1310 Club Dr, Vallejo, CA 94592 USA; [Widjaja, Felicia; Chen, Yingtong; Parenteau, China; Hendren, Robert L.] Univ Calif San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 USA";"Touro University California; University of California System; University of California San Francisco";Wolf, K (corresponding author), Touro Univ Calif, Coll Osteopath Med, 1310 Club Dr, Vallejo, CA 94592 USA.;"kwolf2@touro.edu; Felicia.Widjaja@ucsf.edu; wokeefe@myoakhill.org; Yingtong.Chen@ucsf.edu; RobertHendren@ucsf.edu";"Chen, Yingtong/KCL-7041-2024; Wolf, Kimberly/KMY-7780-2024";"Wolf, Kimberly/0000-0001-8897-9812; Hendren, Robert/0000-0001-8470-4862";;;;"Accorsi A, 2014, J AM OSTEOPATH ASSOC, V114, P374, DOI 10.7556/jaoa.2014.074; Alcantara J, 2011, EXPLORE-NY, V7, P384, DOI 10.1016/j.explore.2011.08.001; Almaali HMMA, 2017, J ACUPUNCT MERIDIAN, V10, P375, DOI 10.1016/j.jams.2017.09.001; Bodison SC, 2018, AM J OCCUP THER, V72, DOI 10.5014/ajot.2018.029413; Bramati-Castellarin I, 2016, J BODYW MOV THER, V20, P461, DOI 10.1016/j.jbmt.2016.01.001; Brondino N, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/258589; Cardoso-de-Mello-E-Mello-Ribeiro AP, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/148285; Cerritelli F, 2016, J NEUROL SCI, V369, P333, DOI 10.1016/j.jns.2016.08.062; Cerritelli F, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-65; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Dang K, 2017, J CLIN MED, V6, DOI 10.3390/jcm6100097; Degenhardt BF, 2014, J AM OSTEOPATH ASSOC, V114, P154, DOI 10.7556/jaoa.2014.033; DiFrancisco-Donoghue J, 2017, NEUROREHABILITATION, V40, P145, DOI 10.3233/NRE-161400; Emtiazy Majid, 2016, Iran J Med Sci, V41, pS64; Ernst E., 2003, PHYS THER, V8, P85, DOI DOI 10.1179/108331903225002425; Fornari M, 2017, J AM OSTEOPATH ASSOC, V117, P559, DOI 10.7556/jaoa.2017.110; Giles PD, 2013, J ALTERN COMPLEM MED, V19, P92, DOI 10.1089/acm.2011.0031; Gleberzon Brian J, 2012, J Can Chiropr Assoc, V56, P128; Henderson AT, 2010, J AM OSTEOPATH ASSOC, V110, P324; Hitscherich K, 2016, J AM OSTEOPATH ASSOC, V116, P170, DOI 10.7556/jaoa.2016.033; Hodge LM, 2012, INT J OSTEOPATH MED, V15, P13, DOI 10.1016/j.ijosm.2011.11.004; Hodge LM, 2011, EXP BIOL MED, V236, P1109, DOI 10.1258/ebm.2011.011057; Hodge LM, 2010, LYMPHAT RES BIOL, V8, P103, DOI 10.1089/lrb.2009.0011; Hodge Lisa M., 2007, Lymphatic Research and Biology, V5, P127, DOI 10.1089/lrb.2007.1001; Holingue C, 2018, AUTISM RES, V11, P24, DOI 10.1002/aur.1854; Knott EM, 2005, J AM OSTEOPATH ASSOC, V105, P447; Kratz SV, 2017, J BODYW MOV THER, V21, P19, DOI 10.1016/j.jbmt.2016.06.006; Lee MS, 2011, J CLIN PSYCHIAT, V72, P406, DOI 10.4088/JCP.09r05848whi; Levy SE, 2003, J DEV BEHAV PEDIATR, V24, P418, DOI 10.1097/00004703-200312000-00003; Lmt AB, 2014, Int J Therapeutic Massage Bodywork: Res, Educat Pract, V7, DOI [10.3822/ijtmb.v7i4.246, DOI 10.3822/IJTMB.V7I4.246]; Lyra L, 2017, SAO PAULO MED J, V135, P192, DOI 10.1590/1516-3180.2017.0058200317; Maenner MJ, 2012, J AUTISM DEV DISORD, V42, P1520, DOI 10.1007/s10803-011-1379-6; McLay LLK, 2016, DEV NEUROREHABIL, V19, P123, DOI 10.3109/17518423.2014.904452; Müller A, 2014, J AM OSTEOPATH ASSOC, V114, P470, DOI 10.7556/jaoa.2014.098; Muhammad Durrani, 2015, AAO J, V25; Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111; Pomykala M, 2008, J AM OSTEOPATH ASSOC, V108, P665; Prevost CP, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2447-2; Saggio G, 2011, J AM OSTEOPATH ASSOC, V111, P143; Schander A, 2012, EXP BIOL MED, V237, P58, DOI 10.1258/ebm.2011.011220; Sergueef N, 2002, ALTERN THER HEALTH M, V8, P74; Shi XR, 2011, J AM OSTEOPATH ASSOC, V111, P660; Silva Louisa, 2013, Int J Ther Massage Bodywork, V6, P12; Silva Louisa M T, 2015, Autism Res Treat, V2015, P904585, DOI 10.1155/2015/904585; Swender DA, 2014, J AM OSTEOPATH ASSOC, V114, P450, DOI 10.7556/jaoa.2014.095; Tsuji S, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00058; Warren LR, 2017, J ALTERN COMPLEM MED, V23, P844, DOI 10.1089/acm.2016.0257; Weitlauf AS, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2017-0347; Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91";49;2;2;0;1;ELSEVIER SCI LTD;London;125 London Wall, London, ENGLAND;1746-0689;1878-0164;;INT J OSTEOPATH MED;Int. J. Osteopath. Med.;MAR;2024;51;;;;;;;;100700;10.1016/j.ijosm.2023.100700;http://dx.doi.org/10.1016/j.ijosm.2023.100700;;janv-24;5;"Medicine, General & Internal; Rehabilitation";Science Citation Index Expanded (SCI-EXPANDED);"General & Internal Medicine; Rehabilitation";GR9O8;;;;;24/11/2024;WOS:001154520800001;View Full Record in Web of Science
J;"Frye, RE; DeLaTorre, R; Taylor, HB; Slattery, J; Melnyk, S; Chowdhury, N; James, SJ";;;;"Frye, R. E.; DeLaTorre, R.; Taylor, H. B.; Slattery, J.; Melnyk, S.; Chowdhury, N.; James, S. J.";;;Metabolic effects of sapropterin treatment in autism spectrum disorder: a preliminary study;TRANSLATIONAL PSYCHIATRY;;;English;Article;;;;;;"autism; monoamine neurotransmitters; nitric oxide; sapropterin; tetrahydrobiopterin";"NITRIC-OXIDE LEVELS; OXIDATIVE STRESS; CEREBROSPINAL-FLUID; TETRAHYDROBIOPTERIN; CHILDREN; INTERVENTION; NEUROTROPHIN; INFLAMMATION; DIAGNOSIS";Sapropterin, a synthetic form of tetrahydrobiopterin (BH4), has been reported to improve symptoms in children with autism spectrum disorder (ASD). However, as BH4 is involved in multiple metabolic pathway that have been found to be dysregulated in ASD, including redox, pterin, monoamine neurotransmitter, nitric oxide (NO) and immune metabolism, the metabolic pathway by which sapropterin exerts its therapeutic effect in ASD effect remains unclear. This study investigated which metabolic pathways were associated with symptomatic improvement during sapropterin treatment. Ten participants (ages 2-6 years old) with current social and/or language delays, ASD and a central BH4 concentration <= 30 nMl(-1) were treated with a daily morning 20 mg kg(-1) dose of sapropterin for 16 weeks in an open-label fashion. At baseline, 8 weeks and 16 weeks after starting the treatment, measures of language, social function and behavior and biomarkers of redox, pterin, monoamine neurotransmitter, NO and immune metabolism were obtained. Two participants discontinued the study, one from mild adverse effects and another due to noncompliance. Overall, improvements in subscales of the Preschool Language Scale (PLS), Vineland Adaptive Behavior Scale (VABS), Aberrant Behavior Checklist (ABC) and autism symptoms questionnaire (ASQ) were seen. Significant changes in biomarkers of pterin, redox and NO were found. Improvement on several subscales of the PLS, VABS, ABC and ASQ were moderated by baseline and changes in biomarkers of NO and pterin metabolism, particularly baseline NO metabolism. These data suggest that behavioral improvement associated with daily 20 mg kg(-1) sapropterin treatment may involve NO metabolism, particularly the status of pretreatment NO metabolism.;"[Frye, R. E.; Slattery, J.; Melnyk, S.; Chowdhury, N.; James, S. J.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Dept Pediat, Little Rock, AR 72202 USA; [DeLaTorre, R.] Univ Texas Heath, Childrens Learning Inst, Houston, TX USA; [Taylor, H. B.] Inst Rehabil Res Mem Hermann, Houston, TX USA";"Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences";Frye, RE (corresponding author), Univ Arkansas Med Sci, Arkansas Childrens Hosp, Res Inst, Dept Pediat, Slot 512-41B,Room R4041,13 Childrens Way, Little Rock, AR 72202 USA.;REFrye@uams.edu;Frye, Richard/AAB-5543-2020;;BioMarin Pharmaceutical;BioMarin Pharmaceutical(Johnson & Johnson);This research was funded by BioMarin Pharmaceutical, as an investigator initiated study. Study drug was provided by BioMarin Pharmaceutical.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 1990, KISO RINSHOU; [Anonymous], 1990, RINSHO IYAKU; [Anonymous], 1990, Rinsho Iyaku; APA, 1994, AM PSYCHIATR ASSOC, V4th; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003; Bölte S, 2011, J AUTISM DEV DISORD, V41, P66, DOI 10.1007/s10803-010-1024-9; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Buie T, 2010, PEDIATRICS, V125, pS1, DOI 10.1542/peds.2009-1878C; Constantino J., 2002, SOCIAL RESPONSIVENES; Danfors T, 2005, J CLIN PSYCHOPHARM, V25, P485, DOI 10.1097/01.jcp.0000177667.35016.e9; Delorme R, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-108; Essa MM, 2012, BIOL TRACE ELEM RES, V147, P25, DOI 10.1007/s12011-011-9280-x; Fernell E, 1997, DEV MED CHILD NEUROL, V39, P313; Frye RE, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00052; Frye RE, 2010, NEUROTHERAPEUTICS, V7, P241, DOI 10.1016/j.nurt.2010.05.004; HOWELLS DW, 1987, CLIN CHIM ACTA, V167, P23, DOI 10.1016/0009-8981(87)90081-7; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2009, FASEB J, V23, P2374, DOI 10.1096/fj.08-128926; Kim HW, 2009, AM J MED GENET B, V150B, P300, DOI 10.1002/ajmg.b.30798; Klaiman C, 2013, J CHILD ADO IN PRESS; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Landry SH, 1997, J CLIN EXP NEUROPSYC, V19, P261, DOI 10.1080/01688639708403856; Landry SH, 2008, DEV PSYCHOL, V44, P1335, DOI 10.1037/a0013030; Laranjinha J, 2012, ANN NY ACAD SCI, V1259, P10, DOI 10.1111/j.1749-6632.2012.06582.x; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Melnyk S, 2012, J AUTISM DEV DISORD, V42, P367, DOI 10.1007/s10803-011-1260-7; Ming X, 2008, J CHILD NEUROL, V23, P6, DOI 10.1177/0883073807307102; Nagahata M, 1990, RINSHO IYAKU, V6, P1877; NAKANE Y, 1992, INT CONGR SER, V965, P337; NARUSE H, 1989, No To Hattatsu, V21, P181; NARUSE H, 1987, P JPN ACAD B-PHYS, V63, P231, DOI 10.2183/pjab.63.231; Naruse H, 1985, PRELIMINARY STUDY CL; Priya MDL, 2011, CLIN CHIM ACTA, V412, P1036, DOI 10.1016/j.cca.2011.02.021; Rice Catherine, 2009, Morbidity and Mortality Weekly Report, V58, P1; Rose S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.61; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol DA, 2012, MOL PSYCHIATR, V17, P290, DOI 10.1038/mp.2010.136; Sajdel-Sulkowska EM, 2011, CEREBELLUM, V10, P43, DOI 10.1007/s12311-010-0223-4; Sarti P, 2012, ADV EXP MED BIOL, V942, P75, DOI 10.1007/978-94-007-2869-1_4; Schaefer GB, 2008, GENET MED, V10, P4, DOI 10.1097/GIM.0b013e31815efdd7; Sögüt S, 2003, CLIN CHIM ACTA, V331, P111, DOI 10.1016/S0009-8981(03)00119-0; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Sweeten TL, 2004, BIOL PSYCHIAT, V55, P434, DOI 10.1016/j.biopsych.2003.09.001; Takesada M, 1990, INT S NEUR INF AUT T; TANI Y, 1994, NEUROSCI LETT, V181, P169, DOI 10.1016/0304-3940(94)90586-X; Thöny B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Tostes MHFS, 2012, PHARMACOPSYCHIATRY, V45, P241, DOI 10.1055/s-0032-1301914; Zimmerman I.L., 2002, PRESCHOOL LANGUAGE S, VFourth";49;48;52;0;18;NATURE PUBLISHING GROUP;LONDON;MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2158-3188;;;TRANSL PSYCHIAT;Transl. Psychiatr.;MAR;2013;3;;;;;;;;e237;10.1038/tp.2013.14;http://dx.doi.org/10.1038/tp.2013.14;;;9;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;174VG;23462988;gold, Green Published;;;24/11/2024;WOS:000321184100002;View Full Record in Web of Science
J;"Scahill, L; Jeon, S; Boorin, SJ; McDougle, CJ; Aman, MG; Dziura, J; McCracken, JT; Caprio, S; Arnold, LE; Nicol, G; Deng, YH; Challa, SA; Vitiello, B";;;;"Scahill, Lawrence; Jeon, Sangchoon; Boorin, Susan J.; McDougle, Christopher J.; Aman, Michael G.; Dziura, James; McCracken, James T.; Caprio, Sonia; Arnold, L. Eugene; Nicol, Ginger; Deng, Yanhong; Challa, Saankari A.; Vitiello, Benedetto";;;Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"autism spectrum disorder; risperidone; weight gain; metabolic syndrome; insulin resistance";"PERVASIVE DEVELOPMENTAL DISORDERS; CARDIOVASCULAR RISK; CARDIOMETABOLIC RISK; INSULIN-RESISTANCE; GLUCOSE-TOLERANCE; CHOLESTEROL RATIO; ADOLESCENTS; OBESITY; ASSOCIATION; ADIPONECTIN";"Objective: We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD). Method: This was a 24-week, multisite, randomized trial of risperidone only versus risperidone plus parent training in 124 children (mean age 6.9 +/- 2.35 years; 105 boys and 19 girls) with ASD and serious behavioral problems. We monitored height, weight, waist circumference, and adverse effects during the trial. Fasting blood samples were obtained before treatment and at week 16. Results: In 97 children with a mean of 22.9 +/- 2.8 weeks of risperidone exposure, there was a 5.4 +/- 3.4 kg weight gain over 24 weeks (p<.0001); waist circumference increased from 60.7 +/- 10.4 cm to 66.8 +/- 11.3 cm (p<.0001). At baseline, 59 of 97 children (60.8%) were classified as having normal weight; by week 24, only 25 of 85 (29.4%) remained in that group. Growth curve analysis showed a significant change in body mass index (BMI) z scores from pretreatment to week 24 (p<.0001). This effect was significantly greater for children with reported increased appetite in the first 8 weeks. From before treatment to week 16, there were significant increases in glucose (p=.02), hemoglobin Alc (p=.01), insulin (p<.0001), homeostatic model assessment insulin resistance (HOMA-IR; p<.001), alanine aminotransferase (p=.01), and leptin (p<.0001). Adiponectin declined (p=.003). At baseline, 7 children met conventional criteria for metabolic syndrome; by week 16, 12 additional children were so classified. Conclusion: Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome. Appetite, weight, waist circumference, liver function tests, blood lipids, and glucose warrant monitoring.";"[Scahill, Lawrence; Challa, Saankari A.] Emory Univ, Sch Med, Atlanta, GA USA; [Scahill, Lawrence] Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA; [Jeon, Sangchoon; Boorin, Susan J.] Yale Univ, Sch Nursing, West Haven, CT USA; [McDougle, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA; [McDougle, Christopher J.] Lurie Ctr Autism, Boston, MA USA; [Aman, Michael G.; Arnold, L. Eugene] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [Dziura, James; Caprio, Sonia] Yale Univ, Sch Med, New Haven, CT USA; [McCracken, James T.] Univ Calif Los Angeles, Div Child Psychiat, Los Angeles, CA USA; [Nicol, Ginger] Washington Univ, St Louis, MO 63130 USA; [Deng, Yanhong] Yale Univ, New Haven, CT 06520 USA; [Vitiello, Benedetto] NIMH, Bethesda, MD 20892 USA";"Emory University; Yale University; Harvard University; Harvard Medical School; Massachusetts General Hospital; University System of Ohio; Ohio State University; Yale University; University of California System; University of California Los Angeles; Washington University (WUSTL); Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)";Scahill, L (corresponding author), Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA.;lawrence.scahill@emory.edu;"deng, yan/KCK-8563-2024; Nicol, Ginger/AAN-1176-2021; Vitiello, Benedetto/AAC-1758-2022; Jeon, sangchoon/E-3800-2013";"Jeon, sangchoon/0000-0003-2855-2053; Nicol, Ginger/0000-0001-5823-6129";"NIMH, Yale [U10MH66764]; NIMH, Indiana University [U10MH66766]; NIMH, Ohio State University [U10MH66768]; Yale CTSA [UL1 RR024139]; IU CTSA [UL1 RR025761]; OSU CTSA [UL1 RR025755]; Atlanta Clinical and Translational Science Institute at Emory University from the National Center for Research Resources [UL1TR000454]; Marcus Foundation; Children's Hospital of Atlanta Trust Fund";"NIMH, Yale; NIMH, Indiana University; NIMH, Ohio State University; Yale CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); IU CTSA; OSU CTSA; Atlanta Clinical and Translational Science Institute at Emory University from the National Center for Research Resources; Marcus Foundation; Children's Hospital of Atlanta Trust Fund";"This work was funded by NIMH by the following RUPP grants: Yale, U10MH66764; Indiana University, U10MH66766, Ohio State University, U10MH66768; and Janssen/Johnson and Johnson Pharmaceutical Research and Development provided active risperidone for the study. This publication was also supported by the Yale CTSA UL1 RR024139, IU CTSA UL1 RR025761, OSU CTSA UL1 RR025755, and Atlanta Clinical and Translational Science Institute UL1TR000454 at Emory University from the National Center for Research Resources. Dr. Scahill also received support from the Marcus Foundation and the Children's Hospital of Atlanta Trust Fund.";"Ahima RS, 2008, J CLIN INVEST, V118, P2380, DOI 10.1172/JCI36284; Almandil NB, 2013, PEDIATR DRUGS, V15, P139, DOI 10.1007/s40272-013-0016-6; AMAN MG, 1985, AM J MENT DEF, V89, P492; Aman M, 2015, J CHILD ADOL PSYCHOP, V25, P482, DOI 10.1089/cap.2015.0005; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; [Anonymous], 2002, HEALTH-LONDON, DOI DOI 10.1016/S0882-5963(97)80058-9; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Arango C, 2014, J AM ACAD CHILD PSY, V53, P1179, DOI 10.1016/j.jaac.2014.08.009; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Beavers GA, 2013, J APPL BEHAV ANAL, V46, P1, DOI 10.1002/jaba.30; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Bocca G, 2013, HORM RES PAEDIAT, V80, P201, DOI 10.1159/000354662; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Daniels SR, 2008, PEDIATRICS, V122, P198, DOI 10.1542/peds.2008-1349; Demb H, 2011, J CLIN PSYCHOPHARM, V31, P669, DOI 10.1097/JCP.0b013e31822befa9; Di Bonito P, 2012, DIABETES CARE, V35, P158, DOI 10.2337/dc11-1456; Fernández JR, 2004, J PEDIATR-US, V145, P439, DOI 10.1016/j.jpeds.2004.06.044; Frye Richard E, 2013, Autism Res Treat, V2013, P609705, DOI 10.1155/2013/609705; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Haupt DW, 2007, NEUROPSYCHOPHARMACOL, V32, P2561, DOI 10.1038/sj.npp.1301392; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Katzmarzyk PT, 2012, PEDIATR OBES, V7, pE42, DOI 10.1111/j.2047-6310.2012.00073.x; Levy-Marchal C, 2010, J CLIN ENDOCR METAB, V95, P5189, DOI 10.1210/jc.2010-1047; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Luby J, 2006, J CHILD ADOL PSYCHOP, V16, P575, DOI 10.1089/cap.2006.16.575; Martin A, 2004, AM J PSYCHIAT, V161, P1125, DOI 10.1176/appi.ajp.161.6.1125; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Morrato EH, 2010, ARCH PEDIAT ADOL MED, V164, P344, DOI 10.1001/archpediatrics.2010.48; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; Nobili V, 2006, HEPATOLOGY, V44, P458, DOI 10.1002/hep.21262; Nurmi EL, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.26; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Pyrzak B, 2010, EUR J MED RES, V15, P147; Quijada Z, 2008, PEDIATR DIABETES, V9, P464, DOI 10.1111/j.1399-5448.2008.00406.x; Raucci R, 2013, CYTOKINE, V61, P1, DOI 10.1016/j.cyto.2012.08.036; Research Units on Pediatric Psychopharmacology Autism Network, 2005, AM J PSYCHIAT, V162, P1142; Scahill L, 2012, J AM ACAD CHILD PSY, V51, P136, DOI 10.1016/j.jaac.2011.11.010; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Sparrow Sparrow SS. SS., VINELAND 2 VINELAND; Tanner J. M., 1962, Growth at Adolescence, V2nd; Troost PW, 2005, J AM ACAD CHILD PSY, V44, P1137, DOI 10.1097/01.chi.0000177055.11229.76; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; Weiss R, 2009, PEDIATR DIABETES, V10, P360, DOI 10.1111/j.1399-5448.2008.00504.x; Winer JC, 2006, J CLIN ENDOCR METAB, V91, P4415, DOI 10.1210/jc.2006-0733; Wink LK, 2014, J CHILD ADOL PSYCHOP, V24, P78, DOI 10.1089/cap.2013.0099; Zimmet P, 2007, PEDIATR DIABETES, V8, P299, DOI 10.1111/j.1399-5448.2007.00271.x";47;53;55;1;13;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;MAY;2016;55;5;;;;;415;423;;10.1016/j.jaac.2016.02.016;http://dx.doi.org/10.1016/j.jaac.2016.02.016;;;9;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";DL1AA;27126856;Green Accepted;;;24/11/2024;WOS:000375363100014;View Full Record in Web of Science
J;"Shawahna, R; Fahed, B; Qadri, D; Sharawi, L; Soroghli, M; Dweik, M";;;;"Shawahna, Ramzi; Fahed, Basel; Qadri, Dana; Sharawi, Lamees; Soroghli, Mai; Dweik, Maen";;;Awareness and Knowledge of Autism Spectrum Disorders Among Pharmacists: A Cross-Sectional Study in Palestinian Pharmacy Practice;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Autism spectrum disorders; Awareness; Knowledge; Pharmacists; Palestine";"CHILDREN; GUIDELINES; ADULTS";Pharmacists are trusted and easily accessible healthcare providers. We assessed awareness and knowledge of symptoms, etiology, and treatment of autism spectrum disorders (ASDs) among pharmacists practicing in Palestine. The pharmacists reported low familiarity with ASDs. The median score on the 12-item knowledge section was 50.0% with an interquartile range of 16.7%. Having course(s) or lecture(s) on ASDs during pharmacy degree program was significantly associated with familiarity (p value < 0.001), knowledge (p value < 0.001), and confidence (p value < 0.05) scores. Nearly 62% of the pharmacists reported as not feeling confident enough in their ability to counsel parents about medications used for their children with ASDs and their side effects. This study revealed gaps in awareness and knowledge of ASDs among pharmacists.;"[Shawahna, Ramzi] An Najah Natl Univ, Dept Physiol Pharmacol & Toxicol, Fac Med & Hlth Sci, New Campus,Bldg 19,Off 1340,POB 7, Nablus, Palestine; [Shawahna, Ramzi] An Najah Natl Univ, An Najah BioSci Unit, Ctr Poisons Control Chem & Biol Anal, Nablus, Palestine; [Shawahna, Ramzi; Fahed, Basel; Qadri, Dana; Sharawi, Lamees; Soroghli, Mai; Dweik, Maen] An Najah Natl Univ, Dept Pharm, Fac Med & Hlth Sci, Nablus, Palestine";"An Najah National University; An Najah National University; An Najah National University";"Shawahna, R (corresponding author), An Najah Natl Univ, Dept Physiol Pharmacol & Toxicol, Fac Med & Hlth Sci, New Campus,Bldg 19,Off 1340,POB 7, Nablus, Palestine.;Shawahna, R (corresponding author), An Najah Natl Univ, An Najah BioSci Unit, Ctr Poisons Control Chem & Biol Anal, Nablus, Palestine.;Shawahna, R (corresponding author), An Najah Natl Univ, Dept Pharm, Fac Med & Hlth Sci, Nablus, Palestine.";ramzi_shawahna@hotmail.com;;;;;;"Alkaissi A., 2015, MED NURS, V16, P1; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; *AUT SPEAKS, 2016, WHAT IS AUT; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Esbensen AJ, 2009, J AUTISM DEV DISORD, V39, P1339, DOI 10.1007/s10803-009-0750-3; Freeman BJ, 1997, J AUTISM DEV DISORD, V27, P641, DOI 10.1023/A:1025850715183; Gillespie-Lynch K, 2015, J AUTISM DEV DISORD, V45, P2553, DOI 10.1007/s10803-015-2422-9; Grabenstein JD., 1993, INT J PHARM PRAC, V2, P5, DOI DOI 10.1111/ijpp.1993.2.issue-1; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Hattier MA, 2011, RES DEV DISABIL, V32, P2346, DOI 10.1016/j.ridd.2011.07.028; HOSHINO Y, 1982, FOLIA PSYCHIAT NEU J, V36, P115; KANNER L, 1957, Psychiatr Res Rep Am Psychiatr Assoc, P55; Kaplan G, 2012, PEDIATR CLIN N AM, V59, P175, DOI 10.1016/j.pcl.2011.10.005; Khanna R, 2014, CURR PHARM TEACH LEA, V6, P150, DOI 10.1016/j.cptl.2013.09.010; Khanna R, 2012, RES SOC ADMIN PHARM, V8, P464, DOI 10.1016/j.sapharm.2011.11.002; Lauritsen MB, 2005, J CHILD PSYCHOL PSYC, V46, P963, DOI 10.1111/j.1469-7610.2004.00391.x; Leung A. K., 1999, AM FAM PHYSICIAN, V59, P3135; Luleci NE, 2016, INT J CLIN PHARM-NET, V38, P1477, DOI 10.1007/s11096-016-0394-2; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Marrosu F, 1987, Funct Neurol, V2, P355; McAuley J W, 1999, J Am Pharm Assoc (Wash), V39, P499; McAuley JW, 2009, EPILEPSY BEHAV, V14, P141, DOI 10.1016/j.yebeh.2008.10.014; Mohiuddin S, 2013, AUTISM, V17, P645, DOI 10.1177/1362361312453776; Novella S., 2016, SKEPTICAL INQUIRER, V31, P26; Rice C, 2010, DISABIL HEALTH J, V3, P186, DOI 10.1016/j.dhjo.2009.10.008; Rosenberg RE, 2009, J AUTISM DEV DISORD, V39, P1099, DOI 10.1007/s10803-009-0723-6; Roth Y, 2016, SEIZURE-EUR J EPILEP, V34, P60, DOI 10.1016/j.seizure.2015.11.007; Schwartz H, 2008, LANG SPEECH HEAR SER, V39, P66, DOI 10.1044/0161-1461(2008/007); Smith MJ, 2008, PEDIATRICS, V121, pE836, DOI 10.1542/peds.2007-1760; Steckler T, 2014, PSYCHOPHARMACOLOGY, V231, P977, DOI 10.1007/s00213-014-3460-2; Strunk JA, 2009, J SCH NURS, V25, P445, DOI 10.1177/1059840509348221; Sweileh WM, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-179; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; Wiggins LD, 2006, J DEV BEHAV PEDIATR, V27, pS79, DOI 10.1097/00004703-200604002-00005";34;29;31;1;10;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;JUN;2017;47;6;;;;;1618;1627;;10.1007/s10803-017-3085-5;http://dx.doi.org/10.1007/s10803-017-3085-5;;;10;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;EV0UK;28251394;;;;24/11/2024;WOS:000401460700004;View Full Record in Web of Science
J;"Hadoush, H; Nazzal, M; Almasri, NA; Khalil, H; Alafeef, M";;;;"Hadoush, Hikmat; Nazzal, Mohammad; Almasri, Nihad A.; Khalil, Hanan; Alafeef, Maha";;;Therapeutic Effects of Bilateral Anodal Transcranial Direct Current Stimulation on Prefrontal and Motor Cortical Areas in Children with Autism Spectrum Disorders: A Pilot Study;AUTISM RESEARCH;;;English;Article;;;;;;"autism spectrum disorders; transcranial direct current stimulation; autism treatment evaluation checklist; prefrontal cortex; mirror neurons";"TREATMENT EVALUATION CHECKLIST; MIRROR NEURON SYSTEM; NETWORKS; MECHANISMS; IMITATION; GABA";"Dysfunctional frontal cortical areas associated with clinical features are observed in children with autism spectrum disorder (ASD). This study attempted to identify any potential therapeutic effects of bilateral anodal transcranial direct current stimulation (tDCS) applied over the left and right prefrontal and motor areas on the clinical characteristics of children with ASD. Fifty children with confirmed ASD medical diagnoses were divided equally and randomly into a tDCS treatment group and a control group. The tDCS treatment group underwent 10 sessions (20-min durations, five per week) of bilateral anodal tDCS stimulation applied simultaneously over the left and right prefrontal and motor areas, whereas the control group underwent the same procedures but with the use of sham tDCS stimulation. Total scores and sub-scores of autism treatment evaluation checklist (ATEC) (language and communication; sociability; sensory awareness; and behavioral, health, and physical conditions) were measured before and after the tDCS treatment sessions of both groups. There were significant decreases in total ATEC scores (P = 0.014), sociability sub-scores (P = 0.021), and behavioral, health, and physical condition sub-scores (P = 0.011) in the tDCS treatment group. No significant changes were observed in total ATEC scores and sub-scores in the control group. In conclusion, compared to the control group, bilateral anodal tDCS showed potential therapeutic effects on children with ASD in terms of improvements in sociability, behavior, health, and physical conditions with no reported side effects. Autism Res 2020, 13: 828-836. (c) 2020 International Society for Autism Research, Wiley Periodicals, Inc. Lay Summary Dysfunctional frontal cortical areas are associated with clinical features in children with autism spectrum disorder (ASD). Transcranial direct current stimulation (tDCS) is found to be a safe, noninvasive method to stimulate cortical regions and thus have therapeutic effects on children with ASD. (c) 2020 International Society for Autism Research, Wiley Periodicals, Inc.";"[Hadoush, Hikmat; Nazzal, Mohammad; Khalil, Hanan] Jordan Univ Sci & Technol, Dept Rehabil Sci, Fac Appl Med Sci, POB 3030, Irbid 22110, Jordan; [Almasri, Nihad A.] Univ Jordan, Sch Rehabil Sci, Dept Physiotherapy, Amman, Jordan; [Alafeef, Maha] Jordan Univ Sci & Technol, Dept Biomed Engn, Irbid, Jordan";"Jordan University of Science & Technology; University of Jordan; Jordan University of Science & Technology";Hadoush, H (corresponding author), Jordan Univ Sci & Technol, Dept Rehabil Sci, Fac Appl Med Sci, POB 3030, Irbid 22110, Jordan.;hmhadoush@just.edu.jo;"Almasri, Nihad/C-5394-2015; Nazzal, Mohammad/ABJ-3979-2022; Hadoush, Himat/L-8437-2019; Khalil, Hanan/HKP-0688-2023; almasri, nihad/AAJ-9906-2021";"almasri, nihad/0000-0002-3079-7327; Khalil, Hanan/0000-0001-7741-8892";;;;"Amatachaya A, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/928631; Amatachaya A, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/173073; [Anonymous], 2013, DIAGNOSTIC STAT MANU, VFifth, P1000, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016; Behroozmand R, 2015, NEUROIMAGE, V109, P418, DOI 10.1016/j.neuroimage.2015.01.040; Cardinale RC, 2013, JAMA PSYCHIAT, V70, P975, DOI 10.1001/jamapsychiatry.2013.382; Carr L, 2003, P NATL ACAD SCI USA, V100, P5497, DOI 10.1073/pnas.0935845100; Coghlan S, 2012, NEUROSCI BIOBEHAV R, V36, P2044, DOI 10.1016/j.neubiorev.2012.07.005; Conson M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126448; D'Urso G, 2015, WORLD J BIOL PSYCHIA, V16, P361, DOI 10.3109/15622975.2015.1014411; D'Urso G, 2014, BIOL PSYCHIAT, V76, pE5, DOI 10.1016/j.biopsych.2013.11.009; Demirtas-Tatlidede A, 2013, NEUROPHARMACOLOGY, V64, P566, DOI 10.1016/j.neuropharm.2012.06.020; Esposito G, 2011, BRAIN DEV-JPN, V33, P367, DOI 10.1016/j.braindev.2010.07.006; Floris DL, 2018, PROG BRAIN RES, V238, P207, DOI 10.1016/bs.pbr.2018.06.010; Floris DL, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0096-6; Fournier KA, 2010, GAIT POSTURE, V32, P6, DOI 10.1016/j.gaitpost.2010.02.007; Geier DA, 2013, J MENT HEALTH RES IN, V6, P255, DOI 10.1080/19315864.2012.681340; Godwin D, 2015, P NATL ACAD SCI USA, V112, P3799, DOI 10.1073/pnas.1414466112; Hadoush H, 2018, NEUROREHABILITATION, V42, P63, DOI 10.3233/NRE-172212; Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024; Jansiewicz EM, 2006, J AUTISM DEV DISORD, V36, P613, DOI 10.1007/s10803-006-0109-y; Magiati I, 2011, J INTELL DISABIL RES, V55, P302, DOI 10.1111/j.1365-2788.2010.01359.x; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Oberman LM, 2007, PSYCHOL BULL, V133, P310, DOI 10.1037/0033-2909.133.2.310; Ozonoff S, 2008, J AUTISM DEV DISORD, V38, P644, DOI 10.1007/s10803-007-0430-0; Provost B, 2007, J AUTISM DEV DISORD, V37, P321, DOI 10.1007/s10803-006-0170-6; Puts NAJ, 2017, AUTISM RES, V10, P608, DOI 10.1002/aur.1691; Ramachandran V.S., 2000, Mirror neurons and imitation learning as the driving force behind the great leap forward in human evolution; Ramsey R, 2013, J COGNITIVE NEUROSCI, V25, P670, DOI 10.1162/jocn_a_00345; Rimland B., 2000, Autism Treatment Evaluation Checklist (ATEC); Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 2010, EXP BRAIN RES, V200, P223, DOI 10.1007/s00221-009-2002-3; Rogers SallyJ., 1991, DEV PSYCHOPATHOL, V3, P137, DOI [DOI 10.1017/S0954579400000043, 10.1017/S0954579400000043]; Russo C, 2017, NEUROMODULATION, V20, P215, DOI 10.1111/ner.12574; Samson D, 2005, BRAIN, V128, P1102, DOI 10.1093/brain/awh464; Schneider HD, 2011, CLIN LINGUIST PHONET, V25, P640, DOI 10.3109/02699206.2011.570852; Stagg CJ, 2014, ELIFE, V3, DOI 10.7554/eLife.01465; Tacikowski P, 2017, CEREB CORTEX, V27, P3768, DOI 10.1093/cercor/bhx004; Treasure T, 1998, BRIT MED J, V317, P362; van Steenburgh J, 2016, NEUROLOGY, V86; Wingate M, 2014, MMWR SURVEILL SUMM, V63";41;33;36;1;14;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1939-3792;1939-3806;;AUTISM RES;Autism Res.;MAY;2020;13;5;;;;;828;836;;10.1002/aur.2290;http://dx.doi.org/10.1002/aur.2290;;;9;"Behavioral Sciences; Psychology, Developmental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology";LL5CF;32149480;;;;24/11/2024;WOS:000531574100014;View Full Record in Web of Science
J;"Pal, M; Mandal, N; Ray, A; Saha, PK";;;;"Pal, Mainak; Mandal, Nikhiles; Ray, Anirban; Saha, Pradip Kumar";;;The Role of Repetitive Transcranial Magnetic Stimulation in the Treatment of Autism Spectrum Disorder;JOURNAL OF INDIAN ASSOCIATION FOR CHILD AND ADOLESCENT MENTAL HEALTH;;;English;Article;;;;;;"Autism spectrum disorder; repetitive transcranial magnetic stimulation; Indian Scale for Assessment of Autism; dorsolateral prefrontal cortex";"RTMS; CHILDREN; POTENTIALS; COGNITION; SAFETY; TRIAL; TMS";Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with impairments in language acquisition, social functioning, and restricted and repetitive behaviors. There is no definitive management for the ASD spectrum. The management options available are not beyond criticism. Hence, the search for new options is actively in progress. Noninvasive brain stimulation interventions such as repetitive transcranial magnetic stimulation (rTMS) appears to be a promising tool for the treatment of ASD. However, the available literature on TMS use in ASD is preliminary. Methods: This was a hospital-based longitudinal study conducted over 50 patients with ASD of 6 to 16 years of age. The Indian Scale for Assessment of Autism (ISAA) was used for the assessment of the extent of disability in these children. They were given 10 sessions of rTMS over a period of 10 days over the left dorsolateral prefrontal cortex (l-DLPFC) and reassessed for any improvement in ISAA score after 1 day and 3 months of completion of all the sessions of rTMS. Results: There was no statistically significant change in the total ISAA score or any of the 6 domains of ISAA after 1 day and 3 months of giving 10 sessions of TMS. There were no significant adverse effects after giving rTMS. In a few patients, mild headache, neck pain, or discomfort at the stimulation site was noted. Conclusion: This study has shown that low-frequency rTMS does not have any significant improvement on the various symptoms of ASD. However, there are no major adverse effects after giving rTMS. Also, it points toward the need for further studies.;"[Pal, Mainak; Mandal, Nikhiles; Ray, Anirban; Saha, Pradip Kumar] IPGME & R, Inst Psychiat COE, Dept Psychiat, Kolkata, West Bengal, India; [Ray, Anirban] New Jalpaiguri Govt Med Coll, Dept Psychiat, Jalpaiguri 735101, West Bengal, India";Institute of Post Graduate Medical Education & Research (IPGMER), Kolkata;Ray, A (corresponding author), New Jalpaiguri Govt Med Coll, Dept Psychiat, Jalpaiguri 735101, West Bengal, India.;dranirbanray@gmail.com;;Ray, Anirban/0000-0002-1025-6304;;;;"Abujadi C, 2018, REV BRAS PSIQUIATR, V40, P309, DOI 10.1590/1516-4446-2017-2279; Ameis SH, 2017, J CHILD ADOL PSYCHOP, V27, P413, DOI 10.1089/cap.2016.0146; [Anonymous], 2017, ARCHIV PAEDIAT DEV P; Avirame K, 2017, NEUROCASE, V23, P187, DOI 10.1080/13554794.2017.1361451; Baruth Joshua M, 2010, J Neurother, V14, P179; Casanova MF, 2012, TRANSL NEUROSCI, V3, P170, DOI 10.2478/s13380-012-0022-0; Casanova MF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00851; Casanova MF, 2003, NEUROSCIENTIST, V9, P496, DOI 10.1177/1073858403253552; Cristancho P, 2014, J ECT, V30, pE46, DOI 10.1097/YCT.0000000000000156; Darwish ME, 2021, EGYPT J OTOLARYNGOL, V37, DOI 10.1186/s43163-021-00116-7; Dean A.G., 2011, Epi Info, a database and statistics program for public health professionals; Dobek CE, 2015, NEUROPSYCH DIS TREAT, V11, P2975, DOI 10.2147/NDT.S91126; Enticott PG, 2014, BRAIN STIMUL, V7, P206, DOI 10.1016/j.brs.2013.10.004; Enticott PG, 2012, BRAIN STIMUL, V5, P30, DOI 10.1016/j.brs.2011.02.001; Enticott PG, 2011, J ECT, V27, P41, DOI 10.1097/YCT.0b013e3181f07948; Fecteau S, 2011, EUR J NEUROSCI, V34, P158, DOI 10.1111/j.1460-9568.2011.07726.x; Fombonne E, 2006, PEDIATRICS, V118, pE139, DOI 10.1542/peds.2005-2993; Goldman-Rakic PS., 1987, HDB PHYSL 1, V5, P40, DOI [DOI 10.1002/CPHY.CP010509, 10.1002/cphy.cp010509]; Gómez L, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7030063; Grossheinrich N, 2009, BIOL PSYCHIAT, V65, P778, DOI 10.1016/j.biopsych.2008.10.029; Hoogendam JM, 2010, BRAIN STIMUL, V3, P95, DOI 10.1016/j.brs.2009.10.005; Kaur M, 2019, J PSYCHIATR RES, V113, P79, DOI 10.1016/j.jpsychires.2019.03.015; Kumar R, 1999, MOVEMENT DISORD, V14, P157; Lerner AJ, 2019, CLIN NEUROPHYSIOL, V130, P1409, DOI 10.1016/j.clinph.2019.03.016; Ni HC, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00255; Niederhofer H, 2012, CLIN NEUROPSYCHIATR, V9, P107; Panerai S, 2014, AUTISM, V18, P638, DOI 10.1177/1362361313495717; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Rajapakse T, 2013, TRANSL NEUROSCI, V4, P217, DOI 10.2478/s13380-013-0116-3; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sadock BJ., 2017, KAPLAN SADOCKS COMPR, V44, P3571; Schrader LM, 2004, CLIN NEUROPHYSIOL, V115, P2728, DOI 10.1016/j.clinph.2004.06.018; Sokhadze E., 2016, NeuroRegulation, V3, P101, DOI DOI 10.15540/NR.3.3.101; Sokhadze E, 2010, APPL PSYCHOPHYS BIOF, V35, P147, DOI 10.1007/s10484-009-9121-2; Sokhadze EM, 2014, APPL PSYCHOPHYS BIOF, V39, P237, DOI 10.1007/s10484-014-9264-7; Sokhadze EM, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00134; Sokhadze EM, 2012, APPL PSYCHOPHYS BIOF, V37, P91, DOI 10.1007/s10484-012-9182-5; Sokhadze EM, 2009, J AUTISM DEV DISORD, V39, P619, DOI 10.1007/s10803-008-0662-7; Spence SJ, 2009, PEDIATR RES, V65, P599, DOI 10.1203/PDR.0b013e31819e7168; Thapar A., 2015, RUTTERS CHILD ADOLES, P666; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Wang Y, 2016, APPL PSYCHOPHYS BIOF, V41, P47, DOI 10.1007/s10484-015-9311-z; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2; Yang YX, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00293";44;2;2;2;5;SAGE PUBLICATIONS LTD;LONDON;1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND;0973-1342;2754-6349;;J INDIAN ASSOC CHILD;J. Indian Assoc. Child Adolesc. Ment. Health;JUL;2022;18;3;;;;;252;259;;10.1177/09731342221141028;http://dx.doi.org/10.1177/09731342221141028;;DEC 2022;8;Pediatrics;Emerging Sources Citation Index (ESCI);Pediatrics;7J5SL;;;;;24/11/2024;WOS:000897901100001;View Full Record in Web of Science
J;"Yilmaz, Z; Al-Taie, A";;;;"Yilmaz, Zekiye; Al-Taie, Anmar";;;A cross-sectional study of community pharmacists' self-reported disease knowledge and competence in the treatment of childhood autism spectrum disorder;INTERNATIONAL JOURNAL OF CLINICAL PHARMACY;;;English;Article;;;;;;"Autism spectrum disorder; Children; Community pharmacists; Knowledge; Pharmacotherapy";"CHILDREN; HEALTH; AWARENESS; ADULTS; CARE; IRRITABILITY; INTERVENTION; MANAGEMENT; SYMPTOMS; ATTITUDE";Background Autism spectrum disorder (ASD) is a neurodevelopmental disease that can cause significant social, communication, and behavioural challenges. Given the rising prevalence of autism and multiple medication use, healthcare professionals, including community pharmacists, are required to have sufficient ASD knowledge to affect positively the disease prognosis and related comorbidities.Aim To assess community pharmacists' knowledge of disease and pharmacotherapy of ASD, along with the provision of patient education and counselling provided by, community pharmacists in Turkey.Method This was a descriptive, cross-sectional study conducted among community pharmacists in Turkey using a structured, validated questionnaire to assess ASD knowledge, awareness, and the provision of patient education and counselling by community pharmacists.Results 486 community pharmacists were included, with a mean age of 39.69 +/- 13.10 years, and most (n = 151, 31.1%) in the age range between 20 and 29 years. 96.3% of community pharmacists never had training about ASD. 32.9% of the participants were aware of the medicines for ASD treatment, and 25.7% were aware of the drugs' side effects. The mean overall knowledge about childhood autism among health workers questionnaire (KCAHW) score was 11.83 +/- 3.91, and there was a statistically significant KCAHW score difference between other pharmacists and those with ASD training (p = 0.006).Conclusion There is a lack of disease and pharmacotherapy knowledge about childhood ASD among Turkish community pharmacists, particularly about communication impairment, type, onset, and comorbidities, as well as poor knowledge about drug pharmacotherapy and patient counselling services. This potentially creates a barrier to the adequate provision of healthcare to autistic patients.;"[Yilmaz, Zekiye] Univ Acibadem Mehmet Ali Aydinlar, Fac Pharm, Dept Clin Pharm, Kayisdagi Cad 32, TR-34758 Atasehir, Istanbul, Turkey; [Al-Taie, Anmar] Istinye Univ, Fac Pharm, Dept Clin Pharm, Istanbul, Turkey";"Acibadem University; Istinye University";Yilmaz, Z (corresponding author), Univ Acibadem Mehmet Ali Aydinlar, Fac Pharm, Dept Clin Pharm, Kayisdagi Cad 32, TR-34758 Atasehir, Istanbul, Turkey.;zkubraozden@gmail.com;ALTAIE, Anmar/ITV-8235-2023;YILMAZ, ZEKIYE/0000-0002-0041-6140;;;;"Al-Taie A, 2020, BIOMED BIOTECH RES J, V4, P349, DOI 10.4103/bbrj.bbrj_174_20; ALI NH, 2021, ACTA PHARM SCI, V59, P291, DOI DOI 10.23893/1307-2080.APS.05917; [Anonymous], 2021, AUTISM; Apikoglu S, 2022, INT J CLIN PHARM-NET, V44, P1223, DOI 10.1007/s11096-022-01413-8; Bakare Muideen O, 2008, Clin Pract Epidemiol Ment Health, V4, P17, DOI 10.1186/1745-0179-4-17; Centers for Disease Control and Prevention. Autism spectrum disorder (ASD), 2020, WHAT IS AUT SPECTR D; Corsano P, 2020, J CHILD HEALTH CARE, V24, P486, DOI 10.1177/1367493519875339; Croen LA, 2015, AUTISM, V19, P814, DOI 10.1177/1362361315577517; Daniels AM, 2014, J AM ACAD CHILD PSY, V53, P141, DOI 10.1016/j.jaac.2013.11.002; DeFilippis Melissa, 2016, Psychopharmacol Bull, V46, P18; Erdogan ON, 2012, FARMACIA, V60, P749; Eseigbe E.E., 2015, AUTISM RES TREAT, V2015; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Gillespie-Lynch K, 2015, J AUTISM DEV DISORD, V45, P2553, DOI 10.1007/s10803-015-2422-9; Govindan R, 2020, INDIAN J COMMUN MED, V45, P382, DOI 10.4103/ijcm.IJCM_290_19; Guan J, 2017, AM J PUBLIC HEALTH, V107, P791, DOI 10.2105/AJPH.2017.303696; Hahler EM., 2015, Curr Dev Disord Rep, V2, P58, DOI [10.1007/s40474-014-0033-3, DOI 10.1007/S40474-014-0033-3]; Hartley-McAndrew M., 2014, North American Journal of Medicine and Science, V7, P97; Hindi AMK, 2019, BMC FAM PRACT, V20, DOI 10.1186/s12875-019-0912-0; Huffman LC, 2011, J DEV BEHAV PEDIATR, V32, P56, DOI 10.1097/DBP.0b013e3182040acf; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3448; Igwe Monday N, 2011, Child Adolesc Psychiatry Ment Health, V5, P1, DOI 10.1186/1753-2000-5-1; Imran N, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-107; Khanna R, 2012, RES SOC ADMIN PHARM, V8, P464, DOI 10.1016/j.sapharm.2011.11.002; Knights E, 2020, INT J PHARM PRACT, V28, P41, DOI 10.1111/ijpp.12566; Koegel LK, 2014, INT J SPEECH-LANG PA, V16, P50, DOI 10.3109/17549507.2013.861511; Larsson Elin C., 2008, Pharmacy Pract (Granada), V6, P74; Luleci NE, 2016, INT J CLIN PHARM-NET, V38, P1477, DOI 10.1007/s11096-016-0394-2; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; McCormack G, 2020, REV J AUTISM DEV DIS, V7, P226, DOI 10.1007/s40489-019-00189-4; McGuire K, 2016, PEDIATRICS, V137, pS136, DOI 10.1542/peds.2015-2851L; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Myers SM, 2007, EXPERT OPIN PHARMACO, V8, P1579, DOI 10.1517/14656566.8.11.1579; National Institutes of Health, WHAT AR TREATM AUT; Nickel RE, 2017, INDIAN J PEDIATR, V84, P53, DOI 10.1007/s12098-015-1894-0; Nicolaidis C, 2014, MED CLIN N AM, V98, P1169, DOI 10.1016/j.mcna.2014.06.011; Özgür BG, 2019, PSYCHIAT CLIN PSYCH, V29, P765, DOI 10.1080/24750573.2019.1637326; Peacock G, 2012, J DEV BEHAV PEDIATR, V33, P2, DOI 10.1097/DBP.0b013e31823969de; Pisacane R, 2013, US PHARM, V38, P19; Rahbar MH, 2011, J AUTISM DEV DISORD, V41, P465, DOI 10.1007/s10803-010-1068-x; Rice CE, 2012, PUBLIC HEALTH REV, V34, DOI 10.1007/BF03391685; Salama HM, 2017, FAM MED COMMUNITY HE, V5, P266, DOI 10.15212/FMCH.2017.0136; Sampson Wireko-Gyebi, 2018, Clin Pract Epidemiol Ment Health, V14, P99, DOI 10.2174/1745017901814010099; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Tekin ÇS, 2020, ISTANB J PHARM, V50, P142, DOI 10.26650/IstanbulJPharm.2019.0069; Turk Eczacilari Birligi, 2020, HAST KAM ECZ IL; U.S. National Library of Medicine. Dailymed, DAIL AR TABL; Unigwe S, 2017, BRIT J GEN PRACT, V67, pE445, DOI 10.3399/bjgp17X690449; UpToDate, AUTISM SPECTRUM DISO; Wongpakaran R, 2017, J CLIN PHARM THER, V42, P329, DOI 10.1111/jcpt.12518; Yilmaz Z, 2020, INDIAN J PHARM EDUC, V54, pS695, DOI 10.5530/ijper.54.3s.170; Zerbo O, 2015, J AUTISM DEV DISORD, V45, P4002, DOI 10.1007/s10803-015-2579-2";52;5;5;4;9;SPRINGER;DORDRECHT;VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS;2210-7703;2210-7711;;INT J CLIN PHARM-NET;Int. J. Clin. Phar,.;OCT;2023;45;5;;;SI;;1088;1097;;10.1007/s11096-022-01530-4;http://dx.doi.org/10.1007/s11096-022-01530-4;;DEC 2022;10;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;W0VC0;36547799;;;;24/11/2024;WOS:000903208500001;View Full Record in Web of Science
J;"Okazaki, K; Yamamuro, K; Iida, J; Kishimoto, T";;;;"Okazaki, Kosuke; Yamamuro, Kazuhiko; Iida, Junzo; Kishimoto, Toshifumi";;;Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report;ANNALS OF GENERAL PSYCHIATRY;;;English;Article;;;;;;"Guanfacine; Atomoxetine; Methylphenidate; Attention deficit; hyperactivity disorder; Autism spectrum disorder; Tourette syndrome";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; RAT PREFRONTAL CORTEX; EXTENDED-RELEASE; EXTRACELLULAR DOPAMINE; LONG-TERM; CHILDREN; EFFICACY; NORADRENALINE; ADOLESCENTS";BackgroundPatients with attention deficit/hyperactivity disorder (ADHD) often experience comorbid conditions, such as autism spectrum disorder (ASD) and Tourette syndrome (TS). Although pharmacotherapies are effective for treating ADHD, they are likely to elicit a variety of adverse effects. It is, thus, important to select an effective and well-tolerated pharmacotherapeutic treatment for patients with ADHD/ASD comorbid with TS.Case presentationWe report the case of a 10-year-old boy with ADHD/ASD comorbid with TS who was treated with guanfacine (GUAN). He experienced several side effects of atomoxetine (ATX) and methylphenidate (MPH) before being treated with GUAN. In the presented case, symptoms of ADHD as well as tic symptoms were improved by treatment with GUAN.ConclusionGUAN might be effective and well tolerated in the treatment of patients with ADHD/ASD comorbid with TS who experience side effects of ATX and MPH.;"[Okazaki, Kosuke; Yamamuro, Kazuhiko; Kishimoto, Toshifumi] Nara Med Univ, Sch Med, Dept Psychiat, 840 Shijo Cho, Kashihara, Nara 6348521, Japan; [Iida, Junzo] Nara Med Univ, Sch Med, Fac Nursing, Kashihara, Nara, Japan";"Nara Medical University; Nara Medical University";Okazaki, K (corresponding author), Nara Med Univ, Sch Med, Dept Psychiat, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.;psy-nara-ok@naramed-u.ac.jp;;;;;;"Albin Roger L, 2006, Adv Neurol, V99, P99; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; [Anonymous], 2009, ATT DEF HYP DIS DIAG; Arnsten AF, 2007, J CHILD ADOL PSYCHOP, V17, P393, DOI 10.1089/cap.2006.0098; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Biederman J, 2008, CNS SPECTRUMS, V13, P1047, DOI 10.1017/S1092852900017107; Bloch MH, 2009, J AM ACAD CHILD PSY, V48, P884, DOI 10.1097/CHI.0b013e3181b26e9f; Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9; COULTER CL, 1995, BRAIN RES, V690, P217, DOI 10.1016/0006-8993(95)00614-V; Dalsgaard S, 2014, J CHILD ADOL PSYCHOP, V24, P302, DOI 10.1089/cap.2014.0020; Devoto P, 2001, MOL PSYCHIATR, V6, P657, DOI 10.1038/sj.mp.4000904; Dooley Joseph M, 2006, Semin Pediatr Neurol, V13, P231, DOI 10.1016/j.spen.2006.09.004; Franowicz JS, 2002, J NEUROSCI, V22, P8771; Frazier J.A., 2001, Journal of Attentional Disorders, V4, P203; Gizer IR, 2009, HUM GENET, V126, P51, DOI 10.1007/s00439-009-0694-x; GOETZ CG, 1987, ANN NEUROL, V21, P307, DOI 10.1002/ana.410210313; Hervas A, 2014, EUR NEUROPSYCHOPHARM, V24, P1861, DOI 10.1016/j.euroneuro.2014.09.014; Jensen CM, 2015, ADHD-ATTEND DEFICIT, V7, P27, DOI 10.1007/s12402-014-0142-1; Kawaura K, 2014, BEHAV BRAIN RES, V270, P349, DOI 10.1016/j.bbr.2014.05.044; KIECHEL JR, 1980, BRIT J CLIN PHARMACO, V10, pS25, DOI 10.1111/j.1365-2125.1980.tb04901.x; LOWE TL, 1982, JAMA-J AM MED ASSOC, V247, P1168, DOI 10.1001/jama.247.8.1168; Newcorn JH, 2013, J AM ACAD CHILD PSY, V52, P921, DOI 10.1016/j.jaac.2013.06.006; RAITERI M, 1977, EUR J PHARMACOL, V41, P133, DOI 10.1016/0014-2999(77)90202-3; Sallee FR, 2010, POSTGRAD MED, V122, P78, DOI 10.3810/pgm.2010.09.2204; Scahill L, 2000, CHILD ADOL PSYCH CL, V9, P541; Scahill L, 2001, AM J PSYCHIAT, V158, P1067, DOI 10.1176/appi.ajp.158.7.1067; Sesack SR, 1998, J NEUROSCI, V18, P2697; Sonuga-Barke EJS, 2005, BIOL PSYCHIAT, V57, P1231, DOI 10.1016/j.biopsych.2004.09.008; SORKIN EM, 1986, DRUGS, V31, P301, DOI 10.2165/00003495-198631040-00003; Spencer T, 1996, J AM ACAD CHILD PSY, V35, P409, DOI 10.1097/00004583-199604000-00008; Tanda G, 1997, EUR J NEUROSCI, V9, P2077, DOI 10.1111/j.1460-9568.1997.tb01375.x; Taylor E, 2004, EUR CHILD ADOLES PSY, V13, P7, DOI 10.1007/s00787-004-1002-x; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Volkow ND, 2012, J NEUROSCI, V32, P841, DOI 10.1523/JNEUROSCI.4461-11.2012; Wang M, 2007, CELL, V129, P397, DOI 10.1016/j.cell.2007.03.015; Wigal SB, 2009, CNS DRUGS, V23, P21, DOI 10.2165/00023210-200923000-00004; Yamamoto BK, 1998, J NEUROCHEM, V71, P274; Yoshida Y, 2004, EUR CHILD ADOLES PSY, V13, P307, DOI 10.1007/s00787-004-0391-1";38;4;4;0;1;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1744-859X;;ANN GEN PSYCHIATR;Ann. Gen. Psychiatr.;mars-11;2019;18;;;;;;;;2;10.1186/s12991-019-0226-6;http://dx.doi.org/10.1186/s12991-019-0226-6;;;5;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;HO4FB;30899317;Green Published, gold;;;24/11/2024;WOS:000460876600001;View Full Record in Web of Science
J;"Wink, LK; Minshawi, NF; Shaffer, RC; Plawecki, MH; Posey, DJ; Horn, PS; Adams, R; Pedapati, EV; Schaefer, TL; McDougle, CJ; Swiezy, NB; Erickson, CA";;;;"Wink, Logan K.; Minshawi, Noha F.; Shaffer, Rebecca C.; Plawecki, Martin H.; Posey, David J.; Horn, Paul S.; Adams, Ryan; Pedapati, Ernest V.; Schaefer, Tori L.; McDougle, Christopher J.; Swiezy, Naomi B.; Erickson, Craig A.";;;D-Cycloserine enhances durability of social skills training in autism spectrum disorder;MOLECULAR AUTISM;;;English;Article;;;;;;"Autism; Autism spectrum disorder; D-Cycloserine; Social skills training";"EXPOSURE THERAPY; ADOLESCENTS; CHILDREN; TRIAL; INDIVIDUALS; EXTINCTION; BEHAVIOR; ADULTS";Background: D-Cycloserine (DCS) enhances extinction learning across species, but it has proven challenging to identify consistent benefit of DCS when added to therapeutic interventions. We conducted a placebo-controlled trial of DCS to potentiate social skills training in autism spectrum disorder (ASD) but found substantial improvement in both the DCS and placebo groups at the conclusion of active treatment. Here, we assess the impact of DCS 11 weeks following active treatment to evaluate the impact of DCS on treatment response durability. Methods: Study participants included 60 outpatient youth with ASD, ages 5-11 years, all with IQ above 70, and significantly impaired social functioning who completed a 10-week active treatment phase during which they received weekly single doses of 50 mg of DCS or placebo administered 30 min prior to group social skills training. Following the 10-week active treatment phase, blinded follow-up assessments occurred at week 11 and week 22. The primary outcome measure for our durability of treatment evaluation was the parent-rated social responsiveness scale (SRS) total raw score at week 22. Results: Analysis of the SRS total raw score demonstrated significant decrease for the DCS group compared to the placebo group (p = 0.042) indicating greater maintenance of treatment effect in the DCS group. DCS was well tolerated, with irritability being the most frequently reported adverse effect in both groups. Conclusions: The findings of this study suggest that DCS may help youth with ASD to maintain skills gained during sort-term social skills training. Larger-scale studies with longer follow-up will be necessary to further understand the long-term impact of DCS paired with structured social skills training.;"[Erickson, Craig A.] Cincinnati Childrens Hosp, Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA";"Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati";Erickson, CA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.;craig.erickson@cchmc.org;"pedapati, ernest/GPT-0086-2022; Erickson, Craig/M-8933-2017; Swiezy, Naomi/AAZ-5697-2021; Horn, Paul/LPA-6457-2024; PLAWECKI, MARTIN/T-2467-2018";PLAWECKI, MARTIN/0000-0003-0708-9514;US Department of Defense;US Department of Defense(United States Department of Defense);This study was funded by the US Department of Defense.;"American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; [Anonymous], 2002, COGN NEUR SOC ANN M; [Anonymous], CHILD SYMPTOM INVENT; Blundell J, 2010, J NEUROSCI, V30, P2115, DOI 10.1523/JNEUROSCI.4517-09.2010; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Erickson CA, 2008, GLUTAMATE NEUROPSYCH, P197; Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9; Guastella AJ, 2008, BIOL PSYCHIAT, V63, P544, DOI 10.1016/j.biopsych.2007.11.011; Hampel F.R., 1986, J ROYAL STAT SOC SER, V35, P565; Jones W, 2008, ARCH GEN PSYCHIAT, V65, P946, DOI 10.1001/archpsyc.65.8.946; KANNER L, 1968, ACTA PAEDOPSYCHIATR, V35, P100; King BH, 2001, J AM ACAD CHILD PSY, V40, P658, DOI 10.1097/00004583-200106000-00010; Klin A, 2002, ARCH GEN PSYCHIAT, V59, P809, DOI 10.1001/archpsyc.59.9.809; Kushner MG, 2007, BIOL PSYCHIAT, V62, P835, DOI 10.1016/j.biopsych.2006.12.020; Laugeson EA, 2012, J AUTISM DEV DISORD, V42, P1025, DOI 10.1007/s10803-011-1339-1; Lee EJ, 2015, CURR OPIN PHARMACOL, V20, P8, DOI 10.1016/j.coph.2014.10.007; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; Lord C, 1997, J AUTISM DEV DISORD, V27, P501, DOI 10.1023/A:1025873925661; Minshawi NF, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-015-0062-8; Nave AM, 2012, J CLIN PSYCHIAT, V73, P1179, DOI 10.4088/JCP.11m07564; Parnas AS, 2005, NEUROBIOL LEARN MEM, V83, P224, DOI 10.1016/j.nlm.2005.01.001; Posey D, 2008, ANN M AM AC CHILD AD, P219; Posey DJ, 2004, AM J PSYCHIAT, V161, P2115, DOI 10.1176/appi.ajp.161.11.2115; Pozdol SL, 2007, 33 ASS BEH AN INT; Reichow Brian, 2013, Evid Based Child Health, V8, P266, DOI 10.1002/ebch.1903; Ressler KJ, 2004, ARCH GEN PSYCHIAT, V61, P1136, DOI 10.1001/archpsyc.61.11.1136; Roid G.H., 2005, STANFORD BINET INTEL, VFifth; Soorya LV, 2015, J AM ACAD CHILD PSY, V54, P208, DOI 10.1016/j.jaac.2014.12.005; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Spezio ML, 2007, J AUTISM DEV DISORD, V37, P929, DOI 10.1007/s10803-006-0232-9; Stone W., 2003, TRIAD Social Skills Assessment Manual; Tse J, 2007, J AUTISM DEV DISORD, V37, P1960, DOI 10.1007/s10803-006-0343-3; Urbano M, 2014, CLIN NEUROPHARMACOL, V37, P69, DOI 10.1097/WNF.0000000000000033; Wilcox RR, 2011, J APPL STAT, V38, P1359, DOI 10.1080/02664763.2010.498507; Wilhelm S, 2008, AM J PSYCHIAT, V165, P335, DOI 10.1176/appi.ajp.2007.07050776; Won H, 2012, NATURE, V486, P261, DOI 10.1038/nature11208";38;31;32;2;13;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;janv-25;2017;8;;;;;;;;2;10.1186/s13229-017-0116-1;http://dx.doi.org/10.1186/s13229-017-0116-1;;;8;"Genetics & Heredity; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Genetics & Heredity; Neurosciences & Neurology";EP0RP;28138381;gold, Green Published;;;24/11/2024;WOS:000397094700001;View Full Record in Web of Science
J;"Adams, JB; Bhargava, A; Coleman, DM; Frye, RE; Rossignol, DA";;;;"Adams, James B.; Bhargava, Anisha; Coleman, Devon M.; Frye, Richard E.; Rossignol, Daniel A.";;;Ratings of the Effectiveness of Nutraceuticals for Autism Spectrum Disorders: Results of a National Survey;JOURNAL OF PERSONALIZED MEDICINE;;;English;Article;;;;;;"autism; autism spectrum disorder; nutraceuticals; survey; vitamins; minerals; B12; folinic acid";"OXIDATIVE STRESS; DOUBLE-BLIND; CLINICAL-TRIAL; RELEASE MELATONIN; N-ACETYLCYSTEINE; CHILDREN; SUPPLEMENTATION; EFFICACY; IMPROVES; SYMPTOMS";Autism spectrum disorder (ASD) often involves a wide range of co-occurring medical conditions (comorbidities) and biochemical abnormalities such as oxidative stress and mitochondrial dysfunction. Nutritional supplements (Nutraceuticals) are often used to treat both core ASD symptoms and comorbidities, but some have not yet been formally evaluated in ASD. The potential biological mechanisms of nutraceuticals include correction of micronutrient deficiencies due to a poor diet and support for metabolic processes such as redox regulation, mitochondrial dysfunction and melatonin production. This paper reports on the results of the National Survey on Treatment Effectiveness for Autism, focusing on nutraceuticals. The Survey involved 1286 participants from across the United States. Participants rated the overall perceived benefits and adverse effects of each nutraceutical, and also indicated the specific symptoms changed and adverse effects. From these ratings the top-rated nutraceuticals for each of 24 symptoms are listed. Compared to psychiatric and seizure medications rated through the same Survey, on average nutraceuticals had significantly higher ratings of Overall Benefit (1.59 vs. 1.39, p = 0.01) and significantly lower ratings of Overall Adverse Effects (0.1 vs. 0.9, p < 0.001). Folinic acid and vitamin B12 were two of the top-rated treatments. This study suggests that nutraceuticals may have clinical benefits and favorable adverse effect profiles.;"[Adams, James B.; Coleman, Devon M.] Arizona State Univ, Sch Engn Matter Transport & Energy, POB 876106, Tempe, AZ 85287 USA; [Bhargava, Anisha] Columbia Mailman Sch Publ Hlth, 722 W 168th St, New York, NY 10032 USA; [Frye, Richard E.] Phoenix Childrens Hosp, Div Neurol, Sect Neurodev Disorders, Barrow Neurol Inst, 1919 E Thomas Rd, Phoenix, AZ 85016 USA; [Rossignol, Daniel A.] Rossignol Med Ctr, 24541 Pacific Pk Dr,Suite 210, Aliso Viejo, CA 92656 USA";"Arizona State University; Arizona State University-Tempe; Barrow Neurological Institute; Phoenix Children's Hospital";Adams, JB (corresponding author), Arizona State Univ, Sch Engn Matter Transport & Energy, POB 876106, Tempe, AZ 85287 USA.;"jim.adams@asu.edu; abharg25@asu.edu; devon_marie@live.com; rfrye@phoenixchildrens.com; rossignolmd@gmail.com";"Rose, Shannon/JZE-1449-2024; Adams, James/C-6066-2014; Rossignol, Daniel/I-5947-2019";"Adams, James/0000-0001-8683-4062; Frye, Richard/0000-0003-4442-2937; Bhargava, Anisha/0009-0005-7429-4026; Rossignol, Daniel/0000-0002-4405-8664";"Autism Research Institute; Zoowalk for Autism Research";"Autism Research Institute; Zoowalk for Autism Research";This research was funded in part by the Autism Research Institute and the Zoowalk for Autism Research.;"Adams JB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030369; Adams JB, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-111; Adams JB, 2006, J ALTERN COMPLEM MED, V12, P59, DOI 10.1089/acm.2006.12.59; Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; ARI, ARI PUBL 34 PARENT R; Batebi N, 2021, CHILD PSYCHIAT HUM D, V52, P928, DOI 10.1007/s10578-020-01072-8; Benke PJ, 2018, PEDIATR NEUROL, V79, P61, DOI 10.1016/j.pediatrneurol.2017.10.013; Bjorklund G, 2020, FREE RADICAL BIO MED, V160, P149, DOI 10.1016/j.freeradbiomed.2020.07.017; Canals-Sans J, 2022, J AUTISM DEV DISORD, V52, P361, DOI 10.1007/s10803-021-04928-7; Chan AS, 2014, RES AUTISM SPECT DIS, V8, P681, DOI 10.1016/j.rasd.2014.03.007; Chen L, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-020-01135-3; Coleman DM, 2019, J CHILD ADOL PSYCHOP, V29, P107, DOI 10.1089/cap.2018.0121; Cortesi F, 2012, J SLEEP RES, V21, P700, DOI 10.1111/j.1365-2869.2012.01021.x; Craig F., 2019, Minerva Pediatr, DOI [10.23736/s0026-4946.19.05371-4, DOI 10.23736/S0026-4946.19.05371-4]; Delhey LM, 2017, J CLIN MED, V6, DOI 10.3390/jcm6020018; DOLSKE MC, 1993, PROG NEURO-PSYCHOPH, V17, P765, DOI 10.1016/0278-5846(93)90058-Z; Dosman CF, 2007, PEDIATR NEUROL, V36, P152, DOI 10.1016/j.pediatrneurol.2006.11.004; Dunn K, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035280; Ezugha H, 2010, J CHILD NEUROL, V25, P1232, DOI 10.1177/0883073809361165; Fahmy SF, 2013, RES AUTISM SPECT DIS, V7, P159, DOI 10.1016/j.rasd.2012.07.006; Frustaci A, 2012, FREE RADICAL BIO MED, V52, P2128, DOI 10.1016/j.freeradbiomed.2012.03.011; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Frye RE, 2013, MOL PSYCHIATR, V18, P369, DOI 10.1038/mp.2011.175; Frye Richard E, 2013, Autism Res Treat, V2013, P609705, DOI 10.1155/2013/609705; Frye RE, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-37; Fu BQ, 2017, IMMUNITY, V47, P1100, DOI [10.1016/j.immuni.2017.11.018, 10.15585/mmwr.ss6904a1]; Garstang J, 2006, CHILD CARE HLTH DEV, V32, P585, DOI 10.1111/j.1365-2214.2006.00616.x; Geier DA, 2011, MED SCI MONITOR, V17, pPI15, DOI 10.12659/MSM.881792; Ghanizadeh A, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-196; Gringas P, 2017, J AM ACAD CHILD PSY, V56, P948, DOI 10.1016/j.jaac.2017.09.414; Gringras P, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6664; Guevara-Campos J, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9060137; Guo M, 2018, BRAIN RES BULL, V137, P35, DOI 10.1016/j.brainresbull.2017.11.001; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Hendren RL, 2016, J CHILD ADOL PSYCHOP, V26, P774, DOI 10.1089/cap.2015.0159; Holingue C, 2018, AUTISM RES, V11, P24, DOI 10.1002/aur.1854; Hollocks MJ, 2019, PSYCHOL MED, V49, P559, DOI 10.1017/S0033291718002283; Howsmon DP, 2018, BIOENG TRANSL MED, V3, P156, DOI 10.1002/btm2.10095; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2009, AM J CLIN NUTR, V89, P425, DOI 10.3945/ajcn.2008.26615; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Kern JK, 2011, MED SCI MONITOR, V17, pCR677, DOI 10.12659/MSM.882125; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; LeClerc Sheena, 2015, P T, V40, P389; Lee TM, 2021, AUST NZ J PSYCHIAT, V55, P196, DOI 10.1177/0004867420952540; Li BB, 2022, NUTR NEUROSCI, V25, P835, DOI 10.1080/1028415X.2020.1815332; McGuinness G, 2020, EXCLI J, V19, P892, DOI 10.17179/excli2020-2487; Meguid NA, 2019, ACTA NEUROL BELG, V119, P577, DOI 10.1007/s13760-019-01181-9; Mousavinejad E, 2018, PSYCHIAT RES, V265, P62, DOI 10.1016/j.psychres.2018.03.061; Munasinghe SA, 2010, J AUTISM DEV DISORD, V40, P1131, DOI 10.1007/s10803-010-0974-2; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; Owen-Smith AA, 2015, RES AUTISM SPECT DIS, V17, P40, DOI 10.1016/j.rasd.2015.05.002; Page SD, 2022, J AUTISM DEV DISORD, V52, P255, DOI 10.1007/s10803-021-04947-4; Parellada M, 2017, EUR NEUROPSYCHOPHARM, V27, P1319, DOI 10.1016/j.euroneuro.2017.08.426; PFEIFFER SI, 1995, J AUTISM DEV DISORD, V25, P481, DOI 10.1007/BF02178295; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P276, DOI 10.1055/s-2008-1065354; Renard E, 2020, BIOCHIMIE, V173, P57, DOI 10.1016/j.biochi.2020.04.019; Rose S, 2018, MOL DIAGN THER, V22, P571, DOI 10.1007/s40291-018-0352-x; Rossignol DA, 2012, MOL PSYCHIATR, V17, P290, DOI 10.1038/mp.2010.136; Rossignol D.A., 2020, HDB AUTISM PERVASIVE; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Rossignol DA, 2009, ANN CLIN PSYCHIATRY, V21, P213; Russo AJ, 2011, NUTR METAB INSIGHTS, V4, P49, DOI [10.4137/NMI.S8761, 10.4137/NMI.S6827]; Saad K, 2015, CLIN PSYCHOPHARM NEU, V13, P188, DOI 10.9758/cpn.2015.13.2.188; Sharp WG, 2013, J AUTISM DEV DISORD, V43, P2159, DOI 10.1007/s10803-013-1771-5; Song LY, 2020, CLIN PSYCHOPHARM NEU, V18, P203, DOI 10.9758/cpn.2020.18.2.203; Sun CH, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060337; Thorsen M, 2020, PROG MOL BIOL TRANSL, V173, P331, DOI 10.1016/bs.pmbts.2020.04.018; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Wright B, 2011, J AUTISM DEV DISORD, V41, P175, DOI 10.1007/s10803-010-1036-5";71;12;14;0;5;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2075-4426;;J PERS MED;J. Pers. Med.;SEP;2021;11;9;;;;;;;878;10.3390/jpm11090878;http://dx.doi.org/10.3390/jpm11090878;;;21;"Health Care Sciences & Services; Medicine, General & Internal";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Health Care Sciences & Services; General & Internal Medicine";UV6OC;34575655;Green Published, gold;;;24/11/2024;WOS:000699594100001;View Full Record in Web of Science
J;"Muit, JJ; Bothof, N; Kan, CC";;;;"Muit, J. J.; Bothof, N.; Kan, C. C.";;;Pharmacotherapy of ADHD in Adults With Autism Spectrum Disorder: Effectiveness and Side Effects;JOURNAL OF ATTENTION DISORDERS;;;English;Article;;;;;;"ADHD; autism spectrum disorders; comorbidity; adult ADHD treatment; pharmacotherapy";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; METHYLPHENIDATE TREATMENT; PSYCHIATRIC-DISORDERS; CHILDREN; SYMPTOMS; ATOMOXETINE; PLACEBO; HYPERACTIVITY; PSYCHOSTIMULANTS";Objective: Symptoms of ADHD are expected to be more difficult to treat in patients with a combination of ADHD and autism spectrum disorder (ASD) as opposed to only ADHD. Little evidence is available on the influence of ASD on the effects of pharmacotherapy in adults with ADHD. This study addresses this gap. Method: 60 adults with ADHD and comorbid ASD were selected from an outpatient clinic and compared with 226 adults from the same clinic with only ADHD. Similar treatment regimens were received. Results: Significant decreases in symptoms of ADHD were found in both groups. A diagnosis of ASD did not affect the reduction in symptoms of ADHD. No significant group differences in side effects or vital signs were found. Conclusion: Results show that medication for ADHD can effectively and safely be prescribed to patients with ADHD and comorbid ASD. Suggestions for future research are discussed.;"[Muit, J. J.; Kan, C. C.] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands; [Bothof, N.] GGZ Oost Brabant, Boekelo, Netherlands";Radboud University Nijmegen;Muit, JJ (corresponding author), Radboud Univ Nijmegen, Dept Psychiat, Med Ctr, POB 910, NL-6500 HB Nijmegen, Netherlands.;bob.muit@radboudumc.nl;Kan, Cornelis/L-4423-2015;;;;;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; Aman MG, 2014, RES DEV DISABIL, V35, P1412, DOI 10.1016/j.ridd.2014.03.006; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; [Anonymous], ADHD BIJ VOLWASSENEN; [Anonymous], VERG ADHD MED; [Anonymous], MED; [Anonymous], RICHTL ADHD BIJ VOLW; [Anonymous], 2018, BR PSYCHOL SOC; Arnett AB, 2015, J CHILD PSYCHOL PSYC, V56, P632, DOI 10.1111/jcpp.12337; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Beery SH, 2017, J ATTEN DISORD, V21, P62, DOI 10.1177/1087054712469256; Brugha TS, 2011, ARCH GEN PSYCHIAT, V68, P459, DOI 10.1001/archgenpsychiatry.2011.38; Castells X, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007813.pub2; Caye A, 2016, EUR CHILD ADOLES PSY, V25, P1151, DOI 10.1007/s00787-016-0831-8; Conners C. K, 1999, Conners Adult ADHD Rating Scales (CAARS): Technical Manual; Cortese S, 2012, EXPERT REV NEUROTHER, V12, P461, DOI [10.1586/ERN.12.23, 10.1586/ern.12.23]; Dakwar E, 2012, J CLIN PSYCHIAT, V73, P960, DOI [10.4088/JCP.12m07895, 10.4088/JCP.11m07484]; Di Martino A, 2004, J CHILD ADOL PSYCHOP, V14, P207, DOI 10.1089/1044546041649011; Fayyad J, 2017, ADHD-ATTEND DEFICIT, V9, P47, DOI 10.1007/s12402-016-0208-3; Findling RL, 2005, J CLIN PSYCHIAT, V66, P26; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Gargaro BA, 2011, NEUROSCI BIOBEHAV R, V35, P1081, DOI 10.1016/j.neubiorev.2010.11.002; Ghuman JK, 2009, J CHILD ADOL PSYCHOP, V19, P329, DOI 10.1089/cap.2008.0137; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hartman CA, 2016, NEUROSCI BIOBEHAV R, V71, P529, DOI 10.1016/j.neubiorev.2016.09.003; Hazell P, 2007, J PAEDIATR CHILD H, V43, P19, DOI 10.1111/j.1440-1754.2007.00995.x; Jahromi LB, 2009, J AUTISM DEV DISORD, V39, P395, DOI 10.1007/s10803-008-0636-9; Jensen CM, 2015, ADHD-ATTEND DEFICIT, V7, P27, DOI 10.1007/s12402-014-0142-1; Kan CC., 2013, Multidisciplinaire richtlijn diagnostiek en behandeling van autismespectrumstoornissen bij volwassenen; Kooij J. J. S., 2009, DIAGNOSTISCH INTERVI; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Luteijn EF, 2000, EUR CHILD ADOLES PSY, V9, P168, DOI 10.1007/s007870070040; Michielsen M, 2012, BRIT J PSYCHIAT, V201, P298, DOI 10.1192/bjp.bp.111.101196; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; NICE guideline, 2018, ATTENTION DEFICIT HY; Nickels KC, 2008, J DEV BEHAV PEDIATR, V29, P75, DOI 10.1097/DBP.0b013e31815f24f7; Pearson DA, 2013, J CHILD ADOL PSYCHOP, V23, P337, DOI 10.1089/cap.2012.0096; Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028; Reiersen Angela M, 2008, Expert Rev Neurother, V8, P657, DOI 10.1586/14737175.8.4.657; Rösler M, 2006, EUR ARCH PSY CLIN N, V256, P3, DOI 10.1007/s00406-006-1001-7; Roy M, 2009, J ATTEN DISORD, V12, P381, DOI 10.1177/1087054708320436; Santosh PJ, 2006, CHILD CARE HLTH DEV, V32, P575, DOI 10.1111/j.1365-2214.2006.00631.x; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Sinzig J, 2009, J ATTEN DISORD, V13, P117, DOI 10.1177/1087054708326261; Stigler KA, 2004, J CHILD ADOL PSYCHOP, V14, P49, DOI 10.1089/104454604773840481; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Tumuluru RV, 2017, J CHILD ADOL PSYCHOP, V27, P708, DOI 10.1089/cap.2016.0187; Verbeeck W, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009504.pub2; Vuijk R, 2014, NEDERLANDS INTERVIEW; Willcutt E, 2012, NEUROTHERAPEUTICS, V9, P490, DOI 10.1007/s13311-012-0135-8";50;6;6;2;15;SAGE PUBLICATIONS INC;THOUSAND OAKS;2455 TELLER RD, THOUSAND OAKS, CA 91320 USA;1087-0547;1557-1246;;J ATTEN DISORD;J. Atten. Disord.;JAN;2020;24;2;;;SI;;215;225;1,09E+15;10.1177/1087054719866255;http://dx.doi.org/10.1177/1087054719866255;;oct-19;11;"Psychology, Developmental; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";JZ2KS;31625426;hybrid, Green Published;;;24/11/2024;WOS:000491600100001;View Full Record in Web of Science
J;"Adams, JB; Kirby, J; Audhya, T; Whiteley, P; Bain, J";;;;"Adams, James B.; Kirby, Jasmine; Audhya, Tapan; Whiteley, Paul; Bain, Jaclyn";;;Vitamin/mineral/micronutrient supplement for autism spectrum disorders: a research survey;BMC PEDIATRICS;;;English;Article;;;;;;"Autism; Autism spectrum disorder (ASD); Vitamins; Minerals; Micronutrients";"OXIDATIVE STRESS; MULTIVITAMIN/MINERAL SUPPLEMENT; CHILDREN; BIOMARKERS; SYMPTOMS; IMPROVES; THERAPY; TRIAL; ACID";Background Vitamin and mineral supplements are widely used by children and adults diagnosed with autism spectrum disorder (ASD). Several studies have reported benefits of such supplements in resolving nutritional deficiencies, treating various metabolic problems and improving symptoms and overall quality of life. Methods This research survey collected evaluations from 161 people about the effectiveness of ANRC-Essentials Plus (ANRC-EP), a vitamin/mineral/micronutrient supplement designed for children and adults with autism. Although this was an open-label survey, results were compared with a three-month randomized double-blind placebo-controlled study of an earlier version of the supplement. Evaluations included the Parent Global Impressions of Autism (PGIA) and the Overall Benefit/Adverse Effect scale of the National Survey on Treatment Effectiveness for Autism (NSTEA). Results The participants reported substantially higher Average PGIA Scores than the placebo group in a similar previous study, with an estimated effect size of 0.66. Based on the NSTEA questionnaire, 73% of participants rated the Overall Benefit as Moderate, Good, or Great, with scores that were substantially higher than the NSTEA study found for multi-vitamins, the average of 58 nutraceuticals, and the average of 28 psychiatric and seizure medications. The Overall Adverse Effect score was low (0.25/3.0), similar or slightly higher than other nutraceuticals, and much lower than the average of 28 psychiatric and seizure medications (0.9/3.0). Sub-analysis found that the Overall Benefit of ANRC-EP was not significantly affected by gender, age, autism severity, diet quality, self-limited diet, use of psychiatric or seizure medications, dosage, developmental history, intellectual disability, or seizures. This indicates that ANRC-EP may be beneficial for a wide range of children and adults with ASD. A limitation of this study is the retrospective nature of the survey, and that participants who had good benefits were more likely to respond. Conclusions This study found that ANRC-EP had significant benefits for a wide range of symptoms, and low adverse effects.;"[Adams, James B.; Kirby, Jasmine] Arizona State Univ, Tempe, AZ 85287 USA; [Audhya, Tapan] NYU, New York, NY USA; [Whiteley, Paul] ESPA Res, Sunderland, England; [Bain, Jaclyn] Southwest Coll Naturopath Med, Tempe, AZ USA";"Arizona State University; Arizona State University-Tempe; New York University";Adams, JB (corresponding author), Arizona State Univ, Tempe, AZ 85287 USA.;jim.adams@asu.edu;;Whiteley, Paul/0009-0006-1779-6588;"Autism Research Institute; Autism Nutrition Research Center (ANRC)";"Autism Research Institute; Autism Nutrition Research Center (ANRC)";The study was primarily funded by the Autism Research Institute, with funds from the annual Zoowalk fundraiser. The Autism Nutrition Research Center (ANRC) provided compensation to participants in the form of a 50% discount on their next purchase in return for completing the survey.;"Adams JB, 2021, J PERS MED, V11, DOI 10.3390/jpm11090878; Adams JB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030369; Adams JB, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-111; Adams JB, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-34; Adams JB, 2006, J ALTERN COMPLEM MED, V12, P59, DOI 10.1089/acm.2006.12.59; Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; Ames BN, 2002, AM J CLIN NUTR, V75, P616, DOI 10.1093/ajcn/75.4.616; Batebi N, 2021, CHILD PSYCHIAT HUM D, V52, P928, DOI 10.1007/s10578-020-01072-8; Benke PJ, 2018, PEDIATR NEUROL, V79, P61, DOI 10.1016/j.pediatrneurol.2017.10.013; Chen L, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-020-01135-3; Coleman DM, 2019, J CHILD ADOL PSYCHOP, V29, P107, DOI 10.1089/cap.2018.0121; DOLSKE MC, 1993, PROG NEURO-PSYCHOPH, V17, P765, DOI 10.1016/0278-5846(93)90058-Z; Dosman CF, 2007, PEDIATR NEUROL, V36, P152, DOI 10.1016/j.pediatrneurol.2006.11.004; Fahmy SF, 2013, RES AUTISM SPECT DIS, V7, P159, DOI 10.1016/j.rasd.2012.07.006; Fortenberry Megan, 2020, J Pediatr Pharmacol Ther, V25, P735, DOI 10.5863/1551-6776-25.8.735; Frustaci A, 2012, FREE RADICAL BIO MED, V52, P2128, DOI 10.1016/j.freeradbiomed.2012.03.011; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Geier DA, 2011, MED SCI MONITOR, V17, pPI15, DOI 10.12659/MSM.881792; Gogou M, 2017, BRAIN DEV-JPN, V39, P656, DOI 10.1016/j.braindev.2017.03.029; Gorrindo P, 2012, AUTISM RES, V5, P101, DOI 10.1002/aur.237; Guo M, 2018, BRAIN RES BULL, V137, P35, DOI 10.1016/j.brainresbull.2017.11.001; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2009, AM J CLIN NUTR, V89, P425, DOI 10.3945/ajcn.2008.26615; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Javadfar Z, 2020, NUTRITION, V79-80, DOI 10.1016/j.nut.2020.110986; Kirby AV, 2022, AUTISM RES, V15, P751, DOI 10.1002/aur.2670; Kittana M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14010026; Li BB, 2022, NUTR NEUROSCI, V25, P835, DOI 10.1080/1028415X.2020.1815332; Li MY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071628; Meguid NA, 2019, ACTA NEUROL BELG, V119, P577, DOI 10.1007/s13760-019-01181-9; Mousavinejad E, 2018, PSYCHIAT RES, V265, P62, DOI 10.1016/j.psychres.2018.03.061; Nye C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003497; Raghavan R, 2020, AM J CLIN NUTR, V112, P1304, DOI 10.1093/ajcn/nqaa208; Raghavan R, 2018, PAEDIATR PERINAT EP, V32, P100, DOI 10.1111/ppe.12414; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P276, DOI 10.1055/s-2008-1065354; Rose S, 2018, MOL DIAGN THER, V22, P571, DOI 10.1007/s40291-018-0352-x; Song LY, 2020, CLIN PSYCHOPHARM NEU, V18, P203, DOI 10.9758/cpn.2020.18.2.203; Stewart PA, 2015, J ACAD NUTR DIET, V115, P1237, DOI 10.1016/j.jand.2015.03.026; Wallace TC, 2014, J AM COLL NUTR, V33, P94, DOI 10.1080/07315724.2013.846806";39;10;10;5;18;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-2431;;BMC PEDIATR;BMC Pediatr.;oct-13;2022;22;1;;;;;;;590;10.1186/s12887-022-03628-0;http://dx.doi.org/10.1186/s12887-022-03628-0;;;16;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;5H4NO;36229781;gold, Green Published;;;24/11/2024;WOS:000867657400003;View Full Record in Web of Science
J;"Hernandez, MH; Bote, V; Serra-LLovich, A; Cendros, M; Salazar, J; Mestres, C; Guijarro, S; Alvarez, A; Lamborena, C; Mendez, I; Sanchez, B; Hervas, A; Arranz, MJ";;;;"Hernandez, Marta H.; Bote, Valentin; Serra-LLovich, Alexandre; Cendros, Marc; Salazar, Juliana; Mestres, Conxita; Guijarro, Silvina; Alvarez, Aida; Lamborena, Cristina; Mendez, Iria; Sanchez, Bernardo; Hervas, Amaia; Arranz, Maria J.";;;CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders;PHARMACOGENOMICS & PERSONALIZED MEDICINE;;;English;Article;;;;;;"CES1; autistic spectrum disorders; ASD; methylphenidate; attention deficit hyperactivity disorders; ADHD";"NOREPINEPHRINE TRANSPORTER GENE; ASSOCIATION; PHARMACOGENETICS; POLYMORPHISMS; CHILDREN";Purpose: Autistic spectrum disorders (ASD) children and adolescents usually present comorbidities, with 40-70% of them affected by attention deficit hyperactivity disorders (ADHD). The first option of pharmacological treatment for these patients is methylphe-nidate (MPH). ASD children present more side effects and poorer responses to MPH than ADHD children. The objective of our study is to identify genetic biomarkers of response to MPH in ASD children and adolescents to improve its efficacy and safety. Patients and Methods: A retrospective study with a total of 140 ASD children and adolescents on MPH treatment was included. Fifteen polymorphisms within genes coding for the MPH target NET1 (SLC6A2) and for its primary metabolic pathway (CES1) were genotyped. Multivariate analyses including response phenotypes (efficacy, side-effects, presence of somnolence, irritability, mood alterations, aggressivity, shutdown, other side-effects) were performed for every polymorphism and haplotype. Results: Single marker analyses considering gender, age, and dose as covariates showed association between CES1 variants and MPH-induced side effects (rs2244613-G (p=0.04), rs2302722-C (p=0.02), rs2307235-A (p=0.03), and rs8192950-T alleles (p=0.03)), and marginal association between the CES1 rs2302722-C allele and presence of somnolence (p=0.05) and the SLC6A2 rs36029-G allele and shutdown (p=0.05). A CES1 haplotype combination was associated with efficacy and side effects (p=0.02 and 0.03 respectively). SLC6A2 haplotype combination was associated with somnolence (p=0.05). Conclusion: CES1 genetic variants may influence the clinical outcome of MPH treatment in ASD comorbid with ADHD children and adolescents.;"[Hernandez, Marta H.; Serra-LLovich, Alexandre; Cendros, Marc; Arranz, Maria J.] Fundacio Docencia & Recerca Mutua Terrassa, Res Lab Unit, Terrassa, Spain; [Hernandez, Marta H.; Mestres, Conxita; Arranz, Maria J.] Univ Ramon Llull, Sch Hlth Sci Blanquerna, Barcelona, Spain; [Bote, Valentin; Guijarro, Silvina; Alvarez, Aida; Lamborena, Cristina; Mendez, Iria; Sanchez, Bernardo; Hervas, Amaia] Hosp Univ Mutua Terrassa, Dept Child & Adolescent Psychiat, Terrassa, Spain; [Cendros, Marc] EUGEN Genom & Farmacogenet, Barcelona, Spain; [Salazar, Juliana] Inst Recerca Biomed St Pau IIB St Pau, Translat Med Oncol Lab, Barcelona, Spain; [Arranz, Maria J.] Fundacio Docencia & Recerca Mutua Terrassa, Res Lab Unit, C St Antoni 19, Terrassa 08221, Spain";"Universitat Ramon Llull; Hospital Universitario Mutua Terrassa";Arranz, MJ (corresponding author), Fundacio Docencia & Recerca Mutua Terrassa, Res Lab Unit, C St Antoni 19, Terrassa 08221, Spain.;mjarranz@mutuaterrassa.es;"Blanco, Iria/AAQ-5677-2021; Salazar, Juliana/AAW-1616-2021; HERNANDEZ, MARTA/F-3250-2019; Mestres, Concepcio/H-1632-2017";"HERNANDEZ, MARTA/0000-0002-6983-413X; Salazar, Juliana/0000-0002-3581-4499; Mestres, Concepcio/0000-0002-0494-3108; Hervas, Amaia/0000-0003-0051-5752";"Secretaria de Recerca i Universitats de la Generalitat de Catalunya i la Universitat Ramon Llull; Institute of Health Carlos III; [2021-URL-Proj-002]; [FIS PI21/01946]";"Secretaria de Recerca i Universitats de la Generalitat de Catalunya i la Universitat Ramon Llull; Institute of Health Carlos III(Instituto de Salud Carlos IIISpanish Government); ;";Acknowledgments This project was supported by grants from Secretaria de Recerca i Universitats de la Generalitat de Catalunya i la Universitat Ramon Llull (2021-URL-Proj-002) and by a grant from the Institute of Health Carlos III (FIS PI21/01946) .;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; Angyal N, 2018, PROG NEURO-PSYCHOPH, V84, P122, DOI 10.1016/j.pnpbp.2018.01.013; Antshel KM, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1020-5; Arranz M., 2016, GENETIC INFLUENCES R; Brown JT, 2017, PHARMACOGENOMICS, V18, P403, DOI 10.2217/pgs-2016-0167; Bruxel EM, 2013, PHARMACOGENOMICS J, V13, P476, DOI 10.1038/tpj.2012.25; Dimatteo C, 2016, THROMB RES, V144, P1, DOI 10.1016/j.thromres.2016.05.025; Fabbri C, 2013, AM J MED GENET B, V162, P487, DOI 10.1002/ajmg.b.32184; Gomez-Sanchez CI, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10912-y; Hervas A., 2021, J TRANSL GENET GENOM, V5, P278, DOI [10.20517/jtgg.2021.25, DOI 10.20517/JTGG.2021.25]; Hervás A, 2016, REV NEUROLOGIA, V62, pS9; Joensen B, 2017, J RES PHARM PRACT, V6, P65, DOI 10.4103/jrpp.JRPP_16_161; Johnson KA, 2013, J CHILD ADOL PSYCHOP, V23, P655, DOI 10.1089/cap.2013.0032; Labriet A, 2019, PHARMACOGENOMICS, V20, P1179, DOI 10.2217/pgs-2019-0091; Loomes R, 2017, J AM ACAD CHILD PSY, V56, P466, DOI 10.1016/j.jaac.2017.03.013; Marshe VS, 2017, AM J PSYCHIAT, V174, P468, DOI 10.1176/appi.ajp.2016.16050617; Ming X, 2008, BRAIN DEV-JPN, V30, P454, DOI 10.1016/j.braindev.2007.12.007; Myer N M, 2018, Mol Psychiatry, V23, P1929, DOI 10.1038/mp.2017.234; Nemoda Z, 2009, NEUROPHARMACOLOGY, V57, P731, DOI 10.1016/j.neuropharm.2009.08.014; Park S, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-22; Sharma SR, 2018, PHARMACOL THERAPEUT, V190, P91, DOI 10.1016/j.pharmthera.2018.05.007; Song J, 2014, CLIN NEUROPHARMACOL, V37, P136, DOI 10.1097/WNF.0000000000000045; Song J, 2011, INT CLIN PSYCHOPHARM, V26, P107, DOI 10.1097/YIC.0b013e32834152d1; Stage C, 2019, BASIC CLIN PHARMACOL, V125, P54, DOI 10.1111/bcpt.13212; Stein MA, 2014, J CHILD ADOL PSYCHOP, V24, P238, DOI 10.1089/cap.2013.0102; Stevens T, 2019, PHARMACOGENET GENOM, V29, P136, DOI 10.1097/FPC.0000000000000376; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Sun ZJ, 2004, J PHARMACOL EXP THER, V310, P469, DOI 10.1124/jpet.104.067116; Thakur GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049616; Vizeli P, 2018, EUR J CLIN PHARMACOL, V74, P275, DOI 10.1007/s00228-017-2392-2; Whirl-Carrillo M, 2021, CLIN PHARMACOL THER, V110, P563, DOI 10.1002/cpt.2350; World Health Organization. WHO, ABOUT US; Xiao FY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07736-1; Yang L, 2004, J AM ACAD CHILD PSY, V43, P1154, DOI 10.1097/01.chi.0000131134.63368.46; Yang L, 2013, J NEURAL TRANSM, V120, P1127, DOI 10.1007/s00702-012-0955-z; Zhao ZG, 2016, EUR J CLIN PHARMACOL, V72, P1195, DOI 10.1007/s00228-016-2094-1";36;2;2;2;4;DOVE MEDICAL PRESS LTD;ALBANY;PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND;;1178-7066;;PHARMACOGEN PERS MED;Pharmacogn. Pers. Med.;;2022;15;;;;;;951;957;;10.2147/PGPM.S377210;http://dx.doi.org/10.2147/PGPM.S377210;;;7;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;6E9VQ;36393977;Green Published, gold;;;24/11/2024;WOS:000883720300001;View Full Record in Web of Science
J;"Lin, CH; Zeng, T; Lu, CW; Li, DY; Liu, YY; Li, BM; Chen, SQ; Deng, YH";;;;"Lin, Chu-hui; Zeng, Ting; Lu, Cui-wei; Li, De-yang; Liu, Yi-ying; Li, Bing-mei; Chen, Sheng-qiang; Deng, Yu-hong";;;Efficacy and safety of Bacteroides fragilis BF839 for pediatric autism spectrum disorder: a randomized clinical trial;FRONTIERS IN NUTRITION;;;English;Article;;;;;;"autism spectrum disorder in children; probiotics; Bacteroides fragilis BF839; abnormal behavior; gastrointestinal symptoms";"SYMPTOM RATING-SCALE; GUT MICROBIOTA; CHILDREN; POLYSACCHARIDE; PROBIOTICS";Background: The clinical utility of Bacteroides fragilis in treating autism spectrum disorder (ASD) remains unclear. Therefore, this randomized, double-blind, placebo-controlled study aimed to explore the therapeutic effects and safety of B. fragilis BF839 in the treatment of pediatric ASD. Methods: We examined 60 children aged 2-10 years diagnosed with ASD, and participants received either BF839 powder (10 g/bar with >= 106 CFU/bar of viable bacteria, two bars/day) or placebo for 16 weeks. The primary outcomes was Autism Behavior Checklist (ABC) score. The secondary outcomes were Childhood Autism Rating Scale (CARS), Social Responsiveness Scale (SRS), Normal Development of Social Skills from Infants to Junior High School Children (S-M), Gastrointestinal Symptom Rating Scale (GSRS) scores, and fecal microbiome composition. Assessments were performed on day 0 and at weeks 8 and 16. Results: Compared with the placebo group, the BF839 group showed significant improvement in the ABC body and object use scores at week 16, which was more pronounced in children with ASD aged <4 years. Among children with a baseline CARS score >= 30, the BF839 group showed significant improvements at week 16 in the ABC total score, ABC body and object use score, CARS score, and GSRS score compared to the placebo group. Only two patients (6.67%) in the BF839 group experienced mild diarrhea. Compared with baseline and placebo group levels, the BF839 group showed a significant post-intervention increase in abundance of bifidobacteria and change in the metabolic function of neuroactive compounds encoded by intestinal microorganisms. Conclusion: BF839 significantly and safely improved abnormal behavior and gastrointestinal symptoms in children with ASD.;"[Lin, Chu-hui; Zeng, Ting; Deng, Yu-hong] Guangzhou Med Univ, Affiliated Hosp 2, Dept Clin Nutr, Guangzhou, Peoples R China; [Lu, Cui-wei; Li, De-yang; Chen, Sheng-qiang] Guangzhou Med Univ, Med Adm Coll, Guangzhou, Peoples R China; [Li, De-yang] Chinese Acad Sci, Inst Psychol, Beijing, Peoples R China; [Liu, Yi-ying] Weierkang Specialist Outpatient Dept, Guangzhou, Peoples R China; [Li, Bing-mei; Deng, Yu-hong] Guangzhou Med Univ, Affiliated Hosp 2, Inst Neurosci, Dept Neurol, Guangzhou, Peoples R China; [Li, Bing-mei; Deng, Yu-hong] Key Lab Neurogenet & Channelopathies Guangdong Pro, Guangzhou, Peoples R China; [Li, Bing-mei; Deng, Yu-hong] Minist Educ China, Guangzhou, Peoples R China";"Guangzhou Medical University; Guangzhou Medical University; Chinese Academy of Sciences; Institute of Psychology, CAS; Guangzhou Medical University";"Deng, YH (corresponding author), Guangzhou Med Univ, Affiliated Hosp 2, Dept Clin Nutr, Guangzhou, Peoples R China.;Deng, YH (corresponding author), Guangzhou Med Univ, Affiliated Hosp 2, Inst Neurosci, Dept Neurol, Guangzhou, Peoples R China.;Deng, YH (corresponding author), Key Lab Neurogenet & Channelopathies Guangdong Pro, Guangzhou, Peoples R China.;Deng, YH (corresponding author), Minist Educ China, Guangzhou, Peoples R China.";1376708863@qq.com;Shengqiang, Chen/ACH-7927-2022;"Lu, Cuiwei/0000-0003-2138-9273; Li, Deyang/0000-0002-3670-4590";General Guidance Project of Guangzhou Health Science and Technology [BF839];General Guidance Project of Guangzhou Health Science and Technology;The authors sincerely thank Guangzhou Totem Life Medicine Research Co., Ltd. for cooperating in the production of BF839 and the placebo products. The authors thank Shenzhen 01 Life Institute Co., Ltd. for providing the Flora Detection and technical guidance. The authors would like to thank all patients who participated in the study. Furthermore, the authors would also like to thank Editage (www.editage.cn) for English language editing.;"Adams JB, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-22; Alam R, 2017, AM J MED GENET B, V174, P651, DOI 10.1002/ajmg.b.32567; An DD, 2014, CELL, V156, P123, DOI 10.1016/j.cell.2013.11.042; Arnold LE, 2019, J CHILD ADOL PSYCHOP, V29, P659, DOI 10.1089/cap.2018.0156; Bercik P, 2011, NEUROGASTROENT MOTIL, V23, P1132, DOI 10.1111/j.1365-2982.2011.01796.x; Bhat S, 2014, REV NEUROSCIENCE, V25, P841, DOI 10.1515/revneuro-2014-0056; Butcher NJ, 2022, JAMA-J AM MED ASSOC, V328, P2252, DOI 10.1001/jama.2022.21022; Cao M, 2017, TRENDS NEUROSCI, V40, P494, DOI 10.1016/j.tins.2017.06.003; Chang CJ, 2019, J FOOD DRUG ANAL, V27, P615, DOI 10.1016/j.jfda.2018.12.011; Dasgupta S, 2014, CELL HOST MICROBE, V15, P413, DOI 10.1016/j.chom.2014.03.006; Ding HT, 2017, J AUTISM DEV DISORD, V47, P480, DOI 10.1007/s10803-016-2960-9; El-Ansary A, 2018, METAB BRAIN DIS, V33, P1155, DOI 10.1007/s11011-018-0212-8; Eribo OA, 2022, INFECT IMMUN, V90, DOI 10.1128/IAI.00321-21; Erturk-Hasdemir D, 2018, ANN NY ACAD SCI, V1417, P116, DOI 10.1111/nyas.13660; [??? Feng Shuzhen], 2015, [??????, Microbiology China], V42, P1366; Fung TC, 2017, NAT NEUROSCI, V20, P145, DOI 10.1038/nn.4476; Gan HZ, 2023, FRONT PEDIATR, V11, DOI 10.3389/fped.2023.1120728; Goo N, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118497; Horder J, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0155-1; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Kaluzna-Czaplinska J, 2012, NUTRITION, V28, P124, DOI 10.1016/j.nut.2011.08.002; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Kilcast D., 1998, Food Qual Prefer, V9, P291, DOI [10.1016/S0950-3293(98)00004-4, DOI 10.1016/S0950-3293(98)00004-4]; Kong XJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051552; Kong XJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092128; Li Yu-Qin, 2021, Zhongguo Dang Dai Er Ke Za Zhi, V23, P1103, DOI 10.7499/j.issn.1008-8830.2108085; Lin C., 2022, J Epilepsy, V8, P298, DOI [10.7507/2096-0247.202204008, DOI 10.7507/2096-0247.202204008]; [??? Lin Chuhui], 2022, [????????, Chinese Journal of Neuromedicine], V21, P341; Lin Chuhui, 2021, Sheng Wu Gong Cheng Xue Bao, V37, P3828, DOI 10.13345/j.cjb.210198; Liu Chao, 2015, Zhongguo Dang Dai Er Ke Za Zhi, V17, P1277; Liu FT, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0389-6; Liu M, 2023, EXP NEUROL, V361, DOI 10.1016/j.expneurol.2022.114298; Liu YW, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040820; MacDonald R, 2014, RES DEV DISABIL, V35, P3632, DOI 10.1016/j.ridd.2014.08.036; Mao YK, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2478; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; National Health Commission of the Peoples Republic of China, New Resource Foods (Before 2007). December 1; Ochoa-Repáraz J, 2010, MUCOSAL IMMUNOL, V3, P487, DOI 10.1038/mi.2010.29; Ochoa-Repáraz J, 2010, J IMMUNOL, V185, P4101, DOI 10.4049/jimmunol.1001443; Parracho H. M. R. T., 2010, International Journal of Probiotics and Prebiotics, V5, P69; Perna S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205232; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Revicki DA, 1998, QUAL LIFE RES, V7, P75; Sanctuary MR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210064; Shaaban SY, 2018, NUTR NEUROSCI, V21, P676, DOI 10.1080/1028415X.2017.1347746; Shen Jun, 2013, Front Neuroenergetics, V5, P1, DOI 10.3389/fnene.2013.00001; Smith AM, 2019, BIOL PSYCHIAT, V85, P345, DOI 10.1016/j.biopsych.2018.08.016; SOUZA Gabriela Santos, 2016, Arq. Gastroenterol., V53, P146, DOI 10.1590/S0004-28032016000300005; Srikantha P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092115; Strati F, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0242-1; Tabouy L, 2018, BRAIN BEHAV IMMUN, V73, P310, DOI 10.1016/j.bbi.2018.05.015; [?? Tang Ting], 2020, [????????, Jounral of Chongqing Medical University], V45, P85; Tarlungeanu DC, 2016, CELL, V167, P1481, DOI 10.1016/j.cell.2016.11.013; Tomova A, 2015, PHYSIOL BEHAV, V138, P179, DOI 10.1016/j.physbeh.2014.10.033; Tuerk C, 2021, J NEUROPSYCHOL, V15, P477, DOI 10.1111/jnp.12230; Valles-Colomer M, 2019, NAT MICROBIOL, V4, P623, DOI 10.1038/s41564-018-0337-x; Vieira-Silva S, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.88, 10.1038/nmicrobiol.2016.88]; Wang L, 2011, APPL ENVIRON MICROB, V77, P6718, DOI 10.1128/AEM.05212-11; Wang X, 2019, AUTISM RES, V12, P576, DOI 10.1002/aur.2079; Wang Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104784; Wieronska JM., 2011, Anxiety Disord, P135, DOI DOI 10.5772/19919; Yang YF., 2016, Chin J Child Health Care, V24, P1011; Yin DG., 2001, Matern Child Health Care China, V33, P2877, DOI [10.7620/zgfybj.j.issn.1001-4411.2018.12.81, DOI 10.7620/ZGFYBJ.J.ISSN.1001-4411.2018.12.81]; Yin HM, 2023, LIFE SCI, V324, DOI 10.1016/j.lfs.2023.121734; Yuhong D., 2021, Journal of Epilepsy, V7, P288, DOI [10.7507/2096-0247.20210046, DOI 10.7507/2096-0247.20210046]; Zeng Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21243; Zhang B, 2022, METAB BRAIN DIS, V37, P219, DOI 10.1007/s11011-021-00805-5; Zhang JJ., 1995, Chin J Biol, V8, P63, DOI [10.13200/j.cjb.1995.02.63.zhangjj.006, DOI 10.13200/J.CJB.1995.02.63.ZHANGJJ.006]; Zhang JJ., 1991, Ningxia Med J, V13, P216; Zhao HJ, 2019, GASTROINTEST ENDOSC, V89, pAB512, DOI 10.1016/j.gie.2019.03.857";70;0;0;3;3;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;2296-861X;;;FRONT NUTR;Front. Nutr.;sept-03;2024;11;;;;;;;;1447059;10.3389/fnut.2024.1447059;http://dx.doi.org/10.3389/fnut.2024.1447059;;;12;Nutrition & Dietetics;Science Citation Index Expanded (SCI-EXPANDED);Nutrition & Dietetics;G1X9K;39290561;gold;;;24/11/2024;WOS:001314650500001;View Full Record in Web of Science
J;"Buie, T; Campbell, DB; Fuchs, GJ; Furuta, GT; Levy, J; Van de Water, J; Whitaker, AH; Atkins, D; Bauman, ML; Beaudet, AL; Carr, EG; Gershon, MD; Hyman, SL; Jirapinyo, P; Jyonouchi, H; Kooros, K; Kushak, R; Levitt, P; Levy, SE; Lewis, JD; Murray, KF; Natowicz, MR; Sabra, A; Wershil, BK; Weston, SC; Zeltzer, L; Winter, H";;;;"Buie, Timothy; Campbell, Daniel B.; Fuchs, George J., III; Furuta, Glenn T.; Levy, Joseph; Van de Water, Judy; Whitaker, Agnes H.; Atkins, Dan; Bauman, Margaret L.; Beaudet, Arthur L.; Carr, Edward G.; Gershon, Michael D.; Hyman, Susan L.; Jirapinyo, Pipop; Jyonouchi, Harumi; Kooros, Koorosh; Kushak, Rafail; Levitt, Pat; Levy, Susan E.; Lewis, Jeffery D.; Murray, Katherine F.; Natowicz, Marvin R.; Sabra, Aderbal; Wershil, Barry K.; Weston, Sharon C.; Zeltzer, Lonnie; Winter, Harland";;;Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report;PEDIATRICS;;;English;Article;;;;;;"autism spectrum disorder; gastrointestinal; constipation; chronic diarrhea; abdominal discomfort; problem behavior; gluten-free casein-free diet";"AUTISM SPECTRUM DISORDERS; INDUCED ENTEROCOLITIS SYNDROME; LYMPHOID-NODULAR HYPERPLASIA; COMMON DIETARY PROTEINS; NORTH-AMERICAN-SOCIETY; PROBLEM BEHAVIOR; PEDIATRIC-GASTROENTEROLOGY; CYTOKINE PRODUCTION; REGRESSIVE AUTISM; ADVERSE-REACTIONS";"Autism spectrum disorders (ASDs) are common and clinically heterogeneous neurodevelopmental disorders. Gastrointestinal disorders and associated symptoms are commonly reported in individuals with ASDs, but key issues such as the prevalence and best treatment of these conditions are incompletely understood. A central difficulty in recognizing and characterizing gastrointestinal dysfunction with ASDs is the communication difficulties experienced by many affected individuals. A multidisciplinary panel reviewed the medical literature with the aim of generating evidence-based recommendations for diagnostic evaluation and management of gastrointestinal problems in this patient population. The panel concluded that evidence-based recommendations are not yet available. The consensus expert opinion of the panel was that individuals with ASDs deserve the same thoroughness and standard of care in the diagnostic workup and treatment of gastrointestinal concerns as should occur for patients without ASDs. Care providers should be aware that problem behavior in patients with ASDs may be the primary or sole symptom of the underlying medical condition, including some gastrointestinal disorders. For these patients, integration of behavioral and medical care may be most beneficial. Priorities for future research are identified to advance our understanding and management of gastrointestinal disorders in persons with ASDs. Pediatrics 2010; 125: S1-S18";"[Buie, Timothy; Kushak, Rafail; Winter, Harland] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Buie, Timothy; Bauman, Margaret L.] Learning & Dev Disabil Evaluat & Rehabil Serv, Lexington, MA USA; [Buie, Timothy; Winter, Harland] Mass Gen Hosp Children, Pediat Gastrointestinal Unit, Div Pediat Gastroenterol & Nutr, Boston, MA 02114 USA; [Bauman, Margaret L.; Kushak, Rafail] Mass Gen Hosp Children, Dept Pediat, Boston, MA 02114 USA; [Bauman, Margaret L.] Mass Gen Hosp Children, Dept Neurol, Boston, MA 02114 USA; [Campbell, Daniel B.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA; [Fuchs, George J., III] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Little Rock, AR 72205 USA; [Furuta, Glenn T.] Childrens Hosp Denver, Sect Pediat Gastroenterol Hepatol & Nutr, Aurora, CO USA; [Furuta, Glenn T.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA; [Levy, Joseph] NYU, Sch Med, Dept Pediat Adm, NYU Langone LangoneMed Ctr, New York, NY USA; [Van de Water, Judy] Univ Calif Davis, Dept Internal Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Whitaker, Agnes H.] Columbia Univ, Dept Psychiat, Div Child & Adolescent Psychiat, New York Presbyterian Hosp, New York, NY USA; [Atkins, Dan] Childrens Hosp, Div Ambulatory Pediat, Dept Pediat, Natl Jewish Hlth, Denver, CO USA; [Atkins, Dan] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA; [Beaudet, Arthur L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Carr, Edward G.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA; [Gershon, Michael D.] Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Hyman, Susan L.] Univ Rochester, Med Ctr, Golisano Childrens Hosp Strong, Div Neurodev & Behav Pediat, Rochester, NY 14642 USA; [Jirapinyo, Pipop] Mahidol Univ, Dept Pediat, Siriraj Hosp, Bangkok 10700, Thailand; [Jyonouchi, Harumi] Univ Med & Dent New Jersey, New Jersey Med Sch, Div Allergy Immunol & Infect Dis Pediat, Newark, NJ 07103 USA; [Kooros, Koorosh] Univ Rochester, Med Ctr, Golisano Childrens Hosp Strong, Div Pediat Gastroenterol & Nutr, Rochester, NY 14642 USA; [Levitt, Pat] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; [Levitt, Pat] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA; [Levy, Susan E.] Univ Penn, Childrens Hosp Philadelphia, Div Child Dev Rehabil & Metab Dis, Dept Pediat, Philadelphia, PA 19104 USA; [Lewis, Jeffery D.] Childrens Ctr Digest Hlth Care LLC, Atlanta, GA USA; [Natowicz, Marvin R.] Cleveland Clin, Inst Pathol & Lab Med, Cleveland, OH 44106 USA; [Natowicz, Marvin R.] Cleveland Clin, Inst Gen Med, Cleveland, OH 44106 USA; [Natowicz, Marvin R.] Cleveland Clin, Inst Neurol, Cleveland, OH 44106 USA; [Natowicz, Marvin R.] Cleveland Clin, Inst Pediat, Cleveland, OH 44106 USA; [Sabra, Aderbal] UNIGRANRIO, Brasilian Acad Med, Escola Med, Dept Pediat, Rio De Janeiro, Brazil; [Wershil, Barry K.] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med NW, Div Gastroenterol Hepatol & Nutr, Chicago, IL 60614 USA; [Weston, Sharon C.] Childrens Hosp Boston, Dept Gastroenterol & Nutr, Peabody, MA USA; [Zeltzer, Lonnie] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Pediat Pain Program, Los Angeles, CA 90095 USA";"Harvard University; Harvard Medical School; University of Southern California; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; New York University; NYU Langone Medical Center; University of California System; University of California Davis; Columbia University; NewYork-Presbyterian Hospital; Children's Hospital Colorado; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Baylor College of Medicine; State University of New York (SUNY) System; Stony Brook University; Columbia University; University of Rochester; Mahidol University; Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; University of Rochester; University of Southern California; University of Southern California; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Universidade do Grande Rio; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Harvard University; Boston Children's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA";Buie, T (corresponding author), Mass Gen Hosp Children, Pediat Gastrointestinal Unit, Div Pediat Gastroenterol & Nutr, CRPZ 5-560,175 Cambridge St, Boston, MA 02114 USA.;"tbuie@partners.org; hwinter@partners.org";"Weston, Sharon/CAG-8647-2022; Levitt, Pat/GYJ-3125-2022; Fuchs, George/GLV-1285-2022";"Levitt, Pat/0000-0002-9717-1695; Weston, Sharon/0000-0001-7143-7101; Campbell, Daniel/0000-0002-5945-3632";"Northwest Autism Foundation; Autism Research Institute; Autism Society of America; Easter Seals Oregon";"Northwest Autism Foundation; Autism Research Institute; Autism Society of America; Easter Seals Oregon";The meeting and consensus report were sponsored by the Autism Forum. The forum's goal in this initiative is to establish best practices for the care of co-occurring medical conditions that may affect the developmental outcome of persons with ASDs. Autism Forum programs are developed under the guidance of the Northwest Autism Foundation and in association with, and support of, the Autism Research Institute, Autism Society of America, and Easter Seals Oregon.Dr Carr passed away before publication of this supplement. He was an enthusiastic and articulate contributor whose comments were enlightening and greatly improved the manuscript. We shall miss his passion and deep commitment to improving the lives and quality of care of people with autism spectrum disorders.;"Afzal N, 2003, PEDIATRICS, V112, P939, DOI 10.1542/peds.112.4.939; *AM DIET ASS, FOOD NUTR INF CONS R; [Anonymous], NIH PUBLICATION; Arnold GL, 2003, J AUTISM DEV DISORD, V33, P449, DOI 10.1023/A:1025071014191; Ashwood P, 2006, J NEUROIMMUNOL, V173, P126, DOI 10.1016/j.jneuroim.2005.12.007; Ashwood P, 2003, J CLIN IMMUNOL, V23, P504, DOI 10.1023/B:JOCI.0000010427.05143.bb; Ashwood P, 2006, J LEUKOCYTE BIOL, V80, P1, DOI 10.1189/jlb.1205707; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Black C, 2002, BRIT MED J, V325, P419, DOI 10.1136/bmj.325.7361.419; Braunschweig D, 2008, NEUROTOXICOLOGY, V29, P226, DOI 10.1016/j.neuro.2007.10.010; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Cabanlit M, 2007, ANN NY ACAD SCI, V1107, P92, DOI 10.1196/annals.1381.010; Campbell DB, 2009, PEDIATRICS, V123, P1018, DOI 10.1542/peds.2008-0819; Carr E.G., 1999, American Association on Mental Retardation Monograph Series; Carr EG, 2007, J AUTISM DEV DISORD, V37, P413, DOI 10.1007/s10803-006-0176-0; Carr EG, 2006, BEHAV MODIF, V30, P901, DOI 10.1177/0145445506290080; Carr EG, 2003, AM J MENT RETARD, V108, P117, DOI 10.1352/0895-8017(2003)108<0117:MDAABS>2.0.CO;2; Carr EG., 1995, Ment Retard Dev Disabl Res Rev, V1, P94, DOI DOI 10.1002/MRDD.1410010204; CARR EG, 2008, AUTISM ADVOCATE, V50, P46; Christison GW, 2006, J DEV BEHAV PEDIATR, V27, pS162, DOI 10.1097/00004703-200604002-00015; Croen LA, 2005, ARCH PEDIAT ADOL MED, V159, P151, DOI 10.1001/archpedi.159.2.151; Croen LA, 2008, BIOL PSYCHIAT, V64, P583, DOI 10.1016/j.biopsych.2008.05.006; Croonenberghs J, 2002, NEUROPSYCHOBIOLOGY, V45, P1, DOI 10.1159/000048665; Curtin Carol, 2005, BMC Pediatr, V5, P48, DOI 10.1186/1471-2431-5-48; DeFelice ML, 2003, AM J GASTROENTEROL, V98, P1777, DOI 10.1016/S0002-9270(03)00444-1; DEufemia P, 1996, ACTA PAEDIATR, V85, P1076, DOI 10.1111/j.1651-2227.1996.tb14220.x; Di Lorenzo C, 2005, PEDIATRICS, V115, P812, DOI 10.1542/peds.2004-2497; Di Lorenzo C, 2005, J PEDIATR GASTR NUTR, V40, P249, DOI 10.1097/01.MPG.0000154661.39488.AC; Dosman CF, 2007, PEDIATR NEUROL, V36, P152, DOI 10.1016/j.pediatrneurol.2006.11.004; Elder JH, 2006, J AUTISM DEV DISORD, V36, P413, DOI 10.1007/s10803-006-0079-0; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; Filipek PA, 2000, NEUROLOGY, V55, P468, DOI 10.1212/WNL.55.4.468; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; Furlano RI, 2001, J PEDIATR-US, V138, P366, DOI 10.1067/mpd.2001.111323; GARTY BZ, 1994, CLIN DIAGN LAB IMMUN, V1, P667, DOI 10.1128/CDLI.1.6.667-669.1994; Gupta S, 1998, J NEUROIMMUNOL, V85, P106, DOI 10.1016/S0165-5728(98)00021-6; GUYATT FH, 2008, BRIT MED J, V336, P924; Hediger ML, 2008, J AUTISM DEV DISORD, V38, P848, DOI 10.1007/s10803-007-0453-6; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Horvath Karoly, 2002, Curr Gastroenterol Rep, V4, P251, DOI 10.1007/s11894-002-0071-6; Iacono G, 2007, CLIN GASTROENTEROL H, V5, P361, DOI 10.1016/j.cgh.2006.12.010; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Jyonouchi H, 2005, NEUROPSYCHOBIOLOGY, V51, P77, DOI 10.1159/000084164; Jyonouchi H, 2002, NEUROPSYCHOBIOLOGY, V46, P76, DOI 10.1159/000065416; Jyonouchi H, 2005, J PEDIATR-US, V146, P605, DOI 10.1016/j.jpeds.2005.01.027; Kuehn BM, 2007, JAMA-J AM MED ASSOC, V297, P940, DOI 10.1001/jama.297.9.940; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; LIGHTDALE JR, 2001, CLIN PERSPECT GASTRO, V1, P56; Lord C., 2001, ED CHILDREN AUTISM; Martin LA, 2008, BRAIN BEHAV IMMUN, V22, P806, DOI 10.1016/j.bbi.2007.12.007; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; McAtee M, 2004, J POSIT BEHAV INTERV, V6, P148, DOI 10.1177/10983007040060030301; McManus R, 2003, NEW ENGL J MED, V348, P2573, DOI 10.1056/NEJMcibr035033; Ming X, 2008, J CHILD NEUROL, V23, P6, DOI 10.1177/0883073807307102; Molloy CA, 2003, AUTISM, V7, P165, DOI 10.1177/1362361303007002004; Murch SH, 2004, LANCET, V363, P750, DOI 10.1016/S0140-6736(04)15715-2; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; *N AM SOC PED GAST, 2006, J PEDIAT GASTROENTER, V43, pE1; *NAT DAIR COUNC, NUTR PROD INF; Nikolov RN, 2009, J AUTISM DEV DISORD, V39, P405, DOI 10.1007/s10803-008-0637-8; Nowak-Wegrzyn A, 2006, MED CLIN N AM, V90, P97, DOI 10.1016/j.mcna.2005.08.012; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Parracho HMRT, 2005, J MED MICROBIOL, V54, P987, DOI 10.1099/jmm.0.46101-0; Rudolph CD, 2001, J PEDIATR GASTR NUTR, V32, pS1, DOI 10.1097/00005176-200100002-00001; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schaefer GB, 2008, GENET MED, V10, P301, DOI 10.1097/GIM.0b013e31816b5cc9; Scurlock AM, 2005, IMMUNOL ALLERGY CLIN, V25, P369, DOI 10.1016/j.iac.2005.02.005; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Torrente F, 2004, AM J GASTROENTEROL, V99, P598, DOI 10.1111/j.1572-0241.2004.04142.x; Torrente F, 2002, MOL PSYCHIATR, V7, P375, DOI 10.1038/sj/mp/4001077; Valicenti-McDermott M, 2006, J DEV BEHAV PEDIATR, V27, pS128, DOI 10.1097/00004703-200604002-00011; VANDENBRANDE P, 1988, J CLIN IMMUNOL, V8, P296, DOI 10.1007/BF00916558; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; VOLKMAR F, 2000, J AM ACAD CHILD ADOL, V39, P938; Volkmar Fred, 1999, Journal of the American Academy of Child and Adolescent Psychiatry, V38, p32S; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; White JF, 2003, EXP BIOL MED, V228, P639, DOI 10.1177/153537020322800601; Wills S, 2007, ANN NY ACAD SCI, V1107, P79, DOI 10.1196/annals.1381.009; Wills S, 2009, BRAIN BEHAV IMMUN, V23, P64, DOI 10.1016/j.bbi.2008.07.007; BMJ CLIN EVIDENCE WH; [No title captured]";83;526;620;4;95;AMER ACAD PEDIATRICS;ELK GROVE VILLAGE;141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA;0031-4005;1098-4275;;PEDIATRICS;Pediatrics;JAN;2010;125;;;S;;;S1;S18;;10.1542/peds.2009-1878C;http://dx.doi.org/10.1542/peds.2009-1878C;;;18;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;548OZ;20048083;Bronze, Green Submitted;;;24/11/2024;WOS:000273976300001;View Full Record in Web of Science
J;"Sesso, G; Bargnesi, F; Mutti, G; Berloffa, S; Viglione, V; Fantozzi, P; Tolomei, G; Guccione, F; Muratori, P; Milone, A; Masi, G";;;;"Sesso, Gianluca; Bargnesi, Francesca; Mutti, Giulia; Berloffa, Stefano; Viglione, Valentina; Fantozzi, Pamela; Tolomei, Greta; Guccione, Fulvio; Muratori, Pietro; Milone, Annarita; Masi, Gabriele";;;Extended-Release Lithium Treatment for Adolescents with Bipolar Disorder with or Without Comorbid Autism Spectrum Disorder: Protocol of a Longitudinal Prospective Naturalistic Study for the Assessment of Efficacy and Tolerability;JOURNAL OF CLINICAL MEDICINE;;;English;Article;;;;;;"lithium; bipolar disorder; autism spectrum disorder; adolescents; suicidality; emotional dysregulation";"DOUBLE-BLIND; OPEN-LABEL; PHARMACOLOGICAL-TREATMENTS; MAINTENANCE TREATMENT; DIVALPROEX SODIUM; I DISORDER; CHILDREN; PHARMACOTHERAPY; TRIAL; PREVALENCE";"Background: Lithium is the gold-standard treatment for Bipolar Disorder (BD) in both adults and adolescents, effectively managing mood episodes and reducing suicide risk. While its efficacy in neurotypical youth is well established, its use in adolescents with Autism Spectrum Disorder (ASD) and comorbid BD remains under-researched. Here, we present the protocol for a study aiming to evaluate the efficacy and tolerability of Extended-Release Lithium Salts in treating adolescents with BD and comorbid ASD compared to neurotypical BD patients. Methods: This longitudinal prospective naturalistic comparative study will enroll lithium-na & iuml;ve adolescents aged 12-18 with BD, with or without comorbid ASD, from the Department of Child and Adolescent Psychiatry and Psychopharmacology. Participants will be followed for six months while receiving Extended-Release Lithium Salts treatment. Primary outcomes will include mood instability, suicidality, emotional dysregulation, and aggression, assessed through a range of clinical rating scales and diagnostic tools at baseline, three months, and six months. Secondary outcomes will focus on the safety and tolerability of Extended-Release Lithium Salts, with measures including side effect ratings, physical exams, and laboratory tests. Results: We hypothesize that Extended-Release Lithium Salts will demonstrate non-inferiority in treating BD symptoms in adolescents with comorbid ASD compared to those without ASD. Conclusions: This study is poised to fill a significant gap in the literature by providing critical data on the use of lithium for adolescents with BD and ASD. Findings will inform clinical practice and future research, potentially guiding more personalized treatment approaches for this complex and vulnerable population.";"[Sesso, Gianluca] IMT Sch Adv Studies, I-55100 Lucca, Italy; [Sesso, Gianluca; Berloffa, Stefano; Viglione, Valentina; Fantozzi, Pamela; Tolomei, Greta; Guccione, Fulvio; Muratori, Pietro; Milone, Annarita; Masi, Gabriele] IRCCS Stella Maris Fdn, Dev Psychiat & Psychopharmacol Unit, I-56128 Pisa, Italy; [Bargnesi, Francesca; Mutti, Giulia] Univ Pisa, Dept Clin & Expt Med, I-56100 Pisa, Italy";"IMT School for Advanced Studies Lucca; IRCCS Fondazione Stella Maris; University of Pisa";Muratori, P (corresponding author), IRCCS Stella Maris Fdn, Dev Psychiat & Psychopharmacol Unit, I-56128 Pisa, Italy.;"gianluca.sesso@fsm.unipi.it; francesca.bargnesi@fsm.unipi.it; giulia.mutti@fsm.unipi.it; stefano.berloffa@fsm.unipi.it; valentina.viglione@fsm.unipi.it; pamela.fantozzi@fsm.unipi.it; greta.tolomei@fsm.unipi.it; fulvio.guccione@fsm.unipi.it; pietro.muratori@fsm.unipi.it; annarita.milone@fsm.unipi.it; gabriele.masi@fsm.unipi.it";"Berloffa, Stefano/AAJ-4686-2021; milone, annarita/T-8312-2017; Tolomei, Greta/JWO-3254-2024; Muratori, Pietro/J-3538-2016; Sesso, Gianluca/JVY-9209-2024; Fantozzi, Pamela/ABF-9073-2020; Masi, Gabriele/K-2643-2018; Viglione, Valentina/ADE-8121-2022";"Muratori, Pietro/0000-0001-7779-779X; Sesso, Gianluca/0000-0003-0435-2962; Fantozzi, Pamela/0000-0001-5492-8929; milone, annarita/0000-0003-3170-1187; Masi, Gabriele/0000-0001-7770-926X; Viglione, Valentina/0000-0003-4164-3101";"Italian Ministry of Health (Ricerca Corrente 2023 and the 5 x 1000 voluntary contributions) [2023]; Italian Ministry of Health";"Italian Ministry of Health (Ricerca Corrente 2023 and the 5 x 1000 voluntary contributions); Italian Ministry of Health(Ministry of Health, Italy)";This work was supported by the Italian Ministry of Health (Ricerca Corrente 2023 and the 5 x 1000 voluntary contributions).;"Amadori S, 2022, EXPERT OPIN PHARMACO, V23, P1753, DOI 10.1080/14656566.2022.2138332; Berry-Kravis E, 2008, J DEV BEHAV PEDIATR, V29, P293, DOI 10.1097/DBP.0b013e31817dc447; Borue X, 2016, J AM ACAD CHILD PSY, V55, P1064, DOI 10.1016/j.jaac.2016.08.011; Boström AED, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-36973-4; Brancati GE, 2021, J AFFECT DISORDERS, V293, P186, DOI 10.1016/j.jad.2021.06.033; Canitano R, 2015, CLIN NEUROPHARMACOL, V38, P177, DOI 10.1097/WNF.0000000000000096; Cipriani A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3646; Dickstein DP, 2009, J CHILD ADOL PSYCHOP, V19, P61, DOI 10.1089/cap.2008.044; Doyle CA, 2012, EXPERT OPIN PHARMACO, V13, P1615, DOI 10.1517/14656566.2012.674110; Duffy A, 2018, BIPOLAR DISORD, V20, P583, DOI 10.1111/bdi.12690; Fantozzi P, 2023, CHILDREN-BASEL, V10, DOI 10.3390/children10010077; Findling RL, 2005, J AM ACAD CHILD PSY, V44, P409, DOI 10.1097/01.chi.0000155981.83865.ea; Findling RL, 2015, PEDIATRICS, V136, P885, DOI 10.1542/peds.2015-0743; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P80, DOI 10.1089/cap.2012.0063; Geller B, 1998, J AFFECT DISORDERS, V51, P165, DOI 10.1016/S0165-0327(98)00178-5; Geller B, 2012, ARCH GEN PSYCHIAT, V69, P515, DOI 10.1001/archgenpsychiatry.2011.1508; Gupta S, 2018, J DEV BEHAV PEDIATR, V39, P523, DOI 10.1097/DBP.0000000000000599; Hafeman DM, 2020, J AM ACAD CHILD PSY, V59, P1146, DOI 10.1016/j.jaac.2019.06.013; Hauser M, 2013, BIPOLAR DISORD, V15, P507, DOI 10.1111/bdi.12094; Hayes JF, 2016, JAMA PSYCHIAT, V73, P630, DOI 10.1001/jamapsychiatry.2016.0432; Jerrell JA, 2008, HUM PSYCHOPHARM CLIN, V23, P53, DOI 10.1002/hup.900; Joshi G, 2012, CNS NEUROSCI THER, V18, P28, DOI 10.1111/j.1755-5949.2010.00219.x; Ko A, 2014, J CHILD ADOL PSYCHOP, V24, P382, DOI 10.1089/cap.2013.0120; Kowatch RA, 2000, J AM ACAD CHILD PSY, V39, P713, DOI 10.1097/00004583-200006000-00009; Kugimiya T, 2021, BIPOLAR DISORD, V23, P33, DOI 10.1111/bdi.12983; Leu-Semenescu S, 2015, NEUROLOGY, V85, P1655, DOI 10.1212/WNL.0000000000002104; Liu HY, 2011, J AM ACAD CHILD PSY, V50, P749, DOI 10.1016/j.jaac.2011.05.011; Malone RP, 2000, ARCH GEN PSYCHIAT, V57, P649, DOI 10.1001/archpsyc.57.7.649; Margari L, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00159; Masi G, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10100750; Masi G, 2010, PSYCHIAT RES, V177, P192, DOI 10.1016/j.psychres.2009.01.022; Masi G, 2009, CNS DRUGS, V23, P59, DOI 10.2165/0023210-200923010-00004; Mintz Mark, 2019, Psychopharmacol Bull, V49, P28; Miura T, 2014, LANCET PSYCHIAT, V1, P351, DOI 10.1016/S2215-0366(14)70314-1; Munesue T, 2008, J AFFECT DISORDERS, V111, P170, DOI 10.1016/j.jad.2008.02.015; Öhlund L, 2020, THER ADV PSYCHOPHARM, V10, DOI 10.1177/2045125320947502; Patel NC, 2006, J AM ACAD CHILD PSY, V45, P289, DOI 10.1097/01.chi.0000194569.70912.a7; Perugi G, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0758-x; Pisano S, 2019, CURR NEUROPHARMACOL, V17, P318, DOI 10.2174/1570159X16666171219142120; Rosenberg Rebecca E, 2011, Autism Res Treat, V2011, P405849, DOI 10.1155/2011/405849; Salpekar JA, 2015, J AM ACAD CHILD PSY, V54, P999, DOI 10.1016/j.jaac.2015.09.016; Secci I, 2023, FRONT PSYCHIATRY, V14, DOI 10.3389/fpsyt.2023.1151293; Serret S, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0490-1; Sesso G, 2023, CURR NEUROPHARMACOL, V21, P911, DOI 10.2174/1570159X20666220706104117; Siegel M, 2014, J CHILD ADOL PSYCHOP, V24, P399, DOI 10.1089/cap.2014.0019; STROBER M, 1992, J AM ACAD CHILD PSY, V31, P16, DOI 10.1097/00004583-199201000-00004; Tondo L, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0715-0; Tueth MJ, 1998, J CLIN PSYCHIAT, V59, P66; Van Meter A, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18r12180; Vannucchi G, 2014, CNS SPECTRUMS, V19, P157, DOI 10.1017/S1092852913000941";50;0;0;0;0;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2077-0383;;J CLIN MED;J. Clin. Med.;OCT;2024;13;20;;;;;;;6196;10.3390/jcm13206196;http://dx.doi.org/10.3390/jcm13206196;;;9;Medicine, General & Internal;Science Citation Index Expanded (SCI-EXPANDED);General & Internal Medicine;K3C0Y;39458145;gold;;;24/11/2024;WOS:001342679600001;View Full Record in Web of Science
J;"Alsayouf, HA; Talo, H; Biddappa, ML; Reyes, ED";;;;"Alsayouf, Hamza A.; Talo, Haitham; Biddappa, Marisa L.; de los Reyes, Emily";;;Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study;CHILDREN-BASEL;;;English;Article;;;;;;"autism spectrum disorder; risperidone; aripiprazole; antipsychotic agents; case study";"SPECTRUM DISORDER; ANTIPSYCHOTIC MEDICATION; PRESCHOOL-CHILDREN; CLINICAL CHARACTERISTICS; ATYPICAL ANTIPSYCHOTICS; REPETITIVE BEHAVIORS; DOUBLE-BLIND; ADOLESCENTS; TRENDS; PSYCHOPHARMACOLOGY";Risperidone and aripiprazole are approved by the USA Food and Drug Administration for the treatment of irritability and aggression in children from the ages of 5 and 6 years, respectively. However, there are no approved medications for the treatment of autism spectrum disorder (ASD) core signs and symptoms. Nevertheless, early intervention is recognized as key to improving long-term outcomes. This retrospective case study included 10 children (mean age, 2 years 10 months) with ASD who presented with persistent irritability and aggression before 4 years of age that was unresponsive to behavioral interventions and sufficiently severe to consider pharmacological intervention with risperidone or aripiprazole combined with standard supportive therapies. Besides ameliorating comorbid behaviors, improvement was observed in ASD core signs and symptoms for all patients, with minimal-to-no symptoms observed in 60% of patients according to the Childhood Autism Rating Scale 2-Standard Test and Clinical Global Impression scales. Excessive weight gain in two patients was the only adverse effect observed that required intervention. This is the first study to suggest that ASD can potentially be treated in very young children (<4 years). Clinical trials are urgently required to validate these findings among this pediatric population.;"[Alsayouf, Hamza A.; Talo, Haitham; Biddappa, Marisa L.] Dubai Healthcare City, Kids Neuro Clin & Rehab Ctr, Al Razi Med Complex, Dubai 1015, U Arab Emirates; [de los Reyes, Emily] Ohio State Univ, Nationwide Childrens Hosp, Pediat Neurol, Columbus, OH 43210 USA";"University System of Ohio; Ohio State University; Nationwide Childrens Hospital";Alsayouf, HA (corresponding author), Dubai Healthcare City, Kids Neuro Clin & Rehab Ctr, Al Razi Med Complex, Dubai 1015, U Arab Emirates.;"leeamra1000@gmail.com; htalo@yahoo.com; marisa.lobobiddappa@gmail.com; Emily.delosReyes@nationwidechildrens.org";;alsayouf, hamza/0000-0002-3646-7599;;;;"Alsayouf HA, 2020, NEUROPSYCH DIS TREAT, V16, P2779, DOI 10.2147/NDT.S277294; Amer Diabet Assoc, 2004, DIABETES CARE, V27, P596, DOI 10.2337/diacare.27.2.596; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; Anagnostou E, 2018, CURR OPIN NEUROL, V31, P119, DOI 10.1097/WCO.0000000000000542; Anagnostou E, 2016, JAMA PSYCHIAT, V73, P928, DOI 10.1001/jamapsychiatry.2016.1232; [Anonymous], 2009, US Food and Drug Administration approves ABILIFY (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients (ages 6 to 17 years); Asakawa T, 2018, CNS NEUROSCI THER, V24, P863, DOI 10.1111/cns.13036; Bal VH, 2019, AUTISM RES, V12, P89, DOI 10.1002/aur.2004; Boon-Yasidhi Vitharon, 2014, Psychiatry J, V2014, P136158, DOI 10.1155/2014/136158; Boon-Yasidhi Vitharon, 2002, Journal of the Medical Association of Thailand, V85, pS784; Brian JA, 2019, PAED CHILD HEALT-CAN, V24, P444, DOI 10.1093/pch/pxz117; Brophy S, 2018, J CHILD ADOL PSYCHOP, V28, P180, DOI 10.1089/cap.2017.0003; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Caccia S, 2013, PEDIATR DRUGS, V15, P217, DOI 10.1007/s40272-013-0024-6; Camacho J, 2014, NEUROSCI LETT, V579, P163, DOI 10.1016/j.neulet.2014.07.031; Carbone PS, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-2314; Centers for Disease Control, 2018, DAT STAT AUT SPECTR; Cheon KA, 2011, BRAIN RES, V1417, P77, DOI 10.1016/j.brainres.2011.08.020; Chirdkiatgumchai V, 2013, PEDIATRICS, V132, P615, DOI 10.1542/peds.2013-1546; Cicala G, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00152; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Dawkins T, 2016, J AUTISM DEV DISORD, V46, P3361, DOI 10.1007/s10803-016-2860-z; Diler RS, 2002, CURR THER RES CLIN E, V63, P91, DOI 10.1016/S0011-393X(02)80009-1; Esbensen AJ, 2009, J AUTISM DEV DISORD, V39, P57, DOI 10.1007/s10803-008-0599-x; Fanton J, 2009, CHILD ADOL PSYCH CL, V18, P753, DOI 10.1016/j.chc.2009.02.005; Fayyazi Afshin, 2014, Iran J Child Neurol, V8, P33; Food and Drug Administration, 2006, APPR RISP RISP RISP; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Gleason MM, 2007, J AM ACAD CHILD PSY, V46, P1532, DOI 10.1097/chi.0b013e3181570d9e; Haddad PM, 2004, DRUGS, V64, P2291, DOI 10.2165/00003495-200464200-00003; Handen BL, 2015, J AM ACAD CHILD PSY, V54, P905, DOI 10.1016/j.jaac.2015.08.013; Harrison JN, 2012, J PEDIATR HEALTH CAR, V26, P139, DOI 10.1016/j.pedhc.2011.10.009; Hashemi E, 2017, CEREB CORTEX, V27, P1931, DOI 10.1093/cercor/bhw021; Hergüner MÖ, 2008, PEDIATR NEUROL, V38, P411, DOI 10.1016/j.pediatrneurol.2008.02.007; Ho J, 2011, PAED CHILD HEALT-CAN, V16, P575, DOI 10.1093/pch/16.9.575; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447; James SN, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100827; Jensen KG, 2015, J AM ACAD CHILD PSY, V54, P25, DOI 10.1016/j.jaac.2014.10.002; Kent JM, 2013, J AUTISM DEV DISORD, V43, P1773, DOI 10.1007/s10803-012-1723-5; Kimura G, 2015, INT J MED SCI, V12, P135, DOI 10.7150/ijms.10453; Lai MC, 2020, LANCET NEUROL, V19, P434, DOI 10.1016/S1474-4422(20)30034-X; Lamy M, 2020, PEDIATR DRUGS, V22, P473, DOI 10.1007/s40272-020-00408-0; Lopez-De Fede A, 2014, SAGE OPEN, V4, DOI 10.1177/2158244014555116; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Luby J, 2006, J CHILD ADOL PSYCHOP, V16, P575, DOI 10.1089/cap.2006.16.575; Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002; Masi G, 2003, J CLIN PSYCHIAT, V64, P1039, DOI 10.4088/JCP.v64n0909; Masi G, 2001, J CHILD NEUROL, V16, P395, DOI 10.1177/088307380101600602; Masi G, 2001, J AM ACAD CHILD PSY, V40, P1206, DOI 10.1097/00004583-200110000-00015; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Militerni R, 2002, EUR CHILD ADOLES PSY, V11, P210, DOI 10.1007/s00787-002-0279-x; Nachshen J., 2008, SCREENING ASSESSMENT; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Nair A, 2013, BRAIN, V136, P1942, DOI 10.1093/brain/awt079; Ng QX, 2017, J CHILD ADOL PSYCHOP, V27, P112, DOI 10.1089/cap.2016.0124; Olfson M, 2010, J AM ACAD CHILD PSY, V49, P13, DOI 10.1016/j.jaac.2009.09.003; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Persico AM, 2015, EUR NEUROPSYCHOPHARM, V25, P1513, DOI 10.1016/j.euroneuro.2015.06.009; Politte LC, 2014, PSYCHOPHARMACOLOGY, V231, P1023, DOI 10.1007/s00213-013-3068-y; Posey DJ, 1999, J CHILD ADOL PSYCHOP, V9, P273, DOI 10.1089/cap.1999.9.273; Pringsheim T, 2019, J CHILD ADOL PSYCHOP, V29, P740, DOI 10.1089/cap.2019.0018; Rizzo R, 2013, EUR CHILD ADOLES PSY, V22, P577, DOI 10.1007/s00787-013-0413-y; Roke Y, 2009, J CHILD ADOL PSYCHOP, V19, P403, DOI 10.1089/cap.2008.0120; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Schopler E., 2010, CHILDHOOD AUTISM RAT; Schwam JS, 1998, J AM ACAD CHILD PSY, V37, P572, DOI 10.1097/00004583-199806000-00005; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013; Yilmaz S, 2014, J PEDIATR NEUROSCI, V9, P105, DOI 10.4103/1817-1745.139266; Zwaigenbaum L, 2015, PEDIATRICS, V136, pS60, DOI 10.1542/peds.2014-3667E";70;17;19;4;8;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2227-9067;;CHILDREN-BASEL;Children-Basel;MAY;2021;8;5;;;;;;;318;10.3390/children8050318;http://dx.doi.org/10.3390/children8050318;;;14;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;SG7CQ;33921933;gold, Green Published;;;24/11/2024;WOS:000653598300001;View Full Record in Web of Science
J;"Shaker, E; El Agami, O; Salamah, A";;;;"Shaker, Esraa; El Agami, Osama; Salamah, Abeer";;;Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder;CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS;;;English;Article;;;;;;"ASD (autism spectrum disorder); CARS (childhood autism rating scale); GABA (Gamma-amino-butyric acid); bumetanide; CCC (Cation-chloride Cotransporters); NKCC1; FDA";"INTERVENTION; BEHAVIOR";Background Autism Spectrum Disorder (ASD) is a common child neurodevelopmental disorder, whose pathogenesis is not completely understood. Until now, there is no proven treatment for the core symptoms of ASD. However, some evidence indicates a crucial link between this disorder and GABAergic signals which are altered in ASD. Bumetanide is a diuretic that reduces chloride, shifts gamma-amino-butyric acid (GABA) from excitation to inhibition, and may play a significant role in the treatment of ASD. Objective The objective of this study is to assess the safety and efficacy of bumetanide as a treatment for ASD. Methods Eighty children, aged 3-12 years, with ASD diagnosed by Childhood Autism Rating Scale (CARS), > 30 were included in this double-blind, randomized, and controlled study. Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1, 3, and 6 months of treatment. Results The use of bumetanide in group 1 improved the core symptoms of ASD in a shorter time with minimal and tolerable adverse effects. There was a statistically significant decrease in CARS and most of its fifteen items in group 1 versus group 2 after 6 months of treatment (p-value <0.001). Conclusion Bumetanide has an important role in the treatment of core symptoms of ASD. Trial Registration The study was registered at clinical Trials.gov (https://clinicaltrials.gov/). Registration identification number: NCT04766177.;"[Shaker, Esraa; El Agami, Osama; Salamah, Abeer] Kafr El Sheikh Univ, Fac Med, Dept Pediat, Kafr Al Sheikh, Egypt";"Egyptian Knowledge Bank (EKB); Kafrelsheikh University";Salamah, A (corresponding author), Kafr El Sheikh Univ, Fac Med, Dept Pediat, Kafr Al Sheikh, Egypt.;abeersalamah84@yahoo.com;;;;;;"Bradstreet JJ, 2007, MED HYPOTHESES, V68, P979, DOI 10.1016/j.mehy.2006.10.015; Cellot G, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00070; COHEN M, 1981, J CLIN PHARMACOL, V21, P537, DOI 10.1002/j.1552-4604.1981.tb05662.x; Delpire E, 2002, ANNU REV PHYSIOL, V64, P803, DOI 10.1146/annurev.physiol.64.081501.155847; Dhossche Dirk, 2002, Med Sci Monit, V8, pPR1; Du L, 2015, J CHILD ADOL PSYCHOP, V25, P585, DOI 10.1089/cap.2015.0045; Feng JY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018661; Fernell E, 2021, ACTA PAEDIATR, V110, P1548, DOI 10.1111/apa.15723; Geier DA, 2006, NEUROENDOCRINOL LETT, V27, P833; Gillberg C, 2014, J AUTISM DEV DISORD, V44, P3274, DOI 10.1007/s10803-014-2163-1; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; Hadjikhani N, 2015, AUTISM, V19, P149, DOI 10.1177/1362361313514141; Hajri Melek, 2019, Tunis Med, V97, P971; Kharod SC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00310; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Lemonnier E, 2010, ACTA PAEDIATR, V99, P1885, DOI 10.1111/j.1651-2227.2010.01933.x; Li QY, 2022, TRANSL PSYCHIAT, V12, DOI 10.1038/s41398-022-01987-x; Moulton E, 2019, J AUTISM DEV DISORD, V49, P2733, DOI 10.1007/s10803-016-2936-9; Naviaux RK, 2017, ANN CLIN TRANSL NEUR, V4, P491, DOI 10.1002/acn3.424; Rossignol DA, 2009, ANN CLIN PSYCHIATRY, V21, P213; Sprengers JJ, 2021, J AM ACAD CHILD PSY, V60, P865, DOI 10.1016/j.jaac.2020.07.888; Vahia VN, 2013, INDIAN J PSYCHIAT, V55, P220, DOI 10.4103/0019-5545.117131; Vivanti G, 2018, AUTISM RES, V11, P16, DOI 10.1002/aur.1900; Weintraub K, 2011, NATURE, V479, P22, DOI 10.1038/479022a; Zhang LL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0692-2; Zhang SS, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01750-w";27;2;3;5;13;BENTHAM SCIENCE PUBL;BUSUM;PO BOX 294, BUSUM, 1400 AG, NETHERLANDS;1871-5273;1996-3181;;CNS NEUROL DISORD-DR;CNS Neurol. Disord.-Drug Targets;;2024;23;4;;;;;536;542;;10.2174/1871527322666230404114911;http://dx.doi.org/10.2174/1871527322666230404114911;;;7;"Neurosciences; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pharmacology & Pharmacy";GZ6U1;37021422;;;;24/11/2024;WOS:001156551000005;View Full Record in Web of Science
J;"Momtazmanesh, S; Amirimoghaddam-Yazdi, Z; Moghaddam, HS; Mohammadi, MR; Akhondzadeh, S";;;;"Momtazmanesh, Sara; Amirimoghaddam-Yazdi, Zeinab; Moghaddam, Hossein Sanjari; Mohammadi, Mohammad Reza; Akhondzadeh, Shahin";;;Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial;PSYCHIATRY AND CLINICAL NEUROSCIENCES;;;English;Article;;;;;;"autism spectrum disorder; irritability; oxidative stress; risperidone; sulforaphane";"OXIDATIVE STRESS; ABERRANT BEHAVIOR; RISPERIDONE; DEPRESSION; THERAPY; BIOMARKERS; EFFICACY; MODERATE; PATHWAY; ANXIETY";"Aim Irritability related to autism spectrum disorder (ASD) complicates the management of ASD patients at home and in clinical settings. In this randomized, double-blind, placebo-controlled clinical trial, we aimed to investigate the beneficial effects of adjuvant treatment with risperidone and sulforaphane in alleviating the irritability of children with ASD. Methods Sixty drug-free patients aged 4-12 years were randomly assigned to one of two groups receiving risperidone plus sulforaphane or placebo. Risperidone was started with a daily dose of 0.25 mg in patients weighing <20 kg and 0.5 mg in those weighing >= 20 kg and increased stepwise to reach a maximum of 1 mg (<20 kg), 2.5 mg (20-45 kg), and 3.5 mg (>45 kg). Sulforaphane was administered at a daily dose of 50 mu mol (<= 45 kg) or 100 mu mol (>45 kg). The participants were assessed with the Aberrant Behavior Checklist - Community Edition at baseline and at Weeks 5 and 10. Results Compared to the placebo group, ASD patients in the sulforaphane group showed greater improvements in Irritability score (primary outcome measure; P = 0.001) and Hyperactivity/Noncompliance score (secondary outcome measure; P = 0.015), and significant Time x Treatment effect for Irritability (P = 0.007) and Hyperactivity/Noncompliance (P = 0.008). However, no difference was seen in improvements in the other secondary measures: Lethargy/Social Interaction score, Stereotypic Behavior score, Inappropriate Speech score, and frequency of adverse events. Conclusion Our results support the safety and efficacy of sulforaphane as an adjuvant to risperidone for improvement of irritability and hyperactivity symptoms in children with ASD.";"[Momtazmanesh, Sara; Amirimoghaddam-Yazdi, Zeinab; Moghaddam, Hossein Sanjari; Mohammadi, Mohammad Reza; Akhondzadeh, Shahin] Univ Tehran Med Sci, Roozbeh Hosp, Psychiat Res Ctr, Tehran, Iran";Tehran University of Medical Sciences;Akhondzadeh, S (corresponding author), Univ Tehran Med Sci, Roozbeh Hosp, Psychiat Res Ctr, Tehran, Iran.;s.akhond@neda.net;"Akhondzadeh, Shahin/F-2914-2018; Sanjari Moghaddam, Hossein/AAS-6514-2021; Mohammadi, Mohammad Reza/ABD-9550-2021; Momtazmanesh, Sara/AAE-1022-2020";Momtazmanesh, Sara/0000-0002-3946-1854;Tehran University of Medical Sciences and Health Services [37048];Tehran University of Medical Sciences and Health Services(Tehran University of Medical Sciences);This study is Dr Zeinab Amirimoghaddam-Yazdi's postgraduate thesis toward the Iranian Board of Psychiatry. This study was funded by Tehran University of Medical Sciences and Health Services (Grant number 37048).;"Adams JB, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-34; Ahmad SF, 2017, MOL NEUROBIOL, V54, P4390, DOI 10.1007/s12035-016-9977-0; Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005; Akhondzadeh S, 2010, PROG NEURO-PSYCHOPH, V34, P32, DOI 10.1016/j.pnpbp.2009.09.012; AMAN MG, 1995, AM J MENT RETARD, V100, P283; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Amiri S, 2008, PROG NEURO-PSYCHOPH, V32, P145, DOI 10.1016/j.pnpbp.2007.07.025; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053; Asadabadi M, 2013, PSYCHOPHARMACOLOGY, V225, P51, DOI 10.1007/s00213-012-2796-8; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Bent S, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0218-4; Briones-Herrera A, 2018, FOOD FUNCT, V9, P2589, DOI [10.1039/c8fo00018b, 10.1039/C8FO00018B]; Charman T, 2011, BRAIN RES, V1380, P10, DOI 10.1016/j.brainres.2010.10.075; CHOUINARD G, 1979, AM J PSYCHIAT, V136, P228; Chouinard G, 2005, SCHIZOPHR RES, V76, P247, DOI 10.1016/j.schres.2005.02.013; Christensen Deborah L, 2018, MMWR Surveill Summ, V65, P1, DOI [10.15585/mmwr.ss6503a1, 10.15585/mmwr.ss6513a1]; de Figueiredo SM, 2015, RECENT PATENTS ENDOC, V9, P24, DOI 10.2174/1872214809666150505164138; Ferreira-Chamorro P, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01332; Ghaleiha A, 2015, PSYCHIAT RES, V229, P181, DOI 10.1016/j.psychres.2015.07.043; Ghaleiha A, 2014, J PSYCHOPHARMACOL, V28, P677, DOI 10.1177/0269881113508830; Ghaleiha A, 2013, PEDIATR DRUGS, V15, P505, DOI 10.1007/s40272-013-0036-2; Haroon E, 2012, NEUROPSYCHOPHARMACOL, V37, P137, DOI 10.1038/npp.2011.205; Helverschou SB, 2011, AUT CHILD PSYCHO, P53, DOI 10.1007/978-1-4419-8065-6_5; Hernández-Rabaza V, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0505-y; Hollis F, 2017, CURR OPIN NEUROBIOL, V45, P178, DOI 10.1016/j.conb.2017.05.018; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Khajavi D, 2012, J CLIN PSYCHIAT, V73, P1428, DOI 10.4088/JCP.12m07706; Kim JW, 2018, CLIN PSYCHOPHARM NEU, V16, P246, DOI 10.9758/cpn.2018.16.3.246; Klomparens EA, 2019, BRAIN CIRC, V5, P74, DOI 10.4103/bc.bc_7_19; Kumar B, 2012, PHARMACOL REP, V64, P1291, DOI 10.1016/S1734-1140(12)70927-1; Li XH, 2009, J NEUROIMMUNOL, V207, P111, DOI 10.1016/j.jneuroim.2008.12.002; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lynch Rhoda, 2017, Glob Adv Health Med, V6, p2164957X17735826, DOI 10.1177/2164957X17735826; Masi A, 2017, NEUROSCI BULL, V33, P194, DOI 10.1007/s12264-017-0103-8; McGuire K, 2016, PEDIATRICS, V137, pS136, DOI 10.1542/peds.2015-2851L; Molloy CA, 2006, J NEUROIMMUNOL, V172, P198, DOI 10.1016/j.jneuroim.2005.11.007; Mukherjee SB, 2017, INDIAN J PEDIATR, V84, P307, DOI 10.1007/s12098-016-2272-2; Nadeem A, 2019, BEHAV BRAIN RES, V364, P213, DOI 10.1016/j.bbr.2019.02.031; Parker W, 2017, J INT MED RES, V45, P407, DOI 10.1177/0300060517693423; Perry A, 2009, J AUTISM DEV DISORD, V39, P1066, DOI 10.1007/s10803-009-0704-9; Sedlak Thomas W, 2018, Mol Neuropsychiatry, V3, P214, DOI 10.1159/000487639; Shahmansouri N, 2014, J AFFECT DISORDERS, V155, P216, DOI 10.1016/j.jad.2013.11.003; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Smaga I, 2015, PHARMACOL REP, V67, P569, DOI 10.1016/j.pharep.2014.12.015; Steele ML, 2013, REDOX BIOL, V1, P441, DOI 10.1016/j.redox.2013.08.006; Sun Y, 2017, Austin J Cerebrovasc Dis Stroke, V4, DOI 10.26420/austinjcerebrovascdisstroke.2017.1054; Tchaconas A, 2013, CURR OPIN PEDIATR, V25, P130, DOI 10.1097/MOP.0b013e32835c2b70; Vanduchova A, 2019, J MED FOOD, V22, P121, DOI 10.1089/jmf.2018.0024; Xu NG, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/531518; Yui K, 2016, CNS NEUROL DISORD-DR, V15, P587, DOI 10.2174/1871527315666160413121751; Zhang JC, 2017, J NUTR BIOCHEM, V39, P134, DOI 10.1016/j.jnutbio.2016.10.004";52;29;33;0;16;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1323-1316;1440-1819;;PSYCHIAT CLIN NEUROS;Psychiatry Clin. Neurosci.;JUL;2020;74;7;;;;;398;405;;10.1111/pcn.13016;http://dx.doi.org/10.1111/pcn.13016;;MAY 2020;8;"Clinical Neurology; Neurosciences; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Neurosciences & Neurology; Psychiatry";ME5OL;32347624;Bronze;;;24/11/2024;WOS:000535356000001;View Full Record in Web of Science
J;"Vanwong, N; Srisawasdi, P; Ngamsamut, N; Nuntamool, N; Puangpetch, A; Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Kittitharaphan, W; Sukasem, C";;;;"Vanwong, Natchaya; Srisawasdi, Pornpen; Ngamsamut, Nattawat; Nuntamool, Nopphadol; Puangpetch, Apichaya; Chamkrachangpada, Bhunnada; Hongkaew, Yaowaluck; Limsila, Penkhae; Kittitharaphan, Wiranpat; Sukasem, Chonlaphat";;;Hyperuricemia in Children and Adolescents with Autism Spectrum Disorder Treated with Risperidone: The Risk Factors for Metabolic Adverse Effects;FRONTIERS IN PHARMACOLOGY;;;English;Article;;;;;;"serum uric acid levels; risperidone; autism spectrum disorder; hyperuricemia; metabolic adverse effects";"SERUM URIC-ACID; VISCERAL FAT ACCUMULATION; HDL-CHOLESTEROL RATIO; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; OBESE CHILDREN; DOUBLE-BLIND; ASSOCIATION; OLANZAPINE; PLACEBO";Background: Atypical antipsychotics have been found to be associated with hyperuricemia. Risperidone, one of the atypical antipsychotics, might be related to the hyperuricemia among autism spectrum disorder (ASD) patients. The aims of this study were to determine the prevalence of hyperuricemia in ASD patients treated with risperidone and to determine associations between serum uric acid levels and risperidone dosage, treatment duration, and metabolic parameters. Methods: 127 children and adolescents with ASD treated with risperidone and 76 age-matched risperidone-naive patients with ASD were recruited. The clinical data and laboratory data were analyzed. Hyperuricemia was defined as serum uric acid >5.5 mg/dl. Results: Hyperuricemia was present in 44.70% of risperidone-naive patients with ASD and 57.50% of ASD patients treated with risperidone. The fasting uric acid levels were significantly higher in the risperidone group than in the risperidone-naive group (5.70 vs. 5.35 mg/dl, P = 0.01). The increased uric acid concentrations were significantly associated with adolescent patients treated with risperidone. The higher dose of risperidone and/or the longer treatment time were associated with the increased uric acid levels. Uric acid levels significantly rose with body mass index (BMI), waist circumference (WC), triglyceride (TG) levels, triglycerides to high-density lipoprotein cholesterol ratio (TG/HDL-C), insulin levels, homeostatic model assessment index (HOMA-IR), high-sensitivity CRP (hs-CRP) levels, and leptin levels. Conversely, the levels of HDL-C and adiponectin were negatively correlated with uric acid levels. In multiple regression analysis, there were age, BMI, TG/HDL-C ratio, and adiponectin levels remained significantly associated with uric acid levels. Conclusion: Hyperuricemia may play a role in metabolic adverse effect in children and adolescents with ASDs receiving the high dose and/or the long-term treatment with risperidone.;"[Vanwong, Natchaya; Nuntamool, Nopphadol; Puangpetch, Apichaya; Hongkaew, Yaowaluck; Sukasem, Chonlaphat] Mahidol Univ, Ramathibodi Hosp, Dept Pathol, Div Pharmacogen & Personalized Med,Fac Med, Bangkok, Thailand; [Vanwong, Natchaya; Nuntamool, Nopphadol; Puangpetch, Apichaya; Hongkaew, Yaowaluck; Sukasem, Chonlaphat] Ramathibodi Hosp, Somdech Phra Debaratana Med Ctr, Lab Pharmacogen, Bangkok, Thailand; [Srisawasdi, Pornpen] Mahidol Univ, Div Clin Chem, Ramathibodi Hosp, Dept Pathol,Fac Med, Bangkok, Thailand; [Ngamsamut, Nattawat; Chamkrachangpada, Bhunnada; Limsila, Penkhae; Kittitharaphan, Wiranpat] Yuwaprasart Waithayopathum Child & Adolescent Psy, Dept Mental Hlth Serv, Minist Publ Hlth, Samut Prakarn, Thailand; [Nuntamool, Nopphadol] Mahidol Univ, Fac Sci, Mol Med, Bangkok, Thailand";"Mahidol University; Mahidol University; Mahidol University; Mahidol University";"Sukasem, C (corresponding author), Mahidol Univ, Ramathibodi Hosp, Dept Pathol, Div Pharmacogen & Personalized Med,Fac Med, Bangkok, Thailand.;Sukasem, C (corresponding author), Ramathibodi Hosp, Somdech Phra Debaratana Med Ctr, Lab Pharmacogen, Bangkok, Thailand.";chonlaphat.suk@mahidol.ac.th;"Srisawasdi, Pornpen/AAV-6237-2021; Vanwong, Natchaya/ABA-4512-2021";;"Pharmacogenomics for Autistic Child Project, Khoon Poom Foundation, The Project in Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee; Office of National Research Council of Thailand; Faculty of Medicine Ramathibodi Hospital; Mahidol University";"Pharmacogenomics for Autistic Child Project, Khoon Poom Foundation, The Project in Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee; Office of National Research Council of Thailand; Faculty of Medicine Ramathibodi Hospital; Mahidol University";This study was supported by grants of the (1) Pharmacogenomics for Autistic Child Project, Khoon Poom Foundation, The Project in Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee, (2) Office of National Research Council of Thailand (3) Faculty of Medicine Ramathibodi Hospital and (4) Mahidol University. The authors thank all the staffs in Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital and all the children and adolescents with ASDs who participated in the study.;"Baldwin W, 2011, DIABETES, V60, P1258, DOI 10.2337/db10-0916; Cardoso AS, 2013, J PEDIAT-BRAZIL, V89, P412, DOI 10.1016/j.jped.2012.12.008; Chauhan A, 2011, J NEUROCHEM, V117, P209, DOI 10.1111/j.1471-4159.2011.07189.x; Choi YJ, 2014, FASEB J, V28, P3197, DOI 10.1096/fj.13-247148; de Miranda Josiane Aparecida, 2015, Rev Paul Pediatr, V33, P431, DOI 10.1016/j.rpped.2015.03.009; de Oliveira EP, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-12; Dehghan A, 2008, DIABETES CARE, V31, P361, DOI 10.2337/dc07-1276; Feig DI, 2003, HYPERTENSION, V42, P247, DOI 10.1161/01.HYP.0000085858.66548.59; Ford ES, 2007, CIRCULATION, V115, P2526, DOI 10.1161/CIRCULATIONAHA.106.657627; Fruehwald-Schultes B, 1999, METABOLISM, V48, P677, DOI 10.1016/S0026-0495(99)90163-4; Frye RE, 2015, EPILEPSY BEHAV, V47, P147, DOI 10.1016/j.yebeh.2014.08.134; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI 10.1172/JCI20042162S; Giannini C, 2011, DIABETES CARE, V34, P1869, DOI 10.2337/dc10-2234; Gill A, 2013, J CLIN DIAGN RES, V7, P1295, DOI 10.7860/JCDR/2013/6017.3121; Godin O, 2015, SCHIZOPHR RES, V168, P388, DOI 10.1016/j.schres.2015.07.047; Gonzaga NC, 2014, J PAEDIATR CHILD H, V50, P707, DOI 10.1111/jpc.12610; Hongo M, 2010, CIRC J, V74, P1570, DOI 10.1253/circj.CJ-09-0837; Jinnah HA, 2013, HAND CLINIC, V113, P1827, DOI 10.1016/B978-0-444-59565-2.00052-6; Johnson RJ, 2011, SEMIN NEPHROL, V31, P394, DOI 10.1016/j.semnephrol.2011.08.002; Kamath DY, 2015, INDIAN J MED RES, V142, P261, DOI 10.4103/0971-5916.166582; Kryzhanovskaya L, 2009, J AM ACAD CHILD PSY, V48, P60, DOI 10.1097/CHI.0b013e3181900404; Lee H, 2009, J BIOL CHEM, V284, P10601, DOI 10.1074/jbc.M808742200; Lindberg D, 2015, CURR MOL MED, V15, P275, DOI 10.2174/1566524015666150330163724; Lu JJY, 2008, KAOHSIUNG J MED SCI, V24, P144, DOI 10.1016/S1607-551X(08)70142-6; Marotta T, 2010, OBESITY, V18, P1608, DOI 10.1038/oby.2009.446; Matsuura F, 1998, METABOLISM, V47, P929, DOI 10.1016/S0026-0495(98)90346-8; Page T, 2000, BBA-MOL BASIS DIS, V1500, P291, DOI 10.1016/S0925-4439(99)00113-1; Peng TC, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/127596; Ságodi L, 2015, ORVOSI HETILAP, V156, P888, DOI 10.1556/650.2015.30140; Stelmach MJ, 2015, IRISH J MED SCI, V184, P463, DOI 10.1007/s11845-014-1146-8; Tamba S, 2008, INTERNAL MED, V47, P1175, DOI 10.2169/internalmedicine.47.0603; Tohen M, 2007, AM J PSYCHIAT, V164, P1547, DOI 10.1176/appi.ajp.2007.06111932; Tohen M, 2008, J CLIN PSYCHIAT, V69, P1776, DOI 10.4088/JCP.v69n1113; Trepiccione F., 2015, G ITAL NEFROL, V32, P62; Wasilewska A, 2012, ACTA PAEDIATR, V101, P497, DOI 10.1111/j.1651-2227.2011.02582.x; Zhang Ming-Chen, 2014, Zhongguo Dang Dai Er Ke Za Zhi, V16, P878";36;21;22;0;14;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1663-9812;;;FRONT PHARMACOL;Front. Pharmacol.;janv-05;2017;7;;;;;;;;527;10.3389/fphar.2016.00527;http://dx.doi.org/10.3389/fphar.2016.00527;;;8;Pharmacology & Pharmacy;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pharmacology & Pharmacy;EG7AM;28105014;gold, Green Published;;;24/11/2024;WOS:000391197500001;View Full Record in Web of Science
J;"Okamoto, Y; Ishitobi, M; Wada, Y; Kosaka, H";;;;"Okamoto, Yuko; Ishitobi, Makoto; Wada, Yuji; Kosaka, Hirotaka";;;The Potential of Nasal Oxytocin Administration for Remediation of Autism Spectrum Disorders;CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS;;;English;Article;;;;;;"Autism spectrum disorders; long-term administration; open-label trial; oxytocin; randomized controlled trials; single-dose; treatment";"INTRANASAL OXYTOCIN; PLASMA OXYTOCIN; AMYGDALA REACTIVITY; CEREBROSPINAL-FLUID; SOCIAL COGNITION; NEURAL CIRCUITRY; CHILDREN; DEFICITS; ADULTS; BRAIN";Administration of oxytocin has been proposed as a treatment for the core symptoms of autism spectrum disorder (ASD), including social-communicative deficit. Previous clinical trials have investigated the efficacy and safety of oxytocin intranasal single-dose and long-term administration for individuals with ASD. All studies suggest that single-dose and long-term administration are well tolerated, and no severe adverse events have been reported. However, the efficacy of long-term oxytocin administration is controversial. Some studies have reported significant improvement of the core symptoms of ASD by long-term oxytocin administration, while other studies showed no such improvement. To elucidate the factors influencing the efficacy of oxytocin administration, it is necessary to examine the effects of administration schedules (e.g., dosage amount, frequency per day) and participant characteristics (e.g., age, sex, intellectual ability). In addition to doubts about the efficacy of particular methods of administration, questions remain about the mechanism of action of intranasal oxytocin on the central nervous system. Examination of changes in the neural underpinnings of social behavior and simultaneous oxytocin levels in blood or cerebrospinal fluid could prove important in elucidating the pharmacokinetics of intranasal oxytocin administration, which could be essential for establishing optimal oxytocin treatments for individuals with ASD.;"[Okamoto, Yuko; Wada, Yuji; Kosaka, Hirotaka] Univ Fukui, Res Ctr Child Mental Dev, Fukui 9101193, Japan; [Okamoto, Yuko; Wada, Yuji; Kosaka, Hirotaka] Chiba Univ, Hamamatsu Univ Sch Med, Osaka Univ,Kanazawa Univ, Div Dev Higher Brain Funct,Dept Child Dev,United, Fukui 9101193, Japan; [Okamoto, Yuko; Wada, Yuji; Kosaka, Hirotaka] Univ Fukui, Fukui 9101193, Japan; [Ishitobi, Makoto; Wada, Yuji; Kosaka, Hirotaka] Univ Fukui, Dept Neuropsychiat, Fac Med Sci, Fukui 9101193, Japan; [Ishitobi, Makoto] Natl Inst Mental Hlth, Dept Child & Adolescent Mental Hlth, Natl Ctr Neurol & Psychiat, Kodaira, Tokyo 1878553, Japan";"University of Fukui; Osaka University; Kanazawa University; University of Fukui; University of Fukui; National Center for Neurology & Psychiatry - Japan";Kosaka, H (corresponding author), Univ Fukui, Res Ctr Child Mental Dev, Fukui 9101193, Japan.;hirotaka@u-fukui.ac.jp;Kosaka, Hirotaka/AFG-5500-2022;"Okamoto, Yuko/0000-0001-5905-9486; Kosaka, Hirotaka/0000-0003-2210-5025";"JSPS [15K08093]; Grants-in-Aid for Scientific Research [15K08093] Funding Source: KAKEN";"JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))";Part of this research was the result of the Center of Community from MEXT, and the project Integrated research on neuropsychiatric disorders, which was carried out under the Strategic Research Program for Brain Sciences from MEXT and AMED. This work was partly funded by the Grants-in-Aid for Scientific Research from the JSPS (15K08093).;"Al-Ayadhi Laila Y, 2005, Neurosciences (Riyadh), V10, P47; Alabdali A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-4; Anagnostou E, 2014, BRAIN RES, V1580, P188, DOI 10.1016/j.brainres.2014.01.049; Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; [Anonymous], MOL PSYCHIAT; Aoki Y, 2015, MOL PSYCHIATR, V20, P447, DOI 10.1038/mp.2014.74; Aoki Y, 2014, BRAIN, V137, P3073, DOI 10.1093/brain/awu231; Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146; Bakermans-Kranenburg MJ, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.34; Bales KL, 2013, BIOL PSYCHIAT, V74, P180, DOI 10.1016/j.biopsych.2012.08.025; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1111/1469-7610.00715; Baumgartner T, 2008, NEURON, V58, P639, DOI 10.1016/j.neuron.2008.04.009; Carter MJ, 2014, THER RECREAT J, V48, P275; Chang SWC, 2012, P NATL ACAD SCI USA, V109, P959, DOI 10.1073/pnas.1114621109; Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3; Dal Monte O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103677; Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025; Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015; Domes G, 2014, NEUROPSYCHOPHARMACOL, V39, P698, DOI 10.1038/npp.2013.254; Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007; Feldman R, 2014, BRIT J PSYCHIAT, V205, P107, DOI 10.1192/bjp.bp.113.137513; Goldman MB, 2011, PSYCHOPHARMACOLOGY, V216, P101, DOI 10.1007/s00213-011-2193-8; Gordon I, 2013, P NATL ACAD SCI USA, V110, P20953, DOI 10.1073/pnas.1312857110; Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8; Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026; Guastella AJ, 2015, J CHILD PSYCHOL PSYC, V56, P444, DOI 10.1111/jcpp.12305; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; Heinrichs M, 2009, FRONT NEUROENDOCRIN, V30, P548, DOI 10.1016/j.yfrne.2009.05.005; Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021; Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.biopsych.2006.05.030; Huang HP, 2014, NEUROPSYCHOPHARMACOL, V39, P1102, DOI 10.1038/npp.2013.310; Jacobson JD, 2014, PSYCHONEUROENDOCRINO, V40, P159, DOI 10.1016/j.psyneuen.2013.11.014; Jokinen J, 2012, PSYCHONEUROENDOCRINO, V37, P482, DOI 10.1016/j.psyneuen.2011.07.016; Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038; Kim S, 2014, BRAIN RES, V1580, P133, DOI 10.1016/j.brainres.2013.10.050; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Kosaka H, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-110; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Labuschagne I, 2010, NEUROPSYCHOPHARMACOL, V35, P2403, DOI 10.1038/npp.2010.123; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001; Leng G, 2016, BIOL PSYCHIAT, V79, pE51, DOI 10.1016/j.biopsych.2015.06.022; Leng G, 2016, BIOL PSYCHIAT, V79, P243, DOI 10.1016/j.biopsych.2015.05.003; LoParo D, 2015, MOL PSYCHIATR, V20, P640, DOI 10.1038/mp.2014.77; MacDonald K, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00035; McCullough ME, 2013, NEUROSCI BIOBEHAV R, V37, P1485, DOI 10.1016/j.neubiorev.2013.04.018; Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270; Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3; Modi ME, 2014, PSYCHONEUROENDOCRINO, V45, P49, DOI 10.1016/j.psyneuen.2014.02.011; Munesue T, 2010, NEUROSCI RES, V67, P181, DOI 10.1016/j.neures.2010.03.004; Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111; Posey DJ, 2008, CHILD ADOL PSYCH CL, V17, P787, DOI 10.1016/j.chc.2008.06.010; Preti A, 2014, J CHILD ADOL PSYCHOP, V24, P54, DOI 10.1089/cap.2013.0040; Quintana DS, 2016, BIOL PSYCHIAT, V79, pE49, DOI 10.1016/j.biopsych.2015.06.021; Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009; Scheele D, 2014, NEUROPSYCHOPHARMACOL, V39, P2078, DOI 10.1038/npp.2014.78; Strathearn L, 2009, NEUROPSYCHOPHARMACOL, V34, P2655, DOI 10.1038/npp.2009.103; Striepens N, 2013, SCI REP-UK, V3, DOI 10.1038/srep03440; Szeto A, 2011, PSYCHOSOM MED, V73, P393, DOI 10.1097/PSY.0b013e31821df0c2; Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048; Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102; Taurines R, 2014, ADHD-ATTEND DEFICIT, V6, P231, DOI 10.1007/s12402-014-0145-y; Tomova A, 2015, PHYSIOL BEHAV, V138, P179, DOI 10.1016/j.physbeh.2014.10.033; Viero C, 2010, CNS NEUROSCI THER, V16, pe138, DOI 10.1111/j.1755-5949.2010.00185.x; Watanabe T, 2015, BRAIN, V138, DOI 10.1093/brain/awv249; Watanabe T, 2014, JAMA PSYCHIAT, V71, P166, DOI 10.1001/jamapsychiatry.2013.3181; Weintraub K, 2011, NATURE, V479, P22, DOI 10.1038/479022a; Wu N, 2012, J AFFECT DISORDERS, V138, P468, DOI 10.1016/j.jad.2012.01.009; Yamasue H, 2016, PSYCHIAT CLIN NEUROS, V70, P89, DOI 10.1111/pcn.12364";70;22;25;1;21;BENTHAM SCIENCE PUBL;BUSUM;PO BOX 294, BUSUM, 1400 AG, NETHERLANDS;1871-5273;1996-3181;;CNS NEUROL DISORD-DR;CNS Neurol. Disord.-Drug Targets;;2016;15;5;;;;;564;577;;10.2174/1871527315666160413120845;http://dx.doi.org/10.2174/1871527315666160413120845;;;14;"Neurosciences; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pharmacology & Pharmacy";DS2EU;27071789;Green Published, Green Submitted;;;24/11/2024;WOS:000380566300007;View Full Record in Web of Science
J;"Olsson, NC; Flygare, O; Coco, C; Görling, A; Råde, A; Chen, Q; Lindstedt, K; Berggren, S; Serlachius, E; Jonsson, U; Tammimies, K; KjeIlin, L; Bölte, S";;;;"Olsson, Nora Choque; Flygare, Oskar; Coco, Christina; Gorling, Anders; Rade, Anna; Chen, Qi; Lindstedt, Katarina; Berggren, Steve; Serlachius, Eva; Jonsson, Ulf; Tammimies, Kristiina; KjeIlin, Lars; Bolte, Sven";;;Social Skills Training for Children and Adolescents With Autism Spectrum Disorder: A Randomized Controlled Trial;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"autism spectrum disorder; treatment; intervention; gender; adolescence";YOUTH;"Objective: Social skills group training (SSGT) for children and adolescents with autism spectrum disorder (ASD) is widely applied, but effectiveness in real-world practice has not yet been properly evaluated. This study sought to bridge this gap. Method: This 12-week pragmatic randomized controlled trial of SSGT compared to standard care alone was conducted at 13 child and adolescent psychiatry outpatient units in Sweden. Twelve sessions of manualized SSGT (KONTAKT) were delivered by regular clinical staff. Participants (N = 296; 88 females and 208 males) were children (n = 172) and adolescents (n = 124) aged 8 to 17 years with ASD without intellectual disability. The primary outcome was the Social Responsiveness Scale rating by parents and blinded teachers. Secondary outcomes included parent- and teacher-rated adaptive behaviors, trainer-rated global functioning and clinical severity, and self-reported child and caregiver stress. Assessments were made at baseline, posttreatment, and 3-month follow-up. Moderator analyses were conducted for age and gender. Results: Significant treatment effects on the primary outcome were limited to parent ratings for the adolescent subgroup (posttreatment: -8.3; 95% CI = -14.2 to -1.9; p = .012, effect size [ES] = 0.32; follow-up: -8.6; 95% CI = -15.4 to -1.8; p = .015, ES = 0.33) and females (posttreatment: -8.9; 95% CI = -16.2 to -1.6; p = .019, ES = 0.40). Secondary outcomes indicated moderate effects on adaptive functioning and clinical severity. Conclusion: SSGT for children and adolescents with ASD in regular mental health services is feasible and safe. However, the modest and inconsistent effects underscore the importance of continued efforts to improve SSGT beyond current standards.";"[Olsson, Nora Choque; Flygare, Oskar; Coco, Christina; Gorling, Anders; Rade, Anna; Berggren, Steve; Jonsson, Ulf; Tammimies, Kristiina; Bolte, Sven] Karolinska Inst, Neuropsychiat Unit, Ctr Neurodev Disorders KIND, Stockholm, Sweden; [Olsson, Nora Choque; Flygare, Oskar; Coco, Christina; Gorling, Anders; Rade, Anna; Berggren, Steve; Jonsson, Ulf; Tammimies, Kristiina; Bolte, Sven] Stockholm Cty Council, Ctr Psychiat Res, Child & Adolescent Psychiat, Stockholm, Sweden; [Serlachius, Eva] Ctr Psychiat Res, Child & Adolescent Psychiat, Stockholm, Sweden; [Chen, Qi] Karolinska Inst, Stockholm, Sweden; [Lindstedt, Katarina; KjeIlin, Lars] Orebro Univ, Univ Hlth Care Res Ctr, Fac Med & Hlth, Orebro, Sweden";"Karolinska Institutet; Stockholm County Council; Karolinska Institutet; Orebro University";"Bölte, S (corresponding author), Karolinska Inst, Child & Adolescent Psychiat Res Ctr, Ctr Neurodev Disorders KIND, Gavlegatan 22B, S-11330 Stockholm, Sweden.;Bölte, S (corresponding author), Stockholm Cty Council, Gavlegatan 22B, S-11330 Stockholm, Sweden.";sven.bolte@ki.se;"Olsson, Nora/AAJ-9696-2021; Bölte, Sven/AAH-8675-2019; Lindstedt, Katarina/JBS-4515-2023; Flygare, Oskar/N-6035-2014; Serlachius, Eva/E-8956-2013";"Bolte, Sven/0000-0002-4579-4970; Tammimies, Kristiina/0000-0002-8324-4697; Flygare, Oskar/0000-0002-2017-3940; Coco, Christina/0000-0001-7963-8637; Choque Olsson, Nora/0000-0002-3147-1986; Serlachius, Eva/0000-0001-7115-6422; Jonsson, Ulf/0000-0002-5761-2943";"Foundation Sunnerdahls Disability; Majblomman; Stockholm County Council; Pediatric Research Foundation at Astrid Lindgren Children's Hospital; Swedish Research Council for Health, Working Life and Welfare; Jane and Dan Olsson foundation; Swedish Research Council; Swedish Social Insurance Agency; Swedish Foundation for Strategic Research; Jeansson Foundations; Ake Wiberg Foundation; Swedish Foundation for International Cooperation in Research and Higher Education; Swedish Brain Foundation; Swedish National Board of Institutional Care; Autism and Asperger Society Stockholm; Hjarnfonden; Vinnova; Swedish Research Council for Health Working Life and Welfare (FORTE); FORMAS; Research Foundation at Astrid Lindgren Children's Hospital; Swedish Association of Local Authorities and Regions; Trygg Hansa; Forsakringskassan; Stiftelsen Markus och Amalia Wallenbergs Min-nesfond; Stiftelsen Sunnerdahls Handikappfond; European Union (H2020); Niclas Oberg Foundation Life Watch; Tore Nilsson Stiftelse; Stiftelse Kempe-Carlgrenska Fonden; Shire; Roche; Eli Lilly and Co.; GLGroup; System Analytic; Kompetento; Expo Medico; ProPhase; Kohlhammer; Pysslingen group";"Foundation Sunnerdahls Disability; Majblomman; Stockholm County Council(Stockholm County Council); Pediatric Research Foundation at Astrid Lindgren Children's Hospital; Swedish Research Council for Health, Working Life and Welfare(Swedish Research Council for Health Working Life & Welfare (Forte)); Jane and Dan Olsson foundation; Swedish Research Council(Swedish Research Council); Swedish Social Insurance Agency; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Jeansson Foundations; Ake Wiberg Foundation; Swedish Foundation for International Cooperation in Research and Higher Education; Swedish Brain Foundation; Swedish National Board of Institutional Care; Autism and Asperger Society Stockholm; Hjarnfonden; Vinnova(Vinnova); Swedish Research Council for Health Working Life and Welfare (FORTE)(Swedish Research Council for Health Working Life & Welfare (Forte)); FORMAS(Swedish Research Council Formas); Research Foundation at Astrid Lindgren Children's Hospital; Swedish Association of Local Authorities and Regions; Trygg Hansa; Forsakringskassan; Stiftelsen Markus och Amalia Wallenbergs Min-nesfond; Stiftelsen Sunnerdahls Handikappfond; European Union (H2020)(European Union (EU)Marie Curie Actions); Niclas Oberg Foundation Life Watch; Tore Nilsson Stiftelse; Stiftelse Kempe-Carlgrenska Fonden; Shire; Roche(Roche Holding); Eli Lilly and Co.(Eli Lilly); GLGroup; System Analytic; Kompetento; Expo Medico; ProPhase; Kohlhammer; Pysslingen group";Dr. Choque Olsson has received grants and personal fees from Foundation Sunnerdahls Disability, Majblomman, Stockholm County Council, and the Pediatric Research Foundation at Astrid Lindgren Children's Hospital. Dr Serlachius has received grants from the Swedish Research Council for Health, Working Life and Welfare, the Stockholm County Council and Jane and Dan Olsson foundation Dr. Jonsson has received grants from the Swedish Research Council and the Swedish Social Insurance Agency. Dr. Tammimies has received grants from Swedish Research Council, the Stockholm County Council, the Swedish Foundation for Strategic Research, Jeansson Foundations, Ake Wiberg Foundation, the Swedish Foundation for International Cooperation in Research and Higher Education, and the Swedish Brain Foundation. She has also received the L'Oreal-UNESCO for Women in Science prize in Sweden. Dr. Kjellin has received grants from the Swedish Research Council for Health, Working life and Welfare and the Swedish National Board of Institutional Care Dr. Bolte has received grants from the Swedish Research Council, the Stockholm County Council, the Autism and Asperger Society Stockholm, Hjarnfonden, Vinnova, Swedish Research Council for Health Working Life and Welfare (FORTE), FORMAS, The Free mans Grand Lodge of Sweden, Sallskapet Barnavard, Swedish Board of Health and Welfare, Pediatric Research Foundation at Astrid Lindgren Children's Hospital, Swedish Association of Local Authorities and Regions, Trygg Hansa, Forsakringskassan, Stiftelsen Markus och Amalia Wallenbergs Min-nesfond, Stiftelsen Sunnerdahls Handikappfond, European Union (FP7, H2020), Niclas Oberg Foundation Life Watch, Tore Nilsson Stiftelse, Stiftelse Kempe-Carlgrenska Fonden. During the conduct of the study, he received personal fees from Shire, Roche, Eli Lilly and Co., GLGroup, System Analytic, Kompetento, Expo Medico, ProPhase, Kohlhammer, UTB, and Huber/Hogrefe. He is an author of the German and Swedish KONTAKT manuals and receives royalties Mr Flygare has received grants from the Stockholm County Council. Mr Berggren has received grants from the Stockholm County Council and personal fees from Kompetento, Expo Medico, and Pysslingen group. Dr. Chen, Mrs. Coco, Mr. Garling, Mrs. Rade, and Mrs. Lindstedt report no biomedical financial interests or potential conflicts of interest.;"[Anonymous], 1992, COMMUN DIS REP CDR W; Bölte S, 2008, AUTISM RES, V1, P354, DOI 10.1002/aur.49; Bolte S, 2008, KONTAKT FRANKFURTER; Choque Olsson N, 2014, J AUTISM DEV DISORD, V44, P1773, DOI 10.1007/s10803-013-2029-y; Choque OlssonN., 2015, Translational Developmental Psychiatry, V3, P29825, DOI DOI 10.3402/TDP.V3.29825; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Constantino J. N., 2012, SOCIAL RESPONSIVENES; de Schipper E, 2015, AUTISM RES, V8, P782, DOI 10.1002/aur.1485; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Freitag CM, 2016, J CHILD PSYCHOL PSYC, V57, P596, DOI 10.1111/jcpp.12509; Gates JA, 2017, CLIN PSYCHOL REV, V52, P164, DOI 10.1016/j.cpr.2017.01.006; Happé F, 2014, J CHILD PSYCHOL PSYC, V55, P553, DOI 10.1111/jcpp.12162; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Herbrecht E, 2009, EUR CHILD ADOLES PSY, V18, P327, DOI 10.1007/s00787-008-0734-4; Jonsson U, 2016, AUTISM, V20, P295, DOI 10.1177/1362361315583817; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Lai MC, 2015, J AM ACAD CHILD PSY, V54, P11, DOI 10.1016/j.jaac.2014.10.003; Laugeson EA, 2012, J AUTISM DEV DISORD, V42, P1025, DOI 10.1007/s10803-011-1339-1; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; Olsson NC, 2016, SCAND J CHILD ADOLES, V4, P46, DOI 10.21307/sjcapp-2016-009; Olsson NC, 2016, AUTISM, V20, P995, DOI 10.1177/1362361315621885; Osika W, 2007, INT J BEHAV MED, V14, P108, DOI 10.1007/BF03004176; OSU Research Unit on Pediatric Psychopharmacology, 2005, OSU AUT CGI; Rosenthal M, 2013, NEUROPSYCHOLOGY, V27, P13, DOI 10.1037/a0031299; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Wagner A, 2007, BIOL PSYCHIAT, V61, P504, DOI 10.1016/j.biopsych.2007.01.001; Wechsler D., 2004, Wechsler Intelligence Scale for Children,4thEdition (WISC IV), V4th; Whitehouse AJO, 2009, J ADOLESCENCE, V32, P309, DOI 10.1016/j.adolescence.2008.03.004; Zeedyk SM, 2014, RES AUTISM SPECT DIS, V8, P1173, DOI 10.1016/j.rasd.2014.06.001";29;75;91;2;39;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;JUL;2017;56;7;;;;;585;592;;10.1016/j.jaac.2017.05.001;http://dx.doi.org/10.1016/j.jaac.2017.05.001;;;8;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";EZ9LG;28647010;Green Published, hybrid;;;24/11/2024;WOS:000405051300007;View Full Record in Web of Science
J;"Potter, LA; Scholze, DA; Biag, HMB; Schneider, A; Chen, YJ; Nguyen, DV; Rajaratnam, A; Rivera, SM; Dwyer, PS; Tassone, F; Al Olaby, RR; Choudhary, NS; Salcedo-Arellano, MJ; Hagerman, RJ";;;;"Potter, Laura A.; Scholze, Danielle A.; Biag, Hazel Maridith B.; Schneider, Andrea; Chen, Yanjun; Nguyen, Danh V.; Rajaratnam, Akash; Rivera, Susan M.; Dwyer, Patrick S.; Tassone, Flora; Al Olaby, Reem R.; Choudhary, Nimrah S.; Salcedo-Arellano, Maria J.; Hagerman, Randi J.";;;A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"sertraline; autism spectrum disorder; controlled trial; targeted treatment; nonsyndromic autism spectrum disorder";"NEUROTROPHIC FACTOR; ANXIETY DISORDERS; MOUSE MODEL; ABNORMALITIES; GENES";Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in observational studies and anecdotal reports to improve language development in young children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young children with FXS found significant improvement in expressive language development as measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe whether sertraline is also indicated in nonsyndromic ASD. Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD aged 24 to 72 months. Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline (32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo arm discontinued. Intent-to-treat analysis showed no significant difference from placebo on the primary outcomes (MSEL expressive language raw score and age equivalent combined score) or secondary outcomes. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events possibly related to study treatment occurred. Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown.;"[Potter, Laura A.; Biag, Hazel Maridith B.; Schneider, Andrea; Rivera, Susan M.; Tassone, Flora; Salcedo-Arellano, Maria J.; Hagerman, Randi J.] UC Davis Hlth, Med Invest Neurodev Disorders MIND Inst, Sacramento, CA 95817 USA; [Scholze, Danielle A.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Schneider, Andrea; Hagerman, Randi J.] UC Davis Hlth, Dept Pediat, Sacramento, CA USA; [Schneider, Andrea] Calif Northstate Univ, Coll Psychol, Elk Grove, CA USA; [Chen, Yanjun] Univ Calif Irvine, Inst Clin & Translat Sci, Irvine, CA USA; [Nguyen, Danh V.] Univ Calif Irvine, Sch Med, Dept Med, Orange, CA USA; [Rajaratnam, Akash] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; [Rivera, Susan M.] UC Davis Hlth, Dept Psychiat & Behav Sci, Sacramento, CA USA; [Dwyer, Patrick S.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA; [Tassone, Flora; Choudhary, Nimrah S.] UC Davis Hlth, Dept Biochem & Mol Med, Sacramento, CA USA; [Al Olaby, Reem R.] Calif Northstate Univ, Coll Hlth Sci, Rancho Cordova, CA USA";"University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine; University of California System; University of California Irvine; University System of Ohio; Case Western Reserve University; University of California System; University of California Davis";Potter, LA (corresponding author), UC Davis Hlth, Med Invest Neurodev Disorders MIND Inst, Sacramento, CA 95817 USA.;Lfapotter@gmail.com;"Dwyer, Patrick/GLV-4992-2022; Schneider, Andrea/F-5800-2013";"Salcedo, Maria/0000-0002-2412-9146; Potter, Laura/0000-0001-6912-9214";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [R40MCH 27701]; MIND Institute Intellectual and Developmental Disabilities Research Center - National Institute of Child Health and Human Development [U54 HD079125]; National Center for Advancing Translational Sciences; National Institutes of Health [UL1 TR001860]";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS); MIND Institute Intellectual and Developmental Disabilities Research Center - National Institute of Child Health and Human Development; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)";This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number R40MCH 27701. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Other support includes the MIND Institute Intellectual and Developmental Disabilities Research Center which is funded by the National Institute of Child Health and Human Development (U54 HD079125). This publication was also made possible by National Center for Advancing Translational Sciences and National Institutes of Health (grant UL1 TR001860).;"Abbeduto L, 2019, J AUTISM DEV DISORD, V49, P960, DOI 10.1007/s10803-018-3796-2; Abdallah Morsi W, 2013, J Mol Psychiatry, V1, P16, DOI 10.1186/2049-9256-1-16; AlOlaby RR, 2017, BRAIN DEV-JPN, V39, P483, DOI 10.1016/j.braindev.2017.01.012; [Anonymous], 2016, J DEV BEHAV PEDIAT; Baer S, 2018, CLIN GENET, V94, P141, DOI 10.1111/cge.13254; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Basson MA, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00029; Beesdo K, 2009, PSYCHIAT CLIN N AM, V32, P483, DOI 10.1016/j.psc.2009.06.002; Bianchi P, 2010, J NEUROSCI, V30, P8769, DOI 10.1523/JNEUROSCI.0534-10.2010; Boccuto L, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-16; Chandana SR, 2005, INT J DEV NEUROSCI, V23, P171, DOI 10.1016/j.ijdevneu.2004.08.002; Chugani DC, 2016, J PEDIATR-US, V170, P45, DOI 10.1016/j.jpeds.2015.11.033; Coleman DM, 2019, J CHILD ADOL PSYCHOP, V29, P107, DOI 10.1089/cap.2018.0121; Cordeiro L, 2011, J NEURODEV DISORD, V3, P57, DOI 10.1007/s11689-010-9067-y; Dawson G, 2012, J AM ACAD CHILD PSY, V51, P1150, DOI 10.1016/j.jaac.2012.08.018; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772; Dink J.W., 2015, EyetrackingR: An R Library for Eye-Tracking Data Analysis; Ezell J, 2019, J AUTISM DEV DISORD, V49, P1131, DOI 10.1007/s10803-018-3804-6; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Hasan M, 2016, NEUROSCIENCE, V319, P168, DOI 10.1016/j.neuroscience.2016.01.045; He Q, 2019, MOL PSYCHIATR, V24, P1732, DOI 10.1038/s41380-018-0048-y; Hoenig JM, 2001, AM STAT, V55, P19, DOI 10.1198/000313001300339897; Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Ismail FY, 2017, EUR J PAEDIATR NEURO, V21, P23, DOI 10.1016/j.ejpn.2016.07.007; Jansson LC, 2012, NEUROSCIENCE, V224, P223, DOI 10.1016/j.neuroscience.2012.08.038; Kerns CM, 2014, J AUTISM DEV DISORD, V44, P2851, DOI 10.1007/s10803-014-2141-7; Lauterborn JC, 2007, J NEUROSCI, V27, P10685, DOI 10.1523/JNEUROSCI.2624-07.2007; LeBlanc JJ, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/921680; Lo SQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07400-8; Lucchelli Juan Pablo, 2018, Case Rep Psychiatry, V2018, P6278501, DOI 10.1155/2018/6278501; Margolis KG, 2016, J CLIN INVEST, V126, P2221, DOI 10.1172/JCI84877; Mei F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021568; Meredith RM, 2015, NEUROSCI BIOBEHAV R, V50, P180, DOI 10.1016/j.neubiorev.2014.12.001; Miller LJ, 1999, AM J MED GENET, V83, P268, DOI 10.1002/(SICI)1096-8628(19990402)83:4<268::AID-AJMG7>3.3.CO;2-B; Qin XY, 2017, JAMA PEDIATR, V171, P493, DOI 10.1001/jamapediatrics.2017.0110; Reinhard SM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00280; Roberts JE, 2018, AM J MED GENET B, V177, P665, DOI 10.1002/ajmg.b.32674; Saghazadeh A, 2017, J AUTISM DEV DISORD, V47, P1018, DOI 10.1007/s10803-016-3024-x; Salum GA, 2013, REV BRAS PSIQUIATR, V35, pS3, DOI [10.1590/1516-4446-2013-S108, 10.1590/1516-4446-2013-s108]; Su T, 2011, PSYCHOPHARMACOLOGY, V215, P291, DOI 10.1007/s00213-010-2130-2; Tassone F, 2013, J AUTISM DEV DISORD, V43, P530, DOI 10.1007/s10803-012-1580-2; Wenger TL, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0090-z; White SW, 2009, CLIN PSYCHOL REV, V29, P216, DOI 10.1016/j.cpr.2009.01.003; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2; Winarni Tri Indah, 2012, Case Rep Genet, V2012, P280813, DOI 10.1155/2012/280813; Yoo KH., 2017, Journal of Psychology and Clinical Psychiatry, V1, P1, DOI [10.15406/jpcpy.2017.07.00465, DOI 10.15406/JPCPY.2017.07.00465]; Youssef EA, 2018, NEUROPSYCHOPHARMACOL, V43, P503, DOI 10.1038/npp.2017.177; Ziats MN, 2016, GENET MED, V18, P1111, DOI 10.1038/gim.2016.9";50;19;21;3;7;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;nov-06;2019;10;;;;;;;;810;10.3389/fpsyt.2019.00810;http://dx.doi.org/10.3389/fpsyt.2019.00810;;;11;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;JP9TQ;31780970;Green Published, gold;;;24/11/2024;WOS:000498599800001;View Full Record in Web of Science
J;"Küçükköse, M; Kabukçu Basay, B";;;;"Kucukkose, Mustafa; Kabukcu Basay, Burge";;;Acute Dystonia due to Aripiprazole Use in Two Children with Autism Spectrum Disorder in the First Five Years of Life;TURK PSIKIYATRI DERGISI;;;Turkish;Article;;;;;;"Dystonia; aripiprazole; child";"EXTRAPYRAMIDAL SYMPTOMS; PARTIAL AGONIST";Autism spectrum disorders (ASD) are neuropsychiatric disorders characterized by impairment in social interactions, in verbal and nonverbal communication, and restricted and stereotyped patterns of interest and behavior within the first 3 years of life. Pharmacologic interventions may be needed for the treatment of temper tantrums, aggression, hyperactivity, and stereotypes in children with ASD. The approval of aripiprazole by the United States Food and Drug Administration (USFDA) for the treatment of temper tantrums in children and adolescents with ASD has gained increased interest for the use in these patients. Aripiprazole is a partial agonist for the dopamine D2, serotonin 5-HT1A receptors, and an antagonist for 5HT2A receptors. Because aripiprazole is a partial agonist, it has been is speculated that aripiprazole has a protective effect for extrapyramidal side effects, movement disorders, and metabolic problems. But the increased use in children and adolescents is associated with an increase in the number of case reports related with such problems. Nevertheless, our review of the literature uncovered limited data regarding the association between acute dystonia and aripiprazole use in ASD children under five years of age is. In this paper, we present two cases of autistic spectrum disorder children with ages under 5 years that developed acute dystonia taking aripiprazole.;"[Kucukkose, Mustafa] Aydin Devlet Hastanesi, Cocuk & Ergen Ruh Sagligi & Hastaliklari, Aydin, Turkey; [Kabukcu Basay, Burge] Pamukkale Univ Tip Fak, Cocuk & Ergen Ruh Sagligi & Hastaliklari, Denizli, Turkey";"Aydin State Hospital; Pamukkale University";Küçükköse, M (corresponding author), Aydin Devlet Hastanesi, Cocuk & Ergen Ruh Sagligi & Hastaliklari, Aydin, Turkey.;mkucukkose79@gmail.com;;;;;;"Annagur BB, 2008, NOROPSIKIYATRI ARS, V47, P351; Burris KD, 2002, J PHARMACOL EXP THER, V302, P381, DOI 10.1124/jpet.102.033175; Chavez Benjamin, 2007, Paediatr Drugs, V9, P249, DOI 10.2165/00148581-200709040-00006; DeLeon A, 2004, CLIN THER, V26, P649, DOI 10.1016/S0149-2918(04)90066-5; Goga JK, 2012, J CLIN PSYCHOPHARM, V32, P837, DOI 10.1097/JCP.0b013e318272d468; Gokcen C, 2014, DUNSEN ADAM, V27, P160, DOI 10.5350/DAJPN2014270209; Jordan S, 2002, EUR J PHARMACOL, V441, P137, DOI 10.1016/S0014-2999(02)01532-7; KEEPERS GA, 1991, AM J PSYCHIAT, V148, P85; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Saha AR, 2001, WORLD J BIOL PSYC S1, V2, P305; Schonberger RB, 2004, PEDIATRICS, V114, P1743, DOI 10.1542/peds.2004-1268; Singh MK, 2007, J AM ACAD CHILD PSY, V46, P306, DOI 10.1097/chi.0b013e31802ed925; STIGLER KA, 2003, CHILD ADOLESCENT PSY, V8, P6; Thabet FI, 2013, CLIN NEUROPHARMACOL, V36, P29, DOI 10.1097/WNF.0b013e3182767efb; Varkula M, 2008, J CLIN PSYCHOPHARM, V28, P245, DOI 10.1097/JCP.0b013e31816740ad; Yeung PP, 2001, EUR NEUROPSYCHOPHA S, V11, P241";16;0;0;12;15;TURKIYE SINIR VE RUH SAGLIGI DERNEGI;YENISEHIR;PK 401, YENISEHIR, 06442, TURKEY;1300-2163;;;TURK PSIKIYATR DERG;Turk. Psikiyatr. Derg.;SPR;2017;28;1;;;;;;;;10.5080/u13549;http://dx.doi.org/10.5080/u13549;;;3;Psychiatry;Social Science Citation Index (SSCI);Psychiatry;ER1WE;;gold;;;24/11/2024;WOS:000398584900010;View Full Record in Web of Science
J;"Zeng, P; Zhang, CZ; Fan, ZX; Yang, CJ; Cai, WY; Huang, YF; Xiang, ZJ; Wu, JY; Zhang, J; Yang, J";;;;"Zeng, Ping; Zhang, Cheng-zhi; Fan, Zhi-xing; Yang, Chao-jun; Cai, Wan-yin; Huang, Yi-fan; Xiang, Zu-jin; Wu, Jing-yi; Zhang, Jing; Yang, Jian";;;Effect of probiotics on children with autism spectrum disorders: a meta-analysis;ITALIAN JOURNAL OF PEDIATRICS;;;English;Article;;;;;;"Probiotics; Autism spectrum disorder (ASD); Severity; Gastrointestinal; Meta-analysis";"GUT MICROBIOTA; BRAIN AXIS";Background Researches have found that alteration of intestinal flora may be closely related to the development of autism spectrum disorder (ASD). However, whether probiotics supplementation has a protective effect on ASD remains controversial. This meta-analysis aimed to analyze the outcome of probiotics in the treatment of ASD children. Methods The Pubmed, Cochrane Library, Web of Science and Embase were searched until Sep 2022. Randomized controlled trials (RCTs) relevant to the probiotics and placebo treatment on ASD children were screened. Quality assessment of the included RCTs was evaluated by the Cochrane collaboration's tool. The primary outcomes were ASD assessment scales, including ABC (aberrant behavior checklist) and CBCL (child behavior checklist) for evaluating the behavior improvement, SRS (social responsiveness scale) for social assessment, DQ (developmental quotient) for physical and mental development and CGI-I (clinical global impression improvement) for overall improvement. The secondary outcome was total 6-GSI (gastrointestinal severity index). Results In total, 6 RCTs from 6 studies with 302 children were included in the systemic review. Total 6-GSI (MD=-0.59, 95%CI [-1.02,-0.17], P < 0.05) decreased significantly after oral administration of probiotics. Whereas, there was no statistical difference in ABC, CBCL, SRS, DQ and CGI-I between probiotics and placebo groups in ASD children. Conclusion Probiotics treatment could improve gastrointestinal symptoms, but there was no significant improvement in ASD.;"[Zeng, Ping; Zhang, Cheng-zhi; Fan, Zhi-xing; Yang, Chao-jun; Cai, Wan-yin; Huang, Yi-fan; Xiang, Zu-jin; Wu, Jing-yi; Zhang, Jing; Yang, Jian] China Three Gorges Univ, Coll Clin Med Sci 1, Dept Cardiol, Yichang 443003, Peoples R China; [Zeng, Ping; Zhang, Cheng-zhi; Fan, Zhi-xing; Yang, Chao-jun; Cai, Wan-yin; Huang, Yi-fan; Xiang, Zu-jin; Wu, Jing-yi; Zhang, Jing; Yang, Jian] Yichang Cent Peoples Hosp, Yichang 443003, Peoples R China; [Zeng, Ping; Zhang, Cheng-zhi; Fan, Zhi-xing; Yang, Chao-jun; Cai, Wan-yin; Huang, Yi-fan; Xiang, Zu-jin; Wu, Jing-yi; Zhang, Jing; Yang, Jian] China Three Gorges Univ, Inst Cardiovasc Dis, Yichang, Peoples R China; [Zeng, Ping; Zhang, Cheng-zhi; Fan, Zhi-xing; Yang, Chao-jun; Cai, Wan-yin; Huang, Yi-fan; Xiang, Zu-jin; Wu, Jing-yi; Zhang, Jing; Yang, Jian] Hubei Key Lab Ischem Cardiovasc Dis, Yichang, Peoples R China; [Zeng, Ping; Zhang, Cheng-zhi; Fan, Zhi-xing; Yang, Chao-jun; Cai, Wan-yin; Huang, Yi-fan; Xiang, Zu-jin; Wu, Jing-yi; Zhang, Jing; Yang, Jian] HuBei Clin Res Ctr Ischem Cardiovasc Dis, Yichang, Peoples R China";"China Three Gorges University; China Three Gorges University";"Zhang, J; Yang, J (corresponding author), China Three Gorges Univ, Coll Clin Med Sci 1, Dept Cardiol, Yichang 443003, Peoples R China.;Zhang, J; Yang, J (corresponding author), Yichang Cent Peoples Hosp, Yichang 443003, Peoples R China.;Zhang, J; Yang, J (corresponding author), China Three Gorges Univ, Inst Cardiovasc Dis, Yichang, Peoples R China.;Zhang, J; Yang, J (corresponding author), Hubei Key Lab Ischem Cardiovasc Dis, Yichang, Peoples R China.;Zhang, J; Yang, J (corresponding author), HuBei Clin Res Ctr Ischem Cardiovasc Dis, Yichang, Peoples R China.";"zhangjing@ctgu.edu.cn; yangjian@ctgu.edu.cn";"Zeng, Ping/ISV-1960-2023; HUANG, YIFAN/ABC-5159-2020";;National Natural Science Foundation of China;National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC));No specific personnel or institutes to be acknowledged.;"Adams JB, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-22; AMAN MG, 1985, AM J MENT DEF, V89, P485; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Billeci L, 2023, AUTISM, V27, P117, DOI 10.1177/13623613221082710; Dong HY, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.619994; Famitafreshi H, 2018, CNS NEUROL DISORD-DR, V17, P590, DOI 10.2174/1871527317666180706141654; Farzi A, 2018, NEUROTHERAPEUTICS, V15, P5, DOI 10.1007/s13311-017-0600-5; Gilbert JA, 2013, CELL, V155, P1446, DOI 10.1016/j.cell.2013.11.035; Golson ME, 2022, AUTISM, V26, P1423, DOI 10.1177/13623613211050440; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Kong XJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051552; Li Yu-Qin, 2021, Zhongguo Dang Dai Er Ke Za Zhi, V23, P1103, DOI 10.7499/j.issn.1008-8830.2108085; Liu XF, 2015, J AGR FOOD CHEM, V63, P7885, DOI 10.1021/acs.jafc.5b02404; Liu YW, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040820; Mensi MM, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062036; Moody EJ, 2017, J AUTISM DEV DISORD, V47, P3550, DOI 10.1007/s10803-017-3255-5; Muratori F, 2011, EPIDEMIOL PSYCH SCI, V20, P329, DOI 10.1017/S204579601100045X; Narzisi A, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796018000483; Patusco R, 2018, ADV NUTR, V9, P637, DOI 10.1093/advances/nmy031; Ristori MV, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112812; Santocchi E, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.550593; Sherwin E, 2019, SCIENCE, V366, P587, DOI 10.1126/science.aar2016; Snigdha S, 2022, PHARMACOL THERAPEUT, V231, DOI 10.1016/j.pharmthera.2021.107978; Song WJ, 2022, J MED MICROBIOL, V71, DOI 10.1099/jmm.0.001510; Sorboni SG, 2022, CLIN MICROBIOL REV, V35, DOI 10.1128/CMR.00338-20; Sun N, 2023, PROBIOTICS ANTIMICRO, V15, P558, DOI 10.1007/s12602-021-09867-4; Szatmari P, 2015, JAMA PSYCHIAT, V72, P276, DOI 10.1001/jamapsychiatry.2014.2463; Tomé-Castro XM, 2021, BENEF MICROBES, V12, P5, DOI 10.3920/BM2020.0111; Wang Y, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104784; Yap CX, 2021, CELL, V184, P5916, DOI 10.1016/j.cell.2021.10.015; Yousefi B, 2022, NEUROSCI BIOBEHAV R, V132, P998, DOI 10.1016/j.neubiorev.2021.10.046; Yu Y, 2021, J GENET GENOMICS, V48, P755, DOI 10.1016/j.jgg.2021.07.001";34;1;1;7;7;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;1720-8424;1824-7288;;ITAL J PEDIATR;Ital. J. Pediatr.;juin-21;2024;50;1;;;;;;;120;10.1186/s13052-024-01692-z;http://dx.doi.org/10.1186/s13052-024-01692-z;;;9;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;UZ8O8;38902804;gold;;;24/11/2024;WOS:001251981000001;View Full Record in Web of Science
J;"Ayuse, T; Ozaki-Honda, Y; Kurata, S; Mishima, G; Kiriishi, K; Magata, N; Kawasaki, H; Yamaguchi-Komeyama, K; Tanoue, N; Ayuse, T";;;;"Ayuse, Terumi; Ozaki-Honda, Yu; Kurata, Shinji; Mishima, Gaku; Kiriishi, Kensuke; Magata, Nobuaki; Kawasaki, Hanako; Yamaguchi-Komeyama, Kaori; Tanoue, Naomi; Ayuse, Takao";;;Study on the preventive effect of ramelteon on the onset of sleep disorder after general anesthesia in patients with autism spectrum disorder A study protocol;MEDICINE;;;English;Article;;;;;;"autism spectrum disorder; general anesthesia; Insomnia; sleep disorder";"EMERGENCE AGITATION; DOUBLE-BLIND; CHILDREN; MELATONIN; PREMEDICATION";"Background: The persistent loss of consciousness caused by general anesthesia without the existence of repeated 90-minute cycles of non-REM and REM sleep might significantly disturb and suppress the cycle of normal physiological sleep in postoperative periods after general anesthesia. Patients with autism spectrum disorders (ASD) with existing circadian rhythm disorder are reported to rapidly deteriorate due to acute sleep disorder during the perioperative period after general anesthesia. A melatonin receptor agonist, ramelteon (Rozerem), which is a sleep cycle regulator, is used as a therapeutic drug for patients with sleep disorders, but there are no studies on the prevention of postoperative sleep disorder after general anesthesia. In this study, we investigate whether prophylactic administration of a sleep-inducing substance, a melatonin receptor agonist, is effective against sleep disorder after general anesthesia in patients with ASD. Methods/design: This study is intended for patients with ASD aged 12 years and above who undergo treatment at Nagasaki University Hospital, Isahaya General Hospital Dentistry, and Sasebo City General Medical Center Dentistry and undergo dental treatment under general anesthesia. A melatonin receptor agonist (Rozerem) will be taken 7 days prior and 7 days postsurgery in patients diagnosed with insomnia. A randomized comparison will be made between 2 groups: an experimental group that is additionally administered Rozerem and a control group. The primary endpoint is the incidence of NREM-REM sleep disorders that occur within 3 to 5 days after general anesthesia. The secondary endpoint is the incidence of circadian rhythm sleep disorders (rate of occurrence of sleep-retardation syndrome with drowsiness and strong fatigue). Discussion: Postoperative sleep disorders after general anesthesia has been reported in patients with ASD; however, effective preventive pharmacological treatments have not been established. A sleep cycle regulator, ramelteon (Rozerem), is used as a therapeutic drug for patients with sleep disorders by decreasing the difficulty of falling asleep in insomnia. If sleep disorder can be prevented after the administration of general anesthesia in patients with ASD, we can support social participation while maintaining their quality of life. Trial registration: The study was registered with the jRCT1071200030.";"[Ayuse, Terumi; Kiriishi, Kensuke; Magata, Nobuaki; Kawasaki, Hanako; Yamaguchi-Komeyama, Kaori; Tanoue, Naomi; Ayuse, Takao] Nagasaki Univ Hosp, Dept Special Care Dent, 1-7-1 Sakamoto, Nagasaki, Japan; [Ozaki-Honda, Yu; Kurata, Shinji; Mishima, Gaku; Ayuse, Takao] Nagasaki Univ Hosp, Dept Dent Anesthesiol, Nagasaki, Japan; [Ayuse, Takao] Nagasaki Univ, Grad Sch Biomed Sci, Dept Translat Med Sci, Div Clin Physiol, Nagasaki, Japan";"Nagasaki University; Nagasaki University; Nagasaki University";Ayuse, T (corresponding author), Nagasaki Univ Hosp, Dept Special Care Dent, 1-7-1 Sakamoto, Nagasaki, Japan.;ayuse@nagasaki-u.ac.jp;;Ayuse, Takao/0000-0002-6202-1312;"Nagasaki University Hospital; JSPS KAKENHI; Nagasaki University Graduate School of Biomedical Sciences";"Nagasaki University Hospital; JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Nagasaki University Graduate School of Biomedical Sciences";This study is funded by the Institutional budget (Nagasaki University Hospital) for Terumi Ayuse and partly by JSPS KAKENHI GRANT-IN-AID for Yu Ozaki-Honda.r The study is sponsored by the Nagasaki University Graduate School of Biomedical Sciences (the sponsor representative is Dr. Ayuse).;"Baker EK, 2015, SLEEP, V38, P1765, DOI 10.5665/sleep.5160; Borazan H, 2010, J ANESTH, V24, P155, DOI 10.1007/s00540-010-0891-8; Carmassi C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00366; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Foster J, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0378-2; Glickman G, 2010, NEUROSCI BIOBEHAV R, V34, P755, DOI 10.1016/j.neubiorev.2009.11.017; Gögenur I, 2008, BRIT J ANAESTH, V100, P45, DOI 10.1093/bja/aem340; Goldman SE, 2021, J AUTISM DEV DISORD, V51, P550, DOI 10.1007/s10803-020-04561-w; Gunes S, 2019, NEUROPSYCH DIS TREAT, V15, P763, DOI 10.2147/NDT.S195738; Kawai M, 2019, DRUG DES DEV THER, V13, P1729, DOI 10.2147/DDDT.S198123; Kendall T, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4865; Mannion A, 2014, REV J AUTISM DEV DIS, V1, P101, DOI 10.1007/s40489-013-0009-y; McLay L, 2020, AUTISM, V24, P1829, DOI 10.1177/1362361320924216; McLay L, 2021, J AUTISM DEV DISORD, V51, P418, DOI 10.1007/s10803-020-04548-7; Mihara T, 2015, EUR J ANAESTH, V32, P862, DOI 10.1097/EJA.0000000000000323; Narasingharao K, 2016, J CLIN DIAGN RES, V10, pVE1, DOI 10.7860/JCDR/2016/24175.8922; Oh ES, 2021, AM J GERIAT PSYCHIAT, V29, P90, DOI 10.1016/j.jagp.2020.05.006; Posar A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00265; Poulsen RC, 2018, SLEEP MED REV, V37, P35, DOI 10.1016/j.smrv.2016.12.002; Samarkandi A, 2005, EUR J ANAESTH, V22, P189, DOI 10.1017/S0265021505000335; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1136/bmj.c332, 10.1016/j.jclinepi.2010.02.005, 10.1186/1741-7015-8-18, 10.1016/j.ijsu.2011.09.004, 10.4103/0976-500X.72352]";21;2;2;3;16;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0025-7974;1536-5964;;MEDICINE;Medicine (Baltimore);oct-23;2020;99;43;;;;;;;e22826;10.1097/MD.0000000000022826;http://dx.doi.org/10.1097/MD.0000000000022826;;;5;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;OP6IA;33120808;Green Published, gold;;;24/11/2024;WOS:000588186800084;View Full Record in Web of Science
J;"Hoefer, J; Hoffmann, F; Kamp-Becker, I; Kuepper, C; Poustka, L; Roepke, S; Roessner, V; Stroth, S; Wolff, N; Bachmann, CJ";;;;"Hoefer, Juliana; Hoffmann, Falk; Kamp-Becker, Inge; Kuepper, Charlotte; Poustka, Luise; Roepke, Stefan; Roessner, Veit; Stroth, Sanna; Wolff, Nicole; Bachmann, Christian J.";;;Complementary and alternative medicine use in adults with autism spectrum disorder in Germany: results from a multi-center survey;BMC PSYCHIATRY;;;English;Article;;;;;;"Autism spectrum disorder; Autism; Complementary and alternative medicine; CAM; Prevalence; Adults; Germany";"CONTROLLED-TRIAL; CHILDREN; ADOLESCENTS";"BackgroundComplementary and Alternative Medicine (CAM) is widely used both in the general population and for the treatment of somatic and psychiatric disorders. Studies on CAM use among patients with autism spectrum disorder (ASD) have so far only focused on children and adolescents. The aim of this study was to investigate patterns of CAM use among adults with ASD.MethodsA questionnaire survey concerning current and lifetime use of CAM was distributed to adults with ASD between November 2015 and June 2016. Participants diagnosed by experienced clinicians using the current diagnostic gold standard were recruited from four ASD outpatient clinics in Germany. Questionnaire data was then linked to supplementary clinical data.ResultsThe final sample consisted of 192 adults (response: 26.8%) with a mean age of 31.5years (80% male; diagnoses: Asperger's syndrome (58%), childhood autism (27%), atypical autism (12%)). 45% of the respondents stated that they were currently using or had used at least one CAM modality in their life. Among the participants with lifetime CAM use, almost half had used two or more different types of CAM. Alternative medical systems (e.g. homeopathy, acupuncture) were most frequently used, followed by mind-body interventions (e.g. yoga, biofeedback, animal assisted therapy). Overall, 20% of respondents stated that they would like to try at least one listed CAM modality in the future.ConclusionsThis is the first study on CAM use in adults with ASD, demonstrating considerable CAM use in this population. Given the popularity of CAM, patients should be informed about the effectiveness and potentially dangerous side effects of CAM treatments, as evidence for the majority of CAM methods in ASD is still limited.";"[Hoefer, Juliana; Hoffmann, Falk] Carl von Ossietzky Univ Oldenburg, Dept Hlth Serv Res, Ammerlander Heerstr 140, D-26129 Oldenburg, Germany; [Kamp-Becker, Inge; Stroth, Sanna] Philipps Univ Marburg, Dept Child & Adolescent Psychiat Psychosomat & Ps, Hans Sachs Str 4, D-35039 Marburg, Germany; [Kuepper, Charlotte; Roepke, Stefan] Charite Univ Med Berlin, Dept Psychiat, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany; [Poustka, Luise] Univ Med Ctr Gottingen, Dept Child & Adolescent Psychiat, Von Siebold Str 5, D-37075 Gottingen, Germany; [Roessner, Veit; Wolff, Nicole] Tech Univ Dresden, Fac Med, Dept Child & Adolescent Psychiat, Fetscherstr 74, D-01307 Dresden, Germany; [Bachmann, Christian J.] Heinrich Heine Univ Dusseldorf, LVR Klinikum Dusseldorf, Dept Child & Adolescent Psychiat, Berg Landstr 2, D-40629 Dusseldorf, Germany";"Carl von Ossietzky Universitat Oldenburg; Philipps University Marburg; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen; UNIVERSITY GOTTINGEN HOSPITAL; Technische Universitat Dresden; Heinrich Heine University Dusseldorf";Hoefer, J (corresponding author), Carl von Ossietzky Univ Oldenburg, Dept Hlth Serv Res, Ammerlander Heerstr 140, D-26129 Oldenburg, Germany.;juliana.hoefer@uni-oldenburg.de;"Roessner, Veit/AAQ-8760-2020; Hoffmann, Falk/F-5201-2013";"Roessner, Veit/0000-0002-1873-7081; Roepke, Stefan/0000-0003-3165-8684";German Federal Ministry of Education and Research [FKZ 01EE1409F];German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF));This work was funded by the German Federal Ministry of Education and Research (FKZ 01EE1409F). The funding organization had no influence on the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.;"[Anonymous], UMSETZUNG BILDUNGSSK; [Anonymous], 2006, WECHSLER INTELLIGENZ; [Anonymous], ARCH GEN PSYCHIAT; [Anonymous], CRITICAL INTEGRATIVE; [Anonymous], 1992, Wortschatztest (WST); [Anonymous], CLASS ED ISCED 2011; [Anonymous], REVIS BERN HUBER; [Anonymous], DIAGNOSTISCHE BEOBAC; [Anonymous], DTSCH BEARBEITUNG NO; [Anonymous], HAMBURG WECHSLER INT; [Anonymous], 2017, EPIDEMIOL PSYCH SCI, DOI [DOI 10.1017/S2045796017000774, 10.1017/S2045796017000774]; [Anonymous], 1991, Hamburg-Wechsler Intelligenztest fr Erwachsene: HAWIE-R; [Anonymous], COMPLEMENTARY ALTERN; [Anonymous], 2013, American Journal of Psychiatry; [Anonymous], COMPL ALT INT HLTH W; [Anonymous], ACTA PSYCHIAT SCAND; [Anonymous], INT STANDARD CLASSIF; [Anonymous], 2000, TRAD MED DEF; [Anonymous], 2009, STANDARD PROGR MATRI; [Anonymous], MOL PSYCHIAT; [Anonymous], GESUNDHEITSBERICHTER; Bachmann CJ, 2018, AUTISM, V22, P283, DOI 10.1177/1362361316673977; Bahceci B, 2013, COMPLEMENT THER CLIN, V19, P221, DOI 10.1016/j.ctcp.2013.06.005; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Beecham J., 1992, MEASURING MENTAL HLT, V2nd; Bent S, 2014, J AM ACAD CHILD PSY, V53, P658, DOI 10.1016/j.jaac.2014.01.018; Blumberg Stephen J, 2013, Natl Health Stat Report, P1; Bolte S., 2006, DIAGNOSTISCHES INTER; Brondino N, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/258589; DeFilippis Melissa, 2018, Psychopharmacol Bull, V48, P40; Feng L, 2010, ARCH GERONTOL GERIAT, V50, P243, DOI 10.1016/j.archger.2009.04.013; Gabriels RL, 2015, J AM ACAD CHILD PSY, V54, P541, DOI 10.1016/j.jaac.2015.04.007; Hanssen B, 2005, SCAND J PRIM HEALTH, V23, P57, DOI 10.1080/02813430510018419; Harris PE, 2012, INT J CLIN PRACT, V66, P924, DOI 10.1111/j.1742-1241.2012.02945.x; Höfer J, 2019, AUTISM, V23, P1865, DOI 10.1177/1362361318823545; Höfer J, 2017, AUTISM, V21, P387, DOI 10.1177/1362361316646559; Jobski K, 2017, ACTA PSYCHIAT SCAND, V135, P8, DOI 10.1111/acps.12644; Kamp-Becker I, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1362-7; Kaufman A., 2009, K ABC KAUFMAN ASSESS; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Levy SE, 2015, CHILD ADOL PSYCH CL, V24, P117, DOI 10.1016/j.chc.2014.09.004; Linde K, 2014, FORSCH KOMPLEMENTMED, V21, P111, DOI 10.1159/000360917; Lindly O, 2017, COMPLEMENT THER MED, V35, P47, DOI 10.1016/j.ctim.2017.09.003; McFarland B, 2002, AM J PUBLIC HEALTH, V92, P1616, DOI 10.2105/AJPH.92.10.1616; Metcalfe A, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-58; Millar W J, 2001, Health Rep, V13, P9; NICE, Clinical guideline CG142; Nilsson J, 2016, ANTICANCER RES, V36, P3243; Pedersen CG, 2009, EUR J CANCER, V45, P3172, DOI 10.1016/j.ejca.2009.09.005; Petermann F., 2009, Wechsler preschool and primary scale - Third edition. Deutschsprachige Adaption nach D. Wechsler; Petermann F., 2011, WECHSLER INTELLIGENC; Rey JM, 2008, J AM ACAD CHILD PSY, V47, P364, DOI 10.1097/CHI.0b013e31816520e5; UNESCO, 2006, INT STAND CLASS ED I";54;13;14;2;30;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;FEB 1;2019;19;;;;;;;;53;10.1186/s12888-019-2043-5;http://dx.doi.org/10.1186/s12888-019-2043-5;;;8;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;HJ8SR;30709386;Green Published, Green Accepted, gold;;;24/11/2024;WOS:000457470600001;View Full Record in Web of Science
J;"Hirst, K; Zamzow, RM; Stichter, JP; Beversdorf, DQ";;;;"Hirst, Kathy; Zamzow, Rachel M.; Stichter, Janine P.; Beversdorf, David Q.";;;A Pilot Feasibility Study Assessing the Combined Effects of Early Behavioral Intervention and Propranolol on Autism Spectrum Disorder (ASD);CHILDREN-BASEL;;;English;Article;;;;;;"autism; propranolol; early intervention; clinical trial";"BETA-ADRENERGIC MODULATION; COGNITIVE FLEXIBILITY; YOUNG-CHILDREN; NORADRENERGIC MODULATION; PEDIATRIC MIGRAINE; RANDOMIZED-TRIAL; SODIUM VALPROATE; ADOLESCENTS; PREVENTION; MEMANTINE";Autism spectrum disorder (ASD), a neurodevelopmental disorder typified by differences in social communication as well as restricted and repetitive behaviors, is often responsive to early behavioral intervention. However, there is limited information on whether such intervention can be augmented with pharmacological approaches. We conducted a double-blinded, placebo-controlled feasibility trial to examine the effects of the beta-adrenergic antagonist propranolol combined with early intensive behavioral intervention (EIBI) for children with ASD. Nine participants with ASD, ages three to ten, undergoing EIBI were enrolled and randomized to a 12-week course of propranolol or placebo. Blinded assessments were conducted at baseline, 6 weeks, and 12 weeks. The primary outcome measures focusing on social interaction were the General Social Outcome Measure-2 (GSOM-2) and Social Responsiveness Scale-Second Edition (SRS-2). Five participants completed the 12-week visit. The sample size was insufficient to evaluate the treatment efficacy. However, side effects were infrequent, and participants were largely able to fully participate in the procedures. Conducting a larger clinical trial to investigate propranolol's effects on core ASD features within the context of behavioral therapy will be beneficial, as this will advance and individualize combined therapeutic approaches to ASD intervention. This initial study helps to understand feasibility constraints on performing such a study.;"[Hirst, Kathy; Stichter, Janine P.; Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev, Columbia, MO 65211 USA; [Zamzow, Rachel M.; Beversdorf, David Q.] Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO 65211 USA; [Beversdorf, David Q.] Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Radiol, Columbia, MO 65211 USA; [Beversdorf, David Q.] Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Neurol, Columbia, MO 65211 USA; [Beversdorf, David Q.] Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Psychol Sci, Columbia, MO 65211 USA";"University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia";"Beversdorf, DQ (corresponding author), Univ Missouri, Thompson Ctr Autism & Neurodev, Columbia, MO 65211 USA.;Beversdorf, DQ (corresponding author), Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO 65211 USA.;Beversdorf, DQ (corresponding author), Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Radiol, Columbia, MO 65211 USA.;Beversdorf, DQ (corresponding author), Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Neurol, Columbia, MO 65211 USA.;Beversdorf, DQ (corresponding author), Univ Missouri, William & Nancy Thompson Endowed Chair Radiol, Dept Psychol Sci, Columbia, MO 65211 USA.";"khirst@lakeregional.com; rachel.zamzow@gmail.com; stichterj@missouri.edu; beversdorfd@health.missouri.edu";Beversdorf, David/M-2786-2016;Beversdorf, David/0000-0002-0298-0634;Autism Science Foundation;Autism Science Foundation;This work was funded by the Autism Science Foundation Pre-doctoral Fellowship Award.;"Alexander JK, 2007, J COGNITIVE NEUROSCI, V19, P468, DOI 10.1162/jocn.2007.19.3.468; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Ashrafi MR, 2005, EUR J PAEDIATR NEURO, V9, P333, DOI 10.1016/j.ejpn.2005.05.004; Bai D, 2019, JAMA PSYCHIAT, V76, P1035, DOI 10.1001/jamapsychiatry.2019.1411; Baranek GT, 2006, J CHILD PSYCHOL PSYC, V47, P591, DOI 10.1111/j.1469-7610.2005.01546.x; Bartz JA, 2008, PROG BRAIN RES, V170, P451, DOI 10.1016/S0079-6123(08)00435-4; Beversdorf D.Q., 2013, Psychopharmacology; Beversdorf David, 2008, Mo Med, V105, P390; Beversdorf DQ, 2008, NEUROCASE, V14, P378, DOI 10.1080/13554790802368661; Beversdorf DQ, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100834; Beversdorf DQ, 2011, COGN BEHAV NEUROL, V24, P11, DOI 10.1097/WNN.0b013e318204d20e; Beversdorf DQ, 2002, NEUROREPORT, V13, P2505, DOI 10.1097/00001756-200212200-00025; Beversdorf DQ, 1999, NEUROREPORT, V10, P2763, DOI 10.1097/00001756-199909090-00012; Bidabadi Elham, 2010, Paediatr Drugs, V12, P269, DOI 10.2165/11316270-000000000-00000; Billeci L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00467; Bodner KE, 2012, J INT NEUROPSYCH SOC, V18, P556, DOI 10.1017/S1355617712000070; Campbell HL, 2008, PHARMACOL BIOCHEM BE, V88, P222, DOI 10.1016/j.pbb.2007.08.003; Chez MG, 2007, J CHILD NEUROL, V22, P574, DOI 10.1177/0883073807302611; Cohen H, 2006, J DEV BEHAV PEDIATR, V27, pS145, DOI 10.1097/00004703-200604002-00013; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Corbett BA, 2019, BIOL PSYCHOL, V140, P119, DOI 10.1016/j.biopsycho.2018.12.010; Dawson G, 2008, DEV PSYCHOPATHOL, V20, P775, DOI 10.1017/S0954579408000370; Du L, 2015, J CHILD ADOL PSYCHOP, V25, P585, DOI 10.1089/cap.2015.0045; Eikeseth S, 2002, BEHAV MODIF, V26, P49, DOI 10.1177/0145445502026001004; Eikeseth S, 2007, BEHAV MODIF, V31, P264, DOI 10.1177/0145445506291396; Eiland LS, 2007, ANN PHARMACOTHER, V41, P1181, DOI 10.1345/aph.1K049; Eldevik S, 2006, J AUTISM DEV DISORD, V36, P211, DOI 10.1007/s10803-005-0058-x; Eldevik S, 2009, J CLIN CHILD ADOLESC, V38, P439, DOI 10.1080/15374410902851739; Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9; Erickson CA, 2014, J AUTISM DEV DISORD, V44, P958, DOI 10.1007/s10803-013-1963-z; FAIGEL HC, 1991, CLIN PEDIATR, V30, P441, DOI 10.1177/000992289103000706; Frazier TW, 2014, AUTISM, V18, P31, DOI 10.1177/1362361313500382; Gaugler T, 2014, NAT GENET, V46, P881, DOI 10.1038/ng.3039; Geschwind DH, 2009, ANNU REV MED, V60, P367, DOI 10.1146/annurev.med.60.053107.121225; Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.biopsych.2006.05.030; Howard JS, 2005, RES DEV DISABIL, V26, P359, DOI 10.1016/j.ridd.2004.09.005; Howlin P, 2009, AJIDD-AM J INTELLECT, V114, P23, DOI 10.1352/2009.114:23;nd41; Hu VW, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-118; Kampman KM, 2001, DRUG ALCOHOL DEPEN, V63, P69, DOI 10.1016/S0376-8716(00)00193-9; Kanne SM, 2014, J AUTISM DEV DISORD, V44, P168, DOI 10.1007/s10803-013-1862-3; Keeshin B.R., 2012, Child Adolesc Psychopharmacol News, V17, P5, DOI DOI 10.1521/CAPN.2012.17.2.5; Kelley BJ, 2007, NEUROCASE, V13, P320, DOI 10.1080/13554790701846148; LADER M, 1988, J CLIN PSYCHIAT, V49, P213; Landa RJ, 2008, NAT CLIN PRACT NEURO, V4, P138, DOI 10.1038/ncpneuro0731; LAVERDURE B, 1991, Encephale, V17, P481; London EB, 2020, J CLIN PSYCHOPHARM, V40, P122, DOI 10.1097/JCP.0000000000001175; Lord C., 2012, AUTISM DIAGNOSTIC OB; Lovaas O.I., 1981, Teaching Developmentally Disabled Children: The Me Book; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; Matson JL, 2008, J DEV PHYS DISABIL, V20, P175, DOI 10.1007/s10882-007-9088-y; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Nguyen A, 2010, FASEB J, V24, P3036, DOI 10.1096/fj.10-154484; RATEY JJ, 1987, J AUTISM DEV DISORD, V17, P439, DOI 10.1007/BF01487073; Remington B, 2007, AM J MENT RETARD, V112, P418, DOI 10.1352/0895-8017(2007)112[418:EIBIOF]2.0.CO;2; Rogers SJ, 2008, J CLIN CHILD ADOLESC, V37, P8, DOI 10.1080/15374410701817808; Sagar-Ouriaghli I, 2018, J PSYCHOPHARMACOL, V32, P641, DOI 10.1177/0269881118756245; Sallows GO, 2005, AM J MENT RETARD, V110, P417, DOI 10.1352/0895-8017(2005)110[417:IBTFCW]2.0.CO;2; Sandin S, 2017, JAMA-J AM MED ASSOC, V318, P1182, DOI 10.1001/jama.2017.12141; Sans V, 2009, PEDIATRICS, V124, pE423, DOI 10.1542/peds.2008-3458; Searcy CP, 2012, MIL MED, V177, P649, DOI 10.7205/MILMED-D-11-00390; Sheinkopf SJ, 1998, J AUTISM DEV DISORD, V28, P15, DOI 10.1023/A:1026054701472; Sheinkopf SJ, 2019, BIOL PSYCHOL, V142, P13, DOI 10.1016/j.biopsycho.2019.01.003; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Smith T, 2000, AM J MENT RETARD, V105, P269, DOI 10.1352/0895-8017(2000)105<0269:RTOIEI>2.0.CO;2; Smith T, 1997, AM J MENT RETARD, V102, P238, DOI 10.1352/0895-8017(1997)102<0238:IBTFPW>2.0.CO;2; Sparrow S., 2014, The Vineland-II Adaptive Behavior Scales; Spence SH, 2001, BEHAV RES THER, V39, P1293, DOI 10.1016/S0005-7967(00)00098-X; Stichter JP, 2012, ASSES EFF INTERV, V38, P40, DOI 10.1177/1534508412455213; Towbin KE, 2003, CHILD ADOL PSYCH CL, V12, P23, DOI 10.1016/S1056-4993(02)00049-4; Veenstra-VanderWeele J., 2013, Int. Meet. Autism Res, V13, p102.001; Veenstra-VanderWeele J, 2012, NEUROPSYCHOPHARMACOL, V37, P196, DOI 10.1038/npp.2011.185; Volkmar FR, 2001, J CLIN CHILD PSYCHOL, V30, P80, DOI 10.1207/S15374424JCCP3001_9; Zamzow RM, 2016, PSYCHOPHARMACOLOGY, V233, P1171, DOI 10.1007/s00213-015-4199-0; Zamzow RM, 2014, J CLIN EXP NEUROPSYC, V36, P431, DOI 10.1080/13803395.2014.904844; Zimmerman IL., 2011, PRESCHOOL LANGUAGE S, DOI [10.1037/t15141-000, DOI 10.1037/T15141-000]";77;1;1;1;5;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2227-9067;;CHILDREN-BASEL;Children-Basel;OCT;2023;10;10;;;;;;;1639;10.3390/children10101639;http://dx.doi.org/10.3390/children10101639;;;12;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;W8LS3;37892301;Green Published, gold;;;24/11/2024;WOS:001094094300001;View Full Record in Web of Science
J;"Wink, LK; Reisinger, DL; Horn, P; Shaffer, RC; O'Brien, K; Schmitt, L; Dominick, KR; Pedapati, EV; Erickson, CA";;;;"Wink, Logan K.; Reisinger, Debra L.; Horn, Paul; Shaffer, Rebecca C.; O'Brien, Kaela; Schmitt, Lauren; Dominick, Kelli R.; Pedapati, Ernest V.; Erickson, Craig A.";;;Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Autism; Ketamine; Clinical trial";"SOCIAL COMMUNICATION BEHAVIORS; DOUBLE-BLIND; CHILDREN; ANTIDEPRESSANT; EFFICACY; DEPRESSION; SCALE; PHARMACODYNAMICS; INDIVIDUALS; NORKETAMINE";Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects.;"[Wink, Logan K.; Reisinger, Debra L.; Horn, Paul; Shaffer, Rebecca C.; O'Brien, Kaela; Schmitt, Lauren; Dominick, Kelli R.; Pedapati, Ernest V.; Erickson, Craig A.] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA; [Wink, Logan K.; Horn, Paul; Shaffer, Rebecca C.; Schmitt, Lauren; Dominick, Kelli R.; Pedapati, Ernest V.; Erickson, Craig A.] Univ Cincinnati, Coll Med, 3230 Eden Ave, Cincinnati, OH 45221 USA";"Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati";"Erickson, CA (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.;Erickson, CA (corresponding author), Univ Cincinnati, Coll Med, 3230 Eden Ave, Cincinnati, OH 45221 USA.";craig.erickson@cchmc.org;"Erickson, Craig/M-8933-2017; Dominick, Kelli/AAK-3798-2020; pedapati, ernest/GPT-0086-2022; Horn, Paul/LPA-6457-2024";"Reisinger, Debra/0000-0002-6498-0808; Dominick, Kelli/0000-0003-3775-2479";"Roivant Sciences; National Institute of Metal Health-National Institute of Child Health and Human Development; Autism Speaks; National Institute of Neurological Disorders and Stroke (NINDS); American Academy of Child and Adolescent Psychiatry; Cincinnati Children's Hospital Medical Center; National Institute of Health; Cincinnati Children's Hospital Research Foundation; National Institutes of Health; United States Centers for Disease Control; FRAXA foundation; State of Ohio; Cures Within Reach";"Roivant Sciences; National Institute of Metal Health-National Institute of Child Health and Human Development; Autism Speaks; National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); American Academy of Child and Adolescent Psychiatry; Cincinnati Children's Hospital Medical Center; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Children's Hospital Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Centers for Disease Control; FRAXA foundation; State of Ohio; Cures Within Reach";Funding for this project was provided by Cures Within Reach and Roivant Sciences. The authors report no competing financial interests related to the work described. Dr. Wink has received funding from the National Institute of Metal Health-National Institute of Child Health and Human Development via a T32 fellowship, as well as research funding from Autism Speaks. Dr. Wink has consulted for Ovid Therapeutics. Dr. Horn, Dr. Reisinger, Dr. Shaffer, Ms. O'Brien, and Dr. Schmitt have no conflicts to disclose. Dr. Dominick has received research support from the National Institute of Neurological Disorders and Stroke (NINDS), American Academy of Child and Adolescent Psychiatry, and Cincinnati Children's Hospital Medical Center. She is a clinical trial site investigator for F. Hoffman-La Roche Ltd. and Ovid Therapeutics. Dr. Pedapati has received research support from the National Institute of Health, American Academy of Child and Adolescent Psychiatry, and Cincinnati Children's Hospital Research Foundation. He is a clinical trial site investigator for the Marcus Autism Center for an investigational medical device. He receives compensation for consulting for Proctor & Gamble, Eccrine Systems, and Autism Speaks. He receives book royalties from Springer. Dr. Erickson receives current consulting revenue from Lenire Bioscience, Stalicla, and Confluence Pharmaceuticals. Dr. Erickson receives current research support from the National Institutes of Health, the United States Centers for Disease Control, the FRAXA foundation, Autism Speaks, the State of Ohio, and from the Cincinnati Children's Hospital Research Foundation. Drs. Wink and Erickson are inventors on a patent describing use of ketamine in autism.;"Aan Het Rot M, 2012, BIOL PSYCHIAT, V72, P537, DOI 10.1016/j.biopsych.2012.05.003; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P485; Anagnostou E, 2015, AUTISM, V19, P622, DOI 10.1177/1362361314542955; [Anonymous], 2012, MMWR-MORBID MORTAL W; [Anonymous], 2009, ANN EMERG MED, V54, P432; [Anonymous], 1976, ECDEU ASSESSMENT MAN; Azari P, 2012, CNS DRUGS, V26, P215, DOI 10.2165/11595200-000000000-00000; Belsito KM, 2001, J AUTISM DEV DISORD, V31, P175, DOI 10.1023/A:1010799115457; Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Bremner JD, 1998, J TRAUMA STRESS, V11, P125, DOI 10.1023/A:1024465317902; Carlson GC, 2012, PHARMACOL BIOCHEM BE, V100, P850, DOI 10.1016/j.pbb.2011.02.003; Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001; Choudhury PR, 2012, PHARMACOL BIOCHEM BE, V100, P841, DOI 10.1016/j.pbb.2011.06.023; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Correia CT, 2010, GENES BRAIN BEHAV, V9, P841, DOI 10.1111/j.1601-183X.2010.00627.x; Erickson CA, 2008, GLUTAMATE NEUROPSYCH, P197; Esbensen AJ, 2003, J AUTISM DEV DISORD, V33, P617, DOI 10.1023/B:JADD.0000005999.27178.55; Ethridge LE, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0140-1; Fung LK, 2014, J AUTISM DEV DISORD, V44, P2971, DOI 10.1007/s10803-014-2144-4; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Green SM, 1999, ANN EMERG MED, V34, P492, DOI 10.1016/S0196-0644(99)80051-1; Green SM, 1999, ACAD EMERG MED, V6, P86, DOI 10.1111/j.1553-2712.1999.tb00102.x; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Interagency Autism Coordinating Committee, 2010, IACC STRAT PLAN AUT, P66; Jones B, 2015, DESIGN ANAL CROSS OV; King BH, 2001, J AM ACAD CHILD PSY, V40, P658, DOI 10.1097/00004583-200106000-00010; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Krystal JH, 2013, BIOL PSYCHIAT, V73, P1133, DOI 10.1016/j.biopsych.2013.03.026; Lapidus KAB, 2014, BIOL PSYCHIAT, V76, P970, DOI 10.1016/j.biopsych.2014.03.026; Lara DR, 2013, INT J NEUROPSYCHOPH, V16, P2111, DOI 10.1017/S1461145713000485; Lord C., 2014, AUTISM DIAGNOSTIC OB; Luckenbaugh DA, 2014, J AFFECT DISORDERS, V159, P56, DOI 10.1016/j.jad.2014.02.017; Malinovsky JM, 1996, BRIT J ANAESTH, V77, P203, DOI 10.1093/bja/77.2.203; MARSHBURN EC, 1992, J AUTISM DEV DISORD, V22, P357, DOI 10.1007/BF01048240; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Minshawi N, 2015, MOL AUTISM; Minshawi NF, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-015-0062-8; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Norris M, 2019, RES AUTISM SPECT DIS, V62, P1, DOI 10.1016/j.rasd.2019.02.001; Orser BA, 1997, ANESTHESIOLOGY, V86, P903, DOI 10.1097/00000542-199704000-00021; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Papolos DF, 2013, J AFFECT DISORDERS, V147, P431, DOI 10.1016/j.jad.2012.08.040; Posey D., 2009, AM COLL NEUR 48 ANN, P208; Posey D. J., 2008, CHIC ANN M AM AC CHI; Posey DJ, 2008, CHILD ADOL PSYCH CL, V17, P787, DOI 10.1016/j.chc.2008.06.010; Posey DJ, 2004, AM J PSYCHIAT, V161, P2115, DOI 10.1176/appi.ajp.161.11.2115; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Scahill L, 2013, J AUTISM DEV DISORD, V43, P739, DOI 10.1007/s10803-012-1689-3; Uzunova G, 2014, CURR NEUROPHARMACOL, V12, P71, DOI 10.2174/1570159X113116660046; Vermeulen E, 2017, J PHARM PHARMACOL, V69, P439, DOI 10.1111/jphp.12637; Wang HS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00028; Wink LK, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0116-1; Wink LK, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0088-6; Wink LK, 2014, J CLIN PSYCHIAT, V75, P835, DOI 10.4088/JCP.13cr08917; Yanagihara Y, 2003, BIOPHARM DRUG DISPOS, V24, P37, DOI 10.1002/bdd.336; Zanos P, 2018, MOL PSYCHIATR, V23, P801, DOI 10.1038/mp.2017.255; Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856; Zarate CA, 2012, BIOL PSYCHIAT, V71, P939, DOI 10.1016/j.biopsych.2011.12.010";60;17;19;1;4;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;APR;2021;51;4;;;;;1392;1399;;10.1007/s10803-020-04542-z;http://dx.doi.org/10.1007/s10803-020-04542-z;;juil-20;8;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;RA5WM;32642957;;;;24/11/2024;WOS:000546511600002;View Full Record in Web of Science
J;"Wink, LK; Adams, R; Wang, ZM; Klaunig, JE; Plawecki, MH; Posey, DJ; McDougle, CJ; Erickson, CA";;;;"Wink, Logan K.; Adams, Ryan; Wang, Zemin; Klaunig, James E.; Plawecki, Martin H.; Posey, David J.; McDougle, Christopher J.; Erickson, Craig A.";;;A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder;MOLECULAR AUTISM;;;English;Article;;;;;;"Autism; Autism spectrum disorder; Social impairment; N-acetylcysteine; Oxidative stress";"CONTROLLED CLINICAL-TRIAL; OXIDATIVE STRESS; DOUBLE-BLIND; RISPERIDONE; CHILDREN; HOMOCYSTEINE; SAMPLE; PLASMA";Background: Social impairment is a defining feature of autism spectrum disorder (ASD) with no demonstrated effective pharmacologic treatments. The goal of this study was to evaluate efficacy, safety, and tolerability of oral N-acetylcysteine (NAC), an antioxidant whose function overlaps with proposed mechanisms of ASD pathophysiology, targeting core social impairment in youth with ASD. Methods: This study was a 12-week randomized, double-blind, placebo-controlled trial of oral NAC in youth with ASD. Study participants were medically healthy youth age 4 to 12 years with ASD, weighing >= 15 kg, and judged to be moderately ill based on the Clinical Global Impressions Severity scale. The participants were randomized via computer to active drug or placebo in a 1: 1 ratio, with the target dose of NAC being 60 mg/kg/day in three divided doses. The primary outcome measure of efficacy was the Clinical Global Impressions Improvement (CGI-I) scale anchored to core social impairment. To investigate the impact of NAC on oxidative stress markers in peripheral blood, venous blood samples were collected at screen and week 12. Results: Thirty-one patients were enrolled (NAC = 16, placebo = 15). Three participants were lost to follow-up, and three left the trial due to adverse effects. The average daily dose of NAC at week 12 was 56.2 mg/kg (SD = 9.7) with dose ranging from 33.6 to 64.3 mg/kg. The frequency of adverse events was so low that comparisons between groups could not be conducted. At week 12, there was no statistically significant difference between the NAC and placebo groups on the CGI-I (p > 0.69) but the glutathione (GSH) level in blood was significantly higher in the NAC group (p < 0.05). The oxidative glutathione disulfide (GSSG) level increased in the NAC group, however only at a trend level of significance (p = 0.09). There was no significant difference between the NAC and placebo groups in the GSH/GSSG ratio, DNA strand break and oxidative damage, and blood homocysteine levels at week 12 (ps > 0.16). Conclusions: The results of this trial indicate that NAC treatment was well tolerated, had the expected effect of boosting GSH production, but had no significant impact on social impairment in youth with ASD.;"[Wink, Logan K.; Adams, Ryan; Erickson, Craig A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4002, Cincinnati, OH 45229 USA; [Wang, Zemin; Klaunig, James E.] Indiana Univ, Sch Publ Hlth, Invest Toxicol & Pathol, Bloomington, IN USA; [Plawecki, Martin H.] Indiana Univ Sch Med, Dept Psychiat, Christian Sarkine Autism Treatment Ctr, Riley Hosp Children,Indiana Univ Hlth, Indianapolis, IN 46202 USA; [McDougle, Christopher J.] Massachusetts Gen Hosp, Dept Psychiat, Lurie Ctr Autism, Boston, MA 02114 USA; [McDougle, Christopher J.] Massachusetts Gen Hosp, Dept Pediat, Lurie Ctr Autism, Boston, MA 02114 USA; [McDougle, Christopher J.] Harvard Univ, Sch Med, MassGen Hosp Children, Boston, MA USA";"Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University Health; James Whitcomb Riley Hospital Children; IU Health University Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital";Erickson, CA (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4002, Cincinnati, OH 45229 USA.;Craig.erickson@cchmc.org;"Erickson, Craig/M-8933-2017; Klaunig, James/I-6177-2016; PLAWECKI, MARTIN/T-2467-2018";"PLAWECKI, MARTIN/0000-0003-0708-9514; Wang, Zemin/0000-0003-4189-578X; Klaunig, James/0000-0002-4736-2223";Autism Speaks Treatment Grant;Autism Speaks Treatment Grant;Autism Speaks Treatment Grant.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], PUBLICATION US DHEW; [Anonymous], DIAGN STAT MAN MEN D; Berk M, 2013, TRENDS PHARMACOL SCI, V34, P167, DOI 10.1016/j.tips.2013.01.001; Buxbaum JD, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-34; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Collins AR, 1997, MUTAT RES-FUND MOL M, V375, P183, DOI 10.1016/S0027-5107(97)00013-4; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Deepmala, 2015, NEUROSCI BIOBEHAV R, V55, P294, DOI 10.1016/j.neubiorev.2015.04.015; Erickson CA, 2008, GLUTAMATE NEUROPSYCH, P197; Ghanizadeh A, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-196; Ghanizadeh A, 2012, J RES MED SCI, V17, P985; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2009, FASEB J, V23, P2374, DOI 10.1096/fj.08-128926; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; KANNER L, 1968, ACTA PAEDOPSYCHIATR, V35, P100; Kern JK, 2006, J TOXICOL ENV HEAL B, V9, P485, DOI 10.1080/10937400600882079; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Marler S, 2014, J CHILD ADOL PSYCHOP, V24, P231, DOI 10.1089/cap.2013.0137; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Melnyk S, 2012, J AUTISM DEV DISORD, V42, P367, DOI 10.1007/s10803-011-1260-7; Muthen L., 1998, MPLUS USERS GUIDE; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Probst R, 1998, CLIN CHEM, V44, P1567; Reichow Brian, 2013, Evid Based Child Health, V8, P266, DOI 10.1002/ebch.1903; Roid G.H., 1997, LEITER INT PERFORMAN, DOI DOI 10.1037/T05120-000; Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; VESTER B, 1991, EUR J CLIN CHEM CLIN, V29, P549";34;68;69;0;12;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;APR 21;2016;7;;;;;;;;26;10.1186/s13229-016-0088-6;http://dx.doi.org/10.1186/s13229-016-0088-6;;;9;"Genetics & Heredity; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Genetics & Heredity; Neurosciences & Neurology";DJ8MG;27103982;gold, Green Published;;;24/11/2024;WOS:000374465800001;View Full Record in Web of Science
J;"Roke, Y; van Harten, PN; Franke, B; Galesloot, TE; Boot, AM; Buitelaar, JK";;;;"Roke, Yvette; van Harten, Peter N.; Franke, Barbara; Galesloot, Tessel E.; Boot, Annemieke M.; Buitelaar, Jan K.";;;The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys;PHARMACOGENETICS AND GENOMICS;;;English;Article;;;;;;"adolescents; genetics; prolactin; risperidone";"DISRUPTIVE BEHAVIOR DISORDER; AUTISM SPECTRUM DISORDERS; BONE-MINERAL DENSITY; INDUCED HYPERPROLACTINEMIA; ANTIPSYCHOTIC TREATMENT; CHILDREN; POLYMORPHISM; ASSOCIATION; 9-HYDROXYRISPERIDONE; PHARMACOKINETICS";Objective To investigate the effect of the Taq1A variant in the Dopamine D2 receptor gene (DRD2) and common functional genetic variants in the cytochrome P450 2D6 gene (CYP2D6) on prolactin levels in risperidone-treated boys with autism spectrum disorders and disruptive behavior disorders.Methods Forty-seven physically healthy 10-year-old to 19-year-old boys with autism spectrum disorders and/or disruptive behavior disorders, chronically treated (mean 52 months, range 16-126 months) with an antipsychotic, were recruited into this observational study. Prolactin levels, hyperprolactinemia, risperidone levels, and 9-hydroxyrisperidone levels were assessed and the participants were genotyped for common CYP2D6 polymorphisms and the Taq1A allele of the dopamine D2 receptor gene. Group differences were tested using Student's t-test, (2), and logistic regression analysis.Results Prolactin levels were associated positively and significantly with risperidone levels (P=0.05), 9-hydroxyrisperidone levels (P0.0001), and with the oral risperidone dose in milligrams per kilogram (P0.0001). Furthermore, multiple regression analysis showed no correlations between prolactin level and the presence of at least one Taq1A A1 allele of the DRD2 gene (P=0.12).Conclusion Although CYP2D6 might have an effect, the presence of at least one Taq1A A1 allele of the D2DR gene did not contribute toward susceptibility to risperidone-induced hyperprolactinemia, and as a result, toward prolactin-related adverse events such as amenorrhea, galactorrhea, and sexual dysfunctioning. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.;"[Roke, Yvette; van Harten, Peter N.] GGZ Cent Psychiat Ctr, NL-3818 EW Amersfoort, Netherlands; [van Harten, Peter N.] Maastricht Univ, Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Franke, Barbara] Radboud Univ Nijmegen, Dept Human Genet, Ctr Neurosci, Donders Inst Brain Cognit & Behav,Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Franke, Barbara] Radboud Univ Nijmegen, Dept Psychiat, Ctr Neurosci, Donders Inst Brain Cognit & Behav,Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Galesloot, Tessel E.] Radboud Univ Nijmegen, Dept Epidemiol Biostat & HTA, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Karakter Child & Adolescent Psychiat Univ Ctr, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Dept Cognit Neurosci, Donders Inst Brain Cognit & Behav, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Boot, Annemieke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Paediat, Div Paediat Endocrinol, Groningen, Netherlands";"Maastricht University; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; University of Groningen";Roke, Y (corresponding author), GGZ Cent Psychiat Ctr, Utrechteseweg 266, NL-3818 EW Amersfoort, Netherlands.;y.roke@ggzcentraal.nl;"Buitelaar, Jan/AAY-7522-2020; Galesloot, Tessel/P-6667-2015; Franke, Barbara/D-4836-2009";"Franke, Barbara/0000-0003-4375-6572; Boot, Annemieke/0000-0002-2426-3222";"Foundation De Open Ankh', Soesterberg, the Netherlands; Foundation to support VCVGZ', Arnhem, the Netherlands; Fund for Scientific Research of Sexuality', Amsterdam, the Netherlands";"Foundation De Open Ankh', Soesterberg, the Netherlands(Netherlands Government); Foundation to support VCVGZ', Arnhem, the Netherlands(Netherlands Government); Fund for Scientific Research of Sexuality', Amsterdam, the Netherlands(Netherlands Government)";"This study was funded by Foundation De Open Ankh', Soesterberg, the Netherlands; Foundation to support VCVGZ', Arnhem, the Netherlands; Fund for Scientific Research of Sexuality', Amsterdam, the Netherlands.";"Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; Anderson GM, 2007, BIOL PSYCHIAT, V61, P545, DOI 10.1016/j.biopsych.2006.02.032; Blaicher W, 1999, GYNECOL OBSTET INVES, V48, P179, DOI 10.1159/000010169; Bork JA, 1999, J CLIN PSYCHIAT, V60, P469, DOI 10.4088/JCP.v60n0709; Calarge CA, 2010, J CLIN PSYCHIAT, V71, P338, DOI 10.4088/JCP.08m04595gre; Calarge CA, 2009, PHARMACOGENET GENOM, V19, P373, DOI 10.1097/FPC.0b013e328329a60f; Calarge CA, 2011, J CHILD ADOL PSYCHOP, V21, P163, DOI 10.1089/cap.2010.0038; Coker F, 2010, CNS DRUGS, V24, P563, DOI 10.2165/11533140-000000000-00000; Correll CU, 2008, INT REV PSYCHIATR, V20, P195, DOI 10.1080/09540260801889179; Correll CU, 2008, J CLIN PSYCHIAT, V69, P26; de Leon J, 2005, J CLIN PSYCHIAT, V66, P15, DOI 10.4088/JCP.v66n0103; Emlinger M, 2002, CLIN CHEM LAB MED, V40, P1151; Fredriks AM, 2000, PEDIATR RES, V47, P316, DOI 10.1203/00006450-200003000-00006; Fredriks AM, 2000, ARCH DIS CHILD, V82, P107, DOI 10.1136/adc.82.2.107; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Halbreich U, 2003, PSYCHONEUROENDOCRINO, V28, P53, DOI 10.1016/S0306-4530(02)00112-9; Hendset M, 2009, J CLIN PSYCHOPHARM, V29, P537, DOI 10.1097/JCP.0b013e3181c17df0; Howard L, 2007, BRIT J PSYCHIAT, V190, P129, DOI 10.1192/bjp.bp.106.023671; Jönsson EG, 1999, SCHIZOPHR RES, V40, P31, DOI 10.1016/S0920-9964(99)00033-X; KEARNS GL, 1989, CLIN PHARMACOKINET, V17, P29, DOI 10.2165/00003088-198900171-00005; Knegtering R, 2005, AM J PSYCHIAT, V162, P1010, DOI 10.1176/appi.ajp.162.5.1010; Kuwabara H, 2012, J NUCL MED, V53, P805, DOI 10.2967/jnumed.111.098186; López-Rodríguez R, 2011, J CLIN PSYCHOPHARM, V31, P555, DOI 10.1097/JCP.0b013e31822cfff2; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McKenna TJ, 2009, CLIN ENDOCRINOL, V71, P466, DOI 10.1111/j.1365-2265.2009.03577.x; Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692; Menoyo A, 2006, CELL BIOCHEM FUNCT, V24, P381, DOI 10.1002/cbf.1258; Mihara K, 2001, AM J MED GENET, V105, P271, DOI 10.1002/ajmg.1303; Molitch ME, 2005, MAYO CLIN PROC, V80, P1050, DOI 10.4065/80.8.1050; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; Novalbos J, 2010, J CLIN PSYCHOPHARM, V30, P504, DOI 10.1097/JCP.0b013e3181ee84c7; Roke Y, 2012, J CHILD ADOL PSYCHOP, V22, P432, DOI 10.1089/cap.2011.0109; Roke Y, 2012, EUR J ENDOCRINOL, V167, P855, DOI 10.1530/EJE-12-0521; Roke Y, 2012, HORM RES PAEDIAT, V77, P235, DOI 10.1159/000337910; Sachse C, 1997, AM J HUM GENET, V60, P284; SEEMAN P, 1987, SYNAPSE, V1, P399, DOI 10.1002/syn.890010503; Staller J, 2006, J CHILD ADOL PSYCHOP, V16, P317, DOI 10.1089/cap.2006.16.317; Stigler KA, 2009, J CHILD ADOL PSYCHOP, V19, P265, DOI 10.1089/cap.2008.093; Thompson J, 1997, PHARMACOGENETICS, V7, P479, DOI 10.1097/00008571-199712000-00006; Troost PW, 2007, J CLIN PSYCHOPHARM, V27, P52, DOI 10.1097/JCP.0b013e31802e68d5; Verhelst Johan, 2003, Treat Endocrinol, V2, P23, DOI 10.2165/00024677-200302010-00003; Vitiello B, 2009, EUR NEUROPSYCHOPHARM, V19, P629, DOI 10.1016/j.euroneuro.2009.04.008; WEIZMAN R, 1987, LIFE SCI, V40, P2247, DOI 10.1016/0024-3205(87)90060-9; Wink LK, 2010, CURR TREAT OPTION NE, V12, P529, DOI 10.1007/s11940-010-0091-8; Yasui-Furukori N, 2008, PROG NEURO-PSYCHOPH, V32, P1491, DOI 10.1016/j.pnpbp.2008.05.006; Young RM, 2004, BRIT J PSYCHIAT, V185, P147, DOI 10.1192/bjp.185.2.147";46;35;37;0;13;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;1744-6872;1744-6880;;PHARMACOGENET GENOM;Pharmacogenet. Genomics;SEP;2013;23;9;;;;;487;493;;10.1097/FPC.0b013e3283647c33;http://dx.doi.org/10.1097/FPC.0b013e3283647c33;;;7;"Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);"Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy";202MG;23851570;;;;24/11/2024;WOS:000323220200005;View Full Record in Web of Science
J;"Hollander, E; Uzunova, G; Taylor, BP; Noone, R; Racine, E; Doernberg, E; Freeman, K; Ferretti, CJ";;;;"Hollander, Eric; Uzunova, Genoveva; Taylor, Bonnie P.; Noone, Rachel; Racine, Emma; Doernberg, Ellen; Freeman, Katherine; Ferretti, Casara Jean";;;Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder;WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY;;;English;Article;;;;;;"Autism spectrum disorder; pharmacotherapy; Trichuris suis ova; cytokines; repetitive behaviors";"MATERNAL IMMUNE ACTIVATION; BIOMARKERS; BRAIN; FEVER; CHILDREN; THERAPY; HYGIENE; SYSTEM; SCALE";Objectives: Inflammatory mechanisms are implicated in the aetiology of autism spectrum disorder (ASD), and use of the immunomodulator Trichuris suis Ova (TSO) is a novel treatment approach. This pilot study determined the effect sizes for TSO versus placebo on repetitive behaviours, irritability and global functioning in adults with ASD. Methods: A 28-week double-blind, randomised two-period crossover study of TSO versus placebo in ten ASD adults, aged 17-35, was completed, with a 4-week washout between each 12-week period at Montefiore Medical Center, Albert Einstein College of Medicine. Subjects with ASD, history of seasonal, medication or food allergies, Y-BOCS >= 6 and IQ >= 70 received 2,500 TSO ova or matching placebo every 2 weeks of each 12-week period. Results: Large effect sizes for improvement in repetitive behaviours (d = 1.0), restricted interests (d = 0.82), rigidity (d = 0.79) and irritability (d = 0.78) were observed after 12 weeks of treatment. No changes were observed in the social-communication domain. Differences between treatment groups did not reach statistical significance. TSO had only minimal, non-serious side effects. Conclusions: This proof-of-concept study demonstrates the feasibility of TSO for the treatment of ASD, including a favourable safety profile, and moderate to large effect sizes for reducing repetitive behaviours and irritability. Clinicaltrials.gov: NCT01040221;"[Hollander, Eric; Uzunova, Genoveva; Taylor, Bonnie P.; Noone, Rachel; Racine, Emma; Doernberg, Ellen; Ferretti, Casara Jean] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Autism & Obsess Compuls Spectrum Program, 111 East 210th St, Bronx, NY 10467 USA; [Hollander, Eric; Uzunova, Genoveva; Taylor, Bonnie P.; Noone, Rachel; Racine, Emma; Doernberg, Ellen; Ferretti, Casara Jean] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Anxiety & Depress Res Program, 111 East 210th St, Bronx, NY 10467 USA; [Freeman, Katherine] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA";"Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva University; Montefiore Medical Center; Albert Einstein College of Medicine; Yeshiva University; State University System of Florida; Florida Atlantic University";"Hollander, E (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Autism & Obsess Compuls Spectrum Program, 111 East 210th St, Bronx, NY 10467 USA.;Hollander, E (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Anxiety & Depress Res Program, 111 East 210th St, Bronx, NY 10467 USA.";eholland@montefiore.org;;;;;;"Anagnostou E, 2011, J NEUROPSYCH CLIN N, V23, P332, DOI 10.1176/appi.neuropsych.23.3.332; [Anonymous], CURRENT NEUROPHARMAC; Arrode-Brusés G, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-83; Bager P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022346; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Careaga M, 2017, BIOL PSYCHIAT, V81, P391, DOI 10.1016/j.biopsych.2016.10.020; Chen ZH, 2016, J NEUROCHEM, V136, P10, DOI 10.1111/jnc.13062; Choi GB, 2016, SCIENCE, V351, P933, DOI 10.1126/science.aad0314; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Foss-Feig JH, 2016, J AUTISM DEV DISORD, V46, P342, DOI 10.1007/s10803-015-2539-x; Frazier TW, 2014, AUTISM, V18, P31, DOI 10.1177/1362361313500382; Garud Sagar, 2009, Therap Adv Gastroenterol, V2, P99, DOI 10.1177/1756283X09102329; Jouvin MH, 2012, J ALLERGY CLIN IMMUN, V130, P3, DOI 10.1016/j.jaci.2012.05.028; Jyonouchi H, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0187-2; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Khan AR, 2013, INT J PARASITOL, V43, P293, DOI 10.1016/j.ijpara.2012.12.002; KIM SW, 1994, PSYCHIAT RES, V51, P203, DOI 10.1016/0165-1781(94)90039-6; Klaver EJ, 2013, INT J PARASITOL, V43, P191, DOI 10.1016/j.ijpara.2012.10.021; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Li XH, 2009, J NEUROIMMUNOL, V207, P111, DOI 10.1016/j.jneuroim.2008.12.002; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Masi A, 2017, NEUROSCI BULL, V33, P194, DOI 10.1007/s12264-017-0103-8; Mead J, 2015, IMMUNOL LETT, V163, P49, DOI 10.1016/j.imlet.2014.11.006; Megremi ASF, 2013, MED HYPOTHESES, V80, P391, DOI 10.1016/j.mehy.2013.01.007; Molloy CA, 2006, J NEUROIMMUNOL, V172, P198, DOI 10.1016/j.jneuroim.2005.11.007; Patel S, 2018, MOL PSYCHIATR, V23, P1794, DOI 10.1038/mp.2017.201; Rook GAW, 2015, BRAIN RES, V1617, P47, DOI 10.1016/j.brainres.2014.04.004; Rose D, 2014, BIOMARK MED, V8, P1171, DOI [10.2217/BMM.14.39, 10.2217/bmm.14.39]; Roth J, 2014, COMPR PHYSIOL, V4, P1563, DOI 10.1002/cphy.c130033; Sandborn WJ, 2013, ALIMENT PHARM THER, V38, P255, DOI 10.1111/apt.12366; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Suzuki K, 2013, JAMA PSYCHIAT, V70, P49, DOI 10.1001/jamapsychiatry.2013.272; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Voldsgaard A, 2015, MULT SCLER J, V21, P1723, DOI 10.1177/1352458514568173; Weinstock JV, 2013, INT J PARASITOL, V43, P245, DOI 10.1016/j.ijpara.2012.10.016; Wetie AGN, 2015, AUTISM RES, V8, P338, DOI 10.1002/aur.1450; Zwaigenbaum L, 2015, PEDIATRICS, V136, pS10, DOI 10.1542/peds.2014-3667C";38;11;13;0;2;TAYLOR & FRANCIS LTD;ABINGDON;2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND;1562-2975;1814-1412;;WORLD J BIOL PSYCHIA;World J. Biol. Psychiatry;APR 20;2020;21;4;;;;;291;299;;10.1080/15622975.2018.1523561;http://dx.doi.org/10.1080/15622975.2018.1523561;;;9;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;LU7FV;30230399;;;;24/11/2024;WOS:000537917700005;View Full Record in Web of Science
J;"Kara, ZP; Çakir, B; Durman, DK; Dogan, BSU";;;;"Kara, Zeliha Pala; Cakir, Busra; Durman, Deniz Kaleli; Dogan, B. Sonmez Uydes";;;The role of pharmacists in the management of autism spectrum disorder: A survey to determine the knowledge and perception of the parents;ISTANBUL JOURNAL OF PHARMACY;;;English;Article;;;;;;"Autism spectrum disorder; pharmacist role; pharmacological therapy; complemenatry and alternative medicine";"DISABILITIES MONITORING NETWORK; AGED 8 YEARS; UNITED-STATES; 11 SITES; CHILDREN; PREVALENCE; BEHAVIOR";Autism spectrum disorder (ASD) is one of the neuropsychiatric disorders of childhood and has many causes including genetic, neurobiological, environmental, as well as other risk factors that can trigger the disorder. The aim of this survey is to determine the knowledge of the families about ASD, the most prescribed medications, their side effects and the alternative therapies used besides to the pharmacological treatment. This study was survey-based and conducted among parents of children with ASD (N=50). Risperidone, aripiprazole, and valproate were the most prescripted drugs (64%) and weight gain (n=14), increased aggressive behavior (n=11) and drowsiness/sedation (n=11) were reported as the main side effects. Besides to pharmacological therapy, most of ASD children have used complementary and alternative medicine like gluten and casein-free diet (n =23) or the sugar diet (n=15), as well as omega-3 (n=43), multivitamins (n=40), heavy metal chelation agents (n=27), vitamin B12 (n=18), zinc (n=17) vitamin D (n=9), and probiotics (n= 7). It is revealed that pharmacists should be able to inform the parents about the general characteristics of ASD, and new treatment approaches, and provide a rational use of prescribed drugs in children with autism.;"[Kara, Zeliha Pala; Cakir, Busra; Durman, Deniz Kaleli; Dogan, B. Sonmez Uydes] Istanbul Univ, Fac Pharm, Dept Pharmacol, Istanbul, Turkey";Istanbul University;Kara, ZP (corresponding author), Istanbul Univ, Fac Pharm, Dept Pharmacol, Istanbul, Turkey.;zpala@istanbul.edu.tr;"Cakir, Banu/AAC-6603-2022; Kara, Zeliha/AAD-7791-2020; Durman, Deniz/AAD-4959-2020; CAKIR, BANU/I-9381-2013";CAKIR, BANU/0000-0001-6645-6527;;;;"Aman MG, 2008, CHILD ADOL PSYCH CL, V17, P713, DOI 10.1016/j.chc.2008.06.009; [Anonymous], 2018, AUTISM SPECTRUM DISO; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Baumer Nicole, 2018, Continuum (Minneap Minn), V24, P248, DOI 10.1212/CON.0000000000000578; BOLTON P, 1994, J CHILD PSYCHOL PSYC, V35, P877, DOI 10.1111/j.1469-7610.1994.tb02300.x; Breik N, 2018, J PHARM PHARM SCI, V21, p74S, DOI 10.18433/jpps29829; Cattane Nadia, 2020, Neurosci Biobehav Rev, V117, P253, DOI 10.1016/j.neubiorev.2018.07.001; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Davis TN, 2013, RES AUTISM SPECT DIS, V7, P49, DOI 10.1016/j.rasd.2012.06.005; DeFilippis Melissa, 2018, Psychopharmacol Bull, V48, P40; DiGuiseppi C, 2010, J DEV BEHAV PEDIATR, V31, P181, DOI 10.1097/DBP.0b013e3181d5aa6d; Gialloreti LE, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020217; Goel R, 2018, INT REV PSYCHIATR, V30, P78, DOI 10.1080/09540261.2018.1458706; Gyawali S, 2019, PSYCHIAT CLIN NEUROS, V73, P466, DOI 10.1111/pcn.12860; Hall SS, 2008, AM J MENT RETARD, V113, P44, DOI 10.1352/0895-8017(2008)113[44:CSAABI]2.0.CO;2; Hellings JA, 2005, J NEUROPSYCH CLIN N, V17, P29, DOI 10.1176/appi.neuropsych.17.1.29; Hoefer J, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2043-5; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; James S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010766.pub2; Kawicka Anna, 2013, Rocz Panstw Zakl Hig, V64, P1; Lovato DV, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00409; Luleci NE, 2016, INT J CLIN PHARM-NET, V38, P1477, DOI 10.1007/s11096-016-0394-2; Novaes CM, 2008, ARQ NEURO-PSIQUIAT, V66, P646, DOI 10.1590/S0004-282X2008000500008; Oshikoya KA, 2019, DRUGS-REAL WOR OUTC, V6, P59, DOI 10.1007/s40801-019-0151-7; Pelch KE, 2019, ENVIRON HEALTH PERSP, V127, DOI 10.1289/EHP4386; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; Shafiq S, 2018, EXPERT OPIN PHARMACO, V19, P1475, DOI 10.1080/14656566.2018.1509069; Sharma SR, 2018, PHARMACOL THERAPEUT, V190, P91, DOI 10.1016/j.pharmthera.2018.05.007; Tye C, 2019, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00751; Wink LK, 2017, J CHILD ADOL PSYCHOP, V27, P91, DOI 10.1089/cap.2015.0123; Wongpakaran R, 2017, J CLIN PHARM THER, V42, P329, DOI 10.1111/jcpt.12518";31;0;0;1;10;ISTANBUL UNIV, FAC PHARMACY;ISTANBUL;DEPT PHARMACEUTICAL TECHNOLOGY, ISTANBUL, 34116, TURKEY;;2587-2087;;ISTANB J PHARM;Istanb. J. Pharm.;DEC;2019;49;3;;;;;180;185;;10.26650/IstanbulJPharm.2019.19042;http://dx.doi.org/10.26650/IstanbulJPharm.2019.19042;;;6;Pharmacology & Pharmacy;Emerging Sources Citation Index (ESCI);Pharmacology & Pharmacy;KI1TD;;Green Submitted, hybrid;;;24/11/2024;WOS:000511129700011;View Full Record in Web of Science
J;"Bishop, JR; Najjar, F; Rubin, LH; Guter, SJ; Owley, T; Mosconi, MW; Jacob, S; Cook, EH";;;;"Bishop, Jeffrey R.; Najjar, Fedra; Rubin, Leah H.; Guter, Stephen J.; Owley, Thomas; Mosconi, Matthew W.; Jacob, Suma; Cook, Edwin H.";;;Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder;PHARMACOGENETICS AND GENOMICS;;;English;Article;;;;;;"autism spectrum disorder; CYP2C19; escitalopram";"PSYCHOTROPIC MEDICATION USE; CYP2C19-ASTERISK-17 ALLELE; REPETITIVE BEHAVIORS; DOUBLE-BLIND; CHILDREN; ADOLESCENTS; FLUOXETINE; CITALOPRAM; TRIAL; DRUG";Background and aimSelective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD.Participants and methodsParticipants completed the Aberrant Behavior Checklist - Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5mg per day, with weekly increases to 20mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose.ResultsABC-CV scores improved over the course of treatment (P<0.0001). No differences were identified in the rate of improvement across metabolizer groups for the ABC-CV irritability subscale, which was the primary outcome for clinical symptoms. There was a trend for a metabolizer group by time interaction with respect to dose (P=0.10). This interaction was driven by the linear rate of change from week 1 to study endpoint between the reduced metabolizers and ultrarapid metabolizer groups (P=0.05). Post-hoc analyses identified significant differences in the rate of dose escalation between ultrarapid metabolizers and extensive metabolizers and for ultrarapid metabolizers compared with reduced metabolizers (P's<0.04), whereby ultrarapid metabolizers showed a slower rate of change in dose over time.ConclusionCYP2C19 ultrarapid metabolizers were associated with reduced tolerance to a fixed titration schedule of open-label escitalopram in this ASD study sample. Possible explanations may involve the altered kinetics of faster metabolizers or previously unknown activities of escitalopram metabolites.;"[Bishop, Jeffrey R.] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA; [Jacob, Suma] Univ Minnesota, Coll Med, Dept Psychiat, Minneapolis, MN 55455 USA; [Najjar, Fedra; Rubin, Leah H.; Guter, Stephen J.; Owley, Thomas; Cook, Edwin H.] Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL USA; [Mosconi, Matthew W.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Mosconi, Matthew W.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA";"University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas";Bishop, JR (corresponding author), Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, 308 Harvard St SE,7-115 Weaver Densford Hall, Minneapolis, MN 55455 USA.;jrbishop@umn.edu;"Bishop, Jeffrey/K-6559-2015; Mosconi, Matt/L-1885-2018; Jacob, Suma/J-7941-2013";"Guter, Stephen/0000-0002-4476-2045; Jacob, Suma/0000-0001-7434-7398";"NICHD/NINDS/NIEHS [P50HD055751]; NIMH [P50MH094267, K08MH083888, K23092696, K01MH098798, K23MH082121, K01MH064539]";"NICHD/NINDS/NIEHS; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))";This work has been supported by NICHD/NINDS/NIEHS P50HD055751 (E.H.C.), NIMH P50MH094267 (E.H.C.), K08MH083888 (J.R.B.), K23092696 (M.W.M.), K01MH098798 (L.H.R.), K23MH082121 (S.J.), and K01MH064539 (T.O.).;"AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; [Anonymous], 2001, AUTISM DIAGNOSTIC OB; [Anonymous], 2000, Diagnostic and statistical manual of mental disorders, V4th; [Anonymous], 2006, Longitudinal Data Analysis; Chang M, 2014, CLIN PHARMACOKINET, V53, P801, DOI 10.1007/s40262-014-0162-1; COOK EH, 1992, J AM ACAD CHILD PSY, V31, P739, DOI 10.1097/00004583-199207000-00024; Drozda K, 2014, PHARMACOTHERAPY, V34, P166, DOI 10.1002/phar.1398; Dunn D. M., 2019, Peabody Picture Vocabulary Test, V5th; Dunn L. M., 2007, PEABODY PICTURE VOCA, DOI DOI 10.1037/T15144-000; Elliott C.D., 1990, Differential Abilities Scales administration and scoring manual; Elliott CD, 2007, DIFFERENTIAL ABILITI; Findling RL, 2006, J CHILD ADOL PSYCHOP, V16, P131, DOI 10.1089/cap.2006.16.131; Frazier TW, 2011, J CHILD ADOL PSYCHOP, V21, P571, DOI 10.1089/cap.2011.0057; Gabriele S, 2014, EUR NEUROPSYCHOPHARM, V24, P919, DOI 10.1016/j.euroneuro.2014.02.004; Hodgson K, 2014, J PSYCHOPHARMACOL, V28, P133, DOI 10.1177/0269881113512041; Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627; Hollander E, 2012, AM J PSYCHIAT, V169, P292, DOI 10.1176/appi.ajp.2011.10050764; Ji Y, 2014, BRIT J CLIN PHARMACO, V78, P373, DOI 10.1111/bcp.12348; Kaplan G, 2012, PEDIATR CLIN N AM, V59, P175, DOI 10.1016/j.pcl.2011.10.005; Kim KA, 2010, J CLIN PHARM THER, V35, P697, DOI 10.1111/j.1365-2710.2009.01069.x; King BH, 2013, JAMA PEDIATR, V167, P1045, DOI 10.1001/jamapediatrics.2013.2698; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Kodish I, 2011, PEDIATR CLIN N AM, V58, P55, DOI 10.1016/j.pcl.2010.10.002; Logan SL, 2012, ANN EPIDEMIOL, V22, P1, DOI 10.1016/j.annepidem.2011.10.007; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001; Mrazek DA, 2011, PHARMACOGENET GENOM, V21, P1, DOI 10.1097/FPC.0b013e328340bc5a; Mullen EM., 1995, MULLEN SCALES EARLY; Najjar F, 2015, J CHILD ADOL PSYCHOP, V25, P467, DOI 10.1089/cap.2014.0158; Owley T, 2005, J AM ACAD CHILD PSY, V44, P343, DOI 10.1097/01.chi.0000153229.80215.a0; Owley T, 2010, AUTISM RES, V3, P1, DOI 10.1002/aur.109; Rao N, 2007, CLIN PHARMACOKINET, V46, P281, DOI 10.2165/00003088-200746040-00002; Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e; Rosenberg RE, 2010, J AUTISM DEV DISORD, V40, P342, DOI 10.1007/s10803-009-0878-1; Rosenborg SO, 2008, EUR J CLIN PHARMACOL, V64, P1175, DOI 10.1007/s00228-008-0529-z; Rudberg I, 2008, CLIN PHARMACOL THER, V83, P322, DOI 10.1038/sj.clpt.6100291; Rutter M., 2003, SCQ SOCIAL COMMUNICA; Rutter M., 2012, AUTISM DIAGNOSTIC OB; Scott SA, 2012, PHARMACOGENET GENOM, V22, P159, DOI 10.1097/FPC.0b013e32834d4962; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); Wingate M, 2014, MMWR SURVEILL SUMM, V63";44;21;21;1;13;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;1744-6872;1744-6880;;PHARMACOGENET GENOM;Pharmacogenet. Genomics;NOV;2015;25;11;;;;;548;554;;10.1097/FPC.0000000000000173;http://dx.doi.org/10.1097/FPC.0000000000000173;;;7;"Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);"Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy";CU1RW;26313485;Green Accepted;;;24/11/2024;WOS:000363300000004;View Full Record in Web of Science
J;"Malow, BA; Katz, T; Reynolds, AM; Shui, A; Carno, M; Connolly, HV; Coury, D; Bennett, AE";;;;"Malow, Beth A.; Katz, Terry; Reynolds, Ann M.; Shui, Amy; Carno, Margaret; Connolly, Heidi V.; Coury, Daniel; Bennett, Amanda E.";;;Sleep Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study;PEDIATRICS;;;English;Article;;;;;;;"ABERRANT BEHAVIOR CHECKLIST; QUALITY-OF-LIFE; PEDIATRIC INSOMNIA; ADOLESCENTS; PREVALENCE; VALIDITY";"OBJECTIVES: Sleep difficulties are common in children with autism spectrum disorders, with wide-ranging effects on the child's daytime behavior. We reviewed data within our Autism Speaks Autism Treatment Network Registry to determine the prevalence of sleep difficulties and patterns of medication use. METHODS: Data from 1518 children ages 4 to 10 years were analyzed to determine the number of children documented to have sleep difficulties by parent-completed questionnaires and clinician-completed forms and how these findings related to the use of sleep medications. RESULTS: The Children's Sleep Habits Questionnaire total score was >= 41 (associated with clinically significant sleep problems in past research) in 71% of children. The prevalence of sleep diagnoses was less frequent (30% of children aged 4-10 years; P < .0001). Medications for sleep were prescribed in 46% of 4- to 10-year-olds given a sleep diagnosis. The most common medication used for sleep was melatonin followed by alpha-agonists, with a variety of other medications taken for sleep (anticonvulsants, antidepressants, atypical antipsychotics, and benzodiazepines). Children taking medications for sleep had worse daytime behavior and pediatric quality of life than children not taking sleep medications. CONCLUSIONS: Parent concerns about sleep may not be reflected in the information gathered during a clinic visit, supporting the need to develop screening practice pathways for sleep in autism spectrum disorders. Furthermore, many medications taken for sleep have adverse effects, supporting the need for evidence-based interventions in this population.";"[Malow, Beth A.] Vanderbilt Univ, Sch Med, Dept Neurol, Sleep Disorders Div, 221 Kirkland Hall, Nashville, TN 37235 USA; [Katz, Terry; Reynolds, Ann M.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Shui, Amy] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; [Carno, Margaret; Connolly, Heidi V.] Univ Rochester, Dept Pediat, Rochester, NY USA; [Coury, Daniel] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Bennett, Amanda E.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA";"Vanderbilt University; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Massachusetts General Hospital; University of Rochester; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia";Malow, BA (corresponding author), Vanderbilt Univ, Med Ctr, 1161 21st Ave South,Room A-0116, Nashville, TN 37232 USA.;beth.malow@vanderbilt.edu;"Coury, Daniel/L-6556-2019; Katz, Terry/ACU-0256-2022; Malow, Beth/KPA-4500-2024";"Malow, Beth/0000-0002-1624-7636; Katz, Terry/0000-0001-7953-2701; Reynolds, Ann/0000-0002-0836-746X; Coury, Daniel/0000-0001-9754-3914";US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program [UA3 MC11054];US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA));This Network activity was supported by Autism Speaks and cooperative agreement UA3 MC11054 through the US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program to the Massachusetts General Hospital. This work was conducted through the Autism Speaks Autism Treatment Network.;"Achenbach T.M., 2010, Manual for the ASEBA schoolage makes profiles; AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 2001, MANUAL ASEBA PRESCHO; Coury D, 2010, CURR OPIN NEUROL, V23, P131, DOI 10.1097/WCO.0b013e32833722fa; Couturier JL, 2005, J AM ACAD CHILD PSY, V44, P815, DOI 10.1097/01.chi.0000166377.22651.87; Delahaye J, 2014, RES AUTISM SPECT DIS, V8, P292, DOI 10.1016/j.rasd.2013.12.015; Goldman SE, 2012, J AUTISM DEV DISORD, V42, P531, DOI 10.1007/s10803-011-1270-5; Goldman SE, 2011, RES AUTISM SPECT DIS, V5, P1223, DOI 10.1016/j.rasd.2011.01.010; Goodlin-Jones BL, 2008, J AM ACAD CHILD PSY, V47, P930, DOI 10.1097/CHI.0b013e3181799f7c; Hill AP, 2014, RES AUTISM SPECT DIS, V8, P1121, DOI 10.1016/j.rasd.2014.05.006; Karabekiroglu K, 2009, CHILD PSYCHIAT HUM D, V40, P99, DOI 10.1007/s10578-008-0108-7; Krakowiak P, 2008, J SLEEP RES, V17, P197, DOI 10.1111/j.1365-2869.2008.00650.x; Malow BA, 2014, J AUTISM DEV DISORD, V44, P216, DOI 10.1007/s10803-013-1866-z; Malow BA, 2012, PEDIATRICS, V130, pS106, DOI 10.1542/peds.2012-0900I; Mazurek MO, 2015, SLEEP MED, V16, P270, DOI 10.1016/j.sleep.2014.11.006; Mazurek MO, 2013, RES AUTISM SPECT DIS, V7, P455, DOI 10.1016/j.rasd.2012.11.004; Mindell JA, 2006, PEDIATRICS, V117, pE1223, DOI 10.1542/peds.2005-1693; Owens JA, 2003, PEDIATRICS, V111, pE628, DOI 10.1542/peds.111.5.e628; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2005, J CLIN SLEEP MED, V1, P49; Reynolds AM, 2011, PEDIATR CLIN N AM, V58, P685, DOI 10.1016/j.pcl.2011.03.009; Rutter M., 2012, AUTISM DIAGNOSTIC OB; Sikora DM, 2012, PEDIATRICS, V130, pS83, DOI 10.1542/peds.2012-0900F; Souders MC, 2009, SLEEP, V32, P1566, DOI 10.1093/sleep/32.12.1566; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Vriend JL, 2011, J PEDIATR PSYCHOL, V36, P1017, DOI 10.1093/jpepsy/jsr044";26;76;93;1;26;AMER ACAD PEDIATRICS;ELK GROVE VILLAGE;141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA;0031-4005;1098-4275;;PEDIATRICS;Pediatrics;FEB;2016;137;;;2;;;S98;S104;;10.1542/peds.2015-2851H;http://dx.doi.org/10.1542/peds.2015-2851H;;;7;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;DF5LR;26908483;Bronze;;;24/11/2024;WOS:000371393700007;View Full Record in Web of Science
J;Shawahna, R;;;;Shawahna, Ramzi;;;Self-rated familiarity with autism spectrum disorders among practicing nurses: a cross-sectional study in the palestinian nursing practice;BMC NURSING;;;English;Article;;;;;;"Autism spectrum disorder; Familiarity; Knowledge; Nurses; Palestine";"KNOWLEDGE; CHILDREN; AWARENESS";Background Autism spectrum disorders (ASDs) are one of the most prevalent neurodevelopmental disabilities of early childhood. Practicing nurses are in a key position to help patients with ASDs and/or their caregivers/families. This study was conducted to assess self-rated familiarity with ASDs among practicing nurses in Palestine. The study also aimed to identify the sociodemographic and practice variables that could predict high self-rated familiarity scores. Methods This was a cross-sectional study using a questionnaire. The study was conducted in the period between January 2019 and May 2019. The questionnaire collected: 1) the sociodemographic, pedagogic, and practice variables of the nurses, 2) their self-rated familiarity with signs and symptoms, treatment options, and community resources of ASDs, 3) their self-rated confidence in their abilities to provide counseling for parents/family/caregivers on the drugs prescribed for children/patients with ASDs and their potential adverse effects, and 4) their willingness to receive education/training on issues in ASDs. Results The questionnaire was completed by 357 practicing nurses. The practicing nurses self-reported inadequate familiarity with symptoms, treatment, and community resources of ASDs. The mean familiarity score was 35.8% (SD: 18.9%). The nurses also expressed low confidence in their ability to provide counseling services to caregivers/families of children with ASDs. About 75% of the nurses agreed that they could benefit from taking a continuing educational/training program in the area of ASDs and about 82% of the nurses agreed that the nursing school curriculum should include courses in the area of ASDs. The multiple linear regression model showed that higher familiarity scores were predicted by having longer practical experience, having a higher academic degree in nursing, and having a continuing educational course/program on ASDs. Conclusion Findings of this study highlighted inadequate familiarity with issues of ASDs among practicing nurses. Higher familiarity was predicted by the length of practical experience, higher academic degree in nursing, and having continuing educational course/program on ASDs. Specifically designed pedagogic interventions might be helpful in increasing familiarity of practicing nurses on ASDs. More investigations are still needed to evaluate if these interventions can improve familiarity and services provided to patients with ASDs.;"[Shawahna, Ramzi] An Najah Natl Univ, Fac Med & Hlth Sci, Dept Physiol Pharmacol & Toxicol, New Campus,Bldg 19,Off 1340,POB 7, Nablus, Palestine; [Shawahna, Ramzi] An Najah Natl Univ, Ctr Poisons Control Chem & Biol Anal, An Najah BioSci Unit, Nablus, Palestine";"An Najah National University; An Najah National University";"Shawahna, R (corresponding author), An Najah Natl Univ, Fac Med & Hlth Sci, Dept Physiol Pharmacol & Toxicol, New Campus,Bldg 19,Off 1340,POB 7, Nablus, Palestine.;Shawahna, R (corresponding author), An Najah Natl Univ, Ctr Poisons Control Chem & Biol Anal, An Najah BioSci Unit, Nablus, Palestine.";ramzi_shawahna@hotmail.com;;;;;;"Ahmed FY, 2020, Egyptian Nursing Journal, V17, P117; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI DOI 10.1176/APPI.BOOKS.9780890425596.744053; [Anonymous], 2013, CHANGES PREVALENCE P; [Anonymous], 2008, CONCISE ENCY STAT, P95; Beauvois L, 2020, J PSYCHOSOC NURS MEN, V58, P7, DOI 10.3928/02793695-20201112-02; Bullock Linda F C, 2002, J Sch Nurs, V18, P360; Christensen DL., 2012, US MMWR SURVEILLANCE, V2016, P65; Chugani DC, 2016, J PEDIATR-US, V170, P45, DOI 10.1016/j.jpeds.2015.11.033; Corden K, 2022, REV J AUTISM DEV DIS, V9, P386, DOI 10.1007/s40489-021-00263-w; Daniel W., 1999, Biostatistics: a foundation for analysis in the health sciences, V7th; Daoud JI, 2018, J PHYS CONF SER, V949, DOI 10.1088/1742-6596/949/1/012009; Fealy GM, 2004, J ADV NURS, V46, P649, DOI 10.1111/j.1365-2648.2004.03056.x; Gardner MR, 2016, NURS EDUC, V41, P212, DOI 10.1097/NNE.0000000000000237; Gillespie-Lynch K, 2015, J AUTISM DEV DISORD, V45, P2553, DOI 10.1007/s10803-015-2422-9; GILLIAM JE, 1980, INT J NURS STUD, V17, P189, DOI 10.1016/0020-7489(80)90044-9; Griscti O, 2006, J ADV NURS, V55, P449, DOI 10.1111/j.1365-2648.2006.03940.x; Harrison AJ, 2017, AUTISM, V21, P262, DOI 10.1177/1362361316638786; Hayat AA, 2019, PAK J MED SCI, V35, P951, DOI 10.12669/pjms.35.4.605; House SA, 2016, J PEDIATR-US, V169, P277, DOI 10.1016/j.jpeds.2015.10.027; Iannuzzi D, 2019, J AUTISM DEV DISORD, V49, P1493, DOI 10.1007/s10803-018-3846-9; Igwe Monday N, 2011, Child Adolesc Psychiatry Ment Health, V5, P1, DOI 10.1186/1753-2000-5-1; Jordan S, 2002, J ADV NURS, V37, P155, DOI 10.1046/j.1365-2648.2002.02064.x; KANNER L, 1957, Psychiatr Res Rep Am Psychiatr Assoc, P55; Keklik D, 2021, PERSPECT PSYCHIATR C, V57, P1637, DOI 10.1111/ppc.12729; Khanna R, 2014, CURR PHARM TEACH LEA, V6, P150, DOI 10.1016/j.cptl.2013.09.010; Khanna R, 2012, RES SOC ADMIN PHARM, V8, P464, DOI 10.1016/j.sapharm.2011.11.002; Kim Hae-Young, 2013, Restor Dent Endod, V38, P52; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Mansour E, 2021, ONLINE INFORM REV, V45, P1189, DOI 10.1108/OIR-11-2020-0494; Matson JL, 2011, RES AUTISM SPECT DIS, V5, P230, DOI 10.1016/j.rasd.2010.04.004; Rice C, 2010, DISABIL HEALTH J, V3, P186, DOI 10.1016/j.dhjo.2009.10.008; Schwartz H, 2008, LANG SPEECH HEAR SER, V39, P66, DOI 10.1044/0161-1461(2008/007); Shawahna R, 2017, ENCY AUTISM SPECTRUM, P1; Shawahna R, 2021, BMC MED EDUC, V21, DOI 10.1186/s12909-021-02865-8; Shawahna R, 2017, J AUTISM DEV DISORD, V47, P1618, DOI 10.1007/s10803-017-3085-5; Strunk JA, 2009, J SCH NURS, V25, P445, DOI 10.1177/1059840509348221; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; Vohra Rini, 2016, Drugs Real World Outcomes, V3, P409; West S. G., 1995, STRUCTURAL EQUATION, P56, DOI DOI 10.1037/0008-400X.26.2.210; Wingate M, 2014, MMWR SURVEILL SUMM, V63";40;4;5;2;9;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;1472-6955;;;BMC NURS;BMC Nurs.;DEC 3;2021;20;1;;;;;;;241;10.1186/s12912-021-00764-3;http://dx.doi.org/10.1186/s12912-021-00764-3;;;11;Nursing;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Nursing;XI3UZ;34861861;gold, Green Published;;;24/11/2024;WOS:000726042300001;View Full Record in Web of Science
J;"Blank, E; Gilbert, DL; Wu, SW; Larsh, T; Elmaghraby, R; Liu, R; Smith, E; Westerkamp, G; Liu, YC; Horn, PS; Greenstein, E; Sweeney, JA; Erickson, CA; Pedapati, EV";;;;"Blank, Elizabeth; Gilbert, Donald L.; Wu, Steve W.; Larsh, Travis; Elmaghraby, Rana; Liu, Rui; Smith, Elizabeth; Westerkamp, Grace; Liu, Yanchen; Horn, Paul S.; Greenstein, Ethan; Sweeney, John A.; Erickson, Craig A.; Pedapati, Ernest V.";;;Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;"Article; Early Access";;;;;;"Autism; Depression; Fluid cognition; Transcranial Magnetic Stimulation; Brain Stimulation; Neuromodulation";"TREATMENT-RESISTANT DEPRESSION; MAJOR DEPRESSION; PLACEBO-RESPONSE; RANDOMIZED-TRIAL; METAANALYSIS; VALIDATION; RATIONALE; BEHAVIORS; INTERVIEW; HISTORY";Purpose Major depressive disorder (MDD) disproportionately affects those living with autism spectrum disorder (ASD) and is associated with significant impairment and treatment recidivism.Methods We studied the use of accelerated theta burst stimulation (ATBS) for the treatment of refractory MDD in ASD (3 treatments daily x 10 days). This prospective open-label 12-week trial included 10 subjects with a mean age of 21.5 years, randomized to receive unilateral or bilateral stimulation of the dorsolateral prefrontal cortex.Results One participant dropped out of the study due to intolerability. In both treatment arms, depressive symptoms, scored on the Hamilton Depression Rating Scale scores, diminished substantially. At 12 weeks post-treatment, full remission was sustained in 5 subjects and partial remission in 3 subjects. Treatment with ATBS, regardless of the site of stimulation, was associated with a significant, substantial, and sustained improvement in depressive symptomatology via the primary outcome measure, the Hamilton Depression Rating Scale. Additional secondary measures, including self-report depression scales, fluid cognition, and sleep quality, also showed significant improvement. No serious adverse events occurred during the study. Mild transient headaches were infrequently reported, which are expected side effects of ATBS.Conclusion Overall, ATBS treatment was highly effective and well-tolerated in individuals with ASD and co-occurring MDD. The findings support the need for a larger, sham-controlled randomized controlled trial to further evaluate efficacy of ATBS in this population.;"[Blank, Elizabeth; Elmaghraby, Rana; Liu, Rui; Westerkamp, Grace; Liu, Yanchen; Greenstein, Ethan; Erickson, Craig A.; Pedapati, Ernest V.] Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat, Cincinnati, OH 45229 USA; [Gilbert, Donald L.; Wu, Steve W.; Larsh, Travis; Horn, Paul S.; Pedapati, Ernest V.] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati 45229, OH USA; [Sweeney, John A.; Erickson, Craig A.; Pedapati, Ernest V.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA; [Smith, Elizabeth] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH USA";"Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center";"Pedapati, EV (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat, Cincinnati, OH 45229 USA.;Pedapati, EV (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati 45229, OH USA.;Pedapati, EV (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA.";ernest.pedapati@cchmc.org;"Gilbert, Donald/D-6443-2016; Horn, Paul/LPA-6457-2024; Liu, Rui/AAE-4571-2021";Liu, Rui/0000-0001-6602-808X;Cincinnati Children's Research Foundation;Cincinnati Children's Research Foundation;No Statement Available;"Abraham PF, 2008, J AFFECT DISORDERS, V111, P21, DOI 10.1016/j.jad.2008.01.024; Association A.P., 2013, DIAGNOSTIC STAT MANU, V5; Beam W, 2009, BRAIN STIMUL, V2, P50, DOI 10.1016/j.brs.2008.09.006; Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2; Blumberger DM, 2016, J PSYCHIATR NEUROSCI, V41, pE58, DOI 10.1503/jpn.150265; Blumberger DM, 2012, WORLD J BIOL PSYCHIA, V13, P423, DOI 10.3109/15622975.2011.579163; Brini S, 2023, CLIN PSYCHOL REV, V100, DOI 10.1016/j.cpr.2022.102236; Bruni TP, 2014, J PSYCHOEDUC ASSESS, V32, P365, DOI 10.1177/0734282913517525; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cai DB, 2023, ASIAN J PSYCHIATR, V85, DOI 10.1016/j.ajp.2023.103618; Cassidy S, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0226-4; Cassidy S, 2014, LANCET PSYCHIAT, V1, P142, DOI 10.1016/S2215-0366(14)70248-2; Chistyakov AV, 2015, J AFFECT DISORDERS, V170, P225, DOI 10.1016/j.jad.2014.08.035; Crane NA, 2017, BRAIN, V140, P472, DOI 10.1093/brain/aww326; de Boer NS, 2021, NEUROSCI BIOBEHAV R, V125, P122, DOI 10.1016/j.neubiorev.2021.01.013; Duprat R, 2016, J AFFECT DISORDERS, V200, P6, DOI 10.1016/j.jad.2016.04.015; Elmaghraby R, 2022, NEUROMODULATION, V25, P494, DOI 10.1111/ner.13455; FDA, 2011, Repetitive Transcranial Magnetic Stimulation (rTMS) Systems-Class II Special Controls Guidance for Industry and FDA Staff; Feroe AG, 2021, JAMA PEDIATR, V175, P957, DOI 10.1001/jamapediatrics.2021.1329; Fitzgerald PB, 2020, BRAIN STIMUL, V13, P137, DOI 10.1016/j.brs.2019.08.013; Fitzgerald PB, 2013, INT J NEUROPSYCHOPH, V16, P1975, DOI 10.1017/S1461145713000369; Fitzgerald PB, 2012, J AFFECT DISORDERS, V139, P193, DOI 10.1016/j.jad.2012.02.017; Gwynette MF, 2020, AUTISM RES, V13, P346, DOI 10.1002/aur.2266; Hirvikoski T, 2016, BRIT J PSYCHIAT, V208, P232, DOI 10.1192/bjp.bp.114.160192; Hollocks MJ, 2019, PSYCHOL MED, V49, P559, DOI 10.1017/S0033291718002283; Hong YJH, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00029; Horvath Jared C, 2010, J Vis Exp, DOI 10.3791/2345; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Huashuang Z, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.875591; Hudson CC, 2019, J ABNORM CHILD PSYCH, V47, P165, DOI 10.1007/s10802-018-0402-1; Kim NY, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00378; Kim TD, 2019, EXP NEUROBIOL, V28, P1, DOI 10.5607/en.2019.28.1.1; Lord C., 2012, AUTISM DIAGNOSTIC OB; Matson JL, 2007, RES DEV DISABIL, V28, P567, DOI 10.1016/j.ridd.2006.08.001; McCracken JT, 2021, EUR NEUROPSYCHOPHARM, V48, P3, DOI 10.1016/j.euroneuro.2021.05.010; Neuteboom D., 2023, Psychiatry Research; Oberman LM, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.642847; Osman A, 2004, PSYCHOL ASSESSMENT, V16, P120, DOI 10.1037/1040-3590.16.2.120; Osman A, 2001, ASSESSMENT, V8, P443, DOI 10.1177/107319110100800409; Pezzimenti F, 2019, CHILD ADOL PSYCH CL, V28, P397, DOI 10.1016/j.chc.2019.02.009; Posner K., 2008, COLUMBIA SUICIDE SEV; Razza LB, 2018, PROG NEURO-PSYCHOPH, V81, P105, DOI 10.1016/j.pnpbp.2017.10.016; Reuben DB, 2013, NEUROLOGY, V80, pS65, DOI 10.1212/WNL.0b013e3182872e01; Rosenberg RE, 2010, J AUTISM DEV DISORD, V40, P342, DOI 10.1007/s10803-009-0878-1; Rossi S, 2021, CLIN NEUROPHYSIOL, V132, P269, DOI 10.1016/j.clinph.2020.10.003; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Sackeim HA, 2019, J PSYCHIATR RES, V113, P125, DOI 10.1016/j.jpsychires.2019.03.021; Sandercock RK, 2020, AUTISM, V24, P2256, DOI 10.1177/1362361320942981; Sehatzadeh S, 2019, J PSYCHIATR NEUROSCI, V44, P151, DOI 10.1503/jpn.180056; Sharp R, 2015, OCCUP MED-OXFORD, V65, P340, DOI 10.1093/occmed/kqv043; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P34, DOI 10.4088/JCP.09m05305whi; Simard I, 2015, NEUROIMAGE-CLIN, V9, P467, DOI 10.1016/j.nicl.2015.09.007; Soulières I, 2009, HUM BRAIN MAPP, V30, P4082, DOI 10.1002/hbm.20831; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Trevizol AP, 2019, INT J GERIATR PSYCH, V34, P822, DOI 10.1002/gps.5091; Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Weissman CR, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.17m11692; Williams K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004677.pub3, 10.1002/14651858.CD007407.pub3]; Xu Y, 2023, Nat Mental Health, V10, P792, DOI [10.1038/s44220-023-00118-9, DOI 10.1038/S44220-023-00118-9]; Zemplényi A, 2022, BMC PSYCHIATRY, V22, DOI 10.1186/s12888-022-04078-9; Zheng ST, 2021, J AUTISM DEV DISORD, V51, P4488, DOI 10.1007/s10803-021-04885-1";66;0;0;1;1;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;2024 MAY 15;2024;;;;;;;;;;10.1007/s10803-024-06244-2;http://dx.doi.org/10.1007/s10803-024-06244-2;;MAY 2024;15;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;QQ6H0;38744742;hybrid;;;24/11/2024;WOS:001222368900002;View Full Record in Web of Science
J;"London, EB; Zimmerman-Bier, BL; Yoo, JH; Gaffney, JW";;;;"London, Eric B.; Zimmerman-Bier, Barbie L.; Yoo, J. Helen; Gaffney, Joseph W.";;;High-Dose Propranolol for Severe and Chronic Aggression in Autism Spectrum Disorder;JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"propranolol; aggression; autism; irritability; challenging behavior";"SELF-INJURIOUS-BEHAVIOR; INTELLECTUAL DISABILITIES; RUPP AUTISM; CHILDREN; PEOPLE; ADOLESCENTS; EXPENDITURES; RISPERIDONE; BLOCKERS; NETWORK";BackgroundDespite the use of behavioral interventions and psychotropic medications, many individuals with autism spectrum disorder (ASD) who engage in severe aggression remain refractory to conventional treatment. Propranolol, a beta-blocker, has accumulated much anecdotal evidence as a promising option. However, well-designed studies are rare, and the apprehension about cardiovascular side effects from large doses continues to exist.PurposeThe aims of this study were (1) to demonstrate the feasibility of treating aggression with high-dose propranolol using telehealth study visits and (2) to document cardiac safety.MethodsThis study utilized a randomized, double-blind, placebo-controlled, crossover design. Dosing was titrated up in a flexible but stepwise fashion until therapeutic response was obtained or up to 200 mg tid. Following washout, those who were assigned propranolol were crossed over to placebo and vice versa. Six participants between the ages 12-19 participated. The primary outcome measures were the final Clinical Global Impression Improvement Scale (CGI-I) and the Aberrant Behavior Checklist-Community Irritability (ABC-C/I) scores at 200 mg tid.ResultsThe CGI-I indicated a 50% reduction in symptoms in the propranolol phase, while the ABC-I indicated a 37% reduction in comparison to placebo. The effect sizes (r) for the CGI-I and the ABC-C/I were large, -0.74 and -0.64, respectively. The average blood pressure was 122/68 during the placebo phase and 109/72 during the propranolol phase. All Holter monitor exams were unremarkable.ConclusionThese results suggest that propranolol is an effective option in decreasing aggression in individuals with ASD. As this was a small study, a larger clinical trial is needed.;"[London, Eric B.; Yoo, J. Helen] New York State Inst Basic Res, Dept Psychol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA; [Zimmerman-Bier, Barbie L.; Gaffney, Joseph W.] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA; [Zimmerman-Bier, Barbie L.; Gaffney, Joseph W.] Rutgers State Univ, Childrens Hlth Inst, New Brunswick, NJ USA";"Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers University System; Rutgers University New Brunswick";London, EB (corresponding author), New York State Inst Basic Res, Dept Psychol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.;"naarlondon@gmail.com; zimmerba@rwjms.rutgers.edu; jhelenyoo@gmail.com; gaffnejw@rwjms.rutgers.edu";Yoo, Jiyeon/GOV-7096-2022;Yoo, Jiyeon/0000-0002-9794-853X;"New Jersey Governor's Council for Medical Research and Treatment of Autism, New Jersey Department of Health Grant [CAUT17APL025]; New York State Office for People with Developmental Disabilities";"New Jersey Governor's Council for Medical Research and Treatment of Autism, New Jersey Department of Health Grant; New York State Office for People with Developmental Disabilities";This study was funded by the New Jersey Governor's Council for Medical Research and Treatment of Autism, New Jersey Department of Health Grant # CAUT17APL025, and supported in part by the New York State Office for People with Developmental Disabilities. The authors have no relevant financial or nonfinancial interests to disclose.;"Adler BA, 2015, AUTISM, V19, P102, DOI 10.1177/1362361314524641; AMAN MG, 1995, AM J MENT RETARD, V100, P283; Arnold LE, 2003, J AM ACAD CHILD PSY, V42, P1443, DOI 10.1097/00004583-200312000-00011; Bachmann CJ, 2013, RES DEV DISABIL, V34, P2551, DOI 10.1016/j.ridd.2013.05.028; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Carroll D, 2014, CHILD ADOL PSYCH CL, V23, P57, DOI 10.1016/j.chc.2013.08.002; Cidav Z, 2013, J AUTISM DEV DISORD, V43, P924, DOI 10.1007/s10803-012-1637-2; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; DAWSON AK, 1984, J PHARMACOL EXP THER, V229, P91; Devilbiss DM, 2011, J NEUROPHYSIOL, V105, P69, DOI 10.1152/jn.00445.2010; Fish R, 2005, J INTELLECT DISABILI, V9, P93, DOI 10.1177/1744629505049726; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Guy W., 1976, ECDEU ASSESSMENT MAN; Haruvi-Lamdan N, 2020, AUTISM, V24, P884, DOI 10.1177/1362361320912143; Hawkins S, 2005, J APPL RES INTELLECT, V18, P19, DOI 10.1111/j.1468-3148.2004.00207.x; Hurlemann R, 2010, PSYCHOL MED, V40, P1839, DOI 10.1017/S0033291709992376; JENKINS SC, 1987, MAYO CLIN PROC, V62, P204, DOI 10.1016/S0025-6196(12)62444-6; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Laverty C, 2023, J INTELL DISABIL RES, V67, P295, DOI 10.1111/jir.13004; Laverty C, 2020, MOL AUTISM, V11, DOI 10.1186/s13229-019-0307-z; Lecavalier L, 2006, J INTELL DISABIL RES, V50, P172, DOI 10.1111/j.1365-2788.2005.00732.x; London EB, 2020, J CLIN PSYCHOPHARM, V40, P122, DOI 10.1097/JCP.0000000000001175; Mandell DS, 2008, J AUTISM DEV DISORD, V38, P1059, DOI 10.1007/s10803-007-0481-2; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Mandell DS, 2006, J AUTISM DEV DISORD, V36, P475, DOI 10.1007/s10803-006-0088-z; Matson JL, 2014, RES DEV DISABIL, V35, P3386, DOI 10.1016/j.ridd.2014.08.025; McDougle CJ, 2000, CHILD ADOL PSYCH CL, V9, P201; Myrbakk E, 2008, RES DEV DISABIL, V29, P316, DOI 10.1016/j.ridd.2007.06.002; Orsolini L, 2016, EXPERT OPIN DRUG SAF, V15, P1329, DOI 10.1080/14740338.2016.1201475; RATEY JJ, 1987, J CLIN PSYCHOPHARM, V7, P35; Ruedrich S, 1999, MENT RETARD DEV D R, V5, P290, DOI 10.1002/(SICI)1098-2779(1999)5:4<290::AID-MRDD6>3.3.CO;2-Y; Rumball F, 2021, RES DEV DISABIL, V110, DOI 10.1016/j.ridd.2020.103848; Sagar-Ouriaghli I, 2018, J PSYCHOPHARMACOL, V32, P641, DOI 10.1177/0269881118756245; Santos SL, 2021, BIOL PSYCHIAT, V89, P1150, DOI 10.1016/j.biopsych.2021.01.005; Scahill L, 2012, J AM ACAD CHILD PSY, V51, P136, DOI 10.1016/j.jaac.2011.11.010; Silver JM, 1999, J NEUROPSYCH CLIN N, V11, P328, DOI 10.1176/jnp.11.3.328; Van Schalkwyk GI, 2015, J AUTISM DEV DISORD, V45, P3061, DOI 10.1007/s10803-015-2471-0; Wang DW, 2010, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00144; Ward F, 2013, RES DEV DISABIL, V34, P4293, DOI 10.1016/j.ridd.2013.08.015; WILLIAMS DT, 1982, J AM ACAD CHILD PSY, V21, P129, DOI 10.1016/S0002-7138(09)60911-0";40;0;0;1;1;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0271-0749;1533-712X;;J CLIN PSYCHOPHARM;J. Clin. Psychopharmacol.;SEP-OCT;2024;44;5;;;;;462;467;;10.1097/JCP.0000000000001895;http://dx.doi.org/10.1097/JCP.0000000000001895;;;6;"Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pharmacology & Pharmacy; Psychiatry";E1E9M;39174017;hybrid;;;24/11/2024;WOS:001300519400011;View Full Record in Web of Science
J;"Dekker, V; Nauta, MH; Timmerman, ME; Mulder, EJ; van der Veen-Mulders, L; van den Hoofdakker, BJ; van Warners, S; Vet, LJJ; Hoekstra, PJ; de Bildt, A";;;;"Dekker, Vera; Nauta, Maaike H.; Timmerman, Marieke E.; Mulder, Erik J.; van der Veen-Mulders, Lianne; van den Hoofdakker, Barbara J.; van Warners, Sjoukje; Vet, Leonieke J. J.; Hoekstra, Pieter J.; de Bildt, Annelies";;;Social skills group training in children with autism spectrum disorder: a randomized controlled trial;EUROPEAN CHILD & ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"Social skills training; Effectiveness; Autism spectrum disorder; Randomized controlled trial";"HIGH-FUNCTIONING CHILDREN; INTERVENTIONS; ADOLESCENTS; PROGRAM; ASD";"In 122 high-functioning children with autism spectrum disorder (ASD; 9-13years; 19 girls), we investigated the effectiveness of a 15-session social skills group training (SST) with and without parent and teacher involvement (PTI) in a randomized controlled trial with three conditions: SST (n=47), SST-PTI (n=51), and care-as-usual (CAU, n=24). Hierarchical linear modeling was used for immediate and 6-month follow-up analyses. Measures were administered before randomization (blind), post-treatment and at follow-up (not blind). Trial registration: Dutch Trial Register; http://www.trialregister.nl; NTR2405. At post-treatment, children in both SSTs had improved significantly more than CAU on the primary outcome, Vineland Socialization (SST: Cohen's d=0.39; 95% CI -2.23 to 3.11 and SST-PTI: d=0.43; 95% CI -2.19 to 3.15) and on the secondary outcome parent-SSRS Cooperation (SST: d=0.43; 95% CI -0.23 to 1.15 and SST-PTI: d=0.45; 95% CI -0.21 to 1.17), with no difference between post-treatment and follow-up. Additionally, children in SST-PTI improved significantly more on the teacher-SSRS than in CAU [Cooperation d=0.42 (95% CI -0.33 to 1.13); Assertion d=0.34 (95% CI -0.39 to 1.11); Self-Control d=0.61 (95% CI -0.08 to 1.34)] and in SST [Cooperation d=0.34 (95% CI -0.37 to 1.05); Self-Control d=0.59 (95% CI -0.13 to 1.32)]. The current study corroborates earlier findings in smaller samples and wider age ranges, with small but statistically significant effects of SST for high-functioning pre-adolescent children with ASD. Parental and teacher involvement intensified treatment, yet did not yield an additional effect relative to SST for children only, as reported by parents. 6months after training, no further improvement or decline was found.";"[Dekker, Vera; van der Veen-Mulders, Lianne; van den Hoofdakker, Barbara J.; Vet, Leonieke J. J.; Hoekstra, Pieter J.; de Bildt, Annelies] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands; [Dekker, Vera; Nauta, Maaike H.; van der Veen-Mulders, Lianne; van den Hoofdakker, Barbara J.; van Warners, Sjoukje; Hoekstra, Pieter J.; de Bildt, Annelies] Univ Ctr Child & Adolescent Psychiat, Accare, POB 660, NL-9700 AR Groningen, Netherlands; [Nauta, Maaike H.; van den Hoofdakker, Barbara J.] Univ Groningen, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands; [Timmerman, Marieke E.] Univ Groningen, Dept Psychometr & Stat, Groningen, Netherlands; [Mulder, Erik J.] GGZ Drenthe, Ctr Intellectual Disabil & Psychiat, Assen, Netherlands";"University of Groningen; University of Groningen; University of Groningen; University of Groningen";"de Bildt, A (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands.;de Bildt, A (corresponding author), Univ Ctr Child & Adolescent Psychiat, Accare, POB 660, NL-9700 AR Groningen, Netherlands.";a.de.bildt@accare.nl;;Nauta, Maaike H./0000-0001-7694-1382;Netherlands Organization for Health Research and Development (ZonMw) [157003005];Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development);The Dutch manual is available upon request from the first author. This work was funded by the Netherlands Organization for Health Research and Development (ZonMw, nr 157003005). The authors gratefully acknowledge all children, parents, teachers, and therapists participating in this study.;"[Anonymous], J AUTISM DEV DISORD; [Anonymous], ADI R AUTISM DIAGNOS; [Anonymous], 2012, West. Psychol. Serv.; Barry TD, 2003, J AUTISM DEV DISORD, V33, P685, DOI 10.1023/B:JADD.0000006004.86556.e0; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Deckers A, 2016, J AUTISM DEV DISORD, V46, P3493, DOI 10.1007/s10803-016-2887-1; Dekker V, 2016, J AUTISM DEV DISORD, V46, P2890, DOI 10.1007/s10803-016-2829-y; Dekker V, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-189; Freitag CM, 2016, J CHILD PSYCHOL PSYC, V57, P596, DOI 10.1111/jcpp.12509; Gates JA, 2017, CLIN PSYCHOL REV, V52, P164, DOI 10.1016/j.cpr.2017.01.006; Gresham F. M., 1990, The Social Skills Rating System; Jonsson U, 2016, AUTISM, V20, P295, DOI 10.1177/1362361315583817; Koning C, 2013, RES AUTISM SPECT DIS, V7, P1282, DOI 10.1016/j.rasd.2011.07.011; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; McMahon CM, 2013, ADOLESC HEALTH MED T, V4, P23, DOI 10.2147/AHMT.S25402; Olsson NC, 2017, J AM ACAD CHILD PSY, V56, P585, DOI 10.1016/j.jaac.2017.05.001; Owens G, 2008, J AUTISM DEV DISORD, V38, P1944, DOI 10.1007/s10803-008-0590-6; Rao PA, 2008, J AUTISM DEV DISORD, V38, P353, DOI 10.1007/s10803-007-0402-4; Schulz KF, 2011, INT J SURG, V9, P672, DOI 10.1016/j.ijsu.2011.09.004; Soorya LV, 2015, J AM ACAD CHILD PSY, V54, P208, DOI 10.1016/j.jaac.2014.12.005; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Wechsler D., 1999, WECHSLER INTELLIGENC, V3rd; Yoo HJ, 2014, AUTISM RES, V7, P145, DOI 10.1002/aur.1354";23;27;30;2;29;SPRINGER;NEW YORK;ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES;1018-8827;1435-165X;;EUR CHILD ADOLES PSY;Eur. Child Adolesc. Psych.;MAR;2019;28;3;;;;;415;424;;10.1007/s00787-018-1205-1;http://dx.doi.org/10.1007/s00787-018-1205-1;;;10;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";HO7DE;30032394;hybrid, Green Published;;;24/11/2024;WOS:000461094500012;View Full Record in Web of Science
J;"Schroder, CM; Banaschewski, T; Fuentes, J; Hill, CM; Hvolby, A; Posserud, MB; Bruni, O";;;;"Schroder, Carmen M.; Banaschewski, Tobias; Fuentes, Joaquin; Hill, Catherine Mary; Hvolby, Allan; Posserud, Maj-Britt; Bruni, Oliviero";;;Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders;EXPERT OPINION ON PHARMACOTHERAPY;;;English;Article;;;;;;"Prolonged-release melatonin; insomnia; child; adolescent; autism spectrum disorder";"DAYTIME CHALLENGING BEHAVIOR; SMITH-MAGENIS-SYNDROME; QUALITY-OF-LIFE; SLEEP PROBLEMS; YOUNG-CHILDREN; PATTERNS; EFFICACY; ASSOCIATIONS; PRESCHOOL; SYMPTOMS";Introduction: Insomnia is common among children and adolescents with Autism spectrum disorder (ASD). The first drug licensed for insomnia in this population, a pediatric-appropriate prolonged-release melatonin (PedPRM) formulation is described. Areas covered: Literature search on PedPRM efficacy and safety profile in clinical trials, and a proposed decision-making algorithm to optimize outcome in the treatment of insomnia in children and adolescents with ASD. Expert opinion: PedPRM treatment effectively improves sleep onset, duration and consolidation, and daytime externalizing behaviors in children and adolescents with ASD and subsequently caregivers' quality of life and satisfaction with their children's sleep. The coated, odorless and taste-free mini-tablets are well-accepted in this population who often have sensory hypersensitivity and problems swallowing standard tablet preparations. The most frequent long-term treatment-related adverse events were fatigue (6.3%), somnolence (6.3%), and mood swings (4.2%) with no evidence of delay in height, BMI, or pubertal development, or withdrawal effects. The starting dose is 2 mg once daily independent of age or weight, escalated to 5-10 mg/day if predefined treatment success criteria are unmet. Slow melatonin metabolizers (similar to 10% of children), may require lower doses. Given its long-term efficacy, safety and acceptance, PedPRM may ameliorate long-term consequences of insomnia in this population.;"[Schroder, Carmen M.] Strasbourg Univ Hosp, Dept Child & Adolescent Psychiat, F-67000 Strasbourg, France; [Schroder, Carmen M.] Strasbourg Univ Hosp, Excellence Ctr Autism & Neurodev Disorders STRAS, F-67000 Strasbourg, France; [Schroder, Carmen M.] Univ Strasbourg, Med Sch, F-67000 Strasbourg, France; [Schroder, Carmen M.] CNRS, Inst Cellular & Integrat Neurosci, UPR 3212, Strasbourg, France; [Schroder, Carmen M.] Sleep Disorders Ctr, Strasbourg, France; [Schroder, Carmen M.] Int Res Ctr ChronoSomnol, Strasbourg, France; [Banaschewski, Tobias] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Child & Adolescent Psychiat & Psychotherapy, Mannheim, Germany; [Fuentes, Joaquin] Policlin Gipuzkoa, Child & Adolescent Psychiat Unit, Serv Child & Adolescent Psychiat, San Sebastian, Spain; [Fuentes, Joaquin] GAUTENA Autism Soc, San Sebastian, Spain; [Hill, Catherine Mary] Univ Southampton, Fac Med, Sch Clin Expt Sci, Southampton, Hants, England; [Hill, Catherine Mary] Southampton Childrens Hosp, Dept Sleep Med, Southampton, Hants, England; [Hvolby, Allan] Psychiat Reg South Denmark, Dept Child & Adolescent Psychiat, Esbjerg, Denmark; [Hvolby, Allan] Univ Southern Denmark, Dept Reg Hlth Res, Odense, Denmark; [Posserud, Maj-Britt] Univ Bergen, Fac Med, Dept Clin Med, Bergen, Norway; [Bruni, Oliviero] Sapienza Univ, Dept Dev & Social Psychol, Rome, Italy";"Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; CHU Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Central Institute of Mental Health; Ruprecht Karls University Heidelberg; University of Southampton; University of Southern Denmark; University of Bergen; Sapienza University Rome";Schroder, CM (corresponding author), Dept Child & Adolescent Psychiat, 1 Pl Hop, F-67091 Strasbourg, France.;schroderc@unistra.fr;"Banaschewski, Tobias/ABE-5985-2020; Posserud, Maj-Britt/K-4355-2017; Hvolby, Allan/ABB-5538-2020; Bruni, Oliviero/A-4029-2008";"Hvolby, Allan/0000-0003-3820-8918; Hill, Catherine/0000-0003-2372-5904; Bruni, Oliviero/0000-0003-2207-1398";;;;"Agostoni C, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1467; Allik H, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-1; ANDERS TF, 1992, PEDIATRICS, V90, P554; Andersen LPH, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0052-2; [Anonymous], 2007, E-Journal of Applied Psychology, DOI [10.7790/ejap.v3i1.82, DOI 10.7790/EJAP.V3I1.82]; [Anonymous], 2013, Autism Spectrum Disorder. Diagnostic and Statistical Manual of Mental Disorders, V5th; Bech P, 2003, INT J METH PSYCH RES, V12, P85, DOI 10.1002/mpr.145; Benabou M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18016-3; Braam W, 2010, J INTELL DISABIL RES, V54, P547, DOI 10.1111/j.1365-2788.2010.01283.x; Buckley AW, 2020, NEUROLOGY, V94, P392, DOI 10.1212/WNL.0000000000009033; Carnett A, 2020, DEV NEUROREHABIL, V23, P271, DOI 10.1080/17518423.2019.1646340; CDC, AUT DEV DIS MON ADDM; Chua HM, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010002; Cohen S, 2018, AUTISM RES, V11, P391, DOI 10.1002/aur.1899; Combs D, 2016, SCI REP-UK, V6, DOI 10.1038/srep27921; Cortesi F, 2012, J SLEEP RES, V21, P700, DOI 10.1111/j.1365-2869.2012.01021.x; Coury D., 2019, SLEEP PROBLEMS CHILD; Coury D., 2019, BEHAV ASS SLEEP DIST; Coury D., 2019, SENSITIVITY SOUNDS T; Cuomo BM, 2017, PHARMACOTHERAPY, V37, P555, DOI 10.1002/phar.1920; Dahl R E, 1996, Semin Pediatr Neurol, V3, P44, DOI 10.1016/S1071-9091(96)80028-3; Dahl RE, 2007, SLEEP, V30, P1079, DOI 10.1093/sleep/30.9.1079; Davis Katherine Finn, 2004, J Pediatr Health Care, V18, P65, DOI 10.1016/S0891-5245(03)00149-4; De Leersnyder H, 2006, TRENDS ENDOCRIN MET, V17, P291, DOI 10.1016/j.tem.2006.07.007; Delahaye J, 2014, RES AUTISM SPECT DIS, V8, P292, DOI 10.1016/j.rasd.2013.12.015; Devnani PA, 2015, J PEDIATR NEUROSCI, V10, P304, DOI 10.4103/1817-1745.174438; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; Doo S, 2006, DEV MED CHILD NEUROL, V48, P650, DOI 10.1017/S001216220600137X; Elrod MG, 2015, J DEV BEHAV PEDIATR, V36, P166, DOI 10.1097/DBP.0000000000000140; Fritz JA, 2003, J ORTHOP SPORT PHYS, V33, P163, DOI 10.2519/jospt.2003.33.4.163; Goldman SE, 2011, RES AUTISM SPECT DIS, V5, P1223, DOI 10.1016/j.rasd.2011.01.010; Goodman A, 2009, J AM ACAD CHILD PSY, V48, P400, DOI 10.1097/CHI.0b013e3181985068; Gordon N, 2000, BRAIN DEV-JPN, V22, P213, DOI 10.1016/S0387-7604(00)00120-0; Gringas P, 2017, J AM ACAD CHILD PSY, V56, P948, DOI 10.1016/j.jaac.2017.09.414; Gringras P, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6664; Gunes A, 2008, PHARMACOGENOMICS, V9, P625, DOI 10.2217/14622416.9.5.625; Henderson JA, 2011, RES AUTISM SPECT DIS, V5, P758, DOI 10.1016/j.rasd.2010.09.003; Hirshkowitz M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/j.sleh.2014.12.010; Hollway JA, 2011, RES DEV DISABIL, V32, P939, DOI 10.1016/j.ridd.2010.12.035; Honomichl RD, 2002, J AUTISM DEV DISORD, V32, P553, DOI 10.1023/A:1021254914276; Hunnphreys JS, 2014, ARCH DIS CHILD, V99, P114, DOI 10.1136/archdischild-2013-304083; Hunter JE, 2020, RES AUTISM SPECT DIS, V79, DOI 10.1016/j.rasd.2020.101677; Hvolby A, 2021, J SLEEP RES, V30, DOI 10.1111/jsr.13122; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447; Johnson CR, 2018, SLEEP MED, V44, P61, DOI 10.1016/j.sleep.2018.01.008; Kotagal S, 2012, PEDIATR NEUROL, V47, P242, DOI 10.1016/j.pediatrneurol.2012.05.007; Krakowiak P, 2008, J SLEEP RES, V17, P197, DOI 10.1111/j.1365-2869.2008.00650.x; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Lalanne S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031490; Leekam SR, 2007, J AUTISM DEV DISORD, V37, P894, DOI 10.1007/s10803-006-0218-7; Malow BA., 2019, ASS CHILD ADOLESCENT; Malow BA, 2021, J AM ACAD CHILD PSY, V60, P252, DOI 10.1016/j.jaac.2019.12.007; Malow BA, 2012, PEDIATRICS, V130, pS106, DOI 10.1542/peds.2012-0900I; Maras A, 2018, J CHILD ADOL PSYCHOP, V28, P699, DOI 10.1089/cap.2018.0020; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; Masters Alina, 2014, Brain Disord Ther, V4; May T, 2015, BEHAV SLEEP MED, V13, P2, DOI 10.1080/15402002.2013.829064; McConachie H, 2018, J AUTISM DEV DISORD, V48, P1596, DOI 10.1007/s10803-017-3402-z; McConachie H, 2018, J AUTISM DEV DISORD, V48, P1041, DOI 10.1007/s10803-017-3282-2; Meltzer LJ, 2006, PSYCHIAT CLIN N AM, V29, P1059, DOI 10.1016/j.psc.2006.08.004; MINDE K, 1994, J AM ACAD CHILD PSY, V33, P1114, DOI 10.1097/00004583-199410000-00007; Mindell JA, 2006, SLEEP, V29, P1263; Montgomery-Downs HE, 2006, PEDIATRICS, V117, P741, DOI 10.1542/peds.2005-1067; Nguyen AKD, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.16m11127; Owens JA, 2006, J CLIN SLEEP MED, V2, P77; Pisula E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186536; Reid GJ, 2009, J SLEEP RES, V18, P49, DOI 10.1111/j.1365-2869.2008.00692.x; Revicki DA, 1999, PHARMACOECONOMICS, V15, P423, DOI 10.2165/00019053-199915050-00001; Robinson AM, 2004, CHILD CARE HLTH DEV, V30, P139, DOI 10.1111/j.1365-2214.2004.00395.x; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Schroder CM, 2019, J AUTISM DEV DISORD, V49, P3218, DOI 10.1007/s10803-019-04046-5; Shelton AR, 2021, NEUROTHERAPEUTICS, V18, P156, DOI 10.1007/s13311-020-00982-8; Stormark KM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224139; Taira M, 1998, PSYCHIAT CLIN NEUROS, V52, P182, DOI 10.1111/j.1440-1819.1998.tb01018.x; Thomson SA, 2009, PEDIATRICS, V123, pE235, DOI 10.1542/peds.2008-2059; Tordjman S, 2005, BIOL PSYCHIAT, V57, P134, DOI 10.1016/j.biopsych.2004.11.003; Touchette É, 2005, ARCH PEDIAT ADOL MED, V159, P242, DOI 10.1001/archpedi.159.3.242; Touchette E, 2007, SLEEP, V30, P1213, DOI 10.1093/sleep/30.9.1213; Veatch OJ, 2015, J AUTISM DEV DISORD, V45, P100, DOI 10.1007/s10803-014-2197-4; WALDHAUSER F, 1984, NEUROENDOCRINOLOGY, V39, P307, DOI 10.1159/000123997; Wiggs L, 2001, BRIT J HEALTH PSYCH, V6, P257, DOI 10.1348/135910701169197; Williams PG, 2004, J SLEEP RES, V13, P265; Williams SR, 2012, AM J HUM GENET, V90, P941, DOI 10.1016/j.ajhg.2012.04.013; Yavuz-Kodat E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061978; Zisapel N, 2018, BRIT J PHARMACOL, V175, P3190, DOI 10.1111/bph.14116";85;19;19;2;16;TAYLOR & FRANCIS LTD;ABINGDON;2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND;1465-6566;1744-7666;;EXPERT OPIN PHARMACO;Expert Opin. Pharmacother.;DEC 12;2021;22;18;;;;;2445;2454;;10.1080/14656566.2021.1959549;http://dx.doi.org/10.1080/14656566.2021.1959549;;AUG 2021;10;Pharmacology & Pharmacy;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pharmacology & Pharmacy;XJ8TN;34314281;hybrid, Green Published;;;24/11/2024;WOS:000683191900001;View Full Record in Web of Science
J;"Sadeh, H; Meiri, G; Zigdon, D; Ilan, M; Faroy, M; Michaelovski, A; Sadaka, Y; Dinstein, I; Menashe, I";;;;"Sadeh, Hadar; Meiri, Gal; Zigdon, Dikla; Ilan, Michal; Faroy, Michal; Michaelovski, Analya; Sadaka, Yair; Dinstein, Ilan; Menashe, Idan";;;Adherence to treatment and parents' perspective about effectiveness of melatonin in children with autism spectrum disorder and sleep disturbances;CHILD AND ADOLESCENT PSYCHIATRY AND MENTAL HEALTH;;;English;Article;;;;;;"Autism spectrum disorder; Sleep; Insomnia; Drug effectiveness";"ADOLESCENTS; INSOMNIA; SAFETY";"Objective Melatonin is considered an effective pharmacological treatment for the sleep disturbances that are reported in > 50% of children with autism spectrum disorder (ASD). However, real-life data about the long-term course and effectiveness of melatonin treatment in children with ASD is lacking. Methods In this retrospective cohort study, we assessed the adherence to melatonin treatment and parents' perspective of its effect on sleep quality and daytime behavior in children with ASD via a parental phone survey of children in the Azrieli National Center for Autism and Neurodevelopment Research (ANCAN) database. Cox regression analysis was used to assess the effect of key demographic and clinical characteristics on treatment adherence. Results Melatonin was recommended for similar to 8% of children in the ANCAN database. These children were characterized by more severe symptoms of autism. The median adherence time for melatonin treatment exceeded 88 months, with the most common reason for discontinuation being a lack of effectiveness (14%). Mild side-effects were reported in 14% of children, and 86%, 54%, and 45% experienced improvements in sleep onset, sleep duration and night awakenings, respectively. Notably, melatonin also improved the daytime behaviors of > 28% of the children. Adherence to treatment was independently associated with improvements in night awakenings and educational functioning (aHR = 0.142, 95%CI = 0.036-0.565; and aHR = 0.195, 95%CI = 0.047-0.806, respectively). Conclusions Based on parents' report, melatonin is a safe and effective treatment that improves both sleep difficulties and daily behavior of children with ASD.";"[Sadeh, Hadar; Meiri, Gal; Zigdon, Dikla; Faroy, Michal] Soroka Univ Med Ctr, Presch Psychiat Unit, Beer Sheva, Israel; [Sadeh, Hadar; Meiri, Gal; Zigdon, Dikla; Ilan, Michal; Faroy, Michal; Michaelovski, Analya; Sadaka, Yair; Dinstein, Ilan; Menashe, Idan] Azrieli Natl Ctr Autism & Neurodev Res, Beer Sheva, Israel; [Michaelovski, Analya] Soroka Univ Med Ctr, Zusman Child Dev Ctr, Beer Sheva, Israel; [Sadaka, Yair] Minist Hlth, Child Dev Clin, Beer Sheva, Israel; [Dinstein, Ilan] Ben Gurion Univ Negev, Psychol & Brain & Cognit Dept, Beer Sheva, Israel; [Menashe, Idan] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Epidemiol Biostat & Community Hlth Sci, Beer Sheva, Israel";"Ben Gurion University; Soroka Medical Center; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Ben Gurion University";"Menashe, I (corresponding author), Azrieli Natl Ctr Autism & Neurodev Res, Beer Sheva, Israel.;Menashe, I (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Epidemiol Biostat & Community Hlth Sci, Beer Sheva, Israel.";idanmen@bgu.ac.il;"Dinstein, Ilan/L-3325-2016; Menashe, Idan/W-6214-2019";;We would like to thank the parents who participated in this study by answering our phone survey. We also thank Ms. Inez Mureinik for critical review of the manuscript.;We would like to thank the parents who participated in this study by answering our phone survey. We also thank Ms. Inez Mureinik for critical review of the manuscript.;We would like to thank the parents who participated in this study by answering our phone survey. We also thank Ms. Inez Mureinik for critical review of the manuscript.;"Abdulamir HA, 2016, SAUDI MED J, V37, P29, DOI 10.15537/smj.2016.1.13183; Arazi A, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e09681; Banaschewski T, 2022, J AUTISM DEV DISORD, V52, P3758, DOI 10.1007/s10803-021-05236-w; Bayley N., 2006, BAYLEY SCALES INFANT; Buckley AW, 2020, NEUROLOGY, V94, P392, DOI 10.1212/WNL.0000000000009033; Carr R, 2007, J PINEAL RES, V43, P351, DOI 10.1111/j.1600-079X.2007.00485.x; Chen HY, 2021, BMC PSYCHIATRY, V21, DOI 10.1186/s12888-021-03405-w; Cohen S, 2014, J NEURODEV DISORD, V6, DOI 10.1186/1866-1955-6-44; Cortese S, 2020, CNS DRUGS, V34, P415, DOI 10.1007/s40263-020-00710-y; Erland LAE, 2017, J CLIN SLEEP MED, V13, P275, DOI 10.5664/jcsm.6462; Esposito S, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1835-1; Gagnon K, 2018, Melatonin and comorbidities in children with Autism Spectrum Disorder, P197, DOI [10.1007/s40474-018-0147-0, DOI 10.1007/S40474-018-0147-0]; Goldscheider C., 1996, Israel's Changing Society: Population, Ethnicity and Development; Hoebert M, 2009, J PINEAL RES, V47, P1, DOI 10.1111/j.1600-079X.2009.00681.x; Hollway JA, 2011, RES DEV DISABIL, V32, P1399, DOI 10.1016/j.ridd.2011.04.001; Johnson KP, 2021, CHILD ADOL PSYCH CL, V30, P195, DOI 10.1016/j.chc.2020.08.012; Kennaway DJ, 2015, J PAEDIATR CHILD H, V51, P584, DOI 10.1111/jpc.12840; Lalanne S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031490; Lord C., 2012, AUTISM DIAGNOSTIC OB; Malow BA, 2021, J AM ACAD CHILD PSY, V60, P252, DOI 10.1016/j.jaac.2019.12.007; Malow BA, 2012, PEDIATRICS, V130, pS106, DOI 10.1542/peds.2012-0900I; Maras A, 2018, J CHILD ADOL PSYCHOP, V28, P699, DOI 10.1089/cap.2018.0020; Marvin AR, 2021, RES AUTISM SPECT DIS, V80, DOI 10.1016/j.rasd.2020.101699; Meiri G, 2018, J CHILD ADOL PSYCHOP, V28, P232, DOI 10.1089/cap.2017.0092; Meiri G, 2017, J AUTISM DEV DISORD, V47, P2918, DOI 10.1007/s10803-017-3207-0; Nogueira HA, 2023, PROG NEURO-PSYCHOPH, V123, DOI 10.1016/j.pnpbp.2022.110695; Oakland T., 2008, ABAS-II Clinical Use and Interpretation, DOI [10.1016/B978-0-12-373586-7.X0001-X, DOI 10.1016/B978-0-12-373586-7.X0001-X]; Owens JA, 2000, SLEEP, V23, P1043; Rasmussen L, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100339; Reiter RJ, 2014, PHYSIOLOGY, V29, P325, DOI 10.1152/physiol.00011.2014; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Schreck KA, 2004, RES DEV DISABIL, V25, P57, DOI 10.1016/j.ridd.2003.04.007; Schroder CM, 2021, EXPERT OPIN PHARMACO, V22, P2445, DOI 10.1080/14656566.2021.1959549; Schroder CM, 2019, J AUTISM DEV DISORD, V49, P3218, DOI 10.1007/s10803-019-04046-5; Semyonov M, 2011, SOC FORCES, V89, P935, DOI 10.1353/sof.2011.0006; Sivertsen B, 2012, AUTISM, V16, P139, DOI 10.1177/1362361311404255; Tordjman S, 2013, INT J MOL SCI, V14, P20508, DOI 10.3390/ijms141020508; Tordjman S, 2012, PSYCHONEUROENDOCRINO, V37, P1990, DOI 10.1016/j.psyneuen.2012.04.013; Tse ACY, 2020, AUTISM, V24, P2298, DOI 10.1177/1362361320936827; Wechsler D., 2002, Wechsler Preschool and Primary Scale of Intelligence; Williams PG, 2004, J SLEEP RES, V13, P265; Xiong M, 2023, NEUROPEDIATRICS, V54, P167, DOI 10.1055/s-0043-1761437; Zimmerman I.L., 2010, Preschool Language Scale, V5th";43;2;2;2;10;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1753-2000;;CHILD ADOL PSYCH MEN;Child Adolesc. Psychiatry Ment. Health;oct-27;2023;17;1;;;;;;;123;10.1186/s13034-023-00669-w;http://dx.doi.org/10.1186/s13034-023-00669-w;;;9;"Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Psychiatry";W9NS0;37891596;Green Published, gold;;;24/11/2024;WOS:001094829500002;View Full Record in Web of Science
J;"Zimmerman, AW; Singh, K; Connors, SL; Liu, H; Panjwani, AA; Lee, LC; Diggins, E; Foley, A; Melnyk, S; Singh, IN; James, SJ; Frye, RE; Fahey, JW";;;;"Zimmerman, Andrew W.; Singh, Kanwaljit; Connors, Susan L.; Liu, Hua; Panjwani, Anita A.; Lee, Li-Ching; Diggins, Eileen; Foley, Ann; Melnyk, Stepan; Singh, Indrapal N.; James, S. Jill; Frye, Richard E.; Fahey, Jed W.";;;Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder;MOLECULAR AUTISM;;;English;Article;;;;;;"Sulforaphane; Clinical trial; Autism spectrum disorder (ASD); Biomarkers; Placebo effects";"BIOMARKER; VALIDITY; PLASMA; NRF2; INDIVIDUALS; PATHWAY; SCORES; REDOX; GENE";"Background Sulforaphane (SF), an isothiocyanate in broccoli, has potential benefits relevant to autism spectrum disorder (ASD) through its effects on several metabolic and immunologic pathways. Previous clinical trials of oral SF demonstrated positive clinical effects on behavior in young men and changes in urinary metabolomics in children with ASD. Methods We conducted a 15-week randomized parallel double-blind placebo-controlled clinical trial with 15-week open-label treatment and 6-week no-treatment extensions in 57 children, ages 3-12 years, with ASD over 36 weeks. Twenty-eight were assigned SF and 29 received placebo (PL). Clinical effects, safety and tolerability of SF were measured as were biomarkers to elucidate mechanisms of action of SF in ASD. Results Data from 22 children taking SF and 23 on PL were analyzed. Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between SF and PL groups at 7 and 15 weeks. The effect sizes on the OACIS were non-statistically significant but positive, suggesting a possible trend toward greater improvement in those on treatment with SF (Cohen's d 0.21; 95% CI - 0.46, 0.88 and 0.10; 95% CI - 0.52, 0.72, respectively). Both groups improved in all subscales when on SF during the open-label phase. Caregiver ratings on secondary outcome measures improved significantly on the Aberrant Behavior Checklist (ABC) at 15 weeks (Cohen's d - 0.96; 95% CI - 1.73, - 0.15), but not on the Social Responsiveness Scale-2 (SRS-2). Ratings on the ABC and SRS-2 improved with a non-randomized analysis of the length of exposure to SF, compared to the pre-treatment baseline (p < 0.001). There were significant changes with SF compared to PL in biomarkers of glutathione redox status, mitochondrial respiration, inflammatory markers and heat shock proteins. Clinical laboratory studies confirmed product safety. SF was very well tolerated and side effects of treatment, none serious, included rare insomnia, irritability and intolerance of the taste and smell. Limitations The sample size was limited to 45 children with ASD and we did not impute missing data. We were unable to document significant changes in clinical assessments during clinical visits in those taking SF compared to PL. The clinical results were confounded by placebo effects during the open-label phase. Conclusions SF led to small yet non-statistically significant changes in the total and all subscale scores of the primary outcome measure, while for secondary outcome measures, caregivers' assessments of children taking SF showed statistically significant improvements compared to those taking PL on the ABC but not the SRS-2. Clinical effects of SF were less notable in children compared to our previous trial of a SF-rich preparation in young men with ASD. Several of the effects of SF on biomarkers correlated to clinical improvements. SF was very well tolerated and safe and effective based on our secondary clinical measures. Trial registration: This study was prospectively registered at clinicaltrials.gov (NCT02561481) on September 28, 2015. Funding was provided by the U.S. Department of Defense.";"[Zimmerman, Andrew W.; Singh, Kanwaljit; Connors, Susan L.; Diggins, Eileen; Foley, Ann] Univ Massachusetts, Dept Pediat Neurol & Psychiat, Med Sch, 55 N Lake Ave, Worcester, MA 01655 USA; [Liu, Hua; Fahey, Jed W.] Johns Hopkins Univ, Cullman Chemoprotect Ctr, Dept Pharmacol & Mol Sci, Sch Med, 725 N Wolfe St, Baltimore, MD 21205 USA; [Panjwani, Anita A.; Fahey, Jed W.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA; [Panjwani, Anita A.; Fahey, Jed W.] Johns Hopkins Univ, iMIND Hopkins, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA; [Panjwani, Anita A.] Purdue Univ, Dept Psychol Sci, 703 3rd St, W Lafayette, IN 47907 USA; [Lee, Li-Ching] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA; [Melnyk, Stepan; James, S. Jill] Univ Arkansas Med Sci, Dept Pediat, 4301 Markham St, Little Rock, AR 72205 USA; [Singh, Indrapal N.; Frye, Richard E.] Univ Arizona, Barrow Neurol Inst, Coll Med, Phoenix Childrens Hosp, 475 N 5th St, Phoenix, AZ 85004 USA; [Singh, Indrapal N.; Frye, Richard E.] Univ Arizona, Dept Child Hlth, Coll Med, 475 N 5th St, Phoenix, AZ 85004 USA; [Fahey, Jed W.] Johns Hopkins Univ, Dept Med, Div Clin Pharmacol, Sch Med, 600 N Wolfe St, Baltimore, MD 21287 USA";"University of Massachusetts System; University of Massachusetts Worcester; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Purdue University System; Purdue University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Arkansas System; University of Arkansas Medical Sciences; Phoenix Children's Hospital; University of Arizona; Barrow Neurological Institute; University of Arizona; Johns Hopkins University";Zimmerman, AW (corresponding author), Univ Massachusetts, Dept Pediat Neurol & Psychiat, Med Sch, 55 N Lake Ave, Worcester, MA 01655 USA.;Andrew.Zimmerman@umassmemorial.org;"Panjwani, Anita/AAX-3898-2021; Singh, Kanwaljit/B-2210-2016";Zimmerman, Andrew/0000-0001-6877-9338;U.S. Department of Defense, U.S. Army Medical Research and Materiel Command [AR140087, W81XWH-15-1-0156];U.S. Department of Defense, U.S. Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC));Funding for this research was provided by the U.S. Department of Defense, U.S. Army Medical Research and Materiel Command, AR140087 (Contract W81XWH-15-1-0156).;"Althouse AD, 2016, ANN THORAC SURG, V101, P1644, DOI 10.1016/j.athoracsur.2015.11.024; An JY, 2016, NEUROSCI BIOBEHAV R, V68, P442, DOI 10.1016/j.neubiorev.2016.06.013; [Anonymous], 2017, GLOB ADV HLTH MED, DOI DOI 10.1177/2164957X17735826; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003; Aslebagh R, 2019, P ASME C MASS SPECTR; Ballatori N, 2009, MOL ASPECTS MED, V30, P13, DOI 10.1016/j.mam.2008.08.004; Bent S, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0218-4; Butter E, 2006, 46 ANN N I MENT HLTH; Charman T, 2005, J CHILD PSYCHOL PSYC, V46, P500, DOI 10.1111/j.1469-7610.2004.00377.x; Chez MG, 2007, PEDIATR NEUROL, V36, P361, DOI 10.1016/j.pediatrneurol.2007.01.012; Choque Olsson N, 2014, J AUTISM DEV DISORD, V44, P1773, DOI 10.1007/s10803-013-2029-y; Curran LK, 2007, PEDIATRICS, V120, pE1386, DOI 10.1542/peds.2007-0360; Dinkova-Kostova AT, 2017, TRENDS FOOD SCI TECH, V69, P257, DOI 10.1016/j.tifs.2017.02.002; Efteltharian MM, 2018, CYTOKINE, V108, P120, DOI 10.1016/j.cyto.2018.03.034; Egner PA, 2011, CANCER PREV RES, V4, P384, DOI 10.1158/1940-6207.CAPR-10-0296; Fahey JW, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071489; Fahey JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140963; Frazier TW, 2014, AUTISM, V18, P31, DOI 10.1177/1362361313500382; FREEMAN BJ, 1988, J AM ACAD CHILD PSY, V27, P428, DOI 10.1097/00004583-198807000-00008; Gan NQ, 2010, J BIOL CHEM, V285, P35528, DOI 10.1074/jbc.M110.152686; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Holmstrom Kira M., 2016, Current Opinion in Toxicology, V1, P80, DOI 10.1016/j.cotox.2016.10.002; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jones RM, 2017, AUTISM RES, V10, P1567, DOI 10.1002/aur.1798; King BH, 2013, JAMA PEDIATR, V167, P1045, DOI 10.1001/jamapediatrics.2013.2698; Klomparens EA, 2019, BRAIN CIRC, V5, P74, DOI 10.4103/bc.bc_7_19; Lim JKM, 2019, P NATL ACAD SCI USA, V116, P9433, DOI 10.1073/pnas.1821323116; Liu H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62714-4; Liu H, 2016, CNS NEUROL DISORD-DR, V15, P602, DOI 10.2174/1871527315666160413120414; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARSHBURN EC, 1992, J AUTISM DEV DISORD, V22, P357, DOI 10.1007/BF01048240; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Melnyk S, 2012, J AUTISM DEV DISORD, V42, P367, DOI 10.1007/s10803-011-1260-7; Momtazmanesh S, 2020, PSYCHIAT CLIN NEUROS, V74, P398, DOI 10.1111/pcn.13016; Murias M, 2018, AUTISM RES, V11, P166, DOI 10.1002/aur.1894; Nadeem A, 2020, PSYCHONEUROENDOCRINO, V113, DOI 10.1016/j.psyneuen.2019.104554; Ness SL, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00111; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Pecorelli A, 2020, FASEB J, V34, P6521, DOI 10.1096/fj.201902677R; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Rose S, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.61; Rose S, 2018, MOL DIAGN THER, V22, P571, DOI 10.1007/s40291-018-0352-x; Rossignol DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00150; RUDY TE, 1992, J CRIT CARE, V7, P30, DOI 10.1016/0883-9441(92)90006-S; Singh K, 2020, ANN CLIN TRANSL NEUR, V7, P683, DOI 10.1002/acn3.51034; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Subramanian M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3339/fnins.2015.00373, 10.3389/fnins.2015.00313]; Tahata S, 2018, CANCER PREV RES, V11, P429, DOI 10.1158/1940-6207.CAPR-17-0268; Tsatsanis KD, 2003, J AUTISM DEV DISORD, V33, P23, DOI 10.1023/A:1022274219808; Valacchi G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00858; Wise RA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163716; Xie J, 2017, ONCOTARGET, V8, P82390, DOI 10.18632/oncotarget.19326; Yagishita Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24193593; Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6; Zhang LL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0692-2";57;39;42;1;13;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;MAY 25;2021;12;1;;;;;;;38;10.1186/s13229-021-00447-5;http://dx.doi.org/10.1186/s13229-021-00447-5;;;22;"Genetics & Heredity; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Genetics & Heredity; Neurosciences & Neurology";SH5PD;34034808;Green Published, gold;;;24/11/2024;WOS:000654187000001;View Full Record in Web of Science
J;"Bouhadoun, S; Poulin, C; Berrahmoune, S; Myers, KA";;;;"Bouhadoun, Sarah; Poulin, Chantal; Berrahmoune, Saoussen; Myers, Kenneth A.";;;A retrospective analysis of memantine use in a pediatric neurology clinic;BRAIN & DEVELOPMENT;;;English;Article;;;;;;"Memantine; N-methyl-D-aspartate receptor; Developmental and epileptic encephalopathy; Autistic spectrum disorder; Attention deficit hyperactivity disorder; GRIN2A";"DOUBLE-BLIND; RECEPTOR ANTAGONISTS; MEMORY DYSFUNCTION; CHILDREN; DISORDER; EFFICACY; MUTATION; THERAPY; SAFETY; TRIAL";Background: Memantine is an N-methyl-D-aspartate receptor (NMDA-R) antagonist, approved for dementia, but also studied in pediatric autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Methods: We reviewed children treated with memantine in a single-centre pediatric neurology clinic. Clinical data extracted included age, sex, weight, clinical history, reason for memantine prescription, period of treatment trial and dosage, treatment response, side effects, and concomitant medications. Results: Eight patients met inclusion criteria with diagnoses including developmental and epileptic encephalopathy, focal epilepsy, ASD, ADHD. Four reported clear cognitive improvement, though two of these started other concurrent treatments at the time of memantine initiation. One of three patients with poorly-controlled epilepsy, a girl with a GRIN2A variant of uncertain significance, had a clear reduction in seizure frequency. No serious adverse events were noted. Conclusions: Memantine is generally well-tolerated in children, and may have potential benefit for a broad range of pediatric neurodevelopmental disorders. (C) 2021 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.;"[Bouhadoun, Sarah] McGill Univ, Fac Med, Montreal, PQ, Canada; [Poulin, Chantal; Myers, Kenneth A.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Neurol,Dept Pediat, Montreal, PQ, Canada; [Berrahmoune, Saoussen; Myers, Kenneth A.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada; [Myers, Kenneth A.] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Neurol & Neurosurg, Montreal, PQ, Canada";"McGill University; McGill University; McGill University; McGill University";Myers, KA (corresponding author), McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Glen Site,1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.;kenneth.myers@mcgill.ca;;Myers, Kenneth/0000-0001-7831-4593;;;;"Aman MG, 2017, J CHILD ADOL PSYCHOP, V27, P403, DOI 10.1089/cap.2015.0146; Barnes CA, 1996, EUR J NEUROSCI, V8, P565, DOI 10.1111/j.1460-9568.1996.tb01241.x; BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; Chez MG, 2007, J CHILD NEUROL, V22, P574, DOI 10.1177/0883073807302611; Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9; Findling RL, 2007, J CHILD ADOL PSYCHOP, V17, P19, DOI 10.1089/cap.2006.0044; Ghaleiha A, 2013, INT J NEUROPSYCHOPH, V16, P783, DOI 10.1017/S1461145712000880; Hardan AY, 2019, AUTISM, V23, P2096, DOI 10.1177/1362361318824103; Kahlfuss S, 2014, MOL CELL BIOL, V34, P820, DOI 10.1128/MCB.01273-13; Karahmadi Mojgan, 2018, Adv Biomed Res, V7, P131, DOI 10.4103/abr.abr_100_18; KORNHUBER J, 1989, EUR J PHARMACOL, V166, P589, DOI 10.1016/0014-2999(89)90384-1; KORNHUBER J, 1994, J NEURAL TRANSM-SUPP, P91; Leeman-Markowski BA, 2018, EPILEPSY BEHAV, V88, P315, DOI 10.1016/j.yebeh.2018.06.047; Li D, 2016, AM J HUM GENET, V99, P802, DOI 10.1016/j.ajhg.2016.07.013; Marchezan J, 2018, NEUROIMMUNOMODULAT, V25, P300, DOI 10.1159/000492225; Marimuthu P, 2016, ANN INDIAN ACAD NEUR, V19, P344, DOI 10.4103/0972-2327.179971; MCLEAN MJ, 1987, POL J PHARMACOL PHAR, V39, P513; Myers KA, 2019, PEDIATR NEUROL, V91, P62, DOI 10.1016/j.pediatrneurol.2018.11.007; Owley T, 2006, J CHILD ADOL PSYCHOP, V16, P517, DOI 10.1089/cap.2006.16.517; Pierson TM, 2014, ANN CLIN TRANSL NEUR, V1, P190, DOI 10.1002/acn3.39; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Simma N, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0075-5; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Wu HM, 2009, NEUROPSYCHOPHARMACOL, V34, P2344, DOI 10.1038/npp.2009.64";24;9;9;0;1;ELSEVIER;AMSTERDAM;RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS;0387-7604;1872-7131;;BRAIN DEV-JPN;Brain Dev.;NOV;2021;43;10;;;;;997;1003;;10.1016/j.braindev.2021.05.012;http://dx.doi.org/10.1016/j.braindev.2021.05.012;;oct-21;7;"Clinical Neurology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics";WR6JU;34074563;;;;24/11/2024;WOS:000714604900003;View Full Record in Web of Science
J;"Liang, X; Haegele, JA; Tse, ACY; Li, MH; Zhang, H; Zhao, S; Li, SX";;;;"Liang, Xiao; Haegele, Justin A.; Tse, Andy Choi-Yeung; Li, Minghui; Zhang, Hui; Zhao, Shi; Li, Shirley Xin";;;The impact of the physical activity intervention on sleep in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis;SLEEP MEDICINE REVIEWS;;;English;Article;;;;;;"Autism spectrum disorders; Sleep; Physical activity interventions; Children and adolescents";"EXERCISE; QUALITY; 6-SULPHATOXYMELATONIN; BEHAVIORS; DISTURBANCES; MELATONIN; COGNITION; EXCRETION; HABITS";Pharmacological treatments (i.e., melatonin) and non-pharmacological therapies (e.g., parent-based sleep education programs and behavioural interventions) have been found to result in improved sleep in children and adolescents with autism spectrum disorder (ASD). However, there are several limitations to these treatment approaches, including concerns about the possible side-effects and safety, high-cost and uncertainties of longterm effects. Physical activity (PA) intervention is a promising behavioural intervention that has received increasing attention. However, the effects of PA intervention on sleep are still unclear in this clinical group. This study aimed to synthesize available empirical studies concerning the effects of PA interventions on sleep in children and adolescents with ASD. Following PRISMA guidelines, seven electronic databases: APA PsychInfo, CINAHL Ultimate, ERIC, MEDLINE, PubMed, SPORTDiscus, and Web of Science, were searched from inception to March 2023. Randomized controlled trials/quasi-experimental designs with comparison groups were included. Initially, 444 articles were identified, 13 articles underwent systematic review, and 8 studies with control groups and sufficient statistical data were selected for meta-analysis. Compared to no-treatment control groups, PA interventions had a large positive effect on parent-reported general sleep problems, night awakenings, sleep resistance, sleep duration and actigraphy-assessed sleep efficiency in children and adolescents with ASD.;"[Liang, Xiao; Zhang, Hui] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Peoples R China; [Haegele, Justin A.] Old Dominion Univ, Dept Human Movement Sci, Norfolk, VA USA; [Tse, Andy Choi-Yeung] Educ Univ Hong Kong, Dept Hlth & Phys Educ, Hong Kong, Peoples R China; [Li, Minghui] Ningbo Univ, Fac Sports Sci, Ningbo, Peoples R China; [Zhang, Hui] Hong Kong Polytech Univ, Res Inst Intelligent Wearable Syst, Hong Kong, Peoples R China; [Zhao, Shi] Tianjin Med Univ, Sch Publ Hlth, Tianjin, Peoples R China; [Zhao, Shi] Tianjin Med Univ, Tianjin Key Lab Environm Nutr & Publ Hlth, Tianjin, Peoples R China; [Zhao, Shi] Tianjin Med Univ, Key Lab Prevent & Control Major Dis Populat MoE, Tianjin, Peoples R China; [Li, Shirley Xin] Univ Hong Kong, Dept Psychol, Hong Kong, Peoples R China; [Li, Shirley Xin] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China; [Liang, Xiao] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China";"Hong Kong Polytechnic University; Old Dominion University; Education University of Hong Kong (EdUHK); Ningbo University; Hong Kong Polytechnic University; Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; University of Hong Kong; University of Hong Kong; Hong Kong Polytechnic University";Liang, X (corresponding author), Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China.;shawn.liang@polyu.edu.hk;"Li, Shirley/AAG-5497-2021; Tse, Andy/AAF-7431-2020; Zhang, Hui/HQZ-0850-2023; Zhao, Shi/AAW-6992-2021";"Zhao, Shi/0000-0001-8722-6149; Zhang, Hui/0000-0001-8313-0756; Liang, Xiao/0000-0002-9874-3376";;;;"AdibSaber F, 2021, J Child Mental Health, V7, P111, DOI [10.52547/jcmh.7.4.8, DOI 10.52547/JCMH.7.4.8]; Adkins KW, 2012, PEDIATRICS, V130, pS139, DOI 10.1542/peds.2012-0900K; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Amiri S, 2021, SLEEP MED, V84, P205, DOI 10.1016/j.sleep.2021.05.013; Ansari S, 2021, SLEEP MED, V82, P78, DOI 10.1016/j.sleep.2021.03.045; Antczak D, 2020, SLEEP MED REV, V51, DOI 10.1016/j.smrv.2020.101278; Babinska K, 2019, BRATISL MED J, V120, P849, DOI 10.4149/BLL_2019_141; Banno M, 2018, PEERJ, V6, DOI 10.7717/peerj.5172; Bello B, 2023, SLEEP BREATH, V27, P431, DOI 10.1007/s11325-022-02675-2; Bonardi JMT, 2016, SLEEP MED, V25, P122, DOI 10.1016/j.sleep.2016.06.025; Bourgeron T, 2007, COLD SPRING HARB SYM, V72, P645, DOI 10.1101/sqb.2007.72.020; Brand S, 2015, NEUROPSYCH DIS TREAT, V11, P1911, DOI 10.2147/NDT.S85650; Burman D, 2023, SLEEP VIGIL, V7, P9, DOI [10.1007/s41782-022- 00222- 3, DOI 10.1007/S41782-022-00222-3, 10.1007/s41782-022-00222-3]; Carlson LA, 2019, INT J SPORT PHYSIOL, V14, P351, DOI 10.1123/ijspp.2018-0073; Carnett A, 2021, J DEV PHYS DISABIL, V33, P977, DOI 10.1007/s10882-020-09783-5; Cortesi F, 2010, SLEEP MED, V11, P659, DOI 10.1016/j.sleep.2010.01.010; Cuomo BM, 2017, PHARMACOTHERAPY, V37, P555, DOI 10.1002/phar.1920; Deliens G, 2015, REV J AUTISM DEV DIS, V2, P343, DOI 10.1007/s40489-015-0057-6; Díaz-Román A, 2018, EVID-BASED MENT HEAL, V21, P146, DOI 10.1136/ebmental-2018-300037; Driver HS, 2000, SLEEP MED REV, V4, P387, DOI 10.1053/smrv.2000.0110; Drollette ES, 2014, DEV COGN NEUROS-NETH, V7, P53, DOI 10.1016/j.dcn.2013.11.001; Dworak M, 2008, SLEEP MED, V9, P266, DOI 10.1016/j.sleep.2007.04.017; Elrod MG, 2015, J DEV BEHAV PEDIATR, V36, P166, DOI 10.1097/DBP.0000000000000140; Erickson KI, 2019, MED SCI SPORT EXER, V51, P1242, DOI 10.1249/MSS.0000000000001936; Gehricke JG, 2022, RES AUTISM SPECT DIS, V97, DOI 10.1016/j.rasd.2022.102005; Geoffray M-M, 2016, J Physiol Paris, V110, P434, DOI 10.1016/j.jphysparis.2017.06.002; Gevi F, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0109-5; Glavin EE, 2021, J HEALTH PSYCHOL, V26, P2636, DOI 10.1177/1359105320926530; Healy S, 2018, AUTISM RES, V11, P818, DOI 10.1002/aur.1955; Hedges LV., 2014, STAT METHODS META AN; Herbert R, 1998, Health Inf Manag, V28, P186; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kamp-Becker I, 2018, EUR CHILD ADOLES PSY, V27, P1193, DOI 10.1007/s00787-018-1143-y; Keogh S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221428; Khazaie H, 2023, CURR PSYCHOL, V42, P28846, DOI 10.1007/s12144-022-03810-8; Kirkpatrick B, 2019, SLEEP MED, V53, P141, DOI 10.1016/j.sleep.2018.08.034; Kredlow MA, 2015, J BEHAV MED, V38, P427, DOI 10.1007/s10865-015-9617-6; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Lawson LM, 2022, THER RECREAT J, V56, P487, DOI 10.18666/TRJ-2022-V56-I4-11554; Lawson LM, 2017, THER RECREAT J, V51, P97, DOI 10.18666/TRJ-2017-V51-I2-7899; Liang X, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.36129; Liang X, 2023, PSYCHIAT RES, V328, DOI 10.1016/j.psychres.2023.115447; Liang X, 2022, SPORTS MED, V52, P75, DOI 10.1007/s40279-021-01545-3; Liang X, 2021, INT J BEHAV NUTR PHY, V18, DOI 10.1186/s12966-021-01135-6; Liang X, 2020, PREV MED REP, V19, DOI 10.1016/j.pmedr.2020.101147; Magnusson J.E., 2012, J Exerc Physiol, V15, P71; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Melke J, 2008, MOL PSYCHIATR, V13, P90, DOI 10.1038/sj.mp.4002016; Moon EC, 2011, J PEDIATR PSYCHOL, V36, P47, DOI 10.1093/jpepsy/jsq057; Narasingharao K, 2017, J CLIN DIAGN RES, V11, pVC1, DOI 10.7860/JCDR/2017/25894.9502; Nogueira HA, 2023, PROG NEURO-PSYCHOPH, V123, DOI 10.1016/j.pnpbp.2022.110695; Oriel KN, 2016, FOCUS AUTISM DEV DIS, V31, P254, DOI 10.1177/1088357614559212; Orwin RG., 1994, Evaluating coding decisions; Owens JA, 2000, SLEEP, V23, P1043; Page MJ, 2021, INT J SURG, V88, DOI [10.1016/j.jclinepi.2021.02.003, 10.1016/j.ijsu.2021.105906, 10.1186/s13643-021-01626-4]; Pan CY, 2011, RES AUTISM SPECT DIS, V5, P733, DOI 10.1016/j.rasd.2010.08.007; Pobocik K., 2020, Int J Sports Exerc Med, V6, P161, DOI [10.23937/2469-5718/1510161, DOI 10.23937/2469-5718/1510161]; Richdale AL, 2009, SLEEP MED REV, V13, P403, DOI 10.1016/j.smrv.2009.02.003; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Roth K, 2015, MED SCI SPORT EXER, V47, P2542, DOI 10.1249/MSS.0000000000000703; Sherrington C, 2010, BRIT J SPORT MED, V44, P836, DOI 10.1136/bjsm.2009.066357; Souders MC, 2009, SLEEP, V32, P1566, DOI 10.1093/sleep/32.12.1566; Tanksale R, 2021, AUTISM, V25, P995, DOI 10.1177/1362361320974841; Tordjman S, 2005, BIOL PSYCHIAT, V57, P134, DOI 10.1016/j.biopsych.2004.11.003; Tordjman S, 2012, PSYCHONEUROENDOCRINO, V37, P1990, DOI 10.1016/j.psyneuen.2012.04.013; Toscano CVA, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.1027799; Tremblay MS, 2020, CAN MED ASSOC J, V192, pE1728, DOI 10.1503/cmaj.202345; Tse ACY, 2022, AUTISM, V26, P1712, DOI 10.1177/13623613211062952; Tse CYA, 2019, AUTISM, V23, P1699, DOI 10.1177/1362361318823910; Wachob D, 2015, J AUTISM DEV DISORD, V45, P2641, DOI 10.1007/s10803-015-2424-7; Wang WL, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02566-4; Wiggins LD, 2019, SOC PSYCH PSYCH EPID, V54, P693, DOI 10.1007/s00127-019-01674-1; Wiggs L, 2004, DEV MED CHILD NEUROL, V46, P372; Yavuz-Kodat E, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00551; Zeidan J, 2022, AUTISM RES, V15, P778, DOI 10.1002/aur.2696; ,, 2010, Global recommendations on physical activity for health";76;2;2;22;33;W B SAUNDERS CO LTD;LONDON;32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND;1087-0792;1532-2955;;SLEEP MED REV;Sleep Med. Rev.;APR;2024;74;;;;;;;;101913;10.1016/j.smrv.2024.101913;http://dx.doi.org/10.1016/j.smrv.2024.101913;;mars-24;12;"Clinical Neurology; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;QP8U3;38442500;;;;24/11/2024;WOS:001222173300001;View Full Record in Web of Science
J;"Chugani, DC; Chugani, HT; Wiznitzer, M; Parikh, S; Evans, PA; Hansen, RL; Nass, R; Janisse, JJ; Dixon-Thomas, P; Behen, M; Rothermel, R; Parker, JS; Kumar, A; Muzik, O; Edwards, DJ; Hirtz, D";;;;"Chugani, Diane C.; Chugani, Harry T.; Wiznitzer, Max; Parikh, Sumit; Evans, Patricia A.; Hansen, Robin L.; Nass, Ruth; Janisse, James J.; Dixon-Thomas, Pamela; Behen, Michael; Rothermel, Robert; Parker, Jacqueline S.; Kumar, Ajay; Muzik, Otto; Edwards, David J.; Hirtz, Deborah";;Autism Ctr Excellence Network;Efficacy of Low-Dose Buspirone for Restricted and Repetitive Behavior in Young Children with Autism Spectrum Disorder: A Randomized Trial;JOURNAL OF PEDIATRICS;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; BRAIN-SEROTONIN SYNTHESIS; BLOOD SEROTONIN; 5-HT1A RECEPTOR; MICROGLIAL ACTIVATION; LOCOMOTOR-ACTIVITY; DORSAL RAPHE; MOUSE; ANXIETY; RAT";"Objectives To determine safety and efficacy of the 5HT1A serotonin partial agonist buspirone on core autism and associated features in children with autism spectrum disorder (ASD). Study design Children 2-6 years of age with ASD (N=166) were randomized to receive placebo or 2.5 or 5.0 mg of buspirone twice daily. The primary objective was to evaluate the effects of 24 weeks of buspirone on the Autism Diagnostic Observation Schedule (ADOS) Composite Total Score. Secondary objectives included evaluating the effects of buspirone on social competence, repetitive behaviors, language, sensory dysfunction, and anxiety and to assess side effects. Positron emission tomography measures of tryptophan metabolism and blood serotonin concentrations were assessed as predictors of buspirone efficacy. Results There was no difference in the ADOS Composite Total Score between baseline and 24 weeks among the 3 treatment groups (P=.400); however, the ADOS Restricted and Repetitive Behavior score showed a time-by-treatment effect (P=.006); the 2.5-mg buspirone group showed significant improvement (P=.003), whereas placebo and 5.0-mg buspirone groups showed no change. Children in the 2.5-mg buspirone group were more likely to improve if they had fewer foci of increased brain tryptophan metabolism on positron emission tomography (P=.018) or if they showed normal levels of blood serotonin (P=.044). Adverse events did not differ significantly among treatment groups. Conclusions Treatment with 2.5 mg of buspirone in young children with ASD might be a useful adjunct therapy to target restrictive and repetitive behaviors in conjunction with behavioral interventions.";"[Chugani, Diane C.; Chugani, Harry T.; Dixon-Thomas, Pamela; Behen, Michael; Parker, Jacqueline S.; Kumar, Ajay; Muzik, Otto] Wayne State Univ, Sch Med, Carman & Ann Adams Dept Pediat, Detroit, MI USA; [Chugani, Diane C.; Chugani, Harry T.; Behen, Michael; Parker, Jacqueline S.; Kumar, Ajay; Muzik, Otto] Childrens Hosp Michigan, Detroit, MI USA; [Chugani, Harry T.; Kumar, Ajay; Muzik, Otto] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI USA; [Wiznitzer, Max] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Neurosci Inst, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Parikh, Sumit] Case Western Reserve Univ, Cleveland Clin Neurogenet & Metab, Neurosci Inst, Lerner Coll Med, Cleveland, OH 44106 USA; [Evans, Patricia A.] Univ Texas SW Med Ctr Dallas, Childrens Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Evans, Patricia A.] Univ Texas SW Med Ctr Dallas, Childrens Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Hansen, Robin L.] Univ Calif Davis, Med Invest Neurodeve Disorders MIND Inst, Dept Pediat, Davis, CA 95616 USA; [Nass, Ruth] NYU, Langone Med Ctr, Dept Neurol, New York, NY USA; [Nass, Ruth] NYU, Langone Med Ctr, Dept Child & Adolescent Psychiat, New York, NY USA; [Janisse, James J.] Wayne State Univ, Sch Med, Dept Med & Publ Hlth Sci, Detroit, MI USA; [Rothermel, Robert] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Kumar, Ajay; Muzik, Otto] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA; [Edwards, David J.] Univ Waterloo, Sch Pharm, Waterloo, ON N2L 3G1, Canada; [Hirtz, Deborah] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA";"Wayne State University; Children's Hospital of Michigan; Wayne State University; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Ohio; Case Western Reserve University; Case Western Reserve University Hospital; University System of Ohio; Case Western Reserve University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Davis; NYU Langone Medical Center; New York University; New York University; NYU Langone Medical Center; Wayne State University; Wayne State University; Wayne State University; University of Waterloo; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)";Chugani, DC (corresponding author), Nemours Al DuPont Hosp Children, 1600 Rockland Rd,ARB 291, Wilmington, DE 19803 USA.;Diane.Chugani@nemours.org;;Golla, Sailaja/0000-0003-1411-7608;National Institute of Neurological Disorders and Stroke [5U01 NS61264];National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS));Supported by the National Institute of Neurological Disorders and Stroke (cooperative agreement 5U01 NS61264). The authors declare no conflicts of interest.;"AMAN MG, 1995, AM J MENT RETARD, V100, P283; AMAN MG, 1985, AM J MENT DEF, V89, P485; ANDERSON GM, 1987, J CHILD PSYCHOL PSYC, V28, P885, DOI 10.1111/j.1469-7610.1987.tb00677.x; [Anonymous], ADI R AUTISM DIAGNOS; [Anonymous], 1997, Leiter International Performance Scale-Revised (Leiter-R); Batista CEA, 2009, MOL IMAGING BIOL, V11, P460, DOI 10.1007/s11307-009-0225-0; BLIER P, 1993, J PHARMACOL EXP THER, V265, P7; Bodfish J.W., 1999, W CAROLINA CTR RES R; Bromley RL, 2013, J NEUROL NEUROSUR PS, V84, P637, DOI 10.1136/jnnp-2012-304270; Buitelaar JK, 1998, J CLIN PSYCHIAT, V59, P56, DOI 10.4088/JCP.v59n0203; Canal CE, 2015, ACS CHEM NEUROSCI, V6, P1259, DOI 10.1021/acschemneuro.5b00099; Carey RJ, 2004, PSYCHOPHARMACOLOGY, V177, P46, DOI 10.1007/s00213-004-1917-4; Carey RJ, 2004, BRAIN RES, V1019, P134, DOI 10.1016/j.brainres.2004.05.091; Chawarska K, 2009, J CHILD PSYCHOL PSYC, V50, P1235, DOI 10.1111/j.1469-7610.2009.02101.x; CHEN NH, 1995, J NEUROCHEM, V64, P1585; Christensen J, 2013, JAMA-J AM MED ASSOC, V309, P1696, DOI 10.1001/jama.2013.2270; Chugani DC, 2000, J CEREBR BLOOD F MET, V20, P2, DOI 10.1097/00004647-200001000-00002; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Chugani DC, 1997, ANN NEUROL, V42, P666, DOI 10.1002/ana.410420420; Cook E H Jr, 1990, J Neuropsychiatry Clin Neurosci, V2, P268; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; Dunn W, 1999, SENSORY PROFILE EXAM; Edwards DJ, 2006, J CLIN PHARMACOL, V46, P508, DOI 10.1177/0091270006286903; Elliott CD., 2007, DIFFERENTIAL ABILITY, V2nd; Gabriele S, 2014, EUR NEUROPSYCHOPHARM, V24, P919, DOI 10.1016/j.euroneuro.2014.02.004; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; Gotham K, 2013, AUTISM RES, V6, P33, DOI 10.1002/aur.1263; Gould GG, 2011, J NEUROCHEM, V116, P291, DOI 10.1111/j.1471-4159.2010.07104.x; GOZLAN H, 1983, NATURE, V305, P140, DOI 10.1038/305140a0; Guthrie W, 2013, J CHILD PSYCHOL PSYC, V54, P582, DOI 10.1111/jcpp.12008; HOSHINO Y, 1984, NEUROPSYCHOBIOLOGY, V11, P22, DOI 10.1159/000118045; Ide S, 2005, NEUROSCI LETT, V386, P14, DOI 10.1016/j.neulet.2005.05.056; Ikram H, 2011, PHARMACOL BIOCHEM BE, V99, P444, DOI 10.1016/j.pbb.2011.04.007; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lin HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055248; Lord C, 2006, ARCH GEN PSYCHIAT, V63, P694, DOI 10.1001/archpsyc.63.6.694; Lord C., 1999, MANUAL AUTISM DIAGNO; McCormick LH, 1997, ARCH FAM MED, V6, P368, DOI 10.1001/archfami.6.4.368; Mignon L, 2002, PSYCHOPHARMACOLOGY, V163, P85, DOI 10.1007/s00213-002-1121-3; Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010; Morgan JT, 2010, BIOL PSYCHIAT, V68, P368, DOI 10.1016/j.biopsych.2010.05.024; Mullen EM., 1995, MULLEN SCALES EARLY; Muzik O, 1997, J CEREBR BLOOD F MET, V17, P659; PEROUTKA SJ, 1985, BIOL PSYCHIAT, V20, P971, DOI 10.1016/0006-3223(85)90194-5; Pinto D, 2014, AM J HUM GENET, V94, P677, DOI 10.1016/j.ajhg.2014.03.018; POMPEIANO M, 1992, J NEUROSCI, V12, P440; REALMUTO GM, 1989, J CLIN PSYCHOPHARM, V9, P122, DOI 10.1097/00004714-198904000-00009; Rodgers J, 2012, J AUTISM DEV DISORD, V42, P2404, DOI 10.1007/s10803-012-1531-y; Samaco RC, 2009, P NATL ACAD SCI USA, V106, P21966, DOI 10.1073/pnas.0912257106; Scahill L, 2006, J AM ACAD CHILD PSY, V45, P1114, DOI 10.1097/01.chi.0000220854.79144.e7; SCHAIN RJ, 1961, J PEDIATR-US, V58, P315, DOI 10.1016/S0022-3476(61)80261-8; Shireen Erum, 2005, J Coll Physicians Surg Pak, V15, P753; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; SPROUSE JS, 1988, NEUROPHARMACOLOGY, V27, P707, DOI 10.1016/0028-3908(88)90079-2; Suzuki K, 2013, JAMA PSYCHIAT, V70, P49, DOI 10.1001/jamapsychiatry.2013.272; Tamada K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015126; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Veenstra-VanderWeele J, 2012, NEUROPSYCHOPHARMACOL, V37, P196, DOI 10.1038/npp.2011.185; VERGE D, 1986, J NEUROSCI, V6, P3474; White SW, 2009, CLIN PSYCHOL REV, V29, P216, DOI 10.1016/j.cpr.2009.01.003; Winter C, 2008, EUR NEUROPSYCHOPHARM, V18, P712, DOI 10.1016/j.euroneuro.2008.06.001; ZOGHBI HY, 1989, ANN NEUROL, V25, P56, DOI 10.1002/ana.410250109";63;53;62;0;13;MOSBY-ELSEVIER;NEW YORK;360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA;0022-3476;1097-6833;;J PEDIATR-US;J. Pediatr.;MAR;2016;170;;;;;;45;+;;10.1016/j.jpeds.2015.11.033;http://dx.doi.org/10.1016/j.jpeds.2015.11.033;;;13;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;DE7MH;26746121;hybrid;;;24/11/2024;WOS:000370820500013;View Full Record in Web of Science
J;"Vo, LC; Snyder, C; McCracken, C; McDougle, CJ; McCracken, JT; Aman, MG; Tierney, E; Arnold, LE; Levi, D; Kelleman, M; Carroll, D; Morrissey, J; Vitiello, B; Scahill, L";;;;"Vo, Lan Chi; Snyder, Christopher; McCracken, Courtney; McDougle, Christopher J.; McCracken, James T.; Aman, Michael G.; Tierney, Elaine; Arnold, L. Eugene; Levi, Daniel; Kelleman, Michael; Carroll, Deirdre; Morrissey, John; Vitiello, Benedetto; Scahill, Lawrence";;;No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"risperidone; electrocardiogram; QTc; autism spectrum disorder; cardiac conduction";"ABERRANT BEHAVIOR CHECKLIST; QT INTERVAL; ANTIPSYCHOTIC TREATMENT; ADOLESCENTS; RISK; DRUG; ARIPIPRAZOLE; MEDICATIONS; SAFETY";"Objectives: Risperidone is approved for the treatment of serious behavioral problems in children with autism spectrum disorder (ASD). This study examined the effects of risperidone on cardiac conduction in children with ASD. Methods: Data were collected from an 8-week, five-site trial conducted by the Research Units on Pediatric Psychopharmacology Autism Network. Children (age 5-17 years) were randomly assigned to risperidone (n = 49) or placebo (n = 52) under double-blind conditions. Risperidone was superior to placebo in reducing serious behavioral problems. A standard 12-lead, electrocardiogram (ECG) was obtained in most subjects at screening and week 8. A pediatric electrophysiologist blind to treatment assignment reviewed all available ECGs for readability, abnormalities, and cardiac conduction parameters, including QTc. The electrophysiologist measurements were compared to machine readings. A second blinded electrophysiologist examined all available ECGs for abnormalities and a 20% random sample for QTc. Results: Of the 101 randomized subjects in the trial, complete pretreatment and week 8 data were available on 65 subjects (placebo n = 30; risperidone n = 35). The electrophysiologist did not identify any cardiac conduction adverse effects of risperidone and there was no difference in mean change on the QTc compared to placebo. The Bland-Altman plot showed a systematic bias in QTc measurements by the electrophysiologist and machine. Machine readings produced higher values than the electrophysiologist for shorter QTc intervals and machine scoring was lower than electrophysiologist readings for longer QTc values (p = 0.001). Two electrophysiologists had overall percent agreements of 82.9% (95% CI: 76.3 to 89.6) on qualitative assessment and 88.6% (95% CI: 79.3 to 98.0) on QTc interval. Conclusion: Using conventional doses during acute treatment in children with ASD and serious behavioral problems, there was no difference in the mean change in QTc between risperidone and placebo. Compared to the electrophysiologist, the machine readings may miss elevated QTc measurements.";"[Vo, Lan Chi] Emory Univ, Sch Med, Dept Psychiat, Atlanta, GA 30322 USA; [Snyder, Christopher] Rainbow Babies & Childrens Hosp, Div Pediat Cardiol, Univ Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [McCracken, Courtney; Kelleman, Michael] Childrens Hosp Atlanta, Atlanta, GA USA; [McCracken, Courtney; Kelleman, Michael] Emory Univ, Sch Med, Atlanta, GA USA; [McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Lurie Ctr Autism, Boston, MA USA; [McCracken, James T.] Univ Calif Los Angeles, Div Child Psychiat, Los Angeles, CA USA; [Aman, Michael G.; Arnold, L. Eugene] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [Tierney, Elaine] Kennedy Krieger Inst, Baltimore, MD USA; [Levi, Daniel; Morrissey, John] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA; [Carroll, Deirdre] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA; [Vitiello, Benedetto] NIMH, Bethesda, MD 20892 USA; [Scahill, Lawrence] Emory Univ, Sch Med, Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA";"Emory University; University System of Ohio; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Emory University; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California Los Angeles; University System of Ohio; Ohio State University; Kennedy Krieger Institute; University of California System; University of California Los Angeles; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Emory University";Scahill, L (corresponding author), Emory Univ, Sch Med, Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA.;lawrence.scahill@emory.edu;Vitiello, Benedetto/AAC-1758-2022;;"National Institute of Mental Health [N01MH70009, N01MH70010, N01MH70001, N01MH80011, R25MH101079]; National Institutes of Health [M01 RR00750, M01 RR00052, M01 RR00034, M01 RR06022]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1 TR000454]; Marcus Foundation; Children's Hospital Trust Fund";"National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Marcus Foundation; Children's Hospital Trust Fund";"Supported by contracts from the National Institute of Mental Health (N01MH70009, to Dr. Scahill; N01MH70010, to Dr. J. McCracken; N01MH70001, to Dr. McDougle; and N01MH80011, to Dr. Aman). General Clinical Research Center grants from the National Institutes of Health (M01 RR00750, to Indiana University; M01 RR00052, to Johns Hopkins University; M01 RR00034, to Ohio State University; and M01 RR06022, to Yale University). The project was the National Center for Advancing Translational Sciences of the National Institutes of Health UL1 TR000454 (Emory University) as well as the Marcus Foundation and the Children's Hospital Trust Fund. Dr. Vo has received training support from the National Institute of Mental Health (R25MH101079) to Emory University.";"Alda JA, 2016, J CHILD ADOL PSYCHOP, V26, P449, DOI 10.1089/cap.2015.0151; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman M, 2015, J CHILD ADOL PSYCHOP, V25, P482, DOI 10.1089/cap.2015.0005; [Anonymous], CURR DEV DISORD REP; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Blair J, 2005, J AM ACAD CHILD PSY, V44, P73, DOI 10.1097/01.chi.0000145372.61239.bb; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Caroff SN, 2002, J CLIN PSYCHIAT, V63, P12; Correll CU, 2007, J CHILD ADOL PSYCHOP, V17, P647, DOI 10.1089/cap.2006.0117; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Cuddy Thomas Edward, 2009, Prev Cardiol, V12, P27; Hert M, 2012, NAT REV ENDOCRINOL, V8, P114, DOI 10.1038/nrendo.2011.156; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Galli-Tsinopoulou A, 2014, J PEDIATR ENDOCR MET, V27, P237, DOI 10.1515/jpem-2013-0193; [Gay W. Health P.R.B.N.I.o.M. Health P.R.B.N.I.o.M.], 1976, ECDEU Assessment Manual for Psychopharmacology, Revised, US Dept Health, Education, and Welfare publication (ADM), P534; Germanò E, 2014, PROG NEURO-PSYCHOPH, V51, P23, DOI 10.1016/j.pnpbp.2013.10.020; Gopal S, 2013, J CLIN PSYCHOPHARM, V33, P157, DOI 10.1097/JCP.0b013e318283983f; Hondeghem LM, 2006, J CARDIOVASC ELECTR, V17, P337, DOI 10.1111/j.1540-8167.2006.00347.x; Jensen KG, 2015, J AM ACAD CHILD PSY, V54, P25, DOI 10.1016/j.jaac.2014.10.002; Karamatskos E, 2012, EXPERT OPIN DRUG SAF, V11, P1047, DOI 10.1517/14740338.2012.726984; Kimura G, 2015, INT J MED SCI, V12, P135, DOI 10.7150/ijms.10453; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; McClellan J, 2013, J AM ACAD CHILD PSY, V52, P976, DOI 10.1016/j.jaac.2013.02.008; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Mccracken JT, 2005, AM J PSYCHIAT, V162, P1361; McNally P, 2007, EUR CHILD ADOLES PSY, V16, P33, DOI 10.1007/s00787-006-0573-0; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Patterson S, 2005, DRUG INF J, V39, P243; Salvi V, 2010, BRIT J PHARMACOL, V159, P34, DOI 10.1111/j.1476-5381.2009.00427.x; Scahill L, 2016, J AM ACAD CHILD PSY, V55, P415, DOI 10.1016/j.jaac.2016.02.016; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Schwartz PJ, 2009, CIRCULATION, V120, P1761, DOI 10.1161/CIRCULATIONAHA.109.863209; Shah RR, 2005, HEART RHYTHM, V2, P758, DOI 10.1016/j.hrthm.2005.03.023; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Sikich L, 2004, NEUROPSYCHOPHARMACOL, V29, P133, DOI 10.1038/sj.npp.1300327; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Townsend C, 2013, PREDICTING DRUG INDU; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P561, DOI 10.1089/cap.2006.16.561; Vieweg WVR, 2013, PSYCHOPHARMACOLOGY, V228, P515, DOI 10.1007/s00213-013-3192-8";41;8;9;0;7;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;DEC;2016;26;10;;;;;900;908;;10.1089/cap.2016.0090;http://dx.doi.org/10.1089/cap.2016.0090;;;9;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";EH5TT;27726426;Green Published;;;24/11/2024;WOS:000391836500006;View Full Record in Web of Science
J;"Hu, WQ; Zhao, MH; Lian, JR; Li, DD; Wen, JH; Tan, J";;;;"Hu, Weiqiang; Zhao, Menghua; Lian, Junrong; Li, Dandan; Wen, Jinhua; Tan, Jun";;;Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer's Disease and Autism Spectrum Disorder;CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS;;;English;Article;;;;;;"Lithium cholesterol sulfate; lithium chloride; Alzheimer's disease; Autism spectrum disorder; phosphorylated GSK3 beta; phosphorylated tau; TNF alpha";"REDUCES TAU PHOSPHORYLATION; ADOLESCENTS; EXPRESSION; AGITATION; TOXICITY; CHLORIDE; CHILDREN; MODEL";Background and Objective: Recent studies have shown that lithium treatment can reduce symptoms of Alzheimer's disease (AD) and Autism Spectrum Disorder (ASD). However, the present lithium salts clinically available have serious short-term and long-term side effects, requiring frequent monitoring of blood chemistry and plasma lithium levels to avoid toxicity. Consequently, there is a demand for a safer and more effective lithium formulation to treat these diseases. Methods: Hence, we firstly synthesized lithium cholesterol sulfate (LiCS) and compared its pharmacological effects with that of lithium chloride (LiCl) and sodium cholesterol sulfate (NaCS) on markers of neurodegenerative disease in cell cultures. Results: LiCS was more potent than LiCl in increasing inhibitory GSK3 beta (Ser9) phosphorylation (pGSK3 beta) in both CHO and SH-SY5Y cells. These agents dose-dependently increased pGSK3 beta, starting at 10 mu M for LiCS and 60 mu M for LiCl and maximally by approximately 100% at 60 mu M for LiCS and 1.25 mM for LiCl, without altering total GSK3 beta levels. In HEK293/tau cells, LiCS reduced tau (Thr231) phosphorylation (ptau) starting at 10 mu M and maximally by 63% at 40 mu M without altering total tau levels, but ptau levels were not altered by LiCl at any dose between 60 mu M and 1.25 mM. In BV2 cells, LiCS and LiCl decreased LPS-induced TNF alpha levels, starting at 20 mu M for LiCS and 5 mM for LiCl, and maximally by approximately 30% at 80 mu M for LiCS and 20 mM for LiCl. NaCS at any dose between 5 and 90 mu M did not alter pGSK3 beta, ptau or LPS-induced TNF alpha. Conclusion: LiCS may become a new drug with good pharmacological potential for the treatment of neurodegenerative disorders, such as AD and ASD, by allowing lithium to more readily access intracellular pathological processes.;"[Hu, Weiqiang; Zhao, Menghua; Wen, Jinhua] Nanchang Univ, Dept GCP Psychosomat Med, Affiliated Hosp 1, Nanchang 330006, Peoples R China; [Hu, Weiqiang] Nanchang Univ, Coll Pharm, Nanchang 330006, Peoples R China; [Lian, Junrong; Li, Dandan] Nanchang Univ, Huankui Coll, Nanchang 330006, Peoples R China; [Tan, Jun] Guizhou Med Univ, Key Lab Endem & Ethn Dis, Minist Educ, Guiyang 550004, Peoples R China";"Nanchang University; Nanchang University; Nanchang University; Guizhou Medical University";"Wen, JH (corresponding author), Nanchang Univ, Dept GCP Psychosomat Med, Affiliated Hosp 1, Nanchang 330006, Peoples R China.;Tan, J (corresponding author), Guizhou Med Univ, Key Lab Endem & Ethn Dis, Minist Educ, Guiyang 550004, Peoples R China.";"wenjh8606@163.com; tanj866@126.com";Li, Dandan/HPH-9109-2023;;"National Natural Science Foundation of China [81660620, 81860661]; Department of Science and Technology of Jiangxi Province [20171ACB21059, 20192BCBL23018]";"National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Science and Technology of Jiangxi Province";This study was supported by the National Natural Science Foundation of China (81660620, 81860661) and the Department of Science and Technology of Jiangxi Province (20171ACB21059, 20192BCBL23018).;"Al-Horani RA, 2010, TETRAHEDRON, V66, P2907, DOI 10.1016/j.tet.2010.02.015; Bandyopadhyay B, 2007, J BIOL CHEM, V282, P16454, DOI 10.1074/jbc.M700192200; Battaglia S, 2022, PSYCHOPHYSIOLOGY, V59, DOI 10.1111/psyp.14122; Battaglia S, 2022, TRENDS NEUROSCI, V45, P504, DOI 10.1016/j.tins.2022.04.003; Battaglia S, 2022, MOL PSYCHIATR, V27, P784, DOI 10.1038/s41380-021-01326-4; Beel AJ, 2010, BBA-MOL CELL BIOL L, V1801, P975, DOI 10.1016/j.bbalip.2010.03.008; Blumberg Stephen J, 2013, Natl Health Stat Report, P1; Borgomaneri S, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11091203; Boyko M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/916234; Caccamo A, 2007, AM J PATHOL, V170, P1669, DOI 10.2353/ajpath.2007.061178; Candini M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82223-2; Canitano R, 2015, CLIN NEUROPHARMACOL, V38, P177, DOI 10.1097/WNF.0000000000000096; Choi SE, 2010, VASC PHARMACOL, V53, P264, DOI 10.1016/j.vph.2010.09.004; Clayton KA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00680; Devanand DP, 2018, CONTEMP CLIN TRIALS, V71, P33, DOI 10.1016/j.cct.2018.05.019; Devanand DP, 2017, ALZ DIS ASSOC DIS, V31, P73, DOI 10.1097/WAD.0000000000000161; Donazzolo E, 2017, CHEM PHYS LIPIDS, V204, P43, DOI 10.1016/j.chemphyslip.2017.03.004; DRAYER NM, 1965, BIOCHEM BIOPH RES CO, V18, P126, DOI 10.1016/0006-291X(65)90894-6; DURNAS C, 1992, DRUG AGING, V2, P20, DOI 10.2165/00002512-199202010-00004; Ellena G, 2020, EXP BRAIN RES, V238, P2009, DOI 10.1007/s00221-020-05829-4; Fitzpatrick SE, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S84585; Gassowska M, 2016, TOXICOLOGY, V347, P17, DOI 10.1016/j.tox.2016.03.002; Habib A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.279; Hirschowitz BI, 2002, J CLIN GASTROENTEROL, V34, P523, DOI 10.1097/00004836-200205000-00008; Kim S, 2015, CELL BIOL INT, V39, P177, DOI 10.1002/cbin.10352; Lovestone S, 1999, BIOL PSYCHIAT, V45, P995, DOI 10.1016/S0006-3223(98)00183-8; Matsunaga S, 2015, J ALZHEIMERS DIS, V48, P403, DOI 10.3233/JAD-150437; Merten M, 2001, CIRCULATION, V103, P2032; Oruch R, 2014, EUR J PHARMACOL, V740, P464, DOI 10.1016/j.ejphar.2014.06.042; Przybylska M, 1998, BIOCHEM MOL BIOL INT, V46, P399; Ranaivo HR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-68; Richardson T, 2017, EXPERT OPIN DRUG MET, V13, P1105, DOI 10.1080/17425255.2017.1386653; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Seneff S, 2012, MED HYPOTHESES, V78, P213, DOI 10.1016/j.mehy.2011.10.026; Serret S, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0490-1; Siegel M, 2014, J CHILD ADOL PSYCHOP, V24, P399, DOI 10.1089/cap.2014.0019; Smith AJ, 2014, RSC ADV, V4, P12362, DOI 10.1039/c3ra46962j; Strott CA, 2003, J LIPID RES, V44, P1268, DOI 10.1194/jlr.R300005-JLR200; Theoharides TC, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.77; Valvassori SS, 2019, PHARMACOL BIOCHEM BE, V183, P56, DOI 10.1016/j.pbb.2019.05.009; Varela N, 1998, JCR-J CLIN RHEUMATOL, V4, P1, DOI 10.1097/00124743-199802000-00001; Wang J, 2017, NAT REV NEUROL, V13, P704, DOI 10.1038/nrneurol.2017.147; Wu XY, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00234; Yang Y, 2015, BRAIN RES, V1623, P30, DOI 10.1016/j.brainres.2015.04.024";45;4;4;3;12;BENTHAM SCIENCE PUBL;BUSUM;PO BOX 294, BUSUM, 1400 AG, NETHERLANDS;1871-5273;1996-3181;;CNS NEUROL DISORD-DR;CNS Neurol. Disord.-Drug Targets;;2023;22;8;;;;;1250;1258;;10.2174/1871527321666220825114236;http://dx.doi.org/10.2174/1871527321666220825114236;;;9;"Neurosciences; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pharmacology & Pharmacy";M9QS2;36028968;;;;24/11/2024;WOS:001033493000010;View Full Record in Web of Science
J;"Mazza, JAD; Ferreira, LS; Martins-Vieira, AD; Beserra, DDL; Rodrigues, VA; Malcher-Lopes, R; Caixeta, FV";;;;"Mazza, Jeanne Alves de Souza; Ferreira, Lisiane Seguti; Martins-Vieira, Alice de Faria; Beserra, Doris Day Lopes; Rodrigues, Victor Alves; Malcher-Lopes, Renato; Caixeta, Fabio V.";;;Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management;PHARMACEUTICALS;;;English;Article;;;;;;"idiopathic autism; cannabinoid treatment; cannabis; pediatric neurodevelopmental disorders";"PHARMACOLOGICAL-TREATMENT; SYMPTOMS";Autism Spectrum Disorder (ASD) encompasses a wide range of neurodevelopmental conditions characterized by deficits in social interaction, communication and behavior. Current pharmacological options are limited and feature significant side effects. In this study, we conducted a retrospective, observational, and cross-sectional cohort study to evaluate the effects of Cannabidiol (CBD)-dominant, full-spectrum cannabis extract, containing Tetrahydrocannabinol (THC) in a ratio of 33:1 (CBD:THC), on non-syndromic children and adolescents (5-18 years old) with moderate to severe ASD. Thirty volunteers were recruited, underwent neuropsychological evaluations and were treated with individualized doses of CBD-dominant extract. Clinical assessments were conducted by the designated clinician. Additionally, parents or caregivers were independently interviewed to assess perceived treatment effects. We found significant improvements in various symptomatic and non-symptomatic aspects of ASD, with minimal untoward effects, as reported by both clinical assessments and parental perceptions. The observed improvements included increased communicative skills, attention, learning, eye contact, diminished aggression and irritability, and an overall increase in both the patient's and family's quality of life. Despite its limitations, our findings suggest that treatment with full-spectrum CBD-dominant extract may be a safe and effective option for core and comorbid symptoms of ASD, and it may also increase overall quality of life for individuals with ASD and their families.;"[Mazza, Jeanne Alves de Souza; Ferreira, Lisiane Seguti; Beserra, Doris Day Lopes; Rodrigues, Victor Alves] Univ Hosp Brasilia, Campus Darcy Ribeiro, BR-70840901 Brasilia, Brazil; [Martins-Vieira, Alice de Faria; Malcher-Lopes, Renato; Caixeta, Fabio V.] Univ Brasilia, Dept Physiol Sci, Campus Darcy Ribeiro, BR-70910900 Brasilia, Brazil";Universidade de Brasilia;Caixeta, FV (corresponding author), Univ Brasilia, Dept Physiol Sci, Campus Darcy Ribeiro, BR-70910900 Brasilia, Brazil.;"jeannemazzamed@gmail.com; lisianeseguti@gmail.com; alice.faria.martins@gmail.com; dorislopesb@gmail.com; victoralvesrodrigues2017@gmail.com; malcherlopes@gmail.com; fvcaixeta@unb.br";Ferreira, Lisiane/AAK-7412-2020;;Fundao de Apoio a Pesquisa do Distrito Federal-FAP-DF [00193-00000895/2021-69];Fundao de Apoio a Pesquisa do Distrito Federal-FAP-DF;"F.V.C. was supported by Fundac & atilde;o de Apoio a Pesquisa do Distrito Federal-FAP-DF(Grant # 00193-00000895/2021-69).";"Adler BA, 2015, AUTISM, V19, P102, DOI 10.1177/1362361314524641; Alsayouf HA, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8050318; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Aran A, 2021, MOL AUTISM, V12, DOI 10.1186/s13229-021-00420-2; Aran A, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-019-0256-6; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Barchel D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01521; Chesney E, 2020, NEUROPSYCHOPHARMACOL, V45, P1799, DOI 10.1038/s41386-020-0667-2; Chez MG, 2006, EPILEPSY BEHAV, V8, P267, DOI 10.1016/j.yebeh.2005.11.001; da Silva EA Jr, 2024, TRENDS PSYCHIATR PSY, V46, DOI 10.47626/2237-6089-2021-0396; Devlin B, 2012, CURR OPIN GENET DEV, V22, P229, DOI 10.1016/j.gde.2012.03.002; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Fleury-Teixeira P, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01145; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Hacohen M, 2022, TRANSL PSYCHIAT, V12, DOI 10.1038/s41398-022-02104-8; Hirota T, 2014, J AUTISM DEV DISORD, V44, P948, DOI 10.1007/s10803-013-1952-2; Khachadourian V, 2023, TRANSL PSYCHIAT, V13, DOI 10.1038/s41398-023-02374-w; Malcher-Lopes R., 2014, Rev. Biol, V13, P43, DOI [10.7594/revbio.13.01.07, DOI 10.7594/REVBIO.13.01.07]; Markram K, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00224; Montagner PSS, 2023, FRONT PSYCHIATRY, V14, DOI 10.3389/fpsyt.2023.1210155; Mostafavi M, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100833; Pandina G, 2020, PSYCHIAT CLIN N AM, V43, P629, DOI 10.1016/j.psc.2020.08.003; Poleg S, 2019, PROG NEURO-PSYCHOPH, V89, P90, DOI 10.1016/j.pnpbp.2018.08.030; Russo EB, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01969; Schleider LBL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37570-y; Schnabel A, 2020, AUTISM, V24, P26, DOI 10.1177/1362361319844636; Schnitzler E, 2022, CURR NEUROL NEUROSCI, V22, P531, DOI 10.1007/s11910-022-01218-2; Seeman P, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.195; Shuster J, 2014, J AUTISM DEV DISORD, V44, P90, DOI 10.1007/s10803-013-1854-3; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Szabo B, 2005, HANDB EXP PHARMACOL, V168, P327; Takarae Y, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7100129; Turnock A, 2022, AUTISM ADULTHOOD, V4, P76, DOI 10.1089/aut.2021.0005; White CM, 2019, J CLIN PHARMACOL, V59, P923, DOI 10.1002/jcph.1387; Ziats CA, 2021, PEDIATR NEUROL, V114, P21, DOI 10.1016/j.pediatrneurol.2020.06.011";35;0;0;3;3;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;1424-8247;;PHARMACEUTICALS-BASE;Pharmaceuticals;JUN;2024;17;6;;;;;;;686;10.3390/ph17060686;http://dx.doi.org/10.3390/ph17060686;;;19;"Chemistry, Medicinal; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;WP2N6;38931353;gold, Green Published;;;24/11/2024;WOS:001256014000001;View Full Record in Web of Science
J;"Soorya, LV; Fogg, L; Ocampo, E; Printen, M; Youngkin, S; Halpern, D; Kolevzon, A; Lee, S; Grodberg, D; Anagnostou, E";;;;"Soorya, Latha Valluripalli; Fogg, Louis; Ocampo, Edith; Printen, Madison; Youngkin, Sarah; Halpern, Danielle; Kolevzon, Alexander; Lee, Soo; Grodberg, David; Anagnostou, Evdokia";;;Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"memantine; autism spectrum disorder; memory; cognitive enhancement";"OPEN-LABEL TRIAL; DYSFUNCTION; GLUTAMATE; ACAMPROSATE; MECHANISMS; EFFICACY; BEHAVIOR; DEFICITS; MEMORY; ADULTS";Objective: Studies interrogating therapeutics which alter the excitation-inhibition balance in the treatment of autism spectrum disorder (ASD) have reported mixed results on social and behavioral outcomes. Methods: The aim of this randomized, double-blind placebo-controlled pilot trial was to evaluate neurocognitive effects of memantine over a 24-week trial. Twenty-three children ages 6-12 years old with ASD were randomized to memantine or placebo. Primary outcomes included measures of apraxia and expressive language with evaluations at midpoint (week 12) and endpoint (week 24). Secondary outcomes included memory and adaptive behavior measures. Exploratory outcomes included changes in overall cognitive functioning and behavior (e.g., Aberrant Behavior Checklist). Results: Results suggest that memantine was well-tolerated. Dropout rates were high across groups with only 14 participants completing the 6-month trial. Memantine was not associated with improvements in apraxia and expressive language. Treatment with memantine was associated with improvements in verbal recognition memory as measured by the Narrative Memory-Recognition (NEPSY-II) (F = 5.05, p = .03). In addition, exploratory analyses of changes in Intelligence quotient (IQ) suggest improvements on verbal IQ (d = 1.8). Conclusions: Results suggest future studies of memantine in ASD may benefit from shifting treatment targets from social and behavioral outcomes to exploration of effects of memantine on cognition, potentially as an adjunct to learning and educational interventions. ClinicalTrials.gov: NCT01372449.;"[Soorya, Latha Valluripalli; Ocampo, Edith; Printen, Madison; Youngkin, Sarah; Lee, Soo] Rush Univ, Dept Psychiat & Behav Sci, Med Ctr, Chicago, IL 60612 USA; [Fogg, Louis] Rush Univ, Dept Nursing, Med Ctr, Chicago, IL 60612 USA; [Halpern, Danielle; Kolevzon, Alexander] Icahn Sch Med, Dept Psychiat, New York, NY USA; [Grodberg, David] Yale Univ, Child Study Ctr, New Haven, CT USA; [Anagnostou, Evdokia] Holland Bloorview Childrens Rehabil Hosp, Toronto, ON, Canada";"Rush University; Rush University; Icahn School of Medicine at Mount Sinai; Yale University; University of Toronto; Holland Bloorview Kids Rehabilitation Hospital";Soorya, LV (corresponding author), Rush Univ, Med Ctr, Dept Psychiat, 1645 West Jackson Blvd,Suite 603, Chicago, IL 60612 USA.;latha_soorya@rush.edu;;;;;;"Aldred S, 2003, J AUTISM DEV DISORD, V33, P93, DOI 10.1023/A:1022238706604; Aman MG, 2017, J CHILD ADOL PSYCHOP, V27, P403, DOI 10.1089/cap.2015.0146; Bachurin S, 2001, ANN NY ACAD SCI, V939, P219; Barnes CA, 1996, EUR J NEUROSCI, V8, P565, DOI 10.1111/j.1460-9568.1996.tb01241.x; Berry-Kravis EM, 2018, NAT REV DRUG DISCOV, V17, P280, DOI 10.1038/nrd.2017.221; Biederman J, 2017, J ATTEN DISORD, V21, P343, DOI 10.1177/1087054714538656; Bruining H, 2015, PEDIATRICS, V136, pE539, DOI 10.1542/peds.2014-4133; Chao HT, 2010, NATURE, V468, P263, DOI 10.1038/nature09582; Chez MG, 2007, J CHILD NEUROL, V22, P574, DOI 10.1177/0883073807302611; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Dunn W., 1999, Sensory profile, V555; Erickson CA, 2007, PSYCHOPHARMACOLOGY, V191, P141, DOI 10.1007/s00213-006-0518-9; Erickson CA, 2013, PSYCHOPHARMACOLOGY, V228, P75, DOI 10.1007/s00213-013-3022-z; Erickson CA, 2011, J CHILD ADOL PSYCHOP, V21, P565, DOI 10.1089/cap.2011.0034; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Green J, 2018, J CHILD PSYCHOL PSYC, V59, P424, DOI 10.1111/jcpp.12892; Greenhill LL, 2004, J AM ACAD CHILD PSY, V43, P1488, DOI 10.1097/01.chi.0000142668.29191.13; Hardan AY, 2019, AUTISM, V23, P2096, DOI 10.1177/1362361318824103; Hickman L A., 1997, The Apraxia Profile: A Descriptive Assessment Toolfor Children; Joshi G, 2016, J CLIN PSYCHOPHARM, V36, P262, DOI 10.1097/JCP.0000000000000499; Karahmadi Mojgan, 2018, Adv Biomed Res, V7, P131, DOI 10.4103/abr.abr_100_18; Korkman M., 2007, HARCOURT ASSESS J PS, V28, P175; Lee EJ, 2015, CURR OPIN PHARMACOL, V20, P8, DOI 10.1016/j.coph.2014.10.007; Lee E, 2017, BIOL PSYCHIAT, V81, P838, DOI 10.1016/j.biopsych.2016.05.011; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; Lu S, 2018, ANN CLIN PSYCHIATRY, V30, P234; Mechler K., 2017, Z KINDER JUGENDPSYCH, P1; Moreno-Fuenmayor H, 1996, Invest Clin, V37, P113; Nelson SB, 2015, NEURON, V87, P684, DOI 10.1016/j.neuron.2015.07.033; Nikvarz N, 2017, PHARMACOPSYCHIATRY, V50, DOI 10.1055/s-0042-108449; Owley T, 2006, J CHILD ADOL PSYCHOP, V16, P517, DOI 10.1089/cap.2006.16.517; Parsons CG, 2013, NEUROTOX RES, V24, P358, DOI 10.1007/s12640-013-9398-z; Purcell AE, 2001, NEUROLOGY, V57, P1618, DOI 10.1212/WNL.57.9.1618; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Roid GH., 2012, STANFORD BINET INTEL; ROLF LH, 1993, ACTA PSYCHIAT SCAND, V87, P312, DOI 10.1111/j.1600-0447.1993.tb03378.x; Shinohe A, 2006, PROG NEURO-PSYCHOPH, V30, P1472, DOI 10.1016/j.pnpbp.2006.06.013; Sparrow SS., 2005, APA PSYCTESTS; Uzunova G, 2014, CURR NEUROPHARMACOL, V12, P71, DOI 10.2174/1570159X113116660046; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); Weschler D., 2003, Wechsler Intelligence Scale for Children, V4th; Williams K.T., 2007, EVT 2 EXPRESSIVE VOC; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Yang JC, 2014, NEUROPSYCHOPHARMACOL, V39, P2760, DOI 10.1038/npp.2014.122; Yang JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep21719; Zheng W, 2018, PSYCHOL MED, V48, P72, DOI 10.1017/S0033291717001271";48;13;13;1;3;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;sept-01;2021;31;7;;;;;475;484;;10.1089/cap.2021.0010;http://dx.doi.org/10.1089/cap.2021.0010;;;10;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";US2LV;34543081;;;;24/11/2024;WOS:000697266600004;View Full Record in Web of Science
J;"Hollander, E; Soorya, L; Chaplin, W; Anagnostou, E; Taylor, BP; Ferretti, CJ; Wasserman, S; Swanson, E; Settipani, C";;;;"Hollander, Eric; Soorya, Latha; Chaplin, William; Anagnostou, Evdokia; Taylor, Bonnie P.; Ferretti, Casara J.; Wasserman, Stacey; Swanson, Erika; Settipani, Cara";;;A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders;AMERICAN JOURNAL OF PSYCHIATRY;;;English;Article;;;;;;;"SEROTONIN TRANSPORTER GENE; CHILDHOOD AUTISM; RATING-SCALE; CHILDREN; ADOLESCENTS; FLUVOXAMINE; EFFICACY";"Objective: The effects of fiuoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). Method: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fiuoxetine trial. Thirty-seven were randomly assigned to fiuoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day. Repetitive behaviors were measured with the compulsion subscale of the Yale-Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. Results: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fiuoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fiuoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fiuoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fiuoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. Conclusions: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.";"[Hollander, Eric] Albert Einstein Coll Med, Autism & Obsess Compuls Spectrum Program, Dept Psychiat & Behav Sci, New York, NY USA; Montefiore Med Ctr, New York, NY USA; Mt Sinai Sch Med, Seaver Autism Ctr Res & Treatment, Dept Psychiat, New York, NY USA";"Yeshiva University; Montefiore Medical Center; Icahn School of Medicine at Mount Sinai";Hollander, E (corresponding author), Albert Einstein Coll Med, Autism & Obsess Compuls Spectrum Program, Dept Psychiat & Behav Sci, New York, NY USA.;eholland@montefiore.org;;;"Food and Drug Administration [FD-R-002026-01]; Studies to Advance Autism Research and Treatment (STAART) Center of Excellence from NIMH [1U54 MH-066673]; Seaver Foundation; Mount Sinai General Clinical Research Center";"Food and Drug Administration(United States Department of Health & Human ServicesUS Food & Drug Administration (FDA)); Studies to Advance Autism Research and Treatment (STAART) Center of Excellence from NIMH; Seaver Foundation; Mount Sinai General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))";Funded by Food and Drug Administration orphan product grant FD-R-002026-01 and supported by Studies to Advance Autism Research and Treatment (STAART) Center of Excellence grant 1U54 MH-066673 from NIMH, by the Seaver Foundation, and by the Mount Sinai General Clinical Research Center. Mount Sinai School of Medicine licensed an orphan designation for fluoxetine in autism to Neuropharm, Ltd.;"Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P116, DOI 10.1089/cap.2005.15.116; AMAN MG, 1985, AM J MENT DEF, V89, P485; Anagnostou E, 2005, NEUROPSYCHOPHARMACOL, V30, pS153; Bethea TC, 2007, BIOL PSYCHIAT, V61, P521, DOI 10.1016/j.biopsych.2006.09.021; Bole S, 2001, Z KINDER JUGENDPSYCH, V29, P221; Bridge JA, 2009, AM J PSYCHIAT, V166, P42, DOI 10.1176/appi.ajp.2008.08020247; Buchsbaum MS, 2001, INT J NEUROPSYCHOPH, V4, P119, DOI 10.1017/S1461145701002280; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Devlin B, 2005, MOL PSYCHIATR, V10, P1110, DOI 10.1038/sj.mp.4001724; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Hohmann CF, 2007, BRAIN RES, V1139, P163, DOI 10.1016/j.brainres.2006.12.095; Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627; Hollander E, 2003, PSYCHIAT RES, V117, P11, DOI 10.1016/S0165-1781(02)00304-9; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Hranilovic D, 2007, J AUTISM DEV DISORD, V37, P1934, DOI 10.1007/s10803-006-0324-6; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lord C, 2006, ARCH GEN PSYCHIAT, V63, P694, DOI 10.1001/archpsyc.63.6.694; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001; MESIBOV GB, 1989, J AM ACAD CHILD PSY, V28, P538, DOI 10.1097/00004583-198907000-00012; Piven J, 1996, J AM ACAD CHILD PSY, V35, P523, DOI 10.1097/00004583-199604000-00019; Ramoz N, 2006, BIOL PSYCHIAT, V60, P186, DOI 10.1016/j.biopsych.2006.01.009; RUTTER M, 1967, BRIT J PSYCHIAT, V113, P1183, DOI 10.1192/bjp.113.504.1183; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Sugie Y, 2005, J AUTISM DEV DISORD, V35, P377, DOI 10.1007/s10803-005-3305-2";27;127;149;1;23;AMER PSYCHIATRIC PUBLISHING, INC;ARLINGTON;1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA;0002-953X;;;AM J PSYCHIAT;Am. J. Psychiat.;MAR;2012;169;3;;;;;292;299;;10.1176/appi.ajp.2011.10050764;http://dx.doi.org/10.1176/appi.ajp.2011.10050764;;;8;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;900CO;22193531;;;;24/11/2024;WOS:000300864400010;View Full Record in Web of Science
J;"Scahill, L; Shillingsburg, MA; Ousley, O; Pileggi, ML; Kilbourne, RL; Buckley, D; Gillespie, SE; McCracken, C";;;;"Scahill, Lawrence; Shillingsburg, M. Alice; Ousley, Opal; Pileggi, Moira L.; Kilbourne, Rebecca L.; Buckley, Derianne; Gillespie, Scott E.; McCracken, Courtney";;;A Randomized Trial of Direct Instruction Language for Learning in Children With Autism Spectrum Disorder;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"autism; children; clinical trial; language delay";SCHOOL-AGE-CHILDREN;Objective: To compare Direct Instruction Language for Learning (DI) plus treatment as usual (TAU) with TAU alone in children with autism spectrum disorder and moderate language delay. Method: In this study, 83 children (age range, 4 years to 7 years 11 months) were randomly assigned to DI+TAU (n = 42) or TAU (n = 41) for 6 months. Trained therapists delivered DI in twice-weekly, 90-minute sessions for 24 weeks. The primary outcome was the standard score on the ageappropriate version of the Clinical Evaluation of Language Fundamentals (CELF). The key secondary measure was the proportion of children rated by a clinician blinded to treatment as much improved or very much improved on the Clinical Global Impressions-Improvement (CGI-I) scale. Results: Attrition was 12%. At end point, DI+TAU participants showed a 4.8-point (8.1%) increase on CELF vs 2.3 points (4.1%) in TAU participants (difference = 2.55, p = .14, effect size = 0.25), rendering this a negative trial on the prespecified primary outcome. In post hoc analysis that adjusted for IQ, mean difference was 3.5 (p = .04, effect size = 0.33). On CGI-I, 54.8% (23/42) of DI+TAU participants were rated much improved or very much improved compared with 21.9% (9/41) of TAU participants (chi(2) = 9.4, p = .002). On the clinically meaningful threshold of >5 points on CELF, 55.5% of DI+TAU participants achieved this benchmark vs 29.3% of TAU participants (chi(2) = 3.6, p = .06). Complete CELF data were available for 72 participants. In the combined sample, baseline CELF scores <= 50 were associated with no improvement. Conclusion: On CELF, DI+TAU did not meet the prespecified difference from TAU. When adjusted for IQ, DI+TAU was superior to TAU on CELF at end point. DI+TAU was superior to TAU on CGI-I.;"[Scahill, Lawrence; Ousley, Opal; Gillespie, Scott E.] Emory Univ, Sch Med, Atlanta, GA USA; [Scahill, Lawrence; Ousley, Opal; Pileggi, Moira L.; Kilbourne, Rebecca L.; Buckley, Derianne; Gillespie, Scott E.] Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA; [Shillingsburg, M. Alice] May Inst, Randolph, MA USA; [McCracken, Courtney] Kaiser Permanente, Atlanta, GA USA";"Emory University; Kaiser Permanente";Scahill, L (corresponding author), Marcus Autism Ctr, 1920 Briarcliff Rd, Atlanta, GA 30329 USA.;lawrence.scahill@emory.edu;Ousley, Opal/ABF-8808-2021;"Gillespie, Scott/0000-0003-1295-3602; Scahill, Lawrence/0000-0001-5073-1707; Pileggi, Moira/0000-0001-6326-6496";"US Department of Defense [W81XWH-15-1-0154]; Marcus Foundation; Children's Trust";"US Department of Defense(United States Department of Defense); Marcus Foundation; Children's Trust";The project was supported by grant W81XWH-15-1-0154 from the US Department of Defense, the Marcus Foundation, and the Children's Trust.;"Adams C, 2012, INT J LANG COMM DIS, V47, P233, DOI 10.1111/j.1460-6984.2011.00146.x; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Anderson DK, 2007, J CONSULT CLIN PSYCH, V75, P594, DOI 10.1037/0022-006X.75.4.594; [Anonymous], 2007, MISSING DATA RANDOMI; [Anonymous], AUTISM SPECTRUM DISO; [Anonymous], 2005, VINELAND ADAPTIVE BE; [Anonymous], PUBL WORKSH PAT FOC; [Anonymous], PATIENT FOCUSED DRUG; [Anonymous], LANGUAGE LEARNING TE; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Boucher J, 2012, J CHILD PSYCHOL PSYC, V53, P219, DOI 10.1111/j.1469-7610.2011.02508.x; Corsello C, 2007, J CHILD PSYCHOL PSYC, V48, P932, DOI 10.1111/j.1469-7610.2007.01762.x; Ebert KD, 2016, INT J SPEECH-LANG PA, V18, P354, DOI 10.3109/17549507.2015.1101158; Elliott CD., 2007, DIFFERENTIAL ABILITY, V2nd; Engelmann S., 1999, Language for learning; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Hampton LH, 2016, J INTELL DISABIL RES, V60, P444, DOI 10.1111/jir.12283; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-139; Kraemer HC, 2016, AM J PSYCHIAT, V173, P672, DOI 10.1176/appi.ajp.2016.15101333; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Reilly S, 2014, INT J LANG COMM DIS, V49, P416, DOI 10.1111/1460-6984.12102; [Rosenbaum S. Committee on the Evaluation of the Supplemental Security Income (SSI) Disability Program for Children with Speech Disorders and Language Disorders Board on the Health of Select Populations Board on Children Youth and Families Institute of Medicine Division of Behavioral and Social Sciences and Education National Academies of Sciences Engineering and Medicine Committee on the Evaluation of the Supplemental Security Income (SSI) Disability Program for Children with Speech Disorders and Language Disorders Board on the Health of Select Populations Board on Children Youth and Families Institute of Medicine Division of Behavioral and Social Sciences and Education National Academies of Sciences Engineering and Medicine], 2016, Speech and language disorders in children: Implications for the social security administration's supplemental security income program, DOI DOI 10.17226/21872; Sandbank M, 2020, J SPEECH LANG HEAR R, V63, P1537, DOI 10.1044/2020_JSLHR-19-00167; Scahill L, 2017, J CHILD ADOL PSYCHOP, V27, P125, DOI 10.1089/cap.2016.0107; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Scahill L, 2014, J AM ACAD CHILD PSY, V53, P97, DOI 10.1016/j.jaac.2013.09.018; Sheridan E, 2021, RES CHILD ADOLES PSY, V49, P1527, DOI 10.1007/s10802-021-00843-8; Shillingsburg MA, 2015, FOCUS AUTISM DEV DIS, V30, P44, DOI 10.1177/1088357614532498; Stockard J, 2018, REV EDUC RES, V88, P479, DOI 10.3102/0034654317751919; Tager-Flusberg H, 2013, AUTISM RES, V6, P468, DOI 10.1002/aur.1329; Watkins C., 2003, Journal of Direct Instruction, P4; Weldon AB, 2021, J SCHOOL HEALTH, V91, P183, DOI 10.1111/josh.12988; Wiig E.H., 2004, CELF PRESCHOOL 2; Wiig E.H., 2003, Clinical Evaluation of Language Fundamentals - 4th Edition Spanish, V4th";37;2;4;3;11;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;JUN;2022;61;6;;;;;772;781;;10.1016/j.jaac.2021.11.034;http://dx.doi.org/10.1016/j.jaac.2021.11.034;;MAY 2022;10;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";3H0BK;35093490;Bronze;;;24/11/2024;WOS:000831709300012;View Full Record in Web of Science
J;"Rothärmel, M; Szymoniak, F; Pollet, C; Beherec, L; Quesada, P; Leclerc, S; Belhaine, A; Rosier, A; Guillin, O";;;;"Rotharmel, Maud; Szymoniak, Fanny; Pollet, Charlotte; Beherec, Laurene; Quesada, Pierre; Leclerc, Sophie; Belhaine, Amina; Rosier, Antoine; Guillin, Olivier";;;Eleven Years of Clozapine Experience in Autism Spectrum Disorder: Efficacy and Tolerance;JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism spectrum disorders; clozapine; disruptive behavior; tolerance";"QUALITY-OF-LIFE; ATYPICAL ANTIPSYCHOTICS; CHILDREN; ADOLESCENTS; AGGRESSION; ARIPIPRAZOLE; IRRITABILITY; RISPERIDONE; ADULTS";"Background Autism spectrum disorders (ASDs) are neurodevelopmental disorders that comprise wide graduated clinical expressions but similar core symptoms (repetitive, stereotyped behavior, and social communication disabilities). Many patients with ASD have disruptive behaviors like aggressiveness, temper tantrums, or self-injury that interfere with their socializations, their learning abilities, and their quality of life. These behaviors represent a common target for pharmacology. Beherec et al (J Clin Psychopharmacol. 2011;31:341-344) (first cohort), showed the efficacy of clozapine on disruptive behaviors in 6 patients with autism who were older than 16 years. The aim of this study was to assess the efficacy and tolerance of clozapine in a new cohort and the long-term effect in our first cohort. Procedures Concerning the replication study, we conducted a retrospective study of the changes of aggressive behaviors for all patients with ASD who were treated with clozapine from 2011 to 2017. Disruptive behaviors were monitored from 1 to 6 months before and after the initiation of the clozapine. Results All the patients of the first cohort were still on clozapine after an average of 11 + 2.6 years, with the same efficacy and no serious adverse effect was noted. For the replication study, 13 patients were included. Clozapine resulted in a significant decrease in the number of the days with aggression (65.2% + 32.6%). Once again, no serious adverse effect was notified. All the patients had a better quality of life. Conclusions Our study confirms that clozapine could be an efficacious and well-tolerated treatment for ASD patients with disruptive behaviors who do not respond to other antipsychotics on the long term.";"[Rotharmel, Maud; Szymoniak, Fanny; Quesada, Pierre; Leclerc, Sophie; Belhaine, Amina; Guillin, Olivier] Ctr Hosp Rouvray, Univ Dept Psychiat, Sotteville Les Rouen, France; [Pollet, Charlotte] Clin Oceane, Le Havre, France; [Beherec, Laurene] Ctr Hosp Maison Blanche, Dept 75G23, Paris, France; [Leclerc, Sophie; Belhaine, Amina; Rosier, Antoine; Guillin, Olivier] Ctr Hosp Rouvray, Ctr Ressource Autisme Haute Normandie, Sotteville Les Rouen, France; [Guillin, Olivier] CHU Rouen, Rouen, France; [Guillin, Olivier] Normandy Univ, Fac Med, Rouen, France";"Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; Universite de Rouen Normandie; CHU de Rouen; Universite de Rouen Normandie";Rothärmel, M (corresponding author), Ctr Hosp Rouvray, Dept Psychiat 76G03, 4 Rue Paul Eluard, F-76300 Sotteville Les Rouen, France.;maud.rotharmel@ch-lerouvray.fr;;;;;;"Beherec L, 2011, J CLIN PSYCHOPHARM, V31, P341, DOI 10.1097/JCP.0b013e318218f4a1; Chen NC, 2001, J CLIN PSYCHIAT, V62, P479, DOI 10.4088/JCP.v62n0612h; Clerici M, 2014, GEN HOSP PSYCHIAT, V36, P698, DOI 10.1016/j.genhosppsych.2014.08.005; Frogley C, 2012, INT J NEUROPSYCHOPH, V15, P1351, DOI 10.1017/S146114571100201X; Gobbi G, 2001, J PSYCHIATR NEUROSCI, V26, P340; Gunes H, 2015, J CHILD ADOL PSYCHOP, V25, P727, DOI 10.1089/cap.2015.0101; Herzinger CV, 2007, J AUTISM DEV DISORD, V37, P1430, DOI 10.1007/s10803-006-0219-6; Lambrey S, 2010, J CHILD ADOL PSYCHOP, V20, P79, DOI 10.1089/cap.2009.0057; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Matson J, 2008, J INTELLECT DEV DIS, V33, P323, DOI 10.1080/13668250802492600; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2008, J CLIN PSYCHIAT, V69, P15; Meltzer HY, 2003, ARCH GEN PSYCHIAT, V60, P82, DOI 10.1001/archpsyc.60.1.82; Moyal WN, 2014, PEDIATR DRUGS, V16, P123, DOI 10.1007/s40272-013-0050-4; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041; Politte LC, 2014, PSYCHOPHARMACOLOGY, V231, P1023, DOI 10.1007/s00213-013-3068-y; Sahoo S, 2017, ASIAN J PSYCHIATR, V29, P194, DOI 10.1016/j.ajp.2017.07.012; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Tyrer F, 2006, J INTELL DISABIL RES, V50, P295, DOI 10.1111/j.1365-2788.2005.00774.x; van Heijst BFC, 2015, AUTISM, V19, P158, DOI 10.1177/1362361313517053; Yalcin O, 2016, J CHILD ADOL PSYCHOP, V26, P815, DOI 10.1089/cap.2015.0020; Zuddas A, 1996, AM J PSYCHIAT, V153, P738";24;17;18;0;12;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0271-0749;1533-712X;;J CLIN PSYCHOPHARM;J. Clin. Psychopharmacol.;DEC;2018;38;6;;;;;577;581;;10.1097/JCP.0000000000000955;http://dx.doi.org/10.1097/JCP.0000000000000955;;;5;"Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pharmacology & Pharmacy; Psychiatry";HA2QK;30285998;;;;24/11/2024;WOS:000450084600008;View Full Record in Web of Science
J;"Al Awami, R; Albanna, A";;;;"Al Awami, Raed; Albanna, Ammar";;;Sedation After a Trial of Mixed Amphetamine Salts in a Boy with Attention-Deficit/Hyperactivity Disorder;AMERICAN JOURNAL OF CASE REPORTS;;;English;Article;;;;;;"Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Development Disorders, Pervasive; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Case Reports";"CHILDREN; METHYLPHENIDATE; AUTISM; SPECTRUM; ADHD; ADOLESCENTS; STIMULANT; SYMPTOMS";Objective: Unusual or unexpected effect of treatment Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder that manifests in early childhood. Pharmacotherapy, including psychostimulants, is considered the cornerstone of ADHD management. Although stimulants have been associated with adverse effects, sedation following the administration of an amphetamine-based stimulant is an extremely rare adverse effect. Case Report: We report the case of a 6-year-old boy presenting with ADHD and a history of autism spectrum disorder (ASD). After discussing treatment options with his parents, he was started on a low dose of a methylphenidate medication. He was unable to tolerate the medication due to anorexia, insomnia, and irritability despite multiple adjustments in the dosages. A trial of immediate-release mixed amphetamine salts was initiated, starting from a low dose. The boy developed sedation and lethargy shortly after the administration of this medication. Conclusions: Sedation is a rare adverse drug reaction to mixed amphetamine salts. Clinicians should proactively monitor for the possible adverse effects in patients with ASD and ADHD, including unexpected symptoms such as sedation. Reporting of adverse drug reactions should be encouraged to promote the post-marketing surveillance of medications.;"[Al Awami, Raed] King Fahad Specialist Hosp, Dept Psychiat, Dammam, Saudi Arabia; [Albanna, Ammar] Al Jalila Childrens Special Hosp, Mental Hlth Ctr Excellence, Dubai, U Arab Emirates; [Albanna, Ammar] Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates";;"Albanna, A (corresponding author), Al Jalila Childrens Special Hosp, Mental Hlth Ctr Excellence, Dubai, U Arab Emirates.;Albanna, A (corresponding author), Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates.";AAlBanna@ajch.ae;;;;;;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; [Anonymous], 2013, DIAGNOSTIC STAT MANU; Bruining H, 2015, PEDIATRICS, V136, pE539, DOI 10.1542/peds.2014-4133; Clavenna A, 2014, ARCH DIS CHILD, V99, P866, DOI 10.1136/archdischild-2013-304170; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hennissen L, 2017, CNS DRUGS, V31, P199, DOI 10.1007/s40263-017-0410-7; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; JASELSKIS CA, 1992, J CLIN PSYCHOPHARM, V12, P322; Kelly BD, 2013, J PEDIATR UROL, V9, pE1, DOI 10.1016/j.jpurol.2012.03.017; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Majeed MH, 2019, PRIM CARE COMPANION, V21; Moran LV, 2019, NEW ENGL J MED, V380, P1128, DOI 10.1056/NEJMoa1813751; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nishino S, 2009, SLEEP, V32, P1407, DOI 10.1093/sleep/32.11.1407; Pearson DA, 2013, J CHILD ADOL PSYCHOP, V23, P337, DOI 10.1089/cap.2012.0096; Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724; Politte LC, 2018, NEUROPSYCHOPHARMACOL, V43, P1772, DOI 10.1038/s41386-018-0039-3; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; Stahl SM, 2010, J CLIN PSYCHIAT, V71, P12, DOI 10.4088/JCP.09bs05890pur; Storebo OJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012069.pub2; Tatro DS, 2006, DRUG INTERACTIONS FA; TECCE JJ, 1974, SCIENCE, V185, P451, DOI 10.1126/science.185.4149.451; Weiss MD, 2018, ADHD-ATTEND DEFICIT, V10, P113, DOI 10.1007/s12402-017-0242-9; Wilens TE, 2006, J AM ACAD CHILD PSY, V45, P408, DOI 10.1097/01.chi.0000199027.68828.b3; Wolraich ML., 2019, PEDIATRICS, V144, DOI DOI 10.1542/PEDS.2019-3997";26;3;3;1;4;INT SCIENTIFIC INFORMATION, INC;MELVILLE;150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA;;1941-5923;;AM J CASE REP;Am. J. Case Rep.;DEC 17;2020;21;;;;;;;;e928269;10.12659/AJCR.928269;http://dx.doi.org/10.12659/AJCR.928269;;;4;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;PH8JQ;33328428;Green Published;;;24/11/2024;WOS:000600652100001;View Full Record in Web of Science
J;"Scahill, L; McCracken, JT; King, BH; Rockhill, C; Shah, B; Politte, L; Sanders, R; Minjarez, M; Cowen, J; Mullett, J; Page, C; Ward, D; Deng, YH; Loo, S; Dziura, J; McDougle, CJ";;;;"Scahill, Lawrence; McCracken, James T.; King, Bryan H.; Rockhill, Carol; Shah, Bhavik; Politte, Laura; Sanders, Roy; Minjarez, Mendy; Cowen, Jennifer; Mullett, Jennifer; Page, Chris; Ward, Denise; Deng, Yanhong; Loo, Sandra; Dziura, James; McDougle, Christopher J.";;Res Units Pediat Psychopharmacolog;Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder;AMERICAN JOURNAL OF PSYCHIATRY;;;English;Article;;;;;;;"ABERRANT BEHAVIOR CHECKLIST; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; YOUNG-PEOPLE; DOUBLE-BLIND; SYMPTOMS; PLACEBO; ADHD; ATOMOXETINE; ADOLESCENTS; PREVALENCE";"Objective: Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD. Method: In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness, and distractibility. Results: Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks. The guanfacine group showed a 43.6% decline in scores on the Aberrant Behavior Checklist-hyperactivity subscale (least squares mean from 34.2 to 19.3) compared with a 13.2% decrease in the placebo group (least squares mean from 34.2 to 29.7; effect size=1.67). The rate of positive response (much improved or very much improved on the Clinical Global Impression-Improvement scale) was 50% (15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo. A brief cognitive battery tapping working memory and motor planning showed no group differences before or after 8 weeks of treatment. The modal dose of guanfacine at week 8 was 3 mg/day (range: 1-4 mg/day), and the modal dose was 3 mg/day (range: 2-4 mg/day) for placebo. Four guanfacine-treated subjects (13.3%) and four placebo subjects (12.5%) exited the study before week 8. The most common adverse events included drowsiness, fatigue, and decreased appetite. There were no significant changes on ECG in either group. For subjects in the guanfacine group, blood pressure declined in the first 4 weeks, with return nearly to baseline by endpoint (week 8). Pulse rate showed a similar pattern but remained lower than baseline at endpoint. Conclusions: Extended-release guanfacine appears to be safe and effective for reducing hyperactivity, impulsiveness, and distractibility in children with ASD.";"[Scahill, Lawrence] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Seattle Childrens Hosp, Dept Psychiat & Behav Sci, Seattle, WA USA; Massachusetts Gen Hosp, Lurie Ctr Autism, Dept Child & Adolescent Psychiat, Lexington, MA USA; Marcus Autism Ctr, Atlanta, GA USA; Yale Univ, Dept Biostat, New Haven, CT USA; Yale Univ, Dept Emergency Med, New Haven, CT USA; Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA";"Emory University; University of California System; University of California Los Angeles; Seattle Children's Hospital; Harvard University; Massachusetts General Hospital; Yale University; Yale University; Harvard University; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA";Scahill, L (corresponding author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.;Lawrence.scahill@emory.edu;deng, yan/KCK-8563-2024;;"NIMH [R01MH083707, RO1MH83739, RO1MH083747, R01MH86927]; Yale Clinical and Transitional Science Award from the NIH National Center for Research Resources [UL1 RR024139]; Atlanta Clinical and Translational Science Institute, Emory University; NIH National Center for Advancing Translational Sciences [UL1TR000454]; Roche; Seaside Therapeutics";"NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Yale Clinical and Transitional Science Award from the NIH National Center for Research Resources; Atlanta Clinical and Translational Science Institute, Emory University; NIH National Center for Advancing Translational Sciences; Roche(Roche Holding); Seaside Therapeutics";"Supported by NIMH grants to Dr Scahill (R01MH083707), Dr. McDougle (RO1MH83739), Dr. McCracken (RO1MH083747), and Dr. King (R01MH86927); by a Yale Clinical and Transitional Science Award (UL1 RR024139) from the NIH National Center for Research Resources; and by Atlanta Clinical and Translational Science Institute, Emory University, which is supported by the NIH National Center for Advancing Translational Sciences under award UL1TR000454. Dr. Scahill has served as a consultant for Bracket, Coronado, MedAdvante, Neuren, Roche, and Shire, and he has served on the speaker's bureau for the Tourette Syndrome Association. Dr. McCracken has served as a consultant for Dart Neuroscience and Roche; he has received research support from Roche; he has received study drug and matching placebo from Shire; and he has served on the speaker's bureau for the Tourette Syndrome Association. Dr. King has received research support from Roche and Seaside Therapeutics. All other authors report no financial relationships with commercial interests.";"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], NEPSYIL ADM MANUAL; [Anonymous], TXB AUTISM SPECTRUM; [Anonymous], 2005, VINELAND ADAPTIVE BE; [Anonymous], PUBLICATION ADM; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Arnsten AFT, 2011, PHARMACOL BIOCHEM BE, V99, P211, DOI 10.1016/j.pbb.2011.01.020; Aston-Jones G, 2005, J COMP NEUROL, V493, P99, DOI 10.1002/cne.20723; Biederman J, 2008, PEDIATRICS, V121, pE73, DOI 10.1542/peds.2006-3695; BOARD AW, 1988, CLIN THER, V10, P761; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Carter MJ, 2014, THER RECREAT J, V48, P275; Corsello C, 2007, J CHILD PSYCHOL PSYC, V48, P932, DOI 10.1111/j.1469-7610.2007.01762.x; DuPaul G.J., 1998, ADHD RATING SCALE 4, P1; Elliott CD., 2007, DIFFERENTIAL ABILITY, V2nd; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Faraone SV, 2013, CLIN THER, V35, P1778, DOI 10.1016/j.clinthera.2013.09.005; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2006, J AUTISM DEV DISORD, V36, P271, DOI 10.1007/s10803-005-0060-3; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Hallett V, 2013, J AUTISM DEV DISORD, V43, P2341, DOI 10.1007/s10803-013-1775-1; Handen BL, 2008, J DEV BEHAV PEDIATR, V29, P303, DOI 10.1097/DBP.0b013e3181739b9d; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hoffman BB., 2001, GOODMAN GILMANS PHAR, V10th, P215; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Michelson D, 2002, AM J PSYCHIAT, V159, P1896, DOI 10.1176/appi.ajp.159.11.1896; Molenberghs G, 2004, BIOSTATISTICS, V5, P445, DOI 10.1093/biostatistics/kxh001; Mullen EM., 1995, MULLEN SCALES EARLY; Reiersen AM, 2008, J AM ACAD CHILD PSY, V47, P662, DOI 10.1097/CHI.0b013e31816bff88; Reiersen AM, 2007, J CHILD PSYCHOL PSYC, V48, P464, DOI 10.1111/j.1469-7610.2006.01720.x; Roid GH., 2012, STANFORD BINET INTEL; Rosenberg RE, 2010, J AUTISM DEV DISORD, V40, P342, DOI 10.1007/s10803-009-0878-1; Scahill L, 2006, J CHILD ADOL PSYCHOP, V16, P589, DOI 10.1089/cap.2006.16.589; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Steele M, 2006, CLIN THER, V28, P1892, DOI 10.1016/j.clinthera.2006.11.006";40;112;114;0;21;AMER PSYCHIATRIC PUBLISHING, INC;WASHINGTON;800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA;0002-953X;1535-7228;;AM J PSYCHIAT;Am. J. Psychiat.;DEC;2015;172;12;;;;;1197;1206;;10.1176/appi.ajp.2015.15010055;http://dx.doi.org/10.1176/appi.ajp.2015.15010055;;;10;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;CX6UJ;26315981;Green Submitted, Bronze;;;24/11/2024;WOS:000365836900007;View Full Record in Web of Science
J;"Roke, Y; Buitelaar, JK; Boot, AM; Tenback, D; van Harten, PN";;;;"Roke, Yvette; Buitelaar, Jan K.; Boot, Annemieke M.; Tenback, Diederik; van Harten, Peter N.";;;Risk of Hyperprolactinemia and Sexual Side Effects in Males 10-20 Years Old Diagnosed with Autism Spectrum Disorders or Disruptive Behavior Disorder and Treated with Risperidone;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; ELEVATED PROLACTIN LEVELS; RANDOMIZED OPEN-LABEL; LONG-TERM; SELF-ASSESSMENT; ANTIPSYCHOTIC MEDICATION; ATYPICAL ANTIPSYCHOTICS; SUBAVERAGE INTELLIGENCE; ADVERSE EVENTS; DOUBLE-BLIND";"Objective: The aim of this study was to investigate the long-term treatment effects of risperidone on prolactin levels and prolactin-related side effects in pubertal boys with autism spectrum disorders (ASD) and disruptive behavior disorders (DBD). Method: Physical healthy 10-20-year-old males with ASD (n = 89) and/or DBD (n = 9) chronically treated (mean 52 months, range 16-126 months) with risperidone (group 1, n = 51) or not treated with any antipsychotic (group 2, n = 47) were recruited to this observational study from the child psychiatry outpatient clinic. Morning non-fasting serum prolactin levels were measured and prolactin-related side effects were assessed by means of questionnaires and physical examination. Group differences were tested with Student's t, chi(2), Fisher exact, and Mann-Whitney tests, and logistic regression analysis, according to the type and distribution of data. Results: Hyperprolactinemia was present in 47% of subjects in group 1 but only in 2% of subjects in group 2 (odds ratio 71.9; 95% CI, 7.7; 676.3). Forty-six percent of subjects in group1 had asymptomatic hyperprolactinemia. Current risperidone dose and 9-OH risperidone plasma level were significant predictors of hyperprolactinemia (p = 0.035 and p = 0.03, respectively). Gynecomastia and sexual dysfunction were present in 43% and 14% of the subjects in group1, respectively, compared with 21% and 0% of subjects in group 2 (p = 0.05 and p = 0.01). Gynecomastia was not significantly associated with hyperprolactinemia. Conclusions: Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone. Young males treated with risperidone are more likely to report diminished sexual functioning than are those not treated with antipsychotics.";"[Roke, Yvette; Tenback, Diederik; van Harten, Peter N.] GGZ Cent Psychiat Ctr, Amersfoort, Netherlands; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, NL-6525 ED Nijmegen, Netherlands; [Buitelaar, Jan K.] Karakter Child & Adolescent Psychiat Univ Ctr, Nijmegen, Netherlands; [Boot, Annemieke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Pediat Endocrinol, NL-9713 AV Groningen, Netherlands; [van Harten, Peter N.] Maastricht Univ, S Limburg Mental Hlth Res & Teaching Network, Dept Psychiat & Psychol, EURON,Med Ctr, Maastricht, Netherlands";"Radboud University Nijmegen; Radboud University Nijmegen; University of Groningen; Maastricht University";Roke, Y (corresponding author), GGZ Cent, Ctr Psychiat, POB 3051, NL-3800 DB Amersfoort, Netherlands.;y.geest@gmail.com;Buitelaar, Jan/AAY-7522-2020;Boot, Annemieke/0000-0002-2426-3222;"Foundation De Open Ankh, Soesterberg, The Netherlands; Fund for Scientific Research of Sexuality, Amsterdam, The Netherlands";"Foundation De Open Ankh, Soesterberg, The Netherlands; Fund for Scientific Research of Sexuality, Amsterdam, The Netherlands(Netherlands Government)";"This research was supported by Foundation De Open Ankh, Soesterberg, The Netherlands; Foundation to support VCVGZ, Arnhem, The Netherlands; and Fund for Scientific Research of Sexuality, Amsterdam, The Netherlands.";"Aman MG, 2002, AM J PSYCHIAT, V159, P1337, DOI 10.1176/appi.ajp.159.8.1337; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; Anderson GM, 2007, BIOL PSYCHIAT, V61, P545, DOI 10.1016/j.biopsych.2006.02.032; Bembo SA, 2004, CLEV CLIN J MED, V71, P511, DOI 10.3949/ccjm.71.6.511; Biederman J, 2005, J CHILD ADOL PSYCHOP, V15, P311, DOI 10.1089/cap.2005.15.311; Blaicher W, 1999, GYNECOL OBSTET INVES, V48, P179, DOI 10.1159/000010169; Bobes J, 2003, J SEX MARITAL THER, V29, P125, DOI 10.1080/713847170; Calarge CA, 2010, J CLIN PSYCHIAT, V71, P338, DOI 10.4088/JCP.08m04595gre; Chan NPT, 2008, J PAEDIATR CHILD H, V44, P353, DOI 10.1111/j.1440-1754.2008.01311.x; Citrome Leslie, 2008, J Psychopharmacol, V22, P90, DOI 10.1177/0269881107087373; Coker F, 2010, CNS DRUGS, V24, P563, DOI 10.2165/11533140-000000000-00000; Correll CU, 2008, INT REV PSYCHIATR, V20, P195, DOI 10.1080/09540260801889179; Correll CU, 2008, J CLIN PSYCHIAT, V69, P26; Correll CU, 2006, J AM ACAD CHILD PSY, V45, P771, DOI 10.1097/01.chi.0000220851.94392.30; Correll CU, 2006, CHILD ADOL PSYCH CL, V15, P177, DOI 10.1016/j.chc.2005.08.007; Croonenberghs J, 2005, J AM ACAD CHILD PSY, V44, P64, DOI 10.1097/01.chi.0000145805.24274.09; Cutler AJ, 2003, PSYCHONEUROENDOCRINO, V28, P69, DOI 10.1016/S0306-4530(02)00113-0; DUKE PM, 1980, PEDIATRICS, V66, P918; Emlinger M, 2002, CLIN CHEM LAB MED, V40, P1151; Findling RL, 2004, AM J PSYCHIAT, V161, P677, DOI 10.1176/appi.ajp.161.4.677; Fredriks AM, 2000, PEDIATR RES, V47, P316, DOI 10.1203/00006450-200003000-00006; Fredriks AM, 2000, ARCH DIS CHILD, V82, P107, DOI 10.1136/adc.82.2.107; Graham SM, 2011, EXPERT OPIN DRUG SAF, V10, P575, DOI 10.1517/14740338.2011.560112; Greenaway M, 2009, J CAN ACAD CHILD ADO, V18, P250; Haddad PM, 2004, DRUGS, V64, P2291, DOI 10.2165/00003495-200464200-00003; Halbreich U, 2003, PSYCHONEUROENDOCRINO, V28, P53, DOI 10.1016/S0306-4530(02)00112-9; Hanavadi S, 2006, BREAST, V15, P276, DOI 10.1016/j.breast.2005.04.007; Ho J, 2011, J CAN ACAD CHILD ADO, V20, P234; Knegtering H, 2006, J SEX MARITAL THER, V32, P315, DOI 10.1080/00926230600666378; Knegtering H, 2003, PSYCHONEUROENDOCRINO, V28, P109, DOI 10.1016/S0306-4530(02)00130-0; Knegtering R, 2005, AM J PSYCHIAT, V162, P1010, DOI 10.1176/appi.ajp.162.5.1010; Knegtering R, 2004, J CLIN PSYCHOPHARM, V24, P56, DOI 10.1097/01.jcp.0000106220.36344.04; Leone M, 2007, J SPORT MED PHYS FIT, V47, P361; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2008, J CLIN PSYCHIAT, V69, P15; McKenna TJ, 2009, CLIN ENDOCRINOL, V71, P466, DOI 10.1111/j.1365-2265.2009.03577.x; Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692; Migliardi G, 2009, PROG NEURO-PSYCHOPH, V33, P1496, DOI 10.1016/j.pnpbp.2009.08.009; Molitch ME, 2005, MAYO CLIN PROC, V80, P1050, DOI 10.4065/80.8.1050; Pollock A, 1998, CLIN ENDOCRINOL, V49, P513, DOI 10.1046/j.1365-2265.1998.00569.x; Reyes M, 2006, J CHILD ADOL PSYCHOP, V16, P260, DOI 10.1089/cap.2006.16.260; Roke Y, 2009, J CHILD ADOL PSYCHOP, V19, P403, DOI 10.1089/cap.2008.0120; Saito E, 2004, J CHILD ADOL PSYCHOP, V14, P350, DOI 10.1089/cap.2004.14.350; Saranac L, 2010, HORM RES PAEDIAT, V73, P187, DOI 10.1159/000284360; Schall JI, 2002, J PEDIATR-US, V141, P223, DOI 10.1067/mpd.2002.125907; Sikich L, 2004, NEUROPSYCHOPHARMACOL, V29, P133, DOI 10.1038/sj.npp.1300327; Snyder R, 2002, J AM ACAD CHILD PSY, V41, P1026, DOI 10.1097/00004583-200209000-00002; Staller J, 2006, J CHILD ADOL PSYCHOP, V16, P317, DOI 10.1089/cap.2006.16.317; Stephen Matthew D, 2008, Endocr Pract, V14, P840; Stevens JR, 2005, J CHILD ADOL PSYCHOP, V15, P893, DOI 10.1089/cap.2005.15.893; Stigler KA, 2009, J CHILD ADOL PSYCHOP, V19, P265, DOI 10.1089/cap.2008.093; Szarfman A, 2006, PHARMACOTHERAPY, V26, P748, DOI 10.1592/phco.26.6.748; Turgay A, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e34; Turrone P, 2002, AM J PSYCHIAT, V159, P133, DOI 10.1176/appi.ajp.159.1.133; Verhelst Johan, 2003, Treat Endocrinol, V2, P23, DOI 10.2165/00024677-200302010-00003; Vitiello B, 2009, EUR NEUROPSYCHOPHARM, V19, P629, DOI 10.1016/j.euroneuro.2009.04.008; Wacharasindhu Suttipong, 2002, Journal of the Medical Association of Thailand, V85, P308; Wink LK, 2010, CURR TREAT OPTION NE, V12, P529, DOI 10.1007/s11940-010-0091-8; Wolters HA, 2003, ACTA NEUROPSYCHIATR, V15, P274, DOI 10.1034/j.1601-5215.2003.00038.x";59;37;39;0;6;MARY ANN LIEBERT INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;DEC;2012;22;6;;;;;432;439;;10.1089/cap.2011.0109;http://dx.doi.org/10.1089/cap.2011.0109;;;8;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";055TH;23234586;Green Submitted;;;24/11/2024;WOS:000312440000006;View Full Record in Web of Science
J;"Vasa, RA; Mazurek, MO; Mahajan, R; Bennett, AE; Bernal, MP; Nozzolillo, AA; Arnold, LE; Coury, DL";;;;"Vasa, Roma A.; Mazurek, Micah O.; Mahajan, Rajneesh; Bennett, Amanda E.; Bernal, Maria Pilar; Nozzolillo, Alixandra A.; Arnold, L. Eugene; Coury, Daniel L.";;;Assessment and Treatment of Anxiety in Youth With Autism Spectrum Disorders;PEDIATRICS;;;English;Article;;;;;;;"YOUNG-PEOPLE; CHILDREN; SYMPTOMS; SLEEP; INDIVIDUALS; ADOLESCENTS; PARENT";OBJECTIVES: Anxiety is one of the most prevalent co-occurring symptoms in youth with autism spectrum disorder (ASD). The assessment and treatment recommendations proposed here are intended to help primary care providers with the assessment and treatment of anxiety in ASD. METHODS: The Autism Speaks Autism Treatment Network/Autism Intervention Research on Physical Health Anxiety Workgroup, a multidisciplinary team of clinicians and researchers with expertise in ASD, developed the clinical recommendations. The recommendations were based on available scientific evidence regarding anxiety treatments, both in youth with ASD and typically developing youth, and clinical consensus of the workgroup where data were lacking. RESULTS: Assessment of anxiety requires a systematic approach to evaluating symptoms and potential contributing factors across various developmental levels. Treatment recommendations include psychoeducation, coordination of care, and modified cognitive-behavioral therapy, particularly for children and adolescents with high-functioning ASD. Due to the limited evidence base in ASD, medications for anxiety should be prescribed cautiously with close monitoring of potential benefits and side effects. CONCLUSIONS: Assessment and treatment of clinical anxiety in youth with ASD require a standardized approach to improve outcomes for youth with ASD. Although this approach provides a framework for clinicians, clinical judgment is recommended when making decisions about individual patients.;"[Vasa, Roma A.; Mahajan, Rajneesh] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA; [Vasa, Roma A.; Mahajan, Rajneesh] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Mazurek, Micah O.] Univ Missouri, Dept Hlth Psychol, Columbia, MO USA; [Mazurek, Micah O.] Thompson Ctr Autism & Neurodev Disorder, Columbia, MO USA; [Bennett, Amanda E.] Childrens Hosp Philadelphia, Div Dev & Behav Pediat, Philadelphia, PA 19104 USA; [Bernal, Maria Pilar] Childrens Hlth Council, Palo Alto, CA USA; [Nozzolillo, Alixandra A.] Massachusetts Gen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA USA; [Nozzolillo, Alixandra A.] Harvard Univ, Sch Med, Boston, MA USA; [Arnold, L. Eugene] Ohio State Univ, Nisonger Ctr Excellence Dev Disabil, Columbus, OH 43210 USA; [Coury, Daniel L.] Ohio State Univ, Dept Dev & Behav Pediat, Columbus, OH 43210 USA";"Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; University of Missouri System; University of Missouri Columbia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Harvard Medical School; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University";Vasa, RA (corresponding author), Kennedy Krieger Inst, Ctr Autism & Related Disorders, 3901 Greenspring Ave, Baltimore, MD 21211 USA.;vasa@kennedykrieger.org;"Coury, Daniel/L-6556-2019; Mazurek, Micah/ABE-8748-2020";"Mazurek, Micah/0000-0001-7715-6538; Coury, Daniel/0000-0001-9754-3914";US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program [UA3 MC11054];US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA));This research activity was supported by a cooperative agreement UA3 MC11054 through the US Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program to the Massachusetts General Hospital. This work was conducted through the Autism Speaks Autism Treatment Network serving as the Autism Intervention Research Network on Physical Health.;"[Anonymous], PEDIAT ANXIETY DISOR; [Anonymous], PEDIATRICS S2; Ashburner J, 2010, RES AUTISM SPECT DIS, V4, P18, DOI 10.1016/j.rasd.2009.07.002; Buie T, 2010, PEDIATRICS, V125, pS1, DOI 10.1542/peds.2009-1878C; Carter MJ, 2014, THER RECREAT J, V48, P275; Cassidy A, 2008, EARLY CHILD DEV CARE, V178, P115, DOI 10.1080/03004430701491721; Chiri G, 2012, MATERN CHILD HLTH J, V16, P1081, DOI 10.1007/s10995-011-0833-6; Dabrowska A, 2010, J INTELL DISABIL RES, V54, P266, DOI 10.1111/j.1365-2788.2010.01258.x; Davis TE, 2012, BEHAV THER, V43, P142, DOI 10.1016/j.beth.2011.05.003; Gjevik E, 2011, J AUTISM DEV DISORD, V41, P761, DOI 10.1007/s10803-010-1095-7; Golnik A, 2009, PEDIATRICS, V123, P966, DOI 10.1542/peds.2008-1321; Guénolé F, 2011, SLEEP MED REV, V15, P379, DOI 10.1016/j.smrv.2011.02.001; Hagopian L., 2014, Handbook of Autism and Anxiety, P155; Hsia YF, 2014, PSYCHOPHARMACOLOGY, V231, P999, DOI 10.1007/s00213-013-3263-x; Ji NY, 2015, CURR OPIN PSYCHIATR, V28, P91, DOI 10.1097/YCO.0000000000000132; Kerns CM, 2015, BEHAV THER, V46, P29, DOI 10.1016/j.beth.2014.03.005; Kerns CM, 2015, AUTISM, V19, P969, DOI 10.1177/1362361314558465; Kerns CM, 2014, J AUTISM DEV DISORD, V44, P2851, DOI 10.1007/s10803-014-2141-7; Kotagal S, 2012, PEDIATR NEUROL, V47, P242, DOI 10.1016/j.pediatrneurol.2012.05.007; Kreiser NL, 2014, CLIN PSYCHOL-SCI PR, V21, P18, DOI 10.1111/cpsp.12057; Lecavalier L, 2014, J AUTISM DEV DISORD, V44, P1128, DOI 10.1007/s10803-013-1974-9; Lerner MD, 2012, J AUTISM DEV DISORD, V42, P2680, DOI 10.1007/s10803-012-1525-9; Lickel A, 2012, J AUTISM DEV DISORD, V42, P992, DOI 10.1007/s10803-011-1330-x; Lidstone J, 2014, RES AUTISM SPECT DIS, V8, P82, DOI 10.1016/j.rasd.2013.10.001; Losh M, 2006, DEV PSYCHOL, V42, P809, DOI 10.1037/0012-1649.42.5.809; Magiati I, 2014, RES AUTISM SPECT DIS, V8, P546, DOI 10.1016/j.rasd.2014.01.015; Mahajan R, 2012, PEDIATRICS, V130, pS125, DOI 10.1542/peds.2012-0900J; Negreiros J, 2014, CLIN PSYCHOL-SCI PR, V21, P3, DOI 10.1111/cpsp.12060; Nguyen M, 2014, CLIN PEDIATR, V53, P211, DOI 10.1177/0009922813502123; Ozsivadjian A, 2012, AUTISM, V16, P107, DOI 10.1177/1362361311431703; Politte LC, 2014, HARVARD REV PSYCHIAT, V22, P76, DOI 10.1097/HRP.0000000000000030; Read K.L., 2013, Pediatric anxiety disorders: A clinical guide, P269; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Storch EA, 2012, J DEV PHYS DISABIL, V24, P575, DOI 10.1007/s10882-012-9290-4; Strawn JR, 2015, DEPRESS ANXIETY, V32, P149, DOI 10.1002/da.22329; Thompson SA, 2000, BMJ-BRIT MED J, V321, P1002, DOI 10.1136/bmj.321.7267.1002; Ung D, 2015, CHILD PSYCHIAT HUM D, V46, P533, DOI 10.1007/s10578-014-0494-y; van Steensel FJA, 2013, AUTISM, V17, P681, DOI 10.1177/1362361312455875; van Steensel FJA, 2011, CLIN CHILD FAM PSYCH, V14, P302, DOI 10.1007/s10567-011-0097-0; Vasa RA, 2014, J AUTISM DEV DISORD, V44, P3215, DOI 10.1007/s10803-014-2184-9; Walkup J, 2001, J CHILD ADOL PSYCHOP, V11, P1, DOI 10.1089/104454601750143320; White SW, 2015, BEHAV THER, V46, P40, DOI 10.1016/j.beth.2014.05.005; White SW, 2009, CLIN PSYCHOL REV, V29, P216, DOI 10.1016/j.cpr.2009.01.003; Wigham S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085268; Wood JJ, 2010, CLIN PSYCHOL-SCI PR, V17, P281, DOI 10.1111/j.1468-2850.2010.01220.x";45;79;88;0;39;AMER ACAD PEDIATRICS;Itasca;345 Park Boulevard, Itasca, IL, UNITED STATES;0031-4005;1098-4275;;PEDIATRICS;Pediatrics;FEB;2016;137;;;2;;;S115;S123;;10.1542/peds.2015-2851J;http://dx.doi.org/10.1542/peds.2015-2851J;;;9;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;DF5LR;26908467;Bronze;;;24/11/2024;WOS:000371393700009;View Full Record in Web of Science
J;"Simonoff, E; Mowlem, F; Pearson, O; Anagnostou, E; Donnelly, C; Hollander, E; King, BH; McCracken, JT; Scahill, L; Sikich, L; Pickles, A";;;;"Simonoff, Emily; Mowlem, Florence; Pearson, Oliver; Anagnostou, Evdokia; Donnelly, Craig; Hollander, Eric; King, Bryan H.; McCracken, James T.; Scahill, Lawrence; Sikich, Linmarie; Pickles, Andrew";;;Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism; autistic disorder; randomized controlled trial; selective serotonin reuptake inhibitors; anxiety";"PERVASIVE DEVELOPMENTAL DISORDERS; PSYCHIATRIC-DISORDERS; CROSSOVER TRIAL; ADVERSE EVENTS; METHYLPHENIDATE; ASSOCIATION; ADOLESCENTS; FLUOXETINE; CHILDHOOD; PRESCHOOL";Objective: Anxiety disorders are among the most common co-occurring conditions in autism spectrum disorder (ASD). Despite their prevalence and impact, there are no randomized controlled trials (RCTs) aimed at evaluating the efficacy of selective serotonin reuptake inhibitors (SSRIs) for anxiolysis in this population, who may have a different biological basis for anxiety.Methods: Secondary analyses of the STAART double-blind, placebo-controlled RCT of citalopram in children with ASD examined whether citalopram reduced anxiety measured on the parent-reported Child and Adolescent Symptom Inventory-4 (CASI-4) as the primary outcome. An intention-to-treat analysis involving all 149 participants used multiple imputations for missing data and included baseline stratification factors of age group and site, among others. We prespecified as clinically significant a 33% reduction in anxiety in citalopram versus placebo, coinciding with 80% power. We tested whether communicative ability on the Vineland Communication score moderated treatment effect and explored whether initial anxiety was associated with greater adverse events, which could impact on dose titration and achieving optimal dose.Results: Both groups showed substantial reduction in anxiety. Citalopram was associated with a nonsignificant 16.5% greater reduction (observed coefficient = -0.181, bootstrap standard error = 0.126, p = 0.151, confidence interval = -0.428 to 0.066). Anxiety reports were significantly lower in children with reduced communicative ability, but communicative ability did not moderate the treatment effect (interaction p = 0.294). Initial anxiety levels were not associated with increased adverse effects (interaction ps 0.162-0.954).Conclusion: Citalopram did not statistically significantly improve anxiety in children with ASD. Clinicians should be cautious in their use of SSRIs for this indication. There remains a need for well-powered clinical trials testing the efficacy of SSRIs among autistic children with anxiety disorders.;"[Simonoff, Emily] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Child & Adolescent Psychiat, Box 85,DeCrespigny Pk, London SE5 8AF, England; [Mowlem, Florence; Pearson, Oliver; Pickles, Andrew] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Biostat & Hlth Informat, London, England; [Mowlem, Florence; Pearson, Oliver; Pickles, Andrew] Kings Coll London, Maudsley Biomed Res Ctr Mental Hlth, London, England; [Anagnostou, Evdokia] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada; [Anagnostou, Evdokia] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Donnelly, Craig] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Hollander, Eric] Albert Einstein Coll Med, Psychiat Res Inst Montefiore Einstein, Autism & Obsess Compuls Spectrum Program, Bronx, NY 10467 USA; [King, Bryan H.] Univ Calif San Francisco, Dept Psychiat, Weill Inst Neurosci, San Francisco, CA USA; [McCracken, James T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Scahill, Lawrence] Emory Univ, Sch Med, Dept Pediat, Marcus Autism Ctr, Atlanta, GA USA; [Sikich, Linmarie] Duke Univ, Sch Med, Dept Psychiat, Duke Ctr Autism & Brain Dev, Durham, NC USA";"University of London; King's College London; University of London; King's College London; University of Toronto; Holland Bloorview Kids Rehabilitation Hospital; University of Toronto; Dartmouth College; Yeshiva University; Montefiore Medical Center; Albert Einstein College of Medicine; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Emory University; Duke University";Simonoff, E (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Child & Adolescent Psychiat, Box 85,DeCrespigny Pk, London SE5 8AF, England.;emily.simonoff@kcl.ac.uk;"Simonoff, Emily/B-7593-2011; Pickles, Andrew/A-9625-2011";"Pearson, Oliver/0000-0003-1149-9284; Pickles, Andrew/0000-0003-1283-0346; Simonoff, Emily/0000-0002-5450-0823";;;;"Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P116, DOI 10.1089/cap.2005.15.116; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; [Anonymous], 2021, Stata statistical software: Release 17; Baldwin D, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1199; Buchsbaum MS, 2001, INT J NEUROPSYCHOPH, V4, P119, DOI 10.1017/S1461145701002280; Gabriele S, 2014, EUR NEUROPSYCHOPHARM, V24, P919, DOI 10.1016/j.euroneuro.2014.02.004; Gadow KD, 2004, J AUTISM DEV DISORD, V34, P379, DOI 10.1023/B:JADD.0000037415.21458.93; Gadow KD., 2002, CHILD SYNPTOM INVENT; Greenhill LL, 2004, J AM ACAD CHILD PSY, V43, P1488, DOI 10.1097/01.chi.0000142668.29191.13; Guy W., 1976, Clinical global impression. ECDEU assessment manual for psychopharmacology, P218; Hallett V, 2013, J CHILD PSYCHOL PSYC, V54, P1176, DOI 10.1111/jcpp.12068; Hallett V, 2013, J AUTISM DEV DISORD, V43, P2341, DOI 10.1007/s10803-013-1775-1; Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627; Houghton R, 2017, AUTISM RES, V10, P2037, DOI 10.1002/aur.1848; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Hsia YF, 2014, PSYCHOPHARMACOLOGY, V231, P999, DOI 10.1007/s00213-013-3263-x; KANNER L, 1968, ACTA PAEDOPSYCHIATR, V35, P100; Kent R., 2017, Anxiety in Children and Adolescents with Autism Spectrum Disorder, P5, DOI [10.1016/B978-0-12-805122-1.00002-8, DOI 10.1016/B978-0-12-805122-1.00002-8S, DOI 10.1016/B978-0-12-805122-1.00002-8]; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Lever AG, 2016, J AUTISM DEV DISORD, V46, P1916, DOI 10.1007/s10803-016-2722-8; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Mikita N, 2015, J CHILD PSYCHOL PSYC, V56, P1118, DOI 10.1111/jcpp.12382; National Collaborating Centre for Mental Health, 2013, MANAGEMENT SUPPORT C; Oswald DP, 2007, J CHILD ADOL PSYCHOP, V17, P348, DOI 10.1089/cap.2006.17303; Safer DJ, 2006, J CHILD ADOL PSYCHOP, V16, P159, DOI 10.1089/cap.2006.16.159; Salazar F, 2015, J AUTISM DEV DISORD, V45, P2283, DOI 10.1007/s10803-015-2361-5; Scahill L, 2006, J AM ACAD CHILD PSY, V45, P1114, DOI 10.1097/01.chi.0000220854.79144.e7; Scahill L, 2019, J AM ACAD CHILD PSY, V58, P887, DOI 10.1016/j.jaac.2018.10.016; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Simonoff E, 2013, J CHILD PSYCHOL PSYC, V54, P703, DOI 10.1111/jcpp.12098; Simonoff E, 2013, J CHILD PSYCHOL PSYC, V54, P186, DOI 10.1111/j.1469-7610.2012.02606.x; Sprafkin J., 1997, CHILD ADOLESCENT SYM; Strawn JR, 2014, BIPOLAR DISORD, V16, P523, DOI 10.1111/bdi.12113; Stringer D, 2020, AUTISM, V24, P1011, DOI 10.1177/1362361320908972; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; Thorkelson G, 2019, J CHILD ADOL PSYCHOP, V29, P705, DOI 10.1089/cap.2019.0001; Vasa RA, 2014, J AUTISM DEV DISORD, V44, P3215, DOI 10.1007/s10803-014-2184-9; Wagner KD, 2004, AM J PSYCHIAT, V161, P1079, DOI 10.1176/appi.ajp.161.6.1079; Walkup JT, 2008, NEW ENGL J MED, V359, P2753, DOI 10.1056/NEJMoa0804633; Walkup JT, 2001, NEW ENGL J MED, V344, P1279, DOI 10.1056/NEJM200104263441703; Wallace S., 2014, 100 PUTTING FAMILIES; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Williams K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004677.pub3, 10.1002/14651858.CD007407.pub3]";48;2;3;0;1;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;MAY 1;2022;32;4;;;;;233;241;;10.1089/cap.2021.0137;http://dx.doi.org/10.1089/cap.2021.0137;;;9;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";1J9QB;35501967;Green Published, Green Submitted;;;24/11/2024;WOS:000798245200004;View Full Record in Web of Science
J;"Ameis, SH; Blumberger, DM; Croarkin, PE; Mabbott, DJ; Lai, MC; Desarkar, P; Szatmari, P; Daskalakis, ZJ";;;;"Ameis, Stephanie H.; Blumberger, Daniel M.; Croarkin, Paul E.; Mabbott, Donald J.; Lai, Meng-Chuan; Desarkar, Pushpal; Szatmari, Peter; Daskalakis, Zafiris J.";;;Treatment of Executive Function Deficits in autism spectrum disorder with repetitive transcranial magnetic stimulation: A double-blind, sham-controlled, pilot trial;BRAIN STIMULATION;;;English;Article;;;;;;"Autism; Clinical trial; Repetitive transcranial magnetic stimulation; Intervention; Executive functioning; Youth";"NEGATIVE SYMPTOMS; ADAPTIVE-BEHAVIOR; RANDOMIZED-TRIAL; SCHIZOPHRENIA; CHILDREN; RTMS; CONNECTIVITY; DEPRESSION; SEX/GENDER; EFFICACY";Background: In youth and young adults with autism spectrum disorder (ASD), executive function (EF) deficits may be a promising treatment target with potential impact on everyday functioning. Objective: To conduct a pilot randomized, double-blind, parallel, controlled trial evaluating repetitive transcranial magnetic stimulation (rTMS) for EF deficits in ASD. Method: In Toronto, Ontario (November 2014 to June 2017), a 20-session, 4-week course of 20 Hz rTMS targeting dorsolateral prefrontal cortex (DLPFC) (90%RMT) was compared to sham stimulation in 16-35 year-olds with ASD (28 male/12 female), without intellectual disability, who had impaired everyday EF performance (n = 20 active/n = 20 sham). Outcome measures evaluated protocol feasibility and clinical effects of active vs. sham rTMS on EF performance. The moderating effect of baseline functioning was explored. Results: Of eligible participants, 95% were enrolled and 95% of randomized participants completed the protocol. Adverse events across treatment arms were mild-to-moderate. There was no significant difference between active vs. sham rTMS on EF performance. Baseline adaptive functioning moderated the effect of rTMS, such that participants with lower baseline functioning experienced significant EF improvement in the active vs. sham group. Conclusions: Our pilot RCT demonstrated the feasibility and acceptability of using high frequency rTMS targeting DLPFC in youth and young adults with autism. No evidence for efficacy of active versus sham rTMS on EF performance was found. However, we found promising preliminary evidence of EF performance improvement following active versus sham rTMS in participants with ASD with more severe adaptive functioning deficits. Future work could focus on examining efficacy of rTMS in this higher-need population. Crown Copyright (C) 2020 Published by Elsevier Inc.;"[Ameis, Stephanie H.; Mabbott, Donald J.; Lai, Meng-Chuan; Szatmari, Peter] Hosp Sick Children, Ctr Brain & Mental Hlth, Sick Kids Res Inst, Program Neurosci & Mental Hlth, Toronto, ON, Canada; [Ameis, Stephanie H.; Lai, Meng-Chuan; Szatmari, Peter] Ctr Addict & Mental Hlth, Margaret & Wallace McCain Ctr Child Youth & Famil, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada; [Ameis, Stephanie H.; Blumberger, Daniel M.; Lai, Meng-Chuan; Desarkar, Pushpal; Szatmari, Peter; Daskalakis, Zafiris J.] Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON, Canada; [Blumberger, Daniel M.; Desarkar, Pushpal; Daskalakis, Zafiris J.] Ctr Addict & Mental Hlth, Temerty Ctr Therapeut Brain Intervent, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada; [Croarkin, Paul E.] Mayo Clin, Div Child & Adolescent Psychiat, Dept Psychiat & Psychol, Rochester, MN USA; [Mabbott, Donald J.; Lai, Meng-Chuan] Univ Toronto, Dept Psychol, Toronto, ON, Canada";"University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; Centre for Addiction & Mental Health - Canada; Mayo Clinic; University of Toronto";Ameis, SH (corresponding author), Ctr Addict & Mental Hlth, 80 Workman Way 5224, Toronto, ON M6J 1H4, Canada.;stephanie.ameis@camh.ca;"Lai, Meng-Chuan/K-7407-2016; Ameis, Stephanie/AEC-1647-2022; Croarkin, Paul/I-3310-2014";"Ameis, Stephanie/0000-0002-7282-6077; Noda, Yoshihiro/0000-0002-2155-0357; Croarkin, Paul/0000-0001-6843-6503";"CFAK; University of Toronto, Faculty of Medicine, Dean's Fund New Staff Grant; Alternate Funding Plan of the Academic Health Sciences Centres of Ontario; Ontario Mental Health Foundation (OMHF); Canadian Institutes of Health Research (CIHR); National Institutes of Mental Health (NIMH); O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Centre for Addiction and Mental Health (CAMH); O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Hospital for Sick Children; O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the University of Toronto; Slaight Family Child and Youth Mental Health Innovation Fund (CAMH Foundation); Catherine and Maxwell Meighen Foundation (CAMH Foundation); Department of Psychiatry, University of Toroto; Ontario Brain Institute via the Province of Ontario Neurodevelopmental Disorders (POND) Network; CIHR; NIH; Brain Canada; Temerty Family Foundation through the CAMH Foundation; Temerty Family Foundation through the Campbell Family Mental Health Research Institute; OMHF; NIMH; Temerty Family; Grant Family; Centre for Addiction and Mental Health Foundation; Campbell Institute; Patsy and Jamie Anderson in Child and Youth Mental Health; Scottish Rite Charitable Foundation of Canada Research Grant; Caskey/Francis Clinical Research Award; [R01 MH113700]";"CFAK; University of Toronto, Faculty of Medicine, Dean's Fund New Staff Grant; Alternate Funding Plan of the Academic Health Sciences Centres of Ontario; Ontario Mental Health Foundation (OMHF); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Institutes of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Centre for Addiction and Mental Health (CAMH); O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Hospital for Sick Children; O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the University of Toronto; Slaight Family Child and Youth Mental Health Innovation Fund (CAMH Foundation); Catherine and Maxwell Meighen Foundation (CAMH Foundation); Department of Psychiatry, University of Toroto; Ontario Brain Institute via the Province of Ontario Neurodevelopmental Disorders (POND) Network; CIHR(Canadian Institutes of Health Research (CIHR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brain Canada; Temerty Family Foundation through the CAMH Foundation; Temerty Family Foundation through the Campbell Family Mental Health Research Institute; OMHF; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Temerty Family; Grant Family; Centre for Addiction and Mental Health Foundation; Campbell Institute; Patsy and Jamie Anderson in Child and Youth Mental Health; Scottish Rite Charitable Foundation of Canada Research Grant; Caskey/Francis Clinical Research Award;";"This publication was made possible through the Catherine and Maxwell Meighen FoundationAmerican Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Award for Child and Adolescent Psychiatry Residents and Junior Faculty (to SHA), supported by CFAK; its contents are the responsibility of the authors and do not necessarily reflect the official views of AACAP. This research was also supported by: the University of Toronto, Faculty of Medicine, Dean's Fund New Staff Grant, the Innovation Fund from the Alternate Funding Plan of the Academic Health Sciences Centres of Ontario, an Ontario Mental Health Foundation (OMHF) Project A Grant and New Investigator Fellowship (to SHA). SHA receives support from the Canadian Institutes of Health Research (CIHR), and the National Institutes of Mental Health (NIMH). SHA and M-CL are supported by the O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Centre for Addiction and Mental Health (CAMH),The Hospital for Sick Children and University of Toronto, the Slaight Family Child and Youth Mental Health Innovation Fund and The Catherine and Maxwell Meighen Foundation (both via CAMH Foundation). This work was also supported in part by an Academic Scholars Award from the Department of Psychiatry, University of Toroto (to SHA and M-CL). M-CL is also supported by the Ontario Brain Institute via the Province of Ontario Neurodevelopmental Disorders (POND) Network. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family Foundation through the CAMH Foundation and the Campbell Family Mental Health Research Institute. ZJD was supported by the OMHF, CIHR, NIMH and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health Foundation and the Campbell Institute. PEC was supported by R01 MH113700. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. PS is supported by the Patsy and Jamie Anderson in Child and Youth Mental Health. PD is currently supported by Scottish Rite Charitable Foundation of Canada Research Grant and Caskey/Francis Clinical Research Award.";"Ameis SH, 2017, J CHILD ADOL PSYCHOP, V27, P413, DOI 10.1089/cap.2016.0146; Ameis SH, 2016, AM J PSYCHIAT, V173, P1213, DOI 10.1176/appi.ajp.2016.15111435; Barr MS, 2013, BIOL PSYCHIAT, V73, P510, DOI 10.1016/j.biopsych.2012.08.020; Benson N, 2010, PSYCHOL ASSESSMENT, V22, P121, DOI 10.1037/a0017767; Barahona-Corrêa JB, 2018, FRONT INTEGR NEUROSC, V12, DOI 10.3389/fnint.2018.00027; Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2; Chatham CH, 2018, AUTISM RES, V11, P270, DOI 10.1002/aur.1874; Cole MW, 2013, NAT NEUROSCI, V16, P1348, DOI 10.1038/nn.3470; Craig F, 2016, NEUROPSYCH DIS TREAT, V12, P1191, DOI 10.2147/NDT.S104620; Dajani DR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36566; Daskalakis ZJ, 2006, EXP BRAIN RES, V174, P403, DOI 10.1007/s00221-006-0472-0; de Jesus DR, 2014, CLIN NEUROPHYSIOL, V125, P755, DOI 10.1016/j.clinph.2013.09.011; Demetriou EA, 2018, MOL PSYCHIATR, V23, P1198, DOI 10.1038/mp.2017.75; Dlabac-de Lange JJ, 2015, PSYCHOL MED, V45, P1263, DOI 10.1017/S0033291714002360; Duncan L, 2018, PSYCHOL ASSESSMENT, V30, P916, DOI 10.1037/pas0000541; Enticott PG, 2014, BRAIN STIMUL, V7, P206, DOI 10.1016/j.brs.2013.10.004; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; George MS, 2009, BRAIN STIMUL, V2, P14, DOI 10.1016/j.brs.2008.06.001; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Guse B, 2010, J NEURAL TRANSM, V117, P105, DOI 10.1007/s00702-009-0333-7; Hasan A, 2016, SCHIZOPHRENIA BULL, V42, P608, DOI 10.1093/schbul/sbv142; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Howlin P, 2012, CAN J PSYCHIAT, V57, P275, DOI 10.1177/070674371205700502; Huber TJ, 2003, PSYCHIAT RES, V120, P103, DOI 10.1016/S0165-1781(03)00170-7; Hull L, 2017, AUTISM, V21, P706, DOI 10.1177/1362361316669087; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Kim SYH, 2007, BRIT J PSYCHIAT, V191, P38, DOI 10.1192/bjp.bp.106.033324; Koshino H, 2005, NEUROIMAGE, V24, P810, DOI 10.1016/j.neuroimage.2004.09.028; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Lai MC, 2017, J NEUROSCI RES, V95, P380, DOI 10.1002/jnr.23948; Lai MC, 2015, J AM ACAD CHILD PSY, V54, P11, DOI 10.1016/j.jaac.2014.10.003; Lazoff T, 2010, CAN J PSYCHIAT, V55, P715, DOI 10.1177/070674371005501105; Lee EC, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-41; Loomes R, 2017, J AM ACAD CHILD PSY, V56, P466, DOI 10.1016/j.jaac.2017.03.013; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Luna B, 2002, NEUROLOGY, V59, P834, DOI 10.1212/WNL.59.6.834; Lynch CJ, 2017, BIOL PSYCHIAT-COGN N, V2, P537, DOI 10.1016/j.bpsc.2017.03.008; McClintock SM, 2018, J CLIN PSYCHIAT, V79, P35, DOI 10.4088/JCP.16cs10905; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; Mogg A, 2007, SCHIZOPHR RES, V93, P221, DOI 10.1016/j.schres.2007.03.016; Pellicano Elizabeth, 2012, Autism Res Treat, V2012, P146132, DOI 10.1155/2012/146132; Pinkham AE, 2020, PSYCHOL MED, V50, P2557, DOI 10.1017/S0033291719002708; Plitt M, 2015, P NATL ACAD SCI USA, V112, pE6699, DOI 10.1073/pnas.1510098112; Rosa M, 2017, J AUTISM DEV DISORD, V47, P2153, DOI 10.1007/s10803-017-3137-x; Rosenthal M, 2013, NEUROPSYCHOLOGY, V27, P13, DOI 10.1037/a0031299; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rusjan PM, 2010, HUM BRAIN MAPP, V31, P1643, DOI 10.1002/hbm.20964; Selya AS, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00111; Sokhadze EM, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00134; Sokhadze EM, 2012, APPL PSYCHOPHYS BIOF, V37, P91, DOI 10.1007/s10484-012-9182-5; SPARROW SS, 1985, J PEDIATR PSYCHOL, V10, P215, DOI 10.1093/jpepsy/10.2.215; SZATMARI P, 1989, J AUTISM DEV DISORD, V19, P213, DOI 10.1007/BF02211842; Szatmari P, 2015, JAMA PSYCHIAT, V72, P276, DOI 10.1001/jamapsychiatry.2014.2463; Tillmann J, 2019, AUTISM RES, V12, P645, DOI 10.1002/aur.2081; Vogan VM, 2014, J NEURODEV DISORD, V6, DOI 10.1186/1866-1955-6-19; Wang Y, 2017, NEUROPSYCHOL REV, V27, P46, DOI 10.1007/s11065-016-9336-y; Whitehead AL, 2016, STAT METHODS MED RES, V25, P1057, DOI 10.1177/0962280215588241; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3; Wölwer W, 2014, BRAIN STIMUL, V7, P559, DOI 10.1016/j.brs.2014.04.011";60;49;53;10;31;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;1935-861X;1876-4754;;BRAIN STIMUL;Brain Stimul.;MAY-JUN;2020;13;3;;;;;539;547;;10.1016/j.brs.2020.01.007;http://dx.doi.org/10.1016/j.brs.2020.01.007;;;9;"Clinical Neurology; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;LO3IP;32289673;gold, Green Accepted;;;24/11/2024;WOS:000533522600006;View Full Record in Web of Science
J;"Parellada, M; Llorente, C; Calvo, R; Gutierrez, S; Lázaro, L; Graell, M; Guisasola, M; Dorado, ML; Boada, L; Romo, J; Dulin, E; Sanz, I; Arango, C; Moreno, C";;;;"Parellada, Mara; Llorente, Cloe; Calvo, Rosa; Gutierrez, Silvia; Lazaro, Luisa; Graell, Montserrat; Guisasola, Maria; Luisa Dorado, Maria; Boada, Leticia; Romo, Jose; Dulin, Elena; Sanz, Inmaculada; Arango, Celso; Moreno, Carmen";;;Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior;EUROPEAN NEUROPSYCHOPHARMACOLOGY;;;English;Article;;;;;;"Randomized controlled trials; Autism Spectrum Disorder; Fatty acids, omega-3; Fatty acids, unsaturated; Biomarkers";"POLYUNSATURATED FATTY-ACIDS; BODY-MASS INDEX; DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS; YOUNG-CHILDREN; OMEGA-3-FATTY-ACIDS; BRAIN; AGE; SUPPLEMENTATION; INCREASE";"A high omega 6/omega 3 ratio [fatty acid (FA) index] in the cell membrane has been associated with inadequate brain development. It has started to be used as a biomarker of treatment efficacy in human diseases. The aim of this study was to investigate if omega-3 supplementation improves erythrocyte membrane omega 6/omega 3, plasma antioxidant status (TAS) and autistic behaviors. A randomized, crossover, placebo-controlled study was designed to investigate the effect of 8 weeks of supplementation with omega 3 (962 mg/d and 1155 mg/d for children and adolescents, respectively). Sixty-eight children and adolescents with Autism Spectrum Disorders (ASD) completed the full protocol. Primary outcome measures were erythrocyte membrane FA composition and TAS. Secondary outcome measures were Social Responsiveness Scale and Clinical Global Impression-Severity. Treatment with omega 3 improved the erythrocyte membrane omega 6/omega 3 ratio (treatment effect p<0.008, d=0.66; within subjects effect p<0.007, d=0.5) without changing TAS. There was a within subjects significant improvement in Social Motivation and Social Communication subscales scores, with a moderate to large effect size (p=0.004, d=0.73 and p=0.025, d=0.79 respectively), but no treatment effect (treatment-placebo order). Carryover effects cannot be discarded as responsible for the results in behavioral measures. In conclusion, supplementation with (03 FA might be studied as an add-on to behavioral therapies in ASD. Optimal duration of treatment requires further investigation. With regard to side effects, the effect of this supplementation on the lipid profile needs monitoring. (C) 2017 Elsevier B.V. and ECNP. All rights reserved.";"[Parellada, Mara; Llorente, Cloe; Luisa Dorado, Maria; Boada, Leticia; Romo, Jose; Arango, Celso; Moreno, Carmen] Hosp Gen Univ Gregorio Maranon, Child & Adolescent Psychiat Dept, Madrid, Spain; [Parellada, Mara; Boada, Leticia; Arango, Celso; Moreno, Carmen] CIBERSAM, IiSGM, Barcelona, Spain; [Parellada, Mara; Guisasola, Maria; Arango, Celso; Moreno, Carmen] Univ Complutense, Sch Med, Madrid, Spain; [Guisasola, Maria] Hosp Gen Univ Gregorio Maranon, Expt Med, Madrid, Spain; [Calvo, Rosa; Lazaro, Luisa] Hosp Clin Barcelona, CIBERSAM, Barcelona, Spain; [Gutierrez, Silvia; Graell, Montserrat] UCM, Fac Med, Hosp Gen Univ Gregorio Maranon, Hosp Infantil Nino Jesus Madrid,CIBERSAM, Madrid, Spain; [Dulin, Elena; Sanz, Inmaculada] Hosp Gen Univ Gregorio Maranon, Biochem Dept, Madrid, Spain";"General University Gregorio Maranon Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; University of Barcelona; Complutense University of Madrid; General University Gregorio Maranon Hospital; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Complutense University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; General University Gregorio Maranon Hospital; General University Gregorio Maranon Hospital";Parellada, M (corresponding author), UCM, Hosp Gen Univ Gregorio Maranon, Child & Adolescent Psychiat Dept, IiSGM,CIBERSAM, Ibiza 43, Madrid 28009, Spain.;parelladahggm@gmail.com;"Moreno, Carmen/AAQ-1079-2021; Parellada, Mara/AAQ-1272-2021; Arango, Celso/AAZ-8314-2021; Arango, Celso/H-6433-2015; Calvo-Escalona, Rosa/L-3556-2017";"Parellada, Mara/0000-0001-7977-3601; Moreno, Carmen/0000-0003-0541-4846; Arango, Celso/0000-0003-3382-4754; Lazaro, Luisa/0000-0002-8425-5750; Calvo-Escalona, Rosa/0000-0001-9572-4228";"Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III [FIS EC07/90076]; Alicia Koplowitz Foundation (FAK); [CB/07/09/0023]";"Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III; Alicia Koplowitz Foundation (FAK);";"The study was funded by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (FIS EC07/90076); (CB/07/09/0023), and the Alicia Koplowitz Foundation(FAK 2017).";"Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; [Anonymous], STAT POWER ANAL BEHA; [Anonymous], MOL PSYCHIAT; [Anonymous], 1976, CDEU ASSESSMENT MANU; Arab K, 2006, BRIT J NUTR, V95, P18, DOI 10.1079/BJN20051626; Azad GF, 2016, SCH MENT HEALTH, V8, P368, DOI 10.1007/s12310-015-9168-6; Baker JP, 2013, NEW ENGL J MED, V369, P1089, DOI 10.1056/NEJMp1306380; Bell JG, 2004, PROSTAG LEUKOTR ESS, V71, P201, DOI 10.1016/j.plefa.2004.03.008; Bent S, 2014, J AM ACAD CHILD PSY, V53, P658, DOI 10.1016/j.jaac.2014.01.018; Bent S, 2011, J AUTISM DEV DISORD, V41, P545, DOI 10.1007/s10803-010-1078-8; Bos DJ, 2016, EUR NEUROPSYCHOPHARM, V26, P546, DOI 10.1016/j.euroneuro.2015.12.031; Brigandi SA, 2015, INT J MOL SCI, V16, P10061, DOI 10.3390/ijms160510061; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Chang J, 2015, NAT NEUROSCI, V18, P191, DOI 10.1038/nn.3907; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Constantino JN, 2000, J DEV BEHAV PEDIATR, V21, P2, DOI 10.1097/00004703-200002000-00002; Corsi L., 2015, INT J FOOD SCI NUTR, P1; Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598; De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772; Delorme R, 2013, NAT MED, V19, P685, DOI 10.1038/nm.3193; DiStefano C., 2016, AUTISM RES; Ferreira CF, 2015, NEUROCHEM RES, V40, P1870, DOI 10.1007/s11064-015-1679-x; Flock MR, 2014, PROSTAG LEUKOTR ESS, V91, P161, DOI 10.1016/j.plefa.2014.07.006; Flock MR, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000513; Gupta S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6748; Haag M, 2003, CAN J PSYCHIAT, V48, P195, DOI 10.1177/070674370304800308; Harris WS, 2007, PHARMACOL RES, V55, P217, DOI 10.1016/j.phrs.2007.01.013; Harris WS, 2013, PROSTAG LEUKOTR ESS, V88, P257, DOI 10.1016/j.plefa.2012.12.004; Helland IB, 2008, PEDIATRICS, V122, pE472, DOI 10.1542/peds.2007-2762; Iossifov I, 2014, NATURE, V515, P216, DOI 10.1038/nature13908; Jakobik V, 2009, EUR J PEDIATR, V168, P141, DOI 10.1007/s00431-008-0719-9; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Kim HY, 2011, BIOCHEM J, V435, P327, DOI 10.1042/BJ20102118; Koren G, 2015, CAN FAM PHYSICIAN, V61, P41; Krug D. A., 1980, SCREENING INSTRUMENT; Lingjaerde O, 1987, Acta Psychiatr Scand Suppl, V334, P1; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Luchtman DW, 2013, NEUROPHARMACOLOGY, V64, P550, DOI 10.1016/j.neuropharm.2012.07.019; Makrides M, 2010, JAMA-J AM MED ASSOC, V304, P1675, DOI 10.1001/jama.2010.1507; Mankad D, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0010-7; Marteinsdottir I, 1998, PROG NEURO-PSYCHOPH, V22, P1007, DOI 10.1016/S0278-5846(98)00052-9; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Meguid NA, 2008, CLIN BIOCHEM, V41, P1044, DOI 10.1016/j.clinbiochem.2008.05.013; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; Parellada M, 2013, EUR PSYCHIAT, V28, P102, DOI 10.1016/j.eurpsy.2011.06.004; Parellada M, 2012, J PSYCHIATR RES, V46, P394, DOI 10.1016/j.jpsychires.2011.10.004; Parikshak NN, 2013, CELL, V155, P1008, DOI 10.1016/j.cell.2013.10.031; Parletta N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156432; Persico AM, 2015, EUR NEUROPSYCHOPHARM, V25, P1513, DOI 10.1016/j.euroneuro.2015.06.009; Richard D, 2008, PHARMACOL RES, V57, P451, DOI 10.1016/j.phrs.2008.05.002; Richardson AJ, 2005, PEDIATRICS, V115, P1360, DOI 10.1542/peds.2004-2164; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sands SA, 2005, LIPIDS, V40, P343, DOI 10.1007/s11745-006-1392-2; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Simopoulos AP, 2011, WORLD REV NUTR DIET, V102, P10, DOI 10.1159/000327785; Smesny S, 2014, MOL PSYCHIATR, V19, P317, DOI 10.1038/mp.2013.7; Stoner R, 2014, NEW ENGL J MED, V370, P1209, DOI 10.1056/NEJMoa1307491; van Elst K, 2014, NEUROSCI BIOBEHAV R, V45, P369, DOI 10.1016/j.neubiorev.2014.07.004; Vancassel S, 2001, PROSTAG LEUKOTR ESS, V65, P1, DOI 10.1054/plef.2001.0281; Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013; Weiser M. J., 2015, PROSTAGLANDINS LEUKO; Weiser MJ, 2016, PROSTAG LEUKOTR ESS, V106, P27, DOI 10.1016/j.plefa.2015.10.005";64;44;46;0;29;ELSEVIER SCIENCE BV;AMSTERDAM;PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS;0924-977X;1873-7862;;EUR NEUROPSYCHOPHARM;Eur. Neuropsychopharmacol.;DEC;2017;27;12;;;;;1319;1330;;10.1016/j.euroneuro.2017.08.426;http://dx.doi.org/10.1016/j.euroneuro.2017.08.426;;;12;"Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";FO2WL;28935269;;;;24/11/2024;WOS:000416657800012;View Full Record in Web of Science
J;"Nardello, R; Guccione, F; Gliubizzi, C; Marino, A; Capizzi, M; Mangano, S";;;;"Nardello, Rosaria; Guccione, Fulvio; Gliubizzi, Claudia; Marino, Antonio; Capizzi, Mariarita; Mangano, Salvatore";;;Resolution of enuresis with aripiprazole in children with psychiatric disorders: two case reports;JOURNAL OF MEDICAL CASE REPORTS;;;English;Article;;;;;;"Aripiprazole; Atypical antipsychotic; Enuresis";;Background Aripiprazole is a third-generation atypical antipsychotic drug that acts as a stabilizer of the dopaminergic and serotonergic system. As partial agonist of the dopamine (D2) and serotonin (5-HT1A) receptors, it appears to be effective in reducing mania in patients with bipolar disorder, tics in Tourette Syndrome, aggression in schizophrenia and autism spectrum disorder. Enuresis has been reported among its side effects. Only a few studies, with conflicting results, have investigated the relationship between aripiprazole and enuresis. Case presentation We report the disappearance of enuresis in a Caucasian girl with intellectual disability and oppositional defiant disorder and in a Caucasian boy with intellectual disability and early-onset psychosis, both following initiation of treatment with aripiprazole. Conclusion The aim of this study was to contribute to the literature on the use of aripripazole in subjects with enuresis. Our findings lead us to suggest that aripiprazole is less burdened with side effects, including bedwetting, than other antipsychotic drugs.;"[Nardello, Rosaria; Guccione, Fulvio; Gliubizzi, Claudia; Marino, Antonio; Capizzi, Mariarita; Mangano, Salvatore] Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Via A Giordano, Palermo, Italy";University of Palermo;Nardello, R (corresponding author), Univ Palermo, Dept Hlth Promot Mother & Child Care Internal Med, Via A Giordano, Palermo, Italy.;rosaria.nardello@unipa.it;"Marino, AntonioAlessandro/KMA-3392-2024; Capizzi, Mariarita/LRB-8411-2024";", Mariarita Capizzi/0009-0007-3686-8441; Nardello, Rosaria/0000-0002-1041-6910";;;;"Bozkurt H, 2011, NOROPSIKIYATRI ARS, V48, P164, DOI 10.4274/npa.y5795; Casey AB, 2017, ACS CHEM NEUROSCI, V8, P1135, DOI 10.1021/acschemneuro.7b00087; Gunes S, 2017, CLIN NEUROPHARMACOL, V40, P175, DOI 10.1097/WNF.0000000000000223; Haid B, 2017, EUR UROL FOCUS, V3, P198, DOI 10.1016/j.euf.2017.08.010; Kantrowitz JT, 2006, SCHIZOPHR RES, V84, P174, DOI 10.1016/j.schres.2006.01.023; Karakurt MN, 2015, J CHILD ADOL PSYCHOP, V25, P518, DOI 10.1089/cap.2015.0003; Karatoprak S, 2020, CLIN NEUROPHARMACOL, V43, P123, DOI 10.1097/WNF.0000000000000396; Kilinç S, 2017, J CHILD ADOL PSYCHOP, V27, P213, DOI 10.1089/cap.2016.0127; Lee MJ, 2010, J KOREAN MED SCI, V25, P333, DOI 10.3346/jkms.2010.25.2.333; Mendhekar DN, 2010, WORLD J BIOL PSYCHIA, V11, P514, DOI 10.3109/15622970903369965; Palaniappan P, 2015, INDIAN J PHARMACOL, V47, P574, DOI 10.4103/0253-7613.165176; Ramage AG, 2006, BRIT J PHARMACOL, V147, pS120, DOI 10.1038/sj.bjp.0706504";12;1;1;0;5;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1752-1947;;J MED CASE REP;J. Med. Case Rep.;APR 21;2021;15;1;;;;;;;209;10.1186/s13256-021-02691-y;http://dx.doi.org/10.1186/s13256-021-02691-y;;;3;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;WD2LC;33883037;Green Published, gold;;;24/11/2024;WOS:000704777900003;View Full Record in Web of Science
J;"Jakobsen, KD; Bruhn, CH; Pagsberg, AK; Fink-Jensen, A; Nielsen, J";;;;"Jakobsen, Klaus Damgaard; Bruhn, Christina Hedegaard; Pagsberg, Anne-Katrine; Fink-Jensen, Anders; Nielsen, Jimmi";;;Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole;JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"aripiprazole; neuropsychiatric disorders in children and adolescents; adverse events; neuroleptic malignant syndrome; suicidal ideation";"SPECTRUM DISORDER; AUTISM; ANTIPSYCHOTICS";"Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to discuss adverse drug reaction (ADR) reports concerning aripiprazole-associated neurological and psychiatric events in children and adolescents. The ADR report database at Danish Medicines Agency was searched for all ADRs involving children and adolescents (<18 years) reported by the search term [aripiprazole] AND all spontaneous reports since the introduction of aripiprazole in 2003 until December 31, 2015. Nineteen case reports were included in the study and included both patients with psychotic disorders (PS group) and nonpsychotic disorders (non-PS group). The PS group consisted of 5 patients with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events as neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients.";"[Jakobsen, Klaus Damgaard] Aalborg Univ, Dept Clin Med, Aalborg, Denmark; [Jakobsen, Klaus Damgaard; Nielsen, Jimmi] Aalborg Univ Hosp, Dept Psychiat, Aalborg, Denmark; [Bruhn, Christina Hedegaard] Danish Med Agcy, Copenhagen, Denmark; [Pagsberg, Anne-Katrine] Univ Copenhagen, Ctr Child & Adolescent Mental Hlth, Mental Hlth Serv, Copenhagen, Denmark; [Pagsberg, Anne-Katrine; Fink-Jensen, Anders] Univ Copenhagen, Mental Hlth Ctr Copenhagen, Dept O, Capital Reg Denmark, Copenhagen, Denmark; [Fink-Jensen, Anders] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark";"Aalborg University; Aalborg University; Aalborg University Hospital; University of Copenhagen; University of Copenhagen; University of Copenhagen";Jakobsen, KD (corresponding author), Aalborg Univ Hosp, Ctr Schizophrenia, Brandevej 5, DK-9220 Aalborg OE, Denmark.;kdjakobsen@gmail.com;Nielsen, Jimmi/G-2990-2010;"Fink-Jensen, Anders/0000-0001-7143-1236; Pagsberg, Anne Katrine/0000-0003-0818-8338; Nielsen, Jimmi/0000-0002-9868-7028";"Novo Nordisk; H. Lundbeck; Pfizer";"Novo Nordisk(Novo NordiskNovo Nordisk Foundation); H. Lundbeck(Lundbeck Corporation); Pfizer(Pfizer)";Dr Jakobsen has been a consultant for AstraZeneca, on the advisory board for Bristol-Myers Squibb and received speaker's honoraria from Lundbeck Pharma. Mrs Christina Hedegaard Bruhn is an employee of the Danish Medicines Agency. Dr Fink-Jensen has received an unrestricted research grant from Novo Nordisk. Dr Nielsen has received speaker honoraria from Hemocue, Lundbeck, and Bristol-Myers Squibb and research grants from H. Lundbeck and Pfizer. Dr Pagsberg has no disclosures.;"Bhat S, 2014, REV NEUROSCIENCE, V25, P841, DOI 10.1515/revneuro-2014-0056; Cohen D, 2012, J CLIN PSYCHOPHARM, V32, P309, DOI 10.1097/JCP.0b013e3182549259; Correll CU, 2011, CLIN THER, V33, pB16, DOI 10.1016/j.clinthera.2011.11.016; Deb S, 2014, RES DEV DISABIL, V35, P711, DOI 10.1016/j.ridd.2013.12.004; Doey T, 2012, J AFFECT DISORDERS, V138, pS15, DOI 10.1016/j.jad.2012.02.031; European Medicines Agency (EMA), Guideline on Good Pharmacovigilance Practices (GVP); Findling RL, 2013, BIPOLAR DISORD, V15, P138, DOI 10.1111/bdi.12042; Fraguas D, 2011, EUR NEUROPSYCHOPHARM, V21, P621, DOI 10.1016/j.euroneuro.2010.07.002; Ghanizadeh A, 2015, INDIAN J MED RES, V142, P269, DOI 10.4103/0971-5916.166584; Jensen KG, 2015, J AM ACAD CHILD PSY, V54, P25, DOI 10.1016/j.jaac.2014.10.002; Ji NY, 2015, CURR OPIN PSYCHIATR, V28, P91, DOI 10.1097/YCO.0000000000000132; Kirino E, 2012, EUR CHILD ADOLES PSY, V21, P361, DOI 10.1007/s00787-012-0270-0; Lindsey RL, 2003, J AM ACAD CHILD PSY, V42, P1268, DOI 10.1097/01.chi.0000095540.18151.b0; McKeage K, 2014, CNS DRUGS, V28, P171, DOI 10.1007/s40263-013-0134-2; Nielsen J, 2010, NEUROPSYCHOPHARMACOL, V35, P1997, DOI 10.1038/npp.2010.78; Polcwiartek C, 2015, PSYCHOPHARMACOLOGY, V232, P3297, DOI 10.1007/s00213-015-4024-9; Rummel-Kluge C, 2012, SCHIZOPHRENIA BULL, V38, P167, DOI 10.1093/schbul/sbq042; Schimmelmann BG, 2013, CURR OPIN PSYCHIATR, V26, P219, DOI 10.1097/YCO.0b013e32835dcc2a; Serajee FJ, 2015, PEDIATR CLIN N AM, V62, P687, DOI 10.1016/j.pcl.2015.03.007; Thapar A, 2016, LANCET, V387, P1240, DOI 10.1016/S0140-6736(15)00238-X; Yang CS, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0504-z; Zheng W, 2016, HUM PSYCHOPHARM CLIN, V31, P11, DOI 10.1002/hup.2498";22;11;12;2;21;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0271-0749;1533-712X;;J CLIN PSYCHOPHARM;J. Clin. Psychopharmacol.;OCT;2016;36;5;;;;;496;499;;10.1097/JCP.0000000000000548;http://dx.doi.org/10.1097/JCP.0000000000000548;;;4;"Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pharmacology & Pharmacy; Psychiatry";DX2KD;27504593;;;;24/11/2024;WOS:000384197000016;View Full Record in Web of Science
J;"Zhang, LL; Huang, CC; Dai, Y; Luo, Q; Ji, YT; Wang, K; Deng, SN; Yu, JH; Xu, MY; Du, XJ; Tang, Y; Shen, C; Feng, JF; Sahakian, BJ; Lin, CP; Li, F";;;;"Zhang, Lingli; Huang, Chu-Chung; Dai, Yuan; Luo, Qiang; Ji, Yiting; Wang, Kai; Deng, Shining; Yu, Juehua; Xu, Mingyu; Du, Xiujuan; Tang, Yun; Shen, Chun; Feng, Jianfeng; Sahakian, Barbara J.; Lin, Ching-Po; Li, Fei";;;Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios;TRANSLATIONAL PSYCHIATRY;;;English;Article;;;;;;;"GABA; BEHAVIOR";Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of gamma-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models. However, clinical evidence of its efficacy in young patients with ASD is limited. This was investigated in the present clinical trial of 83 patients, randomised to the bumetanide group (bumetanide treatment, 0.5mg twice daily) or the control group (no bumetanide treatment). Primary [Children Autism Rating Scale (CARS)], secondary [Clinical Global Impressions (CGI)], and exploratory [inhibitory (gamma-aminobutyric acid, GABA) and excitatory (glutamate, Glx) neurotransmitter concentrations measured in the insular cortex (IC) and visual cortex (VC) by magnetic resonance spectroscopy (MRS)] outcome measures were evaluated at baseline and at the 3-month follow-up. Side effects were monitored throughout the treatment course. Compared with the control group, the bumetanide group showed significant reduction in symptom severity, as indicated by both total CARS score and number of items assigned a score >= 3. The improvement in clinical symptoms was confirmed by CGI. GABA/Glx ratio in both the IC and VC decreased more rapidly over the 3-month period in the bumetanide group than that in the control group. This decrease in the IC was associated with the symptom improvement in the bumetanide group. Our study confirmed the clinical efficacy of bumetanide on alleviating the core symptoms of ASD in young children and it is the first demonstration that the improvement is associated with reduction in GABA/Glx ratios. This study suggests that the GABA/Glx ratio measured by MRS may provide a neuroimaging biomarker for assessing treatment efficacy for bumetanide.;"[Zhang, Lingli; Dai, Yuan; Ji, Yiting; Wang, Kai; Deng, Shining; Yu, Juehua; Xu, Mingyu; Du, Xiujuan; Tang, Yun; Shen, Chun; Sahakian, Barbara J.; Li, Fei] Shanghai Jiao Tong Univ, Xinhua Hosp, Shanghai Inst Pediat Res, Brain & Behav Res Unit,Sch Med,Dev & Behav Pediat, Shanghai, Peoples R China; [Zhang, Lingli; Dai, Yuan; Ji, Yiting; Wang, Kai; Deng, Shining; Yu, Juehua; Xu, Mingyu; Du, Xiujuan; Tang, Yun; Shen, Chun; Sahakian, Barbara J.; Li, Fei] Shanghai Jiao Tong Univ, Brain & Behav Res Unit, Child Primary Care Dept, Xinhua Hosp,Sch Med,Shanghai Inst Pediat Res, Shanghai, Peoples R China; [Zhang, Lingli; Dai, Yuan; Ji, Yiting; Wang, Kai; Deng, Shining; Yu, Juehua; Xu, Mingyu; Du, Xiujuan; Tang, Yun; Shen, Chun; Sahakian, Barbara J.; Li, Fei] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, MOE Shanghai Key Lab Childrens Environm Hlth, Shanghai, Peoples R China; [Zhang, Lingli; Dai, Yuan; Ji, Yiting; Du, Xiujuan; Li, Fei] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Shanghai Inst Pediat Res, Shanghai, Peoples R China; [Huang, Chu-Chung; Luo, Qiang; Shen, Chun; Feng, Jianfeng; Sahakian, Barbara J.; Lin, Ching-Po] Fudan Univ, MOE, Key Lab Computat Neurosci & Brain Inspired Intell, Inst Sci & Technol Brain Inspired Intelligence, Shanghai, Peoples R China; [Huang, Chu-Chung; Luo, Qiang] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai, Peoples R China; [Huang, Chu-Chung; Luo, Qiang] Fudan Univ, Inst Brain Sci, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China; [Huang, Chu-Chung; Luo, Qiang] Fudan Univ, Human Phenom Inst, Shanghai, Peoples R China; [Luo, Qiang; Sahakian, Barbara J.] Univ Cambridge, Dept Psychol, Cambridge, England; [Luo, Qiang; Sahakian, Barbara J.] Univ Cambridge, Dept Psychiat, Cambridge, England; [Luo, Qiang; Sahakian, Barbara J.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England; [Lin, Ching-Po] Natl Yang Ming Univ, Inst Neurosci, Taipei, Taiwan";"Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University; Fudan University; Fudan University; Fudan University; University of Cambridge; University of Cambridge; University of Cambridge; National Yang Ming Chiao Tung University";"Li, F (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Shanghai Inst Pediat Res, Brain & Behav Res Unit,Sch Med,Dev & Behav Pediat, Shanghai, Peoples R China.;Li, F (corresponding author), Shanghai Jiao Tong Univ, Brain & Behav Res Unit, Child Primary Care Dept, Xinhua Hosp,Sch Med,Shanghai Inst Pediat Res, Shanghai, Peoples R China.;Li, F (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, MOE Shanghai Key Lab Childrens Environm Hlth, Shanghai, Peoples R China.;Li, F (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Shanghai Inst Pediat Res, Shanghai, Peoples R China.;Luo, Q; Lin, CP (corresponding author), Fudan Univ, MOE, Key Lab Computat Neurosci & Brain Inspired Intell, Inst Sci & Technol Brain Inspired Intelligence, Shanghai, Peoples R China.;Luo, Q (corresponding author), Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai, Peoples R China.;Luo, Q (corresponding author), Fudan Univ, Inst Brain Sci, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China.;Luo, Q (corresponding author), Fudan Univ, Human Phenom Inst, Shanghai, Peoples R China.;Luo, Q (corresponding author), Univ Cambridge, Dept Psychol, Cambridge, England.;Luo, Q (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge, England.;Luo, Q (corresponding author), Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge, England.;Lin, CP (corresponding author), Natl Yang Ming Univ, Inst Neurosci, Taipei, Taiwan.";"qluo@fudan.edu.cn; chingpolin@gmail.com; feili@shsmu.edu.cn";"xu, mingyu/KMX-9517-2024; ?, ??/IXN-6983-2023; Sahakian, Barbara/AAW-1198-2020; Luo, Qiang/ADI-7405-2022";"Huang, Chu-Chung/0000-0002-9096-9610; Lin, Ching-Po/0000-0001-6848-8776";"Shanghai Municipal Commission of Health and Family Planning [2017ZZ02026, 2018BR33, 2017EKHWYX-02, GDEK201709]; Shanghai Shenkang Hospital Development Center [16CR2025B]; Shanghai Municipal Education Commission [20152234]; National Natural Science Foundation of China [81571031, 81761128035, 81930095, 81873909, 81222012, 912321023, 81701334, 81703249]; Shanghai Committee of Science and Technology [17XD1403200, 17ZR1444400, 19410713500, 18DZ2313505]; Xinhua Hospital of Shanghai Jiao Tong University School of Medicine [2018YJRC03, Talent introduction-014, Top talent-201603]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]; National Key Research and Development Program of China [2018YFC0910503]; 111 Project [B18015]; Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]; Guangdong Key Project in Development of new tools for diagnosis and treatment of Autism [2018B030335001]; Taiwan Ministry of Science and Technology [MOST 108-2321-B-010-010-MY2]; ZJ Lab";"Shanghai Municipal Commission of Health and Family Planning; Shanghai Shenkang Hospital Development Center; Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Committee of Science and Technology(Science & Technology Commission of Shanghai Municipality (STCSM)); Xinhua Hospital of Shanghai Jiao Tong University School of Medicine; National Human Genetic Resources Sharing Service Platform; National Key Research and Development Program of China(National Key Research & Development Program of China); 111 Project(Ministry of Education, China - 111 Project); Shanghai Municipal Science and Technology Major Project; Guangdong Key Project in Development of new tools for diagnosis and treatment of Autism; Taiwan Ministry of Science and Technology; ZJ Lab";We thank Dr. Wei-Guang Li from Shanghai Jiao Tong University, Shanghai, China, for his insightful discussions on the possible molecular mechanisms of bumetanide. During the preparation of this manuscript, Dr Luo was a Visiting Fellow at Clare Hall, Cambridge, the UK. The work was financially supported by the Shanghai Municipal Commission of Health and Family Planning (No. 2017ZZ02026, No. 2018BR33, No. 2017EKHWYX-02 and No. GDEK201709), Shanghai Shenkang Hospital Development Center (No. 16CR2025B), Shanghai Municipal Education Commission (No. 20152234), National Natural Science Foundation of China (No. 81571031, No. 81761128035, No. 81930095, No. 81873909, No. 81222012, No. 912321023, No. 81701334 and No. 81703249), Shanghai Committee of Science and Technology (No. 17XD1403200, No. 17ZR1444400, No. 19410713500, No. 18DZ2313505), Xinhua Hospital of Shanghai Jiao Tong University School of Medicine (2018YJRC03, Talent introduction-014 and Top talent-201603), National Human Genetic Resources Sharing Service Platform (2005DKA21300), the National Key Research and Development Program of China (2018YFC0910503), 111 Project (No. B18015), the Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX01), Guangdong Key Project in Development of new tools for diagnosis and treatment of Autism (2018B030335001), Taiwan Ministry of Science and Technology (MOST 108-2321-B-010-010-MY2), and ZJ Lab.;"Acuña-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2; [Anonymous], 1984, SHANGHAI PSYCHIAT; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Ben-Ari Y, 2017, TRENDS NEUROSCI, V40, P536, DOI 10.1016/j.tins.2017.07.001; Boyd BA, 2010, AUTISM RES, V3, P78, DOI 10.1002/aur.124; Bruining H, 2015, PEDIATRICS, V136, pE539, DOI 10.1542/peds.2014-4133; CASTROVIEJO DA, 1986, NEUROENDOCRINOLOGY, V43, P24; Cloarec R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav0394; de Prado BM, 2000, J PINEAL RES, V29, P209; Du L, 2015, J CHILD ADOL PSYCHOP, V25, P585, DOI 10.1089/cap.2015.0045; Estes A, 2015, J NEURODEV DISORD, V7, DOI 10.1186/s11689-015-9117-6; Fernandez A, 2019, CEREB CORTEX, V29, P3982, DOI 10.1093/cercor/bhy279; Fiorentino M, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0110-z; Gaetz W, 2014, NEUROIMAGE, V86, P1, DOI 10.1016/j.neuroimage.2013.05.068; Gogolla N, 2014, NEURON, V83, P894, DOI 10.1016/j.neuron.2014.06.033; Gonçalves J, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0166-4; Hadjikhani N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21958-x; Hadjikhani N, 2015, AUTISM, V19, P149, DOI 10.1177/1362361313514141; Harris AD, 2015, J MAGN RESON IMAGING, V42, P1431, DOI 10.1002/jmri.24903; Hastings RP, 2012, J APPL RES INTELLECT, V25, P119, DOI 10.1111/j.1468-3148.2011.00680.x; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Inui T, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00354; Karaoui M, 2018, AM J OPHTHALMOL, V192, P39, DOI 10.1016/j.ajo.2018.05.003; Kurth S, 2016, J SLEEP RES, V25, P646, DOI 10.1111/jsr.12427; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Lemonnier E, 2017, TRANSL PSYCHIAT, V7; Lemonnier E, 2010, ACTA PAEDIATR, V99, P1885, DOI 10.1111/j.1651-2227.2010.01933.x; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Loth E, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00188; Lozovaya N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45635-9; Mescher M, 1998, NMR BIOMED, V11, P266, DOI 10.1002/(SICI)1099-1492(199810)11:6<266::AID-NBM530>3.0.CO;2-J; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; Nieuwenhuis S, 2011, NAT NEUROSCI, V14, P1105, DOI 10.1038/nn.2886; Nomi JS, 2019, PROG NEURO-PSYCHOPH, V89, P412, DOI 10.1016/j.pnpbp.2018.10.015; Orefice LL, 2016, CELL, V166, P299, DOI 10.1016/j.cell.2016.05.033; Pierce K, 2019, JAMA PEDIATR, V173, P578, DOI 10.1001/jamapediatrics.2019.0624; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Puskarjov M, 2014, EPILEPSIA, V55, P806, DOI 10.1111/epi.12620; Represa A, 2005, TRENDS NEUROSCI, V28, P278, DOI 10.1016/j.tins.2005.03.010; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Robertson CE, 2017, NAT REV NEUROSCI, V18, P671, DOI 10.1038/nrn.2017.112; Robertson CE, 2016, CURR BIOL, V26, P80, DOI 10.1016/j.cub.2015.11.019; Roux S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00232; Salomone E, 2016, AUTISM, V20, P233, DOI 10.1177/1362361315577218; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Stagg CJ, 2011, CURR BIOL, V21, P480, DOI 10.1016/j.cub.2011.01.069; Sun X, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-018-0246-0; Tavassoli T, 2014, AUTISM, V18, P428, DOI 10.1177/1362361313477246; Tomchek SD, 2007, AM J OCCUP THER, V61, P190, DOI 10.5014/ajot.61.2.190; Turner-Brown LM, 2013, AUTISM, V17, P527, DOI 10.1177/1362361312439633; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190; Uddin LQ, 2015, NAT REV NEUROSCI, V16, P55, DOI 10.1038/nrn3857; Wiebking C, 2014, NEUROIMAGE, V86, P10, DOI 10.1016/j.neuroimage.2013.04.042; Xhima K, 2016, J NEUROSCI, V36, P12296, DOI 10.1523/JNEUROSCI.2962-16.2016";55;79;87;2;26;NATURE PUBLISHING GROUP;LONDON;MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2158-3188;;;TRANSL PSYCHIAT;Transl. Psychiatr.;janv-27;2020;10;1;;;;;;;9;10.1038/s41398-020-0692-2;http://dx.doi.org/10.1038/s41398-020-0692-2;;;12;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;KO9JV;32066666;Green Published, Green Submitted, gold;;;24/11/2024;WOS:000515864000001;View Full Record in Web of Science
J;"Hadoush, H; Hadoush, A";;;;"Hadoush, Hikmat; Hadoush, Ashraf";;;Modulation of Resting-State Brain Complexity After Bilateral Cerebellar Anodal Transcranial Direct Current Stimulation in Children with Autism Spectrum Disorders: a Randomized Controlled Trial Study;CEREBELLUM;;;English;Article;;;;;;"Autism spectrum disorders; Electroencephalography; Brain complexity; Entropy; Transcranial direct current stimulation; Cerebellum";"TIME-SERIES ANALYSIS; APPROXIMATE ENTROPY; MULTISCALE ENTROPY; INJURY";"Background Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental disorders characterized by aberrant neural networks. Cerebellum is best known for its role in controlling motor behaviors; however, recently, there have been significant reports showed that dysfunction in cerebellar-cerebral networks contributes significantly to many of the clinical features of ASD. Hereby, this is a randomized controlled trial (RCT) study examining the potential modulating effects of bilateral anodal tDCS stimulation over cerebellar hemispheres on the resting-state brain complexity in children with ASD. Methods Thirty-six children with ASD (aged 4-14) years old were divided equally and randomly into a tDCS treatment group, which underwent 10 sessions (20-min duration, five sessions/per week) of bilateral anodal tDCS stimulation applied over left and right cerebellar hemispheres, and control group underwent the same procedures, but with sham tDCS stimulation. Resting-state brain complexity was evaluated through recording and calculating the approximate entropy (ApxEnt) values of the resting-state electroencephalograph (EEG) data obtained from a 64-channel EEG system before and after the interventions. Results Repeated measures of ANOVA showed that tDCS had significant effects on the treatment group (Wilks' Lambda = 0.29, F (15, 16) = 2.67, p = 0.03) compared with the control group. Analyzed data showed a significant increase in the averaged ApxEnt values in the right frontal cortical region (F (1, 16) = 10.46, p = 0.005) after the bilateral cerebellar anodal tDCS stimulation. Besides, the Cohen's d effect size showed a large effect size (0.70-0.92) of bilateral cerebellar anodal tDCS on the ApxEnt values increases in the left and right frontal cortical regions, the right central cortical region, and left parietal cortical region. However, there were no any significant differences or increases in the brain complexity before and after the sham tDCS stimulation of the control group. Conclusion Bilateral cerebellar anodal tDCS modulated and increased the brain complexity in children with ASD with no any reported adverse effect. Hereby, cerebellum and cerebellar-cerebral circuitry would serve as a promising target for non-invasive brain stimulation and neuro-modulation as a therapeutic intervention.";"[Hadoush, Hikmat] Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Rehabil Sci, POB 3030, Irbid 22110, Jordan; [Hadoush, Ashraf] Palestine Tech Univ Kadoorie, Fac Engn & Technol, Dept Mech Engn, Tulkarm, Palestine";"Jordan University of Science & Technology; Palestine Technical University - Kadoorie";Hadoush, H (corresponding author), Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Rehabil Sci, POB 3030, Irbid 22110, Jordan.;hmhadoush@just.edu.jo;"Hadoush, Ashraf/IQS-2115-2023; Hadoush, Himat/L-8437-2019";Hadoush, Ashraf/0000-0002-4876-3459;"Scientific Research Support Fund-Jordanian Ministry of Higher Education [MPH/1/20/2014]; Deanship of Research at Jordan University of Science and Technology [275/2015]";"Scientific Research Support Fund-Jordanian Ministry of Higher Education; Deanship of Research at Jordan University of Science and Technology(Jordan University of Science & Technology)";This work is supported by a grant from the Scientific Research Support Fund-Jordanian Ministry of Higher Education (MPH/1/20/2014) and the Deanship of Research at Jordan University of Science and Technology (275/2015).;"Amatachaya A, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/928631; Amatachaya A, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/173073; Bosl W, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-18; Buckner RL, 2011, J NEUROPHYSIOL, V106, P2322, DOI 10.1152/jn.00339.2011; Cardinale RC, 2013, JAMA PSYCHIAT, V70, P975, DOI 10.1001/jamapsychiatry.2013.382; Coben R, 2008, CLIN NEUROPHYSIOL, V119, P1002, DOI 10.1016/j.clinph.2008.01.013; Delgado-Bonal A, 2019, ENTROPY-SWITZ, V21, DOI 10.3390/e21060541; Demirtas-Tatlidede A, 2013, NEUROPHARMACOLOGY, V64, P566, DOI 10.1016/j.neuropharm.2012.06.020; Ferrucci R, 2012, COGNITION EMOTION, V26, P786, DOI 10.1080/02699931.2011.619520; Grimaldi G, 2014, CEREBELLUM, V13, P121, DOI 10.1007/s12311-013-0514-7; Grimaldi G, 2016, NEUROSCIENTIST, V22, P83, DOI 10.1177/1073858414559409; Grimaldi G, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00009; Hadoush H, 2020, AUTISM RES, V13, P828, DOI 10.1002/aur.2290; Hadoush H, 2019, BRAIN TOPOGR, V32, P914, DOI 10.1007/s10548-019-00711-1; Hadoush H, 2019, BEHAV BRAIN RES, V362, P240, DOI 10.1016/j.bbr.2019.01.018; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Kang JN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00201; Limperopoulos C, 2007, PEDIATRICS, V120, P584, DOI 10.1542/peds.2007-1041; Liu T, 2017, NEUROREPORT, V28, P169, DOI 10.1097/WNR.0000000000000724; Okazaki R, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00106; Oldrati V, 2021, BRAIN STRUCT FUNCT, V226, P671, DOI 10.1007/s00429-020-02198-0; Oldrati V, 2018, CEREBELLUM, V17, P228, DOI 10.1007/s12311-017-0877-2; PINCUS SM, 1992, OBSTET GYNECOL, V79, P249; PINCUS SM, 1994, AM J PHYSIOL, V266, pH1643, DOI 10.1152/ajpheart.1994.266.4.H1643; PINCUS SM, 1992, AM J PHYSIOL, V262, pE741, DOI 10.1152/ajpendo.1992.262.5.E741; Pincus SM, 2006, BIPOLAR DISORD, V8, P430, DOI 10.1111/j.1399-5618.2006.00375.x; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Schneider HD, 2011, CLIN LINGUIST PHONET, V25, P640, DOI 10.3109/02699206.2011.570852; Sokunbi MO, 2013, PSYCHIAT RES-NEUROIM, V214, P341, DOI 10.1016/j.pscychresns.2013.10.001; Stoodley CJ, 2016, SEMIN FETAL NEONAT M, V21, P356, DOI 10.1016/j.siny.2016.04.010; Stoodley CJ, 2016, CEREBELLUM, V15, P34, DOI 10.1007/s12311-015-0715-3; Takahashi T, 2013, PROG NEURO-PSYCHOPH, V45, P258, DOI 10.1016/j.pnpbp.2012.05.001; Treasure T, 1998, BRIT MED J, V317, P362; Van Overwalle F, 2020, CEREBELLUM, V19, P833, DOI 10.1007/s12311-020-01155-1; van Steenburgh JJ, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0152-x; Wang J, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-24; Webb SJ, 2015, J AUTISM DEV DISORD, V45, P425, DOI 10.1007/s10803-013-1916-6; Zhang LL, 2020, COMPUT METH PROG BIO, V190, DOI 10.1016/j.cmpb.2019.105240";38;2;2;0;9;SPRINGER;NEW YORK;ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES;1473-4222;1473-4230;;CEREBELLUM;Cerebellum;DEC;2023;22;6;;;;;1109;1117;;10.1007/s12311-022-01481-6;http://dx.doi.org/10.1007/s12311-022-01481-6;;sept-22;9;Neurosciences;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;AZ9Q6;36156195;;;;24/11/2024;WOS:000859929300001;View Full Record in Web of Science
J;"Siniscalco, D; Antonucci, N";;;;"Siniscalco, Dario; Antonucci, Nicola";;;Possible use of Trichuris suis ova in autism spectrum disorders therapy;MEDICAL HYPOTHESES;;;English;Article;;;;;;;"IMMUNE DYSFUNCTION; CHILDREN; IMMUNOMODULATORS; INTERVENTIONS; DIRECTIONS; HELMINTHS; PATHWAYS; PRODUCTS; TARGETS; BARRIER";"Autism and autism spectrum disorders (ASDs) are heterogeneous, severe neurodevelopmental pathologies. The main core symptoms are: dysfunctions in social interactions and communication skills, restricted interests, repetitive and stereotypic verbal and non-verbal behaviors. Several biochemical processes are associated with ASDs: oxidative stress; endoplasmic reticulum stress; decreased methylation capacity; limited production of glutathione; mitochondrial dysfunction; intestinal dysbiosis; increased toxic metal burden; immune dysregulation. Current available treatments for ASDs can be divided into behavioral, nutritional and medical approaches, although no defined standard approach exists. Current drugs fail to benefit the ASD core symptoms and can have marked adverse effects, are mainly palliative and only sometimes efficacy in attenuating specific autistic behaviors. Helminthic therapy shows potential for application as anti-inflammatory agent. Several human diseases can be treated by helminths (i.e. inflammatory bowel disease, asthma, multiple sclerosis and autoimmune diabetes). Trichuris suis ova (TSO) show strong immunomodulatory properties. Authors hypothesize that TSO could be useful in addressing ASD immune dysregulations. TSO could be a novel therapeutic option for ASD management. (C) 2013 Elsevier Ltd. All rights reserved.";"[Siniscalco, Dario] Univ Naples 2, Dept Expt Med, I-80138 Naples, Italy; [Siniscalco, Dario] Forza Silenzio, Ctr Autism, Caserta, Italy; [Siniscalco, Dario] Cancellautismo No Profit Assoc Autism Care, Florence, Italy; [Antonucci, Nicola] Biomed Ctr Autism Res & Treatment, Bari, Italy";Universita della Campania Vanvitelli;Siniscalco, D (corresponding author), Univ Naples 2, Dept Expt Med, Div Pharmacol, Via S Maria Costantinopoli 16, I-80138 Naples, Italy.;dariosin@uab.edu;Siniscalco, Dario/H-4657-2019;Siniscalco, Dario/0000-0002-3779-2596;;;;"Adisakwattana P, 2009, ADV EXP MED BIOL, V666, P95; Akuthota P, 2012, SEMIN HEMATOL, V49, P113, DOI 10.1053/j.seminhematol.2012.01.005; [Anonymous], J REGEN MED; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Ashwood P, 2003, J CLIN IMMUNOL, V23, P504, DOI 10.1023/B:JOCI.0000010427.05143.bb; Ashwood P, 2006, J LEUKOCYTE BIOL, V80, P1, DOI 10.1189/jlb.1205707; Bager P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022346; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1; Bourke CD, 2012, CLIN EXP ALLERGY, V42, P1582, DOI 10.1111/j.1365-2222.2012.04063.x; Careaga M, 2010, NEUROTHERAPEUTICS, V7, P283, DOI 10.1016/j.nurt.2010.05.003; Castro G., 1996, HELMINTHS STRUCTURE, V4th; Chadman KK, 2012, EXPERT OPIN DRUG DIS, V7, P407, DOI 10.1517/17460441.2012.678828; Chen B, 2010, DIGESTION, V81, P127, DOI 10.1159/000252765; Croese J, 2006, GUT, V55, P136, DOI 10.1136/gut.2005.079129; Croft AM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009238.pub2; de Macedo Soares Maria Fernanda, 2008, Inflammation & Allergy Drug Targets, V7, P113; de Magistris L, 2010, J PEDIATR GASTR NUTR, V51, P418, DOI 10.1097/MPG.0b013e3181dcc4a5; de Theije CGM, 2011, EUR J PHARMACOL, V668, pS70, DOI 10.1016/j.ejphar.2011.07.013; Doyle CA, 2012, EXPERT OPIN PHARMACO, V13, P1615, DOI 10.1517/14656566.2012.674110; Elliott DE, 2009, ADV EXP MED BIOL, V666, P157; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Erb KJ, 2009, TRENDS IMMUNOL, V30, P75, DOI 10.1016/j.it.2008.11.005; Ferris J., 2010, SCI AM; Filipek Pauline A, 2006, NeuroRx, V3, P207, DOI 10.1007/BF03207050; Fleming JO, 2013, INT J PARASITOL, V43, P259, DOI 10.1016/j.ijpara.2012.10.025; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Flohr C, 2009, CLIN EXP ALLERGY, V39, P20, DOI 10.1111/j.1365-2222.2008.03134.x; Garud Sagar, 2009, Therap Adv Gastroenterol, V2, P99, DOI 10.1177/1756283X09102329; Goines P.E., 2012, NEUROTOXICOL TERATOL; Gupta S, 2010, J CLIN IMMUNOL, V30, pS90, DOI 10.1007/s10875-010-9402-9; Hampson DR, 2012, CLIN PHARMACOL THER, V91, P189, DOI 10.1038/clpt.2011.245; Harnett W, 2010, NAT REV IMMUNOL, V10, P278, DOI 10.1038/nri2730; Harnett William, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000720; Herbert MR, 2010, CURR OPIN NEUROL, V23, P103, DOI 10.1097/WCO.0b013e328336a01f; Hunter MM, 2004, ALIMENT PHARM THER, V19, P167, DOI 10.1111/j.0269-2813.2004.01803.x; Jouvin MH, 2012, J ALLERGY CLIN IMMUN, V130, P3, DOI 10.1016/j.jaci.2012.05.028; Karst JS, 2012, CLIN CHILD FAM PSYCH, V15, P247, DOI 10.1007/s10567-012-0119-6; Kasari C, 2010, CURR OPIN NEUROL, V23, P137, DOI 10.1097/WCO.0b013e32833775cd; Klaver EJ, 2013, INT J PARASITOL, V43, P191, DOI 10.1016/j.ijpara.2012.10.021; LeBlanc LA, 2012, PEDIATR CLIN N AM, V59, P147, DOI 10.1016/j.pcl.2011.10.006; McCracken JT, 2005, J CLIN PSYCHIAT, V66, P32; Mckay DM, 2009, TRENDS PARASITOL, V25, P109, DOI 10.1016/j.pt.2008.11.008; Nevels RM, 2010, EXP CLIN PSYCHOPHARM, V18, P184, DOI 10.1037/a0018059; Onore C, 2012, BRAIN BEHAV IMMUN, V26, P383, DOI 10.1016/j.bbi.2011.08.007; Ramdoss S, 2012, DEV NEUROREHABIL, V15, P119, DOI 10.3109/17518423.2011.651655; Rossignol DA, 2009, ANN CLIN PSYCHIATRY, V21, P213; Sect Complementary Integrative Med, 2012, PEDIATRICS, V129, P1186, DOI 10.1542/peds.2012-0876; Senel HG, 2010, J AUTISM DEV DISORD, V40, P494, DOI 10.1007/s10803-009-0891-4; Shor DB, 2013, CLIN REV ALLERG IMMU, V45, P211, DOI 10.1007/s12016-012-8352-9; Siniscalco D, 2012, J AUTISM DEV DISORD, V42, P1403, DOI 10.1007/s10803-011-1373-z; Siniscalco D, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/480289; Stankovic M, 2012, SRP ARK CELOK LEK, V140, P236, DOI 10.2298/SARH1204236S; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI 10.1111/j.1572-0241.2003.07660.x; Tandon Mini, 2008, Mo Med, V105, P79; Theoharides TC, 2008, TRENDS PHARMACOL SCI, V29, P375, DOI 10.1016/j.tips.2008.06.002; Toro R, 2010, TRENDS GENET, V26, P363, DOI 10.1016/j.tig.2010.05.007; Vismara LA, 2010, ANNU REV CLIN PSYCHO, V6, P447, DOI 10.1146/annurev.clinpsy.121208.131151; Wills S, 2007, ANN NY ACAD SCI, V1107, P79, DOI 10.1196/annals.1381.009; Wolff MJ, 2012, TRENDS PARASITOL, V28, P187, DOI 10.1016/j.pt.2012.02.008; Wong VCN, 2010, J ALTERN COMPLEM MED, V16, P545, DOI 10.1089/acm.2007.0768; Yamamoto-Furusho JK, 2007, WORLD J GASTROENTERO, V13, P1893, DOI 10.3748/wjg.v13.i13.1893; Yap P, 2012, JOVE-J VIS EXP, DOI 10.3791/3966; Ying Ko Chung, 2012, Issues Ment Health Nurs, V33, P288, DOI 10.3109/01612840.2011.653039";66;16;18;0;24;CHURCHILL LIVINGSTONE;EDINBURGH;JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND;0306-9877;1532-2777;;MED HYPOTHESES;Med. Hypotheses;JUL;2013;81;1;;;;;1;4;;10.1016/j.mehy.2013.03.024;http://dx.doi.org/10.1016/j.mehy.2013.03.024;;;4;Medicine, Research & Experimental;Science Citation Index Expanded (SCI-EXPANDED);Research & Experimental Medicine;173QF;23597946;;;;24/11/2024;WOS:000321093300001;View Full Record in Web of Science
J;"DelRosso, LM; Reuter-Yuill, LM; Cho, Y; Ferri, R; Mogavero, MP; Picchietti, DL";;;;"DelRosso, Lourdes M.; Reuter-Yuill, Lilith M.; Cho, Yeilim; Ferri, Raffaele; Mogavero, Maria P.; Picchietti, Daniel L.";;;Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder;SLEEP MEDICINE;;;English;Article;;;;;;"Restless legs syndrome; Autism spectrum disorder; Ferritin; Ferric carboxymaltose; Iron supplementation; Children";"IRON-DEFICIENCY; DIAGNOSTIC-CRITERIA; SLEEP; PREVALENCE; IMPACT";Background: Restless legs syndrome (RLS) may be underdiagnosed in children with autism spectrum disorder (ASD) due to difficulty expressing the symptoms in their own words. In addition, administration of oral iron may be particularly difficult in children with ASD. Methods: This was a retrospective, open-label case series of children with ASD, restless legs (RL) symptoms, and serum ferritin <30 mu g/L, who either had failed or did not tolerate oral iron, and were subsequently treated with intravenous (IV) ferric carboxymaltose (FCM). Patients received a single dose of IV FCM, 15 mg/kg up to a maximum dose of 750 mg. Data collected pre- and eight weeks post-infusion included presenting symptoms, serum ferritin, iron profile, and Clinical Global Impression Scale (CGI-Severity pre- and CGI-Improvement post-infusion). Adverse effects were assessed. Results: Nineteen children, 4-11 years old (12 male, median age 6, interquartile range (IQR 4-11) were included. A definite RLS diagnosis was identified in 6 verbal children (31.6%). RL symptoms (designated probable RLS) in the 13 other children met all RLS diagnostic criteria except improvement of symptoms with movement, which was not definitively determined. Baseline median values were: ferritin 10 mg/L (IQR 10-16), iron 66.5 mu g/dL (IQR 57-96), TIBC 382 mu g/dL (IQR 360-411) and transferrin saturation 19% (IQR 14-28). Median CGI-S was 4 (moderate symptoms) (IQR 3-4). At eight weeks after IV FCM, all measures were improved. Median ferritin was 68 mu g/L (IQR 62.5-109, p < 0.00045). Median CGI-I was 1 (very much improved) (IQR 1-2). All children meeting definite RLS criteria improved. Three children in the probable RLS group did not improve. Children meeting the full RLS criteria had lower baseline ferritin levels than those with a probable diagnosis (9 mu g/L, IQR 9-10 vs. 13 mu g/L, IQR 10-16, Mann-Whitney test p < 0.045). Adverse effects included lightheadedness, gastrointestinal discomfort, fever, and headache among others. Conclusions: The majority of children (84.2%) with ASD, restless legs symptoms, and serum ferritin <30 mu g/L had clinical improvement and significantly better serum iron parameters after a single IV FCM infusion. Although larger, randomized trials are needed, IV FCM appears to be a promising treatment for this subset of children with ASD. (c) 2022 Elsevier B.V. All rights reserved.;"[DelRosso, Lourdes M.; Cho, Yeilim] Univ Washington, Seattle, WA USA; [DelRosso, Lourdes M.; Cho, Yeilim] Seattle Childrens Hosp, Seattle, WA USA; [Reuter-Yuill, Lilith M.] Western Michigan Univ, Kalamazoo, MI USA; [Reuter-Yuill, Lilith M.] Comprehens Speech & Therapy Ctr, Jackson, MI USA; [Reuter-Yuill, Lilith M.] Southern Illinois Univ, Carbondale, IL USA; [Ferri, Raffaele] Oasi Res Inst IRCCS, Dept Neurol IC, Sleep Res Ctr, Troina, Italy; [Mogavero, Maria P.] Inst Mol Bioimaging & Physiol, Natl Res Council, Milan, Italy; [Mogavero, Maria P.] Ist Sci San Raffaele, Div Neurosci, Sleep Disorders Ctr, Milan, Italy; [Picchietti, Daniel L.] Univ Illinois, Carle Fdn Hosp, Carle Illinois Coll Med, Sch Med, Urbana, IL USA; [Picchietti, Daniel L.] Univ Illinois, Sch Med, Urbana, IL USA";"University of Washington; University of Washington Seattle; Seattle Children's Hospital; Western Michigan University; Southern Illinois University System; Southern Illinois University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign";DelRosso, LM (corresponding author), 4800 SandPoint Way, Seattle, WA 98105 USA.;lourdesdelrosso@me.com;"Ferri, Raffaele/B-5439-2013; DelRosso, Lourdes/O-3962-2017; Mogavero, Maria Paola/AAB-6810-2019";"DelRosso, Lourdes/0000-0003-3349-8426; Mogavero, Maria Paola/0000-0001-6662-2281";;;;"Al-Otaish H, 2018, METAB BRAIN DIS, V33, P843, DOI 10.1007/s11011-018-0186-6; Allen RP, 2014, SLEEP MED, V15, P860, DOI 10.1016/j.sleep.2014.03.025; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Ballester P, 2020, SLEEP MED REV, V54, DOI 10.1016/j.smrv.2020.101357; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Cuomo BM, 2017, PHARMACOTHERAPY, V37, P555, DOI 10.1002/phar.1920; DelRosso LM, 2021, SLEEP MED, V87, P114, DOI 10.1016/j.sleep.2021.08.030; DelRosso LM, 2021, SLEEP, V44, DOI 10.1093/sleep/zsaa155; DelRosso LM, 2020, SLEEP, V43, DOI 10.1093/sleep/zsz234; Dosman CF, 2007, PEDIATR NEUROL, V36, P152, DOI 10.1016/j.pediatrneurol.2006.11.004; Dosman CF, 2006, DEV MED CHILD NEUROL, V48, P1008, DOI 10.1017/S0012162206232225; Hassan WM, 2018, J MOL NEUROSCI, V66, P85, DOI 10.1007/s12031-018-1136-9; Hirata I, 2016, RES DEV DISABIL, V49-50, P86, DOI 10.1016/j.ridd.2015.11.002; Johnson CR, 2018, SLEEP MED, V44, P61, DOI 10.1016/j.sleep.2018.01.008; Johnson KP, 2021, CHILD ADOL PSYCH CL, V30, P195, DOI 10.1016/j.chc.2020.08.012; Kanney ML, 2020, J CLIN SLEEP MED, V16, P2029, DOI 10.5664/jcsm.8756; Latif A, 2002, AUTISM, V6, P103, DOI 10.1177/1362361302006001008; Melke J, 2008, MOL PSYCHIATR, V13, P90, DOI 10.1038/sj.mp.4002016; Mulder EJ, 2010, NEUROPSYCHOBIOLOGY, V61, P27, DOI 10.1159/000258640; Picchietti D, 2007, PEDIATRICS, V120, P253, DOI 10.1542/peds.2006-2767; Picchietti DL, 2013, SLEEP MED, V14, P1253, DOI 10.1016/j.sleep.2013.08.778; Picchietti DL, 2011, J CHILD NEUROL, V26, P1365, DOI 10.1177/0883073811405852; Tomkies A, 2019, J CLIN SLEEP MED, V15, P1469, DOI 10.5664/jcsm.7978; WALTER T, 1993, EUR J CLIN NUTR, V47, P307; Youssef J, 2013, PEDIATR NEUROL, V49, P274, DOI 10.1016/j.pediatrneurol.2013.06.012";25;8;8;0;1;ELSEVIER;AMSTERDAM;RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS;1389-9457;1878-5506;;SLEEP MED;Sleep Med.;DEC;2022;100;;;;;;488;493;;10.1016/j.sleep.2022.09.021;http://dx.doi.org/10.1016/j.sleep.2022.09.021;;;6;Clinical Neurology;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;I4RI4;36265207;;;;24/11/2024;WOS:001002664400011;View Full Record in Web of Science
J;"Yan, H; Siegel, L; Breitbart, S; Gorodetsky, C; Fasano, A; Rahim, A; Loh, A; Kulkarni, AV; Ibrahim, GM";;;;"Yan, Han; Siegel, Lauren; Breitbart, Sara; Gorodetsky, Carolina; Fasano, Alfonso; Rahim, Aliya; Loh, Alvin; Kulkarni, Abhaya, V; Ibrahim, George M.";;;An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocol;PILOT AND FEASIBILITY STUDIES;;;English;Article;;;;;;"Autism spectrum disorder; Deep brain stimulation; Children; Self-injurious behavior; Nucleus accumbens";"REPETITIVE BEHAVIOR; DEVELOPMENTAL-DISABILITIES; YOUNG-ADULTS; INDIVIDUALS; MANAGEMENT; SUBTYPES; SCALE";Background: Children and youth with autism spectrum disorder (ASD) may manifest self-injurious behaviors (SIB) that may become severe and refractory with limited pharmacologic or behavioral treatment options. Here, we present the protocol of a prospective, mixed-methods study to assess the safety and efficacy of deep brain stimulation (DBS) of the nucleus accumbens (NAcc) for children and youth with ASD and severe, refractory SIB. Methods: This is a prospective, single-center, single-cohort, open-label, non-randomized pilot trial of 6 patients. Participants will be recruited through specialized behavioral clinics with persistent severe and refractory SIB following standard and intensive interventions. Following NAcc-DBS, participants will be enrolled in the study for 12 months. The primary objectives of the study are safety and feasibility, assessed by rate of recruitment and identification of factors impacting adherence to follow-up and study protocol. Potential treatment efficacy will be assessed by changes in the Children's Yale-Brown Obsessive-Compulsive Scale in ASD (CYBOCS-ASD), the Behavior Problems Index (BPI), the Inventory of Statements about Self-Injury (ISAS) and the Repetitive Behavior Scale-Revised (RBS-R) questionnaires. Additional clinical outcomes will be assessed, including measures of participant and caregiver quality of life, actigraph measurements, and positron emission tomography (PET) changes following DBS. Discussion: This study will be the first to evaluate the effect of DBS of the NAcc on a pediatric population in a controlled, prospective trial. Secondary outcomes will improve the understanding of behavioral, neuro-imaging, and electrophysiologic changes in children with ASD and SIB treated with DBS. This trial will provide an estimated effect size of NAcc-DBS for severe refractory SIB in children with ASD in preparation for future comparative trials.;"[Yan, Han; Breitbart, Sara; Kulkarni, Abhaya, V; Ibrahim, George M.] Hosp Sick Children, Div Neurosurg, 555 Univ Ave,Room 1503, Toronto, ON M5G 1X8, Canada; [Yan, Han; Kulkarni, Abhaya, V] Univ Toronto, Inst Hlth Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Yan, Han; Kulkarni, Abhaya, V; Ibrahim, George M.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Siegel, Lauren; Breitbart, Sara; Rahim, Aliya] Hosp Sick Children, Neurosci & Mental Hlth Program, 555 Univ Ave,Room 1503, Toronto, ON M5G 1X8, Canada; [Gorodetsky, Carolina; Fasano, Alfonso] Hosp Sick Children, Div Neurol, Toronto, ON, Canada; [Fasano, Alfonso] UHN, Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada; [Fasano, Alfonso] Univ Toronto, Div Neurol, Toronto, ON, Canada; [Fasano, Alfonso] Krembil Brain Inst, Toronto, ON, Canada; [Fasano, Alfonso] Ctr Adv Neurotechnol Innovat Applicat CRANIA, Toronto, ON, Canada; [Rahim, Aliya; Loh, Alvin] Surrey Pl, Toronto, ON, Canada; [Loh, Alvin] Univ Toronto, Dept Paediat, Div Dev Paediat, Toronto, ON, Canada; [Ibrahim, George M.] Univ Toronto, Inst Biomed Engn, Toronto, ON, Canada; [Ibrahim, George M.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada";"University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; University Health Network Toronto; University of Toronto; Krembil Research Institute; University of Toronto; University of Toronto; University of Toronto";"Ibrahim, GM (corresponding author), Hosp Sick Children, Div Neurosurg, 555 Univ Ave,Room 1503, Toronto, ON M5G 1X8, Canada.;Ibrahim, GM (corresponding author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.;Ibrahim, GM (corresponding author), Univ Toronto, Inst Biomed Engn, Toronto, ON, Canada.;Ibrahim, GM (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.";george.m.ibrahim@gmail.com;;Siegel, Lauren/0009-0008-3851-7140;Hospital for Sick Children Centre for Brain and Mental Health, the Sandra Brown Health Outcomes Grant;Hospital for Sick Children Centre for Brain and Mental Health, the Sandra Brown Health Outcomes Grant;This research received funding from the Hospital for Sick Children Centre for Brain and Mental Health, the Sandra Brown Health Outcomes Grant.;"Adler BA, 2015, AUTISM, V19, P102, DOI 10.1177/1362361314524641; AMAN MG, 1985, AM J MENT DEF, V89, P492; AMAN MG, 1985, AM J MENT DEF, V89, P485; Amiri AM, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5010011; Baghdadli A, 2003, J INTELL DISABIL RES, V47, P622, DOI 10.1046/j.1365-2788.2003.00507.x; Benedetti-Isaac JC, 2015, EPILEPSIA, V56, P1152, DOI 10.1111/epi.13025; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Boser K, 2002, J AUTISM DEV DISORD, V32, P563, DOI 10.1023/A:1021207031114; Bradley V, 2018, J INTELL DISABIL RES, V62, P1043, DOI 10.1111/jir.12518; Bronsard G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014358; Cauda F, 2011, J NEUROL NEUROSUR PS, V82, P1304, DOI 10.1136/jnnp.2010.239111; Cif L, 2007, MOVEMENT DISORD, V22, P2126, DOI 10.1002/mds.21723; Davidson B, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18219; De Salles AAF, 2018, NEUROSURGERY, V83, P800, DOI 10.1093/neuros/nyy024; Doherty A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169649; Doshi PK, 2019, WORLD NEUROSURG, V125, P387, DOI 10.1016/j.wneu.2019.02.021; Dowd RS, 2018, J NEUROSURG, V128, P596, DOI 10.3171/2016.10.JNS161573; Duarte-Batista P, 2020, STEREOT FUNCT NEUROS, V98, P95, DOI 10.1159/000505702; Elkaim LM, 2019, DEV MED CHILD NEUROL, V61, P49, DOI 10.1111/dmcn.14063; Goldman S, 2009, DEV MED CHILD NEUROL, V51, P30, DOI 10.1111/j.1469-8749.2008.03178.x; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Haber SN, 2000, J NEUROSCI, V20, P2369; Hagopian LP, 2017, J APPL BEHAV ANAL, V50, P48, DOI 10.1002/jaba.368; Hagopian LP, 2015, J APPL BEHAV ANAL, V48, P523, DOI 10.1002/jaba.236; Ho AL, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.5.FOCUS18157; Houeto JL, 2005, J NEUROL NEUROSUR PS, V76, P992, DOI 10.1136/jnnp.2004.043273; Huisman S, 2018, NEUROSCI BIOBEHAV R, V84, P483, DOI 10.1016/j.neubiorev.2017.02.027; Islam L, 2015, WORLD NEUROSURG, V83, P657, DOI 10.1016/j.wneu.2014.12.024; IWATA BA, 1994, J APPL BEHAV ANAL, V27, P197, DOI 10.1901/jaba.1994.27-197; Kahn L, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.568932; Kakko K, 2019, J CHILD ADOL PSYCHOP, V29, P72, DOI 10.1089/cap.2018.0084; Klonsky ED, 2008, J CONSULT CLIN PSYCH, V76, P22, DOI 10.1037/0022-006X.76.1.22; Lai MC, 2015, J AM ACAD CHILD PSY, V54, P11, DOI 10.1016/j.jaac.2014.10.003; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Langen M, 2014, BIOL PSYCHIAT, V76, P405, DOI 10.1016/j.biopsych.2013.08.013; Langen M, 2011, NEUROSCI BIOBEHAV R, V35, P356, DOI 10.1016/j.neubiorev.2010.02.005; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Le JF, 2012, PEDIATR ANN, V41, pE207, DOI 10.3928/00904481-20120924-13; Lobar SL, 2016, J PEDIATR HEALTH CAR, V30, P359, DOI 10.1016/j.pedhc.2015.09.005; Lucchelli Juan Pablo, 2018, Case Rep Psychiatry, V2018, P6278501, DOI 10.1155/2018/6278501; Malone RP, 2009, DRUGS, V69, P535, DOI 10.2165/00003495-200969050-00003; Marks WA, 2009, SEMIN PEDIATR NEUROL, V16, P90, DOI 10.1016/j.spen.2009.04.001; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Min CH, 2010, IEEE ENG MED BIO, P220, DOI 10.1109/IEMBS.2010.5627850; Miocinovic S, 2013, JAMA NEUROL, V70, P163, DOI 10.1001/2013.jamaneurol.45; Park HR, 2017, ACTA NEUROCHIR, V159, P137, DOI 10.1007/s00701-016-3002-2; RICKETTS RW, 1993, J AM ACAD CHILD PSY, V32, P865, DOI 10.1097/00004583-199307000-00024; Roet M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092729; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; Sabus A, 2019, PHARMACOTHERAPY, V39, P645, DOI 10.1002/phar.2238; Segar DJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1528; Servello D, 2008, J NEUROL NEUROSUR PS, V79, P136, DOI 10.1136/jnnp.2006.104067; Shen MD, 2016, J AM ACAD CHILD PSY, V55, P817, DOI 10.1016/j.jaac.2016.05.020; Sinha S, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1548; Stocco A, 2014, PARKINSONISM RELAT D, V20, P1035, DOI 10.1016/j.parkreldis.2014.06.019; Sturm V, 2013, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00341; Sullivan CRP, 2021, NEUROIMAGE, V225, DOI 10.1016/j.neuroimage.2020.117515; Testini P, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00193; Valentín A, 2017, EUR J PAEDIATR NEURO, V21, P223, DOI 10.1016/j.ejpn.2016.10.011; Vannemreddy P, 2019, NEUROL INDIA, V67, P1220, DOI 10.4103/0028-3886.271239; Venker CE, 2014, J AUTISM DEV DISORD, V44, P546, DOI 10.1007/s10803-013-1903-y; Watabe-Uchida M, 2012, NEURON, V74, P858, DOI 10.1016/j.neuron.2012.03.017; Wilden JA, 2014, J NEUROSURG, V120, P997, DOI 10.3171/2013.12.JNS13205; Yan H, 2019, J NEUROSURG-PEDIATR, V23, P274, DOI 10.3171/2018.9.PEDS18417; Zhang HW, 2013, CLIN NUCL MED, V38, P943, DOI 10.1097/RLU.0000000000000261";65;3;4;4;12;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;2055-5784;;PILOT FEASIBILITY ST;Pilot Feasibility Stud.;FEB 2;2022;8;1;;;;;;;24;10.1186/s40814-022-00988-3;http://dx.doi.org/10.1186/s40814-022-00988-3;;;10;Medicine, Research & Experimental;Emerging Sources Citation Index (ESCI);Research & Experimental Medicine;YS1EH;35109924;gold, Green Published, Green Submitted;;;24/11/2024;WOS:000750427000001;View Full Record in Web of Science
J;"Berloffa, S; Masi, G; Falcone, F; Simonelli, V; Narzisi, A; Valente, E; Viglione, V; Milone, A; Sesso, G";;;;"Berloffa, Stefano; Masi, Gabriele; Falcone, Francesca; Simonelli, Valerio; Narzisi, Antonio; Valente, Elena; Viglione, Valentina; Milone, Annarita; Sesso, Gianluca";;;Clozapine Treatment for Aggressive Behaviors in Youths with Neurodevelopmental Disorders;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism spectrum disorder; intellectual disability; aggression; Clozapine; children; adolescents";"CHILDHOOD-ONSET SCHIZOPHRENIA; BIPOLAR DISORDER; DOUBLE-BLIND; ARIPIPRAZOLE AUGMENTATION; ADOLESCENTS; CHILDREN; OLANZAPINE; AUTISM; RISPERIDONE; PATTERNS";"Objectives: The aim of this study was to assess effectiveness and tolerability of Clozapine in the treatment of aggression in youth with Neurodevelopmental Disorders. Methods: Patients were consecutively admitted at our third-level university hospital with nationwide catchment from June 2018 to October 2022, and followed up to July 2023. Eligibility criteria were as follows: (1) Autism Spectrum Disorder (ASD) and/or Intellectual Disability/Borderline Cognitive Functioning, (2) behavioral dyscontrol with physical aggression; (3) age range between 8 and 18 years; (4) clinical indication for Clozapine treatment after at least two failed trials with other Second-Generation Antipsychotics (SGAs); (5) availability of an at least 6-month-long follow-up. To evaluate the response to Clozapine, we used the Clinical Global Impressions (CGI) rating scales (Clinical Global Impressions-Severity [CGI-S] and Clinical Global Impressions-Improvement [CGI-I]), the Children's Global Assessment Scale (CGAS), and the Aberrant Behavior Checklist (ABC). Results: Twenty-six children and adolescents (21 boys, age 13.47 +/- 2.05 years, follow-up duration 9.77 +/- 3.50 months) were included in the analysis. Clinical severity (CGI-S) and functional impairment (Clinical Global Assessment Scale) significantly improved, as well as the ABC Total Score and the scores in several subscales. Sixteen patients (61.54%) were responders (CGI-I <= 2), and 13 (50.00%) displayed remission of aberrant behaviors (Delta ABC-Total >35), while response/remission condition was not affected by add-on medications and psychotherapy. Most frequent side effects were increased appetite (50.00%), sialorrhea (38.46%), and increased repetitive behaviors (26.92%). Two patients presented epileptic seizures, while no patients presented leucopoenia. Conclusions: Our results suggest that Clozapine may be helpful in ameliorating treatment-resistant aggression in youth with neurodevelopmental conditions. Possible pharmacological strategies for the management of most frequent side effects are also suggested.";"[Berloffa, Stefano; Masi, Gabriele; Falcone, Francesca; Simonelli, Valerio; Narzisi, Antonio; Valente, Elena; Viglione, Valentina; Milone, Annarita; Sesso, Gianluca] IRCCS Stella Maris, Sci Inst Child Neurol & Psychiat, Calambrone, Italy; [Falcone, Francesca; Simonelli, Valerio] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy; [Sesso, Gianluca] IMT Sch Adv Studies Lucca, Mol Mind Lab, Social & Affect Neurosci Grp, Lucca, Italy; [Sesso, Gianluca] IRCCS Stella Maris, Sci Inst Child Neurol & Psychiat, Viale Tirreno 331A, I-56025 Pisa, Italy";"IRCCS Fondazione Stella Maris; University of Pisa; IMT School for Advanced Studies Lucca; IRCCS Fondazione Stella Maris";Sesso, G (corresponding author), IRCCS Stella Maris, Sci Inst Child Neurol & Psychiat, Viale Tirreno 331A, I-56025 Pisa, Italy.;gianluca.sesso@fsm.unipi.it;"milone, annarita/T-8312-2017; Viglione, Valentina/ADE-8121-2022; Berloffa, Stefano/AAJ-4686-2021; Valente, Elena/ABH-2891-2021; narzisi, antonio/AHE-0027-2022; Sesso, Gianluca/JVY-9209-2024";"milone, annarita/0000-0003-3170-1187; Berloffa, Stefano/0000-0002-7139-5420; Valente, Elena/0000-0002-9140-2675; narzisi, antonio/0000-0003-3996-3827; Sesso, Gianluca/0000-0003-0435-2962";Italian Ministry of Health;Italian Ministry of Health(Ministry of Health, Italy);This work has been partially supported by Italian Ministry of Health (Ricerca Corrente 2023 and the ''5x1000'' voluntary contributions);"Adnan M, 2022, J CHILD ADOL PSYCHOP, V32, P2, DOI 10.1089/cap.2021.0092; Aman M., 1986, Aberrant Behavior Checklist Manual; [Anonymous], 2022, DSM5TR, V5th, DOI [DOI 10.1176/APPI.BOOKS.9780890425787, 10.1176/APPI.BOOKS.9780890425787]; [Anonymous], 1961, The psychology of aggression, DOI 10.1037/11160-000; [Anonymous], 1993, M AM PSYCHOL ASS; BAER DM, 1968, J APPL BEHAV ANAL, V1, P91, DOI 10.1901/jaba.1968.1-91; Chalasani L, 2001, CAN J PSYCHIAT, V46, P965, DOI 10.1177/070674370104601010; Chang JS, 2006, J CLIN PSYCHIAT, V67, P461, DOI 10.4088/JCP.v67n0318; de Silva VA, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1049-5; Delgado A, 2020, J PSYCHIATR RES, V125, P21, DOI 10.1016/j.jpsychires.2020.02.026; FRAZIER JA, 1994, J AM ACAD CHILD PSY, V33, P658, DOI 10.1097/00004583-199406000-00006; Frazier JA, 2003, J CLIN PSYCHOPHARM, V23, P87, DOI 10.1097/00004714-200302000-00012; Frogley C, 2012, INT J NEUROPSYCHOPH, V15, P1351, DOI 10.1017/S146114571100201X; Glick ID, 2004, J CLIN PSYCHIAT, V65, P679, DOI 10.4088/jcp.v65n0513; Gunes H, 2015, J CHILD ADOL PSYCHOP, V25, P727, DOI 10.1089/cap.2015.0101; Guy W., 1976, ECDEU ASSESSMENT MAN; Hammock R, 2001, J AUTISM DEV DISORD, V31, P109, DOI 10.1023/A:1005626100084; Kalachnik J., 1998, Psychotropic medication and developmental disabilities: The international consensus handbook, P45; Kasoff LI, 2016, J CHILD ADOL PSYCHOP, V26, P428, DOI 10.1089/cap.2015.0103; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kranzler H, 2005, J AM ACAD CHILD PSY, V44, P55, DOI 10.1097/01.chi.0000145371.23122.5a; Kumar T, 2016, ASIAN J PSYCHIATR, V22, P102, DOI 10.1016/j.ajp.2016.06.006; Kumra S, 1996, ARCH GEN PSYCHIAT, V53, P1090; Kumra S, 2008, BIOL PSYCHIAT, V63, P524, DOI 10.1016/j.biopsych.2007.04.043; Lambrey S, 2010, J CHILD ADOL PSYCHOP, V20, P79, DOI 10.1089/cap.2009.0057; Li XB, 2015, BIPOLAR DISORD, V17, P235, DOI 10.1111/bdi.12272; Lord C., 2012, AUTISM DIAGNOSTIC OB; Masi G, 1998, PANMINERVA MED, V40, P254; Masi G, 2002, J CHILD ADOL PSYCHOP, V12, P93, DOI 10.1089/104454602760219135; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Nielsen J, 2012, BIPOLAR DISORD, V14, P863, DOI 10.1111/bdi.12018; Olfson M, 2012, ARCH GEN PSYCHIAT, V69, P1247, DOI 10.1001/archgenpsychiatry.2012.647; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Praharaj SK, 2005, J PSYCHOPHARMACOL, V19, P426, DOI 10.1177/0269881105053311; Rachamallu V, 2019, AM J THER, V26, pE406, DOI 10.1097/MJT.0000000000000894; Rothärmel M, 2018, J CLIN PSYCHOPHARM, V38, P577, DOI 10.1097/JCP.0000000000000955; Rutter M., 2003, ADI R AUTISM DIAGNOS; Sahoo S, 2017, ASIAN J PSYCHIATR, V29, P194, DOI 10.1016/j.ajp.2017.07.012; Samara MT, 2016, JAMA PSYCHIAT, V73, P199, DOI 10.1001/jamapsychiatry.2015.2955; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Shaw P, 2006, ARCH GEN PSYCHIAT, V63, P721, DOI 10.1001/archpsyc.63.7.721; Sporn AL, 2007, J AM ACAD CHILD PSY, V46, P1349, DOI 10.1097/chi.0b013e31812eed10; Thom RP, 2023, EXPERT REV CLIN PHAR, DOI 10.1080/17512433.2023.2243820; Vangala V R, 1999, Bipolar Disord, V1, P123; Villari V, 2011, J CLIN PSYCHOPHARM, V31, P375, DOI 10.1097/JCP.0b013e31821927d8; Vitiello B, 1997, J AM ACAD CHILD PSY, V36, P307, DOI 10.1097/00004583-199703000-00008; Wilkowska A, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00520; Yalcin O, 2016, J CHILD ADOL PSYCHOP, V26, P815, DOI 10.1089/cap.2015.0020; Zuddas A, 1996, AM J PSYCHIAT, V153, P738";49;3;3;1;3;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;APR 1;2024;34;3;;;;;148;156;;10.1089/cap.2023.0097;http://dx.doi.org/10.1089/cap.2023.0097;;;9;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";NO6F4;38608010;;;;24/11/2024;WOS:001201424100007;View Full Record in Web of Science
J;"Li, YR; Xiao, P; Cao, R; Le, J; Xu, Q; Xiao, FF; Ye, L; Wang, XF; Wang, YZ; Zhang, T";;;;"Li, Youran; Xiao, Pei; Cao, Rong; Le, Jun; Xu, Qiao; Xiao, Fangfei; Ye, Lin; Wang, Xufei; Wang, Yizhong; Zhang, Ting";;;Effects and microbiota changes following oral lyophilized fecal microbiota transplantation in children with autism spectrum disorder;FRONTIERS IN PEDIATRICS;;;English;Article;;;;;;"autism spectrum disorder; fecal microbiota transplantation; gut microbiota; treatment; children";;Background and purpose Autism spectrum disorder (ASD) is a group of heterogeneous neurodevelopmental disorders that is characterized by core features in social communication impairment and restricted, repetitive sensory-motor behaviors. This study aimed to further investigate the utilization of fecal microbiota transplantation (FMT) in children with ASD, both with and without gastrointestinal (GI) symptoms, evaluate the effect of FMT and analyze the alterations in bacterial and fungal composition within the gut microbiota.Methods A total of 38 children diagnosed with ASD participated in the study and underwent oral lyophilized FMT treatment. The dosage of the FMT treatment was determined based on a ratio of 1 g of donor stool per 1 kg of recipient body weight, with a frequency of once every 4 weeks for a total of 12 weeks. In addition, 30 healthy controls (HC) were included in the analysis. The clinical efficacy of FMT was evaluated, while the composition of fecal bacteria and fungi was determined using 16S rRNA and ITS gene sequencing methods.Results Median age of the 38 children with ASD was 7 years. Among these children, 84.2% (32 of 38) were boys and 81.6% (31 of 38) exhibited GI symptoms, with indigestion, constipation and diarrhea being the most common symptoms. Sample collections and assessments were conducted at baseline (week 0), post-treatment (week 12) and follow-up (week 20). At the end of the follow-up phase after FMT treatment, the autism behavior checklist (ABC) scores decreased by 23% from baseline, and there was a 10% reduction in scores on the childhood autism rating scale (CARS), a 6% reduction in scores on the social responsiveness scale (SRS) and a 10% reduction in scores on the sleep disturbance scale for children (SDSC). In addition, short-term adverse events observed included vomiting and fever in 2 participants, which were self-limiting and resolved within 24 h, and no long-term adverse events were observed. Although there was no significant difference in alpha and beta diversity in children with ASD before and after FMT therapy, the FMT treatment resulted in alterations in the relative abundances of various bacterial and fungal genera in the samples of ASD patients. Comparisons between children with ASD and healthy controls (HC) revealed statistically significant differences in microbial abundance before and after FMT. Blautia, Sellimonas, Saccharomycopsis and Cystobasidium were more abundant in children with ASD than in HC, while Dorea were less abundant. After FMT treatment, levels of Blautia, Sellimonas, Saccharomycopsis and Cystobasidium decreased, while levels of Dorea increased. Moreover, the increased abundances of Fusicatenibacter, Erysipelotrichaceae_UCG-003, Saccharomyces, Rhodotorula, Cutaneotrichosporon and Zygosaccharomyces were negatively correlated with the scores of ASD core symptoms.Conclusions Oral lyophilized FMT could improve GI and ASD related symptoms, as well as sleep disturbances, and alter the gut bacterial and fungal microbiota composition in children with ASD.Clinical Trial Registration Chinese Clinical Trial Registry, ChiCTR2200055943. Registered 28 January 2022, www.chictr.org.cn.;"[Li, Youran; Xiao, Pei; Cao, Rong; Le, Jun; Xu, Qiao; Xiao, Fangfei; Ye, Lin; Wang, Xufei; Wang, Yizhong; Zhang, Ting] Shanghai Jiao Tong Univ, Shanghai Childrens Hosp, Sch Med, Dept Gastroenterol Hepatol & Nutr, Shanghai, Peoples R China; [Wang, Yizhong; Zhang, Ting] Shanghai Jiao Tong Univ, Sch Med, Inst Pediat Infect Immun & Crit Care Med, Shanghai, Peoples R China";"Shanghai Jiao Tong University; Shanghai Jiao Tong University";"Wang, YZ; Zhang, T (corresponding author), Shanghai Jiao Tong Univ, Shanghai Childrens Hosp, Sch Med, Dept Gastroenterol Hepatol & Nutr, Shanghai, Peoples R China.;Wang, YZ; Zhang, T (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Pediat Infect Immun & Crit Care Med, Shanghai, Peoples R China.";"wangyz@shchildren.com.cn; zhangt@shchildren.com.cn";?, ??/AAR-2931-2021;;Medical innovation Research project of Shanghai Science and Technology Commission;Medical innovation Research project of Shanghai Science and Technology Commission;No Statement Available;"Abuaish S, 2022, J MOL NEUROSCI, V72, P372, DOI 10.1007/s12031-021-01959-8; Abuaish S, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11081038; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Bresnahan M, 2015, JAMA PSYCHIAT, V72, P466, DOI 10.1001/jamapsychiatry.2014.3034; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Cammarota G, 2019, GUT, V68, P2111, DOI 10.1136/gutjnl-2019-319548; Chaidez V, 2014, J AUTISM DEV DISORD, V44, P1117, DOI 10.1007/s10803-013-1973-x; Chen KN, 2020, MICROB ECOL, V80, P475, DOI 10.1007/s00248-020-01494-w; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Ding X, 2020, J PSYCHIATR RES, V129, P149, DOI 10.1016/j.jpsychires.2020.06.032; Fattorusso A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030521; Goo N, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118497; Gu X, 2023, WORLD J PEDIATR, V19, P813, DOI 10.1007/s12519-022-00655-w; Gupta Arjun, 2017, JAMA, V318, P102, DOI 10.1001/jama.2017.6466; Hirota T, 2023, JAMA-J AM MED ASSOC, V329, P157, DOI 10.1001/jama.2022.23661; Iglesias-Vázquez L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030792; Iovene MR, 2017, MYCOPATHOLOGIA, V182, P349, DOI 10.1007/s11046-016-0068-6; Kang DW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42183-0; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Kang LY, 2023, ASIAN J PSYCHIATR, V79, DOI 10.1016/j.ajp.2022.103359; Leader G, 2022, NUTRIENTS, V14, DOI 10.3390/nu14071471; Li N, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.759435; Li XL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02622; Li YR, 2022, NEUROPSYCH DIS TREAT, V18, P2905, DOI 10.2147/NDT.S382571; Liu FT, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0389-6; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Lou MX, 2022, GUT, V71, P1588, DOI 10.1136/gutjnl-2021-325115; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Parenteral and Enteral Nutrition Branch of Chinese Medical Association, 2020, Zhonghua Wei Chang Wai Ke Za Zhi, V23, P5, DOI 10.3760/cma.j.cn.441530-20200420-00231; Solmi M, 2022, MOL PSYCHIATR, V27, P4172, DOI 10.1038/s41380-022-01630-7; Strati F, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0242-1; Strati F, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01227; Sun HR, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1896-6; Wan YT, 2022, GUT, V71, P910, DOI 10.1136/gutjnl-2020-324015; Wang L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24031819; Wang YZ, 2022, J DIGEST DIS, V23, P482, DOI 10.1111/1751-2980.13135; Yu Y, 2021, J GENET GENOMICS, V48, P755, DOI 10.1016/j.jgg.2021.07.001; Zhang MX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32219-2; Zhang T, 2020, PROTEIN CELL, V11, P251, DOI 10.1007/s13238-019-00684-8; Zou R, 2020, AUTISM RES, V13, P1614, DOI 10.1002/aur.2358";40;0;0;7;7;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;2296-2360;;;FRONT PEDIATR;Front. Pediatr.;MAY 9;2024;12;;;;;;;;1369823;10.3389/fped.2024.1369823;http://dx.doi.org/10.3389/fped.2024.1369823;;;13;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;RQ0M8;38783921;Green Published, gold;;;24/11/2024;WOS:001229008500001;View Full Record in Web of Science
J;"Han, YMY; Chan, MMY; Shea, CKS; Mo, FYM; Yiu, KWK; Chung, RCK; Cheung, MC; Chan, AS";;;;"Han, Yvonne M. Y.; Chan, Melody M. Y.; Shea, Caroline K. S.; Mo, Flora Y. M.; Yiu, Klaire W. K.; Chung, Raymond C. K.; Cheung, Mei-Chun; Chan, Agnes S.";;;Effects of prefrontal transcranial direct current stimulation on social functioning in autism spectrum disorder: A randomized clinical trial;AUTISM;;;English;Article;;;;;;"ASD; behavior; cognition; RCT; social; tDCS";"COGNITIVE FLEXIBILITY; EXECUTIVE FUNCTIONS; YOUNG-CHILDREN; TDCS; CORTEX; METAANALYSIS; HEALTHY; SAFETY; INTERVENTIONS; IRRITABILITY";"This triple-arm, double-blind, randomized clinical trial investigated the effect of multisession prefrontal transcranial direct current stimulation (tDCS) on social functioning in individuals with autism spectrum disorder (ASD). A total of 105 individuals (age 14-21 years) diagnosed with ASD were randomized into the active-tDCS, sham-tDCS, and waitlist control groups. The experimental group received 20 min of 1.5 mA tDCS stimulation (cathode: F3; anode: Fp2) for 10 days with concurrent computerized cognitive remediation training. Changes in overall social functioning, social communication, and restricted, repetitive behaviors (RRB) were measured by the Social Responsiveness Scale-2nd edition (SRS-2). Two-level hierarchical linear mixed-model analysis showed significant group*time interactions for SRS-2 total [F(2, 107.09) = 7.82; p = 0.001] and RRB [F(2, 90.26) = 5.62; p = 0.005] T-scores. When compared with the waitlist control group, the changes in scores were only significant in active-tDCS (SRS-2 total T-score p < 0.001, d = 0.61; SRS-2 RRB T-score p = 0.002, d = 0.88), but not sham-tDCS (SRS-2 total T-score p < 0.12, d = 0.30; SRS-2 RRB T-score p = 0.54, d = 0.17) group. Multiple sessions of prefrontal tDCS coupled with cognitive training is a safe and effective treatment for improving social functioning in people with ASD. Trial Registration: ClinicalTrials.gov (ID: NCT03814083; URL: ).Lay abstractCurrently available pharmacological and behavioral interventions for adolescents and young adults with autism spectrum disorder (ASD) yield only modest effect in alleviating their core behavioral and cognitive symptoms, and some of these treatment options are associated with undesirable side effects. Hence, developing effective treatment protocols is urgently needed. Given emerging evidence shows that the abnormal connections of the frontal brain regions contribute to the manifestations of ASD behavioral and cognitive impairments, noninvasive treatment modalities that are capable in modulating brain connections, such as transcranial direct current stimulation (tDCS), have been postulated to be potentially promising for alleviating core symptoms in ASD. However, whether tDCS can reduce behavioral symptoms and enhance cognitive performance in ASD remains unclear. This randomized controlled trial involving 105 adolescents and young adults with ASD showed that multiple sessions of a tDCS protocol, which was paired up with computerized cognitive training, was effective in improving social functioning in adolescents and young adults with ASD. No prolonged and serious side effects were observed. With more future studies conducted in different clinical settings that recruit participants from a wider age range, this tDCS protocol may be potentially beneficial to a broad spectrum of individuals with autism.";"[Han, Yvonne M. Y.; Chan, Melody M. Y.; Chung, Raymond C. K.] Hong Kong Polytech Univ, Hong Kong, Peoples R China; [Chan, Melody M. Y.] Univ Queensland, Brisbane, Australia; [Shea, Caroline K. S.; Mo, Flora Y. M.; Yiu, Klaire W. K.] Hosp Author, Hong Kong, Peoples R China; [Shea, Caroline K. S.; Mo, Flora Y. M.; Cheung, Mei-Chun; Chan, Agnes S.] Chinese Univ Hong Kong, Hong Kong, Peoples R China; [Han, Yvonne M. Y.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, 11 Yuk Choi Rd, Hong Kong, Peoples R China";"Hong Kong Polytechnic University; University of Queensland; Chinese University of Hong Kong; Hong Kong Polytechnic University";Han, YMY (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, 11 Yuk Choi Rd, Hong Kong, Peoples R China.;yvonne.han@polyu.edu.hk;"; Cheung, Mei Chun/A-1261-2014; Chan, Melody/JQW-1885-2023";"Han, Yvonne/0000-0002-9534-6834; Chan, Agnes/0000-0002-3321-182X; Cheung, Mei Chun/0000-0002-0210-0772; Chan, Melody/0000-0001-9493-0134";"Health and Medical Research Fund [HMRF06173096]; Food and Health Bureau, The Government of the Hong Kong Special Administrative Region";"Health and Medical Research Fund; Food and Health Bureau, The Government of the Hong Kong Special Administrative Region";The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Health and Medical Research Fund (HMRF06173096) from the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region.;"Agarwal M, 2016, PSYCHIAT RES, V235, P97, DOI 10.1016/j.psychres.2015.11.042; Amatachaya A, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/173073; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Amir H, 2020, AGING-US, V12, P13740, DOI 10.18632/aging.103571; Babiloni AH, 2021, SLEEP MED REV, V55, DOI 10.1016/j.smrv.2020.101381; Bachtiar V, 2015, ELIFE, V4, DOI 10.7554/eLife.08789; Backhouse S, 2012, OPHTHAL PHYSL OPT, V32, P294, DOI 10.1111/j.1475-1313.2012.00912.x; Baumert A, 2020, COGN AFFECT BEHAV NE, V20, P34, DOI 10.3758/s13415-019-00726-y; Bejarano-Martín A, 2020, EARLY CHILD RES Q, V51, P430, DOI 10.1016/j.ecresq.2020.01.004; Bell ML, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-118; Beninato M, 2011, J NEUROL PHYS THER, V35, P75, DOI 10.1097/NPT.0b013e318219308c; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Casanova MF, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10070423; Chan MMY, 2021, NEUROSCI BIOBEHAV R, V125, P392, DOI 10.1016/j.neubiorev.2021.02.035; Charman T, 2011, PSYCHOL MED, V41, P619, DOI 10.1017/S0033291710000991; Chen SF, 2016, PSYCHOL MED, V46, P1625, DOI 10.1017/S0033291715002238; Clark VP, 2011, NEUROSCI LETT, V500, P67, DOI 10.1016/j.neulet.2011.05.244; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Coulacoglou C., 2017, PSYCHOMETRICS PSYCHO; D'Alò GL, 2021, HEALTH QUAL LIFE OUT, V19, DOI 10.1186/s12955-021-01669-0; D'Urso G, 2014, BIOL PSYCHIAT, V76, pE5, DOI 10.1016/j.biopsych.2013.11.009; De Smet S, 2021, PROG NEURO-PSYCHOPH, V109, DOI 10.1016/j.pnpbp.2021.110261; Deco G, 2009, PROG NEUROBIOL, V88, P1, DOI 10.1016/j.pneurobio.2009.01.006; Dedoncker J, 2016, BRAIN STIMUL, V9, P501, DOI 10.1016/j.brs.2016.04.006; Demetriou EA, 2018, MOL PSYCHIATR, V23, P1198, DOI 10.1038/mp.2017.75; Fallah MS, 2019, J CHILD ADOL PSYCHOP, V29, P168, DOI 10.1089/cap.2018.0115; Feingold A, 2009, PSYCHOL METHODS, V14, P43, DOI 10.1037/a0014699; Field A., 2013, DISCOVERING STAT USI; Fonteneau C, 2019, BRAIN STIMUL, V12, P668, DOI 10.1016/j.brs.2018.12.977; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Funahashi S, 2013, J PHYSIOL-PARIS, V107, P471, DOI 10.1016/j.jphysparis.2013.05.001; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Garcia-Gonzalez S, 2021, EUR NEUROPSYCHOPHARM, V48, P89, DOI 10.1016/j.euroneuro.2021.02.017; Ghanavati E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40273-7; Gupta S., 2018, The British Journal of Psychiatry Advances, V24, P295, DOI [DOI 10.1192/BJA.2018.2, https://doi.org/10.1192/bja.2018.2]; Hadoush H, 2020, AUTISM RES, V13, P828, DOI 10.1002/aur.2290; Han YMY, 2022, BRAIN STIMUL, V15, P414, DOI 10.1016/j.brs.2022.02.004; Hassan TH, 2013, RES AUTISM SPECT DIS, V7, P541, DOI 10.1016/j.rasd.2012.12.005; Hellyer PJ, 2015, J NEUROSCI, V35, P9050, DOI 10.1523/JNEUROSCI.4648-14.2015; Higgins E S., 2019, Brain Stimulation Therapies for Clinicians, V2nd edn; Hill AT, 2016, BRAIN STIMUL, V9, P197, DOI 10.1016/j.brs.2015.10.006; Horowitz MA, 2021, SCHIZOPHRENIA BULL, V47, P1116, DOI 10.1093/schbul/sbab017; Jackson MP, 2016, CLIN NEUROPHYSIOL, V127, P3425, DOI 10.1016/j.clinph.2016.08.016; Jaschinski W, 2007, OPHTHAL PHYSL OPT, V27, P85, DOI 10.1111/j.1475-1313.2006.00448.x; Kalbe E, 2010, CORTEX, V46, P769, DOI 10.1016/j.cortex.2009.07.010; Kim C, 2011, J NEUROSCI, V31, P4771, DOI 10.1523/JNEUROSCI.5923-10.2011; Kirk HE, 2015, RES DEV DISABIL, V38, P145, DOI 10.1016/j.ridd.2014.12.026; Kissine M, 2021, AUTISM RES, V14, P1186, DOI 10.1002/aur.2477; Kongs K.S., 2000, WISCONSIN CARD SORTI; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; Krishnan A, 2016, NAT NEUROSCI, V19, P1454, DOI 10.1038/nn.4353; Lai MC, 2010, BIOL PSYCHIAT, V68, P1092, DOI 10.1016/j.biopsych.2010.06.027; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Li LM, 2019, HUM BRAIN MAPP, V40, P904, DOI 10.1002/hbm.24420; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Luft CD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03022-2; Mansouri FA, 2009, NAT REV NEUROSCI, V10, P141, DOI 10.1038/nrn2538; Matsumoto H, 2017, CLIN NEUROPHYS PRACT, V2, P19, DOI 10.1016/j.cnp.2016.12.003; McCracken JT, 2021, EUR NEUROPSYCHOPHARM, V48, P3, DOI 10.1016/j.euroneuro.2021.05.010; McLaren ME, 2018, BRAIN STIMUL, V11, P52, DOI 10.1016/j.brs.2017.10.006; Miller KJ, 2005, PEDIATR ANN, V34, P310, DOI 10.1146/annurev-psych-113011-143750; Murdaugh DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050064; Nejati V, 2018, NEUROSCIENCE, V369, P109, DOI 10.1016/j.neuroscience.2017.10.042; Nelson SB, 2015, NEURON, V87, P684, DOI 10.1016/j.neuron.2015.07.033; Neubauer AC, 2003, PERS INDIV DIFFER, V35, P811, DOI 10.1016/S0191-8869(02)00285-4; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Oberman LM, 2016, AUTISM RES, V9, P184, DOI 10.1002/aur.1567; Oberman LM, 2015, J AUTISM DEV DISORD, V45, P524, DOI 10.1007/s10803-013-1960-2; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Portney LG., 2015, FDN CLIN RES APPL PR; Qiu JJ, 2021, NEURAL PLAST, V2021, DOI 10.1155/2021/6627507; Raudenbush SW, 2001, PSYCHOL METHODS, V6, P387, DOI 10.1037//1082-989X.6.4.387; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Resnik DB, 2012, J MED ETHICS, V38, P746, DOI 10.1136/medethics-2011-100319; Richdale AL, 2009, SLEEP MED REV, V13, P403, DOI 10.1016/j.smrv.2009.02.003; Rodrigues R, 2021, J CHILD PSYCHOL PSYC, V62, P680, DOI 10.1111/jcpp.13305; Rothärmel M, 2019, NEUROPSYCHOBIOLOGY, V78, P189, DOI 10.1159/000501025; Sampaio B Jr, 2018, JAMA PSYCHIAT, V75, P158, DOI 10.1001/jamapsychiatry.2017.4040; Shanahan M, 2010, CHAOS, V20, DOI 10.1063/1.3305451; Smith JR, 2023, NEUROPSYCHOL REV, V33, P834, DOI 10.1007/s11065-022-09564-1; Sokhadze EM, 2018, FRONT SYST NEUROSCI, V12, DOI 10.3389/fnsys.2018.00020; Spence SJ, 2009, PEDIATR RES, V65, P599, DOI 10.1203/PDR.0b013e31819e7168; Taylor JL, 2012, PEDIATRICS, V130, P531, DOI 10.1542/peds.2012-0682; Tiede G, 2019, AUTISM, V23, P2080, DOI 10.1177/1362361319836371; Trakoshis S, 2020, ELIFE, V9, DOI 10.7554/eLife.55684; Tucha L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046080; Valiengo LDL, 2020, JAMA PSYCHIAT, V77, P121, DOI 10.1001/jamapsychiatry.2019.3199; van Elst LT, 2014, MOL PSYCHIATR, V19, P1314, DOI 10.1038/mp.2014.62; Volkmar FR, 2013, WORLD PSYCHIATRY, V12, P79, DOI 10.1002/wps.20020; Werner G, 2007, J PHYSIOL-PARIS, V101, P273, DOI 10.1016/j.jphysparis.2007.12.001; Williams DL, 2008, RES AUTISM SPECT DIS, V2, P353, DOI 10.1016/j.rasd.2007.08.005; Wörsching J, 2018, BRAIN STIMUL, V11, P998, DOI 10.1016/j.brs.2018.05.001; Wörsching J, 2016, NEUROSCI BIOBEHAV R, V69, P333, DOI 10.1016/j.neubiorev.2016.08.001; World Health Organization (WHO), 1993, The ICD-10 classification of mental and behavioural disorders; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Zhao XJ, 2020, J PHYSIOL-LONDON, V598, P3727, DOI 10.1113/JP279340; Zhou MS, 2021, J AM ACAD CHILD PSY, V60, P35, DOI 10.1016/j.jaac.2020.03.007; Zikopoulos B, 2013, FRONT HUM NEUROSCI, V7, P1, DOI 10.3389/fnhum.2013.00609";101;4;4;11;31;SAGE PUBLICATIONS LTD;LONDON;1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND;1362-3613;1461-7005;;AUTISM;Autism;NOV;2023;27;8;;;;;2465;2482;;10.1177/13623613231169547;http://dx.doi.org/10.1177/13623613231169547;;MAY 2023;18;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;U5GJ1;37151094;;;;24/11/2024;WOS:000983881300001;View Full Record in Web of Science
J;"Ebrahimi, P; Seyedmirzaei, H; Moradi, K; Bagheri, S; Moeini, M; Mohammadi, MR; Akhondzadeh, S";;;;"Ebrahimi, Parnia; Seyedmirzaei, Homa; Moradi, Kamyar; Bagheri, Sayna; Moeini, Mahdi; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin";;;Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial;INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"adjunctive therapy; autism spectrum disorder; cilostazol; clinical trial";"ABERRANT BEHAVIOR CHECKLIST; MITOCHONDRIAL DYSFUNCTION; CYCLIC-AMP; VALIDITY; VERSION";"We aimed to evaluate cilostazol therapeutic effects on aberrant behaviors of autism spectrum disorder (ASD) children and its safety profile in a double-blind, randomized clinical trial. Sixty-six children with confirmed ASD were allocated to receive either daily 50-mg cilostazol (increased to 100 mg/day after 2 weeks) or matched placebo in addition to risperidone. The Aberrant Behavior Checklist-Community Edition (ABC-C) scale and a checklist of probable adverse effects were used to assess the behavioral outcomes and safety profile at weeks 0, 5, and 10 of the study. Sixty-one participants, with comparable baseline characteristics, completed the trial. Unlike other ABC-C subscales, repeated-measures analysis showed significant effect for time x treatment interaction in the hyperactivity subscale (P = 0.047; partial eta squared = 0.06). We used the median value for the baseline score hyperactivity subscale [median (interquartile range) = 31 (24-37)] to stratify participants to higher hyperactivity and lower hyperactivity subgroups and found that only participants with higher hyperactivity benefit from cilostazol adjunctive therapy (P = 0.028; partial eta squared = 0.14). Cilostazol could be considered as a safe agent with beneficial effects on hyperactivity in children with ASD and higher levels of hyperactivity.";"[Ebrahimi, Parnia; Moradi, Kamyar; Bagheri, Sayna; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin] Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, Tehran, Iran; [Seyedmirzaei, Homa] Univ Tehran Med Sci, INRP, Tehran, Iran; [Moeini, Mahdi] Allameh Tabatabaei Univ, Fac Psychol & Educ, Dept Psychol, Tehran, Iran; [Akhondzadeh, Shahin] Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, South Kargar St, Tehran 13337, Iran";"Tehran University of Medical Sciences; Tehran University of Medical Sciences; Allameh Tabataba'i University; Tehran University of Medical Sciences";Akhondzadeh, S (corresponding author), Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, South Kargar St, Tehran 13337, Iran.;s.akhond@neda.net;"Mohammadi, Mohammad Reza/ABD-9550-2021; Akhondzadeh, Shahin/F-2914-2018; Moradi, Kamyar/KXQ-6495-2024; Seyedmirzaei, Homa/GOK-1177-2022";;Tehran University of Medical Sciences [45982];Tehran University of Medical Sciences(Tehran University of Medical SciencesGolestan University of Medical Sciences);The authors would like to thank the children and their families for their invaluable cooperation. This study was the postgraduate thesis of Dr. Parnia Ebrahimi under supervision of Prof. Shahin Akhondzadeh.This study was supported by a grant from Tehran University of Medical Sciences to Prof. Shahin Akhondzadeh (Grant Number: 45982).All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by P.E., H.S., K.M., S.B., M.M., M.-R.M., and S.A. The first draft of the manuscript was written by P.E. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.This trial was registered with the Iranian Registry of Clinical Trials (IRCT) as IRCT20090117001556N124.;"Abdallah MS, 2021, CNS NEUROSCI THER, V27, P1540, DOI 10.1111/cns.13731; AMAN MG, 1995, AM J MENT RETARD, V100, P283; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053; Ayatollahi A, 2020, CLIN NEUROPHARMACOL, V43, P139, DOI 10.1097/WNF.0000000000000405; Balachandar V, 2021, GENES DIS, V8, P629, DOI 10.1016/j.gendis.2020.07.002; COOK EH, 1990, SYNAPSE, V6, P292, DOI 10.1002/syn.890060309; DeFilippis Melissa, 2016, Psychopharmacol Bull, V46, P18; Delhaye S, 2021, MOL PSYCHIATR, V26, P4570, DOI 10.1038/s41380-020-00997-9; Foxx RM, 2008, CHILD ADOL PSYCH CL, V17, P821, DOI 10.1016/j.chc.2008.06.007; Goto S, 2005, ATHEROSCLEROSIS SUPP, V6, P3, DOI 10.1016/j.atherosclerosissup.2005.09.002; Hendouei F, 2020, J CLIN PHARM THER, V45, P324, DOI 10.1111/jcpt.13076; Ilouz R, 2017, ELIFE, V6, DOI 10.7554/eLife.17681; Ji LN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023751; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kelley DJ, 2008, NEUROSCI BIOBEHAV R, V32, P1533, DOI 10.1016/j.neubiorev.2008.06.005; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Luhach K, 2021, J PHARM PHARMACOL, V73, P1460, DOI 10.1093/jpp/rgab115; Luhach K, 2021, AUTISM RES, V14, P2270, DOI 10.1002/aur.2597; Luhach K, 2021, CLIN EXP PHARMACOL P, V48, P614, DOI 10.1111/1440-1681.13459; Luhach K, 2021, EUR J PHARMACOL, V890, DOI 10.1016/j.ejphar.2020.173663; Marotta R, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10030163; Mehan S, 2020, NEURAL REGEN RES, V15, P1140, DOI 10.4103/1673-5374.270316; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; Ono K, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00559; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; Rezaei F, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2583; Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR; Tai SY, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0800-y; Wingate M, 2014, MMWR SURVEILL SUMM, V63; Xue WD, 2016, SCI REP-UK, V6, DOI 10.1038/srep26331";32;3;3;0;7;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0268-1315;1473-5857;;INT CLIN PSYCHOPHARM;Int. Clin. Psychopharmacol.;MAR;2023;38;2;;;;;89;95;;10.1097/YIC.0000000000000431;http://dx.doi.org/10.1097/YIC.0000000000000431;;;7;"Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pharmacology & Pharmacy; Psychiatry";8L7HS;36165508;;;;24/11/2024;WOS:000923954000004;View Full Record in Web of Science
J;"Youngster, I; Zachor, DA; Gabis, LV; Bar-Chaim, A; Benveniste-Levkovitz, P; Britzi, M; Soback, S; Ziv-Baran, T; Berkovitch, M";;;;"Youngster, Ilan; Zachor, Ditza A.; Gabis, Lidia V.; Bar-Chaim, Adina; Benveniste-Levkovitz, Patricia; Britzi, Malka; Soback, Stefan; Ziv-Baran, Tomer; Berkovitch, Matitiahu";;;CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study;DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY;;;English;Article;;;;;;;"CYTOCHROME-P450 2D6 CYP2D6; BEHAVIORAL SYMPTOMS; CHILDREN; PLASMA; 9-HYDROXYRISPERIDONE; MEDICATIONS; ADOLESCENTS";"AimTo evaluate the association between cytochrome P450 2D6 (CYP2D6) phenotypes in paediatric patients with autistic spectrum disorders (ASD) treated with risperidone, adverse drug reactions (ADRs), and drug efficacy. MethodAn observational cohort study of 40 children (34 males, six females; median age 7y range 3-18y) with autistic disorder, pervasive developmental disorder not otherwise specified, or Asperger syndrome diagnosed using the Autism Diagnostic Interview-Revised and treated with risperidone for at least 3months. Charts were reviewed for demographic and clinical information, response to treatment was assessed by parents and the treating neurologist on a three-point scale, and information about ADRs was collected. Trough plasma levels of risperidone and its metabolites were determined and CYP2D6 genotyping was performed. ResultsTwenty-six patients responded to therapy and 11 patients exhibited ADRs. CYP2D6 genotyping showed two patients to be poor metabolizers, two ultra-rapid metabolizers, seven intermediate metabolizers, and 29 extensive metabolizers. Both ultra-rapid metabolizer patients were non-responders and had no ADRs. In contrast, both poor metabolizer patients were responders but experienced ADRs. No correlation was found between risperidone dosage and either risperidone or drug metabolite plasma levels. There was no difference in risperidone or metabolite plasma levels when comparing responders to non-responders, or when comparing patients with or without ADRs. InterpretationIn patients with ASD treated with risperidone, a CYP2D6 phenotype may be associated with response to treatment and development of ADRs.";"[Youngster, Ilan; Berkovitch, Matitiahu] Assaf Harofeh Med Ctr, Clin Pharmacol Unit, IL-70300 Zerifin, Israel; [Zachor, Ditza A.] Assaf Harofeh Med Ctr, Autism Ctr, IL-70300 Zerifin, Israel; [Gabis, Lidia V.] Safra Childrens Hosp, Child Dev Ctr, Tel Hashomer, Israel; [Bar-Chaim, Adina; Benveniste-Levkovitz, Patricia] Assaf Harofeh Med Ctr, Pharmacogenet Lab, IL-70300 Zerifin, Israel; [Britzi, Malka; Soback, Stefan] Hebrew Univ Jerusalem, Minist Agr, Natl Residue Control Lab, Jerusalem, Israel; [Ziv-Baran, Tomer] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel";"Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Hebrew University of Jerusalem; Tel Aviv University";Youngster, I (corresponding author), Assaf Harofeh Med Ctr, Clin Pharmacol Unit, IL-70300 Zerifin, Israel.;ilan.youngster@yahoo.com;"Ziv-Baran, Tomer/AAA-8408-2022; Youngster, Ilan/AAZ-1225-2020; Gabis, Lidia/AAF-9518-2020; Youngster, Ilan/J-5047-2014";"Zachor, Ditza/0000-0002-1766-2487; Youngster, Ilan/0000-0001-5233-1213";Israeli Society for Clinical Pediatrics (CHIPAK);Israeli Society for Clinical Pediatrics (CHIPAK);This study was supported by a grant from the Israeli Society for Clinical Pediatrics (CHIPAK). The authors have stated that they had no interests that could be perceived as posing a bias or conflict.;"Aman MG, 2007, CLIN THER, V29, P1476, DOI 10.1016/j.clinthera.2007.07.026; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Avenoso A, 2000, J CHROMATOGR B, V746, P173, DOI 10.1016/S0378-4347(00)00323-6; Chen SQ, 1996, CLIN PHARMACOL THER, V60, P522, DOI 10.1016/S0009-9236(96)90148-4; Chou WH, 2003, CLIN CHEM, V49, P542, DOI 10.1373/49.4.542; Correia CT, 2010, PHARMACOGENOMICS J, V10, P418, DOI 10.1038/tpj.2009.63; de Leon J, 2005, J CLIN PSYCHIAT, V66, P15, DOI 10.4088/JCP.v66n0103; de Leon J, 2008, CLIN LAB MED, V28, P599, DOI 10.1016/j.cll.2008.05.003; Dove D, 2012, PEDIATRICS, V130, P717, DOI 10.1542/peds.2012-0683; Hawcutt DB, 2012, ARCH DIS CHILD, V98, P1; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Kang RH, 2009, J CLIN PSYCHOPHARM, V29, P272, DOI 10.1097/JCP.0b013e3181a289e0; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Mas S, 2012, PHARMACOGENOMICS J, V12, P255, DOI 10.1038/tpj.2010.91; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; Pringsheim T, 2011, J CHILD ADOL PSYCHOP, V21, P537, DOI 10.1089/cap.2010.0145; Pringsheim T, 2011, PAED CHILD HEALT-CAN, V16, P581, DOI 10.1093/pch/16.9.581; Rodríguez-Antona C, 2009, PHARMACOGENOMICS, V10, P685, DOI 10.2217/PGS.09.15; Rosenbloom AL, 2010, INT J PEDIATR ENDOCR, DOI 10.1155/2010/159402; Rutter M., 2003, ADI R AUTISM DIAGNOS; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Seto K, 2011, THER DRUG MONIT, V33, P275, DOI 10.1097/FTD.0b013e3182126d83; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Sim SC, 2013, PHARMACOGENOMICS J, V13, P1, DOI 10.1038/tpj.2012.45; Yagihashi T, 2009, HUM PSYCHOPHARM CLIN, V24, P301, DOI 10.1002/hup.1025";26;36;40;0;12;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0012-1622;1469-8749;;DEV MED CHILD NEUROL;Dev. Med. Child Neurol.;OCT;2014;56;10;;;;;990;994;;10.1111/dmcn.12470;http://dx.doi.org/10.1111/dmcn.12470;;;5;"Clinical Neurology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics";AP5PM;24828442;Bronze;;;24/11/2024;WOS:000342131100018;View Full Record in Web of Science
J;"Karimi, Z; Zarifkar, A; Mirzaei, E; Dianatpour, M; Dara, M; Aligholi, H";;;;"Karimi, Zahra; Zarifkar, Asadollah; Mirzaei, Esmaeil; Dianatpour, Mehdi; Dara, Mahintaj; Aligholi, Hadi";;;Therapeutic effects of nanosilibinin in valproic acid-zebrafish model of autism spectrum disorder: Focusing on Wnt signaling pathway and autism spectrum disorder-related cytokines;INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE;;;English;Article;;;;;;"autism spectrum disorder; cytokine; silibinin; valproic acid; Wnt signaling pathway; zebrafish";"RAT MODEL; SILIBININ; CHILDREN; EXPOSURE; BEHAVIOR; BRAIN; EXPRESSION; ANTICONVULSANT; ASSOCIATION; PREVALENCE";In this study, we delved into the intricate world of autism spectrum disorder (ASD) and its connection to the disturbance in the Wnt signaling pathway and immunological abnormalities. Our aim was to evaluate the impact of silibinin, a remarkable modulator of both the Wnt signaling pathway and the immune system, on the neurobehavioral and molecular patterns observed in a zebrafish model of ASD induced by valproic acid (VPA). Because silibinin is a hydrophobic molecule and highly insoluble in water, it was used in the form of silibinin nanoparticles (nanosilibinin, NS). After assessing survival, hatching rate, and morphology of zebrafish larvae exposed to different concentrations of NS, the appropriate concentrations were chosen. Then, zebrafish embryos were exposed to VPA (1 mu M) and NS (100 and 200 mu M) at the same time for 120 h. Next, anxiety and inattentive behaviors and the expression of CHD8, CTNNB, GSK3beta, LRP6, TNFalpha, IL1beta, and BDNF genes were assessed 7 days post fertilization. The results indicated that higher concentrations of NS had adverse effects on survival, hatching, and morphological development. The concentrations of 100 and 200 mu M of NS could ameliorate the anxiety-like behavior and learning deficit and decrease ASD-related cytokines (IL1beta and TNFalpha) in VPA-treated larvae. In addition, only 100 mu M of NS prevented raising the gene expression of Wnt signaling-related factors (CHD8, CTNNB, GSK3beta, and LRP6). In conclusion, NS treatment for the first 120 h showed therapeutic effect on an autism-like phenotype probably via reducing the expression of pro-inflammatory cytokines genes and changing the expression of Wnt signaling components genes. Zebrafish eggs were exposed to valproic acid and valproic acid + nanosilibinin for 120 h post fertilization. Behavioral and molecular test were assessed in 7 days post fertilization. Nanosilibinin decreased anxiety-like behavior, learning impairment and the expression of autism related genes in valproic treated zebrafish. image;"[Karimi, Zahra; Aligholi, Hadi] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran; [Zarifkar, Asadollah] Shiraz Univ Med Sci, Sch Med, Dept Physiol, Shiraz, Iran; [Mirzaei, Esmaeil] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Med Nanotechnol, Shiraz, Iran; [Dianatpour, Mehdi; Dara, Mahintaj] Shiraz Univ Med Sci, Stem Cell Technol Res Ctr, Shiraz, Iran; [Dianatpour, Mehdi] Shiraz Univ Med Sci, Sch Med, Dept Med Genet, Shiraz, Iran";"Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science";"Aligholi, H (corresponding author), Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran.;Zarifkar, A (corresponding author), Shiraz Univ Med Sci, Sch Med, Dept Physiol, Shiraz, Iran.";"zarifkara@sums.ac.ir; aligholi@sums.ac.ir";"Dianatpour, Mehdi/V-3558-2017; Mirzaei, Esmaeil/P-9866-2018";;Shiraz University of Medical Sciences, Shiraz, Iran [18452];Shiraz University of Medical Sciences, Shiraz, Iran(Shiraz University of Medical ScienceGolestan University of Medical Sciences);This research was funded by the Shiraz University of Medical Sciences, Shiraz, Iran (grant no 18452).;"Almeida LEF, 2014, MOL CELL NEUROSCI, V59, P57, DOI 10.1016/j.mcn.2014.01.007; Bannwart CF, 2010, NAT PROD RES, V24, P1747, DOI 10.1080/14786410903314492; Barrett CE, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0160-x; Belmonte MK, 2004, J NEUROSCI, V24, P9228, DOI 10.1523/JNEUROSCI.3340-04.2004; Bromley RL, 2013, J NEUROL NEUROSUR PS, V84, P637, DOI 10.1136/jnnp-2012-304270; Caracci MO, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9603751; Cardenas-Aguayo MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053596; Cattaneo A, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.214; Chen JF, 2018, NEUROTOXICOL TERATOL, V66, P8, DOI 10.1016/j.ntt.2018.01.002; Cheung CWY, 2010, ANTI-CANCER AGENT ME, V10, P186; Christensen J., 2013, JAMA, Journal of the American Medical Association, V309, P1696, DOI 10.1001/jama.2013.2270; Christian J., 2012, Neuroscience and Medicine, V3, P107, DOI DOI 10.4236/NM.2012.31016; Dean JCS, 2002, J MED GENET, V39, P251, DOI 10.1136/jmg.39.4.251; Deckmann I, 2018, NEUROIMMUNOMODULAT, V25, P285, DOI 10.1159/000492113; Deep G, 2010, CANCER METAST REV, V29, P447, DOI 10.1007/s10555-010-9237-0; Durak O, 2016, NAT NEUROSCI, V19, P1477, DOI 10.1038/nn.4400; Dwivedi S, 2019, J PHARMACOL TOX MET, V95, P56, DOI 10.1016/j.vascn.2018.11.006; Frith U, 2005, CURR BIOL, V15, pR786, DOI 10.1016/j.cub.2005.09.033; Gerlai R, 2010, BEHAV BRAIN RES, V207, P223, DOI 10.1016/j.bbr.2009.10.008; Gigliobianco MR, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030134; Girard S, 2010, J IMMUNOL, V184, P3997, DOI 10.4049/jimmunol.0903349; Gottfried C., 2013, RECENT ADV AUTISM SP, VI, DOI [10.5772/54824, DOI 10.5772/54824]; Hill AJ, 2005, TOXICOL SCI, V86, P6, DOI 10.1093/toxsci/kfi110; Horder J, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0155-1; Giorgi VSI, 2012, J REPROD IMMUNOL, V95, P67, DOI 10.1016/j.jri.2012.06.004; Jentink J, 2010, NEW ENGL J MED, V362, P2185, DOI 10.1056/NEJMoa0907328; Joseph TP, 2022, AUTISM RES, V15, P27, DOI 10.1002/aur.2620; Jung UJ, 2014, J MED FOOD, V17, P599, DOI 10.1089/jmf.2013.2926; Jyonouchi H, 2001, J NEUROIMMUNOL, V120, P170, DOI 10.1016/S0165-5728(01)00421-0; Kalueff AV, 2014, TRENDS PHARMACOL SCI, V35, P63, DOI 10.1016/j.tips.2013.12.002; Kalueff AV, 2013, ZEBRAFISH, V10, P70, DOI 10.1089/zeb.2012.0861; Kim KC, 2014, MOL NEUROBIOL, V49, P512, DOI 10.1007/s12035-013-8535-2; Kim S, 2009, MOLECULES, V14, P4300, DOI 10.3390/molecules14114300; Liu XM, 2021, PHYSIOL BEHAV, V241, DOI 10.1016/j.physbeh.2021.113593; Liu XY, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00201; Lord C, 2000, NEURON, V28, P355, DOI 10.1016/S0896-6273(00)00115-X; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Lu P, 2009, J PHARMACOL EXP THER, V331, P319, DOI 10.1124/jpet.109.155069; Lu WY, 2012, CELL SIGNAL, V24, P2291, DOI 10.1016/j.cellsig.2012.07.009; Lucini C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103155; Mabunga DFN, 2015, EXP NEUROBIOL, V24, P285, DOI 10.5607/en.2015.24.4.285; Maenner Matthew J., 2020, MMWR SURVEILLANCE SUMMARIES, V69, P1, DOI [10.15585/mmwr.ss6904a1, DOI 10.15585/MMWR.SS6904A1]; Maryam T, 2023, MOLECULES, V28, DOI 10.3390/molecules28031514; Meador KJ, 2009, NEW ENGL J MED, V360, P1597, DOI 10.1056/NEJMoa0803531; Miyazaki K, 2004, BRAIN DEV-JPN, V26, P292, DOI 10.1016/S0387-7604(03)00168-2; Moore SJ, 2000, J MED GENET, V37, P489, DOI 10.1136/jmg.37.7.489; Mulligan Kimberly A, 2017, Mol Neuropsychiatry, V2, P219, DOI 10.1159/000453266; Nachammai V, 2021, INDIAN J PHARMACOL, V53, P457, DOI 10.4103/ijp.IJP_18_20; Narita M, 2010, NEUROSCI RES, V66, P2, DOI 10.1016/j.neures.2009.09.001; Nelson KB, 2001, ANN NEUROL, V49, P597, DOI 10.1002/ana.1024; Nicolini C, 2018, EXP NEUROL, V299, P217, DOI 10.1016/j.expneurol.2017.04.017; Okerlund ND, 2011, J NEURODEV DISORD, V3, P162, DOI 10.1007/s11689-011-9083-6; Ornoy A, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00316; Patel P, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0267257; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piazza CC, 2003, J APPL BEHAV ANAL, V36, P187, DOI 10.1901/jaba.2003.36-187; Qin LY, 2016, MOL CELL NEUROSCI, V75, P27, DOI 10.1016/j.mcn.2016.06.004; Qin Liyan, 2015, Nan Fang Yi Ke Da Xue Xue Bao, V35, P1162; Ramakrishnan G, 2009, CELL PROLIFERAT, V42, P229, DOI 10.1111/j.1365-2184.2008.00581.x; Robea MA, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11050556; Saghazadeh A, 2017, J AUTISM DEV DISORD, V47, P1018, DOI 10.1007/s10803-016-3024-x; Sahibzada MUK, 2017, DRUG DES DEV THER, V11, P1453, DOI 10.2147/DDDT.S133806; Salcedo-Arellano MJ, 2021, NEUROTHERAPEUTICS, V18, P265, DOI 10.1007/s13311-020-00968-6; Salmani-Javan E, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1193708; Shen L, 2019, APPL MICROBIOL BIOT, V103, P7141, DOI 10.1007/s00253-019-09950-5; Song XY, 2016, NEUROCHEM RES, V41, P1662, DOI 10.1007/s11064-016-1881-5; Stewart AM, 2014, TRENDS NEUROSCI, V37, P264, DOI 10.1016/j.tins.2014.02.011; Stewart AM, 2013, BEHAV BRAIN RES, V236, P110, DOI 10.1016/j.bbr.2012.08.026; Sun WJ, 2016, CELL, V167, P1385, DOI 10.1016/j.cell.2016.10.031; Tropepe V, 2003, GENES BRAIN BEHAV, V2, P268, DOI 10.1034/j.1601-183X.2003.00038.x; Vaid M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023000; Vitale C, 2004, EUR J IMMUNOL, V34, P3028, DOI 10.1002/eji.200425418; Weissberg O, 2021, GENES-BASEL, V12, DOI 10.3390/genes12081133; Williams G, 2001, DEV MED CHILD NEUROL, V43, P202, DOI 10.1017/S001216220100038X; Win-Shwe TT, 2018, J TOXICOL SCI, V43, P631, DOI 10.2131/jts.43.631; Yoo HJ, 2014, PSYCHIAT INVEST, V11, P319, DOI 10.4306/pi.2014.11.3.319; Zhang YH, 2015, INT J MOL MED, V35, P263, DOI 10.3892/ijmm.2014.1996; Zhang YH, 2012, NEUROCHEM RES, V37, P1409, DOI 10.1007/s11064-012-0724-2; Zhuang WT, 2023, FRONT PSYCHIATRY, V14, DOI 10.3389/fpsyt.2023.1143328; Zimmermann FF, 2015, NEUROTOXICOL TERATOL, V52, P36, DOI 10.1016/j.ntt.2015.10.002";80;0;0;2;2;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0736-5748;1873-474X;;INT J DEV NEUROSCI;Int. J. Dev. Neurosci.;AUG;2024;84;5;;;;;454;468;;10.1002/jdn.10348;http://dx.doi.org/10.1002/jdn.10348;;juil-24;15;"Developmental Biology; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Developmental Biology; Neurosciences & Neurology";D0E1R;38961588;;;;24/11/2024;WOS:001261185000001;View Full Record in Web of Science
J;"Anney, R; Klei, L; Pinto, D; Almeida, J; Bacchelli, E; Baird, G; Bolshakova, N; Bölte, S; Bolton, PF; Bourgeron, T; Brennan, S; Brian, J; Casey, J; Conroy, J; Correia, C; Corsello, C; Crawford, EL; de Jonge, M; Delorme, R; Duketis, E; Duque, F; Estes, A; Farrar, P; Fernandez, BA; Folstein, SE; Fombonne, E; Gilbert, J; Gillberg, C; Glessner, JT; Green, A; Green, J; Guter, SJ; Heron, EA; Holt, R; Howe, JL; Hughes, G; Hus, V; Igliozzi, R; Jacob, S; Kenny, GP; Kim, C; Kolevzon, A; Kustanovich, V; Lajonchere, CM; Lamb, JA; Law-Smith, M; Leboyer, M; Le Couteur, A; Leventhal, BL; Liu, XQ; Lombard, F; Lord, C; Lotspeich, L; Lund, SC; Magalhaes, TR; Mantoulan, C; McDougle, CJ; Melhem, NM; Merikangas, A; Minshew, NJ; Mirza, GK; Munson, J; Noakes, C; Nygren, G; Papanikolaou, K; Pagnamenta, AT; Parrini, B; Paton, T; Pickles, A; Posey, DJ; Poustka, F; Ragoussis, J; Regan, R; Roberts, W; Roeder, K; Roge, B; Rutter, ML; Schlitt, S; Shah, N; Sheffield, VC; Soorya, L; Sousa, I; Stoppioni, V; Sykes, N; Tancredi, R; Thompson, AP; Thomson, S; Tryfon, A; Tsiantis, J; Van Engeland, H; Vincent, JB; Volkmar, F; Vorstman, JAS; Wallace, S; Wing, K; Wittemeyer, K; Wood, S; Zurawiecki, D; Zwaigenbaum, L; Bailey, AJ; Battaglia, A; Cantor, RM; Coon, H; Cuccaro, ML; Dawson, G; Ennis, S; Freitag, CM; Geschwind, DH; Haines, JL; Klauck, SM; McMahon, WM; Maestrini, E; Miller, J; Monaco, AP; Nelson, SF; Nurnberger, JI; Oliveira, G; Parr, JR; Pericak-Vance, MA; Piven, J; Schellenberg, GD; Scherer, S; Vicente, AM; Wassink, TH; Wijsman, EM; Betancur, C; Buxbaum, JD; Cook, EH; Gallagher, L; Gill, M; Hallmayer, J; Paterson, AD; Sutcliffe, JS; Szatmari, P; Vieland, VJ; Hakonarson, H; Devlin, B";;;;"Anney, Richard; Klei, Lambertus; Pinto, Dalila; Almeida, Joana; Bacchelli, Elena; Baird, Gillian; Bolshakova, Nadia; Boelte, Sven; Bolton, Patrick F.; Bourgeron, Thomas; Brennan, Sean; Brian, Jessica; Casey, Jillian; Conroy, Judith; Correia, Catarina; Corsello, Christina; Crawford, Emily L.; de Jonge, Maretha; Delorme, Richard; Duketis, Eftichia; Duque, Frederico; Estes, Annette; Farrar, Penny; Fernandez, Bridget A.; Folstein, Susan E.; Fombonne, Eric; Gilbert, John; Gillberg, Christopher; Glessner, Joseph T.; Green, Andrew; Green, Jonathan; Guter, Stephen J.; Heron, Elizabeth A.; Holt, Richard; Howe, Jennifer L.; Hughes, Gillian; Hus, Vanessa; Igliozzi, Roberta; Jacob, Suma; Kenny, Graham P.; Kim, Cecilia; Kolevzon, Alexander; Kustanovich, Vlad; Lajonchere, Clara M.; Lamb, Janine A.; Law-Smith, Miriam; Leboyer, Marion; Le Couteur, Ann; Leventhal, Bennett L.; Liu, Xiao-Qing; Lombard, Frances; Lord, Catherine; Lotspeich, Linda; Lund, Sabata C.; Magalhaes, Tiago R.; Mantoulan, Carine; McDougle, Christopher J.; Melhem, Nadine M.; Merikangas, Alison; Minshew, Nancy J.; Mirza, Ghazala K.; Munson, Jeff; Noakes, Carolyn; Nygren, Gudrun; Papanikolaou, Katerina; Pagnamenta, Alistair T.; Parrini, Barbara; Paton, Tara; Pickles, Andrew; Posey, David J.; Poustka, Fritz; Ragoussis, Jiannis; Regan, Regina; Roberts, Wendy; Roeder, Kathryn; Roge, Bernadette; Rutter, Michael L.; Schlitt, Sabine; Shah, Naisha; Sheffield, Val C.; Soorya, Latha; Sousa, Ines; Stoppioni, Vera; Sykes, Nuala; Tancredi, Raffaella; Thompson, Ann P.; Thomson, Susanne; Tryfon, Ana; Tsiantis, John; Van Engeland, Herman; Vincent, John B.; Volkmar, Fred; Vorstman, J. A. S.; Wallace, Simon; Wing, Kirsty; Wittemeyer, Kerstin; Wood, Shawn; Zurawiecki, Danielle; Zwaigenbaum, Lonnie; Bailey, Anthony J.; Battaglia, Agatino; Cantor, Rita M.; Coon, Hilary; Cuccaro, Michael L.; Dawson, Geraldine; Ennis, Sean; Freitag, Christine M.; Geschwind, Daniel H.; Haines, Jonathan L.; Klauck, Sabine M.; McMahon, William M.; Maestrini, Elena; Miller, Judith; Monaco, Anthony P.; Nelson, Stanley F.; Nurnberger, John I., Jr.; Oliveira, Guiomar; Parr, Jeremy R.; Pericak-Vance, Margaret A.; Piven, Joseph; Schellenberg, Gerard D.; Scherer, StephenW.; Vicente, Astrid M.; Wassink, Thomas H.; Wijsman, Ellen M.; Betancur, Catalina; Buxbaum, Joseph D.; Cook, Edwin H.; Gallagher, Louise; Gill, Michael; Hallmayer, Joachim; Paterson, Andrew D.; Sutcliffe, James S.; Szatmari, Peter; Vieland, Veronica J.; Hakonarson, Hakon; Devlin, Bernie";;;Individual common variants exert weak effects on the risk for autism spectrum disorderspi;HUMAN MOLECULAR GENETICS;;;English;Article;;;;;;;"GENOME-WIDE ASSOCIATION; DE-NOVO MUTATIONS; COPY NUMBER VARIATION; DEVELOPMENTAL DISORDERS; MENTAL-RETARDATION; LINKAGE ANALYSES; GENE; LOCI; DELETIONS; CNTNAP2";While it is apparent that rare variation can play an important role in the genetic architecture of autism spectrum disorders (ASDs), the contribution of common variation to the risk of developing ASD is less clear. To produce a more comprehensive picture, we report Stage 2 of the Autism Genome Project genome-wide association study, adding 1301 ASD families and bringing the total to 2705 families analysed (Stages 1 and 2). In addition to evaluating the association of individual single nucleotide polymorphisms (SNPs), we also sought evidence that common variants, en masse, might affect the risk. Despite genotyping over a million SNPs covering the genome, no single SNP shows significant association with ASD or selected phenotypes at a genome-wide level. The SNP that achieves the smallest P-value from secondary analyses is rs1718101. It falls in CNTNAP2, a gene previously implicated in susceptibility for ASD. This SNP also shows modest association with age of word/phrase acquisition in ASD subjects, of interest because features of language development are also associated with other variation in CNTNAP2. In contrast, allele scores derived from the transmission of common alleles to Stage 1 cases significantly predict case status in the independent Stage 2 sample. Despite being significant, the variance explained by these allele scores was small (Vm 1). Based on results from individual SNPs and their en masse effect on risk, as inferred from the allele score results, it is reasonable to conclude that common variants affect the risk for ASD but their individual effects are modest.;"[Klei, Lambertus; Melhem, Nadine M.; Minshew, Nancy J.; Wood, Shawn; Devlin, Bernie] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15232 USA; [Anney, Richard; Bolshakova, Nadia; Brennan, Sean; Heron, Elizabeth A.; Hughes, Gillian; Kenny, Graham P.; Law-Smith, Miriam; Lombard, Frances; Merikangas, Alison; Gallagher, Louise; Gill, Michael] Trinity Coll Dublin, Sch Med, Dept Psychiat, Autism Genet Grp, Dublin 8, Ireland; [Pinto, Dalila; Howe, Jennifer L.; Paton, Tara; Scherer, StephenW.; Paterson, Andrew D.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1L7, Canada; [Pinto, Dalila; Howe, Jennifer L.; Paton, Tara; Scherer, StephenW.; Paterson, Andrew D.] Univ Toronto, Hosp Sick Children, Ctr Appl Genom, Toronto, ON M5G 1L7, Canada; [Pinto, Dalila; Howe, Jennifer L.; Paton, Tara; Scherer, StephenW.; Paterson, Andrew D.] Univ Toronto, Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1L7, Canada; [Almeida, Joana; Duque, Frederico; Oliveira, Guiomar] Hosp Pediat Coimbra, P-3000076 Coimbra, Portugal; [Bacchelli, Elena; Maestrini, Elena] Univ Bologna, Dept Biol, I-40126 Bologna, Italy; [Baird, Gillian] Guys & St Thomas NHS Trust, London SE1 9RT, England; [Baird, Gillian] Kings Coll London, London SE1 9RT, England; [Boelte, Sven; Duketis, Eftichia; Poustka, Fritz; Schlitt, Sabine; Freitag, Christine M.] Goethe Univ Frankfurt, Dept Child & Adolescent Psychiat Psychosomat & Ps, D-60528 Frankfurt, Germany; [Rutter, Michael L.] Kings Coll London, Inst Psychiat, MRC, Social Genet & Dev Psychiat Ctr, London SE5 8AF, England; [Bolton, Patrick F.] Kings Coll London, Dept Psychiat, London SE5 8AF, England; [Bourgeron, Thomas] Inst Pasteur, F-75015 Paris, France; [Bourgeron, Thomas] Univ Paris 07, CNRS, URA 2182, Fdn FondaMental, F-75015 Paris, France; [Brian, Jessica; Noakes, Carolyn; Roberts, Wendy] Univ Toronto, Autism Res Unit, Hosp Sick Children & Bloorview Kids Rehabil, Toronto, ON M5G 1Z8, Canada; [Casey, Jillian; Conroy, Judith; Green, Andrew; Regan, Regina; Shah, Naisha; Ennis, Sean] Univ Coll Med Sci, Sch Med, Dublin 4, Ireland; [Correia, Catarina; Magalhaes, Tiago R.; Vicente, Astrid M.] Inst Nacl Saude Dr Ricardo Jorge, P-1649016 Lisbon, Portugal; [Correia, Catarina; Magalhaes, Tiago R.; Vicente, Astrid M.] Inst Gulbenkian Ciencias, P-1649016 Lisbon, Portugal; [Correia, Catarina; Igliozzi, Roberta; Magalhaes, Tiago R.; Vicente, Astrid M.] BioFIG Ctr Biodivers Funct & Integrat Genom, P-1749016 Lisbon, Portugal; [Corsello, Christina; Hus, Vanessa] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; [Crawford, Emily L.; Lund, Sabata C.; Thomson, Susanne; Sutcliffe, James S.] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Vanderbilt Kennedy Ctr, Nashville, TN 37232 USA; [Crawford, Emily L.; Lund, Sabata C.; Thomson, Susanne; Sutcliffe, James S.] Vanderbilt Univ, Med Ctr, Ctr Human Genet, Nashville, TN 37232 USA; [Crawford, Emily L.; Lund, Sabata C.; Thomson, Susanne; Sutcliffe, James S.] Vanderbilt Univ, Med Ctr, Ctr Res, Nashville, TN 37232 USA; [Crawford, Emily L.; Lund, Sabata C.; Thomson, Susanne; Sutcliffe, James S.] Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA; [Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN 37232 USA; [de Jonge, Maretha; Van Engeland, Herman] Univ Med Ctr, Dept Child Psychiat, NL-3508 GA Utrecht, Netherlands; [Delorme, Richard] Hop Robert Debre, APHP, F-75019 Paris, France; [Estes, Annette] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA; [Munson, Jeff] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Wijsman, Ellen M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Wijsman, Ellen M.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Farrar, Penny; Holt, Richard; Mirza, Ghazala K.; Pagnamenta, Alistair T.; Ragoussis, Jiannis; Sousa, Ines; Sykes, Nuala; Wing, Kirsty; Monaco, Anthony P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Fernandez, Bridget A.] Mem Univ Newfoundland, Disciplines Genet & Med, St John, NF A1B 3V6, Canada; [Folstein, Susan E.] Univ Miami, Sch Med, Dept Psychiat, Miami, FL 33136 USA; [Fombonne, Eric] McGill Univ, Div Psychiat, Montreal, PQ H3A 1A1, Canada; [Gilbert, John; Cuccaro, Michael L.; Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL 33101 USA; [Gillberg, Christopher; Nygren, Gudrun] Univ Gothenburg, Sahlgrenska Acad, Gillberg Neuropsychiat Ctr, Gothenburg, Sweden; [Glessner, Joseph T.; Kim, Cecilia; Hakonarson, Hakon] Childrens Hosp Philadelphia, Div Human Genet, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Green, Jonathan] Univ Manchester, Acad Dept Child Psychiat, Manchester M9 7AA, Lancs, England; [Guter, Stephen J.; Jacob, Suma; Cook, Edwin H.] Univ Illinois, Inst Juvenile Res, Dept Psychiat, Chicago, IL 60608 USA; [Kolevzon, Alexander; Soorya, Latha; Tryfon, Ana; Zurawiecki, Danielle; Buxbaum, Joseph D.] Mt Sinai Sch Med, Friedman Brain Inst, Dept Psychiat, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA; [Kustanovich, Vlad; Lajonchere, Clara M.] Autism Speaks, Autism Genet Resource Exchange, Los Angeles, CA 90036 USA; [Lamb, Janine A.] Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England; [Pickles, Andrew] Univ Manchester, Dept Med, Sch Epidemiol & Hlth Sci, Manchester M13 9PT, Lancs, England; [Leboyer, Marion] Univ Paris 12, Fdn FondaMental, Grp Hosp Menri Mondor Albert Chenevier, AP HP,INSERM,U995,Dept Psychiat, F-94000 Creteil, France; [Le Couteur, Ann; Parr, Jeremy R.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Le Couteur, Ann; Parr, Jeremy R.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Leventhal, Bennett L.] Nathan Kline Inst Psychiat Res NKI, Orangeburg, NY 10962 USA; [Leventhal, Bennett L.] NYU, Ctr Child Study, Dept Child & Adolescent Psychiat, New York, NY 10016 USA; [Liu, Xiao-Qing] Univ Manitoba, Dept Obstet Gynecol & Reprod Sci, Winnipeg, MB, Canada; [Lord, Catherine] Weill Cornell Med Coll, Ctr Autism & Developing Brain, White Plains, NY USA; [Lotspeich, Linda; Hallmayer, Joachim] Stanford Univ, Sch Med, Dept Psychiat, Div Child & Adolescent Psychiat & Child Dev, Stanford, CA 94304 USA; [Mantoulan, Carine; Roge, Bernadette] Univ Toulouse Le Mirail, Ctr Eudes & Rech Psychopathol, F-31200 Toulouse, France; [McDougle, Christopher J.; Posey, David J.; Nurnberger, John I., Jr.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; [Papanikolaou, Katerina; Tsiantis, John] Univ Athens, Sch Med, Agia Sophia Childrens Hosp, Univ Dept Child Psychiat, GR-11527 Athens, Greece; [Parrini, Barbara; Tancredi, Raffaella; Battaglia, Agatino] Stella Maris Inst Child & Adolescent Neuropsychia, I-56128 Pisa, Italy; [Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; [Sheffield, Val C.] Univ Iowa, Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA; [Sheffield, Val C.] Univ Iowa, Carver Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; [Stoppioni, Vera] Osped Santa Croce, I-61032 Fano, Italy; [Thompson, Ann P.; Szatmari, Peter] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON L8N 3Z5, Canada; [Vincent, John B.] Univ Toronto, Ctr Addict & Mental Hlth, Clarke Inst, Toronto, ON M5G 1X8, Canada; [Vincent, John B.] Univ Toronto, Dept Psychiat, Toronto, ON M5G 1X8, Canada; [Volkmar, Fred] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Vorstman, J. A. S.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Psychiat, NL-3584 CX Utrecht, Netherlands; [Zwaigenbaum, Lonnie] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2J3, Canada; [Bailey, Anthony J.] Univ British Columbia, BC Mental Hlth & Addict Res Unit, Vancouver, BC V5Z 4H4, Canada; [Cantor, Rita M.; Nelson, Stanley F.] Univ Calif Los Angeles, Los Angeles Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; [Geschwind, Daniel H.] Univ Calif Los Angeles, Los Angeles Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Coon, Hilary; McMahon, William M.; Miller, Judith] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84108 USA; [Dawson, Geraldine] Autism Speaks, New York, NY USA; [Dawson, Geraldine] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA; [Piven, Joseph] Univ N Carolina, Carolina Inst Dev Disabil, Chapel Hill, NC 27599 USA; [Klauck, Sabine M.] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany; [Monaco, Anthony P.] Tufts Univ, Off President, Boston, MA 02111 USA; [Wallace, Simon; Wittemeyer, Kerstin] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; [Schellenberg, Gerard D.] Univ Penn, Philadelphia, PA 19104 USA; [Hakonarson, Hakon] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Wassink, Thomas H.] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Betancur, Catalina] INSERM, U952, F-75005 Paris, France; [Betancur, Catalina] CNRS, UMR 7224, F-75005 Paris, France; [Betancur, Catalina] UPMC Univ Paris 06, F-75005 Paris, France; [Vieland, Veronica J.] Ohio State Univ, Columbus, OH 43205 USA; [Vieland, Veronica J.] Nationwide Childrens Hosp, Res Inst, Battelle Ctr Math Med, Columbus, OH 43205 USA";"Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Trinity College Dublin; University of Toronto; University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Hospital for Sick Children (SickKids); Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of Bologna; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Goethe University Frankfurt; University of London; King's College London; University of London; King's College London; Pasteur Network; Universite Paris Cite; Institut Pasteur Paris; Universite Paris Cite; Pasteur Network; Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); University of Toronto; Holland Bloorview Kids Rehabilitation Hospital; Hospital for Sick Children (SickKids); Instituto Nacional de Saude Dr. Ricardo Jorge; Instituto Gulbenkian de Ciencia; Universidade de Lisboa; University of Michigan System; University of Michigan; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Utrecht University; Utrecht University Medical Center; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Robert-Debre - APHP; Hopital Universitaire Ambroise-Pare - APHP; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Oxford; Wellcome Centre for Human Genetics; Memorial University Newfoundland; University of Miami; McGill University; University of Miami; University of Gothenburg; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Manchester; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Icahn School of Medicine at Mount Sinai; University of Manchester; University of Manchester; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Newcastle University - UK; Newcastle University - UK; Nathan Kline Institute for Psychiatric Research; New York University; University of Manitoba; Cornell University; Weill Cornell Medicine; Stanford University; Universite de Toulouse; Universite de Toulouse - Jean Jaures; Indiana University System; Indiana University Bloomington; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; The Aghia Sophia Children's Hospital; National & Kapodistrian University of Athens; Athens Medical School; IRCCS Fondazione Stella Maris; Carnegie Mellon University; University of Iowa; Howard Hughes Medical Institute; University of Iowa; McMaster University; University of Toronto; Centre for Addiction & Mental Health - Canada; University of Toronto; Yale University; Utrecht University; Utrecht University Medical Center; University of Alberta; University of British Columbia; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Utah System of Higher Education; University of Utah; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Helmholtz Association; German Cancer Research Center (DKFZ); Tufts University; University of Oxford; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Iowa; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital";Devlin, B (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15232 USA.;devlinbj@upmc.edu;"Gallagher, Louise/LEM-6610-2024; Correia, Catarina/JAN-4447-2023; Melhem, Nadine/G-1510-2013; Lázaro Almeida, Joana/GMX-4849-2022; bacchelli, elena/R-3675-2016; Papanikolaou, Katerina/AAB-4771-2020; De Jonge, Maretha/F-4942-2013; Bal, Vanessa/AAN-2381-2020; Leboyer, Marion/AAW-3648-2021; Brennan, Sean/KIC-3670-2024; Volkmar, Fred/AEB-0666-2022; Oliveira, Guiomar/AAF-3911-2021; Haines, Jonathan/C-3374-2012; Dawson, Geraldine/J-8421-2016; Bölte, Sven/AAH-8675-2019; Scherer, Stephen/B-3785-2013; Green, Jonathan/L-2529-2018; liu, xiao/HMD-7454-2023; Heron, Elizabeth/HCI-9636-2022; Nelson, Stanley/D-4771-2009; Coon, Hilary/KPA-9883-2024; Hakonarson, Hakon/ABZ-4865-2022; Buxbaum, Joseph/G-6001-2010; Green, Andrew/AAJ-7592-2020; Maestrini, Elena/K-7508-2012; Rutter, Michael/C-8570-2013; Bailey, Anthony/J-2860-2014; Ragoussis, Ioannis/AAD-9790-2022; Sutcliffe, James/C-1348-2012; Moura Vicente, Astrid/F-8692-2014; Duque, Frederico/H-3692-2014; Tancredi, Raffaella/C-3868-2018; Pinto, Dalila/C-4218-2016; Pickles, Andrew/A-9625-2011; Igliozzi, Roberta/AAA-4568-2021; Monaco, Anthony/A-4495-2010; Betancur, Catalina/K-3791-2017; Paterson, Andrew/A-4088-2011; Battaglia, Agatino/AAG-1406-2020; Fombonne, Eric/M-4893-2018; Jacob, Suma/J-7941-2013";"Anney, Richard/0000-0002-6083-407X; Rutter, Michael Llewellyn/0000-0003-1577-7405; Correia, Catarina/0000-0001-5481-2010; R Magalhaes, Tiago/0000-0002-5528-2119; Green, Jonathan/0000-0002-0143-181X; Guter, Stephen/0000-0002-4476-2045; Ennis, Sean/0000-0002-4330-1386; Estes, Annette/0000-0003-2687-4155; Gill, Michael/0000-0003-0206-5337; Sutcliffe, James/0000-0001-5200-6007; Green, Andrew/0000-0002-1077-7417; Oliveira, Guiomar/0000-0002-7049-1277; Moura Vicente, Astrid/0000-0001-7134-8037; Wijsman, Ellen/0000-0002-2725-6669; Melhem, Nadine/0000-0001-8572-8487; Liu, Xiao-Qing/0000-0002-4034-5156; LEBOYER, Marion/0000-0001-5473-3697; Duque, Frederico/0000-0001-5684-1472; Bolshakova, Nadia/0000-0003-2173-6562; Tancredi, Raffaella/0000-0003-3517-4919; McNeil, Kirsty/0000-0003-0437-3608; Bolte, Sven/0000-0002-4579-4970; BACCHELLI, ELENA/0000-0001-8800-9568; Scherer, Stephen W./0000-0002-8326-1999; Pinto, Dalila/0000-0002-8769-0846; Buxbaum, Joseph/0000-0001-8898-8313; Oliveira, Guiomar Goncalves/0000-0003-4031-3880; Pickles, Andrew/0000-0003-1283-0346; Igliozzi, Roberta/0000-0002-1245-972X; MAESTRINI, ELENA/0000-0001-5924-3179; Delorme, Richard/0000-0002-5614-3663; Lund, Sabata/0000-0002-6092-5131; Bal, Vanessa/0000-0003-0750-823X; Bourgeron, Thomas/0000-0001-8164-9220; Ragoussis, Ioannis/0000-0002-8515-0934; Freitag, Christine Margarete/0000-0001-9676-4782; Nurnberger, John/0000-0002-7674-1767; Gallagher, Louise/0000-0001-9462-2836; Lamb, Janine/0000-0002-7248-0539; Monaco, Anthony/0000-0001-7480-3197; Coon, Hilary/0000-0002-8877-5446; Sheffield, Val/0000-0002-6282-0835; Simpson, Nuala/0000-0003-3390-9993; Glessner, Joseph/0000-0001-5131-2811; Girao Meireles de Sousa, Ines/0000-0001-6983-8870; Merikangas, Alison/0000-0003-2253-839X; Betancur, Catalina/0000-0002-3327-4804; Paterson, Andrew/0000-0002-9169-118X; Heron, Elizabeth/0000-0003-2219-4005; Dawson, Geraldine/0000-0003-1410-2764; Wassink, Thomas/0000-0002-0952-8333; Battaglia, Agatino/0000-0002-7128-7606; Fombonne, Eric/0000-0002-8605-3538; Jacob, Suma/0000-0001-7434-7398; Parr, Jeremy/0000-0002-2507-7878; Roeder, Kathryn/0000-0002-8869-6254";"AGP: Autism Speaks (USA); Health Research Board (HRB; Ireland) [AUT/2006/1, AUT/2006/2, PD/2006/48]; Medical Research Council (MRC; UK); Genome Canada/Ontario Genomics Institute; Hilibrand Foundation (USA); US National Institutes of Health (NIH) [HD035469, HD055748, HD055751, HD055782, HD055784, MH52708, MH55284, MH057881, MH061009, MH06359, MH066673, MH080647, MH081754, MH66766, NS026630, NS042165, NS049261]; Cnadian Institutes for Health Research (CIHR); Assistance Publique - Hopitaux de Paris (France); Autism Speaks UK; Canada Foundation for Innovation/Ontario Innovation Trust; Deutsche Forschungsgemeinschaft (Germany) [Po 255/17-4]; EC Sixth FP AUTISM MOLGEN; National Childrens Research Centre (Ireland); Fundacao Calouste Gulbenkian (Portugal); Fondation de France; Fondation FondaMental (France); Fondation Orange (France); Fondation pour la Recherche Medicale (France); Fundacao para a Ciencia e Tecnologia (Portugal); Hospital for Sick Children Foundation; University of Toronto (Canada); INSERM (France); Institut Pasteur (France); Italian Ministry of Health; John P Hussman Foundation (USA); McLaughlin Centre (Canada); Ontario Ministry of Research and Innovation (Canada); Seaver Foundation (USA); Swedish Science Council; Centre for Applied Genomics (Canada); Utah Autism Foundation (USA); Wellcome Trust (UK) [075491/Z/04]; Royal Netherlands Academy of Arts and Sciences [TMF/DA/5801]; Netherlands Organization for Scientific Research [825.06.031]; Trinity Centre for High Performance Computing; Science Foundation Ireland; Autism Speaks; MRC [G0601030] Funding Source: UKRI; National Institute on Deafness and Other Communication Disorders; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke [P50HD055784] Funding Source: NIH RePORTER";"AGP: Autism Speaks (USA); Health Research Board (HRB; Ireland)(Health Research Board - Ireland); Medical Research Council (MRC; UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Genome Canada/Ontario Genomics Institute(Genome Canada); Hilibrand Foundation (USA); US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cnadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Assistance Publique - Hopitaux de Paris (France); Autism Speaks UK; Canada Foundation for Innovation/Ontario Innovation Trust(Canada Foundation for Innovation); Deutsche Forschungsgemeinschaft (Germany)(German Research Foundation (DFG)); EC Sixth FP AUTISM MOLGEN; National Childrens Research Centre (Ireland); Fundacao Calouste Gulbenkian (Portugal); Fondation de France(Fondation de France); Fondation FondaMental (France); Fondation Orange (France); Fondation pour la Recherche Medicale (France)(Fondation pour la Recherche Medicale); Fundacao para a Ciencia e Tecnologia (Portugal)(Fundacao para a Ciencia e a Tecnologia (FCT)); Hospital for Sick Children Foundation; University of Toronto (Canada)(University of Toronto); INSERM (France)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut Pasteur (France); Italian Ministry of Health(Ministry of Health, Italy); John P Hussman Foundation (USA); McLaughlin Centre (Canada); Ontario Ministry of Research and Innovation (Canada)(Ministry of Research and Innovation, Ontario); Seaver Foundation (USA); Swedish Science Council; Centre for Applied Genomics (Canada); Utah Autism Foundation (USA); Wellcome Trust (UK)(Wellcome Trust); Royal Netherlands Academy of Arts and Sciences; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Trinity Centre for High Performance Computing; Science Foundation Ireland(Science Foundation Ireland (SFI)); Autism Speaks; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute on Deafness and Other Communication Disorders; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)NIH National Institute of Neurological Disorders & Stroke (NINDS))";"The authors thank the main funders of the AGP: Autism Speaks (USA), the Health Research Board (HRB; Ireland; AUT/2006/1, AUT/2006/2, PD/2006/48), The Medical Research Council (MRC; UK), Genome Canada/Ontario Genomics Institute and the Hilibrand Foundation (USA). Additional support for individual groups was provided by the US National Institutes of Health (NIH grants: HD035469, HD055748, HD055751, HD055782, HD055784, MH52708, MH55284, MH057881, MH061009, MH06359, MH066673, MH080647, MH081754, MH66766, NS026630, NS042165, NS049261), the Canadian Institutes for Health Research (CIHR), Assistance Publique - Hopitaux de Paris (France), Autism Speaks UK, Canada Foundation for Innovation/Ontario Innovation Trust, Deutsche Forschungsgemeinschaft (grant: Po 255/17-4) (Germany), EC Sixth FP AUTISM MOLGEN, The National Childrens Research Centre (Ireland), Fundacao Calouste Gulbenkian (Portugal), Fondation de France, Fondation FondaMental (France), Fondation Orange (France), Fondation pour la Recherche Medicale (France), Fundacao para a Ciencia e Tecnologia (Portugal), the Hospital for Sick Children Foundation and University of Toronto (Canada), INSERM (France), Institut Pasteur (France), the Italian Ministry of Health (convention 181 of 19.10.2001), the John P Hussman Foundation (USA), McLaughlin Centre (Canada), Ontario Ministry of Research and Innovation (Canada), the Seaver Foundation (USA), the Swedish Science Council, The Centre for Applied Genomics (Canada), the Utah Autism Foundation (USA) and the Wellcome Trust core award 075491/Z/04 (UK). D. P. is supported by fellowships from the Royal Netherlands Academy of Arts and Sciences (TMF/DA/5801) and the Netherlands Organization for Scientific Research (Rubicon 825.06.031). S. W. S. holds the GlaxoSmithKline-CIHR Pathfinder Chair in Genetics and Genomics at the University of Toronto and the Hospital for Sick Children (Canada). Computational infrastructure for RJLA was supported by the Trinity Centre for High Performance Computing (http://www.tchpc.tcd.ie/) funded through grants from Science Foundation Ireland. Funding to pay the Open Access publication charges for this article was provided by Autism Speaks.";"Alarcon M, 2008, AM J HUM GENET, V82, P150, DOI 10.1016/j.ajhg.2007.09.005; Anney R, 2010, HUM MOL GENET, V19, P4072, DOI 10.1093/hmg/ddq307; Anney RJL, 2011, EUR J HUM GENET, V19, P1082, DOI 10.1038/ejhg.2011.75; [Anonymous], 2011, GEMTOOLS FAST EFFICI; Arking DE, 2008, AM J HUM GENET, V82, P160, DOI 10.1016/j.ajhg.2007.09.015; Bakkaloglu B, 2008, AM J HUM GENET, V82, P165, DOI 10.1016/j.ajhg.2007.09.017; Betancur C, 2011, BRAIN RES, V1380, P42, DOI 10.1016/j.brainres.2010.11.078; Casey JP., 2011, Hum Genet; Chapman NH, 2011, HUM GENET, V129, P59, DOI 10.1007/s00439-010-0899-z; Ching MSL, 2010, AM J MED GENET B, V153B, P937, DOI 10.1002/ajmg.b.31063; Cook EH, 2008, NATURE, V455, P919, DOI 10.1038/nature07458; Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307; Crossett A, 2010, STAT MED, V29, P2932, DOI 10.1002/sim.4057; Curran S, 2011, AM J MED GENET B, V156B, P633, DOI 10.1002/ajmg.b.31201; Davis LK, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-3; Devlin B, 2012, CURR OPIN GENET DEV, V22, P229, DOI 10.1016/j.gde.2012.03.002; Devlin B, 2011, BRAIN RES, V1380, P78, DOI 10.1016/j.brainres.2010.11.026; Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933; Fernandez BA, 2010, J MED GENET, V47, P195, DOI 10.1136/jmg.2009.069369; Ferreira MAR, 2007, BEHAV GENET, V37, P631, DOI 10.1007/s10519-007-9149-0; Glessner JT, 2009, NATURE, V459, P569, DOI 10.1038/nature07953; Gregor A, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-106; Hiller M, 2006, AM J HUM GENET, V78, P291, DOI 10.1086/500151; Hussman JP, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-18; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Jackman C, 2009, PEDIATR NEUROL, V40, P310, DOI 10.1016/j.pediatrneurol.2008.10.013; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Kumar RA, 2008, HUM MOL GENET, V17, P628, DOI 10.1093/hmg/ddm376; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.0.CO;2-M; Lee AB, 2010, GENET EPIDEMIOL, V34, P51, DOI 10.1002/gepi.20434; Liu JJ, 2001, AM J HUM GENET, V69, P327, DOI 10.1086/321980; Liu XQ, 2008, BIOL PSYCHIAT, V64, P561, DOI 10.1016/j.biopsych.2008.05.023; Liu XQ, 2011, J AM ACAD CHILD PSY, V50, P687, DOI 10.1016/j.jaac.2011.05.002; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Luca D, 2008, AM J HUM GENET, V82, P453, DOI 10.1016/j.ajhg.2007.11.003; Ma DQ, 2009, ANN HUM GENET, V73, P263, DOI 10.1111/j.1469-1809.2009.00523.x; Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009; Mefford HC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000962; Mikhail FM, 2011, AM J MED GENET A, V155A, P2386, DOI 10.1002/ajmg.a.34177; Neale BM, 2012, NATURE, V485, P242, DOI 10.1038/nature11011; O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989; Pagnamenta AT, 2011, J MED GENET, V48, P48, DOI 10.1136/jmg.2010.079426; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Poot M, 2010, NEUROGENETICS, V11, P81, DOI 10.1007/s10048-009-0205-1; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Ripke S, 2011, NAT GENET, V43, P969, DOI 10.1038/ng.940; Risch N, 2001, THEOR POPUL BIOL, V60, P215, DOI 10.1006/tpbi.2001.1538; Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945; Sanders SJ, 2011, NEURON, V70, P863, DOI 10.1016/j.neuron.2011.05.002; Sato D, 2012, AM J HUM GENET, V90, P879, DOI 10.1016/j.ajhg.2012.03.017; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Sehested LT, 2010, AM J MED GENET A, V152A, P3115, DOI 10.1002/ajmg.a.33476; Sullivan P, 2012, MOL PSYCHIATR, V17, P2, DOI 10.1038/mp.2011.94; Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985; Talkowski ME, 2011, AM J HUM GENET, V89, P551, DOI 10.1016/j.ajhg.2011.09.011; Vaags AK, 2012, AM J HUM GENET, V90, P133, DOI 10.1016/j.ajhg.2011.11.025; Vernes SC, 2008, NEW ENGL J MED, V359, P2337, DOI 10.1056/NEJMoa0802828; Vieland VJ, 2011, J NEURODEV DISORD, V3, P113, DOI 10.1007/s11689-011-9072-9; Vorstman JAS, 2011, MOL PSYCHIATR, V16, P442, DOI 10.1038/mp.2010.26; Wang K, 2009, NATURE, V459, P528, DOI 10.1038/nature07999; Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974; Weiss LA, 2009, NATURE, V461, P802, DOI 10.1038/nature08490; Williamson CM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001347; Wisniowiecka-Kowalnik B, 2010, AM J MED GENET B, V153B, P983, DOI 10.1002/ajmg.b.31064; Yaspan BL, 2011, HUM GENET, V129, P563, DOI 10.1007/s00439-011-0956-2; Zweier C, 2009, AM J HUM GENET, V85, P655, DOI 10.1016/j.ajhg.2009.10.004";68;279;319;0;68;OXFORD UNIV PRESS;OXFORD;GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND;0964-6906;;;HUM MOL GENET;Hum. Mol. Genet.;nov-01;2012;21;21;;;;;4781;4792;;10.1093/hmg/dds301;http://dx.doi.org/10.1093/hmg/dds301;;;12;"Biochemistry & Molecular Biology; Genetics & Heredity";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Biochemistry & Molecular Biology; Genetics & Heredity";025DN;22843504;Green Published, Green Submitted;;;24/11/2024;WOS:000310165500016;View Full Record in Web of Science
J;"Velez, MP; Dayan, N; Shellenberger, J; Pudwell, J; Kapoor, D; Vigod, SN; Ray, JG";;;;"Velez, Maria P.; Dayan, Natalie; Shellenberger, Jonas; Pudwell, Jessica; Kapoor, Dia; Vigod, Simone N.; Ray, Joel G.";;;Infertility and Risk of Autism Spectrum Disorder in Children;JAMA NETWORK OPEN;;;English;Article;;;;;;;"ASSISTED REPRODUCTIVE TECHNOLOGY; BORN; ASSOCIATION; CONCEPTION; PREGNANCY; HEALTH; MORBIDITY; DIAGNOSIS; OUTCOMES; STRESS";"Importance Previous studies on the risk of childhood autism spectrum disorder (ASD) following fertility treatment did not account for the infertility itself or the mediating effect of obstetrical and neonatal factors.Objective To assess the association between infertility and its treatments on the risk of ASD and the mediating effect of selected adverse pregnancy outcomes on that association.Design, Setting, and Participants This was a population-based cohort study in Ontario, Canada. Participants were all singleton and multifetal live births at 24 or more weeks' gestation from 2006 to 2018. Data were analyzed from October 2022 to October 2023.Exposures The exposure was mode of conception, namely, (1) unassisted conception, (2) infertility without fertility treatment (ie, subfertility), (3) ovulation induction (OI) or intrauterine insemination (IUI), or (4) in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).Main Outcome and Measures The study outcome was a diagnosis of ASD at age 18 months or older. Cox regression models generated hazard ratios (HR) adjusted for maternal and infant characteristics. Mediation analysis further accounted for the separate effect of (1) preeclampsia, (2) cesarean birth, (3) multifetal pregnancy, (4) preterm birth at less than 37 weeks, and (5) severe neonatal morbidity.Results A total of 1 370 152 children (703 407 male [51.3%]) were included: 1 185 024 (86.5%) with unassisted conception, 141 180 (10.3%) with parental subfertility, 20 429 (1.5%) following OI or IUI, and 23 519 (1.7%) following IVF or ICSI. Individuals with subfertility or fertility treatment were older and resided in higher-income areas; the mean (SD) age of each group was as follows: 30.1 (5.2) years in the unassisted conception group, 33.3 (4.7) years in the subfertility group, 33.1 (4.4) years in the OI or IUI group, and 35.8 (4.9) years in the IVF or ICSI group. The incidence rate of ASD was 1.93 per 1000 person-years among children in the unassisted conception group. Relative to the latter, the adjusted HR for ASD was 1.20 (95% CI, 1.15-1.25) in the subfertility group, 1.21 (95% CI, 1.09-1.34) following OI or IUI, and 1.16 (95% CI, 1.04-1.28) after IVF or ICSI. Obstetrical and neonatal factors appeared to mediate a sizeable proportion of the aforementioned association between mode of conception and ASD risk. For example, following IVF or ICSI, the proportion mediated by cesarean birth was 29%, multifetal pregnancy was 78%, preterm birth was 50%, and severe neonatal morbidity was 25%.Conclusions and Relevance In this cohort study, a slightly higher risk of ASD was observed in children born to individuals with infertility, which appears partly mediated by certain obstetrical and neonatal factors. To optimize child neurodevelopment, strategies should further explore these other factors in individuals with infertility, even among those not receiving fertility treatment.";"[Velez, Maria P.; Pudwell, Jessica; Kapoor, Dia] Queens Univ, Dept Obstet & Gynaecol, Kingston, ON, Canada; [Velez, Maria P.; Shellenberger, Jonas; Vigod, Simone N.; Ray, Joel G.] ICES, Toronto, ON, Canada; [Dayan, Natalie] McGill Univ, Dept Med Obstet & Gynaecol, Hlth Ctr, Montreal, PQ, Canada; [Dayan, Natalie] McGill Univ, Res Inst, Hlth Ctr, Montreal, PQ, Canada; [Dayan, Natalie] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Vigod, Simone N.] Univ Toronto, Temerty Fac Med, Dept Psychiat, Toronto, ON, Canada; [Vigod, Simone N.] Womens Coll Hosp, Toronto, ON, Canada; [Vigod, Simone N.] Womens Coll Res Inst, Toronto, ON, Canada; [Ray, Joel G.] Univ Toronto, St Michaels Hosp, Temerty Fac Med, Dept Med & Obstet & Gynaecol, Toronto, ON, Canada; [Velez, Maria P.] Queens Univ, 76 Stuart St,Victory 4, Kingston, ON K7L 2V7, Canada";"Queens University - Canada; University of Toronto; McGill University; McGill University; McGill University; University of Toronto; University of Toronto; Womens College Hospital; University of Toronto; Womens College Hospital; University of Toronto; Saint Michaels Hospital Toronto; Queens University - Canada";Velez, MP (corresponding author), Queens Univ, 76 Stuart St,Victory 4, Kingston, ON K7L 2V7, Canada.;maria.velez@queensu.ca;;Shellenberger, Jonas/0000-0002-8676-6650;"Canadian Institutes of Health Research [PJT-165840]; ICES - Ontario Ministry of Health and the Ministry of Long-Term Care";"Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); ICES - Ontario Ministry of Health and the Ministry of Long-Term Care";This study was funded by the Canadian Institutes of Health Research, grant No. PJT-165840. Inaddition, this study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Healthand the Ministry of Long-Term Care. This document used data adapted from the Statistics Canada Postal CodeConversion File, which is based on data licensed from Canada Post Corporation, and/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under license from CanadaPost Corporation and Statistics Canada. Parts of this material are based on data and/or information compiled and provided by The Canadian Institute for Health Information, by the Immigration Refugees and Citizenship Canada Permanent Resident Database current to May 17, 2022, and by the Better Outcomes Registry and Network(BORN), part of the Children's Hospital of Eastern Ontario.;"Adamson D, 2023, FERTIL STERIL, V120, P473, DOI 10.1016/j.fertnstert.2023.01.013; [Anonymous], 2023, Infertility prevalence estimates, 19902021; Augoulea A, 2012, ARCH GYNECOL OBSTET, V286, P99, DOI 10.1007/s00404-012-2357-8; Better Outcomes Registry and Network Ontario, Legacy Data Elements, 2006-2011; Brooks JD, 2021, AUTISM RES, V14, P1037, DOI 10.1002/aur.2491; Brown HK, 2017, JAMA-J AM MED ASSOC, V317, P1544, DOI 10.1001/jama.2017.3415; Burke JP, 2014, AUTISM, V18, P321, DOI 10.1177/1362361312467709; Chen XX, 2020, HUM REPROD, V35, P2336, DOI 10.1093/humrep/deaa192; Chih HJ, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03938-8; Conti E, 2013, HUM REPROD, V28, P3316, DOI 10.1093/humrep/det380; Croen LA, 2007, ARCH PEDIAT ADOL MED, V161, P334, DOI 10.1001/archpedi.161.4.334; Crump C, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2020-032300; Dayan N, 2018, HUM REPROD, V33, P1548, DOI 10.1093/humrep/dey224; Dayan Natalie, 2022, CMAJ Open, V10, pE430, DOI 10.9778/cmajo.20210269; Dayan N, 2019, CAN MED ASSOC J, V191, pE118, DOI 10.1503/cmaj.181124; Diop H, 2019, MATERN CHILD HLTH J, V23, P1489, DOI 10.1007/s10995-019-02770-z; Edlow AG, 2017, PRENATAL DIAG, V37, P95, DOI 10.1002/pd.4932; Elias FTS, 2020, ARCH GYNECOL OBSTET, V302, P31, DOI 10.1007/s00404-020-05593-4; Fine A, 2022, HUM REPROD, V37, P2126, DOI 10.1093/humrep/deac129; Fountain C, 2015, AM J PUBLIC HEALTH, V105, P963, DOI 10.2105/AJPH.2014.302383; Grether JK, 2013, J AUTISM DEV DISORD, V43, P663, DOI 10.1007/s10803-012-1598-5; Hultman CM, 2011, MOL PSYCHIATR, V16, P1203, DOI 10.1038/mp.2010.121; Hvidtjorn D, 2011, J EPIDEMIOL COMMUN H, V65, P497, DOI 10.1136/jech.2009.093823; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447; ICES, 2023, About us; Kamowski-Shakibai MT, 2015, RES AUTISM SPECT DIS, V9, P77, DOI 10.1016/j.rasd.2014.10.009; Katsigianni M, 2019, MOL PSYCHIATR, V24, P1787, DOI 10.1038/s41380-019-0398-0; Kissin DM, 2015, HUM REPROD, V30, P454, DOI 10.1093/humrep/deu338; Klemetti R, 2006, PEDIATRICS, V118, P1819, DOI 10.1542/peds.2006-0735; Knoester M, 2007, HUM REPROD, V22, P3098, DOI 10.1093/humrep/dem261; Krakowiak P, 2012, PEDIATRICS, V129, pE1121, DOI 10.1542/peds.2011-2583; Lange T, 2012, AM J EPIDEMIOL, V176, P190, DOI 10.1093/aje/kwr525; Lo HW, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.48141; Lodge-Tulloch NA, 2021, BMC PREGNANCY CHILDB, V21, DOI 10.1186/s12884-021-03711-x; Lyall K, 2013, INT J ENV RES PUB HE, V10, P3715, DOI 10.3390/ijerph10083715; Lyall K, 2012, PAEDIATR PERINAT EP, V26, P361, DOI 10.1111/j.1365-3016.2012.01294.x; Maher GM, 2018, JAMA PSYCHIAT, V75, P809, DOI 10.1001/jamapsychiatry.2018.0854; Mattsson K, 2021, FERTIL STERIL, V116, P505, DOI 10.1016/j.fertnstert.2021.02.009; McDonald SD, 2009, EUR J OBSTET GYN R B, V146, P138, DOI 10.1016/j.ejogrb.2009.05.035; Menezo YJR, 2015, JAMA PEDIATR, V169, P1066, DOI 10.1001/jamapediatrics.2015.2125; Norman RJ, 2007, LANCET, V370, P685, DOI 10.1016/S0140-6736(07)61345-2; Ontario B., 2019, BORN Data Quality Report 2012-2014-Executive Summary; Richmond E, 2021, BJOG-INT J OBSTET GY, DOI 10.1111/1471-0528.17019; Sandin S, 2013, JAMA-J AM MED ASSOC, V310, P75, DOI 10.1001/jama.2013.7222; Soke GN, 2019, AUTISM RES, V12, P816, DOI 10.1002/aur.2091; Strömberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Vélez MP, 2014, HUM REPROD, V29, P1313, DOI 10.1093/humrep/deu067; Vélez MP, 2013, REPROD BIOMED ONLINE, V26, P506, DOI 10.1016/j.rbmo.2013.01.017; Velez MP, 2022, FERTIL STERIL, V118, P1090, DOI 10.1016/j.fertnstert.2022.09.015; Velez MP, 2019, REPROD HEALTH, V16, DOI 10.1186/s12978-019-0667-z; Walker CK, 2015, JAMA PEDIATR, V169, P154, DOI 10.1001/jamapediatrics.2014.2645; Wang YP, 2022, FERTIL STERIL, V118, P926, DOI 10.1016/j.fertnstert.2022.07.028; Wanigaratne S, 2016, MATERN CHILD HLTH J, V20, P2189, DOI 10.1007/s10995-016-2047-4; Whitelaw N, 2014, HUM REPROD, V29, P1452, DOI 10.1093/humrep/deu094; Zhang TY, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10236";55;6;6;2;6;AMER MEDICAL ASSOC;CHICAGO;330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA;2574-3805;;;JAMA NETW OPEN;JAMA Netw. Open;nov-20;2023;6;11;;;;;;;e2343954;10.1001/jamanetworkopen.2023.43954;http://dx.doi.org/10.1001/jamanetworkopen.2023.43954;;;12;Medicine, General & Internal;Science Citation Index Expanded (SCI-EXPANDED);General & Internal Medicine;Z1DA1;37983032;Green Published, gold;;;24/11/2024;WOS:001109543400007;View Full Record in Web of Science
J;"Valeri, G; Casula, L; Menghini, D; Amendola, FA; Napoli, E; Pasqualetti, P; Vicari, S";;;;"Valeri, Giovanni; Casula, Laura; Menghini, Deny; Amendola, Filomena Alessandra; Napoli, Eleonora; Pasqualetti, Patrizio; Vicari, Stefano";;;Cooperative parent-mediated therapy for Italian preschool children with autism spectrum disorder: a randomized controlled trial;EUROPEAN CHILD & ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"Autism spectrum disorder; Parent-mediated therapy; Preschool children; Additional therapeutic effect";"INTENSIVE BEHAVIORAL INTERVENTION; YOUNG-CHILDREN; TRAINING INTERVENTION; FAMILY CAPACITY; TODDLERS; PROGRAM; STRESS; INDIVIDUALS; SEVERITY; TARGETS";"Parent-mediated intervention is widely used for pre-schoolers with autism spectrum disorder (ASD). Previous studies indicate small-to-moderate effects on social communication skills, but with a wide heterogeneity that requires further research. In this randomized controlled trial (RCT), cooperative parent-mediated therapy (CPMT) an individual parent coaching program for young children with ASD was administered to preschool children with ASD. All children received the same low-intensity psychosocial intervention (LPI) delivered in community settings, to evaluate the potential additional benefit of CPMT. Thirty-four participants with ASD (7 females; 27 males; aged 2, 6, 11 years) and their parents were included in the trial. The primary blinded outcome was social communication skills, assessed using the ADOS-G social communication algorithm score (ADOS-G SC). Secondary outcomes included ASD symptom severity, parent-rated language abilities and emotional/behavioral problems, and self-reported caregiver stress. Evaluations were made at baseline and post-treatment (at 6 months) by an independent multidisciplinary team. Results documented that CPMT showed an additional benefit on LPI with significant improvements of the primary blinded outcome, socio-communication skills, and of some secondary outcomes such as ASD symptom severity, emotional problems and parental stress related to parent-child dysfunctional interaction. No additional benefit was found for language abilities. Findings of our RCT show that CPMT provide an additional significant short-term treatment benefit on ASD core symptoms, when compared with active control group receiving only LPI.";"[Valeri, Giovanni; Casula, Laura; Menghini, Deny; Amendola, Filomena Alessandra; Napoli, Eleonora; Vicari, Stefano] IRCCS Childrens Hosp Bambino Gesu, Dept Neurosci, Piazza St Onofrio 4, I-00165 Rome, Italy; [Pasqualetti, Patrizio] Fatebenefratelli Fdn Hlth Res & Educ, Serv Med Stat & Informat Technol, Rome, Italy";IRCCS Bambino Gesu;Vicari, S (corresponding author), IRCCS Childrens Hosp Bambino Gesu, Dept Neurosci, Piazza St Onofrio 4, I-00165 Rome, Italy.;giovanni.valeri@opbg.net;"Pasqualetti, Patrizio/IZQ-0589-2023; Napoli, Eleonora/AAB-2250-2020; Menghini, Deny/HLH-5705-2023; Vicari, Stefano/J-3008-2012; Valeri, Giovani/AAR-9425-2021";"Menghini, Deny/0000-0002-3459-2601; Valeri, Giovani/0000-0003-1974-8505; Vicari, Stefano/0000-0002-5395-2262; Napoli, Eleonora/0000-0002-1436-2825";;;;"Achenbach TM, 2000, MANUAL ASEBA PRESCHO, V30; Aldred C, 2004, J CHILD PSYCHOL PSYC, V45, P1420, DOI 10.1111/j.1469-7610.2004.00338.x; Anagnostou E, 2015, AUTISM, V19, P622, DOI 10.1177/1362361314542955; [Anonymous], 2013, DIAGNOSTIC STAT MANU, VFifth, P1000, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], 2013, M REP AUT SPECTR DIS, P16; [Anonymous], 2001, ED CHILDR AUT; [Anonymous], PARENTING STRESS IND; [Anonymous], 2014, HDB AUTISM PERVASIVE; [Anonymous], 2009, WHY WE COOPERATE; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Bearss K, 2015, CLIN CHILD FAM PSYCH, V18, P170, DOI 10.1007/s10567-015-0179-5; Carter AS, 2011, J CHILD PSYCHOL PSYC, V52, P741, DOI 10.1111/j.1469-7610.2011.02395.x; Caselli, 2007, NUOVI DATI NORMATIVI, V83; Casenhiser Devin M, 2013, Autism, V17, P220, DOI 10.1177/1362361311422052; Colombi C, 2009, AUTISM, V13, P143, DOI 10.1177/1362361308098514; D'Elia L, 2014, J AUTISM DEV DISORD, V44, P615, DOI 10.1007/s10803-013-1911-y; Daley T.C., 2002, TRANSCULT PSYCHIATRY, V39, P531, DOI [DOI 10.1177/136346150203900409, 10.1177/136346150203900409]; Drew A, 2002, EUR CHILD ADOLES PSY, V11, P266, DOI 10.1007/s00787-002-0299-6; Dyches TT, 2004, J AUTISM DEV DISORD, V34, P211, DOI 10.1023/B:JADD.0000022611.80478.73; Fava L, 2011, RES AUTISM SPECT DIS, V5, P1479, DOI 10.1016/j.rasd.2011.02.009; French L, 2018, J CHILD PSYCHOL PSYC, V59, P444, DOI 10.1111/jcpp.12828; Giovagnoli G, 2015, RES DEV DISABIL, V45-46, P411, DOI 10.1016/j.ridd.2015.08.006; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Green J, 2018, J CHILD PSYCHOL PSYC, V59, P424, DOI 10.1111/jcpp.12892; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Hahler EM., 2015, Curr Dev Disord Rep, V2, P58, DOI [10.1007/s40474-014-0033-3, DOI 10.1007/S40474-014-0033-3]; Hardan AY, 2015, J CHILD PSYCHOL PSYC, V56, P884, DOI 10.1111/jcpp.12354; I.S.S. Istituto Superiore di Sanita, 2011, TRATT DISTR SPETTR A; Ivens J, 2002, ARCH DIS CHILD, V87, P109, DOI 10.1136/adc.87.2.109; Kaminski JW, 2008, J ABNORM CHILD PSYCH, V36, P567, DOI 10.1007/s10802-007-9201-9; Kasari C, 2015, J CONSULT CLIN PSYCH, V83, P554, DOI 10.1037/a0039080; Kasari C, 2014, PEDIATRICS, V134, pE72, DOI 10.1542/peds.2013-3229; Kasari C, 2010, J AUTISM DEV DISORD, V40, P1045, DOI 10.1007/s10803-010-0955-5; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Liebal K, 2008, J AUTISM DEV DISORD, V38, P224, DOI 10.1007/s10803-007-0381-5; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Luiz D.M., 2007, Escala de Desenvolvimento Mental de Griffiths - ACTAS do 12?COLOQUIO de PSICOLOGIA e EDUCACAO 932 Extensao Revista (Revisao de 2006) dos 2 aos 8 anos. Manual de Administracao; Maglione MA, 2012, PEDIATRICS, V130, pS169, DOI 10.1542/peds.2012-0900O; McStay RL, 2014, AUTISM, V18, P502, DOI 10.1177/1362361313485163; Mesibov G.B., 2006, The TEACCH approach to autism spectrum disorders; Muratori F, 2011, EPIDEMIOL PSYCH SCI, V20, P329, DOI 10.1017/S204579601100045X; National Institute for Health and Care Excellence, 2013, AUT SPECTR DIS 19S S; Nefdt N, 2010, J POSIT BEHAV INTERV, V12, P23, DOI 10.1177/1098300709334796; Nevill RE, 2018, AUTISM, V22, P84, DOI 10.1177/1362361316677838; Ospina MB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003755; Pajareya K, 2011, AUTISM, V15, P563, DOI 10.1177/1362361310386502; Poslawsky IE, 2015, AUTISM, V19, P588, DOI 10.1177/1362361314537124; Rickards AL, 2007, J DEV BEHAV PEDIATR, V28, P308, DOI 10.1097/DBP.0b013e318032792e; Roberts J, 2011, RES AUTISM SPECT DIS, V5, P1553, DOI 10.1016/j.rasd.2011.03.001; Roid GH, 2000, LEITER INT PERFORMAN; Salomone E, 2016, AUTISM, V20, P233, DOI 10.1177/1362361315577218; Schreibman L, 2015, J AUTISM DEV DISORD, V45, P2411, DOI 10.1007/s10803-015-2407-8; Siller M, 2013, J EARLY INTERVENTION, V35, P355, DOI 10.1177/1053815114542507; Siller M, 2014, J AUTISM DEV DISORD, V44, P1720, DOI 10.1007/s10803-014-2049-2; Smith T, 2015, J CLIN CHILD ADOLESC, V44, P897, DOI 10.1080/15374416.2015.1077448; Strauss K, 2012, RES DEV DISABIL, V33, P688, DOI 10.1016/j.ridd.2011.11.008; Swanson J, 2011, J EARLY CHILD RES, V9, P66, DOI 10.1177/1476718X10368588; Tonge B, 2014, AUTISM, V18, P166, DOI 10.1177/1362361312458186; Trembath D, 2005, J INTELLECT DEV DIS, V30, P240, DOI 10.1080/13668250500349458; Vivanti G, 2018, AUTISM RES, V11, P16, DOI 10.1002/aur.1900; Vivanti G, 2017, CURR DIR PSYCHOL SCI, V26, P114, DOI 10.1177/0963721416680262; Welterlin A, 2012, J AUTISM DEV DISORD, V42, P1827, DOI 10.1007/s10803-011-1419-2; Wetherby AM, 2014, PEDIATRICS, V134, P1084, DOI 10.1542/peds.2014-0757; Woods JJ, 2011, TOP LANG DISORD, V31, P235, DOI 10.1097/TLD.0b013e318227fde4";66;19;29;7;18;SPRINGER;NEW YORK;ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES;1018-8827;1435-165X;;EUR CHILD ADOLES PSY;Eur. Child Adolesc. Psych.;JUL;2020;29;7;;;;;935;946;;10.1007/s00787-019-01395-5;http://dx.doi.org/10.1007/s00787-019-01395-5;;;12;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";MD1CK;31549310;;;;24/11/2024;WOS:000543712700005;View Full Record in Web of Science
J;"Tron, C; Kloosterboer, SM; van der Nagel, BCH; Wijma, RA; Dierckx, B; Dieleman, GC; van Gelder, T; Koch, BCP";;;;"Tron, Camille; Kloosterboer, Sanne M.; van der Nagel, Bart C. H.; Wijma, Rixt A.; Dierckx, Bram; Dieleman, Gwen C.; van Gelder, Teun; Koch, Birgit C. P.";;;Dried Blood Spots Combined With Ultra-High-Performance Liquid Chromatography-Mass Spectrometry for the Quantification of the Antipsychotics Risperidone, Aripiprazole, Pipamperone, and Their Major Metabolites;THERAPEUTIC DRUG MONITORING;;;English;Article;;;;;;"dried blood spots; antipsychotic drugs; therapeutic drug monitoring; pharmacokinetics; autism spectrum disorders";"PLASMA-CONCENTRATIONS; 2ND-GENERATION ANTIPSYCHOTICS; ATYPICAL ANTIPSYCHOTICS; BIOANALYTICAL METHODS; PSYCHOTROPIC-DRUGS; EBF RECOMMENDATION; LC-MS/MS; HEMATOCRIT; DBS; CHILDREN";Background: Risperidone, aripiprazole, and pipamperone are antipsychotic drugs frequently prescribed for the treatment of comorbid behavioral problems in children with autism spectrum disorders. Therapeutic drug monitoring (TDM) could be useful to decrease side effects and to improve patient outcome. Dried blood spot (DBS) sample collection seems to be an attractive technique to develop TDM of these drugs in a pediatric population. The aim of this work was to develop and validate a DBS assay suitable for TDM and home sampling. Methods: Risperidone, 9-OH risperidone, aripiprazole, dehydroaripiprazole, and pipamperone were extracted from DBS and analyzed by ultra-high-performance liquid chromatography-tandem mass spectrometry using a C18 reversed-phase column with a mobile phase consisting of ammonium acetate/formic acid in water or methanol. The suitability of DBS for TDM was assessed by studying the influence of specific parameters: extraction solution, EDTA carry-over, hematocrit, punching location, spot volume, and hemolysis. The assay was validated with respect to conventional guidelines for bioanalytical methods. Results: The method was linear, specific without any critical matrix effect, and with a mean recovery around 90%. Accuracy and imprecision were within the acceptance criteria in samples with hematocrit values from 30% to 45%. EDTA or hemolysis did not skew the results, and no punching carryover was observed. No significant influence of the spot volume or the punch location was observed. The antipsychotics were all stable in DBS stored 10 days at room temperature and 1 month at 4 or -80 degrees C. The method was successfully applied to quantify the 3 antipsychotics and their metabolites in patient samples. Conclusions: A UHPLC-MS/MS method has been successfully validated for the simultaneous quantification of risperidone, 9-OH risperidone, aripiprazole, dehydroaripiprazole, and pipamperone in DBS. The assay provided good analytical performances for TDM and clinical research applications.;"[Tron, Camille; Kloosterboer, Sanne M.; van der Nagel, Bart C. H.; Wijma, Rixt A.; van Gelder, Teun; Koch, Birgit C. P.] Erasmus MC, Dept Hosp Pharm, S Gravendijkwal 230 POB 2040, NL-3000 CA Rotterdam, Netherlands; [Kloosterboer, Sanne M.; Dierckx, Bram; Dieleman, Gwen C.] Erasmus MC, Dept Child & Adolescent Psychiat Psychol, Rotterdam, Netherlands; [van Gelder, Teun] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands";"Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC";Koch, BCP (corresponding author), Erasmus MC, Dept Hosp Pharm, S Gravendijkwal 230 POB 2040, NL-3000 CA Rotterdam, Netherlands.;b.koch@erasmusmc.nl;Dieleman, Gwen/HZJ-6130-2023;koch, birgit/0000-0002-1202-3643;;;;"[Anonymous], 2001, BIOAN METH VAL GUID; [Anonymous], 2011, Science Medicines Health, Guideline on bioanalytical method validation.; Ansermot N, 2013, J CHROMATOGR A, V1292, P160, DOI 10.1016/j.chroma.2012.12.071; Bachmann CJ, 2014, DTSCH ARZTEBL INT, V111, P25, DOI 10.3238/arztebl.2014.0025; Baumann P, 2006, Rev Med Suisse, V2, P1413; Baumann P, 2004, THER DRUG MONIT, V26, P167, DOI 10.1097/00007691-200404000-00014; Baumann P, 2006, REV MED SUISSE, V2, P1424; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Caccia S, 2013, PEDIATR DRUGS, V15, P217, DOI 10.1007/s40272-013-0024-6; Calarge CA, 2009, J CHILD ADOL PSYCHOP, V19, P101, DOI 10.1089/cap.2008.007; Capiau S, 2013, ANAL CHEM, V85, P404, DOI 10.1021/ac303014b; Cohen D, 2012, J CLIN PSYCHOPHARM, V32, P309, DOI 10.1097/JCP.0b013e3182549259; Denniff P, 2014, ANAL CHEM, V86, P8489, DOI 10.1021/ac5022562; Dinnissen M, 2014, EXPERT OPIN DRUG MET, V11, P1; Edelbroek PM, 2009, THER DRUG MONIT, V31, P327, DOI 10.1097/FTD.0b013e31819e91ce; Evans C, 2015, AAPS J, V17, P292, DOI 10.1208/s12248-014-9695-3; Fan LM, 2012, BIOANALYSIS, V4, P345, DOI [10.4155/bio.11.337, 10.4155/BIO.11.337]; Gradinaru J, 2014, J PHARMACEUT BIOMED, V88, P36, DOI 10.1016/j.jpba.2013.07.041; Hiemke C, 2011, PHARMACOPSYCHIATRY, V44, P195, DOI 10.1055/s-0031-1286287; Ji NY, 2015, CURR OPIN PSYCHIATR, V28, P91, DOI 10.1097/YCO.0000000000000132; Koster RA, 2015, BIOANALYSIS, V7, P345, DOI 10.4155/bio.14.298; Kromdijk W, 2012, J ANTIMICROB CHEMOTH, V67, P1211, DOI 10.1093/jac/dks011; Kubo M, 2005, J CHROMATOGR B, V822, P294, DOI 10.1016/j.jchromb.2005.06.023; Leuthold LA, 2015, ANAL CHEM, V87, P2068, DOI 10.1021/ac503931g; Li FM, 2012, J MASS SPECTROM, V47, P655, DOI 10.1002/jms.3015; Li FM, 2011, BIOANALYSIS, V3, P2321, DOI [10.4155/BIO.11.219, 10.4155/bio.11.219]; Li WK, 2010, BIOMED CHROMATOGR, V24, P49, DOI 10.1002/bmc.1367; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Mauri MC, 2007, CLIN PHARMACOKINET, V46, P359, DOI 10.2165/00003088-200746050-00001; Mauri MC, 2001, EUR PSYCHIAT, V16, P57, DOI 10.1016/S0924-9338(00)00536-8; Meesters RJW, 2013, BIOANALYSIS, V5, P2187, DOI [10.4155/BIO.13.175, 10.4155/bio.13.175]; Meesters RJW, 2012, BIOANALYSIS, V4, P2027, DOI [10.4155/BIO.12.175, 10.4155/bio.12.175]; Ming X, 2008, J CHILD NEUROL, V23, P6, DOI 10.1177/0883073807307102; Patteet L, 2015, BIOANALYSIS, V7, P2119, DOI 10.4155/bio.15.100; Patteet L, 2015, DRUG TEST ANAL, V7, P502, DOI 10.1002/dta.1698; Patteet L, 2015, CLIN CHIM ACTA, V441, P11, DOI 10.1016/j.cca.2014.12.008; Patteet L, 2014, CLIN CHIM ACTA, V429, P51, DOI 10.1016/j.cca.2013.11.024; Patteet L, 2012, THER DRUG MONIT, V34, P629, DOI [10.1097/FTD.0B013E3182708EC5, 10.1097/FTD.0b013e3182708ec5.]; Politte LC, 2014, HARVARD REV PSYCHIAT, V22, P76, DOI 10.1097/HRP.0000000000000030; Polson C, 2003, J CHROMATOGR B, V785, P263, DOI 10.1016/S1570-0232(02)00914-5; Riedel M, 2005, EUR ARCH PSY CLIN N, V255, P261, DOI 10.1007/s00406-004-0556-4; Saar E, 2010, J MASS SPECTROM, V45, P915, DOI 10.1002/jms.1783; Sharma A, 2014, DRUG TEST ANAL, V6, P399, DOI 10.1002/dta.1646; Silvestre JS, 2014, J PSYCHOPHARMACOL, V28, P329, DOI 10.1177/0269881113515064; Taylor MRH, 1997, CLIN LAB HAEMATOL, V19, P1, DOI 10.1046/j.1365-2257.1997.00204.x; Timmerman P, 2013, BIOANALYSIS, V5, P2129, DOI 10.4155/bio.13.173; Timmerman P, 2011, BIOANALYSIS, V3, P1567, DOI [10.4155/BIO.11.132, 10.4155/bio.11.132]; Trabelsi H, 2005, J PHARMACEUT BIOMED, V39, P914, DOI 10.1016/j.jpba.2005.05.031; Whitney Z, 2015, J CHILD ADOL PSYCHOP, V25, P234, DOI 10.1089/cap.2014.0044; Wijma RA, 2016, BIOMED CHROMATOGR, V30, P794, DOI 10.1002/bmc.3610; Wilhelm AJ, 2014, CLIN PHARMACOKINET, V53, P961, DOI 10.1007/s40262-014-0177-7; Yoshimura R, 2001, NEUROPSYCHOBIOLOGY, V44, P129, DOI 10.1159/000054932; Youhnovski N, 2011, RAPID COMMUN MASS SP, V25, P2951, DOI 10.1002/rcm.5182";53;22;22;5;32;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0163-4356;1536-3694;;THER DRUG MONIT;Ther. Drug Monit.;AUG;2017;39;4;;;;;429;440;;10.1097/FTD.0000000000000411;http://dx.doi.org/10.1097/FTD.0000000000000411;;;12;"Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology";Science Citation Index Expanded (SCI-EXPANDED);"Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology";FA7HU;28700523;;;;24/11/2024;WOS:000405617400020;View Full Record in Web of Science
J;"Ooi, YP; Weng, SJ; Jang, LY; Low, L; Seah, J; Teo, S; Ang, RP; Lim, CG; Liew, A; Fung, DS; Sung, M";;;;"Ooi, Y. P.; Weng, S-J; Jang, L. Y.; Low, L.; Seah, J.; Teo, S.; Ang, R. P.; Lim, C. G.; Liew, A.; Fung, D. S.; Sung, M.";;;Omega-3 fatty acids in the management of autism spectrum disorders: findings from an open-label pilot study in Singapore;EUROPEAN JOURNAL OF CLINICAL NUTRITION;;;English;Article;;;;;;;;"The goal of this open-label trial was to examine the efficacy and safety of a 12-week omega-3 fatty acids supplementation among children suffering with Autism Spectrum Disorders (ASD). A total of 41 children and adolescents aged 7-18 years (36 boys, 5 girls; mean age = 11.66, s.d. = 3.05) diagnosed with ASD participated in the study. At post-treatment, participants showed significant improvements on all subscales of the Social Responsiveness Scale (P<0.01) and the Social and Attention Problems syndrome scales of the Child Behavior Checklist (P<0.05). Blood fatty acid levels were significantly correlated with changes in the core symptoms of ASD. Baseline levels of blood fatty acid levels were also predictive of response to the omega-3 treatment. Omega-3 fatty acids supplementation was well-tolerated and did not cause any serious side effects. Our findings lend some preliminary support for the use of omega-3 fatty acids supplementation in addressing ASD. Future randomized controlled trials of omega-3 fatty acids in ASD with blood fatty acid measurements with a larger sample and longer follow-up period is warranted.";"[Ooi, Y. P.] Univ Basel, Dept Psychol, Clin Psychol & Psychotherapy, Basel, Switzerland; [Ooi, Y. P.; Fung, D. S.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 639798, Singapore; [Ooi, Y. P.; Weng, S-J; Jang, L. Y.; Low, L.; Seah, J.; Teo, S.; Lim, C. G.; Liew, A.; Fung, D. S.; Sung, M.] Hlth Promot Board, Child Guidance Clin, Singapore, Singapore; [Weng, S-J; Lim, C. G.; Fung, D. S.] DUKE NUS Grad Med Sch Singapore, Singapore, Singapore; [Ang, R. P.] Nanyang Technol Univ, Natl Inst Educ, Singapore 639798, Singapore";"University of Basel; Nanyang Technological University; National University of Singapore; Nanyang Technological University; National Institute of Education (NIE) Singapore";Sung, M (corresponding author), Child Guidance Clin, 3 Second Hosp Ave,03-01 HPB Bldg, Singapore 168937, Singapore.;min_sung@imh.com.sg;"Ang, Rebecca/D-6582-2016; Ooi, Yoon/D-3944-2015; Fung, Daniel/W-6915-2019";"Ang, Rebecca/0000-0001-6045-7828; Fung, Daniel/0000-0003-0718-9363";;;;"Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; [Anonymous], STAT POWER ANAL BEHA; [Anonymous], 2001, MANUAL ASEBA SCH AGE; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Bell JG, 2004, PROSTAG LEUKOTR ESS, V71, P201, DOI 10.1016/j.plefa.2004.03.008; Bent S, 2011, J AUTISM DEV DISORD, V41, P545, DOI 10.1007/s10803-010-1078-8; Bent S, 2009, J AUTISM DEV DISORD, V39, P1145, DOI 10.1007/s10803-009-0724-5; Carter MJ, 2014, THER RECREAT J, V48, P275; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Freeman MP, 2006, J CLIN PSYCHIAT, V67, P1954, DOI 10.4088/JCP.v67n1217; Meiri G, 2009, J CHILD ADOL PSYCHOP, V19, P449, DOI 10.1089/cap.2008.0123; Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6; Wechsler D, 2003, Weschler Intelligence Scale for Children, Fourth Edition, Australian Administration and Scoring Manual, VFourth; Wechsler D., 2014, WECHSLER PRESCHOOL P; Yehuda S, 2005, NEUROBIOL AGING, V26, pS98, DOI 10.1016/j.neurobiolaging.2005.09.013";15;45;48;0;28;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;0954-3007;1476-5640;;EUR J CLIN NUTR;Eur. J. Clin. Nutr.;AUG;2015;69;8;;;;;969;971;;10.1038/ejcn.2015.28;http://dx.doi.org/10.1038/ejcn.2015.28;;;3;Nutrition & Dietetics;Science Citation Index Expanded (SCI-EXPANDED);Nutrition & Dietetics;CO6JX;25804268;Bronze;;;24/11/2024;WOS:000359264100019;View Full Record in Web of Science
J;"Kong, XJ; Liu, J; Liu, K; Koh, M; Sherman, H; Liu, SY; Tian, RY; Sukijthamapan, P; Wang, JJ; Fong, M; Xu, L; Clairmont, C; Jeong, MS; Li, A; Lopes, M; Hagan, V; Dutton, T; Chan, ST; Lee, H; Kendall, A; Kwong, K; Song, YQ";;;;"Kong, Xue-Jun; Liu, Jun; Liu, Kevin; Koh, Madelyn; Sherman, Hannah; Liu, Siyu; Tian, Ruiyi; Sukijthamapan, Piyawat; Wang, Jiuju; Fong, Michelle; Xu, Lei; Clairmont, Cullen; Jeong, Min-Seo; Li, Alice; Lopes, Maria; Hagan, Veronica; Dutton, Tess; Chan, Suk-Tak (Phoebe); Lee, Hang; Kendall, Amy; Kwong, Kenneth; Song, Yiqing";;;Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial;NUTRIENTS;;;English;Article;;;;;;"autism spectrum disorder (ASD); probiotics; oxytocin; microbiome; inflammation markers";"LACTOBACILLUS-PLANTARUM PS128; MYELIN BASIC-PROTEIN; GUT MICROBIOTA; PLASMA OXYTOCIN; CHILDREN; BEHAVIOR; SERUM; AUTOANTIBODIES; PHYSIOLOGY; DEFICITS";"Autism spectrum disorder (ASD) is a rapidly growing neurodevelopmental disorder. Both probiotics and oxytocin were reported to have therapeutic potential; however, the combination therapy has not yet been studied. We conducted a randomized, double-blinded, placebo-controlled, 2-stage pilot trial in 35 individuals with ASD aged 3-20 years (median = 10.30 years). Subjects were randomly assigned to receive daily Lactobacillus plantarum PS128 probiotic (6 x 10(10) CFUs) or a placebo for 28 weeks; starting on week 16, both groups received oxytocin. The primary outcomes measure socio-behavioral severity using the Social Responsiveness Scale (SRS) and Aberrant Behavior Checklist (ABC). The secondary outcomes include measures of the Clinical Global Impression (CGI) scale, fecal microbiome, blood serum inflammatory markers, and oxytocin. All outcomes were compared between the two groups at baseline, 16 weeks, and 28 weeks into treatment. We observed improvements in ABC and SRS scores and significant improvements in CGI-improvement between those receiving probiotics and oxytocin combination therapy compared to those receiving placebo (p < 0.05). A significant number of favorable gut microbiome network hubs were also identified after combination therapy (p < 0.05). The favorable social cognition response of the combination regimen is highly correlated with the abundance of the Eubacterium hallii group. Our findings suggest synergic effects between probiotics PS128 and oxytocin in ASD patients, although further investigation is warranted.";"[Kong, Xue-Jun; Liu, Jun; Liu, Kevin; Koh, Madelyn; Sherman, Hannah; Liu, Siyu; Tian, Ruiyi; Wang, Jiuju; Fong, Michelle; Clairmont, Cullen; Jeong, Min-Seo; Li, Alice; Lopes, Maria; Hagan, Veronica; Dutton, Tess; Chan, Suk-Tak (Phoebe); Kendall, Amy; Kwong, Kenneth] Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Charlestown, MA 02129 USA; [Kong, Xue-Jun] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA; [Liu, Jun; Sukijthamapan, Piyawat; Xu, Lei; Lee, Hang] Harvard Med Sch, Boston, MA 02115 USA; [Xu, Lei] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Lee, Hang] Massachusetts Gen Hosp, MGH Biostat Ctr, Boston, MA 02114 USA; [Song, Yiqing] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46202 USA";"Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Indiana University System; Indiana University Indianapolis";"Kong, XJ (corresponding author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr, Charlestown, MA 02129 USA.;Kong, XJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.";"xkong1@mgh.harvard.edu; Jun_Liu@hms.harvard.edu; kliu16@mgh.harvard.edu; mkoh@mgh.harvard.edu; htsherman@mgh.harvard.edu; SLIU41@mgh.harvard.edu; RTIAN2@mgh.harvard.edu; Piyawat_Sukijthamapan@DFCI.harvard.edu; Jwang106@mgh.harvard.edu; Michelle_Fong@DFCI.HARVARD.EDU; lei@steele.mgh.harvard.edu; CCLAIRMONT1@mgh.harvard.edu; msjeong@mgh.harvard.edu; CLI36@mgh.harvard.edu; MLOPES6@mgh.harvard.edu; VHAGAN@mgh.harvard.edu; tdutton1@bwh.harvard.edu; stchan@mgh.harvard.edu; hlee5@mgh.harvard.edu; alkendall@mgh.harvard.edu; KKWONG@mgh.harvard.edu; yiqsong@iu.edu";"Chan, Suk-tak/JRX-3173-2023; Liu, Siyu/GYV-4856-2022; WANG, JINGYI/GSJ-1241-2022; Xu, Lei/GRR-9174-2022";"Arichai, Piyawat/0000-0001-9520-2956; Song, Yiqing/0000-0002-2097-7332; Fong, Michelle/0000-0002-9654-690X; Liu, Kevin/0000-0002-8754-3504; Clairmont, Cullen/0000-0002-9672-2205; wang, jiuju/0000-0002-8707-1551";Massachusetts General Hospital [230361, 233263];Massachusetts General Hospital;This research was funded by Massachusetts General Hospital, grant numbers #230361 and #233263.;"Abou-Donia MB, 2019, BEHAV SCI-BASEL, V9, DOI 10.3390/bs9050047; Alam R, 2017, AM J MED GENET B, V174, P651, DOI 10.1002/ajmg.b.32567; AMAN MG, 1985, AM J MENT DEF, V89, P485; Averina OV, 2020, J MED MICROBIOL, V69, P558, DOI 10.1099/jmm.0.001178; Berding K, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00515; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Cao X, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.635925; Chao SH, 2009, INT J FOOD MICROBIOL, V135, P203, DOI 10.1016/j.ijfoodmicro.2009.07.032; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P33, DOI 10.1017/S0954579413000497; Davari S, 2013, NEUROSCIENCE, V240, P287, DOI 10.1016/j.neuroscience.2013.02.055; De Angelis M, 2015, GUT MICROBES, V6, P207, DOI 10.1080/19490976.2015.1035855; Desbonnet L, 2008, J PSYCHIATR RES, V43, P164, DOI 10.1016/j.jpsychires.2008.03.009; Dhir S, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00207; Dinan TG, 2013, BIOL PSYCHIAT, V74, P720, DOI 10.1016/j.biopsych.2013.05.001; El Hage R, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01206; Erdman SE, 2016, INT REV NEUROBIOL, V131, P91, DOI 10.1016/bs.irn.2016.07.004; Esnafoglu E, 2017, INT J DEV NEUROSCI, V61, P86, DOI 10.1016/j.ijdevneu.2017.06.011; Friedman J, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002687; Fritz JH, 2013, INFECT IMMUN, V81, P3500, DOI 10.1128/IAI.00789-13; Fung TC, 2017, NAT NEUROSCI, V20, P145, DOI 10.1038/nn.4476; Garcia-Mantrana I, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00890; Gonzalez-Gronow M, 2015, J NEUROIMMUNOL, V287, P1, DOI 10.1016/j.jneuroim.2015.07.006; Guloksuz SA, 2017, REV BRAS PSIQUIATR, V39, P195, DOI 10.1590/1516-4446-2015-1843; Guo M, 2019, FOOD FUNCT, V10, P6873, DOI 10.1039/c9fo00296k; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Husarova VM, 2016, PSYCHIAT INVEST, V13, P174; Inoue R, 2016, BIOSCI BIOTECH BIOCH, V80, P2450, DOI 10.1080/09168451.2016.1222267; Iritani S, 2018, INT J DEV NEUROSCI, V71, P130, DOI 10.1016/j.ijdevneu.2018.09.002; Jansen LMC, 2006, J AUTISM DEV DISORD, V36, P891, DOI 10.1007/s10803-006-0124-z; Jarett JK, 2019, PEERJ, V7, DOI 10.7717/peerj.7661; Jin D, 2007, NATURE, V446, P41, DOI 10.1038/nature05526; Kang DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068322; Kern JK, 2016, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00519; Kong XJ, 2020, PILOT FEASIBILITY ST, V6, DOI 10.1186/s40814-020-0557-8; Kong XJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092128; Layeghifard M, 2017, TRENDS MICROBIOL, V25, P217, DOI 10.1016/j.tim.2016.11.008; Liao PL, 2019, FOODS, V8, DOI 10.3390/foods8120668; Liu F, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0251-3; Liu WH, 2016, BEHAV BRAIN RES, V298, P202, DOI 10.1016/j.bbr.2015.10.046; Liu WH, 2015, GUT PATHOG, V7, DOI 10.1186/s13099-015-0068-y; Liu YW, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040820; Liu YW, 2016, BRAIN RES, V1631, P1, DOI 10.1016/j.brainres.2015.11.018; Luna RA, 2017, CELL MOL GASTROENTER, V3, P218, DOI 10.1016/j.jcmgh.2016.11.008; Lustgarten MS, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01435; Ma SJ, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00058; Maenner MJ, 2020, MMWR SURVEILL SUMM, V69, P1, DOI 10.15585/mmwr.ss6904a1; Mallick H., 2021, bioRxiv, DOI DOI 10.1101/2021.01.20.427420; Marotta R, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10030163; Masi A, 2015, MOL PSYCHIATR, V20, P440, DOI 10.1038/mp.2014.59; Miller M, 2013, AUTISM RES, V6, P91, DOI 10.1002/aur.1270; Mostafa GA, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-71; Oliphant K, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0704-8; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Parker KJ, 2014, P NATL ACAD SCI USA, V111, P12258, DOI 10.1073/pnas.1402236111; Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010; Rose DR, 2018, BRAIN BEHAV IMMUN, V70, P354, DOI 10.1016/j.bbi.2018.03.025; Savignac HM, 2014, NEUROGASTROENT MOTIL, V26, P1615, DOI 10.1111/nmo.12427; Skuse DH, 2009, TRENDS COGN SCI, V13, P27, DOI 10.1016/j.tics.2008.09.007; Strati F, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0242-1; Teng BL, 2016, NEUROPHARMACOLOGY, V105, P61, DOI 10.1016/j.neuropharm.2015.12.025; Tomova A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082797; Tripathi MK, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101567; Udayappan S, 2016, NPJ BIOFILMS MICROBI, V2, DOI 10.1038/npjbiofilms.2016.9; Wang YJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02509; Watanabe T, 2017, SOC COGN AFFECT NEUR, V12, P496, DOI 10.1093/scan/nsw150; Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162; Ye LH, 2021, CELL HOST MICROBE, V29, P179, DOI 10.1016/j.chom.2020.11.011; Zhang HF, 2016, NEUROSCI BULL, V32, P423, DOI 10.1007/s12264-016-0046-5; Zhang MX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32219-2";71;54;59;5;50;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2072-6643;;NUTRIENTS;Nutrients;MAY;2021;13;5;;;;;;;1552;10.3390/nu13051552;http://dx.doi.org/10.3390/nu13051552;;;17;Nutrition & Dietetics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Nutrition & Dietetics;ST5FL;34062986;Green Published, gold;;;24/11/2024;WOS:000662469000001;View Full Record in Web of Science
J;"Brito, AR; Vairo, GDT; Dias, APBH; Olej, B; Nascimento, OJM; Vasconcelos, MM";;;;"Brito, Adriana Rocha; Teixeira Vairo, Giselle de Paula; Botelho Henriques Dias, Ana Paula; Olej, Beni; Moreira Nascimento, Osvaldo Jose; Vasconcelos, Marcio Moacyr";;;Effect of prednisolone on language function in children with autistic spectrum disorder: a randomized clinical trial;JORNAL DE PEDIATRIA;;;English;Article;;;;;;"Autism; Autistic disorder; Immunomodulation; Corticosteroids; Language";"CHILDHOOD AUTISM; REGRESSION; THERAPY; GUIDE";"Objective: To describe the effect of prednisolone on language in children with autism spectrum disorder. This study is based upon two hypotheses: autism etiology may be closely related to neuroinflammation; and, an effective treatment should restore the individual's language skills. Method: This is a prospective, double-blinded, randomized, placebo-controlled clinical trial, carried out in a federal university hospital. The initial patient sample consisted of 40 subjects, which were randomized into two parallel groups. Inclusion criteria were: male gender, 3-7 years of age, and meeting the Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV) diagnostic criteria. The final sample consisted of 38 patients, of whom 20 were randomized to the placebo group and 18 to the active group. The latter received prednisolone for 24 weeks, at an initial dose of 1 mg/kg/day and a tapering dose from the ninth week onward. Language was measured on four occasions over a 12-month period by applying two Brazilian tools: the Language Development Assessment (ADL) and the Child Language Test in Phonology, Vocabulary, Fluency, and Pragmatics (ABFW). Results: The side effects were mild: two patients had hypertension, five had hyperglycemia, and two had varicella. Prednisolone increased the global ADL score in children younger than 5 years of age who had developmental regression (p = 0.0057). The ABFW's total of communicative acts also responded favorably in those participants with regression (p = 0.054). The ABFW's total of vocal acts showed the most significant results, especially in children younger than 5 years (p = 0.004, power = 0.913). Conclusions: The benefit of prednisolone for language scores was more evident in participants who were younger than five years, with a history of developmental regression, but the trial's low dose may have limited this benefit. The observed side effects do not contraindicate corticosteroid use in autism. (C) 2020 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.";"[Brito, Adriana Rocha; Teixeira Vairo, Giselle de Paula; Botelho Henriques Dias, Ana Paula; Vasconcelos, Marcio Moacyr] Univ Fed Fluminense UFF, Dept Maternoinfantil, Niteroi, RJ, Brazil; [Olej, Beni; Moreira Nascimento, Osvaldo Jose] Univ Fed Fluminense UFF, Dept Med Clin, Niteroi, RJ, Brazil";"Universidade Federal Fluminense; Universidade Federal Fluminense";Vasconcelos, MM (corresponding author), Univ Fed Fluminense UFF, Dept Maternoinfantil, Niteroi, RJ, Brazil.;mmdvascon@gmail.com;Nascimento, Osvaldo/GPT-4153-2022;"Botelho Henriques Dias, Ana Paula/0000-0001-5394-226X; Olej, Beni/0000-0002-0067-983X; do Nascimento O, Osvaldo/0000-0003-3516-485X";CNPq researchgrant [575332/2008-5];CNPq researchgrant(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF));The clinical trial was partially funded by a CNPq researchgrant, through contract number 575332/2008-5, which covered approximately 10% of expenses.;"Castillo MA, 2019, BEHAV SCI-BASEL, V9, DOI 10.3390/bs9060060; [Anonymous], 2013, Diagnostic and statistical manual of mental disorders; Benvenuto A, 2013, BRAIN DEV-JPN, V35, P119, DOI 10.1016/j.braindev.2012.03.015; Boucher J, 2003, INT J PEDIATR OTORHI, V67, pS159, DOI 10.1016/j.ijporl.2003.08.016; Campelo LD, 2009, REV CEFAC, V11; Chez MG, 2010, NEUROTHERAPEUTICS, V7, P293, DOI 10.1016/j.nurt.2010.05.008; Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3; Dawson G, STEM CELLS TRANSL ME; Deckmann I, NEUROIMMUNOMODULATIO; Dias APBH, 2016, REV LOGOP FONIATR AU, V36, P15, DOI [10.1016/j.rlfa.2015.02.001., DOI 10.1016/J.RLFA.2015.02.001]; Duffy FH, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-70; Ericson-Neilsen W, 2014, OCHSNER J, V14, P203; Espírito-Santo H, 2018, REV PORT INVESTIG CO, V4, P43, DOI 10.7342/ismt.rpics.2018.4.1.72; Franco EC, 2014, REV CEFAC, V16; Friedman L, 2019, SEMIN SPEECH LANG, V40, P291, DOI 10.1055/s-0039-1692964; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Harrington JW, 2014, PEDIATR REV, V35, P62, DOI 10.1542/pir.35-2-62; Karahmadi Mojgan, 2018, Adv Biomed Res, V7, P131, DOI 10.4103/abr.abr_100_18; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Miilher Liliane Perroud, 2006, Pró-Fono R. Atual. Cient., V18, P239, DOI 10.1590/S0104-56872006000300003; Onore C, 2012, BRAIN BEHAV IMMUN, V26, P383, DOI 10.1016/j.bbi.2011.08.007; Ozonoff S, 2019, NEUROSCI BIOBEHAV R, V100, P296, DOI 10.1016/j.neubiorev.2019.03.012; Pereira A, 2008, J PEDIAT-BRAZIL, V84, P487, DOI 10.2223/JPED.1828; Rezaei V, 2010, PROG NEURO-PSYCHOPH, V34, P1269, DOI 10.1016/j.pnpbp.2010.07.005; Shenoy S, 2000, J PEDIATR-US, V136, P682, DOI 10.1067/mpd.2000.105355; STEFANATOS GA, 1995, J AM ACAD CHILD PSY, V34, P1107, DOI 10.1097/00004583-199508000-00022; Tuchman Roberto, 2006, Epilepsy Curr, V6, P107, DOI 10.1111/j.1535-7511.2006.00113.x; Tye C, 2019, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00751; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013; Whitehouse AJO, 2008, J COMMUN DISORD, V41, P319, DOI 10.1016/j.jcomdis.2008.01.002";30;7;9;0;9;SOC BRASIL PEDIATRIA;RIO DE JANEIRO, RJ;RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL;0021-7557;1678-4782;;J PEDIAT-BRAZIL;J. Pediatr.;JAN-FEB;2021;97;1;;;;;22;29;;10.1016/j.jped.2019.10.012;http://dx.doi.org/10.1016/j.jped.2019.10.012;;;8;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;QL9KB;32330433;gold, Green Published;;;24/11/2024;WOS:000621398300005;View Full Record in Web of Science
J;"Eack, SM; Hogarty, SS; Greenwald, DP; Litschge, MY; Porton, SA; Mazefsky, CA; Minshew, NJ";;;;"Eack, Shaun M.; Hogarty, Susan S.; Greenwald, Deborah P.; Litschge, Maralee Y.; Porton, Shannondora A.; Mazefsky, Carla A.; Minshew, Nancy J.";;;Cognitive enhancement therapy for adult autism spectrum disorder: Results of an 18-month randomized clinical trial;AUTISM RESEARCH;;;English;Article;;;;;;"adult autism; cognitive remediation; cognitive enhancement; social cognition; neurocognition";"FACIAL EMOTION RECOGNITION; HIGH-FUNCTIONING AUTISM; EXECUTIVE FUNCTION; DIAGNOSTIC INTERVIEW; SUSTAINED ATTENTION; EFFECT SIZES; SCHIZOPHRENIA; CHILDREN; FEASIBILITY; BATTERY";Cognitive remediation is a promising approach to treating core cognitive deficits in adults with autism, but rigorously controlled trials of comprehensive interventions that target both social and non-social cognition over a sufficient period of time to impact functioning are lacking. This study examined the efficacy of cognitive enhancement therapy (CET) for improving core cognitive and employment outcomes in adult autism. Verbal adult outpatients with autism spectrum disorder (N=54) were randomized to an 18-month, single-blind trial of CET, a cognitive remediation approach that integrates computer-based neurocognitive training with group-based training in social cognition, or an active enriched supportive therapy (EST) comparison focused on psychoeducation and condition management. Primary outcomes were composite indexes of neurocognitive and social-cognitive change. Competitive employment was a secondary outcome. Intent-to-treat analyses indicated that CET produced significant differential increases in neurocognitive function relative to EST (d=.46, P=.013). Both CET and EST were associated with large social-cognitive improvements, with CET demonstrating an advantage at 9 (d=.58, P=0.020), but not 18 months (d=.27, P=0.298). Effects on employment indicated that participants treated with CET were significantly more likely to gain competitive employment than those in EST, OR=6.21, P=0.023, which was mediated by cognitive improvement. CET is a feasible and potentially effective treatment for core cognitive deficits in adult autism spectrum disorder. The treatment of cognitive impairments in this population can contribute to meaningful improvements in adult outcomes. Autism Res2018, 11: 519-530. (c) 2017 International Society for Autism Research, Wiley Periodicals, Inc. Lay SummaryCognitive enhancement therapy (CET), an 18-month cognitive remediation intervention designed to improve thinking and social understanding, was found to be more effective than supportive therapy at improving mental quickness, attention, and employment in adults living with autism. Social understanding was equally improved in CET and supportive therapy. Cognitive remediation interventions are feasible and may confer significant functional benefits to adults with autism.;"[Eack, Shaun M.] Univ Pittsburgh, Sch Social Work, 2117 Cathedral Learning, Pittsburgh, PA 15260 USA; [Eack, Shaun M.; Hogarty, Susan S.; Greenwald, Deborah P.; Litschge, Maralee Y.; Porton, Shannondora A.; Mazefsky, Carla A.; Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Minshew, Nancy J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA";"Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh";Eack, SM (corresponding author), Univ Pittsburgh, Sch Social Work, 2117 Cathedral Learning, Pittsburgh, PA 15260 USA.;sme12@pitt.edu;Mazefsky, Carla/ABB-5009-2020;"Mazefsky, Carla/0000-0001-7467-0902; Eack, Shaun/0000-0001-6368-7004";"NIH [MH-85851, MH-95783, RR-24154, HD-55748]; Autism Speaks; Department of Defense; Pennsylvania Department of Health";"NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Autism Speaks; Department of Defense(United States Department of Defense); Pennsylvania Department of Health";This work was supported by NIH grants MH-85851 (NJM and SME), MH-95783 (SME), RR-24154 (SME), and HD-55748 (NJM), as well as grants from Autism Speaks (NJM and SME), the Department of Defense (NJM and SME), and the Pennsylvania Department of Health (NJM). We would like to thank Summer A. F. McKnight, M.S.W., Patricia J. McCarroll, M.S.W., Michelle Perrin, M.B.A., and John J. Markiewicz III for their assistance in completing various aspects of this clinical trial, as well as the participants and families who generously volunteered their time to improving the treatment of adults living with autism.;"[Anonymous], 2014, The R Foundation for Statistical Computing; [Anonymous], 1997, Brief visuospatial memory test-revised: Professional manual; [Anonymous], 1944, MANUAL DIRECTIONS SC; BALDWIN MW, 1992, PSYCHOL BULL, V112, P461, DOI 10.1037/0033-2909.112.3.461; Ben-Yishay Y., 1985, Neuropsychological rehabilitation, P165; Bishop-Fitzpatrick L, 2013, J AUTISM DEV DISORD, V43, P687, DOI 10.1007/s10803-012-1615-8; Bracy O.L., 1994, PSSCogRehab; Brandt J., 2001, Psychol Assess Resour; Brothers L., 1990, CONCEPT NEUROSCI, P27; Chawarska K, 2012, J CHILD PSYCHOL PSYC, V53, P903, DOI 10.1111/j.1469-7610.2012.02538.x; Chung YS, 2014, SCHIZOPHRENIA BULL, V40, P602, DOI 10.1093/schbul/sbt048; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; CORNBLATT BA, 1988, PSYCHIAT RES, V26, P223, DOI 10.1016/0165-1781(88)90076-5; Couture SM, 2010, PSYCHOL MED, V40, P569, DOI 10.1017/S003329170999078X; de Vries M, 2015, J AUTISM DEV DISORD, V45, P2734, DOI 10.1007/s10803-015-2438-1; de Vries M, 2015, J CHILD PSYCHOL PSYC, V56, P566, DOI 10.1111/jcpp.12324; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Eack SM, 2015, SCHIZOPHR RES, V161, P478, DOI 10.1016/j.schres.2014.11.017; Eack SM, 2013, J AUTISM DEV DISORD, V43, P2866, DOI 10.1007/s10803-013-1834-7; Eack SM, 2013, J AUTISM DEV DISORD, V43, P2233, DOI 10.1007/s10803-013-1774-2; Eack SM, 2013, SCHIZOPHR RES, V148, P24, DOI 10.1016/j.schres.2013.05.013; Eack SM, 2009, PSYCHIAT SERV, V60, P1468, DOI 10.1176/appi.ps.60.11.1468; ERWIN RJ, 1992, PSYCHIAT RES, V42, P231, DOI 10.1016/0165-1781(92)90115-J; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Green MF, 2004, BIOL PSYCHIAT, V56, P301, DOI 10.1016/j.biopsych.2004.06.023; Hamilton AFD, 2009, COGNITION, V113, P37, DOI 10.1016/j.cognition.2009.07.007; Harms MB, 2010, NEUROPSYCHOL REV, V20, P290, DOI 10.1007/s11065-010-9138-6; Heaton R.K., 1981, MANUAL WISCONSIN CAR; Hedges LV, 2007, J EDUC BEHAV STAT, V32, P341, DOI 10.3102/1076998606298043; Hogarty G.E., 2002, PERSONAL THERAPY SCH; Hogarty G.E., 2006, COGNITIVE ENHANCEMEN; Hogarty GE, 2004, ARCH GEN PSYCHIAT, V61, P866, DOI 10.1001/archpsyc.61.9.866; HOGARTY GE, 1974, ARCH GEN PSYCHIAT, V31, P609; Howlin P, 2013, J AM ACAD CHILD PSY, V52, P572, DOI 10.1016/j.jaac.2013.02.017; Hudepohl MB, 2015, AUTISM, V19, P107, DOI 10.1177/1362361313512725; Keefe R.S.E., 1999, BRIEF ASSESSMENT COG; Kern RS, 2008, AM J PSYCHIAT, V165, P214, DOI 10.1176/appi.ajp.2007.07010043; Keshavan MS, 2014, AM J PSYCHIAT, V171, P510, DOI 10.1176/appi.ajp.2013.13081075; Kohler CG, 2003, AM J PSYCHIAT, V160, P1768, DOI 10.1176/appi.ajp.160.10.1768; Kohler CG, 2000, BIOL PSYCHIAT, V48, P127, DOI 10.1016/S0006-3223(00)00847-7; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002; Mayer JD, 2004, PSYCHOL INQ, V15, P197, DOI 10.1207/s15327965pli1503_02; Mayer JD, 2003, EMOTION, V3, P97, DOI 10.1037/1528-3542.3.1.97; Mazefsky CA, 2015, J AUTISM DEV DISORD, V45, P3405, DOI 10.1007/s10803-015-2602-7; Minshew N.J., 1993, NEUROPSYCHOLOGY, V7, P209, DOI [10.1037/0894-4105.7.2.209, DOI 10.1037/0894-4105.7.2.209]; Minshew NJ, 2007, ARCH NEUROL-CHICAGO, V64, P945, DOI 10.1001/archneur.64.7.945; Murphy CM, 2014, AM J PSYCHIAT, V171, P1107, DOI 10.1176/appi.ajp.2014.12030352; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; NUECHTERLEIN KH, 1986, SCHIZOPHRENIA BULL, V12, P408, DOI 10.1093/schbul/12.3.408; Philip RCM, 2012, NEUROSCI BIOBEHAV R, V36, P901, DOI 10.1016/j.neubiorev.2011.10.008; Plitt M, 2015, P NATL ACAD SCI USA, V112, pE6699, DOI 10.1073/pnas.1510098112; Pugliese CE, 2015, J AUTISM DEV DISORD, V45, P1579, DOI 10.1007/s10803-014-2309-1; Rosenthal M, 2013, NEUROPSYCHOLOGY, V27, P13, DOI 10.1037/a0031299; Selman R.L., 1990, Making a friend in youth: Developmental theory and pair therapy; Sikora DM, 2012, PEDIATRICS, V130, pS91, DOI 10.1542/peds.2012-0900G; Singer D., 2003, APPL LONGITUDINAL DA, DOI DOI 10.1093/ACPROF:OSO/9780195152968.001.0001; Turner-Brown LM, 2008, J AUTISM DEV DISORD, V38, P1777, DOI 10.1007/s10803-008-0545-y; Warren Z, 2011, PEDIATRICS, V127, pE1303, DOI 10.1542/peds.2011-0426; Wechsler D, 1987, MANUAL WESCHLER MEMO; White T., 2003, NEUROPSYCHOLOGICAL A; Wyer R.S., 1994, Handbook of social cognition, V1; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855";66;50;53;6;46;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1939-3792;1939-3806;;AUTISM RES;Autism Res.;MAR;2018;11;3;;;;;519;530;;10.1002/aur.1913;http://dx.doi.org/10.1002/aur.1913;;;12;"Behavioral Sciences; Psychology, Developmental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology";GA5IN;29286586;Green Accepted;;;24/11/2024;WOS:000428367000010;View Full Record in Web of Science
J;"Clark-Whitney, E; Klein, CB; Hadley, PA; Lord, C; Kim, SH";;;;"Clark-Whitney, Elysha; Klein, Claire Brito; Hadley, Pamela A.; Lord, Catherine; Kim, So Hyun";;;Caregiver Language Input Supports Sentence Diversity in Young Children With Autism Spectrum Disorder;JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH;;;English;Article;;;;;;;"INTERVENTIONS; TODDLERS; GROWTH; SEVERITY; VALIDITY";"Purpose: Sentence diversity is a measure of early language development that has yet to be applied to individuals with autism spectrum disorder (ASD). The primary aim of this study was to identify whether children with ASD show change in sentence diversity over 6 months of treatment with Naturalistic Developmental Behavioral Intervention (NDBI). The secondary aim was to examine possible predictors of changes in children's sentence diversity, including caregiver use of NDBI strategies, naturally occurring instances of caregiver Toy Talk, and child characteristics. Method: Fifty children with ASD (ages 2-4 years) and their caregivers, who were receiving NDBI, engaged in two 10-min video-recorded play interactions, 6 months apart. Child speech was transcribed and coded for sentence diversity. Caregiver input was transcribed and coded for naturally occurring Toy Talk. Zero-inflated negative binomial mixed models were used to explore predictors of change in child sentence diversity. Results: Children's sentence diversity improved over time. Changes in caregiver NDBI strategy use and caregiver baseline Toy Talk were significant predictors of changes in sentence diversity, as were baseline age, nonverbal ratio IQ, and child sex. Additionally, a significant interaction of caregiver baseline Toy Talk and change in caregiver NDBI strategies emerged; the effect of caregiver baseline Toy Talk on children's sentence diversity change was stronger when NDBI strategy use improved. Conclusions: Sentence diversity is a developmentally sensitive measure of language development in ASD. NDBI strategies that facilitate reciprocal social communication, combined with input composed of declarative sentences with noun or third-person pronoun subjects, may provide optimal support for children's sentence development.";"[Clark-Whitney, Elysha; Klein, Claire Brito; Kim, So Hyun] Weill Cornell Med, Ctr Autism & Developing Brain, New York, NY 10021 USA; [Hadley, Pamela A.] Univ Illinois, Urbana, IL USA; [Lord, Catherine] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA";"Cornell University; Weill Cornell Medicine; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Los Angeles";Kim, SH (corresponding author), Weill Cornell Med, Ctr Autism & Developing Brain, New York, NY 10021 USA.;sok2015@med.cornell.edu;"Brito Klein, Claire/IUM-2481-2023; Hadley, Pamela/P-7161-2017; Kim, So Hyun/AAA-4396-2022";"Brito Klein, Claire/0000-0002-3480-2066; Kim, So Hyun/0000-0003-4269-0866; Clark-Whitney, Elysha/0000-0003-2828-7202; Hadley, Pamela/0000-0001-6814-8288; Lord, Catherine/0000-0001-5633-1253";National Institute of Mental Health [1R01 MH114925];National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH));This study was funded by the National Institute of Mental Health (1R01 MH114925), awarded to author So Hyun Kim. The authors would like to thank all of the families who participated in this study for their time. They would also like to thank their data manager Shanping Qui for her efforts coordinating this data set, as well as to the research assistants who coded the interaction videos.;"[Anonymous], 2014, SIG 1 PERSPECTIVES L, DOI DOI 10.1044/LLE21.4.159; [Anonymous], 2015, FINDINGS CONCLUSIONS; Bergelson E, 2019, DEVELOPMENTAL SCI, V22, DOI 10.1111/desc.12715; Bono MA, 2004, J AUTISM DEV DISORD, V34, P495, DOI 10.1007/s10803-004-2545-x; Brooks ME, 2017, R J, V9, P378, DOI 10.32614/RJ-2017-066; Charman T, 2005, J CHILD PSYCHOL PSYC, V46, P500, DOI 10.1111/j.1469-7610.2004.00377.x; Crandall MC, 2019, J SPEECH LANG HEAR R, V62, P1787, DOI 10.1044/2019_JSLHR-L-18-0081; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; Eigsti IM, 2007, J AUTISM DEV DISORD, V37, P1007, DOI 10.1007/s10803-006-0239-2; Eriksson M, 2012, BRIT J DEV PSYCHOL, V30, P326, DOI 10.1111/j.2044-835X.2011.02042.x; Esler AN, 2015, J AUTISM DEV DISORD, V45, P2704, DOI 10.1007/s10803-015-2432-7; Fusaroli R, 2019, COGNITION, V183, P1, DOI 10.1016/j.cognition.2018.10.022; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Hadley PA, 2020, J SPEECH LANG HEAR R, V63, P3236, DOI 10.1044/2020_JSLHR-20-00031; Hadley PA, 2018, AM J SPEECH-LANG PAT, V27, P553, DOI 10.1044/2017_AJSLP-17-0098; Hadley PA, 2017, J SPEECH LANG HEAR R, V60, P2619, DOI 10.1044/2017_JSLHR-L-17-0008; Hadley PA, 2017, LANG LEARN DEV, V13, P54, DOI 10.1080/15475441.2016.1193020; Hadley PA, 2014, LANG SPEECH HEAR SER, V45, P159, DOI 10.1044/2014_LSHSS-13-0055; Hadley PA, 2014, J SPEECH LANG HEAR R, V57, P887, DOI 10.1044/2013_JSLHR-L-13-0008; Hadley PA, 2014, LANG SPEECH HEAR SER, V45, P110, DOI 10.1044/2014_LSHSS-14-0017; Hus V, 2014, J AUTISM DEV DISORD, V44, P2400, DOI 10.1007/s10803-012-1719-1; Kasari C, 2015, J CONSULT CLIN PSYCH, V83, P554, DOI 10.1037/a0039080; Kim S.H., 2014, HDB AUTISM PERVASIVE, V4th ed., P230; Klee T., 2010, LARSP REFERENCE DATA; Klinger LG, 2021, J CLIN CHILD ADOLESC, V50, P517, DOI 10.1080/15374416.2020.1833735; Lee L.L., 1974, DEV SENTENCE ANAL GR; LeGrand KJ, 2021, J SPEECH LANG HEAR R, V64, DOI 10.1044/2021_JSLHR-20-00544; Lenth Russell V, 2024, CRAN; Lord C., 2014, AUTISM DIAGNOSTIC OB; Luyster RJ, 2008, J AUTISM DEV DISORD, V38, P1426, DOI 10.1007/s10803-007-0510-1; Maglione MA, 2012, PEDIATRICS, V130, pS169, DOI 10.1542/peds.2012-0900O; Mazerolle M.J, 2020, AICCMODAVG MODEL SEL; Mazurek MO, 2019, AJIDD-AM J INTELLECT, V124, P438, DOI 10.1352/1944-7558-124.5.438; Miller J.Iglesias., 2012, SALT SYSTEMATIC ANAL; Mullen E. M., 1995, J CHILD LANG, V17, P357, DOI [10.1017/S0305000900013817, DOI 10.1017/S0305000900013817]; Paul R, 2013, J AUTISM DEV DISORD, V43, P418, DOI 10.1007/s10803-012-1583-z; Paul R, 2008, AUTISM RES, V1, P97, DOI 10.1002/aur.12; Pickles A, 2014, J CHILD PSYCHOL PSYC, V55, P1354, DOI 10.1111/jcpp.12269; Rapin I, 1988, Res Publ Assoc Res Nerv Ment Dis, V66, P57; Rispoli M., 2018, Proceedings of the 42nd Annual Boston University Conference on Language Development, P673; Roberts MY, 2011, AM J SPEECH-LANG PAT, V20, P180, DOI 10.1044/1058-0360(2011/10-0055); Roemer EJ, 2022, J AUTISM DEV DISORD, V52, P1984, DOI 10.1007/s10803-021-05099-1; SCARBOROUGH HS, 1991, APPL PSYCHOLINGUIST, V12, P23, DOI 10.1017/S014271640000936X; Schreibman L, 2015, J AUTISM DEV DISORD, V45, P2411, DOI 10.1007/s10803-015-2407-8; Thurm A, 2007, J AUTISM DEV DISORD, V37, P1721, DOI 10.1007/s10803-006-0300-1; UCLA Statistical Consulting Group, 2021, DEC PROB PLOT INT R; Van Hulle CA, 2004, J SPEECH LANG HEAR R, V47, P904, DOI 10.1044/1092-4388(2004/067); Vibert BA, 2020, J AUTISM DEV DISORD, V50, P1364, DOI 10.1007/s10803-019-04342-0; Vivanti G., 2020, Clinical guide to early interventions for children with autism, P93, DOI [DOI 10.1007/978-3-030-41160-2, 10.1007/978-3-030-41160-2, DOI 10.1007/978-3-030-41160-2_6]; Weismer SE, 2015, J CHILD PSYCHOL PSYC, V56, P1327, DOI 10.1111/jcpp.12406; Weismer SE, 2010, J AUTISM DEV DISORD, V40, P1259, DOI 10.1007/s10803-010-0983-1; Weitzman E., 2014, TREATMENT LANGUAGE D, V2nd, P27; Wetherby AM, 2014, PEDIATRICS, V134, P1084, DOI 10.1542/peds.2014-0757";53;7;9;1;14;AMER SPEECH-LANGUAGE-HEARING ASSOC;ROCKVILLE;2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA;1092-4388;1558-9102;;J SPEECH LANG HEAR R;J. Speech Lang. Hear. Res.;APR;2022;65;4;;;;;1465;1477;;10.1044/2021_JSLHR-21-00458;http://dx.doi.org/10.1044/2021_JSLHR-21-00458;;;13;"Audiology & Speech-Language Pathology; Linguistics; Rehabilitation";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Audiology & Speech-Language Pathology; Linguistics; Rehabilitation";3F9AW;35230878;Green Published;;;24/11/2024;WOS:000830953900016;View Full Record in Web of Science
J;"Coleman, DM; Adams, JB; Anderson, AL; Frye, RE";;;;"Coleman, Devon M.; Adams, James B.; Anderson, Amy L.; Frye, Richard E.";;;Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism spectrum disorders; medications; psychiatric medications; seizure medications; online survey";"PHARMACOLOGICAL-TREATMENT; BEHAVIORAL SYMPTOMS; CHILDREN; COMORBIDITIES; EFFICACY; IRRITABILITY; THERAPIES; CLONIDINE; MERCURY; HAIR";"Objective: The objective of this study was to provide an evaluation of the benefits and adverse effects (AEs) of psychiatric and seizure medications commonly used for individuals with autism spectrum disorder (ASD). Methods: As part of the National Survey on Treatment Effectiveness for Autism, we report ratings of 26 psychiatric and seizure medications by 505 participants. Each medication was rated with a standardized scale for overall benefits, overall AEs, and specific symptoms affected. The frequency of use and net perceived benefit (overall benefit minus overall AE) are reported. Results: Most medications were rated as having a slightly greater benefit than AE. Six medications (lamotrigine, oxcarbazepine, clonidine, guanfacine, buspirone, and sertraline) had benefit ratings that were more than twice their adverse rating. Conversely, some medications had slightly negative net benefit ratings (worse AEs than benefits on average), including Adderall, Paroxetine, Quetiapine, Olanzapine, and Topiramate. However, there were wide variations in individual ratings of benefit and AEs, suggesting that clinical response to medications was highly variable, so these scores simply represent averages. A ranking of the top medications (those with the highest net perceived benefit) for each of 18 different symptoms is provided, which may provide some clinical guidance as to which medications may be most worth considering for a given symptom. A comparison of the survey results with the results of clinical trials shows generally good agreement in terms of medication benefits with some differences; in some cases the differences are because the clinical trials did not assess all of the symptoms assessed by this survey. Conclusions: It is hoped that physicians and their patients will find the survey results useful in selecting the most promising medications for a given symptom, and also for monitoring for likely benefits and AEs, especially for medications for which few or no studies have been carried out in ASD populations.";"[Coleman, Devon M.; Adams, James B.; Anderson, Amy L.] Arizona State Univ, Autism Aspergers Res Program, POB 876106, Tempe, AZ 85287 USA; [Frye, Richard E.] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA";"Arizona State University; Arizona State University-Tempe; Phoenix Children's Hospital; Barrow Neurological Institute";Adams, JB (corresponding author), Arizona State Univ, Autism Aspergers Res Program, POB 876106, Tempe, AZ 85287 USA.;jim.adams@asu.edu;"Anderson, Amy/KDO-2505-2024; Frye, Richard/AAB-5543-2020";Anderson, Amy/0009-0003-7324-2406;;;;"Abdallah MW, 2011, EUR CHILD ADOLES PSY, V20, P599, DOI 10.1007/s00787-011-0220-2; Adams J. B., 2008, Toxicological and Environmental Chemistry, V90, P739, DOI 10.1080/02772240701699294; Adams JB, 2007, J TOXICOL ENV HEAL A, V70, P1046, DOI 10.1080/15287390601172080; Adams JB, 2006, BIOL TRACE ELEM RES, V110, P193, DOI 10.1385/BTER:110:3:193; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; Autism Research Institute, 2009, USITC PUBL, V34; Bishop JR, 2015, PHARMACOGENET GENOM, V25, P548, DOI 10.1097/FPC.0000000000000173; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Doyle CA, 2012, EXPERT OPIN PHARMACO, V13, P1615, DOI 10.1517/14656566.2012.674110; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Frye RE, 2016, CLIN MED INSIGHTS-PE, V10, P43, DOI 10.4137/CMPed.S38337; Frye Richard E, 2013, Front Public Health, V1, P31, DOI 10.3389/fpubh.2013.00031; Frye RE, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-37; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Ghanizadeh A, 2015, PEDIATR NEUROL, V52, P77, DOI 10.1016/j.pediatrneurol.2014.09.017; Ghanizadeh A, 2013, J ATTEN DISORD, V17, P635, DOI 10.1177/1087054712443154; Goin-Kochel RP, 2009, RES AUTISM SPECT DIS, V3, P528, DOI 10.1016/j.rasd.2008.11.001; Houghton R, 2017, AUTISM RES, V10, P2037, DOI 10.1002/aur.1848; JASELSKIS CA, 1992, J CLIN PSYCHOPHARM, V12, P322; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Kolevzon A, 2006, J CLIN PSYCHIAT, V67, P407, DOI 10.4088/JCP.v67n0311; KONSTANTAREAS MM, 1987, J AUTISM DEV DISORD, V17, P585, DOI 10.1007/BF01486973; LeClerc Sheena, 2015, P T, V40, P389; Masi G, 2015, PEDIATR DRUGS, V17, P125, DOI 10.1007/s40272-015-0119-3; Ming X, 2008, BRAIN DEV-JPN, V30, P454, DOI 10.1016/j.braindev.2007.12.007; Niehus R, 2006, J DEV BEHAV PEDIATR, V27, pS120, DOI 10.1097/00004703-200604002-00010; Owen-Smith AA, 2015, RES AUTISM SPECT DIS, V17, P40, DOI 10.1016/j.rasd.2015.05.002; Reichow B, 2013, J AUTISM DEV DISORD, V43, P2435, DOI 10.1007/s10803-013-1793-z; Sochocky N, 2013, CURR CLIN PHARMACOL, V8, P370, DOI 10.2174/15748847113086660073; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2; Wink LK, 2010, CURR TREAT OPTION NE, V12, P529, DOI 10.1007/s11940-010-0091-8";32;30;31;0;7;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;mars-01;2019;29;2;;;;;107;123;;10.1089/cap.2018.0121;http://dx.doi.org/10.1089/cap.2018.0121;;;17;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";HU5EO;30724573;Green Submitted, hybrid, Green Published;;;24/11/2024;WOS:000465299300005;View Full Record in Web of Science
J;"Wink, LK; Pedapati, EV; Horn, PS; McDougle, CJ; Erickson, CA";;;;"Wink, Logan K.; Pedapati, Ernest V.; Horn, Paul S.; McDougle, Christopher J.; Erickson, Craig A.";;;Multiple Antipsychotic Medication Use in Autism Spectrum Disorder;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism; autism spectrum disorder; antipsychotics; physcopharmacology; irritability";"CHILDREN; ADOLESCENTS; POLYPHARMACY; ARIPIPRAZOLE; PROGRAM";Objective: The purpose of this study was to explore the use of multiple antipsychotic medications in patients with autism spectrum disorder (ASD) by reviewing the longitudinal medication management of 1100 patients consecutively treated for behavioral symptoms associated with ASD at a tertiary care specialty clinic. Methods: We identified all patients with ASD treated with daily doses of two or more antipsychotics for at least two visits at our clinic. For each patient meeting inclusion criteria, diagnostic and demographic data were collected. To evaluate clinical need and effectiveness of antipsychotic medications in this sample, we reviewed symptoms targeted with each antipsychotic medication and concomitant medications prescribed. Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scale ratings had been completed at the time of each visit, and the duration of treatment with antipsychotic medications was determined. To evaluate the safety and tolerability of antipsychotic medication use in ASD, we reviewed reported adverse effects and calculated body mass index (BMI) change with treatment. Results: Seventy patients met the inclusion criteria (6.4% of our sample). The majority of patients were moderately to severely ill Caucasian males, as determined by baseline mean CGI-S of 4.7 (SD=0.8), and were diagnosed with autistic disorder and comorbid intellectual disability. The mean age was 15.1 years (SD=10.9), the primary targeted symptoms were agitation/irritability, physical aggression, and self-injury. The majority of patients remained on two or more antipsychotics for >1 year. In this population, patients demonstrated greater symptomatic improvement and generally tolerated treatment without significant adverse effects. Conclusions: The use of two or more antipsychotic medications may be increasingly common in patients with ASD. This retrospective study demonstrates that this treatment approach may be of some clinical benefit, and is generally well tolerated. Prospective studies focusing on the efficacy and safety of concomitant antipsychotic medication usage in ASD should be considered.;"[Wink, Logan K.; Pedapati, Ernest V.; Horn, Paul S.; Erickson, Craig A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA; [McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Lurie Ctr Autism, Boston, MA USA; [McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Lurie Ctr Autism, Boston, MA USA; [McDougle, Christopher J.] Harvard Med Sch, MassGen Hosp Children, Boston, MA USA";"University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Harvard University; Massachusetts General Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital";Wink, LK (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.;logan.wink@cchmc.org;"Erickson, Craig/M-8933-2017; pedapati, ernest/GPT-0086-2022; Horn, Paul/LPA-6457-2024";;"Indiana University School of Medicine Department of Psychiatry; Autism Speaks; John Merck Fund; Riovant Sciences Ltd.; Simons Research Foundation; SynapDx; United Stated Department of Defense";"Indiana University School of Medicine Department of Psychiatry; Autism Speaks; John Merck Fund; Riovant Sciences Ltd.; Simons Research Foundation; SynapDx; United Stated Department of Defense";This work was supported by the Indiana University School of Medicine Department of Psychiatry. Dr. Wink's current research is supported by Autism Speaks, the John Merck Fund, Riovant Sciences Ltd., the Simons Research Foundation, SynapDx, and the United Stated Department of Defense.;"Adler BA, 2015, AUTISM, V19, P102, DOI 10.1177/1362361314524641; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Cohen I L, 1980, Psychopharmacol Bull, V16, P63; Constantine RJ, 2010, CLIN THER, V32, P949, DOI 10.1016/j.clinthera.2010.04.021; Gallego JA, 2012, EXPERT OPIN DRUG SAF, V11, P527, DOI 10.1517/14740338.2012.683523; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Politte LC, 2014, PSYCHOPHARMACOLOGY, V231, P1023, DOI 10.1007/s00213-013-3068-y; Saldaña SN, 2014, PHARMACOTHERAPY, V34, P836, DOI 10.1002/phar.1453; Schubart JR, 2014, AUTISM, V18, P631, DOI 10.1177/1362361313497537; Spencer D, 2013, PEDIATRICS, V132, P833, DOI 10.1542/peds.2012-3774; Stigler KA, 2014, CHILD ADOL PSYCH CL, V23, P73, DOI 10.1016/j.chc.2013.07.005; Toteja N, 2014, INT J NEUROPSYCHOPH, V17, P1095, DOI 10.1017/S1461145712001320; Wink LK, 2014, J CHILD ADOL PSYCHOP, V24, P78, DOI 10.1089/cap.2013.0099";14;14;17;0;14;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;FEB;2017;27;1;;;;;91;+;;10.1089/cap.2015.0123;http://dx.doi.org/10.1089/cap.2015.0123;;;5;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";EL1JJ;26465194;Green Published;;;24/11/2024;WOS:000394376300012;View Full Record in Web of Science
J;"Landa, RJ; Holman, KC; O'Neill, AH; Stuart, EA";;;;"Landa, Rebecca J.; Holman, Katherine C.; O'Neill, Allison H.; Stuart, Elizabeth A.";;;Intervention targeting development of socially synchronous engagement in toddlers with autism spectrum disorder: a randomized controlled trial;JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY;;;English;Article;;;;;;"Autistic disorder; intervention";"JOINT ATTENTION; YOUNG-CHILDREN; COMMUNICATION DEVELOPMENT; PRETEND PLAY; 2ND YEAR; LANGUAGE; IMITATION; PREDICTORS; OUTCOMES; INFANTS";"Background: Social and communication impairments are core deficits and prognostic indicators of autism. We evaluated the impact of supplementing a comprehensive intervention with a curriculum targeting socially synchronous behavior on social outcomes of toddlers with autism spectrum disorders (ASD). Methods: Fifty toddlers with ASD, ages 21 to 33 months, were randomized to one of two six-month interventions: Interpersonal Synchrony or Non-Interpersonal Synchrony. The interventions provided identical intensity (10 hours per week in classroom), student-to-teacher ratio, schedule, home-based parent training (1.5 hours per month), parent education (38 hours), and instructional strategies, except the Interpersonal Synchrony condition provided a supplementary curriculum targeting socially engaged imitation, joint attention, and affect sharing; measures of these were primary outcomes. Assessments were conducted pre-intervention, immediately post-intervention, and, to assess maintenance, at six-month follow-up. Random effects models were used to examine differences between groups over time. Secondary analyses examined gains in expressive language and nonverbal cognition, and time effects during the intervention and follow-up periods. Results: A significant treatment effect was found for socially engaged imitation (p = .02), with more than doubling (17% to 42%) of imitated acts paired with eye contact in the Interpersonal Synchrony group after the intervention. This skill was generalized to unfamiliar contexts and maintained through follow-up. Similar gains were observed for initiation of joint attention and shared positive affect, but between-group differences did not reach statistical significance. A significant time effect was found for all outcomes (p < .001); greatest change occurred during the intervention period, particularly in the Interpersonal Synchrony group. Conclusions: This is the first ASD randomized trial involving toddlers to identify an active ingredient for enhancing socially engaged imitation. Adding social engagement targets to intervention improves short-term outcome at no additional cost to the intervention. The social, language, and cognitive gains in our participants provide evidence for plasticity of these developmental systems in toddlers with ASD. http://www.clinicaltrials.gov/ct2/show/NCT00106210?term = landa&rank = 3.";"[Landa, Rebecca J.] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Ctr Autism & Related Disorders,Dept Psychiat & Be, Baltimore, MD USA; [Holman, Katherine C.] Towson Univ, Dept Special Educ, Towson, MD USA; [O'Neill, Allison H.] Univ Maryland, Sch Publ Hlth, Dept Epidemiol & Biostat, College Pk, MD 20742 USA; [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA; [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA";"Kennedy Krieger Institute; Johns Hopkins University; University System of Maryland; Towson University; University System of Maryland; University of Maryland College Park; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health";Landa, RJ (corresponding author), 3901 Greenspring Ave, Baltimore, MD 21211 USA.;landa@kennedykrieger.org;;Stuart, Elizabeth/0000-0002-9042-8611;"National Institute of Mental Health [154-MH066417]; HRSA [R40 MC 15594]";"National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))";"Rebecca Landa (PI) thanks the National Institute of Mental Health (154-MH066417; Studies to Advance Autism Research and Treatment) and HRSA (R40 MC 15594) for the funding to conduct this study and prepare this manuscript.";"BARSALOU L, 2007, STAT STAT SOFTW REL, V8, P79; Bono MA, 2004, J AUTISM DEV DISORD, V34, P495, DOI 10.1007/s10803-004-2545-x; Booth AE, 2002, DEV PSYCHOL, V38, P948, DOI 10.1037//0012-1649.38.6.948; Bricker D., 2002, ASSESS EVAL HIGH EDU, V2nd; CARR EG, 1978, J APPL BEHAV ANAL, V11, P489, DOI 10.1901/jaba.1978.11-489; Chandler S, 2002, AUTISM, V6, P47, DOI 10.1177/1362361302006001005; Charman T, 1997, DEV PSYCHOL, V33, P781, DOI 10.1037/0012-1649.33.5.781; Charman T, 2003, INT J LANG COMM DIS, V38, P265, DOI 10.1080/136820310000104830; Chawarska K, 2007, J CHILD PSYCHOL PSYC, V48, P128, DOI 10.1111/j.1469-7610.2006.01685.x; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; Drew A, 2002, EUR CHILD ADOLES PSY, V11, P266, DOI 10.1007/s00787-002-0299-6; Harris SL, 2000, J AUTISM DEV DISORD, V30, P137, DOI 10.1023/A:1005459606120; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Ingersoll B, 2006, J AUTISM DEV DISORD, V36, P487, DOI 10.1007/s10803-006-0089-y; Kasari C, 2006, J CHILD PSYCHOL PSYC, V47, P611, DOI 10.1111/j.1469-7610.2005.01567.x; Kasari C, 2008, J CONSULT CLIN PSYCH, V76, P125, DOI 10.1037/0022-006X.76.1.125; Koegel R., 1989, How to teach pivotal behaviors to children with autism; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Landa RJ, 2007, ARCH GEN PSYCHIAT, V64, P853, DOI 10.1001/archpsyc.64.7.853; Lord C., 1993, PRESCHOOL ISSUES AUT, P199; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; Mullen EM., 1995, MULLEN SCALES EARLY; Mundy P, 2009, AUTISM RES, V2, P2, DOI 10.1002/aur.61; Rogers SJ, 2008, J CLIN CHILD ADOLESC, V37, P8, DOI 10.1080/15374410701817808; Rogers SJ, 2003, J CHILD PSYCHOL PSYC, V44, P763, DOI 10.1111/1469-7610.00162; Schertz HH, 2007, J AUTISM DEV DISORD, V37, P1562, DOI 10.1007/s10803-006-0290-z; Sigman M., 1999, Monographs of the Society for Research in Child Development, V64, P114; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; SPEIDEL GE, 1998, MANY FACES IMITATION; Stahmer AC, 2004, J POSIT BEHAV INTERV, V6, P67, DOI 10.1177/10983007040060020201; StataCorp, 2021, Stata statistical software: Release 17; Toth K, 2006, J AUTISM DEV DISORD, V36, P993, DOI 10.1007/s10803-006-0137-7; Wetherby A., 2002, CSBS DP MANUAL COMMU; Wetherby AM, 2007, J AUTISM DEV DISORD, V37, P960, DOI 10.1007/s10803-006-0237-4";37;222;260;6;69;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0021-9630;1469-7610;;J CHILD PSYCHOL PSYC;J. Child Psychol. Psychiatry;JAN;2011;52;1;;;;;13;21;;10.1111/j.1469-7610.2010.02288.x;http://dx.doi.org/10.1111/j.1469-7610.2010.02288.x;;;9;"Psychology, Developmental; Psychiatry; Psychology";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";691WR;21126245;Green Accepted;;;24/11/2024;WOS:000285112000003;View Full Record in Web of Science
J;"Hermans, RA; Ringeling, LT; Liang, KJ; Kloosterboer, SM; de Winter, BCM; Hillegers, MHJ; Koch, BCP; Dierckx, B";;;;"Hermans, Rebecca A.; Ringeling, Lisa T.; Liang, Kajie; Kloosterboer, Sanne M.; de Winter, Brenda C. M.; Hillegers, Manon H. J.; Koch, Birgit C. P.; Dierckx, Bram";;;The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial;BMC PSYCHIATRY;;;English;Article;;;;;;"Randomised controlled trial; Antipsychotic drugs; Risperidone; Aripiprazole; Children; Adolescents; Autism spectrum disorder; Therapeutic drug monitoring; Pharmacokinetics; Pharmacodynamics";"DRIED BLOOD SPOTS; ATYPICAL ANTIPSYCHOTICS; RATING-SCALE; PHARMACOKINETICS; PREVALENCE; RISK";Background: Antipsychotic drugs are an important part of the treatment of irritability and aggression in children with an autism spectrum disorder (ASD). However, significant weight gain and metabolic disturbances are clinically relevant side effects of antipsychotic use in children. In the SPACe study, we showed positive correlations between both risperidone and aripiprazole plasma trough concentrations and weight gain over a 6-month period. The trial SPACe 2: STAR is designed as a follow-up study, in which we aim to research whether therapeutic drug monitoring in clinical practice can prevent severe weight gain, while retaining clinical effectiveness. Methods: SPACe 2: STAR is an international, multicentre, randomised controlled trial (RCT). One hundred forty children aged 6 to 18 who are about to start risperidone or aripiprazole treatment for ASD related behavioural problems will be randomised into one of two groups: a therapeutic drug monitoring (TDM) group, and a care as usual (CAU) group. Participants will be assessed at baseline and 4, 10, 24, and 52 weeks follow-up. In the TDM group, physicians will receive dosing advice based on plasma levels of risperidone and aripiprazole and its metabolites at 4 and 10 weeks. Plasma levels will be measured in dried blood spots (DBS). The primary outcome will be BMI z-score at 24 weeks after start of antipsychotic treatment. Among the secondary outcomes are effectiveness, metabolic laboratory measurements, levels of prolactin, leptin and ghrelin, extrapyramidal side effects, and quality of life. Discussion: This will be the first RCT evaluating the effect of TDM of antipsychotic drugs in children and adolescents. Thus, findings from SPACe 2: STAR will be of great value in optimising treatment in this vulnerable population.;"[Hermans, Rebecca A.; Ringeling, Lisa T.; Kloosterboer, Sanne M.; Hillegers, Manon H. J.; Dierckx, Bram] Erasmus MC, Dept Child & Adolescent Psychiat Psychol, POB 2060, NL-3000 CB Rotterdam, Netherlands; [Hermans, Rebecca A.; Ringeling, Lisa T.; Liang, Kajie; de Winter, Brenda C. M.; Koch, Birgit C. P.] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands; [Hermans, Rebecca A.; Ringeling, Lisa T.; Liang, Kajie; de Winter, Brenda C. M.; Koch, Birgit C. P.] Erasmus MC, Rotterdam Clin Pharmacometr Grp, Rotterdam, Netherlands";"Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC";"Ringeling, LT (corresponding author), Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands.;Ringeling, LT (corresponding author), Erasmus MC, Rotterdam Clin Pharmacometr Grp, Rotterdam, Netherlands.";l.ringeling@erasmusmc.nl;hillegers, manon/L-6794-2016;Ringeling, Lisa/0000-0002-9354-6429;"Netherlands Organisation for Health Research and Development ZonMw; Stichting de Merel, Erasmus University Medical Center MRace [10140022010011]; Erasmus University Medical Center";"Netherlands Organisation for Health Research and Development ZonMw(Netherlands Organization for Health Research and Development); Stichting de Merel, Erasmus University Medical Center MRace; Erasmus University Medical Center";This project has received funding from the Netherlands Organisation for Health Research and Development ZonMw (Project number 10140022010011), Stichting de Merel, Erasmus University Medical Center MRace Grant, and the Department of Hospital Pharmacy from Erasmus Univer-sity Medical Center. The funders approved the design of the trial, but will have no role in the collection, analysis and interpretation of data or in writing manuscripts or the decision to publish.;"Aman MG, 2002, AM J PSYCHIAT, V159, P1337, DOI 10.1176/appi.ajp.159.8.1337; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2009, WERKGROEP RICHTLIJN; Bais Y, 2023, EUR CHILD ADOLES PSY, V32, P1427, DOI 10.1007/s00787-022-01949-0; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Caccia S, 2013, PEDIATR DRUGS, V15, P217, DOI 10.1007/s40272-013-0024-6; Cohen D, 2012, J CLIN PSYCHOPHARM, V32, P309, DOI 10.1097/JCP.0b013e3182549259; de Bruin EI, 2007, J AUTISM DEV DISORD, V37, P877, DOI 10.1007/s10803-006-0215-x; Guy W., 1976, ECDEU ASSESSMENT MAN; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Juonala M, 2011, NEW ENGL J MED, V365, P1876, DOI 10.1056/NEJMoa1010112; Kloosterboer SM, 2020, THER DRUG MONIT, V42, P648, DOI 10.1097/FTD.0000000000000776; Kloosterboer SM, 2018, THER DRUG MONIT, V40, P344, DOI 10.1097/FTD.0000000000000502; Kloosterboer SM, 2021, BRIT J CLIN PHARMACO, V87, P1069, DOI 10.1111/bcp.14465; LANE RD, 1985, J NERV MENT DIS, V173, P353, DOI 10.1097/00005053-198506000-00005; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Mauri MC, 2007, CLIN PHARMACOKINET, V46, P359, DOI 10.2165/00003088-200746050-00001; Meyer JM, 2004, SCHIZOPHR RES, V70, P1, DOI 10.1016/j.schres.2004.01.014; Nielsen RE, 2014, J AM ACAD CHILD PSY, V53, P971, DOI 10.1016/j.jaac.2014.04.023; Ogden CL, 2016, JAMA-J AM MED ASSOC, V315, P2292, DOI 10.1001/jama.2016.6361; Schoretsanitis G, 2018, WORLD J BIOL PSYCHIA, V19, P162, DOI 10.1080/15622975.2018.1439595; SIMPSON GM, 1970, ACTA PSYCHIAT SCAND, P11; Stevens J, 2006, INT J OBESITY, V30, P391, DOI 10.1038/sj.ijo.0803175; Tron C, 2017, THER DRUG MONIT, V39, P429, DOI 10.1097/FTD.0000000000000411; van der Esch CCL, 2021, EUR CHILD ADOLES PSY, V30, P1263, DOI 10.1007/s00787-020-01614-4; Viecili MA, 2015, AJIDD-AM J INTELLECT, V120, P289, DOI 10.1352/1944-7558-120.4.289; WILLIAMS A, 1990, HEALTH POLICY, V16, P199";29;5;6;0;3;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;DEC 20;2022;22;1;;;;;;;814;10.1186/s12888-022-04445-6;http://dx.doi.org/10.1186/s12888-022-04445-6;;;8;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;7F4CA;36539734;Green Published, gold;;;24/11/2024;WOS:000901796500005;View Full Record in Web of Science
J;"Kitzerow, J; Hackbusch, M; Jensen, K; Kieser, M; Noterdaeme, M; Fröhlich, U; Taurines, R; Geissler, J; Wolff, N; Roessner, V; Bast, N; Teufel, K; Kim, Z; Freitag, CM";;;;"Kitzerow, Janina; Hackbusch, Matthes; Jensen, Katrin; Kieser, Meinhard; Noterdaeme, Michele; Froehlich, Ulrike; Taurines, Regina; Geissler, Julia; Wolff, Nicole; Roessner, Veit; Bast, Nico; Teufel, Karoline; Kim, Ziyon; Freitag, Christine M.";;;Study protocol of the multi-centre, randomised controlled trial of the Frankfurt Early Intervention Programme A-FFIP versus early intervention as usual for toddlers and preschool children with Autism Spectrum Disorder (A-FFIP study);TRIALS;;;English;Article;;;;;;"Autism spectrum disorder; NDBI; ASD-specific; Early intervention; A-FFIP; Randomised trial";"DEVELOPMENTAL BEHAVIORAL INTERVENTIONS; SOCIAL COMMUNICATION INTERVENTION; QUALITY-OF-LIFE; YOUNG-CHILDREN; JOINT ATTENTION; REPETITIVE BEHAVIOR; ASD; OUTCOMES; PLAY; INDIVIDUALS";BackgroundNaturalistic developmental behavioural interventions (NDBI) have been shown to improve autism-specific symptoms in young children with Autism Spectrum Disorder (ASD). NDBI approaches, such as the ASD-specific Frankfurt Early Intervention Programme for ASD (A-FFIP), are based on ASD-specific developmental and learning aspects. A-FFIP is a low-intensity intervention which can easily be implemented in the local health care/social welfare system. The aim of the present study is to establish 1-year efficacy of the manualised early intervention programme A-FFIP in toddlers and preschool children with ASD. It is hypothesised that A-FFIP will result in improved ASD-specific symptoms compared to early intervention as usual (EIAU). Child- and family-specific secondary outcomes, as well as moderators and mediators of outcome, will be explored.Methods/designA prospective, multi-centre, parallel-group, randomised controlled, phase-III trial comparing A-FFIP versus EIAU. A total of 134 children (A-FFIP: 67, EIAU: 67) aged 24-66months at baseline assessment meeting the criteria for ASD (DSM-5) will be included. The primary outcome is the absolute change of the total score of the Brief Observation of Social Communication Change (BOSCC-AT) between baseline (T2) and 1-year follow-up (T6). The treatment effect will be tested, adjusted for relevant covariates applying a mixed model for repeated measures. Secondary outcomes are BOSCC social communication and repetitive-behaviour scores, single ASD symptoms, language, cognition, psychopathology, parental well-being and family quality of life. Predictors, moderators and mediating mechanisms will be explored.DiscussionIf efficacy of the manualised A-FFIP early intervention is established, the current study has the potential to change clinical practice strongly towards the implementation of a low-intensity, evidence-based, natural early intervention in ASD. Early intervention in ASD requires specialist training, which subsequently needs to be developed or included into current training curricula.;"[Kitzerow, Janina; Bast, Nico; Teufel, Karoline; Kim, Ziyon; Freitag, Christine M.] Goethe Univ, Univ Hosp Frankfurt, Autism Therapy & Res Ctr Excellence, Dept Child & Adolescent Psychiat Psychosomat & Ps, Deutschordenstr 50, D-60528 Frankfurt, Germany; [Hackbusch, Matthes; Jensen, Katrin; Kieser, Meinhard] Univ Hosp Heidelberg, IMBI, Neuenheimer Feld 130-3, D-69120 Heidelberg, Germany; [Noterdaeme, Michele; Froehlich, Ulrike] Josefinum Augsburg, Dept Child & Adolescent Psychiat & Psychotherapy, Kapellenstr 30, D-86154 Augsburg, Germany; [Taurines, Regina; Geissler, Julia] Univ Hosp Wurzburg, Dept Child & Adolescent Psychiat Psychosomat & Ps, Ctr Mental Hlth, Margarete Hoppel Pl 1, D-97080 Wurzburg, Germany; [Wolff, Nicole; Roessner, Veit] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dept Child & Adolescent Psychiat, Fetscherstr 74, D-01307 Dresden, Germany";"Goethe University Frankfurt; Goethe University Frankfurt Hospital; Ruprecht Karls University Heidelberg; University of Wurzburg; Technische Universitat Dresden; Carl Gustav Carus University Hospital";Freitag, CM (corresponding author), Goethe Univ, Univ Hosp Frankfurt, Autism Therapy & Res Ctr Excellence, Dept Child & Adolescent Psychiat Psychosomat & Ps, Deutschordenstr 50, D-60528 Frankfurt, Germany.;c.freitag@em.uni-frankfurt.de;"Kitzerow, Janina/HHM-2208-2022; Bast, Nico/X-5948-2019; Roessner, Veit/AAQ-8760-2020";"Freitag, Christine Margarete/0000-0001-9676-4782; Kitzerow-Cleven, Janina/0000-0002-1077-9519; Geissler, Julia/0000-0003-1878-9647; Roessner, Veit/0000-0002-1873-7081; Bast, Nico/0000-0001-5721-207X";"German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) [FR 2069/8-1]; Deutsche Forschungsgemeinschaft e.V., Bonn, Germany";"German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft e.V., Bonn, Germany";"This study is funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) Project number: FR 2069/8-1; Deutsche Forschungsgemeinschaft e.V., Kennedyallee 40, 53175 Bonn, Germany, telephone: + 49 (228) 885-1. The funding agency does not have a role in study design, data collection and management, analysis and interpretation of data; writing of the report; or the decision to submit the report for publication.";"Achenbach T., 2013, Child Behavior Checklist: Teacher Report Form For Ages 6-18; Achenbach TM, 2000, CAREGIVER TEACHER RE; Aldred C, 2004, J CHILD PSYCHOL PSYC, V45, P1420, DOI 10.1111/j.1469-7610.2004.00338.x; Anagnostou E, 2015, AUTISM, V19, P622, DOI 10.1177/1362361314542955; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Berube R.L., 2010, Bibliography of published studies using the Achenbach System of Empirically Based Assessment; Bishop-Fitzpatrick L, 2016, J AUTISM DEV DISORD, V46, P2707, DOI 10.1007/s10803-016-2816-3; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Bolte EE, 2013, J AUTISM DEV DISORD, V43, P2491, DOI 10.1007/s10803-013-1798-7; Bolte S., 2006, DIAGNOSTISCHES INTER; BOLTE S, 2008, SKALA ERFASSUNG SOZI; Boyd BA, 2012, J AUTISM DEV DISORD, V42, P1236, DOI 10.1007/s10803-011-1284-z; Brian JA, 2015, CURR OPIN NEUROL, V28, P117, DOI 10.1097/WCO.0000000000000182; Brugha TS, 2011, ARCH GEN PSYCHIAT, V68, P459, DOI 10.1001/archgenpsychiatry.2011.38; Buescher AVS, 2014, JAMA PEDIATR, V168, P721, DOI 10.1001/jamapediatrics.2014.210; Carr T, 2016, AUTISM, V20, P643, DOI 10.1177/1362361315598634; Crowe BHA, 2015, ARCH DIS CHILDHOOD-E, V100, P20, DOI 10.1136/archdischild-2013-305468; Daseking M., 2013, Verhaltensinventar zur Beurteilung exekutiver Funktionen fur das Kindergartenalter: Deutschsprachige Adaptation des Behavior Rating Inventory of Executive FunctionPreschool Version (BRIEF-P) von Gerard A. Gioia; Dawson Geraldine, 2010, Pediatrics, V125, pe17, DOI 10.1542/peds.2009-0958; Divan G, 2019, AUTISM RES, V12, P328, DOI 10.1002/aur.1978; Elsabbagh M, 2016, BIOL PSYCHIAT, V80, P94, DOI 10.1016/j.biopsych.2016.02.019; Erstenyuk V, 2014, RES AUTISM SPECT DIS, V8, P644, DOI 10.1016/j.rasd.2014.03.003; Estes A, 2015, J AM ACAD CHILD PSY, V54, P580, DOI 10.1016/j.jaac.2015.04.005; Falck-Ytter T, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-28; Falkmer T, 2013, EUR CHILD ADOLES PSY, V22, P329, DOI 10.1007/s00787-013-0375-0; Fava L, 2014, INT J DEV NEUROSCI, V39, P49, DOI 10.1016/j.ijdevneu.2014.05.004; Franchini M, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00143; Freitag CM, 2016, J CHILD PSYCHOL PSYC, V57, P596, DOI 10.1111/jcpp.12509; Freitag CM, 2012, J NEURAL TRANSM, V119, P1011, DOI 10.1007/s00702-012-0792-0; Fulceri F, 2016, RES DEV DISABIL, V48, P43, DOI 10.1016/j.ridd.2015.10.015; Gardiner E, 2015, AUTISM RES, V8, P199, DOI 10.1002/aur.1442; Gliga T, 2015, CURR BIOL, V25, P1727, DOI 10.1016/j.cub.2015.05.011; Green J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2881-3; Green J, 2018, J CHILD PSYCHOL PSYC, V59, P424, DOI 10.1111/jcpp.12892; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Gulsrud AC, 2016, J CHILD PSYCHOL PSYC, V57, P606, DOI 10.1111/jcpp.12481; Hardan AY, 2015, J CHILD PSYCHOL PSYC, V56, P884, DOI 10.1111/jcpp.12354; Hus V, 2014, J AUTISM DEV DISORD, V44, P1996, DOI 10.1007/s10803-014-2080-3; ICH Expert Working Group, 1996, ICH HARM TRIP GUID; Ingersoll B, 2012, J AUTISM DEV DISORD, V42, P1768, DOI 10.1007/s10803-011-1423-6; Kaale A, 2012, J CHILD PSYCHOL PSYC, V53, P97, DOI 10.1111/j.1469-7610.2011.02450.x; Kasari C, 2006, J CHILD PSYCHOL PSYC, V47, P611, DOI 10.1111/j.1469-7610.2005.01567.x; Kasari C, 2015, J CONSULT CLIN PSYCH, V83, P554, DOI 10.1037/a0039080; Kasari C, 2010, J AUTISM DEV DISORD, V40, P1045, DOI 10.1007/s10803-010-0955-5; Kim SH, 2019, AUTISM, V23, P1176, DOI 10.1177/1362361318793253; Kitzerow J, 2020, Z KINDER JUG-PSYCH, V48, P103, DOI 10.1024/1422-4917/a000661; Kitzerow J, 2016, AUTISM RES, V9, P940, DOI 10.1002/aur.1588; Kitzerow J, 2014, KINDH ENTWICKL, V23, P34, DOI 10.1026/0942-5403/a000133; Kliem S, 2014, DIAGNOSTICA, V60, P35, DOI 10.1026/0012-1924/a000107; Lane P, 2008, PHARM STAT, V7, P93, DOI 10.1002/pst.267; Lord C., 2012, AUTISM DIAGNOSTIC OB; Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002; Mahoney G, 2016, J AUTISM DEV DISORD, V46, P1860, DOI 10.1007/s10803-016-2720-x; Mallinckrodt CH, 2008, DRUG INF J, V42, P303, DOI 10.1177/009286150804200402; Mallinckrodt Craig H, 2004, Clin Trials, V1, P477, DOI 10.1191/1740774504cn049oa; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; Mirenda P, 2010, J AUTISM DEV DISORD, V40, P1521, DOI 10.1007/s10803-010-1012-0; Mundy P., 2003, MANUAL ABRIDGED EARL; Nilges P, 2015, SCHMERZ, V29, P649, DOI 10.1007/s00482-015-0019-z; Oono IP., 2013, EVIDENCE BASED CHILD, V8, P2380, DOI [DOI 10.1002/EBCH.1952, DOI 10.1002/14651858.CD009774.PUB2]; Papakostas George I, 2008, Dialogues Clin Neurosci, V10, P439; Pellecchia M, 2019, AUTISM, V23, P1075, DOI 10.1177/1362361319854844; Perry A, 2015, J APPL RES INTELLECT, V28, P584, DOI 10.1111/jar.12141; Petermann F, 2014, WPPSI 3 WECHSLER PRE; Peters-Scheffer N, 2012, RES DEV DISABIL, V33, P1763, DOI 10.1016/j.ridd.2012.04.006; Pickles Andrew, 2015, J Child Psychol Psychiatry, V56, P162, DOI 10.1111/jcpp.12291; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Pierce K, 2016, BIOL PSYCHIAT, V79, P657, DOI 10.1016/j.biopsych.2015.03.032; Poustka L., 2015, ADOS-2. Diagnostische Beobachtungsskala fur Autistische Storungen-2. Deutschsprachige Fassung der Autism Diagnostic Observation Schedule-2 von Catherine Lord; Reichow B, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009260.pub2, 10.1002/14651858.CD009260.pub3]; Reuner G, 2014, Bayley-Scales of Infant and Toddler Development, VThird; Robertson CE, 2017, NAT REV NEUROSCI, V18, P671, DOI 10.1038/nrn.2017.112; Rutter M., 2003, ADI R AUTISM DIAGNOS; Salomone E, 2016, CHILD CARE HLTH DEV, V42, P141, DOI 10.1111/cch.12261; Samuel PS, 2012, J INTELL DISABIL RES, V56, P1, DOI 10.1111/j.1365-2788.2011.01486.x; Schreibman L, 2015, J AUTISM DEV DISORD, V45, P2411, DOI 10.1007/s10803-015-2407-8; Siddiqui O, 2009, J BIOPHARM STAT, V19, P227, DOI 10.1080/10543400802609797; Smithson PE, 2013, J AUTISM DEV DISORD, V43, P1967, DOI 10.1007/s10803-012-1747-x; Solomon R, 2014, J DEV BEHAV PEDIATR, V35, P475, DOI 10.1097/DBP.0000000000000096; Stahmer AC, 2011, BRAIN RES, V1380, P229, DOI 10.1016/j.brainres.2010.09.043; Sturm A, 2017, J CHILD PSYCHOL PSYC, V58, P1053, DOI 10.1111/jcpp.12731; Szatmari P, 2015, JAMA PSYCHIAT, V72, P276, DOI 10.1001/jamapsychiatry.2014.2463; Teufel K, 2017, A FFIP AUTISMUSSPEZI; Tiede G, 2019, AUTISM, V23, P2080, DOI 10.1177/1362361319836371; van Etten HM, 2015, REV J AUTISM DEV DIS, V2, P310, DOI 10.1007/s40489-015-0054-9; Vivanti G, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00058; Weitlauf AmyS., 2014, Therapies for Children with Autism Spectrum Disorder: Behavioral Interventions Update; Yang D, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.213";89;5;5;1;21;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1745-6215;;TRIALS;Trials;FEB 24;2020;21;1;;;;;;;217;10.1186/s13063-019-3881-7;http://dx.doi.org/10.1186/s13063-019-3881-7;;;17;Medicine, Research & Experimental;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Research & Experimental Medicine;KU7ZX;32093772;Green Published, Green Submitted, gold;;;24/11/2024;WOS:000519932700001;View Full Record in Web of Science
J;"Sprengers, JJ; van Andel, DM; Zuithoff, NPA; Keijzer-Veen, MG; Schulp, AJA; Scheepers, FE; Lilien, MR; Oranje, B; Bruining, H";;;;"Sprengers, Jan J.; van Andel, Dorinde M.; Zuithoff, Nicolaas P. A.; Keijzer-Veen, Mandy G.; Schulp, Annelien J. A.; Scheepers, Floortje E.; Lilien, Marc R.; Oranje, Bob; Bruining, Hilgo";;;Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"ASD; bumetanide; RCT; children; SRS";"DIURETIC BUMETANIDE; CHILDREN; BEHAVIOR";"Objective: Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD). We tested efficacy of bumetanide on core symptom domains using a single center, parallel-group, participant-randomized, double-blind, placebo-controlled phase-2 superiority trial in a tertiary hospital in the Netherlands. Method: Unmedicated children aged 7 to 15 years with ASD and IQ >55 were block-randomized 1:1 to oral-solution bumetanide versus placebo, titrated to a maximum of 1.0 mg twice daily for 91 days (D91), followed by a 28-day wash-out period. The primary outcome was difference in Social Responsiveness Scale-2 (SRS-2) total score at D91, analyzed by modified intention-to-treat with linear mixed models. Results: A total of 92 participants (mean age 10.5 [SD 2.4] years) enrolled between June 2016 and December 2018. In all, 47 children were allocated to bumetanide and 45 to placebo. Two participants dropped out per treatment arm. After 91 days, bumetanide was not superior to placebo on the primary outcome, the SRS-2 (mean difference -3.16, 95% CI = -9.68 to 3.37, p = .338). A superior effect was found on one of the secondary outcomes, the Repetitive Behavior Scale-Revised (mean difference -4.16, 95% CI = -8.06 to -0.25, p = .0375), but not on the Sensory Profile (mean difference 5.64, 95% CI = -11.30 to 22.57, p = .508) or the Aberrant Behavior Checklist Irritability Subscale (mean difference -0.65, 95% CI = -2.83 to 1.52, p = .552). No significant wash-out effect was observed. Significant adverse effects were predominantly diuretic effects (orthostatic hypotension (17 [36%] versus 5 [11%], p = .007); hypokalemia (24 [51%] versus 0 [0%], p < .0001), the occurrence of which did not statistically influence treatment outcome. Conclusion: The trial outcome was negative in terms of no superior effect on the primary outcome. The secondary outcomes suggest efficacy on repetitive behavior symptoms for a subset of patients.";"[Sprengers, Jan J.; van Andel, Dorinde M.; Scheepers, Floortje E.; Oranje, Bob; Bruining, Hilgo] Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Utrecht, Netherlands; [Bruining, Hilgo] Vrije Univ Amsterdam, Amsterdam UMC, N You Ctr, Amsterdam Neurosci,Amsterdam Reprod & Dev, Amsterdam, Netherlands; [Zuithoff, Nicolaas P. A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Keijzer-Veen, Mandy G.; Schulp, Annelien J. A.; Lilien, Marc R.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Utrecht, Netherlands";"Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; University of Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis";Bruining, H (corresponding author), Univ Amsterdam, Dept Child & Adolescent Psychiat, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.;h.bruining@amsterdamumc.nl;"Keijzer-Veen, Mandy/AAZ-1592-2021; Oranje, Bob/GNP-1739-2022";"van Andel, Dorinde/0000-0002-6082-0612; Sprengers, Jan/0000-0001-5418-9791; Keijzer-Veen, Mandy/0000-0003-0727-7451; Lilien, Marc/0000-0002-8956-0324";Netherlands Organisation for Health Research and Development (ZonMw) [836041015];Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development);"The study was funded by the Netherlands Organisation for Health Research and Development (ZonMw; GGG#836041015) . Neither the funder of the study, nor Neurochlore, who provided the study medication, had a role in study design, data collection, data analysis, data interpretation, or writing of the report. Data on (S) AEs were shared with Neurochlore for the Development Safety Update Report of the oral bumetanide solution. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.";"Aman MG, 2017, J CHILD ADOL PSYCHOP, V27, P403, DOI 10.1089/cap.2015.0146; American Psychiatric Association, 2000, DIAGNOSTIC STAT MANU, V4th ed; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; Anagnostou E, 2015, AUTISM, V19, P622, DOI 10.1177/1362361314542955; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373, DOI 10.1001/jama.2013.281053; Ben-Ari Y, 2017, TRENDS NEUROSCI, V40, P536, DOI 10.1016/j.tins.2017.07.001; Cellot G, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00070; Charman T, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0145-9; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Courchesne E, 2019, MOL PSYCHIATR, V24, P88, DOI 10.1038/s41380-018-0056-y; de la Torre-Ubieta L, 2016, NAT MED, V22, P345, DOI 10.1038/nm.4071; Dean OM, 2017, AUST NZ J PSYCHIAT, V51, P241, DOI 10.1177/0004867416652735; Fitzmaurice G. M., 2004, Applied Longitudinal Analysis; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; Groenwold RHH, 2014, CAN MED ASSOC J, V186, P1153, DOI 10.1503/cmaj.131353; Hadjikhani N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21958-x; Hadjikhani N, 2015, AUTISM, V19, P149, DOI 10.1177/1362361313514141; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-456; Kharod SC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00310; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.101; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Lemonnier E, 2013, ACTA PAEDIATR, V102, pe288, DOI 10.1111/apa.12235; Lemonnier E, 2010, ACTA PAEDIATR, V99, P1885, DOI 10.1111/j.1651-2227.2010.01933.x; Light GA, 2020, NEUROPSYCHOPHARMACOL, V45, P237, DOI 10.1038/s41386-019-0519-0; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Loth E, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0146-8; Lyall K, 2017, ANNU REV PUBL HEALTH, V38, P81, DOI 10.1146/annurev-publhealth-031816-044318; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Muskens JB, 2017, EUR CHILD ADOLES PSY, V26, P1093, DOI 10.1007/s00787-017-1020-0; O'Callaghan CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110761; Parker KJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7356; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Rodgaard EM, 2019, JAMA PSYCHIAT, V76, P1124, DOI 10.1001/jamapsychiatry.2019.1956; Schauder KB, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00268; Schulte JT, 2018, NEUROSCI BIOBEHAV R, V90, P260, DOI 10.1016/j.neubiorev.2018.05.001; Thompson DD, 2015, J CLIN EPIDEMIOL, V68, P1068, DOI 10.1016/j.jclinepi.2014.11.001; Veenstra-VanderWeele J, 2017, NEUROPSYCHOPHARMACOL, V42, P1390, DOI 10.1038/npp.2016.237; Zablotsky Benjamin, 2015, Natl Health Stat Report, P1";42;64;69;2;21;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;JUL;2021;60;7;;;;;865;876;;10.1016/j.jaac.2020.07.888;http://dx.doi.org/10.1016/j.jaac.2020.07.888;;juin-21;12;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";TG6AI;32730977;hybrid;;;24/11/2024;WOS:000671485000015;View Full Record in Web of Science
J;"Roy, R; Leadbitter, K; Shields, G; Taylor, C; Aldred, C; Juneja, M; Gulati, S; Vajaratkar, V; Davies, L; Emsley, R; Patel, V; Divan, G; Green, J";;;;"Roy, Reetabrata; Leadbitter, Kathy; Shields, Gemma; Taylor, Carol; Aldred, Catherine; Juneja, Monica; Gulati, Sheffali; Vajaratkar, Vivek; Davies, Linda; Emsley, Richard; Patel, Vikram; Divan, Gauri; Green, Jonathan";;COMPASS Team;A randomised controlled trial of clinical and cost-effectiveness of the PASS Plus intervention for young children with autism spectrum disorder in New Delhi, India: study protocol for the COMPASS trial;TRIALS;;;English;Article;;;;;;"Autism spectrum disorder; Randomised controlled trial; Parent-mediated intervention; Non-specialist workers; Cost-effectiveness";"EFFECTIVENESS THRESHOLDS; COUNTRIES";"Background Autism Spectrum Disorder (ASD) is a neurodevelopmental disability affecting at least 5 million children in South Asia. Majority of these children are without access to evidence-based care. The UK Pre-school Autism Communication Therapy (PACT) is the only intervention to have shown sustained impact on autism symptoms. It was systematically adapted for non-specialist community delivery in South Asia, as the 'Parent-mediated Autism Social Communication Intervention for non-Specialists (PASS)' and extended 'PASS Plus' interventions. RCTs of both showed feasibility, acceptability and positive effect on parent and child dyadic outcomes. Methods The Communication-centred Parent-mediated treatment for Autism Spectrum Disorder in South Asia (COMPASS) trial is now a scale-up two- centre, two-arm single (rater) blinded random allocation parallel group study of the PASS Plus intervention in addition to treatment as usual (TAU) compared to TAU alone, plus health economic evaluation embedded in the India health system. Two hundred forty children (approximately 120 intervention/120 TAU) with ASD aged 2-9 years will be recruited from two tertiary care government hospitals in New Delhi, India. Accredited Social Health Activists will be one of the intervention delivery agents. Families will undertake up to 12 communication sessions over 8 months and will be offered the Plus modules which address coexisting problems. The trial's primary endpoint is at 9 months from randomisation, with follow-up at 15 months. The primary outcome is autism symptom severity; secondary outcomes include parent-child communication, child adaptation, quality of life and parental wellbeing. Primary analysis will follow intention-to-treat principles using linear mixed model regressions with group allocation and repeated measures as random effects. The cost-effectiveness analysis will use a societal perspective over the 15-month period of intervention and follow-up. Discussion If clinically and cost-effective, this programme will fill an important gap of scalable interventions delivered by non-specialist health workers within the current care pathways for autistic children and their families in low-resource contexts. The programme has been implemented through the COVID-19 pandemic when restrictions were in place; intervention delivery and evaluation processes have been adapted to address these conditions.";"[Roy, Reetabrata; Divan, Gauri] Sangath, Porvorim, India; [Leadbitter, Kathy; Shields, Gemma; Taylor, Carol; Aldred, Catherine; Davies, Linda; Green, Jonathan] Univ Manchester, Manchester, Lancs, England; [Juneja, Monica] Maulana Azad Med Coll & Associated Lok Nayak Hosp, Delhi, India; [Gulati, Sheffali] All India Inst Med Sci, Delhi, India; [Vajaratkar, Vivek] Goa Med Coll, Panaji, India; [Emsley, Richard] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Biostat & Hlth Informat, London, England; [Patel, Vikram] Harvard Med Sch, Boston, MA 02115 USA; [Green, Jonathan] Royal Manchester Childrens Hosp, Manchester, Lancs, England";"University of Manchester; Maulana Azad Medical College; All India Institute of Medical Sciences (AIIMS) New Delhi; Goa Medical College & Hospital; University of London; King's College London; Harvard University; Harvard Medical School; Royal Manchester Children's Hospital";Roy, R (corresponding author), Sangath, Porvorim, India.;"r.roy@sangath.in; kathy.leadbitter@manchester.ac.uk; gemma.shields@manchester.ac.uk; carol.taylor-2@manchester.ac.uk; catherine@pacttraining.co.uk; drmonicajuneja@gmail.com; sheffaligulati@gmail.com; vivek.vajaratkar@sangath.in; davies@manchester.ac.uk; richard.emsley@kcl.ac.uk; Vikram_Patel@hms.harvard.edu; gauri.divan@sangath.in; jonathan.green@manchester.ac.uk";"Green, Jonathan/L-2529-2018; Patel, Vikram/ADE-3787-2022; Emsley, Richard/N-1342-2016";"Divan, Gauri/0000-0001-6212-8358; Leadbitter, Kathy/0000-0002-0744-2800; Naithani, Lavangi/0000-0002-6787-3258; Roy, Reetabrata/0000-0002-1430-369X; Emsley, Richard/0000-0002-1218-675X";"Medical Research Council (MRC); Department of Health and Social Care (DHSC); Foreign, Commonwealth & Development Office (FCDO); Wellcome Trust [MR/R006164/1]; Joint Global Health Trials Programme";"Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health and Social Care (DHSC); Foreign, Commonwealth & Development Office (FCDO); Wellcome Trust(Wellcome Trust); Joint Global Health Trials Programme";"Joint Global Health Trials Programme; Medical Research Council (MRC), the Department of Health and Social Care (DHSC), the Foreign, Commonwealth & Development Office (FCDO), and Wellcome Trust (WT). Grant reference: MR/R006164/1. Core funding 1,945,645; pound with the addition of COVID-19 Disruption funding (University of Manchester, May 2021) 193,377; pound costed variation to contract 427,736 pound (JGHT, March 2022). Total 2,566,758 pound.";"Aldred C, 2012, J AUTISM DEV DISORD, V42, P447, DOI 10.1007/s10803-011-1248-3; [Anonymous], 1995, J Psychoeduc Assess; Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; Brezis RS, 2015, CULT MED PSYCHIAT, V39, P277, DOI 10.1007/s11013-015-9434-y; Chaudhary D, 2022, BMC HEALTH SERV RES, V22, DOI 10.1186/s12913-022-08508-y; Crowe BHA, 2015, ARCH DIS CHILDHOOD-E, V100, P20, DOI 10.1136/archdischild-2013-305468; Daley T, 2013, INT M AUT RES C, P2022; de Leeuw A, 2020, AUTISM RES, V13, P1029, DOI 10.1002/aur.2276; Divan G, 2019, AUTISM RES, V12, P328, DOI 10.1002/aur.1978; Divan G, 2012, AUTISM RES, V5, P190, DOI 10.1002/aur.1225; Einfeld S., 2002, Manual for the Developmental Behaviour Checklist: Primary Carer Version (DBCP) & Teacher Version (DBC-T), V2nd, P16; Faria R, 2014, PHARMACOECONOMICS, V32, P1157, DOI 10.1007/s40273-014-0193-3; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Husereau D, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-067975; Ilias K, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00280; Juneja M, 2014, Indian Pediatr, V51, P457; Juneja M, 2014, INDIAN PEDIATR, V51, P359, DOI 10.1007/s13312-014-0417-9; Kazibwe J, 2022, VALUE HEALTH, V25, P385, DOI 10.1016/j.jval.2021.08.014; Kendall T, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4865; National Institute for Health and Care Excellence, 2022, GUID METH TECHN APPR; Orkin AM, 2021, JAMA-J AM MED ASSOC, V326, P257, DOI 10.1001/jama.2021.9941; Patel V, 2010, LANCET, V376, P2086, DOI 10.1016/S0140-6736(10)61508-5; Pichon-Riviere A, 2023, LANCET GLOB HEALTH, V11, pE833, DOI 10.1016/S2214-109X(23)00162-6; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Pickles A, 2015, J CHILD PSYCHOL PSYC, V56, P162, DOI 10.1111/jcpp.12291; Rahman A, 2016, LANCET PSYCHIAT, V3, P128, DOI 10.1016/S2215-0366(15)00388-0; Sparrow SCD., 2005, VINELAND ADAPTIVE BE; StataCorp, 2017, Stata Statistical Software: Release 15, P2017; Stefanos R, 2020, INTERN EMERG MED, V15, P1085, DOI 10.1007/s11739-020-02450-9; Stevens K, 2012, PHARMACOECONOMICS, V30, P729, DOI 10.2165/11599120-000000000-00000; Walwyn R, 2010, STAT METHODS MED RES, V19, P291, DOI 10.1177/0962280209105017; Wetherby AM, 2001, Communication and Symbolic Behavior Scales Developmental Profile Infant/Toddler Checklist, P5; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; Ziouani S, 2016, VALUE HEALTH, V19, pA471, DOI 10.1016/j.jval.2016.09.726";36;0;0;1;6;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1745-6215;;TRIALS;Trials;oct-12;2023;24;1;;;;;;;667;10.1186/s13063-023-07621-5;http://dx.doi.org/10.1186/s13063-023-07621-5;;;20;Medicine, Research & Experimental;Science Citation Index Expanded (SCI-EXPANDED);Research & Experimental Medicine;LS4T3;37828540;Green Submitted, gold, Green Published;;;24/11/2024;WOS:001188785900001;View Full Record in Web of Science
J;"Wang, JL; Xu, CL; Liu, CY; Zhou, QF; Chao, GQ; Jin, YT";;;;"Wang, Juling; Xu, Chenlu; Liu, Chenyang; Zhou, Qinfeng; Chao, Guanqun; Jin, Yongtang";;;Effects of different doses of lithium on the central nervous system in the rat valproic acid model of autism;CHEMICO-BIOLOGICAL INTERACTIONS;;;English;Article;;;;;;"Lithium; Autism spectrum disorder; VPA; Neuroinflammatory";"HISTONE DEACETYLASE INHIBITORS; IMMUNE ACTIVATION; BRAIN IL-6; MICROGLIA; NEUROINFLAMMATION; CHILDREN; DEFICITS; SUICIDE; ADOLESCENTS; EPIGENETICS";Epidemiological studies have shown that low doses of lithium in the environment can have beneficial effects on mental health. Autism spectrum disorder, a neurodevelopmental disorder in which patients exhibit abnormal behaviors, pharmacological interventions usually relied on a range of psychotropic medications. However, such medications often produce severe side effects or are ineffective in symptoms. Finding alternative ways to improve abnormal behaviors in individuals with autism are warranted, in which case lithium may be a relatively safe and effective medication. Lithium salt therapy is used to treat a variety of neuropsychiatric disorders and has neu-roprotective effects. In this study, we investigated the effects of different doses of lithium on neurobehavioural disorders using the rat model of autism established by valproic acid (VPA) injection. Lithium was observed to have an ameliorative effect on the social cognitive, social memory and anxiety levels in the rat model of autism. Immunofluorescence staining showed that subchronic LiCl administration (1.0 mmol/kg) significantly reduced the number of Iba-1 positive cells in the CA1 region of the hippocampus in VPA group and brought it close to the levels of control group. Significantly lower levels of the pro-inflammatory marker IL-6 were observed in the hippocampus and serum after lithium treatment. In addition, the lithium treatment increased the levels of H3K9 acetylation in the hippocampus of VPA-exposed rats. The results showed a defensive effect of environment -related lithium exposure doses on neurobehavioural deficits in the rat valproic acid model of autism, suggest-ing that it may be a potential drug for the treatment of autism.;"[Wang, Juling; Xu, Chenlu; Liu, Chenyang; Zhou, Qinfeng; Jin, Yongtang] Zhejiang Univ, Sch Publ Hlth, Dept Environm Med, Environm Epigenet Lab, Hangzhou, Zhejiang, Peoples R China; [Chao, Guanqun; Jin, Yongtang] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gen Practice, Med Coll, Hangzhou, Zhejiang, Peoples R China; [Jin, Yongtang] 866 Yu Hang Tang Rd, Hangzhou, Zhejiang, Peoples R China; [Chao, Guanqun] 3 Qing Chun Dong Rd, Hangzhou, Zhejiang, Peoples R China";"Zhejiang University; Zhejiang University";"Jin, YT (corresponding author), 866 Yu Hang Tang Rd, Hangzhou, Zhejiang, Peoples R China.;Chao, GQ (corresponding author), 3 Qing Chun Dong Rd, Hangzhou, Zhejiang, Peoples R China.";"chaoguanqun@zju.edu.cn; jinedu@zju.edu.cn";;;National Natural Sci-ence Foundation of China (NSFC) [81673124];National Natural Sci-ence Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC));Funding This work was supported by a grant from the National Natural Sci-ence Foundation of China (NSFC) (No. 81673124) .;"Andoh M, 2019, PROG MOL BIOL TRANSL, V167, P223, DOI 10.1016/bs.pmbts.2019.06.012; Aral H, 2008, ECOTOX ENVIRON SAFE, V70, P349, DOI 10.1016/j.ecoenv.2008.02.026; Ruiz SMA, 2022, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.792364; Baird-Gunning J, 2017, J INTENSIVE CARE MED, V32, P249, DOI 10.1177/0885066616651582; Bauer ME, 2019, ANN NY ACAD SCI, V1437, P57, DOI 10.1111/nyas.13712; Boi J, 2017, EUR NEUROPSYCHOPHARM, V27, pS1112, DOI 10.1016/S0924-977X(17)31928-4; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Dai YC, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00355; do Amaral-Silva G.K., 2021, FRONT ORAL HLTH, V2; Eissa N, 2019, CHEM-BIOL INTERACT, V312, DOI 10.1016/j.cbi.2019.108775; Elnahas EM, 2021, PROG NEURO-PSYCHOPH, V108, DOI 10.1016/j.pnpbp.2020.110185; Foley AG, 2014, EUR J PHARMACOL, V727, P80, DOI 10.1016/j.ejphar.2014.01.050; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Huang J.H., 2004, Chin. J. Clin. Pharmacol. Ther, V9, P1069; Janka Z, 2019, IDEGGYOGY SZEMLE, V72, P367, DOI 10.18071/isz.72.0367; Jiang NM, 2018, TRENDS MOL MED, V24, P794, DOI 10.1016/j.molmed.2018.06.008; Joensuu M, 2018, PROG NEURO-PSYCHOPH, V84, P362, DOI 10.1016/j.pnpbp.2017.08.023; Kanehisa M, 2017, PSYCHOPHARMACOLOGY, V234, P3335, DOI 10.1007/s00213-017-4729-z; Kannan V, 2013, J NEUROSCI RES, V91, P1133, DOI 10.1002/jnr.23221; Kataoka S, 2013, INT J NEUROPSYCHOPH, V16, P91, DOI 10.1017/S1461145711001714; König D, 2017, NEUROPSYCHIATRIE, V31, P70, DOI 10.1007/s40211-017-0222-5; Kutuk MO, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155152; Lähteenvuo M, 2018, JAMA PSYCHIAT, V75, P347, DOI 10.1001/jamapsychiatry.2017.4711; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Liao XL, 2020, J PSYCHIATR RES, V130, P167, DOI 10.1016/j.jpsychires.2020.07.013; Liaugaudaite V, 2017, J TRACE ELEM MED BIO, V43, P197, DOI 10.1016/j.jtemb.2017.03.009; Lilja T, 2013, EPIGENETICS-US, V8, P246, DOI 10.4161/epi.23752; Lucchina L, 2014, AUTISM RES, V7, P273, DOI 10.1002/aur.1338; Manich G, 2019, NEUROSCIENCE, V405, P118, DOI 10.1016/j.neuroscience.2018.10.030; Manoli DS, 2021, AM J PSYCHIAT, V178, P30, DOI 10.1176/appi.ajp.2020.20111608; Masini E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218290; Matta SM, 2019, BRAIN BEHAV IMMUN, V79, P75, DOI 10.1016/j.bbi.2019.04.037; Meister S, 2021, J REPROD IMMUNOL, V145, DOI 10.1016/j.jri.2021.103287; Mintz Mark, 2019, Psychopharmacol Bull, V49, P28; Moldrich RX, 2013, BEHAV BRAIN RES, V257, P253, DOI 10.1016/j.bbr.2013.09.049; Morgan JT, 2012, BRAIN RES, V1456, P72, DOI 10.1016/j.brainres.2012.03.036; Mostafavi M, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100833; Nardone S, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00329; Nicolini C, 2018, EXP NEUROL, V299, P217, DOI 10.1016/j.expneurol.2017.04.017; Norden DM, 2016, GLIA, V64, P300, DOI 10.1002/glia.22930; Penzes P, 2011, NAT NEUROSCI, V14, P285, DOI 10.1038/nn.2741; Qin LY, 2018, NAT NEUROSCI, V21, P564, DOI 10.1038/s41593-018-0110-8; Ramaswami G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18526-1; Rana AK, 2022, MOL NEUROBIOL, V59, P1706, DOI 10.1007/s12035-021-02719-w; Robb AS, 2010, DEV DISABIL RES REV, V16, P258, DOI 10.1002/ddrr.118; Saxena R, 2020, PROG MOL BIOL TRANSL, V173, P35, DOI 10.1016/bs.pmbts.2020.05.002; Schneider T, 2005, NEUROPSYCHOPHARMACOL, V30, P80, DOI 10.1038/sj.npp.1300518; Siegel M, 2014, J CHILD ADOL PSYCHOP, V24, P399, DOI 10.1089/cap.2014.0019; Siu MT, 2017, ADV EXP MED BIOL, V978, P63, DOI 10.1007/978-3-319-53889-1_4; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Szklarska D, 2019, BIOL TRACE ELEM RES, V189, P18, DOI 10.1007/s12011-018-1455-2; Talati SN, 2009, AM J THER, V16, P274, DOI 10.1097/MJT.0b013e3181822564; Theoharides TC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153611; Tseng CEJ, 2022, BIOL PSYCHIAT, V91, P922, DOI 10.1016/j.biopsych.2021.11.021; van der Kooij MA, 2012, NEUROSCI BIOBEHAV R, V36, P1763, DOI 10.1016/j.neubiorev.2011.10.006; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Vecera J, 2018, J CELL PHYSIOL, V233, P530, DOI 10.1002/jcp.25914; Vuong HE, 2017, ANNU REV NEUROSCI, V40, P21, DOI 10.1146/annurev-neuro-072116-031347; Wei H, 2013, NEUROSCIENCE, V252, P320, DOI 10.1016/j.neuroscience.2013.08.025; Wei HG, 2012, BBA-MOL BASIS DIS, V1822, P831, DOI 10.1016/j.bbadis.2012.01.011; Wood JJ, 2020, JAMA PSYCHIAT, V77, P474, DOI 10.1001/jamapsychiatry.2019.4160; Wu HM, 2017, LIFE SCI, V173, P43, DOI 10.1016/j.lfs.2017.01.012";62;6;6;4;4;ELSEVIER IRELAND LTD;CLARE;ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND;0009-2797;1872-7786;;CHEM-BIOL INTERACT;Chem.-Biol. Interact.;janv-25;2023;370;;;;;;;;110314;10.1016/j.cbi.2022.110314;http://dx.doi.org/10.1016/j.cbi.2022.110314;;DEC 2022;10;"Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology";Science Citation Index Expanded (SCI-EXPANDED);"Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology";9Z0XH;36535311;;;;24/11/2024;WOS:000950872900001;View Full Record in Web of Science
J;"Abujadi, C; Croarkin, PE; Bellini, BB; Brentani, H; Marcolin, MA";;;;"Abujadi, Caio; Croarkin, Paul E.; Bellini, Bianca B.; Brentani, Helena; Marcolin, Marco A.";;;Intermittent theta-burst transcranial magnetic stimulation for autism spectrum disorder: an open-label pilot study;REVISTA BRASILEIRA DE PSIQUIATRIA;;;English;Article;;;;;;"Autism spectrum disorder; intermittent theta burst stimulation; noninvasive brain stimulation; theta-burst stimulation; repetitive transcranial magnetic stimulation";"CORTICAL INHIBITION; SCALE";Objective: Theta-burst stimulation (TBS) modulates synaptic plasticity more efficiently than standard repetitive transcranial magnetic stimulation delivery and may be a promising modality for neuropsychiatric disorders such as autism spectrum disorder (ASD). At present there are few effective interventions for prefrontal cortex dysfunction in ASD. We report on an open-label, pilot study of intermittent TBS (iTBS) to target executive function deficits and restricted, repetitive behaviors in male children and adolescents with ASD. Methods: Ten right-handed, male participants, aged 9-17 years with ASD were enrolled in an open-label trial of iTBS treatment. Fifteen sessions of neuronavigated iTBS at 100% motor threshold targeting the right dorsolateral prefrontal cortex were delivered over 3 weeks. Results: Parent report scores on the Repetitive Behavior Scale Revised and the Yale-Brown Obsessive Compulsive Scale demonstrated improvements with iTBS treatment. Participants demonstrated improvements in perseverative errors on the Wisconsin Card Sorting Test and total time for the Stroop test. The iTBS treatments were well tolerated with no serious adverse effects. Conclusion: These preliminary results suggest that further controlled interventional studies of iTBS for ASD are warranted.;"[Abujadi, Caio; Bellini, Bianca B.; Brentani, Helena] Univ Sao Paulo, Fac Med, Dept Psiquiatria, Sao Paulo, SP, Brazil; [Croarkin, Paul E.] Mayo Clin, Dept Psychiat & Psychol, 200 First St SW, Rochester, MN 55905 USA; [Marcolin, Marco A.] Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo, SP, Brazil";"Universidade de Sao Paulo; Mayo Clinic; Universidade de Sao Paulo";Croarkin, PE (corresponding author), Mayo Clin, Dept Psychiat & Psychol, 200 First St SW, Rochester, MN 55905 USA.;croarkin.paul@mayo.edu;"Croarkin, Paul/I-3310-2014; Brentani, Helena/G-6839-2011";Brentani, Helena/0000-0001-5192-4682;"National Institute of Mental Health (NIMH) [K23 MH100266]; Brain and Behavior Research Foundation Young Investigator Award";"National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Brain and Behavior Research Foundation Young Investigator Award";PEC acknowledges support from National Institute of Mental Health (NIMH) under award number K23 MH100266 and a Brain and Behavior Research Foundation Young Investigator Award. The content of this report is the sole responsibility of the authors and does not necessarily represent the official views of the US Department of Health and Human Services, the National Institutes of Health, or the NIMH.;"Ameis SH, 2017, J CHILD ADOL PSYCHOP, V27, P413, DOI 10.1089/cap.2016.0146; Desarkar P, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00124; Enticott PG, 2013, NEUROPHARMACOLOGY, V68, P202, DOI 10.1016/j.neuropharm.2012.06.017; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Jung NH, 2013, DEV MED CHILD NEUROL, V55, P83, DOI 10.1111/dmcn.12012; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lord C, 2015, ANNU REV CLIN PSYCHO, V11, P53, DOI 10.1146/annurev-clinpsy-032814-112745; Masi A, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.143; Monchi O, 2001, J NEUROSCI, V21, P7733, DOI 10.1523/JNEUROSCI.21-19-07733.2001; Radhu N, 2013, CLIN NEUROPHYSIOL, V124, P1309, DOI 10.1016/j.clinph.2013.01.014; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Wechsler D., WECHSLER INTELLIGENC; Williams K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004677.pub2";15;26;33;6;20;ASSOC BRASILEIRA PSIQUIATRIA;SAO PAULO;SUBSCRIPTION DEPARTMENT, RUA PEDRO DE TOLEDO, 967 - CASA 01, SAO PAULO, SP 04039-032 A, BRAZIL;1516-4446;1809-452X;;REV BRAS PSIQUIATR;Rev. Bras. Psiquiatr.;JUL-SEP;2018;40;3;;;;;309;311;;10.1590/1516-4446-2017-2279;http://dx.doi.org/10.1590/1516-4446-2017-2279;;;3;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;GN9CT;29236921;Green Accepted, gold, Green Published;;;24/11/2024;WOS:000439480900014;View Full Record in Web of Science
J;"Hellings, JA; Jadhav, M; Jain, S; Jadhav, S; Genovese, A";;;;"Hellings, Jessica A.; Jadhav, Mandar; Jain, Seema; Jadhav, Sneha; Genovese, Ann";;;Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"MENTAL-RETARDATION; RATING-SCALE; WEIGHT-GAIN; CHILDREN; RISPERIDONE; ADOLESCENTS; DYSKINESIA; SAFETY; ADULTS";"Objective: New and repurposed drugs are urgently needed to treat individuals with autism spectrum disorders (ASD). Loxapine (LOX) in low doses of 5-15mg/day resembles an atypical antipsychotic (Stahl 2002). Our recent open pilot study of LOX found significant behavioral improvements and overall weight neutrality in 16 adolescents and adults with ASD. The present study examined an outpatient sample for LOX neuromotor tolerability. Methods: Consecutive outpatients with Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR) ASD diagnoses receiving LOX were examined for tardive dyskinesia (TD) and extrapyramidal side effects (EPS) using the Dyskinesia Identification System: Condensed User Scale (DISCUS), and for akathisia using the Barnes Akathisia Rating Scale. Data were also then retrospectively extracted from clinic charts regarding age, gender, diagnoses, LOX doses, treatment duration, concomitant medications, and LOX dosage reductions. Results: Thirty-four subjects (25 male, 9 female) participated. Mean age was 23.4 years at LOX initiation (range 8-52). Thirteen subjects (38.2%) received loxapine for 5 years. Mean LOX dose was 8.9mg/day (range 5-30mg) and mean duration was 4.2 years (range 0.8-13). Fourteen subjects (41.2%) received concomitant atypical antipsychotics. Benztropine was prescribed in 5 of 34 subjects (14.7%). Three subjects manifested tics at baseline, but lower final DISCUS scores. Subject 26, with Prader-Willi syndrome, manifested TD. Apart from LOX 5mg daily he received paroxetine 40mg daily, which reduces LOX metabolism significantly. Akathisia objective scores were positive in 6 subjects (17.6%): Subject 2 scored 3 (pacing was present also at baseline); subjects 6, 7, and 11 each scored 1; and subjects 18 and 23 each scored 2. Six of 9 subjects (66.7%) with expressive language were positive for subjective akathisia. Conclusions: Low dose LOX was well tolerated, with lower than expected TD rates. This confirms clinical resemblance to an atypical antipsychotic. Individuals with neuromuscular problems including Prader-Willi Syndrome receiving LOX require close monitoring. Further study of LOX in ASD is warranted.";"[Hellings, Jessica A.; Jain, Seema] Ohio State Univ, Nisonger Ctr, Dept Psychiat, Columbus, OH 43210 USA; [Hellings, Jessica A.; Jadhav, Mandar; Jadhav, Sneha; Genovese, Ann] Univ Kansas, Med Ctr, Dept Psychiat, Kansas City, KS 66103 USA; [Jadhav, Mandar] Ross Univ, Sch Med, Miramar, FL USA; [Jain, Seema] Ohio State Univ, Coll Med, Columbus, OH 43210 USA";"University System of Ohio; Ohio State University; University of Kansas; University of Kansas Medical Center; University System of Ohio; Ohio State University";Hellings, JA (corresponding author), Ohio State Univ, Nisonger Ctr, Neurodev Psychiat Study Program, 395 McCampbell Hall,1581 Dodd Dr, Columbus, OH 43210 USA.;Jessica.Hellings@osumc.edu;;"Jadhav, Mandar/0000-0001-6762-4086; Jain, Seema/0000-0002-1790-751X";"Autism Speaks-ATN; Forest; National Institute of Mental Health (NIMH); Shire; Sunovion";"Autism Speaks-ATN; Forest; National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Shire; Sunovion";Dr. Hellings is or has recently been an investigator for studies funded by Autism Speaks-ATN, Forest, National Institute of Mental Health (NIMH), Shire, and Sunovion, and has authorship collaborations with Roche. No other authors have conflicts of interest.;"Allison DB, 1999, AM J PSYCHIAT, V156, P1686; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], J CHILD ADOLESC PSYC; [Anonymous], UPTODATE; [Anonymous], J MENT HLTH RES INTE; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; Barnes TRE, 2003, J PSYCHOPHARMACOL, V17, P365, DOI 10.1177/0269881103174013; Benvenuto A, 2013, BRAIN DEV-JPN, V35, P119, DOI 10.1016/j.braindev.2012.03.015; Campbell M, 1997, J AM ACAD CHILD PSY, V36, P835, DOI 10.1097/00004583-199706000-00022; Carter MJ, 2014, THER RECREAT J, V48, P275; Correll CU, 2008, CURR OPIN PSYCHIATR, V21, P151, DOI 10.1097/YCO.0b013e3282f53132; Ereshefsky L, 1999, J CLIN PSYCHIAT, V60, P20; Fletcher R., 2007, Diagnostic Manual -- Intellectual Disability (DM-ID): A Clinical Guide for Diagnosis of Mental Disorders in Persons with Intellectual Disability; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Hellings JA, 1999, MENT RETARD DEV D R, V5, P270, DOI 10.1002/(SICI)1098-2779(1999)5:4<270::AID-MRDD4>3.3.CO;2-9; Hellings JA, 2001, J CHILD ADOL PSYCHOP, V11, P229, DOI 10.1089/10445460152595559; Hellings JA, 2010, J MENT HEALTH RES IN, V3, P132, DOI 10.1080/19315864.2010.494763; Leskovec TJ, 2008, HARVARD REV PSYCHIAT, V16, P97, DOI 10.1080/10673220802075852; Li Z, 2003, PSYCHOPHARMACOLOGY, V167, P315, DOI 10.1007/s00213-003-1418-x; Lieberman JA, 2011, AM J PSYCHIAT, V168, P770, DOI 10.1176/appi.ajp.2011.11010039; Marcus RN, 2011, J CLIN PSYCHIAT, V72, P1270, DOI 10.4088/JCP.09m05933; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Newcomer JW, 2006, CAN J PSYCHIAT, V51, P480, DOI 10.1177/070674370605100803; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; Preskorn SH, 1997, CLIN PHARMACOKINET, V32, P1, DOI 10.2165/00003088-199700321-00003; Reinblatt SP, 2006, J CHILD ADOL PSYCHOP, V16, P639, DOI 10.1089/cap.2006.16.639; Reus L, 2012, NEUROSCI BIOBEHAV R, V36, P1817, DOI 10.1016/j.neubiorev.2012.05.005; SPRAGUE RL, 1989, MENT RETARD, V27, P141; Stahl S., 2013, Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, V4th, DOI DOI 10.1017/9781108975292; Stahl S., 2013, STAHLS ESSENTIAL PSY; Stahl S.M., 2002, Essential psychopharmacology of antipsychotics and mood stabilizers";32;9;9;0;5;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;oct-01;2015;25;8;;;;;618;624;;10.1089/cap.2014.0145;http://dx.doi.org/10.1089/cap.2014.0145;;;7;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";CU9SF;26485086;;;;24/11/2024;WOS:000363884700004;View Full Record in Web of Science
J;"Singh, K; Connors, SL; Macklin, EA; Smith, KD; Fahey, JW; Talalay, P; Zimmerman, AW";;;;"Singh, Kanwaljit; Connors, Susan L.; Macklin, Eric A.; Smith, Kirby D.; Fahey, Jed W.; Talalay, Paul; Zimmerman, Andrew W.";;;Sulforaphane treatment of autism spectrum disorder (ASD);PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA;;;English;Article;;;;;;;"CLINICAL-TRIAL; CHILDREN; BROCCOLI; CHEMOPREVENTION; ACTIVATION; STRESS; CANCER";Autism spectrum disorder (ASD), characterized by both impaired communication and social interaction, and by stereotypic behavior, affects about 1 in 68, predominantly males. The medico-economic burdens of ASD are enormous, and no recognized treatment targets the core features of ASD. In a placebo-controlled, double-blind, randomized trial, young men (aged 13-27) with moderate to severe ASD received the phytochemical sulforaphane (n = 29)-derived from broccoli sprout extracts-or indistinguishable placebo (n = 15). The effects on behavior of daily oral doses of sulforaphane (50-150 mu mol) for 18 wk, followed by 4 wk without treatment, were quantified by three widely accepted behavioral measures completed by parents/caregivers and physicians: the Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS), and Clinical Global Impression Improvement Scale (CGI-I). Initial scores for ABC and SRS were closely matched for participants assigned to placebo and sulforaphane. After 18 wk, participants receiving placebo experienced minimal change (<3.3%), whereas those receiving sulforaphane showed substantial declines (improvement of behavior): 34% for ABC (P < 0.001, comparing treatments) and 17% for SRS scores (P = 0.017). On CGI-I, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007). Upon discontinuation of sulforaphane, total scores on all scales rose toward pretreatment levels. Dietary sulforaphane, of recognized low toxicity, was selected for its capacity to reverse abnormalities that have been associated with ASD, including oxidative stress and lower antioxidant capacity, depressed glutathione synthesis, reduced mitochondrial function and oxidative phosphorylation, increased lipid peroxidation, and neuroinflammmation.;"[Singh, Kanwaljit; Connors, Susan L.; Zimmerman, Andrew W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp Children, Lurie Ctr Autism,Dept Pediat, Lexington, MA 02421 USA; [Singh, Kanwaljit; Zimmerman, Andrew W.] Univ Massachusetts, Sch Med, Dept Pediat Neurol, Worcester, MA 01655 USA; [Macklin, Eric A.] Massachusetts Gen Hosp, Biostat Ctr, Dept Med, Boston, MA 02114 USA; [Smith, Kirby D.] Johns Hopkins Univ, Sch Med, Lewis B & Dorothy Cullman Chemoprotect Ctr, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; [Fahey, Jed W.; Talalay, Paul] Johns Hopkins Univ, Sch Med, Lewis B & Dorothy Cullman Chemoprotect Ctr, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA";"Harvard University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Johns Hopkins University; Johns Hopkins University";Talalay, P (corresponding author), Johns Hopkins Univ, Sch Med, Lewis B & Dorothy Cullman Chemoprotect Ctr, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.;"ptalalay@jhmi.edu; Andrew.Zimmerman@umassmemorial.org";"Singh, Kanwaljit/B-2210-2016; Macklin, Eric/E-2955-2013";Macklin, Eric/0000-0003-1618-3502;"Nancy Lurie Marks Family Foundation; Hussman Foundation; Lewis B. and Dorothy Cullman Foundation; Agnes Gund Foundation; N of One Foundation; Brassica Foundation for Chemoprotection Research";"Nancy Lurie Marks Family Foundation; Hussman Foundation; Lewis B. and Dorothy Cullman Foundation; Agnes Gund Foundation; N of One Foundation; Brassica Foundation for Chemoprotection Research";"We thank the participants and their families who were consistently interested and gave generously of their time; Scott Zeger for discussions on biostatistics; Jessica Helt and Karmen Koesterer for patient testing and Luisa Masclans for data collection; Ann Neumeyer, who chaired the Data Safety Monitoring Board and was consulted regarding safety and side effects; Jennifer Mullett for assisting with study procedures; and Christine Ferrone and Lisa Nowinski for advising us on regulatory matters and outcome measures. The quality of data collection, retrieval, and analysis were certified by Quality Associates Incorporated. The study was supported by gifts from the Nancy Lurie Marks Family Foundation, the Hussman Foundation, the Lewis B. and Dorothy Cullman Foundation, the Agnes Gund Foundation, the N of One Foundation, and the Brassica Foundation for Chemoprotection Research.";"[Anonymous], OSU AUT RAT SCAL; [Anonymous], FRONTIERS PEDIAT; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; [Anonymous], WORKSHOP REPORT FEVE; [Anonymous], AM COLL NEUR 52 ANN; Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5; Brose RD, 2012, HUM MOL GENET, V21, P4237, DOI 10.1093/hmg/dds247; Choque Olsson N, 2014, J AUTISM DEV DISORD, V44, P1773, DOI 10.1007/s10803-013-2029-y; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Constantino JN, 2009, DEV PSYCHOPATHOL, V21, P127, DOI 10.1017/S095457940900008X; Curran LK, 2007, PEDIATRICS, V120, pE1386, DOI 10.1542/peds.2007-0360; Danielsson S, 2005, EPILEPSIA, V46, P918, DOI 10.1111/j.1528-1167.2005.57504.x; DEYKIN EY, 1979, AM J PSYCHIAT, V136, P1310; Dinkova-Kostova AT, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/606104; Egner PA, 2014, CANCER PREV RES, V7, P813, DOI 10.1158/1940-6207.CAPR-14-0103; Egner PA, 2011, CANCER PREV RES, V4, P384, DOI 10.1158/1940-6207.CAPR-10-0296; Fahey Jed W, 2013, Virtual Mentor, V15, P311, DOI 10.1001/virtualmentor.2013.15.4.stas1-1304; Fahey JW, 2012, CANCER PREV RES, V5, P179, DOI 10.1158/1940-6207.CAPR-11-0572; Frackowiak J, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-61; Gan NQ, 2010, J BIOL CHEM, V285, P35528, DOI 10.1074/jbc.M110.152686; Giulivi C, 2010, JAMA-J AM MED ASSOC, V304, P2389, DOI 10.1001/jama.2010.1706; Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039; James SJ, 2009, FASEB J, V23, P2374, DOI 10.1096/fj.08-128926; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5; Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339; Liang K.-Y., 2000, Sankhya: The Indian Journal of Statistics, Series B, V62, P134; Lyall K, 2014, INT J EPIDEMIOL, V43, P443, DOI 10.1093/ije/dyt282; MARSHBURN EC, 1992, J AUTISM DEV DISORD, V22, P357, DOI 10.1007/BF01048240; Mehler MF, 2009, BRAIN RES REV, V59, P388, DOI 10.1016/j.brainresrev.2008.11.001; Napoli E, 2014, PEDIATRICS, V133, pE1405, DOI 10.1542/peds.2013-1545; Rangasamy S, 2013, NEUROTHERAPEUTICS, V10, P742, DOI 10.1007/s13311-013-0227-0; Stetler RA, 2010, PROG NEUROBIOL, V92, P184, DOI 10.1016/j.pneurobio.2010.05.002; Talalay P, 2000, BIOFACTORS, V12, P5, DOI 10.1002/biof.5520120102; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Wiggins JL, 2011, BRAIN RES, V1380, P187, DOI 10.1016/j.brainres.2010.10.102; Wingate M, 2014, MMWR SURVEILL SUMM, V63; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147";39;309;331;0;69;NATL ACAD SCIENCES;WASHINGTON;2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA;0027-8424;1091-6490;;P NATL ACAD SCI USA;Proc. Natl. Acad. Sci. U. S. A.;oct-28;2014;111;43;;;;;15550;15555;;10.1073/pnas.1416940111;http://dx.doi.org/10.1073/pnas.1416940111;;;6;Multidisciplinary Sciences;Science Citation Index Expanded (SCI-EXPANDED);Science & Technology - Other Topics;AR6ZL;25313065;Green Published, Bronze;Y;N;24/11/2024;WOS:000343729500070;View Full Record in Web of Science
J;"Dawson, G; Sun, JM; Baker, J; Carpenter, K; Compton, S; Deaver, M; Franz, L; Heilbron, N; Herold, B; Horrigan, J; Howard, J; Kosinski, A; Major, S; Murias, M; Page, K; Prasad, VK; Sabatos-DeVito, M; Sanfilippo, F; Sikich, L; Simmons, R; Song, A; Vermeer, S; Waters-Pick, B; Troy, J; Kurtzberg, J";;;;"Dawson, Geraldine; Sun, Jessica M.; Baker, Jennifer; Carpenter, Kimberly; Compton, Scott; Deaver, Megan; Franz, Lauren; Heilbron, Nicole; Herold, Brianna; Horrigan, Joseph; Howard, Jill; Kosinski, Andrzej; Major, Samantha; Murias, Michael; Page, Kristin; Prasad, Vinod K.; Sabatos-DeVito, Maura; Sanfilippo, Fred; Sikich, Linmarie; Simmons, Ryan; Song, Allen; Vermeer, Saritha; Waters-Pick, Barbara; Troy, Jesse; Kurtzberg, Joanne";;;A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder;JOURNAL OF PEDIATRICS;;;English;Article;;;;;;;"YOUNG-CHILDREN; MICROGLIA; CELLS";Objective To evaluate whether umbilical cord blood (CB) infusion is safe and associated with improved social and communication abilities in children with autism spectrum disorder (ASD). Study design This prospective, randomized, placebo-controlled, double-blind study included 180 children with ASD, aged 2-7 years, who received a single intravenous autologous (n = 56) or allogeneic (n = 63) CB infusion vs placebo (n = 61) and were evaluated at 6 months postinfusion. Results CB infusion was safe and well tolerated. Analysis of the entire sample showed no evidence that CB was associated with improvements in the primary outcome, social communication (Vineland Adaptive Behavior Scales3 [VABS-3] Socialization Domain), or the secondary outcomes, autism symptoms (Pervasive Developmental Disorder Behavior Inventory) and vocabulary (Expressive One-Word Picture Vocabulary Test). There was also no overall evidence of differential effects by type of CB infused. In a subanalysis of children without intellectual disability (ID), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale, but the OR for improvement was not significant. Children without ID treated with CB showed significant improvements in communication skills (VABS-3 Communication Domain), and exploratory measures including attention to toys and sustained attention (eye-tracking) and increased alpha and beta electroencephalographic power. Conclusions Overall, a single infusion of CB was not associated with improved socialization skills or reduced autism symptoms. More research is warranted to determine whether CB infusion is an effective treatment for some children with ASD.;"[Dawson, Geraldine; Carpenter, Kimberly; Compton, Scott; Deaver, Megan; Franz, Lauren; Heilbron, Nicole; Herold, Brianna; Horrigan, Joseph; Howard, Jill; Major, Samantha; Murias, Michael; Sabatos-DeVito, Maura; Sikich, Linmarie; Vermeer, Saritha] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA; [Dawson, Geraldine; Sun, Jessica M.; Baker, Jennifer; Kosinski, Andrzej; Page, Kristin; Prasad, Vinod K.; Simmons, Ryan; Song, Allen; Waters-Pick, Barbara; Troy, Jesse; Kurtzberg, Joanne] Duke Univ, Sch Med, Marcus Ctr Cellular Cures, Durham, NC USA; [Sanfilippo, Fred] Emory Univ, Sch Med, Atlanta, GA USA; [Song, Allen] Duke Univ, Sch Med, Duke Brain Imaging & Anal Ctr, Durham, NC USA";"Duke University; Duke University; Emory University; Duke University";Dawson, G (corresponding author), Duke Univ, Sch Med, 2608 Erwin Rd,Suite 300, Durham, NC 27705 USA.;geraldine.dawson@duke.edu;"Sanfilippo, Fred/AAY-6503-2020; Troy, Jesse/P-7834-2019; Page, Kristin/AAJ-9063-2021; Compton, Scott/A-6656-2011; Dawson, Geraldine/J-8421-2016; Baker, Jennifer/JEO-9532-2023";"Dawson, Geraldine/0000-0003-1410-2764; Carpenter, Kimberly/0000-0002-3838-798X";Marcus Foundation, Atlanta, GA;Marcus Foundation, Atlanta, GA;"Supported by The Marcus Foundation, Atlanta, GA. K.C. reports technology unrelated to the submitted work that has been licensed and has benefited financially, and has a patent 15141391 pending. G.D. reports personal fees from Janssen, Roche, and Akili, and technology unrelated to the submitted work that has been licensed and has benefited financially, has patents 62757234, 62757226, 15141391, and 62470431 pending. J. Horrrigan reports personal fees from AMO Pharma Ltd. J. Howard reports personal fees from Roche. J.K. has a patent 62470431 pending. F.S. is a paid consultant to The Marcus Foundation as Medical Director. L.S. receives personal fees from Neuren, Roche, and nonfinancial support from Neos Pharmaceuticals. J.S. has a patent 62470431 pending. J.T. reports personal fees from Cohortias, EMMES Corporation, Community Data Roundtable, AegisCN, Gamida Cell, and a patent 62470431 pending. The study sponsor was not involved in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. The other authors declare no conflicts of interest.";"[Anonymous], 2014, TOB TX300 EYE TRACK; Chatham CH, 2018, AUTISM RES, V11, P270, DOI 10.1002/aur.1874; Chez M, 2018, STEM CELL TRANSL MED, V7, P333, DOI 10.1002/sctm.17-0042; Cohen I. L., 2005, PDD BEHAV INVENTORY; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Dawson G, 2017, STEM CELL TRANSL MED, V6, P1332, DOI 10.1002/sctm.16-0474; de la Torre-Ubieta L, 2016, NAT MED, V22, P345, DOI 10.1038/nm.4071; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Drobyshevsky A, 2015, DEV NEUROSCI-BASEL, V37, P349, DOI 10.1159/000374107; Frohlich J, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-019-0280-6; Goines PE, 2013, NEUROTOXICOL TERATOL, V36, P67, DOI 10.1016/j.ntt.2012.07.006; Isaev DY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57902-1; Lv YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-196; Martin NA, 2018, EXPRESSIVE ONE WORD; McEvoy K, 2015, BRAIN IMAGING BEHAV, V9, P104, DOI 10.1007/s11682-014-9343-7; Murias M, 2018, STEM CELL TRANSL MED, V7, P783, DOI 10.1002/sctm.18-0090; Pozzi D, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00111; Rogers SJ, 2019, J AM ACAD CHILD PSY, V58, P853, DOI 10.1016/j.jaac.2019.01.004; Rutter M., 2003, SCQ SOCIAL COMMUNICA; Rutter M., 2012, AUTISM DIAGNOSTIC OB; Saha A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218906; Schork AJ, 2019, NAT NEUROSCI, V22, P353, DOI 10.1038/s41593-018-0320-0; Segal-Gavish H, 2016, AUTISM RES, V9, P17, DOI 10.1002/aur.1530; Shoulars K, 2016, BLOOD, V127, P2346, DOI 10.1182/blood-2015-08-666990; Sparrow S., 2016, VINELAND ADAPTIVE BE, Vthird; Stoll FM, 2016, CEREB CORTEX, V26, P1715, DOI 10.1093/cercor/bhv006; Takano T, 2015, DEV NEUROSCI-BASEL, V37, P195, DOI 10.1159/000398791; Wang J, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-24; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Zantomio D, 2015, NEUROSCI BIOBEHAV R, V52, P172, DOI 10.1016/j.neubiorev.2015.02.006";30;35;37;1;12;MOSBY-ELSEVIER;NEW YORK;360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA;0022-3476;1097-6833;;J PEDIATR-US;J. Pediatr.;JUL;2020;222;;;;;;164;+;;10.1016/j.jpeds.2020.03.01;http://dx.doi.org/10.1016/j.jpeds.2020.03.01;;;15;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;MU8VC;32444220;;;;24/11/2024;WOS:000555944100026;View Full Record in Web of Science
J;"Gabis, LV; Ben-Hur, R; Shefer, S; Jokel, A; Ben Shalom, D";;;;"Gabis, Lidia, V; Ben-Hur, Rotem; Shefer, Shahar; Jokel, Ariela; Ben Shalom, Dorit";;;Improvement of Language in Children with Autism with Combined Donepezil and Choline Treatment;JOURNAL OF MOLECULAR NEUROSCIENCE;;;English;Article;;;;;;"Autism; Language; Donepezil; Choline; Children";"OPEN-LABEL TRIAL; RESONANCE SPECTROSCOPY; DIETARY CHOLINE; MOUSE MODEL; SPECTRUM; GALANTAMINE; ADOLESCENTS; EFFICACY; SLEEP";The safety and efficacy of a novel combination treatment of AChE inhibitors and choline supplement was initiated and evaluated in children and adolescents with autism spectrum disorder (ASD). Safety and efficacy were evaluated on 60 children and adolescents with ASD during a 9-month randomized, double-blind, placebo-controlled trial comprising 12 weeks of treatment preceded by baseline evaluation, and followed by 6 months of washout, with subsequent follow-up evaluations. The primary exploratory measure was language, and secondary measures included core autism symptoms, sleep and behavior. Significant improvement was found in receptive language skills 6 months after the end of treatment as compared to placebo. The percentage of gastrointestinal disturbance reported as a side effect during treatment was higher in the treatment group as compared to placebo. The treatment effect was enhanced in the younger subgroup (younger than 10 years), occurred already at the end of the treatment phase, and was sustained at 6 months post treatment. No significant side effects were found in the younger subgroup. In the adolescent subgroup, no significant improvement was found, and irritability was reported statistically more often in the adolescent subgroup as compared to placebo. Combined treatment of donepezil hydrochloride with choline supplement demonstrates a sustainable effect on receptive language skills in children with ASD for 6 months after treatment, with a more significant effect in those under the age of 10 years.;"[Gabis, Lidia, V; Ben-Hur, Rotem; Shefer, Shahar; Jokel, Ariela] Safra Childrens Hosp, Weinberg Child Dev Ctr, Ramat Gan, Israel; [Gabis, Lidia, V] Tel Aviv Univ, Sadder Sch Med, Tel Aviv, Israel; [Ben-Hur, Rotem; Ben Shalom, Dorit] Ben Gurion Univ Negev, Beer Sheva, Israel";"Tel Aviv University; Ben Gurion University";"Gabis, LV (corresponding author), Safra Childrens Hosp, Weinberg Child Dev Ctr, Ramat Gan, Israel.;Gabis, LV (corresponding author), Tel Aviv Univ, Sadder Sch Med, Tel Aviv, Israel.";Lidia.Gabis@sheba.gov.il;"Gabis, Lidia/AAF-9518-2020; SHALOM, DORIT/ABH-8539-2020";;"local associations-the Israeli Society of Clinical Pediatrics (HIPAK); MATERNA";"local associations-the Israeli Society of Clinical Pediatrics (HIPAK); MATERNA";The study was funded by local associations-the Israeli Society of Clinical Pediatrics (HIPAK) and MATERNA.;"[Anonymous], 2001, AUTISM DIAGNOSTIC OB; [Anonymous], WECHSLER INTELLIGENC; Blusztajn JK, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080815; Buckley AW, 2011, J CHILD ADOL PSYCHOP, V21, P353, DOI 10.1089/cap.2010.0121; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Chez MG., 2003, J PEDIATR NEUROL, V1, P83, DOI DOI 10.1055/S-0035-1557175; Doyle Robert L, 2006, J Atten Disord, V9, P543, DOI 10.1177/1087054705284091; Eissa N, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00304; Gabis L, 2008, J CHILD NEUROL, V23, P766, DOI 10.1177/0883073808315423; Glenn MJ, 2012, BRAIN RES, V1443, P52, DOI 10.1016/j.brainres.2012.01.018; HAMLIN JC, 2013, AUTISM RES TREATMENT, V2013, P1; Handen BL, 2011, J CHILD ADOL PSYCHOP, V21, P43, DOI 10.1089/cap.2010.0024; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Hardan AY, 2002, J CHILD ADOL PSYCHOP, V12, P237, DOI 10.1089/104454602760386923; Hertzman M, 2003, INT J PSYCHIAT MED, V33, P395, DOI 10.2190/JE5Q-1NFT-FL40-7PMW; Karvat G, 2014, NEUROPSYCHOPHARMACOL, V39, P831, DOI 10.1038/npp.2013.274; Kaufman AS, 2014, ENCY SPECIAL ED; Lee M, 2002, BRAIN, V125, P1483, DOI 10.1093/brain/awf160; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Nag N, 2007, NEUROBIOL DIS, V26, P473, DOI 10.1016/j.nbd.2007.02.003; Nicolson R, 2006, J CHILD ADOL PSYCHOP, V16, P621, DOI 10.1089/cap.2006.16.621; Niederhofer H, 2002, BRIT MED J, V325, P1422; Owens JA, 2000, SLEEP, V23, P1043; Ray MA, 2005, NEUROBIOL DIS, V19, P366, DOI 10.1016/j.nbd.2005.01.017; Rimland B, 2018, AUTISM TREATMENT EVA; Sokol DK, 2002, J CHILD NEUROL, V17, P245, DOI 10.1177/088307380201700401; Sparrow SS, 2005, VINELAND ADAPTIVE BE, VSecond, P1; Thomas JD, 2000, NEUROTOXICOL TERATOL, V22, P703, DOI 10.1016/S0892-0362(00)00097-0; Volden J, 2011, AM J SPEECH-LANG PAT, V20, P200, DOI 10.1044/1058-0360(2011/10-0035); Zimmerman IL, 2002, PRESCHOOL LANGUAGE S, P2";30;20;22;2;13;HUMANA PRESS INC;TOTOWA;999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA;0895-8696;1559-1166;;J MOL NEUROSCI;J. Mol. Neurosci.;OCT;2019;69;2;;;;;224;234;;10.1007/s12031-019-01351-7;http://dx.doi.org/10.1007/s12031-019-01351-7;;;11;"Biochemistry & Molecular Biology; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Biochemistry & Molecular Biology; Neurosciences & Neurology";IV9ZU;31230222;;;;24/11/2024;WOS:000484623000005;View Full Record in Web of Science
J;"Siegel, M; Beresford, CA; Bunker, M; Verdi, M; Vishnevetsky, D; Karlsson, C; Teer, O; Stedman, A; Smith, KA";;;;"Siegel, Matthew; Beresford, Carol A.; Bunker, Madisun; Verdi, Mary; Vishnevetsky, Donna; Karlsson, Cassie; Teer, Olivia; Stedman, Amy; Smith, Kahsi A.";;;Preliminary Investigation of Lithium for Mood Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;;Objective: Children with autism spectrum disorder (ASD) have higher rates of comorbid psychiatric disorders, including mood disorders, than the general child population. Although children with ASD may experience irritability (aggression, self-injury, and tantrums), a portion also experience symptoms that are typical of a mood disorder, such as euphoria/elevated mood, mania, hypersexuality, paranoia, or decreased need for sleep. Despite lithium's established efficacy in controlling mood disorder symptoms in the neurotypical population, lithium has been rarely studied in children with ASD. Methods: We performed a retrospective chart review of 30 children and adolescents diagnosed with ASD by the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria who were prescribed lithium in order to assess target symptoms, safety, and tolerability. Clinical Global Impressions - Improvement (CGI-I) ratings were performed by two board-certified child psychiatrists with expertise in ASD. CGI-I scores were dichotomized into improved'' (CGI-I score of 1 or 2) or not improved'' (CGI-I score >= 3). Results: Forty-three percent of patients who received lithium were rated as improved'' on the CGI-I. Seventy-one percent of patients who had two or more pretreatment mood disorder symptoms were rated as improved.'' The presence of mania (p = 0.033) or euphoria/elevated mood (p = 0.041) were the pretreatment symptoms significantly associated with an improved'' rating. The mean lithium blood level was 0.70 mEq/L (SD = 0.26), and the average length of lithium treatment was 29.7 days (SD = 23.9). Forty-seven percent of patients were reported to have at least one side effect, most commonly vomiting (13%), tremor (10%), fatigue (10%), irritability (7%), and enuresis (7%). Conclusions: This preliminary assessment of lithium in children and adolescents with ASD suggests that lithium may be a medication of interest for those who exhibit two or more mood disorder symptoms, particularly mania or euphoria/elevated mood. A relatively high side effect rate merits caution, and these results are limited by the retrospective, uncontrolled study design. Future study of lithium in a prospective trial with treatment-sensitive outcome measures may be indicated.;"[Siegel, Matthew] Tufts Univ, Sch Med, Dept Psychiat, Boston, MA 02111 USA; [Siegel, Matthew; Bunker, Madisun; Verdi, Mary; Teer, Olivia; Stedman, Amy] Spring Harbor Hosp, Westbrook, ME 04092 USA; [Siegel, Matthew; Smith, Kahsi A.] Maine Med Ctr, Res Inst, Scarborough, ME USA; [Beresford, Carol A.; Vishnevetsky, Donna; Karlsson, Cassie] Univ Colorado, Denver, CO 80202 USA; [Beresford, Carol A.] Childrens Hosp, Aurora, CO USA";"Tufts University; Maine Medical Center; University of Colorado System; University of Colorado Denver; Children's Hospital Colorado";Siegel, M (corresponding author), Spring Harbor Hosp, 123 Andover Rd, Westbrook, ME 04092 USA.;siegem@springharbor.org;;;"Maine Medical Center Research Institute; Pond Family Foundation";"Maine Medical Center Research Institute; Pond Family Foundation";This work was performed with general support from the Maine Medical Center Research Institute and the Pond Family Foundation.;"[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1; CAMPBELL M, 1972, J AUTISM CHILD SCHIZ, V2, P234, DOI 10.1007/BF01537617; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; KERBESHIAN J, 1987, J CLIN PSYCHOPHARM, V7, P401; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Siegel M, 2012, J AUTISM DEV DISORD, V42, P1592, DOI 10.1007/s10803-011-1399-2; STEINGARD R, 1987, J AM ACAD CHILD PSY, V26, P932, DOI 10.1097/00004583-198726060-00021";9;43;46;0;13;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;SEP;2014;24;7;;;;;399;402;;10.1089/cap.2014.0019;http://dx.doi.org/10.1089/cap.2014.0019;;;4;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";AP6CD;25093602;;;;24/11/2024;WOS:000342164200006;View Full Record in Web of Science
J;"Harfterkamp, M; Buitelaar, JK; Minderaa, RB; van de Loo-Neus, G; van der Gaag, RJ; Hoekstra, PJ";;;;"Harfterkamp, Myriam; Buitelaar, Jan K.; Minderaa, Ruud B.; van de Loo-Neus, Gigi; van der Gaag, Rutger-Jan; Hoekstra, Pieter J.";;;"Atomoxetine in Autism Spectrum Disorder: No Effects on Social Functioning; Some Beneficial Effects on Stereotyped Behaviors, Inappropriate Speech, and Fear of Change";JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; QUESTIONNAIRE CSBQ; PEDIATRIC-PATIENTS; ANXIETY DISORDER; OPEN-LABEL; CHILDREN; SYMPTOMS; ADOLESCENTS; PLACEBO";Objective: The objective of this study was to investigate the short-term treatment effects of atomoxetine on autism spectrum disorder (ASD) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder (ADHD). Methods: A total of 97 patients 6-17 years of age, with ASD and ADHD, were treated with 1.2 mg/kg/day of atomoxetine during an 8 week double-blind placebo-controlled period. Here, we investigated effects on two parent-based secondary outcome measures, the Aberrant Behavior Checklist (ABC) and the Children's Social Behavior Questionnaire (CSBQ). Results: After 8 weeks of double-blind treatment, atomoxetine administration was associated with significant treatment effects on the ABC subscales Hyperactivity, Inappropriate Speech, and Stereotypic Behavior, and on the CSBQ subscale Fear for Changes. Conclusions: Our study results indicate no beneficial effects of atomoxetine on social functioning. However, atomoxetine may ameliorate restricted and stereotyped behaviors and communication. This study has been registered in ClinicalTrials.gov (www.clinicaltrials.gov) under registration number NCT00380692.;"[Harfterkamp, Myriam; Minderaa, Ruud B.; Hoekstra, Pieter J.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9700 AB Groningen, Netherlands; [Buitelaar, Jan K.; van de Loo-Neus, Gigi; van der Gaag, Rutger-Jan] Karakter Child & Adolescent Psychiat Univ Ctr, Nijmegen, Netherlands; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Dept Cognit Neurosci, NL-6525 ED Nijmegen, Netherlands";"University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen";Harfterkamp, M (corresponding author), Univ Med Ctr Groningen, Dept Psychiat, POB 660, NL-9700 AR Groningen, Netherlands.;maharfterkamp@gmail.com;"Buitelaar, Jan/AAY-7522-2020; van der Gaag, R.J./H-8030-2014";;Eli Lilly and company;Eli Lilly and company(Eli Lilly);This study was funded by Eli Lilly and company.;"Adler LA, 2009, DEPRESS ANXIETY, V26, P212, DOI 10.1002/da.20549; AMAN MG, 1985, AM J MENT DEF, V89, P485; Anagnostou E, 2011, CURR OPIN PEDIATR, V23, P621, DOI 10.1097/MOP.0b013e32834cba3e; [Anonymous], J CHILD ADOLESC PSYC; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Dawson G, 2011, CURR OPIN PEDIATR, V23, P616, DOI 10.1097/MOP.0b013e32834cf082; de Bildt A, 2009, J AUTISM DEV DISORD, V39, P1464, DOI 10.1007/s10803-009-0764-x; Faries D.E., 2001, Journal of Attention Disorders, V5, P107, DOI DOI 10.1177/108705470100500204; Geller D, 2007, J AM ACAD CHILD PSY, V46, P1119, DOI 10.1097/chi.0b013e3180ca8385; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hartman CA, 2006, J AUTISM DEV DISORD, V36, P325, DOI 10.1007/s10803-005-0072-z; Huffman LC, 2011, J DEV BEHAV PEDIATR, V32, P56, DOI 10.1097/DBP.0b013e3182040acf; Jahromi LB, 2009, J AUTISM DEV DISORD, V39, P395, DOI 10.1007/s10803-008-0636-9; Jou RJ, 2005, J CHILD ADOL PSYCHOP, V15, P325, DOI 10.1089/cap.2005.15.325; Karabekiroglu K, 2009, CHILD PSYCHIAT HUM D, V40, P99, DOI 10.1007/s10578-008-0108-7; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Luteijn E, 2000, J AUTISM DEV DISORD, V30, P317, DOI 10.1023/A:1005527300247; Marcus RN, 2011, J CHILD ADOL PSYCHOP, V21, P229, DOI 10.1089/cap.2009.0121; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P599, DOI 10.1089/cap.2006.16.599; Rutter M., 2003, SCQ SOCIAL COMMUNICA; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P611, DOI 10.1089/cap.2006.16.611";25;23;25;0;9;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;nov-01;2014;24;9;;;;;481;485;;10.1089/cap.2014.0026;http://dx.doi.org/10.1089/cap.2014.0026;;;5;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";AT5RM;25369243;Green Submitted;;;24/11/2024;WOS:000344999600003;View Full Record in Web of Science
J;"Tachibana, M; Kagitani-Shimono, K; Mohri, I; Yamamoto, T; Sanefuji, W; Nakamura, A; Oishi, M; Kimura, T; Onaka, T; Ozono, K; Taniike, M";;;;"Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Nakamura, Ayumi; Oishi, Masako; Kimura, Tadashi; Onaka, Tatsushi; Ozono, Keiichi; Taniike, Masako";;;Long-Term Administration of Intranasal Oxytocin Is a Safe and Promising Therapy for Early Adolescent Boys with Autism Spectrum Disorders;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;;"Objective: Oxytocin (OT) has been a candidate for the treatment of autism spectrum disorders (ASD), and the impact of intranasally delivered OT on ASD has been investigated. However, most previous studies were conducted by single-dose administration to adults; and, therefore, the long-term effect of nasal OT on ASD patients and its effect on children remain to be clarified. Methods: We conducted a singled-armed, open-label study in which OT was administered intranasally over the long term to eight male youth with ASD (10-14 years of age; intelligence quotient [IQ] 20-101). The OT administration was performed in a stepwise increased dosage manner every 2 months (8, 16, 24 IU/dose). A placebo period (1-2 weeks) was inserted before each step. The outcome measures were Autism Diagnostic Observation Schedule - Generic (ADOS-G), Child Behavior Checklist (CBCL), and the Aberrant Behavior Checklist (ABC). In addition, side effects were monitored by measuring blood pressure and examining urine and blood samples. Results: Six of the eight participants showed improved scores on the communication and social interaction domains of the ADOS-G. However, regarding the T-scores of the CBCL and the scores of the ABC, we could not find any statistically significant improvement, although several subcategories showed a mild tendency for improvement. Caregivers of five of the eight participants reported certain positive effects of the OT therapy, especially on the quality of reciprocal communication. All participants showed excellent compliance and no side effects. Conclusions: Although our results on the efficacy of long-term nasal OT therapy still remain controversial, to the best of our knowledge, this is the first report documenting the safety of long-term nasal OT therapy for children with ASD. Even though our data are too preliminary to draw any definite conclusions about efficacy, they do suggest this therapy to be safe, promising, and worthy of a large-scale, double-blind placebo-controlled study.";"[Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Taniike, Masako] Osaka Univ, United Grad Sch Child Dev, Mol Res Ctr Childrens Mental Dev, Suita, Osaka 5650871, Japan; [Kagitani-Shimono, Kuriko; Mohri, Ikuko; Yamamoto, Tomoka; Sanefuji, Wakako; Taniike, Masako] Osaka Univ, United Grad Sch Child Dev, Div Dev Sci, Dept Child Dev, Suita, Osaka 5650871, Japan; [Tachibana, Masaya; Kagitani-Shimono, Kuriko; Mohri, Ikuko; Ozono, Keiichi; Taniike, Masako] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan; [Kimura, Tadashi] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; [Nakamura, Ayumi; Oishi, Masako] Osaka Univ Hosp, Dept Pharm, Suita, Osaka, Japan; [Onaka, Tatsushi] Jichi Med Univ, Dept Physiol, Shimotsuke, Tochigi, Japan";"Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Jichi Medical University";Taniike, M (corresponding author), Osaka Univ, United Grad Sch Child Dev, Mol Res Ctr Childrens Mental Dev, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.;masako@kokoro.med.osaka-u.ac.jp;"Onaka, Tatsushi/I-7115-2012; Tachibana, Masaya/AAW-3526-2020; Shimono, Kuriko/IWL-8088-2023";"Tachibana, Masaya/0000-0002-6761-7158; Onaka, Tatsushi/0000-0001-5666-9035";;;;"Achenbach T.M., 1991, University of Vermont, Department of Psychology Pediatrics; AMAN MG, 1985, AM J MENT DEF, V89, P485; ANSSEAU M, 1987, PSYCHONEUROENDOCRINO, V12, P231, DOI 10.1016/0306-4530(87)90009-6; Feifel D, 2010, BIOL PSYCHIAT, V68, P678, DOI 10.1016/j.biopsych.2010.04.039; Green JJ, 2010, NEUROTHERAPEUTICS, V7, P250, DOI 10.1016/j.nurt.2010.05.006; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; Guastella AJ, 2009, PSYCHONEUROENDOCRINO, V34, P917, DOI 10.1016/j.psyneuen.2009.01.005; Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; MacDonald E, 2011, PSYCHONEUROENDOCRINO, V36, P1114, DOI 10.1016/j.psyneuen.2011.02.015; Modi ME, 2012, HORM BEHAV, V61, P340, DOI 10.1016/j.yhbeh.2011.12.010; Nagasawa M, 2009, HORM BEHAV, V55, P434, DOI 10.1016/j.yhbeh.2008.12.002; Pedersen CA, 2011, SCHIZOPHR RES, V132, P50, DOI 10.1016/j.schres.2011.07.027; Rice Catherine, 2009, Morbidity and Mortality Weekly Report, V58, P1; SEIFER DB, 1985, J REPROD MED, V30, P225; Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106; Young LJ, 2012, HORM BEHAV, V61, P227, DOI 10.1016/j.yhbeh.2012.02.019";17;126;136;0;52;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;MAR;2013;23;2;;;;;123;127;;10.1089/cap.2012.0048;http://dx.doi.org/10.1089/cap.2012.0048;;;5;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";109YO;23480321;;;;24/11/2024;WOS:000316407700008;View Full Record in Web of Science
J;"Gross, C; Banerjee, A; Tiwari, D; Longo, F; White, AR; Allen, AG; Schroeder-Carter, LM; Krzeski, JC; Elsayed, NA; Puckett, R; Klann, E; Rivero, RA; Gourley, SL; Bassell, GJ";;;;"Gross, Christina; Banerjee, Anwesha; Tiwari, Durgesh; Longo, Francesco; White, Angela R.; Allen, A. G.; Schroeder-Carter, Lindsay M.; Krzeski, Joseph C.; Elsayed, Nada A.; Puckett, Rosemary; Klann, Eric; Rivero, Ralph A.; Gourley, Shannon L.; Bassell, Gary J.";;;Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model;NEUROPSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"MENTAL-RETARDATION PROTEIN; MESSENGER-RNAS; PHOSPHATIDYLINOSITOL 3-KINASE; THERAPEUTIC TARGET; TRANSLATION; P110-BETA; RECEPTOR; DYSREGULATION; SCHIZOPHRENIA; METABOLISM";Defects in the phosphoinositide 3-kinase (PI3K) pathway are shared characteristics in several brain disorders, including the inherited intellectual disability and autism spectrum disorder, fragile X syndrome (FXS). PI3K signaling therefore could serve as a therapeutic target for FXS and other brain disorders. However, broad inhibition of such a central signal transduction pathway involved in essential cellular functions may produce deleterious side effects. Pharmacological strategies that selectively correct the overactive components of the PI3K pathway while leaving other parts of the pathway intact may overcome these challenges. Here, we provide the first evidence that disease mechanism-based PI3K isoform-specific inhibition may be a viable treatment option for FXS. FXS is caused by loss of the fragile X mental retardation protein (FMRP), which translationally represses specific messenger RNAs, including the PI3K catalytic isoform p110 beta. FMRP deficiency increases p110 beta protein levels and activity in FXS mouse models and in cells from subjects with FXS. Here, we show that a novel, brain-permeable p110 beta-specific inhibitor, GSK2702926A, ameliorates FXS-associated phenotypes on molecular, cellular, behavioral, and cognitive levels in two different FMRP-deficient mouse models. Rescued phenotypes included increased PI3K downstream signaling, protein synthesis rates, and dendritic spine density, as well as impaired social interaction and higher-order cognition. Several p110 beta-selective inhibitors, for example, a molecule from the same chemotype as GSK2702926A, are currently being evaluated in clinical trials to treat cancer. Our results suggest that repurposing p110 beta inhibitors to treat cognitive and behavioral defects may be a promising disease-modifying strategy for FXS and other brain disorders.;"[Gross, Christina; Tiwari, Durgesh; White, Angela R.; Schroeder-Carter, Lindsay M.; Krzeski, Joseph C.; Elsayed, Nada A.] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA; [Gross, Christina] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA; [Banerjee, Anwesha; Bassell, Gary J.] Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; [Longo, Francesco; Puckett, Rosemary; Klann, Eric] NYU, Ctr Neural Sci, New York, NY 10003 USA; [Allen, A. G.; Gourley, Shannon L.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Allen, A. G.; Gourley, Shannon L.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; [Rivero, Ralph A.] GlaxoSmithKline, Collegeville, PA 19426 USA; [Gourley, Shannon L.] Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA; [Bassell, Gary J.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA";"Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Emory University; New York University; Emory University; Emory University; GlaxoSmithKline; Emory University; Emory University";"Gross, C (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA.;Gross, C (corresponding author), Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA.;Bassell, GJ (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.;Gourley, SL (corresponding author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.;Gourley, SL (corresponding author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.;Gourley, SL (corresponding author), Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.;Bassell, GJ (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.";"christina.gross@cchmc.org; shannon.l.gourley@emory.edu; gary.bassell@emory.edu";"Tiwari, Durgesh/GQQ-2540-2022; Banerjee, Anwesha/N-9876-2015; Gourley, Shannon/AAW-6790-2020; Longo, Francesco/ACP-3657-2022";"Tiwari, Durgesh/0000-0002-9985-3593; Bassell, Gary/0000-0003-2622-0127; banerjee, anwesha/0000-0002-2671-4074; Longo, Francesco/0000-0002-1183-0101";"NIH [R21MH103748, 1U54HD082013]; NARSAD Independent Investigator Award from the Brain and Behavior Research Foundation; National Fragile X Foundation; Cincinnati Children's Research Foundation; Office of Research Infrastructure Programs/OD [P51OD011132]; Children's Healthcare of Atlanta";"NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NARSAD Independent Investigator Award from the Brain and Behavior Research Foundation; National Fragile X Foundation; Cincinnati Children's Research Foundation; Office of Research Infrastructure Programs/OD; Children's Healthcare of Atlanta";We thank Jeffrey Rymer, Nathan Petts, Joun Y. Lee, and Jingsheng Gu for technical assistance, and Emanuela Santini as well as all members of the Bassell, Gourley, and Gross labs for helpful discussions. This research was funded by NIH grants R21MH103748 (to C.G., S.L.G.) and 1U54HD082013 (to G.J.B.), a NARSAD Independent Investigator Award from the Brain and Behavior Research Foundation (to C.G.), two Summer Student Fellowships from the National Fragile X Foundation (to J.C.K., N.A.E.), the Cincinnati Children's Research Foundation (to C.G.), and Children's Healthcare of Atlanta (to S.L.G.). The Yerkes National Primate Research Center is supported by the Office of Research Infrastructure Programs/OD P51OD011132.;"Ascano M, 2012, NATURE, V492, P382, DOI 10.1038/nature11737; Banerjee A, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0077-9; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Berry-Kravis E, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aab4109; Bhattacharya A, 2016, NEUROPSYCHOPHARMACOL, V41, P1991, DOI 10.1038/npp.2015.369; Bhattacharya A, 2012, NEURON, V76, P325, DOI 10.1016/j.neuron.2012.07.022; Biever A, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00075; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Crawley JN, 2016, TRENDS GENET, V32, P139, DOI 10.1016/j.tig.2016.01.001; Crino PB, 2016, NAT REV NEUROL, V12, P379, DOI 10.1038/nrneurol.2016.81; Darnell JC, 2011, CELL, V146, P247, DOI 10.1016/j.cell.2011.06.013; Davis PE, 2015, NEUROTHERAPEUTICS, V12, P572, DOI 10.1007/s13311-015-0359-5; Dbouk HA, 2010, ONCOTARGET, V1, P729, DOI 10.18632/oncotarget.207; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; Dwivedi Y, 2008, NEUROPSYCHOPHARMACOL, V33, P2324, DOI 10.1038/sj.npp.1301641; Gantois I, 2017, NAT MED, V23, P674, DOI 10.1038/nm.4335; Gross C, 2015, NEUROTHERAPEUTICS, V12, P584, DOI 10.1007/s13311-015-0355-9; Gross C, 2015, CELL REP, V11, P681, DOI 10.1016/j.celrep.2015.03.065; Gross C, 2012, MOL MED, V18, P336, DOI 10.2119/molmed.2011.00363; Gross C, 2010, J NEUROSCI, V30, P10624, DOI 10.1523/JNEUROSCI.0402-10.2010; Guo WR, 2015, CELL REP, V13, P2297, DOI 10.1016/j.celrep.2015.11.013; Huang GN, 2008, SCIENCE, V319, P476, DOI 10.1126/science.1151227; Huber KM, 2002, P NATL ACAD SCI USA, V99, P7746, DOI 10.1073/pnas.122205699; Kazdoba TM, 2014, INTRACTABLE RARE DIS, V3, P118, DOI 10.5582/irdr.2014.01024; Kim JI, 2011, NAT NEUROSCI, V14, P1447, DOI 10.1038/nn.2937; Law AJ, 2012, P NATL ACAD SCI USA, V109, P12165, DOI 10.1073/pnas.1206118109; Li BY, 2014, AM J CLIN EXP UROL, V2, P188; Lin H, 2012, BIOORG MED CHEM LETT, V22, P2230, DOI 10.1016/j.bmcl.2012.01.092; Lipton JO, 2014, NEURON, V84, P275, DOI 10.1016/j.neuron.2014.09.034; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Muddashetty RS, 2007, J NEUROSCI, V27, P5338, DOI 10.1523/JNEUROSCI.0937-07.2007; Murakami H, 2000, AM J PHYSIOL-HEART C, V279, pH1022, DOI 10.1152/ajpheart.2000.279.3.H1022; Papaleo F, 2016, J NEUROSCI, V36, P4859, DOI 10.1523/JNEUROSCI.4632-15.2016; Park S, 2008, NEURON, V59, P70, DOI 10.1016/j.neuron.2008.05.023; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pilarski R, 2013, JNCI-J NATL CANCER I, V105, P1607, DOI 10.1093/jnci/djt277; Qin M, 2002, P NATL ACAD SCI USA, V99, P15758, DOI 10.1073/pnas.242377399; Richter JD, 2015, NAT REV NEUROSCI, V16, P595, DOI 10.1038/nrn4001; Ronesi JA, 2012, NAT NEUROSCI, V15, P431, DOI 10.1038/nn.3033; Scharf SH, 2015, CURR OPIN PHARMACOL, V20, P124, DOI 10.1016/j.coph.2014.11.004; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/nmeth.1314, 10.1038/NMETH.1314]; Sharma A, 2010, J NEUROSCI, V30, P694, DOI 10.1523/JNEUROSCI.3696-09.2010; Silverman JL, 2010, NAT REV NEUROSCI, V11, P490, DOI 10.1038/nrn2851; Smith GC, 2013, FEBS J, V280, P5337, DOI 10.1111/febs.12428; Thomas AM, 2011, BEHAV BRAIN RES, V223, P310, DOI 10.1016/j.bbr.2011.04.049; Udagawa T, 2013, NAT MED, V19, P1473, DOI 10.1038/nm.3353; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Weiler IJ, 2004, P NATL ACAD SCI USA, V101, P17504, DOI 10.1073/pnas.0407533101; Yan QJ, 2004, GENES BRAIN BEHAV, V3, P337, DOI 10.1111/j.1601-183X.2004.00087.x";49;26;33;1;7;NATURE PUBLISHING GROUP;LONDON;MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;0893-133X;1740-634X;;NEUROPSYCHOPHARMACOL;Neuropsychopharmacology;JAN;2019;44;2;;;;;324;333;;10.1038/s41386-018-0150-5;http://dx.doi.org/10.1038/s41386-018-0150-5;;;10;"Neurosciences; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";HH0AL;30061744;Green Published, Bronze;;;24/11/2024;WOS:000455374000012;View Full Record in Web of Science
J;"Hollander, E; Chaplin, W; Soorya, L; Wasserman, S; Novotny, S; Rusoff, J; Feirsen, N; Pepa, L; Anagnostou, E";;;;"Hollander, Eric; Chaplin, William; Soorya, Latha; Wasserman, Stacey; Novotny, Sherry; Rusoff, Jade; Feirsen, Nicole; Pepa, Lauren; Anagnostou, Evdokia";;;Divalproex Sodium vs Placebo for the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorders;NEUROPSYCHOPHARMACOLOGY;;;English;Article;;;;;;"ASD; irritability; divalproex; children; adolescents";"DOUBLE-BLIND; VALPROIC ACID; RATING-SCALE; AGGRESSION; RISPERIDONE; BEHAVIOR; BIPOLAR; LITHIUM; TRIAL; MANIA";"Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by social and language deficits and by repetitive behaviors and interests. Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care. This study examined the effect of divalproex sodium for irritability/aggression in children and adolescents with ASD. This was a 12-week randomized, double-blind, placebo-controlled trial. All efficacy measures were obtained by an independent evaluator blinded to randomization condition and side effects. A total of 55 subjects gavetheir consent and 27 were randomized in a 1 : 1 manner (mean age 9.46 +/- 2.46, mean nonverbal IQ 63.3 +/- 23.9). Two subjects from the active group and one subject from the placebo group discontinued the study because of either a lack of efficacy or side effects (increased irritability). Primary outcome measures were Aberrant Behavior Checklist-Irritability subscale and Clinical Global Impression-Improvement, which focused on irritability. Overall, 62.5% of divalproex subjects vs 9% of placebo subjects were responders (CGI-irritability OR: 16.7, Fisher's exact p = 0.008). A statistically significant improvement was also noted on the ABC-Irritability subscale (p = 0.048). There was a trend for responders to have higher valproate blood levels compared with nonresponders. This study suggests the efficacy of divalproex for the treatment of irritability in children and adolescents with ASD. Larger sample follow-up studies are warranted. Neuropsychopharmacology (2010) 35, 990-998; doi:10.1038/npp.2009.202; published online 9 December 2009";"[Hollander, Eric] Univ Hosp, Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat, Bronx, NY 10467 USA; [Chaplin, William] St Johns Univ, Dept Psychol, Jamaica, NY 11439 USA; [Soorya, Latha; Wasserman, Stacey; Novotny, Sherry; Rusoff, Jade; Feirsen, Nicole; Pepa, Lauren] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Anagnostou, Evdokia] Univ Toronto, Dept Pediat, Toronto, ON, Canada";"Yeshiva University; Montefiore Medical Center; Albert Einstein College of Medicine; State University of New York (SUNY) System; Saint John's University; Icahn School of Medicine at Mount Sinai; University of Toronto";Hollander, E (corresponding author), Univ Hosp, Montefiore Med Ctr, Albert Einstein Coll Med, Dept Psychiat, 111 E 210th St, Bronx, NY 10467 USA.;eholland@montefiore.org;;;"NINDS [R21 NS4 3979-01]; National Center for Research Resources (NCRR) [MO1-RR00071]";"NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))";We thank Dr Audrey King, Ms Karen Zagusrky, Ms Nadia Tanel, and Ms Stephanie Lee for their assistance with data collection. This project was funded by NINDS R21 NS4 3979-01, E Hollander, PI. Active medication and matching placebo were provided by Abbott Laboratories. In addition, this publication was made possible by Grant Number MO1-RR00071 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH.;"Allen MH, 2006, AM J PSYCHIAT, V163, P272, DOI 10.1176/appi.ajp.163.2.272; AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman Michael G, 2004, Semin Pediatr Neurol, V11, P225, DOI 10.1016/j.spen.2004.07.006; Amiet C, 2008, BIOL PSYCHIAT, V64, P577, DOI 10.1016/j.biopsych.2008.04.030; Belsito KM, 2001, J AUTISM DEV DISORD, V31, P175, DOI 10.1023/A:1010799115457; Bjork JM, 2001, PSYCHIAT RES, V101, P131, DOI 10.1016/S0165-1781(01)00220-7; Buitelaar JK, 2001, J CLIN PSYCHIAT, V62, P239, DOI 10.4088/JCP.v62n0405; Casanova MF, 2003, NEUROSCIENTIST, V9, P496, DOI 10.1177/1073858403253552; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Coccaro E F, 1991, J Neuropsychiatry Clin Neurosci, V3, pS44; CRAFT M, 1987, BRIT J PSYCHIAT, V150, P685, DOI 10.1192/bjp.150.5.685; Damore J, 1998, J AM ACAD CHILD PSY, V37, P248, DOI 10.1097/00004583-199803000-00006; Donovan SJ, 1997, J CLIN PSYCHIAT, V58, P12, DOI 10.4088/JCP.v58n0102; Gottlicher M, 2004, Ann Hematol, V83 Suppl 1, pS91; Guy W., 1976, ECDEU Assessment Manual for Psychopharmacology, V76, P217; Hellings JA, 2005, J CHILD ADOL PSYCHOP, V15, P682, DOI 10.1089/cap.2005.15.682; Hollander E, 2001, J CLIN PSYCHIAT, V62, P530, DOI 10.4088/JCP.v62n07a05; Hollander E, 2005, AM J PSYCHIAT, V162, P621, DOI 10.1176/appi.ajp.162.3.621; Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P1186, DOI 10.1038/sj.npp.1300153; Jesner OS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005040.pub2; KASTNER T, 1993, J CLIN PSYCHOPHARM, V13, P448; KERBESHIAN J, 1987, J CLIN PSYCHOPHARM, V7, P401; LORD C, 1998, ASD DIAGNOSTIC OBSER; Manji H K, 2000, Curr Psychiatry Rep, V2, P479, DOI 10.1007/s11920-000-0006-6; MATTES JA, 1992, J NERV MENT DIS, V180, P601, DOI 10.1097/00005053-199209000-00013; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; MCDOUGLE CJ, 1995, AM J PSYCHIAT, V152, P772; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Roid G.H., 1995, LEITER INT PERFORMAN; Roid G.H., 1997, LEITER INT PERFORMAN, DOI DOI 10.1037/T05120-000; RUTTER M, 1994, ASD DIAGNOSTIC INTER; Söderpalm B, 2002, EUR J PAIN-LONDON, V6, P3, DOI 10.1053/eujp.2001.0315; SOVNER R, 1989, J CLIN PSYCHIAT, V50, P40; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; STOLL AL, 1994, J CLIN PSYCHOPHARM, V14, P311; Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102; TEINGARD R, 1987, J AM ACAD CHILD ADOL, V26, P932; VEBRANT P, 1994, NEUROPEDIATRICS, V25, P284; Wasserman S, 2006, INT CLIN PSYCHOPHARM, V21, P363, DOI 10.1097/01.yic.0000224787.13782.0f; Williams SK, 2006, J AM ACAD CHILD PSY, V45, P431, DOI 10.1097/01.chi.0000196423.80717.32; Yasuda S, 2009, MOL PSYCHIATR, V14, P51, DOI 10.1038/sj.mp.4002099; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429; Youngstrom EA, 2003, J AFFECT DISORDERS, V77, P179, DOI 10.1016/S0165-0327(02)00108-8";43;139;147;0;14;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;0893-133X;1740-634X;;NEUROPSYCHOPHARMACOL;Neuropsychopharmacology;MAR;2010;35;4;;;;;990;998;;10.1038/npp.2009.202;http://dx.doi.org/10.1038/npp.2009.202;;;9;"Neurosciences; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";554HA;20010551;Green Published, Bronze, Green Accepted;;;24/11/2024;WOS:000274424900015;View Full Record in Web of Science
J;"Hellings, JA; Singh, SC; Singh, S; Cheng, AL";;;;"Hellings, Jessica A.; Singh, Saras Chen; Singh, Sham; Cheng, An-Lin";;;Minimally Verbal Individuals with Autism Spectrum Disorders/Intellectual Disability and Challenging Behaviors: Can Strategic Psychiatric Treatment Help?;DISABILITIES;;;English;Article;;;;;;"minimally verbal; epilepsy; psychiatric diagnosis; strategic approach; treatments";"DEFICIT HYPERACTIVITY DISORDER; REPETITIVE BEHAVIORS; ANTIEPILEPTIC DRUGS; EPILEPSY; CHILDREN; POLYPHARMACY; PLACEBO; ADULTS; ATOMOXETINE; LOXAPINE";"(1) Background: Psychiatrists are increasingly required to treat minimally verbal (MV) individuals with autism spectrum disorder (ASD), intellectual disability (ID) and behavior problems without much published guidance. (2) Methods: We reviewed 80 charts of MV patients managed strategically for challenging behaviors, following IRB approval. Data extracted included demographics, ASD/ID level, diagnoses, epilepsy and medications. In this descriptive study, we examined the course of assessment and treatment and made recommendations for a strategic, person-centered approach. (3) Results: Of 53 males and 27 females, mean age 34 years (range 7-76), all had ID; 75 had ASD (94%). Diagnoses included seizures in 40/80 (50%), frequent aggression (89%), self-injury (80%), attention-deficit hyperactivity disorder (ADHD) (64%) and obsessive compulsive disorder (OCD) (34%). The commonest medication classes adjusted were antiseizure medications, antipsychotics, and non-stimulant ADHD medications. (4) Conclusions: Clinical impressions suggested that this strategic psychiatric approach was beneficial, notably a review of antiseizure and all other medications for polypharmacy, behavioral and other side effects, followed by a review of possible childhood/current ADHD and a trial of low-dose non-stimulant ADHD medications if warranted. Low-dose risperidone was often effective and tolerable for irritability and self-injury.";"[Hellings, Jessica A.] Univ Missouri, Dept Psychiat, Kansas City, MO 64108 USA; [Singh, Saras Chen; Singh, Sham] Univ Missouri, Sch Med, Kansas City, MO 64108 USA; [Singh, Saras Chen] Florida Atlantic Univ, Dept Psychiat, Boca Raton, FL 33431 USA; [Singh, Sham] Bonmente Psychiat, 320 Pine Ave 1030, Long Beach, CA 90802 USA; [Cheng, An-Lin] Univ Missouri, Dept Biomed & Hlth Informat, Kansas City, MO 64108 USA";"University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; State University System of Florida; Florida Atlantic University; University of Missouri System; University of Missouri Kansas City";Hellings, JA (corresponding author), Univ Missouri, Dept Psychiat, Kansas City, MO 64108 USA.;jessica.hellings@uhkc.org;;;Robert Wilson estate;Robert Wilson estate;This study was not funded, but funding for publication costs only was provided by a donation from the Robert Wilson estate to the University of Missouri-Kansas City Friends of Psychiatry foundation.;"American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Astaneh AN, 2012, INT J PSYCHIAT MED, V43, P261, DOI 10.2190/PM.43.3.e; Ayani N, 2021, J CLIN PSYCHOPHARM, V41, P397, DOI 10.1097/JCP.0000000000001416; Bhatti I, 2013, J AUTISM DEV DISORD, V43, P1017, DOI 10.1007/s10803-012-1647-0; Brodie MJ, 2016, PHARMACOL REV, V68, P563, DOI 10.1124/pr.115.012021; Burbidge C, 2010, J INTELL DISABIL RES, V54, P1078, DOI 10.1111/j.1365-2788.2010.01338.x; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Dias MC, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.102; Fletcher R., 2017, Diagnostic ManualIntellectual Disability-2: A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disability; Flinker A, 2015, P NATL ACAD SCI USA, V112, P2871, DOI 10.1073/pnas.1414491112; Fox RA, 1998, RES DEV DISABIL, V19, P275, DOI 10.1016/S0891-4222(98)00003-1; Gautam P, 2015, J CLIN DIAGN RES, V9, pVD1, DOI 10.7860/JCDR/2015/13533.6475; Ghaemmaghami M, 2021, J APPL BEHAV ANAL, V54, P122, DOI 10.1002/jaba.762; GLUE P, 1989, BIOL PSYCHIAT, V26, P250, DOI 10.1016/0006-3223(89)90037-1; GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441; Grier E, 2018, CAN FAM PHYSICIAN, V64, pS15; Guy W., 1976, US Dept Health, Education, and Welfare publication; Hässler F, 2015, J NEURAL TRANSM, V122, P93, DOI 10.1007/s00702-014-1219-x; Harfterkamp M, 2013, J CHILD ADOL PSYCHOP, V23, P194, DOI 10.1089/cap.2012.0012; Hellings J.A., 2017, Diagnostic ManualIntellectual Disability-2: A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disability; Hellings J.A., 2023, Ann. Psychiatry Ment. Health, V11, P1183; Hellings J, 2023, WORLD J PSYCHIATR, V13, P262, DOI 10.5498/wjp.v13.i6.262; Hollander E, 2006, INT J NEUROPSYCHOPH, V9, P209, DOI 10.1017/S1461145705005791; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; Hurley A.D., 2016, Diagnostic Manual-Intellectual Disability: A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disability, V2nd ed.; Jain S, 2016, J AUTISM DEV DISORD, V46, P1344, DOI 10.1007/s10803-015-2675-3; Koegel LK, 2020, J AUTISM DEV DISORD, V50, P2957, DOI 10.1007/s10803-020-04402-w; Li Z, 2003, PSYCHOPHARMACOLOGY, V167, P315, DOI 10.1007/s00213-003-1418-x; Mano-Sousa BJ, 2021, CURR NEUROPHARMACOL, V19, P538, DOI 10.2174/1570159X18666200529151741; Matson JL, 2011, RES DEV DISABIL, V32, P621, DOI 10.1016/j.ridd.2010.12.012; Pickles A, 2014, J CHILD PSYCHOL PSYC, V55, P1354, DOI 10.1111/jcpp.12269; Piedad J, 2012, CNS DRUGS, V26, P319, DOI 10.2165/11599780-000000000-00000; POINDEXTER AR, 1993, AM J MENT RETARD, V98, P34; Posar A, 2022, REV PAUL PEDIATR, V40, DOI 10.1590/1984-0462/2022/40/2020158; Rose V, 2016, J INTELL DISABIL RES, V60, P464, DOI 10.1111/jir.12284; Rossignol DA, 2021, J PERS MED, V11, DOI 10.3390/jpm11111141; SINGH NN, 1993, J INTELL DISABIL RES, V37, P65; Spertus J, 2018, NPJ SCHIZOPHR, V4, DOI 10.1038/s41537-018-0053-9; Srivastava AK, 2014, NEUROSCI BIOBEHAV R, V46, P161, DOI 10.1016/j.neubiorev.2014.02.015; Tager-Flusberg H, 2017, AUTISM, V21, P852, DOI 10.1177/1362361316654605; Tager-Flusberg H, 2013, AUTISM RES, V6, P468, DOI 10.1002/aur.1329; Tiger JH, 2008, BEHAV ANAL PRACT, V1, P16; Vadlamani LN, 2020, INDIAN J PSYCHOL MED, V42, p27S, DOI 10.1177/0253717620960694; Watkins LV, 2022, EPILEPTIC DISORD, V24, P9, DOI 10.1684/epd.2021.1366; Whitney DG, 2020, J MANAG CARE SPEC PH, V26, P1153, DOI 10.18553/jmcp.2020.26.9.1153; Williams AE, 2016, NEUROPSYCH DIS TREAT, V12, P287, DOI 10.2147/NDT.S81549; Yaun A.L., 2007, Children with Disabilities, V6th ed.";49;0;0;3;3;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2673-7272;;DISABILITIES-BASEL;Disabilities;JUN;2024;4;2;;;;;277;289;;10.3390/disabilities4020018;http://dx.doi.org/10.3390/disabilities4020018;;;13;Rehabilitation;Emerging Sources Citation Index (ESCI);Rehabilitation;ZI8U8;;gold;;;24/11/2024;WOS:001274766700001;View Full Record in Web of Science
J;"Foldes, ST; Jensen, AR; Jacobson, A; Vassall, S; Foldes, E; Guthery, A; Brown, D; Levine, T; Tyler, WJ; Frye, RE";;;;"Foldes, Stephen T.; Jensen, Amanda R.; Jacobson, Austin; Vassall, Sarah; Foldes, Emily; Guthery, Ann; Brown, Danni; Levine, Todd; Tyler, William James; Frye, Richard E.";;;Transdermal Electrical Neuromodulation for Anxiety and Sleep Problems in High-Functioning Autism Spectrum Disorder: Feasibility and Preliminary Findings;JOURNAL OF PERSONALIZED MEDICINE;;;English;Article;;;;;;"alpha-amylase; autism spectrum disorder; anxiety; cortisol; heart rate variability; neuromodulation; sleep anxiety; transdermal electrical neuromodulation; neurostimulation";"HEART-RATE-VARIABILITY; TRIGEMINAL NERVE-STIMULATION; CORTISOL CIRCADIAN-RHYTHMS; SERIAL ADDITION TEST; ACUPOINT STIMULATION; CHILDREN; STRESS; SYMPTOMS; ADULTS; YOUTH";"Background: Autism spectrum disorder (ASD) is associated with anxiety and sleep problems. We investigated transdermal electrical neuromodulation (TEN) of the cervical nerves in the neck as a safe, effective, comfortable and non-pharmacological therapy for decreasing anxiety and enhancing sleep quality in ASD. Methods: In this blinded, sham-controlled study, seven adolescents and young adults with high-functioning ASD underwent five consecutive treatment days, one day of the sham followed by four days of subthreshold TEN for 20 min. Anxiety-provoking cognitive tasks were performed after the sham/TEN. Measures of autonomic nervous system activity, including saliva alpha-amylase and cortisol, electrodermal activity, and heart rate variability, were collected from six participants. Results: Self-rated and caretaker-rated measures of anxiety were significantly improved with TEN treatment as compared to the sham, with effect sizes ranging from medium to large depending on the rating scale. Sleep scores from caretaker questionnaires also improved, but not significantly. Performance on two of the three anxiety-provoking cognitive tasks and heart rate variability significantly improved with TEN stimulation as compared to the sham. Four of the seven (57%) participants were responders, defined as a & GE; 30% improvement in self-reported anxiety. Salivary alpha-amylase decreased with more TEN sessions and decreased from the beginning to the end of the session on TEN days for responders. TEN was well-tolerated without significant adverse events. Conclusions: This study provides preliminary evidence that TEN is well-tolerated in individuals with ASD and can improve anxiety.";"[Foldes, Stephen T.; Jacobson, Austin; Brown, Danni] Phoenix Childrens Hosp, Barrow Neurol Inst, Div Res, Phoenix, AZ 85016 USA; [Foldes, Stephen T.] Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA; [Foldes, Stephen T.; Tyler, William James] Arizona State Univ, Sch Biol & Hlth Sci, Tempe, AZ 85287 USA; [Foldes, Stephen T.; Frye, Richard E.] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ 85004 USA; [Jensen, Amanda R.] Phoenix Childrens Hosp, Barrow Neurol Inst, Div Neurol, Sect Neurodev Disorders, Phoenix, AZ 85016 USA; [Vassall, Sarah] Vanderbilt Univ, Div Psychol, Nashville, TN 37240 USA; [Foldes, Emily] Arizona State Univ, Speech & Hearing Sci, Tempe, AZ 85287 USA; [Guthery, Ann; Levine, Todd] Phoenix Childrens Hosp, Barrow Neurol Inst, Div Psychiat, Phoenix, AZ 85016 USA";"Barrow Neurological Institute; Phoenix Children's Hospital; Barrow Neurological Institute; Arizona State University; Arizona State University-Tempe; University of Arizona; Barrow Neurological Institute; Phoenix Children's Hospital; Vanderbilt University; Arizona State University; Arizona State University-Tempe; Phoenix Children's Hospital; Barrow Neurological Institute";Frye, RE (corresponding author), Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ 85004 USA.;"stephen.foldes@dignityhealth.org; jensen1@phoenixchildrens.com; ajacobson2@phoenixchildrens.com; sarah.g.vassall@Vanderbilt.Edu; elfoldes@gmail.com; aguthery@phoenixchildrens.com; dbrown4@phoenixchildrens.com; tlevine2@phoenixchildrens.com; wtyler@asu.edu; rfrye@phoenixchildrens.com";"Foldes, Stephen/Y-4304-2019; Tyler, William/J-1818-2012; Rose, Shannon/JZE-1449-2024";"Frye, Richard/0000-0003-4442-2937; Tyler, William/0000-0002-7758-5022";"NSF Cooperative Grant I/UCRC for Building Reliable Advances and Innovation in Neurotechnology [1650566]; Direct For Computer & Info Scie & Enginr; Division Of Computer and Network Systems [1650566] Funding Source: National Science Foundation";"NSF Cooperative Grant I/UCRC for Building Reliable Advances and Innovation in Neurotechnology; Direct For Computer & Info Scie & Enginr; Division Of Computer and Network Systems(National Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE))";FundingThis research was funded by an NSF Cooperative Grant I/UCRC for Building Reliable Advances and Innovation in Neurotechnology (1650566).;"ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ASTONJONES G, 1991, PROG BRAIN RES, V88, P47; Baker EK, 2019, AUTISM, V23, P531, DOI 10.1177/1362361317745857; Behrens B, 2019, CHILD PSYCHIAT HUM D, V50, P473, DOI 10.1007/s10578-018-0854-0; Benedek M, 2010, J NEUROSCI METH, V190, P80, DOI 10.1016/j.jneumeth.2010.04.028; Berridge CW, 2003, BRAIN RES REV, V42, P33, DOI 10.1016/S0165-0173(03)00143-7; Birmaher B, 1997, J AM ACAD CHILD PSY, V36, P545, DOI 10.1097/00004583-199704000-00018; Blakeley-Smith A, 2012, RES AUTISM SPECT DIS, V6, P707, DOI 10.1016/j.rasd.2011.07.020; Blech B, 2020, CURR PAIN HEADACHE R, V24, DOI 10.1007/s11916-020-00914-3; Brotman DJ, 2007, LANCET, V370, P1089, DOI 10.1016/S0140-6736(07)61305-1; Brown CC, 2019, PHARMACOECONOMICS, V37, P609, DOI 10.1007/s40273-019-00789-2; Buckley AW, 2020, NEUROLOGY, V94, P392, DOI 10.1212/WNL.0000000000009033; Bujnakova I, 2016, PHYSIOL RES, V65, pS673, DOI 10.33549/physiolres.933528; Cai RY, 2019, INT J PSYCHOPHYSIOL, V137, P54, DOI 10.1016/j.ijpsycho.2018.12.010; Cakir J, 2020, RES AUTISM SPECT DIS, V72, DOI 10.1016/j.rasd.2019.101502; Caporino NE, 2017, J AM ACAD CHILD PSY, V56, P696, DOI 10.1016/j.jaac.2017.05.018; Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Casanova MF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00851; Chalmers JA, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00080; Cook IA, 2013, EPILEPSY BEHAV, V28, P221, DOI 10.1016/j.yebeh.2013.05.008; Corbett BA, 2006, PSYCHONEUROENDOCRINO, V31, P59, DOI 10.1016/j.psyneuen.2005.05.011; Corbett BA, 2008, J PSYCHIATR NEUROSCI, V33, P227; Corbett BA, 2021, PSYCHONEUROENDOCRINO, V125, DOI 10.1016/j.psyneuen.2020.105115; Corbett BA, 2009, AUTISM RES, V2, P39, DOI 10.1002/aur.64; Couto LB, 2006, J CHEM NEUROANAT, V32, P28, DOI 10.1016/j.jchemneu.2006.03.003; Daluwatte C, 2015, RES DEV DISABIL, V37, P209, DOI 10.1016/j.ridd.2014.11.019; Deliens G, 2019, DEV MED CHILD NEUROL, V61, P1368, DOI 10.1111/dmcn.14235; Deliens G, 2015, REV J AUTISM DEV DIS, V2, P343, DOI 10.1007/s40489-015-0057-6; Dewrang P, 2010, RES AUTISM SPECT DIS, V4, P461, DOI 10.1016/j.rasd.2009.11.003; Dijkhuis RR, 2019, J AUTISM DEV DISORD, V49, P2524, DOI 10.1007/s10803-019-04000-5; Dunn K, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035280; Eldridge SM, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5239; Fein D, 2013, J CHILD PSYCHOL PSYC, V54, P195, DOI 10.1111/jcpp.12037; Ferguson BJ, 2017, AUTISM RES, V10, P276, DOI 10.1002/aur.1646; Fountain C, 2012, PEDIATRICS, V129, pE1112, DOI 10.1542/peds.2011-1601; Giannotti F, 2006, J AUTISM DEV DISORD, V36, P741, DOI 10.1007/s10803-006-0116-z; Grondhuis SN, 2012, RES AUTISM SPECT DIS, V6, P1345, DOI 10.1016/j.rasd.2012.04.006; Habib A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216198; Harder R, 2016, CLIN AUTON RES, V26, P423, DOI 10.1007/s10286-016-0375-5; Hartley SL, 2018, J CLIN CHILD ADOLESC, V47, pS88, DOI 10.1080/15374416.2016.1152552; Hodge D, 2014, RES DEV DISABIL, V35, P1631, DOI 10.1016/j.ridd.2014.03.037; Holingue C, 2018, AUTISM RES, V11, P24, DOI 10.1002/aur.1854; Hollocks MJ, 2019, PSYCHOL MED, V49, P559, DOI 10.1017/S0033291718002283; Hollocks MJ, 2016, J AUTISM DEV DISORD, V46, P3295, DOI 10.1007/s10803-016-2878-2; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447; Jin Y, 2017, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00609; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; Keogh S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221428; Kuiper MWM, 2017, BIOL PSYCHOL, V128, P141, DOI 10.1016/j.biopsycho.2017.07.006; Kushki A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059730; Kuusikko S, 2008, J AUTISM DEV DISORD, V38, P1697, DOI 10.1007/s10803-008-0555-9; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Levine TP, 2012, RES AUTISM SPECT DIS, V6, P177, DOI 10.1016/j.rasd.2011.04.003; Maenner M.J., 2020, WEEKLY REPORT SURVEI, V69, P12, DOI [10.15585/mmwr.ss6904a1, DOI 10.15585/MMWR.SS6904A1]; Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002; McGough JJ, 2019, J AM ACAD CHILD PSY, V58, P403, DOI 10.1016/j.jaac.2018.11.013; Moore M, 2017, CHILDREN-BASEL, V4, DOI 10.3390/children4080072; Myles BS, 2001, EDUC TRAIN MENT RET, V36, P304; Olsson MB, 2013, ACTA PAEDIATR, V102, P635, DOI 10.1111/apa.12229; Padgett DA, 2003, TRENDS IMMUNOL, V24, P444, DOI 10.1016/S1471-4906(03)00173-X; Panju S, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0057-5; Pardo G, 2022, J NEUROL, V269, P1282, DOI 10.1007/s00415-021-10674-8; Park JH, 2014, RES AUTISM SPECT DIS, V8, P1471, DOI 10.1016/j.rasd.2014.07.014; Parsons TD, 2014, J NEUROSCI METH, V222, P15, DOI 10.1016/j.jneumeth.2013.10.006; Peirce J, 2019, BEHAV RES METHODS, V51, P195, DOI 10.3758/s13428-018-01193-y; Qiu JJ, 2021, NEURAL PLAST, V2021, DOI 10.1155/2021/6627507; Rogge N, 2019, J AUTISM DEV DISORD, V49, P2873, DOI 10.1007/s10803-019-04014-z; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol D.A., 2021, HDB AUTISM PERVASIVE; Scahill L, 2019, J AM ACAD CHILD PSY, V58, P887, DOI 10.1016/j.jaac.2018.10.016; Schiltz HK, 2021, AUTISM RES, V14, P1220, DOI 10.1002/aur.2481; Scully D, 1998, BRIT J SPORT MED, V32, P111, DOI 10.1136/bjsm.32.2.111; Speer KE, 2020, EUR J INVEST HEALTH, V10, P390, DOI 10.3390/ejihpe10010029; Stern JA, 2014, RES AUTISM SPECT DIS, V8, P1225, DOI 10.1016/j.rasd.2014.06.008; Taylor JL, 2014, PSYCHONEUROENDOCRINO, V49, P207, DOI 10.1016/j.psyneuen.2014.07.015; Thapa R, 2019, AUTISM RES, V12, P922, DOI 10.1002/aur.2104; Tilford JM, 2015, J AUTISM DEV DISORD, V45, P3613, DOI 10.1007/s10803-015-2507-5; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; Trevizol AP, 2015, BRAIN STIMUL, V8, P676, DOI 10.1016/j.brs.2015.02.008; Trevizol AP, 2015, BRAIN STIMUL, V8, P659, DOI 10.1016/j.brs.2014.12.009; Tyler WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13865; van Steensel FJA, 2017, J CHILD FAM STUD, V26, P1753, DOI 10.1007/s10826-017-0687-7; Vidyashree HM, 2019, INT J YOGA, V12, P73, DOI 10.4103/ijoy.IJOY_66_17; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Wang XX, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/8832694; Wang Y, 2016, APPL PSYCHOPHYS BIOF, V41, P47, DOI 10.1007/s10484-015-9311-z; Williams K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004677.pub3, 10.1002/14651858.CD007407.pub3]; Zhang Ji-Shui, 2017, Zhen Ci Yan Jiu, V42, P249; Zhang R, 2012, RES DEV DISABIL, V33, P1136, DOI 10.1016/j.ridd.2012.02.001";90;6;6;2;11;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2075-4426;;J PERS MED;J. Pers. Med.;DEC;2021;11;12;;;;;;;1307;10.3390/jpm11121307;http://dx.doi.org/10.3390/jpm11121307;;;23;"Health Care Sciences & Services; Medicine, General & Internal";Science Citation Index Expanded (SCI-EXPANDED);"Health Care Sciences & Services; General & Internal Medicine";YK3SM;34945779;gold, Green Published;;;24/11/2024;WOS:000745137000001;View Full Record in Web of Science
J;"Parellada, M; Cáceres, ASJ; Palmer, M; Delorme, R; Jones, EJH; Parr, JR; Anagnostou, E; Murphy, DGM; Loth, E; Wang, PP; Charman, T; Strydom, A; Arango, C";;;;"Parellada, Mara; Jose Caceres, Antonia San; Palmer, Melanie; Delorme, Richard; Jones, Emily J. H.; Parr, Jeremy R.; Anagnostou, Evdokia; Murphy, Declan G. M.; Loth, Eva; Wang, Paul P.; Charman, Tony; Strydom, Andre; Arango, Celso";;AIMS-2-TRIALS-CT1 Grp;A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"autism; arbaclofen; social function; randomized controlled trial; children; adolescent";"PRESYNAPTIC INHIBITION; VALIDITY; CURRENTS; MODEL; SCALE";"Background: Autism Spectrum Disorder (ASD or autism) is characterized by difficulties in social communication and interaction, which negatively impact on individuals and their families' quality of life. Currently no pharmacological interventions have been shown to be effective for improving social communication in autism. Previous trials have indicated the potential of arbaclofen for improving social function among autistic children and adolescents with fluent speech. The AIMS2TRIALS-Clinical Trial 1 (AIMS-CT1) will examine whether arbaclofen is superior to placebo in improving social function and other secondary outcomes over 16 weeks, along with safety and tolerability profiles. Methods: AIMS-CT1 is an international, multi-site, double-blind, parallel group Phase II randomized clinical trial. It will include 130 males and females aged 5:0-17:11 years, with a diagnosis of ASD and fluent speech. Eligible participants will be randomized on a ratio of 1:1 for a 16-week treatment period. Medication will be titrated over 5 weeks. The primary outcome is the effect on social function from weeks 0 to 16 measured on the Socialization domain of the Vineland Adaptive Behavior Scales, 3rd edition(TM). Secondary outcome measures include the CGI-S (Clinical Global Impression-Severity), CGI-I (Clinical Global Impression-Improvement), other areas of adaptive function, social communication and other autism symptoms, co-occurring behavior problems and health-related quality of life. Genetic and electrophysiological markers will be examined as potential stratifiers for treatment response. Exploratory novel digital technologies will also be used to measure change, examining simultaneously the validity of digital biomarkers in natural environments. The safety and tolerability of the drug will also be examined. Our protocol is very closely aligned with a parallel Canadian trial of 90 participants (ARBA Study, US NCT number: NCT03887676) to allow for secondary combined analyses. Outcomes will be compared using both an Intent-to-reat and Per Protocol approach. Discussion: The outcomes of this trial, combined with the parallel Canadian trial, will contribute to the evidence base for medications used to help social difficulties among young autistic individuals; demonstrate the capabilities of the AIMS-2-TRIALS network of academic centers to deliver clinical trials; and support future drug development.";"[Parellada, Mara; Arango, Celso] Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth, Madrid, Spain; [Parellada, Mara; Jose Caceres, Antonia San; Arango, Celso] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain; [Parellada, Mara; Jose Caceres, Antonia San; Arango, Celso] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain; [Parellada, Mara; Arango, Celso] Univ Complutense, Sch Med, Madrid, Spain; [Palmer, Melanie] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Child & Adolescent Psychiat, London, England; [Delorme, Richard] Robert Debre Hosp, AP HP, Child & Adolescent Psychiat Dept, Paris, France; [Delorme, Richard] Inst Pasteur, Human Genet & Cognit Funct, Paris, France; [Jones, Emily J. H.] Birkbeck Coll, Ctr Brain & Cognit Dev, London, England; [Parr, Jeremy R.] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Parr, Jeremy R.] Newcastle Upon Tyne Hosp Natl Hlth Serv NHS Fdn T, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Parr, Jeremy R.] Cumbria Northumberland Tyne & Wear Natl Hlth Serv, Complex Neurodev Disorders Serv, Newcastle Upon Tyne, Tyne & Wear, England; [Anagnostou, Evdokia] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Anagnostou, Evdokia] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada; [Murphy, Declan G. M.; Loth, Eva; Strydom, Andre] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, London, England; [Murphy, Declan G. M.; Loth, Eva] Kings Coll London, Sackler Inst Translat Neurodev, Inst Psychiat Psychol & Neurosci, London, England; [Wang, Paul P.] Clin Res Associates LLC, New York, NY USA; [Charman, Tony] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, London, England; [Charman, Tony] South London & Maudsley Natl Hlth Serv NHS Fdn Tr, London, England";"General University Gregorio Maranon Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Complutense University of Madrid; University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire Robert-Debre - APHP; Pasteur Network; Universite Paris Cite; Institut Pasteur Paris; University of London; Birkbeck University London; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Toronto; University of Toronto; Holland Bloorview Kids Rehabilitation Hospital; University of London; King's College London; University of London; King's College London; University of London; King's College London";"Parellada, M (corresponding author), Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth, Madrid, Spain.;Parellada, M (corresponding author), Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.;Parellada, M (corresponding author), Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain.;Parellada, M (corresponding author), Univ Complutense, Sch Med, Madrid, Spain.";"parellada@hggm.es; carango@hggm.es";"Jones, Emily/H-8358-2019; Parellada, Mara/AAQ-1272-2021; Arango, Celso/AAZ-8314-2021; Murphy, Declan/JQI-8340-2023; Calvo-Escalona, Rosa/L-3556-2017; Arango, Celso/H-6433-2015; Charman, Tony/A-2085-2014";"Murphy, Declan/0000-0002-6664-7451; Jones, Emily/0000-0001-5747-9540; Calvo-Escalona, Rosa/0000-0001-9572-4228; Del Bianco, Teresa/0000-0002-7162-0042; Parr, Jeremy/0000-0002-2507-7878; Arango, Celso/0000-0003-3382-4754; Charman, Tony/0000-0003-1993-6549; Parellada, Mara/0000-0001-7977-3601";"Innovative Medicines Initiative 2 Joint Undertaking [777394]; European Union's Horizon 2020 research and innovation program; EFPIA; Autism Speaks; Autistica; Simons Foundation; Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Maranon, Madrid, Spain";"Innovative Medicines Initiative 2 Joint Undertaking; European Union's Horizon 2020 research and innovation program(Horizon 2020); EFPIA; Autism Speaks; Autistica(Autistica); Simons Foundation; Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Maranon, Madrid, Spain";This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under the grant agreement No. 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program, EFPIA, Autism Speaks, Autistica, and the Simons Foundation. The protocol was fully written by the mentioned authors, with no participation of the funders in the study design or other parts of the clinical trial process. This study is sponsored by Celso Arango, CA, carango@hggm.es, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Maranon, Madrid, Spain.;"Ajram LA, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.104; Aman M.G., 1994, Aberrant Behavior Checklist-Community. Supplementary Manual; American Psychiatric Association, DIAGNOSTIC STAT MANU, V5th; [Anonymous], 2001, MANUAL ASEBA SCH AGE; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Bolognani F, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat7838; Buescher AVS, 2014, JAMA PEDIATR, V168, P721, DOI 10.1001/jamapediatrics.2014.210; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Chao HT, 2010, NATURE, V468, P263, DOI 10.1038/nature09582; Constantino J. N., 2012, SOCIAL RESPONSIVENES; de la Torre-Ubieta L, 2016, NAT MED, V22, P345, DOI 10.1038/nm.4071; Dickinson A, 2016, BRAIN RES, V1648, P277, DOI 10.1016/j.brainres.2016.07.011; Eimer M., 2011, OXFORD HDB FACE PERC, P329, DOI [10.1093/OXFORDHB/9780199559053.013.0017, DOI 10.1093/OXFORDHB/9780199559053.013.0017]; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Erickson CA, 2014, J AUTISM DEV DISORD, V44, P958, DOI 10.1007/s10803-013-1963-z; Fatemi SH, 2009, J AUTISM DEV DISORD, V39, P223, DOI 10.1007/s10803-008-0646-7; Fleming TR, 2020, JAMA-J AM MED ASSOC, V324, P33, DOI 10.1001/jama.2020.9286; Greenhill LL, 2004, J AM ACAD CHILD PSY, V43, P1488, DOI 10.1097/01.chi.0000142668.29191.13; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Guy W., 1976, Clinical global impression. ECDEU assessment manual for psychopharmacology, P218; Isaacson JS, 1997, NEURON, V18, P143, DOI 10.1016/S0896-6273(01)80053-2; Janssen KC, 2017, SLEEP MED, V33, P30, DOI 10.1016/j.sleep.2017.01.014; Kanne SM, 2014, J AUTISM DEV DISORD, V44, P168, DOI 10.1007/s10803-013-1862-3; Kirschstein T, 2009, CLIN EEG NEUROSCI, V40, P146, DOI 10.1177/155005940904000305; Lord C, 2000, NEURON, V28, P355, DOI 10.1016/S0896-6273(00)00115-X; Maenner MJ, 2020, MMWR SURVEILL SUMM, V69, P1, DOI 10.15585/mmwr.ss6904a1; Marín O, 2016, NAT MED, V22, P1229, DOI 10.1038/nm.4225; McAlonan GM, 2021, BRAIN RESPONSE GABAB; McDermott MM, 2020, JAMA-J AM MED ASSOC, V323, P2135, DOI 10.1001/jama.2020.4689; Mentch J, 2019, J NEUROSCI, V39, P8398, DOI 10.1523/JNEUROSCI.0836-19.2019; Olmos-Serrano JL, 2010, J NEUROSCI, V30, P9929, DOI 10.1523/JNEUROSCI.1714-10.2010; Ouyang G, 2020, NEUROIMAGE, V205, DOI 10.1016/j.neuroimage.2019.116304; Pacey LKK, 2009, MOL PHARMACOL, V76, P18, DOI 10.1124/mol.109.056127; Parellada M, 2014, EUR PSYCHIAT, V29, P11, DOI 10.1016/j.eurpsy.2013.02.005; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Rutter M., 2012, AUTISM DIAGNOSTIC OB; Rutter M., 2003, SOCIAL COMMUNICATION; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; Siafis S, 2020, MOL AUTISM, V11, DOI 10.1186/s13229-020-00372-z; Sinclair D, 2017, NEUROSCI BIOBEHAV R, V76, P235, DOI 10.1016/j.neubiorev.2016.05.029; Sohal VS, 2019, MOL PSYCHIATR, V24, P1248, DOI 10.1038/s41380-019-0426-0; Sohn JW, 2007, J PHYSIOL-LONDON, V580, P411, DOI 10.1113/jphysiol.2006.125914; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Sparrow S.S., 2016, Vineland-3 Adaptive Behavior Scales: Comprehensive Parent/Caregiver Form report; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Veenstra-VanderWeele J, 2017, NEUROPSYCHOPHARMACOL, V42, P1390, DOI 10.1038/npp.2016.237";47;6;7;1;5;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;AUG 24;2021;12;;;;;;;;701729;10.3389/fpsyt.2021.701729;http://dx.doi.org/10.3389/fpsyt.2021.701729;;;13;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;UQ7OD;34504446;Green Published, gold;;;24/11/2024;WOS:000696249300001;View Full Record in Web of Science
J;"Dogan, M; Albayrak, Y; Erbas, O";;;;"Dogan, Murat; Albayrak, Yakup; Erbas, Oyutun";;;Torasemide Improves the Propionic Acid-Induced Autism in Rats: A Histopathological and Imaging Study;ALPHA PSYCHIATRY;;;English;Article;;;;;;"Autism; diuretic; torasemide; treatment";"NERVE GROWTH-FACTOR; MITOCHONDRIAL DYSFUNCTION; CEREBELLAR CORTICES; SPECTRUM DISORDER; YOUNG-CHILDREN; ANIMAL-MODEL; ABNORMALITIES; METABOLISM; MICROBIOTA; DEFICITS";"Objective: Autism spectrum disorder is a neurodevelopmental disease in which impaired social behaviors, impaired sociality, and restricted and repetitive behaviors are seen. Bumetanide is a loop diuretic that inhibits Na+-K+-2Cl(-) cotransporter 1 and it is currently used in clinical phase studies in patients with autism spectrum disorder. In present research, it is purposed to demonstrate the beneficial effects of torasemide which is another Na+-K+-2Cl(-) cotransporter 1 inhibitor on an experimental autism model induced with propionic acid by providing imaging and brain tissue investigations. Methods: Male Wistar rats were used in the present study (n = 30). Propionic acid of 250 mg/kg/day was administrated intraperitoneally in rats to induce autism for 5 days. Three groups were created for present study as follows: group 1, normal control (n = 10); group 2, propionic acid and saline given group (n = 10); group 3, propionic acid + torasemide -administrated group (n = 10). Results: Torasemide group scored higher on behavioral tests compared to saline group. The brain levels of malondialdehyde, tumor necrosis factor-alpha, interleukin-2, interleukin-17, and Nuclear Factor kappa B (NF-kappa B), Glial fibrillary acidic protein (GFAP) were remarkably higher in propionic acid + saline group. In histopathology assessments, torasemide group had higher neuronal count of Cornu Ammonis 1, neuronal count of Cornu Ammonis 2 in hippocampus, and Purkinje cells in cerebellum. GFAP immunostaining index (Cornu Ammonis 1) and cerebellum were lower in torasemide group. Magnetic resonance spectroscopy revealed that mean lactate value was higher in propionic acid + saline group compared to torasemide group. Conclusion: Our experimental results showed that torasemide might enhance gamma-aminobutyric acid activity. Torasemide can be considered another promising Na+-K+-2Cl(-) cotransporter 1 inhibitor in the treatment of autism with a longer half-life and less side effects after further studies.";"[Dogan, Murat] Hekim Med Co, Istanbul, Turkiye; [Albayrak, Yakup] Tekirdag Namik Kemal Univ, Dept Psychiat, Fac Med, Tekirdag, Turkiye; [Erbas, Oyutun] Demiroglu Bilim Univ, Dept Physiol, Fac Med, Istanbul, Turkiye";"Namik Kemal University; Demiroglu Bilim University";Albayrak, Y (corresponding author), Tekirdag Namik Kemal Univ, Dept Psychiat, Fac Med, Tekirdag, Turkiye.;dr.fuge@hotmail.com;"ERBAS, OYTUN/ABA-7380-2021; Albayrak, Yakup/ABA-7651-2020";Erbas, Oytun/0000-0001-5427-8428;;;;"Abuaish S, 2022, J MOL NEUROSCI, V72, P372, DOI 10.1007/s12031-021-01959-8; Abujamel TS, 2022, NUTRIENTS, V14, DOI 10.3390/nu14030608; Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders : DSM-IV; Amin Z, 2006, PHARMACOL BIOCHEM BE, V84, P635, DOI 10.1016/j.pbb.2006.06.007; Araghi-Niknam M, 2003, CELL MOL NEUROBIOL, V23, P945, DOI 10.1023/B:CEMN.0000005322.27203.73; Arumugam S, 2017, CARDIOVASC THER, V35, DOI 10.1111/1755-5922.12283; Baron-Cohen S, 2000, NEUROSCI BIOBEHAV R, V24, P355, DOI 10.1016/S0149-7634(00)00011-7; Ben-Ari Y, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11030396; Bhat S, 2014, REV NEUROSCIENCE, V25, P841, DOI 10.1515/revneuro-2014-0056; Bonnet U, 2000, EUR NEUROPSYCHOPHARM, V10, P97, DOI 10.1016/S0924-977X(99)00063-2; Cellot G, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00070; Chaddad A, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0373-0; Chaddad A, 2017, SCI REP-UK, V7, DOI 10.1038/srep45639; Chugani DC, 1999, PROG NEURO-PSYCHOPH, V23, P635, DOI 10.1016/S0278-5846(99)00022-6; Ciafrè S, 2020, RIV PSICHIATR, V55, P4, DOI 10.1708/3301.32713; Cooper LB, 2022, CLIN CARDIOL, V45, P265, DOI 10.1002/clc.23733; Corrigan NM, 2012, J AUTISM DEV DISORD, V42, P105, DOI 10.1007/s10803-011-1216-y; Courchesne E, 2011, NEUROLOGY, V76, P2111, DOI DOI 10.1212/01.WNL.0000399191.79091.28; Crutel V, 2021, J AUTISM DEV DISORD, V51, P2959, DOI 10.1007/s10803-020-04709-8; Deidda G, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00119; DeLong GR, 2005, CLIN NEUROPSYCHIATR; Denucci BL, 2021, REPROD TOXICOL, V106, P82, DOI 10.1016/j.reprotox.2021.10.010; Durankus F, 2022, INT J DEV NEUROSCI, V82, P716, DOI 10.1002/jdn.10221; Edmonson C, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-3; El-Ansary AK, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-74; Erbas O, 2018, INT J DEV NEUROSCI, V69, P68, DOI 10.1016/j.ijdevneu.2018.07.001; Erbas O, 2015, METAB BRAIN DIS, V30, P739, DOI 10.1007/s11011-014-9630-4; Erny D, 2017, IMMUNOLOGY, V150, P7, DOI 10.1111/imm.12645; Foley KA, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087072, 10.1371/journal.pone.0108413]; Friedman SD, 2003, NEUROLOGY, V60, P100, DOI 10.1212/WNL.60.1.100; Frye Richard E, 2013, Front Public Health, V1, P31, DOI 10.3389/fpubh.2013.00031; Goh S, 2014, JAMA PSYCHIAT, V71, P665, DOI 10.1001/jamapsychiatry.2014.179; Gottwald B, 2004, J NEUROL NEUROSUR PS, V75, P1524, DOI 10.1136/jnnp.2003.018093; Guo DJ, 2021, MOL PSYCHIATR, V26, P1505, DOI 10.1038/s41380-019-0472-7; Hadjikhani N, 2015, AUTISM, V19, P149, DOI 10.1177/1362361313514141; Hampel P, 2021, NEUROPHARMACOLOGY, V185, DOI 10.1016/j.neuropharm.2021.108449; Hampel P, 2021, EPILEPSY BEHAV, V114, DOI 10.1016/j.yebeh.2020.107616; Hampel P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27995-w; Herbert MR, 2003, BRAIN, V126, P1182, DOI 10.1093/brain/awg110; Hong MP, 2019, EXPERT OPIN INV DRUG, V28, P709, DOI 10.1080/13543784.2019.1649656; Howlin P, 2012, CAN J PSYCHIAT, V57, P275, DOI 10.1177/070674371205700502; Kaila K, 2014, NAT REV NEUROSCI, V15, P637, DOI 10.1038/nrn3819; Kaushik G, 2016, FRONT CHEM, V4, DOI 10.3389/fchem.2016.00012; Khera R, 2022, MOLECULES, V27, DOI 10.3390/molecules27030889; Kumar RA, 2009, CURR NEUROL NEUROSCI, V9, P188, DOI 10.1007/s11910-009-0029-2; Laurence JA, 2005, CEREBELLUM, V4, P206, DOI 10.1080/14734220500208846; Lawler CP, 2004, MENT RETARD DEV D R, V10, P292, DOI 10.1002/mrdd.20043; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; Lu ATH, 2013, MOL PSYCHIATR, V18, P226, DOI 10.1038/mp.2011.155; Lunden JW, 2019, PEDIATR RES, V85, P146, DOI 10.1038/s41390-018-0214-6; Marotta R, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10030163; Medavarapu S, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.3901; Möhler H, 2012, NEUROPHARMACOLOGY, V62, P42, DOI 10.1016/j.neuropharm.2011.08.040; Purcell AE, 2001, NEUROLOGY, V57, P1618, DOI 10.1212/WNL.57.9.1618; Sahin K, 2022, NUTRIENTS, V14, DOI 10.3390/nu14061280; Sever IH, 2022, NEUROSCI LETT, V779, DOI 10.1016/j.neulet.2022.136622; Sharma AR, 2022, CNS NEUROL DISORD-DR, V21, P399, DOI 10.2174/1871527320666210806165430; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Silvestrin RB, 2013, BRAIN RES, V1495, P52, DOI 10.1016/j.brainres.2012.11.048; Skaper SD, 2017, IMMUNOLOGY, V151, P1, DOI 10.1111/imm.12717; Solmaz V, 2020, NEUROPEPTIDES, V83, DOI 10.1016/j.npep.2020.102073; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; Sünnetçi E, 2021, CLIN PSYCHOPHARM NEU, V19, P84, DOI 10.9758/cpn.2021.19.1.84; Sussman D, 2015, NEUROIMAGE-CLIN, V8, P170, DOI 10.1016/j.nicl.2015.04.008; Xie MJ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.748627; Xu QF, 2020, J CLIN NEUROSCI, V78, P327, DOI 10.1016/j.jocn.2020.03.049; Yang YJ, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-22; Yu TG, 2015, BRIT J RADIOL, V88, DOI 10.1259/bjr.20140418";71;6;6;0;9;AVES;SISLI;BUYUKDERE CAD 105-9, MECIDIYEKOY, SISLI, ISTANBUL 34394, TURKEY;;2757-8038;;ALPHA PSYCHIAT;Alpha Psychiat.;JAN;2023;24;1;;;;;22;31;;10.5152/alphapsychiatry.2023.22975;http://dx.doi.org/10.5152/alphapsychiatry.2023.22975;;;10;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;8O4IY;36879996;Green Published;;;24/11/2024;WOS:000925800500005;View Full Record in Web of Science
J;"Johnson, CR; Handen, BL; Zimmer, M; Sacco, K; Turner, K";;;;"Johnson, Cynthia R.; Handen, Benjamin L.; Zimmer, Michelle; Sacco, Kelley; Turner, Kylan";;;Effects of Gluten Free/Casein Free Diet in Young Children with Autism: A Pilot Study;JOURNAL OF DEVELOPMENTAL AND PHYSICAL DISABILITIES;;;English;Article;;;;;;"Gluten-fee; Casein-free diet; Autism; Dietary restrictions";"CASEIN-FREE DIET; SPECTRUM DISORDERS";With reports of the growing incidence of autism spectrum disorder ASD in the United States, a large number of families of affected children is seeking alternative or complementary forms of treatment. One of the more popular interventions has been use of elimination regimes, such as the gluten and casein free (GFCF) diet. This pilot study involved a three-month, prospective, open label, randomized, parallel groups design of a GFCF diet compared to a healthy, low sugar diet (attention control) for young children with ASD. Both treatment groups evidenced some gains across a range of variables, including measures of behavior, language, and ratings of the core features of ASD. No statistically significant differences were noted between treatment groups. While our results do not support use of a GFCF diet in ASD, it is possible that a greater period of time is required for treatment before gains can be observed. Moreover, no significant nutritional differences or side effects were observed on the GFCF diet compared to the control diet. However, adherence to the GFCF diet proved difficult based on our adherence data.;"[Johnson, Cynthia R.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Autism Ctr, Pittsburgh, PA 15213 USA; [Zimmer, Michelle] Univ Cincinnati, Cincinnati, OH USA; [Turner, Kylan] Univ Pittsburgh, Sch Educ, Pittsburgh, PA 15260 USA";"Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; University of Cincinnati; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh";Johnson, CR (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Autism Ctr, 3420 5th Ave, Pittsburgh, PA 15213 USA.;Cynthia.Johnson@chp.edu;Handen, Benjamin/GRY-0095-2022;Turner, Kylan/0000-0002-9511-5059;;;;"Achenbach T.M., 2002, Child behavior checklist /1.5-5 (CBCL 1.5-5); Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; [Anonymous], SPSS WIND; Arnold GL, 2003, J AUTISM DEV DISORD, V33, P449, DOI 10.1023/A:1025071014191; Arnold LE, 2000, J AUTISM DEV DISORD, V30, P99, DOI 10.1023/A:1005451304303; Brudnak MA, 2002, MED HYPOTHESES, V58, P422, DOI 10.1054/mehy.2001.1513; Elder JH, 2006, J AUTISM DEV DISORD, V36, P413, DOI 10.1007/s10803-006-0079-0; *ESHA RES INC, 2005, FOOD PROC NUTR FITN; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Goday P, 2008, NUTR CLIN PRACT, V23, P581, DOI 10.1177/0884533608326277; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; GUY W, 1976, US DHEW, V7633; Hediger ML, 2008, J AUTISM DEV DISORD, V38, P848, DOI 10.1007/s10803-007-0453-6; JOHNSON SB, 1986, HEALTH PSYCHOL, V5, P545, DOI 10.1037/0278-6133.5.6.545; Knivsberg A. M., 1995, SCANDANAVIAN J ED RE, V39, P222; Knivsberg AM, 2002, NUTR NEUROSCI, V5, P251, DOI 10.1080/10284150290028945; Levy SE, 2003, PEDIATR ANN, V32, P685, DOI 10.3928/0090-4481-20031001-10; Lord C., 2002, AUTISM DIAGNOSTIC OB; MILLWARD C, 2008, COCHRAN LIB, V1, P1; Mullen EM., 1995, MULLEN SCALES EARLY; *NAT RES COUNC, 2001, DIV BEHAV SOC SCI ED; Newschaffer CJ, 2003, PUBLIC HEALTH REP, V118, P393, DOI 10.1093/phr/118.5.393; Rutter M., 2003, SOCIAL COMMUNICATION; Seung H, 2007, J MED SPEECH-LANG PA, V15, P337; Tapp J., 2003, Procoder for Digital Video";26;55;64;2;97;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;1056-263X;1573-3580;;J DEV PHYS DISABIL;J. Dev. Phys. Disabil.;JUN;2011;23;3;;;;;213;225;;10.1007/s10882-010-9217-x;http://dx.doi.org/10.1007/s10882-010-9217-x;;;13;"Education, Special; Psychology, Developmental; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychology; Rehabilitation";753SQ;;;;;24/11/2024;WOS:000289800400004;View Full Record in Web of Science
J;"da Silva, JF; Honorato, MM; Cremaschi, RMD; Coelho, FMS";;;;"da Silva, Joao Ferreira; Honorato, Marcos Manoel; Cremaschi, Renata Maria de Carvalho; Coelho, Fernando Morgadinho Santos";;;Efficacy and tolerance profile of risperidone use in people with autism spectrum disorder in a clinic in Santarem, Para, Brazil. A retrospective study;JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE;;;English;Article;;;;;;"Autism; Treatment; Risperidone";"CHILDREN; PREVALENCE; ADOLESCENTS";Objectives: This study aimed to obtain the profile of efficacy and tolerance of risperidone in the treatment of people with autism spectrum disorder.Materials and Methods: This research was a cross-sectional and retrospective study. The medical records of 100 patients diagnosed with ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) were analyzed and measures of central tendency and correlation between variables such as gender, age at diagnosis, symptoms, daily dose, comorbidities, polytherapy, adverse drug effects, and outcome (improvement, worsening, and drug discontinuation) were calculated using Pearson's R test with a level of statistical significance P < 0.05.Results: The male gender was the most affected, corresponding to 80% of the participants. The mean age at diagnosis was 6.88 +/- 6.24 and the mean dose was 1.89 +/- 1.68 mg/day. The use of risperidone for patients with aggressiveness, hyperactivity, insomnia, or self-harm improved in 76% of patients and adverse effects were reported in 27% of cases. The presence of self-harm implied lower chances of improvement (P = 0.05/r = -0.20). Adverse effects were strong predictors of discontinuation (P = 0.01/r = 0.39), and epileptic patients were more likely to have them (P = 0.02/r = 0.20). Male gender was associated with dosages lower than 2 mg/day (P = 0.05/r = 0.23).Conclusion: Risperidone is a good option in the management of secondary symptoms of ASD, generally requiring low doses and presenting an acceptable profile of adverse effects. The age of diagnosis does not affect the drug's efficiency, but it can make the management of ASD difficult.;"[da Silva, Joao Ferreira; Honorato, Marcos Manoel] State Univ Para, Ctr Biol & Hlth Sci, Santarem, Portugal; [Cremaschi, Renata Maria de Carvalho; Coelho, Fernando Morgadinho Santos] Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Sao Paulo, Brazil";Universidade Federal de Sao Paulo (UNIFESP);da Silva, JF (corresponding author), State Univ Para, Ctr Biol & Hlth Sci, Santarem, Portugal.;johnx.ferreira@gmail.com;Coelho, Fernando/E-6728-2016;"Ferreira da Silva, Joao/0000-0003-3957-6907; CREMASCHI, RENATA/0000-0002-8205-4816";;;;"Al-Huseini S, 2022, AUTISM RES TREAT, V2022; Alsayouf HA, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8050318; Bargiela S, 2016, J AUTISM DEV DISORD, V46, P3281, DOI 10.1007/s10803-016-2872-8; Besag FMC, 2018, NEUROPSYCH DIS TREAT, V14, P1, DOI 10.2147/NDT.S120509; Chopko TC, 2018, ACS CHEM NEUROSCI, V9, P1520, DOI 10.1021/acschemneuro.8b00159; D'Alò GL, 2021, HEALTH QUAL LIFE OUT, V19, DOI 10.1186/s12955-021-01669-0; Dawson G, 2012, J AM ACAD CHILD PSY, V51, P1150, DOI 10.1016/j.jaac.2012.08.018; de Castro CB, 2016, REV BRAS NEUROL, V52, P20; de Lima Reis DD, 2019, PARA RES MED J, V3, P1; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Estrin GL, 2021, REV J AUTISM DEV DIS, V8, P454, DOI 10.1007/s40489-020-00225-8; Fu BQ, 2017, IMMUNITY, V47, P1100, DOI [10.1016/j.immuni.2017.11.018, 10.15585/mmwr.ss6904a1]; Galli J, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.736696; Ghanizadeh A, 2014, CHILD PSYCHIAT HUM D, V45, P185, DOI 10.1007/s10578-013-0390-x; Hesapcioglu ST, 2020, RES AUTISM SPECTRUM, V72, P1; Kaat AJ, 2013, RES AUTISM SPECT DIS, V7, P1579, DOI 10.1016/j.rasd.2013.08.012; LAMPL Y, 1991, CLIN NEUROPHARMACOL, V14, P251, DOI 10.1097/00002826-199106000-00009; Lincoln J, 2021, RSD, V10, P1; Lobar SL, 2016, J PEDIATR HEALTH CAR, V30, P359, DOI 10.1016/j.pedhc.2015.09.005; Lord C, 2006, ARCH GEN PSYCHIAT, V63, P694, DOI 10.1001/archpsyc.63.6.694; Lupindo BM, 2023, CURR PSYCHOL, V42, P24181, DOI 10.1007/s12144-022-03514-z; Mannion A, 2016, RES AUTISM SPECT DIS, V22, P20, DOI 10.1016/j.rasd.2015.11.002; Piras M, 2022, J CLIN PSYCHIAT, V83, DOI 10.4088/JCP.21m14110; Posar A, 2020, PEDIATR ANN, V49, pE278, DOI 10.3928/19382359-20200511-01; Salari N, 2022, ITAL J PEDIATR, V48, DOI 10.1186/s13052-022-01310-w; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Szalavitz M., 2016, Scientific American, V27, P48, DOI DOI 10.1038/SCIENTIFICAMERICANMIND0316-48; Verrotti A, 2011, OBES REV, V12, pe32, DOI 10.1111/j.1467-789X.2010.00800.x; Yang YJD, 2017, J NEURODEV DISORD, V9, DOI 10.1186/s11689-017-9183-z; Zhang Y, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0699-8";30;0;0;1;2;SCIENTIFIC SCHOLAR LLC;PITTSFORD;50, WOODGREEN DR, PITTSFORD, NY 14534 USA;0976-3147;0976-3155;;J NEUROSCI RURAL PRA;J. Neurosci. Rural Pract.;APR-JUN;2023;14;2;;;;;308;312;;10.25259/JNRP_53_2022;http://dx.doi.org/10.25259/JNRP_53_2022;;;5;Clinical Neurology;Emerging Sources Citation Index (ESCI);Neurosciences & Neurology;H2FK9;37181171;gold, Green Published;;;24/11/2024;WOS:000994172900018;View Full Record in Web of Science
J;"Qiu, JJ; Kong, XJ; Li, JH; Yang, J; Huang, YT; Huang, MS; Sun, BB; Su, JY; Chen, HE; Wan, GB; Kong, J";;;;"Qiu, Jiujun; Kong, Xuejun; Li, Jihan; Yang, Jie; Huang, Yiting; Huang, Minshi; Sun, Binbin; Su, Jiayi; Chen, Helen; Wan, Guobin; Kong, Jian";;;Transcranial Direct Current Stimulation (tDCS) over the Left Dorsal Lateral Prefrontal Cortex in Children with Autism Spectrum Disorder (ASD);NEURAL PLASTICITY;;;English;Article;;;;;;;"ABERRANT BEHAVIOR CHECKLIST; SLEEP HABITS QUESTIONNAIRE; COGNITIVE CONTROL NETWORK; CHILDHOOD AUTISM; RATING-SCALE; CONNECTIVITY; BRAIN; MOTOR; INDIVIDUALS; ADOLESCENTS";Recently, transcranial direct current stimulation (tDCS) has been applied to relieve symptoms in individuals with autism spectrum disorder (ASD). In this prospective, parallel, single-blinded, randomized study, we investigate the modulation effect of three-week tDCS treatment at the left dorsal lateral prefrontal cortex (DLPFC) in children with ASD. 47 children with ASD were enrolled, and 40 (20 in each group) completed the study. The primary outcomes are Childhood Autism Rating Scale (CARS), Aberrant Behavior Checklist (ABC), and the Repetitive Behavior Scale-Revised (RBS-R). We found that children with ASD can tolerate three-week tDCS treatment with no serious adverse events detected. A within-group comparison showed that real tDCS, but not sham tDCS, can significantly reduce the scores of CARS, Children's Sleep Habits Questionnaire (CSHQ), and general impressions in CARS (15th item). Real tDCS produced significant score reduction in the CSHQ and in CARS general impressions when compared to the effects of sham tDCS. The pilot study suggests that three-week left DLPFC tDCS is well-tolerated and may hold potential in relieving some symptoms in children with ASD.;"[Qiu, Jiujun; Li, Jihan; Yang, Jie; Huang, Minshi; Sun, Binbin; Su, Jiayi; Wan, Guobin] Southern Med Univ, Affiliated Shenzhen Matern & Child Healthcare Hos, Dept Child Psychiat & Rehabil, Shenzhen, Peoples R China; [Kong, Xuejun] Harvard Med Sch, Massachusetts Gen Hosp, MGH HST Martinos Ctr Biomed Imaging, 149 13th St,1118A, Charlestown, MA 02129 USA; [Huang, Yiting; Chen, Helen; Kong, Jian] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA";"Southern Medical University - China; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital";"Wan, GB (corresponding author), Southern Med Univ, Affiliated Shenzhen Matern & Child Healthcare Hos, Dept Child Psychiat & Rehabil, Shenzhen, Peoples R China.;Kong, J (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.";"gbw1978@aliyun.com; jkong2@mgh.harvard.edu";"Sun, Binbin/H-8115-2015; huang, yiting/HDM-3648-2022";;"Key Realm R&D Program of Guangdong Province [2019B030335001]; Sanming Project of Medicine in Shenzhen [SZSM201512009]; Shenzhen Maternity & Child Healthcare Hospital Science Foundation [FYA2017002]";"Key Realm R&D Program of Guangdong Province; Sanming Project of Medicine in Shenzhen; Shenzhen Maternity & Child Healthcare Hospital Science Foundation";This study was funded by the Key Realm R&D Program of Guangdong Province (2019B030335001), the Sanming Project of Medicine in Shenzhen (SZSM201512009), and the Shenzhen Maternity & Child Healthcare Hospital Science Foundation (FYA2017002).;"Amatachaya A, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/928631; Amatachaya A, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/173073; Antal A, 2017, CLIN NEUROPHYSIOL, V128, P1774, DOI 10.1016/j.clinph.2017.06.001; Antonenko D, 2017, J NEUROSCI, V37, P4065, DOI 10.1523/JNEUROSCI.0079-17.2017; Bastani A, 2012, CLIN NEUROPHYSIOL, V123, P644, DOI 10.1016/j.clinph.2011.08.029; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Osório AAC, 2019, DEV MED CHILD NEUROL, V61, P298, DOI 10.1111/dmcn.14104; Carmassi C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00366; Chan AS, 2007, NEUROPSYCHOLOGY, V21, P74, DOI 10.1037/0894-4105.21.1.74; Christakou A, 2013, MOL PSYCHIATR, V18, P236, DOI 10.1038/mp.2011.185; Cieslik EC, 2013, CEREB CORTEX, V23, P2677, DOI 10.1093/cercor/bhs256; Clark VP, 2014, NEUROIMAGE, V85, P889, DOI 10.1016/j.neuroimage.2013.08.071; Coffman BA, 2014, NEUROIMAGE, V85, P895, DOI 10.1016/j.neuroimage.2013.07.083; Cole MW, 2007, NEUROIMAGE, V37, P343, DOI 10.1016/j.neuroimage.2007.03.071; Costanzo F, 2015, BRAIN STIMUL, V8, P1233, DOI 10.1016/j.brs.2015.08.009; D'Mello AM, 2017, J NEUROSCI, V37, P1604, DOI 10.1523/JNEUROSCI.2818-16.2017; Dickinson A, 2016, BRAIN RES, V1648, P277, DOI 10.1016/j.brainres.2016.07.011; Edgar JC, 2019, HUM BRAIN MAPP, V40, P3288, DOI 10.1002/hbm.24598; Egorova N, 2015, PAIN, V156, P1342, DOI 10.1097/j.pain.0000000000000163; Esmaeilpour Z, 2020, HUM BRAIN MAPP, V41, P1950, DOI 10.1002/hbm.24908; Ferrucci R, 2014, NEUROIMAGE, V85, P918, DOI 10.1016/j.neuroimage.2013.04.122; Finisguerra A, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00135; Flöel A, 2014, NEUROIMAGE, V85, P934, DOI 10.1016/j.neuroimage.2013.05.098; Fregni F, 2015, Clin Res Regul Aff, V32, P22; Gómez L, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7030063; Hadoush H, 2020, AUTISM RES, V13, P828, DOI 10.1002/aur.2290; Hendry A, 2020, J AUTISM DEV DISORD, V50, P4085, DOI 10.1007/s10803-020-04465-9; Huang YT, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00388; Ibrahim K, 2019, BIOL PSYCHIAT-COGN N, V4, P1031, DOI 10.1016/j.bpsc.2019.01.009; Ioannides AA, 2009, NEUROIMAGE, V44, P455, DOI 10.1016/j.neuroimage.2008.09.030; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kang JN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00201; Keehn RJJ, 2019, CEREB CORTEX, V29, P3319, DOI 10.1093/cercor/bhy201; Kessler RC, 2017, EPIDEMIOL PSYCH SCI, V26, P22, DOI 10.1017/S2045796016000020; Koenigs M, 2010, J NEUROSCI, V30, P16041, DOI 10.1523/JNEUROSCI.3745-10.2010; Kong J, 2019, BRAIN IMAGING BEHAV, V13, P482, DOI 10.1007/s11682-018-9875-3; Lee JC, 2019, CHILD ADOL PSYCH CL, V28, P61, DOI 10.1016/j.chc.2018.07.009; Legrain V, 2009, PAIN, V144, P230, DOI 10.1016/j.pain.2009.03.020; Liu J, 2019, BRAIN BEHAV IMMUN, V82, P253, DOI 10.1016/j.bbi.2019.08.193; Liu ZJ, 2014, SLEEP BIOL RHYTHMS, V12, P187, DOI 10.1111/sbr.12061; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Lukito S, 2020, PSYCHOL MED, V50, P894, DOI 10.1017/S0033291720000574; MESIBOV GB, 1989, J AM ACAD CHILD PSY, V28, P538, DOI 10.1097/00004583-198907000-00012; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Ming X, 2008, J CHILD NEUROL, V23, P6, DOI 10.1177/0883073807307102; Murias M, 2007, BIOL PSYCHIAT, V62, P270, DOI 10.1016/j.biopsych.2006.11.012; Muzur A, 2002, TRENDS COGN SCI, V6, P475, DOI 10.1016/S1364-6613(02)01992-7; Naro A, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00376; Navarese EP, 2018, JAMA-J AM MED ASSOC, V319, P1566, DOI 10.1001/jama.2018.2525; Nelson JT, 2014, NEUROIMAGE, V85, P909, DOI 10.1016/j.neuroimage.2012.11.061; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Owens JA, 2000, SLEEP, V23, P1043; Palm U, 2016, J NEURAL TRANSM, V123, P1219, DOI 10.1007/s00702-016-1572-z; Rosen ML, 2016, CEREB CORTEX, V26, P2059, DOI 10.1093/cercor/bhv028; Sanchack KE, 2016, AM FAM PHYSICIAN, V94, P972; Schmidt JD, 2013, RES DEV DISABIL, V34, P1190, DOI 10.1016/j.ridd.2013.01.002; Schneider HD, 2011, CLIN LINGUIST PHONET, V25, P640, DOI 10.3109/02699206.2011.570852; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Sharma SR, 2018, PHARMACOL THERAPEUT, V190, P91, DOI 10.1016/j.pharmthera.2018.05.007; Sheline YI, 2010, P NATL ACAD SCI USA, V107, P11020, DOI 10.1073/pnas.1000446107; Sun Wan-qi, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P713; Tao J, 2017, SCI REP-UK, V7, DOI 10.1038/srep41581; Tu YH, 2021, NEUROIMAGE, V237, DOI 10.1016/j.neuroimage.2021.118100; Tu YH, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101273118; van Steenburgh JJ, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0152-x; Vosskuhl J, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00211; Watt N, 2008, J AUTISM DEV DISORD, V38, P1518, DOI 10.1007/s10803-007-0532-8";67;15;17;3;25;HINDAWI LTD;LONDON;ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND;2090-5904;1687-5443;;NEURAL PLAST;Neural. Plast.;juin-19;2021;2021;;;;;;;;6627507;10.1155/2021/6627507;http://dx.doi.org/10.1155/2021/6627507;;;11;Neurosciences;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;TH7NN;34257640;Green Published, gold;;;24/11/2024;WOS:000672272200001;View Full Record in Web of Science
J;"Fleury-Teixeira, P; Caixeta, FV; da Silva, LCR; Brasil-Neto, JP; Malcher-Lopes, R";;;;"Fleury-Teixeira, Paulo; Caixeta, Fabio Viegas; Ramires da Silva, Leandro Cruz; Brasil-Neto, Joaquim Pereira; Malcher-Lopes, Renato";;;Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use;FRONTIERS IN NEUROLOGY;;;English;Article;;;;;;"autism spectrum disorders; cannabidiol; epilepsy; Cannabis sativa; endocannabinoid system";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TREATMENT-RESISTANT EPILEPSY; PEDIATRIC EPILEPSY; ENDOCANNABINOID SYSTEM; MOUSE MODEL; CHILDREN; CLOZAPINE; ANXIETY; COMORBIDITY; ASSOCIATION";"Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and CBD-enriched Cannabis sativa extract (CE) for the treatment of autistic symptoms in refractory epilepsy patients. There is also increasing data support for the hypothesis that non-epileptic autism shares underlying etiological mechanisms with epilepsy. Here we report an observational study with a cohort of 18 autistic patients undergoing treatment with compassionate use of standardized CBD-enriched CE (with a CBD to THC ratio of 75/1). Among the 15 patients who adhered to the treatment (10 non-epileptic and five epileptic) only one patient showed lack of improvement in autistic symptoms. Due to adverse effects, three patients discontinued CE use before 1 month. After 6-9 months of treatment, most patients, including epileptic and non-epileptic, showed some level of improvement in more than one of the eight symptom categories evaluated: Attention Deficit/Hyperactivity Disorder; Behavioral Disorders; Motor Deficits; Autonomy Deficits; Communication and Social Interaction Deficits; Cognitive Deficits; Sleep Disorders and Seizures, with very infrequent and mild adverse effects. The strongest improvements were reported for Seizures, Attention Deficit/Hyperactivity Disorder, Sleep Disorders, and Communication and Social Interaction Deficits. This was especially true for the 10 non-epileptic patients, nine of which presented improvement equal to or above 30% in at least one of the eight categories, six presented improvement of 30% or more in at least two categories and four presented improvement equal to or above 30% in at least four symptom categories. Ten out of the 15 patients were using other medicines, and nine of these were able to keep the improvements even after reducing or with drawing other medications. The results reported here are very promising and indicate that CBD-enriched CE may ameliorate multiple ASD symptoms even in non-epileptic patients, with substantial increase in life quality for both ASD patients and caretakers.";"[Fleury-Teixeira, Paulo] ePrimeCare Healthcare SA, Belo Horizonte, MG, Brazil; [Caixeta, Fabio Viegas; Brasil-Neto, Joaquim Pereira; Malcher-Lopes, Renato] Univ Brasilia, Dept Physiol Sci, Brasilia, DF, Brazil; [Ramires da Silva, Leandro Cruz] Univ Fed Minas Gerais, Clin Hosp, Belo Horizonte, MG, Brazil; [Ramires da Silva, Leandro Cruz] Assoc Brasileira Pacientes Cannabis Med, Belo Horizonte, MG, Brazil";"Universidade de Brasilia; Universidade Federal de Minas Gerais";Malcher-Lopes, R (corresponding author), Univ Brasilia, Dept Physiol Sci, Brasilia, DF, Brazil.;malcherlopes@gmail.com;"Malcher-Lopes, Renato/I-5170-2015; Brasil-Neto, Joaquim/A-1171-2009; Caixeta, Fabio/N-9405-2019; Caixeta, Fabio/J-9048-2014";"Malcher-Lopes, Renato/0000-0002-4941-9908; Caixeta, Fabio/0000-0003-0919-342X";FAP-DF [0193-001486/2017];FAP-DF;FC was supported by FAP-DF (Grant 0193-001486/2017).;"Aguirre-Velázquez CG, 2017, NEUROL RES INT, V2017, DOI 10.1155/2017/2985729; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Angelidou A, 2011, J AUTISM DEV DISORD, V41, P1579, DOI 10.1007/s10803-010-1171-z; Antel J, 2012, Handb Exp Pharmacol, P433, DOI 10.1007/978-3-642-24716-3_20; Bang M, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8614680; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6; Blessing EM, 2015, NEUROTHERAPEUTICS, V12, P825, DOI 10.1007/s13311-015-0387-1; Bozzi Y, 2018, EUR J NEUROSCI, V47, P534, DOI 10.1111/ejn.13595; Busquets-Garcia A, 2013, NAT MED, V19, P603, DOI 10.1038/nm.3127; Cao XS, 2017, NEUROSCI RES, V116, P3, DOI 10.1016/j.neures.2016.09.005; Cawthorpe David, 2017, Perm J, V21, P16, DOI 10.7812/TPP/16-088; Cheng N, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00034; Chez MG, 2006, EPILEPSY BEHAV, V8, P267, DOI 10.1016/j.yebeh.2005.11.001; Cilio MR, 2014, EPILEPSIA, V55, P787, DOI 10.1111/epi.12635; D'Agati D, 2017, J ECT, V33, P7, DOI 10.1097/YCT.0000000000000346; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Doyle Carolyn A, 2012, Dialogues Clin Neurosci, V14, P263; Dreifuss F E, 1988, Am J Med, V84, P34, DOI 10.1016/0002-9343(88)90055-1; Duggal HS, 2004, J CLIN PSYCHIAT, V65, P1145; Eapen V, 2017, ASIAN J PSYCHIATR, V30, P1, DOI 10.1016/j.ajp.2017.07.025; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Fitzpatrick SE, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S84585; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Griffiths KK, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4314025; Hazen EP, 2014, HARVARD REV PSYCHIAT, V22, P112, DOI 10.1097/01.HRP.0000445143.08773.58; Hesami O, 2016, J CLIN DIAGN RES, V10, pNC1, DOI 10.7860/JCDR/2016/16263.7339; Hirota T, 2014, J AUTISM DEV DISORD, V44, P948, DOI 10.1007/s10803-013-1952-2; Hu YB, 2017, AUTISM RES, V10, P1184, DOI 10.1002/aur.1789; Hussain SA, 2015, EPILEPSY BEHAV, V47, P138, DOI 10.1016/j.yebeh.2015.04.009; Ijff DM, 2013, HAND CLINIC, V111, P707, DOI 10.1016/B978-0-444-52891-9.00073-7; Iseger TA, 2015, SCHIZOPHR RES, V162, P153, DOI 10.1016/j.schres.2015.01.033; Jones RM, 2017, AUTISM RES, V10, P1567, DOI 10.1002/aur.1798; Jung KM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2045; Karhson DS, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0203-y; Kern JK, 2015, BRAIN CONNECT, V5, P321, DOI 10.1089/brain.2014.0324; Kerr DM, 2013, BEHAV BRAIN RES, V249, P124, DOI 10.1016/j.bbr.2013.04.043; Kerr DM, 2016, PHARMACOL RES, V113, P228, DOI 10.1016/j.phrs.2016.08.033; Khalil R, 2018, CNS NEUROSCI THER, V24, P669, DOI 10.1111/cns.13001; Koliqi Rozafa, 2015, Mater Sociomed, V27, P167, DOI 10.5455/msm.2015.27.167-171; Kral TVE, 2013, J PEDIATR NURS, V28, P548, DOI 10.1016/j.pedn.2013.01.008; Langbehn DR, 2000, PHARMACOPSYCHIATRY, V33, P196; Lei J, 2017, NEUROPSYCH DIS TREAT, V13, P1613, DOI 10.2147/NDT.S120710; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Lorenz R, 2004, NEUROENDOCRINOL LETT, V25, P40; Mahajan R, 2012, PEDIATRICS, V130, pS125, DOI 10.1542/peds.2012-0900J; Malcher-Lopes R., 2014, Rev. Biol, V13, P43, DOI [10.7594/revbio.13.01.07, DOI 10.7594/REVBIO.13.01.07]; Markram K, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00224; Masi A, 2017, PSYCHOL MED, V47, P1323, DOI 10.1017/S0033291716003457; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; Nicolai J, 2001, INTENS CARE MED, V27, P943, DOI 10.1007/s001340100937; O'Connell BK, 2017, EPILEPSY BEHAV, V70, P341, DOI 10.1016/j.yebeh.2016.11.012; Pan PY, 2016, PSYCHIAT RES, V241, P108, DOI 10.1016/j.psychres.2016.05.001; Polyak A, 2015, AM J MED GENET B, V168, P600, DOI 10.1002/ajmg.b.32338; Porter BE, 2013, EPILEPSY BEHAV, V29, P574, DOI 10.1016/j.yebeh.2013.08.037; Press CA, 2015, EPILEPSY BEHAV, V45, P49, DOI 10.1016/j.yebeh.2015.02.043; Qin M, 2015, BEHAV BRAIN RES, V291, P164, DOI 10.1016/j.bbr.2015.05.003; Ridler C, 2017, NAT REV NEUROL, V13, DOI 10.1038/nrneurol.2017.86; Rosemergy I, 2016, SEIZURE-EUR J EPILEP, V35, P56, DOI 10.1016/j.seizure.2016.01.009; Rosenberg EC, 2017, EPILEPSIA, V58, pE96, DOI 10.1111/epi.13815; Sahoo S, 2017, ASIAN J PSYCHIATR, V29, P194, DOI 10.1016/j.ajp.2017.07.012; Sandler AD, 2001, PEDIATRICS, V107, P1221; Schroeder JC, 2017, CURR TOP BEHAV NEURO, V30, P311, DOI 10.1007/7854_2015_407; Seeman P, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.195; Shannon Scott, 2016, Perm J, V20, P16, DOI 10.7812/TPP/16-005; Shuster J, 2014, J AUTISM DEV DISORD, V44, P90, DOI 10.1007/s10803-013-1854-3; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Slomski A, 2017, JAMA-J AM MED ASSOC, V318, P323, DOI 10.1001/jama.2017.8846; Stadnick N, 2017, AUTISM, V21, P841, DOI 10.1177/1362361316654083; Stoppelbein L, 2005, INT REV NEUROBIOL, V71, P343, DOI 10.1016/S0074-7742(05)71014-X; Todd Richard D, 2005, Curr Psychiatry Rep, V7, P133, DOI 10.1007/s11920-005-0010-y; Tordjman S, 2017, Neurosci Biobehav Rev, V80, P210, DOI 10.1016/j.neubiorev.2017.01.030; Treat L, 2017, EPILEPSIA, V58, P123, DOI 10.1111/epi.13617; Trottier G, 1999, J PSYCHIATR NEUROSCI, V24, P103; Tzadok M, 2016, SEIZURE-EUR J EPILEP, V35, P41, DOI 10.1016/j.seizure.2016.01.004; Walsh P, 2011, NAT REV NEUROSCI, V12, P603, DOI 10.1038/nrn3113; Wink LK, 2014, J CHILD ADOL PSYCHOP, V24, P78, DOI 10.1089/cap.2013.0099; Wood JR, 2005, PHYSIOL GENOMICS, V20, P233, DOI 10.1152/physiolgenomics.00193.2004; Ziats MN, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00065; Zuardi AW, 2012, CURR PHARM DESIGN, V18, P5131, DOI 10.2174/138161212802884681; ZUARDI AW, 1993, J PSYCHOPHARMACOL, V7, P82, DOI 10.1177/026988119300700112; ZUARDI AW, 1982, PSYCHOPHARMACOLOGY, V76, P245, DOI 10.1007/BF00432554; ZUARDI AW, 1995, J CLIN PSYCHIAT, V56, P485";83;53;55;2;30;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-2295;;;FRONT NEUROL;Front. Neurol.;oct-31;2019;10;;;;;;;;1145;10.3389/fneur.2019.01145;http://dx.doi.org/10.3389/fneur.2019.01145;;;9;"Clinical Neurology; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;JO6FQ;31736860;Green Published, gold;;;24/11/2024;WOS:000497673700001;View Full Record in Web of Science
J;"Schleider, LBL; Mechoulam, R; Saban, N; Meiri, G; Novack, V";;;;"Schleider, Lihi Bar-Lev; Mechoulam, Raphael; Saban, Naama; Meiri, Gal; Novack, Victor";;;Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy;SCIENTIFIC REPORTS;;;English;Article;;;;;;;"ENDOCANNABINOID SYSTEM; DRONABINOL; OXYTOCIN; CHILDREN; PREVALENCE; AGITATION; DISORDER; BEHAVIOR; BRAIN";"There has been a dramatic increase in the number of children diagnosed with autism spectrum disorders (ASD) worldwide. Recently anecdotal evidence of possible therapeutic effects of cannabis products has emerged. The aim of this study is to characterize the epidemiology of ASD patients receiving medical cannabis treatment and to describe its safety and efficacy. We analysed the data prospectively collected as part of the treatment program of 188 ASD patients treated with medical cannabis between 2015 and 2017. The treatment in majority of the patients was based on cannabis oil containing 30% CBD and 1.5% THC. Symptoms inventory, patient global assessment and side effects at 6 months were primary outcomes of interest and were assessed by structured questionnaires. After six months of treatment 82.4% of patients (155) were in active treatment and 60.0% (93) have been assessed; 28 patients (30.1%) reported a significant improvement, 50 (53.7%) moderate, 6 (6.4%) slight and 8 (8.6%) had no change in their condition. Twenty-three patients (25.2%) experienced at least one side effect; the most common was restlessness (6.6%). Cannabis in ASD patients appears to be well tolerated, safe and effective option to relieve symptoms associated with ASD.";"[Schleider, Lihi Bar-Lev; Novack, Victor] Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Clin Cannabis Res Inst, Beer Sheva, Israel; [Schleider, Lihi Bar-Lev; Novack, Victor] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel; [Schleider, Lihi Bar-Lev; Saban, Naama] Tikun Olam LTD, Res Dept, Tel Aviv, Israel; [Mechoulam, Raphael] Hebrew Univ Jerusalem, Inst Drug Res, Sch Pharm, Jerusalem, Israel; [Meiri, Gal] Ben Gurion Univ Negev, Negev Autism Ctr, Beer Sheva, Israel; [Meiri, Gal] Ben Gurion Univ Negev, Soroka Univ Med, Beer Sheva, Israel; [Meiri, Gal] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel";"Ben Gurion University; Soroka Medical Center; Ben Gurion University; Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University; Ben Gurion University";"Novack, V (corresponding author), Ben Gurion Univ Negev, Soroka Univ, Med Ctr, Clin Cannabis Res Inst, Beer Sheva, Israel.;Novack, V (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.";VictorNo@clalit.org.il;"Meiri, Gal/AAP-5356-2020; Novack, Victor/LEL-9974-2024";"Bar-Lev Schleider, Lihi/0000-0003-4349-3442; Novack, Victor/0000-0001-8706-9622";Tikun Olam LTD.;Tikun Olam LTD.;Tikun Olam LTD. supported the study.;"Anderson CL, 2017, J PEDIATR NEUROL, V15, P143, DOI 10.1055/s-0037-1598109; Aran A, 2018, NEUROLOGY, V90; BAX M, 1994, DEV MED CHILD NEUROL, V36, P659; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6; Boyle CA, 2011, PEDIATRICS, V127, P1034, DOI 10.1542/peds.2010-2989; Busquets-Garcia A, 2013, NAT MED, V19, P603, DOI 10.1038/nm.3127; Colizzi M, 2016, NEUROSCI BIOBEHAV R, V64, P359, DOI 10.1016/j.neubiorev.2016.03.010; Crippa JAS, 2011, J PSYCHOPHARMACOL, V25, P121, DOI 10.1177/0269881110379283; Croen LA, 2002, J AUTISM DEV DISORD, V32, P207, DOI 10.1023/A:1015453830880; Fabre LF., 1981, J Clin Pharmacol, V21, p377S382S; Green JJ, 2010, NEUROTHERAPEUTICS, V7, P250, DOI 10.1016/j.nurt.2010.05.006; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Jung KM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2045; Kerr DM, 2013, BEHAV BRAIN RES, V249, P124, DOI 10.1016/j.bbr.2013.04.043; Kruger T, 2006, J DEV BEHAV PEDIATR, V27, P433, DOI 10.1097/00004703-200610000-00029; Kurz R., 2010, Can Underwrit, V5, P4; Lin IF, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-20; Liu QR, 2009, GENES BRAIN BEHAV, V8, P519, DOI 10.1111/j.1601-183X.2009.00498.x; Lundström S, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1961; Maccarrone M, 2010, NEUROPSYCHOPHARMACOL, V35, P1500, DOI 10.1038/npp.2010.19; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Radbruch L, 2003, SCHMERZ, V17, P274, DOI 10.1007/s00482-003-0232-z; SALZMAN C, 1977, AM J DRUG ALCOHOL AB, V4, P251, DOI 10.3109/00952997709002763; Salzman C, 1976, AM J PSYCHIAT; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Volicer L, 1997, INT J GERIATR PSYCH, V12, P913, DOI 10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D; Walsh D, 2003, SUPPORT CARE CANCER, V11, P137, DOI 10.1007/s00520-002-0387-7; Walther S, 2006, PSYCHOPHARMACOLOGY, V185, P524, DOI 10.1007/s00213-006-0343-1; Walther S, 2011, J CLIN PSYCHOPHARM, V31, P256, DOI 10.1097/JCP.0b013e31820e861c; Wei D, 2015, P NATL ACAD SCI USA, V112, P14084, DOI 10.1073/pnas.1509795112; Zamberletti E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091916";33;96;100;2;30;NATURE PORTFOLIO;BERLIN;HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY;2045-2322;;;SCI REP-UK;Sci Rep;janv-17;2019;9;;;;;;;;200;10.1038/s41598-018-37570-y;http://dx.doi.org/10.1038/s41598-018-37570-y;;;7;Multidisciplinary Sciences;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Science & Technology - Other Topics;HH7ZS;30655581;Green Published, gold;;;24/11/2024;WOS:000455951300048;View Full Record in Web of Science
J;"Krahn, TM; Fenton, A";;;;"Krahn, Timothy M.; Fenton, Andrew";;;The Extreme Male Brain Theory of Autism and the Potential Adverse Effects for Boys and Girls with Autism;JOURNAL OF BIOETHICAL INQUIRY;;;English;Article;;;;;;"Autism; Gender; Sex; Brain; Stereotyping; Diagnosis; Empathy";"PERVASIVE DEVELOPMENTAL DISORDERS; SEX-DIFFERENCES; SPECTRUM DISORDERS; FOLLOW-UP; ANOREXIA-NERVOSA; MIND; CHILDREN; LANGUAGE; ATTENTION; GENDER";Autism, typically described as a spectrum neurodevelopmental disorder characterized by impairments in verbal ability and social reciprocity as well as obsessive or repetitious behaviours, is currently thought to markedly affect more males than females. Not surprisingly, this encourages a gendered understanding of the Autism Spectrum. Simon Baron-Cohen, a prominent authority in the field of autism research, characterizes the male brain type as biased toward systemizing. In contrast, the female brain type is understood to be biased toward empathizing. Since persons with autism are characterized as hyper-systemizers and hypo-empathizers, Baron-Cohen suggests that, whether they are male or female, most possess an extreme male brain profile. We argue that Baron-Cohen is misled by an unpersuasive gendering of certain capacities or aptitudes in the human population. Moreover, we suggest that this may inadvertently favour boys in diagnosing children with Autism Spectrum Disorders. If this is correct, it could also have rather serious consequences for treatment and services for girls (and women) on the Autism Spectrum.;"[Krahn, Timothy M.] Dalhousie Univ, Fac Med, Halifax, NS B3H 3M6, Canada; [Fenton, Andrew] Calif State Univ Fresno, Dept Philosophy, Fresno, CA 93740 USA";"Dalhousie University; California State University System; California State University Fresno";Krahn, TM (corresponding author), Dalhousie Univ, Fac Med, 1379 Seymour St, Halifax, NS B3H 3M6, Canada.;"tim.krahn@dal.ca; andrew.fenton@gmail.com";;Fenton, Andrew/0000-0002-8811-2917;Canadian Institutes of Health Research [NNF 80045];Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR));Thanks to Susan Sherwin and the Novel Tech Ethics research team for feedback on previous drafts of this paper as well as audience members who attended an oral conference presentation on the topic at the American Society for Bioethics and Humanities annual conference in 2009. Funding for this project was provided by the Canadian Institutes of Health Research, NNF 80045, States of Mind: Emerging Issues in Neuroethics.;"Abbeduto L., 2007, Language disorders from a developmental perspective, P195; [Anonymous], 1993, UNDERSTANDING OTHER; [Anonymous], 2006, Social justice: The moral foundation of public health and health policy; [Anonymous], 2005, BBC NEWS; [Anonymous], 2009, JEZEBEL; [Anonymous], PHENOMENOLOGY COGNIT; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Baron-Cohen S, 2002, TRENDS COGN SCI, V6, P248, DOI 10.1016/S1364-6613(02)01904-6; Baron-Cohen S., 2005, ORIGINS SOCIAL MIND, P468; Baron-Cohen S., 2003, The Essential Difference: Male and Female Brains and the Truth About Autism; Baron -Cohen S., 1997, MINDBLINDNESS ESSAY; Baron-Cohen S., 2009, COEVOLUTION LANGUAGE; Baron-Cohen S., 1993, UNDERSTANDING OTHER; Baron-Cohen S., 2005, The lost self: Pathologies of the brain and identity, P166; Baron-Cohen Simon., 2009, NEW YORK TIMES; Brasic J.R., 2011, Medscape reference; Bryson SE, 2003, CAN J PSYCHIAT, V48, P506, DOI 10.1177/070674370304800802; Burman DD, 2008, NEUROPSYCHOLOGIA, V46, P1349, DOI 10.1016/j.neuropsychologia.2007.12.021; Caplan P., 1999, THINKING CRITICALLY, V2nd; CARMEN FH, 1981, AM J PSYCHIAT, V138, P1319; Connellan J, 2000, INFANT BEHAV DEV, V23, P113, DOI 10.1016/S0163-6383(00)00032-1; Cowley G., 2003, NEWSWEEK; Davidson J, 2007, GENDER PLACE CULT, V14, P659, DOI 10.1080/09663690701659135; de Villiers J., 2000, Understanding other minds: Perspectives from autism, P83; Donvan J., 2008, ABC NEWS; Downs E., 2008, J GAZETTE; Dyck MJ, 2001, EUR CHILD ADOLES PSY, V10, P105, DOI 10.1007/s007870170033; Ellefsen A, 2007, J AUTISM DEV DISORD, V37, P437, DOI 10.1007/s10803-006-0178-y; FAHERTY C, 2002, AUTISM TODAY; Farrant BM, 2006, CHILD DEV, V77, P1842, DOI 10.1111/j.1467-8624.2006.00977.x; Fausto-Sterling A., 2000, SEXING BODY GENDER P; Fausto-Sterling Anne., 1985, MYTHS GENDER BIOL TH; FENSON L, 1994, MONOGR SOC RES CHILD, V59, pR5; Fenson L., 1994, MONOGRAPHS SOC RES C, V59, P174, DOI DOI 10.2307/1166093; Fine C., 2010, COMMUNICATION; Fine Cordelia., 2010, DELUSIONS GENDER OUR; Fisch GS, 2005, AM J MED GENET A, V135A, P117, DOI 10.1002/ajmg.a.30497; Flora C., 2006, PSYCHOL TODAY NOV; Fombonne E, 2005, J CLIN PSYCHIAT, V66, P3; Frith U, 1999, MIND LANG, V14, P1; Frith U., 1989, DIAGNOSIS TREATMENT, P29; GILLBERG C, 1991, J AM ACAD CHILD PSY, V30, P375, DOI 10.1097/00004583-199105000-00004; GILLBERG C, 1992, BEHAV NEUROL, V5, P27, DOI 10.3233/BEN-1992-5105; Gillberg C., 2000, BIOL AUTISTIC SYNDRO; Gillberg C, 2006, J AUTISM DEV DISORD, V36, P429, DOI 10.1007/s10803-006-0081-6; Ginn J, 1996, BRIT J SOCIOL, V47, P167, DOI 10.2307/591122; Hale CM, 2003, DEVELOPMENTAL SCI, V6, P346, DOI 10.1111/1467-7687.00289; Happé F, 1999, TRENDS COGN SCI, V3, P216, DOI 10.1016/S1364-6613(99)01318-2; HAPPE FGE, 1995, CHILD DEV, V66, P843, DOI 10.1111/j.1467-8624.1995.tb00909.x; Happé F, 2006, NAT NEUROSCI, V9, P1218, DOI 10.1038/nn1770; Hill A., 2009, GUARDIAN OBSERVER; Howlin P, 2000, J CHILD PSYCHOL PSYC, V41, P561, DOI 10.1111/1469-7610.00643; Jordan-Young RebeccaM., 2010, Brain Storm: The Flaws in the Science of Sex Differences; Karrass J, 2002, J CHILD LANG, V29, P519, DOI 10.1017/S0305000902005196; Kindlon D., 1999, Raising Cain: Protecting the emotional life of boys; Kitayama S., 2010, HDB CULTURAL PSYCHOL; Kopp S, 1997, J CHILD PSYCHOL PSYC, V38, P257, DOI 10.1111/j.1469-7610.1997.tb01859.x; Kopp Svenny, 1992, Eur Child Adolesc Psychiatry, V1, P89, DOI 10.1007/BF02091791; Kopp S, 2010, J ATTEN DISORD, V14, P167, DOI 10.1177/1087054709332458; Kraemer S, 2000, BRIT MED J, V321, P1609, DOI 10.1136/bmj.321.7276.1609; Liss M, 2001, J AUTISM DEV DISORD, V31, P219, DOI 10.1023/A:1010707417274; Lloyd G., 1984, MAN REASON MALE FEMA; London E, 2007, BRAIN PATHOL, V17, P408, DOI 10.1111/j.1750-3639.2007.00103.x; MCLENNAN JD, 1993, J AUTISM DEV DISORD, V23, P217, DOI 10.1007/BF01046216; Miller CA, 2001, J COMMUN DISORD, V34, P73, DOI 10.1016/S0021-9924(00)00042-3; Minshew N.J., 2006, PATIENT BASED APPROA, P419; Minshew NJ, 1998, MENT RETARD DEV D R, V4, P129, DOI 10.1002/(SICI)1098-2779(1998)4:2<129::AID-MRDD10>3.0.CO;2-X; Minter M, 1998, BRIT J DEV PSYCHOL, V16, P183, DOI 10.1111/j.2044-835X.1998.tb00918.x; Mwachofi AK, 2009, DISABIL REHABIL, V31, P693, DOI 10.1080/09638280802305929; Nash A, 2007, J INTERDISCIPLINARY, V2, P1; Nicholas JS, 2008, ANN EPIDEMIOL, V18, P130, DOI 10.1016/j.annepidem.2007.10.013; Nilsson EW, 1999, J AM ACAD CHILD PSY, V38, P1389, DOI 10.1097/00004583-199911000-00013; Nydén A, 2000, EUR CHILD ADOLES PSY, V9, P180, DOI 10.1007/s007870070041; PAECHTER C.F., 2007, BEING BOYS BEING GIR; Pereira M., 1999, LANGUAGE DEV SOCIAL; Petersen A, 2004, ENGENDERING EMOTIONS, P1, DOI 10.1057/9780230512610; Peterson CC, 1999, PSYCHOL SCI, V10, P126, DOI 10.1111/1467-9280.00119; PETERSON CC, 1995, J CHILD PSYCHOL PSYC, V36, P459, DOI 10.1111/j.1469-7610.1995.tb01303.x; Reddy WilliamM., 2001, The Navigation of Feeling: A Framework for the History of Emotions; Rogers LJ, 2010, KAOHSIUNG J MED SCI, V26, pS4, DOI 10.1016/S1607-551X(10)70051-6; ROONEY P, 1994, AM PHILOS QUART, V31, P1; Schick B., 2002, ASHA LEADER 1203; Sherwin Susan., 1992, No Longer Patient: Feminist Ethics and Health Care; Skuse DH, 2009, J AM ACAD CHILD PSY, V48, P128, DOI 10.1097/CHI.0b013e31819176b8; Smith T, 1998, J AUTISM DEV DISORD, V28, P343, DOI 10.1023/A:1026020905266; Smith T., 2002, MEDSCAPE PSYCHIAT ME; Spelke ES, 2005, AM PSYCHOL, V60, P950, DOI 10.1037/0003-066X.60.9.950; Steele S, 2003, J AUTISM DEV DISORD, V33, P461, DOI 10.1023/A:1025075115100; Stobbe M., 2007, MSNBC; Tager-Flusberg H, 2007, CURR DIR PSYCHOL SCI, V16, P311, DOI 10.1111/j.1467-8721.2007.00527.x; Tavris C, 1998, Nebr Symp Motiv, V45, P1; Thompson T., 2003, Journal of Learning Disabilities, V7, P345, DOI [DOI 10.1177/1469004703074003, 10.1177/1469004703074003]; Traustadottir R., 2000, WOMEN INTELLECTUAL D; VENTER A, 1992, J CHILD PSYCHOL PSYC, V33, P489, DOI 10.1111/j.1469-7610.1992.tb00887.x; VOLKMAR FR, 1993, J AUTISM DEV DISORD, V23, P579, DOI 10.1007/BF01046103; Wallentin M, 2009, BRAIN LANG, V108, P175, DOI 10.1016/j.bandl.2008.07.001; Walsh P.N., 2002, Health of women with intellectual disabilities; WOLFF S, 1995, J CHILD PSYCHOL PSYC, V36, P793, DOI 10.1111/j.1469-7610.1995.tb01330.x; World Health Organization, 2009, WOMEN AND HEALTH: TODAY'S EVIDENCE TOMORROW'S AGENDA, P1; Yoder JD, 2003, PSYCHOL WOMEN QUART, V27, P281, DOI 10.1111/1471-6402.00108; Zahn-Waxler C., 2006, DEV PSYCHOL, V2nd, P76, DOI DOI 10.1002/9780470939383.CH4; Zahn-Waxler C, 2008, ANNU REV CLIN PSYCHO, V4, P275, DOI 10.1146/annurev.clinpsy.3.022806.091358";102;38;56;1;89;SPRINGER;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;1176-7529;1872-4353;;J BIOETHIC INQ;J. Bioethical Inq.;MAR;2012;9;1;;;;;93;103;;10.1007/s11673-011-9350-y;http://dx.doi.org/10.1007/s11673-011-9350-y;;;11;"Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences";898WW;23180205;;;;24/11/2024;WOS:000300774100012;View Full Record in Web of Science
J;"Carminati, GG; Gerber, F; Darbellay, B; Kosel, MM; Deriaz, N; Chabert, J; Fathi, M; Bertschy, G; Ferrero, F; Carminati, F";;;;"Carminati, Giuliana Galli; Gerber, Fabienne; Darbellay, Barbara; Kosel, Markus Mathaus; Deriaz, Nicolas; Chabert, Jocelyne; Fathi, Marc; Bertschy, Gilles; Ferrero, Francois; Carminati, Federico";;;Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder;PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY;;;English;Article;;;;;;"Autism spectrum disorder; Behavioral disorder; Aggressiveness; Venlafaxine";"PERVASIVE DEVELOPMENTAL DISORDERS; MENTAL-RETARDATION; RATING-SCALE; SELF-INJURY; CHILDREN; ADULTS; ADOLESCENTS; PAROXETINE; SEROTONIN; PHARMACOTHERAPY";Objective: To test the efficacy of venlafaxine at a dose of 18.75 mg/day on the reduction of behavioral problems such as irritability and hyperactivity/noncompliance in patients with intellectual disabilities and autism spectrum disorder (ASD). Our secondary hypothesis was that the usual doses of zuclopenthixol and/or clonazepam would decrease in the venlafaxine-treated group. Methods: In a randomized double-blind study, we compared six patients who received venlafaxine along with their usual treatment (zuclopenthixol and/or clonazepam) with seven patients who received placebo plus usual care. Irritability, hyperactivity/noncompliance, and overall clinical improvement were measured after 2 and 8 weeks, using validated clinical scales. Results: Univariate analyses showed that the symptom of irritability improved in the entire sample (p = 0.023 after 2 weeks, p = 0.061 at study endpoint), although no difference was observed between the venlafaxine and placebo groups. No significant decrease in hyperactivity/noncompliance was observed during the study. At the end of the study, global improvement was observed in 33% of participants treated with venlafaxine and in 71% of participants in the placebo group (p = 0.29). The study found that decreased cumulative doses of clonazepam and zuclopenthixol were required for the venlafaxine group. Multivariate analyses (principal component analyses) with at least three combinations of variables showed that the two populations could be clearly separated (p < 0.05). Moreover, in all cases, the venlafaxine population had lower values for the Aberrant Behavior Checklist (ABC), Behavior Problems Inventory (BPI), and levels of urea with respect to the placebo group. In one case, a reduction in the dosage of clonazepam was also suggested. For an additional set of variables (ABC factor 2, BPI frequency of aggressive behaviors, hematic ammonia at Day 28, and zuclopenthixol and clonazepam intake), the separation between the two samples was statistically significant as was the Bartlett's test, but the Kaiser-Meyer-Olkin Measure of Sampling Adequacy was below the accepted threshold. This set of variables showed a reduction in the cumulative intake of both zuclopenthixol and clonazepam. Conclusion: Despite the small sample sizes, this study documented a statistically significant effect of venlafaxine. Moreover, we showed that lower doses of zuclopenthixol and clonazepam were needed in the venlafaxine group, although this difference was not statistically significant. This was confirmed by multivariate analyses, where this difference reached statistical significance when using a combination of variables involving zuclopenthixol. Larger-scale studies are recommended to better investigate the effectiveness of venlafaxine treatment in patients with intellectual disabilities and ASD. (C) 2015 Elsevier Inc. All rights reserved.;"[Carminati, Giuliana Galli] SNUBH, Seoul, South Korea; [Gerber, Fabienne; Darbellay, Barbara; Kosel, Markus Mathaus] Hop Univ Geneve, Dept Sante Mental & Psychiat, Serv Specialites Psychiat, Unite Dev Mental, CH-1225 Chene Bourg, Switzerland; [Deriaz, Nicolas] Clin Grangettes, Serv Pediat, CH-1224 Chene Bougeries, Switzerland; [Chabert, Jocelyne] Hop Cantonal Geneva, Hop Univ Geneve, Ctr Rech Clin, Unite Invest Clin, CH-1211 Geneva 14, Switzerland; [Fathi, Marc] Hop Cantonal Geneva, Hop Univ Geneve, Serv Med Lab, Dept Pathol Clin,Lab Cent Chim Clin, CH-1211 Geneva 14, Switzerland; [Bertschy, Gilles] Hop Univ Strasbourg, Serv Psychiat 2, Pole Psychiat & Sante Mentale, F-67091 Strasbourg, France; [Ferrero, Francois] Univ Geneva, CH-1205 Geneva, Switzerland; [Carminati, Federico] CERN, CH-1211 Geneva 23, Switzerland";"University of Geneva; University of Geneva; University of Geneva; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; University of Geneva; European Organization for Nuclear Research (CERN)";Carminati, GG (corresponding author), Av Ste Cecile 29, CH-1217 Meyrin, Switzerland.;giuliana.gallicarminati@gmail.com;"Kosel, Markus/AAN-9168-2021; Bertschy, Gilles/A-4349-2010";Bertschy, Gilles/0000-0002-0827-7659;"Unit of Mental Development of the Department of Mental Health and Psychiatry of the Geneva University Hospitals, Geneva, Switzerland; Fondation Handicap Mental & Societe (FHMS), Geneva, Switzerland [CGR 73166 PS-Venlafaxine]";"Unit of Mental Development of the Department of Mental Health and Psychiatry of the Geneva University Hospitals, Geneva, Switzerland; Fondation Handicap Mental & Societe (FHMS), Geneva, Switzerland";"The Unit of Mental Development of the Department of Mental Health and Psychiatry of the Geneva University Hospitals, Geneva, Switzerland and the Fondation Handicap Mental & Societe (FHMS), Geneva, Switzerland, (N. CGR 73166 PS-Venlafaxine), supported this study. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.";"AMAN MG, 1985, AM J MENT DEF, V89, P485; Anderson GM, 2002, J AM ACAD CHILD PSY, V41, P1513, DOI 10.1097/00004583-200212000-00025; [Anonymous], DIAGN CRIT LEARN DIS; [Anonymous], 1976, CDEU ASSESSMENT MANU; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Baghdadli A, 2002, ENCEPHALE, V28, P248; Béhérec L, 2014, ENCEPHALE, V40, P188, DOI 10.1016/j.encep.2012.01.014; Benvenuto A, 2013, BRAIN DEV-JPN, V35, P119, DOI 10.1016/j.braindev.2012.03.015; Canitano R, 2011, PROG NEURO-PSYCHOPH, V35, P18, DOI 10.1016/j.pnpbp.2010.10.015; Carminati GG, 2006, PROG NEURO-PSYCHOPH, V30, P312, DOI 10.1016/j.pnpbp.2005.10.002; COOK EH, 1992, J AM ACAD CHILD PSY, V31, P739, DOI 10.1097/00004583-199207000-00024; Davanzo PA, 1998, AM J MENT RETARD, V102, P427; ELLINGROD VL, 1994, AM J HOSP PHARM, V51, P3033, DOI 10.1093/ajhp/51.24.3033; Farmer C, 2013, DRUGS, V73, P303, DOI 10.1007/s40265-013-0021-7; Figueras G, 1999, BIOL PSYCHIAT, V46, P518, DOI 10.1016/S0006-3223(98)00344-8; Godleski LS, 2005, PROG NEURO-PSYCHOPH, V29, P141, DOI 10.1016/j.pnpbp.2004.08.009; Hellings JA, 1996, J CLIN PSYCHIAT, V57, P333; Hollander E, 2000, J CHILD NEUROL, V15, P132, DOI 10.1177/088307380001500214; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Luiselli JK, 2001, BEHAV MODIF, V25, P62, DOI 10.1177/0145445501251004; Matson JL, 2011, RES AUTISM SPECT DIS, V5, P230, DOI 10.1016/j.rasd.2010.04.004; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; MCDOUGLE CJ, 1990, J AUTISM DEV DISORD, V20, P537, DOI 10.1007/BF02216058; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001; Memari AH, 2012, RES DEV DISABIL, V33, P563, DOI 10.1016/j.ridd.2011.10.001; MESIBOV GB, 1989, J AM ACAD CHILD PSY, V28, P538, DOI 10.1097/00004583-198907000-00012; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; MORTON WA, 1995, ANN PHARMACOTHER, V29, P387, DOI 10.1177/106002809502900410; Mück-Seler D, 2002, PROG NEURO-PSYCHOPH, V26, P1235, DOI 10.1016/S0278-5846(02)00259-2; Mulder EJ, 2004, J AM ACAD CHILD PSY, V43, P491, DOI 10.1097/00004583-200404000-00016; Namerow LB, 2003, J DEV BEHAV PEDIATR, V24, P104, DOI 10.1097/00004703-200304000-00005; Pérez V, 1998, J CLIN PSYCHOPHARM, V18, P222, DOI 10.1097/00004714-199806000-00007; R_Core_Team, 2014, R LANG ENV STAT COMP; Reiss S, 1997, J INTELL DISABIL RES, V41, P448, DOI 10.1111/j.1365-2788.1997.tb00736.x; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; Santosh PJ, 1999, LANCET, V354, P233, DOI 10.1016/S0140-6736(98)07059-7; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; Spivak B, 2004, NEUROPSYCHOBIOLOGY, V50, P157, DOI 10.1159/000079108; Spooren W, 2012, TRENDS PHARMACOL SCI, V33, P669, DOI 10.1016/j.tips.2012.09.004; Steingard RJ, 1997, J CHILD ADOL PSYCHOP, V7, P9, DOI 10.1089/cap.1997.7.9; Weeden M, 2011, RES AUTISM SPECT DIS, V5, P108, DOI 10.1016/j.rasd.2010.02.005; West L, 2009, J PEDIATR HEALTH CAR, V23, P75, DOI 10.1016/j.pedhc.2008.12.001; Whitaker-Azmitia PM, 2005, INT J DEV NEUROSCI, V23, P75, DOI 10.1016/j.ijdevneu.2004.07.022";44;14;17;0;23;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0278-5846;1878-4216;;PROG NEURO-PSYCHOPH;Prog. Neuro-Psychopharmacol. Biol. Psychiatry;FEB 4;2016;65;;;;;;;;;10.1016/j.pnpbp.2015.09.002;http://dx.doi.org/10.1016/j.pnpbp.2015.09.002;;;11;"Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";CY9EC;26361994;;;;24/11/2024;WOS:000366709200010;View Full Record in Web of Science
J;"Kasahara, S; Kanda, S; Takahashi, M; Fujioka, M; Morita, T; Matsudaira, K; Sato, N; Hattori, M; Momose, T; Niwa, SI; Uchida, K";;;;"Kasahara, Satoshi; Kanda, Shoichiro; Takahashi, Miwako; Fujioka, Mao; Morita, Taito; Matsudaira, Ko; Sato, Naoko; Hattori, Motoshi; Momose, Toshimitsu; Niwa, Shin-Ichi; Uchida, Kanji";;;Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder;FRONTIERS IN PEDIATRICS;;;English;Article;;;;;;"autosomal dominant polycystic kidney disease; lower back pain; cystic fibrosis transmembrane conductance regulator; attention deficit hyperactivity disorder; autism spectrum disorder; guanfacine; methylphenidate; cerebral blood flow";"DEFICIT/HYPERACTIVITY DISORDER; CYSTIC-FIBROSIS; HOSPITAL ANXIETY; SYMPTOMS; SCALE; ADHD; CHILDREN; SYSTEM; HEALTH";"Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease characterized by the bilateral development of multiple cysts in the kidneys. Pain management is a clinically important issue, especially because approximately 60% of patients with ADPKD experience chronic pain related to hemorrhage from renal cysts, which significantly reduces their daily life. The cystic fibrosis transmembrane conductance regulator, the molecule responsible for cyst formation in ADPKD, is also the cause of cystic fibrosis. Since attention deficit hyperactivity disorder (ADHD) is known to occur frequently in conjunction with cystic fibrosis, ADPKD may be associated with ADHD. However, to our knowledge, no study has investigated 1) ADHD or autism spectrum disorder (ASD) as comorbidities with ADPKD, 2) the effects of ADHD medications on chronic pain in ADPKD, or 3) cerebral blood flow corresponding to guanfacine (GF) or methylphenidate (MP) treatment for chronic pain. We report the case of a 15-year-old girl with ADPKD, who had chronic back pain associated with ADPKD and had to withdraw from high school because the pain interfered with her daily life. Although she took antihypertensive medications to prevent bleeding, they did not provide adequate blood pressure control. The patient was referred to a child psychiatrist and diagnosed with ASD; however, the pain did not improve. Subsequently, she was referred to our pain center. The diagnosis of ADHD was confirmed and treatment with ADHD medications was initiated. Monotherapy with MP, atomoxetine, and GF resulted in hypertension and hypotension as side effects; however, a combination of MP 18 mg and GF 4 mg provided pain relief and moderate blood pressure control, and the patient was able to go on to college. During the course of treatment, there was an improvement in the distribution of cerebral blood flow in the prefrontal and insular cortices. Confirmation of an ADHD diagnosis comorbid with ASD enabled the use of ADHD medications. The combination of MP and GF improved chronic back pain and high blood pressure due to ADPKD and cerebral blood flow. Screening for ADHD is important in the treatment of ADPKD.";"[Kasahara, Satoshi; Morita, Taito; Uchida, Kanji] Univ Tokyo Hosp, Pain Relief Ctr, Tokyo, Japan; [Kasahara, Satoshi; Matsudaira, Ko] Fukushima Med Univ, Sch Med, Dept Pain Med, Fukushima, Japan; [Kanda, Shoichiro] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Kanda, Shoichiro; Hattori, Motoshi] Tokyo Womens Med Univ, Dept Pediat Nephrol, Tokyo, Japan; [Takahashi, Miwako] Natl Inst Quantum Sci & Technol, Inst Quantum Med Sci, Chiba, Japan; [Fujioka, Mao] Univ Tokyo Hosp, Dept Neuropsychiat, Tokyo, Japan; [Sato, Naoko] Univ Tokyo Hosp, Nursing Dept, Tokyo, Japan; [Momose, Toshimitsu] Univ Tokyo, Inst Engn Innovat, Sch Engn, Tokyo 1138656, Japan; [Niwa, Shin-Ichi] Fukushima Med Univ, Aizu Med Ctr, Dept Psychiat, Fukushima, Japan";"University of Tokyo; Fukushima Medical University; University of Tokyo; Tokyo Women's Medical University; National Institutes for Quantum Science & Technology; University of Tokyo; University of Tokyo; University of Tokyo; Fukushima Medical University";"Kasahara, S (corresponding author), Univ Tokyo Hosp, Pain Relief Ctr, Tokyo, Japan.;Kasahara, S (corresponding author), Fukushima Med Univ, Sch Med, Dept Pain Med, Fukushima, Japan.";namahagenator@gmail.com;Kasahara, Satoshi/AAK-5259-2020;TAKAHASHI, Miwako/0000-0002-1953-7428;Japan Society for the Promotion of Science [20K07755];Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science);The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (Grant number: 20K07755).;"American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Antshel KM, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1020-5; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2; Balestroni Gianluigi, 2012, Monaldi Arch Chest Dis, V78, P155; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brikell I, 2019, EPILEPSIA, V60, P284, DOI 10.1111/epi.14640; Cohen-Cymberknoh M, 2023, J CYST FIBROS, V22, P772, DOI 10.1016/j.jcf.2023.04.004; Cohen-Cymberknoh M, 2018, J CYST FIBROS, V17, P281, DOI 10.1016/j.jcf.2017.11.020; Conners CK., 2008, Conners. 3rd ed [manual]: Multi-health systems; Stokely MY, 2006, J NEUROSCI RES, V84, P1727, DOI 10.1002/jnr.21076; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Georgiopoulos AM, 2018, J CYST FIBROS, V17, P276, DOI 10.1016/j.jcf.2017.08.011; Georgiopoulos AM, 2011, PSYCHOSOMATICS, V52, P160, DOI 10.1016/j.psym.2010.12.016; Gimpel C, 2019, NAT REV NEPHROL, V15, P713, DOI 10.1038/s41581-019-0155-2; Harris PC., 2002, Polycystic Kidney Disease, Autosomal Dominant; Jensen M.P., 2011, Handbook of Pain Assessment; Kasahara S, 2023, FRONT PSYCHIATRY, V14, DOI 10.3389/fpsyt.2023.1221694; Kasahara S, 2023, CLIN CASE REP, V11, DOI 10.1002/ccr3.7552; Kasahara S, 2023, FRONT PAIN RES, V4, DOI 10.3389/fpain.2023.1159134; Kasahara S, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-28931-3; Kasahara S, 2022, CLIN CASE REP, V10, DOI 10.1002/ccr3.6422; Kasahara S, 2022, FRONT PAIN RES, V3, DOI 10.3389/fpain.2022.926946; Kasahara S, 2021, PSYCHOSOM MED, V83, P492, DOI 10.1097/PSY.0000000000000947; Kasahara S, 2021, PAIN PHYSICIAN, V24, pE299; Kasahara S, 2020, PSYCHOSOM MED, V82, P346, DOI 10.1097/PSY.0000000000000789; Legrain V, 2011, PROG NEUROBIOL, V93, P111, DOI 10.1016/j.pneurobio.2010.10.005; Lukacs GL, 2012, TRENDS MOL MED, V18, P81, DOI 10.1016/j.molmed.2011.10.003; McCracken JT, 2016, J AM ACAD CHILD PSY, V55, P657, DOI 10.1016/j.jaac.2016.05.015; Mochizuki T, 2013, CLIN EXP NEPHROL, V17, P317, DOI 10.1007/s10157-012-0741-0; Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Schreckenberger M, 2005, NEUROLOGY, V64, P1175, DOI 10.1212/01.WNL.0000156353.17305.52; Shteinberg M, 2021, LANCET, V397, P2195, DOI 10.1016/S0140-6736(20)32542-3; Skieterska K, 2016, BIOCHEM SOC T, V44, P601, DOI 10.1042/BST20150281; Solazzo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190430; Spitzer N, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3048; Stahl SM., 2020, Prescribers guide: Stahls essential psychopharmacology, P487; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Suzuki H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229228; van Luijk F, 2023, NEPHROL DIAL TRANSPL, V38, P618, DOI 10.1093/ndt/gfac158; Wang JY, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.861159; Wilens TE, 2012, J AM ACAD CHILD PSY, V51, P74, DOI 10.1016/j.jaac.2011.10.012; Yoshida Y, 2004, EUR CHILD ADOLES PSY, V13, P307, DOI 10.1007/s00787-004-0391-1; Zain E, 2023, FRONT PSYCHIATRY, V14, DOI 10.3389/fpsyt.2023.1091399; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x";47;2;2;0;0;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;2296-2360;;;FRONT PEDIATR;Front. Pediatr.;nov-01;2023;11;;;;;;;;1283823;10.3389/fped.2023.1283823;http://dx.doi.org/10.3389/fped.2023.1283823;;;9;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;Y2SL1;38027301;Green Published, gold;;;24/11/2024;WOS:001103814100001;View Full Record in Web of Science
J;"Hoover, DW; Romero, EMG";;;;"Hoover, Daniel W.; Romero, Elizabeth M. G.";;;The Interactive Trauma Scale: A Web-Based Measure for Children with Autism;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Autism; Trauma; Measure; Web-based";"ADVERSE CHILDHOOD EXPERIENCES; POSTTRAUMATIC-STRESS-DISORDER; SPECTRUM DISORDER; PEER VICTIMIZATION; ANXIETY DISORDERS; YOUNG-CHILDREN; ASSOCIATION; RELIABILITY; YOUTH; EXPOSURE";This study examined the feasibility, acceptability, and psychometric characteristics of a web-based touchscreen app prototype designed to assess self-reported trauma exposure and symptoms in children with autism spectrum disorder (ASD). The prototype was piloted with 20 clinically referred children previously diagnosed with ASD and having various known trauma exposures. User satisfaction and reported ease of use was high. The measure was sensitive to reports of teasing and bullying, endorsed by 75% and 70% of participants, respectively. Validity was assessed via comparisons with the UCLA Posttraumatic Stress Disorder Reaction Index and analysis of participants' trauma exposures and symptoms. Clinical implications are discussed including issues of trauma screening, diagnosis, and treatment planning for traumatized youth with ASD.;"[Hoover, Daniel W.] Kennedy Krieger Inst, Ctr Child & Family Traumat Stress, 1741 Ashland Ave, Baltimore, MD 21205 USA; [Hoover, Daniel W.] Johns Hopkins Sch Med, 1741 Ashland Ave, Baltimore, MD 21205 USA; [Romero, Elizabeth M. G.] Gallaudet Univ, Counseling Serv, Washington, DC 20002 USA; [Romero, Elizabeth M. G.] Gallaudet Univ, Psychol Serv, Washington, DC 20002 USA";"Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins Medicine";"Hoover, DW (corresponding author), Kennedy Krieger Inst, Ctr Child & Family Traumat Stress, 1741 Ashland Ave, Baltimore, MD 21205 USA.;Hoover, DW (corresponding author), Johns Hopkins Sch Med, 1741 Ashland Ave, Baltimore, MD 21205 USA.";hooverd@kennedykrieger.org;;Hoover, Daniel/0000-0003-4755-9541;Verizon Wireless Company;Verizon Wireless Company;Measure development and this research were supported by a grant from the Verizon Wireless Company.;"Adams RE, 2014, J AUTISM DEV DISORD, V44, P861, DOI 10.1007/s10803-013-1938-0; Akshoomoff N, 2013, MONOGR SOC RES CHILD, V78, P119, DOI 10.1111/mono.12038; [Anonymous], 2013, DIAGNOSTIC STAT MANU, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2010, J AM ACAD CHILD PSY; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Becker A, 2004, EUR CHILD ADOLES PSY, V13, P17, DOI 10.1007/s00787-004-2004-4; Berg KL, 2016, DEV MED CHILD NEUROL, V58, P1124, DOI 10.1111/dmcn.13161; Briere J, 2001, CHILD ABUSE NEGLECT, V25, P1001, DOI 10.1016/S0145-2134(01)00253-8; Brooks BA, 2016, CLIN PEDIATR, V55, P927, DOI 10.1177/0009922815616887; Copeland WE, 2007, ARCH GEN PSYCHIAT, V64, P577, DOI 10.1001/archpsyc.64.5.577; Eklund K, 2018, SCHOOL PSYCHOL QUART, V33, P30, DOI 10.1037/spq0000244; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Geller PA, 2007, PSYCHIAT QUART, V78, P157, DOI 10.1007/s11126-006-9035-6; Hoover DW, 2018, CURR OPIN PSYCHIATR, V31, P128, DOI 10.1097/YCO.0000000000000390; Hoover DW, 2015, REV J AUTISM DEV DIS, V2, P287, DOI 10.1007/s40489-015-0052-y; Kaat AJ, 2015, J AUTISM DEV DISORD, V45, P3219, DOI 10.1007/s10803-015-2481-y; Kerns CM, 2015, BEHAV THER, V46, P29, DOI 10.1016/j.beth.2014.03.005; Kerns CM, 2017, J AUTISM DEV DISORD, V47, P2275, DOI 10.1007/s10803-017-3111-7; Kerns CM, 2017, J CLIN CHILD ADOLESC, V46, P88, DOI 10.1080/15374416.2016.1233501; Kerns CM, 2015, J AUTISM DEV DISORD, V45, P3475, DOI 10.1007/s10803-015-2392-y; Kobak KA, 2011, TELEMED E-HEALTH, V17, P804, DOI 10.1089/tmj.2011.0060; Kuhn E, 2017, J CONSULT CLIN PSYCH, V85, P267, DOI 10.1037/ccp0000163; Kupersmidt JB, 2011, PSYCHOL ASSESSMENT, V23, P834, DOI 10.1037/a0023621; Lanktree CB, 2008, CHILD ABUSE NEGLECT, V32, P621, DOI 10.1016/j.chiabu.2007.10.003; Layne CM, 2014, PSYCHOL TRAUMA-US, V6, pS40, DOI 10.1037/a0037799; Maclean MJ, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1817; Mahan S, 2011, RES AUTISM SPECT DIS, V5, P119, DOI 10.1016/j.rasd.2010.02.007; Maïano C, 2016, AUTISM RES, V9, P601, DOI 10.1002/aur.1568; Mannion A, 2013, RES AUTISM SPECT DIS, V7, P1595, DOI 10.1016/j.rasd.2013.09.006; Matson JL, 2014, RES DEV DISABIL, V35, P952, DOI 10.1016/j.ridd.2014.02.012; Mayes SD, 2013, RES AUTISM SPECT DIS, V7, P109, DOI 10.1016/j.rasd.2012.07.009; Mazefsky CA, 2011, RES AUTISM SPECT DIS, V5, P164, DOI 10.1016/j.rasd.2010.03.006; McKown C, 2016, J PSYCHOEDUC ASSESS, V34, P322, DOI 10.1177/0734282915604564; McLaughlin KA, 2013, J AM ACAD CHILD PSY, V52, P815, DOI 10.1016/j.jaac.2013.05.011; Mehtar M, 2011, RES AUTISM SPECT DIS, V5, P539, DOI 10.1016/j.rasd.2010.06.020; Neely L, 2013, RES AUTISM SPECT DIS, V7, P509, DOI 10.1016/j.rasd.2012.12.004; Neumann MM, 2018, EARLY CHILD RES Q, V42, P239, DOI 10.1016/j.ecresq.2017.10.006; Praver F, 2000, Child Maltreat, V5, P273, DOI 10.1177/1077559500005003007; Pynoos R.S., 2013, UCLA PTSD Reaction Index for Children/Adolescents DSM-5; Renk K, 2004, CLIN PSYCHOL REV, V24, P239, DOI 10.1016/j.cpr.2004.01.004; Schriber RA, 2014, J PERS SOC PSYCHOL, V106, P112, DOI 10.1037/a0034950; Schutte JL, 2015, TELEMED E-HEALTH, V21, P176, DOI 10.1089/tmj.2014.0011; Steinberg AM, 2013, J TRAUMA STRESS, V26, P1, DOI 10.1002/jts.21780; Storch EA, 2012, J DEV PHYS DISABIL, V24, P575, DOI 10.1007/s10882-012-9290-4; Valenti M, 2012, J AUTISM DEV DISORD, V42, P954, DOI 10.1007/s10803-011-1323-9; Van der Meer M, 2017, INT J METHODS PSYCHI; Walters JB, 2013, J CHILD SEX ABUS, V22, P72, DOI 10.1080/10538712.2013.735357; Zablotsky B, 2013, J DEV BEHAV PEDIATR, V34, P1, DOI 10.1097/DBP.0b013e31827a7c3a; Zeedyk SM, 2014, RES AUTISM SPECT DIS, V8, P1173, DOI 10.1016/j.rasd.2014.06.001";49;16;20;1;14;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;APR;2019;49;4;;;;;1686;1692;;10.1007/s10803-018-03864-3;http://dx.doi.org/10.1007/s10803-018-03864-3;;;7;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;HS2QW;30604349;;;;24/11/2024;WOS:000463707600028;View Full Record in Web of Science
J;"Wu, YF; Zhang, Y; Ding, L; Dong, Y; Jin, BX; Rong, YZ; Chen, Z; Li, ZW; Lu, LM";;;;"Wu, Yifan; Zhang, Yu; Ding, Lu; Dong, Yu; Jin, Bingxu; Rong, Yuzhi; Chen, Zhen; Li, Zhaowei; Lu, Liming";;;THE EFFECT OF TAI CHI FAN ON AUTISTIC CHILDREN AND CHANGES IN THEIR INTESTINAL MICROECOLOGY;REVISTA INTERNACIONAL DE MEDICINA Y CIENCIAS DE LA ACTIVIDAD FISICA Y DEL DEPORTE;;;English;Article;;;;;;"Autism Spectrum Disorder; Medicine; Chinese Traditional; Tai Ji; Gastrointestinal Microbiome";"SPECTRUM; MICROBIOTA; BRAIN";Background: The incidence of autism spectrum disorder (ASD) is still on the rise worldwide. Tai Chi fan is considered a non-pharmacological treatment with potential benefits for the treatment of ASD. However, there is currently insufficient evidence to support this claim. Objective: This study aims to determine the efficacy and safety of Tai Chi fan in improving ASD, and explore its possible impact on intestinal microecology. Methods: Based on a Randomized Controlled Trial (RCT) design and a gut microecology analysis program ,this study recruited 40 children with ASD and randomly assigned them to either a Tai Chi fan group or a control group. The intervention consisted of eight weeks of Tai Chi fan exercise and rehabilitation as standard treatment, followed by a two-week follow-up. The primary outcome was autism severity, measured by the Autism Treatment Evaluation Checklist (ATEC) and the secondary outcome was the assessment of autism and its related symptoms using the Childhood Autism Rating Scale (CARS), Social Responsiveness Scale (SRS), and Autism Behavior Checklist (ABC). All above scales with higher scores indicating a greater degree of autism. The Test of Gross Motor Development, Third Edition (TGMD-3) was used to evaluate gross motor development, with higher scores indicating better gross motor development. The study also collected 16s rDNA intestinal microecology samples to explore the association between the structure and function of gut microecology and the effect of Tai Chi fan exercise. Overall, the study aims to fully leverage the clinical and intestinal microecology data to assess the clinical effectiveness of Tai Chi fan exercise on autism spectrum disease. Discussion: We believe that the results of this study will enhance our comprehension of how Tai Chi fan exercise influences the clinical symptomatic manifestations linked with ASD and changes in intestinal micromorphology. These insights could potentially fortify the clinical evidence supporting the use of Tai Chi fan exercise in treating patients with ASD.;"[Wu, Yifan; Zhang, Yu; Li, Zhaowei] Guangzhou Univ Chinese Med, Sch Phys Educ & Publ Hlth, Guangzhou 510006, Peoples R China; [Ding, Lu; Dong, Yu; Lu, Liming] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Clin Res & Big Data Lab, Guangzhou 510006, Peoples R China; [Jin, Bingxu] Panyu Hosp Tradit Chinese Med, Guangzhou 511400, Peoples R China; [Rong, Yuzhi] Zhanjiang Special Educ Sch, Zhanjiang 524000, Peoples R China; [Chen, Zhen] Wuchuan Special Educ Sch, Wuchuan 524500, Peoples R China";"Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine";"Li, ZW (corresponding author), Guangzhou Univ Chinese Med, Sch Phys Educ & Publ Hlth, Guangzhou 510006, Peoples R China.;Lu, LM (corresponding author), Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Clin Res & Big Data Lab, Guangzhou 510006, Peoples R China.";"195278892@qq.com; lulimingleon@gzucm.edu.cn";;;"Science and Technology Innovation and Sports Culture Development Research Project of the Guangdong Sports Bureau [GDSS2022M012]; National Natural Science Foundation of China [82174527]; Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202004, 2020B1111100008]";"Science and Technology Innovation and Sports Culture Development Research Project of the Guangdong Sports Bureau; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine";"This study was funded by the Science and Technology Innovation and Sports Culture Development Research Project of the Guangdong Sports Bureau (GDSS2022M012) ; the National Natural Science Foundation of China (82174527) , the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202004) ; the special project of Lingnan Modernization of Traditional Chinese Medicine within the 2019 Guangdong Provincial Research and Development Program (2020B1111100008) . The funder did not influence the study design, data collection, analysis, publication decision, or manuscript.";"Baez-Sanchez A. D., 2021, Letters in Biomathematics, DOI [10.30707/LiB8.1.1647878866.032781, DOI 10.30707/LIB8.1.1647878866.032781]; Bahrami F, 2016, J AUTISM DEV DISORD, V46, P978, DOI 10.1007/s10803-015-2643-y; Bahrami F, 2012, RES DEV DISABIL, V33, P1183, DOI 10.1016/j.ridd.2012.01.018; Barnhill K., 2016, Case reports in Psychiatry, V2016; Bremer E, 2016, AUTISM, V20, P899, DOI 10.1177/1362361315616002; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Cheng N, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00034; De Angelis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076993; de Pablo GS, 2023, J AM ACAD CHILD PSY, V62, P151, DOI 10.1016/j.jaac.2022.03.033; Dinan TG, 2017, J PHYSIOL-LONDON, V595, P489, DOI 10.1113/JP273106; Du W., 2020, Preventive medicine, V32, P425; Estes ML, 2017, IMMUNITY, V47, P816, DOI 10.1016/j.immuni.2017.10.019; Finegold SM, 2011, MED HYPOTHESES, V77, P270, DOI 10.1016/j.mehy.2011.04.032; Finegold SM, 2010, ANAEROBE, V16, P444, DOI 10.1016/j.anaerobe.2010.06.008; Fulceri F, 2019, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02683; Geschwind DH, 2009, ANNU REV MED, V60, P367, DOI 10.1146/annurev.med.60.053107.121225; Iglesias-Vázquez L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030792; Jones RA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172482; Kang DW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42183-0; Lanning BA, 2014, J AUTISM DEV DISORD, V44, P1897, DOI 10.1007/s10803-014-2062-5; Li G., 2024, Sports Medicine and Health Science; Liu T., 2016, Effect of physical activity on the stereotypic behaviors of children with autism spectrum disorder; Lyall K, 2017, ANNU REV PUBL HEALTH, V38, P81, DOI 10.1146/annurev-publhealth-031816-044318; MacDonald M, 2012, FOCUS AUTISM DEV DIS, V27, P12, DOI 10.1177/1088357611428333; McPartland J, 2012, HAND CLINIC, V106, P407, DOI 10.1016/B978-0-444-52002-9.00023-1; Montiel-Castro AJ, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00070; Nazemzadegan G.H., 2016, Iranian rehabilitation journal, V14, P121, DOI [DOI 10.18869/NRIP.IRJ.14.2.121, 10.18869/nrip.irj.14.2.121]; Pan CY, 2010, AUTISM, V14, P9, DOI 10.1177/1362361309339496; Phung JN, 2021, RES AUTISM SPECT DIS, V83, DOI 10.1016/j.rasd.2021.101758; Ristori MV, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112812; [??? Song Yongjia], 2022, [?????????????, Modernization of Traditional Chinese Medicine and Materia Medica--World Science and Technology], V24, P2796; Strati F, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0242-1; Tomova A, 2015, PHYSIOL BEHAV, V138, P179, DOI 10.1016/j.physbeh.2014.10.033; Wang SM, 2022, FRONT HUM NEUROSCI, V16, DOI 10.3389/fnhum.2022.926346; Yilmaz I, 2004, PEDIATR INT, V46, P624, DOI 10.1111/j.1442-200x.2004.01938.x; Zeidan J, 2022, AUTISM RES, V15, P778, DOI 10.1002/aur.2696; [??? Zheng Weidong], 2020, [?????????????, Modernization of Traditional Chinese Medicine and Materia Medica--World Science and Technology], V22, P1348";37;0;0;10;10;RED IRIS;MADRID;EDIF BRONCE, PLAZA DE MANUEL GOMEZ MORENO, S-N 2A PLANTA, MADRID, 28020, SPAIN;1577-0354;;;REV INT MED CIENC AC;Rev. Int. Med. Cienc. Act. Fis. Dep.;JUN;2024;24;96;;;;;234;250;;10.15366/rimcafd2024.96.014;http://dx.doi.org/10.15366/rimcafd2024.96.014;;;17;Sport Sciences;Science Citation Index Expanded (SCI-EXPANDED);Sport Sciences;XY4G8;;;;;24/11/2024;WOS:001265222300014;View Full Record in Web of Science
J;"Wang, L; Clark, EA; Hanratty, L; Koblan, KS; Foley, A; Dedic, N; Bristow, LJ";;;;"Wang, Lien; Clark, Erin A.; Hanratty, Lynsey; Koblan, Kenneth S.; Foley, Andrew; Dedic, Nina; Bristow, Linda J.";;;TAAR1 and 5-HT1B receptor agonists attenuate autism-like irritability and aggression in rats prenatally exposed to valproic acid;PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR;;;English;Article;;;;;;"Trace amine-associated receptor 1 (TAAR1); Serotonin 5-HT1B receptor; Prenatal valproic acid; Frustration; Irritability; Aggression; Autism spectrum disorder";"SPECTRUM DISORDERS; MONOAMINERGIC NEUROTRANSMISSION; BEHAVIOR; MICE; CHILDREN; REWARD; MODEL; INTERVENTIONS; RISPERIDONE; ACTIVATION";Despite the rising prevalence of autism spectrum disorder (ASD), there remains a significant unmet need for pharmacotherapies addressing its core and associative symptoms. While some atypical antipsychotics have been approved for managing associated irritability and aggression, their use is constrained by substantial side effects. This study aimed firstly to develop behavioral measures to explore frustration, irritability and aggression phenotypes in the rat prenatal valproic acid (VPA) model of ASD. Additionally, we investigated the potential of two novel mechanisms, 5-HT1B and TAAR1 agonism, to alleviate these behaviors. Male offspring exposed to prenatal VPA were trained to achieve stable performance on a cued operant task, followed by pharmacological assessment in an operant frustration test, bottle brush test and resident intruder test. VPA exposed rats demonstrated behaviors indicative of frustration and irritability, as well as increased aggression compared to controls. The irritability-like behavior and aggression were further exacerbated in animals previously experiencing a frustrative event during the operant test. Single administration of the 5-HT1B agonist CP-94253 or TAAR1 agonist RO5263397 attenuated the frustration-like behavior compared to vehicle. Additionally, both agonists reduced irritability-like behavior under both normal and frustrative conditions. While CP-94253 reduced aggression in the resident intruder test under both conditions, RO5263397 only produced effects in rats that previously experienced a frustrative event. Our study describes previously uncharacterized phenotypes of frustration, irritability, and aggression in the rat prenatal VPA model of ASD. Administration of selective TAAR1 or 5-HT1B receptor agonists alleviated these deficits, warranting further exploration of both targets in ASD treatment.;"[Wang, Lien; Clark, Erin A.; Koblan, Kenneth S.; Dedic, Nina; Bristow, Linda J.] Sumitomo Pharm Amer Inc, 84 Waterford Dr, Marlborough, MA 01752 USA; [Hanratty, Lynsey; Foley, Andrew] Berand Neuropharmacol Ltd, Dublin, Ireland";;"Dedic, N; Bristow, LJ (corresponding author), Sumitomo Pharm Amer Inc, 84 Waterford Dr, Marlborough, MA 01752 USA.";"Nina.Dedic@us.sumitomo-pharma.com; ljbneuro@outlook.com";;;Sumitomo Pharma America, Inc.;Sumitomo Pharma America, Inc.;This work was supported by funding from Sumitomo Pharma America, Inc..;"Aishworiya R, 2022, NEUROTHERAPEUTICS, V19, P248, DOI 10.1007/s13311-022-01183-1; Al-Beltagi Mohammed, 2022, World J Virol, V11, P411, DOI 10.5501/wjv.v11.i6.411; Aleyasin H, 2018, CURR OPIN NEUROBIOL, V49, P184, DOI 10.1016/j.conb.2018.02.013; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Bannai M, 2007, PSYCHOPHARMACOLOGY, V193, P295, DOI 10.1007/s00213-007-0780-5; Berry MD, 2017, PHARMACOL THERAPEUT, V180, P161, DOI 10.1016/j.pharmthera.2017.07.002; Bölte S, 2019, CELL MOL LIFE SCI, V76, P1275, DOI 10.1007/s00018-018-2988-4; Bouwknecht JA, 2001, BIOL PSYCHIAT, V49, P557, DOI 10.1016/S0006-3223(00)01018-0; Bromley RL, 2013, J NEUROL NEUROSUR PS, V84, P637, DOI 10.1136/jnnp-2012-304270; Brotman MA, 2017, AM J PSYCHIAT, V174, P520, DOI 10.1176/appi.ajp.2016.16070839; Burokas A, 2012, ADDICT BIOL, V17, P770, DOI 10.1111/j.1369-1600.2011.00423.x; Burrows EL, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0055-7; Leno VC, 2021, J NEURODEV DISORD, V13, DOI 10.1186/s11689-021-09374-1; Chaliha D, 2020, DEV NEUROSCI-BASEL, V42, P12, DOI 10.1159/000509109; Chen JF, 2018, NEUROTOXICOL TERATOL, V66, P8, DOI 10.1016/j.ntt.2018.01.002; Choi H, 2024, MOL AUTISM, V15, DOI 10.1186/s13229-024-00585-6; Christensen J, 2013, JAMA-J AM MED ASSOC, V309, P1696, DOI 10.1001/jama.2013.2270; Colizzi M, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10060341; Dedic N, 2023, MOL METAB, V80, DOI 10.1016/j.molmet.2024.101883; Dedic N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413185; Dedic N, 2019, J PHARMACOL EXP THER, V371, P1, DOI 10.1124/jpet.119.260281; Dinnissen M, 2015, EXPERT OPIN DRUG MET, V11, P111, DOI 10.1517/17425255.2015.981151; Dölen G, 2013, NATURE, V501, P179, DOI 10.1038/nature12518; du Jardin KG, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00978; DUDLEY RT, 1995, LEARN MOTIV, V26, P63, DOI 10.1016/0023-9690(95)90011-X; Espinoza S, 2015, NEUROPSYCHOPHARMACOL, V40, P2217, DOI 10.1038/npp.2015.65; Fish EW, 2008, PSYCHOPHARMACOLOGY, V197, P145, DOI 10.1007/s00213-007-1017-3; Fish EW, 1999, PSYCHOPHARMACOLOGY, V146, P391, DOI 10.1007/PL00005484; Fitzpatrick SE, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S84585; Foley AG, 2012, NEUROPHARMACOLOGY, V63, P750, DOI 10.1016/j.neuropharm.2012.05.042; Gainetdinov RR, 2018, PHARMACOL REV, V70, P549, DOI 10.1124/pr.117.015305; Ghosn F, 2023, RES DEV DISABIL, V140, DOI 10.1016/j.ridd.2023.104567; Golden SA, 2019, J NEUROSCI, V39, P3996, DOI 10.1523/JNEUROSCI.0151-19.2019; Gowin JL, 2010, PSYCHOPHARMACOLOGY, V210, P521, DOI 10.1007/s00213-010-1851-6; Halff EF, 2023, TRENDS NEUROSCI, V46, P60, DOI 10.1016/j.tins.2022.10.010; Hara Y, 2017, PSYCHOPHARMACOLOGY, V234, P3217, DOI 10.1007/s00213-017-4703-9; Hellings J, 2023, WORLD J PSYCHIATR, V13, P262, DOI 10.5498/wjp.v13.i6.262; Hosie S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00234; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Kas MJ, 2014, PSYCHOPHARMACOLOGY, V231, P1125, DOI 10.1007/s00213-013-3268-5; Kat R, 2022, NEUROSCI BIOBEHAV R, V139, DOI 10.1016/j.neubiorev.2022.104722; Kataoka S, 2013, INT J NEUROPSYCHOPH, V16, P91, DOI 10.1017/S1461145711001714; Kimbrough A, 2017, ALCOHOL CLIN EXP RES, V41, P1886, DOI 10.1111/acer.13484; Koblan KS, 2020, NEW ENGL J MED, V382, P1497, DOI 10.1056/NEJMoa1911772; Kononoff J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31921-5; Koolhaas JM, 2013, JOVE-J VIS EXP, DOI 10.3791/4367; Kuo HY, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10030560; Lecavalier L, 2006, J INTELL DISABIL RES, V50, P172, DOI 10.1111/j.1365-2788.2005.00732.x; Lee A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126515; Li XX, 2024, COMP BIOCHEM PHYS C, V275, DOI 10.1016/j.cbpc.2023.109783; Lischinsky JE, 2020, NAT NEUROSCI, V23, P1317, DOI 10.1038/s41593-020-00715-2; Liu JF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00279; Liu JF, 2020, CELL MOL NEUROBIOL, V40, P229, DOI 10.1007/s10571-020-00792-8; Maenner MJ, 2023, MMWR SURVEILL SUMM, V72, P1, DOI 10.15585/mmwr.ss7202a1; Mayes SD, 2017, J MENT HEALTH RES IN, V10, P345, DOI 10.1080/19315864.2017.1338804; Menezes M, 2021, AUTISM, V25, P2199, DOI 10.1177/13623613211014721; Monti JM, 1995, NEUROPHARMACOLOGY, V34, P1647, DOI 10.1016/0028-3908(95)00112-3; Nelson RJ, 2007, NAT REV NEUROSCI, V8, P536, DOI 10.1038/nrn2174; Newschaffer CJ, 2003, PUBLIC HEALTH REP, V118, P393, DOI 10.1093/phr/118.5.393; Nicolini C, 2018, EXP NEUROL, V299, P217, DOI 10.1016/j.expneurol.2017.04.017; Norton SA, 2020, NEUROSCIENCE, V434, P8, DOI 10.1016/j.neuroscience.2020.02.029; O'Brien G, 2004, AUTISM, V8, P125, DOI 10.1177/1362361304042718; Olivier B, 2005, EUR J PHARMACOL, V526, P207, DOI 10.1016/j.ejphar.2005.09.066; Oprea G., 2022, Bulletin of Integrative Psychiatry.; Papini M.R., 1997, Rev Gen Psychol, V1, P175, DOI [DOI 10.1037/1089-2680.1.2.175, 10.1037/1089-2680.1.2.175]; Parsons LH, 1998, J NEUROSCI, V18, P10078; Przegalinski E, 2007, EUR J PHARMACOL, V559, P165, DOI 10.1016/j.ejphar.2006.12.012; Ramboz S, 1996, BEHAV BRAIN RES, V73, P305; Rasalam AD, 2005, DEV MED CHILD NEUROL, V47, P551, DOI 10.1017/S0012162205001076; Revel FG, 2013, MOL PSYCHIATR, V18, P543, DOI 10.1038/mp.2012.57; Revel FG, 2012, NEUROPSYCHOPHARMACOL, V37, P2580, DOI 10.1038/npp.2012.109; Revel FG, 2011, P NATL ACAD SCI USA, V108, P8485, DOI 10.1073/pnas.1103029108; Robb AS, 2010, DEV DISABIL RES REV, V16, P258, DOI 10.1002/ddrr.118; Rodier PM, 1996, J COMP NEUROL, V370, P247, DOI 10.1002/(SICI)1096-9861(19960624)370:2<247::AID-CNE8>3.0.CO;2-2; Román V, 2021, PSYCHOPHARMACOLOGY, V238, P2381, DOI 10.1007/s00213-021-05851-6; Sapkota A, 2016, J ANIM SCI, V94, P2117, DOI 10.2527/jas.2015-0013; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; Sauer M.A.K., 2021, Autism Spectrum Disorders: Etiology and Pathology, P1, DOI 10.36255/exonpublications.autismspectrumdisorders.2021.etiology; Schmeisser MJ, 2012, NATURE, V486, P256, DOI 10.1038/nature11015; Sukhodolsky DG, 2016, J CHILD ADOL PSYCHOP, V26, P58, DOI 10.1089/cap.2015.0120; Takahashi Aki, 2014, Curr Top Behav Neurosci, V17, P3, DOI 10.1007/7854_2013_263; Tartaglione AM, 2019, NEUROPHARMACOLOGY, V159, DOI 10.1016/j.neuropharm.2018.12.024; Tricklebank MD, 2019, SEROTONIN SYSTEM: HISTORY, NEUROPHARMACOLOGY, AND PATHOLOGY, P155, DOI 10.1016/B978-0-12-813323-1.00009-8; Troost PW, 2005, J AM ACAD CHILD PSY, V44, P1137, DOI 10.1097/01.chi.0000177055.11229.76; Vanwong N, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.565074; Velez L, 2010, BEHAV GENET, V40, P201, DOI 10.1007/s10519-009-9325-5; Walsh JJ, 2021, NEUROPSYCHOPHARMACOL, V46, P2000, DOI 10.1038/s41386-021-01091-6; Walsh JJ, 2018, NATURE, V560, P589, DOI 10.1038/s41586-018-0416-4; Williams G, 2001, DEV MED CHILD NEUROL, V43, P202, DOI 10.1017/S001216220100038X; Xue ZX, 2018, NEUROPHARMACOLOGY, V129, P36, DOI 10.1016/j.neuropharm.2017.11.012; Yang SM, 2024, NEUROPSYCHOPHARMACOL, V49, P1091, DOI 10.1038/s41386-023-01779-x; Zarate-Lopez D, 2024, CURR NEUROPHARMACOL, V22, P260, DOI 10.2174/1570159X22666231003121513; Zhukov IS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232214066; Zimmermann FF, 2015, NEUROTOXICOL TERATOL, V52, P36, DOI 10.1016/j.ntt.2015.10.002";94;0;0;1;1;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0091-3057;1873-5177;;PHARMACOL BIOCHEM BE;Pharmacol. Biochem. Behav.;DEC;2024;245;;;;;;;;173862;10.1016/j.pbb.2024.173862;http://dx.doi.org/10.1016/j.pbb.2024.173862;;sept-24;11;"Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);"Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy";F8X8U;39197535;;;;24/11/2024;WOS:001312588200001;View Full Record in Web of Science
J;"Stutzman, D; Dopheide, J";;;;"Stutzman, Danielle; Dopheide, Julie";;;Acetylcysteine for treatment of autism spectrum disorder symptoms;AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY;;;English;Article;;;;;;;"N-ACETYLCYSTEINE; CHILDREN; ADOLESCENTS; TRIAL; ANTIPSYCHOTICS; PSYCHIATRY; BEHAVIOR";"Purpose. Successful use of acetylcysteine to control irritability and aggressive behaviors in a hospitalized adolescent patient with autism spectrum disorder (ASD) is described. Summary. A 17-year-old Hispanic male with ASD and intellectual disability was hospitalized for inpatient psychiatric treatment due to impulsive and violent behavior. Despite receiving various medications in the initial weeks of hospitalization, including intramuscular lorazepam and diphenhydramine injections (four days a week on average), the patient continued to exhibit aggressive and unpredictable behaviors. Treatment with 20% acetylcysteine oral solution was initiated at a dosage of 600 mg twice daily as an adjunct to quetiapine therapy. Over the next six weeks, reductions in the patient's aggressive behavior, tantrums, and irritability were noted. The use of as-needed medications to control aggression was decreased, and the dosage of quetiapine was lowered from 700 to 400 mg daily over the course of the hospitalization. Acetylcysteine was well tolerated, with no observed or reported adverse effects. Unlike clonidine or guanfacine (other medications used for ASD-related behavioral symptoms), acetylcysteine is not sedating; moreover, it lacks the metabolic, extrapyramidal, and endocrine adverse effects of atypical antipsychotics. Published data from small controlled trials and case reports suggest that acetylcys-teine use is associated with improvements in irritability and aggression in prepubertal children with ASD; these therapeutic benefits may be associated with acetylcysteine's glutamatergic, dopaminergic, antioxidant, and anti-inflammatory properties. Conclusion. Treatment with acetylcysteine improved ASD symptoms, including irritability and aggression, in a teenage patient.";"[Stutzman, Danielle] Univ So Calif, Postgrad Year Psychiat Pharm Resident 2, Los Angeles, CA USA; [Dopheide, Julie] USC, Sch Pharm, Clin Pharm Psychiat & Behav Sci, Los Angeles, CA 90007 USA; [Dopheide, Julie] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA";"University of Southern California; University of Southern California; University of Southern California";Dopheide, J (corresponding author), USC, Sch Pharm, Clin Pharm Psychiat & Behav Sci, Los Angeles, CA 90007 USA.;dopheide@usc.edu;;"Stutzman, Danielle/0000-0001-7350-4275; Dopheide, Julie/0000-0001-7054-0588";;;;"AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 2004, AC SOL PACK INS; Berk M, 2008, BIOL PSYCHIAT, V64, P468, DOI 10.1016/j.biopsych.2008.04.022; Berk M, 2008, TRENDS PHARMACOL SCI, V29, P346, DOI 10.1016/j.tips.2008.05.001; Berk M, 2013, TRENDS PHARMACOL SCI, V34, P167, DOI 10.1016/j.tips.2013.01.001; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Bulut M, 2009, WORLD J BIOL PSYCHIA, V10, P626, DOI 10.1080/15622970903144004; Carlson GC., 2011, PHARM BIOCH BEHAV, V100, P850; Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057; Ghanizadeh A, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-196; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Hendren RL, 2013, CHILD ADOL PSYCH CL, V22, P443, DOI 10.1016/j.chc.2013.03.002; Lafleur DL, 2006, PSYCHOPHARMACOLOGY, V184, P254, DOI 10.1007/s00213-005-0246-6; LaRowe SD, 2006, AM J ADDICTION, V15, P105, DOI 10.1080/10550490500419169; Marler S, 2014, J CHILD ADOL PSYCHOP, V24, P231, DOI 10.1089/cap.2013.0137; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Politte LC, 2014, PSYCHOPHARMACOLOGY, V231, P1023, DOI 10.1007/s00213-013-3068-y; Seida JC, 2012, PEDIATRICS, V129, pE771, DOI 10.1542/peds.2011-2158; Siegel M, 2014, CHILD ADOL PSYCH CL, V23, P125, DOI 10.1016/j.chc.2013.07.004; Soorya L, 2008, CHILD ADOL PSYCH CL, V17, P753, DOI 10.1016/j.chc.2008.06.003; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013";21;6;7;0;12;AMER SOC HEALTH-SYSTEM PHARMACISTS;BETHESDA;7272 WISCONSIN AVE, BETHESDA, MD 20814 USA;1079-2082;1535-2900;;AM J HEALTH-SYST PH;Am. J. Health-Syst. Pharm.;nov-15;2015;72;22;;;;;1956;1959;;10.2146/ajhp150072;http://dx.doi.org/10.2146/ajhp150072;;;4;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;CW2EN;26541950;;;;24/11/2024;WOS:000364804000009;View Full Record in Web of Science
J;"Politte, LC; Scahill, L; Figueroa, J; McCracken, JT; King, B; McDougle, CJ";;;;"Politte, Laura C.; Scahill, Lawrence; Figueroa, Janet; McCracken, James T.; King, Bryan; McDougle, Christopher J.";;;A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures;NEUROPSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; SLEEP HABITS QUESTIONNAIRE; PSYCHOMETRIC PROPERTIES; ATOMOXETINE; MEDICATION; BEHAVIOR; SCALE; METHYLPHENIDATE; HYPERACTIVITY";"In a prior report, we showed that extended-release guanfacine (GEXR) is safe and effective for children with autism spectrum disorder (ASD) accompanied by ADHD symptoms. Here, we examine the impact of GEXR on oppositional behavior, anxiety, repetitive behavior, and sleep disturbance. Sixty-two subjects with ASD (53 boys, 9 girls; ages 5-14 years) were randomly assigned to GEXR (n = 30) or placebo (n = 32) for 8 weeks. Outcomes include the Home Situation Questionnaire-Modified for ASD (HSQ-ASD), Anxiety scale of the Child and Adolescent Symptom Inventory (CASI), Children's Yale-Brown Obsessive-Compulsive Scale-Modified for ASD (CYBOCS-ASD), and Children's Sleep Habits Questionnaire (CSHQ). A repeated measures linear mixed model was used to determine the effects of treatment group and time on HSQ scores. For other measures, change from baseline was evaluated with Analysis of Covariance (ANCOVA). After 8 weeks of treatment, parent ratings of oppositional behavior on the HSQ declined by 44% (per item mean from 3.4 to 1.9) in the GEXR group compared to 12% (from 3.3 to 2.9) for placebo (p = 0.004). Repetitive behavior on the CYBOCS-ASD showed a significantly greater decline in GEXR-treated participants compared to placebo (24% vs. < 1%, p = 0.01). No group differences were observed on CASI Anxiety or CSHQ (p = 0.64 and 0.75, respectively). GEXR was effective in reducing oppositional behavior and, more modestly, repetitive behavior. GEXR was not superior to placebo for anxiety, though baseline anxiety ratings were low. GEXR did not significantly improve sleep habits. Future studies could focus on repetitive behavior or anxiety, symptoms with limited treatment options.";"[Politte, Laura C.] Univ N Carolina, Sch Med, Carolina Inst Dev Disabil, Dept Psychiat, Carrboro, NC 27510 USA; [Scahill, Lawrence] Emory Univ, Sch Med, Dept Pediat, Marcus Autism Ctr, Atlanta, GA USA; [Figueroa, Janet] Emory Univ, Sch Med, Dept Pediat, Pediat Biostat Core, Atlanta, GA USA; [McCracken, James T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [King, Bryan] Univ Calif San Francisco, Sch Med, Dept Psychiat, UCSF Weill Inst Neurosci, San Francisco, CA USA; [McDougle, Christopher J.] Harvard Med Sch, Dept Psychiat, Lurie Ctr Autism, Boston, MA USA";"University of North Carolina; Emory University; Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Harvard University; Harvard Medical School";Politte, LC (corresponding author), Univ N Carolina, Sch Med, Carolina Inst Dev Disabil, Dept Psychiat, Carrboro, NC 27510 USA.;laura.politte@cidd.unc.edu;;;"NIMH [R01MH083707, RO1MH83739, RO1MH083747, R01MH86927]; Yale Clinical and Transitional Science Award from the NIH National Center for Research Resources [UL1 RR024139]; Atlanta Clinical and Translational Science Institute, Emory University; NIH National Center for Advancing Translational Sciences [UL1TR000454, UL1TR001111]; North Carolina Translational and Clinical Sciences Institute; Roche; Seaside Therapeutics";"NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Yale Clinical and Transitional Science Award from the NIH National Center for Research Resources; Atlanta Clinical and Translational Science Institute, Emory University; NIH National Center for Advancing Translational Sciences; North Carolina Translational and Clinical Sciences Institute; Roche(Roche Holding); Seaside Therapeutics";"The study was supported by NIMH grants to Dr. Scahill (R01MH083707), Dr. McDougle (RO1MH83739), Dr. McCracken (RO1MH083747), and Dr. King (R01MH86927); by a Yale Clinical and Transitional Science Award (UL1 RR024139) from the NIH National Center for Research Resources; and by Atlanta Clinical and Translational Science Institute, Emory University, which is supported by the NIH National Center for Advancing Translational Sciences under award UL1TR000454. Shire Pharmaceuticals provided active extended-release guanfacine and placebo. Dr. LCP receives research support from a Career Development Award with the North Carolina Translational and Clinical Sciences Institute, which is supported by NIH National Center for Advancing Translational Sciences under award UL1TR001111. Dr. LCP has received study drug from Nutramax, Inc. Dr. LS has served as a consultant for Bracket, Roche, and Shire, and he has served on the speaker's bureau for the Tourette Syndrome Association. Dr. JTM has served as a consultant for Dart Neuroscience and Roche; he has received research support from Roche; he has received study drug and matching placebo from Shire; and he has served on the speaker's bureau for the Tourette Syndrome Association. Dr. BK has received research support from Roche and Seaside Therapeutics.";"Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; [Anonymous], 2000, TASK FORCE HDB PSYCH; Barkley R.A., 1987, Advances in Behavioral Assessment of Children and Families, P157; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Carter MJ, 2014, THER RECREAT J, V48, P275; Chowdhury M, 2016, AUTISM, V20, P528, DOI 10.1177/1362361315593941; Connor DF, 2013, J CHILD ADOL PSYCHOP, V23, P244, DOI 10.1089/cap.2012.0119; Efron D, 2014, SLEEP MED, V15, P472, DOI 10.1016/j.sleep.2013.10.018; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Fiks AG, 2015, J CHILD ADOL PSYCHOP, V25, P362, DOI 10.1089/cap.2014.0122; Findling RL, 2014, J CHILD ADOL PSYCHOP, V24, P245, DOI 10.1089/cap.2013.0103; Fombonne E, 2009, PEDIATR RES, V65, P591, DOI 10.1203/PDR.0b013e31819e7203; Gadow K., 1994, CHILD SYMPTOM INVENT; Gadow K.D., 1997, Adolescent Symptom Inventory-4 screening manual; Giannotti F, 2011, J SLEEP RES, V20, P338, DOI 10.1111/j.1365-2869.2010.00882.x; Hallett V, 2013, J AUTISM DEV DISORD, V43, P2341, DOI 10.1007/s10803-013-1775-1; Handen BL, 2015, J AM ACAD CHILD PSY, V54, P905, DOI 10.1016/j.jaac.2015.08.013; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Johnson CR, 2016, SLEEP MED, V20, P5, DOI 10.1016/j.sleep.2015.12.005; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; Malow BA, 2006, SLEEP, V29, P1563, DOI 10.1093/sleep/29.12.1563; Martinez-Raga J, 2015, NEUROPSYCH DIS TREAT, V11, DOI 10.2147/NDT.S65735; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Murphy TK, 2017, J CHILD ADOL PSYCHOP, V27, P762, DOI 10.1089/cap.2017.0024; Owens JA, 2000, SLEEP, V23, P1043; Pearson DA, 2013, J CHILD ADOL PSYCHOP, V23, P337, DOI 10.1089/cap.2012.0096; Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028; Reed HE, 2009, J CHILD NEUROL, V24, P936, DOI 10.1177/0883073808331348; Reichow B, 2013, J AUTISM DEV DISORD, V43, P2435, DOI 10.1007/s10803-013-1793-z; Rugino TA, 2018, J ATTEN DISORD, V22, P14, DOI 10.1177/1087054714554932; Rutter M., 2003, SOCIAL COMMUNICATION; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; Scahill L, 2006, J AM ACAD CHILD PSY, V45, P1114, DOI 10.1097/01.chi.0000220854.79144.e7; Scahill L, 2016, J AM ACAD CHILD PSY, V55, P415, DOI 10.1016/j.jaac.2016.02.016; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Sprafkin J, 2002, J CLIN CHILD ADOLESC, V31, P513, DOI 10.1207/153744202320802188; Strawn JR, 2017, J CHILD ADOL PSYCHOP, V27, P29, DOI 10.1089/cap.2016.0132; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P611, DOI 10.1089/cap.2006.16.611; Wang M, 2007, CELL, V129, P397, DOI 10.1016/j.cell.2007.03.015";42;43;51;2;8;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;0893-133X;1740-634X;;NEUROPSYCHOPHARMACOL;Neuropsychopharmacology;JUL;2018;43;8;;;;;1772;1778;;10.1038/s41386-018-0039-3;http://dx.doi.org/10.1038/s41386-018-0039-3;;;7;"Neurosciences; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";GJ8IQ;29540864;Bronze, Green Published;;;24/11/2024;WOS:000435633100020;View Full Record in Web of Science
J;"Bradstreet, JJ; Sych, N; Antonucci, N; Klunnik, M; Ivankova, O; Matyashchuk, I; Demchuk, M; Siniscalco, D";;;;"Bradstreet, James Jeffiey; Sych, Nataliia; Antonucci, Nicola; Klunnik, Mariya; Ivankova, Olena; Matyashchuk, Irina; Demchuk, Mariya; Siniscalco, Dario";;;Efficacy of Fetal Stem Cell Transplantation in Autism Spectrum Disorders: An Open-Labeled Pilot Study;CELL TRANSPLANTATION;;;English;Article;;;;;;"Autism; Fetal stem cells; Transplantation; Cell therapy; Biopharmacy";"BLOOD MONONUCLEAR-CELLS; BONE-MARROW; CORD BLOOD; CHILDREN; THERAPY; ADULT";Autism spectrum disorders (ASDs) are heterogeneous complex neurodevelopmental pathologies defined by behavioral symptoms, but which have well-characterized genetic, immunological, and physiological comorbidities. Despite extensive research efforts, there are presently no agreed upon therapeutic approaches for either the core behaviors or the associated comorbidities. In particular, the known autoimmune disorders associated with autism are appealing targets for potential stem cell therapeutics. Of the various stem cell populations, fetal stem cells (FSCs) offer the potent immunoregulatory functions found in primordial mesenchymal stem cells, while exhibiting rapid expansion capacity and recognized plasticity. These properties enhance their potential for clinical use. Furthermore, FSCs are potent and implantable biopharmacies capable of delivering trophic signals to the host, which could influence brain development. This study investigated the safety and efficacy of FSC transplantations in treating children diagnosed with ASDs. Subjects were monitored at pre, and then 6 and 12 months following the transplantations, which consisted of two doses of intravenously and subcutaneously administered FSCs. The Autism Treatment Evaluation Checklist (ATEC) test and Aberrant Behavior Checklist (ABC) scores were performed. Laboratory examinations and clinical assessment of adverse effects were performed in order to evaluate treatment safety. No adverse events of significance were observed in ASD children treated with FSCs, including no transmitted infections or immunological complications. Statistically significant differences (p < 0.05) were shown on ATEC/ABC scores for the domains of speech, sociability, sensory, and overall health, as well as reductions in the total scores when compared to pretreatment values. We recognize that the use of FSCs remains controversial for the present. The results of this study, however, warrant additional investigations into the mechanisms of cell therapies for ASDs, while prompting the exploration of FSCs as biopharmacies capable of manufacturing the full array of cell-signaling chemistry. This manuscript is published as part of the International Association of Neurorestoratology (IANR) special issue of Cell Transplantation.;"[Bradstreet, James Jeffiey] Int Child Dev Resource Ctr, Chateau Elan, GA USA; [Sych, Nataliia; Klunnik, Mariya; Ivankova, Olena; Matyashchuk, Irina; Demchuk, Mariya] Cell Therapy Ctr EmCell, Clin Dept, Kiev, Ukraine; [Antonucci, Nicola; Siniscalco, Dario] Biomed Ctr Autism Res & Treatment, Bari, Italy; [Siniscalco, Dario] Ctr Autism La Forza Silenzio, Caserta, Italy; [Siniscalco, Dario] Cancellautismo Nonprofit Assoc Autism Care, Florence, Italy";;Siniscalco, D (corresponding author), Univ Naples 2, Dept Expt Med, Via S Maria Costantinopoli 16, I-80138 Naples, Italy.;dariosin@uab.edu;"Siniscalco, Dario/H-4657-2019; Demchuk, Andrew/E-1103-2012";Siniscalco, Dario/0000-0002-3779-2596;;;;"Abdulrazzak H, 2010, J R SOC INTERFACE, V7, pS689, DOI 10.1098/rsif.2010.0347.focus; [Anonymous], J REGEN MED; [Anonymous], 2013, J STEM CELL RES THER; [Anonymous], AUTISMOPEN ACCESS S; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1; Blake J., 2013, BRIEF HIST AUTISM AU; Blumberg Stephen J, 2013, Natl Health Stat Report, P1; Bradstreet J.J., 2012, Autism Insights, V4, P31, DOI [10.4137/AUI.S10485, DOI 10.4137/AUI.S10485]; Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469; Chen PM, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-49; de Magistris L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/729349; Doyle CA, 2012, EXPERT OPIN PHARMACO, V13, P1615, DOI 10.1517/14656566.2012.674110; Galende E, 2010, CELL REPROGRAM, V12, P117, DOI 10.1089/cell.2009.0077; Gupta S, 2010, J CLIN IMMUNOL, V30, pS90, DOI 10.1007/s10875-010-9402-9; Lv YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-196; Min CK, 2001, BONE MARROW TRANSPL, V28, P935, DOI 10.1038/sj.bmt.1703258; Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140; Nevels RM, 2010, EXP CLIN PSYCHOPHARM, V18, P184, DOI 10.1037/a0018059; O'Donoghue K, 2004, BEST PRACT RES CL OB, V18, P853, DOI 10.1016/j.bpobgyn.2004.06.010; Payakachat N, 2012, EXPERT REV PHARM OUT, V12, P485, DOI [10.1586/erp.12.29, 10.1586/ERP.12.29]; Sharma A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/623875; Simard AR, 2004, FASEB J, V18, P998, DOI 10.1096/fj.04-1517fje; Siniscalco D., 2012, AUTISM, V2, pe106, DOI DOI 10.4172/2165-7890.1000; Siniscalco D, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/262438; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Siniscalco D, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00140; Siniscalco D, 2012, J AUTISM DEV DISORD, V42, P1403, DOI 10.1007/s10803-011-1373-z; Siniscalco D, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/480289; Siniscalco D, 2011, FRONT INTEGR NEUROSC, V5, DOI 10.3389/fnint.2011.00079; Steenblock D., 2006, UMBILICAL STEM CELL, P16; Theoharides TC, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-168; Titova N. D., 2007, IMMUNOPATHOL ALLERGO, V4, P38; Wang LM, 2013, STEM CELLS DEV, V22, P3192, DOI 10.1089/scd.2013.0023";34;43;43;3;23;SAGE PUBLICATIONS INC;THOUSAND OAKS;2455 TELLER RD, THOUSAND OAKS, CA 91320 USA;0963-6897;1555-3892;;CELL TRANSPLANT;Cell Transplant.;;2014;23;;;1;;;S105;S112;;10.3727/096368914X684916;http://dx.doi.org/10.3727/096368914X684916;;;8;"Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation";Science Citation Index Expanded (SCI-EXPANDED);"Cell Biology; Research & Experimental Medicine; Transplantation";AY9KT;25302490;Bronze;;;24/11/2024;WOS:000347869500012;View Full Record in Web of Science
J;"Ye, C; Zhang, XY; Cui, JQ; Chen, QY; Qin, HL; Li, N; Du, YS; Zhao, XX; Yang, R; Lu, JB; Lv, XQ; Ma, CL; Wang, Y; Chen, SD; Kuang, GF; Zhao, DM; Fang, SF; Zhang, XJ; Yang, BR; Wang, YX; Li, L; Yuan, S; Zhou, X; Zhang, BH; Jiang, L; Ji, H";;;;"Ye Chen; Zhang Xueying; Cui Jiaqu; Chen Qiyi; Qin Huanlong; Li Ning; Du Yasong; Zhao Xiaoxin; Yang Rong; Lu Jubao; Lv Xiaoqiong; Ma Chunlian; Wang Yu; Chen Shidong; Kuang Guifang; Zhao Dongmei; Fang Shuanfeng; Zhang Xujing; Yang Binrang; Wang Yanxia; Li Ling; Yuan Song; Zhou Xiang; Zhang Beihua; Jiang Lin; Ji Hong";;FTACMT Working Grp;FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder;BMJ OPEN;;;English;Article;;;;;;"microbiology; child & adolescent psychiatry; gastroenterology";"GUT MICROBIOTA; ABNORMALITIES; MICROFLORA";Introduction Autism spectrum disorder (ASD) is a complicated diffuse developmental disorder that commonly involves gastrointestinal distress and dysbacteriosis. Emerging lines of evidence have shown faecal microbiota transplantation (FMT) to be a potential therapeutic strategy for improving the clinical outcomes of patients with ASD by re-establishing their intestinal microflora. We are undertaking the first-ever multicentre, double-blind, randomised controlled trial of FMT for the treatment of children with both ASD and gastrointestinal symptoms and will assess the feasibility and efficacy outcomes of this strategy. Methods In total, 318 children with both ASD and gastrointestinal symptoms will be enrolled (from 15 hospitals in China) to receive either FMT intervention (n=212) or a placebo (control, n=106). Children aged 3-6 years will take two capsules two times a day, and those older than 6 years will take three capsules two times a day. Each patient will receive four treatment courses, with each 12-day course being repeated every month. Outcomes will be evaluated at baseline, throughout the period of intervention, and at subsequent follow-ups for 2 months. The primary trial objective is to investigate the remodelling effect of FMT on the intestinal microflora in patients with ASD. The secondary objective focuses on the clinical efficacy and safety of FMT, including its improvement of the clinical response and metabonomics. Ethics and dissemination Ethical approval was obtained from the hospital Ethics Committee of each Faecal Transfer for ASD China Multicenter Trial Working Group. The ongoing FMT clinical trial is intended to support the approval of the new technology and its administration. The results of this trial will provide high-quality evidence to inform the future clinical application of this new therapy.;"[Ye Chen; Zhang Xueying; Cui Jiaqu; Chen Qiyi; Qin Huanlong; Li Ning; Yang Rong; Lu Jubao; Lv Xiaoqiong; Ma Chunlian] Shanghai Tenth Peoples Hosp, Dept Colorectal Dis, Shanghai, Peoples R China; [Du Yasong; Zhao Xiaoxin] Shanghai Mental Hlth Ctr, Child & Adolescent Psychiat, Shanghai, Peoples R China; [Wang Yu] Shanghai Childrens Hosp, Child Healthcare Dept, Shanghai, Peoples R China; [Chen Shidong] Shanghai First Peoples Hosp, Rehabil Med Dept, Shanghai, Peoples R China; [Kuang Guifang] Qingdao Women & Childrens Hosp, Dept Pediat Mental Hlth, Qingdao, Peoples R China; [Zhao Dongmei] Shandong Univ, Inst Child Hlth, Qilu Childrens Hosp, Jinan, Peoples R China; [Fang Shuanfeng] Zhengzhou Univ, Child Healthcare Dept, Hosp 3, Zhengzhou, Peoples R China; [Fang Shuanfeng] Henan Prov Women & Childrens Hosp, Zhengzhou, Peoples R China; [Zhang Xujing] Hebei Mental Hlth Ctr, Clin Psychol, Baoding, Peoples R China; [Yang Binrang] Shenzhen Childrens Hosp, Child Healthcare Dept, Shenzhen, Peoples R China; [Wang Yanxia] Qingdao Univ, Affiliated Hosp, Child Healthcare Dept, Qingdao, Peoples R China; [Li Ling] Hainan Women & Childrens Med Ctr, Child Rehabil Dept, Haikou, Hainan, Peoples R China; [Yuan Song] Zhoushan Second Peoples Hosp, Psychiat Dept, Zhoushan, Peoples R China; [Zhou Xiang] Zhuhai Maternal & Child Hlth Care Hosp, Dept Children Psychol, Zhuhai, Peoples R China; [Zhang Beihua] Tongji Univ, Yangzhi Affiliated Rehabil Hosp, Shanghai, Peoples R China; [Jiang Lin] Dalian Seveth Peoples Hosp, Psychiat Dept, Dalian, Peoples R China; [Ji Hong] Wuhu 1 Peoples Hosp, Wuhu, Anhui, Peoples R China";"Shanghai Jiao Tong University; Shandong University; Zhengzhou University; Shenzhen Children's Hospital; Qingdao University; Tongji University";Chen, QY (corresponding author), Shanghai Tenth Peoples Hosp, Dept Colorectal Dis, Shanghai, Peoples R China.;qiyichen2011@163.com;"Yang, Binrang/AAY-9848-2020; Zhao, Xiaoxin/AAB-2811-2021; YE, Chen/KFR-3858-2024; huanlong, Qin/B-3844-2015; Wang, Yu/GZL-9655-2022; li, xia/HHZ-7468-2022; zhang, xueying/JMB-7808-2023; Wang, Yu/KGL-3101-2024";Cui, Jiaqu/0000-0003-4203-1406;"Clinical Research Plan of SHDC [SHDC2020CR1030B]; Shanghai Action Plan on Science, Technology and Innovation [21Y11908300]";"Clinical Research Plan of SHDC; Shanghai Action Plan on Science, Technology and Innovation";This project was supported by Clinical Research Plan of SHDC (No. SHDC2020CR1030B and No.SHDC2020CR4026) and Shanghai Action Plan on Science, Technology and Innovation (21Y11908300).;"Adams JB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030369; Altieri L, 2011, BIOMARKERS, V16, P252, DOI 10.3109/1354750X.2010.548010; AMIDON GL, 1994, ANNU REV PHARMACOL, V34, P321; [Anonymous], 2020, ZHONGHUA WEI CHANG W, V23, P14; Bibbò S, 2017, MINERVA GASTROENT D, V63, P420, DOI 10.23736/S1121-421X.17.02374-1; Bolte ER, 1998, MED HYPOTHESES, V51, P133, DOI 10.1016/S0306-9877(98)90107-4; Brondino N, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/258589; Buffington SA, 2016, CELL, V165, P1762, DOI 10.1016/j.cell.2016.06.001; Buie T, 2010, PEDIATRICS, V125, pS1, DOI 10.1542/peds.2009-1878C; Cani PD, 2018, GUT, V67, P1716, DOI 10.1136/gutjnl-2018-316723; Carabotti M, 2015, ANN GASTROENTEROL, V28, P203; Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914; Finegold SM, 2017, ANAEROBE, V45, P133, DOI 10.1016/j.anaerobe.2017.02.008; Geier DA, 2009, NEUROCHEM RES, V34, P386, DOI 10.1007/s11064-008-9782-x; Kang DW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42183-0; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Kim S, 2017, NATURE, V549, P528, DOI 10.1038/nature23910; Li N, 2019, Zhonghua Wei Chang Wai Ke Za Zhi, V22, P861, DOI 10.3760/cma.j.issn.1671-0274.2019.09.011; Liu YW, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040820; MacFabe Derrick F., 2015, Microbial Ecology in Health and Disease, V26, P28177, DOI 10.3402/mehd.v26.28177; Minalyan Artem, 2017, Curr Gastroenterol Rep, V19, P42, DOI 10.1007/s11894-017-0577-6; Minot S, 2013, P NATL ACAD SCI USA, V110, P12450, DOI 10.1073/pnas.1300833110; Parenteral, 2020, ZHONGHUA WEI CHANG W, V23, P5; Parracho HMRT, 2005, J MED MICROBIOL, V54, P987, DOI 10.1099/jmm.0.46101-0; Qiyi C., 2020, CHINESE J DIGESTION, V40, P768; Sandler RH, 2000, J CHILD NEUROL, V15, P429, DOI 10.1177/088307380001500701; Sharon G, 2019, CELL, V177, P1600, DOI 10.1016/j.cell.2019.05.004; Shultz SR, 2015, BEHAV BRAIN RES, V278, P542, DOI 10.1016/j.bbr.2014.10.050; Wang Y, 2014, BRAIN BEHAV IMMUN, V38, P1, DOI 10.1016/j.bbi.2013.12.015; Yang YS, 2018, LIFE SCI, V194, P111, DOI 10.1016/j.lfs.2017.12.027; Yuen RKC, 2015, NAT MED, V21, P185, DOI 10.1038/nm.3792; Zhang FM, 2012, AM J GASTROENTEROL, V107, P1755, DOI 10.1038/ajg.2012.251";32;8;11;2;27;BMJ PUBLISHING GROUP;LONDON;BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND;2044-6055;;;BMJ OPEN;BMJ Open;JAN;2022;12;1;;;;;;;e051613;10.1136/bmjopen-2021-051613;http://dx.doi.org/10.1136/bmjopen-2021-051613;;;8;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;YQ0HX;35105621;Green Published, gold;;;24/11/2024;WOS:000749001500062;View Full Record in Web of Science
J;"Buckley, AW; Hirtz, D; Oskoui, M; Armstrong, MJ; Batra, A; Bridgemohan, C; Coury, D; Dawson, G; Donley, D; Findling, RL; Gaughan, T; Gloss, D; Gronseth, G; Kessler, R; Merillat, S; Michelson, D; Owens, J; Pringsheim, T; Sikich, L; Stahmer, A; Thurm, A; Tuchman, R; Warren, Z; Wetherby, A; Wiznitzer, M; Ashwal, S";;;;"Buckley, Ashura Williams; Hirtz, Deborah; Oskoui, Maryam; Armstrong, Melissa J.; Batra, Anshu; Bridgemohan, Carolyn; Coury, Daniel; Dawson, Geraldine; Donley, Diane; Findling, Robert L.; Gaughan, Thomas; Gloss, David; Gronseth, Gary; Kessler, Riley; Merillat, Shannon; Michelson, David; Owens, Judith; Pringsheim, Tamara; Sikich, Linmarie; Stahmer, Aubyn; Thurm, Audrey; Tuchman, Roberto; Warren, Zachary; Wetherby, Amy; Wiznitzer, Max; Ashwal, Stephen";;;Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology;NEUROLOGY;;;English;Article;;;;;;;"MELATONIN TREATMENT; RELEASE MELATONIN; HEALTH; CHILDHOOD; MANAGEMENT; SYMPTOMS; THERAPY; SAFETY; SCALE";ObjectiveTo review pharmacologic and nonpharmacologic strategies for treating sleep disturbances in children and adolescents with autism spectrum disorder (ASD) and to develop recommendations for addressing sleep disturbance in this population.MethodsThe guideline panel followed the American Academy of Neurology 2011 guideline development process, as amended. The systematic review included studies through December 2017. Recommendations were based on evidence, related evidence, principles of care, and inferences.Major recommendations (Level B)For children and adolescents with ASD and sleep disturbance, clinicians should assess for medications and coexisting conditions that could contribute to the sleep disturbance and should address identified issues. Clinicians should counsel parents regarding strategies for improved sleep habits with behavioral strategies as a first-line treatment approach for sleep disturbance either alone or in combination with pharmacologic or nutraceutical approaches. Clinicians should offer melatonin if behavioral strategies have not been helpful and contributing coexisting conditions and use of concomitant medications have been addressed, starting with a low dose. Clinicians should recommend using pharmaceutical-grade melatonin if available. Clinicians should counsel children, adolescents, and parents regarding potential adverse effects of melatonin use and the lack of long-term safety data. Clinicians should counsel that there is currently no evidence to support the routine use of weighted blankets or specialized mattress technology for improving disrupted sleep. If asked about weighted blankets, clinicians should counsel that the trial reported no serious adverse events with blanket use and that blankets could be a reasonable nonpharmacologic approach for some individuals.;"[Buckley, Ashura Williams; Gaughan, Thomas; Kessler, Riley; Thurm, Audrey] NIMH, Pediat & Dev Neurosci Branch, NIH, Bethesda, MD 20892 USA; [Hirtz, Deborah] Univ Vermont, Med Ctr, Dept Neurol Sci, Burlington, VT USA; [Oskoui, Maryam] McGill Univ, Hlth Ctr, Dept Pediat Neurol, Montreal, PQ, Canada; [Armstrong, Melissa J.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA; [Batra, Anshu] Our Special Kids Pediat Care, Dev Pediat, Los Angeles, CA USA; [Bridgemohan, Carolyn] Boston Childrens Hosp, Div Dev Med, Boston, MA USA; [Owens, Judith] Boston Childrens Hosp, Ctr Pediat Sleep Disorders, Boston, MA USA; [Coury, Daniel] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Coury, Daniel] Ohio State Univ, Coll Med, Dept Psychiat, Columbus, OH 43210 USA; [Dawson, Geraldine; Sikich, Linmarie] Duke Univ, Sch Med, Duke Ctr Autism & Brain Dev, Durham, NC USA; [Donley, Diane] Northern Michigan Neurol, Traverse City, MI USA; [Findling, Robert L.] Johns Hopkins Univ, Dept Child & Behav Sci, Baltimore, MD USA; [Gloss, David] Charleston Area Med Ctr, Dept Neurol, Charleston, WV USA; [Gronseth, Gary] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; [Merillat, Shannon] Amer Acad Neurol, Minneapolis, MN USA; [Michelson, David; Ashwal, Stephen] Loma Linda Univ, Sch Med, Dept Pediat, Div Pediat Neurol, Loma Linda, CA 92350 USA; [Pringsheim, Tamara] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Stahmer, Aubyn] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA; [Stahmer, Aubyn] Univ Calif Davis, MIND Inst, Davis, CA 95616 USA; [Tuchman, Roberto] Nicklaus Childrens Hosp, Div Neurol, Miami, FL USA; [Tuchman, Roberto] Miami Childrens Hosp, Miami, FL USA; [Warren, Zachary] Vanderbilt Kennedy Ctr, Treatment & Res Inst Autism Spectrum Disorders, Nashville, TN USA; [Wetherby, Amy] Florida State Univ, Coll Med, Autism Inst, Tallahassee, FL 32306 USA; [Wiznitzer, Max] Rainbow Babies & Childrens Hosp, Div Neurol, 2101 Adelbert Rd, Cleveland, OH 44106 USA";"National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Vermont; University of Vermont Medical Center; McGill University; State University System of Florida; University of Florida; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Duke University; Johns Hopkins University; University of Kansas; University of Kansas Medical Center; Loma Linda University; University of Calgary; University of California System; University of California Davis; University of California System; University of California Davis; Vanderbilt University; State University System of Florida; Florida State University; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University System of Ohio; Case Western Reserve University; Case Western Reserve University Hospital";Buckley, AW (corresponding author), NIMH, Pediat & Dev Neurosci Branch, NIH, Bethesda, MD 20892 USA.;guidelines@aan.com;"Pringsheim, Tamara/L-5955-2019; Dawson, Geraldine/J-8421-2016; Stahmer, Aubyn/KHU-4703-2024; Coury, Daniel/L-6556-2019; Warren, Zachary/KWU-8831-2024";"Warren, Zachary/0000-0001-9677-9386; Dawson, Geraldine/0000-0003-1410-2764; Stahmer, Aubyn/0000-0002-1596-9848; Coury, Daniel/0000-0001-9754-3914; Armstrong, Melissa/0000-0002-2163-1907";American Academy of Neurology (AAN);American Academy of Neurology (AAN);This document was developed with financial support from the American Academy of Neurology (AAN). Authors who serve or served as AAN subcommittee members (D.H., M.O., D.D., D.M., S.A.) or as methodologists (M.J.A., D.G., G.G., T.P.) or as staff (S.M.) were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of the manuscript were reviewed.;"Adkins KW, 2012, PEDIATRICS, V130, pS139, DOI 10.1542/peds.2012-0900K; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Academy of Neurology, 2011, CLIN PRACTICE GUIDEL; American Academy of Sleep Medicine, 2015, CAS BOOK SLEEP MED; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Biran V, 2014, DEV MED CHILD NEUROL, V56, P717, DOI 10.1111/dmcn.12415; Bootzin RR, 2005, CLIN PSYCHOL REV, V25, P629, DOI 10.1016/j.cpr.2005.04.007; Bruni O, 2015, EUR J PAEDIATR NEURO, V19, P122, DOI 10.1016/j.ejpn.2014.12.007; Carmassi C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00366; Cerezo AB, 2016, J FOOD COMPOS ANAL, V45, P80, DOI 10.1016/j.jfca.2015.09.013; Cohen S, 2014, J NEURODEV DISORD, V6, DOI 10.1186/1866-1955-6-44; Cortesi F, 2012, J SLEEP RES, V21, P700, DOI 10.1111/j.1365-2869.2012.01021.x; Cummings C, 2012, PAED CHILD HEALT-CAN, V17, P331, DOI 10.1093/pch/17.6.331; Delahaye J, 2014, RES AUTISM SPECT DIS, V8, P292, DOI 10.1016/j.rasd.2013.12.015; Einfeld S.L., 2002, Manual for the developmental behaviour checklist second edition: Primary carer version (DBC-P) teacher version (DBC-T); Erland LAE, 2017, J CLIN SLEEP MED, V13, P275, DOI 10.5664/jcsm.6462; Fallone G, 2005, SLEEP, V28, P1561, DOI 10.1093/sleep/28.12.1561; Frazier TW, 2017, J CLIN SLEEP MED, V13, P95, DOI 10.5664/jcsm.6398; Goldman SE, 2012, J AUTISM DEV DISORD, V42, P531, DOI 10.1007/s10803-011-1270-5; Gottlieb DJ, 2003, PEDIATRICS, V112, P870, DOI 10.1542/peds.112.4.870; Gringas P, 2017, J AM ACAD CHILD PSY, V56, P948, DOI 10.1016/j.jaac.2017.09.414; Gringras P, 2014, PEDIATRICS, V134, P298, DOI 10.1542/peds.2013-4285; Hartz I, 2012, SCAND J PUBLIC HEALT, V40, P704, DOI 10.1177/1403494812464446; Henderson K, 2011, J DISABIL POLICY STU, V22, P106, DOI 10.1177/1044207310396210; Hodge D, 2014, RES DEV DISABIL, V35, P1631, DOI 10.1016/j.ridd.2014.03.037; Hoebert M, 2009, J PINEAL RES, V47, P1, DOI 10.1111/j.1600-079X.2009.00681.x; Johnson CR, 2013, SLEEP MED, V14, P995, DOI 10.1016/j.sleep.2013.05.013; Kennaway DJ, 2015, J PAEDIATR CHILD H, V51, P584, DOI 10.1111/jpc.12840; Koulouglioti C, 2008, PUBLIC HEALTH NURS, V25, P106, DOI 10.1111/j.1525-1446.2008.00687.x; Lumeng JC, 2007, PEDIATRICS, V120, P1020, DOI 10.1542/peds.2006-3295; Malow BA, 2014, J AUTISM DEV DISORD, V44, P216, DOI 10.1007/s10803-013-1866-z; Malow BA, 2012, PEDIATRICS, V130, pS106, DOI 10.1542/peds.2012-0900I; Medic G, 2017, NAT SCI SLEEP, V9, P151, DOI 10.2147/NSS.S134864; Meltzer LJ, 2008, J PEDIATR PSYCHOL, V33, P380, DOI 10.1093/jpepsy/jsn005; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2010, ARCH PEDIAT ADOL MED, V164, P608, DOI 10.1001/archpediatrics.2010.96; Park JH, 2012, PSYCHIAT RES, V197, P275, DOI 10.1016/j.psychres.2011.09.018; Patzold LM, 1998, J PAEDIATR CHILD H, V34, P528, DOI 10.1046/j.1440-1754.1998.00291.x; Perez-Chada D, 2007, SLEEP, V30, P1698, DOI 10.1093/sleep/30.12.1698; Perfect MM, 2010, J CLIN PSYCHOL, V66, P1205, DOI 10.1002/jclp.20732; Reynolds AM, 2011, PEDIATR CLIN N AM, V58, P685, DOI 10.1016/j.pcl.2011.03.009; Richdale AL, 1999, DEV MED CHILD NEUROL, V41, P60, DOI 10.1017/S0012162299000122; Robinson AM, 2004, CHILD CARE HLTH DEV, V30, P139, DOI 10.1111/j.1365-2214.2004.00395.x; Schreck KA, 2004, RES DEV DISABIL, V25, P57, DOI 10.1016/j.ridd.2003.04.007; Schwebel DC, 2008, J PEDIATR PSYCHOL, V33, P323, DOI 10.1093/jpepsy/jsm109; Shi L, 2013, CURR MED CHEM, V20, P2017, DOI 10.2174/09298673113209990114; Tudor ME, 2012, FOCUS AUTISM DEV DIS, V27, P254, DOI 10.1177/1088357612457989; van Geijlswijk IM, 2011, PSYCHOPHARMACOLOGY, V216, P111, DOI 10.1007/s00213-011-2202-y; van Geijlswijk IM, 2010, PSYCHOPHARMACOLOGY, V212, P379, DOI 10.1007/s00213-010-1962-0; Veatch Olivia J, 2015, Curr Sleep Med Rep, V1, P131; Wright B, 2011, J AUTISM DEV DISORD, V41, P175, DOI 10.1007/s10803-010-1036-5";52;107;113;2;23;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0028-3878;1526-632X;;NEUROLOGY;Neurology;mars-03;2020;94;9;;;;;392;404;;10.1212/WNL.0000000000009033;http://dx.doi.org/10.1212/WNL.0000000000009033;;;13;Clinical Neurology;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;LC9UA;32051244;Bronze, Green Published;;;24/11/2024;WOS:000525678200005;View Full Record in Web of Science
J;"van Pelt, BJ; Idris, S; Jagersma, G; Duvekot, J; Maras, A; van Der Ende, J; van Haren, NEM; Greaves-Lord, K";;;;"van Pelt, B. J.; Idris, S.; Jagersma, G.; Duvekot, J.; Maras, A.; van Der Ende, J.; van Haren, N. E. M.; Greaves-Lord, K.";;;The ACCEPT-study: design of an RCT with an active treatment control condition to study the effectiveness of the Dutch version of PEERS® for adolescents with autism spectrum disorder;BMC PSYCHIATRY;;;English;Article;;;;;;"Autism; RCT; Peers (R); Social skills; Adolescents";"SOCIAL-SKILLS INTERVENTIONS; NEGATIVE EVALUATION; TRAINING-PROGRAM; SELF-EFFICACY; CHILDREN; PARENT; MODERATORS; MEDIATORS; VALIDITY; OUTCOMES";Background Social skills interventions are commonly deployed for adolescents with autism spectrum disorder (ASD). Because effective and appropriate social skills are determined by cultural factors that differ throughout the world, the effectiveness of these interventions relies on a good cultural fit. Therefore, the ACCEPT study examines the effectiveness of the Dutch Program for the Education and Enrichment of Relational Skills (PEERS (R)) social skills intervention. Methods/design This study is a two-arm parallel group randomized controlled trial (RCT) in which adolescents are randomly assigned (after baseline assessment) to one of two group interventions (PEERS (R) vs. active control condition). In total, 150 adolescents are to be included, with multi-informant involvement of their parents and teachers. The ACCEPT study uses an active control condition (puberty psychoeducation group training, focussing on social-emotional development) and explores possible moderators and mediators in improving social skills. The primary outcome measure is the Contextual Assessment of Social Skills (CASS). The CASS assesses social skills performance in a face to face social interaction with an unfamiliar, typically developing peer, making this a valuable instrument to assess the social conversational skills targeted in PEERS (R). In addition, to obtain a complete picture of social skills, self-, parent- and teacher-reported social skills are assessed using the Social Skills improvement System (SSiS-RS) and Social Responsiveness Scale (SRS-2). Secondary outcome measures (i.e. explorative mediators) include social knowledge, social cognition, social anxiety, social contacts and feelings of parenting competency of caregivers. Moreover, demographic and diagnostic measures are assessed as potential moderators of treatment effectiveness. Assessments of adolescents, parents, and teachers take place at baseline (week 0), intermediate (week 7), post intervention (week 14), and at follow-up (week 28). Conclusion This is the first RCT on the effectiveness of the PEERS (R) parent-assisted curriculum which includes an active control condition. The outcome of social skills is assessed using observational assessments and multi-informant questionnaires. Additionally, factors related to social learning are assessed at several time points, which will enable us to explore potential mediators and moderators of treatment effect.;"[van Pelt, B. J.; Idris, S.; Duvekot, J.; van Der Ende, J.; van Haren, N. E. M.; Greaves-Lord, K.] Erasmus MC Sophia, Dept Child & Adolescent Psychiat Psychol, Wytemaweg 8, NL-3015 CN Rotterdam, Netherlands; [van Pelt, B. J.; Jagersma, G.; Maras, A.; Greaves-Lord, K.] Yulius Org Mental Hlth, Raadtsingel 93c, NL-3311 JG Dordrecht, Netherlands; [Idris, S.] Univ Teknol MARA, Fac Med, Dept Psychiat, Clin Psychol Unit, Shah Alam 68100, Selangor, Malaysia; [Greaves-Lord, K.] Autism Team Northern Netherlands, Dept Youth Mental Hlth & Autism, Lentis Psychiat Inst Groningen, Jonx, Groningen, Netherlands; [Greaves-Lord, K.] Univ Groningen, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands";"Erasmus University Rotterdam; Erasmus MC; Universiti Teknologi MARA; University of Groningen";"van Pelt, BJ (corresponding author), Erasmus MC Sophia, Dept Child & Adolescent Psychiat Psychol, Wytemaweg 8, NL-3015 CN Rotterdam, Netherlands.;van Pelt, BJ (corresponding author), Yulius Org Mental Hlth, Raadtsingel 93c, NL-3311 JG Dordrecht, Netherlands.";b.vanpelt@erasmusmc.nl;"IDRIS, SAKINAH/GWC-3338-2022; van Haren, Neeltje/AAC-7656-2020";"Idris (Dr.), Sakinah/0000-0002-3189-986X; van Pelt, BJ/0000-0003-0887-7440";Dutch philanthropic foundation;Dutch philanthropic foundation;The study is supported and funded by a Dutch philanthropic foundation that is committed to improving current diagnostics, training and treatment in adolescents and (young) adults with autism. The Foundation has had no influence in the design of the study, data collection, analysis or interpretation of data, publication of results or writing this manuscript.;"[Anonymous], J AUTISM DEV DISORD; [Anonymous], WETENSCHAPPELIJK TIJ; [Anonymous], AUTISM RES; [Anonymous], COMP EFFECT REV; [Anonymous], 2010, THESIS; [Anonymous], 2012, West. Psychol. Serv.; [Anonymous], HDB COMMUNICATION SO; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Beauchaine TP, 2005, J CONSULT CLIN PSYCH, V73, P371, DOI 10.1037/0022-006X.73.3.371; Bellini S., 2004, Focus on Autism and Other Developmental Disabilities, V19, P78, DOI [DOI 10.1177/10883576040190020201, 10.1177/10883576040190020201]; Bushwick NL, 2001, NEW IDEAS PSYCHOL, V19, P49, DOI 10.1016/S0732-118X(00)00016-7; Carleton RN, 2007, J ANXIETY DISORD, V21, P131, DOI 10.1016/j.janxdis.2006.03.010; Carleton RN, 2006, DEPRESS ANXIETY, V23, P297, DOI 10.1002/da.20142; Coleman PK, 2000, FAM RELAT, V49, P13, DOI 10.1111/j.1741-3729.2000.00013.x; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Davenport M, 2018, RES AUTISM SPECT DIS, V52, P23, DOI 10.1016/j.rasd.2018.05.003; Dolan BK, 2016, J AUTISM DEV DISORD, V46, P2251, DOI 10.1007/s10803-016-2738-0; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Frazier TW, 2014, AUTISM, V18, P31, DOI 10.1177/1362361313500382; Gresham FM., 2008, SOCIAL SKILLS IMPROV; Hays JR, 2002, PSYCHOL REP, V90, P355, DOI 10.2466/PR0.90.2.355-359; Hinshaw SP, 2007, J PEDIATR PSYCHOL, V32, P664, DOI 10.1093/jpepsy/jsl055; Humphrey N, 2011, AUTISM, V15, P397, DOI 10.1177/1362361310387804; JOHNSTON C, 1989, J CLIN CHILD PSYCHOL, V18, P167, DOI 10.1207/s15374424jccp1802_8; Karst JS, 2015, J AUTISM DEV DISORD, V45, P752, DOI 10.1007/s10803-014-2231-6; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; Laugeson EA, 2011, SOCIAL SKILLS FOR TEENAGERS WITH DEVELOPMENTAL AND AUTISM SPECTRUM DISORDERS, P1; Laugeson EA, 2012, J AUTISM DEV DISORD, V42, P1025, DOI 10.1007/s10803-011-1339-1; Laugeson EA, 2009, J AUTISM DEV DISORD, V39, P596, DOI 10.1007/s10803-008-0664-5; LEARY MR, 1983, PERS SOC PSYCHOL B, V9, P371, DOI 10.1177/0146167283093007; Lerner Matthew D, 2012, Dialogues Clin Neurosci, V14, P307; Mandelberg J, 2014, J MENT HEALTH RES IN, V7, P45, DOI 10.1080/19315864.2012.730600; Marchica L., 2016, J ED SOCIAL POLICY, V3, P54; Maric M, 2012, CLIN CHILD FAM PSYCH, V15, P177, DOI 10.1007/s10567-012-0114-y; Rao PA, 2008, J AUTISM DEV DISORD, V38, P353, DOI 10.1007/s10803-007-0402-4; Ratto AB, 2011, J AUTISM DEV DISORD, V41, P1277, DOI 10.1007/s10803-010-1147-z; Raudenbush Stephen W., 2002, HIERARCHICAL LINEAR, V1; Reaven Judy, 2012, Autism Res Treat, V2012, P423905, DOI 10.1155/2012/423905; Reichow B, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008511.pub2; Renno P, 2013, J AUTISM DEV DISORD, V43, P2135, DOI 10.1007/s10803-013-1767-1; Roeyers H., 2011, SRS Screeningslijst voor autismespectrumstoornissen. Handleiding; Schohl KA, 2014, J AUTISM DEV DISORD, V44, P532, DOI 10.1007/s10803-013-1900-1; Shattuck PT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027176; Tse J, 2007, J AUTISM DEV DISORD, V37, P1960, DOI 10.1007/s10803-006-0343-3; Visser K, 2013, EUR CHILD ADOLES PSY, V22, pS209; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); White SW, 2015, FOCUS AUTISM DEV DIS, V30, P3, DOI 10.1177/1088357614539836; White SW, 2007, J AUTISM DEV DISORD, V37, P1858, DOI 10.1007/s10803-006-0320-x; Wolstencroft J, 2018, J AUTISM DEV DISORD, V48, P2293, DOI 10.1007/s10803-018-3485-1; Yoo HJ, 2014, AUTISM RES, V7, P145, DOI 10.1002/aur.1354";50;6;7;0;21;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;juin-01;2020;20;1;;;;;;;274;10.1186/s12888-020-02650-9;http://dx.doi.org/10.1186/s12888-020-02650-9;;;14;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;LU9GO;32487179;Green Published, gold;;;24/11/2024;WOS:000538055300005;View Full Record in Web of Science
J;"Arranz, MJ; Salazar, J; Bote, V; Artigas-Baleri, A; Serra-LLovich, A; Triviño, E; Roige, J; Lombardia, C; Cancino, M; Hernandez, M; Cendros, M; Duran-Tauleria, E; Maraver, N; Hervas, A";;;;"Arranz, Maria J.; Salazar, Juliana; Bote, Valentin; Artigas-Baleri, Alicia; Serra-LLovich, Alexandre; Trivino, Emma; Roige, Jordi; Lombardia, Carlos; Cancino, Martha; Hernandez, Marta; Cendros, Marc; Duran-Tauleria, Enric; Maraver, Natalia; Hervas, Amaia";;;Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers;PHARMACEUTICS;;;English;Article;;;;;;"ASD; pharmacogenetic intervention; pharmacotherapy; personalisation of treatment; antipsychotics; antidepressants; anxiolytics";"SEROTONIN TRANSPORTER GENE; ASSOCIATION; POLYMORPHISM; METAANALYSIS; ESCITALOPRAM; RISPERIDONE; VALIDITY; CHILDREN";"BACKGROUND: Autistic spectrum disorders (ASD) are severe neurodevelopmental alterations characterised by deficits in social communication and repetitive and restricted behaviours. About a third of patients receive pharmacological treatment for comorbid symptoms. However, 30-50% do not respond adequately and/or present severe and long-lasting side effects. METHODS: Genetic variants in CYP1A2, CYP2C19, CYP2D6 and SLC6A4 were investigated in N = 42 ASD sufferers resistant to pharmacological treatment. Clinical recommendations based on their pharmacogenetic profiles were provided within 24-48 h of receiving a biological sample. RESULTS: A total of 39 participants (93%) improved after the pharmacogenetic intervention according to their CGI scores (difference in basal-final scores: 2.26, SD 1.55) and 37 participants (88%) according to their CGAS scores (average improvement of 20.29, SD 11.85). Twenty-three of them (55%) achieved symptom stability (CGI <= 3 and CGAS improvement >= 20 points), requiring less frequent visits to their clinicians and hospital stays. Furthermore, the clinical improvement was higher than that observed in a control group (N = 62) with no pharmacogenetic interventions, in which 66% responded to treatment (difference in CGI scores: -0.87, SD 9.4, p = 1 x 10(-5); difference in CGAS scores: 6.59, SD 7.76, p = 5 x 10(-8)). CONCLUSIONS: The implementation of pharmacogenetic interventions has the potential to significantly improve the clinical outcomes in severe comorbid ASD populations with drug treatment resistance and poor prognosis.";"[Arranz, Maria J.; Serra-LLovich, Alexandre; Hernandez, Marta; Cendros, Marc] Fundacio Docencia & Recerca Mutua Terrassa, Terrassa 08221, Spain; [Arranz, Maria J.] Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid 28029, Spain; [Salazar, Juliana] Inst Recerca Biomed St Pau IIB St Pau, Translat Med Oncol Lab, Barcelona 08041, Spain; [Bote, Valentin; Cancino, Martha; Hervas, Amaia] Hosp Univ Mutua Terrassa, Dept Child Psychiat, Terrassa 08221, Spain; [Artigas-Baleri, Alicia] Hosp Santa Creu & Sant Pau, Genet Dept, Barcelona 08025, Spain; [Trivino, Emma; Roige, Jordi; Lombardia, Carlos] Genet Dept, Catlab, Barcelona 08232, Spain; [Hernandez, Marta] Univ Ramon Llull, Sch Hlth Sci Blanquerna, Barcelona 08024, Spain; [Cendros, Marc] EUGENOMIC Genom & Farmacogenet, Barcelona 08029, Spain; [Duran-Tauleria, Enric; Maraver, Natalia; Hervas, Amaia] Inst Global Atencio Integral Neurodesenvolupament, Barcelona 08007, Spain";"CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Hospital Universitario Mutua Terrassa; Hospital of Santa Creu i Sant Pau; Universitat Ramon Llull";"Arranz, MJ (corresponding author), Fundacio Docencia & Recerca Mutua Terrassa, Terrassa 08221, Spain.;Arranz, MJ (corresponding author), Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid 28029, Spain.";"mjarranz@mutuaterrassa.es; jsalazar@santpau.cat; vbote@mutuaterrassa.cat; a.artigasbaleri@gmail.com; alexserra@mutuaterrassa.cat; etrivino@catlab.cat; jroige@catlab.cat; clombardia@catlab.cat; mccancino@mutuaterrassa.cat; martahhl@blanquerna.url.edu; mcendros@gmail.com; eduran@igain.cat; nmaraver@igain.cat; 32989ahz@comb.cat";"Salazar, Juliana/AAW-1616-2021; HERNANDEZ, MARTA/F-3250-2019";"Arranz, Maria J/0000-0002-6757-9198; Salazar, Juliana/0000-0002-3581-4499; Hervas, Amaia/0000-0003-0051-5752; Artigas-Baleri, Alicia/0000-0003-0486-268X; HERNANDEZ, MARTA/0000-0002-6983-413X; Cendros, Marc/0000-0002-6648-922X";Catalonian Government (Generalitat de Catalunya) [SLT006/17/00148];Catalonian Government (Generalitat de Catalunya)(Generalitat de Catalunya);This study was supported by a research grant from the Catalonian Government (Peris grants for oriented research projects, reference SLT006/17/00148, Generalitat de Catalunya).;"Altar CA, 2015, PHARMACOGENOMICS J, V15, P443, DOI 10.1038/tpj.2014.85; Altar CA, 2013, INT REV PSYCHIATR, V25, P509, DOI 10.3109/09540261.2013.825579; Arranz MJ, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0511-9; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Bishop JR, 2015, PHARMACOGENET GENOM, V25, P548, DOI 10.1097/FPC.0000000000000173; Brown JT, 2021, EXPERT OPIN DRUG MET, V17, P655, DOI 10.1080/17425255.2021.1922668; Brown JT, 2017, PHARMACOGENOMICS, V18, P403, DOI 10.2217/pgs-2016-0167; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Correia CT, 2010, PHARMACOGENOMICS J, V10, P418, DOI 10.1038/tpj.2009.63; Dodsworth T, 2018, CHILD ADOL PSYCH MEN, V12, DOI 10.1186/s13034-018-0243-2; Dragioti E, 2019, JAMA PSYCHIAT, V76, P1241, DOI 10.1001/jamapsychiatry.2019.2859; Fabbri C., 2016, GENETIC INFLUENCES R; Fagerness J, 2014, AM J MANAG CARE, V20, pE146; Gutiérrez B, 1998, BIOL PSYCHIAT, V43, P843, DOI 10.1016/S0006-3223(97)00540-4; Hall-Flavin DK, 2013, PHARMACOGENET GENOM, V23, P535, DOI 10.1097/FPC.0b013e3283649b9a; Henneberry E, 2021, J AUTISM DEV DISORD, V51, P4370, DOI 10.1007/s10803-021-05237-9; Komaryk A, 2021, J CAN ACAD CHILD ADO, V30, P36; Libowitz MR, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.623681; Mano-Sousa BJ, 2021, CURR NEUROPHARMACOL, V19, P538, DOI 10.2174/1570159X18666200529151741; Naranjo MEG, 2016, PHARMACOGENOMICS J, V16, P485, DOI 10.1038/tpj.2016.47; Owley T, 2010, AUTISM RES, V3, P1, DOI 10.1002/aur.109; Pérez V, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1412-1; Porcelli S, 2012, EUR NEUROPSYCHOPHARM, V22, P239, DOI 10.1016/j.euroneuro.2011.10.003; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Shindler AE, 2020, J AUTISM DEV DISORD, V50, P76, DOI 10.1007/s10803-019-04231-6; Smith T, 2015, INT J MOL SCI, V16, P4416, DOI 10.3390/ijms16034416; Thümmler S, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00002; Vanwong N, 2017, J CHILD ADOL PSYCHOP, V27, P185, DOI 10.1089/cap.2014.0171; Winner JG, 2015, CURR MED RES OPIN, V31, P1633, DOI 10.1185/03007995.2015.1063483; Yoshida K, 2021, CAN J PSYCHIAT, V66, P1019, DOI 10.1177/0706743720971950; Zhou MS, 2021, J AM ACAD CHILD PSY, V60, P35, DOI 10.1016/j.jaac.2020.03.007; Zhou Y, 2017, CLIN PHARMACOL THER, V102, P688, DOI 10.1002/cpt.690";32;7;7;0;3;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;1999-4923;;PHARMACEUTICS;Pharmaceutics;MAY;2022;14;5;;;;;;;999;10.3390/pharmaceutics14050999;http://dx.doi.org/10.3390/pharmaceutics14050999;;;12;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;1Q5OO;35631585;Green Published, gold;;;24/11/2024;WOS:000802736600001;View Full Record in Web of Science
J;"Wang, YL; Wang, F; Kong, Y; Gao, TS; Zhu, QY; Han, L; Sun, B; Guan, LY; Zhang, ZY; Qian, YX; Xu, LX; Li, Y; Fang, H; Jiao, GK; Ke, XY";;;;"Wang, Yonglu; Wang, Fei; Kong, Yue; Gao, Tianshu; Zhu, Qingyao; Han, Lu; Sun, Bei; Guan, Luyang; Zhang, Ziyi; Qian, Yuxin; Xu, Lingxi; Li, Yun; Fang, Hui; Jiao, Gongkai; Ke, Xiaoyan";;;High definition transcranial direct current stimulation of the Cz improves social dysfunction in children with autism spectrum disorder: A randomized, sham, controlled study;AUTISM RESEARCH;;;English;Article;;;;;;"autism spectrum disorder (ASD); high definition 5-channel transcranial direct current stimulation (HD-tDCS); social dysfunction; vertex (Cz)";"NONINVASIVE BRAIN-STIMULATION; WHITE-MATTER INTEGRITY; HUMAN MOTOR CORTEX; TEMPOROPARIETAL JUNCTION; DIAGNOSTIC INTERVIEW; SLEEP; SAFETY; ASSOCIATION; DEFICITS; NETWORK";The purpose of this study was to determine the effect of the Cz of high-definition 5-channel tDCS (HD-tDCS) on social function in 4-12 years-old children with autism spectrum disorder (ASD). This study was a randomized, double-blind, pseudo-controlled trial in which 45 ASD children were recruited and divided into three groups with sex, age, and rehabilitation treatment as control variables. Each group of 15 children with ASD was randomly administered active HD-tDCS with the Cz as the central anode, active HD-tDCS with the left dorsolateral prefrontal cortex (F3) as the central anode, and sham HD-tDCS with the Cz as the central anode with 14 daily sessions in 3 weeks. The Social Responsiveness Scale Chinese Version (SRS-Chinese Version) was compared 1 week after stimulation with values recorded 1 week prior to stimulation. At the end of treatment, both the anodal Cz and anodal left DLFPC tDCS decreased the measures of SRS-Chinese Version. The total score of SRS-Chinese Version decreased by 13.08%, social cognition decreased by 18.33%, and social communication decreased by 10.79%, which were significantly improved over the Cz central anode active stimulation group, especially in children with young age, and middle and low function. There was no significant change in the total score and subscale score of SRS-Chinese Version over the Cz central anode sham stimulation group. In the F3 central anode active stimulation group, the total score of SRS-Chinese Version decreased by 13%, autistic behavior decreased by 19.39%, and social communication decreased by 14.39%, which were all significantly improved. However, there was no significant difference in effect between the Cz and left DLPFC stimulation conditions. HD-tDCS of the Cz central anode may be an effective treatment for social dysfunction in children with ASD.Lay SummaryThis preliminary study showed that HD-tDCS at the Cz was feasible, safe, and potentially effective in improving the symptoms of ASD social dysfunction in children. HD-tDCS was well tolerated and no adverse reactions were reported. All participants showed significant improvements in social cognition, social understanding, verbal expression, and logical thinking. In addition, further research is needed to expand the sample size, including which types of ASD children are more likely to benefit from treatment.;"[Wang, Yonglu; Wang, Fei; Kong, Yue; Gao, Tianshu; Zhu, Qingyao; Han, Lu; Sun, Bei; Guan, Luyang; Zhang, Ziyi; Qian, Yuxin; Xu, Lingxi; Li, Yun; Fang, Hui; Jiao, Gongkai; Ke, Xiaoyan] Nanjing Med Univ, Affiliated Brain Hosp, Child Mental Hlth Res Ctr, Nanjing, Peoples R China; [Fang, Hui; Jiao, Gongkai; Ke, Xiaoyan] Nanjing Med Univ, Affiliated Brain Hosp, Child Mental Hlth Res Ctr, Nanjing 210029, Peoples R China";"Nanjing Medical University; Nanjing Medical University";"Fang, H; Jiao, GK; Ke, XY (corresponding author), Nanjing Med Univ, Affiliated Brain Hosp, Child Mental Hlth Res Ctr, Nanjing 210029, Peoples R China.";"fanghuisd@126.com; jiaogongkai@njmu.edu.cn; kexiaoyan@njmu.edu.cn";"li, yanze/JHT-4361-2023; Li, You/GRX-6269-2022; Wang, Xinyi/KHV-4909-2024";Guan, Luyang/0000-0003-2221-6008;"Science and technology development Foundation, Nanjing Medical University [20210225]; Medical Science and technology development Foundation, Nanjing Department of Health [YKK21115]; STI2030-Major Projects [2021ZD0204004]";"Science and technology development Foundation, Nanjing Medical University; Medical Science and technology development Foundation, Nanjing Department of Health; STI2030-Major Projects";"Science and technology development Foundation, Nanjing Medical University, Grant/Award Number: 20210225; Medical Science and technology development Foundation, Nanjing Department of Health, Grant/Award Number: YKK21115; STI2030-Major Projects, Grant/Award Number: 2021ZD0204004";"Aldridge FJ, 2012, J AUTISM DEV DISORD, V42, P294, DOI 10.1007/s10803-011-1242-9; ALNAES E, 1973, ACTA PHYSIOL SCAND, V87, P96, DOI 10.1111/j.1748-1716.1973.tb05370.x; Amatachaya A, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/173073; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Auvichayapat N, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00070; Avino T, 2021, BRAIN RES, V1760, DOI 10.1016/j.brainres.2021.147350; Barbati SA, 2022, FRONT CELL NEUROSCI, V16, DOI 10.3389/fncel.2022.945777; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Cen CQ, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-016-1185-y; Charest J, 2021, J AM COLL HEALTH, V69, P378, DOI 10.1080/07448481.2019.1679152; Chhabra H, 2021, ACTA NEUROPSYCHIATR, V33, P242, DOI 10.1017/neu.2021.14; Chib VS, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.44; Chojnicka I, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01916; Chojnicka I, 2012, PSYCHIATR POL, V46, P249; Clark AL, 2017, NEUROIMAGE-CLIN, V14, P308, DOI 10.1016/j.nicl.2016.12.017; Dipasquale V, 2017, INT J MOL CELL MED, V6, P148, DOI 10.22088/acadpub.BUMS.6.3.148; Elumalai P, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-12171-y; Erden G, 2022, J GEN PSYCHOL, V149, P371, DOI 10.1080/00221309.2020.1862038; Esse Wilson J, 2018, J ECT, V34, pe10, DOI [10.1097/YCT.0000000000000472, 10.1097/YCT.0000000000000445]; Filmer HL, 2019, CORTEX, V115, P324, DOI 10.1016/j.cortex.2019.02.012; Fitzgerald J, 2019, J AUTISM DEV DISORD, V49, P2664, DOI 10.1007/s10803-016-2803-8; Fombonne E, 2021, J AUTISM DEV DISORD, V51, P4271, DOI 10.1007/s10803-021-05005-9; Frase L, 2016, NEUROPSYCHOPHARMACOL, V41, P2577, DOI 10.1038/npp.2016.65; Fujino J, 2021, BRAIN STIMUL, V14, P682, DOI 10.1016/j.brs.2021.04.009; Garcia-Gonzalez S, 2021, EUR NEUROPSYCHOPHARM, V48, P89, DOI 10.1016/j.euroneuro.2021.02.017; Germann J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00603-0; Giovannella M., 2017, Brain Stimulation, V10, P383; Gómez L, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7030063; Gómez-Fernández L, 2018, REV MEX NEUROCIENC, V19, P8, DOI 10.31190/rmn.2018.19.3.08.20; Graham SF, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-01685-z; Grimaldi D, 2020, NEUROBIOL DIS, V141, DOI 10.1016/j.nbd.2020.104865; Haigh SM, 2020, AUTISM RES, V13, P702, DOI 10.1002/aur.2271; Han YMY, 2022, BRAIN STIMUL, V15, P414, DOI 10.1016/j.brs.2022.02.004; Hui K, 2020, NEUROSCI BIOBEHAV R, V110, P77, DOI 10.1016/j.neubiorev.2018.08.001; Hunter JE, 2021, SLEEP MED, V80, P301, DOI 10.1016/j.sleep.2021.01.062; Kim S, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110906; Krishnan C, 2015, BRAIN STIMUL, V8, P76, DOI 10.1016/j.brs.2014.10.012; Leaf JB, 2021, J AUTISM DEV DISORD, V51, P4395, DOI 10.1007/s10803-020-04481-9; Lebersfeld JB, 2021, J AUTISM DEV DISORD, V51, P4101, DOI 10.1007/s10803-020-04839-z; Li GF, 2020, FRONT HUM NEUROSCI, V14, DOI 10.3389/fnhum.2020.565132; Li PY, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102144; Li Z, 2022, EPIDEMIOL PSYCH SCI, V31, DOI 10.1017/S2045796022000178; Liang D, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.745671; Liu J., 2015, Science China. Life Sciences, V8, P4; Lu HL, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.564447; Maenner MJ, 2020, MMWR SURVEILL SUMM, V69, P1, DOI 10.15585/mmwr.ss6904a1; Magnin M, 2010, P NATL ACAD SCI USA, V107, P3829, DOI 10.1073/pnas.0909710107; Marotta R, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10030163; Mash LE, 2018, DEV NEUROBIOL, V78, P456, DOI 10.1002/dneu.22570; Mielke D, 2013, NEUROL RES, V35, P1029, DOI 10.1179/1743132813Y.0000000248; Mishima T, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0204-19.2019; Missitzi J, 2011, J PHYSIOL-LONDON, V589, P297, DOI 10.1113/jphysiol.2010.200600; Nakai N, 2021, ADV EXP MED BIOL, V1293, P523, DOI 10.1007/978-981-15-8763-4_36; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Oliveras-Rentas RE, 2012, J AUTISM DEV DISORD, V42, P655, DOI 10.1007/s10803-011-1289-7; Ostrowski J, 2022, J NEURAL TRANSM, V129, P861, DOI 10.1007/s00702-022-02507-3; Parlikar R, 2021, ASIAN J PSYCHIATR, V56, DOI 10.1016/j.ajp.2020.102542; Pelletier SJ, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu047; Philip NS, 2017, AM J PSYCHIAT, V174, P628, DOI 10.1176/appi.ajp.2017.16090996; Qiu JJ, 2021, NEURAL PLAST, V2021, DOI 10.1155/2021/6627507; Rizzo G, 2018, NEUROSCIENCE, V385, P166, DOI 10.1016/j.neuroscience.2018.05.051; Saemundsen E, 2003, J AUTISM DEV DISORD, V33, P319, DOI 10.1023/A:1024410702242; Saidi M, 2021, MED HYPOTHESES, V153, DOI 10.1016/j.mehy.2021.110615; Sellaro R, 2016, ANN NY ACAD SCI, V1369, P218, DOI 10.1111/nyas.13098; Tan ZQ, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.806876; Terashima H., 2022, Microscopy (Oxford, England), V71, pi81; Trofimov AO, 2018, ADV EXP MED BIOL, V1072, P59, DOI 10.1007/978-3-319-91287-5_10; Tso WWY, 2018, CHILD CARE HLTH DEV, V44, P378, DOI 10.1111/cch.12548; Turski CA, 2017, RESTOR NEUROL NEUROS, V35, P631, DOI 10.3233/RNN-170757; Veatch OJ, 2017, AUTISM RES, V10, P1221, DOI 10.1002/aur.1765; Vogan VM, 2016, J AUTISM DEV DISORD, V46, P2138, DOI 10.1007/s10803-016-2744-2; Wang Q, 2021, BRAIN IMAGING BEHAV, V15, P2583, DOI 10.1007/s11682-021-00460-5; Wang WH, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00556; Wang YL, 2023, BRAIN SCI, V13, DOI 10.3390/brainsci13020280; Woodward ND, 2017, BIOL PSYCHIAT-COGN N, V2, P76, DOI 10.1016/j.bpsc.2016.09.002; Xia YF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75460-4; Yamada Y, 2021, FRONT HUM NEUROSCI, V15, DOI 10.3389/fnhum.2021.631838; Yoon SH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040966; Zhou TY, 2020, NEUROIMAGE-CLIN, V28, DOI 10.1016/j.nicl.2020.102500";79;2;2;4;18;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1939-3792;1939-3806;;AUTISM RES;Autism Res.;OCT;2023;16;10;;;;;2035;2048;;10.1002/aur.3018;http://dx.doi.org/10.1002/aur.3018;;sept-23;14;"Behavioral Sciences; Psychology, Developmental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology";X4MO8;37695276;;;;24/11/2024;WOS:001065373400001;View Full Record in Web of Science
J;"Chu, LT; Shen, L; Ma, CH; Chen, JJ; Tian, Y; Zhang, CC; Gong, ZL; Li, MF; Wang, CJ; Pan, LZ; Zhu, PY; Wu, DM; Wang, Y; Yu, GJ";;;;"Chu, Liting; Shen, Li; Ma, Chenhuan; Chen, Jinjin; Tian, Yuan; Zhang, Chuncao; Gong, Zilan; Li, Mengfan; Wang, Chengjie; Pan, Lizhu; Zhu, Peiying; Wu, Danmai; Wang, Yu; Yu, Guangjun";;;Effects of a Nonwearable Digital Therapeutic Intervention on Preschoolers With Autism Spectrum Disorder in China: Open-Label Randomized Controlled Trial;JOURNAL OF MEDICAL INTERNET RESEARCH;;;English;Article;;;;;;"autism spectrum disorder; digital therapy; nonwearable; preschoolers; randomized controlled trial; autism; neurodevelopmental disorder; difficulty with communication; social interaction; ADHD; attention-deficit/hyperactivity disorder; digital therapy; digital intervention";"SEX-DIFFERENCES; CLASSIFICATION; DIAGNOSIS; CHILDREN";"Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause difficulty with communication and social interactions as well as complicated family dynamics. Digital health interventions can reduce treatment costs and promote healthy lifestyle changes. These therapies can be adjunctive or replace traditional treatments. However, issues with cooperation and compliance prevent preschool patients with ASD from applying these tools. In this open-label, randomized controlled trial, we developed a nonwearable digital therapy called virtual reality-incorporated cognitive behavioral therapy (VR-CBT). Objective: The aim of this study was to assess the adjunctive function of VR-CBT by comparing the effects of VR-CBT plus learning style profile (LSP) intervention with those of LSP-only intervention in preschool children with ASD. Methods: This trial was performed in China on 78 preschool children (age 3-6 years, IQ>70) diagnosed with ASD who were randomized to receive a 20-week VR-CBT plus LSP intervention (intervention group, 39/78, 50%) or LSP intervention only (control group, 39/78, 50%). The primary outcome was the change of scores from baseline to week 20, assessed by using the parent-rated Autism Behavior Checklist (ABC). Secondary outcomes included the Childhood Autism Rating Scale (CARS), Attention-Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV), and behavioral performance data (accuracy and reaction time) in go/no-go tasks. All primary and secondary outcomes were analyzed in the intention-to-treat population. Results: After the intervention, there was an intervention effect on total ABC (beta=-5.528; P<.001) and CARS scores (beta=-1.365; P=.02). A similar trend was observed in the ABC subscales: sensory (beta=-1.133; P=.047), relating (beta=-1.512; P=.03), body and object use (beta=-1.211; P=.03), and social and self-help (beta=-1.593; P=.03). The intervention also showed statistically significant effects in improving behavioral performance (go/no-go task, accuracy, beta=2.923; P=.04). Moreover, a significant improvement of ADHD hyperactivity-impulsivity symptoms was observed in 53 children with comorbid ADHD based on ADHD-RS-IV (beta=-1.269; P=.02). No statistically significant intervention effect was detected in the language subscale of ABC (beta=-.080; P=.83). Intervention group girls had larger improvements in ABC subscales, that is, sensory and body and object use and in the CARS score and accuracy of go/no-go task (all P<.05) than the control group girls. Statistically significant intervention effects could be observed in hyperactivity-impulsivity symptoms in the intervention group boys with comorbid ADHD compared with those in the control group boys (beta=-1.333; P=.03).Conclusions: We found potentially positive effects of nonwearable digital therapy plus LSP on core symptoms associated with ASD, leading to a modest improvement in the function of sensory, motor, and response inhibition, while reducing impulsivity and hyperactivity in preschoolers with both ASD and ADHD. VR-CBT was found to be an effective and feasible adjunctive digital tool. Trial Registration:";"[Chu, Liting; Ma, Chenhuan; Chen, Jinjin; Tian, Yuan; Zhang, Chuncao; Gong, Zilan; Li, Mengfan; Wang, Chengjie; Pan, Lizhu; Zhu, Peiying; Wu, Danmai; Wang, Yu; Yu, Guangjun] Shanghai Jiao Tong Univ, Shanghai Childrens Hosp, Sch Med, Dept Child Hlth Care, Shanghai, Peoples R China; [Chu, Liting] Shanghai Municipal Ctr Dis Control & Prevent, Div Child & Adolescent Hlth, Shanghai, Peoples R China; [Shen, Li] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Ctr Translat Med, Shanghai, Peoples R China; [Yu, Guangjun] Chinese Univ Hong Kong, Sch Med, 2001 Longxiang Ave, Shenzhen 518172, Peoples R China";"Shanghai Jiao Tong University; Shanghai Center for Disease Control & Prevention; Shanghai Jiao Tong University; The Chinese University of Hong Kong, Shenzhen";Yu, GJ (corresponding author), Chinese Univ Hong Kong, Sch Med, 2001 Longxiang Ave, Shenzhen 518172, Peoples R China.;guangjunyu@cuhk.edu.cn;Zhu, peiying/KIL-4285-2024;"Ma, Chenhuan/0009-0001-2247-4878; Chu, Liting/0000-0002-8703-8479; TIAN, yuan/0000-0002-3084-7689";"General Program of the National Natural Science Foundation [71874110]; Major Research Plan Project of the National Natural Science Foundation [91846302]; special key project for clinical research and cultivation of Shanghai Children's Hospital affiliated to Shanghai Jiao Tong University School of Medicine [2021YLYZ02]; Shanghai Health and Hygiene Commission on Aging and Maternal and Child Health [2020YJZX0207]; 3-year action plan for the construction of the Shanghai public health system [GWV-10.1-XK14]";"General Program of the National Natural Science Foundation; Major Research Plan Project of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); special key project for clinical research and cultivation of Shanghai Children's Hospital affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Health and Hygiene Commission on Aging and Maternal and Child Health; 3-year action plan for the construction of the Shanghai public health system";This work was supported by the General Program of the National Natural Science Foundation (71874110), Major Research Plan Project of the National Natural Science Foundation (91846302), special key project for clinical research and cultivation of Shanghai Children's Hospital affiliated to Shanghai Jiao Tong University School of Medicine (2021YLYZ02), project of the Shanghai Health and Hygiene Commission on Aging and Maternal and Child Health (2020YJZX0207), and 3-year action plan for the construction of the Shanghai public health system (GWV-10.1-XK14).;"Alpert JS, 2021, AM J MED, V134, P701, DOI 10.1016/j.amjmed.2020.10.022; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Anderson G, 2019, CURR PHARM DESIGN, V25, P4319, DOI 10.2174/138161282541191230102715; [Anonymous], Guidelines on physical activity, sedentary behavior, sleep for children under 5 years of age; Aubrey JS, 2018, COMMON SENSE; Baird G, 2003, BRIT MED J, V327, P488, DOI 10.1136/bmj.327.7413.488; Bargiela S, 2016, J AUTISM DEV DISORD, V46, P3281, DOI 10.1007/s10803-016-2872-8; Bashiri Azadeh, 2017, Korean J Pediatr, V60, P337, DOI 10.3345/kjp.2017.60.11.337; Bell ML, 2018, PSYCHO-ONCOLOGY, V27, P2125, DOI 10.1002/pon.4777; Bölte S, 2011, AUTISM, V15, P497, DOI 10.1177/1362361310391116; Chen MH, 2015, RES AUTISM SPECT DIS, V10, P1, DOI 10.1016/j.rasd.2014.10.014; Chen YJ, 2020, J CLIN NURS, V29, P503, DOI 10.1111/jocn.15088; Chenhuan MA, 2020, CHINESE J CHILD HLTH, V28, P482, DOI [10.11852/zgetbjzz2019-0890, DOI 10.11852/ZGETBJZZ2019-0890]; Chu JH, 2022, WORLD J CLIN CASES, V10, P1206, DOI 10.12998/wjcc.v10.i4.1206; Cook A, 2022, EUR J SPEC NEEDS EDU, V37, P371, DOI 10.1080/08856257.2021.1878659; Cremone-Caira A, 2020, CLIN NEUROPHYSIOL, V131, P406, DOI 10.1016/j.clinph.2019.09.024; De Luca R, 2021, APPL NEUROPSYCH-CHIL, V10, P90, DOI 10.1080/21622965.2019.1610964; Demetriou EA, 2018, MOL PSYCHIATR, V23, P1198, DOI 10.1038/mp.2017.75; Deng LL, 2022, ASSIST TECHNOL, V34, P242, DOI 10.1080/10400435.2020.1757787; Elder JH, 2017, PSYCHOL RES BEHAV MA, V10, P283, DOI 10.2147/PRBM.S117499; Friedlander D, DISSERTATION; Georgescu AL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00807; Goncalves A, 2022, IEEE T VIS COMPUT GR, V28, P4452, DOI 10.1109/TVCG.2021.3091485; Gong Y., 1988, Acta Psychologica Sinica, V20, P30; Greene RK, 2022, CLIN NEUROPSYCHOL, V36, P943, DOI 10.1080/13854046.2021.1942220; Gulliford M, 2019, LANCET DIGIT HEALTH, V1, pE382, DOI 10.1016/S2589-7500(19)30194-3; Hodges H, 2020, TRANSL PEDIATR, V9, P55, DOI 10.21037/tp.2019.09.09; Hu XY, 2019, NEW FRONT EDUC RES, P55, DOI 10.1007/978-981-13-8203-1_5; Joshi G, 2017, J ATTEN DISORD, V21, P846, DOI 10.1177/1087054714543368; Kaimara P, 2022, VIRTUAL REAL-LONDON, V26, P697, DOI 10.1007/s10055-021-00563-w; Katusic MZ, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2020-049899; Kodak T, 2020, PEDIATR CLIN N AM, V67, P525, DOI 10.1016/j.pcl.2020.02.007; Kumm AJ, 2022, J AUTISM DEV DISORD, V52, P2300, DOI 10.1007/s10803-021-05084-8; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; Low J, 2009, BRIT J DEV PSYCHOL, V27, P425, DOI 10.1348/026151008X334728; Ma CH, 2022, FRONT PEDIATR, V10, DOI 10.3389/fped.2022.831621; Mandy W, 2012, J AUTISM DEV DISORD, V42, P1304, DOI 10.1007/s10803-011-1356-0; Masi A, 2017, NEUROSCI BULL, V33, P183, DOI 10.1007/s12264-017-0100-y; McCleery JP, 2020, AUTISM RES, V13, P1418, DOI 10.1002/aur.2352; Mesa-Gresa P, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18082486; Monden Y, 2015, NEUROIMAGE-CLIN, V9, P1, DOI 10.1016/j.nicl.2015.06.011; Newbutt N, THESIS; Osório JMA, 2021, AUTISM RES, V14, P2412, DOI 10.1002/aur.2580; Putra PU, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-01050-7; Riva G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113434; Rydell P, 2013, LEARNING STYLE PROFI; Sanchack KE, 2016, AM FAM PHYSICIAN, V94, P972; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Su Y, 2015, J ATTEN DISORD, V19, P1022, DOI 10.1177/1087054712461177; Vahabzadeh A, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/mental.9631; VOLKMAR FR, 1988, J AUTISM DEV DISORD, V18, P81, DOI 10.1007/BF02211820; Voss C, 2019, JAMA PEDIATR, V173, P446, DOI 10.1001/jamapediatrics.2019.0285; Wang Y, 2018, PSYCHIAT RES, V266, P168, DOI 10.1016/j.psychres.2018.05.057; Werling DM, 2013, CURR OPIN NEUROL, V26, P146, DOI 10.1097/WCO.0b013e32835ee548; Yi ZY, 2021, J PSYCHOPATHOL BEHAV, V43, P376, DOI 10.1007/s10862-020-09837-0; Zhang MY, 2022, BEHAV SCI-BASEL, V12, DOI 10.3390/bs12050138; Zhou H, 2020, NEUROSCI BULL, V36, P961, DOI 10.1007/s12264-020-00530-6";58;4;5;20;52;JMIR PUBLICATIONS, INC;TORONTO;130 QUEENS QUAY East, Unit 1100, TORONTO, ON M5A 0P6, CANADA;1438-8871;;;J MED INTERNET RES;J. Med. Internet Res.;AUG 24;2023;25;;;;;;;;e45836;10.2196/45836;http://dx.doi.org/10.2196/45836;;;16;"Health Care Sciences & Services; Medical Informatics";Science Citation Index Expanded (SCI-EXPANDED);"Health Care Sciences & Services; Medical Informatics";R5SF8;37616029;Green Published, gold;;;24/11/2024;WOS:001064943000005;View Full Record in Web of Science
J;Doenyas, C;;;;Doenyas, Ceymi;;;Novel Personalized Dietary Treatment for Autism Based on the Gut-Immune-Endocrine-Brain Axis;FRONTIERS IN ENDOCRINOLOGY;;;English;Article;;;;;;"autism; autism spectrum disorder; diet; personalized; immune; endocrine";"CASEIN-FREE DIET; GLUTEN-FREE; SPECTRUM DISORDER; KETOGENIC DIET; CHILDREN; MICROBIOTA; BLIND; PROTEINS; INTERVENTION; BEHAVIOR";Autism spectrum disorder (ASD) is a neurodevelopmental condition manifesting with impaired social interaction and communication, and restricted and repetitive behaviors and interests. In this perspective article, a more comprehensive approach than the gut-brain axis, hereby termed the gut-immune-endocrine-brain axis, is taken, based on which a personalized treatment plan for ASD is presented. ASD has no known etiology or cure, making desperate parents willing to try any treatment that worked for an individual with ASD, without much regard for its effectiveness, safety or side effects. This has been the case for restrictive dietary interventions as gluten-free/casein-free and ketogenic diets and recently, probiotics have emerged as the new such fad. One of the concerns about these dietary and probiotic treatments is their non-specificity: they may not be effective for all individuals with ASD, not all probiotic strains may have the beneficial qualities advertised indiscriminately for probiotics, and strains conferring benefits in one condition may not be probiotic in another. Not all children with ASD show immune reactivity to dietary proteins in wheat and milk, and wheat and milk may not be the only dietary elements to which reactivity is exhibited, where dietary aquaporins that resemble human aquaporins may elicit antibody reactivity in genetically susceptible individuals, which may include individuals with ASD. These observations are utilized to formulate a three-step plan to create effective, targeted, personalized treatments with as few side effects as possible, enabled by a systems approach connecting the various findings for dietary, immune, and neuroautoimmune reactivity in individuals with ASD.;[Doenyas, Ceymi] Koc Univ, Res Ctr Translat Med, Istanbul, Turkey;Koc University;Doenyas, C (corresponding author), Koc Univ, Res Ctr Translat Med, Istanbul, Turkey.;oeymidoenyas@alumni.princeton.edu;Doenyas, Ceymi/I-7102-2019;;;;;"Adams JB, 2009, J TOXICOL-US, V2009, DOI 10.1155/2009/532640; Adams JB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030369; Adams JB, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-22; American Psychiatric Association, 2013, DESK REF DIAGN CRIT; Anadure RK, 2019, GUT BRAIN AXIS MED U; [Anonymous], 2002, GUIDELINES EVALUATIO; Ashwood P, 2006, J LEUKOCYTE BIOL, V80, P1, DOI 10.1189/jlb.1205707; Azhari A, 2019, DEV PSYCHOBIOL, V61, P752, DOI 10.1002/dev.21803; Buffington SA, 2016, CELL, V165, P1762, DOI 10.1016/j.cell.2016.06.001; Carter CJ, 2016, NEUROCHEM INT, V101, P83, DOI 10.1016/j.neuint.2016.10.011; Cielinska A., 2017, CIIT, V3, P1, DOI [10.24966/CIIT-8844/100009, DOI 10.24966/CIIT-8844/100009, 10.24966/ciit-8844/100009]; Davani-Davari D, 2019, FOODS, V8, DOI 10.3390/foods8030092; De Santis B, 2019, NUTR NEUROSCI, V22, P132, DOI 10.1080/1028415X.2017.1357793; DEufemia P, 1996, ACTA PAEDIATR, V85, P1076, DOI 10.1111/j.1651-2227.1996.tb14220.x; Doenyas C, 2018, PHYSIOL BEHAV, V194, P577, DOI 10.1016/j.physbeh.2018.07.014; Edelson SB, 1998, TOXICOL IND HEALTH, V14, P799, DOI 10.1177/074823379801400603; El-Rashidy O, 2017, METAB BRAIN DIS, V32, P1935, DOI 10.1007/s11011-017-0088-z; Elder JH, 2006, J AUTISM DEV DISORD, V36, P413, DOI 10.1007/s10803-006-0079-0; Evangeliou A, 2003, J CHILD NEUROL, V18, P113, DOI 10.1177/08830738030180020501; Fallon J, 2005, MED HYPOTHESES, V64, P312, DOI 10.1016/j.mehy.2004.06.023; Fido A, 2005, AUTISM, V9, P290, DOI 10.1177/1362361305053255; Fülling C, 2019, NEURON, V101, P998, DOI 10.1016/j.neuron.2019.02.008; Geier DA, 2009, J NEUROL SCI, V280, P101, DOI 10.1016/j.jns.2008.08.021; Grimaldi R, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0523-3; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Hyman SL, 2016, J AUTISM DEV DISORD, V46, P205, DOI 10.1007/s10803-015-2564-9; Jyonouchi H, 2002, NEUROPSYCHOBIOLOGY, V46, P76, DOI 10.1159/000065416; Kern JK, 2007, J TOXICOL ENV HEAL A, V70, P715, DOI 10.1080/15287390601188060; Knivsberg A.M., 1995, Scandinavian Journal of Educational Research, V39, P223, DOI DOI 10.1080/0031383950390304; Knivsberg AM, 2002, NUTR NEUROSCI, V5, P251, DOI 10.1080/10284150290028945; Kopec AM, 2018, BRAIN RES, V1693, P214, DOI 10.1016/j.brainres.2018.01.009; Lambert J, 2019, IMMUNOL RES, V67, P12, DOI 10.1007/s12026-018-9046-z; Leccioli V, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111203; Lee RWY, 2018, PHYSIOL BEHAV, V188, P205, DOI 10.1016/j.physbeh.2018.02.006; Mayer EA, 2014, J NEUROSCI, V34, P15490, DOI 10.1523/JNEUROSCI.3299-14.2014; Montiel-Castro AJ, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00070; Munasinghe SA, 2010, J AUTISM DEV DISORD, V40, P1131, DOI 10.1007/s10803-010-0974-2; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; Obrenovich M., 2017, BAO MICROBIOL, V2, P22, DOI 10.2174/1871527315666160202123107; PANKSEPP J, 1979, TRENDS NEUROSCI, V2, P174, DOI 10.1016/0166-2236(79)90071-7; Pennesi CM, 2012, NUTR NEUROSCI, V15, P85, DOI 10.1179/1476830512Y.0000000003; Provensi G, 2019, P NATL ACAD SCI USA, V116, P9644, DOI 10.1073/pnas.1820832116; Reichelt KL, 2009, ANN CLIN PSYCHIATRY, V21, P205; Reichelt Karl L., 1991, Brain Dysfunction, V4, P308; Reichelt KL, 2003, NUTR NEUROSCI, V6, P19, DOI 10.1080/1028415021000042839; Reid G, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00424; Roberts EM, 2007, ENVIRON HEALTH PERSP, V115, P1482, DOI 10.1289/ehp.10168; Ruskin DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065021; Sanctuary MR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210064; Sandin S, 2014, JAMA-J AM MED ASSOC, V311, P1770, DOI 10.1001/jama.2014.4144; Sgritta M, 2019, NEURON, V101, P246, DOI 10.1016/j.neuron.2018.11.018; Shaaban SY, 2018, NUTR NEUROSCI, V21, P676, DOI 10.1080/1028415X.2017.1347746; Sharon G, 2019, CELL, V177, P1600, DOI 10.1016/j.cell.2019.05.004; Shattock Paul, 2002, Expert Opin Ther Targets, V6, P175; SPONHEIM E, 1991, Tidsskrift for den Norske Laegeforening, V111, P704; Stigler KA, 2009, RES AUTISM SPECT DIS, V3, P840, DOI 10.1016/j.rasd.2009.01.007; Tabouy L, 2018, BRAIN BEHAV IMMUN, V73, P310, DOI 10.1016/j.bbi.2018.05.015; Tomova A, 2015, PHYSIOL BEHAV, V138, P179, DOI 10.1016/j.physbeh.2014.10.033; van Sadelhoff JHJ, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00247; Vojdani A, 2004, NUTR NEUROSCI, V7, P151, DOI 10.1080/10284150400004155; Vojdani A, 2002, J NEUROIMMUNOL, V129, P168, DOI 10.1016/S0165-5728(02)00180-7; Vyas U, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/872716; Whiteley P., 2010, AUTISM INSIGHTS, V2010, P39, DOI DOI 10.4137/AUI; Whiteley P., 1999, AUTISM, V3, P45, DOI DOI 10.1177/1362361399003001005; Whiteley P, 2010, NUTR NEUROSCI, V13, P87, DOI 10.1179/147683010X12611460763922; Zmora N, 2018, CELL, V174, P1388, DOI 10.1016/j.cell.2018.08.041";67;8;9;1;22;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-2392;;;FRONT ENDOCRINOL;Front. Endocrinol.;AUG 13;2019;10;;;;;;;;508;10.3389/fendo.2019.00508;http://dx.doi.org/10.3389/fendo.2019.00508;;;8;Endocrinology & Metabolism;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Endocrinology & Metabolism;IQ1SE;31456745;gold, Green Published;;;24/11/2024;WOS:000480529800001;View Full Record in Web of Science
J;"Lilja, MM; Sandblom, E; Lichtenstein, P; Serlachius, E; Hellner, C; Bhagia, J; Halldner, L";;;;"Lilja, Maria M.; Sandblom, Emil; Lichtenstein, Paul; Serlachius, Eva; Hellner, Clara; Bhagia, Jyoti; Halldner, Linda";;;The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort;JOURNAL OF NEURODEVELOPMENTAL DISORDERS;;;English;Article;;;;;;;"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; SPECTRUM DISORDERS; MISSING DATA; ADOLESCENTS; ATOMOXETINE; METHYLPHENIDATE; TRIAL; SYMPTOMS; EFFICACY";Background: Attention deficit hyperactivity disorder (ADHD) is a common childhood behavioral condition that globally affects an average of around 5% of children and is associated with several adverse life outcomes. Comorbidity with autism spectrum disorder (ASD) is highly prevalent. Pharmacological treatment for ADHD symptoms has been shown to be effective. However, the prevailing perception is that children with ADHD and concomitant ASD symptoms report poorer efficacy and more side effects. This has been supported by studies on this population, but prospective studies directly comparing children with ADHD and different levels of ASD symptoms are lacking. We aimed to assess if children with ADHD and concomitant ASD symptoms differ regarding effects and side-effects of pharmacological ADHD treatment compared to children with ADHD without ASD traits. This is to our knowledge the second study to directly compare the effect of ADHD medication between ADHD patients with different levels of ASD symptoms. Methods: In a non-randomized, observational, prospective cohort study, 323 patients aged 6 to 17 years who were diagnosed with ADHD and starting pharmacological treatment were divided into two groups: one with high level of ASD symptoms (ASD group, N=71) and one with low level of ASD symptoms (non-ASD group, N = 252). Treatment outcome was measured as ADHD symptoms, and evaluated using the Swanson, Nolan and Pelham Teacher and Parent ADHD rating scale-version IV (SNAP-IV). Side-effects were evaluated using the Pediatric Side Effects Checklist (P-SEC), at 3 months follow-up. Results: From baseline to 3 months, there was no significant difference in neither treatment effect nor number of clinically significant adverse events experienced between the ASD group and the non-ASD group. Conclusions: Our results did not implicate that ADHD patients with concomitant ASD symptoms have decreased treatment effect of ADHD medication than patients with ADHD without concomitant ASD symptoms. Neither did the results support that ADHD patients with ASD symptoms experienced significantly more side-effects than ADHD patients without ASD symptoms. Although, we did not analyze different medications separately, this is in line with the only previous study directly comparing methylphenidate treatment in children with or without ASD.;"[Lilja, Maria M.; Sandblom, Emil; Halldner, Linda] Umea Univ, Dept Clin Sci Child & Adolescent Psychiat, Univ Torget 4, SE-90736 Umea, Sweden; [Lilja, Maria M.; Sandblom, Emil; Halldner, Linda] Child & Adolescent Psychiat Clin, Stockholm, Sweden; [Lichtenstein, Paul; Halldner, Linda] Karolinska Inst, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden; [Serlachius, Eva; Hellner, Clara] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, POB 281, SE-17177 Stockholm, Sweden; [Serlachius, Eva; Hellner, Clara] Stockholm Hlth Care Serv, Stockholm, Region Stockhol, Sweden; [Bhagia, Jyoti] Mayo Clin, Dept Psychiat & Psychol, 200 First St SW, Rochester, MN 55905 USA";"Umea University; Karolinska Institutet; Karolinska Institutet; Mayo Clinic";"Lilja, MM (corresponding author), Umea Univ, Dept Clin Sci Child & Adolescent Psychiat, Univ Torget 4, SE-90736 Umea, Sweden.;Lilja, MM (corresponding author), Child & Adolescent Psychiat Clin, Stockholm, Sweden.";maria.lilja@umu.se;Serlachius, Eva/E-8956-2013;Lilja, Maria/0000-0003-0789-6906;"Umea University; Region Stockholm (Halso-och sjukvardsforvaltningen); Region Vasterbotten (centrala ALF); ALF-PPG Stockholm; Medical faculty at Umea University [FS 2.1.6-2408-18]; Oskarfonden; The Mayo Clinic-Karolinska Institutet Collaborative Travel Award; Child and Adolescent Psychiatry in Vasterbotten; Region Stockholm (division of Child and Adolescent Psychiatry); Region Vasterbotten (BAS-ALF)";"Umea University; Region Stockholm (Halso-och sjukvardsforvaltningen); Region Vasterbotten (centrala ALF); ALF-PPG Stockholm; Medical faculty at Umea University; Oskarfonden; The Mayo Clinic-Karolinska Institutet Collaborative Travel Award; Child and Adolescent Psychiatry in Vasterbotten; Region Stockholm (division of Child and Adolescent Psychiatry); Region Vasterbotten (BAS-ALF)";Open access funding provided by Umea University. The study is part of the ADAPT study, which was supported by Region Stockholm (Halso-och sjukvardsforvaltningen, and the division of Child and Adolescent Psychiatry), Region Vasterbotten (centrala ALF and BAS-ALF), ALF-PPG Stockholm, the Medical faculty at Umea University (FS 2.1.6-2408-18), Oskarfonden, The Mayo Clinic-Karolinska Institutet Collaborative Travel Award. Maria M Lilja had financial support from the Child and Adolescent Psychiatry in Vasterbotten, as part of the position. Emil Sandblom was funded by Umea University as part of a master's thesis for the medical school.;"Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Bushe CJ, 2014, J PSYCHOPHARMACOL, V28, P204, DOI 10.1177/0269881113478475; Bussing R, 2008, ASSESSMENT, V15, P317, DOI 10.1177/1073191107313888; Chan E, 2016, JAMA-J AM MED ASSOC, V315, P1997, DOI 10.1001/jama.2016.5453; Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4; Dalsgaard S, 2015, LANCET PSYCHIAT, V2, P702, DOI 10.1016/S2215-0366(15)00271-0; Davis NO, 2012, NEUROTHERAPEUTICS, V9, P518, DOI 10.1007/s13311-012-0126-9; Dziura James D., 2013, Yale Journal of Biology and Medicine, V86, P343; Ehlers S, 1999, J AUTISM DEV DISORD, V29, P129, DOI 10.1023/A:1023040610384; Erskine HE, 2017, EPIDEMIOL PSYCH SCI, V26, P395, DOI 10.1017/S2045796015001158; Faraone SV, 2021, NEUROSCI BIOBEHAV R, V128, P789, DOI 10.1016/j.neubiorev.2021.01.022; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; Fountain C, 2011, J EPIDEMIOL COMMUN H, V65, P503, DOI 10.1136/jech.2009.104588; Gargaro BA, 2011, NEUROSCI BIOBEHAV R, V35, P1081, DOI 10.1016/j.neubiorev.2010.11.002; Greenhill LL, 2001, J AM ACAD CHILD PSY, V40, P180, DOI 10.1097/00004583-200102000-00012; Hall CL, 2020, ASSESSMENT, V27, P1258, DOI 10.1177/1073191119842255; Handen BL, 2015, J AM ACAD CHILD PSY, V54, P905, DOI 10.1016/j.jaac.2015.08.013; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hill P, 2001, ARCH DIS CHILD, V84, P404, DOI 10.1136/adc.84.5.404; Hollingdale J, 2020, PSYCHOL MED, V50, P2240, DOI 10.1017/S0033291719002368; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Jensen CM, 2015, ADHD-ATTEND DEFICIT, V7, P27, DOI 10.1007/s12402-014-0142-1; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Johansson V, 2020, J NEURODEV DISORD, V12, DOI 10.1186/s11689-020-09352-z; Joshi G, 2017, J ATTEN DISORD, V21, P846, DOI 10.1177/1087054714543368; Leitner Y, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00268; Mattila ML, 2012, J AUTISM DEV DISORD, V42, P2162, DOI 10.1007/s10803-012-1464-5; Mattila ML, 2009, EUR CHILD ADOLES PSY, V18, P499, DOI 10.1007/s00787-009-0044-5; Mikami AY, 2019, CLIN PSYCHOL REV, V68, P54, DOI 10.1016/j.cpr.2018.12.005; Mowlem FD, 2019, EUR CHILD ADOLES PSY, V28, P481, DOI 10.1007/s00787-018-1211-3; Newcorn JH, 2008, AM J PSYCHIAT, V165, P721, DOI 10.1176/appi.ajp.2007.05091676; Newcorn JH, 2009, J AM ACAD CHILD PSY, V48, P511, DOI 10.1097/CHI.0b013e31819c55b2; Osland ST, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007990.pub3; Patra S, 2019, AUTISM RES, V12, P542, DOI 10.1002/aur.2059; Pavuluri MN, 2004, J AFFECT DISORDERS, V82, pS103, DOI 10.1016/j.jad.2004.05.017; Peacock G, 2012, J DEV BEHAV PEDIATR, V33, P2, DOI 10.1097/DBP.0b013e31823969de; Posserud MB, 2009, J AUTISM DEV DISORD, V39, P126, DOI 10.1007/s10803-008-0609-z; Reale L, 2017, EUR CHILD ADOLES PSY, V26, P1443, DOI 10.1007/s00787-017-1005-z; Reichow B, 2013, J AUTISM DEV DISORD, V43, P2435, DOI 10.1007/s10803-013-1793-z; Ruiz-Goikoetxea M, 2018, NEUROSCI BIOBEHAV R, V84, P63, DOI 10.1016/j.neubiorev.2017.11.007; Santosh PJ, 2006, CHILD CARE HLTH DEV, V32, P575, DOI 10.1111/j.1365-2214.2006.00631.x; Scahill L, 2006, J CHILD ADOL PSYCHOP, V16, P589, DOI 10.1089/cap.2006.16.589; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Shattuck PT, 2009, J AM ACAD CHILD PSY, V48, P474, DOI 10.1097/CHI.0b013e31819b3848; Simonoff E, 2013, J CHILD PSYCHOL PSYC, V54, P527, DOI 10.1111/j.1469-7610.2012.02569.x; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Thomas S, 2018, J ATTEN DISORD, V22, P1002, DOI 10.1177/1087054715587096; Ventura P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082566";52;5;6;1;19;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;1866-1947;1866-1955;;J NEURODEV DISORD;J. Neurodev. Disord.;DEC;2022;14;1;;;;;;;17;10.1186/s11689-022-09424-2;http://dx.doi.org/10.1186/s11689-022-09424-2;;;12;"Clinical Neurology; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;ZN6CQ;35249540;Green Published, gold;;;24/11/2024;WOS:000765120300001;View Full Record in Web of Science
J;"Ballester, P; Espadas, C; Almenara, S; Barrachina, J; Muriel, J; Ramos, E; Toral, N; Belda, C; Peiró, AM";;;;"Ballester, Pura; Espadas, Cristina; Almenara, Susana; Barrachina, Jordi; Muriel, Javier; Ramos, Enrique; Toral, Natalia; Belda, Cesar; Peiro, Ana M.";;;CYP2D6 Genotype and Pharmacovigilance Impact on Autism Spectrum Disorder: A Naturalistic Study with Extreme Phenotype Analysis;PHARMACEUTICALS;;;English;Article;;;;;;"autism; CYP2D6; pharmacogenetics; adverse events; polypharmacy";"PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; PSYCHIATRIC COMORBIDITY; GENETIC POLYMORPHISMS; OPIOID ANALGESICS; CLINICAL-RESPONSE; ADVERSE EVENTS; RISPERIDONE; CHILDREN; CYTOCHROME-P450; ANTIPSYCHOTICS";"The long-term use of psychopharmacology medications in autism spectrum disorder (ASD) hitherto remains controversial due to a lack of evidence about safety and tolerability. In this regard, genotyping the metabolizing enzyme cytochrome P450 (CYP) 2D6, especially its extreme phenotypes, could help to prevent drug-related adverse reactions or adverse events (AEs). There are several medications warranting CYP2D6 screening that are consumed by people with ASD, such as risperidone and aripiprazole to name a few. A naturalistic observational study was carried out in participants with ASD to analyze the influence of the CYP2D6 phenotype in drug tolerability using a local pharmacovigilance system created for this study. In this case, AEs were identified from participants' electronic health records (EHRs) and paper registries. Other variables were collected: socio-demographic information, comorbidities, and psychopharmacology prescriptions (polypharmacy defined as >= 4 simultaneous prescriptions) and doses. The genetic analysis included allelic discrimination (CYP2D6*1, *2, *3, *4, *5, *6, *10, *17, and *41) and copy number variations. All of these were used to determine theoretical phenotypes of the metabolic profiles: poor (PM); intermediate (IM); normal (NM); and ultra-rapid (UM). Sex differences were analyzed. A total of 71 participants (30 +/- 10 years old, 82% male, 45% CYP2D6 NM phenotype (32 participants)) with a median of 3 (IQR 2-4) comorbidities per person, mainly urinary incontinence (32%) and constipation (22%), were included. CYP2D6 UM showed the highest rate of polypharmacy, whilst, IM participants had the highest rates of neurological and psychiatric AEs, even worse if a CYP2D6 inhibitor drug was prescribed simultaneously. CYP2D6 pharmacogenomics and the monitoring of new antipsychotic prescriptions may make a difference in medication safety in adults with ASD. Particularly in those with psychopharmacology polymedication, it can help with AE avoidance and understanding.";"[Ballester, Pura] San Antonio Catholic Univ, Pharmacol Dept, Murcia 30107, Spain; [Espadas, Cristina; Ramos, Enrique; Peiro, Ana M.] Miguel Hernandez Univ Elche UMH, Bioengn Inst, Pediat & Organ Chem Dept, Alicante 03202, Spain; [Almenara, Susana; Barrachina, Jordi; Muriel, Javier; Peiro, Ana M.] Dr Balmis Gen Univ Hosp, Alicante Inst Hlth & Biomed Res ISABIAL, Neuropharmacol Pain Treatment & Neurodev Disorders, Alicante 03010, Spain; [Almenara, Susana; Peiro, Ana M.] Alicante Gen Univ Hosp, Clin Pharmacol Unit, Alicante 03010, Spain; [Muriel, Javier; Peiro, Ana M.] Miguel Hernandez Univ Elche UMH, Pediat & Organ Chem Dept, Clin Pharmacol, Alicante 03202, Spain; [Toral, Natalia] San Francisco De Borja Fdn, San Rafael Ctr, Residential Facil, Alicante 03559, Spain; [Belda, Cesar] Autism Parents Assoc Valencian Community Autism As, Infanta Leonor Ctr, Alicante 03010, Spain";"Universidad Catolica de Murcia; General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); General University Hospital of Alicante";Ballester, P (corresponding author), San Antonio Catholic Univ, Pharmacol Dept, Murcia 30107, Spain.;"pballester@ucam.edu; cristina.espadas@goumh.umh.es; susanaalmenara@gmail.com; jordibernabeu15@gmail.com";"Ballester, Pura/AAD-2635-2022; Peiró, Ana/AAG-3897-2021; Muriel, Javier/AAG-3098-2021";"Peiro, Ana/0000-0002-2385-3749; Ballester, Pura/0000-0002-7345-448X; Almenara de Riquer, Susana/0000-0003-2619-191X; Barrachina, Jordi/0000-0002-4697-2783; Muriel, Javier/0000-0003-0048-9451";"Research in Neurosciences (Madrid, Spain) [UGP14-011]; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO, Valencia, Spain) [UGP15-306]; Universidad Catolica San Antonio de Murcia [PMAFI-17/21]; La Caixa Foundation (Barcelona, Spain) [PT13/0001]";"Research in Neurosciences (Madrid, Spain); Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO, Valencia, Spain); Universidad Catolica San Antonio de Murcia; La Caixa Foundation (Barcelona, Spain)";This project was funded by the Alicia Koplowitz grant for Research in Neurosciences (Madrid, Spain) code: UGP14-011, the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO, Valencia, Spain) code: UGP15-306, and Universidad Catolica San Antonio de Murcia PMAFI-17/21, and Dr. Pura Ballester Navarro received a predoctoral grantfrom La Caixa Foundation (Barcelona, Spain) code: PT13/0001.;"Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Anderson GD, 2008, INT REV NEUROBIOL, V83, P1, DOI 10.1016/S0074-7742(08)00001-9; Bahar MA, 2018, PHARMACOEPIDEM DR S, V27, P621, DOI 10.1002/pds.4422; Belmonte C, 2018, BASIC CLIN PHARMACOL, V122, P596, DOI 10.1111/bcpt.12960; Buck TR, 2014, J AUTISM DEV DISORD, V44, P3063, DOI 10.1007/s10803-014-2170-2; Candiotti KA, 2009, PAIN MED, V10, P799, DOI 10.1111/j.1526-4637.2009.00641.x; Cartwright AL, 2013, ANN PHARMACOTHER, V47, P350, DOI 10.1345/aph.1R333; Caudle KE, 2020, CTS-CLIN TRANSL SCI, V13, P116, DOI 10.1111/cts.12692; Ching HD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009043.pub2; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Correll CU, 2006, CHILD ADOL PSYCH CL, V15, P177, DOI 10.1016/j.chc.2005.08.007; Crews KR, 2014, CLIN PHARMACOL THER, V95, P376, DOI 10.1038/clpt.2013.254; Espadas C, 2020, PSYCHIAT RES, V292, DOI 10.1016/j.psychres.2020.113321; Fijal BA, 2015, J CLIN PHARMACOL, V55, P1167, DOI 10.1002/jcph.530; Gaedigk A, 2017, GENET MED, V19, P69, DOI 10.1038/gim.2016.80; Gerlach M, 2016, EXPERT OPIN DRUG SAF, V15, P1477, DOI 10.1080/14740338.2016.1225721; Haufroid V, 2015, CLIN TOXICOL, V53, P501, DOI 10.3109/15563650.2015.1049355; Houghton R, 2017, AUTISM RES, V10, P2037, DOI 10.1002/aur.1848; Jobski K, 2017, ACTA PSYCHIAT SCAND, V135, P8, DOI 10.1111/acps.12644; Joshi G, 2010, J AUTISM DEV DISORD, V40, P1361, DOI 10.1007/s10803-010-0996-9; Kirchheiner J, 2004, J CLIN PSYCHOPHARM, V24, P647, DOI 10.1097/01.jcp.0000145341.30547.f0; LLerena A, 2014, EXPERT OPIN DRUG MET, V10, P1569, DOI 10.1517/17425255.2014.964204; Lopes GS, 2020, PHARMACOGEN PERS MED, V13, P71, DOI 10.2147/PGPM.S239222; Lötsch J, 2004, CLIN PHARMACOKINET, V43, P983; Arellano AL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008505; Naranjo MEG, 2016, PHARMACOGENOMICS J, V16, P485, DOI 10.1038/tpj.2016.47; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; Puangpetch A, 2016, PHARMACOGEN PERS MED, V9, P131, DOI 10.2147/PGPM.S107772; Rigles B, 2017, J AUTISM DEV DISORD, V47, P187, DOI 10.1007/s10803-016-2905-3; Samer CF, 2013, MOL DIAGN THER, V17, P165, DOI 10.1007/s40291-013-0028-5; Thümmler S, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00002; Vanwong N, 2017, J CHILD ADOL PSYCHOP, V27, P185, DOI 10.1089/cap.2014.0171; Vanwong N, 2016, DRUG METAB PHARMACOK, V31, P156, DOI 10.1016/j.dmpk.2016.01.005; Vohra R, 2017, AUTISM, V21, P995, DOI 10.1177/1362361316665222; Yu BB, 2008, PHILOS T R SOC A, V366, P2377, DOI 10.1098/rsta.2008.0030; Zahari Z, 2014, DRUG METAB PHARMACOK, V29, P29, DOI 10.2133/dmpk.DMPK-13-RV-032";36;0;0;1;3;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;1424-8247;;PHARMACEUTICALS-BASE;Pharmaceuticals;JUL;2023;16;7;;;;;;;954;10.3390/ph16070954;http://dx.doi.org/10.3390/ph16070954;;;14;"Chemistry, Medicinal; Pharmacology & Pharmacy";Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;S7OA2;37513866;Green Published, gold;;;24/11/2024;WOS:001073014700001;View Full Record in Web of Science
J;"Fradkin, Y; De Taboada, L; Naeser, M; Saltmarche, A; Snyder, W; Steingold, E";;;;"Fradkin, Yuliy; De Taboada, Luis; Naeser, Margaret; Saltmarche, Anita; Snyder, William; Steingold, Eugenia";;;Transcranial photobiomodulation in children aged 2-6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology;FRONTIERS IN NEUROLOGY;;;English;Article;;;;;;"ASD; autism; PBM; tPBM; EEG; delta waves; pediatric neurology";"CEREBRAL-BLOOD-FLOW; LASER THERAPY; INFRARED LIGHT; IDENTIFICATION; PREVALENCE; CEREBELLAR; MECHANISMS; DEFICITS";Background Small pilot studies have suggested that transcranial photobiomodulation (tPBM) could help reduce symptoms of neurological conditions, such as depression, traumatic brain injury, and autism spectrum disorder (ASD).Objective To examine the impact of tPBM on the symptoms of ASD in children aged two to six years.Method We conducted a randomized, sham-controlled clinical trial involving thirty children aged two to six years with a prior diagnosis of ASD. We delivered pulses of near-infrared light (40 Hz, 850 nm) noninvasively to selected brain areas twice a week for eight weeks, using an investigational medical device designed for this purpose (Cognilum (TM), JelikaLite Corp., New York, United States). We used the Childhood Autism Rating Scale (CARS, 2nd Edition) to assess and compare the ASD symptoms of participants before and after the treatment course. We collected electroencephalogram (EEG) data during each session from those participants who tolerated wearing the EEG cap.Results The difference in the change in CARS scores between the two groups was 7.23 (95% CI 2.357 to 12.107, p = 0.011). Seventeen of the thirty participants completed at least two EEGs and time-dependent trends were detected. In addition, an interaction between Active versus Sham and Scaled Time was observed in delta power (Coefficient = 7.521, 95% CI -0.517 to 15.559, p = 0.07) and theta power (Coefficient = -8.287, 95% CI -17.199 to 0.626, p = 0.07), indicating a potential trend towards a greater reduction in delta power and an increase in theta power over time with treatment in the Active group, compared to the Sham group. Furthermore, there was a significant difference in the condition (Treatment vs. Sham) in the power of theta waves (net_theta) (Coefficient = 9.547, 95% CI 0.027 to 19.067, p = 0.049). No moderate or severe side effects or adverse effects were reported or observed during the trial.Conclusion These results indicate that tPBM may be a safe and effective treatment for ASD and should be studied in more depth in larger studies. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT04660552, identifier NCT04660552.Conclusion These results indicate that tPBM may be a safe and effective treatment for ASD and should be studied in more depth in larger studies. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT04660552, identifier NCT04660552.;"[Fradkin, Yuliy] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ 08901 USA; [De Taboada, Luis; Steingold, Eugenia] JelikaLite Corp, New York, NY USA; [Naeser, Margaret] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA; [Saltmarche, Anita] Saltmarche Hlth & Associates, Orangeville, ON, Canada; [Snyder, William] Vyir Technol, New York, NY USA";"Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; Boston University";Fradkin, Y (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ 08901 USA.;Yf155@rwjms.rutgers.edu;;;Jelikalite Corp;Jelikalite Corp;This work was supported by the Jelikalite Corp.;"American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2005, Electric Fields of the Brain: The Neurophysics of EEG; Askalsky P, 2019, NEUROPSYCH DIS TREAT, V15, P3255, DOI 10.2147/NDT.S188906; Baglioni C, 2016, PSYCHOL BULL, V142, P969, DOI 10.1037/bul0000053; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Blanco NJ, 2017, NEUROBIOL LEARN MEM, V139, P69, DOI 10.1016/j.nlm.2016.12.016; Bogdanova Y., 2014, ARCH PHYS MED REHAB, V95, pe77, DOI [10.1016/j.apmr.2014.07.247, DOI 10.1016/J.APMR.2014.07.247]; Bosl WJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24318-x; Bullock-Saxton J, 2021, J ALZHEIMERS DIS, V83, P1499, DOI 10.3233/JAD-210170; Caldieraro Marco Antonio, 2019, Photobiomodulation in the Brain, P479, DOI [10.1016/b978-0-12-815305-5.00035-x., DOI 10.1016/B978-0-12-815305-5.00035-X.]; CANTOR DS, 1986, J AUTISM DEV DISORD, V16, P169, DOI 10.1007/BF01531728; Cassano P, 2022, PHOTONICS-BASEL, V9, DOI 10.3390/photonics9080507; Cassano P, 2019, PHOTOBIOMOD PHOTOMED, V37, P651, DOI 10.1089/photob.2019.4678; Ceranoglu TA., 2018, J AM ACAD CHILD PSY, V57, pS233, DOI [10.1016/j.jaac.2018.09.315, DOI 10.1016/j.jaac.2018.09.315]; Ceranoglu TA, 2022, PHOTOBIOMOD PHOTOMED, V40, P4, DOI 10.1089/photob.2020.4986; Chahin SS, 2020, TRANSL PEDIATR, V9, P66, DOI 10.21037/tp.2019.11.06; Chan AS, 2007, NEUROPSYCHOLOGY, V21, P74, DOI 10.1037/0894-4105.21.1.74; Chao LL, 2019, PHOTOBIOMODULATION P, V37, P133, DOI 10.1089/photob.2018.4555; COURCHESNE E, 1994, AM J ROENTGENOL, V162, P123, DOI 10.2214/ajr.162.1.8273650; Courchesne E, 1997, CURR OPIN NEUROBIOL, V7, P269, DOI 10.1016/S0959-4388(97)80016-5; Delhey LM, 2017, J CLIN MED, V6, DOI 10.3390/jcm6020018; DeVane CL, 2019, PHARMACOTHERAPY, V39, P626, DOI 10.1002/phar.2271; DiCicco-Bloom E, 2006, J NEUROSCI, V26, P6897, DOI 10.1523/JNEUROSCI.1712-06.2006; Dmochowski Grzegorz M, 2020, Cereb Cortex Commun, V1, ptgaa004, DOI 10.1093/texcom/tgaa004; Durkut M, 2022, MOL AUTISM, V13, DOI 10.1186/s13229-022-00504-7; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Eissa N, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00304; Finisguerra A, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00135; Frohlich J, 2021, BRAIN, V144, P2257, DOI 10.1093/brain/awab095; Frye RE, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01647-6; Frye RE, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100829; Frye RE, 2016, CLIN MED INSIGHTS-PE, V10, P43, DOI 10.4137/CMPed.S38337; Frye RE, 2011, J PEDIATR NEUROL, V9, P427, DOI 10.3233/JPN-2011-0507; Gaspard N, 2013, JAMA NEUROL, V70, P1288, DOI 10.1001/jamaneurol.2013.3475; Gzielo K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111544; Hamilton C, 2022, NEUROL INT, V14, P884, DOI 10.3390/neurolint14040071; Hampson DR, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.2015.00420, 10.3339/fnins.2075.00420]; Harvey Denise Y, 2022, Handb Clin Neurol, V185, P241, DOI 10.1016/B978-0-12-823384-9.00012-8; Hill AP, 2014, RES AUTISM SPECT DIS, V8, P1121, DOI 10.1016/j.rasd.2014.05.006; Hipskind SG, 2018, PHOTOMED LASER SURG, DOI 10.1089/pho.2018.4489; Jung M, 2014, MOL AUTISM, V5, DOI 10.1186/2040-2392-5-35; Jurek L, 2022, EUR CHILD ADOLES PSY, V31, P1285, DOI 10.1007/s00787-021-01772-z; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim UJ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232416099; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Larrain-Valenzuela J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14744-8; Leisman G, 2018, ADV EXP MED BIOL, V1116, P111, DOI 10.1007/5584_2018_234; Silveira PCL, 2019, MED ENG PHYS, V71, P108, DOI 10.1016/j.medengphy.2019.05.008; Long ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26527; Machado C., 2019, Int J Neurol, V21, P1, DOI [10.5580/IJN.54101, DOI 10.5580/IJN.54101]; Machado Y., 2018, Anatomic and functional connectivity relationship in autistic children (P3. 316); Mapelli L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073894; Martin P., 2018, Arch Phys Med Rehabil, V99, pe104, DOI [10.1016/j.apmr.2018.07.374, DOI 10.1016/J.APMR.2018.07.374]; Naeser MA, 2023, J ALZHEIMERS DIS REP, V7, P77, DOI 10.3233/ADR-220022; Naeser MA, 2020, PHOTOBIOMOD PHOTOMED, V38, P115, DOI 10.1089/photob.2019.4630; Naeser MA, 2016, PHOTOMED LASER SURG, V34, P610, DOI 10.1089/pho.2015.4037; Nair A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00614; Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B; Naviaux RK, 2018, MITOCHONDRION, V43, P1, DOI 10.1016/j.mito.2017.12.007; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Ortiz-Mantilla S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41511-8; Padmanabhan A, 2017, BIOL PSYCHIAT-COGN N, V2, P476, DOI 10.1016/j.bpsc.2017.04.004; Pallanti S, 2022, CHILDREN-BASEL, V9, DOI 10.3390/children9050755; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Pop-Jordanova Nada, 2010, Nonlinear Biomed Phys, V4, P4, DOI 10.1186/1753-4631-4-4; Rojas JC, 2013, BIOCHEM PHARMACOL, V86, P447, DOI 10.1016/j.bcp.2013.06.012; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Rojas JC, 2010, EYE BRAIN, V2, P21; Rose S, 2018, MOL DIAGN THER, V22, P571, DOI 10.1007/s40291-018-0352-x; Rossignol DA, 2012, MOL PSYCHIATR, V17, P290, DOI 10.1038/mp.2010.136; Sachdev RNS, 2015, J NEUROPHYSIOL, V114, P1248, DOI 10.1152/jn.00249.2015; Salehpour F, 2019, PHOTOBIOMOD PHOTOMED, V37, P581, DOI 10.1089/photob.2019.4676; Salehpour F, 2017, REV NEUROSCIENCE, V28, P441, DOI 10.1515/revneuro-2016-0087; Salgado ASI, 2015, LASER MED SCI, V30, P339, DOI 10.1007/s10103-014-1669-2; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004; Singh K, 2020, ANN CLIN TRANSL NEUR, V7, P683, DOI 10.1002/acn3.51034; Soke GN, 2016, J AUTISM DEV DISORD, V46, P3607, DOI 10.1007/s10803-016-2879-1; Spence SJ, 2009, PEDIATR RES, V65, P599, DOI 10.1203/PDR.0b013e31819e7168; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Truong NCD, 2022, FRONT NEUROSCI-SWITZ, V16, DOI 10.3389/fnins.2022.896502; Vaughan CA, 2011, J PSYCHOEDUC ASSESS, V29, P489, DOI 10.1177/0734282911400873; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Wang XL, 2019, NEUROPHOTONICS, V6, DOI 10.1117/1.NPh.6.2.025013; Wang XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30540; Wegiel J, 2010, ACTA NEUROPATHOL, V119, P755, DOI 10.1007/s00401-010-0655-4; Wilson DF, 2014, J APPL PHYSIOL, V117, P1431, DOI 10.1152/japplphysiol.00737.2014; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Xu SJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00806; Zomorrodi R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42693-x";94;3;3;6;7;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-2295;;;FRONT NEUROL;Front. Neurol.;APR 26;2024;15;;;;;;;;1221193;10.3389/fneur.2024.1221193;http://dx.doi.org/10.3389/fneur.2024.1221193;;;16;"Clinical Neurology; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;PY2R5;38737349;Green Published;;;24/11/2024;WOS:001217579700001;View Full Record in Web of Science
J;Ghanizadeh, A;;;;Ghanizadeh, Ahmad;;;Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review;JOURNAL OF ATTENTION DISORDERS;;;English;Article;;;;;;"ADHD; autism; atomoxetine; treatment";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; EXTRACELLULAR LEVELS; PREFRONTAL CORTEX; CHILDREN; METHYLPHENIDATE; HYPERACTIVITY; ADOLESCENTS; EFFICACY";Objective: This study systematically reviews the current literature on the administration of atomoxetine for treating children and adolescents with comorbidity on autism spectrum disorder (ASD) and ADHD. Method: PubMed/Medline and Google Scholar databases were electronically searched to find the published trials on atomoxetine and ASD. Results: Six articles reported the clinical trials of atomoxetine for treatment of ADHD symptoms in patients with autism or pervasive development disorders. Only one study that was placebo-controlled crossover pilot trial reported that it is effective. Atomoxetine may be effective in high-functioning patients with autism or patients with low severity. Those with high severity of ASD may be more vulnerable to the adverse effects of atomoxetine. Conclusion: There are not enough controlled clinical trials for showing the efficacy of atomoxetine for treatment of ADHD symptoms in autism. Although evidence suggests potential efficacy of atomoxetine, the current evidences are not conclusive.;[Ghanizadeh, Ahmad] Shiraz Univ Med Sci, Sch Med, Hafez Hosp, Shiraz, Iran;Shiraz University of Medical Science;Ghanizadeh, A (corresponding author), Shiraz Univ Med Sci, Sch Med, Res Ctr Psychiat & Behav Sci, Hafez Hosp, Shiraz, Iran.;ghanizad@sina.tums.ac.ir;;;;;;"Adler LA, 2009, DEPRESS ANXIETY, V26, P212, DOI 10.1002/da.20549; Aman MG, 2008, CHILD ADOL PSYCH CL, V17, P713, DOI 10.1016/j.chc.2008.06.009; Aman Michael G, 2004, Semin Pediatr Neurol, V11, P225, DOI 10.1016/j.spen.2004.07.006; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Bangs ME, 2008, J AM ACAD CHILD PSY, V47, P209, DOI 10.1097/chi.0b013e31815d88b2; Bangs ME, 2007, J CHILD ADOL PSYCHOP, V17, P407, DOI 10.1089/cap.2007.0066; Bee LS, 2010, SINGAP MED J, V51, P255; Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9; Charnsil C, 2011, J ATTEN DISORD, V15, P684, DOI 10.1177/1087054710376907; Cheng JYW, 2007, PSYCHOPHARMACOLOGY, V194, P197, DOI 10.1007/s00213-007-0840-x; Findling RL, 2008, CLIN THER, V30, P942, DOI 10.1016/j.clinthera.2008.05.006; Gadow KD, 2006, J AUTISM DEV DISORD, V36, P271, DOI 10.1007/s10803-005-0060-3; Garnock-Jones Karly P, 2009, Paediatr Drugs, V11, P203, DOI 10.2165/00148581-200911030-00005; Ghanizadeh A., 2012, J RES MED SCI; Ghanizadeh A, 2010, EUR CHILD ADOLES PSY, V19, P797, DOI 10.1007/s00787-010-0127-3; Ghanizadeh A, 2009, BRAIN DEV-JPN, V31, P15, DOI 10.1016/j.braindev.2008.03.010; Hazell P, 2007, J PAEDIATR CHILD H, V43, P19, DOI 10.1111/j.1440-1754.2007.00995.x; Jou RJ, 2005, J CHILD ADOL PSYCHOP, V15, P325, DOI 10.1089/cap.2005.15.325; Koda K, 2010, J NEUROCHEM, V114, P259, DOI 10.1111/j.1471-4159.2010.06750.x; Kratochvil Christopher J, 2008, Child Adolesc Psychiatry Ment Health, V2, P25, DOI 10.1186/1753-2000-2-25; Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; McCarthy J, 2007, CURR OPIN PSYCHIATR, V20, P472, DOI 10.1097/YCO.0b013e32821f6095; Murray MJ, 2010, CURR PSYCHIAT REP, V12, P382, DOI 10.1007/s11920-010-0145-3; Myers SM, 2007, EXPERT OPIN PHARMACO, V8, P1579, DOI 10.1517/14656566.8.11.1579; Niederhofer H, 2006, AUTISM, V10, P647, DOI 10.1177/1362361306073001; Perwien AR, 2004, J DEV BEHAV PEDIATR, V25, P264, DOI 10.1097/00004703-200408000-00006; Polanczyk G, 2010, CURR PHARM DESIGN, V16, P2462, DOI 10.2174/138161210791959872; Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P599, DOI 10.1089/cap.2006.16.599; Rajapakse T, 2010, SEMIN PEDIATR NEUROL, V17, P254, DOI 10.1016/j.spen.2010.10.008; Sangal RB, 2006, SLEEP, V29, P1573, DOI 10.1093/sleep/29.12.1573; Spencer TJ, 2008, J ATTEN DISORD, V11, P470, DOI 10.1177/1087054707306109; Stigler KA, 2004, J CHILD ADOL PSYCHOP, V14, P49, DOI 10.1089/104454604773840481; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P611, DOI 10.1089/cap.2006.16.611; Valicenti-McDermott M, 2006, J DEV BEHAV PEDIATR, V27, pS128, DOI 10.1097/00004703-200604002-00011; Zeiner P, 2011, ACTA PAEDIATR, V100, P1258, DOI 10.1111/j.1651-2227.2011.02263.x";36;24;25;4;28;SAGE PUBLICATIONS INC;THOUSAND OAKS;2455 TELLER RD, THOUSAND OAKS, CA 91320 USA;1087-0547;1557-1246;;J ATTEN DISORD;J. Atten. Disord.;NOV;2013;17;8;;;;;635;640;;10.1177/1087054712443154;http://dx.doi.org/10.1177/1087054712443154;;;6;"Psychology, Developmental; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";231LZ;22544388;;;;24/11/2024;WOS:000325419400001;View Full Record in Web of Science
J;"Hellings, JA; Reed, G; Cain, SE; Zhou, XH; Barth, FX; Aman, MG; Palaguachi, GI; Mikhnev, D; Teng, RJ; Andridge, R; Logan, M; Butler, MG; Han, JC";;;;"Hellings, Jessica A.; Reed, Gregory; Cain, Sharon E.; Zhou, Xinghua; Barth, Francis X.; Aman, Michael G.; Palaguachi, Gladys I.; Mikhnev, Dmytro; Teng, Rujia; Andridge, Rebecca; Logan, Marilyn; Butler, Merlin G.; Han, Joan C.";;;Loxapine Add-on for Adolescents and Adults with Autism Spectrum Disorders and Irritability;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"NEUROTROPHIC FACTOR BDNF; MENTAL-RETARDATION; CHILDREN; RISPERIDONE; BEHAVIOR; INDIVIDUALS; MEDICATIONS; DYSKINESIA; AGITATION; VALIDITY";"Objectives: Our clinical experience with low dose loxapine (5-15 mg/day) suggests promising efficacy and safety for irritability in autism spectrum disorders (ASD). We studied low dose loxapine prospectively in adolescents and adults with ASD and irritability. Additionally, we measured loxapine and metabolite concentrations, and brain-derived neurotrophic factor (BDNF) as a biomarker of neuromodulation. Methods: We performed a 12 week open trial of add-on loxapine in subjects, ages 13-65 years, diagnosed with ASD, and Aberrant Behavior Checklist-Irritability (ABC-I) subscale scores >14. Loxapine was dosed flexibly up to 15 mg daily, starting with 5 mg on alternate days. From weeks 1 to 6, other psychoactive medications were tapered if possible; from weeks 6 to 12, all medication doses were held stable. The primary outcome was the Clinical Global Impressions-Improvement subscale (CGI-I), ratings of Much Improved or Very Much Improved. Secondary outcomes were the ABC-I, Repetitive Behavior Scale-Revised, and Schalock Quality of Life scale. Serum BDNF and loxapine and metabolite concentrations were assayed. BDNF rs6265 was genotyped. Results: Sixteen subjects were enrolled; 12 completed all visits. Median age was 18 years (range 13-39). Median final loxapine dose was 7.5 mg/day (2.5-15). All 14 subjects (100%) with data at week 12 were rated as Much Improved on CGI-I at 12 weeks. Mean change on ABC-I at 12 weeks was -31%, p=0.01. Mean body mass index (BMI)-Z decreased between weeks 6 and 12, p=0.03. Side effects were minimal, and prolactin elevation occurred in only one subject. BDNF concentrations measured in 11 subjects increased significantly (p=0.04). Subjects with AG genotype for BDNF rs6265 required a lower dose of loxapine at study end, but had similar behavioral and BDNF concentration changes as the GG genotype. Conclusions: Low dose loxapine shows promise as a repurposed drug for irritability in ASD. Loxapine effects on BDNF warrant further study.";"[Hellings, Jessica A.; Aman, Michael G.] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [Hellings, Jessica A.; Reed, Gregory; Cain, Sharon E.; Zhou, Xinghua; Barth, Francis X.; Logan, Marilyn; Butler, Merlin G.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; [Palaguachi, Gladys I.; Mikhnev, Dmytro; Teng, Rujia; Han, Joan C.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Andridge, Rebecca] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA; [Han, Joan C.] Univ Tennessee, Ctr Hlth Sci, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA";"University System of Ohio; Ohio State University; University of Kansas; University of Kansas Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University System of Ohio; Ohio State University; University of Tennessee System; University of Tennessee Health Science Center";Hellings, JA (corresponding author), Ohio State Univ, Nisonger Ctr, Neurodev Psychiat Study Program, 395 McCampbell Hall,1581 Dodd Dr, Columbus, OH 43210 USA.;Jessica.Hellings@osumc.edu;Andridge, Rebecca/C-8457-2012;"Andridge, Rebecca/0000-0001-9991-9647; Han, Joan/0000-0003-4252-2678";"Autism Speaks-Autism Treatment Network (ATN); Forest; National Institute of Mental Health (NIMH); Shire; Sunovion; Eunice Kennedy Shriver National Institute of Child Health and Human Development [1ZIAHD008898]";"Autism Speaks-Autism Treatment Network (ATN); Forest; National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Shire; Sunovion; Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))";"Dr. Hellings is an investigator for studies funded by Autism Speaks-Autism Treatment Network (ATN), Forest, the National Institute of Mental Health (NIMH), Shire, and Sunovion; has been an advisor to Abbott Laboratories; and a consultant to Ferring Pharmaceuticals. Dr. Aman has received research contracts, consulted with, or served on advisory boards of Biomarin Pharmaceuticals, Bristol- Myers Squibb, CogState, Confluence Pharmaceutica, Coronado Bioscience, Forest Research, Hoffman LaRoche, Johnson & Johnson, Novartis, Pfizer, Prophase LLC, and Supernus Pharmaceutica. Dr. Cain has a conflict of interest for Shire. At the time of the research, Dr. Han was funded by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (1ZIAHD008898). No other authors have conflicts of interest.";"Abdallah MW, 2013, ACTA PSYCHIAT SCAND, V128, P61, DOI 10.1111/acps.12020; AMAN MG, 1995, AM J MENT RETARD, V100, P283; Aman MG., 2012, Clinical and Experimental Pharmacology, V2, DOI DOI 10.4172/2161-1459.1000E114; [Anonymous], J MENT HLTH RES INTE; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Centers for Disease Control, 2009, MMWR SURVEILLANCE SU; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; Correll CU, 2006, J AM ACAD CHILD PSY, V45, P771, DOI 10.1097/01.chi.0000220851.94392.30; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Diggle P, 2002, ANAL LONGITUDINAL DA; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Findling RL, 2003, J CLIN PSYCHIAT, V64, P1362, DOI 10.4088/JCP.v64n1113; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Ganz ML, 2007, ARCH PEDIAT ADOL MED, V161, P343, DOI 10.1001/archpedi.161.4.343; Glazer WM, 1999, J CLIN PSYCHIAT, V60, P42; GUALTIERI CT, 1984, AM J PSYCHIAT, V141, P20; Guy W., 1976, ECDEU ASSESSMENT MAN; Han JC, 2013, CORTEX, V49, P2700, DOI 10.1016/j.cortex.2013.02.009; Hellings JA, 2005, J CHILD ADOL PSYCHOP, V15, P885, DOI 10.1089/cap.2005.15.885; Hellings JA, 2001, J CHILD ADOL PSYCHOP, V11, P229, DOI 10.1089/10445460152595559; Hellings JA, 2006, J AUTISM DEV DISORD, V36, P401, DOI 10.1007/s10803-006-0078-1; Hellings JA, 2010, J MENT HEALTH RES IN, V3, P132, DOI 10.1080/19315864.2010.494763; Kapur S, 1997, AM J PSYCHIAT, V154, P1525, DOI 10.1176/ajp.154.11.1525; Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558; Krabbe KS, 2007, DIABETOLOGIA, V50, P431, DOI 10.1007/s00125-006-0537-4; Kuczmarski RJ., 2000, VITAL HLTH STAT SERI, Viii-x, P1; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lesem MD, 2011, BRIT J PSYCHIAT, V198, P51, DOI 10.1192/bjp.bp.110.081513; Li Z, 2003, PSYCHOPHARMACOLOGY, V167, P315, DOI 10.1007/s00213-003-1418-x; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Marcus RN, 2011, J CLIN PSYCHIAT, V72, P1270, DOI 10.4088/JCP.09m05933; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; McClellan J, 2007, J AM ACAD CHILD PSY, V46, P969, DOI 10.1097/CHI.0b013e3180691779; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Moncrieff J, 2010, PSYCHOL MED, V40, P1409, DOI 10.1017/S0033291709992297; Nishimura K, 2007, BIOCHEM BIOPH RES CO, V356, P200, DOI 10.1016/j.bbrc.2007.02.135; Raznahan A, 2009, J NEURODEV DISORD, V1, P215, DOI 10.1007/s11689-009-9012-0; Reinblatt SP, 2006, J CHILD ADOL PSYCHOP, V16, P639, DOI 10.1089/cap.2006.16.639; SCHALOCK RL, 1989, MENT RETARD, V27, P25; Singh AN, 1996, J PSYCHIATR NEUROSCI, V21, P29; SPRAGUE RL, 1991, PSYCHOPHARMACOL BULL, V27, P51; Stahl S.M., 2002, Essential psychopharmacology of antipsychotics and mood stabilizers; Sztrymf B, 2010, CRIT CARE, V14, DOI 10.1186/cc9015; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; Zimmer D, 2000, RAPID COMMUN MASS SP, V14, P1425, DOI 10.1002/1097-0231(20000815)14:15<1425::AID-RCM42>3.0.CO;2-E; Zuccato C, 2009, NAT REV NEUROL, V5, P311, DOI 10.1038/nrneurol.2009.54";47;14;14;0;9;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;mars-01;2015;25;2;;;;;150;159;;10.1089/cap.2014.0003;http://dx.doi.org/10.1089/cap.2014.0003;;;10;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";CD4MT;25782098;Green Published;;;24/11/2024;WOS:000351057800008;View Full Record in Web of Science
J;"Mansouri, M; Pouretemad, H; Roghani, M; Wegener, G; Ardalan, M";;;;"Mansouri, Monireh; Pouretemad, Hamidreza; Roghani, Mehrdad; Wegener, Gregers; Ardalan, Maryam";;;Autistic-like behaviours and associated brain structural plasticity are modulated by oxytocin in maternally separated rats;BEHAVIOURAL BRAIN RESEARCH;;;English;Article;;;;;;"Autism spectrum disorder; Oxytocin; Maternal deprivation; Neural plasticity";"EARLY-LIFE STRESS; NEUROTROPHIC FACTOR; PREFRONTAL CORTEX; SPECTRUM DISORDER; MOUSE; BDNF; HIPPOCAMPUS; EXPRESSION; ANXIETY; CHILDREN";Background: Early psycho-social experiences influence the developing brain and possible onset of various neurodevelopmental disorders, such as Autism Spectrum Disorder (ASD). ASD is characterized by a variety of brain abnormalities, including alteration of oxytocin receptors in the brain. Recently, early life adverse experiences, such as maternal separation (MS), have been shown to constitute risk factors for ASD in preclinical studies. Therefore, the main aims of the current study were to i) explore the association between onset of autistic-like behaviours and molecular/structural changes in the brain following MS, and ii) evaluate the possible beneficial effects of oxytocin treatment on the same parameters. Method and Material: Male rats were exposed to the maternal separation from post-natal day (PND) 1 to PND14. After weaning, daily injections of oxytocin (1 mg/kg, ip) were administered (PND 22-30), followed by examination of autism-related behaviours at adolescence (PND 42-50). Brain structural plasticity was examined using stereological methods, and the plasma level of brain derived neurotrophic factor (BDNF) was analysed using ELISA. Results: We found that maternal separation induced autistic-like behaviours, which was associated with increase in the hippocampal CA1 stratum radiatum (CA1.SR) volume. In addition, we observed increase in the infralimbic brain region volume and in the number of the pyramidal neurons in the same brain region. Maternal separation significantly increased the plasma BDNF levels. Treatment with oxytocin improved autistic like behaviours, normalized the number of neurons and the volume of the infralimbic region as well as the plasma BDNF level (p < 0.05). Conclusion: Maternal separation induced autistic-like behaviours, brain structural impairment together with plasma BDNF level abnormally, which could be improved by oxytocin treatment.;"[Mansouri, Monireh; Pouretemad, Hamidreza] Shahid Beheshti Univ, Inst Cognit & Brain Sci, Dept Cognit Psychol, Tehran, Iran; [Mansouri, Monireh] Shahid Beheshti Univ, Ctr Excellence Cognitivr Neuropsychol, Institue Cognit & Brain Sci, Tehran, Iran; [Wegener, Gregers; Ardalan, Maryam] Aarhus Univ, Dept Clin Med, Translat Neuropsychiat Unit, Aarhus, Denmark; [Pouretemad, Hamidreza] Shahid Beheshti Univ, Dept Psychol, Tehran, Iran; [Roghani, Mehrdad] Shahed Univ, Neurophysiol Res Ctr, Tehran, Iran; [Wegener, Gregers] North West Univ, Ctr Excellence Pharmaceut Sci, Potchefstroom, South Africa; [Wegener, Gregers] Aarhus Univ, AUGUST Ctr, Dept Clin Med, Risskov, Denmark; [Ardalan, Maryam] Univ Gothenburg, Sahlgrenska Acad, Ctr Perinatal Med & Hlth, Inst Neurosci & Physiol, Gothenburg, Sweden";"Shahid Beheshti University; Shahid Beheshti University; Aarhus University; Shahid Beheshti University; Shahed University; North West University - South Africa; Aarhus University; University of Gothenburg";"Pouretemad, H (corresponding author), Shahid Beheshti Univ, Inst Cognit & Brain Sci, Dept Cognit Psychol, Tehran, Iran.;Pouretemad, H (corresponding author), Shahid Beheshti Univ, Dept Psychol, Tehran, Iran.";h-pouretemad@sbu.ac.ir;"Pouretemad, Hamidreza/ABB-3993-2021; Roghani, Mehrdad/L-7629-2018; Wegener, Gregers/A-1019-2011";Wegener, Gregers/0000-0002-0081-0068;Soltani family;Soltani family;We would like to show our gratitude to the Soltani family that financially supported this research.;"A.P. Association, 2013, DIAGN STAT MAN MENT; Almeida LEF, 2014, MOL CELL NEUROSCI, V59, P57, DOI 10.1016/j.mcn.2014.01.007; Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; Ardalan M, 2017, BRIT J PHARMACOL, V174, P483, DOI 10.1111/bph.13714; Ardalan M, 2016, HIPPOCAMPUS, V26, P1414, DOI 10.1002/hipo.22617; Autism I., 2008, SURVEILL SUMM, V61, P1; Auyeung B, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2014.146; Bahi A, 2017, BEHAV BRAIN RES, V326, P281, DOI 10.1016/j.bbr.2017.03.010; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Bi LL, 2013, NEUROPHARMACOLOGY, V72, P148, DOI 10.1016/j.neuropharm.2013.04.048; Brumback A C, 2018, Mol Psychiatry, V23, P2078, DOI 10.1038/mp.2017.213; Businaro R, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0466-6; Cacciotti-Saija C, 2015, SCHIZOPHRENIA BULL, V41, P483, DOI 10.1093/schbul/sbu094; Carr CP, 2013, J NERV MENT DIS, V201, P1007, DOI 10.1097/NMD.0000000000000049; Centers for Disease Control and Prevention, 2021, DAT STAT AUT SPECTR; Chaddad A, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0373-0; Correia CT, 2010, GENES BRAIN BEHAV, V9, P841, DOI 10.1111/j.1601-183X.2010.00627.x; Courchesne E, 2002, MOL PSYCHIATR, V7, pS21, DOI 10.1038/sj.mp.4001169; Courchesne E, 2007, NEURON, V56, P399, DOI 10.1016/j.neuron.2007.10.016; Crawley JN, 2004, MENT RETARD DEV D R, V10, P248, DOI 10.1002/mrdd.20039; Dadds MR, 2014, J AUTISM DEV DISORD, V44, P521, DOI 10.1007/s10803-013-1899-3; Daniels WMU, 2004, METAB BRAIN DIS, V19, P3, DOI 10.1023/B:MEBR.0000027412.19664.b3; Dawson G, 2008, DEV PSYCHOPATHOL, V20, P775, DOI 10.1017/S0954579408000370; Dölen G, 2015, J NEUROENDOCRINOL, V27, P516, DOI 10.1111/jne.12284; Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668; Dong S.M., 2015, ANXIOLYTIC EFFECT OX; Dube SR, 2003, PREV MED, V37, P268, DOI 10.1016/S0091-7435(03)00123-3; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Finlay JM, 2015, BRAIN RES, V1600, P70, DOI 10.1016/j.brainres.2014.10.037; Gould BR, 2003, NEUROSCIENCE, V122, P155, DOI 10.1016/S0306-4522(03)00283-5; Green JJ, 2010, NEUROTHERAPEUTICS, V7, P250, DOI 10.1016/j.nurt.2010.05.006; Green LA, 2001, BIOL PSYCHIAT, V50, P609, DOI 10.1016/S0006-3223(01)01139-8; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; Hammock EAD, 2015, NEUROPSYCHOPHARMACOL, V40, P24, DOI 10.1038/npp.2014.120; He Z., 2017, BIORXIV; Heim C, 2009, MOL PSYCHIATR, V14, P954, DOI 10.1038/mp.2008.112; Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021; Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005; Javaheri E.S. Sayed Javad, 2019, NEUROMOLECULAR MED; Kaidanovich-Beilin O, 2011, JOVE-J VIS EXP, DOI 10.3791/2473; Kaidbey JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54800-z; Karimi P, 2017, J RES MED SCI, V22, DOI 10.4103/1735-1995.200272; Kasarpalkar NJ, 2014, ANN NEUROSCI, V21, P129, DOI 10.5214/ans.0972.7531.210403; Kleijer K.T.E., 2020, ADV ANAT EMBRYOL CEL, V224, P1; Kundakovic M, 2015, NEUROPSYCHOPHARMACOL, V40, P141, DOI 10.1038/npp.2014.140; Lacivita E, 2017, J MED CHEM, V60, P9114, DOI 10.1021/acs.jmedchem.7b00965; Lajud N, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00003; Liu WS, 2005, NEUROL RES, V27, P339, DOI 10.1179/016164105X35602; Loman MM, 2010, NEUROSCI BIOBEHAV R, V34, P867, DOI 10.1016/j.neubiorev.2009.05.007; Lucassen PJ, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a021303; Lukas M, 2010, NEUROPHARMACOLOGY, V58, P78, DOI 10.1016/j.neuropharm.2009.06.020; Luo WJ, 2018, SCI ADV, V4, DOI 10.1126/sciadv.1701799; Marco EM, 2013, NEUROPHARMACOLOGY, V68, P223, DOI 10.1016/j.neuropharm.2012.08.014; Maynard KR, 2018, ELIFE, V7, DOI 10.7554/eLife.33676; Miki T, 2014, J NEUROL SCI, V336, P62, DOI 10.1016/j.jns.2013.10.007; Minami C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176740; Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3; Molle RD, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.126; Monroy E, 2010, J CHEM NEUROANAT, V40, P93, DOI 10.1016/j.jchemneu.2010.05.005; Naninck EFG, 2015, HIPPOCAMPUS, V25, P309, DOI 10.1002/hipo.22374; Ninan I, 2011, J NEUROCHEM, V119, P324, DOI 10.1111/j.1471-4159.2011.07430.x; Ohta K, 2017, J NEUROCHEM, V141, P179, DOI 10.1111/jnc.13977; Oomen CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0003675; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Pasciuto E, 2015, NEUROBIOL LEARN MEM, V124, P71, DOI 10.1016/j.nlm.2015.07.013; Pessoa L, 2008, NAT REV NEUROSCI, V9, P148, DOI 10.1038/nrn2317; Peters S, 2014, PSYCHONEUROENDOCRINO, V42, P225, DOI 10.1016/j.psyneuen.2014.01.021; Pirone A, 2018, FRONT SYNAPTIC NEURO, V10, DOI 10.3389/fnsyn.2018.00035; Qi CC, 2018, BEHAV BRAIN FUNCT, V14, DOI 10.1186/s12993-018-0139-6; Qin XY, 2016, JAMA PEDIATR, V170, P1079, DOI 10.1001/jamapediatrics.2016.1626; Roceri M, 2004, BIOL PSYCHIAT, V55, P708, DOI 10.1016/j.biopsych.2003.12.011; Rojas DC, 2014, J NEURAL TRANSM, V121, P891, DOI 10.1007/s00702-014-1216-0; Roullet FI, 2010, NEUROSCIENCE, V170, P514, DOI 10.1016/j.neuroscience.2010.06.069; Saghazadeh A, 2017, J AUTISM DEV DISORD, V47, P1018, DOI 10.1007/s10803-016-3024-x; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; STEFFENBURG S, 1989, J CHILD PSYCHOL PSYC, V30, P405, DOI 10.1111/j.1469-7610.1989.tb00254.x; Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048; Tan T, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00046; Teng BL, 2013, NEUROPHARMACOLOGY, V72, P187, DOI 10.1016/j.neuropharm.2013.04.038; Thomas AW, 2016, DEV COGN NEUROS-NETH, V18, P49, DOI 10.1016/j.dcn.2015.09.005; Vertes RP, 2004, SYNAPSE, V51, P32, DOI 10.1002/syn.10279; Wang Q, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00049; Wilber AA, 2009, DEV NEUROBIOL, V69, P73, DOI 10.1002/dneu.20691; Wu XY, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00234; Yamasue Hidenori, 2018, Curr Top Behav Neurosci, V35, P449, DOI 10.1007/7854_2017_24; Yang Mu, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0826s56; Yang YJ, 2017, CEREB CORTEX, V27, P2871, DOI 10.1093/cercor/bhw121; Zheng Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep31241";90;23;24;0;16;ELSEVIER;AMSTERDAM;RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS;0166-4328;1872-7549;;BEHAV BRAIN RES;Behav. Brain Res.;sept-01;2020;393;;;;;;;;112756;10.1016/j.bbr.2020.112756;http://dx.doi.org/10.1016/j.bbr.2020.112756;;;12;"Behavioral Sciences; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Behavioral Sciences; Neurosciences & Neurology";MX6ZP;32535183;;;;24/11/2024;WOS:000557870200012;View Full Record in Web of Science
J;"Fung, LK; Mahajan, R; Nozzolillo, A; Bernal, P; Krasner, A; Jo, B; Coury, D; Whitaker, A; Veenstra-Vanderweele, J; Harden, AY";;;;"Fung, Lawrence K.; Mahajan, Rajneesh; Nozzolillo, Alixandra; Bernal, Pilar; Krasner, Aaron; Jo, Booil; Coury, Daniel; Whitaker, Agnes; Veenstra-Vanderweele, Jeremy; Harden, Antonio Y.";;;Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis;PEDIATRICS;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; CONTROLLED PILOT TRIAL; DOUBLE-BLIND; SPECTRUM DISORDERS; PEDIATRIC-PATIENTS; CHILDREN; PLACEBO; RISPERIDONE; ARIPIPRAZOLE; ADOLESCENTS";BACKGROUND: Autism spectrum disorder (ASD) is increasingly recognized as a public health issue. Irritability and aggression (IA) often negatively affect the lives of people with ASD and their families. Although many medications have been tested for IA in ASDs in randomized controlled trials (RCTs), critical quantitative analyses of these trials are lacking in the literature. OBJECTIVES: To systematically review and quantitatively analyze the efficacy and safety of pharmacologic treatments for IA in youth with ASD. DATA SOURCES: Studies were identified from Medline, PsycINFO, Embase, and review articles. METHODS: Original articles on placebo-controlled RCTs of pharmacologic treatments of IA in youth age 2 to 17 years with ASD were included. Data items included study design, study goals, details of study participants, details of intervention, study results, statistical methods, side effects, and risks of bias. The primary study outcome measure was the effect size of reduction in the Aberrant Behavioral Checklist-Irritability (ABC-I) scores in the medication group, as compared with placebo, in RCTs using parallel groups design. RESULTS: Forty-six RCTs were identified. Compared with placebo, 3 compounds resulted in significant improvement in ABC-I at the end of treatment. Risperidone and aripiprazole were found to be the most effective, with the largest effect sizes. Sedation, extrapyramidal sides effects, and weight gain were assessed quantitatively. CONCLUSIONS: Although risperidone and aripiprazole have the strongest evidence in reducing ABC-I in youth with ASD, a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.;"[Fung, Lawrence K.; Jo, Booil; Harden, Antonio Y.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Mahajan, Rajneesh] Kennedy Krieger Inst, Baltimore, MD USA; [Mahajan, Rajneesh] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Nozzolillo, Alixandra] MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA USA; [Bernal, Pilar] Kaiser Permanente No Calif, San Jose, CA USA; [Krasner, Aaron; Whitaker, Agnes; Veenstra-Vanderweele, Jeremy] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA; [Coury, Daniel] Ohio State Univ, Dept Dev & Behav Pediat, Columbus, OH 43210 USA";"Stanford University; Kennedy Krieger Institute; Johns Hopkins University; Harvard University; Massachusetts General Hospital; Kaiser Permanente; Columbia University; NewYork-Presbyterian Hospital; University System of Ohio; Ohio State University";Harden, AY (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd, Stanford, CA 94305 USA.;hardanay@stanford.edu;"Veenstra-VanderWeele, Jeremy/K-1935-2015; Coury, Daniel/L-6556-2019; Fung, Lawrence/R-8354-2016";"Fung, Lawrence/0000-0002-5738-0396; Coury, Daniel/0000-0001-9754-3914";US Department of Health and Human Services, Health Resources and Services Administration (HRSA), Maternal and Child Health Research Program [UA3 MC11054];US Department of Health and Human Services, Health Resources and Services Administration (HRSA), Maternal and Child Health Research Program;Supported by cooperative agreement UA3 MC11054 through the US Department of Health and Human Services, Health Resources and Services Administration (HRSA), Maternal and Child Health Research Program to the Massachusetts General Hospital. This work was conducted through the Autism Speaks Autism Treatment Network serving as the Autism Intervention Research Network on Physical Health. The views expressed in this article do not necessarily reflect the views of Autism Speaks, Inc or HRSA.;"Adams JB, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-111; Aman MG, 2010, J CHILD ADOL PSYCHOP, V20, P415, DOI 10.1089/cap.2009.0120; Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; ANDERSON LT, 1984, AM J PSYCHIAT, V141, P1195; [Anonymous], 2008, US PREV SERV TASK FO; [Anonymous], IRRITABILITY; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Arnold LE, 2012, J CHILD ADOL PSYCHOP, V22, P198, DOI 10.1089/cap.2011.0056; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; BOUVARD MP, 1995, PSYCHIAT RES, V58, P191, DOI 10.1016/0165-1781(95)02601-R; CAMPBELL M, 1978, J AM ACAD CHILD PSY, V17, P640, DOI 10.1016/S0002-7138(09)61017-7; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Danfors T, 2005, J CLIN PSYCHOPHARM, V25, P485, DOI 10.1097/01.jcp.0000177667.35016.e9; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; Ebisch SJH, 2011, HUM BRAIN MAPP, V32, P1013, DOI 10.1002/hbm.21085; Eisenberg N, 2004, CHILD DEV, V75, P334, DOI 10.1111/j.1467-8624.2004.00674.x; Findling RL, 1997, J AUTISM DEV DISORD, V27, P467, DOI 10.1023/A:1025861522935; Findling RL, 2014, J CLIN PSYCHIAT, V75, P22, DOI 10.4088/JCP.13m08500; Frazier TW, 2010, J CHILD ADOL PSYCHOP, V20, P167, DOI 10.1089/cap.2009.0048; GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Hellings JA, 2005, J CHILD ADOL PSYCHOP, V15, P682, DOI 10.1089/cap.2005.15.682; Hellings JA, 2006, J AUTISM DEV DISORD, V36, P401, DOI 10.1007/s10803-006-0078-1; Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; JASELSKIS CA, 1992, J CLIN PSYCHOPHARM, V12, P322; Kent JM, 2013, J AUTISM DEV DISORD, V43, P1773, DOI 10.1007/s10803-012-1723-5; King BH, 2001, J AM ACAD CHILD PSY, V40, P658, DOI 10.1097/00004583-200106000-00010; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Luby J, 2006, J CHILD ADOL PSYCHOP, V16, P575, DOI 10.1089/cap.2006.16.575; Marcus RN, 2011, J CLIN PSYCHIAT, V72, P1270, DOI 10.4088/JCP.09m05933; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Mccracken JT, 2005, AM J PSYCHIAT, V162, P1361; Mendez MA, 2013, NEUROPHARMACOLOGY, V68, P195, DOI 10.1016/j.neuropharm.2012.04.008; Miral S, 2008, EUR CHILD ADOLES PSY, V17, P1, DOI 10.1007/s00787-007-0620-5; Moher D, 2010, INT J SURG, V8, P658, DOI [10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2700]; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Niederhofer H, 2003, HUM PSYCHOPHARM CLIN, V18, P389, DOI 10.1002/hup.491; Niederhofer H, 2004, THERAPY, V1, P87, DOI DOI 10.2217/14750708.1.1.87; Oblak A, 2009, AUTISM RES, V2, P205, DOI 10.1002/aur.88; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Owley T, 2001, J AM ACAD CHILD PSY, V40, P1293, DOI 10.1097/00004583-200111000-00009; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; Remington G, 2001, J CLIN PSYCHOPHARM, V21, P440, DOI 10.1097/00004714-200108000-00012; Samaras K, 2014, JAMA PSYCHIAT, V71, P209, DOI 10.1001/jamapsychiatry.2013.4030; Samson AC, 2014, J AUTISM DEV DISORD, V44, P1766, DOI 10.1007/s10803-013-2022-5; Scahill L, 2012, J AM ACAD CHILD PSY, V51, P136, DOI 10.1016/j.jaac.2011.11.010; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774; SNAITH RP, 1985, BRIT J PSYCHIAT, V147, P127, DOI 10.1192/bjp.147.2.127; Solomon M, 2014, BIOL PSYCHIAT, V76, P412, DOI 10.1016/j.biopsych.2013.08.036; Troost PW, 2005, J AM ACAD CHILD PSY, V44, P1137, DOI 10.1097/01.chi.0000177055.11229.76; Wasserman S, 2006, INT CLIN PSYCHOPHARM, V21, P363, DOI 10.1097/01.yic.0000224787.13782.0f; WillemsenSwinkels SHN, 1996, BIOL PSYCHIAT, V39, P1023, DOI 10.1016/0006-3223(95)00297-9; WILLEMSENSWINKELS SHN, 1995, PSYCHIAT RES, V58, P203, DOI 10.1016/0165-1781(95)02749-M; Wink LK, 2014, J CHILD ADOL PSYCHOP, V24, P78, DOI 10.1089/cap.2013.0099; Woodard C, 2007, AUTISM, V11, P29, DOI 10.1177/1362361307070989";64;151;156;1;29;AMER ACAD PEDIATRICS;Itasca;345 Park Boulevard, Itasca, IL, UNITED STATES;0031-4005;1098-4275;;PEDIATRICS;Pediatrics;FEB;2016;137;;;2;;;S124;S135;e20152851K;10.1542/peds.2015-2851K;http://dx.doi.org/10.1542/peds.2015-2851K;;;12;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;DF5LR;26908468;Bronze;;;24/11/2024;WOS:000371393700010;View Full Record in Web of Science
J;"Pearson, DA; Santos, CW; Aman, MG; Arnold, LE; Casat, CD; Mansour, R; Lane, DM; Loveland, KA; Bukstein, OG; Jerger, SW; Factor, P; Vanwoerden, S; Perez, E; Cleveland, LA";;;;"Pearson, Deborah A.; Santos, Cynthia W.; Aman, Michael G.; Arnold, L. Eugene; Casat, Charles D.; Mansour, Rosleen; Lane, David M.; Loveland, Katherine A.; Bukstein, Oscar G.; Jerger, Susan W.; Factor, Perry; Vanwoerden, Salome; Perez, Evelyn; Cleveland, Lynne A.";;;Effects of Extended Release Methylphenidate Treatment on Ratings of Attention-Deficit/Hyperactivity Disorder (ADHD) and Associated Behavior in Children with Autism Spectrum Disorders and ADHD Symptoms;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; DEFICIT HYPERACTIVITY DISORDER; STIMULANT MEDICATION; PSYCHIATRIC-DISORDERS; MENTAL-RETARDATION; PHARMACOTHERAPY; PREVALENCE; ADOLESCENTS; COMORBIDITY; EFFICACY";"Objective: The purpose of this study was to examine the behavioral effects of four doses of psychostimulant medication, combining extended-release methylphenidate (MPH) in the morning with immediate-release MPH in the afternoon. Method: The sample comprised 24 children (19 boys; 5 girls) who met American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV-TR) criteria for an autism spectrum disorder (ASD) on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS), and had significant symptoms of attention-deficit/hyperactivity disorder (ADHD). This sample consisted of elementary school-age, community-based children (mean chronological age = 8.8 years, SD = 1.7; mean intelligence quotient [IQ] = 85; SD = 16.8). Effects of four dose levels of MPH on parent and teacher behavioral ratings were investigated using a within-subject, crossover, placebo-controlled design. Results: MPH treatment was associated with significant declines in hyperactive and impulsive behavior at both home and school. Parents noted significant declines in inattentive and oppositional behavior, and improvements in social skills. No exacerbation of stereotypies was noted, and side effects were similar to those seen in typically developing children with ADHD. Dose response was primarily linear in the dose range studied. Conclusions: The results of this study suggest that MPH formulations are efficacious and well-tolerated for children with ASD and significant ADHD symptoms.";"[Pearson, Deborah A.; Santos, Cynthia W.; Mansour, Rosleen; Loveland, Katherine A.; Bukstein, Oscar G.; Factor, Perry; Vanwoerden, Salome; Perez, Evelyn; Cleveland, Lynne A.] Univ Texas Houston, Sch Med, Houston, TX 77054 USA; [Aman, Michael G.; Arnold, L. Eugene] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [Casat, Charles D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA; [Lane, David M.] Rice Univ, Dept Psychol, Houston, TX 77251 USA; [Jerger, Susan W.] Univ Texas Dallas, Sch Behav & Brain Sci, Dallas, TX 75230 USA";"University of Texas System; University of Texas Health Science Center Houston; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Rice University; University of Texas System; University of Texas Dallas";Pearson, DA (corresponding author), Univ Texas Houston, Sch Med, Dept Psychiat & Behav Sci, 1941 East Rd, Houston, TX 77054 USA.;Deborah.A.Pearson@uth.tmc.edu;Vanwoerden, Salome/ABE-1312-2020;"Pearson, Deborah/0000-0003-2047-1013; Vanwoerden, Salome/0000-0001-6966-2131";National Institute of Mental Health (NIMH) [MH072263];National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH));This study was funded by grant number MH072263 from the National Institute of Mental Health (NIMH).;"Aman M.G., 1994, Aberrant Behavior Checklist-Community. Supplementary Manual; Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P116, DOI 10.1089/cap.2005.15.116; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1982, J AUTISM DEV DISORD, V12, P385, DOI 10.1007/BF01538326; Aman MG, 2003, J CHILD ADOL PSYCHOP, V13, P29, DOI 10.1089/104454603321666171; Aman MG, 2002, AM J PSYCHIAT, V159, P1337, DOI 10.1176/appi.ajp.159.8.1337; Aman MG, 1996, J DEV PHYS DISABIL, V8, P347, DOI 10.1007/BF02578400; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; Arnold LE, 2000, J AUTISM DEV DISORD, V30, P99, DOI 10.1023/A:1005451304303; BIRMAHER B, 1988, J AM ACAD CHILD PSY, V27, P248, DOI 10.1097/00004583-198803000-00020; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; CAMPBELL M, 1972, J AUTISM CHILD SCHIZ, V2, P343, DOI 10.1007/BF01538168; CAMPBELL M, 1975, BIOL PSYCHIAT, V10, P399; Conners CK, 1997, Conners' Rating Scales-Revised: Instruments for use with children and adolescents; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Di Martino A, 2004, J CHILD ADOL PSYCHOP, V14, P207, DOI 10.1089/1044546041649011; Farmer Cristan A, 2011, Child Adolesc Psychiatry Ment Health, V5, P36, DOI 10.1186/1753-2000-5-36; Frazier J.A., 2001, Journal of Attentional Disorders, V4, P203; Frazier TW, 2011, J CHILD ADOL PSYCHOP, V21, P571, DOI 10.1089/cap.2011.0057; GAN J, 1982, J AM ACAD CHILD PSY, V21, P237, DOI 10.1016/S0002-7138(09)60876-1; GELLER B, 1981, AM J PSYCHIAT, V138, P388; Ghuman JK, 2009, J CHILD ADOL PSYCHOP, V19, P329, DOI 10.1089/cap.2008.0137; Goldstein S, 2004, J AUTISM DEV DISORD, V34, P329, DOI 10.1023/B:JADD.0000029554.46570.68; Greenhill LL, 2001, J AM ACAD CHILD PSY, V40, P180, DOI 10.1097/00004583-200102000-00012; Gringas P., 2000, AUTISM, V4, P229, DOI DOI 10.1177/1362361300004003002; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HOLM S, 1979, SCAND J STAT, V6, P65; HOLTTUM JR, 1994, J AM ACAD CHILD PSY, V33, P577, DOI 10.1097/00004583-199405000-00016; HOSHINO Y, 1977, FOLIA PSYCHIAT NEU J, V31, P605; Jahromi LB, 2009, J AUTISM DEV DISORD, V39, P395, DOI 10.1007/s10803-008-0636-9; Jensen PS, 2007, J AM ACAD CHILD PSY, V46, P989, DOI 10.1097/chi.0b013e3180686d48; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; Loveland K.A., 2005, HDB AUTISM PERVASIVE, V3rd, P247, DOI DOI 10.1002/9780470939345.CH9; Molina BSG, 2009, J AM ACAD CHILD PSY, V48, P484, DOI 10.1097/CHI.0b013e31819c23d0; Nickels KC, 2008, J DEV BEHAV PEDIATR, V29, P75, DOI 10.1097/DBP.0b013e31815f24f7; Nicolson R, 2000, J AUTISM DEV DISORD, V30, P461, DOI 10.1023/A:1005511809545; Pearson DA, 2003, J AM ACAD CHILD PSY, V42, P209, DOI 10.1097/00004583-200302000-00015; Pearson DA, 2006, CHILD NEUROPSYCHOL, V12, P321, DOI 10.1080/09297040600646847; Pearson DA, 2012, J CHILD ADOL PSYCHOP, V22, P284, DOI 10.1089/cap.2011.0067; Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724; Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028; Posey DJ, 2000, HARVARD REV PSYCHIAT, V8, P45, DOI 10.1093/hrp/8.2.45; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; REALMUTO GM, 1989, J CLIN PSYCHOPHARM, V9, P122, DOI 10.1097/00004714-198904000-00009; Reich W., 1997, DIAGNOSTIC INTERVIEW; Reiersen AM, 2007, J CHILD PSYCHOL PSYC, V48, P464, DOI 10.1111/j.1469-7610.2006.01720.x; Riddle MA, 2013, J AM ACAD CHILD PSY, V52, P264, DOI 10.1016/j.jaac.2012.12.007; Roid G. H., 2003, The Stanford-Binet intelligence scales; Rutter M., 2003, ADI R AUTISM DIAGNOS; Santosh PJ, 2006, CHILD CARE HLTH DEV, V32, P575, DOI 10.1111/j.1365-2214.2006.00631.x; Scahill L, 2006, J AM ACAD CHILD PSY, V45, P1114, DOI 10.1097/01.chi.0000220854.79144.e7; Scahill L, 2007, J CHILD ADOL PS NURS, V20, P59, DOI 10.1111/j.1744-6171.2007.00080.x; SCHMIDT K, 1982, J DEV BEHAV PEDIATR, V3, P244, DOI 10.1097/00004703-198212000-00014; Siegel M, 2012, J AUTISM DEV DISORD, V42, P1592, DOI 10.1007/s10803-011-1399-2; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; SPORN A, 1981, AM J PSYCHIAT, V138, P997; SPRAGUE RL, 1977, SCIENCE, V198, P1274, DOI 10.1126/science.337493; Stigler KA, 2004, J CHILD ADOL PSYCHOP, V14, P49, DOI 10.1089/104454604773840481; STRAYHORN JM, 1988, J AM ACAD CHILD PSY, V27, P244, DOI 10.1097/00004583-198803000-00019; Sturm H, 2004, DEV MED CHILD NEUROL, V46, P444, DOI 10.1017/S0012162204000738; Swanson JM, 2001, CATEGORIAL DIMENSION; Thompson Health Care, 2009, PHYS DESK REFERENCE; Ullmann R.K., 2000, ACTeRS teacher and parent forms manual; VITRIOL C, 1981, AM J PSYCHIAT, V138, P1517; VOLKMAR FR, 1985, CLIN PEDIATR, V24, P127, DOI 10.1177/000992288502400301; WAGENAAR WA, 1969, PSYCHOL BULL, V72, P384, DOI 10.1037/h0028329; Waterhouse L, 1996, PSYCHOL REV, V103, P457, DOI 10.1037/0033-295X.103.3.457; WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405";73;74;77;0;39;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;JUN;2013;23;5;;;;;337;351;;10.1089/cap.2012.0096;http://dx.doi.org/10.1089/cap.2012.0096;;;15;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";168LJ;23782128;Green Published;;;24/11/2024;WOS:000320707000006;View Full Record in Web of Science
J;"Bemmer, ER; Boulton, KA; Thomas, EE; Larke, B; Lah, S; Hickie, IB; Guastella, AJ";;;;"Bemmer, Emily R.; Boulton, Kelsie A.; Thomas, Emma E.; Larke, Ben; Lah, Suncica; Hickie, Ian B.; Guastella, Adam J.";;;Modified CBT for social anxiety and social functioning in young adults with autism spectrum disorder;MOLECULAR AUTISM;;;English;Article;;;;;;"Autism; Social anxiety; Group; Intervention; Cognitive-behavioural therapy; Mental health; Social skills";"DIAGNOSTIC OBSERVATION SCHEDULE; COGNITIVE-BEHAVIORAL THERAPY; SKILLS INTERVENTIONS; ADOLESCENTS; INDIVIDUALS; EXPERIENCES; CHILDREN; EFFICACY; DEFICITS";"BackgroundThere is a strong research imperative to investigate effective treatment options for adolescents and adults with autism spectrum disorder (ASD). Elevated social anxiety, difficulties with social functioning and poor mental health have all been identified as core treatment targets for this group. While theoretical models posit a strong bidirectionality between social anxiety and ASD social functioning deficits, few interventions have targeted both domains concurrently. Of the two group interventions previously conducted with adolescents and adults with ASD, significant results have only been observed in either social anxiety or social functioning, and have not generalised to changes in overall mood. The aim of this study was to evaluate the potential benefit, tolerability and acceptability of a group cognitive-behaviour therapy (CBT) intervention in young adults with ASD. Primary treatment outcomes were social anxiety symptoms and social functioning difficulties; secondary outcomes were self-reported mood and overall distress.MethodTen groups of participants completed an eight-week, modified group CBT intervention targeting both social anxiety and social functioning, that included social skills training, exposure tasks and behavioural experiment components. Seventy-eight adolescents and young adults with ASD, without intellectual impairment, aged between 16 and 38 (M=22.77; SD=5.31), were recruited from the community, Headspace centres and the Autism Clinic for Translational Research at the Brain and Mind Centre, University of Sydney. Outcomes (social anxiety, social functioning and mood) were measured pre- and post-intervention via self-report questionnaires (administered either online or through the return of hard-copy booklets), and participants were invited to provide anonymous feedback on the intervention (at the mid-point and end of the intervention).ResultsParticipants demonstrated statistically significant improvements on all outcome measures in response to the intervention. Specifically, social anxiety symptoms decreased (p<.001), and specific subdomains of social functioning improved post-intervention, particularly in social motivation (p=.032) and restricted interests and repetitive behaviours (p=.025). Self-reported symptom improvements also generalised to mood (depression, anxiety and stress; p<.05). All improvements demonstrated small effect sizes. Participant feedback was positive and indicated strong satisfaction with the program.LimitationsThe absence of a control group and follow-up measures, reliance on self-report instruments as outcome measures and the exclusion of those with intellectual disability represent significant limitations to this study.ConclusionsThese findings indicate that a group CBT intervention appears to be a beneficial intervention for self-reported social anxiety, social functioning and overall mental health in adolescents and young adults with ASD. The stand-alone nature of the intervention combined with positive participant feedback indicates it was well tolerated, has potential clinical utility and warrants further study in a randomised-controlled, follow-up design.";"[Bemmer, Emily R.; Boulton, Kelsie A.; Thomas, Emma E.; Larke, Ben; Hickie, Ian B.; Guastella, Adam J.] Univ Sydney, Autism Clin Translat Res, Fac Med & Hlth,Brain & Mind Ctr, Child Neurodev & Mental Hlth Team,Childrens Hosp, 100 Mallet St, Camperdown, NSW 2050, Australia; [Bemmer, Emily R.; Lah, Suncica] Univ Sydney, Sch Psychol, Sydney, NSW 2050, Australia; [Boulton, Kelsie A.; Guastella, Adam J.] Univ Sydney, Childrens Hosp Westmead Clin Sch, Fac Med & Hlth, Child Neurodev & Mental Hlth Team,Brain & Mind Ct, Camperdown, NSW 2050, Australia";"University of Sydney; University of Sydney; University of Sydney";"Guastella, AJ (corresponding author), Univ Sydney, Autism Clin Translat Res, Fac Med & Hlth,Brain & Mind Ctr, Child Neurodev & Mental Hlth Team,Childrens Hosp, 100 Mallet St, Camperdown, NSW 2050, Australia.;Guastella, AJ (corresponding author), Univ Sydney, Childrens Hosp Westmead Clin Sch, Fac Med & Hlth, Child Neurodev & Mental Hlth Team,Brain & Mind Ct, Camperdown, NSW 2050, Australia.";adam.guastella@sydney.edu.au;"Guastella, Adam/JCE-9327-2023; Boulton, Kelsie/AFA-5484-2022; Hickie, Ian/K-8975-2015";"Boulton, Kelsie/0000-0002-9408-7367; Hickie, Ian/0000-0001-8832-9895; Lah, Suncica/0000-0003-2282-4812; Guastella, Adam/0000-0001-8178-4625";"Australian Research Council [LP110200562]; NHMRC [APP1061922, 1046899]; Australian Research Council [LP110200562] Funding Source: Australian Research Council";"Australian Research Council(Australian Research Council); NHMRC(National Health & Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)";The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by an Australian Research Council Linkage Grant (LP110200562) and an NHMRC career development fellowship (APP1061922) to AJG and Senior Principal Research Fellowship to IH (No. 1046899).;"Ainsworth K, 2020, RES AUTISM SPECT DIS, V69, DOI 10.1016/j.rasd.2019.101457; Balderaz L., 2020, Journal of Psychosocial Rehabilitation and Mental Health, V7, P45, DOI [10.1007/s40737-020-00158-9, DOI 10.1007/S40737-020-00158-9]; Bejerot S, 2014, PSYCHIAT RES, V220, P705, DOI 10.1016/j.psychres.2014.08.030; Bellini S., 2006, Focus on Autism and Other Developmental Disorders, V21, P138, DOI DOI 10.1177/10883576060210030201; Boulton K, 2020, MEASURING SOCIAL ANX; Brugha TS, 2011, ARCH GEN PSYCHIAT, V68, P459, DOI 10.1001/archgenpsychiatry.2011.38; Caballo VE, 1998, INTERNATIONAL HANDBOOK OF COGNITIVE AND BEHAVIOURAL TREATMENTS FOR PSYCHOLOGICAL DISORDERS, P23, DOI 10.1016/B978-008043433-9/50004-3; Cage E, 2018, J AUTISM DEV DISORD, V48, P473, DOI 10.1007/s10803-017-3342-7; Carter MJ, 2014, THER RECREAT J, V48, P275; Chang YC, 2012, J DEV PHYS DISABIL, V24, P235, DOI 10.1007/s10882-012-9268-2; Cholemkery H, 2014, J AUTISM DEV DISORD, V44, P1168, DOI 10.1007/s10803-013-1979-4; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Cooper K, 2018, RES AUTISM SPECT DIS, V45, P43, DOI 10.1016/j.rasd.2017.11.002; Cunningham A., 2016, COUNSELING OUTCOME R, V7, P99, DOI DOI 10.1177/2150137816668561; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Gantman A, 2012, J AUTISM DEV DISORD, V42, P1094, DOI 10.1007/s10803-011-1350-6; Gates JA, 2017, CLIN PSYCHOL REV, V52, P164, DOI 10.1016/j.cpr.2017.01.006; Gaus V.L., 2019, Cognitive-behavioral therapy for adults with autism spectrum disorder; Guastella AJ, 2020, ENGAGE PROGRAM COGNI; Hill E, 2004, J AUTISM DEV DISORD, V34, P229, DOI 10.1023/B:JADD.0000022613.41399.14; Hofmann S.G., 2008, COGNITIVE BEHAV THER; Hus V, 2014, J AUTISM DEV DISORD, V44, P1996, DOI 10.1007/s10803-014-2080-3; Joshi G, 2013, J AUTISM DEV DISORD, V43, P1314, DOI 10.1007/s10803-012-1679-5; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Landon J, 2016, RES AUTISM SPECT DIS, V32, P43, DOI 10.1016/j.rasd.2016.08.005; Laugeson EA, 2014, J RATION-EMOT COGN-B, V32, P84, DOI 10.1007/s10942-014-0181-8; Leung CNW, 2019, J AUTISM DEV DISORD, V49, P3440, DOI 10.1007/s10803-019-04066-1; Levy A, 2011, RES AUTISM SPECT DIS, V5, P1271, DOI 10.1016/j.rasd.2011.01.023; Liebowitz M R, 1987, Mod Probl Pharmacopsychiatry, V22, P141; Livingston LA, 2019, J CHILD PSYCHOL PSYC, V60, P102, DOI 10.1111/jcpp.12886; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Maddox BB, 2015, J AUTISM DEV DISORD, V45, P3949, DOI 10.1007/s10803-015-2531-5; Maisel ME, 2016, J ABNORM PSYCHOL, V125, P692, DOI 10.1037/abn0000168; Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI 10.1016/S0005-7967(97)10031-6; Mayo-Wilson E, 2014, LANCET PSYCHIAT, V1, P368, DOI 10.1016/S2215-0366(14)70329-3; McCoy K.M., 2012, COUNSELING HUMAN DEV, V45, P1; Milosavljevic B, 2016, J AUTISM DEV DISORD, V46, P1354, DOI 10.1007/s10803-015-2670-8; National Institute for Health and Care Excellence (NICE), 2013, MAN SUPP CHILDR YOUN; Pallathra AA, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-0989-0; Pallathra AA, 2018, AUTISM RES, V11, P488, DOI 10.1002/aur.1910; Park SH, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113300; Park SH, 2019, AUTISM, V23, P1675, DOI 10.1177/1362361318823925; Pepper KL, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0282-8; Rapee RM, 2009, J CONSULT CLIN PSYCH, V77, P317, DOI 10.1037/a0014800; Reaven J, 2017, Anxiety in Children and Adolescents with Autism Spectrum Disorder, P143; Reichow B, 2010, J AUTISM DEV DISORD, V40, P149, DOI 10.1007/s10803-009-0842-0; Rumney H.L., 2017, Mental Health and Prevention, V5, P12, DOI [DOI 10.1016/J.MHP.2016.12.001, DOI 10.1016/J.MHP.2016.12]; Schroeder JH, 2014, J AUTISM DEV DISORD, V44, P1520, DOI 10.1007/s10803-013-2011-8; Spain D, 2018, RES AUTISM SPECT DIS, V52, P51, DOI 10.1016/j.rasd.2018.04.007; Spain D, 2017, RES AUTISM SPECT DIS, V41-42, P20, DOI 10.1016/j.rasd.2017.07.005; Turcotte P, 2016, J AUTISM DEV DISORD, V46, P2480, DOI 10.1007/s10803-016-2787-4; Wechsler D., 2001, WECHSLER TEST ADULT; Weston L, 2016, CLIN PSYCHOL REV, V49, P41, DOI 10.1016/j.cpr.2016.08.001; White SW, 2013, J AUTISM DEV DISORD, V43, P382, DOI 10.1007/s10803-012-1577-x; White SW, 2010, CLIN CHILD FAM PSYCH, V13, P77, DOI 10.1007/s10567-009-0062-3; White SW., 2014, SOCIAL WORRIES DIFFI, P121; Wood JJ, 2020, JAMA PSYCHIAT, V77, P474, DOI 10.1001/jamapsychiatry.2019.4160; Wood JJ, 2015, BEHAV THER, V46, P7, DOI 10.1016/j.beth.2014.01.002; Wright SD, 2019, GERONTOL GERIATR EDU, V40, P322, DOI 10.1080/02701960.2016.1247073";62;20;25;5;64;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;FEB 8;2021;12;1;;;;;;;11;10.1186/s13229-021-00418-w;http://dx.doi.org/10.1186/s13229-021-00418-w;;;15;"Genetics & Heredity; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Genetics & Heredity; Neurosciences & Neurology";QG5JU;33557903;gold, Green Submitted, Green Published;;;24/11/2024;WOS:000617622200002;View Full Record in Web of Science
J;"Abraham, DA; Udayakumar, N; Rajendran, L; Rajendran, R; Rajanandh, MG";;;;"Abraham, Debi Ann; Udayakumar, Narasimhan; Rajendran, Lavanya; Rajendran, Ramya; Rajanandh, Muhasaparur Ganesan";;;Herbal medicine as a first-line choice of complementary medicine for South Indian parents/caregivers in the management of ASD children;JOURNAL OF HERBAL MEDICINE;;;English;Article;;;;;;"Autism; Caregiver; Herbal Medicine; Ayurveda; Vitamins";"AUTISM SPECTRUM DISORDER; ALTERNATIVE MEDICINE; PREVALENCE; SUPPLEMENTATION; THERAPY";Background: Parents/caregivers of children with Autism Spectrum Disorder (ASD) try different approaches to manage their child's condition, of which one of the popular approaches is using Complementary and Alternative Medicine (CAM) treatment. Objectives: The present study aimed to estimate the prevalence and describe the pattern of CAM usage in a tertiary care South Indian hospital.Methods: A cross-sectional study was conducted among the parents/caregivers of children with ASD to specifically report the usage of CAM in their children. Data was also collected about the type of CAM, source, reasons, expectations, effectiveness, harmful effects, and the treating pediatrician's opinion on CAM usage.Results: A total of 257 parents/caregivers of children with ASD participated in the study. 24.5% of the children were exposed to at least one CAM therapy. The most commonly given CAM therapy was herbal medicine (71.4%). Parents/caregivers tried CAM therapy as their children's core symptoms of ASD did not show much improvement with the existing therapy (80.9%). They expected that CAM therapy would at least control the progression of the disability (61.9%). CAM usage did not produce any adverse effects (100%). The baseline characteristics between the CAM users and non-users were similar expect for gender, which showed a statistically significant difference (p = 0.008). About 55.5% of the parents/caregivers did not discuss the usage of CAM for their child with their treating pediatrician.Conclusion: Herbal medicines are frequently given CAM to children with ASD in India. History of CAM therapy usage should be a part of the medication history interview.;"[Abraham, Debi Ann; Rajendran, Lavanya; Rajendran, Ramya; Rajanandh, Muhasaparur Ganesan] Sri Ramachandra Inst Higher Educ & Res Deemed be U, Sri Ramachandra Fac Pharm, Dept Pharm Practice, Chennai 600 116, Tamil Nadu, India; [Udayakumar, Narasimhan] Sri Ramachandra Inst Higher Educ & Res Deemed be U, Sri Ramachandra Med Coll Res Inst, Chennai 600 116, Tamil Nadu, India";"Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research";Rajanandh, MG (corresponding author), Sri Ramachandra Inst Higher Educ & Res Deemed be U, Sri Ramachandra Fac Pharm, Dept Pharm Practice, Chennai 600 116, Tamil Nadu, India.;rajanandh.mg@sriramachandra.edu.in;"MG, Rajanandh/AAO-6908-2020; Abraham, Debi Ann/JQJ-6173-2023";Abraham, Debi Ann/0000-0001-6020-5807;;;;"Abraham DA, 2021, AMINO ACIDS, V53, P575, DOI 10.1007/s00726-021-02960-6; Adams JB, 2006, J ALTERN COMPLEM MED, V12, P59, DOI 10.1089/acm.2006.12.59; Ali A, 2015, J ADV PHARM TECHNOL, V6, P148, DOI 10.4103/2231-4040.165015; Anirudhan R., 2017, INT J AYUR PHARM RES, V5, P9; Abraham DA, 2020, AMINO ACIDS, V52, P1521, DOI 10.1007/s00726-020-02909-1; Bang M, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8614680; Barnett JE, 2012, PROF PSYCHOL-RES PR, V43, P576, DOI 10.1037/a0028919; Bilgiç A, 2013, NOROPSIKIYATRI ARS, V50, P237, DOI [10.4274/Npa.y6389, 10.4274/npa.y6389]; Bodagh MN, 2019, FOOD SCI NUTR, V7, P96, DOI 10.1002/fsn3.807; Bode A.M., 2011, HERBAL MED BIOMOLECU, DOI [DOI 10.1201/B10787-8, 10.1201/b10787-8]; Burnside K, 2017, AUTISM RES, V10, P1834, DOI 10.1002/aur.1836; Chitra V., 2010, Annals of Biological Research, V1, P142; Clark MLE, 2018, J AUTISM DEV DISORD, V48, P92, DOI 10.1007/s10803-017-3279-x; Cohen Marc Maurice, 2014, J Ayurveda Integr Med, V5, P251, DOI 10.4103/0975-9476.146554; Debi Ann A., 2020, CASE REP CLIN TRIAL, VS0149, P30460; Deshpande R, 2014, ANC SCI LIFE, V33, P146, DOI 10.4103/0257-7941.144617; Dghaim R, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/973878; Gasparotto FM, 2018, CURR DRUG METAB, V19, P454, DOI 10.2174/1389200219666171227202332; Geelhand P, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-019-0266-4; Gogou M, 2017, BRAIN DEV-JPN, V39, P656, DOI 10.1016/j.braindev.2017.03.029; Hanson E, 2007, J AUTISM DEV DISORD, V37, P628, DOI 10.1007/s10803-006-0192-0; Harrington JW, 2006, J DEV BEHAV PEDIATR, V27, pS156, DOI 10.1097/00004703-200604002-00014; Hoefer J, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2043-5; Irvin DW, 2012, RES AUTISM SPECT DIS, V6, P565, DOI 10.1016/j.rasd.2011.07.018; Lee J, 2018, BMC COMPLEM ALTERN M, V18, DOI [10.1186/s12879-018-3031-y, 10.1186/s12906-018-2162-4]; Levy SE, 2008, CHILD ADOL PSYCH CL, V17, P803, DOI 10.1016/j.chc.2008.06.004; Lindly O, 2017, COMPLEMENT THER MED, V35, P47, DOI 10.1016/j.ctim.2017.09.003; Liu J, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1096-1; Lopresti AL, 2017, J PSYCHOPHARMACOL, V31, P287, DOI 10.1177/0269881116686883; Merlin R., RES J PHARM TECH, V14, P231, DOI [10.5958/0974-360X.2021.00040.8, DOI 10.5958/0974-360X.2021.00040.8]; Narasimhan U, 2020, INDIAN J PEDIATR, V87, P400, DOI 10.1007/s12098-019-03142-9; Owen-Smith AA, 2015, RES AUTISM SPECT DIS, V17, P40, DOI 10.1016/j.rasd.2015.05.002; Patten E, 2013, FOCUS AUTISM DEV DIS, V28, P138, DOI 10.1177/1088357612468028; Posar A, 2016, J PEDIATR NEUROSCI, V11, P225, DOI 10.4103/1817-1745.193363; Rajanandh M.G., 2018, J CANC RES PRACTICE, V5, P20, DOI [DOI 10.1016/J.JCRPR.2017.10, 10.1016/j.jcrpr.2017.10.004]; Saad K, 2016, NUTR NEUROSCI, V19, P346, DOI 10.1179/1476830515Y.0000000019; Saleem S.M., 2020, Indian Journal of Forensic and Community Medicine, V7, P1, DOI [10.18231/j.ijfcm.2020.001, DOI 10.18231/2394-6776.2019.0001, DOI 10.18231/J.IJFCM.2020.001]; Salomone E, 2015, EUR J PEDIATR, V174, P1277, DOI 10.1007/s00431-015-2531-7; Saper Robert B, 2021, OVERVIEW HERBAL MED; Sarvesh S, 2018, COMPLEMENT THER CLIN, V30, P103, DOI 10.1016/j.ctcp.2017.12.016; Sibinga EMS, 2004, CLIN PEDIATR, V43, P367, DOI 10.1177/000992280404300408; Sidora-Arcoleo K, 2008, J PEDIATR HEALTH CAR, V22, P221, DOI 10.1016/j.pedhc.2007.07.001; Simon T.K., 2019, INT J ADV SCI RES MA, V4, P319; Soni S, 2008, INDIAN J PHARM SCI, V70, P36, DOI 10.4103/0250-474X.40329; Suryavanshi SV, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.662000; Trudeau MS, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081783; Weiner RH, 2014, EXPLORE-NY, V10, P13, DOI 10.1016/j.explore.2013.10.005; Wong C, 2015, J AUTISM DEV DISORD, V45, P1951, DOI 10.1007/s10803-014-2351-z; Wong HHL, 2006, J AUTISM DEV DISORD, V36, P901, DOI 10.1007/s10803-006-0131-0";49;1;1;1;5;ELSEVIER GMBH;MUNICH;HACKERBRUCKE 6, 80335 MUNICH, GERMANY;2210-8033;2210-8041;;J HERB MED;J. Herb. Med.;JUL;2022;34;;;;;;;;100583;10.1016/j.hermed.2022.100583;http://dx.doi.org/10.1016/j.hermed.2022.100583;;;5;Integrative & Complementary Medicine;Science Citation Index Expanded (SCI-EXPANDED);Integrative & Complementary Medicine;3E8KT;;;;;24/11/2024;WOS:000830228400003;View Full Record in Web of Science
J;"Sharma, AK; Gokulchandran, N; Kulkarni, PP; Sane, HM; Sharma, R; Jose, A; Badhe, PB";;;;"Sharma, Alok K.; Gokulchandran, Nandini; Kulkarni, Pooja P.; Sane, Hemangi M.; Sharma, Ridhima; Jose, Alitta; Badhe, Prerna B.";;;Cell transplantation as a novel therapeutic strategy for autism spectrum disorders: a clinical study;AMERICAN JOURNAL OF STEM CELLS;;;English;Article;;;;;;"Autologous; bone marrow mononuclear cells; autism spectrum disorders; PET CT scan; cell transplantation";"STEM-CELLS; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; BRAIN; CHILDREN; PLASTICITY; PREVENT; INJURY; SCALE; SAFE";Background: Autism spectrum disorders [ASD] is a lifelong disability mainly affecting the development, communication, social interaction and behavior of an individual. Cell transplantation is emerging as a potential therapeutic strategy for ASD. Our previously published proof of concept study showed beneficial effects of cell transplantation in ASD. This study shows effect of cell transplantation in a larger sample size of ASD patients. Methods: 254 patients diagnosed with ASD on DSM V criteria were enrolled in this open label non-randomized study. The intervention included intrathecal transplantation of autologous bone marrow mononuclear cells and neurorehabilitation. On mean follow up of 7.50 months, percentage analysis was performed on all symptomatic changes. Changes in outcome measures, Indian Scale for Assessment of Autism [ISAA] and Childhood Autism Rating Scale [CARS], were analyzed statistically using Wilcoxon Signed-Rank Test. Comparative analysis of Positron Emission Tomography [PET CT] scan brain, performed before and 6 months after intervention, was done in 86 patients to monitor the outcome at cellular level. Change in the standardized uptake values was statistically evaluated using T-Test [P <= 0.05]. Results: Improvements were observed in eye contact, attention and concentration, hyperactivity, sitting tolerance, social interaction, stereotypical behavior, aggressiveness, communication, speech, command following and self-stimulatory behavior. Statistically significant improvement was observed in scores of ISAA and CARS after intervention. A significantly better outcome of the intervention was found in patients at younger age and with shorter duration of disease [<5 years from time of diagnosis]. 86 patients who underwent a repeat PET CT scan showed improved brain metabolism after intervention in areas which correlated to the symptomatic changes. No major procedure related adverse events were recorded. However, 5 patients, with history of seizure and abnormal EEG, had an episode of seizure which was managed using medications. Outcome of intervention in these patients was not affected by seizures as improvements were observed in them. Conclusion: The results of this study indicate that autologous bone marrow mononuclear cells in combination with neurorehabilitation are a safe and effective treatment modality for ASD. It improves the quality of life of patients and helps them to integrate in mainstream lifestyle.;"[Sharma, Alok K.; Gokulchandran, Nandini] NeuroGen Brain & Spine Inst, Dept Med Serv & Clin Res, Mumbai, Maharashtra, India; [Kulkarni, Pooja P.; Sane, Hemangi M.; Jose, Alitta] NeuroGen Brain & Spine Inst, Dept Res & Dev, Mumbai, Maharashtra, India; [Sharma, Ridhima] NeuroGen Brain & Spine Inst, Dept Neurorehabil, Mumbai, Maharashtra, India; [Badhe, Prerna B.] NeuroGen Brain & Spine Inst, Dept Regenerat Lab Serv, Mumbai, Maharashtra, India";;Kulkarni, PP (corresponding author), NeuroGen Brain & Spine Inst, Dept Res & Dev, Plot 19,Sect 40,Off Palm Beach Rd, Nerul 400706, Navi Mumbai, India.;poojakul28@gmail.com;Sharma, Alok/IUP-9816-2023;;;;;"[Anonymous], 2018, INT BIOL BIOMED J; Badhe P, 2014, J PAEDIAT NEUROL, V12, P3; Badhe P, 2014, J STEM CELL RES TRAN, V1, P4; Badhe P, 2014, J NEUROL DISORD, V2, P164; Blenner S, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6238; Bradstreet JJ, 2014, CELL TRANSPLANT, V23, pS105, DOI 10.3727/096368914X684916; Cairns Kevin, 2003, Phys Med Rehabil Clin N Am, V14, pS135, DOI 10.1016/S1047-9651(02)00059-1; Calió ML, 2014, FREE RADICAL BIO MED, V70, P141, DOI 10.1016/j.freeradbiomed.2014.01.024; Carvalho IM, 2015, NEUROMOL MED, V17, P404, DOI 10.1007/s12017-015-8369-3; Chakraborty S, 2015, INDIAN J PSYCHOL MED, V37, P169, DOI 10.4103/0253-7176.155616; Chez M, 2018, STEM CELL TRANSL MED, V7, P333, DOI 10.1002/sctm.17-0042; Darabi Shahram, 2013, Iranian Biomedical Journal, V17, P8, DOI 10.6091/IBJ.1112.2012; Dawson G, 2017, STEM CELL TRANSL MED, V6, P1332, DOI 10.1002/sctm.16-0474; De Felice A, 2015, TOXICS, V3, P89, DOI 10.3390/toxics3010089; Essa MM, 2013, NEUROTOX RES, V23, P393, DOI 10.1007/s12640-012-9354-3; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Frustaci A, 2012, FREE RADICAL BIO MED, V52, P2128, DOI 10.1016/j.freeradbiomed.2012.03.011; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Goines PE, 2013, NEUROTOXICOL TERATOL, V36, P67, DOI 10.1016/j.ntt.2012.07.006; Gottfried C, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00121; Ichim TE, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-30; Jeong SR, 2012, EXP NEUROL, V233, P312, DOI 10.1016/j.expneurol.2011.10.021; Just MA, 2007, CEREB CORTEX, V17, P951, DOI 10.1093/cercor/bhl006; Kim KY, 2012, TRENDS MOL MED, V18, P463, DOI 10.1016/j.molmed.2012.06.002; Kleim JA, 2011, J COMMUN DISORD, V44, P521, DOI 10.1016/j.jcomdis.2011.04.006; Kyurkchiev Dobroslav, 2014, World J Stem Cells, V6, P552, DOI 10.4252/wjsc.v6.i5.552; Lui JH, 2011, CELL, V146, P18, DOI 10.1016/j.cell.2011.06.030; Lv YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-196; Manglunia AS, 2016, INDIAN J NUCL MED, V31, P138, DOI 10.4103/0972-3919.178302; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Ohnishi T, 2000, BRAIN, V123, P1838, DOI 10.1093/brain/123.9.1838; Paranjape A, 2016, AUTISM OPEN ACCESS, V6, P169; Patel AS, 2014, INT NEUROPSYCHIATR D, V2, P175, DOI [10.9734/INDJ/2014/7284, DOI 10.9734/INDJ/2014/7284]; Pösel C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050293; Russell PSS, 2010, WORLD J PEDIATR, V6, P141, DOI 10.1007/s12519-010-0029-y; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Schopler E., 2010, CHILDHOOD AUTISM RAT; Segal-Gavish H, 2016, AUTISM RES, V9, P17, DOI 10.1002/aur.1530; Sharma A., 2015, AM J CASE REP, V3, P304; Sharma A, 2013, J STEM CELL RES THER, V3, P2; Sharma A, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/234095; Sharma A, 2013, J NEURORESTORATOLOGY, V1, P13, DOI 10.2147/JN.S43712; Sharma A, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/905874; Sharma A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/623875; Sharma A, 2012, CELL TRANSPLANT, V21, pS79, DOI 10.3727/096368912X633798; Sharma A, 2013, INT J MANUF MATER ME, V3, P1, DOI 10.4018/ijmmme.2013040101; Siniscalco D, 2018, STEM CELLS CLONING, V11, P55, DOI 10.2147/SCCAA.S155410; Siniscalco D, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/262438; Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763; Song SJ, 2007, STEM CELLS DEV, V16, P747, DOI 10.1089/scd.2007.0027; Sweeten TL, 2004, BIOL PSYCHIAT, V55, P434, DOI 10.1016/j.biopsych.2003.09.001; Theoharides TC, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-168; Trueman R C, 2013, Curr Top Behav Neurosci, V15, P357, DOI 10.1007/7854_2012_223; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Verkhratsky A, 2014, CELL TISSUE RES, V357, P493, DOI 10.1007/s00441-014-1814-z; Watts Timothy John, 2008, Clin Med Pathol, V1, P99; Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006; World Medical Association, 2001, JAMA-J AM MED ASSOC, V79, P373, DOI DOI 10.1001/jama.2013.281053; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zikopoulos B, 2013, FRONT HUM NEUROSCI, V7, P1, DOI 10.3389/fnhum.2013.00609";61;8;9;0;1;E-CENTURY PUBLISHING CORP;MADISON;40 WHITE OAKS LN, MADISON, WI 53711 USA;2160-4150;;;AM J STEM CELLS;Am. J. Stem Cells;;2020;9;5;;;;;89;100;;;;;;12;Cell Biology;Emerging Sources Citation Index (ESCI);Cell Biology;PS0OA;33489466;;;;24/11/2024;WOS:000607627200003;View Full Record in Web of Science
J;"Hess, LG; Fitzpatrick, SE; Nguyen, DV; Chen, YJ; Gaul, KN; Schneider, A; Chitwood, KL; Eldeeb, MA; Polussa, J; Hessl, D; Rivera, S; Hagerman, RJ";;;;"Hess, Laura Greiss; Fitzpatrick, Sarah E.; Nguyen, Danh V.; Chen, Yanjun; Gaul, Kimberly N.; Schneider, Andrea; Chitwood, Kerrie Lemons; Eldeeb, Marwa Abd Al Azaim; Polussa, Jonathan; Hessl, David; Rivera, Susan; Hagerman, Randi J.";;;A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome;JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS;;;English;Article;;;;;;"fragile X syndrome; treatment; sertraline; SSRI; ASD; autism";"SEROTONIN SYNTHESIS; MOUSE MODEL; AUTISM; SPECTRUM; GENE; MECHANISMS; DOPAMINE; INFANTS; PHARMACOTHERAPY; COMMUNICATION";Objective: Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS). Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years. Results: Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale-Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred. Conclusion: This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure-Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood.;"[Hess, Laura Greiss; Fitzpatrick, Sarah E.; Gaul, Kimberly N.; Schneider, Andrea; Chitwood, Kerrie Lemons; Eldeeb, Marwa Abd Al Azaim; Polussa, Jonathan; Hessl, David; Rivera, Susan; Hagerman, Randi J.] Univ Calif Davis, Med Ctr, MIND Inst, 2825 50th St, Sacramento, CA 95817 USA; [Hess, Laura Greiss] Dominican Univ Calif, Dept Occupat Therapy, San Rafael, CA USA; [Fitzpatrick, Sarah E.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Nguyen, Danh V.] Univ Calif Irvine, Sch Med, Dept Med, Orange, CA 92668 USA; [Nguyen, Danh V.; Chen, Yanjun] Univ Calif Irvine, Inst Clin & Translat Sci, Irvine, CA USA; [Gaul, Kimberly N.; Rivera, Susan] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA; [Schneider, Andrea; Hagerman, Randi J.] Univ Calif Davis, Med Ctr, Dept Pediat, Sacramento, CA 95817 USA; [Chitwood, Kerrie Lemons] Calif State Univ, Dept Special Educ, Monterey, CA USA; [Hessl, David] Univ Calif Davis, Med Ctr, Dept Psychiat & Behav Sci, Sacramento, CA 95817 USA";"University of California System; University of California Davis; University System of Ohio; Ohio State University; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis";Hagerman, RJ (corresponding author), Univ Calif Davis, Med Ctr, MIND Inst, 2825 50th St, Sacramento, CA 95817 USA.;rjhagerman@ucdavis.edu;Schneider, Andrea/Y-5200-2019;Fitzpatrick, Sarah/0000-0001-7446-6469;"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [R40MC22641]; National Center for Advancing Translational Sciences, National Institutes of Health, through the Biostatistics, Epidemiology, and Research Design Unit [UL1 TR000002, TL1 TR000133, UL1 TR000153, UL1 TR001414]; National Center for Advancing Translational Sciences [UL1TR001414] Funding Source: NIH RePORTER";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS); National Center for Advancing Translational Sciences, National Institutes of Health, through the Biostatistics, Epidemiology, and Research Design Unit; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))";This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number R40MC22641. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. Other support includes, the MIND Institute Intellectual and Developmental Disabilities Research Center (U54 HD079125), and the National Fragile X Foundation. This publication was also made possible by grants UL1 TR000002 and linked award TL1 TR000133, UL1 TR000153, and UL1 TR001414 from the National Center for Advancing Translational Sciences, National Institutes of Health, through the Biostatistics, Epidemiology, and Research Design Unit.;"Abbeduto L, 2007, MENT RETARD DEV D R, V13, P36, DOI 10.1002/mrdd.20142; Alder J, 2003, J NEUROSCI, V23, P10800; ALTAR CA, 1994, EXP NEUROL, V130, P31, DOI 10.1006/exnr.1994.1182; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; [Anonymous], 2011, PRESCHOOL LANGUAGE S; [Anonymous], 1976, ECDEU ASSESSMENT MAN; Bagni C, 2012, J CLIN INVEST, V122, P4314, DOI 10.1172/JCI63141; Bartkowska K, 2007, DEVELOPMENT, V134, P4369, DOI 10.1242/dev.008227; Berry-Kravis E, 2014, ANN NEUROL, V76, pS174; Berry-Kravis E, 2004, MENT RETARD DEV D R, V10, P42, DOI 10.1002/mrdd.20007; Bianchi P, 2010, J NEUROSCI, V30, P8769, DOI 10.1523/JNEUROSCI.0534-10.2010; Boccuto L, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-16; Budimirovic DB, 2011, DEV NEUROSCI-BASEL, V33, P379, DOI 10.1159/000330213; Chandana SR, 2005, INT J DEV NEUROSCI, V23, P171, DOI 10.1016/j.ijdevneu.2004.08.002; Chugani DC, 2002, MOL PSYCHIATR, V7, pS16, DOI 10.1038/sj.mp.4001167; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; Clifford S, 2007, J AUTISM DEV DISORD, V37, P301, DOI 10.1007/s10803-006-0160-8; Cordeiro L, 2011, J NEURODEV DISORD, V3, P57, DOI 10.1007/s11689-010-9067-y; Cornish KM, 1999, CORTEX, V35, P263, DOI 10.1016/S0010-9452(08)70799-8; Cornish KM, 1998, NEUROPSYCHOLOGIA, V36, P1239, DOI 10.1016/S0028-3932(97)00162-0; Dawson G, 2012, J AM ACAD CHILD PSY, V51, P1150, DOI 10.1016/j.jaac.2012.08.018; Ecker C., 2010, The sensory processing measure - Home form; Farzin F, 2008, VISION RES, V48, P1471, DOI 10.1016/j.visres.2008.03.019; Fernández E, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00191; Gallego PK, 2014, J NEURODEV DISORD, V6, DOI 10.1186/1866-1955-6-29; Gomez-Mancilla B, 2014, EXPERT OPIN INV DRUG, V23, P125, DOI 10.1517/13543784.2014.857400; Goodnick PJ, 1998, J PSYCHOPHARMACOL, V12, pS5, DOI 10.1177/0269881198012003021; Hagerman R.J., 2002, Fragile X Syndrome: Diagnosis, Treatment and Research, V3rd; Hagerman RJ, 2009, PEDIATRICS, V123, P378, DOI 10.1542/peds.2008-0317; Hanson AC, 2014, INTRACTABLE RARE DIS, V3, P110, DOI 10.5582/irdr.2014.01027; Harris SW, 2008, J INF, V113; Hetrick S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004851.pub2; Indah Winarni T, 2012, AUTISM RES TREAT, V2012; Iossifov I, 2012, NEURON, V74, P285, DOI 10.1016/j.neuron.2012.04.009; Jansson LC, 2012, NEUROSCIENCE, V224, P223, DOI 10.1016/j.neuroscience.2012.08.038; Kaufmann WE, 2004, AM J MED GENET A, V129A, P225, DOI 10.1002/ajmg.a.30229; Kitaichi Y, 2010, EUR J PHARMACOL, V647, P90, DOI 10.1016/j.ejphar.2010.08.026; Kogan CS, 2004, NEUROLOGY, V63, P1634, DOI 10.1212/01.WNL.0000142987.44035.3B; Kogan CS, 2004, BRAIN, V127, P591, DOI 10.1093/brain/awh069; Kuhaneck H.Miller., 2010, Sensory Processing Measure-Preschool (SPM-P): Manual; Lauterborn JC, 2007, J NEUROSCI, V27, P10685, DOI 10.1523/JNEUROSCI.2624-07.2007; Lo ST, 2015, AJIDD-AM J INTELLECT, V120, P315, DOI 10.1352/1944-7558-120.4.315; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Meredith RM, 2011, NEUROBIOL DIS, V41, P104, DOI 10.1016/j.nbd.2010.08.026; Mullen EM., 1995, MULLEN SCALES EARLY; Reinhard SM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00280; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; Rutter M., 2012, AUTISM DIAGNOSTIC OB; Santoro MR, 2012, ANNU REV PATHOL-MECH, V7, P219, DOI 10.1146/annurev-pathol-011811-132457; Scharf SH, 2015, CURR OPIN PHARMACOL, V20, P124, DOI 10.1016/j.coph.2014.11.004; Su T, 2011, PSYCHOPHARMACOLOGY, V215, P291, DOI 10.1007/s00213-010-2130-2; Symons FJ, 2010, AJIDD-AM J INTELLECT, V115, P473, DOI 10.1352/1944-7558-115.6.473; Taler M, 2013, NEUROSCI LETT, V550, P93, DOI 10.1016/j.neulet.2013.06.033; Tassone F, 2012, GENOME MED, V4, DOI 10.1186/gm401; Tejada MI, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/195793; Valdovinos MG, 2009, J DEV PHYS DISABIL, V21, P23, DOI 10.1007/s10882-008-9123-7; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wagner KD, 2005, PROG NEURO-PSYCHOPH, V29, P819, DOI 10.1016/j.pnpbp.2005.03.005; Wang H, 2008, NEURON, V59, P634, DOI 10.1016/j.neuron.2008.06.027; Zingerevich C, 2009, J INTELL DISABIL RES, V53, P11, DOI 10.1111/j.1365-2788.2008.01107.x";60;36;42;1;19;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0196-206X;1536-7312;;J DEV BEHAV PEDIATR;J. Dev. Behav. Pediatr.;OCT;2016;37;8;;;;;619;628;;10.1097/DBP.0000000000000334;http://dx.doi.org/10.1097/DBP.0000000000000334;;;10;"Behavioral Sciences; Psychology, Developmental; Pediatrics";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology; Pediatrics";DZ0KA;27560971;Green Submitted, Green Accepted;;;24/11/2024;WOS:000385526100003;View Full Record in Web of Science
J;"Vandana, P; Simkin, DR; Hendren, RL; Arnold, LE";;;;"Vandana, Pankhuree; Simkin, Deborah R.; Hendren, Robert L.; Arnold, L. Eugene";;;Autism Spectrum Disorder and Complementary- Integrative Medicine;CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA;;;English;Article;;;;;;"Autism treatment; Vitamins; minerals; diet; Essential fatty acids";"EQUINE-ASSISTED ACTIVITIES; ALTERNATIVE MEDICINE; N-ACETYLCYSTEINE; CONTROLLED-TRIAL; DOUBLE-BLIND; OXIDATIVE STRESS; FOLIC-ACID; CHILDREN; OMEGA-3-FATTY-ACIDS; MELATONIN";Most families use Complementary and Integrative Treatment of individuals with autism spectrum disorder. It is prudent that practitioners gain knowledge about the benefits and risks of these interventions to have an open, nonjudgmental conversation with families about their role when creating a comprehensive treatment plan. Due to the perceived safety profile of these interventions, families may fail to recognize and report potential adverse effects and drug interactions. In recent years researchers have focused on conducting randomized placebo-controlled studies on these interven-tions. However, larger and more prolonged-duration studies are needed to establish regular usage. Additionally, it may be beneficial to examine the impact of these treatments on comorbid physical and psychiatric comorbidities that negatively impact the QoL. Elimination diets (gluten and/casein-free) based on the theories that food allergens trigger autoimmunity as well as opioid excess  are shown to improve gastrointes-tinal symptoms in a subset of children with ASD without benefits on the core symp-toms of autism. The current review of data points toward the potential benefits of omega-3 fatty acids on hyperactivity, irritability, and social behaviors in a subset of autistic children, with favorable side effect profiles. Vitamin supplementations including B6 1 Mg and Vit C have been studied in several randomized controlled trials and have not shown statistically significant improvements in ASD symptom-atology. However, Folinic Acid improved stereotypy, attention, and communication in autistic individuals with folate deficiencies. Additionally, multivitamins seem to be reasonably well tolerated and may be beneficial in autistic children with concerns for nutritional deficiencies. Several studies have looked at the role of vitamins, amino acids, and supplements in targeting commonly seen disruptive symptoms such as irritability and sleep-related problems and found limited benefits. One such agent, NAC, can be beneficial in targeting residual irritability and hyperactivity when used in combination with risperidone, with excellent tolerability in autistic children. Dosages of 1800 to 2400 mg/d may be required. Mild gastrointestinal side effects have been reported. NAC can also be beneficial in comorbid impulse control disorders such as excoriation disorder or trichotilomania. The use of exclu-sion diets continues to be popular in children and youth with autism, but the current data review does not support improvement in core autistic symptoms. There are concerns about nutritional deficiencies arising from some elimination diets in chil-dren with Celiac disease. Insomnia is one of the most common clinical complaints in ASD, which significantly impacts the quality of life of children and caregivers alike. Frequently used sedative-hypnotics and sedative agent studies do not show long-term efficacy and may worsen daytime behaviors. Sleep hygiene techniques and CBT-I are still considered first-line treatments for insomnia in children with ASD. The effectiveness of melatonin in improving sleep efficiency and total sleep duration on both objective and subjective measures has been established in several randomized placebo-controlled trials, in dosages of 3 to 6 mg daily. Melatonin may be effective even in children who fail behav-ioral interventions for insomnia and is tolerated well with minimal side effects, such as nightmares in a minority of children. 91 Folinic acid seems to be emerging as a poten-tially safe treatment to target communication and stereotypy but larger sized trials are needed to establish clinical effectiveness and safety. Among other CIM treatments that continue to gain popularity, medical marijuana seems the most controversial. Currently, no double-blinded placed controlled trials studying its impact on either the core symptoms of autism or its comorbid psychiatric symptoms have been completed. Epidiolex, a cannabinoid agent, is FDA approved for complex, severe seizure syndromes associated with ASD. Treatments such as chelation, long-term us-age of antibiotics immunoglobulins, secretin, and hyperbaric oxygen therapy have proven to be ineffective. These treatments have been ranked in the table below using the USPSTF scale of evidence-based literature (Table 1). In cases whereby specific treatments do not have substantial evidence either way yet, the SECS criteria (safe, easy, cheap, and sensible) have also been used to recommend clinical usage (Table 2).;"[Vandana, Pankhuree] Columbia Univ, Ctr Autism & Developing Brain, Div Child & Adolescent Psychiat, Valegos Coll Phys & Surg, 21 Bloomingdale Rd, White Plains, NY 10605 USA; [Simkin, Deborah R.] Emory Univ Sch Med, Dept Psychiat, Atlanta, GA USA; [Hendren, Robert L.] Univ Calif San Francisco, Pritzker Bldg, 675 18th St, San Francisco, CA 94143 USA; [Arnold, L. Eugene] Ohio State Univ, Dept Psychiat & Behav Hlth, Mampbell 395E, 1581 Dodd Dr, Columbus, OH 43210 USA; [Vandana, Pankhuree] 4641 Gulfstarr Dr, Suite 106, Destin, FL 32541 USA";"Columbia University; Emory University; University of California System; University of California San Francisco; University System of Ohio; Ohio State University";"Vandana, P (corresponding author), Columbia Univ, Ctr Autism & Developing Brain, Div Child & Adolescent Psychiat, Valegos Coll Phys & Surg, 21 Bloomingdale Rd, White Plains, NY 10605 USA.;Vandana, P (corresponding author), 4641 Gulfstarr Dr, Suite 106, Destin, FL 32541 USA.";pv2359@cumc.columbia.edu;Vandana, Pankhuree/CAI-9656-2022;;;;;"Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; Adams JB, 2011, BMC PEDIATR, V111, P1471; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; Anderson S, 2016, J AUTISM DEV DISORD, V46, P3344, DOI 10.1007/s10803-016-2869-3; [Anonymous], 2008, J PINEAL RES, P57; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Argou-Cardozo Isadora, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6020029; Arnold LE, 2019, J CHILD ADOL PSYCHOP, V29, P659, DOI 10.1089/cap.2018.0156; Batebi N, 2021, CHILD PSYCHIAT HUM D, V52, P928, DOI 10.1007/s10578-020-01072-8; Bent S, 2014, J AM ACAD CHILD PSY, V53, P658, DOI 10.1016/j.jaac.2014.01.018; Bertoglio K, 2010, J ALTERN COMPLEM MED, V16, P555, DOI 10.1089/acm.2009.0177; Bieleninik L, 2017, JAMA-J AM MED ASSOC, V318, P525, DOI 10.1001/jama.2017.9478; Bjorklund G, 2020, MOL NEUROBIOL, V57, P2314, DOI 10.1007/s12035-019-01742-2; Buckley AW, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a022749; Chang JPC, 2020, CLIN PSYCHOPHARM NEU, V18, P469, DOI 10.9758/cpn.2020.18.4.469; Crabtree MJ, 2009, J BIOL CHEM, V284, P28128, DOI 10.1074/jbc.M109.041483; Croall ID, 2021, NUTRIENTS; Czeczot H, 2008, POSTEP HIG MED DOSW, V62, P405; Davies C, 2021, NEUROSCI BIOBEHAV R, V128, P549, DOI 10.1016/j.neubiorev.2021.07.001; De Fraguas, 2019, PEDIATRICS, P2018; Dean OM, 2017, AUST NZ J PSYCHIAT, V51, P241, DOI 10.1177/0004867416652735; Dimolareva M, 2021, J AUTISM DEV DISORD, V51, P2436, DOI 10.1007/s10803-020-04715-w; FDA, FDA APPR NEW IND DRU; Freeman MP, 2006, J CLIN PSYCHIAT, V67, P1954, DOI 10.4088/JCP.v67n1217; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Frye RE, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.53; Frye RE, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00080; Gabriels RL, 2015, J AM ACAD CHILD PSY, V54, P541, DOI 10.1016/j.jaac.2015.04.007; Geretsegger M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004381.pub3; Ghanizadeh A, 2012, J RES MED SCI, V17, P985; Giulivi C, 2010, JAMA-J AM MED ASSOC, V304, P2389, DOI 10.1001/jama.2010.1706; Goldani AAS, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00100; GOODWIN MS, 1969, MENT HYG, V53, P550; Guo BQ, 2019, NUTR RES, V65, P4, DOI 10.1016/j.nutres.2019.02.003; Hagerman R, OVERVIEW NEURODEVELO, V1st, P1; Hamza M, 2017, ENCEPHALE, V43, P374, DOI 10.1016/j.encep.2016.07.007; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Hendren RL, 2018, AUTISM SPECTRUM DISORDERS, P307; Hendren RL, 2016, J CHILD ADOL PSYCHOP, V26, P774, DOI 10.1089/cap.2015.0159; Hopf KP, 2016, J ALTERN COMPLEM MED, V22, P25, DOI 10.1089/acm.2015.0163; Huang A, 2013, J ALTERN COMPLEM MED, V19, P746, DOI 10.1089/acm.2012.0640; James SJ, 2004, AM J CLIN NUTR, V80, P1611, DOI 10.1093/ajcn/80.6.1611; González-Domenech PJ, 2020, J AUTISM DEV DISORD, V50, P935, DOI 10.1007/s10803-019-04333-1; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Karhson DS, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0203-y; Kern JK, 2011, ALTERN THER HEALTH M, V17, P14; Lee B, 2018, EVID-BASED COMPL ALT; Lee MS, 2012, J AUTISM DEV DISORD, V42, P1671, DOI 10.1007/s10803-011-1409-4; Li GY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192867; Liu C, 2019, MEDICINE; Maras A, 2018, J CHILD ADOL PSYCHOP, V28, P699, DOI 10.1089/cap.2018.0020; Mazahery H, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030661; Mazahery H, 2019, J STEROID BIOCHEM, V187, P9, DOI 10.1016/j.jsbmb.2018.10.017; Mazahery H, 2019, J AUTISM DEV DISORD, V49, P1778, DOI 10.1007/s10803-018-3860-y; Mazahery H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020155; McElhanon BO, 2014, PEDIATRICS, V133, P872, DOI 10.1542/peds.2013-3995; Melke J, 2008, MOL PSYCHIATR, V13, P90, DOI 10.1038/sj.mp.4002016; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; Owen-Smith AA, 2015, RES AUTISM SPECT DIS, V17, P40, DOI 10.1016/j.rasd.2015.05.002; Pagan C, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.120; Parletta N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156432; Perrin JM, 2012, PEDIATRICS, P77; Posar A, 2016, J PEDIATR NEUROSCI, V11, P225, DOI 10.4103/1817-1745.193363; Pu DH, 2013, AUTISM RES, V6, P384, DOI 10.1002/aur.1300; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P276, DOI 10.1055/s-2008-1065354; Ramaekers VT, 2016, BIOCHIMIE, V126, P79, DOI 10.1016/j.biochi.2016.04.005; Rossignol DA, 2021, J PERS MED, V11, DOI 10.3390/jpm11111141; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Rutten BPF, 2009, SCHIZOPHRENIA BULL, V35, P1045, DOI 10.1093/schbul/sbp104; Sadeghiyeh T, 2019, ASIAN J PSYCHIATR, V46, P54, DOI 10.1016/j.ajp.2019.09.016; Shang TT, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0461-2; Sharda M, 2019, LANCET CHILD ADOL HL; Sharda M, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0287-3; Simkin DR, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1075-3; Simkin DR, 2020, OBM INTEGR COMPLEMEN, V5, P040; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Sivertsen B, 2012, AUTISM, V16, P139, DOI 10.1177/1362361311404255; Srinivasan SM, 2018, REV J AUTISM DEV DIS, V5, P156, DOI 10.1007/s40489-018-0130-z; Steluti J, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060539; Surén P, 2013, JAMA-J AM MED ASSOC, V309, P570, DOI 10.1001/jama.2012.155925; Tordjman S, 2013, INT J MOL SCI, V14, P20508, DOI 10.3390/ijms141020508; Trivedi MS, 2014, J NUTR BIOCHEM, V25, P1011, DOI 10.1016/j.jnutbio.2014.05.004; Valicenti-McDermott M, 2014, J CHILD NEUROL, V29, P360, DOI 10.1177/0883073812474489; Vancassel S, 2001, PROSTAG LEUKOTR ESS, V65, P1, DOI 10.1054/plef.2001.0281; Vargason T, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00503; Volkmar F, 2014, J AM ACAD CHILD PSY, P237; Waligóra A, 2019, PSYCHIATR POL, V53, P771, DOI 10.12740/PP/89948; Ward SC, 2013, J AUTISM DEV DISORD, V43, P2190, DOI 10.1007/s10803-013-1773-3; Wink LK, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0088-6; Wong VCN, 2009, J AUTISM DEV DISORD, V39, P454, DOI 10.1007/s10803-008-0644-9; Xiong X, 2016, BIOMED RES INT-UK, V2016, P8";91;2;2;5;16;W B SAUNDERS CO-ELSEVIER INC;PHILADELPHIA;1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA;1056-4993;1558-0490;;CHILD ADOL PSYCH CL;Child Adolesc. Psychiatr. N. Am.;APR;2023;32;2;;;;;469;494;;10.1016/j.chc.2022.08.004;http://dx.doi.org/10.1016/j.chc.2022.08.004;;MAY 2023;26;Psychiatry;Social Science Citation Index (SSCI);Psychiatry;H7IC2;37147047;;;;24/11/2024;WOS:000997646300001;View Full Record in Web of Science
J;"Arnold, LE; Luna, RA; Williams, K; Chan, J; Parker, RA; Wu, QL; Hollway, JA; Jeffs, A; Lu, F; Coury, DL; Hayes, C; Savidge, T";;;;"Arnold, L. Eugene; Luna, Ruth Ann; Williams, Kent; Chan, James; Parker, Robert A.; Wu, Qinglong; Hollway, Jill A.; Jeffs, Adelina; Lu, Frances; Coury, Daniel L.; Hayes, Caitlin; Savidge, Tor";;;Probiotics for Gastrointestinal Symptoms and Quality of Life in Autism: A Placebo-Controlled Pilot Trial;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism spectrum disorder; probiotics; gastrointestinal problems; autism; anxiety; quality of life";"ABERRANT BEHAVIOR CHECKLIST; IRRITABLE-BOWEL-SYNDROME; GUT MICROBIOTA; DOUBLE-BLIND; SPECTRUM; RELIABILITY; CHILDREN; SCALE; PSYCHOBIOTICS; LACTOBACILLUS";Objective: A randomized pilot trial of gastrointestinal (GI) symptoms targeting probiotic for quality of life in autism spectrum disorder (ASD). Methods: Thirteen children, 3-12 years of age with ASD, anxiety, and GI symptoms, were randomized into a probiotic crossover trial of 8 weeks each on VISBIOME and placebo separated by a 3-week washout. VISBIOME contains eight probiotic species, mostly Lactobacillus and Bifidobacterium. Primary outcome was the Pediatric Quality of Life Inventory (PedsQL) GI module. Secondary outcomes included gut microbiota analysis, the Parent-Rated Anxiety Scale for ASD (PRAS-ASD), and parent-selected target symptoms. A mixed analysis model was applied. Results: Thirteen children were randomized, with 10 completing the study (77% retention): 6 in probiotic/placebo sequence, 4 in placebo/probiotic sequence. Adherence to study treatment was 96%. There were no serious adverse events (AEs), and more nonserious AEs occurred with placebo than with probiotic, including those attributable to treatment. Only 6 of the 10 guessed the correct treatment at the end of week 8. Over the 19-week trial, each outcome improved from baseline and PedsQL correlated significantly with abundance of Lactobacillus without discernable changes to microbiota composition/diversity. Although probiotic showed more improvement than placebo, PedsQL and PRAS-ASD were not statistically significant, as expected at this sample size. PedsQL effect size was d = 0.49 by the general model and d = 0.79 by simple comparison of week 8 changes. A parent-selected target symptom showed significant improvement in GI complaints on probiotic compared with placebo (p = 0.02, d = 0.79). Probiotic effects carried over through the 3-week washout. Conclusion: The VISBIOME formulation was safe and suggested a health benefit in children with ASD and GI symptoms who retained Lactobacillus. The moderate effect size compared with placebo warrants a larger trial using a parallel-group design.;"[Arnold, L. Eugene; Hollway, Jill A.; Jeffs, Adelina] Ohio State Univ, Dept Psychiat, 395E McCampbell Hall,1581 Dodd Dr, Columbus, OH 43210 USA; [Arnold, L. Eugene; Hollway, Jill A.; Jeffs, Adelina] Ohio State Univ, Nisonger Ctr, Columbus, OH 43210 USA; [Luna, Ruth Ann; Wu, Qinglong; Savidge, Tor] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Luna, Ruth Ann; Wu, Qinglong; Savidge, Tor] Texas Childrens Hosp, Dept Pathol, Texas Childrens Microbiome Ctr, Houston, TX 77030 USA; [Williams, Kent; Coury, Daniel L.; Hayes, Caitlin] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA; [Chan, James; Parker, Robert A.; Lu, Frances] Massachusetts Gen Hosp, Boston, MA 02114 USA";"University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Baylor College of Medicine; Baylor College of Medicine; Baylor College Medical Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Harvard University; Massachusetts General Hospital";Arnold, LE (corresponding author), Ohio State Univ, Dept Psychiat, 395E McCampbell Hall,1581 Dodd Dr, Columbus, OH 43210 USA.;l.arnold@osumc.edu;Coury, Daniel/L-6556-2019;"Coury, Daniel/0000-0001-9754-3914; Lu, Frances/0000-0003-2031-7884";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [UA3 MC11054]; Clinical and Translational Science award from the National Center for Translational Sciences [8UL18TR000090-05]; Autism Speaks [P30-DK56338, U01-AI24290]";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS); Clinical and Translational Science award from the National Center for Translational Sciences; Autism Speaks";This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under cooperative agreement UA3 MC11054-Autism Intervention Research Network on Physical Health, and by a Clinical and Translational Science award 8UL18TR000090-05 to Ohio State University from the National Center for Translational Sciences, and Autism Speaks, P30-DK56338, U01-AI24290 awards to Baylor College of Medicine. This work was conducted through the Autism Speaks Autism Treatment Network serving as the Autism Intervention Research Network on Physical Health. The content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.;"Abidin R. R., 2012, Parenting stress index; Abidin R. R., 1995, PARENTING STRESS IND; AMAN MG, 1987, AM J MENT DEF, V92, P237; AMAN MG, 1985, AM J MENT DEF, V89, P492; AMAN MG, 1985, AM J MENT DEF, V89, P485; Arnold LE, 2003, J AM ACAD CHILD PSY, V42, P1443, DOI 10.1097/00004583-200312000-00011; Bercik P, 2011, NEUROGASTROENT MOTIL, V23, P1132, DOI 10.1111/j.1365-2982.2011.01796.x; Bercik P, 2011, GASTROENTEROLOGY, V141, P599, DOI 10.1053/j.gastro.2011.04.052; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Burnet PWJ, 2013, BIOL PSYCHIAT, V74, P708, DOI 10.1016/j.biopsych.2013.08.002; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Christensen Deborah L, 2018, MMWR Surveill Summ, V65, P1, DOI [10.15585/mmwr.ss6503a1, 10.15585/mmwr.ss6513a1]; Christian LM, 2015, BRAIN BEHAV IMMUN, V45, P118, DOI 10.1016/j.bbi.2014.10.018; Coccorullo P, 2010, J PEDIATR-US, V157, P598, DOI 10.1016/j.jpeds.2010.04.066; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Cussotto S, 2019, PSYCHOPHARMACOLOGY, V236, P1671, DOI 10.1007/s00213-018-5006-5; De Angelis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076993; de Theije CGM, 2014, BRAIN BEHAV IMMUN, V37, P197, DOI 10.1016/j.bbi.2013.12.005; Dinan TG, 2013, BIOL PSYCHIAT, V74, P720, DOI 10.1016/j.biopsych.2013.05.001; Diop L, 2008, NUTR RES, V28, P1, DOI 10.1016/j.nutres.2007.10.001; Doshi-Velez F, 2015, INFLAMM BOWEL DIS, V21, P2281, DOI 10.1097/MIB.0000000000000502; Ferguson BJ, 2017, AUTISM RES, V10, P276, DOI 10.1002/aur.1646; Guandalini S, 2010, J PEDIATR GASTR NUTR, V51, P24, DOI 10.1097/MPG.0b013e3181ca4d95; Hildebrand F, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-30; Hollway JA, 2013, J AUTISM DEV DISORD, V43, P2830, DOI 10.1007/s10803-013-1830-y; Hotel ACP., 2001, PREVENTION, V5, P1; Hsiao EY, 2013, CELL, V155, P1451, DOI 10.1016/j.cell.2013.11.024; Kim HJ, 2005, NEUROGASTROENT MOTIL, V17, P687, DOI 10.1111/j.1365-2982.2005.00695.x; Kohane IS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033224; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li QR, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00120; Lord C., 2012, AUTISM DIAGNOSTIC OB; Louis P, 2012, DIGEST DIS SCI, V57, P1987, DOI 10.1007/s10620-012-2286-1; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Luna RA, 2017, CELL MOL GASTROENTER, V3, P218, DOI 10.1016/j.jcmgh.2016.11.008; MAZUREK MO, 2012, J ABNORM CHILD PSYCH, V41, P65; Messaoudi M, 2011, BRIT J NUTR, V105, P755, DOI 10.1017/S0007114510004319; Needham BD, 2018, DEV NEUROBIOL, V78, P474, DOI 10.1002/dneu.22581; Owens JA, 2000, SLEEP, V23, P1043; Rao AV, 2009, GUT PATHOG, V1, DOI 10.1186/1757-4749-1-6; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Rutter M., 2004, Autism Diagnostic Observation Schedule (ADOS): Manual; Rutter M., 2003, ADI R AUTISM DIAGNOS; Sadeghzadeh M, 2014, INT J PEDIAT, V2014, DOI 10.1155/2014/937212; SCAHILL L, 2017, ANN M AM AC CHILD AD; Scahill L, 2019, J AM ACAD CHILD PSY, V58, P887, DOI 10.1016/j.jaac.2018.10.016; Tiequn B, 2015, INTERNAL MED, V54, P243, DOI 10.2169/internalmedicine.54.2710; Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043; Tomova A, 2015, PHYSIOL BEHAV, V138, P179, DOI 10.1016/j.physbeh.2014.10.033; Varni JW, 2014, J PEDIATR GASTR NUTR, V59, P347, DOI 10.1097/MPG.0000000000000414; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2006, QUAL LIFE RES, V15, P203, DOI 10.1007/s11136-005-1388-z; West R., 2013, PROBIOTICS HLTH, V1, P102, DOI DOI 10.4172/2329-8901.1000102; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593; Zmora N, 2018, CELL, V174, P1388, DOI 10.1016/j.cell.2018.08.041";57;84;87;3;55;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;nov-01;2019;29;9;;;;;659;669;;10.1089/cap.2018.0156;http://dx.doi.org/10.1089/cap.2018.0156;;AUG 2019;11;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";JK5NY;31478755;Green Published;;;24/11/2024;WOS:000485061900001;View Full Record in Web of Science
J;"Reid, SM; Westbury, C; Guzys, AT; Reddihough, DS";;;;"Reid, Susan M.; Westbury, Christine; Guzys, Angela T.; Reddihough, Dinah S.";;;Anticholinergic medications for reducing drooling in children with developmental disability;DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY;;;English;Article;;;;;;;"CEREBRAL-PALSY; GLYCOPYRROLATE; EFFICACY; SIALORRHEA; MANAGEMENT";"Aim To determine: the effectiveness of three anticholinergic medications in reducing drooling in children with developmental disabilities (such as cerebral palsy, intellectual disability, and autism spectrum disorder), the frequency and nature of side effects, and their impact on treatment discontinuation. Method After prescription of benzhexol hydrochloride, glycopyrrolate, or scopolamine patches at a tertiary saliva control clinic, all carers of 110 consecutive, eligible patients were recruited over a 5-year period. They provided data for 52 weeks, or until drug discontinuation, on compliance, drooling, adverse effects, and reasons for cessation. We evaluated and compared best drooling response, side effects, and drug cessation rates using survival analysis, and the effect of baseline variables on the discontinuation rate using proportional hazards regression. Results Among 110 participants (71 males, 39 females; mean age 8y 5mo [SD 4y 3mo], range 1y 11mo-18y 11mo), benzhexol, glycopyrrolate, and scopolamine were prescribed 81, 62, and 17 times respectively, with respective response rates of 85%, 75%, and 65%. Poor head control and poor oromotor function were predictive of poor response. Side effects frequently prompted drug cessation in males more than females (hazard ratio 1.8 [95% confidence interval 1.0-3.2], p=0.048). Glycopyrrolate had the fewest side effects. Interpretation Benzhexol, glycopyrrolate, and scopolamine reduce drooling, but improvement is offset by adverse side effects. Overall, glycopyrrolate performs best. What this paper adds In drooling, glycopyrrolate produced the greatest improvement with fewer side effects compared with benzhexol and scopolamine. Poor head control and poor oromotor function were associated with poor response. Medication side effects were common and often led to treatment discontinuation. Behavioural issues instigated cessation of benzhexol more often in males than females.";"[Reid, Susan M.; Westbury, Christine; Guzys, Angela T.; Reddihough, Dinah S.] Murdoch Childrens Res Inst, Neurodisabil & Rehabil, Melbourne, Vic, Australia; [Reid, Susan M.; Reddihough, Dinah S.] Royal Childrens Hosp, Dept Neurodev & Disabil, Melbourne, Vic, Australia; [Reid, Susan M.; Reddihough, Dinah S.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia";"Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne";Reid, SM (corresponding author), Murdoch Childrens Res Inst, Neurodisabil & Rehabil, 50 Remington Rd, Parkville, Vic 3052, Australia.;sue.reid@mcri.edu.au;Reid, Susan/B-1684-2015;"Reddihough, Dinah/0000-0003-3634-7906; Reid, Sue/0000-0001-9415-5246";"Australia's National Health and Medical Research Council [1072442]; Lorenzo and Pamela Galli Foundation; National Health and Medical Research Council of Australia [1072442] Funding Source: NHMRC";"Australia's National Health and Medical Research Council(National Health & Medical Research Council (NHMRC) of Australia); Lorenzo and Pamela Galli Foundation; National Health and Medical Research Council of Australia(National Health & Medical Research Council (NHMRC) of Australia)";SMR received salary support from Australia's National Health and Medical Research Council in the form of an Early Career Fellowship (#1072442) and from the Lorenzo and Pamela Galli Foundation. AG received salary support from the Trailblazers and DoBees Auxiliaries. We extend our sincere thanks to the participating families and members of the multidisciplinary team at the Melbourne Royal Children's Hospital Saliva Control Clinic.;"[Anonymous], COCHRANE DATABASE SY; Bachrach SJ, 1998, CLIN PEDIATR, V37, P485, DOI 10.1177/000992289803700805; Blasco PA, 1996, ARCH PEDIAT ADOL MED, V150, P932, DOI 10.1001/archpedi.1996.02170340046009; CAMPBRUNO JA, 1989, DEV MED CHILD NEUROL, V31, P309; Evatt ML, 2011, NEUROPSYCH DIS TREAT, V7, P543, DOI 10.2147/NDT.S14028; Hallett K B, 1995, Spec Care Dentist, V15, P234, DOI 10.1111/j.1754-4505.1995.tb00524.x; Jongerius PH, 2003, ARCH DIS CHILD, V88, P911, DOI 10.1136/adc.88.10.911; LEWIS DW, 1994, DEV MED CHILD NEUROL, V36, P484; Liu XH, 2012, STAT MED, V31, P2676, DOI 10.1002/sim.4509; Mier RJ, 2000, ARCH PEDIAT ADOL MED, V154, P1214, DOI 10.1001/archpedi.154.12.1214; Owen S E, 1992, Int J Rehabil Res, V15, P166, DOI 10.1097/00004356-199206000-00011; Parkes J, 2010, DEV MED CHILD NEUROL, V52, P1113, DOI 10.1111/j.1469-8749.2010.03765.x; Parr JR, 2018, ARCH DIS CHILD, V103, P371, DOI 10.1136/archdischild-2017-313763; REDDIHOUGH D, 1990, DEV MED CHILD NEUROL, V32, P985; Reid SM, 2019, J PLAST RECONSTR AES, V72, P1193, DOI 10.1016/j.bjps.2019.02.020; Reid SM, 2012, DEV MED CHILD NEUROL, V54, P1032, DOI 10.1111/j.1469-8749.2012.04382.x; Reid SM, 2010, DEV MED CHILD NEUROL, V52, pe23, DOI 10.1111/j.1469-8749.2009.03519.x; Stern LM, 1997, J PAEDIATR CHILD H, V33, P52, DOI 10.1111/j.1440-1754.1997.tb00991.x; Thomas-Stonell N, 1988, Dysphagia, V3, P73, DOI 10.1007/BF02412423; Zeller RS, 2012, THER CLIN RISK MANAG, V8, P25, DOI 10.2147/TCRM.S27362; Zeller RS, 2012, THER CLIN RISK MANAG, V8, P15, DOI 10.2147/TCRM.S26893";21;23;25;1;6;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0012-1622;1469-8749;;DEV MED CHILD NEUROL;Dev. Med. Child Neurol.;MAR;2020;62;3;;;;;346;+;;10.1111/dmcn.14350;http://dx.doi.org/10.1111/dmcn.14350;;sept-19;9;"Clinical Neurology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics";KH2YO;31495925;Green Published, Bronze;;;24/11/2024;WOS:000485391100001;View Full Record in Web of Science
J;"Carbon, M; Kapoor, S; Sheridan, E; Al-Jadiri, A; Azzo, S; Sarkaria, T; Kane, JM; Saito, E; Correll, CU";;;;"Carbon, Maren; Kapoor, Sandeep; Sheridan, Eva; Al-Jadiri, Aseel; Azzo, Sally; Sarkaria, Tania; Kane, John M.; Saito, Ema; Correll, Christoph U.";;;Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"extrapyramidal; parkinsonism; dyskinesia; second-generation antipsychotic; youth";"BIPOLAR I DISORDER; LONG-TERM SAFETY; SIMPSON-ANGUS SCALE; DOUBLE-BLIND; OPEN-LABEL; ADOLESCENT SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTICS; CHILDREN; PLACEBO; TOLERABILITY";"Objective: Second-generation antipsychotic (SGA) effects in youth were monitored to quantify extrapyramidal side effects (EPS) and to identify risk profiles for treatment-emergent EPS. Method: Data were analyzed for the nonrandomized, prospective Second-generation Antipsychotic Treatment Indications, Effectiveness and Tolerability in Youth (SATIETY) inception cohort study. EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale. Drug-induced parkinsonism was defined by incident mean SAS score >0.33, anticholinergic initiation, or increasing total SAS score >= 2 in patients with baseline EPS. Results: In 342 youth aged 13.6 +/- 3.5 years (male = 58.2%, antipsychotic-naive = 65.8%), 15.2% developed drug-induced parkinsonism. Raw SGA-grouped drug-induced parkinsonism rates were as follows: quetiapine = 1.5%, olanzapine = 13.8%, risperidone = 16.1%, ziprasidone = 20.0%, and aripiprazole = 27.3%. SGA type, dose, higher age, and lower baseline functioning were jointly associated with drug-induced parkinsonism (R-2 = 0.18; p < .0001). Controlling for these factors, drug-induced parkinsonism rates were significantly lower only for quetiapine and olanzapine. Subjectively reported EPS (5%), EPS-related treatment discontinuation (3.3%), and anticholinergic initiation (3%) were infrequent. Anticholinergic initiation was most frequent with risperidone (10.2%; p = .0004). Treatment-emergent dyskinesia ranged from 4.5% (aripiprazole) to 15.5% (olanzapine). SGA type, younger age, white race/ethnicity, and baseline AIMS were jointly associated with treatment-emergent dyskinesia (R-2 = 0.31; p < .0001). Controlling for these factors, treatment-emergent dyskinesia rates differed among SGA subgroups, with higher rates with olanzapine and ziprasidone. At baseline, psychostimulant use was associated with dyskinesia, and number of psychotropic come-dications was associated with subjective EPS. Conclusion: In youth, SGA-related EPS rates did not generally exceed those reported in adults, with particularly low rates with quetiapine and olanzapine.";"[Carbon, Maren; Kapoor, Sandeep; Azzo, Sally; Sarkaria, Tania; Kane, John M.; Saito, Ema; Correll, Christoph U.] Hillside Hosp, Psychiat, Glen Oaks, NY 11004 USA; [Carbon, Maren] Charite, Berlin, Germany; [Kapoor, Sandeep; Kane, John M.; Correll, Christoph U.] Feinstein Inst Med Res, Manhasset, NY USA; [Kane, John M.; Correll, Christoph U.] Hofstra North Shore Long Isl Jewish Sch Med, Hempstead, NY USA; [Al-Jadiri, Aseel] New York Methodist Hosp, Brooklyn, NY USA";"Northwell Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Northwell Health; Hofstra University; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital";Correll, CU (corresponding author), Hillside Hosp, Psychiat, 75-59 263rd St, Glen Oaks, NY 11004 USA.;ccorrell@nshs.edu;"Correll, Christoph/D-3530-2011; Kane, Jeremy/JTU-1481-2023";"Kapoor, Sandeep/0000-0002-1581-6403; Kane, John/0000-0002-2628-9442";"Zucker Hillside Hospital National Institute of Mental Health (NIMH) Advanced Center for Intervention and Services Research for the Study of Schizophrenia [P30MH090590]; Feinstein Institute for Medical Research North Shore-Long Island Jewish Health System General Clinical Research Center; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01RR018535]";"Zucker Hillside Hospital National Institute of Mental Health (NIMH) Advanced Center for Intervention and Services Research for the Study of Schizophrenia(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Feinstein Institute for Medical Research North Shore-Long Island Jewish Health System General Clinical Research Center; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))";This work is supported in parts by The Zucker Hillside Hospital National Institute of Mental Health (NIMH) Advanced Center for Intervention and Services Research for the Study of Schizophrenia (P30MH090590, Dr. Kane), and by The Feinstein Institute for Medical Research North Shore-Long Island Jewish Health System General Clinical Research Center, Grant #M01RR018535 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).;"Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P869, DOI 10.1089/cap.2005.15.869; [Anonymous], COCHRANE DATABASE SY; [Anonymous], DRUG SAFETY; Arango C, 2009, EUR CHILD ADOLES PSY, V18, P418, DOI 10.1007/s00787-009-0749-5; Balázs J, 2007, J CHILD ADOL PSYCHOP, V17, P378, DOI 10.1089/cap.2006.0055; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; Blanchet PJ, 2014, J CLIN PSYCHOPHARM, V34, P36, DOI 10.1097/JCP.0b013e3182a6a2e3; Castro-Fornieles J, 2008, J CHILD ADOL PSYCHOP, V18, P327, DOI 10.1089/cap.2007.0138; Correll CU, 2007, J CHILD ADOL PSYCHOP, V17, P647, DOI 10.1089/cap.2006.0117; Correll CU, 2008, J AM ACAD CHILD PSY, V47, P9, DOI 10.1097/chi.0b013e31815b5cb1; Correll CU, 2010, BIPOLAR DISORD, V12, P116, DOI 10.1111/j.1399-5618.2010.00798.x; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Correll CU, 2006, CHILD ADOL PSYCH CL, V15, P177, DOI 10.1016/j.chc.2005.08.007; DelBello MP, 2008, J CHILD ADOL PSYCHOP, V18, P491, DOI 10.1089/cap.2008.008; Duggan L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001359.pub2; Esper CD, 2008, MOVEMENT DISORD, V23, P401, DOI 10.1002/mds.21854; Findling RL, 2008, AM J PSYCHIAT, V165, P1432, DOI 10.1176/appi.ajp.2008.07061035; Findling RL, 2008, J CLIN PSYCHIAT, V69, P149, DOI 10.4088/JCP.v69n0120; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P531, DOI 10.1089/cap.2012.0068; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P545, DOI 10.1089/cap.2012.0029; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P490, DOI 10.1089/cap.2012.0092; Findling RL, 2013, BIPOLAR DISORD, V15, P138, DOI 10.1111/bdi.12042; Findling RL, 2012, J CHILD ADOL PSYCHOP, V22, P327, DOI 10.1089/cap.2011.0092; Findling RL, 2009, J CHILD ADOL PSYCHOP, V19, P431, DOI 10.1089/cap.2008.0111; Fraguas D, 2011, EUR NEUROPSYCHOPHARM, V21, P621, DOI 10.1016/j.euroneuro.2010.07.002; Frazier JA, 2001, J CHILD ADOL PSYCHOP, V11, P239, DOI 10.1089/10445460152595568; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Haas M, 2009, J CHILD ADOL PSYCHOP, V19, P611, DOI 10.1089/cap.2008.0144; Haas M, 2009, BIPOLAR DISORD, V11, P687, DOI 10.1111/j.1399-5618.2009.00750.x; Haas M, 2009, BRIT J PSYCHIAT, V194, P158, DOI 10.1192/bjp.bp.107.046177; Hong IS, 2010, ANN PHARMACOTHER, V44, P1171, DOI 10.1345/aph.1M643; Ishikawa T, 1996, J NUCL MED, V37, P1760; Janno S, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-5; Kane John M, 2011, J Clin Psychiatry, V72, pe07, DOI 10.4088/JCP.9101tx3c; Koning JPF, 2010, SCHIZOPHRENIA BULL, V36, P723, DOI 10.1093/schbul/sbn146; Kryzhanovskaya LA, 2009, J CLIN PSYCHIAT, V70, P247, DOI 10.4088/JCP.08m03538; Leucht S, 2013, LANCET, V382, P951, DOI 10.1016/S0140-6736(13)60733-3; Lewis R, 1998, CAN J PSYCHIAT, V43, P596, DOI 10.1177/070674379804300608; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McConville B, 2003, J CHILD ADOL PSYCHOP, V13, P75, DOI 10.1089/104454603321666216; Miller DD, 2008, BRIT J PSYCHIAT, V193, P279, DOI 10.1192/bjp.bp.108.050088; Mozes T, 2006, J CHILD ADOL PSYCHOP, V16, P393, DOI 10.1089/cap.2006.16.393; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Pathak S, 2013, J CLIN PSYCHIAT, V74, pE100, DOI 10.4088/JCP.11m07424; Potkin SG, 2003, ARCH GEN PSYCHIAT, V60, P681, DOI 10.1001/archpsyc.60.7.681; Rattehalli RD, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006918.pub2, http://dx.doi.org/10.1002/14651858.CD006918]; SCHOOLER NR, 1982, ARCH GEN PSYCHIAT, V39, P486; Sikich L, 2008, AM J PSYCHIAT, V165, P1420, DOI 10.1176/appi.ajp.2008.08050756; SIMPSON GM, 1970, ACTA PSYCHIAT SCAND, P11; Srisurapanont M., 2004, The Cochrane Database of Systematic Reviews, DOI [DOI 10.1002/14651858.CD000967.PUB2, 10.1002/14651858.CD000967.pub2]; Stentebjerg-Olesen M, 2013, J CHILD ADOL PSYCHOP, V23, P665, DOI 10.1089/cap.2013.0007; Swadi HS, 2010, INT CLIN PSYCHOPHARM, V25, P1, DOI 10.1097/YIC.0b013e3283320511; Tauscher J, 2002, PSYCHOPHARMACOLOGY, V162, P42, DOI 10.1007/s00213-002-1082-6; Tohen M, 2007, AM J PSYCHIAT, V164, P1547, DOI 10.1176/appi.ajp.2007.06111932; Weiden Peter J, 2007, J Psychiatr Pract, V13, P13, DOI 10.1097/00131746-200701000-00003; Zalsman G, 2003, J CHILD ADOL PSYCHOP, V13, P319, DOI 10.1089/104454603322572651";58;29;32;4;20;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;SEP;2015;54;9;;;;;718;727;;10.1016/j.jaac.2015.06.015;http://dx.doi.org/10.1016/j.jaac.2015.06.015;;;10;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";CQ0BL;26299293;Green Accepted;;;24/11/2024;WOS:000360259500006;View Full Record in Web of Science
J;"Mazahery, H; Conlon, C; Beck, KL; Kruger, MC; Stonehouse, W; Camargo, CA ; Meyer, BJ; Tsang, B; Mugridge, O; von Hurst, PR";;;;"Mazahery, Hajar; Conlon, Cathryn; Beck, Kathryn L.; Kruger, Marlena C.; Stonehouse, Welma; Camargo, Carlos A., Jr.; Meyer, Barbara J.; Tsang, Bobby; Mugridge, Owen; von Hurst, Pamela R.";;;Vitamin D and omega-3 fatty acid supplements in children with autism spectrum disorder: a study protocol for a factorial randomised, double-blind, placebo-controlled trial;TRIALS;;;English;Article;;;;;;"Autism; ASD; Vitamin D; Omega-3 fatty acids; Supplements";"ABERRANT BEHAVIOR CHECKLIST; DOCOSAHEXAENOIC ACID SUPPLEMENTATION; POLYUNSATURATED FATTY-ACIDS; GASTROINTESTINAL PROBLEMS; NUTRITIONAL-STATUS; UNITED-STATES; YOUNG-ADULTS; D DEFICIENCY; D-RECEPTOR; PREVALENCE";Background: There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (DHA), have the potential to significantly improve the symptoms of autism spectrum disorder (ASD). However, there are no trials that have measured the effect of both vitamin D and n-3 LCPUFA supplementation on autism severity symptoms. The objective of this 2 x 2 factorial trial is to investigate the effect of vitamin D, n-3 LCPUFAs or a combination of both on core symptoms of ASD. Methods/design: Children with ASD living in New Zealand (n = 168 children) will be randomised to one of four treatments daily: vitamin D (2000 IU), n-3 LCPUFAs (722 mg DHA), vitamin D (2000 IU) + n-3 LCPUFAs (722 mg DHA) or placebo for 12 months. All researchers, participants and their caregivers will be blinded until the data analysis is completed, and randomisation of the active/placebo capsules and allocation will be fully concealed from all mentioned parties. The primary outcome measures are the change in social-communicative functioning, sensory processing issues and problem behaviours between baseline and 12 months. A secondary outcome measure is the effect on gastrointestinal symptoms. Baseline data will be used to assess and correct basic nutritional deficiencies prior to treatment allocation. For safety measures, serum 25-hydroxyvitamin D 25(OH) D and calcium will be monitored at baseline, 6 and 12 months, and weekly compliance and gastrointestinal symptom diaries will be completed by caregivers throughout the study period. Discussion: To our knowledge there are no randomised controlled trials assessing the effects of both vitamin D and DHA supplementation on core symptoms of ASD. If it is shown that either vitamin D, DHA or both are effective, the trial would reveal a non-invasive approach to managing ASD symptoms.;"[Mazahery, Hajar; Conlon, Cathryn; Beck, Kathryn L.; Kruger, Marlena C.; Mugridge, Owen; von Hurst, Pamela R.] Massey Univ, Sch Food & Nutr, Inst Food Sci & Technol, Auckland, New Zealand; [Stonehouse, Welma] CSIRO, Food Nutr & Bioprod, Adelaide, SA, Australia; [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA; [Meyer, Barbara J.] Univ Wollongong, Sch Med, Illawarra, NSW 2522, Australia; [Tsang, Bobby] North Shore Hosp, Waitemata Dist Hlth Board, Auckland, New Zealand";"Massey University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Harvard University; Massachusetts General Hospital; Harvard Medical School; University of Wollongong";von Hurst, PR (corresponding author), Massey Univ, Sch Food & Nutr, Inst Food Sci & Technol, Auckland, New Zealand.;p.r.vonhurst@massey.ac.nz;"Meyer, Barbara/AAC-6078-2019; Stonehouse, Welma/H-2316-2013; Camargo, Carlos/C-2145-2008";"Meyer, Barbara J/0000-0001-7962-7890; Stonehouse, Welma/0000-0002-2856-4962; Beck, Kathryn Louise/0000-0003-1825-1927; Camargo, Carlos/0000-0002-5071-7654; Mazahery, Hajar/0000-0002-3743-2152";Massey University Strategic Innovation Fund, Massey University, New Zealand;Massey University Strategic Innovation Fund, Massey University, New Zealand;Partial funding for the study was provided by Massey University Strategic Innovation Fund, Massey University, New Zealand to cover the pilot study in 2015. Additional support has been provided by Douglas Nutrition, Pty. Ltd., NZ who are supplying the active supplement and identical-appearing placebo, but who have no input into study design, implementation, data management, statistical analysis or reporting of results.;"Adams JB, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-111; Adams JB, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-22; Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; AMAN MG, 1985, AM J MENT DEF, V89, P485; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16; [Anonymous], 2010, WHAT DOES ASD LOOK R; [Anonymous], J AM DIET ASS; [Anonymous], SOCIAL RESPONSIVENES; [Anonymous], NZ AUTISM SPECTRUM D; [Anonymous], 2000, Autism, DOI [10.1177/1362361300004002002, DOI 10.1177/1362361300004002002]; ASLAN A, 1992, AM J GASTROENTEROL, V87, P432; Baumgartner J, 2012, AM J CLIN NUTR, V96, P1327, DOI 10.3945/ajcn.112.041004; Bener A, 2014, J PEDIATR NEUROSCI, V9, P227, DOI 10.4103/1817-1745.147574; Bent S, 2011, J AUTISM DEV DISORD, V41, P545, DOI 10.1007/s10803-010-1078-8; Bloch MH, 2011, J AM ACAD CHILD PSY, V50, P991, DOI 10.1016/j.jaac.2011.06.008; Bölte S, 2011, J AUTISM DEV DISORD, V41, P66, DOI 10.1007/s10803-010-1024-9; Boso M, 2010, MED SCI MONITOR, V16, pCR213; Brigandi SA, 2015, INT J MOL SCI, V16, P10061, DOI 10.3390/ijms160510061; Brinkley J, 2007, J AUTISM DEV DISORD, V37, P1949, DOI 10.1007/s10803-006-0327-3; Brown T., 2010, New Zealand journal of occupational therapy, V57, P56, DOI DOI 10.3316/INFORMIT.431186569500027; Carter MJ, 2014, THER RECREAT J, V48, P275; Chaidez V, 2014, J AUTISM DEV DISORD, V44, P1117, DOI 10.1007/s10803-013-1973-x; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; CLEMENTS MR, 1992, CLIN ENDOCRINOL, V37, P17, DOI 10.1111/j.1365-2265.1992.tb02278.x; Crockett MJ, 2008, SCIENCE, V320, P1739, DOI 10.1126/science.1155577; de Magistris L, 2010, J PEDIATR GASTR NUTR, V51, P418, DOI 10.1097/MPG.0b013e3181dcc4a5; Dovey TM, 2013, APPETITE, V69, P108, DOI 10.1016/j.appet.2013.05.019; Dyck MC, 2011, MED HYPOTHESES, V77, P326, DOI 10.1016/j.mehy.2011.05.006; Enko D, 2014, CLIN LAB, V60, P1541, DOI 10.7754/Clin.Lab.2014.131114; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Fox N., 1998, Trent focus for research and development in primary healthcare: How to use observations in a research porject: Trent Focus; Frazier TW, 2014, J AUTISM DEV DISORD, V44, P2013, DOI 10.1007/s10803-014-2081-2; Gallo S, 2013, JAMA-J AM MED ASSOC, V309, P1785, DOI 10.1001/jama.2013.3404; Graf-Myles J, 2013, J DEV BEHAV PEDIATR, V34, P449, DOI 10.1097/DBP.0b013e3182a00d17; Grant WB, 2013, DERM-ENDOCRINOL, V5, DOI 10.4161/derm.22942; Haubner LY, 2002, BRAIN RES BULL, V58, P1, DOI 10.1016/S0361-9230(01)00764-X; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011-0385, 10.1210/jc.2011-1193]; Horvath Karoly, 2002, Curr Gastroenterol Rep, V4, P251, DOI 10.1007/s11894-002-0071-6; Hyppönen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Fernández-Andrés MI, 2015, RES DEV DISABIL, V38, P202, DOI 10.1016/j.ridd.2014.12.034; Jia FY, 2015, PEDIATRICS, V135, pE196, DOI 10.1542/peds.2014-2121; Jorgensen SP, 2010, ALIMENT PHARM THER, V32, P377, DOI 10.1111/j.1365-2036.2010.04355.x; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kocovská E, 2014, J AUTISM DEV DISORD, V44, P2996, DOI 10.1007/s10803-014-2155-1; Leekam SR, 2007, J AUTISM DEV DISORD, V37, P894, DOI 10.1007/s10803-006-0218-7; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Logan VF, 2013, BRIT J NUTR, V109, P1082, DOI 10.1017/S0007114512002851; Mankad D, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0010-7; Marí-Bauset S, 2015, J AUTISM DEV DISORD, V45, P203, DOI 10.1007/s10803-014-2205-8; Mazahery H, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040236; Mazurek MO, 2013, J ABNORM CHILD PSYCH, V41, P165, DOI 10.1007/s10802-012-9668-x; McNamara RK, 2006, PROSTAG LEUKOTR ESS, V75, P329, DOI 10.1016/j.plefa.2006.07.010; McNamara RK, 2010, AM J CLIN NUTR, V91, P1060, DOI 10.3945/ajcn.2009.28549; Ministry of Health, 2012, FOOD NUTR GUID HLTH; Modahl C, 1998, BIOL PSYCHIAT, V43, P270, DOI 10.1016/S0006-3223(97)00439-3; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Mostafa GA, 2015, BEHAV BRAIN FUNCT, V11, DOI 10.1186/s12993-014-0048-2; Mulder EJ, 2004, J AM ACAD CHILD PSY, V43, P491, DOI 10.1097/00004583-200404000-00016; Nelson M., 1997, DESIGN CONCEPTS NUTR, V2nd, P123; Parham L.D., 2007, Sensory Processing Measure (SPM): Manual; Patrick RP, 2015, FASEB J, V29, P2207, DOI 10.1096/fj.14-268342; Patrick RP, 2014, FASEB J, V28, P2398, DOI 10.1096/fj.13-246546; Pusceddu MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139721; Richardson AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043909; Rockell JEP, 2008, NEW ZEAL MED J, V121, P75; Ross AC, 2011, DIETARY REFERENCE INTAKES FOR CALCIUM AND VITAMIN D, P35; Rossignol DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00150; Sanchez K, 2015, DEV MED CHILD NEUROL, V57, P798, DOI 10.1111/dmcn.12748; Sandin S, 2014, JAMA-J AM MED ASSOC, V311, P1770, DOI 10.1001/jama.2014.4144; Schaaf CP, 2011, NEURON, V70, P806, DOI 10.1016/j.neuron.2011.05.025; Schneider CK, 2006, J AUTISM DEV DISORD, V36, P1053, DOI 10.1007/s10803-006-0141-y; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Strambi M, 2006, BIOL TRACE ELEM RES, V109, P97, DOI 10.1385/BTER:109:2:097; STUMPF WE, 1988, ANAT EMBRYOL, V177, P307, DOI 10.1007/BF00315837; Sun CH, 2013, J NUTR SCI, V2, DOI 10.1017/jns.2013.9; Tague SE, 2011, J CHEM NEUROANAT, V41, P1, DOI 10.1016/j.jchemneu.2010.10.001; Vancassel S, 2001, PROSTAG LEUKOTR ESS, V65, P1, DOI 10.1054/plef.2001.0281; Vidailhet M, 2012, ARCH PEDIATRIE, V19, P316, DOI 10.1016/j.arcped.2011.12.015; Voigt RG, 2014, J PEDIATR GASTR NUTR, V58, P715, DOI 10.1097/MPG.0000000000000260; Wang LW, 2011, J DEV BEHAV PEDIATR, V32, P351, DOI 10.1097/DBP.0b013e31821bd06a; Willemsen LEM, 2008, EUR J NUTR, V47, P183, DOI 10.1007/s00394-008-0712-0; Williams-Hooker R., 2013, ICAN: Infant, Child & Adolescent Nutrition, V5, P113, DOI 10.1177/1941406413478167; Zerwekh JE, 2008, AM J CLIN NUTR, V87, p1087S, DOI 10.1093/ajcn/87.4.1087S; Zimmer MH, 2012, J AUTISM DEV DISORD, V42, P549, DOI 10.1007/s10803-011-1268-z";86;12;12;1;30;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1745-6215;;TRIALS;Trials;juin-23;2016;17;;;;;;;;295;10.1186/s13063-016-1428-8;http://dx.doi.org/10.1186/s13063-016-1428-8;;;13;Medicine, Research & Experimental;Science Citation Index Expanded (SCI-EXPANDED);Research & Experimental Medicine;DQ1WI;27334138;Green Published, gold;;;24/11/2024;WOS:000378990700001;View Full Record in Web of Science
J;"Frye, RE; Sreenivasula, S; Adams, JB";;;;"Frye, Richard E.; Sreenivasula, Swapna; Adams, James B.";;;Traditional and non-traditional treatments for autism spectrum disorder with seizures: an online survey;BMC PEDIATRICS;;;English;Article;;;;;;;"KETOGENIC DIET; EPILEPSY; CHILDREN; EEG; ABNORMALITIES";Background: Despite the high prevalence of seizure, epilepsy and abnormal electroencephalograms in individuals with autism spectrum disorder (ASD), there is little information regarding the relative effectiveness of treatments for seizures in the ASD population. In order to determine the effectiveness of traditional and non-traditional treatments for improving seizures and influencing other clinical factor relevant to ASD, we developed a comprehensive on-line seizure survey. Methods: Announcements (by email and websites) by ASD support groups asked parents of children with ASD to complete the on-line surveys. Survey responders choose one of two surveys to complete: a survey about treatments for individuals with ASD and clinical or subclinical seizures or abnormal electroencephalograms, or a control survey for individuals with ASD without clinical or subclinical seizures or abnormal electroencephalograms. Survey responders rated the perceived effect of traditional antiepileptic drug (AED), non-AED seizure treatments and non-traditional ASD treatments on seizures and other clinical factors (sleep, communication, behavior, attention and mood), and listed up to three treatment side effects. Results: Responses were obtained concerning 733 children with seizures and 290 controls. In general, AEDs were perceived to improve seizures but worsened other clinical factors for children with clinical seizure. Valproic acid, lamotrigine, levetiracetam and ethosuximide were perceived to improve seizures the most and worsen other clinical factors the least out of all AEDs in children with clinical seizures. Traditional non-AED seizure and non-traditional treatments, as a group, were perceived to improve other clinical factors and seizures but the perceived improvement in seizures was significantly less than that reported for AEDs. Certain traditional non-AED treatments, particularly the ketogenic diet, were perceived to improve both seizures and other clinical factors. For ASD individuals with reported subclinical seizures, other clinical factors were reported to be worsened by AEDs and improved by non-AED traditional seizure and non-traditional treatments. The rate of side effects was reportedly higher for AEDs compared to traditional non-AED treatments. Conclusion: Although this survey-based method only provides information regarding parental perceptions of effectiveness, this information may be helpful for selecting seizure treatments in individuals with ASD.;"[Frye, Richard E.] Univ Texas Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; [Sreenivasula, Swapna] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA; [Adams, James B.] Arizona State Univ, Sch Mech Aerosp Chem & Mat Engn, Tempe, AZ USA";"University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Arizona State University; Arizona State University-Tempe";Frye, RE (corresponding author), Univ Texas Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA.;Richard.E.Frye@uth.tmc.edu;Frye, Richard/AAB-5543-2020;;"Autism Research Institute; National Institutes of Health";"Autism Research Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)";The Autism Research Institute provided partial funding for this study. The authors would like to thank Teri Arranga and Drs. Steve Edelson, Martha Herbert, Derrick MacFabe and Dan Rossignol for their advice and assistance with this project. We thank the members of the Elias Think Tank (See Additional file 1, Appendix A) for their advice on developing the survey. We also thank the Autism Research Institute, Autism Speaks, and many other ASD groups for their assistance in advertising the survey. We especially thank the many parents who volunteered their time to participate in this study.Dr. Richard E. Frye received his medical degree from Georgetown University. He completed his pediatric residency training at Jackson Memorial Hospital/University of Miami and child neurology residency training at Children's Hospital Boston/Harvard University. Following residency Dr. Frye completed concurrent fellowships, one in Behavioral Neurology and Learning Disabilities at Children's Hospital Boston/Harvard University and another in Psychology at Boston University. Dr. Frye completed a Ph.D. in Physiology and Biophysics at Georgetown University and a M. S. in Biomedical Science and Biostatistics at Drexel University. Dr. Frye is board certified in Pediatrics and in Neurology with special competency in Child Neurology. Dr. Frye has been funded by the National Institutes of Health to study brain function in individuals with neurodevelopmental disorders. Dr. Frye is the medical-director of the University of Texas medically-based autism clinic. The purpose of this unique clinic is to diagnose and treat medical disorders associated with autism in order to optimize remediation and recovery. Swapna Sreenivasula is currently a graduate student in the School of Public Health at University of Texas. She completed a Bachelor of Medicine and Bachelor of Surgery (M. B. B. S.) at Rangaraya Medical College, Kakinada Andhra Pradesh, India.;"Anderberg M.R., 1973, Probability and Mathematical Statistics; Badawy RAB, 2010, ANN NEUROL, V67, P64, DOI 10.1002/ana.21806; CALANDRE EP, 1990, ACTA NEUROL SCAND, V81, P504; Enticott PG, 2010, DEV MED CHILD NEUROL, V52, pe179, DOI 10.1111/j.1469-8749.2010.03665.x; Evangeliou A, 2003, J CHILD NEUROL, V18, P113, DOI 10.1177/08830738030180020501; Fohlen M, 2004, NEUROPEDIATRICS, V35, P336, DOI 10.1055/s-2004-830410; Frye RE, 2011, PEDIATR RES, V69, p41R, DOI 10.1203/PDR.0b013e318212f16b; Frye RE, 2010, J CHILD NEUROL, V25, P556, DOI 10.1177/0883073809344743; Gallagher S, 2006, DEV MED CHILD NEUROL, V48, P766, DOI 10.1017/S0012162206001630; Hara H, 2007, BRAIN DEV-JPN, V29, P486, DOI 10.1016/j.braindev.2006.12.012; Keenan B., 1993, DEV USING QUESTIONNA; Kim HL, 2006, EPILEPSIA, V47, P394, DOI 10.1111/j.1528-1167.2006.00434.x; Kossoff EH, 2009, NEUROTHERAPEUTICS, V6, P406, DOI 10.1016/j.nurt.2009.01.005; Kwan P, 2001, LANCET, V357, P216, DOI 10.1016/S0140-6736(00)03600-X; Lagae L, 2009, EPILEPSIA, V50, P59, DOI 10.1111/j.1528-1167.2009.02222.x; Levisohn PM, 2007, EPILEPSIA, V48, P33, DOI 10.1111/j.1528-1167.2007.01399.x; Levy SE, 2008, CHILD ADOL PSYCH CL, V17, P803, DOI 10.1016/j.chc.2008.06.004; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; McLellan A, 2005, DEV MED CHILD NEUROL, V47, P666, DOI 10.1017/S0012162205001362; Mikati MA, 2009, EPILEPSY BEHAV, V14, P411, DOI 10.1016/j.yebeh.2008.06.006; Mohamed HE, 2010, J CLIN NEUROSCI, V17, P899, DOI 10.1016/j.jocn.2009.11.005; PALMIERI L, BIOCH BIOPHYS ACTA, V1797, P1130; Parkinson Gillian M, 2006, Pediatr Rehabil, V9, P229, DOI 10.1080/13638490500403080; Parmeggiani A, 2010, BRAIN DEV-JPN, V32, P783, DOI 10.1016/j.braindev.2010.07.003; Patrikelis P, 2009, EPILEPSY BEHAV, V14, P19, DOI 10.1016/j.yebeh.2008.09.013; Pavone P, 2004, NEUROPEDIATRICS, V35, P207, DOI 10.1055/s-2004-821079; Riazi K, 2010, EPILEPSY RES, V89, P34, DOI 10.1016/j.eplepsyres.2009.09.004; Rice Catherine, 2009, Morbidity and Mortality Weekly Report, V58, P1; ROSSIGNOL D, 2011, MOL PSYCH; Schaefer GB, 2008, GENET MED, V10, P4, DOI 10.1097/GIM.0b013e31815efdd7; Senel HG, 2010, J AUTISM DEV DISORD, V40, P494, DOI 10.1007/s10803-009-0891-4; Singh VK, 2009, ANN CLIN PSYCHIATRY, V21, P148; SPECCHIO N, BRAIN DEV, V32, P51; Taylor DC, 1999, EUR CHILD ADOLES PSY, V8, P189, DOI 10.1007/s007870050128; Tuchman R, 2002, LANCET NEUROL, V1, P352, DOI 10.1016/S1474-4422(02)00160-6; Turk J, 2009, ACTA PAEDIATR, V98, P675, DOI 10.1111/j.1651-2227.2008.01184.x; VOLKMAR FR, 1990, J AM ACAD CHILD PSY, V29, P127, DOI 10.1097/00004583-199001000-00020; Waldbaum S, 2010, EPILEPSY RES, V88, P23, DOI 10.1016/j.eplepsyres.2009.09.020; Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314; Ward JH, 1963, J AM STAT SOC, V77, P841";40;54;59;2;24;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;1471-2431;;;BMC PEDIATR;BMC Pediatr.;MAY 18;2011;11;;;;;;;;37;10.1186/1471-2431-11-37;http://dx.doi.org/10.1186/1471-2431-11-37;;;18;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;783PE;21592359;Green Published, gold;;;24/11/2024;WOS:000292095500001;View Full Record in Web of Science
J;"Luckhardt, C; Schutz, M; Muhlherr, A; Mössinger, H; Boxhoorn, S; Dempfle, A; Salvador, R; Ruffini, G; Pereira, HC; Castelo-Branco, M; Latinus, M; Bonnet-Brilhault, F; Siemann, J; Siniatchkin, M; Ecker, C; Freitag, CM";;;;"Luckhardt, Christina; Schutz, Magdalena; Muhlherr, Andreas; Moessinger, Hannah; Boxhoorn, Sara; Dempfle, Astrid; Salvador, Ricardo; Ruffini, Giulio; Pereira, Helena C.; Castelo-Branco, Miguel; Latinus, Marianne; Bonnet-Brilhault, Frederique; Siemann, Julia; Siniatchkin, Michael; Ecker, Christine; Freitag, Christine M.";;;Phase-IIa randomized, double-blind, sham-controlled, parallel group trial on anodal transcranial direct current stimulation (tDCS) over the left and right tempo-parietal junction in autism spectrum disorder-StimAT: study protocol for a clinical trial;TRIALS;;;English;Article;;;;;;"Autism spectrum disorder; Transcranial direct current stimulation; tDCS; Randomized controlled trial; Tempo-parietal junction";"NONINVASIVE BRAIN-STIMULATION; TEMPOROPARIETAL JUNCTION; NEURAL MECHANISMS; SPECIAL NEEDS; LONG-TERM; CHILDREN; SAFETY; ADOLESCENTS; HEALTHY; METAANALYSIS";Background: Autism spectrum disorder (ASD) is characterized by impaired social communication and interaction, and stereotyped, repetitive behaviour and sensory interests. To date, there is no effective medication that can improve social communication and interaction in ASD, and effect sizes of behaviour-based psychotherapy remain in the low to medium range. Consequently, there is a clear need for new treatment options. ASD is associated with altered activation and connectivity patterns in brain areas which process social information. Transcranial direct current stimulation (tDCS) is a technique that applies a weak electrical current to the brain in order to modulate neural excitability and alter connectivity. Combined with specific cognitive tasks, it allows to facilitate and consolidate the respective training effects. Therefore, application of tDCS in brain areas relevant to social cognition in combination with a specific cognitive training is a promising treatment approach for ASD. Methods: A phase-IIa pilot randomized, double-blind, sham-controlled, parallel-group clinical study is presented, which aims at investigating if 10 days of 20-min multi-channel tDCS stimulation of the bilateral tempo-parietal junction (TPJ) at 2.0 mA in combination with a computer-based cognitive training on perspective taking, intention and emotion understanding, can improve social cognitive abilities in children and adolescents with ASD. The main objectives are to describe the change in parent-rated social responsiveness from baseline (within 1 week before first stimulation) to post-intervention (within 7 days after last stimulation) and to monitor safety and tolerability of the intervention. Secondary objectives include the evaluation of change in parent-rated social responsiveness at follow-up (4 weeks after end of intervention), change in other ASD core symptoms and psychopathology, social cognitive abilities and neural functioning post-intervention and at follow-up in order to explore underlying neural and cognitive mechanisms. Discussion: If shown, positive results regarding change in parent-rated social cognition and favourable safety and tolerability of the intervention will confirm tDCS as a promising treatment for ASD core-symptoms. This may be a first step in establishing a new and cost-efficient intervention for individuals with ASD. Protocol version: This study protocol refers to protocol version 1.2 from 24 May 2019.;"[Luckhardt, Christina; Schutz, Magdalena; Muhlherr, Andreas; Moessinger, Hannah; Boxhoorn, Sara; Ecker, Christine; Freitag, Christine M.] Goethe Univ, Univ Hosp Frankfurt, Dept Child & Adolescent Psychiat Psychosomat & Ps, Deutschordenstr 50, D-60528 Frankfurt, Germany; [Dempfle, Astrid] Univ Kiel, Inst Med Informat & Stat IMIS, Brunswiker Str 10, D-24105 Kiel, Germany; [Salvador, Ricardo; Ruffini, Giulio] Neuroelect SLU, Av Tibidabo 47 Bis, Barcelona 08035, Spain; [Pereira, Helena C.; Castelo-Branco, Miguel] Univ Coimbra UC, Acad Clin Ctr, Coimbra Inst Biomed Imaging & Translat Res CIBIT, ICNAS,Fac Med, P-3001451 Coimbra, Portugal; [Latinus, Marianne; Bonnet-Brilhault, Frederique] Univ Tours, CHRU Bretonneau, Ctr Pedopsychiat, iBrain,INSERM,UMR 1253, 2 Bd Tonnelle, F-37044 Tours 9, France; [Bonnet-Brilhault, Frederique] CHRU Tours, Hop Bretonneau, Ctr Hosp Univ Tours CHUT, Ctr Univ Pedopsychiat,Equipe Autism,INSERM,UMR930, 2 Bd Tonnelle, F-37044 Tours 9, France; [Siemann, Julia; Siniatchkin, Michael] Protestant Hosp Bethel, EvKB, Clin Child & Adolescent Psychiat & Psychotherapy, Remterweg 13a, D-33617 Bielefeld, Germany";"Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Kiel; Universidade de Coimbra; Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Tours; Evangelical Hospital Bethel (EvKB) - House Gilead I";Luckhardt, C (corresponding author), Goethe Univ, Univ Hosp Frankfurt, Dept Child & Adolescent Psychiat Psychosomat & Ps, Deutschordenstr 50, D-60528 Frankfurt, Germany.;Christina.Luckhardt@kgu.de;"Salvador, Ricardo/K-2301-2015; Dempfle, Astrid/ABB-8889-2020; Ecker, Christine/E-5194-2010; Luckhardt, Christina/R-9757-2016; Bonnet-Brilhault, Frederique/P-5815-2016; Latinus, Marianne/A-8173-2011; Pereira, Helena Catarina/AEX-9885-2022; Castelo-Branco, Miguel/F-3866-2019";"Freitag, Christine Margarete/0000-0001-9676-4782; Bonnet-Brilhault, Frederique/0000-0003-4763-9066; Latinus, Marianne/0000-0002-4406-2962; Pereira, Helena Catarina/0000-0002-1423-3038; Boxhoorn, Sara/0000-0002-8948-9222; Castelo-Branco, Miguel/0000-0003-4364-6373; Luckhardt, Christina/0000-0002-5259-7174";EU-Project STIPED (Horizon2020) [731827];EU-Project STIPED (Horizon2020);This trial is a part of the EU-Project STIPED (Horizon2020) and is therefore financed through the Grant Agreement No. 731827. The funding body is not involved in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.;"Achenbach TM., 1983, MANUAL CHILD BEHAV C; Alon G, 1998, J NEUROL REHABIL, V12, P65; Aman M., 1986, Aberrant Behavior Checklist Manual; Amatachaya A, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/928631; Amatachaya A, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/173073; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; Antal A, 2017, CLIN NEUROPHYSIOL, V128, P1774, DOI 10.1016/j.clinph.2017.06.001; Baird G, 2006, LANCET, V368, P210, DOI 10.1016/S0140-6736(06)69041-7; Barrett B, 2015, AUTISM, V19, P562, DOI 10.1177/1362361314536626; Baruth Joshua M, 2010, J Neurother, V14, P179; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Berggren S, 2018, DEV NEUROREHABIL, V21, P141, DOI 10.1080/17518423.2017.1305004; Berryhill ME, 2018, J ECT, V34, pE25, DOI 10.1097/YCT.0000000000000534; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Bishop D., 2003, CHILDRENS COMMUNICAT; Boonstra TW, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00270; Breitling C, 2020, CLIN NEUROPHYSIOL, V131, P1146, DOI 10.1016/j.clinph.2019.12.412; Breitling C, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00072; Brem AK, 2014, NEUROIMAGE, V85, P1058, DOI 10.1016/j.neuroimage.2013.07.038; Osório AAC, 2019, DEV MED CHILD NEUROL, V61, P298, DOI 10.1111/dmcn.14104; CARSKADON MA, 1993, J ADOLESCENT HEALTH, V14, P190, DOI 10.1016/1054-139X(93)90004-9; Casanova MF, 2012, TRANSL NEUROSCI, V3, P170, DOI 10.2478/s13380-012-0022-0; Casanova MF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00851; Cascio CJ, 2010, J NEURODEV DISORD, V2, P62, DOI 10.1007/s11689-010-9046-3; Miranda PC, 2013, NEUROIMAGE, V70, P48, DOI 10.1016/j.neuroimage.2012.12.034; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Dedoncker J, 2016, BRAIN STIMUL, V9, P501, DOI 10.1016/j.brs.2016.04.006; Donaldson PH, 2019, SOC NEUROSCI-UK, V14, P681, DOI 10.1080/17470919.2019.1572648; Donaldson PH, 2015, NEUROSCI BIOBEHAV R, V55, P547, DOI 10.1016/j.neubiorev.2015.05.017; Downar J, 2016, TRENDS COGN SCI, V20, P107, DOI 10.1016/j.tics.2015.10.007; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Freitag CM, 2006, EUR CHILD ADOLES PSY, V15, P282, DOI 10.1007/s00787-006-0533-8; Freitag CM, 2016, J CHILD PSYCHOL PSYC, V57, P596, DOI 10.1111/jcpp.12509; Frith U, 2010, PHILOS T R SOC B, V365, P165, DOI 10.1098/rstb.2009.0160; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gates JA, 2017, CLIN PSYCHOL REV, V52, P164, DOI 10.1016/j.cpr.2017.01.006; Geng JJ, 2013, NEUROSCI BIOBEHAV R, V37, P2608, DOI 10.1016/j.neubiorev.2013.08.010; Göder R, 2013, SCHIZOPHR RES, V144, P153, DOI 10.1016/j.schres.2012.12.014; Gómez L, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7030063; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Kana RK, 2014, SOC COGN AFFECT NEUR, V9, P98, DOI 10.1093/scan/nss106; Kang JN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00201; Katz B, 2017, J COGNITIVE NEUROSCI, V29, P1498, DOI 10.1162/jocn_a_01115; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Krishnan C, 2015, BRAIN STIMUL, V8, P76, DOI 10.1016/j.brs.2014.10.012; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lavelle TA, 2014, PEDIATRICS, V133, pE520, DOI 10.1542/peds.2013-0763; Loomes R, 2017, J AM ACAD CHILD PSY, V56, P466, DOI 10.1016/j.jaac.2017.03.013; Lord C, 2015, ADOS 2 DIAGNOSTISCHE; Mars RB, 2012, CEREB CORTEX, V22, P1894, DOI 10.1093/cercor/bhr268; Martínez-González AE, 2018, J AUTISM DEV DISORD, V48, P198, DOI 10.1007/s10803-017-3276-0; Mattai A, 2011, BRAIN STIMUL, V4, P275, DOI 10.1016/j.brs.2011.01.001; McCleery JP, 2011, J NEUROSCI, V31, P12849, DOI 10.1523/JNEUROSCI.1392-11.2011; Mirenda P, 2010, J AUTISM DEV DISORD, V40, P1521, DOI 10.1007/s10803-010-1012-0; Moliadze V, 2015, BRAIN RES BULL, V119, P25, DOI 10.1016/j.brainresbull.2015.09.011; Müller RA, 2011, CEREB CORTEX, V21, P2233, DOI 10.1093/cercor/bhq296; Munz MT, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00307; Muszkat D, 2016, J CHILD ADOL PSYCHOP, V26, P590, DOI 10.1089/cap.2015.0172; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P2220, DOI 10.1016/S1388-2457(03)00235-9; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2004, CLIN NEUROPHYSIOL, V115, P2419, DOI 10.1016/j.clinph.2004.05.001; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Payakachat N, 2012, EXPERT REV PHARM OUT, V12, P485, DOI [10.1586/erp.12.29, 10.1586/ERP.12.29]; Pernet CR, 2015, NEUROIMAGE, V119, P164, DOI 10.1016/j.neuroimage.2015.06.050; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Prehn-Kristensen A, 2014, BRAIN STIMUL, V7, P793, DOI 10.1016/j.brs.2014.07.036; Ravens-Sieberer Ulrike, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P353, DOI 10.1586/14737167.5.3.353; Rimland B., 2005, Autism treatment evaluation checkist (ATEC); Rogers SJ, 2005, J CHILD PSYCHOL PSYC, V46, P1255, DOI 10.1111/j.1469-7610.2005.01431.x; Rothärmel M, 2019, NEUROPSYCHOBIOLOGY, V78, P189, DOI 10.1159/000501025; Ruffini G, 2014, NEUROIMAGE, V89, P216, DOI 10.1016/j.neuroimage.2013.12.002; Santiesteban I, 2012, CURR BIOL, V22, P2274, DOI 10.1016/j.cub.2012.10.018; Schneider HD, 2011, CLIN LINGUIST PHONET, V25, P640, DOI 10.3109/02699206.2011.570852; Schurz M, 2014, NEUROSCI BIOBEHAV R, V42, P9, DOI 10.1016/j.neubiorev.2014.01.009; Schwarzkopf S, 2014, COGNITION, V131, P345, DOI 10.1016/j.cognition.2014.02.003; Simoes M, 2016, PROCESSING FACIAL EX; Siniatchkin M, 2012, BRAIN TOPOGR, V25, P332, DOI 10.1007/s10548-012-0221-6; Sokhadze E, 2010, APPL PSYCHOPHYS BIOF, V35, P147, DOI 10.1007/s10484-009-9121-2; Sokhadze EM, 2016, APPL PSYCHOPHYS BIOF, V41, P81, DOI 10.1007/s10484-015-9313-x; Sokhadze EM, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00134; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Steinhausen HC, 2016, ACTA PSYCHIAT SCAND, V133, P445, DOI 10.1111/acps.12559; Sturm A, 2017, J CHILD PSYCHOL PSYC, V58, P1053, DOI 10.1111/jcpp.12731; Tachibana Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186502; Tadini L, 2011, J ECT, V27, P134, DOI 10.1097/YCT.0b013e3181e631a8; Tewes U., 1999, HAWIK-III. Hamburg-WechslerIntelligenz-Test fur Kinder - Dritte Auflage.Wechsler Intelligence Scale for Children, V3rd; Thapar A, 2021, J AUTISM DEV DISORD, V51, P4321, DOI 10.1007/s10803-020-04685-z; To WT, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00128; van Heijst BFC, 2015, AUTISM, V19, P158, DOI 10.1177/1362361313517053; van Steenburgh JJ, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0152-x; Varga ET, 2011, EPILEPSY RES, V97, P142, DOI 10.1016/j.eplepsyres.2011.07.016; Vistoli D, 2015, SOC NEUROSCI-UK, V10, P391, DOI 10.1080/17470919.2014.1003272; Vogeley K, 2001, NEUROIMAGE, V14, P170, DOI 10.1006/nimg.2001.0789; Webb SJ, 2020, FRONT INTEGR NEUROSC, V13, DOI 10.3389/fnint.2019.00071; Wechsler D., 1997, WAIS 3, V3rd; Williams JHG, 2006, NEUROPSYCHOLOGIA, V44, P610, DOI 10.1016/j.neuropsychologia.2005.06.010; Wilson JE, 2018, J NEURAL TRANSM, V125, P1857, DOI 10.1007/s00702-018-1938-5; Wolstencroft J, 2018, J AUTISM DEV DISORD, V48, P2293, DOI 10.1007/s10803-018-3485-1; Ye H, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00659";100;8;8;4;17;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1745-6215;;TRIALS;Trials;APR 6;2021;22;1;;;;;;;248;10.1186/s13063-021-05172-1;http://dx.doi.org/10.1186/s13063-021-05172-1;;;16;Medicine, Research & Experimental;Science Citation Index Expanded (SCI-EXPANDED);Research & Experimental Medicine;RJ7HZ;33823927;Green Published, gold;;;24/11/2024;WOS:000637773100001;View Full Record in Web of Science
J;"van Andel, DM; Sprengers, JJ; Keijzer-Veen, MG; Schulp, AJA; Lillien, MR; Scheepers, FE; Bruining, H";;;;"van Andel, Dorinde M.; Sprengers, Jan J.; Keijzer-Veen, Mandy G.; Schulp, Annelien J. A.; Lillien, Marc R.; Scheepers, Floortje E.; Bruining, Hilgo";;;Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled Trial;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"ASD; ADHD; epilepsy; bumetanide; RCT; irritability; sensory processing; child";"AUTISM; INHIBITION; BALANCE";BackgroundTreatment development for neurodevelopmental disorders (NDDs) such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) is impeded by heterogeneity in clinical manifestation and underlying etiologies. Symptom traits such as aberrant sensory reactivity are present across NDDs and might reflect common mechanistic pathways. Here, we test the effectiveness of repurposing a drug candidate, bumetanide, on irritable behavior in a cross-disorder neurodevelopmental cohort defined by the presence of sensory reactivity problems. MethodsParticipants, aged 5-15 years and IQ >= 55, with ASD, ADHD, and/or epilepsy and proven aberrant sensory reactivity according to deviant Sensory Profile scores were included. Participants were randomly allocated (1:1) to bumetanide (max 1 mg twice daily) or placebo tablets for 91 days followed by a 28-day wash-out period using permuted block design and minimization. Participants, parents, healthcare providers, and outcome assessors were blinded for treatment allocation. Primary outcome was the differences in ABC-irritability at day 91. Secondary outcomes were differences in SRS-2, RBS-R, SP-NL, BRIEF parent, BRIEF teacher at D91. Differences were analyzed in a modified intention-to-treat sample with linear mixed models and side effects in the intention-to-treat population. ResultsA total of 38 participants (10.1 [SD 3.1] years) were enrolled between June 2017 and June 2019 in the Netherlands. Nineteen children were allocated to bumetanide and nineteen to placebo. Five patients discontinued (n = 3 bumetanide). Bumetanide was superior to placebo on the ABC-irritability [mean difference (MD) -4.78, 95%CI: -8.43 to -1.13, p = 0.0125]. No effects were found on secondary endpoints. No wash-out effects were found. Side effects were as expected: hypokalemia (p = 0.046) and increased diuresis (p = 0.020). ConclusionDespite the results being underpowered, this study raises important recommendations for future cross-diagnostic trial designs.;"[van Andel, Dorinde M.; Sprengers, Jan J.; Scheepers, Floortje E.] Univ Med Ctr Utrecht, Univ Med Ctr Utrecht Brain Ctr, Dept Psychiat, Utrecht, Netherlands; [Keijzer-Veen, Mandy G.; Schulp, Annelien J. A.; Lillien, Marc R.] Wilhelmina Childrens Hosp, Dept Pediat Nephrol, Univ Med Ctr Utrecht, Utrecht, Netherlands; [Bruining, Hilgo] Amsterdam UMC, N You Neurodev Precis Ctr, Amsterdam Neurosci, Amsterdam Reprod & Dev, Amsterdam, Netherlands; [Bruining, Hilgo] Vrije Univ Amsterdam, Child & Adolescent Psychiat & Psychosocial Care, Emma Childrens Hosp, Amsterdam UMC, Amsterdam, Netherlands; [Bruining, Hilgo] Levvel, Ctr Child & Adolescent Psychiat, Amsterdam, Netherlands";"Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; University of Amsterdam; Emma Children's Hospital; Vrije Universiteit Amsterdam; University of Amsterdam";"Bruining, H (corresponding author), Amsterdam UMC, N You Neurodev Precis Ctr, Amsterdam Neurosci, Amsterdam Reprod & Dev, Amsterdam, Netherlands.;Bruining, H (corresponding author), Vrije Univ Amsterdam, Child & Adolescent Psychiat & Psychosocial Care, Emma Childrens Hosp, Amsterdam UMC, Amsterdam, Netherlands.;Bruining, H (corresponding author), Levvel, Ctr Child & Adolescent Psychiat, Amsterdam, Netherlands.";h.bruining@amsterdamumc.nl;Keijzer-Veen, Mandy/AAZ-1592-2021;Sprengers, Jan/0000-0001-5418-9791;Dutch Brain Foundation [HA2015-01-04];Dutch Brain Foundation;This study was supported by a grant from Dutch Brain Foundation (Hersenstichting #HA2015-01-04). This foundation had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.;"Aman MG, 2009, J AM ACAD CHILD PSY, V48, P1143, DOI 10.1097/CHI.0b013e3181bfd669; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Antoine MW, 2019, NEURON, V101, P648, DOI 10.1016/j.neuron.2018.12.026; Baum SH, 2015, PROG NEUROBIOL, V134, P140, DOI 10.1016/j.pneurobio.2015.09.007; Ben-Ari Y, 2012, NEUROSCIENTIST, V18, P467, DOI 10.1177/1073858412438697; Ben-Sasson A, 2007, AM J OCCUP THER, V61, P584, DOI 10.5014/ajot.61.5.584; Boutros N, 2009, CLIN EEG NEUROSCI, V40, P239, DOI 10.1177/155005940904000406; Bozzi Y, 2018, EUR J NEUROSCI, V47, P534, DOI 10.1111/ejn.13595; Bruining H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65500-4; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cheung PPP, 2009, RES DEV DISABIL, V30, P1468, DOI 10.1016/j.ridd.2009.07.009; Doyon N, 2016, NEURON, V89, P1157, DOI 10.1016/j.neuron.2016.02.030; Dunn W, 1999, Sensory Profile: Users Manual, DOI [10.1037/t15155-000, DOI 10.1037/T15155-000]; Dunn W, 2007, INFANT YOUNG CHILD, V20, P84, DOI 10.1097/01.IYC.0000264477.05076.5d; Eftekhari S, 2014, SCIENCE, V346, DOI 10.1126/science.1256009; Ermer J, 1998, AM J OCCUP THER, V52, P283, DOI 10.5014/ajot.52.4.283; Fitzmaurice G. M., 2012, Applied longitudinal analysis; Foss-Feig JH, 2017, BIOL PSYCHIAT, V81, P848, DOI 10.1016/j.biopsych.2017.03.005; Grove J, 2019, NAT GENET, V51, P431, DOI 10.1038/s41588-019-0344-8; Hazen EP, 2014, HARVARD REV PSYCHIAT, V22, P112, DOI 10.1097/01.HRP.0000445143.08773.58; He Q, 2014, J NEUROSCI, V34, P446, DOI 10.1523/JNEUROSCI.4447-13.2014; Heeger DJ, 2017, BIOL PSYCHIAT, V81, P832, DOI 10.1016/j.biopsych.2016.09.019; Hochhauser M, 2010, RES AUTISM SPECT DIS, V4, P746, DOI 10.1016/j.rasd.2010.01.015; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Isaacson JS, 2011, NEURON, V72, P231, DOI 10.1016/j.neuron.2011.09.027; James BJ, 2019, ANN PHARMACOTHER, V53, P537, DOI 10.1177/1060028018817304; Jeste SS, 2015, CURR OPIN NEUROL, V28, P110, DOI 10.1097/WCO.0000000000000181; Kahan BC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-456; Kharod SC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00310; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.101; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Little Lauren M, 2018, Phys Occup Ther Pediatr, V38, P243, DOI 10.1080/01942638.2017.1390809; Loth E, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0146-8; Loth E, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00188; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Naaijen J, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2016.273; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; Nelson SB, 2015, NEURON, V87, P684, DOI 10.1016/j.neuron.2015.07.033; Pressler RM, 2015, LANCET NEUROL, V14, P469, DOI 10.1016/S1474-4422(14)70303-5; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Ruffolo G, 2016, NEUROBIOL DIS, V95, P93, DOI 10.1016/j.nbd.2016.07.014; Sahin M, 2015, SCIENCE, V350, P890, DOI 10.1126/science.aab3897; Satterstrom FK, 2020, CELL, V180, P568, DOI 10.1016/j.cell.2019.12.036; Savardi A, 2021, TRENDS PHARMACOL SCI, V42, P1009, DOI 10.1016/j.tips.2021.09.005; Schulte JT, 2018, NEUROSCI BIOBEHAV R, V90, P260, DOI 10.1016/j.neubiorev.2018.05.001; Selten Martijn, 2018, F1000Res, V7, P23, DOI 10.12688/f1000research.12155.1; Spence SJ, 2009, PEDIATR RES, V65, P599, DOI 10.1203/PDR.0b013e31819e7168; Sprengers JJ, 2021, J AM ACAD CHILD PSY, V60, P865, DOI 10.1016/j.jaac.2020.07.888; Strumbos JG, 2010, J NEUROSCI, V30, P10263, DOI 10.1523/JNEUROSCI.1125-10.2010; Thapar A, 2017, LANCET PSYCHIAT, V4, P339, DOI 10.1016/S2215-0366(16)30376-5; Thompson DD, 2015, J CLIN EPIDEMIOL, V68, P1068, DOI 10.1016/j.jclinepi.2014.11.001; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190; U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, 2006, Health Qual Life Outcomes, V4, P79; van Campen JS, 2015, J NEURODEV DISORD, V7, DOI 10.1186/s11689-015-9130-9; Zhang LL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0692-2";56;5;5;1;4;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;FEB 8;2022;13;;;;;;;;780281;10.3389/fpsyt.2022.780281;http://dx.doi.org/10.3389/fpsyt.2022.780281;;;13;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;ZH0HM;35211042;gold, Green Published;;;24/11/2024;WOS:000760630000001;View Full Record in Web of Science
J;"Aran, A; Harel, M; Cassuto, H; Polyansky, L; Schnapp, A; Wattad, N; Shmueli, D; Golan, D; Castellanos, FX";;;;"Aran, Adi; Harel, Moria; Cassuto, Hanoch; Polyansky, Lola; Schnapp, Aviad; Wattad, Nadia; Shmueli, Dorit; Golan, Daphna; Castellanos, F. Xavier";;;Cannabinoid treatment for autism: a proof-of-concept randomized trial;MOLECULAR AUTISM;;;English;Article;;;;;;"Autism spectrum disorder; Cannabinoids; Cannabidiol; Tetrahydrocannabinol; Clinical trials randomized controlled; Neuropsychology; Behavior; Child psychiatry; Developmental disorders; Entourage effect";;"Background: Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5-21 years) with ASD. Methods: We tested (1) BOL-DP-O-01-W, a whole-plant cannabis extract containing cannabidiol and Delta 9-tetrahydrocannabinol at a 20:1 ratio and (2) BOL-DP-O-01, purified cannabidiol and Delta 9-tetrahydrocannabinol at the same ratio. Participants (N = 150) received either placebo or cannabinoids for 12-weeks (testing efficacy) followed by a 4-week washout and predetermined cross-over for another 12 weeks to further assess tolerability. Registered primary efficacy outcome measures were improvement in behavioral problems (differences between whole-plant extract and placebo) on the Home Situation Questionnaire-ASD (HSQ-ASD) and the Clinical Global Impression-Improvement scale with disruptive behavior anchor points (CGI-I). Secondary measures were Social Responsiveness Scale (SRS-2) and Autism Parenting Stress Index (APSI). Results: Changes in Total Scores of HSQ-ASD (primary-outcome) and APSI (secondary-outcome) did not differ among groups. Disruptive behavior on the CGI-I (co-primary outcome) was either much or very much improved in 49% on whole-plant extract (n = 45) versus 21% on placebo (n = 47; p = 0.005). Median SRS Total Score (secondary-outcome) improved by 14.9 on whole-plant extract (n = 34) versus 3.6 points after placebo (n = 36); p = 0.009). There were no treatment-related serious adverse events. Common adverse events included somnolence and decreased appetite, reported for 28% and 25% on whole-plant extract, respectively (n = 95); 23% and 21% on pure-cannabinoids (n = 93), and 8% and 15% on placebo (n = 94). Limitations : Lack of pharmacokinetic data and a wide range of ages and functional levels among participants warrant caution when interpreting the results. Conclusions: This interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3 months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended.";"[Aran, Adi; Harel, Moria; Cassuto, Hanoch; Polyansky, Lola; Schnapp, Aviad; Wattad, Nadia] Shaare Zedek Med Ctr, Neuropediat Unit, 12 Bayit St, IL-91031 Jerusalem, Israel; [Shmueli, Dorit] Clalit Hlth Serv, Child Dev Ctr, Tel Aviv, Israel; [Golan, Daphna] Maccabi Hlth Serv, Child Dev Ctr, Jerusalem, Israel; [Castellanos, F. Xavier] NYU, Grossman Sch Med, Dept Child & Adolescent Psychiat, New York, NY USA";"Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; New York University";Aran, A (corresponding author), Shaare Zedek Med Ctr, Neuropediat Unit, 12 Bayit St, IL-91031 Jerusalem, Israel.;aaran@szmc.org.il;Castellanos, Francisco/K-1892-2014;"Aran, Adi/0000-0001-9460-4689; Castellanos, Francisco/0000-0001-9192-9437";"BOL Pharma, Revadim, Israel; National Institute for Psychobiology in Israel [203-17-18]";"BOL Pharma, Revadim, Israel; National Institute for Psychobiology in Israel";The study was funded by BOL Pharma, Revadim, Israel and the National Institute for Psychobiology in Israel (#203-17-18). The funding bodies were not involved in any way in the study design, collection, analysis and interpretation of data or in the writing of the manuscript.;"Aran A, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-019-0256-6; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Barchel D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01521; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Boggs DL, 2018, NEUROPSYCHOPHARMACOL, V43, P142, DOI 10.1038/npp.2017.209; Campos AC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00269; Chowdhury M, 2015, AUTISM; Cifelli P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030723; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Devinsky O, 2018, NEW ENGL J MED, V378, P1888, DOI 10.1056/NEJMoa1714631; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631; Ferber SG, 2020, CURR NEUROPHARMACOL, V18, P87, DOI 10.2174/1570159X17666190903103923; Fleury-Teixeira P, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01145; Fusar-Poli L, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10090572; Goel R, 2018, INT REV PSYCHIATR, V30, P78, DOI 10.1080/09540261.2018.1458706; Guerrero-Alba R, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01496; Gunduz-Cinar O, 2013, MOL PSYCHIATR, V18, P813, DOI 10.1038/mp.2012.72; Hosie S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00234; Iannotti FA, 2014, ACS CHEM NEUROSCI, V5, P1131, DOI 10.1021/cn5000524; Kamal BS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00730; Karhson DS, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0203-y; Keller R, 2017, NEUROL SCI, V38, P1353, DOI 10.1007/s10072-017-2974-x; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Lord C, 2018, LANCET, V392, P508, DOI 10.1016/S0140-6736(18)31129-2; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McGuire P, 2018, AM J PSYCHIAT, V175, P225, DOI 10.1176/appi.ajp.2017.17030325; Melancia F, 2018, BRIT J PHARMACOL, V175, P3699, DOI 10.1111/bph.14435; Panelli RJ, 2007, EPILEPSIA, V48, P456, DOI 10.1111/j.1528-1167.2006.00956.x; Pretzsch CM, 2019, NEUROPSYCHOPHARMACOL, V44, P1398, DOI 10.1038/s41386-019-0333-8; Russo EB, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01969; SALZMAN C, 1976, AM J PSYCHIAT, V133, P1029; SALZMAN C, 1977, AM J DRUG ALCOHOL AB, V4, P251, DOI 10.3109/00952997709002763; Scahill L, 2016, J AM ACAD CHILD PSY, V55, P415, DOI 10.1016/j.jaac.2016.02.016; Schleider LBL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37570-y; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Seeman P, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.195; Silva LMT, 2012, J AUTISM DEV DISORD, V42, P566, DOI 10.1007/s10803-011-1274-1; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Szkudlarek HJ, 2019, NEUROPSYCHOPHARMACOL, V44, P817, DOI 10.1038/s41386-018-0282-7; Wang W, 2018, MOL PSYCHIATR, V23, P1798, DOI 10.1038/mp.2017.221; Wei D, 2017, TRENDS NEUROSCI, V40, P385, DOI 10.1016/j.tins.2017.04.005; Zamberletti E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091916";43;79;80;2;54;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;FEB 3;2021;12;1;;;;;;;6;10.1186/s13229-021-00420-2;http://dx.doi.org/10.1186/s13229-021-00420-2;;;11;"Genetics & Heredity; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Genetics & Heredity; Neurosciences & Neurology";QB8RY;33536055;gold, Green Published;;;24/11/2024;WOS:000614405700001;View Full Record in Web of Science
J;"Connery, K; Tippett, M; Delhey, LM; Rose, S; Slattery, JC; Kahler, SG; Hahn, J; Kruger, U; Cunningham, MW; Shimasaki, C; Frye, RE";;;;"Connery, Kathleen; Tippett, Marie; Delhey, Leanna M.; Rose, Shannon; Slattery, John C.; Kahler, Stephen G.; Hahn, Juergen; Kruger, Uwe; Cunningham, Madeleine W.; Shimasaki, Craig; Frye, Richard E.";;;Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism;TRANSLATIONAL PSYCHIATRY;;;English;Article;;;;;;;"NMDA RECEPTOR ENCEPHALITIS; LIMBIC ENCEPHALITIS; MITOCHONDRIAL DYSFUNCTION; ANTINEURONAL ANTIBODIES; SPECTRUM DISORDER; OXIDATIVE STRESS; ACID; BEHAVIOR; AUTOANTIBODIES; SERUM";The identification of brain-targeted autoantibodies in children with autism spectrum disorder (ASD) raises the possibility of autoimmune encephalopathy (AIE). Intravenous immunoglobulin (IVIG) is effective for AIE and for some children with ASD. Here, we present the largest case series of children with ASD treated with IVIG. Through an ASD clinic, we screened 82 children for AIE, 80 of them with ASD. IVIG was recommended for 49 (60%) with 31 (38%) receiving the treatment under our care team. The majority of parents (90%) reported some improvement with 71% reporting improvements in two or more symptoms. In a subset of patients, Aberrant Behavior Checklist (ABC) and/or Social Responsiveness Scale (SRS) were completed before and during IVIG treatment. Statistically significant improvement occurred in the SRS and ABC. The antidopamine D2L receptor antibody, the anti-tubulin antibody and the ratio of the antidopamine D2L to D1 receptor antibodies were related to changes in the ABC. The Cunningham Panel predicted SRS, ABC, parent-based treatment responses with good accuracy. Adverse effects were common (62%) but mostly limited to the infusion period. Only two (6%) patients discontinued IVIG because of adverse effects. Overall, our open-label case series provides support for the possibility that some children with ASD may benefit from IVIG. Given that adverse effects are not uncommon, IVIG treatment needs to be considered cautiously. We identified immune biomarkers in select IVIG responders but larger cohorts are needed to study immune biomarkers in more detail. Our small open-label exploratory trial provides evidence supporting a neuroimmune subgroup in patients with ASD.;"[Connery, Kathleen; Tippett, Marie; Delhey, Leanna M.; Rose, Shannon; Kahler, Stephen G.] Univ Arkansas Med Sci, Little Rock, AR 77205 USA; [Slattery, John C.] BioROSA Technol Inc, San Francisco, CA 94103 USA; [Hahn, Juergen; Kruger, Uwe] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA; [Hahn, Juergen] Rensselaer Polytech Inst, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY 12180 USA; [Cunningham, Madeleine W.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; [Shimasaki, Craig] Mol Labs Inc, Oklahoma City, OK USA; [Frye, Richard E.] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 51205 USA; [Frye, Richard E.] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ 85004 USA";"University of Arkansas System; University of Arkansas Medical Sciences; Rensselaer Polytechnic Institute; Rensselaer Polytechnic Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Barrow Neurological Institute; Phoenix Children's Hospital; University of Arizona";"Frye, RE (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 51205 USA.;Frye, RE (corresponding author), Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ 85004 USA.";rfrye@phoenixchildrens.com;"Rose, Shannon/JZE-1449-2024; Frye, Richard/AAB-5543-2020; Hahn, Juergen/H-8025-2019";"Hahn, Juergen/0000-0002-1078-4203; Rose, Shannon/0000-0003-0595-4367";"Autism Research Institute (San Diego, CA); Arkansas Biosciences Institute (Little Rock, AR); Jonty Foundation (St Paul, MN); Gupta Family Foundation (Atherton, CA); Jager Family Foundation (Chicago, IL); Jane Botsford Johnson Foundation (New York, NY); Arkansas Children's Research Institute (Little Rock, AR)";"Autism Research Institute (San Diego, CA); Arkansas Biosciences Institute (Little Rock, AR); Jonty Foundation (St Paul, MN); Gupta Family Foundation (Atherton, CA); Jager Family Foundation (Chicago, IL); Jane Botsford Johnson Foundation (New York, NY); Arkansas Children's Research Institute (Little Rock, AR)";"This research was supported, in part, by the Autism Research Institute (San Diego, CA), the Arkansas Biosciences Institute (Little Rock, AR), the Jonty Foundation (St Paul, MN), the Gupta Family Foundation (Atherton, CA), the Jager Family Foundation (Chicago, IL), the Jane Botsford Johnson Foundation (New York, NY), and the Arkansas Children's Research Institute (Little Rock, AR). None of the sponsors were involved with the design or conduct of the study, collection, management, analysis, or interpretation of the data; or preparation, review, approval of the manuscript or decision to submit the manuscript for publication. The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.";"Akman CI, 2009, DEV MED CHILD NEUROL, V51, P563, DOI 10.1111/j.1469-8749.2008.03217.x; Bashir S, 2015, J CHIN MED ASSOC, V78, P414, DOI 10.1016/j.jcma.2015.01.008; Ben-Pazi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073516; Blatt GJ, 2011, ANAT REC, V294, P1646, DOI 10.1002/ar.21252; Boris Marvin, 2005, Journal of Nutritional & Environmental Medicine (Abingdon), V15, P169, DOI 10.1080/13590840600681827; Braunschweig D, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.50; Breitenkamp AF, 2015, CURR MOL PHARMACOL, V8, P123, DOI 10.2174/1874467208666150507105235; Careaga M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/935608; Chakrabarty K, 2005, NEUROPSYCHOPHARMACOL, V30, P1735, DOI 10.1038/sj.npp.1300733; Chou IJ, 2013, PEDIATR NEONATOL, V54, P246, DOI 10.1016/j.pedneo.2013.01.016; Constantino J., 2002, SOCIAL RESPONSIVENES; Cox CJ, 2015, J CHILD ADOL PSYCHOP, V25, P76, DOI 10.1089/cap.2014.0048; Creten C, 2011, LANCET, V378, P98, DOI 10.1016/S0140-6736(11)60548-5; DelGiudice-Asch G, 1999, J AUTISM DEV DISORD, V29, P157, DOI 10.1023/A:1023096728131; Delhey LM, 2017, J CLIN MED, V6, DOI 10.3390/jcm6020018; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Foley KA, 2015, BEHAV BRAIN RES, V278, P244, DOI 10.1016/j.bbr.2014.09.032; Foley KA, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087072, 10.1371/journal.pone.0108413]; Frye RE, 2018, MOL PSYCHIATR, V23, P247, DOI 10.1038/mp.2016.168; Frye RE, 2017, J NEUROENDOCRINOL, V29, DOI 10.1111/jne.12461; Frye RE, 2013, MOL PSYCHIATR, V18, P369, DOI 10.1038/mp.2011.175; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.14; Frye RE, 2017, BIOMARK MED, V11, P687, DOI 10.2217/bmm-2017-0109; Frye RE, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00080; Goines P, 2011, BRAIN BEHAV IMMUN, V25, P514, DOI 10.1016/j.bbi.2010.11.017; Grea H, 2017, DIALOGUES CLIN NEURO, V19, P65; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; Gupta S, 1996, J AUTISM DEV DISORD, V26, P439, DOI 10.1007/BF02172828; Gupta S, 2010, J CLIN IMMUNOL, V30, pS90, DOI 10.1007/s10875-010-9402-9; Haberlandt E, 2011, ARCH DIS CHILD, V96, P186, DOI 10.1136/adc.2010.183897; Hacohen Y, 2016, DEV MED CHILD NEUROL, V58, P1092, DOI 10.1111/dmcn.13169; Hacohen Y, 2013, J NEUROL NEUROSUR PS, V84, P748, DOI 10.1136/jnnp-2012-303807; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kalra S, 2015, BBA CLIN, V4, P81, DOI 10.1016/j.bbacli.2015.08.001; Kin-Fan CD, 2017, BEHAV BRAIN RES, V316, P255, DOI 10.1016/j.bbr.2016.09.003; Kirvan CA, 2003, NAT MED, V9, P914, DOI 10.1038/nm892; Kirvan CA, 2006, J NEUROIMMUNOL, V179, P173, DOI 10.1016/j.jneuroim.2006.06.017; Kovacevic M, 2015, J CHILD ADOL PSYCHOP, V25, P65, DOI 10.1089/cap.2014.0067; Küry S, 2017, AM J HUM GENET, V101, P768, DOI 10.1016/j.ajhg.2017.10.003; Labouesse MA, 2015, EPIGENETICS-US, V10, P1143, DOI 10.1080/15592294.2015.1114202; Lin JJ, 2012, PEDIATR NEUROL, V47, P252, DOI 10.1016/j.pediatrneurol.2012.06.013; Masi A, 2015, MOL PSYCHIATR, V20, P440, DOI 10.1038/mp.2014.59; Mostafa GA, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-39; Mostafa GA, 2009, PEDIATR NEUROL, V40, P107, DOI 10.1016/j.pediatrneurol.2008.10.017; Mostafa GA, 2012, EUR J PAEDIATR NEURO, V16, P464, DOI 10.1016/j.ejpn.2011.12.010; Murray MJ, 2011, J AUTISM DEV DISORD, V41, P1586, DOI 10.1007/s10803-011-1178-0; Najjar S, 2013, COGN BEHAV NEUROL, V26, P36, DOI 10.1097/WNN.0b013e31828b6531; Niiederhofer H, 2003, NEUROPSYCHOPHARMACOL, V28, P1014, DOI 10.1038/sj.npp.1300130; Nordahl CW, 2013, BRAIN BEHAV IMMUN, V30, P61, DOI 10.1016/j.bbi.2013.01.084; Oleske J., 2004, ANOTHER VIEW AUTISM; Olexová L, 2016, NEUROSCI LETT, V629, P9, DOI 10.1016/j.neulet.2016.06.035; Olson JA, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e50; Perlmutter SJ, 1998, AM J PSYCHIAT, V155, P1592, DOI 10.1176/ajp.155.11.1592; Perlmutter SJ, 1999, LANCET, V354, P1153, DOI 10.1016/S0140-6736(98)12297-3; Piras IS, 2014, BRAIN BEHAV IMMUN, V38, P91, DOI 10.1016/j.bbi.2013.12.020; Plioplys AV, 1998, J CHILD NEUROL, V13, P79, DOI 10.1177/088307389801300207; Reichow B, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009260.pub2, 10.1002/14651858.CD009260.pub3]; Richetto J, 2013, BRAIN BEHAV IMMUN, V33, P190, DOI 10.1016/j.bbi.2013.07.006; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00150; Rout UK, 2012, EUR CHILD ADOLES PSY, V21, P141, DOI 10.1007/s00787-012-0245-1; Saltik S, 2013, PEDIATR NEUROL, V48, P403, DOI 10.1016/j.pediatrneurol.2012.12.031; Sanefuji M, 2013, BRAIN DEV-JPN, V35, P575, DOI 10.1016/j.braindev.2012.08.003; Scott O, 2014, J CHILD NEUROL, V29, P691, DOI 10.1177/0883073813501875; Spiciarich MC, 2016, PEDIATR NEUROL, V62, P43, DOI 10.1016/j.pediatrneurol.2016.06.004; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Wei R, 2016, BEHAV BRAIN RES, V314, P190, DOI 10.1016/j.bbr.2016.08.006; Yip J, 2009, AUTISM RES, V2, P50, DOI 10.1002/aur.62; Zablotsky Benjamin, 2015, Natl Health Stat Report, P1; Zalewski NL, 2016, MUSCLE NERVE, V54, P220, DOI 10.1002/mus.25027";71;39;40;1;5;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;2158-3188;;;TRANSL PSYCHIAT;Transl. Psychiatr.;AUG 10;2018;8;;;;;;;;148;10.1038/s41398-018-0214-7;http://dx.doi.org/10.1038/s41398-018-0214-7;;;14;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;GP9YC;30097568;Green Published, gold;;;24/11/2024;WOS:000441271300001;View Full Record in Web of Science
J;"Hasanzadeh, E; Mohammadi, MR; Ghanizadeh, A; Rezazadeh, SA; Tabrizi, M; Rezaei, F; Akhondzadeh, S";;;;"Hasanzadeh, Elmira; Mohammadi, Mohammad-Reza; Ghanizadeh, Ahmad; Rezazadeh, Shams-Ali; Tabrizi, Mina; Rezaei, Farzin; Akhondzadeh, Shahin";;;A Double-Blind Placebo Controlled Trial of Ginkgo biloba Added to Risperidone in Patients with Autistic Disorders;CHILD PSYCHIATRY & HUMAN DEVELOPMENT;;;English;Article;;;;;;"Autism; Ginkgo biloba; Clinical trial; Risperidone";"ALTERNATIVE MEDICINE; PHARMACOLOGICAL-TREATMENT; SPECTRUM DISORDERS; ABERRANT BEHAVIOR; CHILDREN; COMPLEMENTARY";Ginkgo biloba has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of Ginkgo biloba extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of autism. Forty-seven outpatients with a DSM-IV-TR diagnosis of autism ages between 4 and 12 years were assigned to this double blinded clinical trial and were randomly divided into two groups. One group received risperidone plus Ginko T.D and the other received risperidone plus placebo. The dose of risperidone was 1-3 mg/day and the dose of Ginko T.D. was 80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg. Patients were assessed using Aberrant Behavior Checklist-Community (ABC-C) rating scale and the side effect check list every 2 weeks until the endpoint. None of the 5 subscales of ABC-C rating scale showed significant differences between the two groups. Incidents of side effects were not significantly different between the two groups. Adding Ginkgo biloba to risperidone did not affect the treatment outcome of ADs. Nevertheless, further observations are needed to confirm this result.;"[Hasanzadeh, Elmira; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin] Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, Tehran 13337, Iran; [Ghanizadeh, Ahmad] Shiraz Univ Med Sci, Hafez Hosp, Res Ctr Psychiat & Behav Sci, Shiraz, Iran; [Rezazadeh, Shams-Ali] Inst Med Plants ACECR, Tehran, Iran; [Tabrizi, Mina] Univ Tehran Med Sci, Dept Med Genet, Tehran, Iran; [Rezaei, Farzin] Kurdistan Univ Med Sci, Qods Hosp, Sanandaj, Iran";"Tehran University of Medical Sciences; Shiraz University of Medical Science; Tehran University of Medical Sciences; Kurdistan University of Medical Sciences";Akhondzadeh, S (corresponding author), Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, S Kargar St, Tehran 13337, Iran.;s.akhond@neda.net;"rezaei, farzin/HHS-0336-2022; Mohammadi, MohammadReza/A-2863-2019; Akhondzadeh, Shahin/F-2914-2018";Akhondzadeh, Shahin/0000-0002-2277-5101;;;;"Akhondzadeh S, 2004, J CLIN PHARM THER, V29, P145, DOI 10.1111/j.1365-2710.2004.00546.x; Akhondzadeh S, 1999, J CLIN PHARM THER, V24, P241, DOI 10.1046/j.1365-2710.1999.00231.x; Akhondzadeh S, 2008, CHILD PSYCHIAT HUM D, V39, P237, DOI 10.1007/s10578-007-0084-3; Akhondzadeh S, 2010, PROG NEURO-PSYCHOPH, V34, P32, DOI 10.1016/j.pnpbp.2009.09.012; Akins RS, 2010, NEUROTHERAPEUTICS, V7, P307, DOI 10.1016/j.nurt.2010.05.002; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], MORBIDITY MORTALITY; Bake S., 2003, NEUROEMBRYOLOGY, V2, P175; Beaubrun G, 2000, PSYCHIATR SERV, V51, P1130, DOI 10.1176/appi.ps.51.9.1130; Bent S, 2010, NEUROTHERAPEUTICS, V7, P232, DOI 10.1016/j.nurt.2010.05.011; Blankenship Kelly, 2010, Ped Health, V4, P375, DOI 10.2217/phe.10.45; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; Hanson E, 2007, J AUTISM DEV DISORD, V37, P628, DOI 10.1007/s10803-006-0192-0; Itil TM, 1998, PSYCHOPHARMACOL BULL, V34, P391; Leskovec TJ, 2008, HARVARD REV PSYCHIAT, V16, P97, DOI 10.1080/10673220802075852; Levy SE, 2008, CHILD ADOL PSYCH CL, V17, P803, DOI 10.1016/j.chc.2008.06.004; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Maclennan KM, 2002, PROG NEUROBIOL, V67, P235, DOI 10.1016/S0301-0082(02)00015-1; Mohammadi MR, 2007, CURR DRUG THER, V2, P97, DOI 10.2174/157488507780619095; Niederhofer H, 2009, PHYTOTHER RES, V23, P1645, DOI 10.1002/ptr.2778; Ratajczak HV, 2011, J IMMUNOTOXICOL, V8, P68, DOI 10.3109/1547691X.2010.545086; Rezaei V, 2010, PROG NEURO-PSYCHOPH, V34, P1269, DOI 10.1016/j.pnpbp.2010.07.005; Steyaert JG, 2008, EUR J PEDIATR, V167, P1091, DOI 10.1007/s00431-008-0764-4; West L, 2009, J PEDIATR HEALTH CAR, V23, P75, DOI 10.1016/j.pedhc.2008.12.001";25;31;33;1;27;SPRINGER;NEW YORK;ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES;0009-398X;1573-3327;;CHILD PSYCHIAT HUM D;Child Psychiat. Hum. Dev.;OCT;2012;43;5;;;;;674;682;;10.1007/s10578-012-0292-3;http://dx.doi.org/10.1007/s10578-012-0292-3;;;9;"Psychology, Developmental; Pediatrics; Psychiatry";Social Science Citation Index (SSCI);"Psychology; Pediatrics; Psychiatry";993TW;22392415;;;;24/11/2024;WOS:000307883500002;View Full Record in Web of Science
J;"Zhang, YT; Zhang, J; Pan, ZY; He, XX";;;;"Zhang, Yiting; Zhang, Jing; Pan, Zhaoyu; He, Xingxiang";;;Effects of Washed Fecal Bacteria Transplantation in Sleep Quality, Stool Features and Autism Symptomatology: A Chinese Preliminary Observational Study;NEUROPSYCHIATRIC DISEASE AND TREATMENT;;;English;Article;;;;;;"SDSC; ABC; CARS; BSFS; microbiota-gut-brain axis";"SPECTRUM DISORDER; MICROBIOTA TRANSPLANTATION; CHILDREN; PREVALENCE; SYMPTOMS; SCALE";Purpose: Autism spectrum disorder is a highly complex neurological and psychosocial disorder characterized by social dysfunction, severe reduction in speech, and a single stereotyped behavior. The treatment methods are currently limited, and children with autism generally suffer from constipation and sleep disorders. It is urgent to find an alternative psychotropic drug, given the drug dependence and adverse reactions that may occur with long-term medication. Patients and Methods: This retrospective study included 49 children with autism at the first affiliated Hospital of Guangdong Pharmaceutical University, who received washed fecal microbiota transplantation (WMT) treatment between June 2019 and July 2021 and compared the sleep disorder scores between the constipation group, control group and blank group. Results: Second WMT could significantly improve the sleep disorder scores in the constipation group (p=0.026) and the decrease in sleep disturbance scale for children (SDSC) score was synchronized with the increase in Bristol stool form scale (BSFS) score. However, there was no significant difference between patients without constipation (p=0.54), and the behavior of autism improved in both groups. Conclusion: WMT could relieve constipation and improve sleep disorders in children with autism, with no deterioration in stool morphology and sleep disorders in other children. Moreover, there were no obvious serious adverse clinical events after WMT.;"[Zhang, Yiting; Pan, Zhaoyu; He, Xingxiang] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Gastroenterol, 19 Nonglinxia Rd, Guangzhou 510062, Peoples R China; [Zhang, Jing] Sun Yat Sen Univ, Foshan Hosp, Foshan, Peoples R China";"Guangdong Pharmaceutical University; Sun Yat Sen University";He, XX (corresponding author), Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Gastroenterol, 19 Nonglinxia Rd, Guangzhou 510062, Peoples R China.;hexingxiang@gdpu.edu.cn;zhang, yiting/LCD-5004-2024;zhang, yiting/0000-0002-3689-1939;"Natural Science Foundation of Guangdong Province [2019A1515010125]; Guangdong Provincial key disciplines Scientific Research Project of Guangdong Education Department [2019-GDXK-0013]; Special Research Project of COVID-19 epidemic Prevention and Control in Colleges and Universities of Guangdong Province [2020KZDZX1132]";"Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Provincial key disciplines Scientific Research Project of Guangdong Education Department; Special Research Project of COVID-19 epidemic Prevention and Control in Colleges and Universities of Guangdong Province";This study was funded by the Natural Science Foundation of Guangdong Province (Project No.: 2019A1515010125), the Guangdong Provincial key disciplines Scientific Research Project of Guangdong Education Department (Project No.: 2019-GDXK-0013), and the Special Research Project of COVID-19 epidemic Prevention and Control in Colleges and Universities of Guangdong Province (Project No.: 2020KZDZX1132).;"Anagnostou E, 2016, JAMA PSYCHIAT, V73, P928, DOI 10.1001/jamapsychiatry.2016.1232; Andreo-Martínez P, 2022, J AUTISM DEV DISORD, V52, P1374, DOI 10.1007/s10803-021-05002-y; Andreo-Martínez P, 2020, ENV MICROBIOL REP, V12, P115, DOI 10.1111/1758-2229.12810; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Battle DE, 2013, CODAS, V25, P191; Bermudez-Martin P, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01103-z; Chen SB, 2019, J NEUROGASTROENTEROL, V25, P148, DOI 10.5056/jnm17085; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Culpin I, 2018, J AM ACAD CHILD PSY, V57, P313, DOI 10.1016/j.jaac.2018.01.023; Martínez-González AE, 2020, REV PSIQUIATR SALUD, V13, P150, DOI 10.1016/j.rpsm.2020.06.002; Martínez-González AE, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55080408; Hedley D, 2018, RES AUTISM SPECT DIS, V46, P1, DOI 10.1016/j.rasd.2017.11.003; Hom MA, 2017, PSYCHIAT RES, V253, P116, DOI 10.1016/j.psychres.2017.03.046; Huang MM, 2014, SLEEP MED, V15, P923, DOI 10.1016/j.sleep.2014.03.023; Hus V, 2007, BIOL PSYCHIAT, V61, P438, DOI 10.1016/j.biopsych.2006.08.044; Hus Y, 2021, NEUROPSYCH DIS TREAT, V17, P3509, DOI 10.2147/NDT.S282569; Ianiro G, 2020, FUTURE MICROBIOL, V15, P1173, DOI 10.2217/fmb-2020-0061; Johnson CR, 2018, SLEEP MED, V44, P61, DOI 10.1016/j.sleep.2018.01.008; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Krajicek E, 2019, CLIN GASTROENTEROL H, V17, P345, DOI 10.1016/j.cgh.2018.09.029; Kulich KR, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-12; Lane MM, 2011, J PEDIATR-US, V159, P437, DOI 10.1016/j.jpeds.2011.03.002; Li Q, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.661223; Lin LZ, 2021, ENVIRON HEALTH-GLOB, V20, DOI 10.1186/s12940-021-00793-0; Liu Z, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2020.1854967; Marraffa C, 2016, J PAEDIATR CHILD H, V52, P461, DOI 10.1111/jpc.13178; Quigley EMM, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0802-6; Randall M, 2018, COCHRANE DB SYST REV, P1, DOI 10.1002/14651858.CD009044.pub2; Sharon G, 2019, CELL, V177, P1600, DOI 10.1016/j.cell.2019.05.004; Shi Q, 2020, CHINESE MED J-PEKING, V133, P2330, DOI 10.1097/CM9.0000000000000954; Soe-Agnie SE, 2018, PSYCHIAT RES, V259, P412, DOI 10.1016/j.psychres.2017.11.007; Sokol MH., 2020, USING FECAL MICROBIO; Tait C, 2021, EUR J INTERN MED, V84, P1, DOI 10.1016/j.ejim.2020.12.023; Taylor CM, 2019, P NUTR SOC, V78, P161, DOI 10.1017/S0029665118002586; VOLKMAR FR, 1988, J AUTISM DEV DISORD, V18, P81, DOI 10.1007/BF02211820; Yang B, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.746990; Zhang FM, 2019, CURR OPIN PHARMACOL, V49, P11, DOI 10.1016/j.coph.2019.04.004; Zhang T, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-01285-0; Zhang T, 2020, PROTEIN CELL, V11, P251, DOI 10.1007/s13238-019-00684-8; Zhou H, 2020, NEUROSCI BULL, V36, P961, DOI 10.1007/s12264-020-00530-6";40;7;9;4;23;DOVE MEDICAL PRESS LTD;ALBANY;PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND;;1178-2021;;NEUROPSYCH DIS TREAT;Neuropsychiatr. Dis. Treat.;;2022;18;;;;;;1165;1173;;10.2147/NDT.S355233;http://dx.doi.org/10.2147/NDT.S355233;;;9;"Clinical Neurology; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Psychiatry";2C0ZH;35719863;Green Published, gold;;;24/11/2024;WOS:000810606300001;View Full Record in Web of Science
J;"Sulistyoningrum, D; Green, T; Palmer, D; Sullivan, T; Wood, S; Makrides, M; Skubisz, M; Best, KP";;;;"Sulistyoningrum, Dian; Green, Tim; Palmer, Debbie; Sullivan, Thomas; Wood, Simon; Makrides, Maria; Skubisz, Monika; Best, Karen P.";;;Study protocol for a randomised controlled trial evaluating the effect of folic acid supplementation beyond the first trimester on maternal plasma unmetabolised folic acid in late gestation;BMJ OPEN;;;English;Article;;;;;;"nutrition & dietetics; obstetrics; public health";"NEURAL-TUBE DEFECTS; CHILDHOOD ASTHMA; EARLY-PREGNANCY; FOLATE INTAKE; WOMEN; VITAMIN-B-12; RISK; ASSOCIATION; PREVENTION; COUNCIL";"Introduction Taking folic acid containing supplements prior to and during early pregnancy reduces the risk of neural tube defects. Neural tube defects occur prior to 28 days postconception, after which, there is no proven benefit of continuing to take folic acid. However, many women continue to take folic acid containing supplements throughout the pregnancy. At higher intakes, folic acid is not converted to its active form and accumulates in circulation as unmetabolised folic acid (UMFA). Recently, concerns have been raised about possible links between late gestation folic acid supplementation and childhood allergy, metabolic disease and autism spectrum disorders. We aim to determine if removing folic acid from prenatal micronutrient supplements after 12 weeks gestation reduces circulating levels of maternal UMFA at 36 weeks gestation. Methods and analysis This is a parallel-design, double-blinded randomised controlled trial. Women >= 12 and <16 weeks' gestation with a singleton pregnancy and able to give informed consent are eligible to participate. Women (n=100; 50 per group) will be randomised to receive either a micronutrient supplement containing 0.8 mg of folic acid or a micronutrient supplement without folic acid daily from enrolment until delivery. The primary outcome is plasma UMFA concentration at 36 weeks gestation. Secondary outcomes include red blood cell folate and total plasma folate concentration. We will assess whether there is a difference in mean UMFA levels at 36 weeks gestation between groups using linear regression with adjustment for baseline UMFA levels and gestational age at trial entry. The treatment effect will be described as a mean difference with 95% CI. Ethics and dissemination Ethical approval has been granted from the Women's and Children's Health Network Research Ethics Committee (HREC/19/WCHN/018). The results of this trial will be presented at scientific conferences and published in peer-reviewed journals.";"[Sulistyoningrum, Dian; Green, Tim; Sullivan, Thomas; Makrides, Maria; Skubisz, Monika; Best, Karen P.] South Australia Hlth & Med Res Inst, SAHMRI Women & Kids Theme, Adelaide, SA, Australia; [Sulistyoningrum, Dian; Green, Tim; Makrides, Maria; Skubisz, Monika; Best, Karen P.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia; [Palmer, Debbie] Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia; [Sullivan, Thomas] Univ Adelaide, Fac Hlth & Med Sci, Sch Publ Hlth, Adelaide, SA, Australia; [Wood, Simon] Curtin Univ, Fac Sci & Engn, Perth, WA, Australia; [Wood, Simon] Univ British Columbia, Fac Land & Food Syst, Vancouver, BC, Canada";"University of Adelaide; The Kids Research Institute Australia; University of Western Australia; University of Adelaide; Curtin University; University of British Columbia";"Best, KP (corresponding author), South Australia Hlth & Med Res Inst, SAHMRI Women & Kids Theme, Adelaide, SA, Australia.;Best, KP (corresponding author), Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.";karen.best@sahmri.com;"Sulistyoningrum, Dian/JJG-0345-2023; Green, Tim/AAA-8601-2019; Palmer, Debra/AAH-6160-2019; Best, Karen/E-3293-2016";"Palmer, Debra/0000-0003-2498-8343; Sulistyoningrum, Dian/0000-0001-9654-2151; Best, Karen/0000-0002-7653-5074; Sullivan, Thomas/0000-0002-6930-5406; Green, Timothy/0000-0002-0667-4300";"South Australian Health and Medical Research Institute (Adelaide, Australia); Women's and Children's Hosptial Foundation [Best_WCHFG_2020]; Royal Australian; New Zealand College of Obstetricians and Gynaecologists; Women's and Children's Hospital Foundation, MS McLeod Postdoctoral Research Fellowship; Australian Government Research Training Program Scholarship from The University of Adelaide";"South Australian Health and Medical Research Institute (Adelaide, Australia); Women's and Children's Hosptial Foundation; Royal Australian; New Zealand College of Obstetricians and Gynaecologists; Women's and Children's Hospital Foundation, MS McLeod Postdoctoral Research Fellowship; Australian Government Research Training Program Scholarship from The University of Adelaide";This study is sponsored by the South Australian Health and Medical Research Institute (Adelaide, Australia). This study is supported by grants in aid from the Women's and Children's Hosptial Foundation (Best_WCHFG_2020). An Ella McKnight Scholarship from the Royal Australian and New Zealand College of Obstetricians and Gynaecologists supports MS. KPB is supported by a Women's and Children's Hospital Foundation, MS McLeod Postdoctoral Research Fellowship. DS is supported by the Australian Government Research Training Program Scholarship from The University of Adelaide. The study product is donated by Factors Group of Companies, Coquitlam, British Columbia, Canada.;"[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 2016, MON HLTH IMP MAND FO; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; Bekkers MBM, 2012, EUR RESPIR J, V39, P1468, DOI 10.1183/09031936.00094511; BLAKLEY RL, 1987, EUR J BIOCHEM, V168, P251, DOI 10.1111/j.1432-1033.1987.tb13413.x; Crider KS, 2018, AM J CLIN NUTR, V107, P1027, DOI 10.1093/ajcn/nqy065; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DeSoto M, 2016, J PEDIAT BIOCH, V2, P251; Dunstan JA, 2012, ALLERGY, V67, P50, DOI 10.1111/j.1398-9995.2011.02714.x; Fortes C, 2019, ARCH DERMATOL RES, V311, P361, DOI 10.1007/s00403-019-01911-2; Granell R, 2008, CLIN EXP ALLERGY, V38, P320, DOI 10.1111/j.1365-2222.2007.02902.x; Håberg SE, 2009, ARCH DIS CHILD, V94, P485, DOI 10.1136/adc.2008.142448corr1; Hodge A, 2000, AUST NZ J PUBL HEAL, V24, P576, DOI 10.1111/j.1467-842X.2000.tb00520.x; Kiefte-de Jong JC, 2012, J NUTR, V142, P731, DOI 10.3945/jn.111.154948; Levine SZ, 2018, JAMA PSYCHIAT, V75, P176, DOI 10.1001/jamapsychiatry.2017.4050; Magdelijns FJH, 2011, PEDIATRICS, V128, pE135, DOI 10.1542/peds.2010-1690; Makrides M, 2019, NEW ENGL J MED, V381, P1035, DOI 10.1056/NEJMoa1816832; Martinussen MP, 2015, EUR J OBSTET GYN R B, V195, P94, DOI 10.1016/j.ejogrb.2015.09.022; McGowan EC, 2020, J ALLER CL IMM-PRACT, V8, P132, DOI 10.1016/j.jaip.2019.06.017; McNulty B, 2013, AM J CLIN NUTR, V98, P92, DOI 10.3945/ajcn.112.057489; McStay CL, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020123; Parr CL, 2017, AM J RESP CRIT CARE, V195, P221, DOI [10.1164/rccm.201604-078800, 10.1164/rccm.201604-0788OC]; Pentieva K, 2016, J NUTR, V146, P494, DOI 10.3945/jn.115.223644; Pfeiffer CM, 2015, J NUTR, V145, P520, DOI 10.3945/jn.114.201210; Plumptre L, 2015, AM J CLIN NUTR, V102, P848, DOI 10.3945/ajcn.115.110783; Raghavan R, 2018, PAEDIATR PERINAT EP, V32, P100, DOI 10.1111/ppe.12414; RANZCOG, 2020, ANT CAR PREGN; Sadler TW, 2005, AM J MED GENET C, V135C, P2, DOI 10.1002/ajmg.c.30049; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1136/bmj.c332, 10.1016/j.jclinepi.2010.02.005, 10.1186/1741-7015-8-18, 10.1016/j.ijsu.2011.09.004, 10.4103/0976-500X.72352]; Veeranki SP, 2015, EPIDEMIOLOGY, V26, P934, DOI 10.1097/EDE.0000000000000380; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; WHO, 2016, WHO Recommendations on Antenatal Care for a Positive Pregnancy Experience; Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y; Yang T, 2017, J CLIN BIOCHEM NUTR, V60, P136, DOI 10.3164/jcbn.16-45; Zayed A, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11020052; Zetstra-van der Woude PA, 2014, PHARMACOEPIDEM DR S, V23, P1059, DOI 10.1002/pds.3652; Zhang M, 2018, J NUTR, V148, P807, DOI 10.1093/jn/nxy030";37;8;8;0;3;BMJ PUBLISHING GROUP;LONDON;BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND;2044-6055;;;BMJ OPEN;BMJ Open;;2020;10;11;;;;;;;e040416;10.1136/bmjopen-2020-040416;http://dx.doi.org/10.1136/bmjopen-2020-040416;;;7;Medicine, General & Internal;Science Citation Index Expanded (SCI-EXPANDED);General & Internal Medicine;PA2DA;33199423;gold, Green Published;;;24/11/2024;WOS:000595442000008;View Full Record in Web of Science
J;"Taliou, A; Zintzaras, E; Lykouras, L; Francis, K";;;;"Taliou, Anilia; Zintzaras, Elias; Lykouras, Lefteris; Francis, Kostantinos";;;An Open-Label Pilot Study of a Formulation Containing the Anti-Inflammatory Flavonoid Luteolin and Its Effects on Behavior in Children With Autism Spectrum Disorders;CLINICAL THERAPEUTICS;;;English;Article;;;;;;"ASD; luteolin; flavonoids; inflammation; brain";"GLOBAL IMPRESSION SCALE; ADAPTIVE-BEHAVIOR; INFLAMMATION; ADOLESCENTS; RISPERIDONE; PROGRESS; DISEASE; SCORES; SAFETY";"Background: Accumulating evidence suggests an association between autism spectrum disorders (ASD) and inflammation in brain regions related to cognitive function. The natural flavonoid luteolin has antioxidant, anti-inflammatory, mast cell blocking, and neuroprotective effects. It was shown to improve cognitive performance in a mouse model of ASD, but its effect in humans has not been adequately studied. Objectives: The goal of this study was to assess the effectiveness and tolerability in white children with ASD of a dietary supplement containing 2 flavonoids (>95% pure), luteolin (100 mg/capsule, from chamomile) and quercetin (70 mg/capsule), and the quercetin glycoside rutin (30 mg/capsule) from the Sophora japonica leaf, formulated in olive kernel oil to increase oral absorption. Methods: Fifty children (4-10 years old; 42 boys and 8 girls) with ASD were enrolled in a 26-week, prospective, open-label trial at the 2nd University Department of Psychiatry at Attikon General Hospital, Athens, Greece. Children were referred for the study by their respective physicians or came from the practice of the senior author. ASD diagnosis by clinical assessment was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, symptom list and corroborated by using the Autism Diagnostic Observation Schedule. The dose of the study formulation used was 1 capsule per 10 kg weight per day with food. The primary outcome measures were the age-equivalent scores in the Vineland Adaptive Behavior Scales domains. Secondary outcomes included the Aberrant Behavior Checklist, the Autism Treatment Evaluation Checklist, and the Clinical Global Impression Improvement score. Data were measured at baseline, week 18, and week 26. Parents were interviewed for any possible improvements they noticed and instructed to report any unusual adverse events. Results: A total of 40 children completed the protocol. There was a significant improvement in adaptive functioning as measured by using the VABS age-equivalent scores (8.43 months in the communication domain, 7.17 months in daily living skills, and 8 months in the social domain; P < 0.005), as well as in overall behavior as indicated by the reduction (26.6%-34.8%) in Aberrant Behavior Checklist subscale scores. Age, sex, and history of allergies had no effect on the results, whereas the initial level of functioning or difficulty did predict the final outcome in most of the measures used. There was a transient (1-8 weeks) increased irritability in 27 of the 50 participants. Conclusions: These results are encouraging in that the combination of the flavonoids luteolin and quercetin seemed to be effective in reducing ASD symptoms, with no major adverse effects. (c) 2013 Elsevier HS Journals, Inc. All rights reserved.";"[Taliou, Anilia; Lykouras, Lefteris; Francis, Kostantinos] Univ Athens, Sch Med, Dept Psychiat 2, Attikon Gen Hosp, Athens 12462, Greece; [Zintzaras, Elias] Univ Larissa, Dept Math & Bioinformat, Larisa, Greece";"Athens Medical School; University Hospital Attikon; National & Kapodistrian University of Athens";Francis, K (corresponding author), Univ Athens, Sch Med, Dept Psychiat 2, Attikon Gen Hosp, 1 Rimini St, Athens 12462, Greece.;cfrancis@otenet.gr;;;Algonot, LLC;Algonot, LLC;"This study was funded by Algonot, LLC, the maker of the study formulation. This support consisted of free formulation to the patients for the duration of the study and a small honorarium to Drs. Taliou, Lykouras, and Francis for the time required to perform the diagnoses, the administration of the outcome instruments, and the tabulation and writing of the results. The biostatistician (Dr. Zintzaras) performed the analysis blinded and pro bono. Study sponsors had no involvement in the study design; in the collection, analysis, and interpretation of data; the writing of the manuscript; or in the decision to submit the manuscript for publication.";"AMAN MG, 1985, AM J MENT DEF, V89, P492; Anderson DK, 2009, J ABNORM CHILD PSYCH, V37, P1019, DOI 10.1007/s10802-009-9326-0; Angelidou A, 2011, J AUTISM DEV DISORD, V41, P1579, DOI 10.1007/s10803-010-1171-z; [Anonymous], BEHAV BRAIN RES; [Anonymous], 2000, Quick Reference to the Diagnostic Criteria From DSM-IV-TR; Ashwood P, 2006, J LEUKOCYTE BIOL, V80, P1, DOI 10.1189/jlb.1205707; Berk M, 2008, J EVAL CLIN PRACT, V14, P979, DOI 10.1111/j.1365-2753.2007.00921.x; Broadstock M, 2007, AUTISM, V11, P335, DOI 10.1177/1362361307078132; Carter AS, 1998, J AUTISM DEV DISORD, V28, P287, DOI 10.1023/A:1026056518470; Charman T, 2004, AUTISM, V8, P89, DOI 10.1177/1362361304040641; El-Ansary A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-265; Fisch GS, 2002, J AUTISM DEV DISORD, V32, P107, DOI 10.1023/A:1014888505185; Forkmann T, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-83; Freeman BJ, 1999, J AUTISM DEV DISORD, V29, P379, DOI 10.1023/A:1023078827457; Gurney JG, 2006, ARCH PEDIAT ADOL MED, V160, P825, DOI 10.1001/archpedi.160.8.825; Hagberg H, 2012, ANN NEUROL, V71, P444, DOI 10.1002/ana.22620; Harris S.L., 1995, Special Services in the Schools, V10, P45; Harwood M, 2007, FOOD CHEM TOXICOL, V45, P2179, DOI 10.1016/j.fct.2007.05.015; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Jyonouchi H, 2010, EXPERT REV CLIN IMMU, V6, P397, DOI [10.1586/eci.10.18, 10.1586/ECI.10.18]; Kadouri A, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-7; Kawanishi S, 2005, ANTIOXID REDOX SIGN, V7, P1728, DOI 10.1089/ars.2005.7.1728; Kempuraj D, 2005, BRIT J PHARMACOL, V145, P934, DOI 10.1038/sj.bjp.0706246; Kim YS, 2011, AM J PSYCHIAT, V168, P904, DOI 10.1176/appi.ajp.2011.10101532; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Magalhaes ES, 2009, J NEUROIMMUNOL, V216, P108, DOI 10.1016/j.jneuroim.2009.09.015; Magiati I, 2011, J INTELL DISABIL RES, V55, P302, DOI 10.1111/j.1365-2788.2010.01359.x; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McPartland J, 2012, HAND CLINIC, V106, P407, DOI 10.1016/B978-0-444-52002-9.00023-1; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Middleton E, 2000, PHARMACOL REV, V52, P673; Moshfegh Alanna J., 2012, Morbidity and Mortality Weekly Report, V61, P92; Pardo CA, 2006, INT REV PSYCHIATR, V17, P485, DOI 10.1080/02646830500381930; Parker-Athill E, 2009, J NEUROIMMUNOL, V217, P20, DOI 10.1016/j.jneuroim.2009.08.012; Rimland B., 2000, Autism Treatment Evaluation Checklist (ATEC); Rogers SJ, 2008, J CLIN CHILD ADOLESC, V37, P8, DOI 10.1080/15374410701817808; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Scahill L, 2004, CNS SPECTRUMS, V9, P22, DOI 10.1017/S1092852900008336; Shimoi K, 1998, FEBS LETT, V438, P220, DOI 10.1016/S0014-5793(98)01304-0; Smile S, 2012, CURR PSYCHIAT REP, V14, P726, DOI 10.1007/s11920-012-0326-3; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; SUBIZA J, 1989, J ALLERGY CLIN IMMUN, V84, P353, DOI 10.1016/0091-6749(89)90420-X; Theoharides TC, 2012, INT J IMMUNOPATH PH, V25, P317, DOI 10.1177/039463201202500201; Theoharides TC, 2008, TRENDS PHARMACOL SCI, V29, P375, DOI 10.1016/j.tips.2008.06.002; Theoharides TC, 2011, J CLIN PSYCHOPHARM, V31, P685, DOI 10.1097/JCP.0b013e318239c190; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P34, DOI 10.1016/j.bbadis.2010.12.017; Theoharides TC, 2009, INT J IMMUNOPATH PH, V22, P859, DOI 10.1177/039463200902200401; Williams SK, 2006, J AM ACAD CHILD PSY, V45, P431, DOI 10.1097/01.chi.0000196423.80717.32";50;151;159;3;43;ELSEVIER;BRIDGEWATER;685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA;0149-2918;1879-114X;;CLIN THER;Clin. Ther.;MAY;2013;35;5;;;;;592;602;;10.1016/j.clinthera.2013.04.006;http://dx.doi.org/10.1016/j.clinthera.2013.04.006;;;11;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;153YA;23688534;;;;24/11/2024;WOS:000319637500008;View Full Record in Web of Science
J;"Sanctuary, MR; Kain, JN; Chen, SY; Kalanetra, K; Lemay, DG; Rose, DR; Yang, HT; Tancredi, DJ; German, JB; Slupsky, CM; Ashwood, P; Mills, DA; Smilowitz, JT; Angkustsiri, K";;;;"Sanctuary, Megan R.; Kain, Jennifer N.; Chen, Shin Yu; Kalanetra, Karen; Lemay, Danielle G.; Rose, Destanie R.; Yang, Houa T.; Tancredi, Daniel J.; German, J. Bruce; Slupsky, Carolyn M.; Ashwood, Paul; Mills, David A.; Smilowitz, Jennifer T.; Angkustsiri, Kathleen";;;Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms;PLOS ONE;;;English;Article;;;;;;;"LYMPHOCYTE CYTOKINE PROFILES; COMMON DIETARY PROTEINS; BOVINE COLOSTRUM; SPECTRUM DISORDERS; HUMAN-MILK; NECROTIZING ENTEROCOLITIS; IMMUNE ACTIVATION; N-GLYCANS; OLIGOSACCHARIDES; BIFIDOBACTERIA";Over half of all children with autism spectrum disorders (ASD) have gastrointestinal (GI) co-morbidities including chronic constipation, diarrhea, and irritable bowel syndrome. The severity of these symptoms has been correlated with the degree of GI microbial dysbiosis. The study objective was to assess tolerability of a probiotic (Bifidobacterium infantis) in combination with a bovine colostrum product (BCP) as a source of prebiotic oligosaccharides and to evaluate GI, microbiome and immune factors in children with ASD and GI co-morbidities. This pilot study is a randomized, double blind, controlled trial of combination treatment (BCP + B. infantis) vs. BCP alone in a cross-over study in children ages 2-11 with ASD and GI co-morbidities (n = 8). This 12-week study included 5 weeks of probiotic-prebiotic supplementation, followed by a two-week washout period, and 5 weeks of prebiotic only supplementation. The primary outcome of tolerability was assessed using validated questionnaires of GI function and atypical behaviors, along with side effects. Results suggest that the combination treatment is well-tolerated in this cohort. The most common side effect was mild gassiness. Some participants on both treatments saw a reduction in the frequency of certain GI symptoms, as well as reduced occurrence of particular aberrant behaviors. Improvement may be explained by a reduction in IL-13 and TNF-alpha production in some participants. Although limited conclusions can be drawn from this small pilot study, the results support the need for further research into the efficacy of these treatments.;"[Sanctuary, Megan R.; Slupsky, Carolyn M.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Kain, Jennifer N.] Univ Calif Davis, Dept Neurobiol Physiol & Behav, Davis, CA 95616 USA; [Chen, Shin Yu; Kalanetra, Karen; German, J. Bruce; Slupsky, Carolyn M.; Mills, David A.; Smilowitz, Jennifer T.] Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA; [Lemay, Danielle G.] USDA ARS, Western Human Nutr Res Ctr, Davis, CA USA; [Lemay, Danielle G.] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; [Rose, Destanie R.; Yang, Houa T.; Ashwood, Paul; Angkustsiri, Kathleen] Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA; [Lemay, Danielle G.; Tancredi, Daniel J.; Angkustsiri, Kathleen] Univ Calif, Dept Pediat, Sch Med, Sacramento, CA 95819 USA; [German, J. Bruce; Smilowitz, Jennifer T.] Univ Calif Davis, Foods Hlth Inst, Davis, CA 95616 USA";"University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; United States Department of Agriculture (USDA); University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis";"Angkustsiri, K (corresponding author), Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA.;Angkustsiri, K (corresponding author), Univ Calif, Dept Pediat, Sch Med, Sacramento, CA 95819 USA.";kangkustsiri@ucdavis.edu;"Mills, David/G-2282-2011; Kalanetra, Karen/AAP-3669-2021; Slupsky, Carolyn/IUQ-2359-2023; Tancredi, Daniel/O-3381-2013";"Ashwood, Paul/0000-0002-4255-1893; Lemay, Danielle/0000-0003-3318-0485; Tancredi, Daniel/0000-0002-3884-7907";"MIND pilot award; National Center for Advancing Translational Sciences, National Institutes of Health [UL1 TR000002, TL1 TR000133]; National Center for Complementary and Integrative Health [R01 AT008759]; U.S. Department of Agriculture [2032-53000-001-00-D]";"MIND pilot award; National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary and Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine (NCCAM)); U.S. Department of Agriculture(United States Department of Agriculture (USDA))";"This research was funded by a MIND pilot award to K.A. (http://www.ucdmc.ucdavis.edu/mindinstitute/); National Center for Advancing Translational Sciences (https://ncats.nih.gov/), National Institutes of Health #UL1 TR000002 to K. A. linked award TL1 TR000133 to M.R.S. and the National Center for Complementary and Integrative Health award R01 AT008759 to D.A.M. Author D.G. L. is funded by the U.S. Department of Agriculture project 2032-53000-001-00-D (https://www.usda.gov/).The United States Department of Agriculture is an equal opportunity provider and employer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.";"Adams JB, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-22; Al-Farsi Yahya M, 2012, Nutrition, V28, pe27, DOI 10.1016/j.nut.2012.01.007; Aldredge DL, 2013, GLYCOBIOLOGY, V23, P664, DOI 10.1093/glycob/cwt007; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Ashwood P, 2006, J NEUROIMMUNOL, V173, P126, DOI 10.1016/j.jneuroim.2005.12.007; Ashwood P, 2004, J CLIN IMMUNOL, V24, P664, DOI 10.1007/s10875-004-6241-6; Ashwood P, 2003, J CLIN IMMUNOL, V23, P504, DOI 10.1023/B:JOCI.0000010427.05143.bb; Boudry C, 2007, RES VET SCI, V83, P91, DOI 10.1016/j.rvsc.2006.11.003; BRINES RD, 1983, BIOCHIM BIOPHYS ACTA, V759, P229, DOI 10.1016/0304-4165(83)90317-3; Brooks HJL, 2006, FEMS IMMUNOL MED MIC, V48, P347, DOI 10.1111/j.1574-695X.2006.00151.x; Buie T, 2010, PEDIATRICS, V125, pS1, DOI 10.1542/peds.2009-1878C; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Cermak SA, 2010, J AM DIET ASSOC, V110, P238, DOI 10.1016/j.jada.2009.10.032; Chichlowski M, 2012, J PEDIATR GASTR NUTR, V55, P321, DOI 10.1097/MPG.0b013e31824fb899; Cordell B., 2013, Int J Clin Med, V4, P309, DOI 10.4236/ijcm.2013.47054; Costea PI, 2018, NAT MICROBIOL, V3, DOI 10.1038/s41564-017-0072-8; Critchfield JW, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/161358; Dahshan A, 2001, J PEDIATR GASTR NUTR, V33, P214, DOI 10.1097/00005176-200108000-00024; Dallas DC, 2014, FOOD RES INT, V63, P203, DOI 10.1016/j.foodres.2014.03.021; De Angelis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076993; de Magistris L, 2010, J PEDIATR GASTR NUTR, V51, P418, DOI 10.1097/MPG.0b013e3181dcc4a5; de Theije CGM, 2011, EUR J PHARMACOL, V668, pS70, DOI 10.1016/j.ejphar.2011.07.013; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; DEufemia P, 1996, ACTA PAEDIATR, V85, P1076, DOI 10.1111/j.1651-2227.1996.tb14220.x; Dicks CR, 2016, GRAS NOTICE 644 NON; Dong X, 2016, ELECTROPHORESIS, V37, P1532, DOI 10.1002/elps.201500561; Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914; Finegold SM, 2010, ANAEROBE, V16, P444, DOI 10.1016/j.anaerobe.2010.06.008; Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58; Frese SA, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0091-8; Furlano RI, 2001, J PEDIATR-US, V138, P366, DOI 10.1067/mpd.2001.111323; Garrido D, 2013, MICROBIOL-SGM, V159, P649, DOI 10.1099/mic.0.064113-0; Garrido D, 2012, MOL CELL PROTEOMICS, V11, P775, DOI 10.1074/mcp.M112.018119; Garrido D, 2012, ADV NUTR, V3, p415S, DOI 10.3945/an.111.001586; German JB, 2002, CURR OPIN CLIN NUTR, V5, P653, DOI 10.1097/00075197-200211000-00007; Goetze O, 2008, BRIT J NUTR, V100, P1077, DOI 10.1017/S0007114508960918; Gurney JG, 2006, ARCH PEDIAT ADOL MED, V160, P825, DOI 10.1001/archpedi.160.8.825; Hertz-Picciotto I, 2006, ENVIRON HEALTH PERSP, V114, P1119, DOI 10.1289/ehp.8483; Hicks AL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04204-w; Hughes HK, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00627; HUNNISETT A, 1990, Journal of Nutritional Medicine, V1, P33, DOI 10.3109/13590849009003132; Iovene M.R., 2016, MYCOPATHOLOGIA; Jansson-Nettelbladt E, 2006, ACTA PAEDIATR, V95, P502, DOI 10.1080/08035250500501625; Jyonouchi H, 2005, NEUROPSYCHOBIOLOGY, V51, P77, DOI 10.1159/000084164; Jyonouchi H, 2002, NEUROPSYCHOBIOLOGY, V46, P76, DOI 10.1159/000065416; Jyonouchi H, 2005, J PEDIATR-US, V146, P605, DOI 10.1016/j.jpeds.2005.01.027; Kaducu FO, 2011, INDIAN J GASTROENTER, V30, P270, DOI 10.1007/s12664-011-0146-0; Kang DW, 2017, MICROBIOME, V5, DOI 10.1186/s40168-016-0225-7; Kang DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068322; Karav S, 2016, APPL ENVIRON MICROB, V82, P3622, DOI 10.1128/AEM.00547-16; KONSTANTAREAS MM, 1987, J AUTISM DEV DISORD, V17, P585, DOI 10.1007/BF01486973; Kral TV., 2013, Journal of pediatric nursing; Kristensen NB, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0300-5; Lockner DW, 2008, J AM DIET ASSOC, V108, P1360, DOI 10.1016/j.jada.2008.05.003; Loennerdal B, 2011, J PEDIATR GASTR NUTR, V53, P606, DOI 10.1097/MPG.0b013e318230a419; Lönnerdal B, 2016, J PEDIATR-US, V173, pS4, DOI 10.1016/j.jpeds.2016.02.070; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maechler M, 2016, R PACKAGE VERSION 2; Mahé F, 2014, PEERJ, V2, DOI 10.7717/peerj.593; McElhanon BO, 2014, PEDIATRICS, V133, P872, DOI 10.1542/peds.2013-3995; McMurdie PJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003531; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Ming X, 2008, J CHILD NEUROL, V23, P6, DOI 10.1177/0883073807307102; Molloy CA, 2006, J NEUROIMMUNOL, V172, P198, DOI 10.1016/j.jneuroim.2005.11.007; Molloy CA, 2003, AUTISM, V7, P165, DOI 10.1177/1362361303007002004; Niehus R, 2006, J DEV BEHAV PEDIATR, V27, pS120, DOI 10.1097/00004703-200604002-00010; Nikolov RN, 2009, J AUTISM DEV DISORD, V39, P405, DOI 10.1007/s10803-008-0637-8; Nwosu CC, 2012, J PROTEOME RES, V11, P2912, DOI 10.1021/pr300008u; O'Sullivan A, 2015, NUTR METAB INSIGHTS, V8, DOI 10.4137/NMI.S29530; O'Sullivan A, 2013, J PROTEOME RES, V12, P481, DOI 10.1021/pr3009176; Oken BS, 2008, BRAIN, V131, P2812, DOI 10.1093/brain/awn116; Parracho HMRT, 2005, J MED MICROBIOL, V54, P987, DOI 10.1099/jmm.0.46101-0; R Development Core Team, 2016, R LANG ENV STAT COMP; Ravel J., 2011, Proceedings of the National Academy of Sciences of the United States of America, V108, P4680, DOI 10.1073/pnas.1002611107; Sanctuary MR, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00040; Sanders ME, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0629-z; Satyaraj E, 2013, BRIT J NUTR, V110, P2216, DOI 10.1017/S000711451300175X; Sela DA, 2010, TRENDS MICROBIOL, V18, P298, DOI 10.1016/j.tim.2010.03.008; Smilowitz JT, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0886-9; Smilowitz JT, 2014, ANNU REV NUTR, V34, P143, DOI 10.1146/annurev-nutr-071813-105721; Song YL, 2004, APPL ENVIRON MICROB, V70, P6459, DOI 10.1128/AEM.70.11.6459-6465.2004; Stelwagen K, 2009, J ANIM SCI, V87, P3, DOI 10.2527/jas.2008-1377; Takimori S, 2011, FEBS J, V278, P3769, DOI 10.1111/j.1742-4658.2011.08299.x; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Underwood MA, 2014, PEDIATR RES, V76, P326, DOI 10.1038/pr.2014.102; Underwood MA, 2013, J PEDIATR-US, V163, P1585, DOI 10.1016/j.jpeds.2013.07.017; Walker L.S., 2006, Rome III: The Functional Gastrointestinal Disorders eds, P963; Wang L, 2011, APPL ENVIRON MICROB, V77, P6718, DOI 10.1128/AEM.05212-11; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Welch BT, 2016, J CROHNS COLITIS; Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g; Wickramasinghe S, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0508-3; Williams BL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024585; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; YOSHIOKA H, 1983, PEDIATRICS, V72, P317; Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593";97;131;139;2;47;PUBLIC LIBRARY SCIENCE;SAN FRANCISCO;1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA;1932-6203;;;PLOS ONE;PLoS One;janv-09;2019;14;1;;;;;;;e0210064;10.1371/journal.pone.0210064;http://dx.doi.org/10.1371/journal.pone.0210064;;;30;Multidisciplinary Sciences;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Science & Technology - Other Topics;HG9VK;30625189;Green Published, Green Submitted, gold;;;24/11/2024;WOS:000455359400072;View Full Record in Web of Science
J;"Kilincaslan, A; Mutluer, TD; Pasabeyoglu, B; Tutkunkardas, MD; Mukaddes, NM";;;;"Kilincaslan, Ayse; Mutluer, Tuba Duzman; Pasabeyoglu, Basak; Tutkunkardas, Mustafa Deniz; Mukaddes, Nahit Motavalli";;;Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"autism spectrumdisorders; attention deficit hyperactivity disorder; intellectual disability; treatment; atomoxetine";"PERVASIVE DEVELOPMENTAL DISORDERS; DEFICIT HYPERACTIVITY DISORDER; RATING-SCALE; CHILDREN; SYMPTOMS; ADOLESCENTS; EFFICACY; BEHAVIOR; PLACEBO; ADHD";Objectives: This naturalistic, retrospective study investigated the effects of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD) symptoms and autistic features in children with autism spectrum disorders (ASDs) and intellectual disability (ID). Methods: Participants (n = 37, age range 6-17 years, mean: 10.16 +/- 3.60) were assessed at baseline, 4th and 12th weeks using Clinical Global Impressions (CGI) scales, DSM-IV-based ADHD-rating scale (ADHD-RS), and amended Turkish version of Aberrant Behavior Checklist (ABC). The primary outcome measure was a treatment response defined by a CGI-improvement score of 1 or 2 together with a decrease of at least 25% in the parent-rated ADHD-RS total score at the end of 12th week. Results: Five patients (13.5%) stopped medication at 4 weeks due to ineffectivity (2) and intolerable side effects (increased motor activity and talkativeness [n = 1], irritability [n = 2], temper outbursts [n = 2], and increased blood pressure [n = 1]). Sixteen patients (43.2%) were judged to be responders according to primary outcome measure. Improvement rate on CGI scale was 48.8%. On ADHD-RS, there were significant reductions between baseline and 4th week and between baseline and 12th week in both hyperactivity and inattention, and between baseline and 12th week in impulsivity scores. Decrease was significant in hyperactivity and social withdrawal subscales of the parent-reported ABC. Responders based on primary outcome measure were not significantly different from nonresponders in terms of sociodemographic features or clinical parameters, including intellectual, language, autism symptom, and ADHD symptom levels. Conclusion: In this chart review, ATX appears to be safe and effective for social withdrawal and ADHD symptoms in children with ASD and ID.;"[Kilincaslan, Ayse; Mutluer, Tuba Duzman; Pasabeyoglu, Basak; Tutkunkardas, Mustafa Deniz; Mukaddes, Nahit Motavalli] Istanbul Univ, Istanbul Fac Med, Dept Child & Adolescent Psychiat, Istanbul, Turkey";Istanbul University;Kilincaslan, A (corresponding author), Esnaf Hastanesi Ek Binasi, Cocuk Ruh Sagligi & Hastaliklari Anabilim Dali, Istanbul Tip Fak, TR-34073 Istanbul, Turkey.;ayse.ka@windowslive.com;"K?l?nçaslan, Ay?e/A-9042-2016; Mutluer, Tuba/HLG-6742-2023";Mutluer, Tuba/0000-0002-6873-8234;;;;"AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman MG, 2008, CHILD ADOL PSYCH CL, V17, P713, DOI 10.1016/j.chc.2008.06.009; Aman MG, 2014, RES DEV DISABIL, V35, P1412, DOI 10.1016/j.ridd.2014.03.006; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; BARKLEY RA, 1990, PEDIATRICS, V86, P184; Charnsil C, 2011, J ATTEN DISORD, V15, P684, DOI 10.1177/1087054710376907; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Dalsgaard S, 2013, J CHILD ADOL PSYCHOP, V23, P432, DOI 10.1089/cap.2012.0111; DuPaul G. J., 1998, ADHD rating Scale-IV: Checklists, norms, and clinical interpretation; El Achkar CM, 2015, EPILEPSY BEHAV, V47, P183, DOI 10.1016/j.yebeh.2014.12.022; Fernández-Jaén A, 2013, J ATTEN DISORD, V17, P497, DOI 10.1177/1087054711423626; Gadow KD, 2006, J AUTISM DEV DISORD, V36, P271, DOI 10.1007/s10803-005-0060-3; Guy W., 1976, Clinical global impression. ECDEU assessment manual for psychopharmacology, P218; Harfterkamp M, 2015, J CHILD ADOL PSYCHOP, V25, P372, DOI 10.1089/cap.2014.0142; Harfterkamp M, 2014, J CHILD ADOL PSYCHOP, V24, P481, DOI 10.1089/cap.2014.0026; Harfterkamp M, 2013, J CHILD ADOL PSYCHOP, V23, P194, DOI 10.1089/cap.2012.0012; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Holtmann M, 2007, PSYCHOPATHOLOGY, V40, P172, DOI 10.1159/000100007; Jou RJ, 2005, J CHILD ADOL PSYCHOP, V15, P325, DOI 10.1089/cap.2005.15.325; Kratochvil Christopher J, 2008, Child Adolesc Psychiatry Ment Health, V2, P25, DOI 10.1186/1753-2000-2-25; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Mazzone L, 2011, CNS DRUGS, V25, P503, DOI 10.2165/11590450-000000000-00000; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Murray MJ, 2010, CURR PSYCHIAT REP, V12, P382, DOI 10.1007/s11920-010-0145-3; Oswald DP, 2007, J CHILD ADOL PSYCHOP, V17, P348, DOI 10.1089/cap.2006.17303; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P599, DOI 10.1089/cap.2006.16.599; Prakash A, 2008, INT J CLIN PRACT, V62, P1147, DOI 10.1111/j.1742-1241.2008.01808.x; Reichow B, 2013, J AUTISM DEV DISORD, V43, P2435, DOI 10.1007/s10803-013-1793-z; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Schwartz S, 2014, J AM ACAD CHILD PSY, V53, P174, DOI 10.1016/j.jaac.2013.11.005; Shibao C, 2007, HYPERTENSION, V50, P47, DOI 10.1161/HYPERTENSIONAHA.107.089961; Streiner D, 2001, Evid Based Ment Health, V4, P70; Sucuoglu B, 1996, 3P Journal: The Journal of Psychiatry Psychology and Psychopharmacology, V4, P116; Sucuoglu B, 2003, TURKISH J PSYCHOL, V18, P93; THORNDIKE L, 1986, STANFORD BINET INTEL; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P611, DOI 10.1089/cap.2006.16.611; Wechsler D, 2003, Weschler Intelligence Scale for Children, Fourth Edition, Australian Administration and Scoring Manual, VFourth; Yerys BE, 2009, AUTISM RES, V2, P322, DOI 10.1002/aur.103; Zeiner P, 2011, ACTA PAEDIATR, V100, P1258, DOI 10.1111/j.1651-2227.2011.02263.x";41;7;7;0;9;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;NOV;2016;26;9;;;;;798;806;;10.1089/cap.2015.0179;http://dx.doi.org/10.1089/cap.2015.0179;;;9;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";EC4QM;27228116;;;;24/11/2024;WOS:000388118400005;View Full Record in Web of Science
S;"Martinez-Alvarez, R; Torres-Diaz, C";;"Chernov, MF; Rzaev, JA; Martnez-Alvarez, R";;"Martinez-Alvarez, Roberto; Torres-Diaz, Cristina";;;Surgery of autism: Is it possible?;NEUROSURGICAL MANAGEMENT OF PSYCHIATRIC DISORDERS, PT B;Progress in Brain Research;;English;"Article; Book Chapter";;;;;;"Autism; Aggressiveness; Capsulotomy; Cingulotomy; Amygdalotomy; Gamma knife; Radiosurgery";"CHILDREN; DIAGNOSIS";Autism spectrum disorder (ASD) is a developmental disability of the brain that can be associated to severe conductual alterations, such as self or heteroaggression and obsessive and compulsive behavior. Many of these patients do not improve with any pharmacological or behavioral therapy and represent a major social problem. We describe the outcome of patients with ASD, treated with radiofrequency brain lesions combined with Gamma Knife radiosurgery for therapy-resistant aggressiveness, obsessive thoughts, and compulsions. The ASD adapted YBOCS, PCQ and EAE scales assessed the therapeutic effect on symptoms. All patients had a significant reduction of their symptoms (YBOCS:34 and 22 PCQ 42 and 35, EAE 11 and 5.5, respectively), although all needed more than one treatment to maintain this improvement. The treatments resulted very safe for the patients and their neurological status has not change. We conclude that in these patients after surgery, there is a marked improvement in behavior, quality of life and relationship with the environment, with no evidence of secondary damage. Changes in connectivity might mediate the clinical improvement, although it is necessary to confirm these results with further studies.;"[Martinez-Alvarez, Roberto; Torres-Diaz, Cristina] Ruber Int Hosp, Dept Funct Neurosurg & Radiosurg, Madrid, Spain; [Torres-Diaz, Cristina] La Princesa Hosp, Dept Neurosurg, Madrid, Spain";Hospital de La Princesa;Martinez-Alvarez, R (corresponding author), Ruber Int Hosp, Dept Funct Neurosurg & Radiosurg, Madrid, Spain.;rob.martinez@telefonica.net;Torres, Cristina/KCX-7330-2024;Torres, Cristina Virginia/0000-0002-3420-0786;;;;"Altschuler E, 1992, Neurosurg Clin N Am, V3, P61; BALASUBRAMANIAM V, 1973, CONFIN NEUROL, V35, P138; Bhat S, 2014, REV NEUROSCIENCE, V25, P841, DOI 10.1515/revneuro-2014-0056; Blumberg SJ, 2016, AUTISM, V20, P783, DOI 10.1177/1362361315607724; Blumberg Stephen J, 2013, Natl Health Stat Report, P1; Gaetz W, 2014, NEUROIMAGE, V86, P1, DOI 10.1016/j.neuroimage.2013.05.068; García-Muñoz L, 2019, REV NEUROLOGIA, V68, P91; Jakobs M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809575; Jiménez F, 2012, STEREOT FUNCT NEUROS, V90, P151, DOI 10.1159/000336746; Keown CL, 2013, CELL REP, V5, P567, DOI 10.1016/j.celrep.2013.10.003; Khan AJ, 2015, BIOL PSYCHIAT, V78, P625, DOI 10.1016/j.biopsych.2015.03.024; Lobar SL, 2016, J PEDIATR HEALTH CAR, V30, P359, DOI 10.1016/j.pedhc.2015.09.005; Peterson BS, 2019, BIOL PSYCHIAT, V85, P584, DOI 10.1016/j.biopsych.2018.11.026; Regis Jean, 2013, Acta Neurochir Suppl, V116, P121, DOI 10.1007/978-3-7091-1376-9_19; Robertson CE, 2016, CURR BIOL, V26, P80, DOI 10.1016/j.cub.2015.11.019; Sano K, 1988, Acta Neurochir Suppl (Wien), V44, P145; Schuetze M, 2016, NEUROPSYCHOPHARMACOL, V41, P2627, DOI 10.1038/npp.2016.64; Sinha S, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1548; Spatola G, 2019, J NEUROSURG, V131, P376, DOI 10.3171/2018.4.JNS171525; Stevens T, 2016, RES AUTISM SPECT DIS, V31, P11, DOI 10.1016/j.rasd.2016.07.003; Stoner R, 2014, NEW ENGL J MED, V370, P1209, DOI 10.1056/NEJMoa1307491; Torres CV, 2017, BIOL PSYCHIAT, V81, pE33, DOI 10.1016/j.biopsych.2016.05.026; Torres CV, 2013, J NEUROSURG, V119, P277, DOI 10.3171/2013.4.JNS121639; Volkmar FR, 2004, J CHILD PSYCHOL PSYC, V45, P135, DOI 10.1046/j.0021-9630.2003.00317.x; Yin DZ, 2018, BIOL PSYCHIAT, V84, P926, DOI 10.1016/j.biopsych.2018.04.006";25;2;2;0;0;ELSEVIER ACADEMIC PRESS INC;SAN DIEGO;525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA;0079-6123;;978-0-12-823769-4;PROG BRAIN RES;Prog. Brain Res.;;2022;272;;B;;;;73;84;;10.1016/bs.pbr.2022.03.001;http://dx.doi.org/10.1016/bs.pbr.2022.03.001;;;12;"Neurosciences; Psychiatry; Surgery";Book Citation Index  Science (BKCI-S);"Neurosciences & Neurology; Psychiatry; Surgery";BU3RF;35667807;;;;24/11/2024;WOS:000893195600005;View Full Record in Web of Science
J;"Harfterkamp, M; van de Loo-Neus, G; Minderaa, RB; van der Gaag, RJ; Escobar, R; Schacht, A; Pamulapati, S; Buitelaar, JK; Hoekstra, PJ";;;;"Harfterkamp, Myriam; van de Loo-Neus, Gigi; Minderaa, Ruud B.; van der Gaag, Rutger-Jan; Escobar, Rodrigo; Schacht, Alexander; Pamulapati, Sireesha; Buitelaar, Jan K.; Hoekstra, Pieter J.";;;A Randomized Double-Blind Study of Atomoxetine Versus Placebo for Attention-Deficit/Hyperactivity Disorder Symptoms in Children With Autism Spectrum Disorder;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"atomoxetine; ADHD; ASD; placebo-controlled";"PERVASIVE DEVELOPMENTAL DISORDERS; DEFICIT HYPERACTIVITY DISORDER; ONCE-DAILY ATOMOXETINE; TEACHER REPORTS; ADOLESCENTS; RISPERIDONE; ADHD; PARENT; TRIAL; METHYLPHENIDATE";"Objective: The efficacy of atomoxetine as treatment of symptoms of attention-deficit/hyperactivity disorder (ADHD) in patients with autism spectrum disorder (ASD) has not been established. Method: In this study, 97 patients aged 6 to 17 years with ADHD and ASD were randomly assigned to double-blind treatment with 1.2 mg/kg/day atomoxetine or placebo for 8 weeks. The primary endpoint was the ADHD Rating Scale (ADHD-RS) score; secondary endpoints were the Clinical Global Impression of ADHD-Improvement (CGI-I) and the Conners Teacher Rating Scale-Revised: Short Form (CTRS-R:S) score. Results: Baseline mean ADHD-RS scores for atomoxetine versus placebo were 40.7 and 38.6; after 8 weeks, mixed-effect model repeated-measure means were 31.6 (95% confidence interval 29.2-33.9) and 38.3 (36.0-40.6), respectively, with a difference in least square means of -6.7 (-10.0 to -3.4; p < .001). The CTRS-R:S Hyperactivity subscore also improved significantly for atomoxetine compared with placebo, but not the other CTRS-R:S subscores. However, there were not significantly more patients on atomoxetine (20.9%) who improved much, or very much according to the CGI-I, than on placebo (8.7%; p = 0.14). Adverse events (mostly nausea, decrease in appetite, fatigue, and early morning awakening) were reported in 81.3% of atomoxetine patients and 65.3% of placebo patients (p > .1). There were no serious adverse events. Conclusions: A tomoxetine moderately improved ADHD symptoms in patients with ASD and was generally well tolerated. Adverse events in this study were similar to those in other studies with ADHD patients without ASD. J. Am. Acad. Child Adolesc. Psychiatry, 2012; 51(7):733-741. Clinical trial registration information A Randomized Double-Blind Study of A tomoxetine Versus Placebo for ADHD Symptoms in Children with ASD; www.clinicaltrials.gov; NCT00380692.";"[Harfterkamp, Myriam] Univ Med Ctr Groningen, Dept Psychiat, NL-9700 AR Groningen, Netherlands; [Harfterkamp, Myriam; Minderaa, Ruud B.; Hoekstra, Pieter J.] Univ Groningen, NL-9700 AB Groningen, Netherlands; [van de Loo-Neus, Gigi; van der Gaag, Rutger-Jan; Buitelaar, Jan K.] Karakter Child & Adolescent Psychiat Univ Ctr Nij, Nijmegen, Netherlands; [Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands; [Escobar, Rodrigo] Eli Lilly & Co, Madrid, Spain; [Schacht, Alexander] Eli Lilly & Co, Homburg, Germany; [Pamulapati, Sireesha] Eli Lilly & Co, Windlesham, Surrey, England";"University of Groningen; University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; Eli Lilly; Eli Lilly; Lilly Deutschland GmbH; Eli Lilly";Harfterkamp, M (corresponding author), Univ Med Ctr Groningen, Dept Psychiat, POB 660, NL-9700 AR Groningen, Netherlands.;m.harfterkamp@accare.nl;"Buitelaar, Jan/AAY-7522-2020; van der Gaag, R.J./H-8030-2014; Hoekstra, Pieter/O-4396-2014";;"Eli Lilly and Co.; Eurocept; Netherlands Organisation for Health Research and Development (ZonMw); National Institute of Mental Health (NIMH); European Union; European Society for Child and Adolescent Psychiatry (ESCAP) in Budapest, Hungary";"Eli Lilly and Co.(Eli Lilly); Eurocept; Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); European Union(European Union (EU)); European Society for Child and Adolescent Psychiatry (ESCAP) in Budapest, Hungary";Dr. Harfterkamp has received travel funding from Eli Lilly and Co., and Eurocept. Dr. van de Loo-Neus has received honoraria for presenting or serving as a consultant for Eli Lilly and Co., UCB Pharma, and Eurocept. Drs. Escobar and Schacht are stakeholders of Eli Lilly and Co. Dr. Buitelaar has served as a consultant for, on the speakers' bureau for, and/or on the advisory boards for Janssen Cilag, Eli Lilly and Co., Bristol-Myer Squibb, Organon/Shering Plough, UCB, Shire, Medice, and Sevier. Dr. Hoekstra has received funding through the Netherlands Organisation for Health Research and Development (ZonMw), the National Institute of Mental Health (NIMH), and the European Union Seventh Framework Programme, as well as honoraria for presentations from Boerhaave, Shire, and Eli Lilly and Co. Drs. Minderaa, van der Gaag, and Pamulapati report no biomedical financial interests or potential conflicts of interest.This work was presented in part at the International Conference sponsored by the European Society for Child and Adolescent Psychiatry (ESCAP) in Budapest, Hungary, August 25, 2009.;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P869, DOI 10.1089/cap.2005.15.869; Aman MG, 2008, J CHILD ADOL PSYCHOP, V18, P227, DOI 10.1089/cap.2007.0133; [Anonymous], 1976, NIMH PUBLICATION; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Biederman J, 2006, BIOL PSYCHIAT, V60, P1106, DOI 10.1016/j.biopsych.2006.03.036; Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P279, DOI 10.1023/A:1022606501530; DuPaul GJ, 1998, J PSYCHOPATHOL BEHAV, V20, P83, DOI 10.1023/A:1023087410712; Eli Lilly and Co, 2008, SUMM PROD CHAR; Faraone SV, 2005, EUR CHILD ADOLES PSY, V14, P20, DOI 10.1007/s00787-005-0415-5; Faries D.E., 2001, Journal of Attention Disorders, V5, P107, DOI DOI 10.1177/108705470100500204; Gadow KD, 2006, J AUTISM DEV DISORD, V36, P271, DOI 10.1007/s10803-005-0060-3; Geller D, 2007, J AM ACAD CHILD PSY, V46, P1119, DOI 10.1097/chi.0b013e3180ca8385; Holtmann M, 2007, PSYCHOPATHOLOGY, V40, P172, DOI 10.1159/000100007; Jou RJ, 2005, J CHILD ADOL PSYCHOP, V15, P325, DOI 10.1089/cap.2005.15.325; Kratochvil CJ, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00008; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Michelson D, 2002, AM J PSYCHIAT, V159, P1896, DOI 10.1176/appi.ajp.159.11.1896; Michelson D, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e83; Montoya A, 2009, CURR MED RES OPIN, V25, P2745, DOI 10.1185/03007990903316152; Nijmeijer JS, 2009, J ABNORM CHILD PSYCH, V37, P443, DOI 10.1007/s10802-008-9282-0; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P599, DOI 10.1089/cap.2006.16.599; Posey DJ, 2004, J CHILD ADOL PSYCHOP, V14, P233, DOI 10.1089/1044546041649084; Rutter M., ADI R AUTISM DIAGNOS; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Spencer T, 1998, AM J PSYCHIAT, V155, P693, DOI 10.1176/ajp.155.5.693; Spencer TJ, 2009, CNS DRUGS, V23, P9, DOI 10.2165/00023210-200923000-00003; Svanborg P, 2009, EUR CHILD ADOLES PSY, V18, P240, DOI 10.1007/s00787-008-0725-5; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P561, DOI 10.1089/cap.2006.16.561; Troost PW, 2006, J CHILD ADOL PSYCHOP, V16, P611, DOI 10.1089/cap.2006.16.611; Weiss M, 2005, J AM ACAD CHILD PSY, V44, P647, DOI 10.1097/01.chi.0000163280.47221.c9";32;100;109;2;20;ELSEVIER SCIENCE BV;AMSTERDAM;PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS;0890-8567;;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;JUL;2012;51;7;;;;;733;741;;10.1016/j.jaac.2012.04.011;http://dx.doi.org/10.1016/j.jaac.2012.04.011;;;9;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";966OP;22721596;;;;24/11/2024;WOS:000305847600009;View Full Record in Web of Science
J;"Capano, L; Dupuis, A; Brian, J; Mankad, D; Genore, L; Adams, RH; Smile, S; Lui, T; Odrobina, D; Foster, JA; Anagnostou, E";;;;"Capano, Lucia; Dupuis, Annie; Brian, Jessica; Mankad, Deepali; Genore, Lisa; Adams, Rianne Hastie; Smile, Sharon; Lui, Toni; Odrobina, Dina; Foster, Jane A.; Anagnostou, Evdokia";;;A pilot dose finding study of pioglitazone in autistic children;MOLECULAR AUTISM;;;English;Article;;;;;;"Pioglitazone; Autism spectrum disorder; Cytokines; Treatment; Clinical trial; Efficacy; Safety profile; Inflammation; Drug therapy; Physiological effects of drugs; Maximum tolerated dose (MTD)";"OBSESSIVE-COMPULSIVE SCALE; ACTIVATED RECEPTOR-GAMMA; DIAGNOSTIC OBSERVATION SCHEDULE; LYMPHOCYTE CYTOKINE PROFILES; ABERRANT BEHAVIOR CHECKLIST; IMMUNE ACTIVATION; SPECTRUM DISORDER; PPAR-GAMMA; INFLAMMATION; ASSOCIATION";BackgroundPioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations.ObjectiveThis pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12years old.MethodsWe conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25mg/kg, 0.5mg/kg, and 0.75mg/kg once daily.ResultsMaximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders.Conclusions and relevancePioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted.Trial registrationClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010.;"[Capano, Lucia; Brian, Jessica; Mankad, Deepali; Smile, Sharon; Anagnostou, Evdokia] Univ Toronto, Holland Bloorview Kids Rehabil Hosp, 150 Kilgour Rd, Toronto, ON M4G 1R8, Canada; [Dupuis, Annie] Univ Toronto, Sick Kids, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Genore, Lisa; Adams, Rianne Hastie; Lui, Toni; Odrobina, Dina] Holland Bloorview Kids Rehabil Hosp, 150 Kilgour Rd, Toronto, ON M4G 1R8, Canada; [Foster, Jane A.] McMaster Univ, St Josephs Hlth Care, 50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada";"University of Toronto; Holland Bloorview Kids Rehabilitation Hospital; University of Toronto; Hospital for Sick Children (SickKids); University of Toronto; Holland Bloorview Kids Rehabilitation Hospital; McMaster University";Capano, L (corresponding author), Univ Toronto, Holland Bloorview Kids Rehabil Hosp, 150 Kilgour Rd, Toronto, ON M4G 1R8, Canada.;lcapano@hollandbloorview.ca;Foster, Jane/AAW-7163-2021;"Foster, Jane/0000-0002-8579-4705; Smile, Sharon/0000-0002-9614-8979";Physician Services Incorporated, University of Toronto Dean's Fund;Physician Services Incorporated, University of Toronto Dean's Fund;Physician Services Incorporated, University of Toronto Dean's Fund.;"Ahmad SF, 2017, PROG NEURO-PSYCHOPH, V79, P472, DOI 10.1016/j.pnpbp.2017.08.002; AL-Ayadhi LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-158; Almasi-Nasrabadi M, 2012, BEHAV BRAIN RES, V231, P138, DOI 10.1016/j.bbr.2012.03.006; AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 2013, DIAGNOSTIC STAT MANU, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2000, DSM 4 T DIAGNOSTIC S, P75; [Anonymous], AUTISM OPEN ACCESS; [Anonymous], 2012, West. Psychol. Serv.; Ashwood P, 2006, J NEUROIMMUNOL, V173, P126, DOI 10.1016/j.jneuroim.2005.12.007; Ashwood P, 2004, J CLIN IMMUNOL, V24, P664, DOI 10.1007/s10875-004-6241-6; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003; Ashwood P, 2008, J NEUROIMMUNOL, V204, P149, DOI 10.1016/j.jneuroim.2008.07.006; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Berria R, 2007, CLIN PHARMACOL THER, V82, P275, DOI 10.1038/sj.clpt.6100146; Boris M, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-3; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brown EC, 2002, RES DEV DISABIL, V23, P45, DOI 10.1016/S0891-4222(01)00091-9; Bryn V, 2017, J MOL NEUROSCI, V61, P1, DOI 10.1007/s12031-016-0847-z; Constantino J. N., 2012, SOCIAL RESPONSIVENES; D'Mello C, 2017, CURR TOP BEHAV NEURO, V31, P73, DOI 10.1007/7854_2016_37; Digman C, 2005, ANN INTERN MED, V143, P465, DOI 10.7326/0003-4819-143-6-200509200-00016; Garay Paula A, 2010, Front Synaptic Neurosci, V2, P136, DOI 10.3389/fnsyn.2010.00136; Ghaleiha A, 2015, PSYCHIAT RES, V229, P181, DOI 10.1016/j.psychres.2015.07.043; Ghosh S, 2007, MOL PHARMACOL, V71, P1695, DOI 10.1124/mol.106.033845; Goines P, 2010, CURR OPIN NEUROL, V23, P111, DOI 10.1097/WCO.0b013e3283373514; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; Greenhill LL, 2004, J AM ACAD CHILD PSY, V43, P1488, DOI 10.1097/01.chi.0000142668.29191.13; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Hashim H, 2013, RES AUTISM SPECT DIS, V7, P199, DOI 10.1016/j.rasd.2012.08.007; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Jyonouchi H, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1003-6; Karakurt F, 2010, EXP CLIN ENDOCR DIAB, V118, P96, DOI 10.1055/s-0029-1234065; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Landreth GE, 2001, NEUROBIOL AGING, V22, P937, DOI 10.1016/S0197-4580(01)00296-2; Lee EJ, 2015, CURR OPIN PHARMACOL, V20, P8, DOI 10.1016/j.coph.2014.10.007; Liu HR, 2004, CARDIOVASC RES, V62, P135, DOI 10.1016/j.cardiores.2003.12.027; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Masi A, 2015, MOL PSYCHIATR, V20, P440, DOI 10.1038/mp.2014.59; Masi A, 2017, NEUROSCI BULL, V33, P194, DOI 10.1007/s12264-017-0103-8; McCusker RH, 2013, J EXP BIOL, V216, P84, DOI 10.1242/jeb.073411; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Nadeem A, 2018, BRAIN BEHAV IMMUN, V67, P335, DOI 10.1016/j.bbi.2017.09.010; Pardo CA, 2006, INT REV PSYCHIATR, V17, P485, DOI 10.1080/02646830500381930; Pardo CA, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-016-0115-7; Prata J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0938-y; Qiu D, 2015, INT J CLIN PHARM TH, V53, P746, DOI 10.5414/CP202339; Reynolds C.R., 2006, BASC-2: Behavior Assessment System for Children, VSecond; Rodriguez Juan I, 2011, Neuron Glia Biol, V7, P205, DOI 10.1017/S1740925X12000142; Ross HE, 2013, BRAIN BEHAV IMMUN, V31, P76, DOI 10.1016/j.bbi.2012.12.021; Rossignol DA, 2012, MOL PSYCHIATR, V17, P290, DOI 10.1038/mp.2010.136; Scahill L, 1997, J AM ACAD CHILD PSY, V36, P844, DOI 10.1097/00004583-199706000-00023; Scahill L, 2016, AUTISM, V20, P145, DOI 10.1177/1362361315574889; Schütz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; Suzuki K, 2013, JAMA PSYCHIAT, V70, P49, DOI 10.1001/jamapsychiatry.2013.272; Tafuri KS, 2013, J CLIN RES PEDIATR E, V5, P236, DOI 10.4274/Jcrpe.981; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; Tsilioni I, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.142; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Wu ZH, 2010, INT J CARDIOL, V138, P151, DOI 10.1016/j.ijcard.2008.08.009; Zdravkovic V, 2006, J PEDIATR-US, V149, P845, DOI 10.1016/j.jpeds.2006.08.049; Zeitler P, 2012, NEW ENGL J MED, V366, P2247, DOI 10.1056/NEJMoa1109333; Zimmerman AW, 2005, PEDIATR NEUROL, V33, P195, DOI 10.1016/j.pediatrneurol.2005.03.014";66;29;31;2;8;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;nov-26;2018;9;;;;;;;;59;10.1186/s13229-018-0241-5;http://dx.doi.org/10.1186/s13229-018-0241-5;;;14;"Genetics & Heredity; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Genetics & Heredity; Neurosciences & Neurology";HB8NO;30498564;Green Published, gold;;;24/11/2024;WOS:000451347400002;View Full Record in Web of Science
J;"Montagner, PSS; Medeiros, W; da Silva, LCR; Borges, CN; Brasil-Neto, J; Barbosa, VDS; Caixeta, FV; Malcher-Lopes, R";;;;"Montagner, Patricia Soares Silva; Medeiros, Wesley; da Silva, Leandro Cruz Ramires; Borges, Clarissa Nogueira; Brasil-Neto, Joaquim; Barbosa, Vinicius de Deus Silva; Caixeta, Fabio V.; Malcher-Lopes, Renato";;;Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"endocannabinoid system; Pica; allotriophagy; Cannabis sativa; CBD; THC; patient-reported outcome survey; autism spectrum disorders";"ENDOCANNABINOID SYSTEM; PHARMACOLOGICAL-TREATMENT; DISRUPTIVE BEHAVIOR; DISORDER; CHILDREN; ARIPIPRAZOLE; DRUGS; YOUTH; PICA; METHYLPHENIDATE";Autism Spectrum Disorders (ASD) may significantly impact the well-being of patients and their families. The therapeutic use of cannabis for ASD has gained interest due to its promising results and low side effects, but a consensus on treatment guidelines is lacking. In this study, we conducted a retrospective analysis of 20 patients with autistic symptoms who were treated with full-spectrum cannabis extracts (FCEs) in a response-based, individually-tailored dosage regimen. The daily dosage and relative proportions of cannabidiol (CBD) and tetrahydrocannabinol (THC) were adjusted based on treatment results following periodic clinical evaluation. Most patients (80%) were treated for a minimum of 6 months. We have used a novel, detailed online patient- or caregiver-reported outcome survey that inquired about core and comorbid symptoms, and quality of life. We also reviewed patients' clinical files, and no individual condition within the autistic spectrum was excluded. This real-life approach enabled us to gain a clearer appraisal of the ample scope of benefits that FCEs can provide for ASD patients and their families. Eighteen patients started with a CBD-rich FCE titrating protocol, and in three of them, the CBD-rich (CBD-dominant) FCE was gradually complemented with low doses of a THC-rich (THC-dominant) FCE based on observed effects. Two other patients have used throughout treatment a blend of two FCEs, one CBD-rich and the other THC-rich. The outcomes were mainly positive for most symptoms, and only one patient from each of the two above-mentioned situations displayed important side effects one who has used only CBD-rich FCE throughout the treatment, and another who has used a blend of CBD-Rich and THC-rich FCEs. Therefore, after FCE treatment, 18 out of 20 patients showed improvement in most core and comorbid symptoms of autism, and in quality of life for patients and their families. For them, side effects were mild and infrequent. Additionally, we show, for the first time, that allotriophagy (Pica) can be treated by FCEs. Other medications were reduced or completely discontinued in most cases. Based on our findings, we propose guidelines for individually tailored dosage regimens that may be adapted to locally available qualified FCEs and guide further clinical trials.;"[Montagner, Patricia Soares Silva] NeuroVinci, Sao Jose, Brazil; [Medeiros, Wesley; Caixeta, Fabio V.; Malcher-Lopes, Renato] Univ Brasilia, Inst Biol Sci, Dept Physiol Sci, Lab Neurosci & Behav, Brasilia, Brazil; [da Silva, Leandro Cruz Ramires] Univ Fed Minas Gerais, Clin Hosp, Belo Horizonte, Brazil; [da Silva, Leandro Cruz Ramires] Brazilian Assoc Med Cannabis Patients, Belo Horizonte, Brazil; [Borges, Clarissa Nogueira] Dept Educ Fed Dist, Specialized Educ Care Div Gifted Students, Brasilia, Brazil; [Brasil-Neto, Joaquim] Unieuro, Euroamer Univ Ctr, Brasilia, Brazil; [Barbosa, Vinicius de Deus Silva] Syrian Lebanese Hosp, Med Cannabis Ctr, Sao Paulo, Brazil; [Barbosa, Vinicius de Deus Silva] Natl Assoc Inclus Autist People, Sao Paulo, Brazil";"Universidade de Brasilia; Universidade Federal de Minas Gerais";Malcher-Lopes, R (corresponding author), Univ Brasilia, Inst Biol Sci, Dept Physiol Sci, Lab Neurosci & Behav, Brasilia, Brazil.;malcherlopes@gmail.com;"Caixeta, Fabio/N-9405-2019; Caixeta, Fabio/J-9048-2014";Caixeta, Fabio/0000-0003-0919-342X;"WeCann Academy; Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF) [30023.128.46472.04012022]";"WeCann Academy; Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))";WM received a grant from WeCann Academy, an international institution for education in endocannabinoid medicine, for data collection and analysis in this work. FC was supported Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF, grant #30023.128.46472.04012022).;"Abruzzo PM, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2076-z; Akyuz E, 2021, CURR NEUROPHARMACOL, V19, P1865, DOI 10.2174/1570159X19666210826125341; Alsayouf HA, 2022, BRAIN SCI, V12, DOI 10.3390/brainsci12050618; de Carvalho ACA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082940; Anorson N, 2021, EUR J PUBLIC HEALTH, V31, P298; Antshel KM, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1020-5; Aran A, 2021, MOL AUTISM, V12, DOI 10.1186/s13229-021-00420-2; Aran A, 2019, MOL AUTISM, V10, DOI 10.1186/s13229-019-0256-6; Aran A, 2019, J AUTISM DEV DISORD, V49, P1284, DOI 10.1007/s10803-018-3808-2; Araujo DJ, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00424; Arnold M, 2024, J AUTISM DEV DISORD, V54, P326, DOI 10.1007/s10803-022-05769-8; Arutiunian V, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-28463-w; Barchel D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01521; Beck KB, 2021, PSYCHIAT CLIN N AM, V44, P95, DOI 10.1016/j.psc.2020.11.008; Bilge S, 2021, J CANNABIS RES, V3, DOI 10.1186/s42238-021-00108-7; Binici NC, 2017, J CHILD ADOL PSYCHOP, V27, P759, DOI 10.1089/cap.2017.0059; Bogale Kaleb, 2021, Med Cannabis Cannabinoids, V4, P97, DOI 10.1159/000517425; Brignell A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012324.pub2; Busquets-Garcia A, 2013, NAT MED, V19, P603, DOI 10.1038/nm.3127; Cao XS, 2017, NEUROSCI RES, V116, P3, DOI 10.1016/j.neures.2016.09.005; Casseus M, 2023, AUTISM RES, V16, P855, DOI 10.1002/aur.2894; Chakrabarti B, 2015, NEUROTHERAPEUTICS, V12, P837, DOI 10.1007/s13311-015-0371-9; Chez MG, 2006, EPILEPSY BEHAV, V8, P267, DOI 10.1016/j.yebeh.2005.11.001; Costa AM, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14121259; Crippa JAS, 2010, REV BRAS PSIQUIATR, V32, pS56; da Silva EA Jr, 2024, TRENDS PSYCHIATR PSY, V46, DOI 10.47626/2237-6089-2021-0396; De Pol M, 2021, PSYCHIAT RES, V306, DOI 10.1016/j.psychres.2021.114256; Di Bartolomeo M, 2021, PHARMACOL RES, V164, DOI 10.1016/j.phrs.2020.105357; Do Val-da Silva RA, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00131; Doyle Carolyn A, 2012, Dialogues Clin Neurosci, V14, P263; Dreifuss F E, 1988, Am J Med, V84, P34, DOI 10.1016/0002-9343(88)90055-1; Dunn K, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-035280; Espadas C, 2020, PSYCHIAT RES, V292, DOI 10.1016/j.psychres.2020.113321; Farinon B, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071935; Fieiras C, 2023, BMJ EVID-BASED MED, V28, P7, DOI 10.1136/bmjebm-2021-111804; Fields VL, 2021, DISABIL HEALTH J, V14, DOI 10.1016/j.dhjo.2020.101052; Fields VL, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2020-0462; Fitzpatrick SE, 2016, NEUROPSYCH DIS TREAT, V12, DOI 10.2147/NDT.S84585; Fletcher S, 2022, CHILD CARE HLTH DEV, V48, P33, DOI 10.1111/cch.12909; Fleury-Teixeira P, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01145; Földy C, 2013, NEURON, V78, P498, DOI 10.1016/j.neuron.2013.02.036; Fombonne E, 2022, J DEV BEHAV PEDIATR, V43, P140, DOI 10.1097/DBP.0000000000001028; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Fyke W, 2021, AUTISM RES, V14, P1375, DOI 10.1002/aur.2520; Ghanizadeh A, 2014, CHILD PSYCHIAT HUM D, V45, P185, DOI 10.1007/s10578-013-0390-x; Grill Magdalena, 2018, Med Cannabis Cannabinoids, V1, P28, DOI 10.1159/000489036; Gulati S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213242; Habib SS, 2017, J CLIN DIAGN RES, V11, pCE01, DOI 10.7860/JCDR/2017/23862.9969; Hacohen M, 2022, TRANSL PSYCHIAT, V12, DOI 10.1038/s41398-022-02104-8; Hellings JA, 2015, J CHILD ADOL PSYCHOP, V25, P618, DOI 10.1089/cap.2014.0145; Heming Sarah M, 2022, Prim Care Companion CNS Disord, V24, DOI 10.4088/PCC.21cr03060; Hergüner A, 2016, J CHILD ADOL PSYCHOP, V26, P80, DOI 10.1089/cap.2015.0184; Hesami O, 2016, J CLIN DIAGN RES, V10, pNC1, DOI 10.7860/JCDR/2016/16263.7339; Hirota T, 2023, JAMA-J AM MED ASSOC, V329, P157, DOI 10.1001/jama.2022.23661; Hirota T, 2014, J AUTISM DEV DISORD, V44, P948, DOI 10.1007/s10803-013-1952-2; Hirsch LE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009043.pub3; Hofer A, 2003, J CLIN PSYCHIAT, V64, P1267, DOI 10.4088/JCP.v64n1019c; Hong M, 2020, J AUTISM DEV DISORD, V50, P333, DOI 10.1007/s10803-019-04255-y; Hossain M, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112922; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3448; Iftikhar A, 2021, MOLECULES, V26, DOI 10.3390/molecules26247699; Ijff DM, 2013, HAND CLINIC, V111, P707, DOI 10.1016/B978-0-444-52891-9.00073-7; Izzo AA, 2012, BRIT J PHARMACOL, V166, P1444, DOI 10.1111/j.1476-5381.2012.01879.x; Ji YT, 2022, FRONT PSYCHIATRY, V13, DOI 10.3389/fpsyt.2022.1072272; Jobski K, 2017, ACTA PSYCHIAT SCAND, V135, P8, DOI 10.1111/acps.12644; Joshi A., 2015, BRIT J APPL SCI TECH, V7, P396, DOI [10.9734/BJAST/2015/14975, DOI 10.9734/BJAST/2015/14975, 10.9734/bjast/2015/14975]; Jung KM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2045; Karhson DS, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0203-y; Kerr DM, 2013, BEHAV BRAIN RES, V249, P124, DOI 10.1016/j.bbr.2013.04.043; KINNELL HG, 1985, BRIT J PSYCHIAT, V147, P80, DOI 10.1192/bjp.147.1.80; Kloosterboer SM, 2021, BRIT J CLIN PHARMACO, V87, P1069, DOI 10.1111/bcp.14465; Koliqi Rozafa, 2015, Mater Sociomed, V27, P167, DOI 10.5455/msm.2015.27.167-171; Konrad-Bindl DS, 2016, NEUROPSYCH DIS TREAT, V12, P2635, DOI 10.2147/NDT.S114185; Krueger DD, 2013, NEURON, V78, P408, DOI 10.1016/j.neuron.2013.04.030; Kwon CS, 2022, NEUROL CLIN, V40, P831, DOI 10.1016/j.ncl.2022.03.011; Lee J, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-70; Lee J, 2023, BMJ CASE REP, V16, DOI 10.1136/bcr-2022-251974; Leno VC, 2021, DEV PSYCHOPATHOL, V33, P1220, DOI 10.1017/S0954579420000449; Li Q, 2022, JAMA PEDIATR, V176, P943, DOI 10.1001/jamapediatrics.2022.1846; Li YJ, 2020, CNS SPECTRUMS, V25, P493, DOI 10.1017/S1092852919001603; Li YJ, 2020, OBES REV, V21, DOI 10.1111/obr.13123; Lilja MM, 2022, J NEURODEV DISORD, V14, DOI 10.1186/s11689-022-09424-2; Liu XP, 2022, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.805929; Ma L, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.28442; Malcher-Lopes R., 2014, Rev. Biol, V13, P43, DOI [10.7594/revbio.13.01.07, DOI 10.7594/REVBIO.13.01.07]; Markram K, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00224; Martini S, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043125; Matson JL, 2013, RES DEV DISABIL, V34, P2564, DOI 10.1016/j.ridd.2013.05.018; Melo C, 2020, AUTISM, V24, P569, DOI 10.1177/1362361319869118; Mohapatra S, 2016, J NEUROSCI RURAL PRA, V7, P141, DOI 10.4103/0976-3147.165355; Mostafavi M, 2020, SEMIN PEDIATR NEUROL, V35, DOI 10.1016/j.spen.2020.100833; Muit JJ, 2020, J ATTEN DISORD, V24, P215, DOI 10.1177/1087054719866255; Naftali T, 2014, DIGEST DIS, V32, P468, DOI 10.1159/000358155; Nicolai J, 2001, INTENS CARE MED, V27, P943, DOI 10.1007/s001340100937; Palimaru Iolanda, 2021, Case Rep Psychiatry, V2021, P7334467, DOI 10.1155/2021/7334467; Pamplona FA, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00759; Pandina G, 2020, PSYCHIAT CLIN N AM, V43, P629, DOI 10.1016/j.psc.2020.08.003; Pietropaolo S, 2020, PROG MOL BIOL TRANSL, V173, P183, DOI 10.1016/bs.pmbts.2020.04.016; Prelock PJ, 2012, PEDIATR CLIN N AM, V59, P129, DOI 10.1016/j.pcl.2011.10.008; Rapport MD, 2002, CLIN PSYCHOL REV, V22, P1107, DOI 10.1016/S0272-7358(02)00129-0; Raz N, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.979403; Rieth SR, 2018, SEMIN SPEECH LANG, V39, P114, DOI 10.1055/s-0038-1627483; Ritter C, 2021, J CHILD ADOL PSYCHOP, V31, P244, DOI 10.1089/cap.2020.0110; Roe K, 2022, NEUROCHEM RES, V47, P1150, DOI 10.1007/s11064-022-03527-x; Roke Y, 2012, J CHILD ADOL PSYCHOP, V22, P432, DOI 10.1089/cap.2011.0109; Rubino T, 2015, HANDB EXP PHARMACOL, V231, P261, DOI 10.1007/978-3-319-20825-1_9; Rutter M, 1979, Ann Acad Med Singap, V8, P301; Sahoo S, 2017, ASIAN J PSYCHIATR, V29, P194, DOI 10.1016/j.ajp.2017.07.012; Schachar RJ, 2023, RES CHILD ADOLES PSY, V51, P17, DOI 10.1007/s10802-022-00958-6; Schleider LBL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37570-y; Schnabel A, 2020, AUTISM, V24, P26, DOI 10.1177/1362361319844636; Schnitzler E, 2022, CURR NEUROL NEUROSCI, V22, P531, DOI 10.1007/s11910-022-01218-2; Servadio M, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.182; Siani-Rose M, 2023, CANNABIS CANNABINOID, V8, P126, DOI 10.1089/can.2021.0129; Siniscalco D, 2013, J AUTISM DEV DISORD, V43, P2686, DOI 10.1007/s10803-013-1824-9; Speed HE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140638; Spencer D, 2013, PEDIATRICS, V132, P833, DOI 10.1542/peds.2012-3774; Stark T, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105938; Stark T, 2019, NEUROPHARMACOLOGY, V146, P212, DOI 10.1016/j.neuropharm.2018.11.035; Strawn JR, 2018, J CHILD ADOL PSYCHOP, V28, P2, DOI 10.1089/cap.2017.0060; Thornton AM, 2021, MOLECULES, V26, DOI 10.3390/molecules26123720; Vaidya CJ, 2022, CURR TOP BEHAV NEURO, V57, P159, DOI 10.1007/7854_2022_334; Vasa RA, 2016, PEDIATRICS, V137, pS115, DOI 10.1542/peds.2015-2851J; Vastolo A, 2021, J ANIM PHYSIOL AN N, V105, P1, DOI 10.1111/jpn.13557; Vats P, 2018, INDIAN PEDIATR, V55, P485, DOI 10.1007/s13312-018-1339-8; Visser JC, 2017, J AM ACAD CHILD PSY, V56, P659, DOI 10.1016/j.jaac.2017.05.022; Vohra Rini, 2016, Drugs Real World Outcomes, V3, P409; Wallace JL, 2013, J PHYSIOL PHARMACOL, V64, P167; Wei D, 2016, CANNABIS CANNABINOID, V1, P81, DOI 10.1089/can.2015.0008; Wood JR, 2005, PHYSIOL GENOMICS, V20, P233, DOI 10.1152/physiolgenomics.00193.2004; Wu HF, 2020, NEUROPHARMACOLOGY, V162, DOI 10.1016/j.neuropharm.2019.107736; Yeh Mason L, 2017, OBM Neurobiol, V1, DOI 10.21926/obm.neurobiol.1702005; Yoo JH, 2020, NEUROIMAGE-CLIN, V26, DOI 10.1016/j.nicl.2019.102030; Zamarripa CA, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2022.54752; Zamberletti E, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00367; Zamberletti E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091916; Zhang MX, 2022, BMC PSYCHIATRY, V22, DOI 10.1186/s12888-022-03734-4; Rosenberg AZ, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.868583; Zou MY, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.200306";139;4;4;1;1;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;AUG 21;2023;14;;;;;;;;1210155;10.3389/fpsyt.2023.1210155;http://dx.doi.org/10.3389/fpsyt.2023.1210155;;;18;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;R0OG1;37671290;Green Published, gold;;;24/11/2024;WOS:001061415200001;View Full Record in Web of Science
J;"McDougle, CJ; Thom, RP; Ravichandran, CT; Palumbo, ML; Politte, LC; Mullett, JE; Keary, CJ; Erickson, CA; Stigler, KA; Mathieu-Frasier, L; Posey, DJ";;;;"McDougle, Christopher J.; Thom, Robyn P.; Ravichandran, Caitlin T.; Palumbo, Michelle L.; Politte, Laura C.; Mullett, Jennifer E.; Keary, Christopher J.; Erickson, Craig A.; Stigler, Kimberly A.; Mathieu-Frasier, Lauren; Posey, David J.";;;A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder;NEUROPSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; PSYCHOMETRIC PROPERTIES; OPEN-LABEL; BUSPIRONE; FLUVOXAMINE; BEHAVIOR";This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD). Participants were ages 5 to 17 years with ASD and clinically significant anxiety (Pediatric Anxiety Rating Scale [PARS] score >= 10). Thirty participants were randomized to mirtazapine (7.5-45 mg/day) or placebo in a 2:1 ratio. The co-primary outcome measures were the PARS and the Clinical Global Impressions-Improvement subscale (CGI-I). Mirtazapine resulted in a statistically significant within group decrease in anxiety on the PARS (ES 1.76, p < 0.001). The improvement in PARS score for mirtazapine versus placebo was clinically meaningful but not statistically significant (ES = 0.63, p = 0.64). Forty-seven percent of participants assigned to mirtazapine (95% CI 22%: 74%) and 20% assigned to placebo (95% CI 2%: 60%) were rated much improved (CGI-I = 2) or very much improved (CGI-I = 1) for anxiety, p = 0.46. No statistically significant differences in mean 10-week changes between mirtazapine and placebo occurred on any outcome measure. There were no statistically significant differences in adverse effect frequency between mirtazapine and placebo. The results are consistent with mirtazapine's safety and tolerability and meet three of four pre-specified indicators of efficacy (statistically significant change in total PARS score for mirtazapine, numerically greater reduction in total PARS score for mirtazapine than placebo, numerically higher number of responders to mirtazapine than placebo, but not greater than 50% of participants receiving mirtazapine rated as responders). Implementation of a larger randomized controlled trial of mirtazapine for the treatment of anxiety in this population is supported.;"[McDougle, Christopher J.; Thom, Robyn P.; Ravichandran, Caitlin T.; Palumbo, Michelle L.; Mullett, Jennifer E.; Keary, Christopher J.] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA; [McDougle, Christopher J.; Thom, Robyn P.; Ravichandran, Caitlin T.; Palumbo, Michelle L.; Mullett, Jennifer E.; Keary, Christopher J.] Lurie Ctr Autism, 1 Maguire Rd, Lexington, MA 02421 USA; [McDougle, Christopher J.; Thom, Robyn P.; Ravichandran, Caitlin T.; Keary, Christopher J.] Harvard Med Sch, Dept Psychiat, 25 Shattuck St, Boston, MA 02115 USA; [Ravichandran, Caitlin T.] McLean Hosp, 115 Mill St, Belmont, MA 02478 USA; [Palumbo, Michelle L.] Harvard Med Sch, Dept Pediat, 25 Shattuck St, Boston, MA 02115 USA; [Politte, Laura C.] WakeMed Childrens Pediat Behav Hlth, 3000 New Bern Ave, Raleigh, NC 27610 USA; [Politte, Laura C.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27515 USA; [Erickson, Craig A.; Mathieu-Frasier, Lauren] Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat, Cincinnati, OH 45229 USA; [Erickson, Craig A.; Mathieu-Frasier, Lauren] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA; [Stigler, Kimberly A.; Posey, David J.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA";"Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital; Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University Bloomington";"McDougle, CJ (corresponding author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.;McDougle, CJ (corresponding author), Lurie Ctr Autism, 1 Maguire Rd, Lexington, MA 02421 USA.;McDougle, CJ (corresponding author), Harvard Med Sch, Dept Psychiat, 25 Shattuck St, Boston, MA 02115 USA.";cmcdougle@mgh.harvard.edu;"Ravichandran, Caitlin/AAH-5562-2020; Thom, Robyn/AAN-2244-2020; Palumbo, Michelle/P-8704-2019; Erickson, Craig/M-8933-2017";;Autism Speaks;Autism Speaks;This work was funded by Autism Speaks.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Birmaher B, 1999, J AM ACAD CHILD PSY, V38, P1230, DOI 10.1097/00004583-199910000-00011; Borm GF, 2007, J CLIN EPIDEMIOL, V60, P1234, DOI 10.1016/j.jclinepi.2007.02.006; Buitelaar JK, 1998, J CLIN PSYCHIAT, V59, P56, DOI 10.4088/JCP.v59n0203; Ceranoglu TA, 2019, J CHILD ADOL PSYCHOP, V29, P28, DOI 10.1089/cap.2018.0021; Chugani DC, 2016, J PEDIATR-US, V170, P45, DOI 10.1016/j.jpeds.2015.11.033; Couturier JL, 2002, J CHILD ADOL PSYCHOP, V12, P243, DOI 10.1089/104454602760386932; deBoer T, 1996, J CLIN PSYCHIAT, V57, P19; Delli CKS, 2018, NEUROSCI BIOBEHAV R, V95, P449, DOI 10.1016/j.neubiorev.2018.10.023; Gambi F, 2005, J PSYCHOPHARMACOL, V19, P483, DOI 10.1177/0269881105056527; Herscu P, 2020, J AUTISM DEV DISORD, V50, P3233, DOI 10.1007/s10803-019-04120-y; Hidalgo RB, 2007, J PSYCHOPHARMACOL, V21, P864, DOI 10.1177/0269881107076996; Janzen H., 2004, Canadian Journal of School Psychology, V19, P235, DOI DOI 10.1177/082957350401900113; Kerns CM, 2021, J CLIN CHILD ADOLESC, V50, P780, DOI 10.1080/15374416.2019.1703712; Kirsch AC, 2020, JAMA PEDIATR, V174, P63, DOI 10.1001/jamapediatrics.2019.4368; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Martin A, 2003, J AUTISM DEV DISORD, V33, P77, DOI 10.1023/A:1022234605695; Mrakotsky C, 2008, J ANXIETY DISORD, V22, P88, DOI 10.1016/j.janxdis.2007.01.005; Owen J R, 1998, Depress Anxiety, V7 Suppl 1, P24, DOI 10.1002/(SICI)1520-6394(1998)7:1+<24::AID-DA7>3.0.CO;2-F; Owens JA, 2000, SLEEP, V23, P1043; Posey DJ, 2001, J CHILD ADOL PSYCHOP, V11, P267, DOI 10.1089/10445460152595586; Schatzberg AlanF., 2015, Manual of clinical psychopharmacology; Silverman W.K., 1996, Anxiety Disorders Interview Schedule for DSM-IV: Child and Parent version; Steingard RJ, 1997, J CHILD ADOL PSYCHOP, V7, P9, DOI 10.1089/cap.1997.7.9; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; Thompson C, 1999, J CLIN PSYCHIAT, V60, P18; van Steensel FJA, 2012, J CLIN CHILD ADOLESC, V41, P731, DOI 10.1080/15374416.2012.698725; van Steensel FJA, 2011, CLIN CHILD FAM PSYCH, V14, P302, DOI 10.1007/s10567-011-0097-0; Wagner A, 2007, BIOL PSYCHIAT, V61, P504, DOI 10.1016/j.biopsych.2007.01.001; Walkup JT, 2001, NEW ENGL J MED, V344, P1279, DOI 10.1056/NEJM200104263441703";31;5;8;1;6;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;0893-133X;1740-634X;;NEUROPSYCHOPHARMACOL;Neuropsychopharmacology;MAY;2022;47;6;;;;;1263;1270;;10.1038/s41386-022-01295-4;http://dx.doi.org/10.1038/s41386-022-01295-4;;mars-22;8;"Neurosciences; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";0Q6AE;35241779;Bronze, Green Published;;;24/11/2024;WOS:000763821200001;View Full Record in Web of Science
J;"Sokhadze, EM; Lamina, EV; Casanova, EL; Kelly, DP; Opris, I; Tasman, A; Casanova, MF";;;;"Sokhadze, Estate M.; Lamina, Eva V.; Casanova, Emily L.; Kelly, Desmond P.; Opris, Ioan; Tasman, Allan; Casanova, Manuel F.";;;Exploratory Study of rTMS Neuromodulation Effects on Electrocortical Functional Measures of Performance in an Oddball Test and Behavioral Symptoms in Autism;FRONTIERS IN SYSTEMS NEUROSCIENCE;;;English;Article;;;;;;"autism spectrum disorder; TMS; ERP; reaction time; executive functions; oddball task; aberrant and repetitive behaviors";"TRANSCRANIAL MAGNETIC STIMULATION; EVENT-RELATED POTENTIALS; SPECTRUM DISORDER; BRAIN-STIMULATION; PROCESSING ABNORMALITIES; MINICOLUMNAR PATHOLOGY; COGNITIVE NEUROSCIENCE; REPETITIVE BEHAVIOR; SELECTIVE ATTENTION; EXECUTIVE FUNCTION";There is no accepted pathology to autism spectrum disorders (ASD) but research suggests the presence of an altered excitatory/inhibitory (E/I) bias in the cerebral cortex. Repetitive transcranial magnetic stimulation (rTMS) offers a non-invasive means of modulating the E/I cortical bias with little in terms of side effects. In this study, 124 high functioning ASD children (IQ > 80, < 18 years of age) were recruited and assigned using randomization to either a waitlist group or one of three different number of weekly rTMS sessions (i.e., 6, 12, and 18). TMS consisted of trains of 1.0 Hz frequency pulses applied over the dorsolateral prefrontal cortex (DLPFC). The experimental task was a visual oddball with illusory Kanizsa figures. Behavioral response variables included reaction time and error rate along with such neurophysiological indices such as stimulus and response-locked event-related potentials (ERP). One hundred and twelve patients completed the assigned number of TMS sessions. Results showed significant changes from baseline to posttest period in the following measures: motor responses accuracy [ lower percentage of committed errors, slower latency of commission errors and restored normative post-error reaction time slowing in both early and later-stage ERP indices, enhanced magnitude of error-related negativity (ERN), improved error monitoring and post-error correction functions]. In addition, screening surveys showed significant reductions in aberrant behavior ratings and in both repetitive and stereotypic behaviors. These differences increased with the total number of treatment sessions. Our results suggest that rTMS, particularly after 18 sessions, facilitates cognitive control, attention and target stimuli recognition by improving discrimination between task-relevant and task-irrelevant illusory figures in an oddball test. The noted improvement in executive functions of behavioral performance monitoring further suggests that TMS has the potential to target core features of ASD.;"[Sokhadze, Estate M.; Lamina, Eva V.; Casanova, Emily L.; Kelly, Desmond P.; Casanova, Manuel F.] Univ South Carolina, Sch Med Greenville, Dept Biomed Sci, Greenville, SC 29605 USA; [Sokhadze, Estate M.; Tasman, Allan; Casanova, Manuel F.] Univ Louisville, Dept Psychiat & Behav Sci, Louisville, KY 40292 USA; [Kelly, Desmond P.; Casanova, Manuel F.] Greenville Hlth Syst, Dept Pediat, Greenville, SC USA; [Opris, Ioan] Univ Miami, Miller Sch Med, Miami, FL 33136 USA";"University of Louisville; Greenville Health System; University of Miami";"Sokhadze, EM (corresponding author), Univ South Carolina, Sch Med Greenville, Dept Biomed Sci, Greenville, SC 29605 USA.;Sokhadze, EM (corresponding author), Univ Louisville, Dept Psychiat & Behav Sci, Louisville, KY 40292 USA.";sokhadze@greenvillemed.sc.edu;"Sokhadze, Estate/AAH-9589-2020; Casanova, Manuel/G-8861-2016";;National Institutes of Health Eureka R01 grant [MH86784];National Institutes of Health Eureka R01 grant;This study was partially supported by National Institutes of Health Eureka R01 grant MH86784 to MC.;"Aman M.G., 1994, Aberrant Behavior Checklist-Community. Supplementary Manual; Aman Michael G, 2004, Semin Pediatr Neurol, V11, P225, DOI 10.1016/j.spen.2004.07.006; [Anonymous], 2010, CUTTING EDGE THERAPI; [Anonymous], RECENT DEV AUTISM RE; [Anonymous], 2013, DIAGNOSTIC STAT MANU; [Anonymous], TRANSCRANIAL MAGNETI; APA A.P. A., 2000, Diagnostic and statistical manual of mental disorders: DSM-IV, V4th; Arbel Y., 2009, PSYCHOPHYSIOLOGY, V46, P1288, DOI DOI 10.1111/J.1469-8986.2009; Arbel Y, 2011, PSYCHOPHYSIOLOGY, V48, P55, DOI 10.1111/j.1469-8986.2010.01042.x; Baron-Cohen S, 2004, J NEUROL NEUROSUR PS, V75, P945, DOI 10.1136/jnnp.2003.018713; BARONCOHEN S, 1989, BRIT J DISORD COMMUN, V24, P199; Baruth Joshua M, 2010, J Neurother, V14, P179; Baruth JM, 2010, TRANSL NEUROSCI, V1, P177, DOI 10.2478/v10134-010-0024-9; Belmonte MK, 2004, J NEUROSCI, V24, P9228, DOI 10.1523/JNEUROSCI.3340-04.2004; Belmonte MK, 2003, COGNITIVE BRAIN RES, V17, P651, DOI 10.1016/S0926-6410(03)00189-7; Bodfish J.W., 1999, REPETITIVE BEHAV SCA, DOI DOI 10.1037/T17338-000; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Bogte H, 2007, NEUROPSYCHOLOGIA, V45, P1707, DOI 10.1016/j.neuropsychologia.2006.12.020; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Casanova MF, 2006, CLIN NEUROSCI RES, V6, P127, DOI 10.1016/j.cnr.2006.06.003; Casanova MF, 2007, BRAIN PATHOL, V17, P422, DOI 10.1111/j.1750-3639.2007.00100.x; Casanova MF, 2006, ACTA NEUROPATHOL, V112, P287, DOI 10.1007/s00401-006-0085-5; Casanova MF, 2015, ACTA PAEDIATR, V104, P346, DOI 10.1111/apa.12943; Casanova MF, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-67; Casanova MF, 2012, TRANSL NEUROSCI, V3, P170, DOI 10.2478/s13380-012-0022-0; Casanova MF, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00851; Casanova MF, 2002, J CHILD NEUROL, V17, P692, DOI 10.1177/088307380201700908; Casanova MF, 2002, J CHILD NEUROL, V17, P142, DOI 10.1177/088307380201700211; Casanova MF, 2003, NEUROSCIENTIST, V9, P496, DOI 10.1177/1073858403253552; Casanova MF, 2002, NEUROLOGY, V58, P428, DOI 10.1212/WNL.58.3.428; CIESIELSKI KT, 1990, ELECTROEN CLIN NEURO, V75, P207, DOI 10.1016/0013-4694(90)90174-I; COURCHESNE E, 1989, J AUTISM DEV DISORD, V19, P1, DOI 10.1007/BF02212714; Croarkin PE, 2011, INT REV PSYCHIATR, V23, P445, DOI 10.3109/09540261.2011.623688; Dapretto M, 2006, NAT NEUROSCI, V9, P28, DOI 10.1038/nn1611; Daskalakis ZJ, 2002, J NEUROPSYCH CLIN N, V14, P406, DOI 10.1176/appi.neuropsych.14.4.406; Davies PL, 2004, DEV NEUROPSYCHOL, V25, P355, DOI 10.1207/s15326942dn2503_6; Enticott PG, 2014, BRAIN STIMUL, V7, P206, DOI 10.1016/j.brs.2013.10.004; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; FRITH U, 1994, COGNITION, V50, P115, DOI 10.1016/0010-0277(94)90024-8; Garvey MA, 2004, EUR J PAEDIATR NEURO, V8, P7, DOI 10.1016/j.ejpn.2003.11.002; Garvey MA, 2008, CLIN NEUROPHYSIOL, V119, P973, DOI 10.1016/j.clinph.2007.11.048; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; George MS, 2003, CNS SPECTRUMS, V8, P496, DOI 10.1017/S1092852900018976; George MS, 1999, ARCH GEN PSYCHIAT, V56, P300, DOI 10.1001/archpsyc.56.4.300; Gershon AA, 2003, AM J PSYCHIAT, V160, P835, DOI 10.1176/appi.ajp.160.5.835; Gilbert DL, 2004, CLIN NEUROPHYSIOL, V115, P1730, DOI 10.1016/j.clinph.2003.10.037; Henderson H, 2006, BRAIN COGNITION, V61, P96, DOI 10.1016/j.bandc.2005.12.009; Hoffman RE, 2002, AM J PSYCHIAT, V159, P1093, DOI 10.1176/appi.ajp.159.7.1093; Hong YJH, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00029; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jeste SS, 2009, J AUTISM DEV DISORD, V39, P495, DOI 10.1007/s10803-008-0652-9; Just MA, 2004, BRAIN, V127, P1811, DOI 10.1093/brain/awh199; KANIZSA G, 1976, SCI AM, V234, P48, DOI 10.1038/scientificamerican0476-48; Kemner C, 1999, BIOL PSYCHIAT, V46, P781, DOI 10.1016/S0006-3223(99)00003-7; KEMNER C, 1994, ELECTROEN CLIN NEURO, V92, P225, DOI 10.1016/0168-5597(94)90066-3; Klomjai W, 2015, ANN PHYS REHABIL MED, V58, P208, DOI 10.1016/j.rehab.2015.05.005; Krishnan C, 2015, BRAIN STIMUL, V8, P76, DOI 10.1016/j.brs.2014.10.012; Le K, 2013, J CLIN NEUROSCI, V20, P251, DOI 10.1016/j.jocn.2012.01.049; Loo CK, 2005, J AFFECT DISORDERS, V88, P255, DOI 10.1016/j.jad.2005.08.001; Luu P, 2001, J CLIN NEUROPHYSIOL, V18, P302, DOI 10.1097/00004691-200107000-00002; Maeda F, 2000, CLIN NEUROPHYSIOL, V111, P800, DOI 10.1016/S1388-2457(99)00323-5; Mars RB, 2005, NEUROIMAGE, V28, P1007, DOI 10.1016/j.neuroimage.2005.06.041; Minshew N J, 1997, J Int Neuropsychol Soc, V3, P303; Mir-Moghtadaei A, 2015, BRAIN STIMUL, V8, P965, DOI 10.1016/j.brs.2015.05.008; Murphy K.R., 2004, STAT POWER ANAL SIMP, V2nd; Ni HC, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00255; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1111/1469-8986.3850752; Oberman Lindsay, 2010, Front Synaptic Neurosci, V2, P26, DOI 10.3389/fnsyn.2010.00026; Oberman LM, 2016, AUTISM RES, V9, P184, DOI 10.1002/aur.1567; Oberman LM, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00544; Oberman LM, 2015, J AUTISM DEV DISORD, V45, P524, DOI 10.1007/s10803-013-1960-2; Opris I, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00336; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1081, DOI 10.1111/j.1469-7610.1991.tb00351.x; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Pascual-Leone A., 2002, Handbook of transcranial magnetic stimulation; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Polich J., 2003, DETECTION CHANGE EVE; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pommier B, 2017, NEUROPHYSIOL CLIN, V47, P35, DOI 10.1016/j.neucli.2017.01.007; Quintana H, 2005, J ECT, V21, P88, DOI 10.1097/01.yct.0000162556.02720.58; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rotenberg A, 2014, NEUROMETHODS, V89, P1, DOI 10.1007/978-1-4939-0879-0; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; RUDIAK D, 1994, ELECTROEN CLIN NEURO, V93, P358, DOI 10.1016/0013-4694(94)00144-A; Rutter M., 2003, ADI R AUTISM DIAGNOS; Sokhadze E., 2016, NeuroRegulation, V3, P101, DOI DOI 10.15540/NR.3.3.101; Sokhadze Estate, 2010, J Neurother, V14, P79; Sokhadze E, 2010, APPL PSYCHOPHYS BIOF, V35, P147, DOI 10.1007/s10484-009-9121-2; Sokhadze E, 2009, APPL PSYCHOPHYS BIOF, V34, P37, DOI 10.1007/s10484-009-9074-5; Sokhadze EM, 2014, APPL PSYCHOPHYS BIOF, V39, P237, DOI 10.1007/s10484-014-9264-7; Sokhadze EM, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00134; Sokhadze Estate M, 2012, J Neurother, V16, P12; Sokhadze EM, 2012, APPL PSYCHOPHYS BIOF, V37, P91, DOI 10.1007/s10484-012-9182-5; Sokhadze EM, 2009, J AUTISM DEV DISORD, V39, P619, DOI 10.1007/s10803-008-0662-7; Srinivasan R, 1998, BEHAV RES METH INS C, V30, P8, DOI 10.3758/BF03209412; Thakkar KN, 2008, BRAIN, V131, P2464, DOI 10.1093/brain/awn099; Townsend J, 2001, COGNITIVE BRAIN RES, V11, P127, DOI 10.1016/S0926-6410(00)00072-0; Uzunova G, 2016, WORLD J BIOL PSYCHIA, V17, P174, DOI 10.3109/15622975.2015.1085597; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Vlamings PHJM, 2008, EUR J NEUROSCI, V28, P399, DOI 10.1111/j.1460-9568.2008.06336.x; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002; Walter G, 2001, J CHILD ADOL PSYCHOP, V11, P69, DOI 10.1089/104454601750143483; Wang Y, 2016, APPL PSYCHOPHYS BIOF, V41, P47, DOI 10.1007/s10484-015-9311-z; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5; Wassermann EM, 2012, PHARMACOL THERAPEUT, V133, P98, DOI 10.1016/j.pharmthera.2011.09.003; Wechsler D, 2003, Weschler Intelligence Scale for Children, Fourth Edition, Australian Administration and Scoring Manual, VFourth; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); Ziemann U, 2004, REV NEUROSCIENCE, V15, P253";113;32;38;7;25;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1662-5137;;;FRONT SYST NEUROSCI;Front. Syst. Neurosci.;MAY 28;2018;12;;;;;;;;20;10.3389/fnsys.2018.00020;http://dx.doi.org/10.3389/fnsys.2018.00020;;;16;Neurosciences;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;GH1VH;29892214;gold, Green Published;;;24/11/2024;WOS:000433190200001;View Full Record in Web of Science
J;"Parker, KJ; Oztan, O; Libove, RA; Mohsin, N; Karhson, DS; Sumiyoshi, RD; Summers, JE; Hinman, KE; Motonaga, KS; Phillips, JM; Carson, DS; Fung, LK; Garner, JP; Hardan, AY";;;;"Parker, Karen J.; Oztan, Ozge; Libove, Robin A.; Mohsin, Noreen; Karhson, Debra S.; Sumiyoshi, Raena D.; Summers, Jacqueline E.; Hinman, Kyle E.; Motonaga, Kara S.; Phillips, Jennifer M.; Carson, Dean S.; Fung, Lawrence K.; Garner, Joseph P.; Hardan, Antonio Y.";;;A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism;SCIENCE TRANSLATIONAL MEDICINE;;;English;Article;;;;;;;"DIAGNOSTIC INTERVIEW; ARGININE-VASOPRESSIN; RECEPTOR; OXYTOCIN; BEHAVIOR; AGGRESSION; TRAITS; INDIVIDUALS; SCALE; 1-DEAMINO-8-D-ARGININE-VASOPRESSIN";"The social impairments of autism spectrum disorder (ASD) have a major impact on quality of life, yet there are no medications that effectively treat these core social behavior deficits. Preclinical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for ASD. Using a double-blind, randomized, placebo-controlled, parallel study design, we tested the efficacy and tolerability of a 4-week intranasal AVP daily treatment in 30 children with ASD. AVP-treated participants aged 6 to 9.5 years received the maximum daily target dose of 24 International Units (IU); participants aged 9.6 to 12.9 years received the maximum daily target dose of 32 IU. Intranasal AVP treatment compared to placebo enhanced social abilities as assessed by change from baseline in this phase 2 trial's primary outcome measure, the Social Responsiveness Scale, 2nd Edition total score (SRS-2 T score; F-1,F-20 = 9.853; P = 0.0052;. eta(2)(p) = 33.0%; Cohen's d = 1.40). AVP treatment also diminished anxiety symptoms and some repetitive behaviors. Most of these findings were more pronounced when we accounted for pretreatment AVP concentrations in blood. AVP was well tolerated with minimal side effects. No AVP-treated participants dropped out of the trial, and there were no differences in the rate of adverse events reported between treatment conditions. Last, no changes from baseline were observed in vital signs, electrocardiogram tracings, height and body weight, or clinical chemistry measurements after 4 weeks of AVP treatment. These preliminary findings suggest that AVP has potential for treating social impairments in children with ASD.";"[Parker, Karen J.; Oztan, Ozge; Libove, Robin A.; Mohsin, Noreen; Karhson, Debra S.; Sumiyoshi, Raena D.; Summers, Jacqueline E.; Hinman, Kyle E.; Phillips, Jennifer M.; Carson, Dean S.; Fung, Lawrence K.; Garner, Joseph P.; Hardan, Antonio Y.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Motonaga, Kara S.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Garner, Joseph P.] Stanford Univ, Dept Comparat Med, Stanford, CA 94305 USA";"Stanford University; Stanford University; Stanford University";Parker, KJ (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.;kjparker@stanford.edu;"Garner, Joseph/C-8422-2009; Karhson, Debra/KQV-0994-2024; Parker, Karen/G-1347-2012; Fung, Lawrence/R-8354-2016";"Phillips, Jennifer/0000-0002-6360-2346; Motonaga, Kara/0000-0003-4917-1081; Hinman, Kyle/0000-0002-3983-9079; Parker, Karen/0000-0002-6836-6338; Fung, Lawrence/0000-0002-5738-0396; Summers, Jacqueline/0000-0001-8800-8733; Karhson, Debra/0000-0002-3850-3119; Oztan, Ozge/0000-0002-1164-8553";"NIH [R21MH100387, R21HD083629, R01HD091972, K08MH111750, T32MH019908]; Autism Speaks Meixner Postdoctoral Fellowship in Translational Research [7895]; Bass Society Pediatric Fellowship; Mosbacher Family Fund for Autism Research; Child Health Research Institute; Yani Calmidis Memorial Fund for Autism Research; Stanford's Department of Psychiatry; Teresa and Charles Michael Endowed Fund";"NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Autism Speaks Meixner Postdoctoral Fellowship in Translational Research; Bass Society Pediatric Fellowship; Mosbacher Family Fund for Autism Research; Child Health Research Institute; Yani Calmidis Memorial Fund for Autism Research; Stanford's Department of Psychiatry; Teresa and Charles Michael Endowed Fund";This research was supported by the NIH (R21MH100387 to K.J.P. and A.Y.H., R21HD083629 to K.J.P., R01HD091972 to K.J.P. and A.Y.H., K08MH111750 to L.K.F., and T32MH019908 to D.S.K.), an Autism Speaks Meixner Postdoctoral Fellowship in Translational Research (#7895 to D.S.C.), a Bass Society Pediatric Fellowship (D.S.C.), the Mosbacher Family Fund for Autism Research (K.J.P.), the Teresa and Charles Michael Endowed Fund for Autism Research and Education (A.Y.H.), the Child Health Research Institute (K.J.P., A.Y.H., and O.O.), the Yani Calmidis Memorial Fund for Autism Research (K.J.P.), and Stanford's Department of Psychiatry (K.J.P., L.K.F, and A.Y.H.).;"Albers HE, 2012, HORM BEHAV, V61, P283, DOI 10.1016/j.yhbeh.2011.10.007; Aman MG, 2017, J CHILD ADOL PSYCHOP, V27, P403, DOI 10.1089/cap.2015.0146; [Anonymous], 2013, Diagnostic and statistical manual of mental disorders; APA A.P. A., 2000, Diagnostic and statistical manual of mental disorders: DSM-IV, V4th; Baribeau DA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00335; Baron-Cohen S., 2001, J DEV LEARNING DISOR, V5, P47; Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360; Bolognani F, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat7838; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Brunnlieb C, 2016, P NATL ACAD SCI USA, V113, P2051, DOI 10.1073/pnas.1518825113; Carson DS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132224; Carson DS, 2014, PEPTIDES, V61, P12, DOI 10.1016/j.peptides.2014.08.003; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Constantino JN, 2005, BIOL PSYCHIAT, V57, P655, DOI 10.1016/j.biopsych.2004.12.014; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Constantino JN, 2003, ARCH GEN PSYCHIAT, V60, P524, DOI 10.1001/archpsyc.60.5.524; Constantino JN, 2011, PEDIATR RES, V69, p55R, DOI 10.1203/PDR.0b013e318212ec6e; Delville W, 1996, PHYSIOL BEHAV, V60, P25, DOI 10.1016/0031-9384(95)02246-5; Donaldson ZR, 2010, BEHAV NEUROSCI, V124, P159, DOI 10.1037/a0018094; Ferris CF, 1997, J NEUROSCI, V17, P4331; Frazier TW, 2014, AUTISM, V18, P31, DOI 10.1177/1362361313500382; Freeman SM, 2014, PSYCHONEUROENDOCRINO, V45, P128, DOI 10.1016/j.psyneuen.2014.03.023; Garvey C A, 1991, J Child Adolesc Psychiatr Ment Health Nurs, V4, P127, DOI 10.1111/j.1744-6171.1991.tb00509.x; Gobrogge KL, 2009, P NATL ACAD SCI USA, V106, P19144, DOI 10.1073/pnas.0908620106; Grafen A., 2002, MODERN STAT LIFE SCI, p[XV, 351]; Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P1220, DOI 10.1016/j.biopsych.2010.03.014; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Johnson ZV, 2017, NEUROSCI BIOBEHAV R, V76, P87, DOI 10.1016/j.neubiorev.2017.01.034; Kagerbauer SM, 2013, J NEUROENDOCRINOL, V25, P668, DOI 10.1111/jne.12038; Korkman M., 2007, NEPSY-II: Clinical and interpretive manual; LACZI F, 1982, PSYCHONEUROENDOCRINO, V7, P185, DOI 10.1016/0306-4530(82)90011-7; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C., 2014, AUTISM DIAGNOSTIC OB; Lossie AC, 2012, BMC GENET, V13, DOI 10.1186/1471-2156-13-106; Mead Roger., 1988, The Design of Experiments: Statistical Principles for Practical Applicati; Neter J., 1996, Applied linear statistical models; Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004; Niemczyk J, 2018, EUR CHILD ADOLES PSY, V27, P1523, DOI 10.1007/s00787-017-1062-3; Oztan O, 2018, ANN NEUROL, V84, P611, DOI 10.1002/ana.25314; Parker KJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam9100; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Parker KJ, 2001, HORM BEHAV, V39, P285, DOI 10.1006/hbeh.2001.1655; Paul MJ, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0150-15.2016; Quintana DS, 2016, MOL PSYCHIATR, V21, P29, DOI 10.1038/mp.2015.166; Ratni H, 2015, J MED CHEM, V58, P2275, DOI 10.1021/jm501745f; Robben JH, 2004, MOL BIOL CELL, V15, P5693, DOI 10.1091/mbc.E04-04-0337; Roid G.H., 2003, STANFORD BINETS INTE; Sclafani V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165401; SORENSEN S, 1984, EUR J CLIN INVEST, V14, P435, DOI 10.1111/j.1365-2362.1984.tb01209.x; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; Thompson R, 2004, PSYCHONEUROENDOCRINO, V29, P35, DOI 10.1016/S0306-4530(02)00133-6; Tottenham N, 2009, PSYCHIAT RES, V168, P242, DOI 10.1016/j.psychres.2008.05.006; Tsikunov SG, 2007, SPAN J PSYCHOL, V10, P178, DOI 10.1017/S1138741600006442; Umbricht D, 2017, NEUROPSYCHOPHARMACOL, V42, P1924, DOI 10.1038/npp.2017.92; Walle JV, 2007, CURR DRUG SAF, V2, P232, DOI 10.2174/157488607781668891; Wang SS, 2008, MOL PSYCHIATR, V13, P786, DOI 10.1038/mp.2008.38; Webb S, 2010, NAT BIOTECHNOL, V28, P772, DOI 10.1038/nbt0810-772; White SW, 2009, CLIN PSYCHOL REV, V29, P216, DOI 10.1016/j.cpr.2009.01.003; Wigham S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085268; WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0; Wotjak CT, 1998, NEUROSCIENCE, V85, P1209, DOI 10.1016/S0306-4522(97)00683-0; Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zhang HF, 2015, PHYSIOL BEHAV, V151, P485, DOI 10.1016/j.physbeh.2015.08.014; Zhang R, 2012, RES DEV DISABIL, V33, P1136, DOI 10.1016/j.ridd.2012.02.001; 2011, PSYCHONEUROENDOCRINO, V36, P294, DOI DOI 10.1016/J.PSYNEUEN.2010.07.023";71;100;105;1;31;AMER ASSOC ADVANCEMENT SCIENCE;WASHINGTON;1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA;1946-6234;1946-6242;;SCI TRANSL MED;Sci. Transl. Med.;MAY 8;2019;11;491;;;;;;;eaau7356;10.1126/scitranslmed.aau7356;http://dx.doi.org/10.1126/scitranslmed.aau7356;;;12;"Cell Biology; Medicine, Research & Experimental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Cell Biology; Research & Experimental Medicine";HX3EG;31043522;Green Accepted, Bronze;;;24/11/2024;WOS:000467273900004;View Full Record in Web of Science
J;"Mehl-Madrona, L; Leung, B; Kennedy, C; Paul, S; Kaplan, BJ";;;;"Mehl-Madrona, Lewis; Leung, Brenda; Kennedy, Carla; Paul, Sarah; Kaplan, Bonnie J.";;;Micronutrients Versus Standard Medication Management in Autism: A Naturalistic Case-Control Study;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"ABERRANT BEHAVIOR CHECKLIST; DOUBLE-BLIND; RATING-SCALE; MITOCHONDRIAL DYSFUNCTION; YOUNG-CHILDREN; FATTY-ACIDS; SUPPLEMENT; RISPERIDONE; MINERALS; VITAMINS";Autism spectrum disorder (ASD) is often accompanied by self-injurious behavior (SIB), aggression, and tantrums, symptoms that have reportedly improved with micronutrient (vitamins and minerals) treatment. The current study took advantage of naturally occurring differences in parental preferences for treatment approaches. The micronutrient group asked for treatment without pharmaceuticals (n = 44, aged 2-28 years at entry [M = 8.39 +/- 5.58]). Their records were matched with those of 44 similar children whose families requested conventional treatment (medication group). Both groups improved on both the Childhood Autism Rating Scale and the Childhood Psychiatric Rating Scale (all p values < 0.0001). Both groups also exhibited significant decreases in total Aberrant Behavior Checklist scores, but the micronutrient group's improvement was significantly greater (p < 0.0001). SIB Intensity was lower in the micronutrient group at the end of the study (p = 0.005), and improvement on the Clinical Global Impressions scale was greater for the micronutrient group (p = 0.0029). It is difficult to determine whether the observed changes were exerted through improvement in mood disorder or through an independent effect on autistic disorder. There were some advantages to treatment with micronutrients-lower activity level, less social withdrawal, less anger, better spontaneity with the examiner, less irritability, lower intensity SIB, markedly fewer adverse events, and less weight gain. Advantages of medication management were insurance coverage, fewer pills, and less frequent dosing.;"[Kaplan, Bonnie J.] Univ Calgary, Dept Pediat, Fac Med, Calgary, AB T2N 1N4, Canada; [Leung, Brenda; Kaplan, Bonnie J.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Paul, Sarah] Univ Saskatchewan, Sch Nursing, Saskatoon, SK, Canada; [Kennedy, Carla] Univ Manitoba, Dept Anthropol, Winnipeg, MB, Canada; [Mehl-Madrona, Lewis] Argosy Univ, Dept Psychol, Honolulu, HI USA; [Mehl-Madrona, Lewis] Univ Hawaii, Dept Family Med, Sch Med, Honolulu, HI 96822 USA";"University of Calgary; University of Calgary; University of Saskatchewan; University of Manitoba; Argosy University; University of Hawaii System";Kaplan, BJ (corresponding author), Behav Res Unit, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.;bonnie.kaplan@albertahealthservices.ca;"Leung, Brenda/J-8729-2015; Giesbrecht, Gerald/F-2667-2016";;"Richmond Foundation of Santa Barbara, California; Health Canada; Alberta Children's Hospital Foundation";"Richmond Foundation of Santa Barbara, California; Health Canada; Alberta Children's Hospital Foundation";We thank the Richmond Foundation of Santa Barbara, California, for its initial financial support to L. M.-M., Health Canada for its salary support for S. P., and the Alberta Children's Hospital Foundation for its ongoing support of B.L. and B.K. L.M.-M. thanks Janzen for providing Risperdal samples for families in financial need. Finally, we acknowledge the efforts of the participants and their families who willingly provided follow-up data beyond that which is usually required for clinical treatment.;"Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P869, DOI 10.1089/cap.2005.15.869; AMAN MG, 1985, AM J MENT DEF, V89, P485; Ames BN, 2004, ARCH BIOCHEM BIOPHYS, V423, P227, DOI 10.1016/j.abb.2003.11.002; Ames BN, 2003, J NUTR, V133, p1544S, DOI 10.1093/jn/133.5.1544S; Ames BN, 2002, AM J CLIN NUTR, V75, P616, DOI 10.1093/ajcn/75.4.616; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; [Anonymous], 1976, ECDEU ASSESSMENT MAN; Baghdadli A, 2003, J INTELL DISABIL RES, V47, P622, DOI 10.1046/j.1365-2788.2003.00507.x; CAMPBELL M, 1985, PSYCHOPHARMACOL BULL, V21, P1047; Canitano R, 2006, J NEURAL TRANSM, V113, P425, DOI 10.1007/s00702-005-0337-x; FISH B, 1985, PSYCHOPHARMACOL BULL, V21, P753; Frazier EA, 2009, J CHILD ADOL PSYCHOP, V19, P453, DOI 10.1089/cap.2008.0157; Gardner A, 2005, CURR PSYCHIATRY REV, V1, P255, DOI 10.2174/157340005774575064; Gately D., 2009, Clinical Medicine: Psychiatry, V2, P3; Gesch CB, 2002, BRIT J PSYCHIAT, V181, P22, DOI 10.1192/bjp.181.1.22; Hallahan B, 2007, BRIT J PSYCHIAT, V190, P118, DOI 10.1192/bjp.bp.106.022707; Itomura M, 2005, J NUTR BIOCHEM, V16, P163, DOI 10.1016/j.jnutbio.2004.10.009; James SJ, 2009, AM J CLIN NUTR, V89, P425, DOI 10.3945/ajcn.2008.26615; Kaplan BJ, 2004, J CHILD ADOL PSYCHOP, V14, P115, DOI 10.1089/104454604773840553; Kaplan BJ, 2002, J CHILD ADOL PSYCHOP, V12, P205, DOI 10.1089/104454602760386897; Kaplan BJ, 2001, J CLIN PSYCHIAT, V62, P936, DOI 10.4088/JCP.v62n1204; Kaplan BJ, 2007, PSYCHOL BULL, V133, P747, DOI 10.1037/0033-2909.133.5.747; Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x; Kemper KJ, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-11; Konradi C, 2004, ARCH GEN PSYCHIAT, V61, P300, DOI 10.1001/archpsyc.61.3.300; MARSHBURN EC, 1992, J AUTISM DEV DISORD, V22, P357, DOI 10.1007/BF01048240; Masi G, 2001, J AM ACAD CHILD PSY, V40, P1206, DOI 10.1097/00004583-200110000-00015; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2008, J CLIN PSYCHIAT, V69, P15; Meguid NA, 2008, CLIN BIOCHEM, V41, P1044, DOI 10.1016/j.clinbiochem.2008.05.013; Mehl-Madrona Lewis., 2007, NARRATIVE MED USE HI; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Mousain-Bosc M, 2006, MAGNESIUM RES, V19, P53; Nye C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003497; OVERALL JE, 1988, J CLIN PSYCHOL, V44, P708, DOI 10.1002/1097-4679(198809)44:5<708::AID-JCLP2270440507>3.0.CO;2-T; Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041; Popper CW, 2001, J CLIN PSYCHIAT, V62, P933, DOI 10.4088/JCP.v62n1203; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; RIMLAND B, 1978, AM J PSYCHIAT, V135, P472, DOI 10.1176/ajp.135.4.472; RIMLAND B, 1988, J CHILD NEUROL, V3, pS68, DOI 10.1177/0883073888003001S13; RUCKLIDGE JJ, J ANXIETY DIS, V23, P836; SCHOPLER E, 1980, J AUTISM DEV DISORD, V10, P91, DOI 10.1007/BF02408436; Simmons M, 2003, J CLIN PSYCHIAT, V64, P338, DOI 10.4088/JCP.v64n0317d; Young LT, 2007, J PSYCHIATR NEUROSCI, V32, P160";45;44;50;0;14;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;APR;2010;20;2;;;;;95;103;;10.1089/cap.2009.0011;http://dx.doi.org/10.1089/cap.2009.0011;;;9;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";587JK;20415604;Green Published;;;24/11/2024;WOS:000276987500002;View Full Record in Web of Science
J;"Tatarinova, TV; Deiss, T; Franckle, L; Beaven, S; Davis, J";;;;"Tatarinova, Tatiana, V; Deiss, Trina; Franckle, Lorri; Beaven, Susan; Davis, Jeffrey";;;The Impact of MNRI Therapy on the Levels of Neurotransmitters Associated with Inflammatory Processes;INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES;;;English;Article;;;;;;"neurotransmitters; inflammation; MNRI";"D-ASPARTATE RECEPTOR; MONOAMINE-OXIDASE; DISORDER; SEROTONIN; CHILDREN; GLYCINE";The neurotransmitter levels of representatives from five different diagnosis groups were tested before and after participation in the MNRI (R)-Masgutova Neurosensorimotor Reflex Intervention. The purpose of this study was to ascertain neurological impact on (1) Developmental disorders, (2) Anxiety disorders/OCD (Obsessive Compulsive Disorder), PTSD (Post-Traumatic Stress disorder), (3) Palsy/Seizure disorders, (4) ADD/ADHD (Attention Deficit Disorder/Attention Deficit Disorder Hyperactive Disorder), and (5) ASD (Autism Spectrum Disorder) disorders. Each participant had a form of neurological dysregulation and typical symptoms respective to their diagnosis. These diagnoses have a severe negative impact on the quality of life, immunity, stress coping, cognitive skills, and social assimilation. This study showed a trend towards optimization and normalization of neurological and immunological functioning, thus supporting the claim that the MNRI method is an effective non-pharmacological neuromodulation treatment of neurological disorders. The effects of MNRI on inflammation have not yet been assessed. The resulting post-MNRI changes in participants' neurotransmitters show significant adjustments in the regulation of the neurotransmitter resulting in being calmer, a decrease of hypervigilance, an increase in stress resilience, behavioral and emotional regulation improvements, a more positive emotional state, and greater control of cognitive processes. In this paper, we demonstrate that the MNRI approach is an intervention that reduces inflammation. It is also likely to reduce oxidative stress and encourage homeostasis of excitatory neurotransmitters. MNRI may facilitate neurodevelopment, build stress resiliency, neuroplasticity, and optimal learning opportunity. There have been no reported side effects of MNRI treatments.;"[Tatarinova, Tatiana, V] Univ Verne, Dept Biol, La Verne, CA 91750 USA; [Tatarinova, Tatiana, V] Vavilov Inst Gen Genet, Funct Genom Grp, Moscow 119991, Russia; [Tatarinova, Tatiana, V] Siberian Fed Univ, Forest Genom Lab, Krasnoyarsk 660041, Russia; [Tatarinova, Tatiana, V] Informat Transmiss Problems Inst, Bioinformat Ctr, Moscow 127051, Russia; [Deiss, Trina] United1Front Fdn, Res Dept, Minneapolis, MN 55111 USA; [Franckle, Lorri] Laser Hlth, Laser Hlth Dept, Orlando, FL 33709 USA; [Beaven, Susan] St Petersburg Free Clin, Family Med, St Petersburg, FL 33701 USA; [Davis, Jeffrey] Prairie Hlth & Wellness, Family Med, Wichita, KS 67206 USA";"Russian Academy of Sciences; Vavilov Institute of General Genetics; Siberian Federal University";"Tatarinova, TV (corresponding author), Univ Verne, Dept Biol, La Verne, CA 91750 USA.;Tatarinova, TV (corresponding author), Vavilov Inst Gen Genet, Funct Genom Grp, Moscow 119991, Russia.;Tatarinova, TV (corresponding author), Siberian Fed Univ, Forest Genom Lab, Krasnoyarsk 660041, Russia.;Tatarinova, TV (corresponding author), Informat Transmiss Problems Inst, Bioinformat Ctr, Moscow 127051, Russia.";"ttatarinova@laverne.edu; deisstrina@gmail.com; lorrifranckle@gmail.com; scbeaven@gmail.com; jeff@prairiehealthwellness.com";"Tatarinova, Tatiana/AAH-1915-2020; Tatarinova, Tatiana/K-3445-2016";Tatarinova, Tatiana/0000-0003-1787-1112;Bridge to Healing Foundation;Bridge to Healing Foundation;The Bridge to Healing Foundation funded this research.;"Akhmatova N., 2017, J. Clin. Cell. Immunol., V8, DOI [10.4172/2155-9899.1000483, DOI 10.4172/2155-9899.1000483]; Anand D, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00228; Anokhin P. K., 1974, Biology and neurophysiology of the conditioned reflex and its role in adaptive behavior; [Anonymous], REFLEXES PORTAL NEUR; [Anonymous], INTRO MED IMMUNOLOGY; [Anonymous], PHYSL BEHAV SCI WORK; [Anonymous], J GENET SYNDR GENE T; [Anonymous], J TRAUMA STRESS DISO; [Anonymous], BIOLOGY; [Anonymous], INT J NEUROREHABILIT; [Anonymous], 2007, AM J CLIN NUTR; [Anonymous], LANGUAGE DEV USING S; [Anonymous], INT J NEUROREHABILIT; [Anonymous], J NEUROL NEUROBIOL; [Anonymous], 1974, Stress without distress; [Anonymous], REFLEXES PORTAL NEUR; [Anonymous], RUSSIAN J IMMUN; [Anonymous], P 17 BIENN M EUR SOC; [Anonymous], CONDITIONED REFLEXES; [Anonymous], J NEUROL SCI; Antonucci Nicola, 2015, Case Rep Psychiatry, V2015, P325061, DOI 10.1155/2015/325061; BAKER GB, 1991, BIOL PSYCHIAT, V29, P15, DOI 10.1016/0006-3223(91)90207-3; Bell C., 2019, Neurosci. Med, V10, P292, DOI [10.4236/nm.2019.103022, DOI 10.4236/NM.2019.103022]; BONHAUS DW, 1989, MOL PHARMACOL, V36, P273; Buowari OY., 2013, Advances in Bioscience and Biotechnology, V04, P126, DOI [DOI 10.4236/ABB.2013.41A018, 10.4236/abb.2013.41A018, 10.4236/abb.2013.41a018]; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Cavaleri Jonathon, 2018, Surg Neurol Int, V9, P169, DOI 10.4103/sni.sni_476_17; Cowan LD, 2002, MENT RETARD DEV D R, V8, P171, DOI 10.1002/mrdd.10035; Delahanty DL, 2005, PSYCHONEUROENDOCRINO, V30, P121, DOI 10.1016/j.psyneuen.2004.06.004; Fischer R, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/610813; Frick A, 2015, JAMA PSYCHIAT, V72, P794, DOI 10.1001/jamapsychiatry.2015.0125; Garlick PJ, 2004, J NUTR, V134, p1633S, DOI 10.1093/jn/134.6.1633S; Giustarini D, 2009, CRIT REV CL LAB SCI, V46, P241, DOI 10.3109/10408360903142326; Gold MS, 2014, POSTGRAD MED, V126, P153, DOI 10.3810/pgm.2014.01.2735; Gu F, 2017, J NEUROSCI RES, V95, P1965, DOI 10.1002/jnr.24027; Haines D.E., 2002, FUNDAMENTAL NEUROSCI; Hall JE, 2011, TXB MED PHYSL; Hoover-Fong JE, 2004, NEUROLOGY, V63, P1847, DOI 10.1212/01.WNL.0000144270.83080.29; Irsfeld M., 2013, WebmedCentral, V4, P4409, DOI DOI 10.9754/J0UMAL.WMC.2013.004459; Jayamohanan H, 2019, ADV PHARM BULL, V9, P374, DOI 10.15171/apb.2019.044; Olguín HJ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9730467; KAGEDAL B, 1988, J CHROMATOGR-BIOMED, V429, P177, DOI 10.1016/S0378-4347(00)83871-2; KNIGGE U, 1991, ACTA ENDOCRINOL-COP, V124, P609, DOI 10.1530/acta.0.1240609; Koberda JL., 2016, Journal of Neurology and Neurobiology, V2, DOI DOI 10.16966/2379-7150.130; Kusaga Akira, 2002, No To Hattatsu, V34, P243; Liu YZ, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00316; Lynn-Bullock CP, 2004, J CHEM NEUROANAT, V27, P129, DOI 10.1016/j.jchemneu.2004.02.003; Marc DT, 2011, NEUROSCI BIOBEHAV R, V35, P635, DOI 10.1016/j.neubiorev.2010.07.007; Masgutova S., 2015, Journal of Neurology and Neurosciences, V6, P59, DOI [DOI 10.21767/2171-6625.100059, 10.21767/2171-6625.100059]; Masgutova S., 2016, Journal of neurology and psychology, V4, P14; Myhrer T, 2003, BRAIN RES REV, V41, P268, DOI 10.1016/S0165-0173(02)00268-0; Niemantsverdriet E., 2015, Cerebrospinal Fluid in Clinical Neurology, P35, DOI [10.1007/978-3-319-01225-4_4, DOI 10.1007/978-3-319-01225-4_4]; Nordahl TE, 2005, ARCH GEN PSYCHIAT, V62, P444, DOI 10.1001/archpsyc.62.4.444; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Panholzer TJ, 1999, CLIN CHEM, V45, P262; Peaeock BN, 2017, COMPR PSYCHIAT, V73, P168, DOI 10.1016/j.comppsych.2016.11.002; Pilecki W, 2012, ADV CLIN EXP MED, V21, P363; Pinna A, 2009, EXPERT OPIN INV DRUG, V18, P1619, DOI 10.1517/13543780903241615; Reyes-Garcia MG, 2007, J NEUROIMMUNOL, V188, P64, DOI 10.1016/j.jneuroim.2007.05.013; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schaumann T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/808367; Schuch V, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00126; Sechenov I.M., 1965, Reflexes of the Brain; Strac DS, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00492; Tank AW, 2015, COMPR PHYSIOL, V5, P1, DOI 10.1002/cphy.c140007; Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113; Wu C, 2015, METAB BRAIN DIS, V30, P367, DOI 10.1007/s11011-014-9560-1; Yoo HJ, 2009, NEUROSCI RES, V63, P172, DOI 10.1016/j.neures.2008.11.007; Yuan R, 2016, BRAIN STRUCT FUNCT, V221, P1971, DOI 10.1007/s00429-015-1018-7; Zhong Z, 2003, CURR OPIN CLIN NUTR, V6, P229, DOI 10.1097/00075197-200303000-00013; Ziegler C, 2018, INT J NEUROPSYCHOPH, V21, P423, DOI 10.1093/ijnp/pyx111; Ziemssen T, 2007, J NEUROL, V254, P8, DOI 10.1007/s00415-007-2003-8";72;2;2;0;15;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;1661-6596;1422-0067;;INT J MOL SCI;Int. J. Mol. Sci.;FEB;2020;21;4;;;;;;;1358;10.3390/ijms21041358;http://dx.doi.org/10.3390/ijms21041358;;;21;"Biochemistry & Molecular Biology; Chemistry, Multidisciplinary";Science Citation Index Expanded (SCI-EXPANDED);"Biochemistry & Molecular Biology; Chemistry";KY4FE;32085403;gold, Green Published;;;24/11/2024;WOS:000522524400185;View Full Record in Web of Science
J;"Jurek, L; Occelli, P; Denis, A; Amestoy, A; Maffre, T; Dauchez, T; Oreve, MJ; Baghdadli, A; Schroder, C; Jay, A; Zelmar, A; Revah-Levy, A; Gallifet, N; Aldred, C; Garg, S; Green, J; Touzet, S; Geoffray, MM";;;;"Jurek, Lucie; Occelli, Pauline; Denis, Angelique; Amestoy, Anouck; Maffre, Thierry; Dauchez, Tom; Oreve, Marie-Joelle; Baghdadli, Amaria; Schroder, Carmen; Jay, Agathe; Zelmar, Amelie; Revah-Levy, Anne; Gallifet, Natacha; Aldred, Catherine; Garg, Shruti; Green, Jonathan; Touzet, Sandrine; Geoffray, Marie-Maude";;IFPAD Study Grp;Efficacy of parent-mediated communication-focused treatment in toddlers with autism (PACT) delivered via videoconferencing: a randomised controlled trial study protocol;BMJ OPEN;;;English;Article;;;;;;;"SPECTRUM DISORDER; YOUNG-CHILDREN; TELEHEALTH; SEVERITY; OUTCOMES";Introduction Intervention in the preschool period is currently recommended for autism spectrum disorder. Therapies delivered by parents are particularly suitable for young children. Preschool Autism Communication Trial (PACT) is a parent-mediated therapy that has shown a significant and sustained impact on autism symptom reduction. However, access to such evidence-based therapies for families is limited due to autism centres located in large urban areas. Using videoconferencing to deliver PACT training to parents may improve accessibility for families living in underserved areas. Methods and analysis This single-blind randomised controlled trial, involving six sites in France, will investigate the efficacy of a telehealth, videoconferencing- -based, parent-mediated PACT therapy on autism symptoms, over a 12-month period. It will compare PACT plus treatment as usual (TAU) against TAU only in a cohort of 238 toddlers (119 per group) aged 18-36 months at inclusion and living with their families more than 40 min away from the specialist centres for autism. Primary outcome will include change of overall autism score on the Autism Diagnostic Observation Scale (ADOS) at 12 months. Secondary outcomes will measure change in child skills, child functioning, impact on parents (stress, health, priorities) and implementation characteristics. Repeated measures analyses will be used to test the effect of PACT intervention on the overall ADOS module 1 score over the 12-month study period. Linear mixed models will be used with time, treatment allocation and the interaction between treatment and time as fixed effects and individual variation as random effect. Ethics and dissemination This protocol (V.5, date: 25 October 2019) is approved by the French National Review Board (reference no 2018-A02516-49). The results will be disseminated via peer-reviewed journals;"[Jurek, Lucie; Jay, Agathe; Gallifet, Natacha; Geoffray, Marie-Maude] Hosp Ctr Vinatier, Acad Dept Child & Adolescent Neurodev Psychiat, Bron, France; [Jurek, Lucie; Occelli, Pauline; Zelmar, Amelie; Touzet, Sandrine; Geoffray, Marie-Maude] Univ Claude Bernard Lyon 1, Res Healthcare Performance RESHAPE, INSERM, U1290, Lyon, France; [Occelli, Pauline; Denis, Angelique; Zelmar, Amelie; Touzet, Sandrine] Hosp Civils Lyon, Pole Sante Publ, Lyon, France; [Amestoy, Anouck; Dauchez, Tom] Ctr Hosp Charles Perrens, Child & Adolescent Psychiat, Bordeaux, France; [Maffre, Thierry] Univ Hosp Ctr Toulouse, Ctr Ressources Autisme Midi Pyrenees, Serv Univ Psychiat Enfant & Adolescent, Toulouse, France; [Oreve, Marie-Joelle] Ctr Hosp Versailles, Serv Univ Psychiat Enfant & Adolescent, Le Chesnay, France; [Baghdadli, Amaria] Univ Hosp Ctr Montpellier, Ctr Ressources Autism, Montpellier, France; [Baghdadli, Amaria] Univ Hosp Ctr Montpellier, Ctr Excellence Autism & Neurodev Disorders, Montpellier, France; [Baghdadli, Amaria] Paris Saclay Univ, INSERM, DevPsy, UVSQ,CESP, Villejuif, France; [Schroder, Carmen] Hopitaux Univ Strasbourg, Dept Child & Adolescent Psychiat, Strasbourg, France; [Schroder, Carmen] Univ Strasbourg, CNRS, Team 9, UPR 3212, Strasbourg, France; [Revah-Levy, Anne] Argenteuil Hlth & Social Serv Ctr, Ctr Soins Psychotherapeut Transit Adolescent, Lachute, PQ, Canada; [Revah-Levy, Anne] Univ Paris, Ctr Res Epidemiol & Stat, ECSTRRA Team, INSERM,UMR 1153, Paris, France; [Aldred, Catherine] Univ Manchester, Manchester, Lancs, England; [Garg, Shruti; Green, Jonathan] Univ Manchester, Fac Biol Med & Hlth Sci, Div Neurosci & Expt Psychol, Manchester, Lancs, England; [Green, Jonathan] Manchester Univ NHS Fdn Trust, Royal Manchester Childrens Hosp, Manchester, Lancs, England";"Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU de Toulouse; Centre Hospitalier de Versailles; Universite Paris Saclay; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Universite Paris Cite; CHU Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Manchester; University of Manchester; Royal Manchester Children's Hospital";"Geoffray, MM (corresponding author), Hosp Ctr Vinatier, Acad Dept Child & Adolescent Neurodev Psychiat, Bron, France.;Geoffray, MM (corresponding author), Univ Claude Bernard Lyon 1, Res Healthcare Performance RESHAPE, INSERM, U1290, Lyon, France.";Marie-Maude.GEOFFRAY@ch-le-vinatier.fr;"Green, Jonathan/L-2529-2018; GARG, SHRUTI/HSF-2918-2023; BAGHDADLI, AMARIA/S-8294-2019; GEOFFRAY, marie-maude/GYV-3526-2022; Jurek, Lucie/ABI-4434-2020; geoffray, marie-maude/A-3157-2019";"geoffray, marie-maude/0000-0002-5528-3613; Baghdadli, Amaria/0000-0002-5679-7544; Green, Jonathan/0000-0002-0143-181X; Touzet, Sandrine/0000-0002-0354-7920; anouck, amestoy/0000-0001-6544-0152; Garg, Shruti/0000-0002-4472-4583";"Programme Hospitalier de Recherche Clinique inter-regional Rhone Alpes from the AURA region [PHRCI-15-065]; Caisse Nationale de solidarite pour l'autonomie (CNSA); Institut national de la sante et de la recherche medicale (Inserm) [IReSP-17-Autisme3-16]";"Programme Hospitalier de Recherche Clinique inter-regional Rhone Alpes from the AURA region; Caisse Nationale de solidarite pour l'autonomie (CNSA); Institut national de la sante et de la recherche medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm))";This study is supported by a grant from the Programme Hospitalier de Recherche Clinique inter-regional Rhone Alpes (PHRCI-15-065) from the AURA region and a grant by the Caisse Nationale de solidarite pour l'autonomie (CNSA) as part of the call for projects launched for IReSP (Institut de Recherche en Sante Publique) in 2016 in collaboration with the Institut national de la sante et de la recherche medicale (Inserm) (IReSP-17-Autisme3-16).;"Aldred C, 2012, J AUTISM DEV DISORD, V42, P447, DOI 10.1007/s10803-011-1248-3; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Baghdadli A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026286; Bearss K, 2018, J AUTISM DEV DISORD, V48, P1020, DOI 10.1007/s10803-017-3363-2; Bonnet P, 2020, ENFANCE, V2, P151, DOI DOI 10.3917/ENF2.202.0151; Dunn G, 2015, HEALTH TECHNOL ASSES, V19, DOI 10.3310/hta19930; Fetters MD, 2013, HEALTH SERV RES, V48, P2134, DOI 10.1111/1475-6773.12117; Finlay L, 2011, PHENOMENOLOGY FOR THERAPISTS: RESEARCHING THE LIVED WORLD, P139; French L, 2018, J CHILD PSYCHOL PSYC, V59, P444, DOI 10.1111/jcpp.12828; Geoffray MM, 2016, PSYCHIAT DANUB, V28, pS66; Gorse P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077757; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Green J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2881-3; Green J, 2018, J CHILD PSYCHOL PSYC, V59, P424, DOI 10.1111/jcpp.12892; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Guba EG L., 1989, 4 GENERATION EVALUAT; Haute Autorite de Sante , 2018, TROUBLE SPECTRE LAUT; HOWLIN P, 1988, CHILD CARE HLTH DEV, V14, P395, DOI 10.1111/j.1365-2214.1988.tb00591.x; Khan K, 2019, J MED INTERNET RES, V21, DOI 10.2196/13478; Kim SH, 2013, J AUTISM DEV DISORD, V43, P1527, DOI 10.1007/s10803-012-1696-4; Kogan MD, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4161; Lachal J, 2012, APPETITE, V58, P1099, DOI 10.1016/j.appet.2012.02.045; Lacharite C., 2013, LOUISE THIER CHRISTI, V17, P183; Leadbitter K, 2018, J AUTISM DEV DISORD, V48, P1052, DOI 10.1007/s10803-017-3350-7; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Lyall K, 2017, ANNU REV PUBL HEALTH, V38, P81, DOI 10.1146/annurev-publhealth-031816-044318; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; Morse JM, 1998, QUAL HEALTH RES, V8, P147, DOI 10.1177/104973239800800201; Mullen EM., 1995, MULLEN SCALES EARLY; Oono IP, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009774.pub2; PARIENTE P D, 1992, European Psychiatry, V7, P15; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Pickles A, 2015, J CHILD PSYCHOL PSYC, V56, P162, DOI 10.1111/jcpp.12291; Richards DA, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-032081; Sandbank M, 2020, PSYCHOL BULL, V146, P1, DOI 10.1037/bul0000215; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Vismara LA, 2018, FOCUS AUTISM DEV DIS, V33, P67, DOI 10.1177/1088357616651064; Vismara LA, 2013, J AUTISM DEV DISORD, V43, P2953, DOI 10.1007/s10803-013-1841-8; Zwaigenbaum L, 2015, PEDIATRICS, V136, pS60, DOI 10.1542/peds.2014-3667E";40;6;8;7;25;BMJ PUBLISHING GROUP;LONDON;BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND;2044-6055;;;BMJ OPEN;BMJ Open;;2021;11;4;;;;;;;e044669;10.1136/bmjopen-2020-044669;http://dx.doi.org/10.1136/bmjopen-2020-044669;;;10;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;RK3RZ;33827837;Green Published, gold;;;24/11/2024;WOS:000638218000005;View Full Record in Web of Science
J;"Hendouei, F; Moghaddam, HS; Mohammadi, MR; Taslimi, N; Rezaei, F; Akhondzadeh, S";;;;"Hendouei, Fatemeh; Moghaddam, Hossein Sanjari; Mohammadi, Mohammad Reza; Taslimi, Negin; Rezaei, Farzin; Akhondzadeh, Shahin";;;Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial;JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS;;;English;Article;;;;;;"autism spectrum disorder; hyperactivity; irritability; neuroinflammation; resveratrol";"INCREASES GLUTAMATE UPTAKE; BTBR MOUSE MODEL; SPECTRUM DISORDERS; ABERRANT BEHAVIOR; AMYGDALA RESPONSE; GROWTH-FACTOR; NITRIC-OXIDE; RISPERIDONE; PHARMACOTHERAPY; DYSREGULATION";"What is known and objective The underlying pathophysiology of autism spectrum disorder (ASD) has been linked to immune dysregulation, oxidative stress and excitation-inhibition imbalance. Among associated symptoms of ASD, management of irritability has gained considerable attention as it complicates adjustment of ASD patients and thus necessitates its pharmacological treatment. Resveratrol is a plant phytoalexin, which has been demonstrated to have neuroprotective effects through its anti-inflammatory and antioxidant properties. This double-blind, placebo-controlled randomized trial was designed to assess the potential therapeutic effects of resveratrol plus risperidone on irritability of ASD patients. Methods Sixty-two patients were assigned randomly into two groups of resveratrol and placebo. Both groups were treated with risperidone twice daily starting at a dose of 0.5 mg with a dose increase of 0.5 mg per week (for the first 3 weeks). Resveratrol dosage was 250 mg twice per day from the beginning of the study. Using the Aberrant Behavior Checklist-Community (ABC-C), patients were assessed for ASD-related behavioural symptoms at baseline, week 5 and week 10. The frequency of adverse events was recorded using a checklist containing 25 possible side effects, including general, gastrointestinal, neurological and cardiovascular complications. Results and discussion Improvements in primary outcome measure (irritability) and three secondary outcome measures (lethargy/social withdrawal, stereotypic behaviour and inappropriate speech subscales) in the resveratrol group were statistically similar to those in the placebo group. The repeated measures analysis showed no time x treatment interaction on these subscale scores. In contrast, patients in the resveratrol group showed greater decline in hyperactivity/non-compliance score as a secondary outcome measure (mean difference [CI = 95%] = 4.51 [0.10-8.92], t = 2.04; P = .04), and repeated measures analysis showed significant effect for time x treatment effect on this subscale score (F = 3.81; df = 1.30; P = .043). There was no significant difference in number and severity of adverse events between the two groups. What is new and conclusion This clinical trial demonstrated no significant effect for adjunctive treatment with resveratrol on irritability of patients with ASD. However, it provided preliminary evidence indicating that resveratrol could improve hyperactivity/non-compliance of ASD patients.";"[Hendouei, Fatemeh; Moghaddam, Hossein Sanjari; Mohammadi, Mohammad Reza; Taslimi, Negin; Akhondzadeh, Shahin] Univ Tehran Med Sci, Roozbeh Hosp, Psychiat Res Ctr, Tehran, Iran; [Rezaei, Farzin] Kurdistan Univ Med Sci, Qods Hosp, Sanandaj, Iran";"Tehran University of Medical Sciences; Kurdistan University of Medical Sciences";Akhondzadeh, S (corresponding author), Univ Tehran Med Sci, Roozbeh Psychiat Hosp, Psychiat Res Ctr, South Kargar St, Tehran 13337, Iran.;s.akhond@neda.net;"Sanjari Moghaddam, Hossein/AAS-6514-2021; zarch, mohammad/AAB-2718-2020; Akhondzadeh, Shahin/F-2914-2018; rezaei, farzin/HHS-0336-2022";;Tehran University of Medical Sciences [36420];Tehran University of Medical Sciences(Tehran University of Medical SciencesGolestan University of Medical Sciences);This study was supported by a grant from Tehran University of Medical Sciences to Prof. Shahin Akhondzadeh (Grant No: 36420).;"Abbasi SH, 2010, SCHIZOPHR RES, V116, P101, DOI 10.1016/j.schres.2009.11.008; Ahmad SF, 2018, NEUROMOL MED, V20, P133, DOI 10.1007/s12017-018-8483-0; Akhondzadeh S, 2010, PROG NEURO-PSYCHOPH, V34, P32, DOI 10.1016/j.pnpbp.2009.09.012; Alegria AA, 2016, AM J PSYCHIAT, V173, P1119, DOI 10.1176/appi.ajp.2016.15081089; AMAN MG, 1985, AM J MENT DEF, V89, P485; Amodeo DA, 2014, AUTISM RES, V7, P555, DOI 10.1002/aur.1395; [Anonymous], 2013, DIAGNOSTIC STAT MANU, VFifth, P1000, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Asadabadi M, 2013, PSYCHOPHARMACOLOGY, V225, P51, DOI 10.1007/s00213-012-2796-8; Ashwood P, 2006, J NEUROIMMUNOL, V173, P126, DOI 10.1016/j.jneuroim.2005.12.007; Ashwood P, 2011, BRAIN BEHAV IMMUN, V25, P40, DOI 10.1016/j.bbi.2010.08.003; Ashwood P, 2008, J NEUROIMMUNOL, V204, P149, DOI 10.1016/j.jneuroim.2008.07.006; Bakheet SA, 2016, MOL CELL NEUROSCI, V77, P1, DOI 10.1016/j.mcn.2016.09.004; Bambini V, 2014, NEUROSCI LETT, V583, P176, DOI 10.1016/j.neulet.2014.09.039; Bauer ME, 2019, ANN NY ACAD SCI, V1437, P57, DOI 10.1111/nyas.13712; Baxter AJ, 2015, PSYCHOL MED, V45, P601, DOI 10.1017/S003329171400172X; Bellaver B, 2014, TOXICOL IN VITRO, V28, P479, DOI 10.1016/j.tiv.2014.01.006; Berecz R, 2004, CURR DRUG TARGETS, V5, P573, DOI 10.2174/1389450043345263; Berman AY, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0038-6; Chadman KK, 2011, PHARMACOL BIOCHEM BE, V97, P586, DOI 10.1016/j.pbb.2010.09.012; Charman T, 2011, PSYCHOL MED, V41, P619, DOI 10.1017/S0033291710000991; Charman T, 2011, BRAIN RES, V1380, P10, DOI 10.1016/j.brainres.2010.10.075; Cheng G, 2009, NEUROSCI LETT, V451, P105, DOI 10.1016/j.neulet.2008.12.045; Chouinard G, 1980, CAN J NEUROL SCI, V233; Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464; de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405; Deepmala, 2015, NEUROSCI BIOBEHAV R, V55, P294, DOI 10.1016/j.neubiorev.2015.04.015; Dong WP, 2008, J VASC SURG, V48, P709, DOI 10.1016/j.jvs.2008.04.007; dos Santos AQ, 2006, ARCH BIOCHEM BIOPHYS, V453, P161, DOI 10.1016/j.abb.2006.06.025; Farmer C, 2013, DRUGS, V73, P303, DOI 10.1007/s40265-013-0021-7; Fontes-Dutra M, 2018, FRONT SYNAPTIC NEURO, V10, DOI 10.3389/fnsyn.2018.00009; Frémont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Ghaleiha A, 2015, PSYCHIAT RES, V229, P181, DOI 10.1016/j.psychres.2015.07.043; Ghaleiha A, 2014, J PSYCHOPHARMACOL, V28, P677, DOI 10.1177/0269881113508830; Ghaleiha A, 2013, PEDIATR DRUGS, V15, P505, DOI 10.1007/s40272-013-0036-2; Harrison NA, 2009, BIOL PSYCHIAT, V66, P407, DOI 10.1016/j.biopsych.2009.03.015; Helverschou SB, 2011, AUT CHILD PSYCHO, P53, DOI 10.1007/978-1-4419-8065-6_5; Ibrahim K, 2019, BIOL PSYCHIAT-COGN N, V4, P1031, DOI 10.1016/j.bpsc.2019.01.009; Johnson MH, 2011, DEV COGN NEUROS-NETH, V1, P7, DOI 10.1016/j.dcn.2010.07.003; Jones EJH, 2014, NEUROSCI BIOBEHAV R, V39, P1, DOI 10.1016/j.neubiorev.2013.12.001; Karlsson P, 2007, PHARMACOKINETICS DOP; Khalaj M, 2018, J PSYCHIATR RES, V103, P104, DOI 10.1016/j.jpsychires.2018.04.022; Kim YA, 2007, J MED FOOD, V10, P218, DOI 10.1089/jmf.2006.143; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Marsh AA, 2008, AM J PSYCHIAT, V165, P712, DOI 10.1176/appi.ajp.2007.07071145; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; McGuire K, 2016, PEDIATRICS, V137, pS136, DOI 10.1542/peds.2015-2851L; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Mikita N, 2015, J CHILD PSYCHOL PSYC, V56, P1118, DOI 10.1111/jcpp.12382; Nicolson R, 1998, J AM ACAD CHILD PSY, V37, P372, DOI 10.1097/00004583-199804000-00014; Perry A, 2009, J AUTISM DEV DISORD, V39, P1066, DOI 10.1007/s10803-009-0704-9; Piver B, 2004, BIOCHEM PHARMACOL, V68, P773, DOI 10.1016/j.bcp.2004.05.008; Robb AS, 2010, DEV DISABIL RES REV, V16, P258, DOI 10.1002/ddrr.118; Rose S, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.29; Saunders J.A., 2013, MOL PSYCHIATR, V6, P69, DOI DOI 10.1038/mp.2010.136; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201; Simao F, 2012, J CEREBR BLOOD F MET, V32, P884, DOI 10.1038/jcbfm.2012.2; Stigler KA, 2008, CHILD ADOL PSYCH CL, V17, P739, DOI 10.1016/j.chc.2008.06.002; Viding E, 2012, AM J PSYCHIAT, V169, P1109, DOI 10.1176/appi.ajp.2012.12020191; de Almeida LMV, 2007, CELL MOL NEUROBIOL, V27, P661, DOI 10.1007/s10571-007-9152-2; Wei HG, 2012, BBA-MOL BASIS DIS, V1822, P831, DOI 10.1016/j.bbadis.2012.01.011; Wendeburg L, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-26; Wiciski M, 2017, BIOMED RES INT, V2017, P7; Wong YT, 2009, FREE RADICAL BIO MED, V46, P799, DOI 10.1016/j.freeradbiomed.2008.12.016; Yáñez M, 2011, BRAIN RES, V1423, P77, DOI 10.1016/j.brainres.2011.09.025";65;34;34;0;14;WILEY-HINDAWI;LONDON;ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND;0269-4727;1365-2710;;J CLIN PHARM THER;J. Clin. Pharm. Ther.;APR;2020;45;2;;;;;324;334;;10.1111/jcpt.13076;http://dx.doi.org/10.1111/jcpt.13076;;nov-19;11;Pharmacology & Pharmacy;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pharmacology & Pharmacy;KR6RQ;31714621;gold;;;24/11/2024;WOS:000495820800001;View Full Record in Web of Science
J;"Mazahery, H; Conlon, CA; Beck, KL; Mugridge, O; Kruger, MC; Stonehouse, W; Camargo, CA; Meyer, BJ; Jones, B; von Hurst, PR";;;;"Mazahery, Hajar; Conlon, Cathryn A.; Beck, Kathryn L.; Mugridge, Owen; Kruger, Marlena C.; Stonehouse, Welma; Camargo, Carlos A., Jr.; Meyer, Barbara J.; Jones, Beatrix; von Hurst, Pamela R.";;;A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder;JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY;;;English;Article;;;;;;"Vitamin D; Omega-3; Autism; Irritability; Hyperactivity; Children";"ATTENTION DEFICIT/HYPERACTIVITY DISORDER; PERVASIVE DEVELOPMENTAL DISORDERS; ABERRANT BEHAVIOR CHECKLIST; DOUBLE-BLIND; SEROTONINERGIC NEUROTRANSMISSION; D SUPPLEMENTATION; ADHD SYMPTOMS; D-RECEPTOR; OPEN-LABEL; ARIPIPRAZOLE";"Irritability and hyperactivity are common in children with Autism Spectrum Disorder (ASD). Because pharmacological treatments may have adverse effects, and despite limited evidence, caregivers/parents often use dietary supplements such as vitamin D and omega-3 fatty acids to address these behavioural symptoms. As a secondary objective of the VIDOMA (Vitamin D and Omega-3 in ASD) trial, we evaluated the efficacy of vitamin D, omega-3 long chain polyunsaturated fatty acid [omega-3 LCPUFA; docosahexaenoic acid (DHA)], or both on irritability and hyperactivity. New Zealand children with ASD (aged 2.5-8 years) participated in a 12-month randomized, double-blind, placebo-controlled trial of vitamin D (2000 IU/day, VID), omega-3 LCPUFA (722 mg/day DHA, OM), or both (2000 IU/day vitamin D + 722 mg/day DHA, VIDOM). The primary outcomes were the Aberrant Behaviour Checklist (ABC) domains of irritability and hyperactivity. Biomarkers (serum 25-hydroxyvitamin D [25(OH)D] and omega-3 index) and primary outcomes were measured at baseline and 12-months. Out of 111 children who completed baseline data collection, 66% completed the study (VID = 19, OM = 23, VIDOM = 15, placebo = 16). After 12 months, children receiving OM (-5.0 +/- 5.0, P = 0.001) and VID (-4.0 +/- 4.9, P = 0.01) had greater reduction in irritability than placebo (0.8 +/- 6.1). Compared to placebo, children on VID also had greater reduction in hyperactivity (-5.2 +/- 6.3 vs. -0.8 +/- 5.6, P = 0.047). Serum 25(OH)D concentration (nmol/L, mean +/- SD) increased by 27 14 in VID and by 36 +/- 17 in VIDOM groups (P < 0.0001), and omega-3 index (%, median (25th, 75th percentiles)) by 4.4 (3.3, 5.9) in OM and by 4.0 (2.0, 6.0) in VIDOM groups (P < 0.0001), indicating a good compliance rate. The results indicate that vitamin D and omega-3 LCPUFA reduced irritability symptoms in children with ASD. Vitamin D also reduced hyperactivity symptoms in these children.";"[Mazahery, Hajar; Conlon, Cathryn A.; Beck, Kathryn L.; Mugridge, Owen; Kruger, Marlena C.; von Hurst, Pamela R.] Massey Univ, Coll Hlth, Auckland 0745, New Zealand; [Stonehouse, Welma] CSIRO, Food & Nutr Flagship, Canberra, ACT, Australia; [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Meyer, Barbara J.] Univ Wollongong, Illawarra Hlth & Med Res Inst, Sch Med, Lipid Res Ctr, North BJ Fields Ave, Wollongong, NSW 2522, Australia; [Jones, Beatrix] Univ Auckland, Auckland, New Zealand";"Massey University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Harvard University; Harvard Medical School; Massachusetts General Hospital; Illawarra Health & Medical Research Institute; University of Wollongong; University of Auckland";von Hurst, PR (corresponding author), Massey Univ, Coll Hlth, Auckland 0745, New Zealand.;"h.mazahery@massey.ac.nz; c.conlon@massey.ac.nz; k.l.beck@massey.ac.nz; o.mugridge@massey.ac.nz; m.c.kruger@massey.ac.nz; welma.stonehouse@csiro.au; ccamargo@partners.org; barbara_meyer@uow.edu.au; beatrix.jones@auckland.ac.nz; p.r.vonhurst@massey.ac.nz";"Meyer, Barbara/AAC-6078-2019; Stonehouse, Welma/H-2316-2013; Camargo, Carlos/C-2145-2008";"Beck, Kathryn Louise/0000-0003-1825-1927; Meyer, Barbara J/0000-0001-7962-7890; Stonehouse, Welma/0000-0002-2856-4962; Mazahery, Hajar/0000-0002-3743-2152; Camargo, Carlos/0000-0002-5071-7654";"Massey University Strategic Innovation Fund, Massey University, New Zealand; Douglas Nutrition, Pty. Ltd., NZ";"Massey University Strategic Innovation Fund, Massey University, New Zealand; Douglas Nutrition, Pty. Ltd., NZ";Partial funding for the study was provided by Massey University Strategic Innovation Fund, Massey University, New Zealand. Additional support was provided by Douglas Nutrition, Pty. Ltd., NZ who supplied the active supplement and identical-appearing placebo, but who had no input into study design, implementation, data management, statistical analysis or reporting of results.;"Alfawaz HA, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-416; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; AMAN MG, 1985, AM J MENT DEF, V89, P492; Aman MG, 2015, J CHILD ADOL PSYCHOP, V25, P282, DOI 10.1089/cap.2015.28999.mga; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Amminger GP, 2007, BIOL PSYCHIAT, V61, P551, DOI 10.1016/j.biopsych.2006.05.007; Antshel KM, 2011, J DEV BEHAV PEDIATR, V32, P439, DOI 10.1097/DBP.0b013e318222355d; Arnold LE, 2000, J AUTISM DEV DISORD, V30, P99, DOI 10.1023/A:1005451304303; Bent S, 2014, J AM ACAD CHILD PSY, V53, P658, DOI 10.1016/j.jaac.2014.01.018; Bent S, 2011, J AUTISM DEV DISORD, V41, P545, DOI 10.1007/s10803-010-1078-8; Brinkley J, 2007, J AUTISM DEV DISORD, V37, P1949, DOI 10.1007/s10803-006-0327-3; Cass WA, 2006, ANN NY ACAD SCI, V1074, P261, DOI 10.1196/annals.1369.023; Cui X, 2013, NEUROSCIENCE, V236, P77, DOI 10.1016/j.neuroscience.2013.01.035; Davis NO, 2012, NEUROTHERAPEUTICS, V9, P518, DOI 10.1007/s13311-012-0126-9; de Bartolomeis A, 2015, CNS DRUGS, V29, P773, DOI 10.1007/s40263-015-0278-3; DELION S, 1994, J NUTR, V124, P2466, DOI 10.1093/jn/124.12.2466; Elshorbagy HH, 2018, ANN PHARMACOTHER, V52, P623, DOI 10.1177/1060028018759471; Enko D, 2014, CLIN LAB, V60, P1541, DOI 10.7754/Clin.Lab.2014.131114; Eyles DW, 2013, FRONT NEUROENDOCRIN, V34, P47, DOI 10.1016/j.yfrne.2012.07.001; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Farmer C, 2013, DRUGS, V73, P303, DOI 10.1007/s40265-013-0021-7; Frazier TW, 2011, J CHILD ADOL PSYCHOP, V21, P571, DOI 10.1089/cap.2011.0057; GRANT S, 1994, DRUGS, V48, P253, DOI 10.2165/00003495-199448020-00009; Hallahan B., 2018, BRIT J PSYCHIAT, V190, P118; Harris WS, 2004, PREV MED, V39, P212, DOI 10.1016/j.ypmed.2004.02.030; Höfer J, 2017, AUTISM, V21, P387, DOI 10.1177/1362361316646559; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011-0385, 10.1210/jc.2011-1193]; Howes OD, 2018, J PSYCHOPHARMACOL, V32, P3, DOI 10.1177/0269881117741766; Ishitobi M, 2013, CLIN NEUROPHARMACOL, V36, P151, DOI 10.1097/WNF.0b013e3182a31ec0; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kerley CP, 2017, ARCH DIS CHILD, V102, P1030, DOI 10.1136/archdischild-2017-312783; Kim HY, 2011, PROSTAG OTH LIPID M, V96, P114, DOI 10.1016/j.prostaglandins.2011.07.002; Kodas E, 2004, J NEUROCHEM, V89, P695, DOI 10.1111/j.1471-4159.2004.02401.x; Lamberti M, 2016, PEDIATR DRUGS, V18, P319, DOI 10.1007/s40272-016-0183-3; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Logan V. F., 2013, BR J NUTR, V109, P1028; Mazahery H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020155; Mazahery H, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1428-8; Mazahery H, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040236; McNamara RK, 2006, PROSTAG LEUKOTR ESS, V75, P329, DOI 10.1016/j.plefa.2006.07.010; Mohammadpour N, 2018, NUTR NEUROSCI, V21, P202, DOI [10.1080/1028415X.2016.1262097, 10.1080/1028415x.2016.1262097]; Moreira JD, 2010, NEUROCHEM INT, V56, P753, DOI 10.1016/j.neuint.2010.02.010; Moriguchi T, 2003, J NEUROCHEM, V87, P297, DOI 10.1046/j.1471-4159.2003.01966.x; Ooi YP, 2015, EUR J CLIN NUTR, V69, P969, DOI 10.1038/ejcn.2015.28; Patrick RP, 2015, FASEB J, V29, P2207, DOI 10.1096/fj.14-268342; Romero M, 2016, INT J CLIN HLTH PSYC, V16, P266, DOI 10.1016/j.ijchp.2016.03.001; Saad K, 2018, J CHILD PSYCHOL PSYC, V59, P20, DOI 10.1111/jcpp.12652; Safavi P, 2016, J ADV PHARM TECHNOL, V7, P43, DOI 10.4103/2231-4040.177203; Sagduyu K, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-6; Srinivasan Shylaja, 2016, Autism Res Treat, V2016, P6763205, DOI 10.1155/2016/6763205; STUMPF WE, 1988, ANAT EMBRYOL, V177, P307, DOI 10.1007/BF00315837; Tang MM, 2016, LIPIDS HEALTH DIS, V15, DOI 10.1186/s12944-016-0236-1; Widenhorn-Müller K, 2014, PROSTAG LEUKOTR ESS, V91, P49, DOI 10.1016/j.plefa.2014.04.004; Zimmer L, 1998, NEUROSCI LETT, V240, P177, DOI 10.1016/S0304-3940(97)00938-5";54;55;61;2;33;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0960-0760;;;J STEROID BIOCHEM;J. Steroid Biochem. Mol. Biol.;MAR;2019;187;;;;;;9;16;;10.1016/j.jsbmb.2018.10.017;http://dx.doi.org/10.1016/j.jsbmb.2018.10.017;;;8;"Biochemistry & Molecular Biology; Endocrinology & Metabolism";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Biochemistry & Molecular Biology; Endocrinology & Metabolism";HN1MU;30744880;;;;24/11/2024;WOS:000459952100002;View Full Record in Web of Science
J;"Boone, KM; Klebanoff, MA; Rogers, LK; Rausch, J; Coury, DL; Keim, SA";;;;"Boone, Kelly M.; Klebanoff, Mark A.; Rogers, Lynette K.; Rausch, Joseph; Coury, Daniel L.; Keim, Sarah A.";;;Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial;EARLY HUMAN DEVELOPMENT;;;English;Article;;;;;;"Behavior; Docosahexaenoic acid (DHA); Gamma-linolenic acid (GLA); Premature birth; Randomized clinical trial; Sleep";"DOCOSAHEXAENOIC ACID; SPECTRUM DISORDERS; OMEGA-3-FATTY-ACIDS; QUESTIONNAIRE; MANAGEMENT; CHILDREN";"Background: Children born extremely preterm disproportionately experience sequelae of preterm birth compared to those born at later gestational ages, including higher prevalence of autism spectrum disorder (ASD) and associated behaviors. Aim: Explore effects of combined dietary docosahexaenoic acid, eicosapentaenoic acid, gamma-linolenic acid, and oleic acid (omega 3-6-9) on caregiver-reported behavior and sleep in toddlers born at >= 29 weeks' gestation who were exhibiting symptoms commonly seen with ASD. Study design: 90-day randomized (1:1), double blinded, placebo-controlled trial. Subjects: Thirty-one children aged 18-38 months received omega 3-6-9 (n = 15) or canola oil placebo (n = 16). Outcome Measures: Mixed effects regression analyses followed intent to treat and explored treatment effects on measures of caregiver-reported behavior (Child Behavior Checklist 1.5-5, Toddler Behavior Assessment Questionnaire - Short Form, Vineland Adaptive Behavior Scales, 2nd Edition) and sleep (Children's Sleep Habits Questionnaire, Brief Infant Sleep Questionnaire). Results: Twenty-nine of 31 (94%; ntx = 13, nplacebo = 16) children randomized had data available for at least one outcome measure, 27 (87%; ntx = 12, nplacebo = 15) had complete outcome data. Children randomized to omega 3-6-9 experienced a medium magnitude benefit of supplementation on anxious and depressed behaviors (delta(Difference) =-1.27, d =-0.58, p = 0.049) and internalizing behaviors (delta(Difference) =-3.41, d =-0.68, p = 0.05); and a large magnitude benefit on interpersonal relationship adaptive behaviors (delta(Difference) = 7.50, d = 0.83, p = 0.01), compared to placebo. No effects were observed on other aspects of behavior or sleep. Conclusions: Findings provide preliminary support for further exploration of omega 3-6-9 during toddlerhood to improve socioemotional outcomes among children born preterm, especially for those showing early symptoms commonly seen with ASD. Results need to be replicated in a larger sample.";"[Boone, Kelly M.; Rausch, Joseph; Keim, Sarah A.] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Abigail Wexner Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA; [Klebanoff, Mark A.; Rogers, Lynette K.] Nationwide Childrens Hosp, Ctr Perinatal Res, Abigail Wexner Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA; [Klebanoff, Mark A.; Rogers, Lynette K.; Rausch, Joseph; Coury, Daniel L.; Keim, Sarah A.] Ohio State Univ, Coll Med, Dept Pediat, 370 W 9th Ave, Columbus, OH 43210 USA; [Klebanoff, Mark A.; Keim, Sarah A.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, 1841 Neil Ave, Columbus, OH 43210 USA; [Klebanoff, Mark A.] Ohio State Univ, Coll Med, Dept Obstet & Gynecol, 370 W 9th Ave, Columbus, OH 43210 USA; [Boone, Kelly M.] 700 Childrens Dr, Columbus, OH 43205 USA";"University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University";Boone, KM (corresponding author), 700 Childrens Dr, Columbus, OH 43205 USA.;"Kelly.Boone@NationwideChildrens.org; Mark.Klebanoff@NationwideChildrens.org; Lynette.Rogers@NationwideChildrens.org; Joseph.Rausch@NationwideChildrens.org; Daniel.Coury@NationwideChildrens.org; Sarah.Keim@NationwideChildrens.org";"Rogers, Lynette/V-6802-2019; Rausch, Joseph/E-8107-2018; Keim, Sarah/F-8929-2013; Coury, Daniel/L-6556-2019";;"Nationwide Children's Hospital Division of Neonatology; The Marci and Bill Ingram Fund for Autism Spectrum Dis-orders Research, Cures Within Reach [UL1TR001070]; National Center For Advancing Translational Sciences/NIH; Abigail Wexner Research Institute at Nationwide Children's Hospital";"Nationwide Children's Hospital Division of Neonatology; The Marci and Bill Ingram Fund for Autism Spectrum Dis-orders Research, Cures Within Reach; National Center For Advancing Translational Sciences/NIH; Abigail Wexner Research Institute at Nationwide Children's Hospital";"We thank the participants; Nationwide Children's Hospital Division of Neonatology; Nationwide Children's Hospital Investigational Drug Service; Nordic Naturals; Welsh, Holme, & Clark Co., Inc. as well as the entire Preemie Tots Research Team: Yvette Bean, Anne Brown, Kendra Heck, Chenali Jayadeva, Julia Less, Sarah Landry, and Kamma Smith for data collection and administrative support. This work was supported by grants from The Marci and Bill Ingram Fund for Autism Spectrum Disorders Research, Cures Within Reach, Award Number Grant UL1TR001070 from the National Center For Advancing Translational Sciences/NIH, and internal support from the Abigail Wexner Research Institute at Nationwide Children's Hospital. Nordic Naturals, Inc., provided the investigational product at no cost; and Welsh, Holme, & Clark Co., Inc., provided canola oil at no cost. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Advancing Translational Sciences or the National Institutes of Health. Neither the study sponsors nor product providers had a role in the study design; the collection, analysis, and interpretation of data; writing of this report; or the decision to submit the manuscript for publication.";"Achenbach T.M., 2010, Manual for the ASEBA schoolage makes profiles; Agrawal S, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0134; Alagawany M, 2022, ANIM BIOTECHNOL, V33, P1678, DOI 10.1080/10495398.2020.1869562; [Anonymous], 2020, How to analyze YRBS sexual minority data. Youth Risk Behavior Surveillance System; Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Bent S, 2014, J AM ACAD CHILD PSY, V53, P658, DOI 10.1016/j.jaac.2014.01.018; Bent S, 2011, J AUTISM DEV DISORD, V41, P545, DOI 10.1007/s10803-010-1078-8; Bernardo J, 2015, J PERINATOL, V35, P208, DOI 10.1038/jp.2014.192; Bertrand PC, 2006, J NUTR, V136, P1570, DOI 10.1093/jn/136.6.1570; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Briggs-Gowan M.J., 2006, BITSEA: Brief Infant-Toddler Social and Emotional Assessment. Examiner's Manual; Goldsmith HH, 1996, CHILD DEV, V67, P218, DOI 10.1111/j.1467-8624.1996.tb01730.x; Huang YS, 2014, BMC PEDIATR, V14, DOI 10.1186/s12887-014-0303-6; Innis SM, 2005, PLACENTA, V26, pS70, DOI 10.1016/j.placenta.2005.01.005; Innis SM, 2001, J NUTR, V131, P118, DOI 10.1093/jn/131.1.118; James S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007992.pub2; Janssen CIF, 2014, PROG LIPID RES, V53, P1, DOI 10.1016/j.plipres.2013.10.002; Johnson CR, 2010, J DEV PHYS DISABIL, V22, P1, DOI 10.1007/s10882-009-9152-x; Johnson M.A.C.B, 2014, J GLYCOMICS LIPIDOMI, V4, P4; Karhu E, 2020, NUTR REV, V78, P515, DOI 10.1093/nutrit/nuz092; Keim SA, 2018, J NUTR, V148, P227, DOI 10.1093/jn/nxx047; Kitajka K, 2002, P NATL ACAD SCI USA, V99, P2619, DOI 10.1073/pnas.042698699; Kuzniewicz MW, 2014, J PEDIATR-US, V164, P20, DOI 10.1016/j.jpeds.2013.09.021; Linsell L, 2019, EUR CHILD ADOLES PSY, V28, P531, DOI 10.1007/s00787-018-1219-8; Loe IM, 2019, EARLY HUM DEV, V130, P87, DOI 10.1016/j.earlhumdev.2019.01.014; Luu TM, 2017, CLIN PERINATOL, V44, P305, DOI 10.1016/j.clp.2017.01.003; Mankad D, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0010-7; Mazahery H, 2019, J STEROID BIOCHEM, V187, P9, DOI 10.1016/j.jsbmb.2018.10.017; Mazahery H, 2019, J AUTISM DEV DISORD, V49, P1778, DOI 10.1007/s10803-018-3860-y; Mazahery H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020155; Meguid NA, 2008, CLIN BIOCHEM, V41, P1044, DOI 10.1016/j.clinbiochem.2008.05.013; Meiri G, 2009, J CHILD ADOL PSYCHOP, V19, P449, DOI 10.1089/cap.2008.0123; Myrhaug HT, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-0933; Ooi YP, 2015, EUR J CLIN NUTR, V69, P969, DOI 10.1038/ejcn.2015.28; Owens JA, 2000, SLEEP, V23, P1043; Patrick L., 2005, AUTISM ASPERGERS DIG, P36; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rothman KJ, 2014, J GEN INTERN MED, V29, P1060, DOI 10.1007/s11606-013-2755-z; Sadeh A, 2004, PEDIATRICS, V113, pE570, DOI 10.1542/peds.113.6.e570; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sathe N, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2017-0346; Shah PE, 2016, J PEDIATR-US, V178, P61, DOI 10.1016/j.jpeds.2016.06.062; Shaw DI, 2007, EUR J NUTR, V46, P321, DOI 10.1007/s00394-007-0669-4; Sheppard KW, 2017, J AUTISM DEV DISORD, V47, P3358, DOI 10.1007/s10803-017-3249-3; Siegel B., 2004, PERVASIVE DEV DISORD; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248; Sparrow SCD., 2005, VINELAND ADAPTIVE BE; Spittle AJ, 2009, J AM ACAD CHILD PSY, V48, P909, DOI 10.1097/CHI.0b013e3181af8235; Squires J., 2002, ASQ SE USERS GUIDE A; Trudeau MS, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081783; Twilhaar ES, 2018, ARCH DIS CHILD-FETAL, V103, pF322, DOI 10.1136/archdischild-2017-312916; Wang CZ, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006696, 10.1097/md.0000000000006696]; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Williamson E, 2017, medical therapies for children with autism spectrum disorder-an update; Winkens B, 2007, CONTEMP CLIN TRIALS, V28, P713, DOI 10.1016/j.cct.2007.04.002; Yiallourou SR, 2018, SLEEP, V41, DOI 10.1093/sleep/zsx193";56;6;6;0;9;ELSEVIER IRELAND LTD;CLARE;ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND;0378-3782;1872-6232;;EARLY HUM DEV;Early Hum. Dev.;JUN;2022;169;;;;;;;;105588;10.1016/j.earlhumdev.2022.105588;http://dx.doi.org/10.1016/j.earlhumdev.2022.105588;;MAY 2022;9;"Obstetrics & Gynecology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Obstetrics & Gynecology; Pediatrics";1Z0ZZ;35644107;Green Accepted, Bronze;;;24/11/2024;WOS:000808563600001;View Full Record in Web of Science
J;"Siafis, S; Rodolico, A; Çiray, O; Murphy, DG; Parellada, M; Arango, C; Leucht, S";;;;"Siafis, Spyridon; Rodolico, Alessandro; Ciray, Ogulcan; Murphy, Declan G.; Parellada, Mara; Arango, Celso; Leucht, Stefan";;;Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder;BRAIN SCIENCES;;;English;Article;;;;;;"response; meta-analysis; continuous outcomes; dichotomous outcomes";"TREATMENT END-POINT; AGREEMENT; BEHAVIORS; CHILDREN; RATES";"Introduction: Response to treatment, according to Clinical Global Impression-Improvement (CGI-I) scale, is an easily interpretable outcome in clinical trials of autism spectrum disorder (ASD). Yet, the CGI-I rating is sometimes reported as a continuous outcome, and converting it to dichotomous would allow meta-analysis to incorporate more evidence. Methods: Clinical trials investigating medications for ASD and presenting both dichotomous and continuous CGI-I data were included. The number of patients with at least much improvement (CGI-I <= 2) were imputed from the CGI-I scale, assuming an underlying normal distribution of a latent continuous score using a primary threshold theta = 2.5 instead of theta = 2, which is the original cut-off in the CGI-I scale. The original and imputed values were used to calculate responder rates and odds ratios. The performance of the imputation method was investigated with a concordance correlation coefficient (CCC), linear regression, Bland-Altman plots, and subgroup differences of summary estimates obtained from random-effects meta-analysis. Results: Data from 27 studies, 58 arms, and 1428 participants were used. The imputation method using the primary threshold (theta = 2.5) had good performance for the responder rates (CCC = 0.93 95% confidence intervals [0.86, 0.96]; beta of linear regression = 1.04 [0.95, 1.13]; bias and limits of agreements = 4.32% [-8.1%, 16.74%]; no subgroup differences chi(2) = 1.24, p-value = 0.266) and odds ratios (CCC = 0.91 [0.86, 0.96]; beta = 0.96 [0.78, 1.14]; bias = 0.09 [-0.87, 1.04]; chi(2) = 0.02, p-value = 0.894). The imputation method had poorer performance when the secondary threshold (theta = 2) was used. Discussion: Assuming a normal distribution of the CGI-I scale, the number of responders could be imputed from the mean and standard deviation and used in meta-analysis. Due to the wide limits of agreement of the imputation method, sensitivity analysis excluding studies with imputed values should be performed.";"[Siafis, Spyridon; Leucht, Stefan] Tech Univ Munich, Sch Med, Dept Psychiat & Psychotherapy, D-81675 Munich, Germany; [Rodolico, Alessandro] Univ Catania, Univ Hosp Gaspare Rodolico, Dept Expt & Clin Med, Psychiat Clin, I-95125 Catania, Italy; [Ciray, Ogulcan] Mardin State Hosp, Dept Child & Adolescent Psychiat, TR-47100 Artuklu, Mardin, Turkey; [Murphy, Declan G.] Kings Coll London, Dept Forens & Neurodev Sci, Inst Psychiat Psychol & Neurosci, London WC2R 2LS, England; [Parellada, Mara; Arango, Celso] Hosp Gen Univ Gregorio Maranon, Inst Psychiat & Mental Hlth, Dept Child & Adolescent Psychiat, Madrid 28003, Spain; [Parellada, Mara; Arango, Celso] Univ Complutense, Sch Med, Madrid 28040, Spain";"Technical University of Munich; University of Munich; University of Catania; Mardin State Hospital; University of London; King's College London; General University Gregorio Maranon Hospital; Complutense University of Madrid";Siafis, S (corresponding author), Tech Univ Munich, Sch Med, Dept Psychiat & Psychotherapy, D-81675 Munich, Germany.;"spyridon.siafis@tum.de; alessandro.rodolico@me.com; remziogulcanciray@gmail.com; declan.murphy@kcl.ac.uk; parellada@hggm.es; carango@hggm.es; stefan.leucht@tum.de";"Rodolico, Alessandro/GQQ-5888-2022; Murphy, Declan/JQI-8340-2023; Parellada, Mara/AAQ-1272-2021; Arango, Celso/AAZ-8314-2021; Leucht, Stefan/Y-2408-2019; Siafis, Spyridon/I-9103-2019; Arango, Celso/H-6433-2015";"Siafis, Spyridon/0000-0001-8264-2039; Murphy, Declan/0000-0002-6664-7451; Rodolico, Alessandro/0000-0003-2196-0601; CIRAY, Remzi Ogulcan/0000-0003-2864-613X; Parellada, Mara/0000-0001-7977-3601; Arango, Celso/0000-0003-3382-4754";"Innovative Medicines Initiative 2 joint undertaking [777394]; European Union's Horizon 2020 research and innovation program; EFPIA; AUTISM SPEAKS; Autistica; SFARI";"Innovative Medicines Initiative 2 joint undertaking; European Union's Horizon 2020 research and innovation program(Horizon 2020); EFPIA; AUTISM SPEAKS; Autistica(Autistica); SFARI";This project received funding from the Innovative Medicines Initiative 2 joint undertaking under grant agreement No. 777394 for the project AIMS 2-TRIALS. This joint undertaking received support from the European Union's Horizon 2020 research and innovation program, EFPIA, AUTISM SPEAKS, Autistica, and SFARI.;"Aman MG, 2004, CNS SPECTRUMS, V9, P36, DOI 10.1017/S1092852900008348; Anagnostou E, 2015, AUTISM, V19, P622, DOI 10.1177/1362361314542955; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Choque Olsson N, 2014, J AUTISM DEV DISORD, V44, P1773, DOI 10.1007/s10803-013-2029-y; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; DerSimonian R, 2015, CONTEMP CLIN TRIALS, V45, P139, DOI 10.1016/j.cct.2015.09.002; Díaz-Caneja CM, 2021, EUR NEUROPSYCHOPHARM, V48, P49, DOI 10.1016/j.euroneuro.2021.02.020; Furukawa TA, 2005, INT CLIN PSYCHOPHARM, V20, P49, DOI 10.1097/00004850-200501000-00010; Furukawa TA, 2011, SCHIZOPHR RES, V126, P212, DOI 10.1016/j.schres.2010.10.016; [Gay W. Health P.R.B.N.I.o.M. Health P.R.B.N.I.o.M.], 1976, ECDEU Assessment Manual for Psychopharmacology, Revised, US Dept Health, Education, and Welfare publication (ADM), P534; Johnston BC, 2016, CAN MED ASSOC J, V188, P25, DOI 10.1503/cmaj.150430; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Liddell TM, 2018, J EXP SOC PSYCHOL, V79, P328, DOI 10.1016/j.jesp.2018.08.009; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; Meister R, 2015, J CLIN EPIDEMIOL, V68, P740, DOI 10.1016/j.jclinepi.2015.02.006; Provenzani U, 2020, AUTISM, V24, P274, DOI 10.1177/1362361319854641; R CORE TEAM, 2019, R: A language and environment for statistical computing; Samara MT, 2013, SCHIZOPHR RES, V151, P209, DOI 10.1016/j.schres.2013.10.029; Scahill L, 2015, AUTISM, V19, P38, DOI 10.1177/1362361313510069; Schwarzer G, 2019, RES SYNTH METHODS, V10, P476, DOI 10.1002/jrsm.1348; Siafis S., 2021, PHARM DIETARY UNPUB PHARM DIETARY UNPUB; Siafis S, 2020, MOL AUTISM, V11, DOI 10.1186/s13229-020-00372-z; Stevenson Mark, 2024, CRAN; Tromans S, 2018, J AUTISM DEV DISORD, V48, P3228, DOI 10.1007/s10803-018-3569-y; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wickham H., 2019, Journal of Open Source Software, V4, P1686, DOI [10.21105/joss.01686, DOI 10.21105/JOSS.01686]";30;4;4;2;5;MDPI;BASEL;ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND;;2076-3425;;BRAIN SCI;Brain Sci.;JUL;2021;11;7;;;;;;;908;10.3390/brainsci11070908;http://dx.doi.org/10.3390/brainsci11070908;;;11;Neurosciences;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;TN6ZP;34356141;Green Accepted, Green Published, gold;;;24/11/2024;WOS:000676380900001;View Full Record in Web of Science
J;"Yamada, N; Nakadoi, Y; Fukuma, R; Ohmori, T";;;;"Yamada, Naoki; Nakadoi, Yoshihiro; Fukuma, Ryosuke; Ohmori, Tetsuro";;;Two children exhibiting social withdrawal, school refusal, and underlying generalized anxiety disorder successfully treated using a selective serotonin reuptake inhibitor;JOURNAL OF MEDICAL INVESTIGATION;;;English;Article;;;;;;"generalized anxiety disorder; social withdrawal; school refusal; selective serotonin reuptake inhibitor";DEPRESSION;Generalized anxiety disorder (GAD) sometimes exists in the background of social withdrawal and school refusal. Although clinical evidence suggests that selective serotonin reuptake inhibitors (SSRIs) are an effective treatment for GAD, they are not officially approved for GAD in Japan. In addition, it has been established that the use of SSRIs increases the risk for suicide and activation syndrome among young individuals. As such, there is currently little domestic clinical experience in prescribing SSRIs to young patients with GAD. The authors report two cases involving 10-year-old patients with GAD who were treated successfully with escitalopram and experienced subsequent improvement in social withdrawal and school refusal. One patient had autistic spectrum disorder and exhibited self-harm associated with anxiety symptoms, requiring careful use of SSRIs under hospitalization. The other patient was treated at an outpatient clinic without any side effects. In each case, improvement of anxiety symptoms with the use of SSRIs facilitated the introduction of psychoeducation and psychotherapy. It is important to accurately diagnose GAD, which may exist in the background of patients exhibiting social withdrawal and school refusal, and to treat the disorder appropriately. J. Med. Invest. 67 : 355-357, August, 2020;"[Yamada, Naoki; Ohmori, Tetsuro] Univ Tokushima, Dept Psychiat, Sch Med, Kuramoto Cho 2-50-1, Tokushima 7708503, Japan; [Yamada, Naoki; Nakadoi, Yoshihiro; Fukuma, Ryosuke] Shikoku Med Ctr Children & Adults, Dept Child Psychiat, Shikoku, Ehime, Japan";Tokushima University;Yamada, N (corresponding author), Univ Tokushima, Dept Psychiat, Sch Med, Kuramoto Cho 2-50-1, Tokushima 7708503, Japan.;;;;;;;"Bandelow B, 2014, DTSCH ARZTEBL INT, V111, P473, DOI 10.3238/arztebl.2014.0473; Driot D, 2017, PRESSE MED, V46, P1124, DOI 10.1016/j.lpm.2017.10.010; Friedman RA, 2007, NEW ENGL J MED, V356, P2343, DOI 10.1056/NEJMp078015; Gale Christopher K, 2016, BMJ Clin Evid, V2016; Gibbons RD, 2006, AM J PSYCHIAT, V163, P1898, DOI 10.1176/appi.ajp.163.11.1898; Stone M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2880";6;4;4;1;10;UNIV TOKUSHIMA SCH MEDICINE;TOKUSHIMA;3-18-15, KURAMOTO-CHO, TOKUSHIMA, 00000, JAPAN;1343-1420;1349-6867;;J MED INVESTIG;J. Med. Investig.;AUG;2020;67;03-avr;;;;;355;357;;;;;;3;Medicine, Research & Experimental;Emerging Sources Citation Index (ESCI);Research & Experimental Medicine;OF2GL;33148915;gold;;;24/11/2024;WOS:000581033000025;View Full Record in Web of Science
J;"Teo, SHJ; Poh, XWW; Lee, TS; Guan, CT; Cheung, YB; Fung, DSS; Zhang, HH; Chin, ZY; Wang, CC; Sung, M; Goh, TJ; Weng, SJ; Tng, XJJ; Lim, CG";;;;"Teo, Sze-Hui Jane; Poh, Xue Wei Wendy; Lee, Tih Shih; Guan, Cuntai; Cheung, Yin Bun; Fung, Daniel Shuen Sheng; Zhang, Hai Hong; Chin, Zheng Yang; Wang, Chuan Chu; Sung, Min; Goh, Tze Jui; Weng, Shih Jen; Tng, Xin Jie Jordon; Lim, Choon Guan";;;Brain-computer interface based attention and social cognition training programme for children with ASD and co-occurring ADHD: A feasibility trial;RESEARCH IN AUTISM SPECTRUM DISORDERS;;;English;Article;;;;;;"ASD; ADHD; Social cognition; Technology; Children; Repetitive behaviours and interests";"AUTISM SPECTRUM DISORDERS; DEFICIT/HYPERACTIVITY DISORDER; REPETITIVE BEHAVIORS; DIAGNOSTIC INTERVIEW; EXECUTIVE FUNCTION; YOUNG-CHILDREN; SYMPTOMS; NEUROFEEDBACK; METHYLPHENIDATE; DISENGAGEMENT";"Background: Current treatment practices for comorbid conditions of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) remain limited. This study examined the feasibility of an EEG brain-computer interface (BCI) programme for children with ASD and cooccurring ADHD. Method: Twenty children were randomised to the intervention or waitlist-control group. Intervention consisted of thrice-weekly sessions of BCI-based training over 8 weeks. Both groups were followed up 4 weeks later. The BCI-based programme comprised of a series of attention and gazemodulated games aimed to train social cognitive skills. Results: All participants completed at least 20 training sessions and none dropped out of the study. No severe adverse events were reported. Side effects included mild headaches, fatigue, irritability and self-injurious behaviours. All were addressed within the same session. Feedback from therapists indicated that participants' interest and motivation could be sustained with appropriate supports. Change scores indicated greater improvement in the intervention group compared to the waitlist-control on ADHD symptoms as measured on the ADHD rating scale; no significant differences were observed on social deficits on the Social Responsiveness Scale (SRS). Pooled data suggests that pre-post improvements could be maintained. Conclusions: Findings indicate the BCI-based program is tolerable for most participants. Positive effects were also reported for ADHD symptoms. A future large clinical trial will incorporate appropriate controls to ascertain the efficacy of our training programme.";"[Teo, Sze-Hui Jane; Poh, Xue Wei Wendy; Fung, Daniel Shuen Sheng; Sung, Min; Goh, Tze Jui; Weng, Shih Jen; Tng, Xin Jie Jordon; Lim, Choon Guan] Inst Mental Hlth, Dept Dev Psychiat, 10 Buangkok View, Singapore 539747, Singapore; [Lee, Tih Shih] Duke Natl Univ Singapore, Med Sch, Neurosci & Behav Disorders Program, 8 Coll Rd, Singapore 169857, Singapore; [Guan, Cuntai] Nanyang Technol Univ, Sch Comp Sci & Engn, 50 Nanyang Ave, Singapore 639798, Singapore; [Cheung, Yin Bun] Duke Natl Univ Singapore, Ctr Quantitat Med, Med Sch, 8 Coll Rd, Singapore 169857, Singapore; [Zhang, Hai Hong; Chin, Zheng Yang; Wang, Chuan Chu] Agcy Sci Technol & Res, Inst Infocomm Res, Healthcare & Medtech Div, 1 Fusionopolis Way,21-01, Singapore 138632, Singapore";"National University of Singapore; Nanyang Technological University; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute for Infocomm Research (I2R)";Lim, CG (corresponding author), Inst Mental Hlth, Dept Dev Psychiat, 10 Buangkok View, Singapore 539747, Singapore.;"jane_sh_teo@imh.com.sg; choon_guan_lim@imh.com.sg";"Fung, Daniel/AAF-4775-2020; Guan, Cuntai/G-7835-2016; Chin, Zheng Yang/CAH-5532-2022";"Guan, Cuntai/0000-0002-0872-3276; Chin, Zheng Yang/0000-0001-8136-4671; Cheung, Yin Bun/0000-0003-0517-7625";"Lee Foundation; Duke-National University of Singapore";"Lee Foundation; Duke-National University of Singapore(National University of Singapore)";This study was supported by a grant donation from Lee Foundation and the Autism Research Fund from Duke-National University of Singapore.;"Agam Y, 2010, NEUROIMAGE, V52, P336, DOI 10.1016/j.neuroimage.2010.04.010; Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Antshel KM, 2011, J DEV BEHAV PEDIATR, V32, P439, DOI 10.1097/DBP.0b013e318222355d; Arnold LE, 2013, J ATTEN DISORD, V17, P410, DOI 10.1177/1087054712446173; Arns M, 2020, APPL PSYCHOPHYS BIOF, V45, P39, DOI 10.1007/s10484-020-09455-2; Coben R, 2010, APPL PSYCHOPHYS BIOF, V35, P13, DOI 10.1007/s10484-009-9102-5; Constantino J., 2002, SOCIAL RESPONSIVENES; Craig F, 2016, NEUROPSYCH DIS TREAT, V12, P1191, DOI 10.2147/NDT.S104620; d'Arc BF, 2017, AUTISM, V21, P100, DOI 10.1177/1362361316630880; Datko M, 2018, EUR J NEUROSCI, V47, P579, DOI 10.1111/ejn.13551; Demetriou EA, 2018, MOL PSYCHIATR, V23, P1198, DOI 10.1038/mp.2017.75; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; DuPaul G. J., 1998, ADHD Rating ScaleIV: Checklists, norms, and clinical interpretation, P79; Elsabbagh M, 2013, BIOL PSYCHIAT, V74, P189, DOI 10.1016/j.biopsych.2012.11.030; Enriquez-Geppert S, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1021-4; Factor RS, 2017, J AUTISM DEV DISORD, V47, P1122, DOI 10.1007/s10803-016-3025-9; Gevensleben H, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00990; Gjevik E, 2011, J AUTISM DEV DISORD, V41, P761, DOI 10.1007/s10803-010-1095-7; Gordon-Lipkin E, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1377; Hanson E, 2013, J AUTISM DEV DISORD, V43, P1459, DOI 10.1007/s10803-012-1677-7; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hoza B, 2007, J PEDIATR PSYCHOL, V32, P655, DOI 10.1093/jpepsy/jsm024; Keehn B, 2016, DEV COGN NEUROS-NETH, V17, P46, DOI 10.1016/j.dcn.2015.12.002; Kouijzer MEJ, 2010, RES AUTISM SPECT DIS, V4, P386, DOI 10.1016/j.rasd.2009.10.007; Kouijzer MEJ, 2009, RES AUTISM SPECT DIS, V3, P496, DOI 10.1016/j.rasd.2008.10.003; Landry R, 2004, J CHILD PSYCHOL PSYC, V45, P1115, DOI 10.1111/j.1469-7610.2004.00304.x; Leekam SR, 2011, PSYCHOL BULL, V137, P562, DOI 10.1037/a0023341; Leon AC, 2011, J PSYCHIATR RES, V45, P626, DOI 10.1016/j.jpsychires.2010.10.008; Leung RC, 2016, CHILD NEUROPSYCHOL, V22, P336, DOI 10.1080/09297049.2015.1005066; Lim CG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216225; Lim CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046692; Lim CG, 2010, PSYCHOPHARMACOL BULL, V43, P73; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C., 2012, AUTISM DIAGNOSTIC OB; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; McFayden TC, 2021, J AUTISM DEV DISORD, V51, P3651, DOI 10.1007/s10803-020-04824-6; Miranda A, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01035; Murray MJ, 2010, CURR PSYCHIAT REP, V12, P382, DOI 10.1007/s11920-010-0145-3; Ozonoff S, 2004, J AUTISM DEV DISORD, V34, P139, DOI 10.1023/B:JADD.0000022605.81989.cc; Pantelis PC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14919-3; Pearson DA, 2013, J CHILD ADOL PSYCHOP, V23, P337, DOI 10.1089/cap.2012.0096; Pineda JA, 2008, RES AUTISM SPECT DIS, V2, P557, DOI 10.1016/j.rasd.2007.12.003; Qian X, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0213-8; Ravizza SM, 2013, DEV PSYCHOPATHOL, V25, P773, DOI 10.1017/S0954579413000163; Riesco-Matías P, 2021, J ATTEN DISORD, V25, P473, DOI 10.1177/1087054718821731; ROTHBART MK, 1990, ADV PSYCHOL, V69, P47, DOI DOI 10.1016/S0166-4115(08)60450-1; Sacrey LAR, 2014, NEUROSCI BIOBEHAV R, V47, P559, DOI 10.1016/j.neubiorev.2014.10.011; Scahill L, 2015, AM J PSYCHIAT, V172, P1197, DOI 10.1176/appi.ajp.2015.15010055; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Sikora DM, 2012, PEDIATRICS, V130, pS91, DOI 10.1542/peds.2012-0900G; SIMON R, 1985, CANCER TREAT REP, V69, P1375; Sinzig J, 2014, INT J DEV DISABIL, V60, P144, DOI 10.1179/2047387714Y.0000000040; Sitaram R, 2017, NAT REV NEUROSCI, V18, P86, DOI 10.1038/nrn.2016.164; Sonuga-Barke E, 2014, CHILD ADOL PSYCH CL, V23, P807, DOI 10.1016/j.chc.2014.05.009; Sprenger L, 2013, RES DEV DISABIL, V34, P3545, DOI 10.1016/j.ridd.2013.07.028; Steiner NJ, 2014, PEDIATRICS, V133, P483, DOI 10.1542/peds.2013-2059; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Thompson L, 2010, APPL PSYCHOPHYS BIOF, V35, P63, DOI 10.1007/s10484-009-9120-3; Tye C, 2014, PSYCHOL MED, V44, P1101, DOI 10.1017/S0033291713001049; van Dongen-Boomsma M, 2013, J CLIN PSYCHIAT, V74, P821, DOI 10.4088/JCP.12m08321; Van Doren J, 2019, EUR CHILD ADOLES PSY, V28, P293, DOI 10.1007/s00787-018-1121-4; van Hoogdalem LE, 2021, J PSYCHOPHYSIOL, V35, P102, DOI 10.1027/0269-8803/a000265; Vernon D., 2004, J. Neurother, V8, P53, DOI [DOI 10.1300/J184V08N0204, 10.1300/J184V08N0204, DOI 10.1300/J184V08N02_04]; White SW, 2015, CLIN PSYCHOL SCI, V3, P797, DOI 10.1177/2167702614549801; Yerys BE, 2009, AUTISM RES, V2, P322, DOI 10.1002/aur.103";67;7;8;10;41;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;1750-9467;1878-0237;;RES AUTISM SPECT DIS;Res. Autism Spectr. Disord.;NOV;2021;89;;;;;;;;101882;10.1016/j.rasd.2021.101882;http://dx.doi.org/10.1016/j.rasd.2021.101882;;nov-21;14;"Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychology; Psychiatry; Rehabilitation";XA7JQ;;;;;24/11/2024;WOS:000720818500001;View Full Record in Web of Science
J;"Hallböök, T; Sjölander, A; Åmark, P; Miranda, M; Bjurulf, B; Dahlin, M";;;;"Hallbook, Tove; Sjolander, Arvid; Amark, Per; Miranda, Maria; Bjurulf, Bjorn; Dahlin, Maria";;;Effectiveness of the ketogenic diet used to treat resistant childhood epilepsy in Scandinavia;EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY;;;English;Article;;;;;;"Ketogenic diet; Epilepsy; Children; Outcome; Side-effects; Scandinavian";"TUBEROUS SCLEROSIS COMPLEX; LONG-TERM; REFRACTORY EPILEPSY; EFFICACY; CHILDREN; EXPERIENCE; RECOMMENDATIONS; UROLITHIASIS; TOLERABILITY; PREVENTION";"Background: This Scandinavian collaborative retrospective study of children treated with ketogenic diet (KD) highlights indications and effectiveness over two years follow-up. Methods: Five centres specialised in KD collected data retrospectively on 315 patients started on KD from 1999 to 2009. Twenty-five patients who stopped the diet within four weeks because of compliance-problems and minor side-effects were excluded. Seizure-type(s), seizure-frequency, anti-epileptic drugs and other treatments, mental retardation, autism-spectrum disorder and motor-dysfunction were identified and treatment-response was evaluated. Results: An intention-to-treat analysis was used. Responders (>50% seizure-frequency reduction) at 6, 12 and 24 months were 50%, 46% and 28% respectively, seizure-free were 16%, 13% and 10%. Still on the diet were 80%, 64% and 41% after 6, 12 and 24 months. No child had an increased seizure-frequency. The best seizure outcome was seen in the group with not-daily seizures at baseline (n = 22), where 45%, 41% and 32% became seizure-free at 6, 12 and 24 months A significant improvement in seizure-frequency was seen in atonic seizures at three months and secondary generalised seizures at three and six months. Side-effects were noted in 29 subjects; most could be treated and only two stopped due to hyperlipidaemia and two due to kidney-stones. In 167 patients treated with potassium-citrate, one developed kidney-stones, compared with six of 123 without potassium-citrate treatment (relative risk = 8.1). Conclusions: As the first study of implementing KD in children in the Scandinavian countries, our survey of 290 children showed that KD is effective and well tolerated, even in such severe patients with therapy-resistant epilepsy, more than daily seizures and intellectual disability in the majority of patients. Long-term efficacy of KD was comparable or even better than reported in newer AEDs. Addition of potassium citrate reduced risk of kidney-stones. Our data indicate that the response might be predicted by seizure-frequency before initiation of the diet but not by age, seizure-type or aetiology. (C) 2014 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.";"[Hallbook, Tove] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden; [Amark, Per; Dahlin, Maria] Karolinska Hosp & Inst, Inst Womens & Childrens Hlth, Dept Neuropediat, Stockholm, Sweden; [Miranda, Maria] Univ Copenhagen, Danish Epilepsy Ctr Dianalund, Herleu Univ Hosp, Pediat Neurol Sect,Dept Pediat, DK-1168 Copenhagen, Denmark; [Bjurulf, Bjorn] Oslo Univ Hosp, Dept Clin Neurosci Children, Women & Childrens Div, Ulleval, Norway; [Sjolander, Arvid] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden";"University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; University of Copenhagen; University of Oslo; Karolinska Institutet";Hallböök, T (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden.;tove.hallbook@telia.com;Sjölander, Arvid/AAR-2993-2021;Bjurulf, Bjorn/0000-0003-1783-8267;Margarethahemmets stiftelse;Margarethahemmets stiftelse;We thank our colleagues Johan Lundgren, Skane University Hospital, Lund, Gunilla Drake and Ragnhildur Kristjansdottir, Queen Silvia Children's Hospital, Gothenburg, Sweden, and Katarzyna Cebula, Epilepsihospitalet Dianalund, Denmark, and the specialist epilepsy nurses at each centre for their contribution of assessments of the patients and collection of data. We received a proportion of funding from the Margarethahemmets stiftelse.;"Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bootsma HPR, 2004, EPILEPSY BEHAV, V5, P380, DOI 10.1016/j.yebeh.2004.03.002; Choi HM, 2011, EPILEPSY RES, V93, P115, DOI 10.1016/j.eplepsyres.2010.11.005; Curatolo P, 2012, CURR NEUROPHARMACOL, V10, P404, DOI 10.2174/157015912804143595; Curatolo P, 2012, EUR J PAEDIATR NEURO, V16, P582, DOI 10.1016/j.ejpn.2012.05.004; Dressler A, 2010, SEIZURE-EUR J EPILEP, V19, P404, DOI 10.1016/j.seizure.2010.06.006; Farasat S, 2006, EPILEPSY BEHAV, V8, P406, DOI 10.1016/j.yebeh.2005.12.002; Freeman JM, 1998, PEDIATRICS, V102, P1358, DOI 10.1542/peds.102.6.1358; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Freeman JM, 2009, EPILEPSIA, V50, P322, DOI 10.1111/j.1528-1167.2008.01740.x; Hallböök T, 2007, EPILEPSIA, V48, P59, DOI 10.1111/j.1528-1167.2006.00834.x; Hallböök T, 2012, EPILEPSY RES, V100, P304, DOI 10.1016/j.eplepsyres.2011.04.017; Hartman AL, 2007, EPILEPSIA, V48, P31, DOI 10.1111/j.1528-1167.2007.00914.x; Hartman AL, 2013, EPILEPSY BEHAV, V26, P266, DOI 10.1016/j.yebeh.2012.09.019; HERZBERG GZ, 1990, J PEDIATR-US, V117, P743, DOI 10.1016/S0022-3476(05)83333-5; HUTTENLOCHER PR, 1990, ANN NEUROL, V28, P699, DOI 10.1002/ana.410280516; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; KINSMAN SL, 1992, EPILEPSIA, V33, P1132, DOI 10.1111/j.1528-1157.1992.tb01770.x; Kossoff EH, 2012, CURR OPIN NEUROL, V25, P173, DOI 10.1097/WCO.0b013e3283515e4a; Kossoff EH, 2009, EPILEPSIA, V50, P304, DOI 10.1111/j.1528-1167.2008.01765.x; Lefevre F, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e46; Lutas A, 2013, TRENDS NEUROSCI, V36, P32, DOI 10.1016/j.tins.2012.11.005; Mackay MT, 2005, J PAEDIATR CHILD H, V41, P353, DOI 10.1111/j.1440-1754.2005.00630.x; McNally MA, 2012, J NEUROCHEM, V121, P28, DOI 10.1111/j.1471-4159.2012.07670.x; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Nordli DR, 2001, PEDIATRICS, V108, P129, DOI 10.1542/peds.108.1.129; Nylen K, 2009, NEUROTHERAPEUTICS, V6, P402, DOI 10.1016/j.nurt.2009.01.021; Patel A, 2010, EPILEPSIA, V51, P1277, DOI 10.1111/j.1528-1167.2009.02488.x; Paul E, 2010, EPILEPSY RES, V90, P151, DOI 10.1016/j.eplepsyres.2010.04.005; Pulsifer MB, 2001, DEV MED CHILD NEUROL, V43, P301, DOI 10.1017/S0012162201000573; Sampath A, 2007, J CHILD NEUROL, V22, P375, DOI 10.1177/0883073807301926; Sharma S, 2009, SEIZURE-EUR J EPILEP, V18, P446, DOI 10.1016/j.seizure.2009.04.001; Spulber G, 2009, EPILEPSIA, V50, P297, DOI 10.1111/j.1528-1167.2008.01769.x; Suo CQ, 2013, SEIZURE-EUR J EPILEP, V22, P174, DOI 10.1016/j.seizure.2012.11.014; Thammongkol S, 2012, EPILEPSIA, V53, pe55, DOI 10.1111/j.1528-1167.2011.03394.x; Zaccara G, 2006, ACTA NEUROL SCAND, V114, P157, DOI 10.1111/j.1600-0404.2006.00705.x";36;37;38;1;20;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;1090-3798;1532-2130;;EUR J PAEDIATR NEURO;Eur. J. Paediatr. Neurol.;JAN;2015;19;1;;;;;29;36;;10.1016/j.ejpn.2014.09.005;http://dx.doi.org/10.1016/j.ejpn.2014.09.005;;;8;"Clinical Neurology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics";AZ5KJ;25457511;;;;24/11/2024;WOS:000348259700004;View Full Record in Web of Science
J;"Janas-Kozik, M; Dudek, D; Heitzman, J; Remberk, B; Samochowiec, J; Slopice, A; Wichniak, A";;;;"Janas-Kozik, Malgorzata; Dudek, Dominika; Heitzman, Janusz; Remberk, Barbara; Samochowiec, Jerzy; Slopice, Agnieszka; Wichniak, Adam";;;Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia;PSYCHIATRIA POLSKA;;;Polish;Article;;;;;;"early-onset schizophrenia; guidelines; treatment";"ANTIPSYCHOTIC TREATMENT; EARLY INTERVENTION; ADOLESCENTS; CHILDREN; SPECTRUM; PSYCHOSIS; EFFICACY; METAANALYSIS; DISORDERS; MORTALITY";Early onset of schizophrenia (before the age of 18 years) is associated with a higher risk of delayed or missed diagnosis, more severe course of the disease, and an increased susceptibility to adverse reactions to antipsychotic drugs. The objective of this paper is to present the recommendations for the diagnostic and therapeutic management of patients with early-onset schizophrenia, developed on the basis of a literature review and a consensus of a group of experts working with schizophrenia therapy. The formal criteria that must be met to diagnose schizophrenia are the same for children and adults. Early-onset schizophrenia must be thoroughly differentiated from uni - or bipolar affective disorder, autism-spectrum disorders (ASDs) and anxiety disorder. Diagnostic assessment for psychotic disorders is also necessary in the case of abnormal, destructive or aggressive behaviour, or self-harm. The mainstay of schizophrenia treatment is pharmacological therapy, which is used in the treatment of acute episodes and in maintenance treatment - prevention of relapses. However, the use of pharmacological interventions in children and adolescents only to reduce the risk of psychosis development is not justified. Antipsychotic agents significantly differ by their tolerance profile and clinical efficacy. Second-generation antipsychotic agents approved for the treatment of early-onset schizophrenia - aripiprazole, lurasidone and paliperidone - enable its effective and safe treatment. The necessary complement to pharmacological therapy is non-pharmacological interventions that should be adapted to the patient's age, cognitive abilities, disease stage and the needs of the whole family.;"[Janas-Kozik, Malgorzata] Slaski Uniwersytet Med Katowicach, Katedra & Oddzial Klin Psychiatrii & Psychoterapi, Ctr Pediatrii Sosnowcu, Ul Gabrieli Zapolskiej 3, PL-41218 Sosnowiec, Poland; [Dudek, Dominika] Uniwersytet Jagiellonski, Coll Med, Katedra Psychiatrii, Klin Psychiatrii Doroslych, Krakow, Poland; [Heitzman, Janusz] Inst Psychiatrii & Neurol Warszawie, Klin Psychiatrii Sadowej, Warsaw, Poland; [Remberk, Barbara] Inst Psychiatrii & Neurol Warszawie, Klin Psychiatrii Dzieci & Mlodziezy, Warsaw, Poland; [Samochowiec, Jerzy] Pomorski Uniwersytet Med Szczecinie, Katedra & Klin Psychiatrii, Szczecin, Poland; [Slopice, Agnieszka] Uniwersytet Med Karola Marcinkowskiego Poznaniu, Klin Psychiatrii Dzieci & Mlodziezy, Poznan, Poland; [Wichniak, Adam] Inst Psychiatrii & Neurol Warszawie, Klin Psychiatiyczna 3, Warsaw, Poland";"Medical University Silesia; Jagiellonian University; Collegium Medicum Jagiellonian University; Pomeranian Medical University; Poznan University of Medical Sciences";Janas-Kozik, M (corresponding author), Slaski Uniwersytet Med Katowicach, Katedra & Oddzial Klin Psychiatrii & Psychoterapi, Ctr Pediatrii Sosnowcu, Ul Gabrieli Zapolskiej 3, PL-41218 Sosnowiec, Poland.;janaskozik@gmail.com;"Heitzman, Janusz/AAE-9986-2019; Samochowiec, Jerzy/G-8175-2014";"Wichniak, Adam/0000-0002-5352-601X; Heitzman, Janusz/0000-0001-9604-6027";;;;"aacap, SCHIZOPHRENIA CHILDR; Abidi S, 2017, CAN J PSYCHIAT, V62, P635, DOI 10.1177/0706743717720197; Almandil NB, 2013, PEDIATR DRUGS, V15, P139, DOI 10.1007/s40272-013-0016-6; Amminger GP, 2011, SCHIZOPHR RES, V131, P112, DOI 10.1016/j.schres.2011.06.009; [Anonymous], 2007, J AM ACAD CHILD PSY, V46, P267, DOI 10.1097/01.chi.0000246070.23695.06; [Anonymous], 1998, Fed Regist, V63, P66631; [Anonymous], 2006, REGULATION EC 1901 2; Arango C, 2020, EUR CHILD ADOLES PSY, V29, P1195, DOI 10.1007/s00787-019-01425-2; Arango C, 2014, SCHIZOPHRENIA BULL, V40, pS138, DOI 10.1093/schbul/sbt198; Bienkowski P, 2015, PSYCHIATR POL, V49, P243, DOI 10.12740/PP/38250; Brown S, 2010, BRIT J PSYCHIAT, V196, P116, DOI 10.1192/bjp.bp.109.067512; Catalan A, 2021, J CHILD PSYCHOL PSYC, V62, P657, DOI 10.1111/jcpp.13322; Chung YS, 2021, EUR CHILD ADOLES PSY, V30, P769, DOI 10.1007/s00787-020-01560-1; Clemmensen L, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-150; Correll CU, 2020, WORLD PSYCHIATRY, V19, P69, DOI 10.1002/wps.20714; De la Serna E, 2023, EUR CHILD ADOLES PSY, V32, P639, DOI 10.1007/s00787-021-01901-8; De Peri L, 2012, CURR PHARM DESIGN, V18, P486, DOI 10.2174/138161212799316253; Díaz-Caneja CM, 2015, NPJ SCHIZOPHR, V1, DOI 10.1038/npjschz.2014.5; Downs J, 2019, SCHIZOPHRENIA BULL, V45, P69, DOI 10.1093/schbul/sbx197; Driver DI, 2013, CHILD ADOL PSYCH CL, V22, P539, DOI 10.1016/j.chc.2013.04.001; Dudek D, 2012, CHOROBA AFEKTYWNA DW, P103; Dudek D, 2018, DEPRESJE OSOB MLODYC, P69; Foss-Feig JH, 2016, J AUTISM DEV DISORD, V46, P342, DOI 10.1007/s10803-015-2539-x; Frazier JA, 2012, J AM ACAD CHILD PSY, V51, P496, DOI 10.1016/j.jaac.2012.02.001; GREEN AH, 1967, ARCH GEN PSYCHIAT, V17, P234; Grover S, 2019, INDIAN J PSYCHIAT, V61, P277, DOI 10.4103/psychiatry.IndianJPsychiatry_556_18; Harvey PD, 2013, EUR NEUROPSYCHOPHARM, V23, P1373, DOI 10.1016/j.euroneuro.2013.08.003; Hawton K, 2005, BRIT J PSYCHIAT, V187, P9, DOI 10.1192/bjp.187.1.9; Hawton K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012013; Hedlund PB, 2009, PSYCHOPHARMACOLOGY, V206, P345, DOI 10.1007/s00213-009-1626-0; Heffernan MLR, 2022, ACS MED CHEM LETT, V13, P92, DOI 10.1021/acsmedchemlett.1c00527; Huhn M, 2019, LANCET, V394, P939, DOI [10.1016/S0140-6736(19)31135-3, 10.1176/appi.focus.18306]; Jensen KG, 2015, J AM ACAD CHILD PSY, V54, P25, DOI 10.1016/j.jaac.2014.10.002; Keefe RSE, 1999, SCHIZOPHRENIA BULL, V25, P201, DOI 10.1093/oxfordjournals.schbul.a033374; Krause M, 2018, EUR NEUROPSYCHOPHARM, V28, P659, DOI 10.1016/j.euroneuro.2018.03.008; Lin A, 2016, SCHIZOPHR RES, V170, P211, DOI 10.1016/j.schres.2015.11.020; Liu XI, 2019, J PEDIATR-US, V208, P236, DOI 10.1016/j.jpeds.2018.12.033; Ly A, 2019, INT J TECHNOL ASSESS, V35, P134, DOI 10.1017/S0266462319000084; Lytle S, 2017, J CHILD ADOL PSYCHOP, V27, P2, DOI 10.1089/cap.2016.0055; Maley CT, 2019, CHILD ADOL PSYCH CL, V28, P91, DOI 10.1016/j.chc.2018.07.004; Matthys A, 2011, MOL NEUROBIOL, V43, P228, DOI 10.1007/s12035-011-8175-3; McClellan J, 2013, J AM ACAD CHILD PSY, V52, P976, DOI 10.1016/j.jaac.2013.02.008; Meyer MS, 2020, EARLY INTERV PSYCHIA, V14, P130, DOI 10.1111/eip.12858; NICE guideline, 2013, PSYCH SCHIZ CHILDR Y; Peralta V, 2022, SCHIZOPHRENIA BULL, V48, P631, DOI 10.1093/schbul/sbab145; Puig O, 2014, J AM ACAD CHILD PSY, V53, P859, DOI 10.1016/j.jaac.2014.05.012; Rabe-Jablonska J, 2012, CHOROBA AFEKTYWNA DW, P55; Ray WA, 2019, JAMA PSYCHIAT, V76, P162, DOI 10.1001/jamapsychiatry.2018.3421; Remberk B, 2015, PSYCHOZY WCZESNYM PO; Remberk B, 2012, PROG NEURO-PSYCHOPH, V39, P348, DOI 10.1016/j.pnpbp.2012.07.007; Robles O, 2011, SCHIZOPHRENIA BULL, V37, P405, DOI 10.1093/schbul/sbp062; Sarkar S, 2013, INDIAN J PHARMACOL, V45, P439, DOI 10.4103/0253-7613.117720; Schimmelmann BG, 2013, CURR OPIN PSYCHIATR, V26, P219, DOI 10.1097/YCO.0b013e32835dcc2a; Schmidt SJ, 2015, EUR PSYCHIAT, V30, P388, DOI 10.1016/j.eurpsy.2015.01.013; Schneider C, 2014, EUR PSYCHIAT, V29, P1, DOI 10.1016/j.eurpsy.2013.08.001; Stentebjerg-Olesen M, 2016, J CHILD ADOL PSYCHOP, V26, P410, DOI 10.1089/cap.2015.0097; Stevens Jonathan R, 2014, Prim Care Companion CNS Disord, V16, DOI 10.4088/PCC.13f01514; Taipale H, 2020, WORLD PSYCHIATRY, V19, P61, DOI 10.1002/wps.20699; Takeuchi H, 2017, J CLIN PSYCHOPHARM, V37, P274, DOI 10.1097/JCP.0000000000000662; Trevisan DA, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00548; Urben S, 2012, PSYCHIAT QUART, V83, P311, DOI 10.1007/s11126-011-9201-3; Vernal DL, 2020, SCHIZOPHR RES, V220, P123, DOI 10.1016/j.schres.2020.03.045; Wichniak A, 2021, PSYCHIATR POL, V55, P967, DOI 10.12740/PP/140287; Wichniak A, 2019, PSYCHIATR POL, V53, P1191, DOI 10.12740/PP/113222; Xu LZ, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-2484-x; Zheng Z, 2018, AUTISM RES, V11, P1110, DOI 10.1002/aur.1977";66;2;3;0;5;WYDAWNICZY POLSKIEGO TOWARZYSTWA;CRACOW;LENARTOWICZA 14 STRREET,, CRACOW, 31-138, POLAND;0033-2674;;;PSYCHIATR POL;Psychiatr. Pol.;;2022;56;4;;;;;675;695;;10.12740/PP/OnlineFirst/149707;http://dx.doi.org/10.12740/PP/OnlineFirst/149707;;;21;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;8J7JW;37074823;Green Submitted, gold;;;24/11/2024;WOS:000922588400002;View Full Record in Web of Science
J;"den Boer, JC; Klip, H; Blonk, A; Lenselink, M; Kaijdoe, SPT; Tielkes, M; van Zandbeek, A; Bres, G; Herinx, M; Staal, WG; Rommelse, N";;;;"den Boer, Jenny C.; Klip, Helen; Blonk, Anita; Lenselink, Monique; Kaijdoe, Shireen P. T.; Tielkes, Melanie; van Zandbeek, Amber; Bres, Gerdine; Herinx, Mandy; Staal, Wouter G.; Rommelse, Nanda";;;Study Protocol: Pegasus: psychotherapy incorporating horses for 'therapy-resistant' adolescents with autism spectrum disorders, a study with series of randomised, baseline controlled n-of-1 trials;BMC PSYCHIATRY;;;English;Article;;;;;;"Autism; Emotion dysregulation; Therapy-resistant; Adolescent; Psychotherapy incorporating horses (PIH)";"EMOTION REGULATION; MENTAL-HEALTH; CHILDREN; INTERVENTIONS; INDIVIDUALS; VALIDATION; STRESS; BRAIN";BackgroundFor people with autism spectrum disorder (ASD), daily life can be highly stressful with many unpredictable events that can evoke emotion dysregulation (ED): a strong difficulty with appropriately negative affect regulation. For some of the patients with ASD, treatment as usual does not prove to be effective for ED. They may be at risk of life-long impairment, development of other disorders and loss of motivation for most regular forms of therapy. A highly promising method that may prove effective for therapy-resistant individuals with ASD is Psychotherapy incorporating horses (PIH). PIH uses the interactions of the horse and the patients on the ground and does not include horseriding. While often met with prejudgment and scepticism, reports from parents and therapists as well as a recent systematic review suggest that PIH may have beneficial effects on youths with ASD. Therefore, we examine clinical outcomes both in the short and in the long terms of PIH offered to adolescents with ASD and severe ED despite regular therapy.MethodsA total of 35 adolescents aged 11-18 years with ASD will receive PIH during 15 sessions once a week with randomization to five different groups differentiating in baseline phase from 2 to 6 weeks. PIH uses horses to promote social awareness and self-awareness as well as relationship management and self-management. The primary outcome is the response to treatment on the Emotion Dysregulation Index (EDI). The secondary outcome measures include ASD symptom severity, quality of life, self-esteem, global and family functioning, and goal attainment. Assessments take place at the baseline (T0), at the end of baseline phase A (T1), after completion of intervention phase B (T2), after the end of post-measurement phase C (T3) and after one year (T4). Qualitative interviews of participants, parents and therapists will be held to reveal facilitators and barriers of PIH and a cost-effectiveness study will be performed.DiscussionThis study aims at contributing to clinical practice for adolescents with ASD and persistent emotion regulation problems despite 1.5 year of treatment by offering Psychotherapy incorporating horses in a study with series of randomised, baseline controlled n-of-1 trials.Trial registrationwww.ClinicalTrials.gov NCT05200351, December 10th 2021.;"[den Boer, Jenny C.] Karakter Child & Adolescent Psychiat, Ede, Netherlands; [Klip, Helen; Kaijdoe, Shireen P. T.; Tielkes, Melanie; Staal, Wouter G.] Karakter Child & Adolescent Psychiat, Nijmegen, Netherlands; [den Boer, Jenny C.; Staal, Wouter G.] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, Nijmegen, Netherlands; [Blonk, Anita; van Zandbeek, Amber] Gagelhoeve, Mill, Netherlands; [Lenselink, Monique] Paardenblik, Wageningen, Netherlands; [Bres, Gerdine; Herinx, Mandy] Horses Co, Heerjansdam, Netherlands; [Staal, Wouter G.] Inst Brain & Cognit, Leiden, Netherlands; [Rommelse, Nanda] Univ Utrecht, Dept Dev Psychol, Utrecht, Netherlands";"Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University";"den Boer, JC (corresponding author), Karakter Child & Adolescent Psychiat, Ede, Netherlands.;den Boer, JC (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, Nijmegen, Netherlands.";J.denboer@karakter.com;Staal, W.G./L-4665-2015;;ZonMw;ZonMw(Netherlands Organization for Health Research and Development);We thank Nynke Tjepkema and Annika Kruithof who were concerned with data collection and Lara Baartmans who helped with the transfer leaflet.;"Achenbach T., 2011, MANUAL ASEBA BRIEF P; Aldao A, 2010, CLIN PSYCHOL REV, V30, P217, DOI 10.1016/j.cpr.2009.11.004; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Baarda BB, Basisboek Kwalitatief onderzoek, Handleiding voor het opzetten en uitvoeren van kwalitatief onderzoek. 4e druk ed2018; Benjamini Y, 2005, J AM STAT ASSOC, V100, P71, DOI 10.1198/016214504000001907; Burnett Heyes S, 2015, CHILD DEV, V86, P1489, DOI 10.1111/cdev.12396; Cohen MM, 2013, NEUROSCIENCE, V249, P53, DOI 10.1016/j.neuroscience.2013.01.023; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Dobson D., 2009, Evidence-based practice of cognitive-behavioral therapy; Dobson D, 2017, Evidence-based practice of cognitive-behavioral therapy, Vxiii; Duncan BLSJ, J Br Ther, V5, P71; Fein D, 2013, J CHILD PSYCHOL PSYC, V54, P195, DOI 10.1111/jcpp.12037; Fombonne E, 2018, J CHILD PSYCHOL PSYC, V59, P717, DOI 10.1111/jcpp.12941; Franck E, 2008, PSYCHOL BELG, V48, P25, DOI 10.5334/pb-48-1-25; Frazier TW, 2012, J AM ACAD CHILD PSY, V51, P28, DOI 10.1016/j.jaac.2011.09.021; Fuller EA, 2020, J AUTISM DEV DISORD, V50, P1683, DOI 10.1007/s10803-019-03927-z; Gillespie-Lynch K, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00438; Goepfert E, 2015, CHILD ADOL PSYCH CL, V24, P571, DOI 10.1016/j.chc.2015.02.009; Goodman G, 2022, PSYCHOTHER RES, V32, P792, DOI 10.1080/10503307.2021.2001603; Hafkenscheid ADB, J Br Ther, P1; Heyvaert M, 2017, J EXP EDUC, V85, P175, DOI 10.1080/00220973.2015.1123667; Janse P, 2014, EUR J PSYCHOL ASSESS, V30, P86, DOI 10.1027/1015-5759/a000172; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kvale S., 2009, INTERVIEWS LEARNING; Malinowski K, 2018, J EQUINE VET SCI, V64, P17, DOI 10.1016/j.jevs.2018.01.011; Manly BFJ, 2007, Int Stat Rev., V75, P269, DOI [10.1111/j.1751-5823.2007.00015_21.x., DOI 10.1111/J.1751-5823.2007.00015_21.X]; Mazefsky CA, 2021, J CLIN CHILD ADOLESC, V50, P596, DOI 10.1080/15374416.2019.1703710; Mazefsky CA, 2018, J AUTISM DEV DISORD, V48, P3736, DOI 10.1007/s10803-016-2907-1; Mazefsky CA, 2015, J AUTISM DEV DISORD, V45, P3405, DOI 10.1007/s10803-015-2602-7; Mazefsky CA, 2014, AUTISM RES, V7, P344, DOI 10.1002/aur.1366; Meijer MaW R, Geen woorden maar paarden, equine assisted coaching & therapie2023; Melissa G, J Evid Based Soc Work, V17, P3279; Mengler L, 2014, NEUROIMAGE, V84, P35, DOI 10.1016/j.neuroimage.2013.08.034; Midgley N., 2017, Mentalization-based treatment for children: A time-limited approach; Miller S.D., 2004, OUTCOME SESSION RATI; Mogensen L, 2015, SOCIOL HEALTH ILL, V37, P255, DOI 10.1111/1467-9566.12208; Nader-Grosbois N., 2014, Psychology, V5, P1750, DOI DOI 10.4236/PSYCH.2014.515182; Nieforth LO, 2023, REV J AUTISM DEV DIS, V10, P255, DOI 10.1007/s40489-021-00291-6; Peters BCM, 2017, J AUTISM DEV DISORD, V47, P3220, DOI 10.1007/s10803-017-3219-9; Peters-Scheffer N, 2011, RES AUTISM SPECT DIS, V5, P60, DOI 10.1016/j.rasd.2010.03.011; Reichow B, 2012, J AUTISM DEV DISORD, V42, P512, DOI 10.1007/s10803-011-1218-9; Roeyers H., 2011, SRS Screeningslijst voor autismespectrumstoornissen. Handleiding; Samson AC, 2015, J CHILD PSYCHOL PSYC, V56, P903, DOI 10.1111/jcpp.12370; Srinivasan SM, 2018, REV J AUTISM DEV DIS, V5, P156, DOI 10.1007/s40489-018-0130-z; Straten LR, 2002, Manual Trimbos/iMTA Questionnaire for Costs Associated with Psychiatric Illness (TIC-P), P2; Sussman D, 2015, NEUROIMAGE-CLIN, V8, P170, DOI 10.1016/j.nicl.2015.04.008; Swain D, 2015, J AUTISM DEV DISORD, V45, P3971, DOI 10.1007/s10803-015-2567-6; The KIDSCREEN Group Europe, 2006, KIDSCREEN QUESTIONNA; Trzmiel T, 2019, COMPLEMENT THER MED, V42, P104, DOI 10.1016/j.ctim.2018.11.004; Veerman JW., 2016, Questionnaire on Family Functioning according to parents; Veerman JW., 2016, Handleiding VGFO. Vragenlijst Gezinsfunctioneren volgens Ouders; Verhulst F., 2013, Handleiding ASEBA, Vragenlijsten voor leeftijden 6 tot en met 18 jaar [Manual ASEBA, questionarios para idades de 6 a 18 anos]; Wechsler D., 2018, Wechsler Adult Intelligence Scale, V4; Wechsler D, 2018, WISC V NL WECHSLER I; Weijers JG, 2020, J CONTEMP PSYCHOTHER, V50, P223, DOI 10.1007/s10879-019-09449-0; Wood W, 2021, J ALTERN COMPLEM MED, V27, P88, DOI 10.1089/acm.2020.0415";56;0;0;4;4;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;juil-10;2024;24;1;;;;;;;499;10.1186/s12888-024-05879-w;http://dx.doi.org/10.1186/s12888-024-05879-w;;;18;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;YL8J9;38987737;gold, Green Published;;;24/11/2024;WOS:001268732200001;View Full Record in Web of Science
J;"Nicholson, MS; Leask, J";;;;"Nicholson, Michelle S.; Leask, Julie";;;Lessons from an online debate about measles-mumps-rubella (MMR) immunization;VACCINE;;;English;Article;;;;;;"Internet; Attitudes; Parents; MMR vaccine; Psychology";"VACCINE PREVENTABLE DISEASES; PARENTS; MEDIA";"Objective: To provide strategies for immunization advocates on how best to participate in online discussion forums about immunization. Methods: Content and thematic analysis of an online discussion forum held following the national screening of a documentary about the measles-mumps-rubella (MMR) vaccine and autism scare. A subsample of branches containing more than 20 posts was analysed. Each distinct message (a post) was coded for the author's manifest position on immunization, author type, topic, and evidence presented or sought. Results: From 103 distinct branches there were 1193 posts sent over a 31/2 h period. We selected the 13 longest branches containing 466 posts from 166 individuals. One third of these individuals were explicitly critical of MMR immunization and one third sought information. The remainder were ambivalent but seeking no information (5%), supportive (14%), or unstated (15%). Among five author categories, only 4% identified themselves as health professionals. Topics included alleged adverse effects of immunization (35%); autism spectrum disorders treatment and causes (31%); vaccine ingredients (12%); a conspiracy (9%); immunization policies (8%); and measles, mumps or rubella (4%). Scientific concepts of evidence failed to compete with lay concepts and personal anecdotes prevailed. Conclusions: Health professionals and other advocates of immunization should engage in similar types of post-broadcast online discussion forums in a planned and strategic manner that accounts for the decision processes of lay people. This involves expanding and diversifying the support base of people contributing to the forum; setting the agenda; introducing messages known to influence behaviour; not overselling vaccination; and avoiding personal attacks. (C) 2011 Elsevier Ltd. All rights reserved.";"[Nicholson, Michelle S.; Leask, Julie] Univ Sydney, Sydney Med Sch, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Leask, Julie] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Westmead, NSW, Australia; [Leask, Julie] Univ Sydney, Sydney Med Sch, Sch Publ Hlth, Sydney, NSW 2006, Australia";"University of Sydney; NSW Health; Sydney Childrens Hospitals Network; The Children's Hospital at Westmead; University of Sydney; University of Sydney";Leask, J (corresponding author), Univ Sydney, Childrens Hosp Westmead, NCIRS, Locked Bag 4001, Westmead, NSW 2145, Australia.;Julie.leask@sydney.edu.au;Leask, Julie/ABE-2077-2020;Leask, Julie/0000-0001-5095-1443;"Australian Government Department of Health and Ageing; NSW Department of Health; Children's Hospital at Westmead; Australian Research Council";"Australian Government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); NSW Department of Health; Children's Hospital at Westmead; Australian Research Council(Australian Research Council)";National Centre for Immunization Research and Surveillance is supported by the Australian Government Department of Health and Ageing, the NSW Department of Health and The Children's Hospital at Westmead.Julie Leask has received support for research via an Australian Research Council Linkage Grant. Sanofi Pasteur are partner investigators in the grant. Some participants in the forum were known to Julie Leask and included three individuals with whom she has a professional relationship.;"[Anonymous], 2005, DOES MMR JAB CAUSE A; Bean SJ, 2011, VACCINE, V29, P1874, DOI 10.1016/j.vaccine.2011.01.003; Betsch C, THERE IS RISK A UNPU; Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647; Bond L, 1998, AUST NZ J PUBL HEAL, V22, P441, DOI 10.1111/j.1467-842X.1998.tb01411.x; Brownlie J, 2006, SOC SCI MED, V62, P433, DOI 10.1016/j.socscimed.2005.05.033; Caplan AL, 2010, LANCET, V375, P444, DOI [10.1016/S0140-6736(09)61675-5, 10.1016/S0140-6736(10)60175-4]; Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22; Downs JS, 2008, VACCINE, V26, P1595, DOI 10.1016/j.vaccine.2008.01.011; Godlee F, 2006, BMJ-BRIT MED J, V2006, P333; Godlee Fiona, 2011, BMJ, V342, pc7452, DOI 10.1136/bmj.c7452; Heathcock R, 2008, MEASLES OUTBREAKS LO; HERSHEY JC, 1994, ORGAN BEHAV HUM DEC, V59, P177, DOI 10.1006/obhd.1994.1055; Hewstone M., 1990, Causal attribution: From cognitive processes to collective beliefs; Hilton S, 2007, ARCH DIS CHILD, V92, P322, DOI 10.1136/adc.2006.109686; Hussain H, 2011, PEDIATRICS, V127, pS100, DOI 10.1542/peds.2010-1722O; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Keelan J, 2007, JAMA-J AM MED ASSOC, V298, P2482, DOI 10.1001/jama.298.21.2482; Keelan J, 2010, VACCINE, V28, P1535, DOI 10.1016/j.vaccine.2009.11.060; Leach M., 2007, Vaccine Anxieties: Global Science, Child Health and Society; Leask J, 2002, SOC SCI MED, V54, P445, DOI 10.1016/S0277-9536(01)00130-7; Leask J, 2002, THESIS U SYDNEY; Leask JA, 1998, AUST NZ J PUBL HEAL, V22, P17, DOI 10.1111/j.1467-842X.1998.tb01140.x; Leask J, 2008, AUST NZ J PUBL HEAL, V32, P224, DOI 10.1111/j.1753-6405.2008.00220.x; Leask J, 2010, MED J AUSTRALIA, V193, P5, DOI 10.5694/j.1326-5377.2010.tb03730.x; PASSMORE J, 1962, HIST THEORY, V2, P105, DOI 10.2307/2504458; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Skea ZC, 2008, SOC SCI MED, V67, P1382, DOI 10.1016/j.socscimed.2008.07.006; Sporton RK, 2001, FAM PRACT, V18, P181, DOI 10.1093/fampra/18.2.181; The NHS Information Centre W. Facilities, 2009, NHS IMM STAT ENGL 20; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wolfe RM, 2002, JAMA-J AM MED ASSOC, V287, P3245, DOI 10.1001/jama.287.24.3245; Wroe AL, 2004, HEALTH PSYCHOL, V23, P33, DOI 10.1037/0278-6133.23.1.33";33;43;48;0;46;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;0264-410X;1873-2518;;VACCINE;Vaccine;MAY 28;2012;30;25;;;SI;;3806;3812;;10.1016/j.vaccine.2011.10.072;http://dx.doi.org/10.1016/j.vaccine.2011.10.072;;;7;"Immunology; Medicine, Research & Experimental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Immunology; Research & Experimental Medicine";954VH;22063388;;;;24/11/2024;WOS:000304975600012;View Full Record in Web of Science
J;"Roording-Ragetlie, S; Spaltman, M; de Groot, E; Klip, H; Buitelaar, J; Slaats-Willemse, D";;;;"Roording-Ragetlie, S.; Spaltman, M.; de Groot, E.; Klip, H.; Buitelaar, J.; Slaats-Willemse, D.";;;Working memory training in children with borderline intellectual functioning and neuropsychiatric disorders: a triple-blind randomised controlled trial;JOURNAL OF INTELLECTUAL DISABILITY RESEARCH;;;English;Article;;;;;;"ADHD; ASD; borderline intellectual functioning; randomised controlled trial; working memory training";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS; MENTAL-RETARDATION; EXECUTIVE FUNCTION; ADHD; PREVALENCE; ADOLESCENTS; MILD; INTERVENTIONS; METAANALYSIS";"Background Poor working memory, lower IQ and maladaptive behaviour form a triple disability known to have negative effects on the academic and social development of children with borderline intellectual functioning (BIF; IQ: 70 < IQ < 85) and neuropsychiatric disorders [attention-deficit hyperactivity disorder (ADHD) and/or autism spectrum disorder (ASD)]. Treatment possibilities for these children are scarce and hardly evidence based. This study primarily investigated whether adaptive computerised working memory training (WMT) may lead to significantly more improvement on a non-trained visuospatial WM task compared with a non-adaptive control WMT (placebo) in children with BIF and neuropsychiatric disorders. As secondary outcome measures, we used the scores on several non-trained neuropsychological near-transfer and far-transfer tasks as well as behavioural measures. Method We conducted a triple-blind placebo-controlled randomised clinical trial in 72 children (aged 10;0-13;11 years, 53 boys, 19 girls) with BIF and comorbid neuropsychiatric disorders (ADHD = 37, ASD = 21, both = 14) that were referred to child and adolescent psychiatry care, between May 2012 and March 2019. Children completed the Dutch version of Cogmed WMT, either the adaptive training version or the non-adaptive placebo version, 25 sessions (30-45 min a day), for 5 weeks. The primary outcome measure was the score on a non-trained visuospatial working memory task. The primary outcome was measured before and directly after 5 weeks of WMT and again 6 months after training. Results A total of 375 children were screened for eligibility and 72 were randomised. No significantly higher levels of improvement over time were found on our primary outcome measure in the experimental WMT group compared with the placebo control WMT, nor in the secondary (near-transfer and far-transfer tasks) or tertiary (behavioural measures) outcome measures. However, this study did show changes over time for these measurements for both the experimental and placebo conditions. Conclusions This study was unable to document superior training effects over time of an adaptive WMT in children with BIF and neuropsychiatric disorders, compared with a placebo (non-adaptive) WMT. The objectively documented changes over time in the non-adaptive WMT arm suggest that these children with persistent impairments in WM may benefit from a structured learning environment that is associated with improvement of neurocognitive functioning and coping strategies. Further research is needed to examine which elements of cognitive training may be useful for which specific patients and to study long-term effects of training.";"[Roording-Ragetlie, S.; Spaltman, M.; de Groot, E.; Klip, H.; Buitelaar, J.] Karakter Child & Adolescent Psychiat, Dept Mild Intellectual Disabil, Nijmegen, Netherlands; [Buitelaar, J.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, Nijmegen, Netherlands; [Buitelaar, J.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, Nijmegen, Netherlands; [Slaats-Willemse, D.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Psychiat, Nijmegen, Netherlands; [Slaats-Willemse, D.] Denkkracht, Dept Karakter Child & Adolescent Psychiat, Nijmegen, Netherlands";"Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen";Roording-Ragetlie, S (corresponding author), Karakter Child & Adolescent Psychiat, Horalaan 5, Ede, Netherlands.;s.roording@karakter.com;Buitelaar, Jan/E-4584-2012;;"MIND Netherlands; Dutch WKK foundation";"MIND Netherlands; Dutch WKK foundation";This project is funded by MIND Netherlands and the Dutch WKK foundation. They did not have any role during execution, analyses, interpretation of the data or decision to submit results.;"Alloway T. P., 2007, AUTOMATED WORKING ME; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; [Anonymous], 2009, DUTCH TRANSLATION BE; [Anonymous], 2001, Working Memory Test Battery for Children (working memoryTB-C); [Anonymous], 1999, EEN MINUUT TEST VORM; [Anonymous], 2009, Amsterdamse Neuropsychologische taken Amsterdam Neuropsychological tasks; Berger E. M., 2020, IZA Discussion Paper no. 13338, DOI DOI 10.2139/SSRN.3622985; Chacko A, 2013, J CLIN CHILD ADOLESC, V42, P769, DOI 10.1080/15374416.2013.787622; Chiang HM, 2014, RES AUTISM SPECT DIS, V8, P974, DOI 10.1016/j.rasd.2014.05.003; Cornish K, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00227; Cortese S, 2015, J AM ACAD CHILD PSY, V54, P164, DOI 10.1016/j.jaac.2014.12.010; Danielsson H, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01230; Danielsson H, 2012, RES DEV DISABIL, V33, P600, DOI 10.1016/j.ridd.2011.11.004; De Vos T., 1992, ARITHMETIC NUMBER FA; Della Sala S., 1997, The Visual patterns Test: A new test of short term visual recall; Dentz A, 2020, APPL COGNITIVE PSYCH, V34, P577, DOI 10.1002/acp.3631; Diamond A, 2011, SCIENCE, V333, P959, DOI 10.1126/science.1204529; Dovis S, 2012, J ABNORM CHILD PSYCH, V40, P669, DOI 10.1007/s10802-011-9601-8; DuPaul G. J., 1998, ADHD rating Scale-IV: Checklists, norms, and clinical interpretation; Dutch Knowledge Centre on MID/Landelijk Kenniscentrum LVB, 2012, EFFECTIVE INTERVENTI; Emerson E, 2015, CHILD CARE HLTH DEV, V41, P249, DOI 10.1111/cch.12144; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; IBM Corp, 2017, IBM SPSS STAT MAC VE; Kasper LJ, 2012, CLIN PSYCHOL REV, V32, P605, DOI 10.1016/j.cpr.2012.07.001; Kenworthy L, 2008, NEUROPSYCHOL REV, V18, P320, DOI 10.1007/s11065-008-9077-7; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Kort W., 2005, WISC 3 NL WECHSLER I; Martinussen R, 2005, J AM ACAD CHILD PSY, V44, P377, DOI 10.1097/01.chi.0000153228.72591.73; Mawjee K, 2017, J ATTEN DISORD, V21, P956, DOI 10.1177/1087054714557356; McNab F, 2009, SCIENCE, V323, P800, DOI 10.1126/science.1166102; Melby-Lervåg M, 2016, PERSPECT PSYCHOL SCI, V11, P512, DOI 10.1177/1745691616635612; Melby-Lervåg M, 2013, DEV PSYCHOL, V49, P270, DOI 10.1037/a0028228; Minear M., 2006, Working Memory and Education, P273; Rapport MD, 2013, CLIN PSYCHOL REV, V33, P1237, DOI 10.1016/j.cpr.2013.08.005; Raven J.C., 1996, MANUAL RAVENS STANDA, V1996; Roeleveld N, 1997, DEV MED CHILD NEUROL, V39, P125, DOI 10.1111/j.1469-8749.1997.tb07395.x; Roording-Ragetlie S., 2018, J CHILD PSYCHOL, V2, P16; Sadeghi M, 2020, J CAN ACAD CHILD ADO, V29, P4; Scholte EM., 2005, Handleiding ADHD Vragenlijst (AVL); Shipstead Z, 2012, PSYCHOL BULL, V138, P628, DOI 10.1037/a0027473; Simonoff E, 2006, J CHILD PSYCHOL PSYC, V47, P828, DOI 10.1111/j.1469-7610.2006.01630.x; Simonoff E, 2013, J CHILD PSYCHOL PSYC, V54, P527, DOI 10.1111/j.1469-7610.2012.02569.x; Söderqvist S, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00271; Sonuga-Barke EJS, 2013, AM J PSYCHIAT, V170, P275, DOI 10.1176/appi.ajp.2012.12070991; Stromme P, 2000, DEV MED CHILD NEUROL, V42, P266, DOI 10.1017/S0012162200000451; Van der Molen, 2007, KORT VERHAALTJE ONTH; Van der Molen MJ, 2014, J INTELL DISABIL RES, V58, P637, DOI 10.1111/jir.12061; Van der Molen MJ, 2010, J INTELL DISABIL RES, V54, P433, DOI 10.1111/j.1365-2788.2010.01285.x; Weckstein SM, 2017, MED SCI MONIT BASIC, V23, P336, DOI 10.12659/MSMBR.904930; Westerinen H, 2017, J INTELL DISABIL RES, V61, P802, DOI 10.1111/jir.12351";52;6;6;1;22;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0964-2633;1365-2788;;J INTELL DISABIL RES;J. Intell. Disabil. Res.;JAN;2022;66;01-févr;;;SI;;178;194;;10.1111/jir.12895;http://dx.doi.org/10.1111/jir.12895;;nov-21;17;"Education, Special; Genetics & Heredity; Clinical Neurology; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Genetics & Heredity; Neurosciences & Neurology; Psychiatry; Rehabilitation";YH4MP;34755919;Green Published;;;24/11/2024;WOS:000716486200001;View Full Record in Web of Science
J;"Rogers, SJ; Estes, A; Lord, C; Munson, J; Rocha, M; Winter, J; Greenson, J; Colombi, C; Dawson, G; Vismara, LA; Sugar, CA; Hellemann, G; Whelan, F; Talbott, M";;;;"Rogers, Sally J.; Estes, Annette; Lord, Catherine; Munson, Jeff; Rocha, Marie; Winter, Jamie; Greenson, Jessica; Colombi, Costanza; Dawson, Geraldine; Vismara, Laurie A.; Sugar, Catherine A.; Hellemann, Gerhard; Whelan, Fiona; Talbott, Meagan";;;A Multisite Randomized Controlled Two-Phase Trial of the Early Start Denver Model Compared to Treatment as Usual;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"autism spectrum disorder; early intervention; toddlers; Early Start Denver Model (ESDM); developmental quotient (DQ)";"AUTISTIC SPECTRUM; YOUNG-CHILDREN; INTERVENTION; TODDLERS";"Objective: This single-blind, randomized, multisite, intent-to-treat study was designed to replicate and extend Dawson et al's (Pediatrics. 2010;125: e17-e23) randomized controlled trial testing the effects of the Early Start Denver Model (ESDM), an intensive play- and routines-based intervention delivered in natural settings. Method: A randomized controlled trial was conducted at 3 universities. One hundred eighteen children 14 to 24 months old with autism spectrum disorder were enrolled and randomly assigned to ESDM or community interventions for 27 months. Eighty-one children completed the full treatment course and all assessments; data from all 118 children were used in analyses. Children assigned to the ESDM intervention received 3 months of weekly parent coaching followed by 24 months of 15 hour per week (on average) 1:1 treatment weekly on average in homes or daycare settings from supervised therapy assistants while parents received coaching 4 hours monthly from a certified ESDM therapist. Results: For the primary analyses, there were time-by-group and time-by-group-by-site interactions for language outcome. In the significant 3-way interaction involving site, 2 sites showed a significant ESDM advantage and the third site showed no significant group differences. In the planned 2-way analysis that pooled data across all 3 sites, there was a significant advantage found for the ESDM group. For the secondary analyses, there were no significant differences between the ESDM and community groups involving developmental quotient, autism severity, or adaptive behavior. The treatment effect of group on language outcomes was not moderated by baseline developmental quotient, autism severity, or language. Conclusion: Results of the primary analysis provide a partial replication of Dawson et al's 2010 language findings.";"[Rogers, Sally J.; Rocha, Marie; Vismara, Laurie A.; Talbott, Meagan] Univ Calif Davis, MIND Inst, 2825 50th St, Sacramento, CA 95817 USA; [Estes, Annette; Munson, Jeff; Greenson, Jessica] Univ Washington, Seattle, WA 98195 USA; [Lord, Catherine; Winter, Jamie] Cornell Univ, Weill Cornell Med, New York, NY 10021 USA; [Colombi, Costanza] Univ Michigan, Ann Arbor, MI 48109 USA; [Dawson, Geraldine] Duke Univ, Durham, NC USA; [Sugar, Catherine A.; Hellemann, Gerhard; Whelan, Fiona] Univ Calif Los Angeles, Los Angeles, CA USA";"University of California System; University of California Davis; University of Washington; University of Washington Seattle; Cornell University; Weill Cornell Medicine; University of Michigan System; University of Michigan; Duke University; University of California System; University of California Los Angeles";Rogers, SJ (corresponding author), Univ Calif Davis, MIND Inst, 2825 50th St, Sacramento, CA 95817 USA.;sjrogers@ucdavis.edu;"Sugar, Catherine/LFR-6706-2024; Rogers, Sally/AAN-7858-2020; Dawson, Geraldine/J-8421-2016; Colombi, Costanza/ABF-1988-2020";"Talbott, Meagan/0000-0001-5480-1549; Colombi, Costanza/0000-0002-3396-8822; Estes, Annette/0000-0003-2687-4155; Dawson, Geraldine/0000-0003-1410-2764; Rogers, Sally/0000-0003-0755-2900";"National Institute of Mental Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development as part of the Autism Centers of Excellence Treatment Network [R01 081757]; Autism Speaks grants [8089, 8376]; Children's Miracle Network";"National Institute of Mental Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development as part of the Autism Centers of Excellence Treatment Network; Autism Speaks grants; Children's Miracle Network";This study was supported by the National Institute of Mental Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development award number R01 081757 (Sally J. Rogers, principal investigator) as part of the Autism Centers of Excellence Treatment Network (clinicaltrials.gov, identifier NCT 00698997), Autism Speaks grants 8089 (to Dr. Rogers) and 8376 (to Dr. Estes), and the Children's Miracle Network (to Dr. Rogers). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.;"American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; [Anonymous], 2012, An early start for your child with autism: Using everyday activities to help kids connect, communicate, and learn; [Anonymous], 2010, EARLY START DENVER M; Boyd BA, 2014, J AUTISM DEV DISORD, V44, P366, DOI 10.1007/s10803-013-1877-9; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Dawson G, 2004, DEV PSYCHOL, V40, P271, DOI 10.1037/0012-1649.40.2.271; Dawson G, 2012, J AM ACAD CHILD PSY, V51, P1150, DOI 10.1016/j.jaac.2012.08.018; Dawson Geraldine, 2010, Pediatrics, V125, pe17, DOI 10.1542/peds.2009-0958; Dietz C, 2006, J AUTISM DEV DISORD, V36, P713, DOI 10.1007/s10803-006-0114-1; Gotham K, 2012, PEDIATRICS; Kleinman JM, 2008, J AUTISM DEV DISORD, V38, P606, DOI 10.1007/s10803-007-0427-8; Lord C, 2006, ARCH GEN PSYCHIAT, V63, P694, DOI 10.1001/archpsyc.63.6.694; Lord C., 2012, AUTISM DIAGNOSTIC OB; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; Mullen EM., 1995, MULLEN SCALES EARLY; National Academy of SciencesNational Research Council, 2001, ED CHILDR AUT; Ozonoff S, 2011, J CHILD PSYCHOL PSYC, V52, P729, DOI 10.1111/j.1469-7610.2011.02425.x; Robins DL, 2001, J AUTISM DEV DISORD, V31, P131, DOI 10.1023/A:1010738829569; Rogers SJ, 2012, J AM ACAD CHILD PSY, V51, P1052, DOI 10.1016/j.jaac.2012.08.003; Sigman M, 1999, MONOGR SOC RES CHILD, V64, P1, DOI 10.1111/1540-5834.00002; Sparrow SCD., 2005, VINELAND ADAPTIVE BE; Swinkels SHN, 2006, J AUTISM DEV DISORD, V36, P723, DOI 10.1007/s10803-006-0115-0; Wetherby A. M., 2002, Communication and symbolic behavior scales: Developmental profile; Winter J, 2013, INT M AUT RES; Yoder Paul J, 2013, Evid Based Commun Assess Interv, V7, P150";26;92;106;4;61;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;SEP;2019;58;9;;;;;853;865;;10.1016/j.jaac.2019.01.004;http://dx.doi.org/10.1016/j.jaac.2019.01.004;;;13;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";KS8BX;30768394;;;;24/11/2024;WOS:000518531500006;View Full Record in Web of Science
J;"Frye, RE; Slattery, J; Delhey, L; Furgerson, B; Strickland, T; Tippett, M; Sailey, A; Wynne, R; Rose, S; Melnyk, S; James, SJ; Sequeira, JM; Quadros, EV";;;;"Frye, R. E.; Slattery, J.; Delhey, L.; Furgerson, B.; Strickland, T.; Tippett, M.; Sailey, A.; Wynne, R.; Rose, S.; Melnyk, S.; James, S. Jill; Sequeira, J. M.; Quadros, E. V.";;;Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial;MOLECULAR PSYCHIATRY;;;English;Article;;;;;;;"CEREBRAL FOLATE-DEFICIENCY; SPECTRUM DISORDERS; MITOCHONDRIAL DYSFUNCTION; RECEPTOR AUTOANTIBODIES; YOUNG-CHILDREN; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; SPOKEN LANGUAGE; RISK; 5-METHYLTETRAHYDROFOLATE";"We sought to determine whether high-dose folinic acid improves verbal communication in children with non-syndromic autism spectrum disorder (ASD) and language impairment in a double-blind placebo control setting. Forty-eight children (mean age 7 years 4 months; 82% male) with ASD and language impairment were randomized to receive 12 weeks of high-dose folinic acid (2 mg kg(-1) per day, maximum 50 mg per day; n = 23) or placebo (n = 25). Children were subtyped by glutathione and folate receptor-a autoantibody (FRAA) status. Improvement in verbal communication, as measured by a ability-appropriate standardized instrument, was significantly greater in participants receiving folinic acid as compared with those receiving placebo, resulting in an effect of 5.7 (1.0,10.4) standardized points with a medium-to-large effect size (Cohen's d = 0.70). FRAA status was predictive of response to treatment. For FRAA-positive participants, improvement in verbal communication was significantly greater in those receiving folinic acid as compared with those receiving placebo, resulting in an effect of 7.3 (1.4,13.2) standardized points with a large effect size (Cohen's d = 0.91), indicating that folinic acid treatment may be more efficacious in children with ASD who are FRAA positive. Improvements in subscales of the Vineland Adaptive Behavior Scale, the Aberrant Behavior Checklist, the Autism Symptom Questionnaire and the Behavioral Assessment System for Children were significantly greater in the folinic acid group as compared with the placebo group. There was no significant difference in adverse effects between treatment groups. Thus, in this small trial of children with non-syndromic ASD and language impairment, treatment with high-dose folinic acid for 12 weeks resulted in improvement in verbal communication as compared with placebo, particularly in those participants who were positive for FRAAs.";"[Frye, R. E.; Furgerson, B.; Strickland, T.; Tippett, M.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Frye, R. E.; Slattery, J.; Delhey, L.; Tippett, M.; Sailey, A.; Wynne, R.; Rose, S.; Melnyk, S.; James, S. Jill] Arkansas Childrens Res Inst, Little Rock, AR USA; [Frye, R. E.; Slattery, J.; Delhey, L.; Sailey, A.; Wynne, R.; Rose, S.; Melnyk, S.; James, S. Jill] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Sequeira, J. M.; Quadros, E. V.] SUNY Brooklyn, Downstate Med Ctr, Dept Med, Brooklyn, NY USA";"Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; State University of New York (SUNY) System; SUNY Downstate Health Sciences University";Frye, RE (corresponding author), Arkansas Childrens Res Inst, Autism Res Program, Slot 512-41B,13 Childrens Way, Little Rock, AR 72202 USA.;REFrye@uams.edu;"Rose, Shannon/JZE-1449-2024; Frye, Richard/AAB-5543-2020";Rose, Shannon/0000-0003-0595-4367;"Lee Silsby Compounding Pharmacy; Autism Speaks [8202]; Brenen Hornstein Autism Research and Education Foundation; Fraternal Order of Eagles; Autism Research Institute; Jane Botsford Johnson Foundation";"Lee Silsby Compounding Pharmacy; Autism Speaks; Brenen Hornstein Autism Research and Education Foundation; Fraternal Order of Eagles; Autism Research Institute; Jane Botsford Johnson Foundation";This research was supported, in part, by Lee Silsby Compounding Pharmacy (to REF), Autism Speaks (#8202 to EVQ), Brenen Hornstein Autism Research and Education Foundation (to REF), Fraternal Order of Eagles (to REF), the Autism Research Institute (to REF) and the Jane Botsford Johnson Foundation (to SJJ). This trial is registered on clinicaltrials. gov as NCT01602016.;"[Anonymous], 2014, Autism Res Treat; Arnold LE, 2012, J CHILD ADOL PSYCHOP, V22, P198, DOI 10.1089/cap.2011.0056; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOARMAN DM, 1990, BIOCHEM PHARMACOL, V40, P2651, DOI 10.1016/0006-2952(90)90583-7; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Butter E., 2006, OHIO AUTISM CLIN IMP; Choque Olsson N, 2014, J AUTISM DEV DISORD, V44, P1773, DOI 10.1007/s10803-013-2029-y; Condouris K, 2003, AM J SPEECH-LANG PAT, V12, P349, DOI 10.1044/1058-0360(2003/080); Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Desai A, 2016, BIOCHIMIE, V126, P31, DOI 10.1016/j.biochi.2016.02.012; Detry MA, 2014, JAMA-J AM MED ASSOC, V312, P85, DOI 10.1001/jama.2014.7523; Edgar JC, 2015, J AUTISM DEV DISORD, V45, P395, DOI 10.1007/s10803-013-1904-x; Frye RE, 2013, MOL PSYCHIATR, V18, P369, DOI 10.1038/mp.2011.175; Frye RE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.14; Frye RE, 2015, N AM J MED SCI, V8, P149; Frye RE, 2016, CLIN MED INSIGHTS-PE, V10, P43, DOI 10.4137/CMPed.S38337; Frye RE, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00080; Frye RE, 2015, EPILEPSY BEHAV, V47, P147, DOI 10.1016/j.yebeh.2014.08.134; Frye Richard E., 2015, Microbial Ecology in Health and Disease, V26, P26878, DOI 10.3402/mehd.v26.26878; Frye Richard E, 2013, Autism Res Treat, V2013, P609705, DOI 10.1155/2013/609705; Frye RE, 2014, BIOMARK MED, V8, P321, DOI 10.2217/bmm.13.158; Frye RE, 2014, FRONT PEDIATR, V2, DOI 10.3389/fped.2014.00066; Garcia-Cazorla A, 2008, NEUROLOGY, V70, P1360, DOI 10.1212/01.wnl.0000309223.98616.e4; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Grapp M, 2012, BRAIN, V135, P2022, DOI 10.1093/brain/aws122; Hasselmann O, 2010, MOL GENET METAB, V99, P58, DOI 10.1016/j.ymgme.2009.08.005; Kaat AJ, 2014, J AUTISM DEV DISORD, V44, P1103, DOI 10.1007/s10803-013-1970-0; Kanne SM, 2014, J AUTISM DEV DISORD, V44, P168, DOI 10.1007/s10803-013-1862-3; Klaiman C, 2013, J CHILD ADOL PSYCHOP, V23, P320, DOI 10.1089/cap.2012.0127; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Luyster R, 2007, J SPEECH LANG HEAR R, V50, P667, DOI 10.1044/1092-4388(2007/047); Matts JP, 1997, STAT MED, V16, P1943, DOI 10.1002/(SICI)1097-0258(19970915)16:17<1943::AID-SIM631>3.0.CO;2-R; Moretti P, 2005, NEUROLOGY, V64, P1088, DOI 10.1212/01.WNL.0000154641.08211.B7; Moretti P, 2008, J AUTISM DEV DISORD, V38, P1170, DOI 10.1007/s10803-007-0492-z; Naviaux JC, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.33; Pérez-Dueñas B, 2011, ARCH NEUROL-CHICAGO, V68, P615, DOI 10.1001/archneurol.2011.80; Psychopharmacology TORUoP, 2005, OSU AUT RAT SCAL; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P276, DOI 10.1055/s-2008-1065354; Ramaekers VT, 2007, NEUROPEDIATRICS, V38, P179, DOI 10.1055/s-2007-991148; Ramaekers VT, 2013, MOL PSYCHIATR, V18, P270, DOI 10.1038/mp.2012.22; Ramaekers VT, 2008, DEV MED CHILD NEUROL, V50, P346, DOI 10.1111/j.1469-8749.2008.02053.x; Ramaekers VT, 2005, NEW ENGL J MED, V352, P1985, DOI 10.1056/NEJMoa043160; Ramaekers VT, 2002, NEUROPEDIATRICS, V33, P301, DOI 10.1055/s-2002-37082; Ramaekers VT, 2003, NEUROLOGY, V61, P506, DOI 10.1212/01.WNL.0000078939.64774.1B; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00150; Schmidt RJ, 2012, AM J CLIN NUTR, V96, P80, DOI 10.3945/ajcn.110.004416; Schreibman L, 2014, J AUTISM DEV DISORD, V44, P1244, DOI 10.1007/s10803-013-1972-y; Sequeira JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152249; Sequeira JM, 2013, CLIN CHEM LAB MED, V51, P545, DOI 10.1515/cclm-2012-0577; Serrano M, 2010, MITOCHONDRION, V10, P429, DOI 10.1016/j.mito.2010.04.001; Shoffner J, 2016, NEUROLOGY, V86, P2258, DOI 10.1212/WNL.0000000000002766; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Steenweg-de Graaff J, 2015, EUR J PUBLIC HEALTH, V25, P431, DOI 10.1093/eurpub/cku126; Surén P, 2013, JAMA-J AM MED ASSOC, V309, P570, DOI 10.1001/jama.2012.155925; Tager-Flusberg H, 2009, J SPEECH LANG HEAR R, V52, P643, DOI 10.1044/1092-4388(2009/08-0136); Tang GM, 2014, NEURON, V83, P1131, DOI 10.1016/j.neuron.2014.07.040; Tilford JM, 2012, PHARMACOECONOMICS, V30, P661, DOI 10.2165/11597200-000000000-00000; Turygin NC, 2013, DEV NEUROREHABIL, V16, P277, DOI 10.3109/17518423.2013.769281; Vahabzadeh A, 2013, JAMA-J AM MED ASSOC, V309, P2208, DOI 10.1001/jama.2013.4876; Verly M, 2014, HUM BRAIN MAPP, V35, P3602, DOI 10.1002/hbm.22424; Volden J, 2011, AM J SPEECH-LANG PAT, V20, P200, DOI 10.1044/1058-0360(2011/10-0035); Wetherby AM, 2014, PEDIATRICS, V134, P1084, DOI 10.1542/peds.2014-0757; White IR, 2012, CLIN TRIALS, V9, P396, DOI 10.1177/1740774512450098; Wink LK, 2014, J CHILD ADOL PSYCHOP, V24, P78, DOI 10.1089/cap.2013.0099; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yuan Y.C., 2011, Multiple Imputation for Missing Data: Concepts and NewDevelopment; Yui K, 2015, MINI-REV MED CHEM, V15, P373, DOI 10.2174/1389557515666150324122930; Zablotsky Benjamin, 2015, Natl Health Stat Report, P1";70;112;128;0;9;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;1359-4184;1476-5578;;MOL PSYCHIATR;Mol. Psychiatr.;FEB;2018;23;2;;;;;247;256;;10.1038/mp.2016.168;http://dx.doi.org/10.1038/mp.2016.168;;;10;"Biochemistry & Molecular Biology; Neurosciences; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry";FT8ZM;27752075;Green Published, hybrid;;;24/11/2024;WOS:000423441700010;View Full Record in Web of Science
J;"van Andel, DM; Sprengers, JJ; Oranje, B; Scheepers, FE; Jansen, FE; Bruining, H";;;;"van Andel, Dorinde M.; Sprengers, Jan J.; Oranje, Bob; Scheepers, Floortje E.; Jansen, Floor E.; Bruining, Hilgo";;;Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study;MOLECULAR AUTISM;;;English;Article;;;;;;"Tuberous sclerosis complex; Bumetanide; Open-label; NKCC1 antagonist; TAND; Irritability; ERP; Neurocognitive task";"BEHAVIOR; SCALE; RECOMMENDATIONS; INHIBITION; VALIDATION; EVEROLIMUS; DISORDERS";Background Tuberous sclerosis complex (TSC) is an autosomal dominant disease that affects multiple organs including the brain. TSC is strongly associated with broad neurodevelopmental disorders, including autism spectrum disorder symptomatology. Preclinical TSC studies have indicated altered neuronal chloride homeostasis affecting the polarity of gamma-aminobutyric acid (GABA) ergic transmission as a potential treatment target. Bumetanide, a selective NKCC1 chloride importer antagonist, may attenuate depolarizing GABA action, and in that way reduce disease burden. In this open-label pilot study, we tested the effect of bumetanide on a variety of neurophysiological, cognitive, and behavioral measures in children with TSC. Methods Participants were treated with bumetanide (2dd 0.5-1.0 mg) for 13 weeks in an open-label trial. The Aberrant Behavior Checklist-Irritability (ABC-I) subscale was chosen as the primary endpoint. Secondary endpoints included other behavioral questionnaires in addition to event-related potentials (ERP) and neuropsychological tests if tolerated. Additionally, the treatment effect on seizure frequency and quality of life was assessed. Endpoint data were collected at baseline, after 91 days of treatment and after a 28-day wash-out period. Results Fifteen patients (8-21-years old) with TSC were included of which 13 patients completed the study. Treatment was well-tolerated with only expected adverse events due to the diuretic effects of bumetanide. Irritable behavior (ABC-I) showed significant improvement after treatment in 11 out of 13 patients (t(12) = 4.41, p = .001, d = .773). A favorable effect was also found for social behavior (Social Responsiveness Scale) (t(11) = 4.01, p = .002, d = .549) and hyperactive behavior (ABC-hyperactivity subscale) (t(12) = 3.65, p = .003, d = .686). Moreover, patients rated their own health-related quality of life higher after treatment. At baseline, TSC patients showed several atypical ERPs versus typically developing peers of which prepulse inhibition was significantly decreased in the TSC group. Neuropsychological measurements showed no change and bumetanide had no effect on seizure frequency. Limitations The sample size and open-label design of this pilot study warrant caution when interpreting outcome measures. Conclusions Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC. More elaborate trials are needed to determine the application and effect size of bumetanide for the TSC population. Trial registration EU Clinical Trial Register, EudraCT 2016-002408-13 (). Registered 25 July 2016.;"[van Andel, Dorinde M.; Sprengers, Jan J.; Oranje, Bob; Scheepers, Floortje E.; Bruining, Hilgo] Univ Med Ctr Utrecht, Brain Ctr, Dept Psychiat, Utrecht, Netherlands; [Jansen, Floor E.] Univ Med Ctr Utrecht, Brain Ctr, Dept Pediat Neurol, Utrecht, Netherlands; [Bruining, Hilgo] Univ Amsterdam, Amsterdam UMC, Dept Child & Adolescent Psychiat, Amsterdam, Netherlands";"Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam";van Andel, DM (corresponding author), Univ Med Ctr Utrecht, Brain Ctr, Dept Psychiat, Utrecht, Netherlands.;D.m.vanandel@umcutrecht.nl;Oranje, Bob/GNP-1739-2022;"Sprengers, Jan/0000-0001-5418-9791; van Andel, Dorinde/0000-0002-6082-0612";Stichting TSC Fonds;Stichting TSC Fonds;This study was supported by a grant from Stichting TSC Fonds. Stichting TSC Fonds had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; Ben-Ari Y, 2017, TRENDS NEUROSCI, V40, P536, DOI 10.1016/j.tins.2017.07.001; Chu-Shore CJ, 2010, EPILEPSIA, V51, P1236, DOI 10.1111/j.1528-1167.2009.02474.x; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Curatolo P, 2015, LANCET NEUROL, V14, P733, DOI 10.1016/S1474-4422(15)00069-1; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; de Vries P, 2005, EUR CHILD ADOLES PSY, V14, P183, DOI 10.1007/s00787-005-0443-1; de Vries PJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00964; de Vries PJ, 2015, PEDIATR NEUROL, V52, P25, DOI 10.1016/j.pediatrneurol.2014.10.004; de Vries PJ, 2010, NEUROTHERAPEUTICS, V7, P275, DOI 10.1016/j.nurt.2010.05.001; Dunn W, 1999, SENSORY PROFILE EXAM; Dunn W., 2006, SENSORY PROFILE SCH; Eftekhari S, 2013, EPILEPSIA, V54, pe9, DOI 10.1111/j.1528-1167.2012.03654.x; Gioia GA., 2015, BRIEF 2 BEHAV RATING, VSecond; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Kahle KT, 2009, J CHILD NEUROL, V24, P572, DOI 10.1177/0883073809333526; Kharod SC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00310; Kingswood JC, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-016-0553-5; Krueger DA, 2017, ANN CLIN TRANSL NEUR, V4, P877, DOI 10.1002/acn3.494; Krueger DA, 2013, PEDIATR NEUROL, V49, P255, DOI 10.1016/j.pediatrneurol.2013.08.002; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Lemonnier E, 2010, ACTA PAEDIATR, V99, P1885, DOI 10.1111/j.1651-2227.2010.01933.x; Löscher W, 2013, NEUROPHARMACOLOGY, V69, P62, DOI 10.1016/j.neuropharm.2012.05.045; Lopes R, 2014, EPILEPSY BEHAV, V33, P87, DOI 10.1016/j.yebeh.2014.02.017; Lozovaya N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5563; Madsen GF, 2015, CHILDREN AUTISM YET; Madsen GF, 2014, AUTISM RES, V7, P94, DOI 10.1002/aur.1337; Miyajima M, 2011, EPILEPSY RES, V94, P149, DOI 10.1016/j.eplepsyres.2011.01.009; Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001; Overwater IE, 2019, NEUROLOGY; Randell E, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1446-6; Ruffolo G, 2016, NEUROBIOL DIS, V95, P93, DOI 10.1016/j.nbd.2016.07.014; Schulte JT, 2018, NEUROSCI BIOBEHAV R, V90, P260, DOI 10.1016/j.neubiorev.2018.05.001; Stunnenberg BC, EFFECT MEXILETINE MU, DOI [10.1001/jama.2018.18020., DOI 10.1001/JAMA.2018.18020]; Talos DM, 2012, ANN NEUROL, V71, P539, DOI 10.1002/ana.22696; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Vlaskamp C, 2017, AUTISM RES, V10, P1857, DOI 10.1002/aur.1821; Wille N, 2010, QUAL LIFE RES, V19, P875, DOI 10.1007/s11136-010-9648-y";43;38;38;0;7;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;MAY 7;2020;11;1;;;;;;;30;10.1186/s13229-020-00335-4;http://dx.doi.org/10.1186/s13229-020-00335-4;;;14;"Genetics & Heredity; Neurosciences";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Genetics & Heredity; Neurosciences & Neurology";LN9SO;32381101;Green Published, gold;;;24/11/2024;WOS:000533271100001;View Full Record in Web of Science
J;"Hsiao, MN; Chien, YL; Tai, YM; Chen, HM; Shih, HH; Chen, LW; Chen, YY; Soong, WT; Chiu, YN; Tsai, WC; Laugeson, E; Tseng, MH; Gau, SSF";;;;"Hsiao, Mei-Ni; Chien, Yi-Ling; Tai, Yueh-Ming; Chen, Heng-Man; Shih, Hsien-Hsueh; Chen, Li-Wei; Chen, Yu-Ying; Soong, Wei-Tsuen; Chiu, Yen-Nan; Tsai, Wen-Che; Laugeson, Elizabeth; Tseng, Mei-Hui; Gau, Susan Shur-Fen";;;A preliminary randomized controlled study of the PEERS® program for Taiwanese autistic adolescents: The effectiveness on reducing school bullying and enhancing social function;AUTISM RESEARCH;;;English;Article;;;;;;"adolescents; autism; school bullying; social skills; randomized clinical trial";"SPECTRUM DISORDER; CHINESE VERSION; PSYCHOMETRIC PROPERTIES; SKILLS INTERVENTIONS; CHILDREN; YOUTH; ENVIRONMENT; PREVALENCE; FRIENDSHIP; EFFICACY";"Individuals with autism spectrum disorder (ASD) often experience lifelong social communication challenges and are more vulnerable to school bullying. Addressing their social difficulties and school bullying requires evidence-based interventions. PEERS (R) (Program for the Education and Enrichment of Relational Skills) was adapted and translated for Taiwanese adolescents. This randomized controlled study aimed to examine the effectiveness of the Taiwanese version of PEERS (R) in reducing school bullying and enhancing social function among autistic adolescents. Twenty-one autistic adolescents (mean age 14.29 +/- 1.67 years; female n = 733.33%) were randomized to a treatment group (TG, n = 10) or a delayed treatment control group (DTG, n = 11). The outcome measures (school bullying, social challenges, social skills knowledge, and social skills performance) were assessed at baseline, post-treatment, and follow-up. The group and time interaction analyses revealed greater magnitudes of reduction in general school bullying (p < 0.001), victimization (p < 0.001), perpetration (p = 0.012), social challenges (p = 0.001), and peer conflicts (p < 0.001), and improvement in social knowledge (p < 0.001) in the TG group than the DTG group. The findings suggest that the PEERS (R) program tailored for Taiwanese adolescents is effective in reducing school bullying, decreasing social challenges, and enhancing social skills among autistic adolescents, with very large effect sizes (Cohen's d ranging from 1.19 to 2.88). Consequently, participation in the PEERS (R) program is recommended for adolescents with social difficulties to improve their social communication and interactions to offset school bullying and other social challenges related to adverse outcomes.";"[Hsiao, Mei-Ni; Chien, Yi-Ling; Soong, Wei-Tsuen; Chiu, Yen-Nan; Tsai, Wen-Che; Gau, Susan Shur-Fen] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan; [Hsiao, Mei-Ni; Tseng, Mei-Hui; Gau, Susan Shur-Fen] Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei, Taiwan; [Chien, Yi-Ling; Soong, Wei-Tsuen; Chiu, Yen-Nan; Tsai, Wen-Che; Gau, Susan Shur-Fen] Natl Taiwan Univ, Coll Med, Dept Psychiat, Taipei, Taiwan; [Tai, Yueh-Ming] Triserv Gen Hosp, Dept Psychiat, Beitou Branch, Taipei, Taiwan; [Chen, Heng-Man; Chen, Yu-Ying] Fdn Autist Children & Adults Taiwan, Taipei, Taiwan; [Shih, Hsien-Hsueh] Far Eastern Mem Hosp, Dept Psychiat, Taipei, Taiwan; [Chen, Li-Wei] Taiwan Proact Early Intervent Assoc, Taipei, Taiwan; [Laugeson, Elizabeth] Univ Calif Los Angeles UCLA, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA";"National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Tri-Service General Hospital; Far Eastern Memorial Hospital; University of California System; University of California Los Angeles";"Tseng, MH; Gau, SSF (corresponding author), Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei, Taiwan.;Gau, SSF (corresponding author), Natl Taiwan Univ Hosp, Dept Psychiat, 7 Chung Shan South Rd, Taipei, Taiwan.;Gau, SSF (corresponding author), Coll Med, 7 Chung Shan South Rd, Taipei, Taiwan.";"mhtseng@ntu.edu.tw; gaushufe@ntu.edu.tw";"Chen, Yi/JBR-7728-2023; Chen, Yi-Lung/AAC-5284-2019; Tseng, Mei-Hui/A-7938-2010";;National Taiwan University Hospital [NTUH 109-M4555];National Taiwan University Hospital(National Taiwan University);National Taiwan University Hospital, Grant/Award Number: NTUH 109-M4555;"Afsharnejad B., 2021, European Child Adolescent Psychiatry, V31, P1; Afsharnejad B, 2020, J AUTISM DEV DISORD, V50, P4297, DOI 10.1007/s10803-020-04477-5; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Babb S, 2021, REM SPEC EDUC, V42, P343, DOI 10.1177/0741932520956362; Barati H., 2012, Iranian Rehabilitation Journal, V10, P35; Bellini S, 2007, REM SPEC EDUC, V28, P153, DOI 10.1177/07419325070280030401; Chang JC, 2023, J FORMOS MED ASSOC, V122, P574, DOI 10.1016/j.jfma.2023.01.008; Chang YC, 2014, AUTISM, V18, P467, DOI 10.1177/1362361313478995; Chen YL, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796018000793; Chien YL, 2023, PSYCHOL MED, V53, P966, DOI 10.1017/S0033291721002385; Chou WJ, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00009; Chou WJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071117; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Corbett BA, 2023, J CONSULT CLIN PSYCH, V91, P411, DOI 10.1037/ccp0000821; Corbett BA, 2017, AUTISM, V21, P333, DOI 10.1177/1362361316643623; Corbett BA, 2011, J AUTISM DEV DISORD, V41, P505, DOI 10.1007/s10803-010-1064-1; D'Urso G, 2022, SOC PSYCHOL EDUC, V25, P293, DOI 10.1007/s11218-021-09684-1; de Sousa ML, 2023, CURR PSYCHOL, V42, P11936, DOI 10.1007/s12144-021-02491-z; Farrington D.P., 2009, CAMPBELL SYST REV, DOI [DOI 10.4073/CSR.2009.623, https://doi.org/10.4073/csr.2009.6, DOI 10.4073/CSR.2009.6]; Fox CL, 2005, BRIT J EDUC PSYCHOL, V75, P313, DOI 10.1348/000709905X25517; Fredrick SS, 2023, J AUTISM DEV DISORD, V53, P3092, DOI 10.1007/s10803-022-05612-0; Gates JA, 2017, CLIN PSYCHOL REV, V52, P164, DOI 10.1016/j.cpr.2017.01.006; Gau SSF, 2013, RES AUTISM SPECT DIS, V7, P349, DOI 10.1016/j.rasd.2012.10.004; Gau SSF, 2011, RES AUTISM SPECT DIS, V5, P809, DOI 10.1016/j.rasd.2010.09.010; Gilmore R, 2022, RES DEV DISABIL, V125, DOI 10.1016/j.ridd.2022.104218; Goldbaum S., 2007, Bullying, victimization, and peer harassment: A handbook of prevention and intervention, P143; Gresham F.M., 1984, SCHOOL PSYCHOL REV, V13, P292; GRESHAM FM, 1981, REV EDUC RES, V51, P139, DOI 10.3102/00346543051001139; Herbrecht E, 2009, EUR CHILD ADOLES PSY, V18, P327, DOI 10.1007/s00787-008-0734-4; Hodges EVE, 1999, DEV PSYCHOL, V35, P94, DOI 10.1037/0012-1649.33.6.1032; Holden R, 2020, AUTISM RES, V13, P988, DOI 10.1002/aur.2292; Hong JK, 2019, J AUTISM DEV DISORD, V49, P1626, DOI 10.1007/s10803-018-3859-4; Hossain M, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112922; Hsiao MN, 2022, J FORMOS MED ASSOC, V121, P1739, DOI 10.1016/j.jfma.2021.12.030; Hymel S, 2015, AM PSYCHOL, V70, P293, DOI 10.1037/a0038928; Idris S, 2022, BMC PSYCHIATRY, V22, DOI 10.1186/s12888-022-03913-3; Idris SB, 2020, RES AUTISM SPECT DIS, V78, DOI 10.1016/j.rasd.2020.101629; Jetelina KK, 2019, J ADOLESCENT HEALTH, V64, P664, DOI 10.1016/j.jadohealth.2018.10.295; Jonsson U, 2019, EUR CHILD ADOLES PSY, V28, P189, DOI 10.1007/s00787-018-1161-9; Jureviciene M., 2012, SOCIALINAI MOKSLAI, V86, P42, DOI [10.33607/bjshs, DOI 10.33607/BJSHS]; Ke FF, 2018, REV EDUC RES, V88, P3, DOI 10.3102/0034654317740334; Kim Y., 2001, Development of KoreanPeer Nomination Inventory (KPNI): An inventory to evaluate school bullying, V40, P867; Koiv K, 2012, PROCD SOC BEHV, V45, P239, DOI 10.1016/j.sbspro.2012.06.560; Lai MC, 2020, LANCET NEUROL, V19, P434, DOI 10.1016/S1474-4422(20)30034-X; Lai MC, 2019, LANCET PSYCHIAT, V6, P819, DOI 10.1016/S2215-0366(19)30289-5; Larke ID, 2006, ISS EDUC RES, V16, P38; Laugeson EA, 2011, SOCIAL SKILLS FOR TEENAGERS WITH DEVELOPMENTAL AND AUTISM SPECTRUM DISORDERS, P1; Laugeson EA, 2014, J AUTISM DEV DISORD, V44, P2244, DOI 10.1007/s10803-014-2108-8; Laugeson EA, 2012, J AUTISM DEV DISORD, V42, P1025, DOI 10.1007/s10803-011-1339-1; Laugeson EA, 2009, J AUTISM DEV DISORD, V39, P596, DOI 10.1007/s10803-008-0664-5; Le L. K.D., 2021, Mental Health Prevention, V24; Lin YJ, 2023, J AUTISM DEV DISORD, V53, P2555, DOI 10.1007/s10803-022-05445-x; Lopata C., 2013, CBT for children and adolescents with high-functioning autism spectrum disorders, P199; LORD C, 1989, J AUTISM DEV DISORD, V19, P185, DOI 10.1007/BF02211841; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 2022, LANCET, V399, P271, DOI 10.1016/S0140-6736(21)01541-5; Maenner MJ, 2021, MMWR SURVEILL SUMM, V70, DOI [10.15585/mmwr.ss7011a1, 10.15585/mmwr.ss7010a1]; Mandelberg J, 2014, J MENT HEALTH RES IN, V7, P45, DOI 10.1080/19315864.2012.730600; Matson J.L., 2017, Handbook of Social Behavior and Skills in children; Matthias C, 2021, J AUTISM DEV DISORD, V51, P4632, DOI 10.1007/s10803-021-04907-y; McCauley JB, 2020, AUTISM RES, V13, P1548, DOI 10.1002/aur.2359; McDaid D, 2019, ANNU REV PUBL HEALTH, V40, P373, DOI 10.1146/annurev-publhealth-040617-013629; Miller A, 2014, REV J AUTISM DEV DIS, V1, P254, DOI 10.1007/s40489-014-0017-6; Moody CT, 2020, CHILD ADOL PSYCH CL, V29, P359, DOI 10.1016/j.chc.2019.11.001; Nangle D. W., 2020, Social skills across the life span: Theory, assessment, and intervention; Nangle DW, 2010, ABCT CLIN ASSESS SER, P1, DOI 10.1007/978-1-4419-0609-0; Olweus D., 1993, MENTAL DISORDER CRIM, P317; Olweus D, 2013, ANNU REV CLIN PSYCHO, V9, P751, DOI 10.1146/annurev-clinpsy-050212-185516; Papamichalaki E., 2021, Developmental and Adolescent Health, V1, P7, DOI [10.54088/id4eyg, DOI 10.54088/ID4EYG]; Park I, 2020, YONSEI MED J, V61, P909, DOI 10.3349/ymj.2020.61.11.909; Ratto AB, 2015, SCI CHINA LIFE SCI, V58, P1010, DOI 10.1007/s11427-012-4295-x; Reichow B, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008511.pub2; Saarento S, 2015, J COMMUNITY APPL SOC, V25, P204, DOI 10.1002/casp.2207; Schohl KA, 2014, J AUTISM DEV DISORD, V44, P532, DOI 10.1007/s10803-013-1900-1; Schwartz D, 2000, DEV PSYCHOL, V36, P646, DOI [10.1037/0012-1649.36.5.646, 10.1037//0012-1649.36.5.646]; Segrin C, 2000, HUM COMMUN RES, V26, P489, DOI 10.1093/hcr/26.3.489; Segrin C, 2019, HEALTH COMMUN, V34, P118, DOI 10.1080/10410236.2017.1384434; Shum KKM, 2019, J AUTISM DEV DISORD, V49, P527, DOI 10.1007/s10803-018-3728-1; Sittanomai Napat, 2021, Siriraj Medical Journal, V73, P471, DOI 10.33192/Smj.2021.61; Smith P., 2016, School bullying in different cultures: Eastern and western perspectives; Sterzing PR, 2012, ARCH PEDIAT ADOL MED, V166, P1058, DOI 10.1001/archpediatrics.2012.790; Swearer S.M., 2001, Journal of Emotional Abuse, V2, P7, DOI DOI 10.1300/J135V02N02_02; Swearer SM, 2004, BULLYING IN AMERICAN SCHOOLS: A SOCIAL-ECOLOGICAL PERSPECTIVE ON PREVENTION AND INTERVENTION, P1; Swearer SM, 2015, AM PSYCHOL, V70, P344, DOI 10.1037/a0038929; Thomeer ML, 2019, J CLIN CHILD ADOLESC, V48, pS119, DOI 10.1080/15374416.2016.1247359; Tung YH, 2021, AM J PSYCHIAT, V178, P730, DOI 10.1176/appi.ajp.2020.20070999; van Roekel E, 2010, J AUTISM DEV DISORD, V40, P63, DOI 10.1007/s10803-009-0832-2; Veytsman E, 2023, J AUTISM DEV DISORD, V53, P1175, DOI 10.1007/s10803-022-05463-9; Volkmar F. R., 2021, Handbook of autism spectrum disorder and the law, P199; Vuattoux D, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.629761; Wilson T.D., 2002, STRANGERS OURSELVES; Wolstencroft J, 2018, J AUTISM DEV DISORD, V48, P2293, DOI 10.1007/s10803-018-3485-1; Wong C, 2015, J AUTISM DEV DISORD, V45, P1951, DOI 10.1007/s10803-014-2351-z; World Health Organization, 2019, INT STAT CLASS DIS R; Yamada T, 2020, J AUTISM DEV DISORD, V50, P976, DOI 10.1007/s10803-019-04325-1; Yao ZJ, 2021, INT J PSYCHOL RES, V14, P66, DOI 10.21500/20112084.4793; Yen CF, 2012, KAOHSIUNG J MED SCI, V28, P500, DOI 10.1016/j.kjms.2012.04.008; Yoo HJ, 2014, AUTISM RES, V7, P145, DOI 10.1002/aur.1354; Zeidan J, 2022, AUTISM RES, V15, P778, DOI 10.1002/aur.2696; Zheng ST, 2021, J AUTISM DEV DISORD, V51, P4488, DOI 10.1007/s10803-021-04885-1";101;0;0;4;4;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1939-3792;1939-3806;;AUTISM RES;Autism Res.;AUG;2024;17;8;;;;;1705;1720;;10.1002/aur.3213;http://dx.doi.org/10.1002/aur.3213;;;16;"Behavioral Sciences; Psychology, Developmental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology";D6V6W;39169699;;;;24/11/2024;WOS:001297546300006;View Full Record in Web of Science
J;"Ghaly, AS; Tobar, SMS; El-Hadidy, MA; Elwasify, M";;;;"Ghaly, Ahmed Sami; Tobar, Salwa Mohamed Salah; El-Hadidy, Mohamed Adel; Elwasify, Mahmoud";;;Prescribed psychiatric interventions for children presented to a university psychiatric clinic in Egypt: a descriptive cross-sectional study;MIDDLE EAST CURRENT PSYCHIATRY-MECPSYCH;;;English;Article;;;;;;"Intervention pattern; Psychotropic drug prescriptions; Mental health; Children";;"Background The number of children diagnosed with psychiatric disorders has significantly increased over the past two decades. This study examined the pattern of psychiatric interventions prescribed for a sample of children with mental health problems in Egypt. A descriptive cross-sectional study was conducted to examine the pattern of psychotropic drug prescribing and intervention (medication, doses, duration, side effects, and improvement) in children aged 2-12 years old in primary and secondary health settings, presented to Mansoura University Hospitals in Egypt over 1 year. The identified patterns were compared with the Maudsley guidelines to detect any significant deviations. Results Among the 272 cases presented to the clinic, attention-deficit hyperactivity disorder (ADHD) and disruptive behavior disorders were the most prevalent diagnoses (85.3%) followed by intellectual disability (7.8%) and autism spectrum disorder (ASD; 5.1%). Antipsychotic drugs and ADHD medications (atomoxetine and methylphenidate) represented the most commonly prescribed medications (56.6% and 44.5% respectively), whereas behavioral therapy was among the least chosen (8.5%) treatment options. About 1/3 of the sample received multiple psychotropic medications. The prescribed intervention strategies did not match the Maudsley's guidelines in 76% of the cases with the absence of psychotherapeutic interventions being the most frequently observed factor (95.7%). Although still inadequate, psychiatrists' intervention strategies were more likely to follow the Maudsley's guidelines (38.3%), whereas pediatricians and neurologists were almost oblivious to them. Conclusions Current pattern of psychiatric interventions prescribed for a sample of children with mental health problems in Egypt are not in accordance with standard guidelines, such as Maudsley's, rendering it imperative to provide relevant educational programs for health care providers.";"[Ghaly, Ahmed Sami; Tobar, Salwa Mohamed Salah; El-Hadidy, Mohamed Adel; Elwasify, Mahmoud] Mansoura Univ, Fac Med, Elmahalla Elkobra, El Gharbia Gove, Egypt";"Egyptian Knowledge Bank (EKB); Mansoura University";Ghaly, AS (corresponding author), Mansoura Univ, Fac Med, Elmahalla Elkobra, El Gharbia Gove, Egypt.;Ahmed.yomo@gmail.com;"Elwasify, Mahmoud/AAN-5686-2020; El-Hadidy, Mohamed/C-7021-2014";;;;;"[Anonymous], 2015, COGNITIVE BEHAV THER; Bauermeister JJ, 2007, J CHILD PSYCHOL PSYC, V48, P831, DOI 10.1111/j.1469-7610.2007.01750.x; Bazzano ATF, 2009, ACAD PEDIATR, V9, P81, DOI 10.1016/j.acap.2008.11.010; Comer JS, 2010, J AM ACAD CHILD PSY, V49, P1001, DOI 10.1016/j.jaac.2010.07.007; Derks EM, 2007, TWIN RES HUM GENET, V10, P765, DOI 10.1375/twin.10.5.765; Efron D, 2003, PEDIATRICS, V111, P372, DOI 10.1542/peds.111.2.372; Frank RG, 2005, MILBANK Q, V83, P271, DOI 10.1111/j.1468-0009.2005.00347.x; Ghanem M, 2000, The translation group of the Arabic version of the Mini International Neuropsychiatric Interview for Children (MINI-kid); Jensen PS, 2007, EUR CHILD ADOLES PSY, V16, P104, DOI 10.1007/s00787-006-0580-1; Kukreja Sanjay, 2013, Mens Sana Monogr, V11, P82, DOI 10.4103/0973-1229.104497; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Mojtabai R, 2010, ARCH GEN PSYCHIAT, V67, P26, DOI 10.1001/archgenpsychiatry.2009.175; Nardi Deena A, 2005, J Psychosoc Nurs Ment Health Serv, V43, P22; Olashore A, 2017, PAN AFR MED J, V26; Pastor P.N., 2008, VITAL HLTH STAT, V10; Patel NC, 2004, ANTIPSYCHOTIC USE CH; Rey JM, 2015, CHILD ADOL PSYCH MEN, V9, DOI 10.1186/s13034-015-0084-1; Russell Paul S S, 2006, Clin Pract Epidemiol Ment Health, V2, P25, DOI 10.1186/1745-0179-2-25; SALDANA SN, 2014, J HUMAN PHARM DRUG T, V34, P836, DOI DOI 10.1002/PHAR.1453; Taylor D., 2015, MAUDSLEY PRESCRIBING, V12th; Woods G., 2016, Irish Journal of Psychological Medicine, V33, P13, DOI 10.1017/ipm.2015.12; Zuvekas SH, 2012, AM J PSYCHIAT, V169, P160, DOI 10.1176/appi.ajp.2011.11030387";22;1;1;0;0;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;;2090-5416;;MIDDLE EAST CURR PSY;Middle East Curr. Psychiatry-MECPsych;nov-20;2020;27;1;;;;;;;53;10.1186/s43045-020-00056-7;http://dx.doi.org/10.1186/s43045-020-00056-7;;;6;Psychiatry;Emerging Sources Citation Index (ESCI);Psychiatry;VL3WO;;gold;;;24/11/2024;WOS:000840613400001;View Full Record in Web of Science
J;"Yalcin, O; Kaymak, G; Erdogan, A; Tanidir, C; Karacetin, G; Kilicoglu, AG; Mutlu, C; Adaletli, H; Gunes, H; Bahali, K; Ayik, B; Uneri, OS";;;;"Yalcin, Ozhan; Kaymak, Gizem; Erdogan, Ayten; Tanidir, Canan; Karacetin, Gul; Kilicoglu, Ali Guven; Mutlu, Caner; Adaletli, Hilal; Gunes, Hatice; Bahali, Kayhan; Ayik, Basak; Uneri, Ozden Sukran";;;A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"clozapine; schizophrenia; early onset schizophrenia; very early onset schizophrenia; autism; autism spectrum disorders";"CHILDHOOD-ONSET SCHIZOPHRENIA; PSYCHIATRIC RATING-SCALE; HIGH-DOSE OLANZAPINE; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; TREATED CHILDREN; OPEN TRIAL; ANTIPSYCHOTICS; AGGRESSION; PANSS";Objective: The aim of this retrospective study is to examine the clinical outcomes and safety of clozapine in children and adolescents with schizophrenia or other psychotic disorders/autism spectrum disorder (ASD) or affective disorders. Methods: The inpatient and outpatient files of all children and adolescents treated with clozapine over a period of 34 months (from October 2011 to July 2014) were reviewed. Demographic and clinical data were examined to describe clinical and metabolic findings, dosing, and tolerability of clozapine treatment in youth with schizophrenia, other psychotic disorders, ASD, or bipolar disorder. Results: The 37 pediatric patients included 26 patients with schizophrenia or other psychotic disorders, 7 patients with ASD complicated by schizophrenia or other psychotic disorders or affective disorders, and 4 patients with ASD only. In all groups (n = 37) there was a significant reduction (p < 0.001) in Brief Psychiatric Rating Scale (BPRS) points after clozapine treatment during the inpatient period (38.78 +/- 27.75 days). In patients with schizophrenia or other psychotic disorders co-occurring with ASD or not (n = 31), there was a significant improvement in psychotic symptoms according to Positive and Negative Syndrome Scale (PANSS) total scores and subscores (p < 0.001). Of the 26 patients with schizophrenia or other psychotic disorders, 8 (30.8%) showed a positive response (>30% symptom reduction on BPRS). In patients with ASD complicated by schizophrenia or other psychotic disorders or bipolar disorders (n = 7), there was a significant reduction (p = 0.017) in BPRS scores after clozapine treatment. The discontinuation rate for clozapine was 10.8%, and the most frequently observed side effect was hypersalivation (54.1%). Neutropenia associated with clozapine was observed in only one patient (2.7%). Conclusions: Clozapine seems to be effective and safe in children and adolescents with schizophrenia or other psychotic disorders co-occuring with ASD or not. There is a need for further studies for determining the efficacy of clozapine in children and adolescents with bipolar affective disorder or ASD.;"[Yalcin, Ozhan; Kaymak, Gizem; Tanidir, Canan; Karacetin, Gul; Kilicoglu, Ali Guven; Mutlu, Caner; Adaletli, Hilal; Gunes, Hatice; Bahali, Kayhan; Ayik, Basak] Bakirkoy Psychiat Neurol Neurosurg Trainee & Res, Child & Adolescent Psychiat Clin, Child & Adolescent Psychiat, Istanbul, Turkey; [Erdogan, Ayten] Duzce Univ, Fac Med, Child & Adolescent Psychiat Clin, Child & Adolescent Psychiat, Duzce, Turkey; [Uneri, Ozden Sukran] Ankara Diskapi Trainee & Res Hosp Children, Child & Adolescent Psychiat, Ankara, Turkey";"Istanbul Bakirkoy Mental Health & Neurology Training & Research Hospital; Duzce University; Ankara Children's Hematology Oncology Training & Research Hospital";Yalcin, O (corresponding author), Bakirkoy Psychiat Neurol Neurosurg Trainee & Res, Child & Adolescent Psychiat Clin, Istanbul, Turkey.;cpozhan@gmail.com;"Yalç?n, Özhan/N-5519-2018; Karacetin, Gul/B-8010-2014; durcan, gizem/AAC-2483-2020; Mutlu, Caner/AFS-8432-2022";;;;;"[Anonymous], THESIS; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Beherec L, 2011, J CLIN PSYCHOPHARM, V31, P341, DOI 10.1097/JCP.0b013e318218f4a1; Chalasani L, 2001, CAN J PSYCHIAT, V46, P965, DOI 10.1177/070674370104601010; Chen NC, 2001, J CLIN PSYCHIAT, V62, P479, DOI 10.4088/JCP.v62n0612h; Cianchetti C, 2011, PSYCHIAT RES, V189, P349, DOI 10.1016/j.psychres.2011.03.020; Cirulli G, 2005, PSYCHIATR BULL, V29, P377, DOI 10.1192/pb.29.10.377; FRAZIER JA, 1994, J AM ACAD CHILD PSY, V33, P658, DOI 10.1097/00004583-199406000-00006; Frogley C, 2012, INT J NEUROPSYCHOPH, V15, P1351, DOI 10.1017/S146114571100201X; Gerbino-Rosen G, 2005, J AM ACAD CHILD PSY, V44, P1024, DOI 10.1097/01.chi.0000171904.23947.54; Gobbi G, 2001, J PSYCHIATR NEUROSCI, V26, P340; Gogtay N, 2008, EXPERT OPIN PHARMACO, V9, P459, DOI [10.1517/14656566.9.3.459, 10.1517/14656566.9.3.459 ]; HUMMER M, 1994, J CLIN PSYCHIAT, V55, P429; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kaya S, 2006, INT J APPL EARTH OBS, V8, P18, DOI 10.1016/j.jag.2005.05.002; Kim Y, 2008, HUM PSYCHOPHARM CLIN, V23, P715, DOI 10.1002/hup.982; Kostakoglu E, 1999, TURK PSIKOL DERG, V14, P23; Kowatch RA, 1995, J CHILD ADOL PSYCHOP, V5, P241, DOI 10.1089/cap.1995.5.241; Kranzler HN, 2013, CHILD ADOL PSYCH CL, V22, P727, DOI 10.1016/j.chc.2013.06.002; Kranzler HN, 2006, CHILD ADOL PSYCH CL, V15, P135, DOI 10.1016/j.chc.2005.08.008; Kumra S, 1996, ARCH GEN PSYCHIAT, V53, P1090; Kumra S, 2008, J CHILD ADOL PSYCHOP, V18, P307, DOI 10.1089/cap.2007.0089; Kumra S, 2008, BIOL PSYCHIAT, V63, P524, DOI 10.1016/j.biopsych.2007.04.043; Lai MC, 2014, LANCET, V383, P896, DOI 10.1016/S0140-6736(13)61539-1; Lambrey S, 2010, J CHILD ADOL PSYCHOP, V20, P79, DOI 10.1089/cap.2009.0057; Leucht S, 2005, SCHIZOPHR RES, V79, P231, DOI 10.1016/j.schres.2005.04.008; Leucht S, 2005, BRIT J PSYCHIAT, V187, P366, DOI 10.1192/bjp.187.4.366; Maher KN, 2013, J CHILD ADOL PSYCHOP, V23, P110, DOI 10.1089/cap.2011.0136; Masi G, 2002, J CHILD ADOL PSYCHOP, V12, P93, DOI 10.1089/104454602760219135; McCellan J, 2013, J AM ACAD CHILD ADOL, V52, P976; Midbari Y, 2013, J CHILD ADOL PSYCHOP, V23, P516, DOI 10.1089/cap.2013.0050; MOZES T, 1994, J AM ACAD CHILD PSY, V33, P65, DOI 10.1097/00004583-199401000-00010; Mukhopadhaya K, 2009, J PSYCHOPHARMACOL, V23, P6, DOI 10.1177/0269881108089582; Noguera A, 2013, J CLIN PSYCHOPHARM, V33, P463, DOI 10.1097/JCP.0b013e3182962480; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Remschmidt H, 2000, Paediatr Drugs, V2, P253, DOI 10.2165/00128072-200002040-00002; Sarkar S, 2013, INDIAN J PHARMACOL, V45, P439, DOI 10.4103/0253-7613.117720; Schneider C, 2014, EUR PSYCHIAT, V29, P1, DOI 10.1016/j.eurpsy.2013.08.001; Shaw P, 2006, ARCH GEN PSYCHIAT, V63, P721, DOI 10.1001/archpsyc.63.7.721; Sikich L, 2008, AM J PSYCHIAT, V165, P1420, DOI 10.1176/appi.ajp.2008.08050756; Sporn AL, 2007, J AM ACAD CHILD PSY, V46, P1349, DOI 10.1097/chi.0b013e31812eed10; Stigler KA, 2008, CHILD ADOL PSYCH CL, V17, P739, DOI 10.1016/j.chc.2008.06.002; Teixeira EH, 2013, J CHILD ADOL PSYCHOP, V23, P44, DOI 10.1089/cap.2011.0148; Turetz M, 1997, BRIT J PSYCHIAT, V170, P507, DOI 10.1192/bjp.170.6.507; Zuddas A, 1996, AM J PSYCHIAT, V153, P738";45;15;15;0;6;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;NOV;2016;26;9;;;;;815;821;;10.1089/cap.2015.0020;http://dx.doi.org/10.1089/cap.2015.0020;;;7;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";EC4QM;26771824;;;;24/11/2024;WOS:000388118400007;View Full Record in Web of Science
J;"Yektas, Ç; Pasabeyoglu, B; Mutlu, C; Erdogan, A";;;;"Yektas, Cigdem; Pasabeyoglu, Basak; Mutlu, Caner; Erdogan, Ayten";;;The prescribing pattern of paliperidone in a pediatric population;PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"Paliperidone; adolescent; efficiacy; side effect; off-label use";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; OPEN-LABEL TRIAL; BIPOLAR DISORDER; ATYPICAL ANTIPSYCHOTICS; AUTISTIC DISORDER; EXTENDED-RELEASE; YOUNG-ADULTS; DOUBLE-BLIND; CHILDREN; ADOLESCENTS";"OBJECTIVES: Paliperidone is a relatively new atypical antipsychotic, offers a potential new treatment option for adolescents, with several advantages including single dosage per day and availability in hepatic problems. However, there is a lack of efficacy and safety data for the use of this medication in various psychiatric disorders among children and adolescents. In this study, we retrospectively investigated the use of paliperidone in various psychiatric disorders among a youth population. METHODS: The children and adolescents treated with paliperidone for any psychiatric problem at the outpatient and inpatient Child and Adolescent Psychiatry clinics of Duzce University Medical Faculty Hospital and Bakirkoy Mental Health Hospital were evaluated for the study. Data were collected retrospectively from the patient records. Patients' charts were reviewed to retrieve additional data on indications of the medications, adverse drug reactions (ADRs) and changes in the clinical condition. The clinical status of individual patients was assessed using the Clinical Global Index (CGI) score for severity and improvement. RESULTS: The mean age of patients was 15.8 +/- 1.3 years, and 59.6% (n = 31) of the group was male and 40.4% (n = 21) was female. Paliperidone was prescribed for median 150 days (quartiles 60 and 487 days). The median average daily dose was 7.6 mg/day (range 3-12 mg/day). The main indications for paliperidone prescription were psychotic disorders and bipolar disorders (BPDs) (17 patients, 32.6%; 16 patients, 30.7%, respectively). The other most common diagnostic group was disruptive behavior disorders (DBDs) associated with attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, intellectual disability, conduct disorders, or oppositional defiant disorders (15 patients; 28.8%) tic/neurological disorder (4 patients; 7.9%). Thirty-five patients (67.4%) did not have a diagnosis of schizophrenia and were considered to have received these drugs off-label. Dosing was notably lower in the group of DBDs patients than for patients with BPD or psychotic disorders. Of the 52 patients receiving paliperidone, 53.9% of patients were concurrently treated at some point with one or more than one of a psychostimulant/ADHD medication, an other antipsychotics, an antidepressant, a mood stabilizer, and any other class of psychotropic drug (such as a sleep medication). Totally, ADRs were recorded in 26 (50%) patients: weight gain (n = 24); extra pyramidal symptoms (n = 8); gastrointestinal system symptoms (n = 4); insomnia (n = 2); hyperprolactinemia (n = 4); sedation (n = 2); and skin affection (n = 1). CONCLUSIONS: In this study group, paliperidone has been commonly used for schizophrenia, but it has also been used for mood disorders, DBDs, and Tourette's disorder in children and adolescents. Results showed clinically meaningful improvements in symptom measurements of different disorders. The drug is generally well tolerated and the most frequent adverse events include rigidity, akathisia, sedation, and increased appetite. Future prospective studies with large samples are needed for definite conclusions.";"[Yektas, Cigdem] Duzce Univ, Dept Child & Adolescent Psychiat, Fac Med, Duzce, Turkey; [Pasabeyoglu, Basak] Uskudar Univ, Psychol Dept, Fac Humanities & Social Sci, Istanbul, Turkey; [Mutlu, Caner] Bakirkoy Training & Res Hosp Psychiat Neurol & Ne, Dept Child & Adolescent Psychiat, Istanbul, Turkey; [Erdogan, Ayten] Beykent Univ, Dept Psychol, Istanbul, Turkey";"Duzce University; Uskudar University; Istanbul Bakirkoy Mental Health & Neurology Training & Research Hospital; Beykent University";Yektas, Ç (corresponding author), Duzce Univ, Dept Child & Adolescent Psychiat, Fac Med, Duzce, Turkey.;drcigdemyektas@hotmail.com;"Mutlu, Caner/AFS-8432-2022; Yekta?, Çi?dem/AAG-4426-2020";yektas, cigdem/0000-0002-5951-7253;;;;"Alexander GC, 2011, PHARMACOEPIDEM DR S, V20, P177, DOI 10.1002/pds.2082; [Anonymous], 2007, J AM ACAD CHILD ADOL, V46, P107; Armenteros JL, 2007, J AM ACAD CHILD PSY, V46, P558, DOI 10.1097/chi.0b013e3180323354; Barzman DH, 2004, J CHILD ADOL PSYCHOP, V14, P593, DOI 10.1089/cap.2004.14.593; Bymaster FP, 2003, PROG NEURO-PSYCHOPH, V27, P1125, DOI 10.1016/j.pnpbp.2003.09.008; Citrome L, 2013, CLIN THER, V35, P1867, DOI 10.1016/j.clinthera.2013.09.006; Clarke WP, 2013, BRIT J PHARMACOL, V170, P532, DOI 10.1111/bph.12295; Cooper WO, 2006, AMBUL PEDIATR, V6, P79, DOI 10.1016/j.ambp.2005.11.002; Dilbaz N, 2009, B CLIN PSYCHOPHARMAC, V19, P316; Filho AGC, 2005, J AM ACAD CHILD PSY, V44, P748, DOI 10.1097/01.chi.0000166986.30592.67; Findling RL, 2005, J CLIN PSYCHIAT, V66, P29; Findling RL, 2012, J CHILD ADOL PSYCHOP, V22, P327, DOI 10.1089/cap.2011.0092; Greenberg WM, 2015, NEUROL THER, V4, P81, DOI 10.1007/s40120-015-0030-4; Joshi G, 2013, PSYCHOPHARMACOLOGY, V227, P449, DOI 10.1007/s00213-013-2970-7; Joshi G, 2012, J AFFECT DISORDERS, V136, P1143, DOI 10.1016/j.jad.2011.09.042; Kantrowitz J, 2007, CORE EVID, V2, P261; Knapp P, 2012, PEDIATRICS, V129, pE1562, DOI 10.1542/peds.2010-1360; Kutcher S, 2004, EUR NEUROPSYCHOPHARM, V14, P11, DOI 10.1016/S0924-977X(03)00045-2; Leslie DL, 2012, AM J MANAG CARE, V18, pE109; Maglione M, 2011, AHRQ COMP EFFECTIVEN, P43; Marino J, 2012, NEUROPSYCH DIS TREAT, V8, P181, DOI 10.2147/NDT.S20675; Fernández-Mayoralas DM, 2012, CLIN NEUROPHARMACOL, V35, P227, DOI 10.1097/WNF.0b013e31826818cd; Menard ML, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-011020; Oh J, 2013, CLIN PSYCHOPHARM NEU, V11, P72, DOI 10.9758/cpn.2013.11.2.72; Olfson M, 2014, JAMA PSYCHIAT, V71, P81, DOI 10.1001/jamapsychiatry.2013.3074; Pathak P, 2010, PSYCHIAT SERV, V61, P123, DOI 10.1176/ps.2010.61.2.123; Perlis RH, 2006, J CLIN PSYCHIAT, V67, P509, DOI 10.4088/JCP.v67n0401; Rettew DC, 2015, PEDIATRICS, V135, P658, DOI 10.1542/peds.2014-2260; Rosato NS, 2012, PEDIATRICS, V129, pE1577, DOI 10.1542/peds.2010-1361; Savitz AJ, 2015, J AM ACAD CHILD PSY, V54, P126, DOI 10.1016/j.jaac.2014.11.009; Seida JC, 2012, PEDIATRICS, V129, pE771, DOI 10.1542/peds.2011-2158; Smarty S, 2007, PSYCHOPHARMACOLOGY, V191, P39, DOI 10.1007/s00213-006-0569-y; Sohn M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003784; Stigler KA, 2012, PSYCHOPHARMACOLOGY, V223, P237, DOI 10.1007/s00213-012-2711-3; Stigler KA, 2010, J CHILD ADOL PSYCHOP, V20, P75, DOI 10.1089/cap.2009.0019; Tramontina S, 2009, J CLIN PSYCHIAT, V70, P756, DOI 10.4088/JCP.08m04726; Weiss M, 2009, J CHILD ADOL PSYCHOP, V19, P575, DOI 10.1089/cap.2009.0050";37;2;2;1;5;TAYLOR & FRANCIS LTD;ABINGDON;2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND;2475-0573;2475-0581;;PSYCHIAT CLIN PSYCH;Psychiatry Clin. Psychopharmacol.;;2018;28;2;;;;;156;162;;10.1080/24750573.2017.1387404;http://dx.doi.org/10.1080/24750573.2017.1387404;;;7;"Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pharmacology & Pharmacy; Psychiatry";GA3BH;;gold, Green Published;;;24/11/2024;WOS:000428201800007;View Full Record in Web of Science
J;"Mezzacappa, A; Lasica, PA; Gianfagna, F; Cazas, O; Hardy, P; Falissard, B; Sutter-Dallay, AL; Gressier, F";;;;"Mezzacappa, Antonia; Lasica, Pierre-Alexandre; Gianfagna, Francesco; Cazas, Odile; Hardy, Patrick; Falissard, Bruno; Sutter-Dallay, Anne-Laure; Gressier, Florence";;;Risk for Autism Spectrum Disorders According to Period of Prenatal Antidepressant Exposure A Systematic Review and Meta-analysis;JAMA PEDIATRICS;;;English;Article;;;;;;;"SEROTONIN REUPTAKE INHIBITORS; DEFICIT HYPERACTIVITY DISORDER; POSTPARTUM DEPRESSION; YOUNG-CHILDREN; PREGNANCY; PSYCHOPATHOLOGY; SYMPTOMS; OUTCOMES; MOTHERS; ANXIETY";"IMPORTANCE Several studies have examined the links between prenatal exposure to antidepressants and autism spectrum disorders (ASDs) in children, with inconsistent results, especially regarding the impact of the trimester of exposure. OBJECTIVE To perform a systematic review of the literature and ameta-analysis of published studies to assess the association between ASDs and fetal exposure to antidepressants during pregnancy for each trimester of pregnancy and preconception. DATA SOURCES PubMed, EMBASE, and PsycINFO databases up to May 2016 were searched in June 2016 for observational studies. For the meta-analyses, data were analyzed on RevMan version 5.2 using a random-effect model. For the review, studies were included if they had been published and were cohort or case-control studies, and for the meta-analysis, studies were included if they were published studies and the data were not derived from the same cohorts. STUDY SELECTION We included all the studies that examined the association between ASDs and antenatal exposure to antidepressants. DATA EXTRACTION AND SYNTHESIS Three reviewers independently screened titles and abstracts, read full-text articles, and extracted data. The quality of the studies was also assessed. MAIN OUTCOMES AND MEASURES Primary outcome was the association between antidepressants during pregnancy and ASDs. Secondary outcomes were the associations between antidepressants in each individual trimester or before pregnancy and ASDs. RESULTS Our literature search identified 10 relevant studies with inconsistent results. For prenatal exposure, the meta-analysis on the 6 case-control studies (117 737 patients) evidenced a positive association between antidepressant exposure and ASDs (odds ratio [OR], 1.81; 95% CI, 1.49-2.20). The association was weaker when controlled for past maternal mental illness (OR, 1.52; 95% CI, 1.09-2.12). A similar pattern was found whatever the trimester of exposure considered (first trimester: OR, 2.09, 95% CI, 1.66-2.64; second: OR, 2.00, 95% CI, 1.55-2.59; and third: OR, 1.90, 95% CI, 1.20-3.02. Controlled for past maternal mental illness: first trimester: OR, 1.79; 95% CI, 1.27-2.52, second: OR, 1.67, 95% CI, 1.14-2.45; and third: OR, 1.54, 95% CI, 0.82-2.90). No association was found when the 2 cohort studies were pooled (772 331 patients) for the whole pregnancy (hazard ratio, 1.26; 95% CI, 0.91-1.74) or for the first trimester. In addition, preconception exposure to antidepressants was significantly associated with an increased risk for ASDs (OR controlled for past maternal illness, 1.77; 95% CI, 1.49-2.09). CONCLUSIONS AND RELEVANCE There is a significant association between increased ASD risk and maternal use of antidepressants during pregnancy; however, it appears to be more consistent during the preconception period than during each trimester. Maternal psychiatric disorders in treatment before pregnancy rather than antenatal exposure to antidepressants could have a major role in the risk for ASDs. Future studies should address the problem of this potential confounder.";"[Mezzacappa, Antonia; Lasica, Pierre-Alexandre; Cazas, Odile; Hardy, Patrick; Gressier, Florence] Bicetre Univ Hosp, AP HP, Dept Psychiat, Le Kremlin Bicetre, France; [Gianfagna, Francesco] Univ Insubria, Dept Clin & Expt Med, EPIMED Res Ctr Epidemiol & Prevent Med, Varese, Italy; [Gianfagna, Francesco] IRCCS, Ist Neurol Mediterraneo Neuromed, Dept Epidemiol & Prevent, Pozzilli, Italy; [Hardy, Patrick; Gressier, Florence] Univ Paris Saclay, Univ Paris Sud, UVSQ, CESP,INSERM,U1178,Bicetre Univ Hosp, Le Kremlin Bicetre, France; [Falissard, Bruno] Univ Paris Saclay, Univ Paris Sud, UVSQ, CESP,INSERM U1178,Dept Biostat, Paris, France; [Sutter-Dallay, Anne-Laure] Bordeaux Univ, Bordeaux Populat Hlth, Univ Dept Adult Psychiat, Res Ctr,INSERM 1219,Charles Perrens Hosp, Bordeaux, France";"Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; University of Insubria; IRCCS Neuromed; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm)";Gressier, F (corresponding author), Univ Paris Sud, Dept Psychiat, Bicetre Univ Hosp, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.;florence.gressier@aphp.fr;"Rouquette, Alexandra/AGY-2116-2022; , sutter-dallay/S-9232-2019; Gianfagna, Francesco/K-4561-2016";Gianfagna, Francesco/0000-0003-4615-0816;;;;"Andrade C, 2013, J CLIN PSYCHIAT, V74, P940, DOI 10.4088/JCP.13ac08607; Andrade SE, 2016, ARCH WOMEN MENT HLTH, V19, P969, DOI 10.1007/s00737-016-0637-1; [Anonymous], 2000, Am J Psychiatry, V157, P1; Biederman J, 2001, AM J PSYCHIAT, V158, P49, DOI 10.1176/appi.ajp.158.1.49; Boukhris T, 2016, JAMA PEDIATR, V170, P117, DOI 10.1001/jamapediatrics.2015.3356; Castro VM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.190; Clements CC, 2015, MOL PSYCHIATR, V20, P727, DOI 10.1038/mp.2014.90; Croen LA, 2011, ARCH GEN PSYCHIAT, V68, P1104, DOI 10.1001/archgenpsychiatry.2011.73; Daniels JL, 2008, PEDIATRICS, V121, pE1357, DOI 10.1542/peds.2007-2296; Doherty JL, 2014, GENOME MED, V6, DOI 10.1186/gm546; Dubber S, 2015, ARCH WOMEN MENT HLTH, V18, P187, DOI 10.1007/s00737-014-0445-4; El Marroun H, 2014, EUR CHILD ADOLES PSY, V23, P973, DOI 10.1007/s00787-014-0558-3; El Marroun H, 2014, BRIT J PSYCHIAT, V205, P95, DOI 10.1192/bjp.bp.113.127746; Eriksson MA, 2012, RES DEV DISABIL, V33, P1642, DOI 10.1016/j.ridd.2012.03.025; Feldman R, 2009, J AM ACAD CHILD PSY, V48, P919, DOI 10.1097/CHI.0b013e3181b21651; Fihrer I, 2009, J AFFECT DISORDERS, V119, P116, DOI 10.1016/j.jad.2009.03.001; Gentile S, 2017, NEUROSCIENCE, V342, P154, DOI 10.1016/j.neuroscience.2015.09.001; Gentile S, 2015, J AFFECT DISORDERS, V182, P132, DOI 10.1016/j.jad.2015.04.048; Gidaya NB, 2014, J AUTISM DEV DISORD, V44, P2558, DOI 10.1007/s10803-014-2128-4; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Hadjikhani N, 2010, MED HYPOTHESES, V74, P880, DOI 10.1016/j.mehy.2009.11.015; Harrington RA, 2014, PEDIATRICS, V133, pE1241, DOI 10.1542/peds.2013-3406; Huybrechts KF, 2015, JAMA-J AM MED ASSOC, V313, P2142, DOI 10.1001/jama.2015.5605; Hviid A, 2013, NEW ENGL J MED, V369, P2406, DOI 10.1056/NEJMoa1301449; Jimenez-Solem E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063034; Jones I, 2014, BRIT J PSYCHIAT, V205, P103, DOI 10.1192/bjp.bp.113.141713; Kaplan YC, 2016, REPROD TOXICOL, V66, P31, DOI 10.1016/j.reprotox.2016.09.013; Kepser LJ, 2015, BEHAV BRAIN RES, V277, P3, DOI 10.1016/j.bbr.2014.05.022; King BH, 2016, JAMA PEDIATR, V170, P111, DOI 10.1001/jamapediatrics.2015.3493; Kobayashi T, 2016, REPROD TOXICOL, V65, P170, DOI 10.1016/j.reprotox.2016.07.016; Larsson HJ, 2005, AM J EPIDEMIOL, V161, P916, DOI 10.1093/aje/kwi123; Leigh B, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-24; Malm H, 2012, THER DRUG MONIT, V34, P607, DOI 10.1097/FTD.0b013e31826d07ea; Man KKC, 2015, NEUROSCI BIOBEHAV R, V49, P82, DOI 10.1016/j.neubiorev.2014.11.020; Mandy W, 2016, J CHILD PSYCHOL PSYC, V57, P271, DOI 10.1111/jcpp.12501; McDonagh MS, 2014, OBSTET GYNECOL, V124, P526, DOI 10.1097/AOG.0000000000000410; McLearn KT, 2006, PEDIATRICS, V118, pE174, DOI 10.1542/peds.2005-1551; McNamara IM, 2008, BRAIN RES, V1189, P203, DOI 10.1016/j.brainres.2007.10.063; Melville JL, 2010, OBSTET GYNECOL, V116, P1064, DOI 10.1097/AOG.0b013e3181f60b0a; National Institute for Health and Care Excellence, 2009, DEPR AD REC MAN; O'Dowd Adrian, 2014, BMJ, V349, pg5315, DOI 10.1136/bmj.g5315; Park HR, 2016, EXP NEUROBIOL, V25, P1, DOI 10.5607/en.2016.25.1.1; Paulson JF, 2006, PEDIATRICS, V118, P659, DOI 10.1542/peds.2005-2948; Pedersen LH, 2015, PEDIATR DRUGS, V17, P443, DOI 10.1007/s40272-015-0141-5; Petersen I, 2011, J CLIN PSYCHIAT, V72, P979, DOI 10.4088/JCP.10m06090blu; Rai D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2059; Rais Theodor B, 2014, Innov Clin Neurosci, V11, P18; Robertson E, 2004, GEN HOSP PSYCHIAT, V26, P289, DOI 10.1016/j.genhosppsych.2004.02.006; Robinson GE, 2015, J NERV MENT DIS, V203, P159, DOI 10.1097/NMD.0000000000000256; Rosenberg K, 2016, AM J NURS, V116, P58, DOI 10.1097/01.NAJ.0000481284.31967.9b; Ruggeri B, 2014, PSYCHOPHARMACOLOGY, V231, P1201, DOI 10.1007/s00213-013-3290-7; Schaefer GB, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020180; Sorensen Merete Juul, 2013, Clin Epidemiol, V5, P449, DOI 10.2147/CLEP.S53009; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Wingate M, 2014, MMWR SURVEILL SUMM, V63; Yang CJ, 2014, NEUROSCIENCE, V267, P1, DOI 10.1016/j.neuroscience.2014.02.021; Yonkers KA, 2014, ANNU REV CLIN PSYCHO, V10, P369, DOI 10.1146/annurev-clinpsy-032813-153626; Yonkers KA, 2009, GEN HOSP PSYCHIAT, V31, P403, DOI [10.1016/j.genhosppsych.2009.04.003, 10.1097/AOG.0b013e3181ba0632]; Zimmerberg B, 2015, DEV PSYCHOBIOL, V57, P141, DOI 10.1002/dev.21264";59;76;91;2;17;AMER MEDICAL ASSOC;CHICAGO;330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA;2168-6203;2168-6211;;JAMA PEDIATR;JAMA Pediatr.;JUN;2017;171;6;;;;;555;563;;10.1001/jamapediatrics.2017.0124;http://dx.doi.org/10.1001/jamapediatrics.2017.0124;;;9;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;EW7SB;28418571;Bronze;;;24/11/2024;WOS:000402714300016;View Full Record in Web of Science
J;"Yuge, K; Nagamitsu, S; Ishikawa, Y; Hamada, I; Takahashi, H; Sugioka, H; Yotsuya, O; Mishima, K; Hayashi, M; Yamashita, Y";;;;"Yuge, Kotaro; Nagamitsu, Shinichiro; Ishikawa, Yuko; Hamada, Izumi; Takahashi, Hiroyuki; Sugioka, Hideyuki; Yotsuya, Osamu; Mishima, Kazuo; Hayashi, Masaharu; Yamashita, Yushiro";;;Long-term melatonin treatment for the sleep problems and aberrant behaviors of children with neurodevelopmental disorders;BMC PSYCHIATRY;;;English;Article;;;;;;"Melatonin; Neurodevelopmental disorders; Sleep onset latency; Children; Sleep problems; Aberrant behaviors; Long-term";"PROLONGED-RELEASE MELATONIN; AUTISM; EFFICACY; INSOMNIA; SUBSTANCES; INFANTS; SAFETY; RISK";"BackgroundClinical evidence is required about the long-term efficacy and safety of melatonin treatment for sleep problems in children with neurodevelopmental disorders (NDDs) who underwent adequate sleep hygiene interventions.MethodsWe conducted a 26-week, multicenter, collaborative, uncontrolled, open-label, phase III clinical trial of melatonin granules in children 6 to 15years of age who had NDDs and sleep problems. The study consisted of the 2-week screening phase, the 26-week medication phases I and II, and the 2-week follow-up phase. Children received 1, 2, or 4mg melatonin granules orally in the medication phases. Variables of sleep status including sleep onset latency (SOL), aberrant behaviors listed on the Aberrant Behavior Check List-Japanese version (ABC-J), and safety were examined. The primary endpoint was SOL in the medication phase I.ResultsBetween June 2016 and July 2018, 99 children (80 males and 19 females, 10.4years in mean age) were enrolled at 17 medical institutions in Japan-74, 60, 22, 9, 6, and 1 of whom had autism spectrum disorder, attention-deficit/hyperactivity disorder, intellectual disabilities, motor disorders, specific learning disorder, and communication disorders, respectively, at baseline. Fifteen children received the maximal dose of 4mg among the prespecified dose levels. SOL recorded with the electronic sleep diary shortened significantly (meanstandard deviation [SD], -36.746.1min; 95% confidence interval [CI], -45.9 to -27.5; P< 0.0001) in the medication phase I from baseline, and the SOL-shortening effect of melatonin persisted in the medication phase II and the follow-up phase. Temper upon wakening and sleepiness after awakening improved significantly (P< 0.0001 each) in the medication phase I from baseline and persisted in the follow-up phase. The following subscales of the ABC-J improved significantly: stereotypic behavior (P=0.0322) in the medication phase I; and irritability, hyperactivity, and inappropriate speech (P< 0.0001) in the medication phase II. Treatment-emergent adverse events did not occur subsequent to week 16 after medication onset, and NDDs did not deteriorate in the follow-up phase.Conclusions Long-term melatonin treatment in combination with adequate sleep hygiene interventions may afford clinical benefits to children with NDDs and potentially elevates their well-being.Trial registration ClinicalTrils.gov, NCT02757066. Registered April 27, 2016.";"[Yuge, Kotaro; Nagamitsu, Shinichiro; Yamashita, Yushiro] Kurume Univ, Dept Pediat & Child Hlth, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan; [Ishikawa, Yuko; Hamada, Izumi; Sugioka, Hideyuki; Yotsuya, Osamu] Nobelpharma Co Ltd, Tokyo, Japan; [Takahashi, Hiroyuki] CMIC Co Ltd, Tokyo, Japan; [Mishima, Kazuo] Akita Univ, Dept Neuropsychiat, Grad Sch Med, Akita, Japan; [Hayashi, Masaharu] Shukutoku Univ, Dept Nursing, Coll Nursing & Nutr, Chiba, Japan";"Kurume University; CMIC Holdings Co Ltd; Akita University";Yuge, K (corresponding author), Kurume Univ, Dept Pediat & Child Hlth, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.;yugekotaro@med.kurume-u.ac.jp;Yuge, Kotaro/ABE-6355-2021;"MISHIMA, KAZUO/0000-0003-1182-1181; Yuge, Kotaro/0000-0002-5801-7898";Nobelpharma Co., Ltd.;Nobelpharma Co., Ltd.;"This work was funded by Nobelpharma Co., Ltd. Nobelpharma Co., Ltd. was involved in the following: 1) the design and conduct of the study; 2) collection, management, analysis, and interpretation of the data; and 3) in the preparation and review of the manuscript. The principal investigator decided to submit the manuscript.";"Abdelgadir IS, 2018, ARCH DIS CHILD, V103, P1155, DOI 10.1136/archdischild-2017-314181; AKERSTEDT T, 1979, PSYCHONEUROENDOCRINO, V4, P219, DOI 10.1016/0306-4530(79)90005-2; Aman M., 1986, Aberrant Behavior Checklist Manual; Aman M.G., 1994, Aberrant Behavior Checklist-Community. Supplementary Manual; American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Andreou G, 2003, PERCEPT MOTOR SKILL, V96, P1283, DOI 10.2466/PMS.96.3.1283-1288; ARENDT J, 1988, CLIN ENDOCRINOL, V29, P205, DOI 10.1111/j.1365-2265.1988.tb00263.x; Arendt J, 2005, J BIOL RHYTHM, V20, P291, DOI 10.1177/0748730405277492; Black Lindsey I, 2018, Natl Health Stat Report, P1; Blackmer AB, 2016, PHARMACOTHERAPY, V36, P84, DOI 10.1002/phar.1686; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; BORBELY AA, 1986, J NEURAL TRANSM, P243; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x; Chase JE, 1997, ANN PHARMACOTHER, V31, P1218, DOI 10.1177/106002809703101015; Dahl R E, 1996, Semin Pediatr Neurol, V3, P44, DOI 10.1016/S1071-9091(96)80028-3; DAWSON D, 1993, J PINEAL RES, V15, P1, DOI 10.1111/j.1600-079X.1993.tb00503.x; Duh-Leong C, 2020, J DEV BEHAV PEDIATR, V41, P1, DOI 10.1097/DBP.0000000000000720; Ednick M, 2009, SLEEP, V32, P1449, DOI 10.1093/sleep/32.11.1449; Fallah MS, 2019, J CHILD ADOL PSYCHOP, V29, P168, DOI 10.1089/cap.2018.0115; Foley HM, 2019, COMPLEMENT THER MED, V42, P65, DOI 10.1016/j.ctim.2018.11.003; Fricke-Oerkermann L, 2007, SLEEP, V30, P1371, DOI 10.1093/sleep/30.10.1371; Garfinkel D, 1998, NUTRITION, V14, P53; Grigg-Damberger M, 2013, CURR OPIN PULM MED, V19, P616, DOI 10.1097/MCP.0b013e328365ab89; Gringas P, 2017, J AM ACAD CHILD PSY, V56, P948, DOI 10.1016/j.jaac.2017.09.414; Johnson CR, 2018, SLEEP MED, V44, P61, DOI 10.1016/j.sleep.2018.01.008; Karasek M, 2006, J PHYSIOL PHARMACOL, V57, P19; Kurz R, 2018, EUR J PAEDIATR NEURO, V22, P803, DOI 10.1016/j.ejpn.2018.05.010; Maras A, 2018, J CHILD ADOL PSYCHOP, V28, P699, DOI 10.1089/cap.2018.0020; Ono Y, 1996, RES DEV DISABIL, V17, P303, DOI 10.1016/0891-4222(96)00015-7; Paavonen EJ, 2000, ACTA PAEDIATR, V89, P223, DOI 10.1080/080352500750028870; Roth T, 1997, J BIOL RHYTHM, V12, P666, DOI 10.1177/074873049701200623; Sadeh A, 2002, CHILD DEV, V73, P405, DOI 10.1111/1467-8624.00414; Scher A, 2008, J PEDIATR PSYCHOL, V33, P396, DOI 10.1093/jpepsy/jsn013; THOMAN EB, 1981, NEUROPEDIATRICS, V12, P45, DOI 10.1055/s-2008-1059638; Tordjman S, 2017, CURR NEUROPHARMACOL, V15, P434, DOI 10.2174/1570159X14666161228122115; Touchette E, 2009, PEDIATRICS, V124, pE985, DOI 10.1542/peds.2008-2005; Velten-Schurian K, 2010, SLEEP MED, V11, P281, DOI 10.1016/j.sleep.2009.03.012; Wasdell MB, 2008, J PINEAL RES, V44, P57, DOI 10.1111/j.1600-079X.2007.00528.x; WEHR TA, 1991, J CLIN ENDOCR METAB, V73, P1276, DOI 10.1210/jcem-73-6-1276; WHITNEY MP, 1993, J DEV BEHAV PEDIATR, V14, P71; Zhdanova IV, 1997, J BIOL RHYTHM, V12, P644, DOI 10.1177/074873049701200620";42;23;24;1;18;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;sept-10;2020;20;1;;;;;;;445;10.1186/s12888-020-02847-y;http://dx.doi.org/10.1186/s12888-020-02847-y;;;14;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;NR7ZH;32912180;Green Published, gold;;;24/11/2024;WOS:000571778700006;View Full Record in Web of Science
J;"Clifford, P; Gevers, C; Jonkman, KM; Boer, F; Begeer, S";;;;"Clifford, Pamela; Gevers, Carolien; Jonkman, Kim M.; Boer, Frits; Begeer, Sander";;;The effectiveness of an attention-based intervention for school-aged autistic children with anger regulating problems: A randomized controlled trial;AUTISM RESEARCH;;;English;Article;;;;;;"Affect; emotion; Behavioral intervention; Children; Clinical Trials; Intervention; Treatment research";"COGNITIVE-BEHAVIORAL INTERVENTION; QUALITY-OF-LIFE; SPECTRUM DISORDER; EMOTION REGULATION; PARENTING STRESS; YOUNG-ADULTS; ADOLESCENTS; ANXIETY; DYSREGULATION; SEVERITY";Anger regulation is a challenge for children with autism spectrum disorders (ASD). We investigated if attention-based cognitive behavioral treatment, based on mindfulness cognitive therapy (MBCT) and dialectical behavior therapy (DBT), reduces aggressive behavior and improves anger coping in school-aged autistic children (n = 51). Children were randomized to an active-control or a treatment condition. The treatment included nine weekly sessions attention-based individual therapy. Parents in both conditions received three weekly psychoeducation group sessions to heighten awareness of expressed emotion (EE). For aggressive behavior, treatment reduced temper tantrums and arguing. No effect was found on destroying things and physical violence. For anger coping, treatment increased adaptive coping strategies of diffusion and social support seeking, but had no effect on assertion, rumination, and maladaptive coping direct anger out and avoidance. Treatment did not impact secondary outcome measures concerning children's quality of life (QoL) and parental stress-levels and psychological well-being. In conclusion, school-aged autistic children are able to acquire self-regulation skills reducing temper tantrums and arguing and increasing the use of adaptive anger coping strategies. The intervention shows potential to improve behavior and regulation, but little transfer to other domains. Limitations and future directions involving the child's social environment, including parents, siblings, and teachers are discussed. Lay Summary Children on the autism spectrum often show aggressive behavior. Treatment can train children to be more aware of their emotions. This study found that this can help reducing temper tantrums and arguing and increasing some coping skills, though no impact was found on several other domains of aggression and coping.;"[Clifford, Pamela; Gevers, Carolien] Wei43, Amsterdam, KN, Netherlands; [Jonkman, Kim M.; Begeer, Sander] Vrije Univ Amsterdam, Dept Clin Neuro & Dev Psychol, Amsterdam, BT, Netherlands; [Jonkman, Kim M.; Begeer, Sander] Vrije Univ Amsterdam, Amsterdam Publ Hlth, Amsterdam, BT, Netherlands; [Boer, Frits] Amsterdam Med Ctr, Child & Adolescent Psychiat, Amsterdam, AZ, Netherlands";"Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam";Begeer, S (corresponding author), Vrije Univ Amsterdam, Dept Clin Neuro & Dev Psychol, Fac Behav & Movement Sci, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.;s.begeer@vu.nl;Begeer, Sander/I-3383-2012;Begeer, Sander/0000-0002-0572-6893;Research Grants ZonMW (The Netherlands) [70-72900-98-14050];Research Grants ZonMW (The Netherlands);Sander Begeer received Research Grants ZonMW (The Netherlands) Grant Number 70-72900-98-14050. Thanks to the participating children, parents and clinicians, at Levvel, Duivendrecht, and Wei43, Amsterdam, The Netherlands.;"Achenbach T. M., 2001, -Age Forms Profiles; Arrindell W A., 2005, Symptom checklist: Handleiding bij een multidimensionale psychopathologie-indicator SCL-90; Bader SH, 2014, J AUTISM DEV DISORD, V44, P2820, DOI 10.1007/s10803-014-2142-6; Baer RA, 2014, PRACT RESOUR MENT, P3, DOI 10.1016/B978-0-12-416031-6.00001-3; Bos MGN, 2018, J AUTISM DEV DISORD, V48, P2727, DOI 10.1007/s10803-018-3519-8; Carr EG, 2007, J POSIT BEHAV INTERV, V9, P3, DOI 10.1177/10983007070090010201; Chalfant AM, 2007, J AUTISM DEV DISORD, V37, P1842, DOI 10.1007/s10803-006-0318-4; Conner CM, 2019, AUTISM, V23, P1273, DOI 10.1177/1362361318810709; Constantino J. N., 2012, SOCIAL RESPONSIVENES; De Brock AJ., 1992, NOSI NIJMEEGSE OUDER; Dempsey AG, 2012, J AUTISM DEV DISORD, V42, P1393, DOI 10.1007/s10803-011-1368-9; Dodge KA, 2003, DEV PSYCHOL, V39, P349, DOI 10.1037/0012-1649.39.2.349; Egberink I.J.L., 2012, COTAN REV 2012; Fernandez-Alcántara M, 2016, RES DEV DISABIL, V55, P312, DOI 10.1016/j.ridd.2016.05.007; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Gevers C., 2009, MULTIPLE COMPLEX DEV, P63; Goel R, 2018, INT REV PSYCHIATR, V30, P78, DOI 10.1080/09540261.2018.1458706; Gross JJ, 2015, PSYCHOL INQ, V26, P1, DOI 10.1080/1047840X.2014.940781; Hartmann K, 2019, B MENNINGER CLIN, V83, P259, DOI 10.1521/bumc.2019.83.3.259; Hill AP, 2014, RES AUTISM SPECT DIS, V8, P1121, DOI 10.1016/j.rasd.2014.05.006; Ibrahim K, 2019, J AUTISM DEV DISORD, V49, P3656, DOI 10.1007/s10803-019-04085-y; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Linehan M, 2015, DBT SKILLS TRAINING; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; Luiselli J.K., 2014, Children and youth with autism spectrum disorder (ASD): recent advances and innovations in assessment, education, and intervention; Mascha K, 2006, BRIT J DEV DISABIL, V52, P19, DOI 10.1179/096979506799103659; Mazefsky CA, 2011, RES AUTISM SPECT DIS, V5, P164, DOI 10.1016/j.rasd.2010.03.006; McStay RL, 2014, AUTISM, V18, P502, DOI 10.1177/1362361313485163; Miers AC, 2007, J ABNORM CHILD PSYCH, V35, P653, DOI 10.1007/s10802-007-9120-9; Patel S, 2017, AUTISM, V21, P181, DOI 10.1177/1362361316633566; Reese RM, 2005, J AUTISM DEV DISORD, V35, P419, DOI 10.1007/s10803-005-5032-0; Ridderinkhof A, 2018, MINDFULNESS, V9, P773, DOI 10.1007/s12671-017-0815-x; Roeyers H., 2011, SRS Screeningslijst voor autismespectrumstoornissen. Handleiding; Samson AC, 2015, J CHILD PSYCHOL PSYC, V56, P903, DOI 10.1111/jcpp.12370; Samson AC, 2014, J AUTISM DEV DISORD, V44, P1766, DOI 10.1007/s10803-013-2022-5; Segal ZV, 2012, Mindfulness -Based Cognitive Therapy for Depression, V2nd; Seymour M, 2013, J AUTISM DEV DISORD, V43, P1547, DOI 10.1007/s10803-012-1701-y; Shivers CM, 2019, CLIN CHILD FAM PSYCH, V22, P172, DOI 10.1007/s10567-018-0269-2; Singh NN, 2011, RES AUTISM SPECT DIS, V5, P1153, DOI 10.1016/j.rasd.2010.12.012; Sofronoff K, 2007, J AUTISM DEV DISORD, V37, P1203, DOI 10.1007/s10803-006-0262-3; Spek AA, 2013, RES DEV DISABIL, V34, P246, DOI 10.1016/j.ridd.2012.08.009; Tanksale R, 2021, AUTISM, V25, P995, DOI 10.1177/1362361320974841; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Verhulp EE, 2013, EUR CHILD ADOLES PSY, V22, P413, DOI 10.1007/s00787-013-0380-3; Verhulst F.C., 1996, Handleiding voor de CBCL/4 18. [Manuel of the CBCL/4-18.]; White SW, 2010, CLIN CHILD FAM PSYCH, V13, P77, DOI 10.1007/s10567-009-0062-3; White SW, 2009, J AUTISM DEV DISORD, V39, P1006, DOI 10.1007/s10803-009-0713-8; Wong C, 2015, J AUTISM DEV DISORD, V45, P1951, DOI 10.1007/s10803-014-2351-z; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x; Zaidman-Zait A, 2017, AUTISM, V21, P155, DOI 10.1177/1362361316633033";50;3;5;10;68;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1939-3792;1939-3806;;AUTISM RES;Autism Res.;OCT;2022;15;10;;;;;1971;1984;;10.1002/aur.2800;http://dx.doi.org/10.1002/aur.2800;;AUG 2022;14;"Behavioral Sciences; Psychology, Developmental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology";5F6UU;36053934;Green Published;;;24/11/2024;WOS:000847712700001;View Full Record in Web of Science
J;"Simpson, S; Dominick, KC; Erickson, CA; Lamy, M";;;;"Simpson, Seth; Dominick, Kelli C.; Erickson, Craig A.; Lamy, Martine";;;Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;"Article; Early Access";;;;;;"Antipsychotic; Autism; Children; Intellectual disability; Long acting injectable; Paliperidone";"SPECTRUM DISORDER; ADOLESCENTS; CHILDREN; RISPERIDONE; ANTIPSYCHOTICS; IRRITABILITY; ARIPIPRAZOLE; METAANALYSIS";This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID.;"[Simpson, Seth] Shodair Childrens Hosp, 2755 Colonial Dr, Helena, MT 59601 USA; [Dominick, Kelli C.; Erickson, Craig A.; Lamy, Martine] Univ Cincinnati, Dept Psychiat, Coll Med, Cincinnati, OH 45267 USA; [Dominick, Kelli C.; Erickson, Craig A.; Lamy, Martine] Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat MLC 4002, Cincinnati, OH 45229 USA";"University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center";"Dominick, KC (corresponding author), Univ Cincinnati, Dept Psychiat, Coll Med, Cincinnati, OH 45267 USA.;Dominick, KC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat MLC 4002, Cincinnati, OH 45229 USA.";Kelli.dominick@cchmc.org;Dominick, Kelli/AAK-3798-2020;"Dominick, Kelli/0000-0003-3775-2479; Lamy, Martine/0000-0001-5873-0813";;;;"AMAN MG, 1985, AM J MENT DEF, V89, P485; Blankenship Kelly, 2010, Ped Health, V4, P375, DOI 10.2217/phe.10.45; Cohen D, 2013, RES AUTISM SPECT DIS, V7, P167, DOI 10.1016/j.rasd.2012.08.001; Fortea A, 2018, J CHILD ADOL PSYCHOP, V28, P252, DOI 10.1089/cap.2017.0096; Gopal S, 2014, INT J CLIN PRACT, V68, P1514, DOI 10.1111/ijcp.12493; Guy W., 1976, ECDEU ASSESSMENT MAN; Institute C. s. H. o. P. R., 2021, Pediatric Z-Score Calculator; Kowalski JL, 2011, J CHILD ADOL PSYCHOP, V21, P491, DOI 10.1089/cap.2011.0035; Leung Jonathan G, 2015, Case Rep Psychiatry, V2015, P364325, DOI 10.1155/2015/364325; Lytle S, 2017, J CHILD ADOL PSYCHOP, V27, P2, DOI 10.1089/cap.2016.0055; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P3063, DOI 10.2147/NDT.S174622; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P1811, DOI 10.2147/NDT.S151802; Mazefsky CA, 2018, J AUTISM DEV DISORD, V48, P3736, DOI 10.1007/s10803-016-2907-1; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; Misawa F, 2016, SCHIZOPHR RES, V176, P220, DOI 10.1016/j.schres.2016.07.018; Stigler KA, 2012, PSYCHOPHARMACOLOGY, V223, P237, DOI 10.1007/s00213-012-2711-3; Stigler KA, 2010, J CHILD ADOL PSYCHOP, V20, P75, DOI 10.1089/cap.2009.0019";18;0;0;1;1;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;2024 MAY 13;2024;;;;;;;;;;10.1007/s10803-024-06372-9;http://dx.doi.org/10.1007/s10803-024-06372-9;;MAY 2024;7;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;QL1U5;38740696;;;;24/11/2024;WOS:001220945700002;View Full Record in Web of Science
J;"Booms, S; Hill, E; Kulhanek, L; Vredeveld, J; Gregg, B";;;;"Booms, Stephanie; Hill, Elizabeth; Kulhanek, Leah; Vredeveld, Jennifer; Gregg, Brigid";;;Iodine Deficiency and Hypothyroidism From Voluntary Diet Restrictions in the US: Case Reports;PEDIATRICS;;;English;Article;;;;;;;NUTRITION;Iodine deficiency is rare in the United States today, and this is largely due to the effectiveness of iodization in the general food supply. Recent trends among specific populations of children in the United States include adopting food restrictions, such casein-free and gluten-free diets. Although the effect of these types of diets on overall nutrition status and certain micronutrients has been studied in children with autism spectrum disorder, the effect of these limitations on iodine levels in children has not been assessed. We present here 2 cases of iodine deficiency resulting from severe food restriction and associated primary hypothyroidism. In 1 case a classic presentation with a goiter was seen. These children were able to discontinue thyroid hormone treatment once iodine levels were normalized. There were no adverse events or unanticipated outcomes. The occurrence of these cases of iodine deficiency in the United States points to the need for thyroid function testing in children with severe food restrictions, especially those who have limited exposure to dairy, baked goods, and table salt.;"[Booms, Stephanie; Hill, Elizabeth; Vredeveld, Jennifer; Gregg, Brigid] Univ Michigan Hlth Syst, Dept Pediat & Communicable Dis, Ann Arbor, MI USA; [Vredeveld, Jennifer] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA; [Kulhanek, Leah] Univ Michigan Hlth Syst, Northville Hlth Ctr, Ann Arbor, MI USA";"University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan";Gregg, B (corresponding author), Univ Michigan, Dept Pediat, Div Endocrinol, CS Mott Childrens Hosp, D1205 MPB 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.;greggb@med.umich.edu;Hill, Elizabeth/AAL-7790-2020;;;;;"Andersson M, 2012, J NUTR, V142, P744, DOI 10.3945/jn.111.149393; [Anonymous], 2015, SERUM RED BLOOD CELL; [Anonymous], 2007, ASS IOD DEF DIS MON; Caldwell KL, 2013, THYROID, V23, P927, DOI 10.1089/thy.2013.0012; König F, 2011, J NUTR, V141, P2049, DOI 10.3945/jn.111.144071; LABIB M, 1989, BMJ-BRIT MED J, V298, P232, DOI 10.1136/bmj.298.6668.232; LEE SL, 2004, ENDOCR PRACT S1, V10, P46; Leniszewski S, 2009, INT J PEDIATR ENDOCR, DOI 10.1155/2009/628034; Leung AM, 2011, J CLIN ENDOCR METAB, V96, pE1303, DOI 10.1210/jc.2011-0256; National Institutes of Health, PAT ED LOW IOD DIET; Pearce EN, 2013, THYROID, V23, P924, DOI 10.1089/thy.2013.0295; Pearce EN, 2013, THYROID, V23, P523, DOI 10.1089/thy.2013.0128; Pearce EN, 2004, J CLIN ENDOCR METAB, V89, P3421, DOI 10.1210/jc.2003-032002; Perrin JM, 2012, PEDIATRICS, V130, pS77, DOI 10.1542/peds.2012-0900E; Perrine CG, 2013, J NUTR, V143, P1155, DOI 10.3945/jn.113.176289; Stewart PA, 2015, J ACAD NUTR DIET, V115, P1237, DOI 10.1016/j.jand.2015.03.026; Suskind DL, 2009, PEDIATR CLIN N AM, V56, P1035, DOI 10.1016/j.pcl.2009.07.004; Yeliosof O, 2015, P 15 INT THYR C OCT, P577; Zimmermann MB, 2008, LANCET, V372, P1251, DOI 10.1016/S0140-6736(08)61005-3; Zimmermann MB, 2009, ENDOCR REV, V30, P376, DOI 10.1210/er.2009-0011";20;11;12;0;17;AMER ACAD PEDIATRICS;ELK GROVE VILLAGE;141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA;0031-4005;1098-4275;;PEDIATRICS;Pediatrics;JUN;2016;137;6;;;;;;;e20154003;10.1542/peds.2015-4003;http://dx.doi.org/10.1542/peds.2015-4003;;;4;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;DP5EZ;27244854;Bronze;;;24/11/2024;WOS:000378520100027;View Full Record in Web of Science
J;"Cakir, B; Sapmaz, SY; Kandemir, H";;;;"Cakir, Burak; Yalin Sapmaz, Sermin; Kandemir, Hasan";;;Use of Antipsychotics: The Experiences, Views, and Monitoring Practices of Child and Adolescent Psychiatrists in Turkey;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"antipsychotics; child and adolescent; metabolic monitoring";"2ND-GENERATION ANTIPSYCHOTICS; POPULATION; TRENDS; MEDICATIONS; SAFETY; YOUTH";Objectives:The aim of this study is to evaluate the antipsychotics prescribed by child psychiatrists and their applications on the follow-up of these drugs. Methods:The universe of this research included consultant physicians and child psychiatry residents working in the field. A questionnaire has been created that assesses the use of antipsychotics and follow-up processes of physicians. The survey involved 19 questions. Contents of the survey were sociodemographic data, short-term and long-term follow-up of antipsychotic drugs, side-effect intervention strategies, and diagnoses of the most commonly preferred antipsychotic medications. The survey was delivered via e-mail and sent as a message to the child and adolescent psychiatrists in Turkey. Results:One hundred sixty-one physicians working in the field of child and adolescent psychiatry participated in the study. Aripiprazole (32.2%), risperidone (30.4%), and quetiapine (14.9%) were three most commonly prescribed antipsychotics. Disruptive behavior-related disorders (28.9%), behavior problems related to autism spectrum disorder (20.7%), behavior problems related to intellectual disability (14.5%), and attention-deficit/hyperactivity disorder (12.4%) were the most common diagnoses requiring antipsychotics medications. Before starting antipsychotic treatment, the most commonly evaluated parameters were body mass index (BMI) (47.2%), waist circumference (10.5%), blood pressure (28.5%), lipid profile (37%), and blood glucose level (41.6%). When the evaluations made at least in a year after starting antipsychotic drug therapy were examined, 80.2% of physicians reported blood glucose, 79.6% lipid profile, 65.7% BMI, 59.1% blood pressure, and 26.6% waist circumference measurement almost always done. Conclusions:The results showed that the adherence to recommendations in guidelines for the screening of antipsychotic-related side effects was low. This study suggests that interventions should be made about antipsychotic monitoring training to physicians.;"[Cakir, Burak; Yalin Sapmaz, Sermin; Kandemir, Hasan] Manisa Celal Bayar Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-45040 Manisa, Turkey";Celal Bayar University;Sapmaz, SY (corresponding author), Manisa Celal Bayar Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-45040 Manisa, Turkey.;drserminyalin@hotmail.com;"ÇAKIR, BURAK/ABI-5392-2020; Kandemir, Hasan/Z-1954-2018; CAKIR, BANU/I-9381-2013";CAKIR, BANU/0000-0001-6645-6527;;;;"Alessi-Severini S, 2012, CAN J PSYCHIAT, V57, P52, DOI 10.1177/070674371205700109; [Anonymous], 2004, J CLIN PSYCHIAT, V65, P267; [Anonymous], 2012, ANATOL J CLIN INVEST; [Anonymous], 2011, PRACT PAR US AT ANT; Aras S, 2005, KLIN PSIKOFARMAKOL B, V15, P127; Chen WX, 2018, CLIN DRUG INVEST, V38, P449, DOI 10.1007/s40261-018-0626-4; Correll CU, 2006, J AM ACAD CHILD PSY, V45, P771, DOI 10.1097/01.chi.0000220851.94392.30; Cotes RO, 2017, J CHILD ADOL PSYCHOP, V27, P916, DOI 10.1089/cap.2017.0034; Edelsohn GA, 2017, J AM ACAD CHILD PSY, V56, P59, DOI 10.1016/j.jaac.2016.10.005; Hálfdánarson O, 2017, EUR NEUROPSYCHOPHARM, V27, P1064, DOI 10.1016/j.euroneuro.2017.07.001; Hayden JD, 2020, J CHILD ADOL PSYCHOP, V30, P119, DOI 10.1089/cap.2019.0087; Huskamp HA, 2016, PSYCHIAT SERV, V67, P1307, DOI 10.1176/appi.ps.201500224; Jensen KG, 2015, J AM ACAD CHILD PSY, V54, P25, DOI 10.1016/j.jaac.2014.10.002; Maayan L, 2011, J CHILD ADOL PSYCHOP, V21, P517, DOI 10.1089/cap.2011.0015; Marsanic VB, 2012, NORD J PSYCHIAT, V66, P2, DOI 10.3109/08039488.2011.556198; McLaren JL, 2017, PSYCHIAT SERV, V68, P958, DOI 10.1176/appi.ps.201500553; Minjon L, 2018, J CLIN PSYCHOPHARM, V38, P489, DOI 10.1097/JCP.0000000000000936; Morrato EH, 2010, ARCH PEDIAT ADOL MED, V164, P344, DOI 10.1001/archpediatrics.2010.48; Nielsen RE, 2014, J AM ACAD CHILD PSY, V53, P971, DOI 10.1016/j.jaac.2014.04.023; Nolt VD, 2017, PEDIATR DRUGS, V19, P139, DOI 10.1007/s40272-016-0209-x; Piovani D, 2016, EUR CHILD ADOLES PSY, V25, P235, DOI 10.1007/s00787-015-0726-0; Pisano S, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0259-2; Pringsheim T, 2011, PAED CHILD HEALT-CAN, V16, P581, DOI 10.1093/pch/16.9.581; Rey JM, 2019, IACAPAP E TXB CHILD; Rodday AM, 2015, J CHILD ADOL PSYCHOP, V25, P351, DOI 10.1089/cap.2014.0156; Roke Y, 2009, J CHILD ADOL PSYCHOP, V19, P403, DOI 10.1089/cap.2008.0120; Ronsley R, 2013, CAN J PSYCHIAT, V58, P361, DOI 10.1177/070674371305800608; Ronsley R, 2012, CAN J PSYCHIAT, V57, P292, DOI 10.1177/070674371205700504; Schröder C, 2017, EUR CHILD ADOLES PSY, V26, P413, DOI 10.1007/s00787-016-0905-7; Ta FV, 2007, COCUK GENCLIK RUH SA, V14, P139; Uzal NE, 2018, ANN PHARMACOTHER, V52, P160, DOI 10.1177/1060028017731421; Walter G, 2008, AUSTRALAS PSYCHIATRY, V16, P253, DOI 10.1080/10398560801958549; Yektas Ç, 2018, CLIN NEUROPHARMACOL, V41, P23, DOI 10.1097/WNF.0000000000000263";33;1;1;0;9;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;FEB 1;2021;31;1;;;;;73;78;;10.1089/cap.2020.0078;http://dx.doi.org/10.1089/cap.2020.0078;;juin-20;6;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Pediatrics; Pharmacology & Pharmacy; Psychiatry";QJ2BU;32614261;;;;24/11/2024;WOS:000547814100001;View Full Record in Web of Science
J;"Kolevzon, A; Levy, T; Barkley, S; Bedrosian-Sermone, S; Davis, M; Foss-Feig, J; Halpern, D; Keller, K; Kostic, A; Layton, C; Lee, RBC; Lerman, B; Might, M; Sandin, S; Siper, PM; Sloofman, LG; Walker, H; Zweifach, J; Buxbaum, JD";;;;"Kolevzon, Alexander; Levy, Tess; Barkley, Sarah; Bedrosian-Sermone, Sandra; Davis, Matthew; Foss-Feig, Jennifer; Halpern, Danielle; Keller, Katherine; Kostic, Ana; Layton, Christina; Lee, Rebecca; Lerman, Bonnie; Might, Matthew; Sandin, Sven; Siper, Paige M.; Sloofman, Laura G.; Walker, Hannah; Zweifach, Jessica; Buxbaum, Joseph D.";;;An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome;HUMAN GENETICS AND GENOMICS ADVANCES;;;English;Article;;;;;;;"DEPENDENT NEUROPROTECTIVE PROTEIN; PATIENT DATA METAANALYSIS; EMERGENCY-DEPARTMENT; INTRAVENOUS KETAMINE; SEDATION; GAMMA; QUESTIONNAIRE; INDIVIDUALS; INSTRUMENT; PREDICTORS";Activity-dependent neuroprotective protein (ADNP) syndrome is a rare genetic condition associated with intellectual disability and autism spectrum disorder. Preclinical evidence suggests that low-dose ketamine may induce expression of ADNP and that neuroprotec-tive effects of ketamine may be mediated by ADNP. The goal of the proposed research was to evaluate the safety, tolerability, and behav-ioral outcomes of low-dose ketamine in children with ADNP syndrome. We also sought to explore the feasibility of using electrophys-iological markers of auditory steady-state response and computerized eye tracking to assess biomarker sensitivity to treatment. This study utilized a single-dose (0.5 mg/kg), open-label design, with ketamine infused intravenously over 40 min. Ten children with ADNP syn-drome ages 6 to 12 years were enrolled. Ketamine was generally well tolerated, and there were no serious adverse events. The most com-mon adverse events were elation/silliness (50%), fatigue (40%), and increased aggression (40%). Using parent-report instruments to assess treatment effects, ketamine was associated with nominally significant improvement in a wide array of domains, including social behavior, attention deficit and hyperactivity, restricted and repetitive behaviors, and sensory sensitivities, a week after administration. Results derived from clinician-rated assessments aligned with findings from the parent reports. Overall, nominal improvement was evident based on the Clinical Global Impressions -Improvement scale, in addition to clinician-based scales reflecting key domains of social communication, attention deficit and hyperactivity, restricted and repetitive behaviors, speech, thinking, and learning, activities of daily living, and sensory sensitivities. Results also highlight the potential utility of electrophysiological measurement of auditory steady-state response and eye-tracking to index change with ketamine treatment. Findings are intended to be hypothesis generating and provide preliminary support for the safety and efficacy of ketamine in ADNP syndrome in addition to identifying useful endpoints for a ketamine clinical development program. However, results must be interpreted with caution given limitations of this study, most importantly the small sample size and absence of a placebo-control group.;"[Kolevzon, Alexander; Levy, Tess; Barkley, Sarah; Foss-Feig, Jennifer; Halpern, Danielle; Keller, Katherine; Kostic, Ana; Layton, Christina; Lerman, Bonnie; Sandin, Sven; Siper, Paige M.; Sloofman, Laura G.; Walker, Hannah; Zweifach, Jessica; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA; [Kolevzon, Alexander; Levy, Tess; Barkley, Sarah; Foss-Feig, Jennifer; Halpern, Danielle; Keller, Katherine; Kostic, Ana; Layton, Christina; Lerman, Bonnie; Sandin, Sven; Siper, Paige M.; Sloofman, Laura G.; Walker, Hannah; Zweifach, Jessica; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Kolevzon, Alexander] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Bedrosian-Sermone, Sandra; Davis, Matthew] ADNP Kids Res Fdn, Vancouver, WA USA; [Lee, Rebecca] Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY USA; [Might, Matthew] Univ Alabama Birmingham, Hugh Kaul Precis Med Inst, Heersink Sch Med, Birmingham, AL USA; [Sandin, Sven] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA; [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA";"Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Alabama System; University of Alabama Birmingham; Karolinska Institutet; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai";"Kolevzon, A (corresponding author), Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.;Kolevzon, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.;Kolevzon, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA.";alexander.kolevzon@mssm.edu;"Sandin, Sven/L-5357-2015; Davis, Matthew/S-8342-2019; Walker, Hannah/KHV-2942-2024";"Kolevzon, Alexander/0000-0001-8129-2671; , Hannah Walker/0009-0001-2008-3742; Lerman, Bonnie/0000-0002-9032-1224; Buxbaum, Joseph/0000-0001-8898-8313; Levy, Tess/0000-0003-2207-0440";"ADNP Kids Research Foundation; Foundation for Mood Disorders; National Center for Advancing Translational Sciences, National Institutes of Health, through the Biomedical Data Translator Program [OT2TR003435, OT2TR002517]";"ADNP Kids Research Foundation; Foundation for Mood Disorders; National Center for Advancing Translational Sciences, National Institutes of Health, through the Biomedical Data Translator Program";We are extremely grateful to the families who participated and to the ADNP Kids Research Foundation and the Foundation for Mood Disorders for their support. Support for mediKanren was provided by the National Center for Advancing Translational Sciences, National Institutes of Health, through the Biomedical Data Translator Program, awards OT2TR003435 and OT2TR002517. Any opinions expressed in this document are those of the Translator community at large and do not necessarily reflect the views of NCATS, individual Translator team members, or affiliated organizations and institutions.;"Abdallah CG, 2015, ANNU REV MED, V66, P509, DOI 10.1146/annurev-med-053013-062946; AMAN MG, 1985, AM J MENT DEF, V89, P492; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI DOI 10.1176/APPI.BOOKS.9780890425596.744053; Arnett AB, 2018, AUTISM RES, V11, P1300, DOI 10.1002/aur.1980; Baumgarten TJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156829; Bedford R, 2012, J AUTISM DEV DISORD, V42, P2208, DOI 10.1007/s10803-012-1450-y; Beery K. E., 2010, The Beery-Buktenica developmental test of visual-motor integration: Administration, scoring, and teaching manual, V6th ed.; Bend EG, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0658-5; Blaj C, 2017, CLIN CANCER RES, V23, P2769, DOI 10.1158/1078-0432.CCR-16-1604; Brannan AM, 1997, J EMOT BEHAV DISORD, V5, P212, DOI 10.1177/106342669700500404; Breen MS, 2020, AM J HUM GENET, V107, P555, DOI 10.1016/j.ajhg.2020.07.003; Brown BP, 2015, NEUROSCIENCE, V290, P31, DOI 10.1016/j.neuroscience.2014.12.076; Byrd W., 2020, MINIKANREN WORKSH; Carr MF, 2012, NEURON, V75, P700, DOI 10.1016/j.neuron.2012.06.014; Chen MH, 2019, J AFFECT DISORDERS, V259, P15, DOI 10.1016/j.jad.2019.08.022; Chen MH, 2019, NEUROPSYCHOPHARMACOL, V44, P2112, DOI 10.1038/s41386-019-0480-y; Conners C.K., 2018, CONNERS 3 CONNERS 20, V3, DOI [10.1007/978-3-319-57111-9_1534, DOI 10.1007/978-3-319-57111-9_1534]; Dunn D.M., 2018, PEABODY PICTURE VOCA, VFifth; Dunn W, 1999, SENSORY PROFILE EXAM; Esbensen AJ, 2003, J AUTISM DEV DISORD, V33, P617, DOI 10.1023/B:JADD.0000005999.27178.55; Farmer C, 2016, CHILD NEUROPSYCHOL, V22, P556, DOI 10.1080/09297049.2015.1020775; Fava M, 2020, MOL PSYCHIATR, V25, P1604, DOI 10.1038/s41380-018-0311-2; Feder A, 2014, JAMA PSYCHIAT, V71, P681, DOI 10.1001/jamapsychiatry.2014.62; Green SM, 2004, ANN EMERG MED, V44, P460, DOI 10.1016/j.annemergmed.2004.06.006; Green SM, 2009, ANN EMERG MED, V54, P158, DOI 10.1016/j.annemergmed.2008.12.011; Green SM, 2009, ANN EMERG MED, V54, P171, DOI 10.1016/j.annemergmed.2009.04.004; Guy W., 1976, ECDEU ASSESSMENT MAN; Hacohen-Kleiman G, 2019, NEUROCHEM RES, V44, P1494, DOI 10.1007/s11064-019-02723-6; Helsmoortel C, 2014, NAT GENET, V46, P380, DOI 10.1038/ng.2899; HODGES JL, 1956, ANN MATH STAT, V27, P324, DOI 10.1214/aoms/1177728261; HOLM S, 1979, SCAND J STAT, V6, P65; Jensen O, 2005, NEUROIMAGE, V26, P347, DOI 10.1016/j.neuroimage.2005.02.008; Kurdi Madhuri S, 2014, Anesth Essays Res, V8, P283, DOI 10.4103/0259-1162.143110; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Light GA, 2017, NEUROPSYCHOPHARMACOL, V42, P2633, DOI 10.1038/npp.2017.81; Lord C., 2012, AUTISM DIAGNOSTIC OB; Lundqvist M, 2016, NEURON, V90, P152, DOI 10.1016/j.neuron.2016.02.028; Mandel S, 2007, J BIOL CHEM, V282, P34448, DOI 10.1074/jbc.M704756200; Mandel S, 2007, DEV BIOL, V303, P814, DOI 10.1016/j.ydbio.2006.11.039; Merenlender-Wagner A, 2015, MOL PSYCHIATR, V20, P126, DOI 10.1038/mp.2013.174; Murrough JW, 2015, PSYCHOL MED, V45, P3571, DOI 10.1017/S0033291715001506; Owens JA, 2000, SLEEP, V23, P1043; Rutter M., 2003, Western Psychological Services, V29, P30; Satterstrom FK, 2020, CELL, V180, P568, DOI 10.1016/j.cell.2019.12.036; Shillington A, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1230; Sinner B, 2005, ANESTH ANALG, V100, P1660, DOI 10.1213/01.ANE.0000150946.18875.48; Siper PM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12030351; Siper PM, 2017, AUTISM RES, V10, P1133, DOI 10.1002/aur.1750; Sivarao DV, 2016, NEUROPSYCHOPHARMACOL, V41, P2232, DOI 10.1038/npp.2016.17; Slikker W, 2007, TOXICOL SCI, V98, P145, DOI 10.1093/toxsci/kfm084; Spanos M, 2020, CONTEMP CLIN TRIALS, V98, DOI 10.1016/j.cct.2020.106103; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Spencer HF, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974-022-02434-w; Sragovich S, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-018-0357-6; Strous JFM, 2022, FRONT NEUROANAT, V16, DOI 10.3389/fnana.2022.795231; Study T.D.D.D., 2017, NATURE, V542, DOI [10.1038/nature21062, DOI 10.1038/NATURE21062]; Sugiyama S, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.644541; Tada M, 2020, CLIN EEG NEUROSCI, V51, P234, DOI 10.1177/1550059419868872; Turner CP, 2012, NEUROSCIENCE, V210, P384, DOI 10.1016/j.neuroscience.2012.02.015; Van Dijck A, 2019, BIOL PSYCHIAT, V85, P287, DOI 10.1016/j.biopsych.2018.02.1173; Vulih-Shultzman I, 2007, J PHARMACOL EXP THER, V323, P438, DOI 10.1124/jpet.107.129551; Williams K. T., 2019, EXPRESSIVE VOCABULAR; Wink LK, 2021, J AUTISM DEV DISORD, V51, P1392, DOI 10.1007/s10803-020-04542-z; Yamamoto J, 2014, CELL, V157, P845, DOI 10.1016/j.cell.2014.04.009; Yan J, 2014, J NEUROSURG ANESTH, V26, P155, DOI 10.1097/ANA.0000000000000027; Yavi M, 2022, DISCOV MENT HEALTH, V2, DOI 10.1007/s44192-022-00012-3";66;10;12;0;3;ELSEVIER;AMSTERDAM;RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS;2666-2477;;;HUM GENET GENOM ADV;Hum. Genet. Genom. Adv.;oct-13;2022;3;4;;;;;;;100138;10.1016/j.xhgg.2022.100138;http://dx.doi.org/10.1016/j.xhgg.2022.100138;;sept-22;13;Genetics & Heredity;Emerging Sources Citation Index (ESCI);Genetics & Heredity;4Z9HI;36119806;gold, Green Published;;;24/11/2024;WOS:000862509800003;View Full Record in Web of Science
J;"Çelebi, F; Koyuncu, A; Coskun, M";;;;"Celebi, Fahri; Koyuncu, Ahmet; Coskun, Murat";;;N-acetylcysteine may reduce repetitive behaviors in children with autism: a case series;PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"Autism; ASD; N-acetylcysteine; NAC; repetitive behaviors";"DOUBLE-BLIND; RISPERIDONE; TRICHOTILLOMANIA; HYPERACTIVITY; INTERVENTIONS; IRRITABILITY; ADOLESCENTS; DISORDERS; TRIAL";Objective: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in social communication and interaction, and restricted, stereotypic, repetitive behaviors. Behavioral problems are common in children with ASD. Herein, we report the effect of N-acetylcysteine (NAC) treatment on repetitive behaviors in 10 children with ASD. Methods: Ten children with ASD were assessed using the Childhood Autism Rating Scale and Aberrant Behavior Checklist (ABC). The clinical follow-up was performed with ABC and Clinical Global Impressions-Improvement (CGI-I). A total of 10 patients were initiated on NAC therapy in addition to their treatment with a stable dose of risperidone to avoid the potential adverse effects of higher doses of risperidone. Two patients discontinued NAC treatment before the third week. Eight patients were treated with an NAC dosage of 1200-2700 mg/day for 6-10 weeks. Results: The mean age of the patients was 8.6 years. Patients received NAC treatment for a mean duration of 8.25 weeks and a mean dosage of 2100 mg/day. Improvement in stereotypic behaviors was statistically significant in addition to the improvement in mean CGI-I score (p =.025 and .006, respectively). Conclusion: NAC adjunction to risperidone treatment may be helpful to reduce repetitive behaviors in children with ASD with limited adverse effects and good tolerability.;"[Celebi, Fahri] Zonguldak Kadin Dogum & Cocuk Hastaliklari Hastan, Dept Child & Adolescent Psychiat, Degirmenbasisk 145, TR-67030 Zonguldak, Turkey; [Koyuncu, Ahmet] Acad Social Phobia Ctr, Istanbul, Turkey; [Coskun, Murat] Istanbul Univ, Istanbul Med Sch, Dept Child & Adolescent Psychiat, Istanbul, Turkey";"Zonguldak Maternity & Child Health Hospital; Istanbul University";Çelebi, F (corresponding author), Zonguldak Kadin Dogum & Cocuk Hastaliklari Hastan, Dept Child & Adolescent Psychiat, Degirmenbasisk 145, TR-67030 Zonguldak, Turkey.;fahricelebi@yahoo.com;"Koyuncu, Ahmet/AAP-1603-2020; Coskun, Murat/A-1377-2017";Coskun, Murat/0000-0002-4808-5870;;;;"Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Afshar H, 2012, J CLIN PSYCHOPHARM, V32, P797, DOI 10.1097/JCP.0b013e318272677d; AMAN MG, 1985, AM J MENT DEF, V89, P485; Aman M, 2015, J CHILD ADOL PSYCHOP, V25, P482, DOI 10.1089/cap.2015.0005; Anderson GM, 2007, BIOL PSYCHIAT, V61, P545, DOI 10.1016/j.biopsych.2006.02.032; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Bloch MH, 2016, J CHILD ADOL PSYCHOP, V26, P327, DOI 10.1089/cap.2015.0109; Bloch MH, 2013, J AM ACAD CHILD PSY, V52, P231, DOI 10.1016/j.jaac.2012.12.020; Carter MJ, 2014, THER RECREAT J, V48, P275; Coskun M, 2009, J CHILD ADOL PSYCHOP, V19, P203, DOI 10.1089/cap.2008.020; Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057; Ghanizadeh A, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-196; Grant JE, 2009, ARCH GEN PSYCHIAT, V66, P756, DOI 10.1001/archgenpsychiatry.2009.60; Hardan AY, 2012, BIOL PSYCHIAT, V71, P956, DOI 10.1016/j.biopsych.2012.01.014; Lafleur DL, 2006, PSYCHOPHARMACOLOGY, V184, P254, DOI 10.1007/s00213-005-0246-6; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Marler S, 2014, J CHILD ADOL PSYCHOP, V24, P231, DOI 10.1089/cap.2013.0137; Memik NC, 2015, KLIN PSIKOFARMAKOL B, V25, P193, DOI 10.5455/bcp.20140811064455; Nikoo M, 2015, CLIN NEUROPHARMACOL, V38, P11, DOI 10.1097/WNF.0000000000000063; Ospina MB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003755; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; Posey DJ, 2007, BIOL PSYCHIAT, V61, P538, DOI 10.1016/j.biopsych.2006.09.028; Schopler E., 1988, The childhood autism rating scale (CARS); Wink LK, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0088-6";24;2;3;0;6;AVES;SISLI;BUYUKDERE CAD 105-9, MECIDIYEKOY, SISLI, ISTANBUL 34394, Turkiye;2475-0573;2475-0581;;PSYCHIAT CLIN PSYCH;Psychiatry Clin. Psychopharmacol.;;2017;27;2;;;;;190;193;;10.1080/24750573.2017.1309817;http://dx.doi.org/10.1080/24750573.2017.1309817;;;4;"Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pharmacology & Pharmacy; Psychiatry";EY4IT;;gold;;;24/11/2024;WOS:000403941900012;View Full Record in Web of Science
J;"Hellings, JA; Boehm, D; Yeh, HW; Butler, MG; Schroeder, SR";;;;"Hellings, Jessica A.; Boehm, Danna; Yeh, Hung Wen; Butler, Merlin G.; Schroeder, Stephen R.";;;Long-Term Aripiprazole in Youth With Developmental Disabilities Including Autism;JOURNAL OF MENTAL HEALTH RESEARCH IN INTELLECTUAL DISABILITIES;;;English;Article;;;;;;"adolescents; long-term; aripiprazole; children; autism";;"We retrospectively reviewed clinic charts of 21 children and adolescents with developmental disabilities including autism spectrum disorders (ASD) treated consecutively with aripiprazole (ARI) for irritability and severe challenging behaviors. Data extracted include age, sex, and race; level of intellectual disability (ID); Diagnostic and Statistical Manual-IV diagnoses including comorbidity, ARI dosage, and treatment duration; other psychoactive medications and Clinical Global Impressions-Improvement (CGI-I) at baseline and end point; weight; height; and side effects. Body mass index (BMI) z scores are compared with Centers for Disease Control norms. Eleven boys and 10 girls with ID and/or ASD ages 8 to 18 years (mean age 13.4 years) received ARI; mean dose was 8.4 mg/day (range 2.5 to 15); average duration was 60.6 weeks (7 to 132). Eleven of 21 patients (52%) met CGI-I response of <= 2. ARI was well tolerated, including together with stimulants, divalproex, or less commonly other medications. Mean BMI was 23.8 +/- 5.9 at baseline and 24.2 +/- 5.2 at end. Mean BMI z score increase was 0.06 +/- 0.67. Four individuals (19%) manifested early intolerable weight gain. In this long-term clinical sample, ARI was effective in 52% and well tolerated. ARI was mostly weight neutral; early weight gain was intolerable in 19%. Larger long-term outcome studies are warranted in this population.";"[Hellings, Jessica A.; Butler, Merlin G.] Univ Kansas, Med Ctr, Dept Psychiat & Behav Sci, Kansas City, KS 66160 USA; [Boehm, Danna] Johnson Cty Mental Hlth, Mission, KS USA; [Yeh, Hung Wen] Univ Kansas, Med Ctr, Ctr Biostat & Adv Informat, Kansas City, KS 66160 USA; [Schroeder, Stephen R.] Univ Kansas, Life Span Inst, Kansas City, KS 66160 USA";"University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas";Hellings, JA (corresponding author), Univ Kansas, Med Ctr, MS 4015,3901 Rainbow Blvd, Kansas City, KS 66160 USA.;jhelling@kumc.edu;Yeh, Hung-Wen/E-8104-2015;Yeh, Hung-wen/0000-0002-9904-3275;NICHD NIH HHS [P01 HD030329, P30 HD002528] Funding Source: Medline;NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD));;"[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Baker R., 2009, 49 ANN NAT CLIN DRUG; Bouchard L, 2010, AM J CLIN NUTR, V91, P309, DOI 10.3945/ajcn.2009.28085; Burris KD, 2002, J PHARMACOL EXP THER, V302, P381, DOI 10.1124/jpet.102.033175; Byerly MJ, 2009, SCHIZOPHR RES, V107, P218, DOI 10.1016/j.schres.2008.09.019; Chang K. D., 2007, AM ACAD CHILD AD PSY; Cooper WO, 2006, AMBUL PEDIATR, V6, P79, DOI 10.1016/j.ambp.2005.11.002; Correll CU, 2009, JAMA-J AM MED ASSOC, V302, P1765, DOI 10.1001/jama.2009.1549; Findling RL, 2003, J CLIN PSYCHIAT, V64, P1362, DOI 10.4088/JCP.v64n1113; Findling RL, 2008, AM J PSYCHIAT, V165, P1432, DOI 10.1176/appi.ajp.2008.07061035; Ghaffari M., 2009, NAT CLIN DRUG EV UN; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Hellings J. A., 2004, NAT CLIN DRUG EV UN; Hellings JA, 2001, J CHILD ADOL PSYCHOP, V11, P229, DOI 10.1089/10445460152595559; Hellings JA, 2006, J AUTISM DEV DISORD, V36, P401, DOI 10.1007/s10803-006-0078-1; Hellings JA, 2010, J MENT HEALTH RES IN, V3, P132, DOI 10.1080/19315864.2010.494763; Malone RP, 2005, CNS DRUGS, V19, P923, DOI 10.2165/00023210-200519110-00003; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Marder SR, 2003, AM J PSYCHIAT, V160, P1405, DOI 10.1176/appi.ajp.160.8.1405; Martin A, 2004, AM J PSYCHIAT, V161, P1125, DOI 10.1176/appi.ajp.161.6.1125; McDougle CJ, 2003, J CLIN PSYCHIAT, V64, P16; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Parikh MS, 2008, J CHILD ADOL PSYCHOP, V18, P157, DOI 10.1089/cap.2007.0041; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; Potkin SG, 2003, ARCH GEN PSYCHIAT, V60, P681, DOI 10.1001/archpsyc.60.7.681; Reynolds GP, 2002, LANCET, V359, P2086, DOI 10.1016/S0140-6736(02)08913-4; Sanford Mark, 2007, Paediatr Drugs, V9, P419, DOI 10.2165/00148581-200709060-00009; Stigler KA, 2004, J CHILD ADOL PSYCHOP, V14, P455; Valicenti-McDermott MR, 2006, J CHILD ADOL PSYCHOP, V16, P549, DOI 10.1089/cap.2006.16.549; Waade RB, 2009, THER DRUG MONIT, V31, P233, DOI 10.1097/FTD.0b013e3181956726; Yokoi F, 2002, NEUROPSYCHOPHARMACOL, V27, P248, DOI 10.1016/S0893-133X(02)00304-4";31;6;6;0;5;ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD;ABINGDON;4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND;1931-5864;1931-5872;;J MENT HEALTH RES IN;J. Ment. Health Res. Intellect. Disabil.;mars-04;2011;4;1;;;;;40;52;;10.1080/19315864.2010.542274;http://dx.doi.org/10.1080/19315864.2010.542274;;;13;"Education, Special; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychiatry; Rehabilitation";V37ZV;28163818;Green Accepted;;;24/11/2024;WOS:000209314600003;View Full Record in Web of Science
J;"Klein, N; Kemper, KJ";;;;"Klein, Nadav; Kemper, Kathi J.";;;Integrative Approaches to Caring for Children with Autism;CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE;;;English;Article;;;;;;;"SPECTRUM DISORDERS; ALTERNATIVE MEDICINE; COMPLEMENTARY; RISK; INTERVENTION; THERAPY; TRIAL; ACID";Parents commonly integrate complementary and alternative medical (CAM) treatments for autism spectrum disorder (ASD) with conventional care. The aims of this article are to (1) describe the most commonly used treatments, (2) assess their efficacy and safety, and (3) organize the information in practical format for practitioners. We organized treatment modalities into four categories: recommended, monitored, tolerated, and therapies that should be avoided. These four categories are based on a two by two table weighing a therapy's effectiveness and safety. To meet the threshold for recommended, its effectiveness needed to be supported by two or more randomized, controlled trials. In addition to promoting an overall healthy lifestyle via nutrition, exercise, sleep, stress management, social support, and avoiding neurotoxins (healthy habits in a healthy habitat), the most promising therapies recommend are applied behavior analysis, parent-implemented training, melatonin supplements to improve sleep, supplements to correct deficiencies, and music therapy. Medications and restrictive diets may be helpful for some children, but use should be monitored given the risk of side effects. Most complementary therapies are safe, so they can be tolerated, but additional research is needed before they should be recommended. Given their risks, costs, and limited evidence of efficacy, chelation, secretin, and hyperbaric oxygen should be avoided.;"[Klein, Nadav; Kemper, Kathi J.] Ohio State Univ, Coll Med, Ctr Integrat Hlth & Wellness, Columbus, OH 43210 USA";"University System of Ohio; Ohio State University";Klein, N (corresponding author), Ohio State Univ, Coll Med, Ctr Integrat Hlth & Wellness, Columbus, OH 43210 USA.;;Klein, Nadav/LNP-2938-2024;;;;;"Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; Akins RS, 2014, J DEV BEHAV PEDIATR, V35, P1, DOI 10.1097/DBP.0000000000000013; Alcantara J, 2011, EXPLORE-NY, V7, P384, DOI 10.1016/j.explore.2011.08.001; [Anonymous], NUTR NEUROSCI; Bertoglio K, 2010, J ALTERN COMPLEM MED, V16, P555, DOI 10.1089/acm.2009.0177; Bradshaw J, 2015, J AUTISM DEV DISORD, V45, P778, DOI 10.1007/s10803-014-2235-2; Case-Smith J, 2008, AM J OCCUP THER, V62, P416, DOI 10.5014/ajot.62.4.416; De Angelis M, 2015, GUT MICROBES, V6, P207, DOI 10.1080/19490976.2015.1035855; Dickerson AS, 2015, SCI TOTAL ENVIRON, V536, P245, DOI 10.1016/j.scitotenv.2015.07.024; DOLSKE MC, 1993, PROG NEURO-PSYCHOPH, V17, P765, DOI 10.1016/0278-5846(93)90058-Z; Dosman C, 2013, PEDIATR REV, V34, pE36, DOI 10.1542/pir.34-10-e36; Gabriels RL, 2015, J AM ACAD CHILD PSY, V54, P541, DOI 10.1016/j.jaac.2015.04.007; Geretsegger M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004381.pub3; Ghanizadeh A, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-13; Huang A, 2013, J ALTERN COMPLEM MED, V19, P746, DOI 10.1089/acm.2012.0640; Hurt E, 2014, CHILD ADOL PSYCH CL, V23, P465, DOI 10.1016/j.chc.2014.02.001; James S, 2015, COCHRANE DATABASE SY; Ji NY, 2015, CURR OPIN PSYCHIATR, V28, P91, DOI 10.1097/YCO.0000000000000132; Kaluzna-Czaplinska J, 2013, ACTA BIOCHIM POL, V60, P137; Kemper KJ, 2008, PEDIATRICS, V122, P1374, DOI 10.1542/peds.2008-2173; Koenig KP, 2012, AM J OCCUP THER, V66, P538, DOI 10.5014/ajot.2012.004390; Lee MS, 2012, J AUTISM DEV DISORD, V42, P1671, DOI 10.1007/s10803-011-1409-4; Lee MS, 2011, J CLIN PSYCHIAT, V72, P406, DOI 10.4088/JCP.09r05848whi; Levy SE, 2015, CHILD ADOL PSYCH CL, V24, P117, DOI 10.1016/j.chc.2014.09.004; Lyall K, 2014, INT J EPIDEMIOL, V43, P443, DOI 10.1093/ije/dyt282; Macfabe Derrick, 2013, Glob Adv Health Med, V2, P52, DOI 10.7453/gahmj.2013.089; Malow B, 2012, J AUTISM DEV DISORD, V42, P1729, DOI 10.1007/s10803-011-1418-3; Marí-Bauset S, 2014, J CHILD NEUROL, V29, P1718, DOI 10.1177/0883073814531330; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Mehl-Madrona L, 2010, J CHILD ADOL PSYCHOP, V20, P95, DOI 10.1089/cap.2009.0011; Ming X, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/679845; Mortimer R, 2014, J MULTIDISCIP HEALTH, V7, P93, DOI 10.2147/JMDH.S55345; Mousain-Bosc M, 2006, MAGNESIUM RES, V19, P53; Neely L, 2015, BEHAV MODIF, V39, P98, DOI 10.1177/0145445514552891; Oberman LM, 2015, J AUTISM DEV DISORD, V45, P524, DOI 10.1007/s10803-013-1960-2; Rosenblatt LE, 2011, J ALTERN COMPLEM MED, V17, P1029, DOI 10.1089/acm.2010.0834; Sect Complementary Integrative Med, 2012, PEDIATRICS, V129, P1186, DOI 10.1542/peds.2012-0876; Smith IC, 2015, J AUTISM DEV DISORD, V45, P2541, DOI 10.1007/s10803-015-2423-8; Stewart PA, 2015, J ACAD NUTR DIET, V115, P1237, DOI 10.1016/j.jand.2015.03.026; Surén P, 2013, JAMA-J AM MED ASSOC, V309, P570, DOI 10.1001/jama.2012.155925; Wetherby AM, 2014, PEDIATRICS, V134, P1084, DOI 10.1542/peds.2014-0757";41;27;42;1;62;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;1538-5442;1538-3199;;CURR PROB PEDIATR AD;Curr. Probl. Pediatr. Adolesc. Health Care;JUN;2016;46;6;;;;;195;201;;10.1016/j.cppeds.2015.12.004;http://dx.doi.org/10.1016/j.cppeds.2015.12.004;;;7;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;DN8HD;26776326;;;;24/11/2024;WOS:000377318900008;View Full Record in Web of Science
J;"Boone, KM; Parrott, A; Rausch, J; Yeates, KO; Klebanoff, MA; Turner, AN; Keim, SA";;;;"Boone, Kelly M.; Parrott, Andria; Rausch, Joseph; Yeates, Keith Owen; Klebanoff, Mark A.; Norris Turner, Abigail; Keim, Sarah A.";;;Fatty Acid Supplementation and Socioemotional Outcomes: Secondary Analysis of a Randomized Trial;PEDIATRICS;;;English;Article;;;;;;;"PRETERM INFANTS; DOCOSAHEXAENOIC ACID; ARACHIDONIC-ACID; FOLLOW-UP; PUFA SUPPLEMENTATION; CHILDREN BORN; TERM INFANTS; AUTISM; GROWTH; RISK";"In this secondary analysis of a randomized clinical trial, we tested the effects of DHA + AA supplementation versus placebo for 180 days on caregiver-reported socioemotional development of toddlers born preterm. BACKGROUND AND OBJECTIVES: Children born preterm experience socioemotional difficulties, including increased risk of autism spectrum disorder (ASD). In this secondary analysis, we tested the effect of combined docosahexaenoic acid (DHA) and arachidonic acid (AA) supplementation during toddlerhood on caregiver-reported socioemotional outcomes of children born preterm. We hypothesized that children randomly assigned to DHA + AA would display better socioemotional outcomes compared with those randomly assigned to a placebo. METHODS: Omega Tots was a single-site randomized, fully masked, parallel-group, placebo-controlled trial. Children (N= 377) were 10 to 16 months at enrollment, born at <35 weeks' gestation, and assigned to 180 days of daily 200-mg DHA + 200-mg AA supplementation or a placebo (400 mg corn oil). Caregivers completed the Brief Infant-Toddler Social and Emotional Assessment and the Pervasive Developmental Disorders Screening Test-II, Stage 2 at the end of the trial. Liner mixed models and log-binomial regression compared socioemotional outcomes between the DHA + AA and placebo groups. RESULTS: Outcome data were available for 83% of children (n(treatment)= 161;n(placebo)= 153). Differences between DHA + AA and placebo groups on Brief Infant-Toddler Social and Emotional Assessment scores were of small magnitude (Cohen'sd <= 0.15) and not statistically significant. Children randomly assigned to DHA + AA had a decreased risk of scoring at-risk for ASD on the Pervasive Developmental Disorders Screening Test-II, Stage 2 (21% vs 32%; risk ratio = 0.66 [95% confidence interval: 0.45 to 0.97]; risk difference = -0.11 [95% confidence interval: -0.21 to -0.01]) compared with children randomly assigned to a placebo. CONCLUSIONS: No evidence of benefit of DHA + AA supplementation on caregiver-reported outcomes of broad socioemotional development was observed. Supplementation resulted in decreased risk of clinical concern for ASD. Further exploration in larger samples of preterm children and continued follow-up of children who received DHA + AA supplementation as they approach school age is warranted.";"[Boone, Kelly M.; Parrott, Andria; Rausch, Joseph; Keim, Sarah A.] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA; [Klebanoff, Mark A.] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Perinatal Res, Columbus, OH USA; [Klebanoff, Mark A.; Norris Turner, Abigail; Keim, Sarah A.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA; [Norris Turner, Abigail] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; [Rausch, Joseph; Klebanoff, Mark A.; Keim, Sarah A.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Klebanoff, Mark A.] Ohio State Univ, Coll Med, Dept Obstet & Gynecol, Columbus, OH 43210 USA; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Dept Psychol, Res Inst, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada";"University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Calgary; Alberta Childrens Hospital; University of Calgary";Boone, KM (corresponding author), Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.;kelly.boone@nationwidechildrens.org;"Keim, Sarah/F-8929-2013; Norris Turner, Abigail/GYD-4753-2022; Yeates, Keith/AAJ-4223-2020; Rausch, Joseph/E-8107-2018";;"Health Resources and Services Administration of the US Department of Health and Human Services [R40MC28316]; March of Dimes [12-FY14-171]; Allen Foundation; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01HD100493]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR001070]; Abigail Wexner Research Institute at Nationwide Children's Hospital; DSM Nutritional Products; Health Resources and Services Administration; National Institutes of Health (NIH); Cures Within Reach";"Health Resources and Services Administration of the US Department of Health and Human Services; March of Dimes(March of Dimes); Allen Foundation; Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Abigail Wexner Research Institute at Nationwide Children's Hospital; DSM Nutritional Products; Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cures Within Reach";"Supported by the Health Resources and Services Administration of the US Department of Health and Human Services (grant R40MC28316), the March of Dimes (grant 12-FY14-171), the Allen Foundation, Cures Within Reach, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant R01HD100493), and the National Center for Advancing Translational Sciences of the National Institutes of Health (grant UL1TR001070), and internal support was received from the Abigail Wexner Research Institute at Nationwide Children's Hospital. DSM Nutritional Products provided the investigational products at no cost and had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The information, content, and/or conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by, the Health Resources and Services Administration, the US Department of Health and Human Services, or the US Government. Funded by the National Institutes of Health (NIH).";"[Anonymous], 2007, STAND INF FORM FORM; Argaw A, 2019, J NUTR, V149, P505, DOI 10.1093/jn/nxy202; Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Bernardo J, 2015, J PERINATOL, V35, P208, DOI 10.1038/jp.2014.192; Bertrand PC, 2006, J NUTR, V136, P1570, DOI 10.1093/jn/136.6.1570; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Boone KM, 2018, CHILD PSYCHIAT HUM D, V49, P493, DOI 10.1007/s10578-017-0768-2; Briggs-Gowan M. J., 2006, APA PSYCTESTS; Carlson S E, 2001, Semin Neonatol, V6, P437, DOI 10.1053/siny.2001.0093; CARLSON SE, 1993, P NATL ACAD SCI USA, V90, P1073, DOI 10.1073/pnas.90.3.1073; Centers for Disease Control and Prevetion, 2019, PRET BIRTH; Chalon S, 2006, PROSTAG LEUKOTR ESS, V75, P259, DOI 10.1016/j.plefa.2006.07.005; Clandinin MT, 2005, J PEDIATR-US, V146, P461, DOI 10.1016/j.jpeds.2004.11.030; CLANDININ MT, 1980, EARLY HUM DEV, V4, P121, DOI 10.1016/0378-3782(80)90015-8; Collins CT, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007314; Fleith M, 2005, CRIT REV FOOD SCI, V45, P205, DOI 10.1080/10408690590956378; Gould JF, 2017, JAMA-J AM MED ASSOC, V317, P1173, DOI 10.1001/jama.2016.21303; Guy A, 2015, J PEDIATR-US, V166, P269, DOI 10.1016/j.jpeds.2014.10.053; Henriksen C, 2008, PEDIATRICS, V121, P1137, DOI 10.1542/peds.2007-1511; Innis SM, 2005, PLACENTA, V26, pS70, DOI 10.1016/j.placenta.2005.01.005; Innis SM, 2002, J PEDIATR-US, V140, P547, DOI 10.1067/mpd.2002.123282; Johnson S, 2010, J PEDIATR-US, V156, P525, DOI 10.1016/j.jpeds.2009.10.041; Keim S, OMEGA TOTS RANDOMIZE; Keim SA, 2018, JAMA PEDIATR, V172, P1126, DOI 10.1001/jamapediatrics.2018.3082; Keim SA, 2018, J NUTR, V148, P227, DOI 10.1093/jn/nxx047; Keim SA, 2015, MATERN CHILD NUTR, V11, P987, DOI 10.1111/mcn.12077; Kitajka K, 2002, P NATL ACAD SCI USA, V99, P2619, DOI 10.1073/pnas.042698699; Koletzko B, 2020, AM J CLIN NUTR, V111, P10, DOI 10.1093/ajcn/nqz252; Kolevzon A, 2007, ARCH PEDIAT ADOL MED, V161, P326, DOI 10.1001/archpedi.161.4.326; Kuratko C, 2013, NUTRITION, V29, P807, DOI 10.1016/j.nut.2012.10.013; Kuzniewicz MW, 2014, J PEDIATR-US, V164, P20, DOI 10.1016/j.jpeds.2013.09.021; Luu TM, 2017, CLIN PERINATOL, V44, P305, DOI 10.1016/j.clp.2017.01.003; Makrides M, 2014, JAMA-J AM MED ASSOC, V311, P1802, DOI 10.1001/jama.2014.2194; O'Connor DL, 2001, PEDIATRICS, V108, P359, DOI 10.1542/peds.108.2.359; Pritchard MA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1949; Puri BK, 2014, PROSTAG LEUKOTR ESS, V90, P179, DOI 10.1016/j.plefa.2014.01.004; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rothman KJ, 2014, J GEN INTERN MED, V29, P1060, DOI 10.1007/s11606-013-2755-z; Shulkin M, 2018, J NUTR, V148, P409, DOI 10.1093/jn/nxx031; Siegel B., 2004, PERVASIVE DEV DISORD; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248; Smithers LG, 2010, AM J CLIN NUTR, V91, P628, DOI 10.3945/ajcn.2009.28603; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Spittle AJ, 2009, J AM ACAD CHILD PSY, V48, P909, DOI 10.1097/CHI.0b013e3181af8235; Südhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456; Thompson RA, 2008, CHILD DEV PERSPECT, V2, P124, DOI 10.1111/j.1750-8606.2008.00054.x; Twilhaar ES, 2018, ARCH DIS CHILD-FETAL, V103, pF322, DOI 10.1136/archdischild-2017-312916; Verhaeghe L, 2016, CHILD PSYCHIAT HUM D, V47, P729, DOI 10.1007/s10578-015-0606-3; Westerberg AC, 2011, ACTA PAEDIATR, V100, P47, DOI 10.1111/j.1651-2227.2010.01946.x";49;6;6;2;10;AMER ACAD PEDIATRICS;ELK GROVE VILLAGE;141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA;0031-4005;1098-4275;;PEDIATRICS;Pediatrics;OCT;2020;146;4;;;;;;;e20200284;10.1542/peds.2020-0284;http://dx.doi.org/10.1542/peds.2020-0284;;;10;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;OG1VI;32887793;Green Published, Bronze;;;24/11/2024;WOS:000581680200060;View Full Record in Web of Science
J;"Downs, J; Dean, H; Lechler, S; Sears, N; Patel, R; Shetty, H; Hotopf, M; Ford, T; Kyriakopoulos, M; Diaz-Caneja, CM; Arango, C; MacCabe, JH; Hayes, RD; Pina-Camacho, L";;;;"Downs, Johnny; Dean, Harry; Lechler, Suzannah; Sears, Nicola; Patel, Rashmi; Shetty, Hitesh; Hotopf, Matthew; Ford, Tamsin; Kyriakopoulos, Marinos; Diaz-Caneja, Covadonga M.; Arango, Celso; MacCabe, James H.; Hayes, Richard D.; Pina-Camacho, Laura";;;Negative Symptoms in Early-Onset Psychosis and Their Association With Antipsychotic Treatment Failure;SCHIZOPHRENIA BULLETIN;;;English;Article;;;;;;"early-onset psychosis; first-episode psychosis; negative symptoms; antipsychotic agents; treatment resistance";"1ST EPISODE; 1ST-EPISODE SCHIZOPHRENIA; SPECTRUM DISORDERS; CLINICAL-PRACTICE; PREDICTORS; HEALTH; COHORT; PSYCHIATRISTS; PREVALENCE; CLOZAPINE";"The prevalence of negative symptoms (NS) at first episode of early-onset psychosis (EOP), and their effect on psychosis prognosis is unclear. In a sample of 638 children with EOP (aged 10-17 y, 51% male), we assessed (1) the prevalence of NS at first presentation to mental health services and (2) whether NS predicted eventual development of multiple treatment failure (MTF) prior to the age of 18 (defined by initiation of a third trial of novel antipsychotic due to prior insufficient response, intolerable adverse-effects or non-adherence). Data were extracted from the electronic health records held by child inpatient and community-based services in South London, United Kingdom. Natural Language Processing tools were used to measure the presence of Marder Factor NS and antipsychotic use. The association between presenting with >= 2 NS and the development of MTF over a 5-year period was modeled using Cox regression. Out of the 638 children, 37.5% showed >= 2 NS at first presentation, and 124 (19.3%) developed MTF prior to the age of 18. The presence of NS at first episode was significantly associated with MTF (adjusted hazard ratio 1.62, 95% CI 1.07-2.46; P = .02) after controlling for a number of potential confounders including psychosis diagnostic classification, positive symptoms, comorbid depression, and family history of psychosis. Other factors associated with MTF included comorbid autism spectrum disorder, older age at first presentation, Black ethnicity, and family history of psychosis. In EOP, NS at first episode are prevalent and may help identify a subset of children at higher risk of responding poorly to antipsychotics.";"[Downs, Johnny; Dean, Harry; Lechler, Suzannah; Sears, Nicola; Hotopf, Matthew; Hayes, Richard D.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England; [Downs, Johnny; Dean, Harry; Lechler, Suzannah; Sears, Nicola; Patel, Rashmi; Hotopf, Matthew; MacCabe, James H.; Hayes, Richard D.] NIHR South London & Maudsley Biomed Res Ctr, London, England; [Downs, Johnny; Patel, Rashmi; Shetty, Hitesh; Hotopf, Matthew; Kyriakopoulos, Marinos; MacCabe, James H.] South London & Maudsley NHS Fdn Trust, London, England; [Downs, Johnny; Kyriakopoulos, Marinos; Pina-Camacho, Laura] Kings Coll London, Dept Child & Adolescent Psychiat, Inst Psychiat Psychol & Neurosci, London, England; [Patel, Rashmi; MacCabe, James H.] Kings Coll London, Inst Psychiat Psychol Neurosci, Dept Psychosis Studies, London, England; [Ford, Tamsin] Univ Exeter, Sch Med, Exeter, Devon, England; [Kyriakopoulos, Marinos] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Diaz-Caneja, Covadonga M.; Arango, Celso; Pina-Camacho, Laura] Univ Complutense, Sch Med, Hosp Gen Univ Gregorio Maranon, Child & Adolescent Psychiat Dept,IiSGM,CIBERSAM, Madrid, Spain";"University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London; University of Exeter; Icahn School of Medicine at Mount Sinai; General University Gregorio Maranon Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Complutense University of Madrid";Pina-Camacho, L (corresponding author), Hosp Gen Univ Gregorio Maranon, Child & Adolescent Psychiat Dept, Ibiza 43, Madrid 28009, Spain.;lpina.iisgm@gmail.com;"Ford, Tamsin/V-5908-2019; Pina-Camacho, Laura/AAH-2770-2021; Hotopf, Matthew/E-4971-2010; Hayes, Richard/D-2382-2010; Sears, Nicola/HKE-7307-2023; Arango, Celso/AAZ-8314-2021; Kyriakopoulos, Marinos/F-8310-2014; Dean, Harry/IAR-5656-2023; Downs, Johnny/AAC-8287-2021; Pina-Camacho, Laura/E-8873-2019; MacCabe, James/E-5210-2010; Patel, Rashmi/O-1327-2013; Martinez Diaz-Caneja, Covadonga/X-8877-2018; Arango, Celso/H-6433-2015";"Hotopf, Matthew/0000-0002-3980-4466; Ford, Tamsin/0000-0001-5295-4904; Kyriakopoulos, Marinos/0000-0002-4594-2646; Pina-Camacho, Laura/0000-0003-1960-6443; MacCabe, James/0000-0002-6754-1018; Hayes, Richard/0000-0003-4453-244X; Patel, Rashmi/0000-0002-9259-8788; Martinez Diaz-Caneja, Covadonga/0000-0001-8538-3175; Arango, Celso/0000-0003-3382-4754; Downs, Johnny/0000-0002-8061-295X";"Medical Research Council (MRC) [MR/L017105/1]; Psychiatry Research Trust Peggy Pollak Research Fellowship in Developmental Psychiatry; MRC [MR/J01219X/1]; MRC CRTF [MR/K002813/1]; Spanish Ministry of Economy, Industry and Competitiveness. Instituto de Salud Carlos III; ERDF Funds from the European Commission, A way of making Europe; CIBERSAM, Madrid Regional Government [S2010/BMD-2422 AGES]; European Union [FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-603196, FP7-HEALTH-2013-2.2.1-2-602478]; European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking [115916; PRISM]; Fundacion Alicia Koplowitz; Fundacion Mutua Madrilena; MRC [MR/K002813/1, MR/J01219X/1, MR/L011794/1, MR/S003118/1, MR/L017105/1] Funding Source: UKRI";"Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Psychiatry Research Trust Peggy Pollak Research Fellowship in Developmental Psychiatry; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC CRTF(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Spanish Ministry of Economy, Industry and Competitiveness. Instituto de Salud Carlos III; ERDF Funds from the European Commission, A way of making Europe; CIBERSAM, Madrid Regional Government; European Union(European Union (EU)); European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking; Fundacion Alicia Koplowitz; Fundacion Mutua Madrilena(Instituto de Salud Carlos III); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))";"J.D. received supported by a Medical Research Council (MRC) Clinical Research Training Fellowship (MR/L017105/1) and Psychiatry Research Trust Peggy Pollak Research Fellowship in Developmental Psychiatry. H.D. and S.L. have received salary support from the Foundation of Professional Services to Adolescents, UK. R.D.H. was funded by an MRC Fellowship (MR/J01219X/1). R.P. was funded by an MRC CRTF (MR/K002813/1). C.A., L.P-C., and C.M.D-C. have held grants from the Spanish Ministry of Economy, Industry and Competitiveness. Instituto de Salud Carlos III, co-financed by ERDF Funds from the European Commission, A way of making Europe, CIBERSAM, Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds and European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (METSY); European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No-115916; PRISM); Fundacion Alicia Koplowitz and Fundacion Mutua Madrilena. M.H., J.H.M. and H.S. receive salary support from the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.";"Alvarez-Jiménez M, 2012, PSYCHOL MED, V42, P595, DOI 10.1017/S0033291711001504; [Anonymous], 2011, The English indices of deprivation 2010 for the Department for Communities and Local Government, DOI DOI 10.21704/AC.V77I2.483; Austin SF, 2013, SCHIZOPHR RES, V150, P163, DOI 10.1016/j.schres.2013.07.031; Bobes J, 2010, J CLIN PSYCHIAT, V71, P280, DOI 10.4088/JCP.08m04250yel; Boeing L, 2007, BRIT J PSYCHIAT, V190, P18, DOI 10.1192/bjp.190.1.18; Campbell F., 2016, Cochrane Database Syst Rev; Chang WC, 2013, PSYCHIAT RES, V209, P353, DOI 10.1016/j.psychres.2013.02.014; Chowdhury GG, 2003, ANNU REV INFORM SCI, V37, P51, DOI 10.1002/aris.1440370103; Cunningham H, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002854; Daniel DG, 2013, SCHIZOPHR RES, V150, P343, DOI 10.1016/j.schres.2013.07.005; Demjaha A, 2014, BIOL PSYCHIAT, V75, pE11, DOI 10.1016/j.biopsych.2013.06.011; Díaz-Caneja CM, 2015, NPJ SCHIZOPHR, V1, DOI 10.1038/npjschz.2014.5; Downs J, 2017, ARCH DIS CHILD, V102, P599, DOI 10.1136/archdischild-2016-311656; Downs J, 2016, EUR CHILD ADOLES PSY, V25, P649, DOI 10.1007/s00787-015-0780-7; Downs JM, 2017, J CLIN PSYCHIAT, V78, pE1233, DOI 10.4088/JCP.16m11422; FIELDS JH, 1994, AM J PSYCHIAT, V151, P249; Gilbody SM, 2002, BRIT J PSYCHIAT, V180, P101, DOI 10.1192/bjp.180.2.101; Green J, 2006, J CHILD PSYCHOL PSYC, V47, P425, DOI 10.1111/j.1469-7610.2005.01516.x; Hassan GAM, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-28; Hayes RD, 2015, SCHIZOPHRENIA BULL, V41, P644, DOI 10.1093/schbul/sbu120; Howes OD, 2014, BRIT J PSYCHIAT, V205, P1, DOI 10.1192/bjp.bp.113.138578; Hunter R, 2012, EUR PSYCHIAT, V27, P432, DOI 10.1016/j.eurpsy.2011.02.015; Jackson MSc Richard G, 2014, AMIA Annu Symp Proc, V2014, P729; Jackson RG, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012012; Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9; Kapila A, 2019, EARLY INTERV PSYCHIA, V13, P509, DOI 10.1111/eip.12511; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kirkpatrick B, 2001, ARCH GEN PSYCHIAT, V58, P165, DOI 10.1001/archpsyc.58.2.165; Laruelle M, 2014, CURR OPIN PHARMACOL, V14, P97, DOI 10.1016/j.coph.2014.01.001; Liao KP, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1885; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Marder SR, 1997, J CLIN PSYCHIAT, V58, P538, DOI 10.4088/JCP.v58n1205; Milev P, 2005, AM J PSYCHIAT, V162, P495, DOI 10.1176/appi.ajp.162.3.495; Milian MJ, 2014, EUR NEUROPSYCHOPHARM, V24, P645, DOI 10.1016/j.euroneuro.2014.03.008; Murphy SN, 2010, J AM MED INFORM ASSN, V17, P124, DOI 10.1136/jamia.2009.000893; Parellada M, 2015, J CLIN PSYCHIAT, V76, pE1441, DOI 10.4088/JCP.13m08863; Patel R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009888; Patel R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007619; Perera G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008721; Perivoliotis D, 2009, PSYCHOPATHOLOGY, V42, P375, DOI 10.1159/000236909; Rapado-Castro M, 2010, J CLIN PSYCHIAT, V71, P327, DOI 10.4088/JCP.08m04845yel; Roberts Angus, 2017, AMA J Ethics, V19, P281, DOI 10.1001/journalofethics.2017.19.3.stas1-1703; Robinson DG, 1999, AM J PSYCHIAT, V156, P544; Sarkar S, 2015, WORLD J PSYCHIATR, V5, P352, DOI 10.5498/wjp.v5.i4.352; Schimmelmann BG, 2007, SCHIZOPHR RES, V95, P1, DOI 10.1016/j.schres.2007.06.004; Schneider C, 2015, EUR NEUROPSYCHOPHARM, V25, P857, DOI 10.1016/j.euroneuro.2015.02.003; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Stentebjerg-Olesen M, 2016, J CHILD ADOL PSYCHOP, V26, P410, DOI 10.1089/cap.2015.0097; Stewart R, 2016, SOC PSYCH PSYCH EPID, V51, P1055, DOI 10.1007/s00127-016-1266-8; Strauss GP, 2012, SCHIZOPHR RES, V135, P134, DOI 10.1016/j.schres.2011.11.007; STRAUSS J S, 1974, Schizophrenia Bulletin, V11, P61; Suzuki T, 2012, PSYCHIAT RES, V197, P1, DOI 10.1016/j.psychres.2012.02.013; Tandon R, 2009, SCHIZOPHR RES, V110, P1, DOI 10.1016/j.schres.2009.03.005; Tasma M, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0817-6; Vyas NS, 2007, EUR CHILD ADOLES PSY, V16, P465, DOI 10.1007/s00787-007-0621-4; White C, 2009, PSYCHOL MED, V39, P1447, DOI 10.1017/S003329170800514X; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Zimmerman M, 2008, J CLIN PSYCHIAT, V69, P1916, DOI 10.4088/JCP.v69n1209";58;40;42;2;8;OXFORD UNIV PRESS;OXFORD;GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND;0586-7614;1745-1701;;SCHIZOPHRENIA BULL;Schizophr. Bull.;JAN;2019;45;1;;;;;69;79;;10.1093/schbul/sbx197;http://dx.doi.org/10.1093/schbul/sbx197;;;11;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;HP2RL;29370404;Green Published, Green Accepted, hybrid;;;24/11/2024;WOS:000461523000012;View Full Record in Web of Science
J;"Wood, JJ; Wood, KS; Cho, AC; Rosenau, KA; Guevara, MC; Galán, C; Bazzano, A; Zeldin, AS; Hellemann, G";;;;"Wood, Jeffrey J.; Wood, Karen Sze; Cho, An Chuen; Rosenau, Kashia A.; Guevara, Maria Cornejo; Galan, Chardee; Bazzano, Alicia; Zeldin, Ari S.; Hellemann, Gerhard";;;Modular Cognitive Behavioral Therapy for Autism-Related Symptoms in Children: A Randomized Controlled Trial;JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY;;;English;Article;;;;;;"cognitive behavioral therapy; randomized controlled trial; autism-related symptoms";"SPECTRUM DISORDERS; ADAPTIVE-BEHAVIOR; SOCIAL-SKILLS; ANXIETY; YOUTH; ADOLESCENTS; SCHOOL; INTERVENTIONS; CHILDHOOD; SERVICE";"Objective: To date, no one-on-one psychotherapy protocol for elementary and middle school-aged children with autism spectrum disorder (ASD) has been found to be efficacious for treating autism-related symptoms such as failure to initiate social interactions. This study compared modular cognitive behavioral therapy (CBT) with enhanced standard community treatment (ESCT) in terms of impact on the severity of autism-related symptoms. Method: Children with ASD (N = 107; aged 6-13 years) were randomly assigned to a treatment condition (CBT or ESCT). Both treatments provided 32 therapy sessions. The CBT condition utilized a modular design, matching specific evidence-based treatment elements to each child's clinical needs (e.g., social-communication symptoms). The ESCT condition provided social skills training and cognitive behavioral training in a structured and linear group therapy format. The primary outcome measure was independent evaluator ratings of peer engagement during school recess using a structured and validated observation system. Parents also made sessionby-session ratings on personalized autism-related symptom profiles throughout treatment. Results: CBT outperformed ESCT on the primary outcome measure (p < .001; d = .50; 95% CI [.06, .93]) and the secondary outcome measure (p = .003; d = .87; 95% CI [.45, 1.27]). Conclusions: The modular one-on-one CBT program evaluated in this study may be beneficial for reducing the severity of autism-related symptoms in some children with ASD. Further research is needed to clarify the extent of the treatment effect and the feasibility of implementation for therapists in the community.";"[Wood, Jeffrey J.; Cho, An Chuen; Rosenau, Kashia A.] Univ Calif Los Angeles, Dept Educ, Div Human Dev & Psychol, Los Angeles, CA 90095 USA; [Wood, Jeffrey J.; Wood, Karen Sze; Guevara, Maria Cornejo; Bazzano, Alicia; Hellemann, Gerhard] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Galan, Chardee] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Zeldin, Ari S.] Naval Med Ctr, San Diego, CA USA";"University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Defense; United States Navy; Naval Medical Center San Diego";Wood, JJ (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.;jeffwood@ucla.edu;Galan, Chardee/AAQ-2998-2021;"Cho, An-Chuen/0000-0001-9848-8689; Rosenau, Kashia/0000-0001-9581-7264; Wood, Jeffrey/0000-0002-0759-6156; /0000-0002-3449-5203; Zeldin, Ari/0000-0002-0519-8832";"National Institute of Mental Health [R01-MH094391]; Autism Speaks";"National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Autism Speaks";This research was supported by a grant from the National Institute of Mental Health (R01-MH094391) and a clinical trials grant from Autism Speaks.;"Ashburner J, 2010, RES AUTISM SPECT DIS, V4, P18, DOI 10.1016/j.rasd.2009.07.002; Attwood T., 2013, CBT for children and adolescents with high-functioning autism spectrum disorders, P27; Aubry A, 2018, FRONT PSYCHOL, V9, DOI [10.3389/fpsyg.2018.00830, 10.3339/fpsyg.2078.00830]; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Bauer DJ, 2008, MULTIVAR BEHAV RES, V43, P210, DOI 10.1080/00273170802034810; Brewin CR, 2006, BEHAV RES THER, V44, P765, DOI 10.1016/j.brat.2006.02.005; Brewin CR, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X14000144; Charman T, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0145-9; Croen LA, 2017, J AUTISM DEV DISORD, V47, P3347, DOI 10.1007/s10803-017-3247-5; Duncan AW, 2015, AUTISM, V19, P64, DOI 10.1177/1362361313510068; Eckshtain D, 2020, J AM ACAD CHILD PSY, V59, P45, DOI 10.1016/j.jaac.2019.04.002; Feingold A, 2013, REV GEN PSYCHOL, V17, P111, DOI 10.1037/a0030048; Ferraioli SJ, 2011, EVIDENCE-BASED PRACTICES AND TREATMENTS FOR CHILDREN WITH AUTISM, P171, DOI 10.1007/978-1-4419-6975-0_6; Frankel F, 2010, J AUTISM DEV DISORD, V40, P827, DOI 10.1007/s10803-009-0932-z; Golya N, 2018, J INTELLECT DEV DIS, V43, P102, DOI 10.3109/13668250.2017.1287886; Gotham K, 2007, J AUTISM DEV DISORD, V37, P613, DOI 10.1007/s10803-006-0280-1; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P1007, DOI 10.1007/s10803-010-1126-4; KANNER L, 1954, Proc Annu Meet Am Psychopathol Assoc, P227; Kasari C, 2012, J CHILD PSYCHOL PSYC, V53, P431, DOI 10.1111/j.1469-7610.2011.02493.x; Kazdin A., 1991, Parent expectancies for therapy scale; Koegel RL, 2001, J CLIN CHILD PSYCHOL, V30, P19, DOI 10.1207/S15374424JCCP3001_4; Lavelle TA, 2014, PEDIATRICS, V133, pE520, DOI 10.1542/peds.2013-0763; Locke J, 2014, J PSYCHOEDUC ASSESS, V32, P62, DOI 10.1177/0734282913485543; Lord C., 2014, AUTISM DIAGNOSTIC OB; Ness SL, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00111; Nock M.K., 2001, Journal of Child and Family Studies, V10, P155, DOI DOI 10.1023/A:1016699424731; Noordhof A, 2015, J ABNORM CHILD PSYCH, V43, P577, DOI 10.1007/s10802-014-9923-4; Pugliese CE, 2015, J AUTISM DEV DISORD, V45, P1579, DOI 10.1007/s10803-014-2309-1; Raudenbush S., 2019, HLM 8: Linear and nonlinear modeling; Reaven J, 2018, J CONSULT CLIN PSYCH, V86, P205, DOI 10.1037/ccp0000285; Roundfield KD, 2017, PSYCHIAT SERV, V68, P876, DOI 10.1176/appi.ps.201600193; RUTTER M, 1968, J CHILD PSYCHOL PSYC, V9, P1, DOI 10.1111/j.1469-7610.1968.tb02204.x; Rutter M., 2003, ADI R AUTISM DIAGNOS; Ryan JJ, 2009, PSYCHOL REP, V104, P874, DOI 10.2466/PR0.104.3.874-878; Southam-Gerow MA, 2014, J CLIN CHILD ADOLESC, V43, P1, DOI 10.1080/15374416.2013.855128; Storch EA, 2013, J AM ACAD CHILD PSY, V52, P132, DOI 10.1016/j.jaac.2012.11.007; Stuart EA, 2017, HEALTH AFFAIR, V36, P337, DOI 10.1377/hlthaff.2016.0824; Sze KM, 2008, BEHAV COGN PSYCHOTH, V36, P403, DOI 10.1017/S1352465808004384; Usher LV, 2015, RES AUTISM SPECT DIS, V17, P25, DOI 10.1016/j.rasd.2015.05.005; Wechsler D, 2003, Weschler Intelligence Scale for Children, Fourth Edition, Australian Administration and Scoring Manual, VFourth; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); Weisz JR, 2017, AM PSYCHOL, V72, P79, DOI 10.1037/a0040360; Weisz JR, 2012, ARCH GEN PSYCHIAT, V69, P274, DOI 10.1001/archgenpsychiatry.2011.147; Weisz JR, 2011, J CONSULT CLIN PSYCH, V79, P369, DOI 10.1037/a0023307; Weston L, 2016, CLIN PSYCHOL REV, V49, P41, DOI 10.1016/j.cpr.2016.08.001; White SW, 2013, J AUTISM DEV DISORD, V43, P382, DOI 10.1007/s10803-012-1577-x; Wood J.J., 2017, Anxiety in children and adolescents with autism spectrum disorder: Evidence-based assessment and treatment, P123, DOI DOI 10.1016/B978-0-12-805122-1.00007-7; Wood J. J., 2011, SCHEMA EMOTION BEHAV; Wood JJ, 2020, JAMA PSYCHIAT, V77, P474, DOI 10.1001/jamapsychiatry.2019.4160; Wood JJ, 2015, BEHAV THER, V46, P83, DOI 10.1016/j.beth.2014.07.003; Wood JJ, 2014, J AUTISM DEV DISORD, V44, P2264, DOI 10.1007/s10803-014-2097-7; Wood JJ, 2011, EVIDENCE-BASED PRACTICES AND TREATMENTS FOR CHILDREN WITH AUTISM, P197, DOI 10.1007/978-1-4419-6975-0_7; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x; Zablotsky B, 2015, J DEV BEHAV PEDIATR, V36, P98, DOI 10.1097/DBP.0000000000000127; Zhang L, 2020, J AUTISM DEV DISORD, V50, P199, DOI 10.1007/s10803-019-04246-z";57;14;17;4;48;AMER PSYCHOLOGICAL ASSOC;WASHINGTON;750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA;0022-006X;1939-2117;;J CONSULT CLIN PSYCH;J. Consult. Clin. Psychol.;FEB;2021;89;2;;;;;110;125;;10.1037/ccp0000621;http://dx.doi.org/10.1037/ccp0000621;;;16;Psychology, Clinical;Social Science Citation Index (SSCI);Psychology;QV0HC;33705167;Green Accepted, hybrid;;;24/11/2024;WOS:000627658300004;View Full Record in Web of Science
J;"van Tilborg, E; Achterberg, EJM; van Kammen, CM; van der Toorn, A; Groenendaal, F; Dijkhuizen, RM; Heijnen, CJ; Vanderschuren, LJMJ; Benders, MNJL; Nijboer, CHA";;;;"van Tilborg, Erik; Achterberg, E. J. Marijke; van Kammen, Caren M.; van der Toorn, Annette; Groenendaal, Floris; Dijkhuizen, Rick M.; Heijnen, Cobi J.; Vanderschuren, Louk J. M. J.; Benders, Manon N. J. L.; Nijboer, Cora H. A.";;;Combined fetal inflammation and postnatal hypoxia causes myelin deficits and autism-like behavior in a rat model of diffuse white matter injury;GLIA;;;English;Article;;;;;;"astrocytes; autism-like behavior; microglia; oligodendrocytes; preterm birth";"SPECTRUM DISORDERS; MAGNESIUM-SULFATE; PRETERM INFANTS; BRAIN-DAMAGE; PERIVENTRICULAR LEUKOMALACIA; PERINATAL BRAIN; CHILDREN BORN; RISK-FACTORS; SOCIAL PLAY; CELL-DEATH";Diffuse white matter injury (WMI) is a serious problem in extremely preterm infants, and is associated with adverse neurodevelopmental outcome, including cognitive impairments and an increased risk of autism-spectrum disorders. Important risk factors include fetal or perinatal inflammatory insults and fluctuating cerebral oxygenation. However, the exact mechanisms underlying diffuse WMI are not fully understood and no treatment options are currently available. The use of clinically relevant animal models is crucial to advance knowledge on the pathophysiology of diffuse WMI, allowing the definition of novel therapeutic targets. In the present study, we developed a multiple-hit animal model of diffuse WMI by combining fetal inflammation and postnatal hypoxia in rats. We characterized the effects on white matter development and functional outcome by immunohistochemistry, MRI and behavioral paradigms. Combined fetal inflammation and postnatal hypoxia resulted in delayed cortical myelination, microglia activation and astrogliosis at P18, together with long-term changes in oligodendrocyte maturation as observed in 10 week old animals. Furthermore, rats with WMI showed impaired motor performance, increased anxiety and signs of autism-like behavior, i.e. reduced social play behavior and increased repetitive grooming. In conclusion, the combination of fetal inflammation and postnatal hypoxia in rats induces a pattern of brain injury and functional impairments that closely resembles the clinical situation of diffuse WMI. This animal model provides the opportunity to elucidate pathophysiological mechanisms underlying WMI, and can be used to develop novel treatment options for diffuse WMI in preterm infants.;"[van Tilborg, Erik; van Kammen, Caren M.; Nijboer, Cora H. A.] Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Lundlaan 6, NL-3584 EA Utrecht, Netherlands; [Achterberg, E. J. Marijke; Vanderschuren, Louk J. M. J.] Univ Utrecht, Dept Anim Sci & Soc, Div Behav Neurosci, Fac Vet Med, NL-3584 CM Utrecht, Netherlands; [van der Toorn, Annette; Dijkhuizen, Rick M.] Univ Med Ctr Utrecht, Ctr Image Sci, Biomed MR Imaging & Spect Grp, NL-3584 CJ Utrecht, Netherlands; [Groenendaal, Floris; Benders, Manon N. J. L.] Univ Med Ctr Utrecht, Dept Neonatol, NL-3584 EA Utrecht, Netherlands; [Heijnen, Cobi J.] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Lab Neuroimmunol, Houston, TX 77030 USA";"Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Texas System; UTMD Anderson Cancer Center";Nijboer, CHA (corresponding author), Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Lundlaan 6, NL-3584 EA Utrecht, Netherlands.;C.Nijboer@umcutrecht.nl;Groenendaal, Floris/AEN-7844-2022;"Dijkhuizen, Rick/0000-0002-4623-4078; Nijboer, Cora/0000-0003-1223-1861; Achterberg, Marijke/0000-0002-7991-1514";Wilhelmina Children's Hospital Research Fund;Wilhelmina Children's Hospital Research Fund;Wilhelmina Children's Hospital Research Fund;"Achterberg EJM, 2015, J NEUROSCI, V35, P161, DOI 10.1523/JNEUROSCI.2945-14.2015; Allin MPG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024525; Ameis SH, 2016, AM J PSYCHIAT, V173, P1213, DOI 10.1176/appi.ajp.2016.15111435; Ameis SH, 2015, CORTEX, V62, P158, DOI 10.1016/j.cortex.2014.10.014; Askew K, 2017, CELL REP, V18, P391, DOI 10.1016/j.celrep.2016.12.041; Back SA, 2014, GLIA, V62, P1790, DOI 10.1002/glia.22658; Back SA, 2014, ANN NEUROL, V75, P469, DOI 10.1002/ana.24132; Billiards SS, 2008, BRAIN PATHOL, V18, P153, DOI 10.1111/j.1750-3639.2007.00107.x; Brehmer F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049023; Brossard-Racine M, 2017, J PEDIATR-US, V182, P28, DOI 10.1016/j.jpeds.2016.10.034; Burnett AC, 2013, EARLY HUM DEV, V89, P215, DOI 10.1016/j.earlhumdev.2013.01.013; Buser JR, 2012, ANN NEUROL, V71, P93, DOI 10.1002/ana.22627; Cai ZW, 2000, PEDIATR RES, V47, P64, DOI 10.1203/00006450-200001000-00013; Castillo A, 2008, PEDIATRICS, V121, P882, DOI 10.1542/peds.2007-0117; Catani M, 2016, BRAIN, V139, P616, DOI 10.1093/brain/awv351; Chau V, 2012, PEDIATR RES, V71, P274, DOI 10.1038/pr.2011.40; Crowther CA, 2003, JAMA-J AM MED ASSOC, V290, P2669, DOI 10.1001/jama.290.20.2669; Darnall RA, 2017, PEDIATR RES, V82, P164, DOI 10.1038/pr.2017.102; Doyle LW, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004661.pub3; Dudova I, 2014, NEUROPSYCH DIS TREAT, V10, P277, DOI 10.2147/NDT.S57057; Estes ML, 2016, SCIENCE, V353, P772, DOI 10.1126/science.aag3194; Favrais G, 2011, ANN NEUROL, V70, P550, DOI 10.1002/ana.22489; Fitzgerald J, 2019, J AUTISM DEV DISORD, V49, P2664, DOI 10.1007/s10803-016-2803-8; Fonck E, 2009, STROKE, V40, P2552, DOI 10.1161/STROKEAHA.108.528091; Ganat Y, 2002, NEUROSCIENCE, V112, P977, DOI 10.1016/S0306-4522(02)00060-X; Gano D, 2016, J PEDIATR-US, V178, P68, DOI 10.1016/j.jpeds.2016.06.053; GARD AL, 1995, DEVELOPMENT, V121, P2187; Gerstner B, 2008, J NEUROSCI, V28, P1236, DOI 10.1523/JNEUROSCI.3213-07.2008; Guo T, 2017, NEUROLOGY, V88, P614, DOI 10.1212/WNL.0000000000003606; Hammad AM, 2017, MOL CELL NEUROSCI, V82, P58, DOI 10.1016/j.mcn.2017.04.008; Hammond TR, 2014, NEURON, V81, P588, DOI 10.1016/j.neuron.2013.11.015; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Hotaling NA, 2015, BIOMATERIALS, V61, P327, DOI 10.1016/j.biomaterials.2015.05.015; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johnson S, 2010, J PEDIATR-US, V156, P525, DOI 10.1016/j.jpeds.2009.10.041; Jordan R, 2003, AUTISM, V7, P347, DOI 10.1177/1362361303007004002; Joseph RM, 2017, AUTISM RES, V10, P224, DOI 10.1002/aur.1644; Kaindl AN, 2009, J CHILD NEUROL, V24, P1112, DOI 10.1177/0883073809337920; Kalueff AV, 2016, NAT REV NEUROSCI, V17, P45, DOI 10.1038/nrn.2015.8; Komitova M, 2013, J NEUROSCI, V33, P13375, DOI 10.1523/JNEUROSCI.5286-12.2013; Korzeniewski SJ, 2014, J PERINAT MED, V42, P731, DOI 10.1515/jpm-2014-0250; Kuzniewicz MW, 2014, J PEDIATR-US, V164, P20, DOI 10.1016/j.jpeds.2013.09.021; Lakshminrusimha S, 2015, J PERINATOL, V35, P8, DOI 10.1038/jp.2014.199; Leviton A, 2013, PEDIATR RES, V73, P362, DOI 10.1038/pr.2012.188; Limperopoulos C, 2008, PEDIATRICS, V121, P758, DOI 10.1542/peds.2007-2158; Ment LR, 2009, LANCET NEUROL, V8, P1042, DOI 10.1016/S1474-4422(09)70257-1; Ment LR, 1998, DEV BRAIN RES, V111, P197, DOI 10.1016/S0165-3806(98)00139-4; Nosarti C, 2016, DEV MED CHILD NEUROL, V58, P35, DOI 10.1111/dmcn.13042; Novais ARB, 2016, GLIA, V64, P2306, DOI 10.1002/glia.23079; Padilla N, 2014, BRAIN RES, V1545, P1, DOI 10.1016/j.brainres.2013.12.007; Pang Y, 2007, GLIA, V55, P1099, DOI 10.1002/glia.20530; Perrone S, 2017, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00143; Peyton C, 2017, AM J NEURORADIOL, V38, P162, DOI 10.3174/ajnr.A4955; Peyton C, 2016, EARLY HUM DEV, V95, P23, DOI 10.1016/j.earlhumdev.2016.01.017; Pritchard MA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1949; Procianoy RS, 2012, PEDIATR CRIT CARE ME, V13, P183, DOI 10.1097/PCC.0b013e3182231074; Raymond M, 2011, J NEUROSCI, V31, P17864, DOI 10.1523/JNEUROSCI.3179-11.2011; Reid MV, 2012, J NEUROPATH EXP NEUR, V71, P640, DOI 10.1097/NEN.0b013e31825cfa81; Resch B, 2012, EARLY HUM DEV, V88, P27, DOI 10.1016/j.earlhumdev.2011.06.011; Robinson S, 2006, J NEUROSURG, V104, P396, DOI 10.3171/ped.2006.104.6.396; Rouse DJ, 2008, NEW ENGL J MED, V359, P895, DOI 10.1056/NEJMoa0801187; Rousset CI, 2006, PEDIATR RES, V59, P428, DOI 10.1203/01.pdr.0000199905.08848.55; Salmaso N, 2014, NAT NEUROSCI, V17, P341, DOI 10.1038/nn.3604; Scafidi J, 2014, NATURE, V506, P230, DOI 10.1038/nature12880; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Shah DK, 2008, J PEDIATR-US, V153, P170, DOI 10.1016/j.jpeds.2008.02.033; Shankaran S, 2006, PEDIATRICS, V118, P1654, DOI 10.1542/peds.2005-2463; Silbereis JC, 2010, DIS MODEL MECH, V3, P678, DOI 10.1242/dmm.002915; Silberstein FC, 1996, J NEUROCHEM, V66, P1409; Stephens BE, 2012, J DEV BEHAV PEDIATR, V33, P535, DOI 10.1097/DBP.0b013e31825fd0af; Tay TL, 2017, NAT NEUROSCI, V20, P793, DOI 10.1038/nn.4547; Thompson DK, 2016, NEUROIMAGE, V134, P328, DOI 10.1016/j.neuroimage.2016.03.070; Travis KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142860; Treyvaud K, 2013, J CHILD PSYCHOL PSYC, V54, P772, DOI 10.1111/jcpp.12040; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Umekawa T, 2015, GLIA, V63, P2220, DOI 10.1002/glia.22887; Ure AM, 2016, AUTISM RES, V9, P543, DOI 10.1002/aur.1558; van Kooij BJM, 2012, AM J NEURORADIOL, V33, P188, DOI 10.3174/ajnr.A2723; Van Steenwinckel J, 2014, BIOCHEM SOC T, V42, P557, DOI 10.1042/BST20130284; van Tilborg E, 2016, PROG NEUROBIOL, V136, P28, DOI 10.1016/j.pneurobio.2015.11.002; Verney C, 2012, J NEUROPATH EXP NEUR, V71, P251, DOI 10.1097/NEN.0b013e3182496429; Vogan VM, 2016, J AUTISM DEV DISORD, V46, P2138, DOI 10.1007/s10803-016-2744-2; Volpe JJ, 2011, INT J DEV NEUROSCI, V29, P423, DOI 10.1016/j.ijdevneu.2011.02.012; Wang YP, 2011, J NEUROSCI, V31, P6053, DOI 10.1523/JNEUROSCI.5524-09.2011; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zonouzi M, 2015, NAT NEUROSCI, V18, P674, DOI 10.1038/nn.3990; Zschocke J, 2005, J BIOL CHEM, V280, P34924, DOI 10.1074/jbc.M502581200";87;52;55;0;32;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0894-1491;1098-1136;;GLIA;Glia;JAN;2018;66;1;;;;;78;93;;10.1002/glia.23216;http://dx.doi.org/10.1002/glia.23216;;;16;Neurosciences;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;FN1ET;28925578;Green Published, hybrid;;;24/11/2024;WOS:000415730300006;View Full Record in Web of Science
J;"Chen, XX; Kong, LH; Piltonen, TT; Gissler, M; Lavebratt, C";;;;"Chen, Xinxia; Kong, Linghua; Piltonen, Terhi T.; Gissler, Mika; Lavebratt, Catharina";;;Association of polycystic ovary syndrome or anovulatory infertility with offspring psychiatric and mild neurodevelopmental disorders: a Finnish population-based cohort study;HUMAN REPRODUCTION;;;English;Article;;;;;;"polycystic ovary syndrome; offspring; psychiatric disorder; neurodevelopmental disorder; transgenerational; obesity; gestational diabetes; anovulatory infertility";"TESTOSTERONE; AUTISM; SYSTEM; HIRSUTISM; REGISTER; EXPOSURE; GROWTH; BIRTH";"STUDY QUESTION: Is maternal polycystic ovary syndrome (PCOS) associated with increased risks for a broad spectrum of psychiatric and mild neurodevelopmental disorders in offspring? SUMMARY ANSWER: Maternal PCOS and/or anovulatory infertility is independently, and jointly with maternal obesity, perinatal problems, cesarean delivery and gestational diabetes, associated with increased risks in offspring for almost all groups of psychiatric and mild neurodevelopmental disorders with onset in childhood or adolescence. WHAT IS KNOWN ALREADY: Maternal PCOS was previously associated with autism spectrum disorder, attention-deficit/ hyperactivity disorders and possibly developmental delay in offspring. Few studies have investigated the association between maternal PCOS and other psychiatric and neurodevelopmental disorders in offspring. STUDY DESIGN, SIZE, DURATION: This was a population-based cohort study in Finland including all live births between 1996 and 2014 (n = 1 105 997). After excluding births to mothers with symptoms similar to PCOS, a total of 1 097 753 births by 590 939 mothers remained. Children were followed up until 31 December 2018, i.e. up to the age of 22 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: National registries were used to link data of the included births and their mothers. Data from 24 682 (2.2%) children born to mothers with PCOS were compared with 1 073 071 (97.8%) children born to mothers without PCOS. Cox proportional hazards modeling was used to evaluate the hazard ratio (HR) and 95% CI for the risk of neuropsychiatric disorders in relation to maternal PCOS. Stratified analyses were performed to test the independent role of PCOS and the joint effects of PCOS with maternal obesity, perinatal problems, cesarean delivery, gestational diabetes and use of fertility treatment. The analysis was adjusted for maternal age, country of birth, marriage status at birth, smoking, parity, psychiatric disorders, prescription of psychotropic N05/ N06 during pregnancy and systemic inflammatory diseases when applicable. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 105 409 (9.8%) children were diagnosed with a neurodevelopmental or psychiatric disorder. Firstly, maternal PCOS was associated with any psychiatric diagnosis (HR 1.32; 95% CI 1.27-1.38) in offspring. Particularly, the risk was increased for sleeping disorders (HR 1.46; 95% CI 1.27-1.67), attention-deficit/hyperactivity disorders and conduct disorders (HR 1.42; 95% CI 1.33-1.52), tic disorders (HR 1.42; 95% CI 1.21-1.68), intellectual disabilities (HR 1.41; 95% CI 1.241.60), autism spectrum disorder (HR 1.40; 95% CI 1.26-1.57), specific developmental disorders (HR 1.37; 95% CI 1.30-1.43), eating disorders (HR 1.36; 95% CI 1.15-1.61), anxiety disorders (HR 1.33; 95% CI 1.26-1.41), mood disorders (HR 1.27; 95% CI 1.18-1.35) and other behavioral and emotional disorders (ICD-10 F98, HR 1.49; 95% CI 1.39-1.59). In short, there was no significant difference between sexes. The results were robust when restricting the analyses to the first-born children or births to mothers without psychiatric diagnosis or purchase of psychotropic medication. Secondly, stratified analysis according to maternal BMI showed that the risk of any neuropsychiatric disorder was increased in offspring to normal-weight mothers with PCOS (HR 1.20; 95% CI 1.09-1.32), and markedly higher in those to severely obese mothers with PCOS (HR 2.11; 95% CI 1.76-2.53) compared to offspring to normal-weight mothers without PCOS. When excluding perinatal problems, mothers with PCOS were still associated with increased risks of any neuropsychiatric disorders in offspring (HR 1.28; 95% CI 1.22-1.34) compared to mothers without PCOS. However, an additional increase was observed for PCOS in combination with perinatal problems (HR 1.99; 95% CI 1.84-2.16). Likewise, excluding cases with maternal gestational diabetes (HR 1.30; 95% CI 1.25-1.36), cesarean delivery (HR 1.29; 95% CI 1.23-1.35) or fertility treatment (HR 1.31; 95% CI 1.25-1.36) did not eliminate the associations. LIMITATIONS, REASONS FOR CAUTION: The register-based prevalence of PCOS was lower than previously reported, suggesting that this study may capture the most severe cases. To combine anovulatory infertility with PCOS diagnosis as PCOS exposure might introduce diagnostic bias. It was not feasible to distinguish between subtypes of PCOS. Furthermore, familial factors might confound the association between maternal PCOS and neuropsychiatric disorders in offspring. Maternal BMI was available for birth cohort 2004-2014 only and there was no information on gestational weight gain. WIDER IMPLICATIONS OF THE FINDINGS: This study provides further evidence that maternal PCOS and/or anovulatory infertility, independently and jointly with maternal obesity, perinatal problems, gestational diabetes and cesarean delivery, implies a broad range of adverse effects on offspring neurodevelopment. These findings may potentially help in counseling and managing pregnancies.";"[Chen, Xinxia] Shandong Univ, Cheeloo Coll Med, Sch Nursing, Jinan, Shandong, Peoples R China; [Chen, Xinxia; Kong, Linghua; Lavebratt, Catharina] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden; [Chen, Xinxia; Kong, Linghua; Lavebratt, Catharina] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden; [Piltonen, Terhi T.] Univ Oulu, Oulu Univ Hosp, Med Res Ctr, Dept Obstet & Gynecol,PEDEGO Res Unit, Oulu, Finland; [Gissler, Mika] Finnish Inst Hlth & Welf, Oulu, Finland; [Gissler, Mika] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Family Med, Stockholm, Sweden; [Gissler, Mika] Univ Turku, Res Ctr Child Psychiat, Turku, Finland";"Shandong University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Oulu; Karolinska Institutet; University of Turku";Lavebratt, C (corresponding author), Karolinska Univ Hosp, Ctr Mol Med, Translat Psychiat Unit, S-17176 Stockholm, Sweden.;catharina.lavebratt@ki.se;"Piltonen, Terhi/CAH-4447-2022; Kong, Linghua/O-5450-2019; liu, yuchen/GYQ-6286-2022";Kong, Linghua/0000-0001-8289-4180;"Shandong University [SDU-KI-2019-08]; Karolinska Institute [SDU-KI-2019-08]; THL Finnish Institute for Health and Welfare: Drug and pregnancy project; Swedish Research Council [2014-10171]; Stockholm County Council [SLL20170292]; Karolinska Institutet Stockholm County Council [SLL20170292]; Swedish Brain Foundation [FO2018-0141, FO2019-0201]; China Scholarship Council; Swedish Research Council [2014-10171] Funding Source: Swedish Research Council";"Shandong University; Karolinska Institute(Karolinska Institutet); THL Finnish Institute for Health and Welfare: Drug and pregnancy project; Swedish Research Council(Swedish Research Council); Stockholm County Council(Stockholm County Council); Karolinska Institutet Stockholm County Council(Stockholm County Council); Swedish Brain Foundation; China Scholarship Council(China Scholarship Council); Swedish Research Council(Swedish Research Council)";This study was supported by the joint research funding of Shandong University and Karolinska Institute (SDU-KI-2019-08), THL Finnish Institute for Health and Welfare: Drug and pregnancy project [M.G.], the Swedish Research Council [2014-10171 to C.L.], the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet Stockholm County Council [SLL20170292 to C.L.], the Swedish Brain Foundation [FO2018-0141 and FO2019-0201 to C.L.]. X.C. was supported by the China Scholarship Council during her training in Karolinska Institute. L.K. was supported by the China Scholarship Council for his PhD study in Karolinska Institute. The sponsor had no role in the study design, data analysis or interpretation, manuscript preparation or the decision for submission.;"Anderson H, 2010, J CLIN ENDOCR METAB, V95, P2180, DOI 10.1210/jc.2009-2651; Artama M, 2011, PHARMACOEPIDEM DR S, V20, P729, DOI 10.1002/pds.2159; Barrett ES, 2018, J DEV ORIG HLTH DIS, V9, P307, DOI 10.1017/S2040174417001118; Bay B, 2013, BMJ-BRIT MED J, V347, P12; Belli GA, 2018, HUM REPROD, V33, P1307, DOI 10.1093/humrep/dey087; Berni TR, 2018, J CLIN ENDOCR METAB, V103, P2116, DOI 10.1210/jc.2017-02667; Cesta CE, 2020, PSYCHOL MED, V50, P616, DOI 10.1017/S0033291719000424; Cesta CE, 2016, PSYCHONEUROENDOCRINO, V73, P196, DOI 10.1016/j.psyneuen.2016.08.005; Cherskov A, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0186-7; Clayton PE, 2007, J CLIN ENDOCR METAB, V92, P804, DOI 10.1210/jc.2006-2017; Escobar-Morreale HF, 2018, NAT REV ENDOCRINOL, V14, P270, DOI 10.1038/nrendo.2018.24; Gumusoglu SB, 2019, BIOL PSYCHIAT, V85, P107, DOI 10.1016/j.biopsych.2018.08.008; Hatanaka Y, 2015, NEUROCHEM INT, V85-86, P53, DOI 10.1016/j.neuint.2015.04.008; Hu M, 2015, P NATL ACAD SCI USA, V112, P14348, DOI 10.1073/pnas.1507514112; Katsigianni M, 2019, MOL PSYCHIATR, V24, P1787, DOI 10.1038/s41380-019-0398-0; Keskimaki I, 1991, INT J HLTH SCI, V2, P7; Khomami MB, 2019, OBES REV, V20, P842, DOI 10.1111/obr.12832; Kim S, 2017, NATURE, V549, P528, DOI 10.1038/nature23910; Kong L, 2018, PEDIATRICS, V142, pI; Kosidou K, 2016, MOL PSYCHIATR, V21, P1441, DOI 10.1038/mp.2015.183; Kosidou K, 2017, BIOL PSYCHIAT, V82, P651, DOI 10.1016/j.biopsych.2016.09.022; Lampi KM, 2010, ACTA PAEDIATR, V99, P1425, DOI 10.1111/j.1651-2227.2010.01835.x; Lee BK, 2017, AUTISM RES, V10, P1544, DOI 10.1002/aur.1797; Lombardo MV, 2012, BIOL PSYCHIAT, V72, P839, DOI 10.1016/j.biopsych.2012.05.027; Manti M, 2018, FASEB J, V32, P4158, DOI 10.1096/fj.201701263RR; McCarthy MM, 2011, NAT NEUROSCI, V14, P677, DOI 10.1038/nn.2834; Money KM, 2018, MOL PSYCHIATR, V23, DOI 10.1038/mp.2017.191; Palomba S, 2012, CLIN ENDOCRINOL, V77, P898, DOI 10.1111/j.1365-2265.2012.04443.x; Qi XY, 2019, NAT MED, V25, P1225, DOI 10.1038/s41591-019-0509-0; Risal S, 2019, NAT MED, V25, P1894, DOI 10.1038/s41591-019-0666-1; Robinson SL, 2020, FERTIL STERIL, V113, P435, DOI 10.1016/j.fertnstert.2019.09.034; Sanchez CE, 2018, OBES REV, V19, P464, DOI 10.1111/obr.12643; Sankilampi U, 2013, ANN MED, V45, P446, DOI 10.3109/07853890.2013.803739; Sucksdorff M, 2015, PEDIATRICS, V136, pE599, DOI 10.1542/peds.2015-1043; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Tata B, 2018, NAT MED, V24, P834, DOI 10.1038/s41591-018-0035-5; Teede HJ, 2018, FERTIL STERIL, V110, P364, DOI 10.1016/j.fertnstert.2018.05.004; Vanky E, 2019, FERTIL STERIL, V111, P1065, DOI 10.1016/j.fertnstert.2019.03.015; Walker CK, 2015, JAMA PEDIATR, V169, P154, DOI 10.1001/jamapediatrics.2014.2645; Zhang TY, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10236";40;38;40;13;45;OXFORD UNIV PRESS;OXFORD;GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND;0268-1161;1460-2350;;HUM REPROD;Hum. Reprod.;OCT;2020;35;10;;;;;2336;2347;;10.1093/humrep/deaa192;http://dx.doi.org/10.1093/humrep/deaa192;;;12;"Obstetrics & Gynecology; Reproductive Biology";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Obstetrics & Gynecology; Reproductive Biology";OW7AE;32866965;Green Published, hybrid;;;24/11/2024;WOS:000593034000019;View Full Record in Web of Science
J;"Damen, L; Grootjen, LN; Juriaans, AF; Donze, SH; Huisman, TM; Visser, JA; Delhanty, PJD; Hokken-Koelega, ACS";;;;"Damen, Layla; Grootjen, Lionne N.; Juriaans, Alicia F.; Donze, Stephany H.; Huisman, T. Martin; Visser, Jenny A.; Delhanty, Patric J. D.; Hokken-Koelega, Anita C. S.";;;Oxytocin in young children with Prader-Willi syndrome: Results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin;CLINICAL ENDOCRINOLOGY;;;English;Article;;;;;;"behaviour; children; hyperphagia; intranasal oxytocin; Prader? Willi syndrome";"GROWTH-HORMONE TREATMENT; REPETITIVE BEHAVIOR; GENETIC SUBTYPES; FOOD-INTAKE; AUTISM; HYPERPHAGIA; DEFICIENT; MAGEL2; ADULTS";Context Prader-Willi syndrome (PWS) is characterized by hypothalamic dysfunction, hyperphagia and a typical behavioural phenotype, with characteristics of autism spectrum disorder (ASD) like stubbornness, temper tantrums and compulsivity. It has been suggested that the oxytocin system in patients with PWS is dysfunctional. In ASD, intranasal oxytocin treatment has favourable effects on behaviour. Objective To evaluate the effects of 3 months of twice daily intranasal oxytocin (dose range 16-40 IU/day), compared to placebo, on behaviour and hyperphagia in children with PWS. Design Randomized, double-blind, placebo-controlled, crossover study in the Dutch PWS Reference Center. Patients Twenty-six children with PWS aged 3-11 years. Main outcome measures (Change in) behaviour and hyperphagia measured by Oxytocin Questionnaire and Dykens hyperphagia questionnaire. Results In the total group, no significant effects of oxytocin on social behaviour or hyperphagia were found. However, in boys, the Oxytocin Questionnaire scores improved significantly during oxytocin treatment, compared to a deterioration during placebo (4.5 (-0.8 to 15.3) vs. -4.0 (-11.3 to 0.8), P = .025). The Dykens hyperphagia questionnaire scores remained similar during oxytocin treatment, while there was a deterioration during placebo (0.0 (-0.8 to 4.3) vs. -3.5 (-6.0 to 0.0), P = .046). Patients with a deletion had significant improvements in both questionnaire scores during oxytocin treatment, but deteriorations during placebo. Oxytocin treatment was well tolerated, and there were no serious adverse events. Conclusions Intranasal oxytocin treatment has positive effects on social and eating behaviour in 3-11 years aged boys with PWS and in children with a deletion without safety concerns. Intranasal oxytocin in children with PWS might be considered, but individual effects should be carefully evaluated and treatment discontinued if no effects are found.;"[Damen, Layla; Grootjen, Lionne N.; Juriaans, Alicia F.; Donze, Stephany H.; Hokken-Koelega, Anita C. S.] Dutch Growth Res Fdn, Rotterdam, Netherlands; [Damen, Layla; Grootjen, Lionne N.; Juriaans, Alicia F.; Donze, Stephany H.; Hokken-Koelega, Anita C. S.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat,Subdiv Endocrinol, Rotterdam, Netherlands; [Damen, Layla; Grootjen, Lionne N.; Juriaans, Alicia F.; Donze, Stephany H.; Hokken-Koelega, Anita C. S.] Dutch Reference Ctr Prader Willi Syndrome, Rotterdam, Netherlands; [Huisman, T. Martin; Visser, Jenny A.; Delhanty, Patric J. D.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands";"Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Erasmus MC; Erasmus University Rotterdam; Erasmus MC";Damen, L (corresponding author), Dutch Growth Res Fdn, Rotterdam, Netherlands.;l.damen@kindengroei.nl;Visser, Jenny/F-8156-2011;Delhanty, Patric/0000-0002-0828-3143;;;;"Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16; [Anonymous], 2019, CASTOR EDC CASTOR EL; Bakker NE, 2015, HORM RES PAEDIAT, V83, P321, DOI 10.1159/000374113; Bakker NE, 2013, J CLIN ENDOCR METAB, V98, P4013, DOI 10.1210/jc.2013-2012; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Constantino JNG C.P, 2005, SOCIAL RESPONSIVENES; Dykens EM, 2008, J CHILD PSYCHOL PSYC, V49, P1001, DOI 10.1111/j.1469-7610.2008.01913.x; Dykens EM, 2007, OBESITY, V15, P1816, DOI 10.1038/oby.2007.216; Dykens EM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98333; Dykens EM, 1999, AM J MENT RETARD, V104, P67, DOI 10.1352/0895-8017(1999)104<0067:MBDIPS>2.0.CO;2; Dykens EM, 1996, J CHILD PSYCHOL PSYC, V37, P995, DOI 10.1111/j.1469-7610.1996.tb01496.x; Einfeld SL, 1999, AM J MED GENET, V82, P123, DOI 10.1002/(SICI)1096-8628(19990115)82:2<123::AID-AJMG4>3.0.CO;2-C; Einfeld SL, 2014, AM J MED GENET A, V164, P2232, DOI 10.1002/ajmg.a.36653; Festen DAM, 2008, CLIN ENDOCRINOL, V68, P919, DOI 10.1111/j.1365-2265.2007.03126.x; Fredriks AM, 2000, PEDIATR RES, V47, P316, DOI 10.1203/00006450-200003000-00006; Fredriks AM, 2000, ARCH DIS CHILD, V82, P107, DOI 10.1136/adc.82.2.107; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; Hartley SL, 2005, AM J MED GENET A, V136A, P140, DOI 10.1002/ajmg.a.30771; HOLM VA, 1993, PEDIATRICS, V91, P398; Höybye C, 2003, GROWTH HORM IGF RES, V13, P322, DOI 10.1016/S1096-6374(03)00077-7; Johnson L, 2016, AM J MED GENET A, V170, P594, DOI 10.1002/ajmg.a.37488; Kuppens RJ, 2016, CLIN ENDOCRINOL, V85, P979, DOI 10.1111/cen.13169; Kuppens RJ, 2015, ENDOCRINE, V50, P633, DOI 10.1007/s12020-015-0614-x; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lawson EA, 2020, J NEUROENDOCRINOL, V32, DOI 10.1111/jne.12805; Lawson EA, 2015, OBESITY, V23, P950, DOI 10.1002/oby.21069; Lo ST, 2015, EUR CHILD ADOLES PSY, V24, P1091, DOI 10.1007/s00787-014-0662-4; Lo ST, 2013, RES DEV DISABIL, V34, P2764, DOI 10.1016/j.ridd.2013.05.024; MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615; Meziane H, 2015, BIOL PSYCHIAT, V78, P85, DOI 10.1016/j.biopsych.2014.11.010; Miller JL, 2017, AM J MED GENET A, V173, P1243, DOI 10.1002/ajmg.a.38160; Miller JL, 2011, AM J MED GENET A, V155A, P1040, DOI 10.1002/ajmg.a.33951; OLSON BR, 1991, PEPTIDES, V12, P113, DOI 10.1016/0196-9781(91)90176-P; Ott V, 2013, DIABETES, V62, P3418, DOI 10.2337/db13-0663; Rice LJ, 2018, CURR OPIN PSYCHIATR, V31, P123, DOI 10.1097/YCO.0000000000000391; Schaller F, 2010, HUM MOL GENET, V19, P4895, DOI 10.1093/hmg/ddq424; Swaab DF, 1997, ACTA PAEDIATR, V86, P50; Tachibana M, 2013, J CHILD ADOL PSYCHOP, V23, P123, DOI 10.1089/cap.2012.0048; Tauber M, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2976; Tauber M, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-47; Veer WGVD, 2013, EFFECT ASSWIJZER; Veltman MWM, 2005, PSYCHIAT GENET, V15, P243, DOI 10.1097/00041444-200512000-00006; Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162; Zhang G, 2011, AM J PHYSIOL-ENDOC M, V301, pE1004, DOI 10.1152/ajpendo.00196.2011";44;26;26;0;8;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0300-0664;1365-2265;;CLIN ENDOCRINOL;Clin. Endocrinol.;MAY;2021;94;5;;;;;774;785;;10.1111/cen.14387;http://dx.doi.org/10.1111/cen.14387;;DEC 2020;12;Endocrinology & Metabolism;Science Citation Index Expanded (SCI-EXPANDED);Endocrinology & Metabolism;RM0QG;33296519;Green Published;;;24/11/2024;WOS:000600583300001;View Full Record in Web of Science
J;"Lin, IF; Kashino, M; Ohta, H; Yamada, T; Tani, M; Watanabe, H; Kanai, C; Ohno, T; Takayama, Y; Iwanami, A; Kato, N";;;;"Lin, I-Fan; Kashino, Makio; Ohta, Haruhisa; Yamada, Takashi; Tani, Masayuki; Watanabe, Hiromi; Kanai, Chieko; Ohno, Taisei; Takayama, Yuko; Iwanami, Akira; Kato, Nobumasa";;;The effect of intranasal oxytocin versus placebo treatment on the autonomic responses to human sounds in autism: a single-blind, randomized, placebo-controlled, crossover design study;MOLECULAR AUTISM;;;English;Article;;;;;;"Autism; Oxytocin; Clinical trial; Auditory; Social cognition; Skin conductance response; Autonomic system";"RECEPTOR GENE OXTR; SPECTRUM DISORDERS; AUDITORY-STIMULI; NORMAL-CHILDREN; SOCIAL COGNITION; NEURAL CIRCUITRY; EYE GAZE; ASSOCIATION; ADULTS; FACES";Background: Many individuals with autism spectrum disorders (ASD) have difficulty with verbal communication, which might be due to a lack of spontaneous orientation toward social auditory stimuli. Previous studies have shown that a single dose of oxytocin improves speech comprehension in autism. The primary aim of this study was to investigate whether the orientation behaviors toward human sounds are different for neurotypical (NT) adults and adults with ASD and whether oxytocin has an effect on their orientation behaviors toward human sounds. Methods: This was a randomized, placebo-controlled, within-subject, crossover design study of intranasal oxytocin versus placebo in 13 NT adults and 16 adults with ASD. Subjects were randomized to 24 IU intranasal oxytocin or placebo on different days, and they were blind to the treatment. The participants then listened passively to human and non-human affective sounds while their skin conductance responses (SCRs) and the changes in peripheral blood vessel constriction were monitored as an indicator of spontaneous orientation. The monitored data were analyzed by a mixed-design ANOVA. Results: Oxytocin enhanced the difference between the SCRs to human and non-human sounds in both the NT and ASD groups (F(1,56) = 6.046, p = 0.017). Further correlation coefficient analysis showed significant correlations between this SCR difference and the scores in the autism spectrum quotient 'attention to detail' and 'social skill' subscales and interpersonal reactivity index and social functioning scale in the ASD group. Oxytocin was well tolerated, and no serious adverse effects were reported. Conclusions: The difference in SCRs implies that oxytocin nasal spray may enhance orientation behaviors toward human sounds in the presence of other environmental sounds in both ASD and NT adults.;"[Lin, I-Fan; Kashino, Makio] NTT Corp, NTT Commun Sci Labs, Atsugi, Kanagawa 2430198, Japan; [Kashino, Makio] JST, CREST, Atsugi, Kanagawa 2430198, Japan; [Ohta, Haruhisa; Yamada, Takashi; Tani, Masayuki; Watanabe, Hiromi; Kanai, Chieko; Ohno, Taisei; Takayama, Yuko; Iwanami, Akira; Kato, Nobumasa] Showa Univ, Dept Psychiat, Sch Med, Shinagawa Ku, Tokyo 1428555, Japan; [Kato, Nobumasa] JST, CREST, Shinagawa Ku, Tokyo 1428555, Japan";"Nippon Telegraph & Telephone Corporation; Japan Science & Technology Agency (JST); Showa University; Japan Science & Technology Agency (JST)";Lin, IF (corresponding author), NTT Corp, NTT Commun Sci Labs, 3-1 Morinosato, Atsugi, Kanagawa 2430198, Japan.;lin.ifan@lab.ntt.co.jp;Lin, Ifan/HHM-7112-2022;Lin, I-Fan/0000-0002-6706-3060;"Japan Science and Technology Agency; NTT Communication Science Laboratories";"Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); NTT Communication Science Laboratories";We would like to thank all the participants for their time and effort. This study is supported by the Japan Science and Technology Agency and NTT Communication Science Laboratories.;"Abrams DA, 2013, P NATL ACAD SCI USA, V110, P12060, DOI 10.1073/pnas.1302982110; Agus TR, 2012, J ACOUST SOC AM, V131, P4124, DOI 10.1121/1.3701865; Anagnostou E, 2012, MOL AUTISM, V3, DOI 10.1186/2040-2392-3-16; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; [Anonymous], 2007, Technical report B-3; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002; Belin P, 2000, NATURE, V403, P309, DOI 10.1038/35002078; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Bradley MM, 2008, PSYCHOPHYSIOLOGY, V45, P602, DOI 10.1111/j.1469-8986.2008.00654.x; Ceponiene R, 2003, P NATL ACAD SCI USA, V100, P5567, DOI 10.1073/pnas.0835631100; Chang MC, 2012, AM J OCCUP THER, V66, P567, DOI 10.5014/ajot.2012.004242; Chevallier C, 2012, TRENDS COGN SCI, V16, P231, DOI 10.1016/j.tics.2012.02.007; Dalton KM, 2005, NAT NEUROSCI, V8, P519, DOI 10.1038/nn1421; Dawson M.E., 2000, ELECTRODERMAL SYSTEM; Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025; Domes G, 2013, BIOL PSYCHIAT, V74, P164, DOI 10.1016/j.biopsych.2013.02.007; Elsabbagh M, 2012, CURR BIOL, V22, P338, DOI 10.1016/j.cub.2011.12.056; Furman DJ, 2011, PSYCHONEUROENDOCRINO, V36, P891, DOI 10.1016/j.psyneuen.2010.12.004; Gervais H, 2004, NAT NEUROSCI, V7, P801, DOI 10.1038/nn1291; Guastella AJ, 2010, BIOL PSYCHIAT, V67, P692, DOI 10.1016/j.biopsych.2009.09.020; Hollander E, 2003, NEUROPSYCHOPHARMACOL, V28, P193, DOI 10.1038/sj.npp.1300021; Hollander E, 2007, BIOL PSYCHIAT, V61, P498, DOI 10.1016/j.biopsych.2006.05.030; Inoue H, 2010, BIOL PSYCHIAT, V68, P1066, DOI 10.1016/j.biopsych.2010.07.019; Jacob S, 2007, NEUROSCI LETT, V417, P6, DOI 10.1016/j.neulet.2007.02.001; Kemp AH, 2012, PSYCHOL SCI, V20, P222; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Klin A, 2002, ARCH GEN PSYCHIAT, V59, P809, DOI 10.1001/archpsyc.59.9.809; Liu XX, 2010, J HUM GENET, V55, P137, DOI 10.1038/jhg.2009.140; MacDonald K, 2010, HARVARD REV PSYCHIAT, V18, P1, DOI 10.3109/10673220903523615; Matsuoka K, 2006, PSYCHIAT CLIN NEUROS, V60, P332, DOI 10.1111/j.1440-1819.2006.01510.x; Ooishi Y, 2012, PSYCHOPHYSIOLOGY, V49, P1059, DOI 10.1111/j.1469-8986.2012.01393.x; Ozonoff S, 2010, J AM ACAD CHILD PSY, V49, P256, DOI 10.1016/j.jaac.2009.11.009; PALKOVITZ RJ, 1980, J AUTISM DEV DISORD, V10, P347, DOI 10.1007/BF02408294; Pelphrey KA, 2005, BRAIN, V128, P1038, DOI 10.1093/brain/awh404; Pelphrey KA, 2002, J AUTISM DEV DISORD, V32, P249, DOI 10.1023/A:1016374617369; Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008; Sauer C, 2012, NEUROPSYCHOPHARMACOL, V37, P1474, DOI 10.1038/npp.2011.333; Schoen SA, 2008, RES AUTISM SPECT DIS, V2, P417, DOI 10.1016/j.rasd.2007.09.002; STEVENS S, 1984, J AUTISM DEV DISORD, V14, P245, DOI 10.1007/BF02409577; Stone WL, 2001, AUTISM, V5, P341, DOI 10.1177/1362361301005004002; Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109; Suied C, 2013, ADV EXP MED BIOL, V787, P443, DOI 10.1007/978-1-4614-1590-9_49; Tost H, 2011, BIOL PSYCHIAT, V70, pE37, DOI 10.1016/j.biopsych.2011.06.034; Tost H, 2010, P NATL ACAD SCI USA, V107, P13936, DOI 10.1073/pnas.1003296107; VANENGELAND H, 1984, J AUTISM DEV DISORD, V14, P261, DOI 10.1007/BF02409578; Venables PH, 1996, BIOL PSYCHOL, V43, P87, DOI 10.1016/0301-0511(96)05183-6; Whitehouse AJO, 2008, DEVELOPMENTAL SCI, V11, P516, DOI 10.1111/j.1467-7687.2008.00697.x; Wu SP, 2005, BIOL PSYCHIAT, V58, P74, DOI 10.1016/j.biopsych.2005.03.013; Yamada T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043220";50;35;37;2;41;BIOMED CENTRAL LTD;LONDON;236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND;2040-2392;;;MOL AUTISM;Mol. Autism;FEB 28;2014;5;;;;;;;;20;10.1186/2040-2392-5-20;http://dx.doi.org/10.1186/2040-2392-5-20;;;10;"Genetics & Heredity; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Genetics & Heredity; Neurosciences & Neurology";AF8KX;24576333;Green Published, gold;;;24/11/2024;WOS:000334965800001;View Full Record in Web of Science
J;"Ghirardi, L; Chen, Q; Chang, Z; Kuja-Halkola, R; Skoglund, C; Quinn, PD; D'Onofrio, BM; Larsson, H";;;;"Ghirardi, Laura; Chen, Qi; Chang, Zheng; Kuja-Halkola, Ralf; Skoglund, Charlotte; Quinn, Patrick D.; D'Onofrio, Brian M.; Larsson, Henrik";;;Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders;JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY;;;English;Article;;;;;;"ADHD medication; injuries; neurodevelopmental disorders";"DEFICIT-HYPERACTIVITY DISORDER; ADHD MEDICATION; YOUNG-PEOPLE; METHYLPHENIDATE; METAANALYSIS; ATOMOXETINE; POPULATION; PREVALENCE; SYMPTOMS; REGISTER";"Background Attention-deficit/hyperactivity disorder (ADHD) is often associated with other neurodevelopmental disorders (NDs) and with risky behaviors and adverse health outcomes, including injuries. Treatment with ADHD medication has been associated with reduced risk of injuries. However, it is unknown whether the association is present in individuals with co-occurring NDs. The aim of the present study was to estimate the association between ADHD medication use and unintentional injuries in Sweden in children and adolescents with ADHD, including those with co-occurring NDs. Methods Using a linkage of several national registers via the unique personal identification number, we identified individuals with a diagnosis of ADHD and of other NDs, including autism spectrum disorder, intellectual disability, communication disorders, learning disorders and motor disorders. The primary outcome was unintentional injuries. Secondary outcome was traumatic brain injury (TBI). Individuals were followed from January 1st 2006 or their 5th birthday or the date of the first unintentional injury, whichever came last, to December 31st 2013 or their 18th birthday or death, whichever came first. We compared the rate of injuries during periods on-treatment with the rate of injuries during periods off-treatment within the same individual using stratified Cox regression to calculate hazard ratio (HR) with 95% confidence intervals (CIs). Results For children and adolescents with ADHD (N = 9,421) the rate of any unintentional injuries (HR = 0.85; 95% CI = 0.78-0.92) and TBIs (HR = 0.27; 95% CIs = 0.20-0.38) during medicated periods was lower than during non-medicated periods. Similar results were found among individuals with co-occurring NDs (N = 2,986), for unintentional injuries (HR = 0.88; 95% CI = 0.77-1.01) and for TBIs (HR = 0.27; 95% CI = 0.16-0.44). Conclusions Beneficial effects of ADHD medication may extend beyond reduction of ADHD core symptoms to prevention of unintentional injuries in children and adolescents, including individuals with co-occurring NDs.";"[Ghirardi, Laura; Chen, Qi; Chang, Zheng; Kuja-Halkola, Ralf; D'Onofrio, Brian M.; Larsson, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Nobels Vag 12A, S-17177 Stockholm, Sweden; [Skoglund, Charlotte] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Quinn, Patrick D.] Indiana Univ, Dept Appl Hlth Sci, Sch Publ Hlth, Bloomington, IN 47405 USA; [D'Onofrio, Brian M.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Larsson, Henrik] Orebro Univ, Sch Med Sci, Orebro, Sweden";"Karolinska Institutet; Karolinska Institutet; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Orebro University";Ghirardi, L (corresponding author), Karolinska Inst, Dept Med Epidemiol & Biostat, Nobels Vag 12A, S-17177 Stockholm, Sweden.;laura.ghirardi@ki.se;"Kuja-Halkola, Ralf/ABA-5061-2020; Chang, Zheng/LBH-0831-2024; Ghirardi, Laura/IQU-6812-2023; Larsson, Henrik/GYD-5161-2022";"Quinn, Patrick/0000-0002-6770-8762; Skoglund, Charlotte/0000-0002-6893-2862; Kuja-Halkola, Ralf/0000-0002-3765-2067; Larsson, Henrik/0000-0002-6851-3297";"Swedish Research Council [201802213, 2014-3831, 2013-2280]; Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) [340-2013-5867]; European Union [643051]; National Institute on Drug Abuse of the National Institutes of Health [R00DA040727]; National Institute of Mental Health of the National Institutes of Health [R01MH102221]";"Swedish Research Council(Swedish Research Council); Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM); European Union(European Union (EU)); National Institute on Drug Abuse of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute of Mental Health of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))";"The authors acknowledge financial support from the Swedish Research Council (2014-3831; 2013-2280). The project has also received funding from Swedish Initiative for Research on Microdata in the Social And Medical Sciences (SIMSAM) framework Grant no. 340-2013-5867. L.G. is supported from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 643051. This report reflects only the authors' views and the European Union is not responsible for any use that may be made of the information it contains. Z.C. was supported by the Swedish Research Council (201802213). P.D.Q. was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R00DA040727. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. B.M.D. was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH102221.";"Allison P.D., 2009, Fixed effect regression models, DOI [10.4135/9781412993869, DOI 10.4135/9781412993869]; Allison PD, 1996, SOCIOL METHOD RES, V25, P207, DOI 10.1177/0049124196025002003; Aman MG, 2003, J CHILD ADOL PSYCHOP, V13, P29, DOI 10.1089/104454603321666171; Balazs J, 2017, WORLD J PSYCHIATR, V7, P44, DOI 10.5498/wjp.v7.i1.44; Brikell I, 2019, EPILEPSIA, V60, P284, DOI 10.1111/epi.14640; Chang Z, 2017, JAMA PSYCHIAT, V74, P597, DOI 10.1001/jamapsychiatry.2017.0659; Chang Z, 2014, J CHILD PSYCHOL PSYC, V55, P878, DOI 10.1111/jcpp.12164; Chang Z, 2014, JAMA PSYCHIAT, V71, P319, DOI 10.1001/jamapsychiatry.2013.4174; Chen Q, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3769; Chen VCH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173762; Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4; Dalsgaard S, 2015, LANCET PSYCHIAT, V2, P702, DOI 10.1016/S2215-0366(15)00271-0; Erskine HE, 2016, J AM ACAD CHILD PSY, V55, P841, DOI 10.1016/j.jaac.2016.06.016; Faraone SV, 2017, J AM ACAD CHILD PSY, V56, P167, DOI 10.1016/j.jaac.2016.11.011; Ghirardi L, 2018, MOL PSYCHIATR, V23, P257, DOI 10.1038/mp.2017.17; Ghirardi L., 2019, J AM ACAD CHILD ADOL, DOI 10.1016/j.jaac.2019.06.010; Giacobini M, 2018, J ATTEN DISORD, V22, P3, DOI 10.1177/1087054714554617; Grzadzinski R, 2016, MOL AUTISM, V7, DOI 10.1186/s13229-016-0072-1; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; Harfterkamp M, 2013, J CHILD ADOL PSYCHOP, V23, P194, DOI 10.1089/cap.2012.0012; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hodgkins P, 2011, CURR MED RES OPIN, V27, P53, DOI 10.1185/03007995.2011.623158; Koolwijk I, 2014, J DEV BEHAV PEDIATR, V35, P591, DOI 10.1097/DBP.0000000000000109; Korrel H, 2017, J CHILD PSYCHOL PSYC, V58, P640, DOI 10.1111/jcpp.12688; Larson K, 2011, PEDIATRICS, V127, P462, DOI 10.1542/peds.2010-0165; Lichtenstein P, 2012, NEW ENGL J MED, V367, P2006, DOI 10.1056/NEJMoa1203241; Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Man KKC, 2015, PEDIATRICS, V135, P40, DOI 10.1542/peds.2014-1738; Merrill RM, 2009, ADV MED SCI-POLAND, V54, P20, DOI 10.2478/v10039-009-0022-7; Mikolajczyk R, 2015, JAMA PEDIATR, V169, P391, DOI 10.1001/jamapediatrics.2014.3275; Mohr-Jensen C, 2016, CLIN PSYCHOL REV, V48, P32, DOI 10.1016/j.cpr.2016.05.002; Nigg JT, 2013, CLIN PSYCHOL REV, V33, P215, DOI 10.1016/j.cpr.2012.11.005; Osland ST, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007990.pub3; Peng XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079476; Prasad V, 2018, CHILD CARE HLTH DEV, V44, P871, DOI 10.1111/cch.12591; Quinn PD, 2017, AM J PSYCHIAT, V174, P877, DOI 10.1176/appi.ajp.2017.16060686; Raman SR, 2013, INJURY PREV, V19, P164, DOI 10.1136/injuryprev-2012-040483; Ruiz-Goikoetxea M, 2018, NEUROSCI BIOBEHAV R, V84, P63, DOI 10.1016/j.neubiorev.2017.11.007; Sariaslan A, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002103; Sayal K, 2018, LANCET PSYCHIAT, V5, P175, DOI 10.1016/S2215-0366(17)30167-0; Simonoff E, 2013, J CHILD PSYCHOL PSYC, V54, P527, DOI 10.1111/j.1469-7610.2012.02569.x; StataCorp, 2017, Stata statistical software: release 17; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; Tai YM, 2013, RES DEV DISABIL, V34, P1100, DOI 10.1016/j.ridd.2012.11.027; Thapar A, 2017, LANCET PSYCHIAT, V4, P339, DOI 10.1016/S2215-0366(16)30376-5; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; WHO, 2014, INJ EUR CALL PUBL HL; Zablotsky B, 2020, J ATTEN DISORD, V24, P94, DOI 10.1177/1087054717713638";50;17;19;4;18;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0021-9630;1469-7610;;J CHILD PSYCHOL PSYC;J. Child Psychol. Psychiatry;FEB;2020;61;2;;;;;140;147;;10.1111/jcpp.13136;http://dx.doi.org/10.1111/jcpp.13136;;oct-19;8;"Psychology, Developmental; Psychiatry; Psychology";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";KC5YV;31625605;Green Accepted;;;24/11/2024;WOS:000490960300001;View Full Record in Web of Science
J;"Saffari, A; Brösse, I; Wiemer-Kruel, A; Wilken, B; Kreuzaler, P; Hahn, A; Bernhard, MK; van Tilburg, CM; Hoffmann, GF; Gorenflo, M; Hethey, S; Kaiser, O; Kölker, S; Wagner, R; Witt, O; Merkenschlager, A; Möckel, A; Roser, T; Schlump, JU; Serfling, A; Spiegler, J; Milde, T; Ziegler, A; Syrbe, S";;;;"Saffari, Afshin; Broesse, Ines; Wiemer-Kruel, Adelheid; Wilken, Bernd; Kreuzaler, Paula; Hahn, Andreas; Bernhard, Matthias K.; van Tilburg, Cornelis M.; Hoffmann, Georg F.; Gorenflo, Matthias; Hethey, Sven; Kaiser, Olaf; Koelker, Stefan; Wagner, Robert; Witt, Olaf; Merkenschlager, Andreas; Moeckel, Andreas; Roser, Timo; Schlump, Jan-Ulrich; Serfling, Antje; Spiegler, Juliane; Milde, Till; Ziegler, Andreas; Syrbe, Steffen";;;Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study;ORPHANET JOURNAL OF RARE DISEASES;;;English;Article;;;;;;"Tuberous sclerosis complex; mTOR inhibitor; Everolimus; Children; Neonates";"CARDIAC RHABDOMYOMA; CONGENITAL LYMPHEDEMA; EVEROLIMUS THERAPY; REGRESSION; NEWBORN; EPILEPSY; CHILDREN; TUMORS; DRUG";"BackgroundTuberous sclerosis complex (TSC) is a multisystem disease with prominent neurologic manifestations such as epilepsy, cognitive impairment and autism spectrum disorder. mTOR inhibitors have successfully been used to treat TSC-related manifestations in older children and adults. However, data on their safety and efficacy in infants and young children are scarce. The objective of this study is to assess the utility and safety of mTOR inhibitor treatment in TSC patients under the age of 2years.ResultsA total of 17 children (median age at study inclusion 2.4years, range 0-6; 12 males, 5 females) with TSC who received early mTOR inhibitor therapy were studied. mTOR inhibitor treatment was started at a median age of 5months (range 0-19months). Reasons for initiation of treatment were cardiac rhabdomyomas (6 cases), subependymal giant cell astrocytomas (SEGA, 5 cases), combination of cardiac rhabdomyomas and SEGA (1 case), refractory epilepsy (4 cases) and disabling congenital focal lymphedema (1 case). In all cases everolimus was used. Everolimus therapy was overall well tolerated. Adverse events were classified according to the Common Terminology Criteria of Adverse Events (CTCAE, Version 5.0). Grade 1-2 adverse events occurred in 12 patients and included mild transient stomatitis (2 cases), worsening of infantile acne (1 case), increases of serum cholesterol and triglycerides (4 cases), changes in serum phosphate levels (2 cases), increase of cholinesterase (2 cases), transient neutropenia (2 cases), transient anemia (1 case), transient lymphopenia (1 case) and recurrent infections (7 cases). No grade 3-4 adverse events were reported. Treatment is currently continued in 13/17 patients. Benefits were reported in 14/17 patients and included decrease of cardiac rhabdomyoma size and improvement of arrhythmia, decrease of SEGA size, reduction of seizure frequency and regression of congenital focal lymphedema. Despite everolimus therapy, two patients treated for intractable epilepsy are still experiencing seizures and another one treated for SEGA showed no volume reduction.ConclusionThis retrospective multicenter study demonstrates that mTOR inhibitor treatment with everolimus is safe in TSC patients under the age of 2years and shows beneficial effects on cardiac manifestations, SEGA size and early epilepsy.";"[Saffari, Afshin; Broesse, Ines; Hoffmann, Georg F.; Koelker, Stefan; Ziegler, Andreas; Syrbe, Steffen] Univ Hosp Heidelberg, Div Child Neurol & Metab Med, Ctr Paediat & Adolescent Med, Heidelberg, Germany; [Wiemer-Kruel, Adelheid] Epilepsy Ctr Kork, Clin Children & Adolescents, Kehl, Germany; [Wilken, Bernd] Kassel Hosp, Dept Pediat Neurol, Kassel, Germany; [Kreuzaler, Paula; Hahn, Andreas] Univ Hosp, Dept Child Neurol, Giessen, Germany; [Bernhard, Matthias K.; Merkenschlager, Andreas] Univ Hosp Children, Dept Neuropediat, Leipzig, Germany; [van Tilburg, Cornelis M.; Kaiser, Olaf; Milde, Till] Hopp Childrens Canc Ctr Heidelberg KiTZ, Heidelberg, Germany; [van Tilburg, Cornelis M.; Witt, Olaf; Milde, Till] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, Heidelberg, Germany; [van Tilburg, Cornelis M.; Witt, Olaf; Milde, Till] German Consortium Translat Canc Res DKTK, Heidelberg, Germany; [van Tilburg, Cornelis M.; Witt, Olaf; Milde, Till] Heidelberg Univ Hosp, KiTZ Clin Trial Unit ZIPO, Dept Pediat Hematol & Oncol, Heidelberg, Germany; [Gorenflo, Matthias] Heidelberg Univ Hosp, Dept Congenital Heart Defects Paediat Cardiol, Heidelberg, Germany; [Hethey, Sven] Bult Ctr Children & Adolescents, Hannover, Germany; [Kaiser, Olaf] Univ Duisburg Essen, Univ Hosp Essen, Dept Paediat 1, Paediat Neurol, Essen, Germany; [Wagner, Robert] Univ Leipzig, Ctr Heart, Dept Pediat Cardiol, Leipzig, Germany; [Moeckel, Andreas; Serfling, Antje] Sana Kliniken Leipziger Land, Borna, Germany; [Roser, Timo] Univ Munich, Hauner Childrens Hosp, Dept Paediat Neurol & Dev Med, Munich, Germany; [Schlump, Jan-Ulrich] Evangel Hosp Oberhausen, Div Children & Adolescents, Oberhausen, Germany; [Spiegler, Juliane] Univ Med Ctr Schleswig Holstein, Dept Pediat, Campus Lubeck, Kiel, Germany";"Ruprecht Karls University Heidelberg; Leipzig University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Duisburg Essen; Leipzig University; Heart Center Leipzig GMBH; University of Munich; University of Kiel; Schleswig Holstein University Hospital";Syrbe, S (corresponding author), Univ Hosp Heidelberg, Div Child Neurol & Metab Med, Ctr Paediat & Adolescent Med, Heidelberg, Germany.;steffen.syrbe@med.uni-heidelberg.de;"Spiegler, Juliane/AAK-1740-2020; Milde, Till/AAR-4528-2021; Syrbe, Steffen/ABE-8020-2020";Milde, Till/0000-0002-7267-1052;Dietmar Hopp Stiftung [1DH1813319];Dietmar Hopp Stiftung;The Dietmar Hopp Stiftung provided financial support for this study (Grant 1DH1813319 to Steffen Syrbe).;"[Anonymous], 2017, US Department of Health and Human Services National Institutes of Health National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE); Aw F, 2017, PEDIATR CARDIOL, V38, P394, DOI 10.1007/s00246-016-1528-y; Breathnach C, 2014, PEDIATRICS, V134, pE1199, DOI 10.1542/peds.2013-3293; Capal JK, 2016, NEUROPSYCH DIS TREAT, V12, P2165, DOI 10.2147/NDT.S91248; Chang JS, 2017, PEDIATR CARDIOL, V38, P1478, DOI 10.1007/s00246-017-1688-4; Chu-Shore CJ, 2010, EPILEPSIA, V51, P1236, DOI 10.1111/j.1528-1167.2009.02474.x; Colaneri M, 2016, CARDIOL YOUNG, V26, P1025, DOI 10.1017/S1047951116000421; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Curatolo P, 2015, LANCET NEUROL, V14, P733, DOI 10.1016/S1474-4422(15)00069-1; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; Demir HA, 2012, PEDIATRICS, V130, pE243, DOI 10.1542/peds.2011-3476; Dogan V, 2015, J TROP PEDIATRICS, V61, P74, DOI 10.1093/tropej/fmu056; Emir S, 2017, TURK PEDIATR ARSIVI, V52, P30, DOI 10.5152/TurkPediatriArs.2017.4309; Franz DN, 2015, ANN NEUROL, V78, P929, DOI 10.1002/ana.24523; French JA, 2016, LANCET, V388, P2153, DOI 10.1016/S0140-6736(16)31419-2; Geffrey AL, 2014, AM J MED GENET A, V164, P1438, DOI 10.1002/ajmg.a.36469; Goyer I, 2015, PEDIATR NEUROL, V52, P450, DOI 10.1016/j.pediatrneurol.2015.01.004; Hirsch RJ, 1999, PEDIATR DERMATOL, V16, P407; Hoshal SG, 2016, PEDIATR INT, V58, P397, DOI 10.1111/ped.12816; Hoshiai S, 2015, SKELETAL RADIOL, V44, P1165, DOI 10.1007/s00256-015-2094-8; Hwang SK, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0222-6; Jenkins D, 2016, PEDIATR DERMATOL, V33, P536, DOI 10.1111/pde.12946; Kingswood JC, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-016-0553-5; Krueger DA, 2018, EUR J PAEDIATR NEURO, V22, P1066, DOI 10.1016/j.ejpn.2018.06.007; Krueger DA, 2013, ANN NEUROL, V74, P679, DOI 10.1002/ana.23960; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Kuki I, 2018, BRAIN DEV-JPN, V40, P415, DOI 10.1016/j.braindev.2018.01.001; Lucas M, 2011, PEDIATR DERMATOL, V28, P194, DOI 10.1111/j.1525-1470.2010.01231.x; Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892; Mettin RR, 2014, BRAIN DEV-JPN, V36, P306, DOI 10.1016/j.braindev.2013.05.006; Mlczoch E, 2015, ULTRASOUND OBST GYN, V45, P618, DOI 10.1002/uog.13434; Moavero R, 2016, EPILEPSY BEHAV CASE, V5, P13, DOI 10.1016/j.ebcr.2015.12.001; Mohamed I., 2014, CASE REPORTS, V2014; Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001; Öztunç F, 2015, CARDIOL YOUNG, V25, P1411, DOI 10.1017/S1047951114002261; Prato G, 2014, J CHILD NEUROL, V29, pNP54, DOI 10.1177/0883073813499969; Samueli S, 2018, EPILEPSIA, V59, pE142, DOI 10.1111/epi.14529; Schubert-Bast S, 2019, EPILEPSY BEHAV, V91, P94, DOI 10.1016/j.yebeh.2018.05.039; Strolin Benedetti M, 2005, Expert Opin Drug Metab Toxicol, V1, P447; Sukulal K, 2012, INDIAN PEDIATR, V49, P845, DOI 10.1007/s13312-012-0178-2; Voudris KA, 2003, PEDIATR DERMATOL, V20, P371, DOI 10.1046/j.1525-1470.2003.20326_3.x; Wagner R, 2015, ECHOCARDIOGR-J CARD, V32, P1876, DOI 10.1111/echo.13015";42;83;90;0;4;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1750-1172;;ORPHANET J RARE DIS;Orphanet J. Rare Dis.;MAY 3;2019;14;;;;;;;;96;10.1186/s13023-019-1077-6;http://dx.doi.org/10.1186/s13023-019-1077-6;;;13;"Genetics & Heredity; Medicine, Research & Experimental";Science Citation Index Expanded (SCI-EXPANDED);"Genetics & Heredity; Research & Experimental Medicine";HW7ZD;31053163;Green Published, gold;;;24/11/2024;WOS:000466907700003;View Full Record in Web of Science
J;"Roy, A; Roy, M; Deb, S; Unwin, G; Roy, A";;;;"Roy, A.; Roy, M.; Deb, S.; Unwin, G.; Roy, A.";;;Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review;JOURNAL OF INTELLECTUAL DISABILITY RESEARCH;;;English;Article;;;;;;"autism; children; hyperactivity; intellectual disability; naltrexone; opioid antagonists";"SELF-INJURIOUS-BEHAVIOR; DOUBLE-BLIND; RATING-SCALE; NALTREXONE TREATMENT; EFFICACY; HALOPERIDOL; MEDICATION; SAFETY; SKILLS";"BackgroundASC (autism spectrum conditions) may result from a failure of striatal beta endorphins to diminish with maturation. Many symptoms of ASC resemble behaviours induced in animals or humans by opiate administration, including decreased socialisation, diminished crying, repetitive stereotypies, insensitivity to pain and motor hyperactivity. Naltrexone, an opioid antagonist, has been used in the management of children with ASC and can produce a clinically significant reduction in the serious and life-threatening behaviour of self-injury for individuals who have not been responsive to any other type of treatment and is important for this reason. It was therefore appropriate to reconsider the available evidence and a systematic review was undertaken. MethodsFour electronic databases were searched for relevant journal articles. In addition, cross-referencing of pertinent reviews and a hand search for articles in major international intellectual disability (ID) journals between the years 2010 and 2012 was carried out to ensure that all relevant articles were identified. We also searched databases for unpublished clinical trials to overcome publication bias. Each database was searched up to present (February 2013) with no restrictions on the date of publication. The search terms consisted of broad expressions used to describe ID and autistic spectrum disorder as well as terms relating to opioid antagonists and specific drugs. All studies identified by the electronic database search and hand search were examined on the basis of title alone for relevance and duplication. The abstracts of the remaining papers were then scrutinised against the inclusion criteria. Where abstracts failed to provide adequate information, the full texts for these papers were obtained. All the full texts were then evaluated against the inclusion proforma. Two reviewers carried out all the stages of the process independently. The reviewers met to discuss their selections and where disagreements arose, these were settled by discussion with a member of the study group. Data from each study meeting the inclusion criteria were extracted on a pre-piloted data extraction form. The quality of each study was further assessed using the Jadad scale, a tool developed to assess the quality of randomised controlled trials. Results155 children participated in 10 studies; 27 received placebo. Of the 128 that received naltrexone 98 (77%) showed statistically significant improvement in symptoms of irritability and hyperactivity. Side effects were mild and the drug was generally well tolerated. ConclusionsNaltrexone may improve hyperactivity and restlessness in children with autism but there was not sufficient evidence that it had an impact on core features of autism in majority of the participants. It is likely that a subgroup of children with autism and abnormal endorphin levels may respond to naltrexone and identifying the characteristics of these children must become a priority.";"[Roy, A.] Univ Manchester, Manchester, Lancs, England; [Roy, M.] Birmingham Community Healthcare Trust, Birmingham, W Midlands, England; [Deb, S.; Unwin, G.] Univ Birmingham, Birmingham, W Midlands, England; [Roy, A.] Coventry & Warwickshire Partnership Trust, Birmingham, W Midlands, England";"University of Manchester; University of Birmingham";Roy, A (corresponding author), Brooklands Hosp, Brian Oliver Ctr, Coleshill Rd, Birmingham B37 7HL, W Midlands, England.;ashok.roy@covwarkpt.nhs.uk;Roy, Ashok/AAF-6396-2020;"Unwin, Gemma/0000-0002-5205-3150; Deb, Shoumitro/0000-0002-1300-8103";;;;"Abidin R., 1995, Parent Stress Inventory, V3rd; Achenbach TM., 1983, MANUAL CHILD BEHAV C; AMAN MG, 1985, AM J MENT DEF, V89, P485; ANDERSON LT, 1984, AM J PSYCHIAT, V141, P1195; [Anonymous], 2002, Morbidity and Mortality Weekly Report. Surveillance Summaries, V61, P1; Baron-Cohen S, 2009, BRIT J PSYCHIAT, V194, P500, DOI 10.1192/bjp.bp.108.059345; Barron J. L., 1993, HDB BEHAV THERAPY PH, P129; BARTHELEMY C, 1990, J AUTISM DEV DISORD, V20, P189, DOI 10.1007/BF02284718; Baumeister A.A., 1973, INT REV RES MENTAL R, V6, P55, DOI DOI 10.1016/S0074-7750(08)60037-3; BOUVARD MP, 1995, PSYCHIAT RES, V58, P191, DOI 10.1016/0165-1781(95)02601-R; CAMPBELL M, 1988, J AM ACAD CHILD PSY, V27, P434, DOI 10.1097/00004583-198807000-00010; CAMPBELL M, 1984, ARCH GEN PSYCHIAT, V41, P650; CAMPBELL M, 1993, J AM ACAD CHILD PSY, V32, P1283, DOI 10.1097/00004583-199311000-00024; Campbell M, 1997, J AM ACAD CHILD PSY, V36, P835, DOI 10.1097/00004583-199706000-00022; CAMPBELL M, 1990, PSYCHOPHARMACOL BULL, V26, P130; CHAMBERLAIN RS, 1990, BIOL PSYCHIAT, V28, P773, DOI 10.1016/0006-3223(90)90513-2; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; ElChaar GM, 2006, ANN PHARMACOTHER, V40, P1086, DOI 10.1345/aph.1G499; Feldman HM, 1999, J AM ACAD CHILD PSY, V38, P587, DOI 10.1097/00004583-199905000-00021; FISH B, 1985, PSYCHOPHARMACOL BULL, V21, P753; Gilliam J. E., 1995, Gilliam autism rating scale for; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kogan MD, 2009, PEDIATRICS, V124, P1395, DOI 10.1542/peds.2009-1522; Kolmen BK, 1997, J AM ACAD CHILD PSY, V36, P1570, DOI 10.1016/S0890-8567(09)66567-9; KOLMEN BK, 1995, J AM ACAD CHILD PSY, V34, P223, DOI 10.1097/00004583-199502000-00018; LEBOYER M, 1992, J AUTISM DEV DISORD, V22, P309, DOI 10.1007/BF01058158; MATSON JL, 1985, PSYCHOPHARMACOL BULL, V21, P855; PANKSEPP J, 1979, TRENDS NEUROSCI, V2, P174, DOI 10.1016/0166-2236(79)90071-7; Sandman C.A., 1995, Mental Retardation and Developmental Disabilities Research Reviews, V1, P130, DOI DOI 10.1002/MRDD.1410010209; SANDMAN CA, 1988, SYNAPSE, V2, P193, DOI 10.1002/syn.890020304; Sandman CA, 2011, PHARMACEUTICALS, V4, P366, DOI 10.3390/ph4020366; Schopler E., 1988, The childhood autism rating scale (CARS); Schroeder S.R., 2002, SELF INJURIOUS BEHAV; Scifo Renato, 1991, Brain Dysfunction, V4, P301; Symons FJ, 2004, MENT RETARD DEV D R, V10, P193, DOI 10.1002/mrdd.20031; Unwin GL, 2011, RES DEV DISABIL, V32, P2121, DOI 10.1016/j.ridd.2011.07.031; WillemsenSwinkels SHN, 1996, BIOL PSYCHIAT, V39, P1023, DOI 10.1016/0006-3223(95)00297-9; WILLEMSENSWINKELS SHN, 1995, PSYCHIAT RES, V58, P203, DOI 10.1016/0165-1781(95)02749-M; Williams PG, 2001, J AUTISM DEV DISORD, V31, P103, DOI 10.1023/A:1005674016014";41;44;45;0;27;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0964-2633;1365-2788;;J INTELL DISABIL RES;J. Intell. Disabil. Res.;APR;2015;59;4;;;SI;;293;306;;10.1111/jir.12122;http://dx.doi.org/10.1111/jir.12122;;;14;"Education, Special; Genetics & Heredity; Clinical Neurology; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Genetics & Heredity; Neurosciences & Neurology; Psychiatry; Rehabilitation";CD6CM;24589346;;;;24/11/2024;WOS:000351176600001;View Full Record in Web of Science
J;"Ernstad, EG; Hanson, C; Wånggren, K; Thurin-Kjellberg, A; Söderberg, CH; Lundberg, ES; Petzold, M; Wennerholm, UB; Bergh, C";;;;"Ernstad, Erica Ginstrom; Hanson, Charles; Wanggren, Kjell; Thurin-Kjellberg, Ann; Soderberg, Cecilia Hulthe; Lundberg, Elisabeth Syk; Petzold, Max; Wennerholm, Ulla-Britt; Bergh, Christina";;;Preimplantation genetic testing and child health: a national register-based study;HUMAN REPRODUCTION;;;English;Article;;;;;;"preimplantation genetic testing; perinatal outcome; child health; in vitro fertilization; intracytoplasmic sperm injection";"IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY; NEONATAL FOLLOW-UP; SINGLETON PREGNANCIES; PERINATAL OUTCOMES; PLACENTA PREVIA; EMBRYO-TRANSFER; CEREBRAL-PALSY; DIAGNOSIS PGD; ESHRE PGD";"STUDY QUESTION Is preimplantation genetic testing (PGT) associated with adverse perinatal outcome and early childhood health? SUMMARY ANSWER Children born after PGT had comparable perinatal outcomes to children born after IVF/ICSI and comparable findings regarding early childhood health. WHAT IS KNOWN ALREADY PGT is offered to couples affected by monogenic disorders (PGT-M) or inherited chromosomal aberrations (PGT-SR), limiting the risk of transferring the disorder to the offspring. PGT, an invasive technique, requires genetic analysis of one or up to ten cells from the embryo and is combined with IVF or ICSI. Several studies, most of them small, have shown comparable results after PGT and IVF/ICSI concerning perinatal outcome. Only a few studies with limited samples have been published on PGT and childhood health. STUDY DESIGN, SIZE, DURATION We performed a register-based study including all singletons born after PGT (n = 390) in Sweden during 1 January 1996-30 September 2019. Singletons born after PGT were compared with all singletons born after IVF/ICSI (n = 61 060) born during the same period of time and with a matched sample of singletons (n = 42 034) born after spontaneous conception selected from the Medical Birth Register. Perinatal outcomes, early childhood health, and maternal outcomes were compared between pregnancies after PGT and IVF/ICSI as well as between pregnancies after PGT and spontaneous conception. Primary outcomes were preterm birth (PTB) and low birthweight (LBW) whereas childhood morbidity was the secondary outcome. PARTICIPANTS/MATERIALS, SETTING, METHODS Data on women who went through PGT and gave birth were obtained from the local databases at the two PGT centres in Sweden, whereas data on IVF treatment for the IVF/ICSI group were obtained from the national IVF registers. These data were then cross-linked to national health registers; the Medical Birth Register, the Patient Register, and the Cause of Death Register. Logistic multivariable regression analysis and Cox proportional hazards models were performed with adjustment for relevant confounders. MAIN RESULTS AND THE ROLE OF CHANCE The mean follow-up time was 4.6 years for children born after PGT and 5.1 years for children born after spontaneous conception, whereas the mean follow-up time was 9.0 years for children born after IVF/ICSI. For perinatal outcomes, PTB occurred in 7.7% of children after PGT and in 7.3% of children after IVF/ICSI, whereas the rates were 4.9% and 5.2% for LBW (adjusted odds ratio (AOR) 1.22, 95% CI 0.82-1.81 and AOR 1.17, 95% CI 0.71-1.91, respectively). No differences were observed for birth defects. In comparison to spontaneous conception, children born after PGT had a higher risk for PTB (AOR 1.73, 95% CI 1.17-2.58). Regarding early childhood health, the absolute risk of asthma was 38/390 (9.7%) in children born after PGT and 6980/61 060 (11.4%) in children born after in IVF/ICSI, whereas the corresponding numbers were 34/390 (8.7%) and 7505/61 060 (12.3%) for allergic disorders. Following Cox proportional hazards models, no significant differences were found for these outcomes. Sepsis, hypothyroidism, attention deficit hyperactivity disorder, autism spectrum disorders, mental retardation, cerebral palsy, and epilepsy were diagnosed in a maximum of three PGT children. No PGT children died during the follow-up period. Regarding maternal outcomes, the rates of placenta praevia and caesarean delivery were significantly higher after PGT in comparison to spontaneous conception (AOR 6. 46, 95% CI 3.38-12.37 and AOR 1.52, 95% CI 1.20-1.92, respectively), whereas no differences were seen comparing pregnancies after PGT and IVF/ICSI. LIMITATIONS, REASONS FOR CAUTION The rather small sample size of children born after PGT made it impossible to adjust for all relevant confounders including fertilization method and culture duration. Moreover, the follow-up time was short for most of the children especially in the PGT group, probably lowering the absolute number of diagnoses in early childhood. WIDER IMPLICATIONS OF THE FINDINGS The results are reassuring and indicate that the embryo biopsy itself has no adverse effect on the perinatal, early childhood, or maternal outcomes. Although the results are comparable to IVF/ICSI also regarding early childhood outcome, they should be taken with caution due to the low number of children with diagnoses and short follow-up time. Long-term follow-up studies on children born after PGT are scarce and should be conducted considering the invasiveness of the technique. STUDY FUNDING/COMPETING INTEREST(S) The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (LUA/ALF 70940), the Board of National Specialised Medical Care at Sahlgrenska University Hospital and Hjalmar Svensson Research Foundation. There are no conflicts of interest to declare.";"[Ernstad, Erica Ginstrom; Wennerholm, Ulla-Britt] Gothenburg Univ, Inst Clin Sci, Dept Obstet & Gynaecol, Sahlgrenska Acad,Sahlgrenska Univ Hosp,East Hosp, Gothenburg, Sweden; [Hanson, Charles; Thurin-Kjellberg, Ann; Bergh, Christina] Gothenburg Univ, Sahlgrenska Univ Hosp, Dept Obstet & Gynaecol, Inst Clin Sci,Sahlgrenska Acad,Reprod Med, Gothenburg, Sweden; [Wanggren, Kjell] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Obstet & Gynaecol, Stockholm, Sweden; [Soderberg, Cecilia Hulthe] Sahlgrens Univ Hosp, Dept Clin Genet, Gothenburg, Sweden; [Lundberg, Elisabeth Syk] Karolinska Univ Hosp, Dept Clin Genet, Stockholm, Sweden; [Lundberg, Elisabeth Syk] Karolinska Inst, Ctr Mol Med, Dept Mol Med & Surg, Stockholm, Sweden; [Petzold, Max] Univ Gothenburg, Inst Med, Sch Publ Hlth & Community Med, Gothenburg, Sweden";"University of Gothenburg; Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; Sahlgrenska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Gothenburg";Ernstad, EG (corresponding author), Univ Gothenburg, Sahlgrenska Univ Hosp East, Inst Clin Sci, Dept Obstet & Gynaecol,Sahlgrenska Acad, SE-41680 Gothenburg, Sweden.;erica.ernstad@vgregion.se;"Wennerholm, Ulla-Britt/AFP-3868-2022; Bergh, Christina/KRP-6600-2024";Ginstrom Ernstad, Erica/0000-0001-5008-5661;;;;"[Anonymous], United States of America; Bay B, 2016, FERTIL STERIL, V106, P1363, DOI 10.1016/j.fertnstert.2016.07.1092; Belva F, 2018, HUM REPROD OPEN, V2018, DOI 10.1093/hropen/hoy013; Berntsen S, 2019, HUM REPROD UPDATE, V25, P137, DOI 10.1093/humupd/dmz001; Brooke HL, 2017, EUR J EPIDEMIOL, V32, P765, DOI 10.1007/s10654-017-0316-1; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Coonen E, 2020, HUM REPROD OPEN, V2020, DOI 10.1093/hropen/hoaa043; De Rycke M, 2017, HUM REPROD, V32, P1974, DOI 10.1093/humrep/dex265; Desmyttere S, 2012, HUM REPROD, V27, P288, DOI 10.1093/humrep/der360; Desmyttere S, 2009, EARLY HUM DEV, V85, P755, DOI 10.1016/j.earlhumdev.2009.10.003; Eapen A, 2020, FERTIL STERIL, V114, P690, DOI 10.1016/j.fertnstert.2020.08.1423; Eldar-Geva T, 2014, FERTIL STERIL, V102, P1016, DOI 10.1016/j.fertnstert.2014.06.023; Ericson A, 2002, HUM REPROD, V17, P929, DOI 10.1093/humrep/17.4.929; Ernstad EG, 2019, AM J OBSTET GYNECOL, V221, DOI 10.1016/j.ajog.2019.03.010; Ernstad EG, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.040; European Network of Publication-Based Registries for the Epidemiological Surveillance of Congenital Anomalies (EUROCAT), US; Faiz A S, 2003, J Matern Fetal Neonatal Med, V13, P175, DOI 10.1080/713605832; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; Hanson C, 2001, ACTA OBSTET GYN SCAN, V80, P331, DOI 10.1034/j.1600-0412.2001.080004331.x; Hardarson T, 2008, HUM REPROD, V23, P2806, DOI 10.1093/humrep/den217; Harton GL, 2011, HUM REPROD, V26, P33, DOI 10.1093/humrep/deq231; Hasson J, 2017, REPROD BIOMED ONLINE, V35, P208, DOI 10.1016/j.rbmo.2017.05.003; Heijligers M, 2018, HUM REPROD, V33, P2150, DOI 10.1093/humrep/dey302; Heijligers M, 2019, FERTIL STERIL, V111, P1151, DOI 10.1016/j.fertnstert.2019.01.035; Hou WH, 2021, FERTIL STERIL, V116, P990, DOI 10.1016/j.fertnstert.2021.06.040; Hvidtjorn D, 2011, J EPIDEMIOL COMMUN H, V65, P497, DOI 10.1136/jech.2009.093823; Ishihara O, 2014, FERTIL STERIL, V101, P128, DOI 10.1016/j.fertnstert.2013.09.025; Källén AJB, 2011, EUR J PAEDIATR NEURO, V15, P247, DOI 10.1016/j.ejpn.2010.12.004; Källén AJB, 2010, EUR J PAEDIATR NEURO, V14, P526, DOI 10.1016/j.ejpn.2010.03.007; Källén B, 2005, FERTIL STERIL, V84, P605, DOI 10.1016/j.fertnstert.2005.03.035; Karami M, 2018, J MATERN-FETAL NEO M, V31, P1940, DOI 10.1080/14767058.2017.1332035; Kuiper D, 2018, HUM REPROD, V33, P147, DOI 10.1093/humrep/dex337; Lewis S, 2021, REPROD BIOMED ONLINE, V42, P609, DOI 10.1016/j.rbmo.2020.11.014; Liebaers I, 2010, HUM REPROD, V25, P275, DOI 10.1093/humrep/dep298; Liu L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46207; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Maheshwari A, 2018, HUM REPROD UPDATE, V24, P35, DOI 10.1093/humupd/dmx031; Maheshwari A, 2013, FERTIL STERIL, V100, P1615, DOI 10.1016/j.fertnstert.2013.08.044; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; National Registry of Assisted Reproduction, Q IVF; Natsuaki MN, 2018, WORLD J PEDIATR, V14, P555, DOI 10.1007/s12519-018-0172-4; Opdahl S, 2015, HUM REPROD, V30, P1724, DOI 10.1093/humrep/dev090; Pinborg A, 2013, HUM REPROD UPDATE, V19, P87, DOI 10.1093/humupd/dms044; Qin JB, 2016, FERTIL STERIL, V105, P73, DOI 10.1016/j.fertnstert.2015.09.007; Rombauts L, 2014, HUM REPROD, V29, P2787, DOI 10.1093/humrep/deu240; Rönö K, 2022, FERTIL STERIL, V117, P1026, DOI 10.1016/j.fertnstert.2022.01.010; Sharpe A, 2018, HUM FERTIL, V21, P120, DOI 10.1080/14647273.2017.1336259; Spangmose AL, 2020, HUM REPROD, V35, P805, DOI 10.1093/humrep/deaa032; Spangmose AL, 2021, HUM REPROD, V36, P2358, DOI 10.1093/humrep/deab122; Strömberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Sunkara SK, 2017, HUM REPROD, V32, P432, DOI 10.1093/humrep/dew317; Svahn MF, 2015, HUM REPROD, V30, P2129, DOI 10.1093/humrep/dev172; Swedish National Board of Health and Welfare, SWED MED BIRTH REG S; van Montfoort A, 2021, HUM REPROD OPEN, V2021, DOI 10.1093/hropen/hoab024; Vermey BG, 2019, BJOG-INT J OBSTET GY, V126, P209, DOI 10.1111/1471-0528.15227; von Versen-Höynck F, 2019, HYPERTENSION, V73, P640, DOI 10.1161/HYPERTENSIONAHA.118.12043; Wang FF, 2021, WORLD J PEDIATR, V17, P364, DOI 10.1007/s12519-021-00442-z; Wijs LA, 2022, HUM REPROD UPDATE, V28, P132, DOI 10.1093/humupd/dmab031; Zhang WY, 2019, FERTIL STERIL, V112, P283, DOI 10.1016/j.fertnstert.2019.03.033; Zheng W, 2021, HUM REPROD UPDATE, V27, P989, DOI 10.1093/humupd/dmab027";60;8;8;0;10;OXFORD UNIV PRESS;OXFORD;GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND;0268-1161;1460-2350;;HUM REPROD;Hum. Reprod.;APR 3;2023;38;4;;;;;739;750;;10.1093/humrep/dead021;http://dx.doi.org/10.1093/humrep/dead021;;FEB 2023;12;"Obstetrics & Gynecology; Reproductive Biology";Science Citation Index Expanded (SCI-EXPANDED);"Obstetrics & Gynecology; Reproductive Biology";C0GP8;36749096;Green Published, hybrid;;;24/11/2024;WOS:000927144000001;View Full Record in Web of Science
J;"Roy, A; Roy, M; Deb, S; Unwin, G; Roy, A";;;;"Roy, A.; Roy, M.; Deb, S.; Unwin, G.; Roy, A.";;;Are opioid antagonists effective in reducing self-injury in adults with intellectual disability? A systematic review;JOURNAL OF INTELLECTUAL DISABILITY RESEARCH;;;English;Article;;;;;;"autism; intellectual disability; learning disability; self-injury";"DEVELOPMENTAL-DISABILITIES; NALTREXONE TREATMENT; MENTAL-RETARDATION; AUTISTIC BEHAVIOR; INFANTILE-AUTISM; MOTIVATION; CHILDREN; PLACEBO; TRIAL";BackgroundSelf-injury in people with intellectual disability (ID) may be due to variety of factors both environmental and biological. As the drive in UK is to manage people with ID and problem behaviours in the community, it is important to critically examine all treatment options available. As abnormalities in the endogenous opioid system may be a factor in some people with ID, we undertook a systematic review to evaluate the evidence for the effectiveness of opioid antagonists. MethodsFour electronic databases were searched for relevant journal articles. In addition, cross-referencing of pertinent reviews and a hand search for articles in major international ID journals between the years 2010 and 2012 was carried out to ensure that all relevant articles were identified. We also searched databases for unpublished clinical trials to overcome publication bias. Each database was searched up to present (February 2013) with no restrictions on the date of publication. The search terms consisted of broad expressions used to describe ID and autistic spectrum disorder as well as terms relating to opioid antagonists and specific drugs. All studies identified by the electronic database search and hand search were examined on the basis of title alone for relevance and duplication. The abstracts of the remaining papers were then scrutinised against the inclusion criteria. Where abstracts failed to provide adequate information, the full texts for these papers were obtained. All the full texts were then evaluated against the inclusion proforma. Two reviewers carried out all the stages of the process independently. The reviewers met to discuss their selections and where disagreements arose, these were settled by discussion with a member of the study group. Data from each study meeting the inclusion criteria was extracted on a pre-piloted data extraction form. The quality of each study was further assessed using the Jadad scale, a tool developed to assess the quality of randomised controlled trials. ResultsOut of 10 randomised control trials eight reported a reduction in the frequency of self-injurious behaviour. This meant that 62 participants out of 124 (50%) showed an improvement of which 61 were statistically significant. Forty-nine participants had autism. Eleven (9%) had minor side-effects. The improvement was more marked in people with severe and profound ID and was not affected by the coexistence of autism. ConclusionsThis review suggests that some people respond to opioid antagonists with a reduction in self-injury but the trials do not predict who they may be. Future research may identify this sub-group when opioid antagonists may prove to be a useful addition in the pharmacotherapy of self-injury.;"[Roy, A.] Univ Manchester, Manchester, Lancs, England; [Roy, M.; Unwin, G.] Univ Birmingham, Birmingham, W Midlands, England; [Deb, S.] Univ London Imperial Coll Sci Technol & Med, London, England; [Roy, A.] Brooklands Hosp, Birmingham B37 7HL, W Midlands, England";"University of Manchester; University of Birmingham; Imperial College London";Roy, A (corresponding author), Brooklands Hosp, Coleshill Rd, Birmingham B37 7HL, W Midlands, England.;Ashok.Roy@covwarkpt.nhs.uk;Roy, Ashok/AAF-6396-2020;"Deb, Shoumitro/0000-0002-1300-8103; Unwin, Gemma/0000-0002-5205-3150";;;;"[Anonymous], NEUROBIOLOGICAL ISSU; Barrera F.J., 1994, Journal of Developmental and Physical Disabilities, V6, P169; Baumeister A. A., 1973, INT REV RES MENT RET, P55; Bodfish JW, 1997, J DEV PHYS DISABIL, V9, P135, DOI 10.1023/A:1024977719165; CAMPBELL M, 1989, J AM ACAD CHILD PSY, V28, P200, DOI 10.1097/00004583-198903000-00009; CAMPBELL M, 1988, PSYCHOPHARMACOL BULL, V24, P135; CARR EG, 1977, PSYCHOL BULL, V84, P800, DOI 10.1037/0033-2909.84.4.800; Cooper SA, 2009, J INTELL DISABIL RES, V53, P200, DOI 10.1111/j.1365-2788.2008.01060.x; Deb S, 2001, J INTELL DISABIL RES, V45, P506, DOI 10.1046/j.1365-2788.2001.00373.x; DEUTSCH SI, 1986, AM J MENT RETARD, V90, P631; Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140; Emerson E., 2011, CHALLENGING BEHAV; Favell J. E., 1980, TREAT SELF INJURIOUS; GIBSON AK, 1995, J DEV PHYS DISABIL, V7, P215, DOI 10.1007/BF02585426; HORNER RH, 1994, J APPL BEHAV ANAL, V27, P401, DOI 10.1901/jaba.1994.27-401; IWATA BA, 1994, J APPL BEHAV ANAL, V27, P197, DOI 10.1901/jaba.1994.27-197; Jadad R A, 1996, CONTROLLED CLIN TRIA, V17, P1; KARS H, 1990, BIOL PSYCHIAT, V27, P741, DOI 10.1016/0006-3223(90)90589-T; Leboyer M., 1988, PSYCHOPHARMACOLOGY B, V24, P135; Morgan C.N., 2002, PSYCHIATRIC B, V26, P127, DOI DOI 10.1192/PB.26.4.127; PANKSEPP J, 1991, J AUTISM DEV DISORD, V21, P243, DOI 10.1007/BF02284764; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; Rojahn J., 1994, Destructive behavior and developmental disabilities, P49; SANDMAN CA, 1983, APPL RES MENT RETARD, V4, P5, DOI 10.1016/S0270-3092(83)80014-9; SANDMAN CA, 1990, AM J MENT RETARD, V95, P93; Sandman CA, 2011, PHARMACEUTICALS, V4, P366, DOI 10.3390/ph4020366; Sandman CA, 1993, EXP CLIN PSYCHOPHARM, V1, P242, DOI 10.1037/1064-1297.1.1-4.242; Schroeder S.R., 2002, SELF INJURIOUS BEHAV; Symons FJ, 2001, EXP CLIN PSYCHOPHARM, V9, P269, DOI 10.1037//1064-1297.9.3.269; THOMPSON T, 1994, AM J MENT RETARD, V99, P85; WILLEMSENSWINKELS SHN, 1995, ARCH GEN PSYCHIAT, V52, P766; Yang LZJ, 2003, BEHAV INTERVENT, V18, P109, DOI 10.1002/bin.131; ZINGARELLI G, 1992, AM J MENT RETARD, V97, P57";33;12;16;0;21;WILEY-BLACKWELL;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0964-2633;1365-2788;;J INTELL DISABIL RES;J. Intell. Disabil. Res.;JAN;2015;59;1;;;;;55;67;;10.1111/jir.12111;http://dx.doi.org/10.1111/jir.12111;;;13;"Education, Special; Genetics & Heredity; Clinical Neurology; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Genetics & Heredity; Neurosciences & Neurology; Psychiatry; Rehabilitation";AW1XX;24397316;;;;24/11/2024;WOS:000346083000006;View Full Record in Web of Science
J;"van Steensel, FJA; Dirksen, CD; Bögels, SM";;;;"van Steensel, F. J. A.; Dirksen, C. D.; Bogels, S. M.";;;Cost-effectiveness of cognitive-behavioral therapy versus treatment as usual for anxiety disorders in children with autism spectrum disorder;RESEARCH IN AUTISM SPECTRUM DISORDERS;;;English;Article;;;;;;"Anxiety; COT; TAU; Cost-effectiveness";"INTERVIEW; SYMPTOMS; EUROQOL; YOUTH; EQ-5D";"The study's aim was to evaluate the cost-effectiveness of CBT compared to treatment as usual (TAU). In total, 49 children aged 8-18 years with ASD and comorbid anxiety disorders, and their parents, participated; 24 were assigned to CBT and 25 were assigned to TAU. Outcome measures were the percentage of children free from their primary anxiety disorder and quality adjusted life years (QALYs). Costs were measured using a retrospective cost-questionnaire. Effects and costs were assessed at pre-, post-, and three months after treatment. Effects and costs were not statistically different between CBT and TAU, however the incremental cost-effectiveness ratio (ICER) demonstrated that CBT dominates TAU. Bootstrapped ICERs demonstrated that CBT has a high probability to be more effective than TAU, however, the probability that either CBT or TAU is more costly did not differ much. Secondary analyses demonstrated fairly robust results. CBT seems a cost-effective intervention compared to TAU, however, long-term follow-ups and comparisons between CBT and specific TAUs are necessary. Cost-effectiveness analyses may help inform policy makers to decide how to treat anxiety disorders in children with ASD. (C) 2013 Elsevier Ltd. All rights reserved.";"[van Steensel, F. J. A.; Bogels, S. M.] Univ Amsterdam, Res Inst Child Dev & Educ, NL-1012 WX Amsterdam, Netherlands; [Dirksen, C. D.] Maastricht Univ, Dept Clin Epidemiol & Med Technol Assessment, Med Ctr, Maastricht, Netherlands";"University of Amsterdam; Maastricht University";van Steensel, FJA (corresponding author), Univ Amsterdam, Res Inst Child Dev & Educ, NL-1012 WX Amsterdam, Netherlands.;f.j.a.vansteensel@uva.nl;;;;;;"[Anonymous], 2007, Economic evaluation in clinical trials; [Anonymous], 2010, HANDLEIDING KOSTENON; [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787; Barrett PM, 2001, J CONSULT CLIN PSYCH, V69, P135, DOI 10.1037//0022-006X.69.1.135; Bastiaansen D, 2005, QUAL LIFE RES, V14, P1599, DOI 10.1007/s11136-004-7711-2; Bodden DHM, 2008, J ABNORM CHILD PSYCH, V36, P487, DOI 10.1007/s10802-007-9194-4; Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Chalfant AM, 2007, J AUTISM DEV DISORD, V37, P1842, DOI 10.1007/s10803-006-0318-4; Farrugia S., 2006, FOCUS AUTISM DEV DIS, V21, P25, DOI DOI 10.1177/10883576060210010401; Lamers LM, 2006, HEALTH ECON, V15, P1121, DOI 10.1002/hec.1124; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Palmer S, 1999, BRIT MED J, V318, P1349, DOI 10.1136/bmj.318.7194.1349; Reaven JA, 2009, FOCUS AUTISM DEV DIS, V24, P27, DOI 10.1177/1088357608327666; Reaven J, 2012, J CHILD PSYCHOL PSYC, V53, P410, DOI 10.1111/j.1469-7610.2011.02486.x; Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e; Silverman W.K., 1996, Anxiety Disorders Interview Schedule for DSM-IV: Child Interview Schedule, V2; Silverman WK, 2001, J AM ACAD CHILD PSY, V40, P937, DOI 10.1097/00004583-200108000-00016; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Smulders Y M, 2006, Ned Tijdschr Geneeskd, V150, P2467; Sofronoff K, 2005, J CHILD PSYCHOL PSYC, V46, P1152, DOI 10.1111/j.1469-7610.2005.00411.x; Stolk EA, 2000, QUAL LIFE RES, V9, P29, DOI 10.1023/A:1008923029886; Storch EA, 2013, J AM ACAD CHILD PSY, V52, P132, DOI 10.1016/j.jaac.2012.11.007; Sung M, 2011, CHILD PSYCHIAT HUM D, V42, P634, DOI 10.1007/s10578-011-0238-1; van Mastrigt G, 2009, OUTCOME ASSESSMENT E, P119; Van Steensel F.J. A., 2013, J AUTISM DEV DISORD, DOI DOI 10.1007/S10803-013-1835-6.EPUB; Van Steensel F. J. A., 2012, ANXIETY QUALITY LIFE, DOI DOI 10.1080/15374416.2012.698725.EPUB; Van Steensel F. J. A., COGNITIVE BEHA UNPUB; Willems DCM, 2009, INT J TECHNOL ASSESS, V25, P391, DOI 10.1017/S0266462309990171; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wood JJ, 2010, CLIN PSYCHOL-SCI PR, V17, P281, DOI 10.1111/j.1468-2850.2010.01220.x; Wood JJ, 2009, J CHILD PSYCHOL PSYC, V50, P224, DOI 10.1111/j.1469-7610.2008.01948.x";32;18;19;0;52;ELSEVIER SCI LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND;1750-9467;1878-0237;;RES AUTISM SPECT DIS;Res. Autism Spectr. Disord.;FEB;2014;8;2;;;;;127;137;;10.1016/j.rasd.2013.11.001;http://dx.doi.org/10.1016/j.rasd.2013.11.001;;;11;"Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Psychology; Psychiatry; Rehabilitation";AA5RF;;;;;24/11/2024;WOS:000331156600009;View Full Record in Web of Science
J;"Al-Ali, BA; Ali, AA; Mahdi, SS; Kadhim, ZHM; Hashim, ZA";;;;"Al-Ali, Basheer Akeel; Ali, Ayat Adnan; Mahdi, Shams Salah; Kadhim, Zahraa Haider Mohammed; Hashim, Zainab Ahmed";;;Determination of Environmental Risk Factors of Autism in Kerbala city / Iraq 2020;LATIN AMERICAN JOURNAL OF PHARMACY;;;English;Article;;;;;;"autism; children; environment; electronic devices";"SPECTRUM DISORDERS; CHILDREN; BIRTH";Autism described as a severe neurodevelopment disorder and belongs to autism spectrum disorders (ASDs). Based on epidemiological studies conducted over the past 50 years, the prevalence of (ASDs) appears to be increasing globally. There are many possible descriptions for this apparent increase, including developed awareness, expansion of diagnostic criteria, well diagnostic tools and improved reporting. With regard to its progressive rise over the last 50 years, lack of actual treatment, and moreover, the difficulties enforced on the society and families of autistic children, the importance of investigation on the reasons of this disease and effort to avoid it become clear. The objective were to determine the environmental risk factors of autism in Kerbala city/Iraq. The study was a case control study through six months from 1st of July 2019 to 30th of January 2020. A study sample was 276 persons (138 cases and 138 controls), age ranging from 1-20 year. The cases were carried out in three private specialized educational institutions for autistic children and controls were drawn from a kindergarten, primary and secondary schools. The data were collected through a special structured validated questionnaire and analyzed by SPSS software. The mean age of the sample (autism cases and controls) was 7.86 +/- 2.02 years. There was a significant difference between 2 groups in relation to age category, gender, address, mother educational level, mother job, and economic state: p < 0.05. Mother's suffering from any tension or nervous tension during pregnancy (OR = 4.811, p = 0.046), and mother take medication during pregnancy (OR = 13.23, p = 0.003), urban residence (OR = 11.252, p = 0.004) were the factors that significantly associated with increased odds of autism cases in children of Kerbala city/Iraq. There was a statistically significant association between the groups of study and the child go to school, child have other diseases, age of child when start watching TV, child use smart device, child has its own device, there is control by parents about using of smart device, child imitate, child continue sleep at night, the family history of autism, mother take antenatal care (p < 0.05). The environmental factors play an important role in the development of autism, these include: urban residence, maternal stress, medication and diseases during pregnancy that can affect the development of child and attributed to autism. Nowadays, with the wide spread usage of electronic devices that cause isolation of the child from his environment in addition to the harmful effects of their radiation that may lead to many disorders in our children. These factors may play an important role with genetics through epigenetic mechanism.;"[Al-Ali, Basheer Akeel] Kerbala Univ, Coll Med, Dept Family & Community Med, Karbala, Iraq; [Ali, Ayat Adnan] Univ Kerbala, Coll Med, Stage 4, Karbala, Iraq";"University of Kerbala; University of Kerbala";Al-Ali, BA (corresponding author), Kerbala Univ, Coll Med, Dept Family & Community Med, Karbala, Iraq.;basheer.a@uokerbala.edu.iq;alali, basheer/AAH-1024-2019;alali, basheer/0000-0002-5156-9198;;;;"American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1002/9780470479216.corpsy0271, DOI 10.1002/9780470479216.CORPSY0271]; Amin SB, 2019, PEDIATR RES, V85, P191, DOI 10.1038/s41390-018-0216-4; [Anonymous], 2021, Autism spectrum disorders: Key facts; Backer A., 2018, CHILDREN, V5, P153; Cheng J, 2019, MED HYPOTHESES, V127, P26, DOI 10.1016/j.mehy.2019.03.012; Gialloreti LE, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020217; Grabrucker Andreas M, 2012, Front Psychiatry, V3, P118, DOI 10.3389/fpsyt.2012.00118; Grether JK, 2010, J AUTISM DEV DISORD, V40, P238, DOI 10.1007/s10803-009-0859-4; Hall L, 2014, AUTISM, V18, P872, DOI 10.1177/1362361313503501; Hardell L, 2018, CHILD DEV, V89, P137, DOI 10.1111/cdev.12831; Hermawati D, 2018, INTRACTABLE RARE DIS, V7, P69, DOI 10.5582/irdr.2018.01007; Hrdlicka M, 2016, NEUROPSYCH DIS TREAT, V12, P1639, DOI 10.2147/NDT.S107239; Jahan A, 2014, Bangladesh Med Res Counc Bull, V40, P113; Johansson S, 2012, ARCH DIS CHILDHOOD, V97, pA97; Kalkbrenner AE, 2020, AUTISM RES, V13, P134, DOI 10.1002/aur.2196; Kareem N.A., 2017, KUFA J NURS SCI, V7, P1; Karimi P, 2017, J RES MED SCI, V22, DOI 10.4103/1735-1995.200272; Lauritsen MB, 2014, J AUTISM DEV DISORD, V44, P394, DOI 10.1007/s10803-013-1875-y; Lauritsen MB, 2005, J CHILD PSYCHOL PSYC, V46, P963, DOI 10.1111/j.1469-7610.2004.00391.x; LI K, 2019, GLOBAL CLIN TRANSLAT, V1, P45, DOI DOI 10.36316/GCATR.01.0006; Modabbernia A, 2017, MOL AUTISM, V8, DOI 10.1186/s13229-017-0121-4; Mohammed H.R., 2019, INDIAN J PUBLIC HLTH, V10, P1158; Ou J., 2019, GLOB CLIN TRANSL RES, V1, P11; Samuel MH, 2019, J AUTISM DEV DISORD, V49, P3127, DOI 10.1007/s10803-019-04034-9; Tawfeeq WF., 2016, Al-Kindy Coll Med J, V12, P95; Ugur C, 2019, PSYCHIAT CLIN PSYCH, V29, P509, DOI 10.1080/24750573.2018.1457489; Wang CZ, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006696, 10.1097/md.0000000000006696]; Zhang MX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32219-2; Zhang P, 2019, INT C BIOL CHEM MED";29;2;2;0;6;COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES;LA PLATA;DEPT CIENTIFICO, CALLE 5 NO 966, LA PLATA, 00000, ARGENTINA;0326-2383;;;LAT AM J PHARM;Lat. Am. J. Pharm.;APR;2021;40;SI;;;1;;308;316;;;;;;9;Pharmacology & Pharmacy;Science Citation Index Expanded (SCI-EXPANDED);Pharmacology & Pharmacy;SK6FC;;;;;24/11/2024;WOS:000656309000046;View Full Record in Web of Science
J;"Müller, AR; den Hollander, B; van de Ven, PM; Roes, KCB; Geertjens, L; Bruining, H; van Karnebeek, CDM; Jansen, FE; de Wit, MCY; ten Hoopen, LW; Rietman, AB; Dierckx, B; Wijburg, FA; Boot, E; Brands, MMG; van Eeghen, AM";;;;"Mueller, A. R.; den Hollander, B.; van de Ven, P. M.; Roes, K. C. B.; Geertjens, L.; Bruining, H.; van Karnebeek, C. D. M.; Jansen, F. E.; de Wit, M. C. Y.; ten Hoopen, L. W.; Rietman, A. B.; Dierckx, B.; Wijburg, F. A.; Boot, E.; Brands, M. M. G.; van Eeghen, A. M.";;;Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials;BMC PSYCHIATRY;;;English;Article;;;;;;"N-of-1; Cannabidiol; CBD; Tuberous sclerosis complex; Sanfilippo disease; Mucopolysaccharidosis; Fragile X syndrome; Behavior; Intellectual disability";"SOCIAL COMMUNICATION QUESTIONNAIRE; SANFILIPPO-SYNDROME; CHILDREN; VALIDITY; INDIVIDUALS; CHECKLIST; DESIGNS; ADULTS; MODEL";Background Many rare genetic neurodevelopmental disorders (RGNDs) are characterized by intellectual disability (ID), severe cognitive and behavioral impairments, potentially diagnosed as a comorbid autism spectrum disorder or attention-deficit hyperactivity disorder. Quality of life is often impaired due to irritability, aggression and self-injurious behavior, generally refractory to standard therapies. There are indications from previous (case) studies and patient reporting that cannabidiol (CBD) may be an effective treatment for severe behavioral manifestations in RGNDs. However, clear evidence is lacking and interventional research is challenging due to the rarity as well as the heterogeneity within and between disease groups and interindividual differences in treatment response. Our objective is to examine the effectiveness of CBD on severe behavioral manifestations in three RGNDs, including Tuberous Sclerosis Complex (TSC), mucopolysaccharidosis type III (MPS III), and Fragile X syndrome (FXS), using an innovative trial design. Methods We aim to conduct placebo-controlled, double-blind, block-randomized, multiple crossover N-of-1 studies with oral CBD (twice daily) in 30 patients (aged >= 6 years) with confirmed TSC, MPS III or FXS and severe behavioral manifestations. The treatment is oral CBD up to a maximum of 25 mg/kg/day, twice daily. The primary outcome measure is the subscale irritability of the Aberrant Behavior Checklist. Secondary outcome measures include (personalized) patient-reported outcome measures with regard to behavioral and psychiatric outcomes, disease-specific outcome measures, parental stress, seizure frequency, and adverse effects of CBD. Questionnaires will be completed and study medication will be taken at the participants' natural setting. Individual treatment effects will be determined based on summary statistics. A mixed model analysis will be applied for analyzing the effectiveness of the intervention per disorder and across disorders combining data from the individual N-of-1 trials. Discussion These N-of-1 trials address an unmet medical need and will provide information on the effectiveness of CBD for severe behavioral manifestations in RGNDs, potentially generating generalizable knowledge at an individual-, disorder- and RGND population level. Trial registration EudraCT: 2021-003250-23, registered 25 August 2022, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003250-23/NL.;"[Mueller, A. R.; den Hollander, B.; van Karnebeek, C. D. M.; Wijburg, F. A.; Brands, M. M. G.; van Eeghen, A. M.] Amsterdam UMC Locat Univ Amsterdam, Emma Childrens Hosp, Dept Pediat, Amsterdam Gastroenterol Endocrinol Metab, Amsterdam, Netherlands; [Mueller, A. R.; Boot, E.; van Eeghen, A. M.] s Heeren Loo Care Grp, Amersfoort, Netherlands; [Mueller, A. R.; den Hollander, B.; Bruining, H.; van Karnebeek, C. D. M.; Brands, M. M. G.; van Eeghen, A. M.] Amsterdam UMC, Emma Ctr Personalized Med, Amsterdam, Netherlands; [den Hollander, B.; van Karnebeek, C. D. M.; Brands, M. M. G.] United Metab Dis, Amsterdam, Netherlands; [van de Ven, P. M.] Univ Med Ctr Utrecht, Dept Data Sci & Biostat, Utrecht, Netherlands; [Roes, K. C. B.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Biostat, Nijmegen, Netherlands; [Geertjens, L.; Bruining, H.] Amsterdam UMC Locat Vrije Univ, Child & Adolescent Psychiat & Psychosocial Care, Amsterdam, Netherlands; [Geertjens, L.; Bruining, H.] Amsterdam UMC, N You Neurodev Precis Ctr, Amsterdam Neurosci, Amsterdam Reprod & Dev, Amsterdam, Netherlands; [Bruining, H.] Levvel, Ctr Child & Adolescent Psychiat, Amsterdam, Netherlands; [van Karnebeek, C. D. M.] Amsterdam UMC, Dept Human Genet, Amsterdam, Netherlands; [Jansen, F. E.] Univ Med Ctr Utrecht, Dept Pediat Neurol Brain, Utrecht, Netherlands; [de Wit, M. C. Y.; ten Hoopen, L. W.; Rietman, A. B.; Dierckx, B.] Erasmus MC, ENCORE Expertise Ctr Neurodev Disorders, Rotterdam, Netherlands; [de Wit, M. C. Y.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [ten Hoopen, L. W.; Rietman, A. B.; Dierckx, B.] Erasmus MC, Sophia Childrens Hosp, Dept Child & Adolescent Psychiat Psychol, Rotterdam, Netherlands; [Boot, E.] Dalglish Family 22Q Clin, Toronto, ON, Canada; [Boot, E.] Maastricht Univ, Med Ctr, Dept Psychiat & Neuropsychol, Maastricht, Netherlands";"Emma Children's Hospital; University of Amsterdam; University of Amsterdam; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Maastricht University";"van Eeghen, AM (corresponding author), Amsterdam UMC Locat Univ Amsterdam, Emma Childrens Hosp, Dept Pediat, Amsterdam Gastroenterol Endocrinol Metab, Amsterdam, Netherlands.;van Eeghen, AM (corresponding author), s Heeren Loo Care Grp, Amersfoort, Netherlands.;van Eeghen, AM (corresponding author), Amsterdam UMC, Emma Ctr Personalized Med, Amsterdam, Netherlands.";a.m.vaneeghen@amsterdamumc.nl;"Rietman, Andre/AAH-8221-2020; de Wit, Marie-Claire/X-4168-2019; Hoopen, Leontine/Z-3218-2019; Brands, Marion/KCX-6734-2024";"Brands, Marion/0000-0002-2025-5997; Rietman, Andre/0000-0002-9004-0836; ten Hoopen, Leontine/0000-0002-3122-7713; de Wit, Marie Claire/0000-0002-9042-4813; Muller, Annelieke/0000-0002-2672-9989";"GWResearch/Jazz pharmaceuticals; Dutch patient advocacy organizations (Stichting Tubereuze Sclerosis Nederland)";"GWResearch/Jazz pharmaceuticals; Dutch patient advocacy organizations (Stichting Tubereuze Sclerosis Nederland)";The authors would like to thank the Dutch patient advocacy organizations (Stichting Tubereuze Sclerosis Nederland, Fragiele X Vereniging Nederland) for their feedback on the study protocol. The Amsterdam UMC and Erasmus MC are member of European Reference Network (ERN) ITHACA. The Amsterdam UMC is member of MetabERN. The UMC Utrecht is member of ERN EpiCare.;"AMAN MG, 1985, AM J MENT DEF, V89, P492; Anagnostou E, 2015, AUTISM, V19, P622, DOI 10.1177/1362361314542955; Araujo A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167167; Berry-Kravis E, 2013, J DEV BEHAV PEDIATR, V34, P508, DOI 10.1097/DBP.0b013e31829d1f20; Berument SK, 1999, BRIT J PSYCHIAT, V175, P444, DOI 10.1192/bjp.175.5.444; Blackston JW, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7040137; Bradbury J, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8010015; Brooks WT, 2013, RES AUTISM SPECT DIS, V7, P247, DOI 10.1016/j.rasd.2012.10.002; Bruining H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65500-4; Budimirovic DB, 2017, J NEURODEV DISORD, V9, DOI 10.1186/s11689-017-9193-x; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Chandler S, 2007, J AM ACAD CHILD PSY, V46, P1324, DOI 10.1097/chi.0b013e31812f7d8d; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Cummings J, 2022, ALZHEIMERS RES THER, V14, DOI 10.1186/s13195-022-01015-6; Curatolo P, 2015, LANCET NEUROL, V14, P733, DOI 10.1016/S1474-4422(15)00069-1; de Vries PJ, 2018, AM J MED GENET C, V178, P309, DOI 10.1002/ajmg.c.31637; Deb S, 2020, BJPSYCH OPEN, V6, DOI 10.1192/bjo.2020.97; Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631; Dunn W, 1999, SENSORY PROFILE EXAM; Efron D, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034362; Elliott R, 2016, PSYCHOL ASSESSMENT, V28, P263, DOI 10.1037/pas0000174; Esbensen AJ, 2003, J AUTISM DEV DISORD, V33, P617, DOI 10.1023/B:JADD.0000005999.27178.55; Fisher RS, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0758-6; Franco V, 2019, DRUGS, V79, P1435, DOI 10.1007/s40265-019-01171-4; Gaasterland CMW, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0866-x; Gaasterland CMW, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0205-4; Ghaleiha A, 2013, PEDIATR DRUGS, V15, P505, DOI 10.1007/s40272-013-0036-2; Gupta S, 2011, J CLIN EPIDEMIOL, V64, P1085, DOI 10.1016/j.jclinepi.2010.12.019; Guy W., 1976, ECDEU ASSESSMENT MAN, DOI [10.1037/e591322011-001, DOI 10.1037/E591322011-001]; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GW Pharma Ltd, Epidyolex (cannabidiol) oral solution; Hagerman RJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.65; Heussler H, 2019, J NEURODEV DISORD, V11, DOI 10.1186/s11689-019-9277-x; Hoyer D, 2010, Encyclopedia of Psychopharmacology; HUNT A, 1983, DEV MED CHILD NEUROL, V25, P350; Iseger TA, 2015, SCHIZOPHR RES, V162, P153, DOI 10.1016/j.schres.2015.01.033; Jung KM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2045; Khandjian EW, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.976480; Kravitz RL, 2014, Agency Healthc Res Qual; Laprairie RB, 2015, BRIT J PHARMACOL, V172, P4790, DOI 10.1111/bph.13250; MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004; McIntosh D. N., 1999, SENSORY PROFILE EXAM, P59, DOI DOI 10.1177/2399654418761889; McLaren JL, 2021, PSYCHIAT SERV, V72, P988, DOI 10.1176/appi.ps.201900465; Mitchell GK, 2015, J PAIN SYMPTOM MANAG, V50, P289, DOI 10.1016/j.jpainsymman.2015.03.009; Müller AR, 2021, NEUROLOGY, V96, P529, DOI 10.1212/WNL.0000000000011597; Müller AR, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-02003-z; Müller AR, 2023, BMC MED, V21, DOI 10.1186/s12916-023-03012-4; nbtwiki, Neurophysiological Biomarker Toolbox; OCEBM Levels of Evidence Working Group, 2011, The Oxford levels of evidence; OCEBM Levels of Evidence Working Group, 2011, OXFORD 2011 LEVELS E; Palumbo JM, 2023, J NEURODEV DISORD, V15, DOI 10.1186/s11689-023-09475-z; Pepperdine CR, 2018, CAN J SCH PSYCHOL, V33, P157, DOI 10.1177/0829573517733845; Poorthuis BJHM, 1999, HUM GENET, V105, P151, DOI 10.1007/s004399900075; Porcino AJ, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m122; Ras M., 2014, ZORG BETER BEGREPEN; Rutter Bailey A, 2003, Manual of the social communication questionnaire; Samanta D, 2022, EPILEPSY BEHAV, V128, DOI 10.1016/j.yebeh.2022.108577; Sansone SM, 2012, J AUTISM DEV DISORD, V42, P1377, DOI 10.1007/s10803-011-1370-2; Sappok T, 2015, AJIDD-AM J INTELLECT, V120, P203, DOI 10.1352/1944-7558-120.3.203; Schmidt JD, 2013, RES DEV DISABIL, V34, P1190, DOI 10.1016/j.ridd.2013.01.002; Schuchman EH, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01779-4; Senn S, 2019, STAT METHODS MED RES, V28, P372, DOI 10.1177/0962280217726801; Serra I, 2019, BEHAV BRAIN RES, V363, P135, DOI 10.1016/j.bbr.2019.01.040; Shamseer L, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1793; Shapiro EG, 2017, MOL GENET METAB, V122, P8, DOI 10.1016/j.ymgme.2017.09.007; Shapiro EG, 2015, MOL GENET METAB, V114, P594, DOI 10.1016/j.ymgme.2015.02.008; Sparrow S. S., 2016, VINELAND ADAPTIVE BE; Stoddard J, 2020, BEHAV THER, V51, P310, DOI 10.1016/j.beth.2019.09.006; Stunnenberg BC, 2018, JAMA-J AM MED ASSOC, V320, P2344, DOI 10.1001/jama.2018.18020; Tartaglia N, 2019, CANNABIS CANNABINOID, V4, P3, DOI 10.1089/can.2018.0053; Tate R.L., 2019, Single-case experimental designs for clinical research and neurorehabilitation settings: Planning, conduct, analysis and reporting; Tate RL, 2013, NEUROPSYCHOL REHABIL, V23, P619, DOI 10.1080/09602011.2013.824383; Thiele EA, 2021, JAMA NEUROL, V78, P285, DOI 10.1001/jamaneurol.2020.4607; Valstar MJ, 2008, J INHERIT METAB DIS, V31, P240, DOI 10.1007/s10545-008-0838-5; Valstar MJ, 2010, ANN NEUROL, V68, P876, DOI 10.1002/ana.22092; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Vermulst A., 2012, OPVOEDINGSBELASTINGV; Warmerdam HAG, 2020, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01369; WEBB DW, 1995, ARCH DIS CHILD, V72, P471, DOI 10.1136/adc.72.6.471; Wiley RW, 2019, APHASIOLOGY, V33, P1, DOI 10.1080/02687038.2018.1454884; Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18; Williams ZJ, 2018, J AUTISM DEV DISORD, V48, P4231, DOI 10.1007/s10803-018-3678-7; Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; Zou SL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030833; Zucker DR, 1997, J CLIN EPIDEMIOL, V50, P401, DOI 10.1016/S0895-4356(96)00429-5";87;1;1;1;2;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;janv-04;2024;24;1;;;;;;;23;10.1186/s12888-023-05422-3;http://dx.doi.org/10.1186/s12888-023-05422-3;;;14;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;EC8A6;38177999;Green Published, gold;;;24/11/2024;WOS:001136795300003;View Full Record in Web of Science
J;"Pastore, I; Bedin, E; Marzari, G; Bassi, F; Gallo, C; Mucignat-Caretta, C";;;;"Pastore, Irene; Bedin, Elena; Marzari, Giulia; Bassi, Francesca; Gallo, Claudio; Mucignat-Caretta, Carla";;;Behavioral guidance for improving dental care in autistic spectrum disorders;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"autism; dentistry; behavior; visual aid; oral health; child support";"ORAL-HEALTH STATUS; PEDIATRIC DENTISTRY; CHILDREN; PREVALENCE";IntroductionAutism spectrum disorders (ASDs) impair many aspects of everyday life and may prevent access to dental care, often limiting it to emergencies. Impaired oral health has long-lasting negative consequences on health status and on the acquisition of oral habits (e.g., oral respiration and grinding) or competencies (e.g., proper speech production). Children with ASD may be scared in the dental setting, which is rich in sensory stimuli and requires physical contact. Due to their behavioral manifestations, they represent a challenge for dentists and hygienists. We created a dedicated pathway with behavioral support for children with ASD to allow dental care and possibly limit the use of general anesthesia.MethodsWe evaluated the effects of behavioral support in a quasi-experimental design by comparing two groups of children with ASD. The first group (n = 84) was visited every 2 months for 3 years and received additional support (visual aids, caregiver training, and longer visit duration). A control group, matched for age and sex, was visited at least twice a year or more, if needed, according to standard healthcare guidelines.ResultsCompliance with the schedule was high throughout the 3 years. The degree of collaboration significantly improved after 1 year in the supported group, while the control group did not change. At the end of the study, collaboration remained significantly higher than at the beginning in the supported group. Half of dental treatments were possible without general anesthesia in supported children. No adverse effect was apparent on collaboration due to COVID-19 restrictions.DiscussionBehavioral techniques improved the compliance of ASD children to regular dentistry visits and treatment. Furthermore, oral hygiene at home was similarly improved, addressing oral health from a lifelong perspective.;"[Pastore, Irene; Bedin, Elena; Marzari, Giulia; Gallo, Claudio] Osped Immacolata Concez, Community Dent Dept, Piove Di Sacco, Italy; [Bassi, Francesca] Univ Padua, Dept Stat Sci, Padua, Italy; [Mucignat-Caretta, Carla] Univ Padua, Dept Mol Med, Padua, Italy";"University of Padua; University of Padua";"Gallo, C (corresponding author), Osped Immacolata Concez, Community Dent Dept, Piove Di Sacco, Italy.;Mucignat-Caretta, C (corresponding author), Univ Padua, Dept Mol Med, Padua, Italy.";"claudio.gallo@aulss6.veneto.it; carla.mucignat@unipd.it";Bassi, Francesca/AAR-1456-2021;Bassi, Francesca/0000-0002-3257-7029;"Nastrificio Victor S.p.A.; Azienda Unita Locale Socio-Sanitaria (AULSS) 6 Euganea";"Nastrificio Victor S.p.A.; Azienda Unita Locale Socio-Sanitaria (AULSS) 6 Euganea";The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Nastrificio Victor S.p.A. and Azienda Unita Locale Socio-Sanitaria (AULSS) 6 Euganea supported the study. The sponsors of this study had no role in study design, data collection, data analysis, data interpretation, report writing, or in the decision to submit it for publication.;"Aderinto N, 2023, ANN MED SURG, V85, P4410, DOI 10.1097/MS9.0000000000001107; AlBhaisi IN, 2022, BMC ORAL HEALTH, V22, DOI 10.1186/s12903-022-02200-7; Aljubour A, 2022, CHILDREN-BASEL, V9, DOI 10.3390/children9050666; Alshatrat SM, 2020, INT J DENT, V2020, DOI 10.1155/2020/3035463; Alvares GA, 2023, SPEC CARE DENT, V43, P17, DOI 10.1111/scd.12746; Andonovski ME, 2022, J STOMATOL ORAL MAXI, V123, pE858, DOI 10.1016/j.jormas.2022.06.026; Bagattoni S, 2021, EUR J PAEDIATR DENT, V22, P243, DOI 10.23804/ejpd.2021.22.03.12; Balian A, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-12176-7; Bartolome-Villar Begona, 2016, J Clin Exp Dent, V8, pe344, DOI 10.4317/jced.52923; Blomqvist M, 2015, BMC ORAL HEALTH, V15, DOI 10.1186/s12903-015-0065-z; Cirio S, 2022, CHILDREN-BASEL, V9, DOI 10.3390/children9050729; Corridore D, 2020, CLIN TER, V171, pE275, DOI 10.7417/CT.2020.2226; Darling SJ, 2021, JAMA PEDIATR, V175, DOI 10.1001/jamapediatrics.2021.3982; Delli K, 2013, MED ORAL PATOL ORAL, V18, pE862, DOI 10.4317/medoral.19084; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Du RNYL, 2021, INT J PAEDIATR DENT, V31, P89, DOI 10.1111/ipd.12688; Erwin J, 2022, HEALTH EXPECT, V25, P1269, DOI 10.1111/hex.13544; Farmani S, 2020, CLIN COSMET INV DENT, V12, P343, DOI 10.2147/CCIDE.S262679; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fenning RM, 2022, PEDIATRICS, V149, DOI 10.1542/peds.2021-050691; Ferrazzano GF, 2020, EUR J PAEDIATR DENT, V21, P9, DOI 10.23804/ejpd.2020.21.01.02; Frankl S, 1962, J Dent Child, V29, P150; Gallo C, 2023, EUR J PAEDIATR DENT, V24, P145, DOI 10.23804/ejpd.2023.1656; Genovese A, 2023, GENES-BASEL, V14, DOI 10.3390/genes14030677; Goyal T, 2023, SPEC CARE DENT, V43, P856, DOI 10.1111/scd.12867; Haynes AB, 2021, JAMA SURG, V156, P879, DOI 10.1001/jamasurg.2021.0552; Junaid M, 2022, PEDIATR RES, V92, P1795, DOI 10.1038/s41390-022-02024-9; Kammer PV, 2022, SPEC CARE DENT, V42, P369, DOI 10.1111/scd.12684; Kwon CS, 2022, NEUROL CLIN, V40, P831, DOI 10.1016/j.ncl.2022.03.011; Levine RS, 2021, BRIT DENT J, V230, P611, DOI 10.1038/s41415-021-2945-8; Limeres-Posse J, 2014, MED ORAL PATOL ORAL, V19, pE467, DOI 10.4317/medoral.19566; Logrieco MGM, 2021, J AUTISM DEV DISORD, V51, P1939, DOI 10.1007/s10803-020-04684-0; Lopez-Velasco Ana, 2021, J Clin Exp Dent, V13, pe303, DOI 10.4317/jced.57852; Loubersac J, 2023, EUR CHILD ADOLES PSY, V32, P375, DOI 10.1007/s00787-021-01792-9; Machado BA, 2022, SPEC CARE DENT, V42, P352, DOI 10.1111/scd.12683; Magidson J, 2002, Canadian Journal of Marketing Research, V20, P36, DOI DOI 10.1037/MET0000095; Mangione F, 2020, CLIN ORAL INVEST, V24, P1677, DOI 10.1007/s00784-019-03023-7; Miller HL, 2024, DEV MED CHILD NEUROL, V66, P16, DOI 10.1111/dmcn.15674; Octavia A, 2023, SPEC CARE DENT, DOI 10.1111/scd.12827; Pagano S, 2022, EUR J PAEDIATR DENT, V23, P54, DOI 10.23804/ejpd.2022.23.01.10; Piraneh H, 2022, BMC PEDIATR, V22, DOI 10.1186/s12887-022-03178-5; Prakash J, 2021, J FAM MED PRIM CARE, V10, P3845, DOI 10.4103/jfmpc.jfmpc_439_21; Sala R, 2020, NEUROPSYCH DIS TREAT, V16, P1605, DOI 10.2147/NDT.S251394; Santosh Anitha, 2021, Int J Clin Pediatr Dent, V14, P548, DOI 10.5005/jp-journals-10005-1972; Shalabi MASA, 2022, PEDIATR DENT, V44, P25; Swiezy N, 2021, RES AUTISM SPECT DIS, V89, DOI 10.1016/j.rasd.2021.101879; Varela I, 2022, DISABIL HEALTH J, V15, DOI 10.1016/j.dhjo.2021.101229; Vermunt J. K., 2013, LG SYNTAX USERS GUID; Vermunt JK, 2003, SOCIOL METHODOL, V33, P213, DOI 10.1111/j.0081-1750.2003.t01-1-00131.x; Yost Q, 2019, PEDIATR DENT, V41, P397; Zeidan J, 2022, AUTISM RES, V15, P778, DOI 10.1002/aur.2696; Zerman N, 2022, FRONT ORAL HEALTH, V3, DOI 10.3389/froh.2022.998831; Zink AG, 2018, PEDIATR DENT, V40, P18; Zoccante L, 2022, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.794516";54;2;3;4;5;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;nov-14;2023;14;;;;;;;;1272638;10.3389/fpsyt.2023.1272638;http://dx.doi.org/10.3389/fpsyt.2023.1272638;;;12;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;Z7UL5;38034927;Green Published, gold;;;24/11/2024;WOS:001114090300001;View Full Record in Web of Science
J;"Morsy, S; Awaji, RMH; Bashowair, RM; Alahmadi, TS; Alshatifi, SW";;;;"Morsy, Suzan; Awaji, Raghad Mohammed Hadi; Bashowair, Reem Mohammed; Alahmadi, Tuqa Shaker; Alshatifi, Shouq Wahid";;;Assessment of the utilization of pharmacotherapy for pediatrics with Autism Spectrum Disorder in Jeddah, KSA;WORLD FAMILY MEDICINE;;;English;Article;;;;;;"Autism; therapeutic; behavior";"DIAGNOSIS; CHILDREN";"Background: Assessing children with autism and the effect of different modalities in management of autism is a critical issue as the disease is a lifelong disorder that has a negative effect on the social health of the families. Aim of the work: Evaluate the pharmacotherapy for children with au-tism spectrum disorder in Jeddah. Method: The current study is a descriptive cross sectional study that was conducted in three private hospitals in Jeddah (KSA); Ibn Sina Hospital, Al Jeddain Gholeel and AlJeddaani AlSafaa. The study included 152 children aged 2-18 years diagnosed with autism according to DSM V criteria. The collected data and the designed questionnaire were filled out by the care giver. Children with concomitant other chronic disease and parents who refused to participate or did not complete the questionnaire were excluded from the study. The collected data were analyzed by SPSS version 20. Results: The mean age of the children was 4.5 +/- 3.2 and the source of the data was mainly from the mother (69.1%). Children were mainly males (75.7%) and the majority of families had only one child with autism (85.5%) and about (45.5%) were diagnosed in the second year of life. The majority of children complained of social withdrawal (85.5%), distraction of attention and repetitive behavior (75%). About (36.2%) of the studied children received combined treatment modalities and the most common pharmacological line used was SSRIs and kebra. Conclusion: Nowadays management of autism depends on a combination of behavioral management, pharmacotherapy, family and educational therapy for the best outcome. The most common pharmacological line used was SSRIs and kebra and about 75% of children who took drugs complained of side effects.";"[Morsy, Suzan; Awaji, Raghad Mohammed Hadi; Bashowair, Reem Mohammed; Alahmadi, Tuqa Shaker; Alshatifi, Shouq Wahid] Ibn Sina Natl Coll Med Studies, Jeddah, Saudi Arabia";Ibn Sina National College for Medical Studies;Morsy, S (corresponding author), Ibn Sina Natl Coll Med Studies, Clin Pharmacol, Jeddah, Saudi Arabia.;s_almorsy@outlook.com;;;;;;"Almandil NB, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16040658; [Anonymous], 2013, RIT METH PRESCR INF; Bergbaum A, 2016, CLIN ANAT, V29, P620, DOI 10.1002/ca.22719; Brkanac Z, 2008, PERS MED, V5, P599, DOI 10.2217/17410541.5.6.599; Chaste Pauline, 2012, Dialogues Clin Neurosci, V14, P281; Dale E, 2006, AUTISM, V10, P463, DOI 10.1177/1362361306066600; Ferreira X, 2016, ACTA MEDICA PORT, V29, P168, DOI 10.20344/amp.6790; Frye Richard E, 2013, Front Public Health, V1, P31, DOI 10.3389/fpubh.2013.00031; Gialloreti LE, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020217; Gronborg TK, 2013, JAMA PEDIATR, V167, P947, DOI 10.1001/jamapediatrics.2013.2259; Gupta A., 2005, ASIA PACIFIC DISABIL, V16, P62; Hirota T, 2014, J AUTISM DEV DISORD, V44, P948, DOI 10.1007/s10803-013-1952-2; Idring S, 2015, J AUTISM DEV DISORD, V45, P1766, DOI 10.1007/s10803-014-2336-y; Kalra Veena, 2005, Indian Journal of Pediatrics, V72, P227; Kent RG, 2013, J CHILD PSYCHOL PSYC, V54, P1242, DOI 10.1111/jcpp.12085; Malhi P, 2014, ANN INDIAN ACAD NEUR, V17, P25, DOI 10.4103/0972-2327.128537; Mugno D, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-22; Myers BJ, 2009, RES AUTISM SPECT DIS, V3, P670, DOI 10.1016/j.rasd.2009.01.004; Oswald DP, 2017, FOCUS AUTISM DEV DIS, V32, P152, DOI 10.1177/1088357615587500; Perumal V., 2014, J PHARM RES, V8, P791, DOI [10.13140/2.1.4813.6320, DOI 10.13140/2.1.4813.6320]; Robinson EB, 2013, P NATL ACAD SCI USA, V110, P5258, DOI 10.1073/pnas.1211070110; Schmidt RJ, 2014, AM J EPIDEMIOL, V180, P890, DOI 10.1093/aje/kwu208; Spain D, 2018, RES AUTISM SPECT DIS, V52, P51, DOI 10.1016/j.rasd.2018.04.007; Sturman N, 2017, COCHRANE DB SYST REV, V21, P11, DOI [10.1002/14651858.CD011144, DOI 10.1002/14651858.CD011144]; van Steensel FJA, 2013, J CHILD FAM STUD, V22, P368, DOI 10.1007/s10826-012-9587-z; Viscidi EW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067797; Volkmar F, 2014, J AM ACAD CHILD PSY, V53, P237, DOI 10.1016/j.jaac.2013.10.013";27;0;0;1;4;MEDI+WORLD INT;RADCLIFFE NORTH;3 DAVIS ST, RADCLIFFE NORTH, 4020, AUSTRALIA;1839-0188;1839-0196;;WORLD FAM MED;World Fam. Med.;JAN;2020;18;1;;;;;139;149;;10.5742/MEWFM.2020.93744;http://dx.doi.org/10.5742/MEWFM.2020.93744;;;11;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;JZ4KM;;;;;24/11/2024;WOS:000505070900020;View Full Record in Web of Science
J;"Penna, HD; Paiva, APM; Romano, AJM; Alves, RL; do Nascimento, P Jr; Módolo, NSP";;;;"Penna, Heber de Moraes; Paiva, Andreia Portela Martins; Romano, Antonio Jose Marques; Alves, Rodrigo Leal; do Nascimento, Paulo; Modolo, Norma Sueli Pinheiro";;;Comparison between oral midazolam versus oral ketamine plus midazolam as preanesthetic medication in autism spectrum disorder: double-blind randomized clinical trial;BRAZILIAN JOURNAL OF ANESTHESIOLOGY;;;English;Article;;;;;;"Autism; Autism spectrum disorder; Dental care; Ketamine; Midazolam; Preanesthetic medication";"S-KETAMINE; CHILDREN; PHARMACOKINETICS; ANESTHESIA";"Background: Conventional dental care is often impossible in patients with Autism Spectrum Dis-order (ASD). Non-collaborative behaviors, sometimes associated with aggressiveness, are usual justifications for premedication in this population. Thereby, this research focuses on the effects of oral midazolam versus oral ketamine plus midazolam as preanesthetic medication in ASD. Methods: The sample included 64 persons with ASD, aged 2 ?59 years, scheduled for dental care under general anesthesia. The primary objective of this study was to compare degrees of seda-tion between two parallel, double-blinded, equally proportional groups randomized to receive oral midazolam (0.5 mg.kg-1, maximum 15 mg) or oral midazolam (0.5 mg.kg-1) associated with oral S(+)-ketamine (3 mg.kg-1, maximum 300 mg). The secondary outcomes were the need of physical stabilization to obtain intravenous line, awakening time, and occurrence of adverse events.Results: According to the dichotomous analysis of sedation level (Ramsay score 1 and 2 versus Ramsay & GE; 3), oral association of S(+)-ketamine and midazolam improved sedation, with increased probability of Ramsay & GE; 3, Relative Risk (RR) = 3.2 (95% Confidence Interval [95% CI] = 1.32 to 7.76) compared to midazolam alone. Combined treatment also made it easier to obtain venous access without physical stabilization, RR = 2.05 (95% CI = 1.14 to 3.68). There were no differences between groups regarding awakening time and the occurrence of adverse events.Conclusion: The association of oral S(+)-ketamine with midazolam provides better preanesthetic sedation rates than midazolam alone and facilitates intravenous line access in patients with autism.& COPY; 2022 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Anestesiologia.This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).";"[Penna, Heber de Moraes; Alves, Rodrigo Leal; do Nascimento, Paulo; Modolo, Norma Sueli Pinheiro] Univ Estadual Paulista UNESP, Fac Med Botucatu, Dept Anestesiol, Botucatu, SP, Brazil; [Penna, Heber de Moraes] Hosp Santa Terezinha, Goiania, GO, Brazil; [Paiva, Andreia Portela Martins] Hosp Santa Terezinha, Odontol Hosp, Goiania, GO, Brazil; [Romano, Antonio Jose Marques] Hosp Geral Goiania Alberto Rassi, Odontopediat & Pacientes Especiais, Goiania, GO, Brazil";Universidade Estadual Paulista;"Penna, HD (corresponding author), Univ Estadual Paulista UNESP, Fac Med Botucatu, Dept Anestesiol, Botucatu, SP, Brazil.;Penna, HD (corresponding author), Hosp Santa Terezinha, Goiania, GO, Brazil.";heberpenna@gmail.com;"Alves, Rodrigo/JLL-7029-2023; Módolo, Norma/W-9448-2019; Nascimento, Patricia/KHW-9080-2024; do Nascimento Junior, Paulo/C-6966-2010";"do Nascimento Junior, Paulo/0000-0002-2323-9159; Penna, Heber/0000-0001-6500-5126; Modolo, Norma Sueli Pinheiro/0000-0002-8549-6820; Alves, Rodrigo/0000-0001-8009-3726";;;;"American Psychiatric Association. American Psychiatric Association. DSM-5 Task Force, 2013, DIAGNOSTIC STAT MANU, V1, P20131; Arnold B, 2015, PEDIATR ANESTH, V25, P1103, DOI 10.1111/pan.12739; Chen C, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024605; de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497; Fanta S, 2015, EUR J CLIN PHARMACOL, V71, P441, DOI 10.1007/s00228-015-1826-y; Funk W, 2000, BRIT J ANAESTH, V84, P335, DOI 10.1093/oxfordjournals.bja.a013435; GRANT IS, 1981, BRIT J ANAESTH, V53, P805, DOI 10.1093/bja/53.8.805; Hedrich WD, 2016, ACTA PHARM SIN B, V6, P413, DOI 10.1016/j.apsb.2016.07.016; Houghton R, 2017, AUTISM RES, V10, P2037, DOI 10.1002/aur.1848; Lukmanji S, 2019, EPILEPSY BEHAV, V98, P238, DOI 10.1016/j.yebeh.2019.07.037; Manso MA, 2019, PEDIATR ANESTH, V29, P1094, DOI 10.1111/pan.13747; Minist?erio da Sau?de, 2020, PESQ NAC SAUD 2019 P; Mion G, 2013, CNS NEUROSCI THER, V19, P370, DOI 10.1111/cns.12099; Organization WH, 2006, CHILD GROWTH STAND B; Ouchi K, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0006-z; Peltoniemi MA, 2012, BASIC CLIN PHARMACOL, V111, P325, DOI 10.1111/j.1742-7843.2012.00908.x; Poonai N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173253; R CORE TEAM, 2019, R: A language and environment for statistical computing; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rodgers H, 2021, PREVALENCE AUTISM IN, P1; Sado J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213074; Sheta SA, 2009, INT J PEDIAT, V2009, DOI 10.1155/2009/274380; Swartz JS, 2017, PEDIATR ANESTH, V27, P856, DOI 10.1111/pan.13189; Taghizadeh N, 2019, PEDIATR ANESTH, V29, P927, DOI 10.1111/pan.13689; Taghizadeh N, 2015, PEDIATR ANESTH, V25, P1076, DOI 10.1111/pan.12732; Trabold B, 2002, PAEDIATR ANAESTH, V12, P690, DOI 10.1046/j.1460-9592.2002.00945.x; Wang PF, 2018, ANESTHESIOLOGY, V129, P756, DOI 10.1097/ALN.0000000000002371; Wingate M, 2014, MMWR SURVEILL SUMM, V63; World Health Organization, 2021, Obesity and overweight; Zanger Ulrich M., 2013, Frontiers in Genetics, V4, P24, DOI 10.3389/fgene.2013.00024; Zheng Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12003-4";31;3;3;0;4;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0104-0014;2352-2291;;BRAZ J ANESTHESIOL;Braz. J. Anesthesiol.;MAY-JUN;2023;73;3;;;;;283;290;;10.1016/j.bjane.2022.09.003;http://dx.doi.org/10.1016/j.bjane.2022.09.003;;MAY 2023;8;Anesthesiology;Science Citation Index Expanded (SCI-EXPANDED);Anesthesiology;L5MX4;36183860;gold, Green Published;;;24/11/2024;WOS:001023716700001;View Full Record in Web of Science
J;"Kong, XJ; Liu, J; Li, J; Kwong, K; Koh, M; Sukijthamapan, P; Guo, JJ; Sun, ZJ; Song, YQ";;;;"Kong, Xue-Jun; Liu, Jun; Li, Jing; Kwong, Kenneth; Koh, Madelyn; Sukijthamapan, Piyawat; Guo, Jason J.; Sun, Zhenyu Jim; Song, Yiqing";;;Probiotics and oxytocin nasal spray as neuro-social-behavioral interventions for patients with autism spectrum disorders: a pilot randomized controlled trial protocol;PILOT AND FEASIBILITY STUDIES;;;English;Article;;;;;;"Autism spectrum disorders; ASD; Oxytocin; OXT; Probiotics; Neuro-social behaviors; Randomized controlled trial";"ACIDIC PROTEIN; CHILDREN; DEFICITS";BackgroundAutism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by impairments in social interaction and communication. Oxytocin (OXT), as a neuropeptide, plays a role in emotional and social behaviors. Lactobacillus reuteri (L. reuteri) supplementation led to an OXT-dependent behavioral improvement in ASD mouse models. Despite some promising results from animal studies, little is known about the efficacy of supplementation with L. reuteri, alone or with exogenous OXT therapy, on social-behavioral functions in ASD patients. This paper presents a protocol for a pilot randomized controlled trial to evaluate the feasibility of conducting a full trial comparing oral supplementation of L. reuteri probiotics and intranasal OXT spray to placebo on the effect of social and behavioral functions in ASD patients. The study will also capture preliminary estimates of the efficacy of the proposed interventions in ASD patients.MethodsThis pilot trial is a two-staged, randomized, double-blind, placebo-controlled, parallel-group study. Throughout the study (0-24 weeks), 60 patients with ASD will be randomly assigned to receive either oral L. reuteri probiotics or placebo. In the second study stage (13-24 weeks), all participants will receive intranasal OXT spray. As primary outcomes, serum OXT levels will be assayed and social behaviors will be assessed via the Autism Behavior Checklist and the Social Responsiveness Scale which are validated questionnaires, an objective emotional facial matching test, and a new video-based eye-tracking test. Secondary outcomes include the GI-severity-index and Bristol Stool Chart to assess GI function and gut microbiome/short-chain fatty acids. All the outcomes will be assessed at baseline and weeks 12 and 24.DiscussionThis pilot study will provide important information on the feasibility of recruitment, blinding and concealment, treatment administration, tolerability and adherence, specimen collection, outcome assessment, potential adverse effects, and the preliminary efficacy on both primary and secondary outcomes. If successful, this pilot study will inform a larger randomized controlled trial fully powered to examine the efficacies of oral L. reuteri probiotics and/or intranasal OXT spray on social-behavioral improvement in ASD patients.Trial registrationClinicalTrials.gov, NCT03337035. Registered 8 November 2017.;"[Kong, Xue-Jun; Liu, Jun; Kwong, Kenneth; Koh, Madelyn] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA; [Kong, Xue-Jun] Beth Israel Deaconess Healthcare, Boston, MA 02215 USA; [Liu, Jun; Sukijthamapan, Piyawat] Harvard Med Sch, Boston, MA 02115 USA; [Li, Jing] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Biostat, Indianapolis, IN 46204 USA; [Guo, Jason J.] Northeastern Univ, Barnett Inst Chem & Biol Anal, Dept Chem & Chem Biol, Boston, MA 02115 USA; [Sun, Zhenyu Jim] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Song, Yiqing] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46204 USA";"Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Indiana University System; Indiana University Indianapolis; Northeastern University; Harvard University; Harvard Medical School; Dana-Farber Cancer Institute; Indiana University System; Indiana University Indianapolis";"Kong, XJ (corresponding author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA.;Kong, XJ (corresponding author), Beth Israel Deaconess Healthcare, Boston, MA 02215 USA.";xkong1@mgh.harvard.edu;;"Arichai, Piyawat/0000-0001-9520-2956; Kwong, Kenneth K./0000-0001-5056-2173";"Massachusetts General Hospital [233263, 230361]; European Research Council (ERC) [233263] Funding Source: European Research Council (ERC)";"Massachusetts General Hospital; European Research Council (ERC)(European Research Council (ERC))";This study is funded by internal grants 233263 (XJK) and 230361 (XJK) from Massachusetts General Hospital. The funding sponsor has no role in the study design, data collection, management, data analysis and interpretation, or writing of the report.;"Al-Ayadhi LY, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-54; Alam R, 2017, AM J MED GENET B, V174, P651, DOI 10.1002/ajmg.b.32567; Andari E, 2010, P NATL ACAD SCI USA, V107, P4389, DOI 10.1073/pnas.0910249107; [Anonymous], 2005, ENCY AUTISM SPECTRUM; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; Buffington SA, 2016, CELL, V165, P1762, DOI 10.1016/j.cell.2016.06.001; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Erdman SE, 2016, INT REV NEUROBIOL, V131, P91, DOI 10.1016/bs.irn.2016.07.004; Esnafoglu E, 2017, INT J DEV NEUROSCI, V61, P86, DOI 10.1016/j.ijdevneu.2017.06.011; Fatheree NY, 2017, J PEDIATR-US, V191, P170, DOI 10.1016/j.jpeds.2017.07.036; Guloksuz SA, 2017, REV BRAS PSIQUIATR, V39, P195, DOI 10.1590/1516-4446-2015-1843; Gutierrez-Castrellon P, 2014, PEDIATRICS, V133, pE904, DOI 10.1542/peds.2013-0652; Hadjikhani N, 2015, AUTISM, V19, P149, DOI 10.1177/1362361313514141; Husarova VM, 2016, PSYCHIAT INVEST, V13, P174; Kong X., 2017, N AM J MED SCI, V10; Kong XJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092128; LAUNAY JM, 1987, J AUTISM DEV DISORD, V17, P333, DOI 10.1007/BF01487064; Laurence JA, 2005, CEREBELLUM, V4, P206, DOI 10.1080/14734220500208846; Liu J, 2019, CURR MED SCI, V39, P173, DOI 10.1007/s11596-019-2016-4; Masi A, 2015, MOL PSYCHIATR, V20, P440, DOI 10.1038/mp.2014.59; Mayer EA, 2014, BIOESSAYS, V36, P933, DOI 10.1002/bies.201400075; Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x; Nicolucci AC, 2017, GASTROENTEROLOGY, V153, P711, DOI 10.1053/j.gastro.2017.05.055; Ooi YP, 2017, PHARMACOPSYCHIATRY, V50, DOI 10.1055/s-0042-109400; Parker KJ, 2017, P NATL ACAD SCI USA, V114, P8119, DOI 10.1073/pnas.1705521114; Pinto-Sanchez MI, 2017, GASTROENTEROLOGY, V153, P448, DOI 10.1053/j.gastro.2017.05.003; Pobbe RLH, 2012, HORM BEHAV, V61, P436, DOI 10.1016/j.yhbeh.2011.10.010; Poutahidis T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078898; Sgritta M, 2019, NEURON, V101, P246, DOI 10.1016/j.neuron.2018.11.018; Stavropoulos KKM, 2013, J CHILD PSYCHOL PSYC, V54, P603, DOI 10.1111/jcpp.12061; Stigler KA, 2009, RES AUTISM SPECT DIS, V3, P840, DOI 10.1016/j.rasd.2009.01.007; Sung V, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-1811; Teng BL, 2016, NEUROPHARMACOLOGY, V105, P61, DOI 10.1016/j.neuropharm.2015.12.025; Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043; Varian BJ, 2017, BRAIN BEHAV IMMUN, V61, P36, DOI 10.1016/j.bbi.2016.11.002; Wan G., 2018, J AUTISM DEV DISORD, V49, P1; Yatawara CJ, 2016, MOL PSYCHIATR, V21, P1225, DOI 10.1038/mp.2015.162";37;22;23;1;13;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;2055-5784;;PILOT FEASIBILITY ST;Pilot Feasibility Stud.;;2020;6;1;;;;;;;20;10.1186/s40814-020-0557-8;http://dx.doi.org/10.1186/s40814-020-0557-8;;;9;Medicine, Research & Experimental;Emerging Sources Citation Index (ESCI);Research & Experimental Medicine;XN0XQ;32082606;gold, Green Published;;;24/11/2024;WOS:000729238200018;View Full Record in Web of Science
J;"Al-Ghabban, HA; Al-Ayadhi, LY";;;;"Al-Ghabban, Hayfa Ali; Al-Ayadhi, Laila Yusuf";;;Role of Autoimmune Regulator Protein (AIRE-P) in the Pathophysiology of Autism Spectrum Disorder (ASD)in Saudi Children;ARCHIVES OF PHARMACY PRACTICE;;;English;Article;;;;;;"Autism spectrum disorder; Autoimmune regulator protein; Autoimmunity; Childhood autism rating scale; Cambridge neuropsychological test automated battery; Childhood neurodevelopmental disorder";"GENE; EXPRESSION; MUTATIONS; TOLERANCE";"Numerous studies show the significance of immunological deficits, abnormal cytokine and immune cell production, and autism. Through the use of the childhood autism rating scale (CARS), the social responsiveness scale (SRS), and the computerized Cambridge neuropsychological test automated battery (CANTAB), the current study aimed to investigate the potential role of the autoimmune regulator protein AIRE-p as an immune biomarker in the pathophysiology of autism in Saudi children. According to the study's findings, plasma levels of AIRE-p in 37 autistic children (n=37) were considerably (p=0.003) lower than those in 37 healthy controls (n=37) at 0.629 (0.776) pg/ml [median (IQR)]. Based on CARS ratings, there was no difference between AIRE-p levels in children with mild to moderate autism (median, 0.661 (0.666) pg/ml; interquartile range, 0.365 (1.114) pg/ml; p = 0.365) and children with severe autism (median, 0.365 (1.114) pg/ml; interquartile range, 0.365). On the basis of SRS, a comparable pattern between mild to moderate and severe autism was also seen. AIRE-p may be involved in the physiology of autism as shown by the reduced AIRE-p plasma levels in patients with ASD. However, unless more studies are carried out using bigger sample sizes to ascertain if the drop in AIRE-p plasma level is only a side effect of autism or whether it plays a pathogenic role in the condition, these results should be viewed with care. If AIRE-p levels may be employed as a biomarker for ASD, further research including larger patient and control cohorts would be required.";"[Al-Ghabban, Hayfa Ali] Imam Mohammad Ibn Saud Islamic Univ, Fac Med, Dept Physiol, Riyadh, Saudi Arabia; [Al-Ayadhi, Laila Yusuf] King Saud Univ, Fac Med, Dept Physiol, Riyadh, Saudi Arabia; [Al-Ayadhi, Laila Yusuf] Autism Res & Treatment Ctr, Riyadh, Saudi Arabia";"Imam Mohammad Ibn Saud Islamic University (IMSIU); King Saud University";Al-Ghabban, HA (corresponding author), Imam Mohammad Ibn Saud Islamic Univ, Fac Med, Dept Physiol, Riyadh, Saudi Arabia.;ghabbana@yahoo.com;AL-Ayadhi, Laila/E-7132-2014;AL-Ayadhi, Laila/0000-0003-3269-0416;National Plan for Science, Technology, and Innovation, King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia [AI-35-355];National Plan for Science, Technology, and Innovation, King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia;The National Plan for Science, Technology, and Innovation, King Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia, Award number: AI-35-355, provided the funding for this research.;"Abramson J, 2016, IMMUNOL REV, V271, P127, DOI 10.1111/imr.12419; Abramson J, 2010, CELL, V140, P123, DOI 10.1016/j.cell.2009.12.030; AL-Ayadhi L, 2013, JCPSP-J COLL PHYSICI, V23, P137, DOI 02.2013/JCPSP.137143; Alayadhi LY, 2016, NEUROSCIENCE, V339, P561, DOI 10.1016/j.neuroscience.2016.10.030; Anderson MS, 2016, NAT REV IMMUNOL, V16, P247, DOI 10.1038/nri.2016.9; [Anonymous], 2013, Am Psychiatr Assoc Washington.; APA. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorder, V5, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596.744053]; Bruserud O, 2016, CURR OPIN IMMUNOL, V43, P8, DOI 10.1016/j.coi.2016.07.003; Cambridge Cognition, 2020, CANTAB The most sensitive and validated cognitive research software available. Cambridge Cognition; Constantino J.N., 2012, SOCIAL RESPONSIVENES, V2; Conteduca G, 2018, AUTOIMMUN REV, V17, P325, DOI 10.1016/j.autrev.2017.10.017; El-Ansary A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164153; El-Ansary A, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-160; Fierabracci A, 2011, AUTOIMMUN REV, V10, P137, DOI 10.1016/j.autrev.2010.08.019; Fornari TA, 2010, MOL CELL BIOCHEM, V342, P21, DOI 10.1007/s11010-010-0464-z; Genovese A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134726; Gesundheit B, 2013, J AUTOIMMUN, V44, P1, DOI 10.1016/j.jaut.2013.05.005; Giménez-Barcons M, 2014, J IMMUNOL, V193, P3872, DOI 10.4049/jimmunol.1400223; Gray WA, 2017, INT J DEV NEUROSCI, V62, P32, DOI 10.1016/j.ijdevneu.2017.07.004; Heidari A, 2021, ACTA NEUROBIOL EXP, V81, P249, DOI 10.21307/ane-2021-023; Khan U, 2018, INT REV CEL MOL BIO, V341, P125, DOI 10.1016/bs.ircmb.2018.05.008; Kont V, 2008, MOL IMMUNOL, V45, P25, DOI 10.1016/j.molimm.2007.05.014; Macedo C, 2009, MOL IMMUNOL, V46, P3240, DOI 10.1016/j.molimm.2009.08.002; Marx A, 2021, SEMIN IMMUNOPATHOL, V43, P45, DOI 10.1007/s00281-021-00842-3; Matta SM, 2019, BRAIN BEHAV IMMUN, V79, P75, DOI 10.1016/j.bbi.2019.04.037; Meloni A, 2010, J BIOL CHEM, V285, P13012, DOI 10.1074/jbc.M109.037747; Moneim NHA, 2020, IMMUNOL RES, V68, P90, DOI 10.1007/s12026-020-09127-7; Moon SJ, 2019, DEV MED CHILD NEUROL, V61, P1030, DOI 10.1111/dmcn.14246; Oftedal BE, 2015, IMMUNITY, V42, P1185, DOI 10.1016/j.immuni.2015.04.021; Perniola R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00098; Pichitpunpong C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214198; Schopler E., 1988, The childhood autism rating scale (CARS); Shao S, 2014, INFLAMMATION, V37, P495, DOI 10.1007/s10753-013-9763-3; Thabtah F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183502; Wang HX, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03099; Wills S, 2007, ANN NY ACAD SCI, V1107, P79, DOI 10.1196/annals.1381.009; Zhao BJ, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3930750; Zhu ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11350; Zhu WF, 2017, IMMUNOGENETICS, V69, P643, DOI 10.1007/s00251-017-0995-5";39;0;0;1;1;ARCHIVES GLOBAL PROFESSIONALS;KARACHI;ARCHIVES GLOBAL PROFESSIONALS, KARACHI, PAKISTAN;2320-5210;2045-080X;;ARCH PHARM PRACT;Arch. Pharm. Pract.;JUL-SEP;2023;14;3;;;;;83;90;;10.51847/GUzYRK8poy;http://dx.doi.org/10.51847/GUzYRK8poy;;;8;Pharmacology & Pharmacy;Emerging Sources Citation Index (ESCI);Pharmacology & Pharmacy;U4RE3;;gold;;;24/11/2024;WOS:001084680300002;View Full Record in Web of Science
J;"Hogendoorn, E; Hartman, CA; Burke, SM; van Dijk, MWG; Rosmalen, JGM";;;;"Hogendoorn, Elske; Hartman, Catharina A.; Burke, Sarah M.; van Dijk, Marijn W. G.; Rosmalen, Judith G. M.";;;Longitudinal relations between autistic-like features and functional somatic symptoms in adolescence;AUTISM;;;English;Article;;;;;;"adolescence; autistic-like features; functional somatic symptoms; longitudinal";"BEHAVIOR QUESTIONNAIRE CSBQ; SPECTRUM DISORDERS; GENERAL-POPULATION; GASTROINTESTINAL SYMPTOMS; CHILDREN; TRAITS; ANXIETY; DISCREPANCIES; ASSOCIATION; PREVALENCE";Autistic-like features and functional somatic symptoms (FSS) frequently co-occur. It remains unknown how autistic-like features and FSS affect each other and develop throughout adolescence. This study examined reciprocal relations between autistic-like features and FSS in adolescence. Participants were 2772 adolescents (52.5% male) from the Tracking Adolescents' Individual Lives Survey population and clinical cohort. Data from four waves were included, covering the ages between 11 and 19 years. Autistic-like features were measured using the Children's Social Behavior Questionnaire. FSS were assessed using the Youth Self Report and Adult Self Report, respectively. Using the random intercept cross-lagged panel model, a stable positive, moderately strong between-persons association was found between autistic-like features and FSS. No within-persons reciprocal effects from wave to wave were observed. Secondary analyses revealed a consistent relation with FSS for three different domains of autistic-like features (social and communication behaviors, repetitive behaviors, and self-regulatory behaviors), and highly similar interrelations in a subsample of adolescents with a clinical autism spectrum disorder diagnosis. In conclusion, the co-occurrence between autistic-like features and FSS is stable throughout adolescence. Clinicians working with adolescents with autistic-like features should be alert to the presence FSS, and vice versa. Lay abstract Adolescents with autistic-like features frequently experience unexplained somatic symptoms too, and vice versa. We followed 2772 adolescents for 8 years, starting at 11 and ending at 19 years of age. At four different moments during this time, we asked these adolescents how often they suffered from unexplained somatic symptoms, such as stomachache and dizziness. We asked their parents to what extent the adolescents showed autistic-like features at those four moments too. Then, we assessed whether the relation between autistic-like features and unexplained somatic symptoms stayed the same between 11 and 19 years old. We also looked at whether there was a reciprocal influence. So far, most studies only looked into the relation between autistic-like features and unexplained somatic symptoms at a specific moment in time. It is important to study how this relation develops over time in adolescence, so we can improve treatment for burdening co-occurring symptoms. In our sample, adolescents who experienced many autistic symptoms also experienced many unexplained somatic symptoms. This relation stayed the same over time. There was no reciprocal influence, so higher autistic-like features did not contribute to higher unexplained somatic symptoms, or the other way around. The findings of this work tell us that in adolescents with autistic-like features it is important to be alert to the presence of unexplained somatic symptoms, and vice versa.;"[Hogendoorn, Elske; Hartman, Catharina A.; Burke, Sarah M.; van Dijk, Marijn W. G.; Rosmalen, Judith G. M.] Univ Groningen, Groningen, Netherlands; [Hogendoorn, Elske] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, CC 72, POB 30001, NL-9700 RB Groningen, Netherlands";"University of Groningen; University of Groningen";Hogendoorn, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, CC 72, POB 30001, NL-9700 RB Groningen, Netherlands.;e.hogendoorn@umcg.nl;"Burke, Sarah/J-6635-2019; Rosmalen, Judith/F-5375-2011";"Rosmalen, Judith/0000-0002-6393-0032; Burke, Sarah/0000-0001-7172-491X; Hogendoorn, Elske/0000-0003-4994-4048";"Netherlands Organization for Scientific Research NWO; Dutch Ministry of Justice (WODC) [940-38-011, 100-001-004, 60-60600-97-118, 261-98-710, 480-01-006, 480-07-001, 452-04-314, 452-06-004, 636340002, 175.010.2003.005, 481-08-013, 481-11-001, 016.130.002, 453-16-007/2735, Vi.C.191.021, 024.001.003]; European Science Foundation; European Research Council [FP-006]; Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32) [ERC-2017-STG-757364, ERC-CoG-2015-681466]; Gratama foundation; Jan Dekker foundation; Accare Centre for Child and Adolescent Psychiatry";"Netherlands Organization for Scientific Research NWO(Netherlands Organization for Scientific Research (NWO)); Dutch Ministry of Justice (WODC); European Science Foundation(European Science Foundation (ESF)); European Research Council(European Research Council (ERC)); Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32); Gratama foundation; Jan Dekker foundation; Accare Centre for Child and Adolescent Psychiatry";"The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TRAILS has been financially supported by various grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMw Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grant 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; ZonMw Longitudinal Cohort Research on Early Detection and Treatment in Mental Health Care grant 636340002; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel funding 481-08-013 and 481-11-001; NWO Vici 016.130.002, 453-16-007/2735, and Vi.C.191.021; NWO Gravitation 024.001.003), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), the European Research Council (ERC-2017-STG-757364 and ERC-CoG-2015-681466), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), the Gratama foundation, the Jan Dekker foundation, the participating universities, and Accare Centre for Child and Adolescent Psychiatry.";"Achenbach T. M., 2001, -Age Forms Profiles; Achenbach TM, 2003, Manual for the ASEBA adult forms & profiles; Aldinger KA, 2015, AUTISM RES, V8, P771, DOI 10.1002/aur.1492; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Bal VH, 2019, AUTISM RES, V12, P89, DOI 10.1002/aur.2004; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Beck JE, 2008, J PEDIATR PSYCHOL, V33, P547, DOI 10.1093/jpepsy/jsm113; Bonvanie IJ, 2017, BRIT J PSYCHOL, V108, P318, DOI 10.1111/bjop.12198; Bos MGN, 2018, J AUTISM DEV DISORD, V48, P2727, DOI 10.1007/s10803-018-3519-8; Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233; Chaidez V, 2014, J AUTISM DEV DISORD, V44, P1117, DOI 10.1007/s10803-013-1973-x; Chiarotti F, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10050274; Constantino JN, 2003, ARCH GEN PSYCHIAT, V60, P524, DOI 10.1001/archpsyc.60.5.524; Crombez G, 2005, PAIN, V116, P4, DOI 10.1016/j.pain.2005.03.035; Dabelea D, 2014, JAMA-J AM MED ASSOC, V311, P1778, DOI 10.1001/jama.2014.3201; de Bildt A, 2009, J AUTISM DEV DISORD, V39, P1350, DOI 10.1007/s10803-009-0749-9; Dharmage SC, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00246; Domènech-Llaberia E, 2004, J AM ACAD CHILD PSY, V43, P598, DOI 10.1097/00004583-200405000-00013; Fulceri F, 2016, DIGEST LIVER DIS, V48, P248, DOI 10.1016/j.dld.2015.11.026; Ganzeboom HBG, 1996, SOC SCI RES, V25, P201, DOI 10.1006/ssre.1996.0010; Garcia G, 2012, CHILD ADOL PSYCH CL, V21, P713, DOI 10.1016/j.chc.2012.07.012; Garfinkel SN, 2016, BIOL PSYCHOL, V114, P117, DOI 10.1016/j.biopsycho.2015.12.003; Grove J, 2019, NAT GENET, V51, P431, DOI 10.1038/s41588-019-0344-8; Gurney JG, 2006, ARCH PEDIAT ADOL MED, V160, P825, DOI 10.1001/archpedi.160.8.825; Hallett V, 2010, AM J PSYCHIAT, V167, P809, DOI 10.1176/appi.ajp.2009.09070990; Hamaker EL, 2015, PSYCHOL METHODS, V20, P102, DOI 10.1037/a0038889; Hartman CA, 2006, J AUTISM DEV DISORD, V36, P325, DOI 10.1007/s10803-005-0072-z; Hatta K, 2019, J AUTISM DEV DISORD, V49, P729, DOI 10.1007/s10803-018-3751-2; Hinz A, 2017, J PSYCHOSOM RES, V96, P27, DOI 10.1016/j.jpsychores.2016.12.017; Horwitz EH, 2020, J AUTISM DEV DISORD, V50, P2973, DOI 10.1007/s10803-020-04403-9; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Janssens KAM, 2014, J PEDIATR-US, V164, P900, DOI 10.1016/j.jpeds.2013.12.003; Janssens KAM, 2011, PEDIATRICS, V128, P553, DOI 10.1542/peds.2010-2364; Janssens KAM, 2010, J CHILD PSYCHOL PSYC, V51, P304, DOI 10.1111/j.1469-7610.2009.02174.x; Jenkinson R, 2020, AUTISM, V24, P1933, DOI 10.1177/1362361320932437; Johnson SA, 2009, J AUTISM DEV DISORD, V39, P1706, DOI 10.1007/s10803-009-0809-1; Kato K, 2010, J PSYCHOSOM RES, V68, P447, DOI 10.1016/j.jpsychores.2010.01.010; Kim H, 2020, YONSEI MED J, V61, P880, DOI 10.3349/ymj.2020.61.10.880; Kim JY, 2022, AUTISM RES, V15, P340, DOI 10.1002/aur.2656; Kinnaird E, 2019, EUR PSYCHIAT, V55, P80, DOI 10.1016/j.eurpsy.2018.09.004; Kuhlthau KA, 2018, AUTISM, V22, P804, DOI 10.1177/1362361317704420; Larkin F, 2023, AUTISM, V27, P602, DOI 10.1177/13623613221109717; Lipsker CW, 2018, J PAIN RES, V11, P2827, DOI 10.2147/JPR.S177534; Looper KJ, 2004, J PSYCHOSOM RES, V57, P373, DOI 10.1016/j.jpsychores.2004.03.005; Louwerse A, 2015, J AUTISM DEV DISORD, V45, P3908, DOI 10.1007/s10803-015-2595-2; Lundström S, 2012, ARCH GEN PSYCHIAT, V69, P46, DOI 10.1001/archgenpsychiatry.2011.144; Mayes SD, 2021, J AUTISM DEV DISORD, V51, P2297, DOI 10.1007/s10803-020-04697-9; McElhanon BO, 2014, PEDIATRICS, V133, P872, DOI 10.1542/peds.2013-3995; MISLEVY RJ, 1991, J EDUC STAT, V16, P150; Moulin V, 2015, J ADOLESCENCE, V45, P307, DOI 10.1016/j.adolescence.2015.10.010; Muskens JB, 2017, EUR CHILD ADOLES PSY, V26, P1093, DOI 10.1007/s00787-017-1020-0; Muthen L. K., 2017, MPLUS USERS GUIDE; Oldehinkel AJ, 2015, INT J EPIDEMIOL, V44, P76, DOI 10.1093/ije/dyu225; Paul AR, 2015, J AUTISM DEV DISORD, V45, P3055, DOI 10.1007/s10803-015-2445-2; Pinquart M, 2012, J PEDIATR PSYCHOL, V37, P376, DOI 10.1093/jpepsy/jsr106; Satorra A, 2001, PSYCHOMETRIKA, V66, P507, DOI 10.1007/BF02296192; Schroeder J., 2011, Journal on Developmental Disabilities, V17, P26; Seltzer MM, 2004, MENT RETARD DEV D R, V10, P234, DOI 10.1002/mrdd.20038; Sharp WG, 2013, J AUTISM DEV DISORD, V43, P2159, DOI 10.1007/s10803-013-1771-5; Spain D, 2018, RES AUTISM SPECT DIS, V52, P51, DOI 10.1016/j.rasd.2018.04.007; Strang JF, 2012, RES AUTISM SPECT DIS, V6, P406, DOI 10.1016/j.rasd.2011.06.015; Taylor JL, 2016, J NEURODEV DISORD, V8, DOI 10.1186/s11689-016-9160-y; van de Looij-Jansen PM, 2011, J EARLY ADOLESCENCE, V31, P443, DOI 10.1177/0272431610366243; Vasa RA, 2018, AUTISM RES, V11, P636, DOI 10.1002/aur.1916; Werling DM, 2013, CURR OPIN NEUROL, V26, P146, DOI 10.1097/WCO.0b013e32835ee548; Williams ZJ, 2022, AUTISM RES, V15, P761, DOI 10.1002/aur.2671; World Health Organization, 2004, ATC DDD SYST; Youssef NN, 2006, PEDIATRICS, V117, P54, DOI 10.1542/peds.2005-0114";68;3;3;3;7;SAGE PUBLICATIONS LTD;LONDON;1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND;1362-3613;1461-7005;;AUTISM;Autism;AUG;2023;27;6;;;;;1690;1701;;10.1177/13623613221143874;http://dx.doi.org/10.1177/13623613221143874;;janv-23;12;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;M8QF3;36588286;Green Published, hybrid;;;24/11/2024;WOS:000906069900001;View Full Record in Web of Science
J;"Whitehouse, AJO; Varcin, KJ; Pillar, S; Billingham, W; Alvares, GA; Barbaro, J; Bent, CA; Blenkley, D; Boutrus, M; Chee, A; Chetcuti, L; Clark, A; Davidson, E; Dimov, S; Dissanayake, C; Doyle, J; Grant, M; Green, CC; Harrap, M; Iacono, T; Matys, L; Maybery, M; Pope, DF; Renton, M; Rowbottam, C; Sadka, N; Segal, L; Slonims, V; Smith, J; Taylor, C; Wakeling, S; Wan, MW; Wray, J; Cooper, MN; Green, J; Hudry, K";;;;"Whitehouse, Andrew J. O.; Varcin, Kandice J.; Pillar, Sarah; Billingham, Wesley; Alvares, Gail A.; Barbaro, Josephine; Bent, Catherine A.; Blenkley, Daniel; Boutrus, Maryam; Chee, Abby; Chetcuti, Lacey; Clark, Alena; Davidson, Emma; Dimov, Stefanie; Dissanayake, Cheryl; Doyle, Jane; Grant, Megan; Green, Cherie C.; Harrap, Megan; Iacono, Teresa; Matys, Lisa; Maybery, Murray; Pope, Daniel F.; Renton, Michelle; Rowbottam, Catherine; Sadka, Nancy; Segal, Leonie; Slonims, Vicky; Smith, Jodie; Taylor, Carol; Wakeling, Scott; Wan, Ming Wai; Wray, John; Cooper, Matthew N.; Green, Jonathan; Hudry, Kristelle";;;Effect of Preemptive Intervention on Developmental Outcomes Among Infants Showing Early Signs of Autism A Randomized Clinical Trial of Outcomes to Diagnosis;JAMA PEDIATRICS;;;English;Article;;;;;;;"SPECTRUM DISORDER; HIGH-RISK; TODDLERS; RESPONSIVENESS; ATTENTION; CHILDREN; SCALE";"IMPORTANCE Intervention for individuals with autism spectrum disorder (ASD) typically commences after diagnosis. No trial of an intervention administered to infants before diagnosis has shown an effect on diagnostic outcomes to date. OBJECTIVE To determine the efficacy of a preemptive intervention for ASD beginning during the prodromal period. DESIGN, SETTING. AND PARTICIPANTS This 2-site, single rater-blinded randomized clinical trial of a preemptive intervention vs usual care was conducted at 2 Australian research centers (Perth, Melbourne). Community sampling was used to recruit 104 infants aged 9 to 14 months showing early behaviors associated with later ASD, as measured by the Social Attention and Communication Surveillance-Revised. Recruitment occurred from June 9, 2016, to March 30, 2018. Final follow-up data were collected on April 15, 2020. INTERVENTIONS Infants were randomized on a 1:1 ratio to receive either a preemptive intervention plus usual care or usual care only over a 5-month period. The preemptive intervention group received a 10-session social communication intervention, iBASIS-Video Interaction to Promote Positive Parenting (iBASIS-VIPP). Usual care comprised services delivered by community clinicians. MAIN OUTCOMES AND MEASURES Infants were assessed at baseline (approximate age. 12 months), treatment end point (approximate age, 18 months), age 2 years, and age 3 years. Primary outcome was the combined blinded measure of ASD behavior severity (the Autism Observation Scale for Infants and the Autism Diagnostic Observation Schedule, second edition) across the 4 assessment points. Secondary outcomes were an independent blinded clinical ASD diagnosis at age 3 years and measures of child development. Analyses were preregistered and comprised 1-tailed tests with an a level of .05. RESULTS Of 171 infants assessed for eligibility, 104 were randomized; 50 infants (mean [SD] chronological age, 12.40 [1.93] months; 38 boys [76.0%]) received the iBASIS-VIPP preemptive intervention plus usual care (1 infant was excluded after randomization), and 53 infants (mean [SD] age, 12.38 [2.02] months; 32 boys [60.4%]) received usual care only. A total of 89 participants (45 in the iBASIS-VIPP group and 44 in the usual care group) were reassessed at age 3 years. The iBASIS-VIPP intervention led to a reduction in ASD symptom severity (area between curves, -5.53; 95% CI, -infinity to to -0.28; P = .04). Reduced odds of ASD classification at age 3 years was found in the iBASIS-VIPP group (3 of 45 participants [6.7%]) vs the usual care group (9 of 44 participants [20.5%]; odds ratio, 0.18; 95% CI, 0-0.68; P = .02). Number needed to treat to reduce ASD classification was 7.2 participants. Improvements in caregiver responsiveness and language outcomes were also observed in the iBASIS-VIPP group. CONCLUSIONS AND RELEVANCE Receipt of a preemptive intervention for ASD from age 9 months among a sample of infants showing early signs of ASD led to reduced ASD symptom severity across early childhood and reduced the odds of an ASD diagnosis at age 3 years.";"[Whitehouse, Andrew J. O.; Varcin, Kandice J.; Pillar, Sarah; Billingham, Wesley; Alvares, Gail A.; Boutrus, Maryam; Chee, Abby; Clark, Alena; Harrap, Megan; Matys, Lisa; Renton, Michelle; Cooper, Matthew N.] Telethon Kids Inst, CliniKids, Nedlands, WA, Australia; [Whitehouse, Andrew J. O.] Univ Western Australia, Crawley, WA, Australia; [Whitehouse, Andrew J. O.; Barbaro, Josephine; Boutrus, Maryam; Chetcuti, Lacey; Dissanayake, Cheryl; Hudry, Kristelle] Cooperat Res Ctr Living Autism, Indooroopilly, Qld, Australia; [Varcin, Kandice J.] Griffith Univ, Sch Allied Hlth Sci, Gold Coast, Qld, Australia; [Barbaro, Josephine; Dissanayake, Cheryl; Sadka, Nancy] La Trobe Univ, Olga Tennison Autism Res Ctr, Sch Psychol & Publ Hlth, Bundoora, Vic, Australia; [Bent, Catherine A.; Chetcuti, Lacey; Dimov, Stefanie; Grant, Megan; Green, Cherie C.; Smith, Jodie; Wakeling, Scott; Hudry, Kristelle] La Trobe Univ, Sch Psychol & Publ Hlth, Dept Psychol & Counselling, Bundoora, Vic, Australia; [Blenkley, Daniel; Pope, Daniel F.; Wan, Ming Wai] Univ Manchester, Sch Hlth Sci, Div Psychol & Mental Hlth, Perinatal Mental Hlth & Parenting Res Unit, Manchester, Lancs, England; [Boutrus, Maryam; Maybery, Murray] Univ Western Australia, Sch Psychol Sci, Crawley, WA, Australia; [Davidson, Emma; Doyle, Jane; Renton, Michelle; Rowbottam, Catherine; Wray, John] Child Dev Serv, Child & Adolescent Hlth Serv, Perth, WA, Australia; [Iacono, Teresa] Coll Sci Hlth & Engn, Living Disabil Res Ctr, Melbourne, Vic, Australia; [Segal, Leonie] Univ South Australia, Australian Ctr Precis Hlth Allied Hlth & Human Mo, South Australian Hlth & Med Res Inst, North Terrace, Adelaide, SA, Australia; [Slonims, Vicky] Kings Coll London, Childrens Neurosci, Evelina London Childrens Hosp, Inst Psychiat Psychol & Neurosci, London, England; [Taylor, Carol; Green, Jonathan] Univ Manchester, Sch Biol Sci, Div Neurosci & Expt Psychol, Manchester, Lancs, England; [Green, Jonathan] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Greater Manchester Mental Hlth NHS Trust, Manchester, Lancs, England";"University of Western Australia; The Kids Research Institute Australia; University of Western Australia; Griffith University; Griffith University - Gold Coast Campus; La Trobe University; La Trobe University; University of Manchester; University of Western Australia; South Australian Health & Medical Research Institute (SAHMRI); University of South Australia; University of London; King's College London; University of Manchester; University of Manchester";Whitehouse, AJO (corresponding author), Univ Western Australia, Telethon Kids Inst, Perth Childrens Hosp, 15 Hosp Ave, Nedlands, WA 6009, Australia.;andrew.whitehouse@telethonkids.org.au;"Bent, Catherine/IAQ-8038-2023; Maybery, Murray/H-5390-2014; Iacono, Teresa/G-1548-2015; Green, Jonathan/L-2529-2018; Pillar, Sarah/KHE-2018-2024; Wan, Ming/AAG-4688-2019; Alvares, Gail/C-1154-2018; Boutrus, Maryam/LLK-1480-2024; Billingham, Wesley/AAU-7335-2021; Green, Cherie/AAC-3662-2019; Smith, Jodie/KFS-2749-2024; Barbaro, Josephine/AFO-8465-2022; Segal, Leonie/B-2357-2009; Whitehouse, Andrew/AGJ-2519-2022; Alvares, Gail/I-1724-2014";"Segal, Leonie/0000-0002-6391-6791; Whitehouse, Andrew/0000-0001-8722-1575; Green, Jonathan/0000-0002-0143-181X; slonims, vicky/0000-0003-3339-2365; Barbaro, Josephine/0000-0001-7359-0097; Maybery, Murray/0000-0002-3760-1382; Boutrus, Maryam/0000-0003-0545-0353; Pillar, Sarah/0000-0002-2681-0605; Hudry, Kristelle/0000-0002-2752-8345; Green, Cherie/0000-0002-3160-2106; Alvares, Gail/0000-0003-3351-5919; Bent, Catherine/0000-0001-8203-4682; Wan, Ming Wai/0000-0002-5353-786X";"Telethon Kids Institute; National Health and Medical Research Council [1077966, 1173896]; Angela Wright Bennett Foundation; Telethon-Perth Children's Hospital Research Fund; La Trobe University Understanding Disease Research Focus Area; Cooperative Research Centre for Living with Autism (Autism CRC); Australian government's Cooperative Research Centre Program; National Health and Medical Research Council of Australia [1173896] Funding Source: NHMRC; MRC [MR/K005863/1] Funding Source: UKRI";"Telethon Kids Institute; National Health and Medical Research Council(National Health & Medical Research Council (NHMRC) of Australia); Angela Wright Bennett Foundation; Telethon-Perth Children's Hospital Research Fund; La Trobe University Understanding Disease Research Focus Area; Cooperative Research Centre for Living with Autism (Autism CRC)(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Australian government's Cooperative Research Centre Program(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); National Health and Medical Research Council of Australia(National Health & Medical Research Council (NHMRC) of Australia); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))";This study was sponsored by the Telethon Kids Institute and supported by grants 1077966 and 1173896 from the National Health and Medical Research Council (Dr Whitehouse) and funding from the AngelaWright Bennett Foundation (Dr Whitehouse), the Telethon-Perth Children's Hospital Research Fund (Drs Whitehouse, Wray, J. Green, and Segal), the La Trobe University Understanding Disease Research Focus Area (Drs Hudry, Dissanayake, Barbaro, Iacono, Slonims, J. Green, and Whitehouse), and the Cooperative Research Centre for Living with Autism (Autism CRC) established and supported by the Australian government's Cooperative Research Centre Program (Drs Hudry, Whitehouse, Barbaro, Iacono, Dissanayake, and Maybery).;"American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Baranek GT., 2015, AUTISM RES TREAT, V2015; Barbaro J., 2018, ANN M INT SOC AUT RE; Barbaro J, 2013, AUTISM, V17, P64, DOI 10.1177/1362361312442597; Barbaro J, 2011, J PEDIATR NURS, V26, P334, DOI 10.1016/j.pedn.2010.04.007; Barbaro J, 2010, J DEV BEHAV PEDIATR, V31, P376, DOI 10.1097/DBP.0b013e3181df7f3c; Brian J, 2016, AUTISM, V20, P888, DOI 10.1177/1362361315614979; Bryson SE, 2008, J AUTISM DEV DISORD, V38, P731, DOI 10.1007/s10803-007-0440-y; Carter AS, 2011, J CHILD PSYCHOL PSYC, V52, P741, DOI 10.1111/j.1469-7610.2011.02395.x; Constantino JN, 2021, ANNU REV CLIN PSYCHO, V17, P365, DOI 10.1146/annurev-clinpsy-081219-110503; Elsabbagh M, 2012, CURR BIOL, V22, P338, DOI 10.1016/j.cub.2011.12.056; Fenson L., 1993, MACARTHUR COMMUNICAT; Gilmore L, 2009, CHILD CARE HLTH DEV, V35, P48, DOI 10.1111/j.1365-2214.2008.00867.x; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Green J., 2020, AUTISM SPECTRUM DISO, P247; Green J, 2017, J CHILD PSYCHOL PSYC, V58, P1330, DOI 10.1111/jcpp.12728; Green J, 2015, LANCET PSYCHIAT, V2, P133, DOI 10.1016/S2215-0366(14)00091-1; Green J, 2013, J AUTISM DEV DISORD, V43, P2502, DOI 10.1007/s10803-013-1797-8; Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3448; Johnson MH, 2021, J CHILD PSYCHOL PSYC, V62, P610, DOI 10.1111/jcpp.13372; Jones EJH, 2017, AUTISM RES, V10, P961, DOI 10.1002/aur.1754; Jones W, 2013, NATURE, V504, P427, DOI 10.1038/nature12715; Juffer F., 2008, Promoting Positive Parenting: An Attachment-Based Intervention; Kasari C, 2014, INFANT BEHAV DEV, V37, P711, DOI 10.1016/j.infbeh.2014.08.007; Klin A, 2020, DEV PSYCHOPATHOL, V32, P1175, DOI 10.1017/S0954579420000802; Lord C., 2012, AUTISM DIAGNOSTIC OB; Lu Naiji, 2013, Shanghai Arch Psychiatry, V25, P259, DOI 10.3969/j.issn.1002-0829.2013.04.009; Mozolic-Staunton B, 2020, RES AUTISM SPECT DIS, V71, DOI 10.1016/j.rasd.2019.101496; Mudge JF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032734; Mullen E. M., 1995, MULLEN SCALES EARLY, DOI DOI 10.1007/978-1-4419-1698-3_596; Ozonoff S, 2018, J AM ACAD CHILD PSY, V57, P849, DOI 10.1016/j.jaac.2018.06.022; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Rogers SJ, 2019, J AUTISM DEV DISORD, V49, P632, DOI 10.1007/s10803-018-3740-5; Rogers SJ, 2012, J AM ACAD CHILD PSY, V51, P1052, DOI 10.1016/j.jaac.2012.08.003; Sandbank M, 2021, JAMA PEDIATR, V175, P341, DOI 10.1001/jamapediatrics.2020.4730; Siller M, 2002, J AUTISM DEV DISORD, V32, P77, DOI 10.1023/A:1014884404276; Sparrow SCD., 2005, VINELAND ADAPTIVE BE; Tamis-LeMonda CS, 2001, CHILD DEV, V72, P748, DOI 10.1111/1467-8624.00313; van't Hof M, 2021, AUTISM, V25, P862, DOI 10.1177/1362361320971107; Wan MW, 2017, INT J BEHAV DEV, V41, P542, DOI 10.1177/0165025416631835; Wan MW, 2013, J CHILD PSYCHOL PSYC, V54, P763, DOI 10.1111/jcpp.12032; Watson LR, 2017, J AUTISM DEV DISORD, V47, P3520, DOI 10.1007/s10803-017-3268-0; Whitehouse A., 2021, QUICK FIL; Whitehouse AJO, 2019, LANCET CHILD ADOLESC, V3, P605, DOI 10.1016/S2352-4642(19)30184-1; Whitehouse AJO, 2017, INT J SPEECH-LANG PA, V19, P208, DOI 10.1080/17549507.2016.1276963; ZELLNER A, 1962, J AM STAT ASSOC, V57, P348, DOI 10.2307/2281644";46;91;96;6;30;AMER MEDICAL ASSOC;CHICAGO;330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA;2168-6203;2168-6211;;JAMA PEDIATR;JAMA Pediatr.;NOV;2021;175;11;;;;;;;e213298;10.1001/jamapediatrics.2021.3298;http://dx.doi.org/10.1001/jamapediatrics.2021.3298;;nov-21;11;Pediatrics;Science Citation Index Expanded (SCI-EXPANDED);Pediatrics;WR7QV;34542577;Green Published, hybrid;;;24/11/2024;WOS:000714558800001;View Full Record in Web of Science
J;"Leffa, DT; Grevet, EH; Bau, CHD; Schneider, M; Ferrazza, CP; da Silva, RF; Miranda, MS; Picon, F; Teche, SP; Sanches, P; Pereira, D; Rubia, K; Brunoni, AR; Camprodon, JA; Caumo, W; Rohde, LA";;;;"Leffa, Douglas Teixeira; Grevet, Eugenio Horacio; Dotto Bau, Claiton Henrique; Schneider, Maite; Ferrazza, Carolina Prietto; da Silva, Roberta Francieli; Miranda, Marina Silva; Picon, Felipe; Teche, Stefania Pigatto; Sanches, Paulo; Pereira, Danton; Rubia, Katya; Brunoni, Andre Russowsky; Camprodon, Joan A.; Caumo, Wolnei; Rohde, Luis Augusto";;;Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder The TUNED Randomized Clinical Trial;JAMA PSYCHIATRY;;;English;Article;;;;;;;"NONINVASIVE BRAIN-STIMULATION; DORSOLATERAL PREFRONTAL CORTEX; METHYLPHENIDATE TREATMENT; WORKING-MEMORY; METAANALYSIS; MEDICATION; ADHD; PREVALENCE; CONTINUITY; ADHERENCE";"IMPORTANCE Transcranial direct current stimulation (tDCS) may improve symptoms of inattention in adults with attention-deficit/hyperactivity disorder (ADHD). However, previous trials are characterized by small sample sizes, heterogeneous methodologies, and short treatment periods using clinic-based tDCS. OBJECTIVE To determine the efficacy and safety of home-based tDCS in treating inattention symptoms in adult patients with ADHD. DESIGN, SETTING. AND PARTICIPANTS Randomized, double-blind, parallel, sham-controlled clinical trial (tDCS for the Treatment of Inattention Symptoms in Adult Patients With ADHD [TUNED]), conducted from July 2019 through July 2021 in a single-center outpatient academic setting. Of 277 potential participants screened by phone, 150 were assessed for eligibility on site, and 64 were included. Participants were adults with ADHD, inattentive or combined subtype. Exclusion criteria included current stimulant drug treatment, current moderate to severe symptoms of depression or anxiety, diagnosis of bipolar disorder with a manic or depressive episode in the last year, diagnosis of schizophrenia or another psychotic disorder, and diagnosis of autism spectrum disorder; 55 of participants completed follow-up after 4 weeks. INTERVENTIONS Thirty-minute daily sessions of home-based tDCS for 4 weeks, 2 mA anodal-right and cathodal-left prefrontal stimulation with 35-cm(2) carbon electrodes. MAIN OUTCOMES AND MEASURES Inattentive scores in the dinician-administered version of the Adult ADHD Self-report Scale version 1.1 (CASRS-I). RESULTS Included in this trial were 64 participants with ADHD (31 [48%] inattentive presentation and 33 [52%] combined presentation), with a mean (SD) age of 38.3 (9.6) years. Thirty participants (47%) were women and 34 (53%) were men. Fifty-five finished the trial. At week 4, the mean (SD) inattention score, as measured with CASRS-I, was 18.88 (5.79) in the active tDCS group and 23.63 (3.97) in the sham tDCS group. Linear mixed-effects models revealed a statistically significant treatment by time interaction for CASRS-I (beta interaction = -3.18; 95% CI, -4.60 to -1.75; P < .001), showing decreased symptoms of inattention in the active tDCS group over the 3 assessments compared to the sham tDCS group. Mild adverse events were more frequent in the active tDCS group, particularly skin redness, headache, and scalp burn. CONCLUSIONS AND RELEVANCE In this randomized clinical trial, daily treatment with a home-based tDCS device over 4 weeks improved attention in adult patients with ADHD who were not taking stimulant medication. Home-based tDCS could be a nonpharmacological alternative for patients with ADHD.";"[Leffa, Douglas Teixeira; Grevet, Eugenio Horacio; Dotto Bau, Claiton Henrique; Schneider, Maite; Ferrazza, Carolina Prietto; da Silva, Roberta Francieli; Miranda, Marina Silva; Picon, Felipe; Teche, Stefania Pigatto; Rohde, Luis Augusto] Hosp Clin Porto Alegre, ADHD Outpatient Program, Porto Alegre, RS, Brazil; [Leffa, Douglas Teixeira; Grevet, Eugenio Horacio; Dotto Bau, Claiton Henrique; Schneider, Maite; Ferrazza, Carolina Prietto; da Silva, Roberta Francieli; Miranda, Marina Silva; Picon, Felipe; Teche, Stefania Pigatto; Rohde, Luis Augusto] Hosp Clin Porto Alegre, Dev Psychiat Program, Porto Alegre, RS, Brazil; [Leffa, Douglas Teixeira; Grevet, Eugenio Horacio; Schneider, Maite; Ferrazza, Carolina Prietto; da Silva, Roberta Francieli; Miranda, Marina Silva; Picon, Felipe; Teche, Stefania Pigatto; Rohde, Luis Augusto] Univ Fed Rio Grande do Sul, Dept Psychiat, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil; [Dotto Bau, Claiton Henrique] Univ Fed Rio Grande do Sul, Inst Biosci, Dept Genet, Porto Alegre, RS, Brazil; [Sanches, Paulo; Pereira, Danton] Hosp Clin Porto Alegre, Lab Biomed Engineer, Porto Alegre, RS, Brazil; [Rubia, Katya] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Child & Adolescent Psychiat, London, England; [Brunoni, Andre Russowsky] Univ Sao Paulo, Dept Psychiat, Serv Interdisciplinary Neuromodulat, Sao Paulo, SP, Brazil; [Brunoni, Andre Russowsky] Univ Sao Paulo, Inst Psychiat, Sao Paulo, SP, Brazil; [Camprodon, Joan A.] Massachusetts Gen Hosp, Div Neuropsychiat & Neuromodulat, Harvard Med Sch, Boston, MA 02114 USA; [Caumo, Wolnei] Hosp Clin Porto Alegre, Lab Pain & Neuromodulat, Porto Alegre, RS, Brazil; [Caumo, Wolnei] Univ Fed Rio Grande do Sul, Sch Med, Postgrad Program Med Sci, Porto Alegre, RS, Brazil; [Caumo, Wolnei] Univ Fed Rio Grande do Sul, Sch Med, Dept Surg, Porto Alegre, RS, Brazil; [Rohde, Luis Augusto] Natl Inst Dev Psychiat Children & Adolescents, Sao Paulo, Brazil";"Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; University of London; King's College London; Universidade de Sao Paulo; Universidade de Sao Paulo; Harvard University; Harvard Medical School; Massachusetts General Hospital; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul";"Rohde, LA (corresponding author), Hosp Clin Porto Alegre, ADHD Outpatient Program, Porto Alegre, RS, Brazil.;Rohde, LA (corresponding author), Hosp Clin Porto Alegre, Dev Psychiat Program, Porto Alegre, RS, Brazil.;Rohde, LA (corresponding author), Univ Fed Rio Grande do Sul, Dept Psychiat, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.";lrohde@terra.com.br;"Rubia, Katya/H-7497-2012; Grevet, Eugenio/ABD-4513-2020; Leffa, Douglas/AAG-5822-2020; Rohde, Luis Augusto/HIR-6458-2022; caumo, wolnei/Q-8728-2016; Prietto Ferrazza, Carolina/JSK-3752-2023; Camprodon, Joan/M-9093-2017; Rohde, Luis Augusto/A-6426-2008; Bau, Claiton/C-9980-2013; Russowsky Brunoni, Andre/H-8394-2012";"Camprodon, Joan/0000-0003-1282-9257; Rohde, Luis Augusto/0000-0002-4552-4188; Bau, Claiton/0000-0001-5644-3845; Teixeira Leffa, Douglas/0000-0002-4890-8451; Prietto Ferrazza, Carolina/0000-0001-6495-619X; Russowsky Brunoni, Andre/0000-0002-6310-3571";"National Council for Scientific and Technological Development [302688/2017-0, 154116/2018-1]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul [17/2551-0001 087-6, 17/2551-0001 476-6, 16/2551-0000249-5, 19/2551-0000716-7]; Brain AMP; Behavior Research Foundation [29486]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo; Brazilian Innovation Agency [1245/13, 0261/18]; University of Sao Paulo Medical School; UK Academy of Medical Sciences (Newton Advanced Fellowship); International Health Cohort Consortium; Brazilian National Council of Scientific Development";"National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul(Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS)); Brain AMP; Behavior Research Foundation; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian Innovation Agency; University of Sao Paulo Medical School; UK Academy of Medical Sciences (Newton Advanced Fellowship); International Health Cohort Consortium; Brazilian National Council of Scientific Development";"This study was supported by grants 302688/2017-0 and 154116/2018-1 from the National Council for Scientific and Technological Development; 17/2551-0001 087-6, 17/2551-0001 476-6, 16/2551-0000249-5, and 19/2551-0000716-7 from Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul; NARSAD Young Investigator grant 29486 from the Brain & Behavior Research Foundation to Dr Leffa; from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo to Dr Brunoni; and 1245/13, and 0261/18 from the Brazilian Innovation Agency. Dr Brunoni receives scholarships and support from the Brazilian National Council of Scientific Development, University of Sao Paulo Medical School, the UK Academy of Medical Sciences (Newton Advanced Fellowship), and the International Health Cohort Consortium. Dr Grevet receives scholarship and support from the Brazilian National Council of Scientific Development.";"Adler LD, 2010, POSTGRAD MED, V122, P184, DOI 10.3810/pgm.2010.01.2112; Alonzo A, 2019, J AFFECT DISORDERS, V252, P475, DOI 10.1016/j.jad.2019.04.041; Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016; Biabani M, 2018, REV NEUROSCIENCE, V29, P463, DOI 10.1515/revneuro-2017-0056; Biederman J, 2019, J CLIN PSYCHOPHARM, V39, P351, DOI 10.1097/JCP.0000000000001055; Biederman J, 2011, EUR NEUROPSYCHOPHARM, V21, P508, DOI 10.1016/j.euroneuro.2010.11.005; Bikson M, 2016, BRAIN STIMUL, V9, P641, DOI 10.1016/j.brs.2016.06.004; Bikson M, 2009, CLIN NEUROPHYSIOL, V120, P1033, DOI 10.1016/j.clinph.2009.03.018; Brietzke AP, 2020, J PAIN, V21, P212, DOI 10.1016/j.jpain.2019.06.013; Brunoni AR, 2016, BRIT J PSYCHIAT, V208, P522, DOI 10.1192/bjp.bp.115.164715; Brunoni AR, 2014, BRAIN COGNITION, V86, P1, DOI 10.1016/j.bandc.2014.01.008; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Cachoeira CT, 2017, PSYCHIAT RES, V247, P28, DOI 10.1016/j.psychres.2016.11.009; Carvalho F, 2018, JOVE-J VIS EXP, DOI 10.3791/57614; Castillo-Saavedra L, 2016, J PAIN, V17, P14, DOI 10.1016/j.jpain.2015.09.009; Caumo W, 2022, J PAIN, V23, P641, DOI 10.1016/j.jpain.2021.11.002; Charvet LE, 2020, BRAIN STIMUL, V13, P686, DOI 10.1016/j.brs.2020.02.011; Cortese S, 2019, J AM ACAD CHILD PSY, V58, P936, DOI 10.1016/j.jaac.2019.04.029; Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4; de Boer NS, 2021, NEUROSCI BIOBEHAV R, V125, P122, DOI 10.1016/j.neubiorev.2021.01.013; Dubreuil-Vall L, 2021, BIOL PSYCHIAT-COGN N, V6, P439, DOI 10.1016/j.bpsc.2020.11.006; Dubreuil-Vall L, 2019, BRAIN STIMUL, V12, P1456, DOI 10.1016/j.brs.2019.06.006; Enck P, 2019, HANDB EXP PHARMACOL, V260, P399, DOI 10.1007/164_2019_269; Faraone SV, 2021, NEUROSCI BIOBEHAV R, V128, P789, DOI 10.1016/j.neubiorev.2021.01.022; Fried R, 2020, J PSYCHOPHARMACOL, V34, P883, DOI 10.1177/0269881120908014; Fusar-Poli P, 2012, AM J PSYCHIAT, V169, P264, DOI 10.1176/appi.ajp.2011.11060940; Gajria K, 2014, NEUROPSYCH DIS TREAT, V10, P1543, DOI 10.2147/NDT.S65721; Hart H, 2013, JAMA PSYCHIAT, V70, P185, DOI 10.1001/jamapsychiatry.2013.277; Hill AT, 2016, BRAIN STIMUL, V9, P197, DOI 10.1016/j.brs.2015.10.006; Hróbjartsson A, 2007, INT J EPIDEMIOL, V36, P654, DOI 10.1093/ije/dym020; Jung DH, 2020, ELIFE, V9, DOI 10.7554/eLife.56359; Kessler RC, 2005, PSYCHOL MED, V35, P245, DOI 10.1017/S0033291704002892; Khan MU, 2019, J CHILD ADOL PSYCHOP, V29, P398, DOI 10.1089/cap.2018.0153; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; Leffa DT, 2018, BRAIN STIMUL, V11, P743, DOI 10.1016/j.brs.2018.04.001; Leffa DT, 2016, EUR NEUROPSYCHOPHARM, V26, P368, DOI 10.1016/j.euroneuro.2015.11.012; Leffa DT., 2021, TRANSCRANIAL DIRECT, P565, DOI [10.1007/978-3-030-76136-3_28, DOI 10.1007/978-3-030-76136-3_28]; Marcus SC, 2005, ARCH PEDIAT ADOL MED, V159, P572, DOI 10.1001/archpedi.159.6.572; Mattos P., 2006, ARCH CLIN PSYCHIAT, V33, P4, DOI [10.1590/S0101-60832006000400004, DOI 10.1590/S0101-60832006000400004]; McGough JJ, 2019, J AM ACAD CHILD PSY, V58, P403, DOI 10.1016/j.jaac.2018.11.013; Mota SM, 2021, FRONT INTEGR NEUROSC, V15, DOI 10.3389/fnint.2021.753995; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Olfson M, 2007, J MANAGE CARE PHARM, V13, P570, DOI 10.18553/jmcp.2007.13.7.570; Perwien Amy, 2004, J Manag Care Pharm, V10, P122; Polanczyk G, 2007, AM J PSYCHIAT, V164, P942, DOI 10.1176/appi.ajp.164.6.942; Polania R, 2018, NAT NEUROSCI, V21, P174, DOI 10.1038/s41593-017-0054-4; Rubia K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082156; Salehinejad M.A., 2021, TRANSCRANIAL DIRECT, P667, DOI [10.1007/978-3-030-76136-3_35, DOI 10.1007/978-3-030-76136-3_35]; Salehinejad MA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215095; Sarkis RA, 2014, Current Behavioral Neuroscience Reports, V1, P74, DOI DOI 10.1007/S40473-014-0009-Y; Simon V, 2009, BRIT J PSYCHIAT, V194, P204, DOI 10.1192/bjp.bp.107.048827; Soff C, 2017, J NEURAL TRANSM, V124, P133, DOI 10.1007/s00702-016-1646-y; Voelker R, 2019, JAMA-J AM MED ASSOC, V321, P2066, DOI 10.1001/jama.2019.6992; Westwood SJ, 2023, PSYCHOL MED, V53, P497, DOI 10.1017/S0033291721001859; Westwood SJ, 2021, J PSYCHIATR NEUROSCI, V46, pE14, DOI 10.1503/jpn.190179; Winterstein AG, 2008, ANN PHARMACOTHER, V42, P24, DOI 10.1345/aph.1K143; Wolraich ML, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-2528";57;26;27;6;38;AMER MEDICAL ASSOC;CHICAGO;330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA;2168-622X;2168-6238;;JAMA PSYCHIAT;JAMA Psychiatry;SEP;2022;79;9;;;;;847;856;;10.1001/jamapsychiatry.2022.2055;http://dx.doi.org/10.1001/jamapsychiatry.2022.2055;;AUG 2022;10;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;4J9JK;35921102;Green Published;;;24/11/2024;WOS:000836399700003;View Full Record in Web of Science
J;"Shah, YD; Stringel, V; Pavkovic, I; Kothare, SV";;;;"Shah, Yash D.; Stringel, Virginia; Pavkovic, Ivan; Kothare, Sanjeev V.";;;Doxepin in children and adolescents with symptoms of insomnia: a single-center experience;JOURNAL OF CLINICAL SLEEP MEDICINE;;;English;Article;;;;;;"autism spectrum disorder; doxepin; insomnia";"AUTISM SPECTRUM DISORDERS; SLEEP PROBLEMS; 6 MG; OUTPATIENT TRIAL; DOUBLE-BLIND; EFFICACY; SAFETY; ADULTS; PREVALENCE; EPIDEMIOLOGY";Study Objectives: Pediatric insomnia is a widespread problem and especially difficult to manage in children with neurodevelopmental disorders. There are currently no US Food and Drug Administration-approved medications to use once first-line therapy fails. The objective of this study was to evaluate the efficacy and tolerability of doxepin in pediatric patients. Methods: This is a retrospective single-center chart review of children and adolescents (2-17 years of age) whose sleep failed to improve with behavioral intervention and melatonin who were then trialed on doxepin. Treatment was initiated at a median starting dose of 2 mg and slowly escalated to a median maintenance dose of 10 mg. Improvement in sleep was recorded using a 4-point Likert scale reported by parents on follow-up visits. Results: A total of 29 patients were included in the analysis. Mean follow-up duration was 6.5 +/- 3.5 months. Of 29 patients, 4 (13.8%) patients discontinued doxepin because of lack of efficacy or side effects. Eight (27.6%) patients showed significant improvement of their insomnia, 8 (27.6%) showed moderate improvement, 10 (34.5%) showed mild improvement, and 3 (10.3%) showed minimal to no improvement on treatment with doxepin (P <.05) Only 2 patients (6.9%) experienced adverse effects in the form of behavioral side effects (aggression) and enuresis. Conclusions: Results of our studies suggest that low-dose doxepin is both effective and well tolerated in pediatric patients with insomnia.;"[Shah, Yash D.; Stringel, Virginia; Pavkovic, Ivan; Kothare, Sanjeev V.] Cohen Childrens Med Ctr, Dept Pediat, Div Child Neurol, New Hyde Pk, NY USA";"Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York";Kothare, SV (corresponding author), Cohen Childrens Med Ctr, Div Pediat Neurol, 2001 Marcus Ave,Suite W290, Lake Success, NY 11042 USA.;skothare@northwell.edu;SHAH, YASH/AAH-7350-2019;"Shah, Yash D./0000-0002-3695-0329; Kothare, Sanjeev/0000-0001-7849-6649";;;;"Archbold KH, 2002, J PEDIATR-US, V140, P97, DOI 10.1067/mpd.2002.119990; Atkin T, 2018, PHARMACOL REV, V70, P197, DOI 10.1124/pr.117.014381; Blader JC, 1997, ARCH PEDIAT ADOL MED, V151, P473, DOI 10.1001/archpedi.1997.02170420043007; Couturier JL, 2005, J AM ACAD CHILD PSY, V44, P815, DOI 10.1097/01.chi.0000166377.22651.87; DeMartinis Nicholas A., 2007, CNS & Neurological Disorders-Drug Targets, V6, P17, DOI 10.2174/187152707779940835; FDA, DRUG APPR PACK; Gursky JT, 2000, HARVARD REV PSYCHIAT, V8, P298, DOI 10.1093/hrp/8.6.298; Hajak G, 2001, J CLIN PSYCHIAT, V62, P453, DOI 10.4088/JCP.v62n0609; Hering E, 1999, J AUTISM DEV DISORD, V29, P143, DOI 10.1023/A:1023092627223; Hindmarch I, 2000, BRIT J CLIN PHARMACO, V49, P118, DOI 10.1046/j.1365-2125.2000.00124.x; HOSHINO Y, 1984, FOLIA PSYCHIAT NEU J, V38, P45; Johnson EO, 2006, PEDIATRICS, V117, pE247, DOI 10.1542/peds.2004-2629; KATWALA J, 2013, ASIAN PAC J TROP DIS, V3, P331, DOI DOI 10.1016/S2222-1808(13)60080-8; Krakowiak P, 2008, J SLEEP RES, V17, P197, DOI 10.1111/j.1365-2869.2008.00650.x; Krystal AD, 2011, SLEEP, V34, P1433, DOI 10.5665/SLEEP.1294; Krystal AD, 2010, SLEEP, V33, P1553, DOI 10.1093/sleep/33.11.1553; Lankford A, 2012, SLEEP MED, V13, P133, DOI 10.1016/j.sleep.2011.09.006; Merenstein D, 2006, ARCH PEDIAT ADOL MED, V160, P707, DOI 10.1001/archpedi.160.7.707; Miano Silvia, 2010, Paediatr Drugs, V12, P75, DOI 10.2165/11316140-000000000-00000; Mindell JA, 1999, CHILD ADOL PSYCH CL, V8, P695; Mindell JA, 2006, SLEEP, V29, P1263; Owens JA, 2000, J DEV BEHAV PEDIATR, V21, P27, DOI 10.1097/00004703-200002000-00005; Polimeni MA, 2005, J INTELL DISABIL RES, V49, P260, DOI 10.1111/j.1365-2788.2005.00642.x; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Roth T, 2007, SLEEP, V30, P1555, DOI 10.1093/sleep/30.11.1555; Roth T, 2010, SLEEP MED, V11, P843, DOI 10.1016/j.sleep.2010.07.006; Sanberg SA, 2018, J AUTISM DEV DISORD, V48, P4250, DOI 10.1007/s10803-018-3644-4; Scharf M, 2008, J CLIN PSYCHIAT, V69, P1557, DOI 10.4088/JCP.v69n1005; Somaxon Pharmaceuticals Inc, HIGHL PRESCR INF; Stahl SM, 2008, CNS SPECTRUMS, V13, P1027, DOI 10.1017/S1092852900017089; Troester MM, 2015, SEMIN PEDIATR NEUROL, V22, P135, DOI 10.1016/j.spen.2015.03.002; van de Wouw E, 2012, RES DEV DISABIL, V33, P1310, DOI 10.1016/j.ridd.2012.03.003; van de Wouw E, 2013, RES DEV DISABIL, V34, P2291, DOI 10.1016/j.ridd.2013.04.012; Winokur A, 2000, BIOL PSYCHIAT, V48, P75, DOI 10.1016/S0006-3223(00)00882-9; Yeung WF, 2015, SLEEP MED REV, V19, P75, DOI 10.1016/j.smrv.2014.06.001";35;6;6;1;4;AMER ACAD SLEEP MEDICINE;DARIEN;2510 N FRONTAGE RD, DARIEN, IL 60561 USA;1550-9389;1550-9397;;J CLIN SLEEP MED;J. Clin. Sleep Med.;MAY 15;2020;16;5;;;;;743;747;;10.5664/jcsm.8338;http://dx.doi.org/10.5664/jcsm.8338;;;5;Clinical Neurology;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Neurosciences & Neurology;ML9LS;32029069;Bronze, Green Published;;;24/11/2024;WOS:000549782900012;View Full Record in Web of Science
J;"Hartmann, A; Ansquer, S; Brefel-Courbon, C; Burbaud, P; Castrioto, A; Czernecki, V; Damier, P; Deniau, E; Drapier, S; Jalenques, I; Marechal, O; Priou, T; Spodenkiewicz, M; Thobois, S; Roubertie, A; Witjas, T; Anheim, M";;;;"Hartmann, A.; Ansquer, S.; Brefel-Courbon, C.; Burbaud, P.; Castrioto, A.; Czernecki, V.; Damier, P.; Deniau, E.; Drapier, S.; Jalenques, I.; Marechal, O.; Priou, T.; Spodenkiewicz, M.; Thobois, S.; Roubertie, A.; Witjas, T.; Anheim, M.";;;French guidelines for the diagnosis and management of Tourette syndrome;REVUE NEUROLOGIQUE;;;English;Article;;;;;;"Tics; Tourette syndrome; Guidelines";PREVALENCE;"The term Gilles de la Tourette syndrome, or the more commonly used term Tourette syndrome (TS) refers to the association of motor and phonic tics which evolve in a context of variable but frequent psychiatric comorbidity. The syndrome is characterized by the association of several motor tics and at least one phonic tic that have no identifiable cause, are present for at least one year and appear before the age of 18. The presence of coprolalia is not necessary to establish or rule out the diagnosis, as it is present in only 10% of cases. The diagnosis of TS is purely clinical and is based on the symptoms defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). No additional tests are required to confirm the diagnosis of TS. However, to exclude certain differential diagnoses, further tests may be necessary. Very frequently, one or more psychiatric comorbidities are also present, including attention deficit hyperactivity disorder, obsessive-compulsive disorder, anxiety, explosive outbursts, self-injurious behaviors, learning disorders or autism spectrum disorder. The condition begins in childhood around 6 or 7 years of age and progresses gradually, with periods of relative waxing and waning of tics. The majority of patients experience improvement by the end of the second decade of life, but symptoms may persist into adulthood in around one-third of patients. The cause of TS is unknown, but genetic susceptibility and certain environmental factors appear to play a role. The treatment of TS and severe forms of tics is often challenging and requires a multidisciplinary approach (involving the general practitioner (GP), pediatrician, psychiatrist, neurologist, school or occupational physicians, psychologist and social workers). In mild forms, education (of young patients, parents and siblings) and psychological management are usually recommended. Medical treatments, including antipsychotics, are essential in the moderate to severe forms of the disease (i.e. when there is a functional and/or psychosocial discomfort linked to tics). Over the past decade, cognitive-behavioral therapies have been validated for the treatment of tics. For certain isolated tics, botulinum toxin injections may also be useful. Psychiatric comorbidities, when present, often require a specific treatment. For very severe forms of TS, treatment by deep brain stimulation offers real therapeutic hope. If tics are suspected and social or functional impairment is significant, specialist advice should be sought, in accordance with the patient's age (psychiatrist/child psychiatrist; neurologist/pediatric neurologist). They will determine tic severity and the presence or absence of comorbidities. The GP will take over the management and prescription of treatment: encouraging treatment compliance, assessing side effects, and combating stigmatization among family and friends. They will also play an important role in rehabilitation therapies, as well as in ensuring that accommodations are made in the patient's schooling or professional environment. # 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.";"[Hartmann, A.; Czernecki, V.; Deniau, E.; Priou, T.] Sorbonne Univ, Ctr Reference Natl Malad Rare Syndrome Gilles de, DMU Neurosci, Grp Hosp Pitie Sapetriere,AP HP, F-75013 Paris, France; [Ansquer, S.] CHU Poitiers, Serv Neurol, F-86021 Poitiers, France; [Brefel-Courbon, C.] Toulouse Univ Hosp, NS Pk FCRIN Network, Parkinson Toulouse Expert Ctr, Inserm,UMR1214,NS Pk FCRIN Network, Toulouse, France; [Brefel-Courbon, C.] Toulouse Univ Hosp, NeuroToul COEN Ctr, Toulouse, France; [Burbaud, P.] CHU Bordeaux, Hop Pellegrin, Serv Neurophysiol Clin Enfant & Adulte, Pole Neurosci Clin, D-50931 Cologne, Germany; [Castrioto, A.] Univ Grenoble Alpes, Hop Pellegrin Enfants, Serv Neurol, Inserm,U1216,CHU Grenoble Alpes, Bordeaux, France; [Damier, P.] Nantes Univ, Serv Neurol, INSERM, CHU Nantes,CIC 1314, Nantes, France; [Drapier, S.] CHU Pontchaillou, Serv Neurol, F-44093 Nantes, France; [Jalenques, I.] Univ Clermont Auvergne, Inst Pascal, Ctr Competences Gilles de la Tourette, Serv Psychiat Adulte & Psychol Med,CNRS,Clermont, F-35000 Clermont Ferrand, France; [Marechal, O.] Univ Clermont Auvergne, Inst Pascal UMR 6602, Dept Psychiat, CHU Clermont Ferrand,CNRS,Clermont Auvergne INP, F-63000 Clermont Ferrand, France; [Spodenkiewicz, M.] Assoc Francaise Syndrome Gilles de la Tourette AF, Neuilly Sur Seine, France; [Thobois, S.] CHU Reunion, Serv Psychiat, F-97410 St Pierre, La Reunion, France; [Thobois, S.] Hosp Civils Lyon, Pierre Wertheimer Neurol Hosp, Expert Parkinson Ctr NS PK FCRIN, Dept Neurol C, Bron, France; [Thobois, S.] Univ Claude Bernard Lyon 1, Fac Med & Maieut Lyon Sud Charles Merieux, F-69600 Oullins, France; [Roubertie, A.] CHU Montpellier, Inst Neurosci Montpellier, Serv Neuropediat, Inserm U1298, Montpellier, France; [Witjas, T.] Aix Marseille Univ, Timone Univ Hosp, Dept Neurol & Movement Disorders, Marseille, France; [Witjas, T.] Aix Marseille Univ, CNRS, Inst Neurosci Timone INT, F-13005 Marseille, France; [Anheim, M.] Hop Univ Strasbourg, Serv Neurol, Strasbourg, France; [Anheim, M.] Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire IGBMC, CNRS UMR7104, INSERM U964, Illkirch Graffenstaden, France; [Anheim, M.] Ctr Reference Malad Neurogenet Rares, Paris, France; [Anheim, M.] Univ Strasbourg, Federat Med Translat Strasbourg FMTS, Strasbourg, France";"Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; CHU Poitiers; Universite de Poitiers; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; CHU Rennes; Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); CHU Clermont Ferrand; Universite Clermont Auvergne (UCA); Polytechnic Institute of Clermont Auvergne; CHU Reunion; CHU Lyon; Universite Claude Bernard Lyon 1; Universite de Montpellier; CHU de Montpellier; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg";"Hartmann, A (corresponding author), Sorbonne Univ, Ctr Reference Natl Malad Rare Syndrome Gilles de, DMU Neurosci, Grp Hosp Pitie Sapetriere,AP HP, F-75013 Paris, France.;Anheim, M (corresponding author), Hop Univ Strasbourg, Serv Neurol, Strasbourg, France.;Anheim, M (corresponding author), Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire IGBMC, CNRS UMR7104, INSERM U964, Illkirch Graffenstaden, France.;Anheim, M (corresponding author), Ctr Reference Malad Neurogenet Rares, Paris, France.;Anheim, M (corresponding author), Univ Strasbourg, Federat Med Translat Strasbourg FMTS, Strasbourg, France.";"andreas.hartmann@aphp.fr; mathieu.anheim@chru-strasbourg.fr";;;BRAIN-TEAM network;BRAIN-TEAM network;The authors thank the BRAIN-TEAM network ( www.brain-team.fr) for its support in the preparation of the manuscript, and Mrs. Natasha Barr for translation.;"Andrén P, 2022, EUR CHILD ADOLES PSY, V31, P403, DOI 10.1007/s00787-021-01845-z; Cipriani A, 2016, LANCET, V388, P881, DOI 10.1016/S0140-6736(16)30385-3; Groth C, 2017, J AM ACAD CHILD PSY, V56, P304, DOI 10.1016/j.jaac.2017.01.010; Hirschtritt ME, 2015, JAMA PSYCHIAT, V72, P325, DOI 10.1001/jamapsychiatry.2014.2650; Hoekstra PJ, 2022, EUR CHILD ADOLES PSY, V31, P371, DOI 10.1007/s00787-021-01927-y; Jafari F, 2022, PEDIATR NEUROL, V137, P6, DOI 10.1016/j.pediatrneurol.2022.08.010; Jalenques I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243912; Levy AM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12091321; Mathews CA, 2022, EUR CHILD ADOLES PSY, V31, P375, DOI 10.1007/s00787-021-01892-6; McGuire JF, 2018, NEUROLOGY, V90, pE1711, DOI 10.1212/WNL.0000000000005474; Müller-Vahl KR, 2022, EUR CHILD ADOLES PSY, V31, P377, DOI 10.1007/s00787-021-01832-4; Nilles C, 2023, MOV DISORD CLIN PRAC, V10, P764, DOI 10.1002/mdc3.13703; Osland ST, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007990.pub3; Pringsheim T, 2023, EUR J NEUROL, V30, P902, DOI 10.1111/ene.15672; Pringsheim T, 2019, NEUROLOGY, V92, P896, DOI 10.1212/WNL.0000000000007466; Roessner V, 2022, EUR CHILD ADOLES PSY, V31, P425, DOI 10.1007/s00787-021-01899-z; Szejko N, 2022, EUR CHILD ADOLES PSY, V31, P383, DOI 10.1007/s00787-021-01842-2; Szejko N, 2022, EUR CHILD ADOLES PSY, V31, P443, DOI 10.1007/s00787-021-01881-9";18;0;0;1;1;MASSON EDITEUR;MOULINEAUX CEDEX 9;21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE;0035-3787;2213-0004;;REV NEUROL-FRANCE;Rev. Neurol.;OCT;2024;180;8;;;;;818;827;;10.1016/j.neurol.2024.04.005;http://dx.doi.org/10.1016/j.neurol.2024.04.005;;;10;Clinical Neurology;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;K2R2P;38760282;;;;24/11/2024;WOS:001342394200001;View Full Record in Web of Science
J;"van Andel, DM; Sprengers, JJ; Königs, M; de Jonge, M; Bruining, H";;;;"van Andel, Dorinde M.; Sprengers, Jan J.; Konigs, Marsh; de Jonge, Maretha, V; Bruining, Hilgo";;;Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled Trial;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"ASD; Bumetanide; RCT; Child; Cognition; Neurocognitive functioning";"EXECUTIVE FUNCTION; MEMORY; DYSFUNCTION; ADOLESCENTS; INHIBITION; MODELS; SKILLS; MIND";"We present the secondary-analysis of neurocognitive tests in the Bumetanide in Autism Medication and Biomarker' (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (<= 1 mg twice-daily) in unmedicated children 7-15 years with ASD. Children with IQ >= 70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to - 0.013,p = .034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to - 0.001,p = .042). This study offers perspectives to include neurocognitive tests in ASD trials.";"[van Andel, Dorinde M.; Sprengers, Jan J.; de Jonge, Maretha, V; Bruining, Hilgo] Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Dept Psychiat, Utrecht, Netherlands; [Konigs, Marsh] Amsterdam UMC, Dept Paediat, Emma Neurosci Grp, Emma Childrens Hosp, Amsterdam, Netherlands; [de Jonge, Maretha, V] Leiden Univ, Fac Social & Behav Sci, Dept Educ & Child Studies, Leiden, Netherlands; [Bruining, Hilgo] Vrije Univ Amsterdam, Child & Adolescent Psychiat & Psychosocial Care, Emma Childrens Hosp, Amsterdam UMC, Amsterdam, Netherlands; [Bruining, Hilgo] Amsterdam UMC, Amsterdam Neurosci, Amsterdam Reprod & Dev, N You Neurodev Precis Ctr, Amsterdam, Netherlands; [Bruining, Hilgo] Ctr Child & Adolescent Psychiat, Levvel, Amsterdam, Netherlands; [Bruining, Hilgo] Univ Amsterdam, Dept Child & Adolescent Psychiat, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands";"Utrecht University; Utrecht University Medical Center; University of Amsterdam; Emma Children's Hospital; Leiden University; Leiden University - Excl LUMC; Emma Children's Hospital; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; University of Amsterdam";"Bruining, H (corresponding author), Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Dept Psychiat, Utrecht, Netherlands.;Bruining, H (corresponding author), Vrije Univ Amsterdam, Child & Adolescent Psychiat & Psychosocial Care, Emma Childrens Hosp, Amsterdam UMC, Amsterdam, Netherlands.;Bruining, H (corresponding author), Amsterdam UMC, Amsterdam Neurosci, Amsterdam Reprod & Dev, N You Neurodev Precis Ctr, Amsterdam, Netherlands.;Bruining, H (corresponding author), Ctr Child & Adolescent Psychiat, Levvel, Amsterdam, Netherlands.;Bruining, H (corresponding author), Univ Amsterdam, Dept Child & Adolescent Psychiat, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.";h.bruining@amsterdamumc.nl;de Jonge, Maretha/CAA-6866-2022;"Konigs, Marsh/0000-0003-0200-0445; Sprengers, Jan/0000-0001-5418-9791";"Netherlands Organisation for Health Research and Development [36041015]; ZonMw Offroad [04510011910052]; NewTDEC Netherlands Organization for Scientific Research (NWO) Dutch National Research Agenda, NWA-ORC Call [NWA.1160.18.200]";"Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development); ZonMw Offroad; NewTDEC Netherlands Organization for Scientific Research (NWO) Dutch National Research Agenda, NWA-ORC Call(Netherlands Organization for Scientific Research (NWO))";"The study was supported by the Netherlands Organisation for Health Research and Development (ZonMw; grant number GGG -#836041015) (ZonMw Offroad Program grant number 04510011910052) and the NewTDEC Netherlands Organization for Scientific Research (NWO) Dutch National Research Agenda, NWA-ORC Call (NWA.1160.18.200). Neither the funder of the study, nor Neurochlore, who provided the study medication, had a role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.";"Cepeda C, 2019, J NEUROSCI RES, V97, P1624, DOI 10.1002/jnr.24503; Dargaei Z, 2018, P NATL ACAD SCI USA, V115, pE1618, DOI 10.1073/pnas.1716871115; Deidda G, 2015, NAT MED, V21, P318, DOI 10.1038/nm.3827; Demetriou EA, 2018, MOL PSYCHIATR, V23, P1198, DOI 10.1038/mp.2017.75; Demetriou EA, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00753; Denève S, 2017, NEURON, V94, P969, DOI 10.1016/j.neuron.2017.05.016; Du L, 2015, J CHILD ADOL PSYCHOP, V25, P585, DOI 10.1089/cap.2015.0045; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Gharaylou Z, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00483; Gillespie-Lynch K, 2012, J AUTISM DEV DISORD, V42, P161, DOI 10.1007/s10803-011-1222-0; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Hadjikhani N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21958-x; Hadjikhani N, 2015, AUTISM, V19, P149, DOI 10.1177/1362361313514141; Handen BL, 2011, J CHILD ADOL PSYCHOP, V21, P43, DOI 10.1089/cap.2010.0024; Happé F, 2006, NAT NEUROSCI, V9, P1218, DOI 10.1038/nn1770; Hill EL, 2004, TRENDS COGN SCI, V8, P26, DOI 10.1016/j.tics.2003.11.003; Jones CRG, 2018, AUTISM RES, V11, P95, DOI 10.1002/aur.1873; Kenny L, 2019, J ABNORM CHILD PSYCH, V47, P1089, DOI 10.1007/s10802-018-0493-8; Königs M, 2021, CORTEX, V143, P12, DOI 10.1016/j.cortex.2021.06.011; Lai CLE, 2017, AUTISM RES, V10, P911, DOI 10.1002/aur.1723; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Leung RC, 2016, CHILD NEUROPSYCHOL, V22, P336, DOI 10.1080/09297049.2015.1005066; Liu SC, 2016, INT J CLIN EXP MED, V9, P23363; Meehan TP, 2012, NEUROSCI BIOBEHAV R, V36, P2232, DOI 10.1016/j.neubiorev.2012.08.002; Mehta MA, 2004, J CHILD PSYCHOL PSYC, V45, P293, DOI 10.1111/j.1469-7610.2004.00221.x; Moavero R, 2018, EXPERT OPIN DRUG SAF, V17, P1015, DOI 10.1080/14740338.2018.1518427; Patel J, 2018, PROG BRAIN RES, V241, P1, DOI 10.1016/bs.pbr.2018.10.002; Pellicano E, 2007, DEV PSYCHOL, V43, P974, DOI 10.1037/0012-1649.43.4.974; Pellicano E, 2010, CHILD DEV, V81, P1400, DOI 10.1111/j.1467-8624.2010.01481.x; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Schulte JT, 2018, NEUROSCI BIOBEHAV R, V90, P260, DOI 10.1016/j.neubiorev.2018.05.001; Sohal VS, 2019, MOL PSYCHIATR, V24, P1248, DOI 10.1038/s41380-019-0426-0; Soucher B, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00267; Sprengers JJ, 2021, J AM ACAD CHILD PSY, V60, P865, DOI 10.1016/j.jaac.2020.07.888; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190; van Andel DM, 2020, MOL AUTISM, V11, DOI 10.1186/s13229-020-00335-4; Velikonja T, 2019, JAMA PSYCHIAT, V76, P135, DOI 10.1001/jamapsychiatry.2018.3645; Wang Y, 2017, NEUROPSYCHOL REV, V27, P46, DOI 10.1007/s11065-016-9336-y; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Zhang LL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0692-2";41;4;4;2;6;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;MAR;2024;54;3;;;;;894;904;;10.1007/s10803-022-05841-3;http://dx.doi.org/10.1007/s10803-022-05841-3;;janv-23;11;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;JR5M2;36626004;hybrid, Green Published;;;24/11/2024;WOS:000911956500008;View Full Record in Web of Science
J;"Berg, KL; Acharya, K; Shiu, CS; Msall, ME";;;;"Berg, Kristin L.; Acharya, Kruti; Shiu, Cheng-Shi; Msall, Michael E.";;;Delayed Diagnosis and Treatment Among Children with Autism Who Experience Adversity;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Autism spectrum disorder; Adverse childhood experiences; Diagnosis; National Survey of Children's Health; Access to treatment";"SPECTRUM DISORDER; CHILDHOOD EXPERIENCES; MEDICAL-CARE; DEVELOPMENTAL-DISABILITIES; RESIDENTIAL INSTABILITY; HEALTH-CARE; AGE; PREVALENCE; ACCESS; ABUSE";"The effects of family adverse childhood experiences (ACEs) on timing of ASD diagnoses and receipt of therapies were measured using data from the 2011-2012 National Survey of Children's Health. Parametric accelerated failure time models estimated the relationship between family ACEs and both timing of ASD diagnosis and receipt of therapies among US children (age 2-17 years; N = 1624). Compared to children without family ACEs, the adjusted effects of 1-2 and ae 3 ACEs resulted in prolonged time of diagnoses with time ratios of 1.17 and 1.23. Report of 1-2 and ae 3 ACEs were associated with a 22 and 27% increase in the median age of entry into services. ACEs may pose significant barriers to diagnoses and treatment of children with ASD.";"[Berg, Kristin L.] Temple Univ, Coll Publ Hlth, 1700 N Broad, Philadelphia, PA 19086 USA; [Berg, Kristin L.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Acharya, Kruti] Univ Illinois, Chicago, IL USA; [Shiu, Cheng-Shi] Delaware Cty Community Coll, Media, PA USA; [Msall, Michael E.] Univ Chicago Med, Chicago, IL USA; [Msall, Michael E.] Univ Chicago, Comer Childrens Hosp, Chicago, IL 60637 USA; [Msall, Michael E.] Kennedy Res Ctr Intellectual & Dev Disabil, Chicago, IL USA";"Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago";"Berg, KL (corresponding author), Temple Univ, Coll Publ Hlth, 1700 N Broad, Philadelphia, PA 19086 USA.;Berg, KL (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.";klberg@temple.edu;Shiu, Chengshi/JCF-0637-2023;"Msall, Michael/0000-0003-2037-5769; Berg, Kristin/0000-0003-1452-2005";"Maternal and Child Health Bureau Health Resources and Services Administration, Department of Health and Human Services [R40MC]; [T73 MC11047 HRSA]";"Maternal and Child Health Bureau Health Resources and Services Administration, Department of Health and Human Services(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA));";This study was supported by Grant R40MC Autism Intervention Research Program, from the Maternal and Child Health Bureau Health Resources and Services Administration, Department of Health and Human Services. Dr. Msall and Dr. Acharya's efforts were also supported in part by T73 MC11047 HRSA.;"ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2003, STAT METHODS SURVIVA; [Anonymous], 2011 2012 NAT SURV C; [Anonymous], CURRENT POPULATION R; [Anonymous], 2013, STATA STAT SOFTW REL; [Anonymous], 2016, NAT SURV CHILDR HLTH; Auslander WF, 1997, HEALTH SOC WORK, V22, P190, DOI 10.1093/hsw/22.3.190; Balistreri KS, 2015, MATERN CHILD HLTH J, V19, P2492, DOI 10.1007/s10995-015-1770-6; Berg KL, 2016, DEV MED CHILD NEUROL, V58, P1124, DOI 10.1111/dmcn.13161; Boyle CA, 2011, PEDIATRICS, V127, P1034, DOI 10.1542/peds.2010-2989; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Centers for Disease Control and Prevention (CDC), 2010, MMWR Morb Mortal Wkly Rep, V59, P1609; Chen CY, 2008, J AUTISM DEV DISORD, V38, P489, DOI 10.1007/s10803-007-0416-y; Christensen DL, 2016, J DEV BEHAV PEDIATR, V37, P1, DOI 10.1097/DBP.0000000000000235; Cronholm PF, 2015, AM J PREV MED, V49, P354, DOI 10.1016/j.amepre.2015.02.001; Daniel K L, 2009, Public Health, V123 Suppl 1, pe11, DOI 10.1016/j.puhe.2009.06.002; Daniels AM, 2014, J AM ACAD CHILD PSY, V53, P141, DOI 10.1016/j.jaac.2013.11.002; Desmond M, 2015, SOC SERV REV, V89, P227, DOI 10.1086/681091; Duchon LM, 1999, MED CARE, V37, P1282, DOI 10.1097/00005650-199912000-00011; Esler AN, 2015, J AUTISM DEV DISORD, V45, P2704, DOI 10.1007/s10803-015-2432-7; Fairbrother G, 2005, MED CARE RES REV, V62, P205, DOI 10.1177/1077558704273805; Felitti V.J., 2010, HIDDEN EPIDEMIC IMPA, P77, DOI DOI 10.1017/CBO9780511777042.010; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fountain C, 2011, J EPIDEMIOL COMMUN H, V65, P503, DOI 10.1136/jech.2009.104588; Freedman BH, 2012, J AUTISM DEV DISORD, V42, P539, DOI 10.1007/s10803-011-1269-y; Goin-Kochel RP, 2006, AUTISM, V10, P439, DOI 10.1177/1362361306066601; Hartley SL, 2010, J FAM PSYCHOL, V24, P449, DOI 10.1037/a0019847; Henley SJ, 2014, MMWR-MORBID MORTAL W, V63, P1; Hertz-Picciotto I, 2009, EPIDEMIOLOGY, V20, P84, DOI 10.1097/EDE.0b013e3181902d15; Howlin P, 1999, DEV MED CHILD NEUROL, V41, P834, DOI 10.1017/S0012162299001656; Janicke DM, 2001, MED CARE, V39, P990, DOI 10.1097/00005650-200109000-00009; Jelleyman T, 2008, J EPIDEMIOL COMMUN H, V62, P584, DOI 10.1136/jech.2007.060103; Kullgren JT, 2012, HEALTH SERV RES, V47, P462, DOI 10.1111/j.1475-6773.2011.01308.x; Larsson HJ, 2005, AM J EPIDEMIOL, V161, P916, DOI 10.1093/aje/kwi123; Levy SE, 2010, J DEV BEHAV PEDIATR, V31, P267, DOI 10.1097/DBP.0b013e3181d5d03b; Maïano C, 2016, AUTISM RES, V9, P601, DOI 10.1002/aur.1568; Mandell DS, 2009, AM J PUBLIC HEALTH, V99, P493, DOI 10.2105/AJPH.2007.131243; Mandell DS, 2002, J AM ACAD CHILD PSY, V41, P1447, DOI 10.1097/00004583-200212000-00016; Mandell DS, 2005, CHILD ABUSE NEGLECT, V29, P1359, DOI 10.1016/j.chiabu.2005.06.006; Mandell DS, 2005, PEDIATRICS, V116, P1480, DOI 10.1542/peds.2005-0185; Mazurek MO, 2014, J DEV BEHAV PEDIATR, V35, P561, DOI 10.1097/DBP.0000000000000097; Patel K, 2006, PHARM STAT, V5, P213, DOI 10.1002/pst.213; Roberts AL, 2016, AUTISM, V20, P26, DOI 10.1177/1362361314566049; Rosenberg Rebecca E, 2011, Autism Res Treat, V2011, P405849, DOI 10.1155/2011/405849; Shattuck PT, 2009, J AM ACAD CHILD PSY, V48, P474, DOI 10.1097/CHI.0b013e31819b3848; Starfield B, 2004, PEDIATRICS, V113, P1493; Twyman KA, 2009, RES AUTISM SPECT DIS, V3, P489, DOI 10.1016/j.rasd.2008.10.002; Valicenti-McDermott M, 2012, J PEDIATR-US, V161, P554, DOI 10.1016/j.jpeds.2012.05.012; Wiggins LD, 2006, J DEV BEHAV PEDIATR, V27, pS79, DOI 10.1097/00004703-200604002-00005; Young Margaret B., 2012, Morbidity and Mortality Weekly Report, V61, P1";50;31;39;1;17;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;JAN;2018;48;1;;;;;45;54;;10.1007/s10803-017-3294-y;http://dx.doi.org/10.1007/s10803-017-3294-y;;;10;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;FS4SX;28864845;;;;24/11/2024;WOS:000419784300005;View Full Record in Web of Science
J;"Lee, SH; Shin, S; Kim, TH; Kim, SM; Do, TY; Park, S; Lee, B; Shin, HJ; Lee, J; Lee, JY; Chang, GT";;;;"Lee, Sun Haeng; Shin, Seungwon; Kim, Tae-hun; Kim, Sang Min; Do, Tae Yoon; Park, Sulgi; Lee, Boram; Shin, Hye Jin; Lee, Jihong; Lee, Jin Yong; Chang, Gyu Tae";;;Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial;TRIALS;;;English;Article;;;;;;"Herbal medicine; Acupuncture; Autism spectrum disorder; Randomized controlled trial; Ukgansangajinpibanha";"BEHAVIOR CHECKLIST; RELIABILITY; YOKUKANSAN; SYMPTOMS; VALIDITY; ADOLESCENTS; PREVALENCE; CONSTRUCT; NETWORK";"BackgroundAutism spectrum disorder (ASD) is characterized by continuous impairment in communication and social interaction and by limited and repetitive behaviors, interests, or activities. Behavioral, educational, and pharmaceutical interventions have been shown to reduce behavioral disabilities, improve verbal/non-verbal communication, and help patients acquire self-reliance skills. However, there has been a lack of systematic verification and consensus regarding the treatment of the core symptoms of ASD because of its unclear etiology. Ukgansangajinpibanha (UGSJB), a legitimately prescribed herbal medicine for nervousness, insomnia, night crying, and malnutrition in South Korea and Japan, has been used for angry, sensitive, nervous, and unsettled children with ASD.Methods/designThis trial is a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, clinical trial. The 4- to 6-year-old children with ASD will be randomly assigned to following groups: A UGSJB granule with acupuncture, twice daily (n=120)A placebo group with acupuncture, twice daily (n=120).The following outcome measures will be used: behavior by the Childhood Autism Rating Scale, Autism Behavior Checklist, and Aberrant Behavior Checklist; social maturity by the Social Maturity Scale; quality of life by the Child Health Questionnaire and EuroQoL Five-dimension Five-level Youth; and parental stress by the Parenting Stress Index at baseline and at 6, 12, and 24weeks after the beginning of treatment.In addition, to evaluate safety, we will investigate the adverse reactions that may be caused by UGSJB granule. Finally, we will make an economic evaluation of UGSJB for the treatment of ASD.DiscussionWe prepared a well-designed clinical trial to investigate the safety and effectiveness of UGSJB on ASD symptoms compared with placebo treatment. The results from this study will provide clinical evidence on the safety, effectiveness, and economic value of UGSJB combined with acupuncture in children with ASD.Trial registrationClinical Research Information Service: KCT0003007 (registered on April 5, 2018)";"[Lee, Sun Haeng; Kim, Sang Min; Do, Tae Yoon; Park, Sulgi; Lee, Boram; Shin, Hye Jin; Lee, Jihong; Lee, Jin Yong; Chang, Gyu Tae] Kyung Hee Univ, Dept Clin Korean Med, Grad Sch, 26 Kyungheedae Ro, Seoul 02447, South Korea; [Lee, Sun Haeng; Do, Tae Yoon; Park, Sulgi; Lee, Jin Yong] Kyung Hee Univ, Dept Pediat Korean Med, Korean Med Hosp, Med Ctr, 23 Kyungheedae Ro, Seoul 02447, South Korea; [Shin, Seungwon] Kyung Hee Univ, Dept Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea; [Kim, Tae-hun] Kyung Hee Univ, Korean Med Clin Trial Ctr, Korean Med Hosp, Med Ctr, 23 Kyungheedae Ro, Seoul 02447, South Korea; [Shin, Hye Jin; Lee, Jihong; Chang, Gyu Tae] Kyung Hee Univ Hosp Gangdong, Dept Pediat Korean Med, 892 Dongnam Ro, Seoul 05278, South Korea";"Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University Hospital";"Chang, GT (corresponding author), Kyung Hee Univ, Dept Clin Korean Med, Grad Sch, 26 Kyungheedae Ro, Seoul 02447, South Korea.;Chang, GT (corresponding author), Kyung Hee Univ Hosp Gangdong, Dept Pediat Korean Med, 892 Dongnam Ro, Seoul 05278, South Korea.";"civil011@empas.com; gtchang@khu.ac.kr";"Lee, Bo Ram/AAQ-9275-2021; Shin, Seungwon/Q-4320-2016; CHANG, GYU/AAI-1906-2020; Lee, Sun Haeng/AAZ-3748-2021";"Lee, Boram/0000-0003-1679-0644; Lee, Sun Haeng/0000-0002-9454-4126";Traditional Korean Medicine R&D program - Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI) [HB16C0075];Traditional Korean Medicine R&D program - Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI);This study was supported by the Traditional Korean Medicine R&D program funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI) (HB16C0075). This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.;"Abidin RR, 2008, GUIDE KOREAN PARENTI; Aizawa R, 2002, PSYCHIAT CLIN NEUROS, V56, P303, DOI 10.1046/j.1440-1819.2002.01006.x; Almaali HMMA, 2017, J ACUPUNCT MERIDIAN, V10, P375, DOI 10.1016/j.jams.2017.09.001; AMAN MG, 1987, AM J MENT DEF, V92, P237; AMAN MG, 1985, AM J MENT DEF, V89, P492; [Anonymous], 2015, HDB KAMP TREATM CHIL; [Anonymous], 2016, ASS DIAGN INT AUT SP; [Anonymous], 1995, SOCIAL MATURITY SCAL; [Anonymous], 2015, Diagnostic and statistical manual of mental disorders, V5th; Bang M, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8614680; ???, 2017, [The Journal of Pediatrics of Korean Medicine, ??????????], V31, P49; Cho Ki-Ho, 2018, [Journal of Korean Medicine, ???????], V39, P17, DOI 10.13048/jkm.18021; Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1; Christensen DL, 2016, J DEV BEHAV PEDIATR, V37, P1, DOI 10.1097/DBP.0000000000000235; Eaves RC, 2006, PSYCHOL SCHOOLS, V43, P129, DOI 10.1002/pits.20122; Fombonne E, 2009, PEDIATR RES, V65, P591, DOI 10.1203/PDR.0b013e31819e7203; Fujiwara H, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1710-7; Ito A, 2013, MOLECULES, V18, P10014, DOI 10.3390/molecules180810014; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; KRUG DA, 1980, J CHILD PSYCHOL PSYC, V21, P221, DOI 10.1111/j.1469-7610.1980.tb01797.x; Lee B, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1057539; Liu C, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014880; Lyra L, 2017, SAO PAULO MED J, V135, P192, DOI 10.1590/1516-3180.2017.0058200317; McElhanon BO, 2014, PEDIATRICS, V133, P872, DOI 10.1542/peds.2013-3995; Miyaoka T, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-215; Muneoka K, 2015, CEREBELLUM, V14, P86, DOI 10.1007/s12311-014-0611-2; Murayama C, 2015, MOLECULES, V20, P14959, DOI 10.3390/molecules200814959; Raat H, 2002, J CLIN EPIDEMIOL, V55, P67, DOI 10.1016/S0895-4356(01)00411-5; Ravens-Sieberer U, 2010, QUAL LIFE RES, V19, P1487, DOI 10.1007/s11136-010-9706-5; Sato R, 2002, PSYCHIATR, V20, P693; Scahill L, 2013, J AUTISM DEV DISORD, V43, P739, DOI 10.1007/s10803-012-1689-3; Shin M.S., 1998, Korean Journal of Clinical Psychology, V17, P1; Shin SH, 2019, 2019 SPRING C WORKSH; Sun YB., 2016, LIAONING J TRADITION, V43, P2105; Tamano H, 2016, EXP ANIM TOKYO, V65, P353, DOI 10.1538/expanim.16-0028; Wake R, 2016, CNS NEUROL DISORD-DR, V15, P551, DOI 10.2174/1871527315666160413120541; Wake R, 2013, J CHILD ADOL PSYCHOP, V23, P329, DOI 10.1089/cap.2012.0108; Yousefi Negin, 2015, Iran J Psychiatry, V10, P144; Zhou N., 2015, J New Chin Med, V47, P200";39;6;6;3;18;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;1745-6215;;;TRIALS;Trials;juil-15;2019;20;;;;;;;;434;10.1186/s13063-019-3537-7;http://dx.doi.org/10.1186/s13063-019-3537-7;;;11;Medicine, Research & Experimental;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Research & Experimental Medicine;IJ2MQ;31307524;Green Published, gold;;;24/11/2024;WOS:000475739900005;View Full Record in Web of Science
J;"Reichow, B; Volkmar, FR; Bloch, MH";;;;"Reichow, Brian; Volkmar, Fred R.; Bloch, Michael H.";;;Systematic Review and Meta-analysis of Pharmacological Treatment of the Symptoms of Attention-Deficit/Hyperactivity Disorder in Children with Pervasive Developmental Disorders;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Autism; Pervasive developmental disorder; Attention deficit/hyperactivity disorder; Methylphenidate; Meta-analysis; Atomoxetine; Clonidine; ADHD; ASD; Autism spectrum disorder; PDD; PDD-NOS";"DEFICIT HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS; PSYCHIATRIC-DISORDERS; MEDICATION USE; ADOLESCENTS; METHYLPHENIDATE; ATOMOXETINE; EFFICACY; PLACEBO; PREVALENCE";Many children with pervasive developmental disorders (PDD) exhibit behaviors and symptoms of attention-deficit/hyperactivity disorder (ADHD). We sought to determine the relative efficacy of medications for treating ADHD symptoms in children with PDD by identifying all double-blind, randomized, placebo-controlled trials examining the efficacy of medications for treating ADHD symptoms in children with PDD. We located seven trials involving 225 children. A random effects meta-analysis of four methylphenidate trials showed methylphenidate to be effective for treating ADHD symptoms in children with PDD (ES = .67). Several adverse events were greater for children were taking methylphenidate compared to placebo. An individual trial of clonidine and two trials of atomoxetine suggest these agents may also be effective in treating ADHD symptoms in children with PDD.;"[Reichow, Brian; Volkmar, Fred R.; Bloch, Michael H.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06519 USA";Yale University;Reichow, B (corresponding author), Yale Univ, Sch Med, Ctr Child Study, 230 South Frontage Rd, New Haven, CT 06519 USA.;brian.reichow@yale.edu;"Volkmar, Fred/AEB-0666-2022; Reichow, Brian/R-8160-2019; Bloch, Michael/O-7845-2017";Reichow, Brian/0000-0001-8305-3105;;;;"Aman MG, 2005, ARCH GEN PSYCHIAT, V62, P1266; Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P869, DOI 10.1089/cap.2005.15.869; [Anonymous], 2011, Meta-analysis Macros for SAS, SPSS, and Stata; [Anonymous], CMAJ; [Anonymous], COMPREHENSIVE METAAN; [Anonymous], 2000, DIAGN STAT MAN, V4th; Arnold LE, 2006, J AM ACAD CHILD PSY, V45, P1196, DOI 10.1097/01.chi.0000231976.28719.2a; Cheng JYW, 2007, PSYCHOPHARMACOLOGY, V194, P197, DOI 10.1007/s00213-007-0840-x; Conners CK., 2001, Conner's Rating Scales-Revised (CSR-R) Technical Manual (includes auxilliary scales: CADS-P and CADS-T); Connor DF, 1999, J AM ACAD CHILD PSY, V38, P1551, DOI 10.1097/00004583-199912000-00017; DuPaul GJ, 1998, J PSYCHOPATHOL BEHAV, V20, P83, DOI 10.1023/A:1023087410712; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; Frazier J.A., 2001, Journal of Attentional Disorders, V4, P203; Gargaro BA, 2011, NEUROSCI BIOBEHAV R, V35, P1081, DOI 10.1016/j.neubiorev.2010.11.002; Ghuman JK, 2009, J CHILD ADOL PSYCHOP, V19, P329, DOI 10.1089/cap.2008.0137; Grzadzinski R, 2011, J AUTISM DEV DISORD, V41, P1178, DOI 10.1007/s10803-010-1135-3; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; Harfterkamp M, 2012, J AM ACAD CHILD PSY, V51, P733, DOI 10.1016/j.jaac.2012.04.011; Hazell P, 2007, J PAEDIATR CHILD H, V43, P19, DOI 10.1111/j.1440-1754.2007.00995.x; Hedges LV., 2014, STAT METHODS META AN; Holtmann M, 2007, PSYCHOPATHOLOGY, V40, P172, DOI 10.1159/000100007; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; JASELSKIS CA, 1992, J CLIN PSYCHOPHARM, V12, P322; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Lecavalier L, 2006, J AUTISM DEV DISORD, V36, P1101, DOI 10.1007/s10803-006-0147-5; Lee DO, 2006, J CHILD ADOL PSYCHOP, V16, P737, DOI 10.1089/cap.2006.16.737; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; McPheeters ML, 2011, PEDIATRICS, V127, pE1312, DOI 10.1542/peds.2011-0427; Moher D, 2010, INT J SURG, V8, P658, DOI [10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2700]; Oswald DP, 2007, J CHILD ADOL PSYCHOP, V17, P348, DOI 10.1089/cap.2006.17303; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; Rosenberg RE, 2010, J AUTISM DEV DISORD, V40, P342, DOI 10.1007/s10803-009-0878-1; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Sinzig J, 2009, J ATTEN DISORD, V13, P117, DOI 10.1177/1087054708326261; Spencer T, 1996, J AM ACAD CHILD PSY, V35, P409, DOI 10.1097/00004583-199604000-00008; Sterne JA, 2008, COCHRANE HDB SYSTEMA, P297, DOI [DOI 10.1002/9780470712184.FMATTER, 10.1002/9780470712184.ch10]; Stigler KA, 2004, J CHILD ADOL PSYCHOP, V14, P49, DOI 10.1089/104454604773840481; Swanson J.M., 1992, The SNAP-IV Rating Scale; van der Meer JMJ, 2012, J AM ACAD CHILD PSY, V51, P1160, DOI 10.1016/j.jaac.2012.08.024; Yerys BE, 2009, AUTISM RES, V2, P322, DOI 10.1002/aur.103";41;79;83;1;44;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;OCT;2013;43;10;;;;;2435;2441;;10.1007/s10803-013-1793-z;http://dx.doi.org/10.1007/s10803-013-1793-z;;;7;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;217FD;23468071;Green Accepted;;;24/11/2024;WOS:000324341500018;View Full Record in Web of Science
J;"Geertjens, L; Cristian, G; Haspels, E; Ramautar, J; van der Wilt, GJ; Verhage, M; Bruining, H";;;;"Geertjens, Lisa; Cristian, Gianina; Haspels, Eva; Ramautar, Jennifer; van der Wilt, Gert Jan; Verhage, Matthijs; Bruining, Hilgo";;;Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol;BMC PSYCHIATRY;;;English;Article;;;;;;"Bumetanide; Autism spectrum disorder; Neurodevelopmental disorders; Children";"GABA; SCALE; MODEL";Background: Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs). Due to their specific actions, these kinds of interventions will only be effective in particular subsets of patients. To anticipate stratified application, we recently completed three bumetanide trials each focusing on different stratification strategies with the additional objective of deriving the most optimal endpoints. Here we publish the protocol of the post-trial access combined cohort study to confirm previous effects and stratification strategies in the trial cohorts and in new participants. Method/design: Participants of the three previous cohorts and a new cohort will be subjected to 6 months bumetanide treatment using multiple baseline Single Case Experimental Designs. The primary outcome is the change, relative to baseline, in a set of patient reported outcome measures focused on direct and indirect effects of sensory processing difficulties. Secondary outcome measures include the conventional questionnaires'social responsiveness scale,' 'repetitive behavior scale,' 'sensory profile' and 'aberrant behavior scale. Resting-state EEG measurements will be performed at several time-points including at Tmax after the first administration. Assessment of cognitive endpoints will be conducted using the novel Emma Tool box, an in-house designed battery of computerized tests to measure neurocognitive functions in children. Discussion: This study aims to replicate previously shown effects of bumetanide in NDD subpopulations, validate a recently proposed treatment prediction effect methodology and refine endpoint measurements.;"[Geertjens, Lisa; Cristian, Gianina; Haspels, Eva; Ramautar, Jennifer; Bruining, Hilgo] Amsterdam UMC, N You Neurodev Precis Ctr, Amsterdam Reprod & Dev, Amsterdam Neurosci, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands; [Geertjens, Lisa; Cristian, Gianina; Haspels, Eva; Ramautar, Jennifer; Bruining, Hilgo] Vrije Univ Amsterdam, Emma Childrens Hosp, Amsterdam UMC, Child & Adolescent Psychiat & Psychosocial Care, De Boelelaan 1105, NL-1081 HV Amsterdam, Netherlands; [Cristian, Gianina; van der Wilt, Gert Jan] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, NL-6500 HB Nijmegen, Netherlands; [Haspels, Eva; Bruining, Hilgo] Ctr Child & Adolescent Psychiat, Levvel, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands; [Verhage, Matthijs] Amsterdam UMC Locat VUmc, Dept Human Genet, Ctr Neurogen & Cognit Res CNCR, De Boelelaan 1105, NL-1081 HV Amsterdam, Netherlands; [Verhage, Matthijs] Vrije Univ Amsterdam, Dept Funct Genom, Ctr Neurogen & Cognit Res CNCR, de Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands; [Verhage, Matthijs] Amsterdam UMC Locat VUmc, de Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands";"Vrije Universiteit Amsterdam; University of Amsterdam; Emma Children's Hospital; Vrije Universiteit Amsterdam; Radboud University Nijmegen; Vrije Universiteit Amsterdam";"Bruining, H (corresponding author), Amsterdam UMC, N You Neurodev Precis Ctr, Amsterdam Reprod & Dev, Amsterdam Neurosci, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands.;Bruining, H (corresponding author), Vrije Univ Amsterdam, Emma Childrens Hosp, Amsterdam UMC, Child & Adolescent Psychiat & Psychosocial Care, De Boelelaan 1105, NL-1081 HV Amsterdam, Netherlands.;Bruining, H (corresponding author), Ctr Child & Adolescent Psychiat, Levvel, Meibergdreef 5, NL-1105 AZ Amsterdam, Netherlands.";h.bruining@amsterdamumc.nl;"Cristian, Gianina/JCO-3727-2023; van der Wilt, G.J./H-8120-2014";Cristian, Gianina/0000-0001-6905-5403;"ZonMW (Goed gebruik genees-middelen); Hersenstichting (Sooner better treatment program); Dutch national research agenda";"ZonMW (Goed gebruik genees-middelen); Hersenstichting (Sooner better treatment program); Dutch national research agenda";This study is a continuation of the aforementioned bumetanide trials for which we previously received funding form ZonMW (Goed gebruik genees-middelen) and the Hersenstichting (Sooner better treatment program). In addition, we received funding from the Dutch national research agenda (in Dutch: nationale wetenschapsagenda, NWA-ORC) which will support the cost to develop the iPSC experiments. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920; Ben-Ari Y, 2012, NEUROSCIENTIST, V18, P467, DOI 10.1177/1073858412438697; Bouwmeester CJ, SINGLE CASE DESIGNS; Bruining H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65500-4; Bruining H, 2015, PEDIATRICS, V136, pE539, DOI 10.1542/peds.2014-4133; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Deidda G, 2015, NAT MED, V21, P318, DOI 10.1038/nm.3827; Ermer J, 1998, AM J OCCUP THER, V52, P283, DOI 10.5014/ajot.52.4.283; Hoogeboom TJ, 2012, BMJ OPEN, V2, DOI [10.1136/bmjopen-2012-001161, 10.1136/bmjopen-2013-003563]; Jandoc R, 2015, J CLIN EPIDEMIOL, V68, P950, DOI 10.1016/j.jclinepi.2014.12.018; Juarez-Martinez EL., 2021, BIOL PSYCHIAT-COGN N; Kharod SC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00310; Koehler MJ, 1998, J EDUC COMPUT RES, V18, P123, DOI 10.2190/HFLM-ER1P-6J25-V0XD; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lemonnier E, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.10; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; Schulte JT, 2018, NEUROSCI BIOBEHAV R, V90, P260, DOI 10.1016/j.neubiorev.2018.05.001; Sprengers JJ, 2021, J AM ACAD CHILD PSY, V60, P865, DOI 10.1016/j.jaac.2020.07.888; van Andel DM, 2020, MOL AUTISM, V11, DOI 10.1186/s13229-020-00335-4; Zhang LL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0692-2";24;1;1;1;3;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;juil-07;2022;22;1;;;;;;;452;10.1186/s12888-022-04033-8;http://dx.doi.org/10.1186/s12888-022-04033-8;;;11;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;2S6BL;35799144;gold, Green Published;;;24/11/2024;WOS:000821875300002;View Full Record in Web of Science
J;"Idris, S; van Pelt, BJ; Jagersma, G; Duvekot, J; Maras, A; van der Ende, J; van Haren, N; Greaves-Lord, K";;;;"Idris, Sakinah; van Pelt, Bjorn Jaime; Jagersma, Gabrine; Duvekot, Jorieke; Maras, Athanasios; van der Ende, Jan; van Haren, Neeltje; Greaves-Lord, Kirstin";;;A randomized controlled trial to examine the effectiveness of the Dutch version of the Program for the Education and Enrichment of Relational Skills (PEERS®);BMC PSYCHIATRY;;;English;Article;;;;;;"Autism Spectrum Disorder; Adolescence; PEERS (R); Social skills intervention; Behavioral observation";"AUTISM SPECTRUM DISORDERS; FALSE DISCOVERY RATE; SOCIAL-SKILLS; TRAINING-PROGRAM; ADOLESCENTS; ADAPTATION; TEENS";"Background: This study examines the effectiveness of the culturally adapted Dutch version of The Program for the Education and Enrichment of Relational Skills (PEERS (R)), utilizing a randomized control trial (RCT) with an active treatment control condition. Methods: 106 adolescents with ASD, aged 12-18 years, were randomly assigned to one of two group interventions: the experimental condition (PEERS (R); n = 54) or the active treatment control condition (Regulation, Organization and Autonomy Didactics; ROAD; n = 52). Effects of interventions on social skills were primarily assessed using an observational measure (CASS - Contextual Assessment Social Skills). Secondary indices of social skills were self, parent and teacher reported questionnaire data (i.e., Social Responsiveness Scale; SRS, and Social Skills Improvement System; SSIS). Treatment satisfaction was also obtained from adolescents and their parents. Results: Results on the observational measure of social skills revealed improvements in positive affect, overall quality of rapport, as well as starting and ending a conversation, irrespective of condition. Compared to ROAD, PEERS (R) participants showed increased overall self-reported social skills (SSIS). Parent reports showed decreased overall social skill impairment (SRS) as well as improved social communication (SSIS subscale), with significantly more progress in the PEERS (R) group. Furthermore, parents of adolescents in the PEERS (R) group were significantly more satisfied with the intervention (M = 8.20, SD = 1.46) than parents of adolescents in the ROAD group (M = 7.52, SD = 1.45). The self-reported treatment satisfaction of adolescents did not differ between conditions. Teacher data showed decreased social skill impairment as measured with the SRS, irrespective of condition. Conclusions: This study reveals promising indications that the Dutch version of PEERS (R) enhances social skills in adolescents with ASD. Yet, further research is needed into how effectiveness can be optimized.";"[Idris, Sakinah; van Pelt, Bjorn Jaime; Duvekot, Jorieke; van der Ende, Jan; van Haren, Neeltje; Greaves-Lord, Kirstin] Erasmus MC Sophia Childrens Hosp, Dept Child & Adolescent Psychiat Psychol, Wytemaweg 8, NL-3015 CN Rotterdam, Netherlands; [Idris, Sakinah] Univ Teknol MARA, Fac Med, Dept Psychiat, Batu Caves 68100, Selangor, Malaysia; [van Pelt, Bjorn Jaime; Maras, Athanasios; Greaves-Lord, Kirstin] Yulius Org Mental Hlth, Burg De Raadtsingel 93c, NL-3311 JG Dordrecht, Netherlands; [Jagersma, Gabrine] Inst Mental Hlth, GGZ Rivierduinen Children & Youth, Leiden, Netherlands; [Greaves-Lord, Kirstin] Autism Team Northern Netherlands, Jonx Dept Youth Mental Hlth, Groningen, Netherlands; [Greaves-Lord, Kirstin] Autism Lentis Psychiat Inst, Groningen, Netherlands; [Greaves-Lord, Kirstin] Univ Groningen, Dept Psychol, Clin Psychol & Expt Psychopathol Unit, Groningen, Netherlands";"Erasmus University Rotterdam; Erasmus MC; University of Groningen";"Idris, S; van Pelt, BJ; Greaves-Lord, K (corresponding author), Erasmus MC Sophia Childrens Hosp, Dept Child & Adolescent Psychiat Psychol, Wytemaweg 8, NL-3015 CN Rotterdam, Netherlands.;Idris, S (corresponding author), Univ Teknol MARA, Fac Med, Dept Psychiat, Batu Caves 68100, Selangor, Malaysia.;van Pelt, BJ; Greaves-Lord, K (corresponding author), Yulius Org Mental Hlth, Burg De Raadtsingel 93c, NL-3311 JG Dordrecht, Netherlands.;Greaves-Lord, K (corresponding author), Autism Team Northern Netherlands, Jonx Dept Youth Mental Hlth, Groningen, Netherlands.;Greaves-Lord, K (corresponding author), Autism Lentis Psychiat Inst, Groningen, Netherlands.;Greaves-Lord, K (corresponding author), Univ Groningen, Dept Psychol, Clin Psychol & Expt Psychopathol Unit, Groningen, Netherlands.";k.greaves-lord@rug.nl;"IDRIS, SAKINAH/GWC-3338-2022; van Haren, Neeltje/AAC-7656-2020";"Idris (Dr.), Sakinah/0000-0002-3189-986X; van Pelt, BJ/0000-0003-0887-7440";Dutch philanthropic foundation;Dutch philanthropic foundation;The study is supported and funded by a Dutch philanthropic foundation that is committed to improving current diagnostics, training, and treatment in adolescents and (young) adults with autism. The Foundation has had no influence in the design of the study, data collection, analysis or interpretation of data, publication of results or writing this manuscript.;"[Anonymous], 2010, THESIS; Bauminger N, 2008, J ABNORM CHILD PSYCH, V36, P135, DOI 10.1007/s10802-007-9156-x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernal G, 2009, PROF PSYCHOL-RES PR, V40, P361, DOI 10.1037/a0016401; Bruni TP, 2014, J PSYCHOEDUC ASSESS, V32, P365, DOI 10.1177/0734282913517525; Constantino J. N., 2012, SOCIAL RESPONSIVENES; DAmico M, 2009, ASSESSMENT CREATIVE; Davenport M, 2018, RES AUTISM SPECT DIS, V52, P23, DOI 10.1016/j.rasd.2018.05.003; Dolan BK, 2016, J AUTISM DEV DISORD, V46, P2251, DOI 10.1007/s10803-016-2738-0; Falkmer T, 2013, EUR CHILD ADOLES PSY, V22, P329, DOI 10.1007/s00787-013-0375-0; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Frankel F, 2010, J AUTISM DEV DISORD, V40, P827, DOI 10.1007/s10803-009-0932-z; Frazier TW, 2014, AUTISM, V18, P31, DOI 10.1177/1362361313500382; Gresham FM., 2008, SOCIAL SKILLS IMPROV; Hox J. J., 2010, MULTILEVEL ANAL TECH, V2nd, DOI DOI 10.4324/9780203852279; Idris SB, 2020, RES AUTISM SPECT DIS, V78, DOI 10.1016/j.rasd.2020.101629; Jagersma GA., 2018, EMPIRISCH ONDERZOEK, V17, P31; Laugeson EA, 2011, SOCIAL SKILLS FOR TEENAGERS WITH DEVELOPMENTAL AND AUTISM SPECTRUM DISORDERS, P1; Laugeson EA, 2012, J AUTISM DEV DISORD, V42, P1025, DOI 10.1007/s10803-011-1339-1; Laugeson EA, 2009, J AUTISM DEV DISORD, V39, P596, DOI 10.1007/s10803-008-0664-5; Lord C., 2012, AUTISM DIAGNOSTIC OB; Mandelberg J, 2014, J MENT HEALTH RES IN, V7, P45, DOI 10.1080/19315864.2012.730600; Maras A., 2015, POWERCOACHING PRAKTI; Marchica L., 2016, J ED SOCIAL POLICY, V3, P54; Mohr DC, 2009, PSYCHOTHER PSYCHOSOM, V78, P275, DOI 10.1159/000228248; Rabin SJ, 2021, J CLIN CHILD ADOLESC, V50, P933, DOI 10.1080/15374416.2020.1796681; Rabin SJ, 2018, AUTISM RES, V11, P1187, DOI 10.1002/aur.1974; Ratto AB, 2011, J AUTISM DEV DISORD, V41, P1277, DOI 10.1007/s10803-010-1147-z; Roeyers H., 2011, SRS Screeningslijst voor autismespectrumstoornissen. Handleiding; Schohl KA, 2014, J AUTISM DEV DISORD, V44, P532, DOI 10.1007/s10803-013-1900-1; Shum KKM, 2019, J AUTISM DEV DISORD, V49, P527, DOI 10.1007/s10803-018-3728-1; Smith TB, 2011, J CLIN PSYCHOL, V67, P166, DOI 10.1002/jclp.20757; van Pelt BJ, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-02650-9; Verhoeven KJF, 2005, OIKOS, V108, P643, DOI 10.1111/j.0030-1299.2005.13727.x; Visser K, 2013, EUR CHILD ADOLES PSY, V22, pS209; Wechsler D., 1999, Wechsler Abbreviated Scale of Intelligence (Norwegian version); Wechsler D, 2003, WAIS; Yamada T, 2020, J AUTISM DEV DISORD, V50, P976, DOI 10.1007/s10803-019-04325-1; Yoo HJ, 2014, AUTISM RES, V7, P145, DOI 10.1002/aur.1354";39;10;12;2;13;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-244X;;BMC PSYCHIATRY;BMC Psychiatry;APR 22;2022;22;1;;;;;;;293;10.1186/s12888-022-03913-3;http://dx.doi.org/10.1186/s12888-022-03913-3;;;16;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;0S5XE;35459118;gold, Green Published;;;24/11/2024;WOS:000786345500007;View Full Record in Web of Science
J;"Wong, CM; Tan, CS; Riard, N; Padmini, YS; Daniel, LM; Prasath, A; Tan, AM; Tan, TC; Sultana, R; Lam, JCM";;;;"Wong, Chui Mae; Tan, Charmain Samantha; Riard, Natasha; Padmini, Yeleswarapu Sita; Daniel, Lourdes Mary; Prasath, Arun; Tan, Ah. Moy; Tan, Thiam Chye; Sultana, Rehena; Lam, Joyce Ching Mei";;;Autologous umbilical cord blood infusion for the treatment of autism in young children: A within-subjects open label study on safety (assessed via caregiver report) and efficacy;AUTISM RESEARCH;;;English;Article;;;;;;"autism spectrum disorder; clinical trial; cord blood; developmental biology; stem cells";"STEM-CELLS; SPECTRUM; SCALE";This study aimed to document the safety and efficacy of a single infusion of autologous umbilical cord blood (UCB) in 20 autistic children aged 24-72 months. A pre-post treatment within-subjects open label design was used. At T = 0, 6, 12, and 18 months, participants underwent detailed and structured safety evaluations (via caregiver report), Vineland Adaptive Behavior Scale (Vineland-3), Stanford Binet Intelligence Scale (SB-5), Expressive One-Word Picture Vocabulary Test, Brief Observation of Social Communication Change (BOSCC), Pervasive Developmental Disorder-Behavior Inventory, Repetitive Behavior Scale-Revised, Sensory Experience Questionnaire (SEQ-2.1), Child Behavior Checklist, Clinical Global Impression-Severity and Improvement (CGI-I) Scales, and eye-gaze tracking. UCB infusion was conducted at T = 6 months, hence, 0-6 months was the control period, and 6-18 months the follow-up period. Of 20 children recruited, 19 completed the study and 1 was withdrawn due to UCB not meeting quality control criteria for infusion. There were 15 males and 4 females with an overall mean (SD) age of 4.15 (0.62) years. Mean (SD) cell dose administered was 38.16 (9.82) million cells/kg. None suffered serious adverse events although there were mild behavioral side effects and one unit grew coagulase negative staphylococcus from a post-thaw sample. There were no significant differences in Vineland-3, SB-5, BOSCC, and SEQ-2.1 scores at T = 12 and T = 18 months. Twelve participants had T = 18 CGI-I scores of 2-3 (minimally to much improved), seven participants had scores of 4 (no change). Autologous UCB infusion in autistic children is generally safe but not without risks, including that of infection. In this within-subjects study, some children showed global symptom improvements while others showed no change. Stem cell therapies for autism should only be conducted under strict clinical trial conditions with clear risk discussions. This open label clinical trial investigated changes in language, social communication, autism symptoms, behavior, and eye-gaze tracking in 20 autistic children, comparing a period when they were on regular behavioral interventions to a period after they had received an infusion of their own cord blood. Nineteen children completed the study, as one had to be withdrawn due to the cord blood unit not meeting quality control criteria to be safe enough for infusion. Although cord blood infusion was found to be generally safe, some children had mild temporary side effects affecting their behavior (increased repetitive behaviors, aggression/irritability, hyperactivity, mood swings, sleep problems). One child's cord blood unit sample also showed bacterial growth, although that child remained well after the infusion. Some children showed global symptom improvements while others showed no change. Stem cell therapies for autism should therefore only be conducted within clinical trials with clear risk discussions, including that of infection.;"[Wong, Chui Mae; Tan, Charmain Samantha; Riard, Natasha; Padmini, Yeleswarapu Sita; Daniel, Lourdes Mary] KK Womens & Childrens Hosp KKH, Dept Child Dev, 100 Bukit Timah Rd, Singapore 229899, Singapore; [Wong, Chui Mae; Padmini, Yeleswarapu Sita; Daniel, Lourdes Mary; Tan, Ah. Moy; Lam, Joyce Ching Mei] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore; [Wong, Chui Mae; Padmini, Yeleswarapu Sita; Daniel, Lourdes Mary; Tan, Ah. Moy; Sultana, Rehena; Lam, Joyce Ching Mei] Duke NUS Med Sch, Singapore, Singapore; [Wong, Chui Mae; Padmini, Yeleswarapu Sita; Daniel, Lourdes Mary; Tan, Ah. Moy; Lam, Joyce Ching Mei] Lee Kong Chian Sch Med, Singapore, Singapore; [Prasath, Arun] Singapore Cord Blood Bank, Singapore, Singapore; [Tan, Ah. Moy; Lam, Joyce Ching Mei] KK Womens & Childrens Hosp, Childrens Blood & Canc Ctr, Singapore, Singapore; [Tan, Thiam Chye] KK Womens & Childrens Hosp, Dept Obstet & Gynaecol, Singapore, Singapore";"KK Women's & Children's Hospital; National University of Singapore; National University of Singapore; Nanyang Technological University; KK Women's & Children's Hospital; KK Women's & Children's Hospital";Wong, CM (corresponding author), KK Womens & Childrens Hosp KKH, Dept Child Dev, 100 Bukit Timah Rd, Singapore 229899, Singapore.;wong.chui.mae@singhealth.com.sg;"Lam, Ching/I-5353-2019; Sultana, Rehena/GLS-5785-2022";Lam, Joyce Ching Mei/0000-0001-9368-4752;"SingHealth Duke-NUS Academic Medicine Philanthropic [01/FY2017/EX/20-A69]; SingHealth Duke-NUS Academic Medicine Research [AM/TP028/2020]";"SingHealth Duke-NUS Academic Medicine Philanthropic; SingHealth Duke-NUS Academic Medicine Research";"SingHealth Duke-NUS Academic Medicine Philanthropic, Grant/Award Number: 01/FY2017/EX/20-A69; SingHealth Duke-NUSA cademic Medicine Research, Grant/AwardNumber: AM/TP028/2020.";"American Psychiatric Association D. & Association A. P, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, V5, DOI 10.1176/appi.books.9780890425596; Baranek GT, 2006, J CHILD PSYCHOL PSYC, V47, P591, DOI 10.1111/j.1469-7610.2005.01546.x; Chawarska K, 2012, J CHILD PSYCHOL PSYC, V53, P903, DOI 10.1111/j.1469-7610.2012.02538.x; Chez M, 2018, STEM CELL TRANSL MED, V7, P333, DOI 10.1002/sctm.17-0042; Cohen IL, 2003, J AUTISM DEV DISORD, V33, P31, DOI 10.1023/A:1022226403878; Coolican J, 2008, J AUTISM DEV DISORD, V38, P190, DOI 10.1007/s10803-007-0368-2; Dawson G, 2020, J PEDIATR-US, V222, P164, DOI [10.1016/j.jpeds.2020.03.01, 10.1016/j.jpeds.2020.03.011]; Dawson G, 2017, STEM CELL TRANSL MED, V6, P1332, DOI 10.1002/sctm.16-0474; Genovese A, 2023, GENES-BASEL, V14, DOI 10.3390/genes14030677; Grzadzinski R, 2016, J AUTISM DEV DISORD, V46, P2464, DOI 10.1007/s10803-016-2782-9; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Liu Q, 2019, WORLD J STEM CELLS, V11, P55, DOI 10.4252/wjsc.v11.i2.55; Lv YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-196; Paton MCB, 2022, CYTOTHERAPY, V24, P2, DOI 10.1016/j.jcyt.2021.07.001; Tamouza R, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.809686; Thapar A, 2021, J AUTISM DEV DISORD, V51, P4321, DOI 10.1007/s10803-020-04685-z";17;0;0;3;3;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1939-3792;1939-3806;;AUTISM RES;Autism Res.;AUG;2024;17;8;;;;;1721;1734;;10.1002/aur.3187;http://dx.doi.org/10.1002/aur.3187;;juin-24;14;"Behavioral Sciences; Psychology, Developmental";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology";D6V6W;38943428;;;;24/11/2024;WOS:001257462000001;View Full Record in Web of Science
J;"Champigny, C; Morin-Parent, F; Bellehumeur-Lefebvre, L; Caku, A; Lepage, JF; Corbin, F";;;;"Champigny, Camille; Morin-Parent, Florence; Bellehumeur-Lefebvre, Laurence; Caku, Artuela; Lepage, Jean-Francois; Corbin, Francois";;;Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"fragile X syndrome; clinical trial; lovastatin; minocycline; intellectual disability; autism spectrum disorder (ASD); dual treatment";"ABERRANT BEHAVIOR CHECKLIST; REGULATED KINASE PATHWAY; GENETIC REMOVAL; MOUSE MODEL; CHILDREN; PLATELETS; SYMPTOMS; DEFICIT; ADULTS";Background: Limited success of previous clinical trials for Fragile X syndrome (FXS) has led researchers to consider combining different drugs to correct the pleiotropic consequences caused by the absence of the Fragile X mental retardation protein (FMRP). Here, we report the results of the LovaMiX clinical trial, the first trial for FXS combining two disease-modifying drugs, lovastatin, and minocycline, which have both shown positive effects when used independently.Aim: The main goals of the study were to assess the safety and efficacy of a treatment combining lovastatin and minocycline for patients with FXS.Design: Pilot Phase II open-label clinical trial. Patients with a molecular diagnostic of FXS were first randomized to receive, in two-step titration either lovastatin or minocycline for 8 weeks, followed by dual treatment with lovastatin 40 mg and minocycline 100 mg for 2 weeks. Clinical assessments were performed at the beginning, after 8 weeks of monotherapy, and at week 20 (12 weeks of combined therapy).Outcome Measures: The primary outcome measure was the Aberrant Behavior Checklist-Community (ABC-C) global score. Secondary outcome measures included subscales of the FXS specific ABC-C (ABC-C-FX), the Anxiety, Depression, and Mood Scale (ADAMS), the Social Responsiveness Scale (SRS), the Behavior Rating Inventory of Executive Functions (BRIEF), and the Vineland Adaptive Behavior Scale second edition (VABS-II).Results: Twenty-one individuals out of 22 completed the trial. There were no serious adverse events related to the use of either drugs alone or in combination, suggesting good tolerability and safety profile of the combined therapy. Significant improvement was noted on the primary outcome measure with a 40% decrease on ABC-C global score with the combined therapy. Several outcome measures also showed significance.Conclusion: The combination of lovastatin and minocycline is safe in patients for FXS individuals and appears to improve several elements of the behavior. These results set the stage for a larger, placebo-controlled double-blind clinical trial to confirm the beneficial effects of the combined therapy.;"[Champigny, Camille; Bellehumeur-Lefebvre, Laurence; Caku, Artuela; Corbin, Francois] Univ Sherbrooke, Dept Biochem & Funct Genom, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada; [Champigny, Camille; Morin-Parent, Florence; Bellehumeur-Lefebvre, Laurence; Caku, Artuela; Lepage, Jean-Francois; Corbin, Francois] Ctr Rech CHUS CRCHUS, Sherbrooke, PQ, Canada; [Lepage, Jean-Francois] Univ Sherbrooke, Dept Pediat, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada";"University of Sherbrooke; University of Sherbrooke";"Corbin, F (corresponding author), Univ Sherbrooke, Dept Biochem & Funct Genom, Fac Med & Hlth Sci, Sherbrooke, PQ, Canada.;Corbin, F (corresponding author), Ctr Rech CHUS CRCHUS, Sherbrooke, PQ, Canada.";francois.corbin@usherbrooke.ca;;Lepage, Jean-Francois/0000-0002-1181-6043;;;;"AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 2016, CPS 2016 COMPENDIUM; Bailey DB, 2012, J DEV BEHAV PEDIATR, V33, P705, DOI 10.1097/DBP.0b013e318272dcbc; Bailey DB, 2012, J DEV BEHAV PEDIATR, V33, P62, DOI 10.1097/DBP.0b013e318236c0e1; Berry-Kravis EM, 2018, NAT REV DRUG DISCOV, V17, P280, DOI 10.1038/nrd.2017.221; Bilousova TV, 2009, J MED GENET, V46, P94, DOI 10.1136/jmg.2008.061796; Budimirovic DB, 2017, J NEURODEV DISORD, V9, DOI 10.1186/s11689-017-9193-x; Çaku A, 2014, AM J MED GENET A, V164, P2834, DOI 10.1002/ajmg.a.36750; Cerezo-Guisado MI, 2007, BIOCHEM J, V401, P175, DOI 10.1042/BJ20060731; Dziembowska M, 2013, AM J MED GENET A, V161, P1897, DOI 10.1002/ajmg.a.36023; Ethridge LE, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.48; Gallagher A, 2012, J NEUROL, V259, P401, DOI 10.1007/s00415-011-6161-3; Gallagher RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028096; Gkogkas CG, 2014, CELL REP, V9, P1742, DOI 10.1016/j.celrep.2014.10.064; Gross C, 2015, NEUROTHERAPEUTICS, V12, P584, DOI 10.1007/s13311-015-0355-9; Guy W., 1976, ECDEU assessment manual for pharmacology, P217, DOI [DOI 10.1037/T48216-000, 10.1037/t48216-000]; Hoeffer CA, 2012, GENES BRAIN BEHAV, V11, P332, DOI 10.1111/j.1601-183X.2012.00768.x; Hou LF, 2006, NEURON, V51, P441, DOI 10.1016/j.neuron.2006.07.005; Knoth IS, 2014, INT J DEV NEUROSCI, V36, P90, DOI 10.1016/j.ijdevneu.2014.05.003; Knox A, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-2; Leigh MJS, 2013, J DEV BEHAV PEDIATR, V34, P147, DOI 10.1097/DBP.0b013e318287cd17; Lessard M, 2012, CLIN GENET, V82, P472, DOI 10.1111/j.1399-0004.2011.01798.x; Morin-Parent F, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0650-z; Muscas M, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0097-19.2019; OBERLE I, 1991, AM J MED GENET, V38, P336, DOI 10.1002/ajmg.1320380234; Osterweil EK, 2013, NEURON, V77, P243, DOI 10.1016/j.neuron.2012.01.034; Paribello C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-91; Pellerin D, 2016, BIOMARKERS, V21, P497, DOI 10.3109/1354750X.2016.1160289; Rotschafer SE, 2012, BRAIN RES, V1439, P7, DOI 10.1016/j.brainres.2011.12.041; Sansone SM, 2012, J AUTISM DEV DISORD, V42, P1377, DOI 10.1007/s10803-011-1370-2; Schneider A, 2013, J PSYCHOPHARMACOL, V27, P956, DOI 10.1177/0269881113494105; Sidhu H, 2014, J NEUROSCI, V34, P9867, DOI 10.1523/JNEUROSCI.1162-14.2014; Siller SS, 2011, DIS MODEL MECH, V4, P673, DOI 10.1242/dmm.008045; Thurman AJ, 2020, J NEURODEV DISORD, V12, DOI 10.1186/s11689-020-09315-4; U.S. Department of health and human services National Institutes of Health National Cancer Institute, 2009, COMMON TERMINOLOGY C, P79; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Wang XL, 2012, J NEUROCHEM, V121, P672, DOI 10.1111/j.1471-4159.2012.07722.x; Zeidler S, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00368";38;7;7;0;6;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;janv-04;2022;12;;;;;;;;762967;10.3389/fpsyt.2021.762967;http://dx.doi.org/10.3389/fpsyt.2021.762967;;;10;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;YK4UN;35058813;gold, Green Published;;;24/11/2024;WOS:000745209900001;View Full Record in Web of Science
J;"Heussler, H; Chan, P; Price, AMH; Waters, K; Davey, MJ; Hiscock, H";;;;"Heussler, Helen; Chan, Patrick; Price, Anna M. H.; Waters, Karen; Davey, Margot J.; Hiscock, Harriet";;;Pharmacological and non-pharmacological management of sleep disturbance in children: An Australian Paediatric Research Network survey;SLEEP MEDICINE;;;English;Article;;;;;;"Australian Paediatric Research Network; Behavior therapy; Melatonin; Paediatric; Sleep disorders";"AUTISM SPECTRUM DISORDERS; EXOGENOUS MELATONIN; BEHAVIOR PROBLEMS; SCHOOL; INSOMNIA; HEALTH";Background: Australian paediatricians use a wide variety of practices when managing sleep disturbances in children, including use of melatonin and behavioral strategies. However, practice patterns around the use of strategies, dosing, and how the patient populations managed, are unknown. Results could inform guidelines for the management of child sleep disturbances. Objective: We aimed to document management practices by Australian general paediatricians for paediatric sleep disturbances through an online survey sent to members of the Australian Paediatric Research Network (APRN) who are recruited from the Royal Australasian College of Physicians. Results: 181 (49%) of 373 eligible paediatricians responded, with 101 prescribing melatonin. The most commonly prescribed medications for poor sleep initiation were melatonin (89.1%), clonidine (48%) and antihistamines (29%). Melatonin doses ranged from 0.5 mg to 12 mg and duration of treatment was as long as 200 weeks. Less than half of the paediatricians were aware of any potential melatonin side effects. Most paediatricians (82%) reported using behavioral strategies for sleep disturbances, most commonly anxiety relaxation techniques (75%) for poor sleep initiation and graduated extinction (i.e. controlled crying, 52%) for disrupted overnight sleep. Conclusions: Australian paediatricians use both pharmacological and non-pharmacological treatments for paediatric sleep disturbances. Melatonin is the most commonly prescribed medication, but wide variation in its prescribing suggests a lack of knowledge of recommended dosages and effectiveness. Given the prevalence and variation in prescribing, there is an urgent need to develop clear guidance for paediatricians managing children with sleep disturbance. (C) 2012 Elsevier B. V. All rights reserved.;"[Heussler, Helen; Chan, Patrick] Mater Childrens Hosp, Dept Resp & Sleep Med, Brisbane, Qld 4101, Australia; [Heussler, Helen] Mater Med Res Inst, Brisbane, Qld 4101, Australia; [Heussler, Helen] Univ Queensland, Sch Med, Herston, Qld 4006, Australia; [Price, Anna M. H.; Hiscock, Harriet] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; [Price, Anna M. H.; Hiscock, Harriet] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Waters, Karen] Sydney Childrens Hosp Network, Resp Support Serv, Sydney, NSW 2000, Australia; [Waters, Karen] Univ Sydney, Sydney, NSW 2000, Australia; [Davey, Margot J.] Monash Med Ctr, Melbourne Childrens Sleep Ctr, Clayton, Vic 3168, Australia; [Hiscock, Harriet] Univ Melbourne, Dept Paediat, Carlton, Vic 3053, Australia";"Mater Health Services; Mater Children's Hospital; Mater Research; University of Queensland; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; NSW Health; Sydney Childrens Hospitals Network; University of Sydney; Monash University; Monash Health; Monash Medical Centre; University of Melbourne";Price, AMH (corresponding author), Royal Childrens Hosp, Ctr Community Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia.;anna.price@mcri.edu.au;"Waters, Karen/B-2840-2013; Hiscock, Harriet/M-6882-2013";"Hiscock, Harriet/0000-0003-3017-2770; Waters, Karen/0000-0001-8699-2175; Price, Anna/0000-0002-8117-8059";;;;"Australian Bureau of Statistics (ABS), 2006, CENS POP HOUS IND PA; Braam W, 2009, DEV MED CHILD NEUROL, V51, P340, DOI 10.1111/j.1469-8749.2008.03244.x; Buscemi N, 2006, BMJ-BRIT MED J, V332, P385, DOI 10.1136/bmj.38731.532766.F6; Buscemi N, 2004, Evid Rep Technol Assess (Summ), P1; Clark AF, 2004, J PSYCHOPHARMACOL, V18, P115, DOI 10.1177/0269881104040249; Corkum P, 2011, PEDIATR CLIN N AM, V58, P667, DOI 10.1016/j.pcl.2011.03.004; Heussler H, 2007, WORLD SLEEP C BRISB; Hiscock H, 2010, J PAEDIATR CHILD H, V48, P6; Hiscock H, 2011, MED J AUSTRALIA, V194, P392, DOI 10.5694/j.1326-5377.2011.tb03028.x; HUETHER G, 1994, ANN NY ACAD SCI, V719, P146, DOI 10.1111/j.1749-6632.1994.tb56826.x; Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003; Khan S, 2011, COCHRANE DATABASE SY, V11; Khanna P, 2009, RACP WORKFORCE SURVE; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; LUBOSHITZKY R, 1995, J CLIN ENDOCR METAB, V80, P2144, DOI 10.1210/jc.80.7.2144; Luboshitzky R, 2000, EXP CLIN ENDOCR DIAB, V108, P142, DOI 10.1055/s-2000-5809; Martin J, 2007, PEDIATRICS, V119, P947, DOI 10.1542/peds.2006-2569; Mindell JA, 2006, SLEEP, V29, P1263; Nikles J, 2012, MED J AUSTRALIA, V196, P384, DOI 10.5694/mja12.10145; Owens JA, 2005, J DEV BEHAV PEDIATR, V26, P312, DOI 10.1097/00004703-200508000-00011; Owens JA, 2003, PEDIATRICS, V111, pE628, DOI 10.1542/peds.111.5.e628; Owens JA, 2002, CURR THER RES CLIN E, V63, pB38, DOI 10.1016/S0011-393X(02)80102-3; Owens JA, 2010, SLEEP MED, V11, P692, DOI 10.1016/j.sleep.2009.11.015; Owens JA, 2009, CHILD ADOL PSYCH CL, V18, P1001, DOI 10.1016/j.chc.2009.04.009; Quach J, 2009, PEDIATRICS, V123, P1287, DOI 10.1542/peds.2008-1860; Quine L, 2001, CHILD CARE HLTH DEV, V27, P201, DOI 10.1046/j.1365-2214.2001.00213.x; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Rossignol DA, 2011, DEV MED CHILD NEUROL, V53, P783, DOI 10.1111/j.1469-8749.2011.03980.x; Rudolph S, 2009, J PAEDIATR CHILD H, V45, P704, DOI 10.1111/j.1440-1754.2009.01598.x; Sadeh A, 2002, CHILD DEV, V73, P405, DOI 10.1111/1467-8624.00414; Stein MA, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.4.e60; Sung V, 2008, ARCH PEDIAT ADOL MED, V162, P336, DOI 10.1001/archpedi.162.4.336; van Geijlswijk IM, 2011, PSYCHOPHARMACOLOGY, V216, P111, DOI 10.1007/s00213-011-2202-y; van Geijlswijk IM, 2010, PSYCHOPHARMACOLOGY, V212, P379, DOI 10.1007/s00213-010-1962-0; Vriend JL, 2011, J PEDIATR PSYCHOL, V36, P1017, DOI 10.1093/jpepsy/jsr044; Waldron DL, 2005, ARCH DIS CHILD, V90, P1206, DOI 10.1136/adc.2005.077289";36;41;48;1;29;ELSEVIER SCIENCE BV;AMSTERDAM;PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS;1389-9457;1878-5506;;SLEEP MED;Sleep Med.;FEB;2013;14;2;;;;;189;194;;10.1016/j.sleep.2012.09.023;http://dx.doi.org/10.1016/j.sleep.2012.09.023;;;6;Clinical Neurology;Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;088XQ;23245853;;;;24/11/2024;WOS:000314871600013;View Full Record in Web of Science
J;"Kasari, C; Kaiser, A; Goods, K; Nietfeld, J; Mathy, P; Landa, R; Murphy, S; Almirall, D";;;;"Kasari, Connie; Kaiser, Ann; Goods, Kelly; Nietfeld, Jennifer; Mathy, Pamela; Landa, Rebecca; Murphy, Susan; Almirall, Daniel";;;Communication Interventions for Minimally Verbal Children With Autism: A Sequential Multiple Assignment Randomized Trial;JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY;;;English;Article;;;;;;"autism spectrum disorders; minimally verbal; school-aged; communication intervention; SMART design";"FOLLOW-UP; JOINT ATTENTION; SPECTRUM; PRESCHOOLERS";"Objective: This study tested the effect of beginning treatment with a speech-generating device (SGD) in the context of a blended, adaptive treatment design for improving spontaneous, communicative utterances in school-aged, minimally verbal children with autism. Method: A total of 61 minimally verbal children with autism, aged 5 to 8 years, were randomized to a blended developmental/behavioral intervention (JASP+EMT) with or without the augmentation of a SGD for 6 months with a 3-month follow-up. The intervention consisted of 2 stages. In stage 1, all children received 2 sessions per week for 3 months. Stage 2 intervention was adapted (by increased sessions or adding the SGD) based on the child's early response. The primary outcome was the total number of spontaneous communicative utterances; secondary measures were the total number of novel words and total comments from a natural language sample. Results: Primary aim results found improvements in spontaneous communicative utterances, novel words, and comments that all favored the blended behavioral intervention that began by including an SGD (JASP+EMT+SGD) as opposed to spoken words alone (JASP+EMT). Secondary aim results suggest that the adaptive intervention beginning with JASP+EMT+SGD and intensifying JASP+EMT+SGD for children who were slow responders led to better posttreatment outcomes. Conclusion: Minimally verbal school-aged children can make significant and rapid gains in spoken spontaneous language with a novel, blended intervention that focuses on joint engagement and play skills and incorporates an SGD. Future studies should further explore the tailoring design used in this study to better understand children's response to treatment. Clinical trial registration information Developmental and Augmented Intervention for Facilitating Expressive Language (CCNIA); http://clinicaltrials.gov/; NCT01013545.";"[Kasari, Connie] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA; [Kasari, Connie; Nietfeld, Jennifer] Vanderbilt Univ, Nashville, TN USA; [Goods, Kelly] First Five Los Angeles, Los Angeles, CA USA; [Mathy, Pamela] Univ Utah, Speech Language & Hearing Clin, Salt Lake City, UT 84112 USA; [Landa, Rebecca] Kennedy Krieger Inst, Baltimore, MD USA; [Murphy, Susan; Almirall, Daniel] Univ Michigan, Ann Arbor, MI 48109 USA";"University of California System; University of California Los Angeles; Vanderbilt University; Utah System of Higher Education; University of Utah; Kennedy Krieger Institute; University of Michigan System; University of Michigan";Kasari, C (corresponding author), Univ Calif Los Angeles, Semel Inst 68 268, Los Angeles, CA 90024 USA.;kasari@gseis.ucla.edu;;"Murphy, Susan A/0000-0002-2032-4286; , Pamela Mathy, Pamela Mathy-Laikko/0009-0001-5222-3084";"National Institute of Child Health and Human Development (NICHD) [R01HD073975-02, R01HD073975-03]; National Institute of Mental Health (NIMH) [R03MH097954-02, RC4MH092722-01]; National Institute on Drug Abuse [NIDA] [P50DA10075]";"National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Drug Abuse [NIDA](United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))";This study was funded by Autism Speaks #5666, Characterizing Cognition in Nonverbal Individuals with Autism, oh initiative begun by Ms. Portia Iverson and Cure Autism Now. Grant support was also provided by the National Institute of Child Health and Human Development (NICHD) R01HD073975-02 (C.K., A.K., S.M., D.A.), and R01HD073975-03 (C.K., R.L.), R03MH097954-02 (D.A), and RC4MH092722-01 (D.A) from the National Institute of Mental Health (NIMH), and P50DA10075 (National Institute on Drug Abuse [NIDA], S.M., D.A.).;"Almirall D, 2012, J CHILD ADOL PSYCHOP, V22, P364, DOI 10.1089/cap.2011.0073; Almirall D, 2012, STAT MED, V31, P1887, DOI 10.1002/sim.4512; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Anderson DK, 2009, J ABNORM CHILD PSYCH, V37, P1019, DOI 10.1007/s10802-009-9326-0; Blischak Doreen, 2003, Augment Altern Commun, V19, P29, DOI 10.1080/0743461032000056478; Carpenter JR, 2007, STAT METHODS MED RES, V16, P259, DOI 10.1177/0962280206075303; Cohen J, 1988, STAT POWER ANAL BEHA, V2, P567, DOI DOI 10.4324/9780203771587; Collins LM, 2007, AM J PREV MED, V32, pS112, DOI 10.1016/j.amepre.2007.01.022; Collins LM, 2004, PREV SCI, V5, P185, DOI 10.1023/B:PREV.0000037641.26017.00; Goods KS, 2013, J AUTISM DEV DISORD, V43, P1050, DOI 10.1007/s10803-012-1644-3; Gordon K, 2011, J CONSULT CLIN PSYCH, V79, P447, DOI 10.1037/a0024379; Howlin P, 2007, J CHILD PSYCHOL PSYC, V48, P473, DOI 10.1111/j.1469-7610.2006.01707.x; Kaale A, 2014, J AM ACAD CHILD PSY, V53, P188, DOI 10.1016/j.jaac.2013.09.019; Kaiser A.P., 2000, EARLY EDUC DEV, V11, P423, DOI [10.1207/s15566935eed1104_4, DOI 10.1207/S15566935EED1104_4]; Kaiser AP, 2013, J SPEECH LANG HEAR R, V56, P295, DOI 10.1044/1092-4388(2012/11-0231); KAISER AP, 1993, J ASSOC PERS SEVERE, V18, P137, DOI 10.1177/154079699301800301; Kasari C, 2008, J CONSULT CLIN PSYCH, V76, P125, DOI 10.1037/0022-006X.76.1.125; Kasari C, 2012, J AM ACAD CHILD PSY, V51, P487, DOI 10.1016/j.jaac.2012.02.019; Kasari C, 2010, J AUTISM DEV DISORD, V40, P1045, DOI 10.1007/s10803-010-0955-5; Lord C, 1999, ADOS. Autism Diagnostic Observation Schedule. Manual; Miller J, 2012, SALT SYSTEMATIC ANAL; Murphy SA, 2005, STAT MED, V24, P1455, DOI 10.1002/sim.2022; Nahum-Shani I, 2012, PSYCHOL METHODS, V17, P457, DOI 10.1037/a0029372; Paul R, 2013, J AUTISM DEV DISORD, V43, P418, DOI 10.1007/s10803-012-1583-z; Pickett E, 2009, COGN BEHAV NEUROL, V22, P1, DOI 10.1097/WNN.0b013e318190d185; RUTTER M, 1967, BRIT J PSYCHIAT, V113, P1183, DOI 10.1192/bjp.113.504.1183; Schlosser RW, 2008, AM J SPEECH-LANG PAT, V17, P212, DOI 10.1044/1058-0360(2008/021); Tager-Flusberg H, 2013, AUTISM RES, V6, P468, DOI 10.1002/aur.1329; Tager-Flusberg H, 2009, J SPEECH LANG HEAR R, V52, P643, DOI 10.1044/1092-4388(2009/08-0136); van der Meer LAJ, 2010, DEV NEUROREHABIL, V13, P294, DOI 10.3109/17518421003671494; Wodka EL, 2013, PEDIATRICS, V131, pE1128, DOI 10.1542/peds.2012-2221; Yoder P, 2006, J CONSULT CLIN PSYCH, V74, P426, DOI 10.1037/0022-006X.74.3.426";32;248;303;2;77;ELSEVIER SCIENCE INC;NEW YORK;STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA;0890-8567;1527-5418;;J AM ACAD CHILD PSY;J. Am. Acad. Child Adolesc. Psychiatr.;JUN;2014;53;6;;;;;635;646;;10.1016/j.jaac.2014.01.019;http://dx.doi.org/10.1016/j.jaac.2014.01.019;;;12;"Psychology, Developmental; Pediatrics; Psychiatry";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Pediatrics; Psychiatry";AI0SO;24839882;Green Published, Green Accepted;;;24/11/2024;WOS:000336560400007;View Full Record in Web of Science
J;"Lindly, OJ; Crossman, MK; Shui, AM; Kuo, DZ; Earl, KM; Kleven, AR; Perrin, JM; Kuhlthau, KA";;;;"Lindly, Olivia J.; Crossman, Morgan K.; Shui, Amy M.; Kuo, Dennis Z.; Earl, Kristen M.; Kleven, Amber R.; Perrin, James M.; Kuhlthau, Karen A.";;;Healthcare access and adverse family impact among US children ages 0-5 years by prematurity status;BMC PEDIATRICS;;;English;Article;;;;;;"Prematurity; Low Birthweight; Early childhood; Healthcare access; Adverse family impact";"LOW-BIRTH-WEIGHT; AUTISM SPECTRUM DISORDER; CENTERED MEDICAL HOME; PRETERM BIRTH; SCHOOL-AGE; PARENT; OUTCOMES; NEEDS; DISABILITIES; DISPARITIES";Background Many children and their families are affected by premature birth. Yet, little is known about their healthcare access and adverse family impact during early childhood. This study aimed to (1) examine differences in healthcare access and adverse family impact among young children by prematurity status and (2) determine associations of healthcare access with adverse family impact among young children born prematurely. Methods This was a secondary analysis of cross-sectional 2016 and 2017 National Survey of Children's Health data. The sample included 19,482 U.S. children ages 0-5 years including 242 very low birthweight (VLBW) and 2205 low birthweight and/or preterm (LBW/PTB) children. Prematurity status was defined by VLBW (i.e., < 1500 g at birth) and LBW/PTB (i.e., 1500-2499 g at birth and/or born at < 37 weeks with or without LBW). Healthcare access measures were adequate health insurance, access to medical home, and developmental screening receipt. Adverse family impact measures were >= $1000 in annual out-of-pocket medical costs, having a parent cut-back or stop work, parental aggravation, maternal health not excellent, and paternal health not excellent. The relative risk of each healthcare access and adverse family impact measure was computed by prematurity status. Propensity weighted models were fit to estimate the average treatment effect of each healthcare access measure on each adverse family impact measure among children born prematurely (i.e., VLBW or LBW/PTB). Results Bivariate analysis results showed that VLBW and/or LBW/PTB children generally fared worse than other children in terms of medical home, having a parent cut-back or stop working, parental aggravation, and paternal health. Multivariable analysis results only showed, however, that VLBW children had a significantly higher risk than other children of having a parent cut-back or stop work. Adequate health insurance and medical home were each associated with reduced adjusted relative risk of >=$1000 in annual out-of-pocket costs, having a parent cut-back or stop work, and parental aggravation among children born prematurely. Conclusions This study's findings demonstrate better healthcare access is associated with reduced adverse family impact among U.S. children ages 0-5 years born prematurely. Population health initiatives should target children born prematurely and their families.;"[Lindly, Olivia J.] No Arizona Univ, Dept Hlth Sci, 1100 S Beaver St,Room 488, Flagstaff, AZ 86011 USA; [Crossman, Morgan K.] Bldg Bright Futures, Williston, VT USA; [Shui, Amy M.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA; [Kuo, Dennis Z.] Univ Buffalo, Dept Pediat, Buffalo, NY USA; [Earl, Kristen M.; Kleven, Amber R.; Perrin, James M.; Kuhlthau, Karen A.] Massachusetts Gen Hosp, Div Gen Acad Pediat, Boston, MA 02114 USA; [Perrin, James M.; Kuhlthau, Karen A.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA";"Northern Arizona University; Harvard University; Massachusetts General Hospital; State University of New York (SUNY) System; University at Buffalo, SUNY; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School";Lindly, OJ (corresponding author), No Arizona Univ, Dept Hlth Sci, 1100 S Beaver St,Room 488, Flagstaff, AZ 86011 USA.;olivia.lindly@nau.edu;;;"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [UA6MC31101]; Agency for Healthcare Research and Quality [T32HS000063]";"Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)";This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under UA6MC31101 Children and Youth with Special Health Care Needs Research Network. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, and the U.S. Government. Dr. Lindly's effort on this study was also supported by grant #T32HS000063 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent official views of the Agency for Healthcare Research and Quality.;"[Anonymous], 2018, 2017 NAT SURV CHILDR; [Anonymous], 2018, 2016 NAT SURV CHILDR; [Anonymous], 2017, 2016 NAT SURV CHILDR; [Anonymous], 2018, 2017 NAT SURV CHILDR; Barre N, 2011, J PEDIATR-US, V158, P766, DOI 10.1016/j.jpeds.2010.10.032; Berman L, 2019, J PEDIATR-US, V205, P98, DOI 10.1016/j.jpeds.2018.08.086; Bethell CD, 2002, AMBUL PEDIATR, V2, P38, DOI 10.1367/1539-4409(2002)002<0038:ICWSHC>2.0.CO;2; Bethell C, 2011, PEDIATRICS, V128, P146, DOI 10.1542/peds.2010-0424; Bethell CD, 2019, HEALTH AFFAIR, V38, P729, DOI 10.1377/hlthaff.2018.05425; Bethell CD, 2011, ACAD PEDIATR, V11, pS22, DOI 10.1016/j.acap.2010.08.011; Boyle EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e896; Boyle JD, 2013, ARCH DIS CHILD-FETAL, V98, pF85, DOI 10.1136/archdischild-2011-300535; Bramlett MD, 2009, MATERN CHILD HLTH J, V13, P151, DOI 10.1007/s10995-008-0339-z; Chan E, 2014, ARCH DIS CHILD-FETAL, V99, pF451, DOI 10.1136/archdischild-2014-306124; Child and Adolescent Health Measurement Initiative, 2009, 30061480101 CDC PO O; Duby JC, 2006, PEDIATRICS, V118, P405, DOI 10.1542/peds.2006-1231; DuGoff EH, 2014, HEALTH SERV RES, V49, P284, DOI 10.1111/1475-6773.12090; Enlow E, 2014, J PERINATOL, V34, P761, DOI 10.1038/jp.2014.75; Enlow E, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2310; Hagan J., 2008, BRIGHT FUTURES GUIDE, V3rd; Halfon N, 2002, MILBANK Q, V80, P433, DOI 10.1111/1468-0009.00019; Hirai AH, 2018, JAMA PEDIATR, V172, P857, DOI 10.1001/jamapediatrics.2018.1524; Honberg LE, 2009, PEDIATRICS, V124, P1273, DOI 10.1542/peds.2009-0372; Johnston KM, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-93; KLEBANOV PK, 1994, PEDIATRICS, V94, P700; Kogan MD, 2010, PEDIATRICS, V125, P673, DOI 10.1542/peds.2009-1055; Kogan MD, 2008, PEDIATRICS, V122, pE1149, DOI 10.1542/peds.2008-1057; Kuo DZ, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2969; Kuo DZ, 2011, MATERN CHILD HLTH J, V15, P794, DOI 10.1007/s10995-010-0648-x; Lakshmanan A, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1604-6; Lakshmanan A, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0602-3; Litt J, 2005, J LEARN DISABIL-US, V38, P130, DOI 10.1177/00222194050380020301; Litt JS, 2018, J PERINATOL, V38, P1391, DOI 10.1038/s41372-018-0180-1; Litt JS, 2018, ACAD PEDIATR, V18, P468, DOI 10.1016/j.acap.2017.07.011; Litt JS, 2015, ACAD PEDIATR, V15, P185, DOI 10.1016/j.acap.2014.08.006; Malin KJ, 2020, EARLY HUM DEV, V140, DOI 10.1016/j.earlhumdev.2019.104930; Martin J., 2018, Births in the United States, 2017; Martin JA, 2018, BIRTHS FINAL DATA 20, V67; Mathewson KJ, 2017, PSYCHOL BULL, V143, P347, DOI 10.1037/bul0000091; McCormick MC, 2011, ANNU REV PUBL HEALTH, V32, P367, DOI 10.1146/annurev-publhealth-090810-182459; McLaurin KK, 2009, PEDIATRICS, V123, P653, DOI 10.1542/peds.2008-1439; McManus BM, 2014, MATERN CHILD HLTH J, V18, P1031, DOI 10.1007/s10995-013-1332-8; Petrou S, 2012, SEMIN FETAL NEONAT M, V17, P170, DOI 10.1016/j.siny.2012.02.001; Purdy IB, 2015, J PERINATOL, V35, pS24, DOI 10.1038/jp.2015.146; Rice Catherine E, 2014, MMWR Suppl, V63, P27; Ronis SD, 2015, J DEV BEHAV PEDIATR, V36, P417, DOI 10.1097/DBP.0000000000000161; Schieve LA, 2016, ANN EPIDEMIOL, V26, P267, DOI 10.1016/j.annepidem.2016.02.012; Schieve LA, 2011, DISABIL HEALTH J, V4, P143, DOI 10.1016/j.dhjo.2010.09.002; Shah PE, 2016, J PEDIATR-US, V178, P61, DOI 10.1016/j.jpeds.2016.06.062; Sia CJ, 2004, PEDIATRICS, V113, P1545; Singer LT, 2007, J PEDIATR-US, V151, P463, DOI 10.1016/j.jpeds.2007.04.012; StataCorp, 2019, Stata Statistical Software; Treyvaud K, 2014, SEMIN FETAL NEONAT M, V19, P131, DOI 10.1016/j.siny.2013.10.008; Treyvaud K, 2014, J PEDIATR-US, V164, P515, DOI 10.1016/j.jpeds.2013.11.001; Turchi Renee M, 2009, Pediatrics, V124 Suppl 4, pS428, DOI 10.1542/peds.2009-1255O; Twardzik E, 2017, DISABIL HEALTH J, V10, P467, DOI 10.1016/j.dhjo.2017.01.009; Witt WP, 2012, QUAL LIFE RES, V21, P1565, DOI 10.1007/s11136-011-0069-3; Zuckerman KE, 2014, ACAD PEDIATR, V14, P398, DOI 10.1016/j.acap.2014.03.011";58;6;8;0;7;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1471-2431;;BMC PEDIATR;BMC Pediatr.;APR 17;2020;20;1;;;;;;;168;10.1186/s12887-020-02058-0;http://dx.doi.org/10.1186/s12887-020-02058-0;;;13;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;LH6SG;32303218;Green Published, gold;;;24/11/2024;WOS:000528914400001;View Full Record in Web of Science
J;"Solmi, M; Fornaro, M; Ostinelli, EG; Zangani, C; Croatto, G; Monaco, F; Krinitski, D; Fusar-Poli, P; Correll, CU";;;;"Solmi, Marco; Fornaro, Michele; Ostinelli, Edoardo G.; Zangani, Caroline; Croatto, Giovanni; Monaco, Francesco; Krinitski, Damir; Fusar-Poli, Paolo; Correll, Christoph U.";;;Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects;WORLD PSYCHIATRY;;;English;Article;;;;;;"Safety; tolerability; children; adolescents; psychopharmacology; antidepressants; antipsychotics; mood stabilizers; psycho-stim-ulants; meta-review";"PLACEBO-CONTROLLED TRIAL; OBSESSIVE-COMPULSIVE DISORDER; DEFICIT HYPERACTIVITY DISORDER; MAJOR DEPRESSIVE DISORDER; AUTISM SPECTRUM DISORDER; BIPOLAR I DISORDER; GENERALIZED ANXIETY DISORDER; COGNITIVE-BEHAVIORAL THERAPY; EXTENDED-RELEASE GUANFACINE; FILM-COATED TABLETS";"Mental disorders frequently begin in childhood or adolescence. Psychotropic medications have various indications for the treatment of mental dis-orders in this age group and are used not infrequently off-label. However, the adverse effects of these medications require special attention during developmentally sensitive periods of life. For this meta-review, we systematically searched network meta-analyses and meta-analyses of randomized controlled trials (RCTs), individual RCTs, and cohort studies reporting on 78 a priori selected adverse events across 19 categories of 80 psychotropic medications - including antidepressants, antipsychotics, anti-attention-deficit/hyperactivity disorder (ADHD) medications and mood stabilizers - in children and adolescents with mental disorders. We included data from nine network meta-analyses, 39 meta-analyses, 90 individual RCTs, and eight cohort studies, including 337,686 children and adolescents. Data on >= 20% of the 78 adverse events were available for six antidepressants (sertraline, escitalopram, paroxetine, fluoxetine, venlafaxine and vilazodone), eight antipsychotics (risperidone, quetiapine, aripiprazole, lurasidone, paliperidone, ziprasidone, olanzapine and asenapine), three anti-ADHD medications (methylphenidate, atomoxetine and guanfacine), and two mood stabilizers (valproate and lithium). Among these medications with data on >= 20% of the 78 adverse events, a safer profile emerged for escitalopram and fluoxetine among antidepressants, lurasidone for antipsychotics, methylphenidate among anti-ADHD medications, and lithium among mood stabilizers. The available literature raised most concerns about the safety of venlafaxine, olanzapine, atomoxetine, guanfacine and valproate. Nausea/vomiting and discontinuation due to adverse event were most frequently associated with antidepressants; sedation, extrapyramidal side effects, and weight gain with antipsychotics; anorexia and insomnia with anti-ADHD medications; sedation and weight gain with mood stabilizers. The results of this comprehensive and updated quantitative systematic meta-review of top-tier evidence regarding the safety of antidepressants, antipsychotics, anti-ADHD medications and mood stabilizers in children and adolescents can inform clinical practice, research and treatment guidelines.";"[Solmi, Marco; Croatto, Giovanni] Univ Padua, Neurosci Dept, Padua, Italy; [Solmi, Marco] Univ Padua, Padua Neurosci Ctr, Padua, Italy; [Solmi, Marco; Fusar-Poli, Paolo] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, Early Psychosis Intervent & Clin Detect EPIC Lab, London, England; [Fornaro, Michele] Univ Naples Federico II, Dept Psychiat, Naples, Italy; [Ostinelli, Edoardo G.] Univ Oxford, Wameford Hosp, Oxford Hlth NHS Fdn Trust, Oxford, England; [Ostinelli, Edoardo G.] Univ Oxford, Dept Psychiat, Oxford, England; [Ostinelli, Edoardo G.; Zangani, Caroline] Univ Milan, Dept Hlth Sci, Milan, Italy; [Monaco, Francesco] ASL Salerno, Dept Mental Hlth, Salerno, Italy; [Krinitski, Damir] Integrated Psychiat Winterthur IPW, Winterthur, Switzerland; [Fusar-Poli, Paolo] South London & Maudsley NHS & Otindat Trust, OASIS Serv, London, England; [Fusar-Poli, Paolo] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Fusar-Poli, Paolo] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Maudsley Biomed Res Ctr, London, England; [Correll, Christoph U.] Northwell Hlth, Zucker Hillside Hosp, Dept Psychiat, New York, NY USA; [Correll, Christoph U.] Zucker Sch Med Hofstra Northwell, Dept Psychiat & Mol Med, Hempstead, NY USA; [Correll, Christoph U.] Feinstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA; [Correll, Christoph U.] Charite Univ Med Berlin, Dept Child & Adolescent Psychiat, Berlin, Germany";"University of Padua; University of Padua; University of London; King's College London; University of Naples Federico II; University of Oxford; University of Oxford; University of Milan; University of Pavia; South London & Maudsley NHS Trust; Northwell Health; Northwell Health; Northwell Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin";"Solmi, M (corresponding author), Univ Padua, Neurosci Dept, Padua, Italy.;Solmi, M (corresponding author), Univ Padua, Padua Neurosci Ctr, Padua, Italy.;Solmi, M (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychosis Studies, Early Psychosis Intervent & Clin Detect EPIC Lab, London, England.";;"Ostinelli, Edoardo/AAS-2694-2021; Correll, Christoph/D-3530-2011; solmi, marco/K-3906-2018; Fusar-Poli, Paolo/D-8605-2011; Ostinelli, Edoardo Giuseppe/G-5495-2018";"Zangani, Caroline/0000-0001-5883-0638; Fusar-Poli, Paolo/0000-0003-3582-6788; solmi, marco/0000-0003-4877-7233; Monaco, Francesco/0000-0002-1854-292X; Ostinelli, Edoardo Giuseppe/0000-0002-8717-0832";"National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility; NIHR Oxford Health Biomedical Research Centre [BRC-1215-20005]";"National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility(National Institutes of Health Research (NIHR)); NIHR Oxford Health Biomedical Research Centre";E.G. Ostinelli is supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility and the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005).;"Albert U, 2019, EUR PSYCHIAT, V58, P19, DOI 10.1016/j.eurpsy.2019.01.017; Aman MG, 2014, J AM ACAD CHILD PSY, V53, P47, DOI 10.1016/j.jaac.2013.09.022; Andrade SE, 2011, PEDIATRICS, V128, P1135, DOI 10.1542/peds.2011-0855; [Anonymous], 2012, 1 2 GENERATION ANTIP; [Anonymous], DOUBL BLIND PLAC CON; [Anonymous], J AUTISM DEV DISORD; [Anonymous], NEFAZODONE HYDROCHLO; [Anonymous], AGENCY HEALTHC RES Q; Ardizzone I, 2010, PSYCHOPHARMACOL BULL, V43, P45; Atkinson S, 2018, J CHILD ADOL PSYCHOP, V28, P55, DOI 10.1089/cap.2017.0099; Bangs ME, 2014, J CHILD ADOL PSYCHOP, V24, P426, DOI 10.1089/cap.2014.0005; Barbui C, 2008, EVID-BASED MENT HEAL, V11, P34, DOI 10.1136/ebmh.11.2.34; Bell GS, 2009, CNS DRUGS, V23, P281, DOI 10.2165/00023210-200923040-00002; Belsito KM, 2001, J AUTISM DEV DISORD, V31, P175, DOI 10.1023/A:1010799115457; Benatti B, 2016, INT CLIN PSYCHOPHARM, V31, P347, DOI 10.1097/YIC.0000000000000137; Biederman J, 2005, PEDIATRICS, V116, pE777, DOI 10.1542/peds.2005-0617; Biederman J, 2002, PEDIATRICS, V110, P258, DOI 10.1542/peds.110.2.258; BIEDERMAN J, 1989, J AM ACAD CHILD PSY, V28, P777, DOI 10.1097/00004583-198909000-00022; Biederman J, 2006, J CLIN PSYCHIAT, V67, P727, DOI 10.4088/JCP.v67n0506; Blader JC, 2009, AM J PSYCHIAT, V166, P1392, DOI 10.1176/appi.ajp.2009.09020233; Braüner JV, 2016, J CLIN PSYCHOPHARM, V36, P500, DOI 10.1097/JCP.0000000000000559; Bridge JA, 2007, JAMA-J AM MED ASSOC, V297, P1683, DOI 10.1001/jama.297.15.1683; Rojas-Mirquez JC, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00375; Catalá-López F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180355; Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383; Ching C, 2019, JAMA PEDIATR, V173, P630, DOI 10.1001/jamapediatrics.2019.0905; Cipriani A, 2016, LANCET, V388, P881, DOI 10.1016/S0140-6736(16)30385-3; Cohen D, 2012, J CLIN PSYCHOPHARM, V32, P309, DOI 10.1097/JCP.0b013e3182549259; Compton MT, 2011, J CLIN PSYCHIAT, V72, P225, DOI 10.4088/JCP.09m05704yel; Compton MT, 2011, J CLIN PSYCHIAT, V72, P1487, DOI 10.4088/JCP.09m05841yel; CONNERS CK, 1972, PSYCHOPHARMACOLOGIA, V26, P321, DOI 10.1007/BF00421898; Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018; Connor DF, 2008, J CHILD ADOL PSYCHOP, V18, P140, DOI 10.1089/cap.2006.0007; Correll CU, 2008, J AM ACAD CHILD PSY, V47, P9, DOI 10.1097/chi.0b013e31815b5cb1; Correll CU, 2020, WORLD PSYCHIATRY, V19, P69, DOI 10.1002/wps.20714; Correll CU, 2018, JAMA PSYCHIAT, V75, P555, DOI 10.1001/jamapsychiatry.2018.0623; Correll CU, 2017, JAMA PSYCHIAT, V74, P675, DOI 10.1001/jamapsychiatry.2017.0624; Correll CU, 2011, J CLIN PSYCHIAT, V72, P655, DOI 10.4088/JCP.11r07064; Correll CU, 2010, BIPOLAR DISORD, V12, P116, DOI 10.1111/j.1399-5618.2010.00798.x; Cortese S, 2019, J AM ACAD CHILD PSY, V58, P167, DOI 10.1016/j.jaac.2018.07.891; Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4; Coughlin CG, 2015, J CHILD ADOL PSYCHOP, V25, P611, DOI 10.1089/cap.2015.0075; Cueva JE, 1996, J AM ACAD CHILD PSY, V35, P480, DOI 10.1097/00004583-199604000-00014; Dagani J, 2017, CAN J PSYCHIAT, V62, P247, DOI 10.1177/0706743716656607; Dalsgaard S, 2014, J CHILD ADOL PSYCHOP, V24, P302, DOI 10.1089/cap.2014.0020; Daviss WB, 2008, J AM ACAD CHILD PSY, V47, P189, DOI 10.1097/chi.0b013e31815d9ae4; DelBello MP, 2017, J AM ACAD CHILD PSY, V56, P1015, DOI 10.1016/j.jaac.2017.10.006; DelBello MP, 2005, J AM ACAD CHILD PSY, V44, P539, DOI 10.1097/01.chi.0000159151.75345.20; DEVEAUGHGEISS J, 1992, J AM ACAD CHILD PSY, V31, P45, DOI 10.1097/00004583-199201000-00008; Dobson ET, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.17r12064; Dragioti E, 2019, JAMA PSYCHIAT, V76, P1241, DOI 10.1001/jamapsychiatry.2019.2859; Dubicka B, 2006, BRIT J PSYCHIAT, V189, P393, DOI 10.1192/bjp.bp.105.011833; Durgam S, 2018, PEDIATR DRUGS, V20, P353, DOI 10.1007/s40272-018-0290-4; Ellul P, 2018, CNS DRUGS, V32, P1103, DOI 10.1007/s40263-018-0571-z; Emslie GJ, 2002, J AM ACAD CHILD PSY, V41, P1205, DOI 10.1097/00004583-200210000-00010; Emslie GJ, 2007, J AM ACAD CHILD PSY, V46, P479, DOI 10.1097/chi.0b013e31802f5f03; Emslie GJ, 2006, J AM ACAD CHILD PSY, V45, P709, DOI 10.1097/01.chi.0000214189.73240.63; Emslie GJ, 2015, J CHILD ADOL PSYCHOP, V25, P293, DOI 10.1089/cap.2014.0076; Emslie GJ, 2014, J CHILD ADOL PSYCHOP, V24, P170, DOI 10.1089/cap.2013.0096; Emslie GJ, 2009, J AM ACAD CHILD PSY, V48, P721, DOI 10.1097/CHI.0b013e3181a2b304; Fallah MS, 2019, J CHILD ADOL PSYCHOP, V29, P168, DOI 10.1089/cap.2018.0115; Fang CM, 2019, J AFFECT DISORDERS, V257, P669, DOI 10.1016/j.jad.2019.07.062; Findling RL, 2008, AM J PSYCHIAT, V165, P1432, DOI 10.1176/appi.ajp.2008.07061035; Findling RL, 2006, EUR CHILD ADOLES PSY, V15, P450, DOI 10.1007/s00787-006-0565-0; Findling RL, 2019, J AM ACAD CHILD PSY, V58, P287, DOI 10.1016/j.jaac.2018.07.901; Findling RL, 2015, J AM ACAD CHILD PSY, V54, P1032, DOI 10.1016/j.jaac.2015.09.007; Findling RL, 2015, J AM ACAD CHILD PSY, V54, P1020, DOI 10.1016/j.jaac.2015.09.017; Findling RL, 2015, J CHILD ADOL PSYCHOP, V25, P384, DOI 10.1089/cap.2015.0027; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P531, DOI 10.1089/cap.2012.0068; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P545, DOI 10.1089/cap.2012.0029; Findling RL, 2013, J CHILD ADOL PSYCHOP, V23, P468, DOI 10.1089/cap.2012.0023; Findling RL, 2012, J CHILD ADOL PSYCHOP, V22, P327, DOI 10.1089/cap.2011.0092; Findling RL, 2009, J CLIN PSYCHIAT, V70, P1441, DOI [10.4088/JCP.09m05164yel, 10.4088/JCP.8125tx9c]; Fish FA, 2012, CURR OPIN PEDIATR, V24, P592, DOI 10.1097/MOP.0b013e328357a7c3; Fornaro M, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00294; Fornaro M, 2017, BIOMED RES INT-UK, V2017, DOI 10.1155/2017/3084859; Fung LK, 2016, PEDIATRICS, V137, pS124, DOI 10.1542/peds.2015-2851K; Galling B, 2016, JAMA PSYCHIAT, V73, P247, DOI 10.1001/jamapsychiatry.2015.2923; GELLER B, 1992, J AM ACAD CHILD PSY, V31, P34, DOI 10.1097/00004583-199201000-00007; Geller DA, 2004, J AM ACAD CHILD PSY, V43, P1387, DOI 10.1097/01.chi.0000138356.29099.f1; Geller DA, 2001, J AM ACAD CHILD PSY, V40, P773, DOI 10.1097/00004583-200107000-00011; Gerlinger G, 2013, WORLD PSYCHIATRY, V12, P155, DOI 10.1002/wps.20040; Ghio L, 2014, J AFFECT DISORDERS, V152, P45, DOI 10.1016/j.jad.2013.10.002; GITTELMANKLEIN R, 1976, ARCH GEN PSYCHIAT, V33, P1217; Goldman R, 2017, J CHILD ADOL PSYCHOP, V27, P516, DOI 10.1089/cap.2016.0189; Gracious BL, 2016, J CLIN PSYCHIAT, V77, P950, DOI 10.4088/JCP.15m09828; Greenhill LL, 2006, J AM ACAD CHILD PSY, V45, P503, DOI 10.1097/01.chi.0000205709.63571.c9; Gronholm PC, 2017, PSYCHOL MED, V47, P1867, DOI 10.1017/S0033291717000344; Haas M, 2009, J CHILD ADOL PSYCHOP, V19, P611, DOI 10.1089/cap.2008.0144; Haas M, 2009, BIPOLAR DISORD, V11, P687, DOI 10.1111/j.1399-5618.2009.00750.x; Hagman J, 2011, J AM ACAD CHILD PSY, V50, P915, DOI 10.1016/j.jaac.2011.06.009; Hammad TA, 2006, ARCH GEN PSYCHIAT, V63, P332, DOI 10.1001/archpsyc.63.3.332; Hazell P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002317.pub2; Hellings JA, 2005, J CHILD ADOL PSYCHOP, V15, P682, DOI 10.1089/cap.2005.15.682; Hemmer SA, 2001, PEDIATR NEUROL, V24, P99, DOI 10.1016/S0887-8994(00)00240-X; Hennissen L, 2017, CNS DRUGS, V31, P199, DOI 10.1007/s40263-017-0410-7; Hervas A, 2014, EUR NEUROPSYCHOPHARM, V24, P1861, DOI 10.1016/j.euroneuro.2014.09.014; Hetrick SE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004851.pub3; Higgins JP, Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2); Hirota T, 2014, J AUTISM DEV DISORD, V44, P948, DOI 10.1007/s10803-013-1952-2; Hirota T, 2014, J AM ACAD CHILD PSY, V53, P153, DOI 10.1016/j.jaac.2013.11.009; Hollander E, 2005, NEUROPSYCHOPHARMACOL, V30, P582, DOI 10.1038/sj.npp.1300627; Hollander E, 2006, J CHILD ADOL PSYCHOP, V16, P541, DOI 10.1089/cap.2006.16.541; Hollander E, 2010, NEUROPSYCHOPHARMACOL, V35, P990, DOI 10.1038/npp.2009.202; Holmskov M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178187; Huhn M, 2019, LANCET, V394, P939, DOI [10.1016/S0140-6736(19)31135-3, 10.1176/appi.focus.18306]; Hung CI, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185119; Hung CI, 2015, NEUROPSYCH DIS TREAT, V11, P2245, DOI 10.2147/NDT.S89498; Ichikawa H, 2017, CHILD PSYCHIAT HUM D, V48, P796, DOI 10.1007/s10578-016-0704-x; Ipser JC, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005170.pub2; Isacsson G, 2014, PEDIATR DRUGS, V16, P115, DOI 10.1007/s40272-013-0061-1; Jain R, 2011, J AM ACAD CHILD PSY, V50, P171, DOI 10.1016/j.jaac.2010.11.005; Jochim J, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004052.pub2; Joseph A, 2017, EUR CHILD ADOLES PSY, V26, P875, DOI 10.1007/s00787-017-0962-6; Julious SA, 2013, STAT METHODS MED RES, V22, P190, DOI 10.1177/0962280211432210; Kahbazi M, 2009, PSYCHIAT RES, V168, P234, DOI 10.1016/j.psychres.2008.06.024; Keller MB, 2001, J AM ACAD CHILD PSY, V40, P762, DOI 10.1097/00004583-200107000-00010; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kisely S, 2006, BRIT J PSYCHIAT, V189, P79, DOI 10.1192/bjp.bp.105.019869; Korno KT, 2018, J RES PHARM PRACT, V7, P205, DOI 10.4103/jrpp.JRPP_18_42; Krause M, 2018, EUR NEUROPSYCHOPHARM, V28, P659, DOI 10.1016/j.euroneuro.2018.03.008; Kryzhanovskaya L, 2009, J AM ACAD CHILD PSY, V48, P60, DOI 10.1097/CHI.0b013e3181900404; Kular A, 2019, EARLY INTERV PSYCHIA, V13, P1208, DOI 10.1111/eip.12756; Kumar A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009582.pub2; Kye CH, 1996, J AM ACAD CHILD PSY, V35, P1139, DOI 10.1097/00004583-199609000-00011; Locher C, 2017, JAMA PSYCHIAT, V74, P1011, DOI 10.1001/jamapsychiatry.2017.2432; Loebel A, 2016, J AUTISM DEV DISORD, V46, P1153, DOI 10.1007/s10803-015-2628-x; Luft MJ, 2018, CURR PROB PEDIATR AD, V48, P50, DOI 10.1016/j.cppeds.2017.12.001; Maneeton B, 2017, NEUROPSYCH DIS TREAT, V13, P1023, DOI 10.2147/NDT.S121517; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P3063, DOI 10.2147/NDT.S174622; Maneeton Narong, 2000, Journal of the Medical Association of Thailand, V83, P1367; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; March JS, 2007, BIOL PSYCHIAT, V62, P1149, DOI 10.1016/j.biopsych.2007.02.025; March JS, 1998, JAMA-J AM MED ASSOC, V280, P1752, DOI 10.1001/jama.280.20.1752; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; McAfee AT, 2008, CURR DRUG SAF, V3, P123, DOI 10.2174/157488608784529233; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Medeiros GC, 2016, REV BRAS PSIQUIATR, V38, P6; Michelson D, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e83; Montejo AL, 2018, WORLD PSYCHIATRY, V17, P3, DOI 10.1002/wps.20509; Newcorn JH, 2008, AM J PSYCHIAT, V165, P721, DOI 10.1176/appi.ajp.2007.05091676; Newcorn JH, 2017, CNS DRUGS, V31, P999, DOI 10.1007/s40263-017-0468-2; Otasowie J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006997.pub2; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Pagsberg AK, 2017, J AM ACAD CHILD PSY, V56, P191, DOI 10.1016/j.jaac.2016.12.013; PAILLEREMARTINOT ML, 1995, AM J PSYCHIAT, V152, P130; Panther Shannon G, 2017, J Pediatr Pharmacol Ther, V22, P423, DOI 10.5863/1551-6776-22.6.423; Parellada M, 2013, EUR CHILD ADOLES PSY, V22, P391, DOI 10.1007/s00787-013-0434-6; Pathak S, 2013, J CLIN PSYCHIAT, V74, pE100, DOI 10.4088/JCP.11m07424; Patra S, 2019, AUTISM RES, V12, P542, DOI 10.1002/aur.2059; Penttilä M, 2014, BRIT J PSYCHIAT, V205, P88, DOI 10.1192/bjp.bp.113.127753; POOL D, 1976, CURR THER RES CLIN E, V19, P99; Pringsheim T, 2011, DRUG SAFETY, V34, P651, DOI 10.2165/11592020-000000000-00000; Punja S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009996.pub2; Ray WA, 2019, JAMA PSYCHIAT, V76, P162, DOI 10.1001/jamapsychiatry.2018.3421; Remington G, 2001, J CLIN PSYCHOPHARM, V21, P440, DOI 10.1097/00004714-200108000-00012; Reyes M, 2006, AM J PSYCHIAT, V163, P402, DOI 10.1176/appi.ajp.163.3.402; Rezaei V, 2010, PROG NEURO-PSYCHOPH, V34, P1269, DOI 10.1016/j.pnpbp.2010.07.005; Riddle MA, 2001, J AM ACAD CHILD PSY, V40, P222, DOI 10.1097/00004583-200102000-00017; Robb AS, 2010, J CHILD ADOL PSYCHOP, V20, P463, DOI 10.1089/cap.2009.0115; Rohden AI, 2017, CLIN THER, V39, P971, DOI 10.1016/j.clinthera.2017.03.017; Rubio JM, 2017, J CLIN PSYCHIAT, V78, P464, DOI 10.4088/JCP.17ac11544; Rubio JM, 2017, J CLIN PSYCHIAT, V78, P358, DOI 10.4088/JCP.17ac11479; Rynn MA, 2007, AM J PSYCHIAT, V164, P290, DOI 10.1176/appi.ajp.164.2.290; Schachter HA, 2001, CAN MED ASSOC J, V165, P1475; Schneider-Thoma J, 2019, LANCET PSYCHIAT, V6, P753, DOI 10.1016/S2215-0366(19)30223-8; Schwartz S, 2014, J AM ACAD CHILD PSY, V53, P174, DOI 10.1016/j.jaac.2013.11.005; Sharma AN, 2016, J PSYCHOPHARMACOL, V30, P416, DOI 10.1177/0269881116636107; Sharma T, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i65; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Singh J, 2011, BIOL PSYCHIAT, V70, P1179, DOI 10.1016/j.biopsych.2011.06.021; Singh Tanvir, 2009, Psychiatry (Edgmont), V6, P30; Solmi M, 2018, EPIDEMIOL PSYCH SCI, V27, P537, DOI 10.1017/S204579601800032X; Spencer TJ, 2006, CLIN THER, V28, P402, DOI 10.1016/j.clinthera.2006.03.006; Stafford MR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117166; Steinhausen HC, 2013, J CHILD ADOL PSYCHOP, V23, P208, DOI 10.1089/cap.2012.0050; Storebo OJ, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009885.pub3, 10.1002/14651858.CD009885.pub2]; Strawn JR, 2015, J AM ACAD CHILD PSY, V54, P283, DOI 10.1016/j.jaac.2015.01.008; Strawn JR, 2015, DEPRESS ANXIETY, V32, P149, DOI 10.1002/da.22329; Stroup TS, 2018, WORLD PSYCHIATRY, V17, P341, DOI 10.1002/wps.20567; Tohen M, 2007, AM J PSYCHIAT, V164, P1547, DOI 10.1176/appi.ajp.2007.06111932; Tumuluru RV, 2017, J CHILD ADOL PSYCHOP, V27, P708, DOI 10.1089/cap.2016.0187; Uthman OA, 2010, CURR MED RES OPIN, V26, P53, DOI 10.1185/03007990903416853; Valuck RJ, 2004, CNS DRUGS, V18, P1119, DOI 10.2165/00023210-200418150-00006; Van Meter AR, 2016, J AM ACAD CHILD PSY, V55, P543, DOI 10.1016/j.jaac.2016.04.017; von Knorring AL, 2006, J CLIN PSYCHOPHARM, V26, P311, DOI 10.1097/01.jcp.0000219051.40632.d5; Wagner KD, 2009, J AM ACAD CHILD PSY, V48, P519, DOI 10.1097/CHI.0b013e31819c55ec; Wagner KD, 2006, AM J PSYCHIAT, V163, P1179, DOI 10.1176/appi.ajp.163.7.1179; Wagner KD, 2006, J AM ACAD CHILD PSY, V45, P280, DOI 10.1097/01.chi.0000192250.38400.9e; Wagner KD, 2004, ARCH GEN PSYCHIAT, V61, P1153, DOI 10.1001/archpsyc.61.11.1153; Wagner KD, 2003, JAMA-J AM MED ASSOC, V290, P1033, DOI 10.1001/jama.290.8.1033; Walkup JT, 2001, NEW ENGL J MED, V344, P1279, DOI 10.1056/NEJM200104263441703; Wang SM, 2017, J PSYCHIATR RES, V84, P292, DOI 10.1016/j.jpsychires.2016.09.034; Wang Z, 2017, JAMA PEDIATR, V171, P1049, DOI 10.1001/jamapediatrics.2017.3036; Wells GA, NEWCASTLE OTTAWA SCA; Wigal SB, 2009, CNS DRUGS, V23, P21, DOI 10.2165/00023210-200923000-00004; Wilens TE, 2012, J AM ACAD CHILD PSY, V51, P74, DOI 10.1016/j.jaac.2011.10.012; Winterstein AG, 2007, PEDIATRICS, V120, pE1494, DOI 10.1542/peds.2007-0675; Yatham LN, 2018, BIPOLAR DISORD, V20, P97, DOI 10.1111/bdi.12609; Yuan JY, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00425; Zito JM, 2017, J CHILD ADOL PSYCHOP, V27, P538, DOI 10.1089/cap.2015.0239";201;156;160;20;127;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;1723-8617;2051-5545;;WORLD PSYCHIATRY;World Psychiatry;JUN;2020;19;2;;;;;214;232;;10.1002/wps.20765;http://dx.doi.org/10.1002/wps.20765;;;19;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;LL3ZH;32394557;Green Published, Bronze;Y;N;24/11/2024;WOS:000531494700021;View Full Record in Web of Science
J;"Ray, WA; Fuchs, DC; Olfson, M; Stein, CM; Murray, KT; Daugherty, J; Cooper, WO";;;;"Ray, Wayne A.; Fuchs, D. Catherine; Olfson, Mark; Stein, Charles M.; Murray, Katherine T.; Daugherty, James; Cooper, William O.";;;Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;"neuroleptic malignant syndrome; antipsychotics; autism spectrum disorders; intellectual disability; schizophrenia spectrum and other psychotic disorders";"2ND-GENERATION ANTIPSYCHOTICS; RISK-FACTORS; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIA; ADOLESCENTS; OUTCOMES; MEDICATIONS; DEPRESSION; CATATONIA; EVENTS";Objective: The incidence of neuroleptic malignant syndrome (NMS), a rare, potentially fatal adverse effect of antipsychotics, among children and youth is unknown. This cohort study estimated NMS incidence in antipsychotic users age 5-24 years and described its variation according to patient and antipsychotic characteristics. Methods: We used national Medicaid data (2004-2013) to identify patients beginning antipsychotic treatment and calculated the incidence of NMS during antipsychotic current use. Adjusted hazard ratios (HRs) assessed the independent contribution of patient and antipsychotic characteristics to NMS risk. Results: The 1,032,084 patients had 131 NMS cases during 1,472,558 person-years of antipsychotic current use, or 8.9 per 100,000 person-years. The following five factors independently predicted increased incidence: age 18-24 years (HR [95% CI] = 2.45 [1.65-3.63]), schizophrenia spectrum and other psychotic disorders (HR = 5.86 [3.16-10.88]), neurodevelopmental disorders (HR = 7.11 [4.02-12.56]), antipsychotic dose >200mg chlorpromazine-equivalents (HR = 1.71 [1.15-2.54]), and first-generation antipsychotics (HR = 4.32 [2.74-6.82]). NMS incidence per 100,000 person-years increased from 1.8 (1.1-3.0) for those with none of these factors to 198.1 (132.8-295.6) for those with 4 or 5 factors. Findings were essentially unchanged in sensitivity analyses that restricted the study data to second-generation antipsychotics, children age 5-17 years, and the 5 most recent calendar years. Conclusion: In children and youth treated with antipsychotics, five factors independently identified patients with increased NMS incidence: age 18-24 years, schizophrenia spectrum and other psychotic disorders, neurodevelopmental disorders, first-generation drugs, and antipsychotic doses greater than 200 mg chlorpromazine-equivalents. Patients with 4 or 5 of these factors had more than 100 times the incidence of those with none. These findings could improve early identification of children and youth with elevated NMS risk, potentially leading to earlier detection and improved outcomes.;"[Ray, Wayne A.; Daugherty, James] Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Room 717, Nashville, TN 37203 USA; [Fuchs, D. Catherine] Vanderbilt Univ, Med Ctr, Dept Psychiat & Behav Sci, Div Child & Adolescent Psychiat, Nashville, TN 37203 USA; [Olfson, Mark] Columbia Univ, New York State Psychiat Inst, Irving Med Ctr, New York, NY USA; [Stein, Charles M.] Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Div Clin Pharmacol, Nashville, TN 37203 USA; [Murray, Katherine T.] Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Div Clin Pharmacol, Nashville, TN 37203 USA; [Murray, Katherine T.] Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Div Cardiovasc Med, Nashville, TN 37203 USA; [Cooper, William O.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37203 USA; [Cooper, William O.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN 37203 USA";"Vanderbilt University; Vanderbilt University; Columbia University; New York State Psychiatry Institute; NewYork-Presbyterian Hospital; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University";Ray, WA (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, 2525 West End Ave,Room 717, Nashville, TN 37203 USA.;wayne.ray@vumc.org;"Cooper, William/KWU-5718-2024; Ray, Wayne/KRQ-6238-2024; Olfson, Mark/AAA-8547-2021";Ray, Wayne/0000-0001-9188-9017;National Institute for Child Health and Human Development [HD097344];National Institute for Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD));The authors disclose that the only financial affiliation is with Grant HD097344 from the National Institute for Child Health and Human Development, which funded the study. The sponsor had no role in study design or conduct. The authors have no other relevant commercial or financial relationships.;"[Anonymous], US; Arnold SF., 1990, PRENTICE HALL, P157; Bennett AE, 2018, CURR PSYCHIAT REP, V20, DOI 10.1007/s11920-018-0967-y; Berardi D, 1998, BIOL PSYCHIAT, V44, P748, DOI 10.1016/S0006-3223(97)00530-1; Berloffa S, 2021, CHILDREN-BASEL, V8, DOI 10.3390/children8121201; Berman BD, 2011, NEUROHOSPITALIST, V1, P41, DOI 10.1177/1941875210386491; Bobo WV, 2013, JAMA PSYCHIAT, V70, P1067, DOI 10.1001/jamapsychiatry.2013.2053; Bushnell G., 2023, HLTH AFF, V42, P937; Centers for Medicare & Medicaid Services (CMS), US; Cooper WO, 2011, NEW ENGL J MED, V365, P1896, DOI 10.1056/NEJMoa1110212; Correll CU, 2006, CHILD ADOL PSYCH CL, V15, P177, DOI 10.1016/j.chc.2005.08.007; Croarkin PE, 2008, J CLIN PSYCHIAT, V69, P1157, DOI 10.4088/JCP.v69n0716; DeBattista C, 2009, CNS DRUGS, V23, P369, DOI 10.2165/00023210-200923050-00002; Duhan S, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.36428; Edelsohn GA, 2017, J AM ACAD CHILD PSY, V56, P59, DOI 10.1016/j.jaac.2016.10.005; Friedman RA, 2007, NEW ENGL J MED, V356, P2343, DOI 10.1056/NEJMp078015; Funayama M, 2018, PSYCHOSOM MED, V80, P370, DOI 10.1097/PSY.0000000000000574; Fung V, 2022, JAMA-HEALTH FORUM, V3, DOI 10.1001/jamahealthforum.2022.1996; Ghaziuddin N, 2017, J CHILD ADOL PSYCHOP, V27, P359, DOI 10.1089/cap.2016.0180; Guinart D, 2021, SCHIZOPHRENIA BULL, V47, P1621, DOI 10.1093/schbul/sbab062; Hartung DM, 2013, PSYCHIAT SERV, V64, P1236, DOI 10.1176/appi.ps.005482012; Hauptman AJ, 2023, LANCET PSYCHIAT, V10, P228, DOI 10.1016/S2215-0366(22)00436-9; Heckers S, 2023, NEW ENGL J MED, V389, P1797, DOI 10.1056/NEJMra2116304; Henderson T, 2011, SAMJ S AFR MED J, V101, P405; Hirsch Glenn S, 2018, Psychopharmacol Bull, V48, P34; Hodgins GE, 2022, PEDIATR DRUGS, V24, P465, DOI 10.1007/s40272-022-00517-y; Hsueh LRT, 2023, PSYCHIAT SERV, V74, P801, DOI 10.1176/appi.ps.20220151; KECK PE, 1989, ARCH GEN PSYCHIAT, V46, P914; Keisler-Starkey K., 2022, CURRENT POPULATION R; Kuwabara SA, 2007, GEN HOSP PSYCHIAT, V29, P317, DOI 10.1016/j.genhosppsych.2007.04.001; Lao KSJ, 2020, CNS DRUGS, V34, P1165, DOI 10.1007/s40263-020-00767-9; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P11, DOI 10.1093/oxfordjournals.schbul.a033303; León-Amenero Deborah, 2021, rev.colomb.psiquiatr., V50, P290, DOI [10.1016/j.rcpeng.2019.10.006, 10.1016/j.rcp.2019.10.003]; Leonard CE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2247-7; Leucht S, 2014, SCHIZOPHRENIA BULL, V40, P314, DOI 10.1093/schbul/sbu001; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; Meltzer HY, 2008, J CLIN PSYCHIAT, V69, P817, DOI 10.4088/JCP.v69n0515; Modi S, 2016, NEUROCRIT CARE, V24, P97, DOI 10.1007/s12028-015-0162-5; Nash KA, 2023, ACAD PEDIATR, V23, P971, DOI 10.1016/j.acap.2022.11.016; Neuhut R, 2009, J CHILD ADOL PSYCHOP, V19, P415, DOI 10.1089/cap.2008.0130; Nielsen RE, 2012, CAN J PSYCHIAT, V57, P512, DOI 10.1177/070674371205700810; Olfson M, 2015, JAMA PSYCHIAT, V72, P867, DOI 10.1001/jamapsychiatry.2015.0500; Olfson M, 2012, ARCH GEN PSYCHIAT, V69, P1247, DOI 10.1001/archgenpsychiatry.2012.647; Owen MJ, 2017, WORLD PSYCHIATRY, V16, P227, DOI 10.1002/wps.20440; Palmsten K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067405; Ray WA, 2024, JAMA PSYCHIAT, V81, P260, DOI 10.1001/jamapsychiatry.2023.4573; Rees E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25532-4; Rogers JP, 2023, J PSYCHOPHARMACOL, V37, P327, DOI 10.1177/02698811231158232; Sachdev P, 1997, AM J PSYCHIAT, V154, P1156; Schneider M, 2020, EUR ARCH PSY CLIN N, V270, P23, DOI 10.1007/s00406-018-0959-2; Shea L, 2024, JAMA PEDIATR, V178, P384, DOI 10.1001/jamapediatrics.2023.6580; Straub L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.40458; Su YP, 2014, ACTA PSYCHIAT SCAND, V130, P52, DOI 10.1111/acps.12222; Tse L, 2015, CURR NEUROPHARMACOL, V13, P395, DOI 10.2174/1570159X13999150424113345; Ty EB, 2001, J CHILD NEUROL, V16, P157, DOI 10.2310/7010.2001.17550; Walther S, 2019, LANCET PSYCHIAT, V6, P610, DOI 10.1016/S2215-0366(18)30474-7; Wijdicks EFM., 2023, UPTODATE; Wojcik NC, 2010, AM J EPIDEMIOL, V172, P469, DOI 10.1093/aje/kwq130; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663, DOI 10.4088/JCP.v64n0607";59;2;2;1;1;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;1557-8992;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;nov-01;2024;34;9;;;;;397;406;;10.1089/cap.2024.0047;http://dx.doi.org/10.1089/cap.2024.0047;;sept-24;10;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";L6N0K;39268665;;;;24/11/2024;WOS:001312717100001;View Full Record in Web of Science
J;"Gillette, MLD; Killian, HJ; Fernandez, C; Sweeney, BR";;;;"Gillette, Meredith L. Dreyer; Killian, Haley J.; Fernandez, Cristina; Sweeney, Brooke R.";;;Treating Obesity in Children and Adolescents with Special Healthcare Needs;CURRENT OBESITY REPORTS;;;English;Article;;;;;;"Pediatric obesity; Special healthcare needs; Autism spectrum disorder; Down syndrome; Metabolic and bariatric surgery";"WEIGHT MANAGEMENT; OUTCOMES; YOUTH";Purpose of Review This paper aims to summarize the literature regarding treatment of obesity in children with special healthcare needs and provide examples of implementation based on the available scientific evidence and the clinical experience of the authors. Recent Findings Due to the complexity of providing treatment for children with obesity and special healthcare needs, multidisciplinary teams are recommended to adapt care to meet the children's unique needs and ensure coordination of care across settings/caregivers. Medication management is often required to assist with the side effects of psychotropic medications. Children with special healthcare needs (SHCN) such as intellectual and developmental disabilities (IDD) should be considered for metabolic and bariatric surgery as they have similar outcomes to children without SHCN. Summary Children with special healthcare needs can be successful in weight management treatment when they have access to comprehensive care including dietary, behavioral, pharmacological, and surgical interventions. Each child requires a tailored approach to ensure their special healthcare needs are addressed within the treatment plan.;"[Gillette, Meredith L. Dreyer; Killian, Haley J.; Fernandez, Cristina; Sweeney, Brooke R.] Ctr Childrens Hlth Lifestyles & Nutr, Kansas City, MO 64108 USA; [Gillette, Meredith L. Dreyer; Killian, Haley J.] Childrens Mercy Kansas City, Div Dev, Kansas City, MO 64108 USA; [Gillette, Meredith L. Dreyer; Killian, Haley J.] Childrens Mercy Kansas City, Div Behav Hlth, Kansas City, MO 64108 USA; [Gillette, Meredith L. Dreyer; Fernandez, Cristina; Sweeney, Brooke R.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA; [Gillette, Meredith L. Dreyer; Fernandez, Cristina; Sweeney, Brooke R.] Childrens Mercy Kansas City, Div Weight Management, Kansas City, MO 64108 USA";"Children's Mercy Hospital; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Children's Mercy Hospital";"Gillette, MLD (corresponding author), Ctr Childrens Hlth Lifestyles & Nutr, Kansas City, MO 64108 USA.;Gillette, MLD (corresponding author), Childrens Mercy Kansas City, Div Dev, Kansas City, MO 64108 USA.;Gillette, MLD (corresponding author), Childrens Mercy Kansas City, Div Behav Hlth, Kansas City, MO 64108 USA.;Gillette, MLD (corresponding author), Univ Missouri, Sch Med, Kansas City, MO 64108 USA.;Gillette, MLD (corresponding author), Childrens Mercy Kansas City, Div Weight Management, Kansas City, MO 64108 USA.";mldreyer@cmh.edu;;Sweeney, Brooke/0000-0001-7436-2803;;;;"Alqahtani AR, 2016, SURG OBES RELAT DIS, V12, P100, DOI 10.1016/j.soard.2015.07.014; Burrell TL, SEMIN PEDIAT NEUROL; Chawner LR, 2019, J AUTISM DEV DISORD, V49, P3504, DOI 10.1007/s10803-019-04075-0; Contreras RE, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01015; Curtin C, 2020, PEDIATRICS, V145, pS126, DOI 10.1542/peds.2019-1895P; Data Resourse Center for Child and Adolescent Health, 2023, NAT SURV CHILDR HLTH; Foster BA, 2021, RES DEV DISABIL, V108, DOI 10.1016/j.ridd.2020.103809; Fox CK, 2019, CURR OBES REP, V8, P201, DOI 10.1007/s13679-019-00347-z; Gillette MLD, 2014, J DEV BEHAV PEDIATR, V35, P266, DOI 10.1097/DBP.0000000000000055; Goddard GR, 2019, SURG OBES RELAT DIS, V15, P1662, DOI 10.1016/j.soard.2019.07.029; Grondhuis SN, 2014, J INTELL DISABIL RES, V58, P787, DOI 10.1111/jir.12090; Healy S, 2019, INT J OBESITY, V43, P1, DOI 10.1038/s41366-018-0233-8; Hornack SE, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2908; Iyigun I, 2020, PEDIATR PULM, V55, P3532, DOI 10.1002/ppul.25097; Jones, 2021, OBES SURG, P1; Kelly Aaron S, 2022, NEJM Evid, V1, DOI 10.1056/evidoa2200014; Kelly AS, 2020, NEW ENGL J MED, V382, P2117, DOI 10.1056/NEJMoa1916038; Killian HJ, 2022, J AUTISM DEV DISORD, V52, P791, DOI 10.1007/s10803-021-04982-1; Kong KL, 2020, AM J CLIN NUTR, V112, P948, DOI 10.1093/ajcn/nqaa175; Leader G, 2020, J AUTISM DEV DISORD, V50, P1401, DOI 10.1007/s10803-019-04357-7; Liu SYW, 2020, PEDIATR OBES, V15, DOI 10.1111/ijpo.12575; Matheson BE, 2019, OBES SURG, V29, P4114, DOI 10.1007/s11695-019-04219-2; McPherson AC, 2021, DISABIL REHABIL, V43, P3015, DOI 10.1080/09638288.2020.1725155; Moore JM, 2021, SURG OBES RELAT DIS, V17, P425, DOI 10.1016/j.soard.2020.09.014; Nor NK, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00038; O'Hara VM, 2020, CURR OBES REP, V9, P451, DOI 10.1007/s13679-020-00410-0; Domecq JP, 2015, J CLIN ENDOCR METAB, V100, P363, DOI 10.1210/jc.2014-3421; Polfuss M, 2018, DISABIL HEALTH J, V11, P442, DOI 10.1016/j.dhjo.2017.12.009; Pona AA, 2017, CHILD OBES, V13, P455, DOI 10.1089/chi.2016.0334; Pratt JSA, 2018, SURG OBES RELAT DIS, V14, P882, DOI 10.1016/j.soard.2018.03.019; Ptomey LT, 2020, J INTELL DISABIL RES, V64, P725, DOI 10.1111/jir.12767; Rubin MB, 2021, DISABIL HEALTH J, V14, DOI 10.1016/j.dhjo.2020.100988; Saad M, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7120305; Simione M, 2020, J PEDIATR GASTR NUTR, V71, P270, DOI 10.1097/MPG.0000000000002741; Sollerhed AC, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020660; Stancil SL, 2019, J CHILD ADOL PSYCHOP, V29, P721, DOI 10.1089/cap.2019.0056; Stanish HI, 2016, J PHYS ACT HEALTH, V13, P102, DOI 10.1123/jpah.2014-0548; Sweeney B, 2021, CLIN OBES, V11, DOI 10.1111/cob.12417; Zhuo CJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01393";39;3;3;2;4;SPRINGER;NEW YORK;ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES;2162-4968;;;CURR OBES REP;Curr. Obes. Rep.;DEC;2022;11;4;;;;;227;235;;10.1007/s13679-022-00484-y;http://dx.doi.org/10.1007/s13679-022-00484-y;;nov-22;9;"Endocrinology & Metabolism; Nutrition & Dietetics";Science Citation Index Expanded (SCI-EXPANDED);"Endocrinology & Metabolism; Nutrition & Dietetics";6W5UQ;36319822;;;;24/11/2024;WOS:000877438300001;View Full Record in Web of Science
J;"Roche, M; Mircher, C; Toulas, J; Prioux, E; Conte, M; Ravel, A; Falquero, S; Labidi, A; Stora, S; Durand, S; Mégarbané, A; Cieuta-Walti, C";;;;"Roche, M.; Mircher, C.; Toulas, J.; Prioux, E.; Conte, M.; Ravel, A.; Falquero, S.; Labidi, A.; Stora, S.; Durand, S.; Megarbane, A.; Cieuta-Walti, C.";;;Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome;JOURNAL OF INTELLECTUAL DISABILITY RESEARCH;;;English;Article;;;;;;"attention deficit hyperactivity disorder; autism spectrum disorder; Down syndrome; methylphenidate; oppositional deficit disorder; trisomy 21";"DEFICIT/HYPERACTIVITY DISORDER; ADOLESCENTS; PREVALENCE; ADHD";"Background Attention deficit hyperactivity disorder (ADHD) is a common co-morbidity that affects up to 44% of children with Down syndrome (DS). There is a need for reliable, good quality research on the use of methylphenidate within this population. The objective of this study is to report our experience regarding the management of ADHD in these children using methylphenidate. Methods This study is a retrospective observation of 21 children with DS, followed at Jerome Lejeune Institute between 2000 and 2018. The diagnosis of ADHD was made using the Diagnostic and Statistical Manual of Mental Disorders criteria. Efficacy was measured as response or non-response on two main symptoms: attention/concentration and hyperactivity/impulsivity. Safety was evaluated by the presence or absence of side effects. Results Sixteen out of the 21 children (76%) showed improvement with methylphenidate. The average age of treatment onset in responding children was 8 years and 10 months versus 6 years and 3 months in non-responders (P = 0.05). Average dose/weight was significantly different in responders and non-responders (0.82 vs. 0.54 mg/kg/day, respectively; P = 0.03). Twelve children out of 21 (57%) experienced side effects; only three experienced side effects severe enough to require treatment interruption. Most common side effects were loss of appetite and difficulties in falling asleep. Conclusion Methylphenidate was effective and safe in treating ADHD in 76% of cases in children with DS, with few serious side effects to report. Early diagnosis of ADHD is important to improve the quality of life, learning, inclusion and socialisation of children with DS.";"[Roche, M.; Mircher, C.; Toulas, J.; Prioux, E.; Conte, M.; Ravel, A.; Falquero, S.; Labidi, A.; Stora, S.; Durand, S.; Megarbane, A.; Cieuta-Walti, C.] Inst Jerome Lejeune, CRB BioJeL, Paris, France; [Megarbane, A.] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Dept Human Genet, Byblos, Lebanon; [Cieuta-Walti, C.] Sherbrooke Med Univ, Dept Pediat Neurol, Sherbrooke, PQ, Canada";Lebanese American University;Cieuta-Walti, C (corresponding author), 37 Rue Volontaires, F-75015 Paris, France.;cecile.cieuta-walti@institutiejeunc.org;Megarbane, Andre/ABD-5574-2021;"Megarbane, andre/0000-0003-0714-2469; ROCHE, Mathilde/0000-0003-2639-0046";;;;"Al-Khudairi R., 2019, BRIT J LEARN DISABIL, P1; American Psychiatric Association, 2005, DMS 4 MANUEL DIAGNOS; American Psychiatric Association, 2015, DSM MANUEL DIAGNOSTI; ANSM, 2017, METH DONN UT SEC EMP, P26; Arnsten AFT, 2011, PHARMACOL BIOCHEM BE, V99, P211, DOI 10.1016/j.pbb.2011.01.020; Capone G, 2006, AM J MED GENET C, V142C, P158, DOI 10.1002/ajmg.c.30097; Capone GT, 2016, J CHILD NEUROL, V31, P957, DOI 10.1177/0883073816634854; Drug Utilisation Sub-Committee, 2018, PUBL REL DOC MAY 201; Ekstein S, 2011, J CHILD NEUROL, V26, P1290, DOI 10.1177/0883073811405201; Golubchik P, 2018, INT J PSYCHIAT CLIN, V22, P109, DOI 10.1080/13651501.2017.1383436; Haute Autorite de Sante, INTUNIV GUANFACINE A; Klassen AF, 2004, PEDIATRICS, V114, pE541, DOI 10.1542/peds.2004-0844; Lipkin PH, 2013, EVID-BASED MENT HEAL, V16, P104, DOI 10.1136/eb-2013-101454; Maris M, 2016, SLEEP, V39, P699, DOI 10.5665/sleep.5554; Mégarbané A, 2013, EUR J HUM GENET, V21, P1253, DOI 10.1038/ejhg.2013.24; Oxelgren UW, 2017, DEV MED CHILD NEUROL, V59, P276, DOI 10.1111/dmcn.13217; Palumbo ML, 2018, EXPERT OPIN PHARMACO, V19, P1875, DOI 10.1080/14656566.2018.1529167; Pearson DA, 2003, J AM ACAD CHILD PSY, V42, P209, DOI 10.1097/00004583-200302000-00015; Perera B, 2018, IRISH J PSYCHOL MED, V35, P213, DOI 10.1017/ipm.2018.7; Prince J, 2008, J CLIN PSYCHOPHARM, V28, pS39, DOI 10.1097/JCP.0b013e318174f92a; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; Storebo OJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5203; Sturman N, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011144.pub2; ZAMETKIN AJ, 1987, J AM ACAD CHILD PSY, V26, P676, DOI 10.1097/00004583-198709000-00011";24;8;8;0;4;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0964-2633;1365-2788;;J INTELL DISABIL RES;J. Intell. Disabil. Res.;AUG;2021;65;8;;;SI;;795;800;;10.1111/jir.12832;http://dx.doi.org/10.1111/jir.12832;;APR 2021;6;"Education, Special; Genetics & Heredity; Clinical Neurology; Psychiatry; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Genetics & Heredity; Neurosciences & Neurology; Psychiatry; Rehabilitation";TX9YR;33880800;;;;24/11/2024;WOS:000641614800001;View Full Record in Web of Science
J;"Peterson, T; Dodson, J; Burgin, S; Sherwin, R; Strale, F Jr";;;;"Peterson, Tami; Dodson, Jessica; Burgin, Sheila; Sherwin, Robert; Strale Jr, Frederick";;;Impacts of Hyperbaric Oxygen Therapy (HBOT) on Verbal Scores in Children With Autism: A Secondary Analysis of the HBOT Trial Using Multivariate Analysis of Variance (MANOVA);CUREUS JOURNAL OF MEDICAL SCIENCE;;;English;Article;;;;;;"multivariate analysis of variance (manova); applied behavior analysis (aba); ablls; vb-mapp; hyperbaric oxygen therapy (hbot); autism spectrum disorder (asd); verbal behavior milestones";"SPECTRUM DISORDER; INFLAMMATION; DYSFUNCTION; PROGRAM; DTT";Introduction A secondary analysis employing advanced statistical methodologies constitutes a robust means of validating initial findings in systematic empiricism. The current research will undertake a secondary analysis of the impacts of Hyperbaric Oxygen Therapy (HBOT) on verbal behaviors in children with autism using the original dataset. This approach aims to enhance the robustness of the initial results, thereby providing a deeper understanding of the data and potentially uncovering additional insights. Materials and methods From January 2018 to July 2021, all cohorts of autistic children (n = 65) were scheduled, evaluated, and treated at The Oxford Center (TOC) in Brighton and Troy, Michigan, USA. Trained research assistants retrospectively extracted pretest and posttest data from electronic medical records from the Verbal Behavior Milestones Assessment and Placement Program (VB-MAPP) and the Assessment of Basic Language and Learning Skills (ABLLS). This data collection focused on children with autism who received either non-HBOT control with Applied Behavior Analysis (ABA) treatment only or ABA + HBOT interventions. For the VB-MAPP, the experimental group (ABA + HBOT) included 23 children, while the control group (ABA only) included 12 children. For the ABLLS, the experimental group (ABA + HBOT) consisted of nine children, compared to 21 children in the control group (ABA only). Demographic information was systematically summarized. Two independent sample t-tests were recomputed from the original study. Multivariate Analysis of Variance (MANOVA) were conducted, followed by one-way Analyses of Variance (ANOVA) post hoc analyses to elucidate the findings. Results The ages in both groups ranged from 2 to 17 years (M = 5.7 years +/- 3.08), with median ages of four years for the experimental group and five years for the control group. The p-values and effect sizes indicated that the two independent sample t-tests from the original study and the MANOVAs from the current research are in agreement. This concordance provided confirmatory evidence for the validity of the pretest and posttest differences in VB-MAPP and ABLLS scores for the control group (ABA only) and the experimental group (ABA + HBOT), highlighting the impact of HBOT on verbal scores in children with autism. Conclusions The results from the two independent sample t-tests from the initial study exhibited high alignment with those derived from the current study's MANOVAs. Both statistical methodologies were applied to the same VB-MAPP and ABLLS datasets. The convergence of results from these two distinct statistical analyses may reinforce the credibility of the original research findings. It supports the hypothesis that the combined ABA and HBOT intervention may offer additional benefits over ABA therapy alone, with verbal milestone behaviors in children with autism.;"[Peterson, Tami; Burgin, Sheila] Oxford Ctr, Hyperbar Oxygen Therapy, Brighton, MI USA; [Dodson, Jessica] Oxford Ctr, Appl Behav Anal, Brighton, MI USA; [Sherwin, Robert] Wayne State Univ, Sch Med, Hyperbar Oxygen Therapy, Detroit, MI USA; [Strale Jr, Frederick] Oxford Ctr, Biostat, Brighton, MI 48116 USA";Wayne State University;Strale, F Jr (corresponding author), Oxford Ctr, Biostat, Brighton, MI 48116 USA.;;;;;;Acknowledgements The authors also thank technical and data specialists Isaac Riddle, Tiffany Hosey, Cloe Malik-MacDonald, Blake Powell, and Malia Kah, for their valued assistance. Data and study materials are available upon reasonable request. Data are stored as de-identified participant data, available upon request to The Oxford Center (fred.strale@theoxfordcenter.com ) .;"Abdel-Rahman EA, 2021, FREE RADICAL RES, V55, P26, DOI 10.1080/10715762.2020.1856376; [Anonymous], 2023, Data and statistics on autism spectrum disorder; [Anonymous], 2022, IBM SPSS Statistics GradPack and Faculty Packs; Anwar A, 2019, J Psychol Behav Stud, V2, P63, DOI [10.32996/jpbs.2022.2.1.7, DOI 10.32996/JPBS.2022.2.1.7]; Bjorklund G, 2018, ACTA NEUROBIOL EXP, V78, P21, DOI 10.21307/ane-2018-005; Bjorklund G, 2016, ACTA NEUROBIOL EXP, V76, P257, DOI 10.21307/ane-2017-025; Boddaert N, 2002, PEDIATR RADIOL, V32, P1, DOI 10.1007/s00247-001-0570-x; De Rubeis S, 2014, NATURE, V515, P209, DOI 10.1038/nature13772; Doenyas C, 2018, NEUROSCIENCE, V374, P271, DOI 10.1016/j.neuroscience.2018.01.060; Eikeseth S., 2014, Handbook of early intervention for autism spectrum disorders, P229, DOI [DOI 10.1007/978-1-4939-0401-3_12, 10.1007/978-1-4939-0401-312, DOI 10.1007/978-1-4939-0401-312]; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Geiger KB, 2012, BEHAV ANAL PRACT, V5, P49; Hallmayer J, 2011, ARCH GEN PSYCHIAT, V68, P1095, DOI 10.1001/archgenpsychiatry.2011.76; Hamdan MA, 2018, INT J SPEC EDUC, V33, P579; Haq SS, 2019, BEHAV ANAL PRACT, V12, P396, DOI 10.1007/s40617-018-00324-3; Lerman DC, 2016, EVID BASE PRAC BEHAV, P47, DOI 10.1007/978-3-319-30925-5_3; Murphy CM, 2016, NEUROPSYCH DIS TREAT, V12, P1669, DOI 10.2147/NDT.S65455; Nohelty K, 2022, BEHAV ANAL PRACT, V15, P643, DOI 10.1007/s40617-021-00603-6; Partington J.W., 1998, ASSESSMENT BASIC LAN; Peterson T, 2024, CUREUS J MED SCIENCE, V16, DOI 10.7759/cureus.53371; Peterson T, 2024, CUREUS J MED SCIENCE, V16, DOI 10.7759/cureus.51654; Podgórska-Bednarz J, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11070916; Rose S, 2018, MOL DIAGN THER, V22, P571, DOI 10.1007/s40291-018-0352-x; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Sigafoos J., 2019, BEHAV INTERVENT, V2nd, P227, DOI DOI 10.1037/0000126-013; Sundberg M.L., 2008, VB MAPP VERBAL BEHAV; Tonge BJ, 2002, MED J AUSTRALIA, V176, P412, DOI 10.5694/j.1326-5377.2002.tb04480.x; World Medical Association, 2023, Declaration of Helsinki";28;0;0;0;0;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;;2168-8184;;CUREUS J MED SCIENCE;Cureus J Med Sci;sept-14;2024;16;9;;;;;;;e69421;10.7759/cureus.69421;http://dx.doi.org/10.7759/cureus.69421;;;17;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;G6U9F;39411644;gold;;;24/11/2024;WOS:001317976200007;View Full Record in Web of Science
J;"Chez, M; Kile, S; Lepage, C; Parise, C; Benabides, B; Hankins, A";;;;"Chez, Michael; Kile, Shawn; Lepage, Christopher; Parise, Carol; Benabides, Bobbie; Hankins, Andrea";;;A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Autism spectrum disorder; Adults; Dextromethorphan; Quinidine; Irritability; Aggression; Placebo controlled crossover trial";"CHILDREN; SAFETY; RISPERIDONE; ADOLESCENTS; ABNORMALITIES; IRRITABILITY; ARIPIPRAZOLE; TOLERABILITY; DISORDER; BRAIN";"Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F-1,F-10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism.";"[Chez, Michael; Kile, Shawn; Lepage, Christopher] Sutter Neurosci Inst, Sacramento, CA USA; [Parise, Carol; Benabides, Bobbie; Hankins, Andrea] Sutter Inst Med Res, 2801 Capitol Ave Suite 400, Sacramento, CA 95816 USA; [Lepage, Christopher] Northwest Passage, Webster, WI USA";;Parise, C (corresponding author), Sutter Inst Med Res, 2801 Capitol Ave Suite 400, Sacramento, CA 95816 USA.;"chezM2@sutterhealth.org; parisec@sutterhealth.org";;Parise, Carol/0000-0002-3098-6160;Avanir Corporation [947135-1107629];Avanir Corporation;This study was supported by an investigator initiated research Grant from Avanir Corporation (Grant No. 947135-1107629).;"Aman M, 2015, J CHILD ADOL PSYCHOP, V25, P482, DOI 10.1089/cap.2015.0005; Baio J, 2018, MMWR SURVEILL SUMM, V67, P1, DOI 10.15585/mmwr.ss6706a1; BAUMAN M, 1985, NEUROLOGY, V35, P866, DOI 10.1212/WNL.35.6.866; Bauman M.L., 1994, NEUROBIOLOGY AUTISM; Chez MG, 2007, J CHILD NEUROL, V22, P574, DOI 10.1177/0883073807302611; Hammond FM, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0609-0; Hellings JA, 2005, J NEUROPSYCH CLIN N, V17, P29, DOI 10.1176/appi.neuropsych.17.1.29; IBM Corp, 2012, Released 2021. IBM SPSS Statistics for Windows; King BH, 2001, J AM ACAD CHILD PSY, V40, P658, DOI 10.1097/00004583-200106000-00010; Marcus RN, 2009, J AM ACAD CHILD PSY, V48, P1110, DOI 10.1097/CHI.0b013e3181b76658; Margari L, 2013, INT CLIN PSYCHOPHARM, V28, P177, DOI 10.1097/YIC.0b013e328362497b; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Orsolini L, 2016, EXPERT OPIN DRUG SAF, V15, P1329, DOI 10.1080/14740338.2016.1201475; Owen R, 2009, PEDIATRICS, V124, P1533, DOI 10.1542/peds.2008-3782; Pattee GL, 2014, CURR MED RES OPIN, V30, P2255, DOI 10.1185/03007995.2014.940040; Perry EK, 2001, AM J PSYCHIAT, V158, P1058, DOI 10.1176/appi.ajp.158.7.1058; Pioro EP, 2014, NEUROL THER, V3, P15, DOI 10.1007/s40120-014-0018-5; Posey DJ, 2004, AM J PSYCHIAT, V161, P2115, DOI 10.1176/appi.ajp.161.11.2115; Purcell AE, 2001, NEUROLOGY, V57, P1618, DOI 10.1212/WNL.57.9.1618; Schreibman L, 2000, J AUTISM DEV DISORD, V30, P373, DOI 10.1023/A:1005535120023; Woodard C, 2005, J AUTISM DEV DISORD, V35, P515, DOI 10.1007/s10803-005-5041-z; Woodard C, 2007, AUTISM, V11, P29, DOI 10.1177/1362361307070989; Zimmerman A, 1991, Patent, Patent No. [4,994,467, 4994467]";23;12;14;1;3;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;MAY;2020;50;5;;;;;1532;1538;;10.1007/s10803-018-3703-x;http://dx.doi.org/10.1007/s10803-018-3703-x;;;7;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;LK9LB;30109474;;;;24/11/2024;WOS:000531179300007;View Full Record in Web of Science
J;"Green, J; Pickles, A; Pasco, G; Bedford, R; Wan, MW; Elsabbagh, M; Slonims, V; Gliga, T; Jones, E; Cheung, C; Charman, T; Johnson, M";;;;"Green, Jonathan; Pickles, Andrew; Pasco, Greg; Bedford, Rachael; Wan, Ming Wai; Elsabbagh, Mayada; Slonims, Vicky; Gliga, Teea; Jones, Emily; Cheung, Celeste; Charman, Tony; Johnson, Mark";;British Autism Study Infant Sibli;Randomised trial of a parent-mediated intervention for infants at high risk for autism: longitudinal outcomes to age 3 years;JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY;;;English;Article;;;;;;"Pre-emptive intervention; prevention trials; autism; autism spectrum disorder; high-risk siblings; parent-mediated intervention";"AT-RISK; SPECTRUM DISORDERS; TODDLERS; PREVENTION; SIBLINGS; SCALE; START";"Background: There has been increasing interest in the potential for pre-emptive interventions in the prodrome of autism, but little investigation as to their effect. Methods:A two-site, two-arm assessor-blinded randomised controlled trial (RCT) of a 12-session parent-mediated social communication intervention delivered between 9 and 14months of age (Intervention in the British Autism Study of Infant Siblings-Video Interaction for Promoting Positive Parenting), against no intervention. Fifty-four infants (28 intervention, 26 nonintervention) at familial risk of autism but not otherwise selected for developmental atypicality were assessed at 9-month baseline, 15-month treatment endpoint, and 27- and 39-month follow-up. Primary outcome: severity of autism prodromal symptoms, blind-rated on Autism Observation Schedule for Infants or Autism Diagnostic Observation Schedule 2nd Edition across the four assessment points. Secondary outcomes: blind-rated parent-child interaction and child language; nonblind parent-rated communication and socialisation. Prespecified intention-to-treat analysis combined estimates from repeated measures within correlated regressions to estimate the overall effect of the infancy intervention over time. Results: Effect estimates in favour of intervention on autism prodromal symptoms, maximal at 27months, had confidence intervals (CIs) at each separate time point including the null, but showed a significant overall effect over the course of the intervention and follow-up period (effect size [ES]=0.32; 95% CI 0.04, 0.60; p=.026). Effects on proximal intervention targets of parent nondirectiveness/synchrony (ES=0.33; CI 0.04, 0.63; p=.013) and child attentiveness/communication initiation (ES=0.36; 95% CI 0.04, 0.68; p=.015) showed similar results. There was no effect on categorical diagnostic outcome or formal language measures. Conclusions: Follow-up to 3years of the first RCT of a very early social communication intervention for infants at familial risk of developing autism has shown a treatment effect, extending 24months after intervention end, to reduce the overall severity of autism prodromal symptoms and enhance parent-child dyadic social communication over this period. We highlight the value of extended follow-up and repeat assessment for early intervention trials.";"[Green, Jonathan] Univ Manchester, Social Dev Res Grp, Sch Biol Sci, Manchester, Lancs, England; [Green, Jonathan] Royal Manchester Childrens Hosp, Manchester, Lancs, England; [Pickles, Andrew; Pasco, Greg; Bedford, Rachael; Charman, Tony] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England; [Pickles, Andrew] South London & Maudsley NHS Fdn Trust, Natl Inst Hlth Res, Med Hlth Biomed Res Ctr, London, England; [Pasco, Greg; Elsabbagh, Mayada; Gliga, Teea; Jones, Emily; Cheung, Celeste; Johnson, Mark] Birkbeck Coll, Ctr Brain & Cognit Dev, London, England; [Wan, Ming Wai] Univ Manchester, Sch Hlth Sci, Manchester, Lancs, England; [Elsabbagh, Mayada] McGill Univ, Dept Psychiat, West Montreal, PQ, Canada; [Slonims, Vicky] Evelina London Childrens Hosp, London, England; [Slonims, Vicky] Kings Coll London, Neurosci Ctr, London, England";"University of Manchester; Royal Manchester Children's Hospital; University of London; King's College London; South London & Maudsley NHS Trust; University of London; Birkbeck University London; University of Manchester; McGill University; University of London; King's College London";Green, J (corresponding author), Univ Manchester, Dept Child & Adolescent Psychiat, Room 3-311,Jean McFarlane Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.;jonathan.green@manchester.ac.uk;"Wan, Ming/AAG-4688-2019; Green, Jonathan/L-2529-2018; Johnson, Mark/ISV-5042-2023; Jones, Emily/H-8358-2019; Salomone, Erica/M-3309-2017; Bedford, Rachael/I-3939-2012; Pickles, Andrew/A-9625-2011; Charman, Tony/A-2085-2014";"Harrop, Clare/0000-0003-3381-3473; Wan, Ming Wai/0000-0002-5353-786X; slonims, vicky/0000-0003-3339-2365; Salomone, Erica/0000-0002-8083-5942; Bedford, Rachael/0000-0002-8581-055X; Jones, Emily/0000-0001-5747-9540; Pasco, Greg/0000-0003-0290-6124; Baron-Cohen, Simon/0000-0001-9217-2544; Pickles, Andrew/0000-0003-1283-0346; Tucker, Leslie/0000-0002-9857-498X; Green, Jonathan/0000-0002-0143-181X; Booth, Rhonda/0000-0003-0133-8110; Elsabbagh, Mayada/0000-0002-7311-9059; Charman, Tony/0000-0003-1993-6549; Johnson, Mark/0000-0003-4229-2585";"BASIS funding consortium [7267]; Waterloo Foundation; Autism Speaks US; UK Medical Research Council [G0701484, MR/K021389/1]; NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College London; Sir Henry Wellcome Postdoctoral Fellowship; MRC [G0701484, MR/K021389/1] Funding Source: UKRI";"BASIS funding consortium; Waterloo Foundation; Autism Speaks US; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College London; Sir Henry Wellcome Postdoctoral Fellowship(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))";"The research was supported by awards from the BASIS funding consortium led by Autistica (No: 7267), The Waterloo Foundation and Autism Speaks US; and from the UK Medical Research Council (G0701484 and MR/K021389/1) and the NIHR Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the funders, NHS, NIHR or the UK Department of Health. R.B. is supported by a Sir Henry Wellcome Postdoctoral Fellowship. The authors are grateful for the generous contributions BASIS families have made towards this study. They acknowledge with thanks the generous collaboration from the originators of the original VIPP intervention (Femmie Juffer, Marian Bakermans Kranenberg, Marinus van IJzendoorn) that forms the basis of our intervention model. The BASIS team was: Simon Baron-Cohen, Patrick Bolton, Rhonda Booth, Ami Brooks, Kim Davies, Janice Fernandes, Isobel Gammer, Claire Harrop, Samina Holsgrove, Michelle Liew, Janet McNally, Helena Ribeiro, Erica Salomone, Carol Taylor, Leslie Tucker.";"Aldred C, 2012, J AUTISM DEV DISORD, V42, P447, DOI 10.1007/s10803-011-1248-3; [Anonymous], 2015, Stata Statistical Software: Release 14; Bakermans-Kranenburg MJ, 2003, PSYCHOL BULL, V129, P195, DOI 10.1037/0033-2909.129.2.195; Baranek Grace T, 2015, Autism Res Treat, V2015, P386951, DOI 10.1155/2015/386951; Bradshaw J, 2015, J AUTISM DEV DISORD, V45, P778, DOI 10.1007/s10803-014-2235-2; Brian J, 2008, AUTISM, V12, P433, DOI 10.1177/1362361308094500; Bryson SE, 2008, J AUTISM DEV DISORD, V38, P731, DOI 10.1007/s10803-007-0440-y; Carter AS, 2011, J CHILD PSYCHOL PSYC, V52, P741, DOI 10.1111/j.1469-7610.2011.02395.x; Dawson G, 2008, DEV PSYCHOPATHOL, V20, P775, DOI 10.1017/S0954579408000370; Elsabbagh M, 2015, J AUTISM DEV DISORD, V45, P283, DOI 10.1007/s10803-014-2192-9; Gammer I, 2015, INFANT BEHAV DEV, V38, P107, DOI 10.1016/j.infbeh.2014.12.017; Green J, 2015, LANCET PSYCHIAT, V2, P133, DOI 10.1016/S2215-0366(14)00091-1; Green J, 2013, J AUTISM DEV DISORD, V43, P2502, DOI 10.1007/s10803-013-1797-8; Green J, 2010, LANCET, V375, P2152, DOI 10.1016/S0140-6736(10)60587-9; Howe GW, 2002, DEV PSYCHOPATHOL, V14, P673, DOI 10.1017/S0954579402004029; Insel TR, 2007, EARLY INTERV PSYCHIA, V1, P5, DOI 10.1111/j.1751-7893.2007.00017.x; Johnson MH, 2015, J CHILD PSYCHOL PSYC, V56, P228, DOI 10.1111/jcpp.12328; Johnson MH, 2011, DEV COGN NEUROS-NETH, V1, P7, DOI 10.1016/j.dcn.2010.07.003; Jones EJH, 2017, AUTISM RES, V10, P961, DOI 10.1002/aur.1754; Juffer F., 2008, Promoting Positive Parenting: An Attachment-Based Intervention; Kasari C, 2014, INFANT BEHAV DEV, V37, P711, DOI 10.1016/j.infbeh.2014.08.007; Koegel LK, 2014, J POSIT BEHAV INTERV, V16, P69, DOI 10.1177/1098300713482977; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Mullen E. M., 1995, MULLEN SCALES EARLY, DOI DOI 10.1007/978-1-4419-1698-3_596; O'Connell ME, 2009, COMMITTEE PREVENTION; Pickles A, 2016, LANCET, V388, P2501, DOI 10.1016/S0140-6736(16)31229-6; Pickles A, 2015, J CHILD PSYCHOL PSYC, V56, P162, DOI 10.1111/jcpp.12291; Poslawsky IE, 2015, AUTISM, V19, P588, DOI 10.1177/1362361314537124; Rahman A, 2016, LANCET PSYCHIAT, V3, P128, DOI 10.1016/S2215-0366(15)00388-0; Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e; Rogers SJ, 2014, J AUTISM DEV DISORD, V44, P2981, DOI 10.1007/s10803-014-2202-y; Rogers SJ, 2012, J AM ACAD CHILD PSY, V51, P1052, DOI 10.1016/j.jaac.2012.08.003; Rutter M., 2012, AUTISM DIAGNOSTIC OB; Rutter M., 2003, SOCIAL COMMUNICATION; Slonims V, 2006, AM J MENT RETARD, V111, P273, DOI 10.1352/0895-8017(2006)111[273:AOMIII]2.0.CO;2; Sparrow S., 2005, Vineland adaptive behavior scales: Survey forms manual, V2nd; Steiner AM, 2013, J AUTISM DEV DISORD, V43, P91, DOI 10.1007/s10803-012-1542-8; Szatmari P, 2016, J AM ACAD CHILD PSY, V55, P179, DOI 10.1016/j.jaac.2015.12.014; Tomasello M, 2008, JEAN NICOD LECT, P1; Wan MW, 2017, INT J BEHAV DEV, V41, P542, DOI 10.1177/0165025416631835; Wan MW, 2013, J CHILD PSYCHOL PSYC, V54, P763, DOI 10.1111/jcpp.12032; Wan MW, 2012, RES DEV DISABIL, V33, P924, DOI 10.1016/j.ridd.2011.12.011; ZELLNER A, 1962, J AM STAT ASSOC, V57, P348, DOI 10.2307/2281644";43;176;201;5;67;WILEY;HOBOKEN;111 RIVER ST, HOBOKEN 07030-5774, NJ USA;0021-9630;1469-7610;;J CHILD PSYCHOL PSYC;J. Child Psychol. Psychiatry;DEC;2017;58;12;;;;;1330;1340;;10.1111/jcpp.12728;http://dx.doi.org/10.1111/jcpp.12728;;;11;"Psychology, Developmental; Psychiatry; Psychology";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Psychiatry";FN1FP;28393350;Green Published, hybrid, Green Accepted;;;24/11/2024;WOS:000415733000006;View Full Record in Web of Science
J;"Hoekstra, PJ; Troost, PW; Lahuis, BE; Mulder, H; Mulder, EJ; Franke, B; Buitelaar, JK; Anderson, GM; Scahill, L; Minderaa, RB";;;;"Hoekstra, Pieter J.; Troost, Pieter W.; Lahuis, Bertine E.; Mulder, Hans; Mulder, Erik J.; Franke, Barbara; Buitelaar, Jan K.; Anderson, George M.; Scahill, Lawrence; Minderaa, Ruud B.";;;Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene;JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY;;;English;Article;;;;;;;"PERVASIVE DEVELOPMENTAL DISORDERS; BODY-WEIGHT; LONG-TERM; THE-759C/T POLYMORPHISM; C/T POLYMORPHISM; 5-HT2C; ADOLESCENTS; CLOZAPINE; SCHIZOPHRENIA; OLANZAPINE";Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age-and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, flexible-dose risperidone treatment (mean dose: 1.70 mg/day) in 32 youths with pervasive developmental disorder (mean age 8.74, range 5-16 years) in relation to 759C/T 5-hydroxytryptamine 2C receptor (HTR2C) promoter and rs1414334 HTR2C intragenic C/G alleles, along with gender, age, and risperidone dose, using repeated measures analyses of variance. Carriers of the HTR2C promoter T allele gained an average of 0.043 +/- 0.017 body mass index-standardized z scores (1.84 +/- 1.51 kg) versus 0.64 +/- 0.35 z (3.23 +/- 1.47 kg) for non-T-allele carriers (p<0.001). Presence of the rs1414334C allele played no significant role. Further, weight gain appeared to be associated with younger age and higher doses of risperidone. The current preliminary findings suggest that the variant T allele of the -759C/T HTR2C promoter polymorphism is protective against risperidone-induced weight gain. Younger children and those treated with higher doses of risperidone may be at higher risk for weight gain.;"[Hoekstra, Pieter J.; Troost, Pieter W.; Mulder, Erik J.; Minderaa, Ruud B.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, NL-9700 AR Groningen, Netherlands; [Lahuis, Bertine E.] Univ Med Ctr Utrecht, Dept Child & Adolescent Psychiat, Utrecht, Netherlands; [Lahuis, Bertine E.] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; [Mulder, Hans] Wilhelmina Hosp Assen, Dept Clin Pharm, Assen, Netherlands; [Mulder, Hans] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands; [Franke, Barbara; Buitelaar, Jan K.] Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, NL-6525 ED Nijmegen, Netherlands; [Anderson, George M.; Scahill, Lawrence] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA";"University of Groningen; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Radboud University Nijmegen; Yale University";Hoekstra, PJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, POB 660, NL-9700 AR Groningen, Netherlands.;p.hoekstra@accare.nl;"Hoekstra, Pieter/O-4396-2014; Buitelaar, Jan/AAY-7522-2020; Franke, Barbara/D-4836-2009";"Scahill, Lawrence/0000-0001-5073-1707; Franke, Barbara/0000-0003-4375-6572";"Korczak Foundation; RUPP Autism Network (U.S. National Institute of Health) [N01MH70009]; Janssen Cilag BV; Janssen Cilag; Abbott; VCB; Shire; Medice; Eli Lilly";"Korczak Foundation; RUPP Autism Network (U.S. National Institute of Health); Janssen Cilag BV; Janssen Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Abbott(Abbott Laboratories); VCB; Shire; Medice; Eli Lilly(Eli Lilly)";"Research support came from the Korczak Foundation and the RUPP Autism Network (U.S. National Institute of Health Grant N01MH70009 to Dr. L. Scahill). The study was partially supported and study medications were donated by Janssen Cilag BV.Dr. P.J. Hoekstra has been a paid consultant to Desitin and Eli Lilly; Dr. J.K. Buitelaar is a paid consultant to or has received support from Janssen Cilag, Abbott, VCB, Shire, Medice, and Eli Lilly; Dr. R.B. Minderaa is a paid consultant to Eli Lilly and Janssen Cilag; Dr. L. Scahill is a paid consultant to Janssen Pharmaceutica, Inc., Bristol-Myers Squibb, and Pfizer; Dr. P.W. Troost has received support from Eli Lilly. The other authors have no financial relationships to disclose. However, data have been analyzed and the article was written by the primary author.";"Aman MG, 2005, J CHILD ADOL PSYCHOP, V15, P869, DOI 10.1089/cap.2005.15.869; Basile VS, 2002, LANCET, V360, P1790, DOI 10.1016/S0140-6736(02)11706-5; Buckland PR, 2005, AM J PSYCHIAT, V162, P613, DOI 10.1176/appi.ajp.162.3.613; Buckland PR, 1997, MOL BRAIN RES, V48, P45, DOI 10.1016/S0169-328X(97)00076-4; Calarge CA, 2009, J CHILD ADOL PSYCHOP, V19, P101, DOI 10.1089/cap.2008.007; CANTON H, 1994, NEUROSCI LETT, V181, P65, DOI 10.1016/0304-3940(94)90561-4; Chia Dennis J, 2006, Adv Pediatr, V53, P23, DOI 10.1016/j.yapd.2006.04.005; Ellingrod VL, 2005, AM J MED GENET B, V134B, P76, DOI 10.1002/ajmg.b.20169; Findling RL, 2004, AM J PSYCHIAT, V161, P677, DOI 10.1176/appi.ajp.161.4.677; Fleischhaker C, 2007, J NEURAL TRANSM, V114, P273, DOI 10.1007/s00702-006-0602-7; Hellings JA, 2001, J CHILD ADOL PSYCHOP, V11, P229, DOI 10.1089/10445460152595559; Lane HY, 2006, J CLIN PSYCHOPHARM, V26, P128, DOI 10.1097/01.jcp.0000203196.65710.2b; Lane HY, 2003, J CLIN PSYCHIAT, V64, P316, DOI 10.4088/JCP.v64n0314; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; LUO SQ, 1991, PHARMACOL BIOCHEM BE, V38, P495, DOI 10.1016/0091-3057(91)90003-K; Martin A, 2004, AM J PSYCHIAT, V161, P1125, DOI 10.1176/appi.ajp.161.6.1125; Martin A, 2000, J CHILD ADOL PSYCHOP, V10, P259, DOI 10.1089/cap.2000.10.259; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Müller DJ, 2006, PHARMACOGENOMICS, V7, P863, DOI 10.2217/14622416.7.6.863; Mulder H, 2007, J CLIN PSYCHOPHARM, V27, P338, DOI 10.1097/JCP.0b013e3180a76dc0; Nilsson BM, 2006, J MED CHEM, V49, P4023, DOI 10.1021/jm058240i; Park YM, 2008, J CLIN PHARM THER, V33, P55, DOI 10.1111/j.1365-2710.2008.00872.x; Pooley EC, 2004, AM J MED GENET B, V126B, P124, DOI 10.1002/ajmg.b.20143; Puhl RM, 2007, PSYCHOL BULL, V133, P557, DOI 10.1037/0033-2909.133.4.557; Reynolds GP, 2002, LANCET, V359, P2086, DOI 10.1016/S0140-6736(02)08913-4; Rosenzweig-Lipson S, 2006, BRAIN RES, V1073, P240, DOI 10.1016/j.brainres.2005.12.052; Ryu S, 2007, PROG NEURO-PSYCHOPH, V31, P673, DOI 10.1016/j.pnpbp.2006.12.021; Safer DJ, 2004, J CLIN PSYCHOPHARM, V24, P429, DOI 10.1097/01.jcp.0000130558.86125.5b; Sargent PA, 1997, PSYCHOPHARMACOLOGY, V133, P309, DOI 10.1007/s002130050407; Shea S, 2004, PEDIATRICS, V114, pE634, DOI 10.1542/peds.2003-0264-F; Somerville EM, 2007, EUR J NEUROSCI, V25, P3115, DOI 10.1111/j.1460-9568.2007.05567.x; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Templeman Lucy A, 2005, Pharmacogenet Genomics, V15, P195, DOI 10.1097/01213011-200504000-00002; Theisen FM, 2004, PSYCHIAT GENET, V14, P139, DOI 10.1097/00041444-200409000-00003; Troost PW, 2005, J AM ACAD CHILD PSY, V44, P1137, DOI 10.1097/01.chi.0000177055.11229.76; Tsai SJ, 2002, LANCET, V360, P1790, DOI 10.1016/S0140-6736(02)11705-3";37;41;43;0;6;MARY ANN LIEBERT INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;1044-5463;;;J CHILD ADOL PSYCHOP;J. Child Adolesc. Psychopharmacol.;DEC;2010;20;6;;;;;473;477;;10.1089/cap.2009.0071;http://dx.doi.org/10.1089/cap.2009.0071;;;5;"Pediatrics; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Pediatrics; Pharmacology & Pharmacy; Psychiatry";699CE;21186965;Green Submitted, Green Published;;;24/11/2024;WOS:000285640700002;View Full Record in Web of Science
J;"Janas-Kozik, M; Slopien, A; Remberk, B; Siwek, M";;;;"Janas-Kozik, Malgorzata; Slopien, Agnieszka; Remberk, Barbara; Siwek, Marcin";;;The place of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents. Recommendations of the Main Board of the Polish Psychiatric Association. Part I. Clinical efficacy and areas of application;PSYCHIATRIA POLSKA;;;Polish;Article;;;;;;"child and adolescent psychiatry; depression; SSRIs - clinical effectiveness and areas of application";"AUTISM SPECTRUM DISORDER; DOUBLE-BLIND EFFICACY; CONTROLLED TRIAL; PRACTICE GUIDELINE; FLUOXETINE; SAFETY; ANTIDEPRESSANTS; ESCITALOPRAM; MULTICENTER; CITALOPRAM";In the adult population of patients with major depression, both psychotherapeutic and pharmacological interventions are effective, but antidepressants remain the mainstay of treatment. In the case of child and adolescent psychiatry, there is still controversy over whether to use pharmacological interventions and which drug to prefer. Although psychotherapeutic treatment is still considered a first-line treatment, antidepressants are widely used to treat depression in children and adolescents, and the number of medications prescribed for this indication has increased over time. In Poland, about 57,000 patients under 18 years of age currently use reimbursed antidepressants. Antidepressants are generally effective and well tolerated by children, but between 31% and 48% will not respond to them and up to 25% will experience side effects.The aim of the study was to present the effectiveness and tolerance of antidepressants used in depression in the pediatric population. Among all SSRIs, the largest amount of data from short-term RCTs and their meta-analyses indicate the effectiveness of fluoxetine in patients diagnosed with depression <18 years of age, which still makes it the drug of first choice in this indication. However, the results of meta-analyses do not allow to draw clear conclusions as to the effectiveness of individual SSRIs in the treatment of depression in children and adolescents. Single placebo-controlled studies show the efficacy of sertraline, escitalopram and citalopram in the treatment of depression in patients <18 years of age, making them important treatment options worth considering. There is no reliable evidence on the effectiveness of fluvoxamine.;"[Janas-Kozik, Malgorzata] Slaski Uniwersytet Med & Katowicach, Katedra & Oddzial Klin Psychiat & Psychoterapii Wi, Katowice, Poland; [Janas-Kozik, Malgorzata] Ctr Zdrowia Dziecka & Rodziny Jana Paw?a II, Sosnowiec, Poland; [Slopien, Agnieszka] Uniwersytet Med Karola Marcinkowskiego Poznaniu, Klin Psychiat Dzieci & Mlodziezy, Poznan, Poland; [Remberk, Barbara] Inst Psychiat & Neurol Warszawie, Klin Psychiat Mlodziezy, Warsaw, Poland; [Siwek, Marcin] Uniwersytet Jagiellonski, Coll Medicum, Wydzial Lekarski, Zaklad Zaburzen Afektywnych,Katedra Psychiat, Krakow, Poland";"Medical University Silesia; Poznan University of Medical Sciences; Institute of Psychiatry & Neurology; Jagiellonian University; Collegium Medicum Jagiellonian University";"Janas-Kozik, M (corresponding author), Slaski Uniwersytet Med & Katowicach, Katedra & Oddzial Klin Psychiat & Psychoterapii Wi, Katowice, Poland.;Janas-Kozik, M (corresponding author), Ctr Zdrowia Dziecka & Rodziny Jana Paw?a II, Sosnowiec, Poland.";janaskozik@gmail.com;Siwek, Marcin/AAS-7764-2021;Siwek, Marcin/0000-0002-3109-1895;;;;"Al Maruf A, 2019, J AFFECT DISORDERS, V254, P98, DOI 10.1016/j.jad.2019.05.025; [Anonymous], 2023, ICD 11; [Anonymous], Dokumentacja lekow zarejestrowanych w Unii Europejskiej; [Anonymous], NICE guideline CG31; [Anonymous], NICE guideline NG134; [Anonymous], Charakterystyki produktow leczniczych; [Anonymous], Dokumentacja produktow leczniczych Agencji Zywnosci i Lekow (FDA); Arango C, 2022, LANCET PSYCHIAT, V9, P113, DOI 10.1016/S2215-0366(21)00390-4; Atkinson SD, 2014, J CHILD ADOL PSYCHOP, V24, P180, DOI 10.1089/cap.2013.0146; Bandelow B, 2023, WORLD J BIOL PSYCHIA, V24, P79, DOI 10.1080/15622975.2022.2086295; Bandelow B, 2023, WORLD J BIOL PSYCHIA, V24, P118, DOI 10.1080/15622975.2022.2086296; Berard R, 2006, J CHILD ADOL PSYCHOP, V16, P59, DOI 10.1089/cap.2006.16.59; Boaden K, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00717; Cheung AH, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-4082; Cipriani A, 2016, LANCET, V388, P881, DOI 10.1016/S0140-6736(16)30385-3; Cipriani A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006117.pub4; Couturier J, 2020, J EAT DISORD, V8, DOI 10.1186/s40337-020-0277-8; Eggart V, 2022, EUR ARCH PSY CLIN N, V272, P1559, DOI 10.1007/s00406-022-01385-w; Emslie GJ, 2002, J AM ACAD CHILD PSY, V41, P1205, DOI 10.1097/00004583-200210000-00010; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Emslie GJ, 2006, J AM ACAD CHILD PSY, V45, P709, DOI 10.1097/01.chi.0000214189.73240.63; Emslie GJ, 2014, J CHILD ADOL PSYCHOP, V24, P170, DOI 10.1089/cap.2013.0096; Emslie GJ, 2009, J AM ACAD CHILD PSY, V48, P721, DOI 10.1097/CHI.0b013e3181a2b304; Feeney A, 2022, J AFFECT DISORDERS, V305, P55, DOI 10.1016/j.jad.2022.02.074; Findling RL, 2022, J AM ACAD CHILD PSY, V61, P1106, DOI 10.1016/j.jaac.2022.01.004; Findling RL, 2020, J CHILD ADOL PSYCHOP, V30, P355, DOI 10.1089/cap.2019.0176; Findling Robert L, 2009, Child Adolesc Psychiatry Ment Health, V3, P11, DOI 10.1186/1753-2000-3-11; Geller DA, 2012, J AM ACAD CHILD PSY, V51, P98, DOI 10.1016/j.jaac.2011.09.019; Hetrick SE, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013674.pub2; Le Noury J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4320; Liang SC, 2022, J PSYCHIATR NEUROSCI, V47, pE299, DOI 10.1503/jpn.210191; MacQueen GM, 2016, CAN J PSYCHIAT, V61, P588, DOI 10.1177/0706743716659276; Maniram J, 2022, NEUROPSYCH DIS TREAT, V18, P1629, DOI 10.2147/NDT.S371013; Ostaszewski K, Kondycja psychiczna mieszkancow Polski. Raport z badan Kompleksowe badanie stanu zdrowia psychicznego spoleczenstwa i jego uwarunkowan-EZOP II; Teng T, 2022, TRANSL PSYCHIAT, V12, DOI 10.1038/s41398-022-01951-9; Thibaut F, 2016, WORLD J BIOL PSYCHIA, V17, P2, DOI 10.3109/15622975.2015.1085598; von Knorring AL, 2006, J CLIN PSYCHOPHARM, V26, P311, DOI 10.1097/01.jcp.0000219051.40632.d5; Wagner KD, 2006, J AM ACAD CHILD PSY, V45, P280, DOI 10.1097/01.chi.0000192250.38400.9e; Wagner KD, 2004, AM J PSYCHIAT, V161, P1079, DOI 10.1176/appi.ajp.161.6.1079; Wagner KD, 2003, JAMA-J AM MED ASSOC, V290, P1033, DOI 10.1001/jama.290.8.1033; Walter HJ, 2023, J AM ACAD CHILD PSY, V62, P479, DOI 10.1016/j.jaac.2022.10.001; Walter HJ, 2020, J AM ACAD CHILD PSY, V59, P1107, DOI 10.1016/j.jaac.2020.05.005; Weihs KL, 2018, J CHILD ADOL PSYCHOP, V28, P36, DOI 10.1089/cap.2017.0100; Yatham LN, 2018, BIPOLAR DISORD, V20, P97, DOI 10.1111/bdi.12609; Yu YJ, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-2477-9; Zhou XY, 2020, LANCET PSYCHIAT, V7, P581, DOI 10.1016/S2215-0366(20)30137-1; US";47;0;0;0;2;WYDAWNICZY POLSKIEGO TOWARZYSTWA;CRACOW;LENARTOWICZA 14 STRREET,, CRACOW, 31-138, POLAND;0033-2674;;;PSYCHIATR POL;Psychiatr. Pol.;;2023;57;5;;;;;899;916;;10.12740/PP/171463;http://dx.doi.org/10.12740/PP/171463;;;18;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;AY3V9;38345118;Green Submitted, gold;;;24/11/2024;WOS:001121978300011;View Full Record in Web of Science
J;"Geoffray, MM; Baltazar, M; Michelon, C; Jurek, L; Baghdadli, A";;;;"Geoffray, Marie-maude; Baltazar, Matias; Michelon, Cecile; Jurek, Lucie; Baghdadli, Amaria";;;Clinical predictors of psychotropic medication prescription in children with ASD of the ELENA cohort;FRONTIERS IN PSYCHIATRY;;;English;Article;;;;;;"autism; psychotropic; children; ASD; predictors";"AUTISM SPECTRUM DISORDERS; ADOLESCENTS; ADULTS; PARENT";"Psychotropic drugs are often used to treat behavior problems in ASD with some evidence supporting efficacity (e.g.: risperidone and irritability) but also significant side effects at the short and longer-term. It is then essential to know better the factors associated with the prescription of these medications and potentially implement early behavioral and psychosocial intervention or cognitive remediation before to use medication. We designed a case-control study based on the population of the ELENA cohort to assess the factors associated with early psychotropic drugs use in children with ASD. Externalized behavior symptoms (measured by the Child Behavior Checklist) is the leading risk factor during the first years of follow-up (aOR = 2.8; CI [1.04; 7.67]; p = 0.04). Age, gender, autism severity, adaptive behaviors, or internalized behaviors were not associated with psychotropic medication prescription. Low IQ and parents who had received training tended to increase the risk of psychotropic medication prescription during follow-up but were not statistically significant. These findings underscore the need for early identification of symptoms of externalizing behaviour, early appropriate information for parents about treatment with and without medication, early analysis of externalising behaviour and targeted treatments.";"[Geoffray, Marie-maude; Baltazar, Matias; Jurek, Lucie] Ctr Hosp Vinatier, Bron, France; [Geoffray, Marie-maude; Jurek, Lucie] Univ Claude Bernard Lyon 1, Lyon, France; [Geoffray, Marie-maude; Jurek, Lucie] INSERM, Rech Performance Soins RESHAPE, U1290, Lyon, Rhone, France; [Michelon, Cecile; Baghdadli, Amaria] Univ Montpellier, Roussillon, Languedoc Rouss, France; [Michelon, Cecile; Baghdadli, Amaria] CHU Montpellier, Roussillon, Languedoc Rouss, France; [Baghdadli, Amaria] Ctr Ressources Autisme Languedoc Roussillon, Roussillon, Languedoc Rouss, France";"Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier";"Geoffray, MM (corresponding author), Ctr Hosp Vinatier, Bron, France.;Geoffray, MM (corresponding author), Univ Claude Bernard Lyon 1, Lyon, France.;Geoffray, MM (corresponding author), INSERM, Rech Performance Soins RESHAPE, U1290, Lyon, Rhone, France.";Marie-Maude.GEOFFRAY@ch-le-vinatier.fr;"Jurek, Lucie/ABI-4434-2020; GEOFFRAY, marie-maude/GYV-3526-2022";;"French Health Ministry (DGOS); CNSA; CHU of Montpellier (AOI)";"French Health Ministry (DGOS); CNSA; CHU of Montpellier (AOI)";This research received support from the French Health Ministry (DGOS) and CNSA. The CHU of Montpellier (AOI) provided additional support. The funders had no role in study design, data collection, analysis, publishing decisions, or manuscript preparation.;"Abidin RR., 2012, PSI4SF PSYCH ASS RES, V4th; Achenbach T.M., 2010, Manual for the ASEBA schoolage makes profiles; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], 2013, Autism Spectrum Disorder in under 19's: support and management; Baghdadli A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026286; Bearss K, 2015, JAMA-J AM MED ASSOC, V313, P1524, DOI 10.1001/jama.2015.3150; Cravero C., 2017, NEUROPSYCHIATR ENFAN, V65, P33, DOI [10.1016/j.neurenf.2016.10.002, DOI 10.1016/J.NEURENF.2016.10.002]; Dellapiazza F, 2022, EUR CHILD ADOLES PSY, V31, DOI 10.1007/s00787-021-01746-1; Downs J, 2016, EUR CHILD ADOLES PSY, V25, P649, DOI 10.1007/s00787-015-0780-7; Ebesutani C, 2010, J PSYCHOPATHOL BEHAV, V32, P373, DOI 10.1007/s10862-009-9174-9; Estes A, 2015, J AM ACAD CHILD PSY, V54, P580, DOI 10.1016/j.jaac.2015.04.005; Fusar-Poli L, 2019, PSYCHIAT RES, V276, P203, DOI 10.1016/j.psychres.2019.04.013; Houghton R, 2018, AUTISM RES, V11, P1690, DOI 10.1002/aur.2040; Howlin P, 2014, J CHILD PSYCHOL PSYC, V55, P49, DOI 10.1111/jcpp.12115; Iadarola S, 2018, J AUTISM DEV DISORD, V48, P1031, DOI 10.1007/s10803-017-3339-2; Jobski K, 2017, ACTA PSYCHIAT SCAND, V135, P8, DOI 10.1111/acps.12644; Lake JK, 2014, J CHILD ADOL PSYCHOP, V24, P486, DOI 10.1089/cap.2014.0011; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C., 2012, AUTISM DIAGNOSTIC OB; Rasmussen L, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100339; Sparrow SCD., 2005, VINELAND ADAPTIVE BE";21;0;0;1;2;FRONTIERS MEDIA SA;LAUSANNE;AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND;1664-0640;;;FRONT PSYCHIATRY;Front. Psychiatry;juil-21;2023;14;;;;;;;;1153543;10.3389/fpsyt.2023.1153543;http://dx.doi.org/10.3389/fpsyt.2023.1153543;;;6;Psychiatry;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Psychiatry;O2HB6;37547200;gold, Green Published;;;24/11/2024;WOS:001042070000001;View Full Record in Web of Science
J;"Peterson, T; Hosey, T; Mosteller, J; Sherwin, R; Strale, F Jr";;;;"Peterson, Tami; Hosey, Tiffany; Mosteller, Jeffrey; Sherwin, Robert; Strale Jr, Frederick";;;A Descriptive Study on the Impacts of Hyperbaric Oxygen Therapy on Autistic Individuals Using Parent Testimonies;CUREUS JOURNAL OF MEDICAL SCIENCE;;;English;Article;;;;;;"interrater reliability; symptom assessment; parent testimonies; hyperbaric oxygen therapy (hbot); autism spectrum disorder (asd)";;"Introduction Hyperbaric oxygen therapy (HBOT) has been influential in treating many physical and psychological ailments, including the symptoms of autism. This current study aims to evaluate HBOT parents' goals and exit interviews describing the positive, negative, or no impacts experienced from the HBOT dives, asking the question, Are your child's symptoms improving? Methods Between January 2020 and July 2023, a Class B monoplace hyperbaric chamber (Sechrist 3300H, Sechrist Industries, Inc., Anaheim, California, United States)was used to administer HBOT sessions to patients with autism. Medical -grade oxygen was pressurized to 1.5-2.0 atmospheres absolute at a rate of 1-2 psi/min, with an average oxygen percentage of 100%, for up to five sessions per week. Retrospective descriptive data and patient information through parent testimonials were collected through a chart review of 30 children and one adult with autism who experienced HBOT sessions. Data were presented through exit interviews describing how parents felt about their child's progress toward goals. Four raters rated parent testimonies on a 5 -point Likert scale (1 = Much worse, 2 = Somewhat worse, 3 = Stayed the same, 4 = Somewhat improved, and 5 = Much improved), and an inter -rater reliability estimate using interclass correlation (2) (r = 0.831) was derived, indicating excellent agreement between raters. Results Parents/caregivers provided testimony in an exit interview with a registered nurse after the individual with autism received an entire course of HBOT dives. Descriptive statistics resulted in Rater #1 (M = 4.19, median = 4, SD = 0.654): 87.1% of Rater #1 ratings were Somewhat improved and Much improved; Rater #2 (M = 4.23, median = 4, SD = 0.717): 83.9% of Rater #2 ratings were Somewhat improved and Much improved; Rater #3 (M = 4.23, median = 4, SD = 0.560): 93.5% of Rater #3 ratings were Somewhat improved and Much improved; and Rater #4 (M = 4.26, median = 4, SD = 0.631): 90.3% of Rater #4 ratings were Somewhat improved and Much improved. One-way ANOVA resulted in F (3,123) = 0.052, p = 0.984, which indicated a nonstatistically significant mean difference between rater groups. Conclusions The current study assessed HBOT parents'/caregivers' goals and exit interviews, describing the effects experienced from the complete course of HBOT dives on their children/individuals. A majority of parents/caregivers declared that their condition had Much improved or Somewhat improved, based on the 5 -point Likert scale. Based on parents'/caregivers' testimonies, HBOT was demonstrated as a safe and effective intervention, and side effects were primarily mild and did not lead to treatment discontinuation. As a result of this analysis, we recommend continued use of HBOT for treatment.";"[Peterson, Tami; Hosey, Tiffany] Oxford Ctr, Hyperbar Oxygen Therapy, Brighton, MI USA; [Mosteller, Jeffrey] Oxford Ctr, Hyperbar Oxygen Therapy, Troy, MI USA; [Sherwin, Robert] Wayne State Univ, Hyperbar Oxygen Therapy, Sch Med, Detroit, MI USA; [Strale Jr, Frederick] Oxford Ctr, Biostat, Brighton, MI 48116 USA";Wayne State University;Strale, F Jr (corresponding author), Oxford Ctr, Biostat, Brighton, MI 48116 USA.;;;;;;;"[Anonymous], IBM SPSS Statistics gradpack and faculty packs; [Anonymous], 2014, Egypt J Med Hum Genet, DOI DOI 10.1016/J.EJMHG.2014.01.004; Bliese PD, 1998, ORGAN RES METHODS, V1, P355, DOI 10.1177/109442819814001; Delayen J.R., 2001, Physics Division Cryogenic Safety Manual; El-Tellawy MM, 2022, PROG NEURO-PSYCHOPH, V113, DOI 10.1016/j.pnpbp.2021.110457; Fischer I, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231911077; Fleiss JL., 1999, DESIGN ANAL CLIN EXP; Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074; Hooper M, 2020, J Med Sci Clin Res, V5, P118; JAMES LR, 1984, J APPL PSYCHOL, V69, P85, DOI 10.1037/0021-9010.69.1.85; Kostiukow Anna, 2020, Pol Merkur Lekarski, V48, P15; Lasheen RM, 2019, EJENTAS, V20, P60, DOI [10.21608/ejentas.2019.10954.1087, DOI 10.21608/EJENTAS.2019.10954.1087]; Mathieu D., 2006, Handbook on Hyperbaric Medicine, P75, DOI DOI 10.1007/1-4020-4448-86; Mathieu D., 2006, Handbook on hyperbaric medicine, P103; Meyer M, 2020, The Science Journal of the Lander College of Arts and Sciences, V13, P64; Ortega MA, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57090864; Podgórska-Bednarz J, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11070916; Rossignol DA, 2012, MOL PSYCHIATR, V17, P389, DOI 10.1038/mp.2011.165; Rossignol Daniel A, 2007, BMC Pediatr, V7, P36, DOI 10.1186/1471-2431-7-36; Rossignol DA, 2006, MED HYPOTHESES, V67, P216, DOI 10.1016/j.mehy.2006.02.009; Rossignol DA, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-21";21;0;0;1;1;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;;2168-8184;;CUREUS J MED SCIENCE;Cureus J Med Sci;mars-06;2024;16;3;;;;;;;e55648;10.7759/cureus.55648;http://dx.doi.org/10.7759/cureus.55648;;;10;Medicine, General & Internal;Emerging Sources Citation Index (ESCI);General & Internal Medicine;QJ5A7;38586763;Green Published, gold;;;24/11/2024;WOS:001220508500029;View Full Record in Web of Science
J;"Foster, BA; Reynolds, K; Callejo-Black, A; Polensek, N; Weill, BC";;;;"Foster, Byron Alexander; Reynolds, Kimberly; Callejo-Black, Alicia; Polensek, Natasha; Weill, Beau C.";;;Weight outcomes in children with developmental disabilities from a multidisciplinary clinic;RESEARCH IN DEVELOPMENTAL DISABILITIES;;;English;Article;;;;;;"Obesity; Developmental disabilities; Multidisciplinary; Interventions; Public health; Children";"FAMILY-BASED TREATMENT; AUTISM SPECTRUM DISORDER; PHYSICAL-ACTIVITY; PSYCHOTROPIC MEDICATION; INTELLECTUAL DISABILITY; CHILDHOOD OBESITY; YOUTH; INTERVENTIONS; BEHAVIORS; ADULTS";Background: Children with developmental disabilities experience disparately high rates of obesity yet there are few reports detailing clinical outcomes for this population. Aim: To describe outcomes of obesity treatment for children with developmental disabilities and a comparison group of children without developmental disabilities. Methods and procedures: We examined weight outcomes of children with and without developmental disabilities seen in a family-centered, multidisciplinary treatment center over a ten-year period. We stratified by age and developmental disability diagnosis. We assessed whether intake demographic or health behavior data was associated with successful reduction of adiposity over six and twelve month follow-up periods, using a >= 5% absolute reduction in percent over the 95th percentile body mass index (BMIp95) as the primary outcome. Outcomes and results: Over a ten-year period, 148 of 556 children in the obesity clinic (27 %) had a developmental disability. In children <12 years of age, 36 % of children with developmental disabilities reduced their adiposity compared with 18 % of children without developmental disabilities at six months, p = .01. This pattern continued at twelve months. Active transport to school was associated with reduced adiposity for those without a disability. Older children with disabilities rarely had a significant reduction (2 of 26 children), and they took more medications with weight-related side effects. Conclusions and implications: Younger children with developmental disabilities experienced relative success in reducing their adiposity. Challenges to addressing obesity in this population include structural barriers to physical activity and medications for behavioral management with weight-related side effects.;"[Foster, Byron Alexander; Reynolds, Kimberly] Oregon Hlth & Sci Univ, Dept Pediat, Sch Med, Portland, OR 97201 USA; [Foster, Byron Alexander] OHSU PSU Sch Publ Hlth, Portland, OR 97201 USA; [Callejo-Black, Alicia] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; [Polensek, Natasha] Oregon Hlth & Sci Univ, Dept Family Med & Pediat, Sch Med, Portland, OR 97201 USA; [Weill, Beau C.] Metropolitan Pediat, Portland, OR USA";"Oregon Health & Science University; University of California System; University of California San Diego; Oregon Health & Science University";Foster, BA (corresponding author), 3181 SW Sam Jackson Pk Rd CDRC P, Portland, OR 97239 USA.;fosterb@ohsu.edu;;Reynolds, Kimberly/0000-0002-6045-1116;NIH [K23DK109199];NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA);NIH K23DK109199.;"Bandini L, 2015, DISABIL HEALTH J, V8, P309, DOI 10.1016/j.dhjo.2015.04.005; Bray GA, 2017, OBES REV, V18, P715, DOI 10.1111/obr.12551; Brown CL, 2015, ACAD PEDIATR, V15, P197, DOI 10.1016/j.acap.2014.11.004; Case L, 2020, DISABIL HEALTH J, V13, DOI 10.1016/j.dhjo.2019.100881; Cermak SA, 2010, J AM DIET ASSOC, V110, P238, DOI 10.1016/j.jada.2009.10.032; Collins K, 2017, RES DEV DISABIL, V69, P49, DOI 10.1016/j.ridd.2017.07.020; Corvey K, 2016, MATERN CHILD HLTH J, V20, P466, DOI 10.1007/s10995-015-1844-5; Curtin C, 2013, J PEDIATR-US, V163, P1402, DOI 10.1016/j.jpeds.2013.06.081; Elder JH, 2015, NUTR DIET SUPPL, V7, P87, DOI 10.2147/NDS.S74718; EPSTEIN LH, 1994, HEALTH PSYCHOL, V13, P373, DOI 10.1037/0278-6133.13.5.373; Foley JT, 2014, RES DEV DISABIL, V35, P705, DOI 10.1016/j.ridd.2013.12.005; Freedman DS, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1072; Gartstein MA, 2018, J APPL DEV PSYCHOL, V56, P21, DOI 10.1016/j.appdev.2018.01.004; Goldschmidt AB, 2014, J CONSULT CLIN PSYCH, V82, P1140, DOI 10.1037/a0037169; Graf-Myles J, 2013, J DEV BEHAV PEDIATR, V34, P449, DOI 10.1097/DBP.0b013e3182a00d17; Harris L, 2018, RES DEV DISABIL, V72, P42, DOI 10.1016/j.ridd.2017.10.021; Hasnain M, 2013, POSTGRAD MED, V125, P117, DOI 10.3810/pgm.2013.09.2706; Hinckson EA, 2013, RES DEV DISABIL, V34, P1170, DOI 10.1016/j.ridd.2012.12.006; Houghton R, 2017, AUTISM RES, V10, P2037, DOI 10.1002/aur.1848; Hyman SL, 2012, PEDIATRICS, V130, pS145, DOI 10.1542/peds.2012-0900L; Jackel C, 2017, J DEV BEHAV PEDIATR, V38, P584, DOI 10.1097/DBP.0000000000000488; Keawutan P, 2017, PEDIATR PHYS THER, V29, P8, DOI 10.1097/PEP.0000000000000327; Kumar S, 2019, J PEDIATR-US, V208, P57, DOI 10.1016/j.jpeds.2018.12.049; Lai B, 2020, ADAPT PHYS ACT Q, V37, P211, DOI 10.1123/apaq.2019-0081; Lee RLT, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101178; Lloyd AB, 2014, APPETITE, V79, P149, DOI 10.1016/j.appet.2014.04.010; Luan D, 2019, PEDIATR OBES, V14, DOI 10.1111/ijpo.12457; Maïano C, 2014, RES DEV DISABIL, V35, P1914, DOI 10.1016/j.ridd.2014.04.014; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; McQuire C, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0688-2; Must A, 2014, CURR OBES REP, V3, P156, DOI 10.1007/s13679-014-0098-7; Nihalani N, 2012, CNS NEUROSCI THER, V18, P57, DOI 10.1111/j.1755-5949.2011.00232.x; Polfuss M, 2019, J PEDIATR NURS, V47, P121, DOI 10.1016/j.pedn.2019.05.009; Pona AA, 2017, CHILD OBES, V13, P455, DOI 10.1089/chi.2016.0334; Spear BA, 2007, PEDIATRICS, V120, pS254, DOI 10.1542/peds.2007-2329F; Ward ZJ, 2017, NEW ENGL J MED, V377, P2145, DOI [10.1056/NEJMoa1703860, 10.1056/nejmoa1703860]; Wilfley DE, 2017, JAMA PEDIATR, V171, P1151, DOI 10.1001/jamapediatrics.2017.2960; Zablotsky B, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0811";38;6;7;2;12;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0891-4222;1873-3379;;RES DEV DISABIL;Res. Dev. Disabil.;JAN;2021;108;;;;;;;;103809;10.1016/j.ridd.2020.103809;http://dx.doi.org/10.1016/j.ridd.2020.103809;;;9;"Education, Special; Rehabilitation";Social Science Citation Index (SSCI);"Education & Educational Research; Rehabilitation";PN8SC;33220529;Green Accepted;;;24/11/2024;WOS:000604741400010;View Full Record in Web of Science
J;"Ventola, PE; Yang, D; Abdullahi, SM; Paisley, CA; Braconnier, ML; Sukhodolsky, DG";;;;"Ventola, Pamela E.; Yang, Daniel; Abdullahi, Sebiha M.; Paisley, Courtney A.; Braconnier, Megan L.; Sukhodolsky, Denis G.";;;Brief Report: Reduced Restricted and Repetitive Behaviors after Pivotal Response Treatment;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Restricted and repetitive behaviors; Pivotal Response Treatment (PRT); Behavior therapy; Repetitive Behavior Scale-Revised (RBS-R)";"AUTISM SPECTRUM DISORDERS; PERVASIVE DEVELOPMENTAL DISORDERS; ANALYSIS ABA INTERVENTION; TYPICAL DEVELOPMENT; YOUNG-CHILDREN; TREATMENT PRT; VALIDATION; INTERESTS; ASSOCIATION; ADOLESCENTS";"Children with ASD show high frequency of restricted and repetitive behaviors (RRBs); however, higher-order RRBs, such as restricted interests, have remained largely resistant to treatment. This study evaluated change in severity of RRBs following a 16-weeks open trial of Pivotal Response Treatment (PRT). Participants included 15 children with ASD ages 4-7 years. RRBs, as measured by the repetitive behavioral scales-revised (RBS-R) and aberrant behaviors checklist, decreased significantly after treatment. These reductions remained significant after controlling for change in social communication skills. PRT shows promise in reducing RRBs; although PRT explicitly addresses pivotal social communication skills, there is a secondary and less direct effect on RRBs.";"[Ventola, Pamela E.; Yang, Daniel; Abdullahi, Sebiha M.; Paisley, Courtney A.; Braconnier, Megan L.; Sukhodolsky, Denis G.] Yale Univ, Sch Med, Yale Child Study Ctr, 230 South Frontage Rd,POB 207900, New Haven, CT 06520 USA";Yale University;Ventola, PE (corresponding author), Yale Univ, Sch Med, Yale Child Study Ctr, 230 South Frontage Rd,POB 207900, New Haven, CT 06520 USA.;pamela.ventola@yale.edu;Sukhodolsky, Denis/Z-3532-2019;"Sukhodolsky, Denis/0000-0002-5401-792X; Yang, Yung-Jui/0000-0002-3487-8730";"Autism Science Foundation; Simons Foundation; Women's Health Research at Yale; Deitz Family; Esme Usdan Family; Dwek Family";"Autism Science Foundation; Simons Foundation; Women's Health Research at Yale; Deitz Family; Esme Usdan Family; Dwek Family";Funding for this study came from Autism Science Foundation, Simons Foundation, Women's Health Research at Yale, Deitz Family, Esme Usdan & Family, and Dwek Family. We wish to thank the families of the children included in this study for their time and participation.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 1999, AUTISM DIAGNOSTIC OB; [Anonymous], ADI R AUTISM DIAGNOS; Bishop SL, 2006, CHILD NEUROPSYCHOL, V12, P247, DOI 10.1080/09297040600630288; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Boyd BA, 2012, J AUTISM DEV DISORD, V42, P1236, DOI 10.1007/s10803-011-1284-z; Carrasco M, 2012, PEDIATRICS, V129, pE1301, DOI 10.1542/peds.2011-3285; Constantino J. N., 2012, SOCIAL RESPONSIVENES; Cuccaro ML, 2003, CHILD PSYCHIAT HUM D, V34, P3, DOI 10.1023/A:1025321707947; Elliott CD., 2007, DIFFERENTIAL ABILITY, V2nd; Esbensen AJ, 2009, J AUTISM DEV DISORD, V39, P57, DOI 10.1007/s10803-008-0599-x; Gabriels RL, 2005, RES DEV DISABIL, V26, P169, DOI 10.1016/j.ridd.2004.05.003; Gabriels RL, 2008, RES AUTISM SPECT DIS, V2, P660, DOI 10.1016/j.rasd.2008.02.002; Goldman SE, 2009, DEV NEUROPSYCHOL, V34, P560, DOI 10.1080/87565640903133509; Hardan AY, 2015, J CHILD PSYCHOL PSYC, V56, P884, DOI 10.1111/jcpp.12354; Harrop C, 2016, AUTISM, V20, P330, DOI 10.1177/1362361315580443; Harrop C, 2014, J AUTISM DEV DISORD, V44, P1207, DOI 10.1007/s10803-013-1986-5; Hattori J, 2006, BRAIN DEV-JPN, V28, P371, DOI 10.1016/j.braindev.2005.11.009; Honey E, 2012, RES AUTISM SPECT DIS, V6, P355, DOI 10.1016/j.rasd.2011.06.009; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Kim SH, 2012, J AUTISM DEV DISORD, V42, P82, DOI 10.1007/s10803-011-1213-1; King BH, 2009, ARCH GEN PSYCHIAT, V66, P583, DOI 10.1001/archgenpsychiatry.2009.30; Koegel R., 1989, How to teach pivotal behaviors to children with autism; Koegel R.L., 2012, PRT POCKET GUIDE PIV; Kuhn DE, 2009, J APPL BEHAV ANAL, V42, P355, DOI 10.1901/jaba.2009.42-355; Lam KSL, 2007, J AUTISM DEV DISORD, V37, P855, DOI 10.1007/s10803-006-0213-z; Lounds J, 2007, AM J MENT RETARD, V112, P401, DOI 10.1352/0895-8017(2007)112[401:TACIAA]2.0.CO;2; Militerni R, 2002, EUR CHILD ADOLES PSY, V11, P210, DOI 10.1007/s00787-002-0279-x; Mohammadzaheri F, 2015, J AUTISM DEV DISORD, V45, P2899, DOI 10.1007/s10803-015-2451-4; Mohammadzaheri F, 2014, J AUTISM DEV DISORD, V44, P2769, DOI 10.1007/s10803-014-2137-3; Mooney EL, 2009, J AUTISM DEV DISORD, V39, P765, DOI 10.1007/s10803-008-0680-5; Nadig A, 2010, NEUROPSYCHOLOGIA, V48, P2730, DOI 10.1016/j.neuropsychologia.2010.05.020; Rapp JT, 2005, RES DEV DISABIL, V26, P527, DOI 10.1016/j.ridd.2004.11.005; Ray-Subramanian CE, 2012, J AUTISM DEV DISORD, V42, P2113, DOI 10.1007/s10803-012-1463-6; Richler J, 2007, J AUTISM DEV DISORD, V37, P73, DOI 10.1007/s10803-006-0332-6; Richler J, 2010, DEV PSYCHOPATHOL, V22, P55, DOI 10.1017/S0954579409990265; Scahill L, 2015, AUTISM, V19, P38, DOI 10.1177/1362361313510069; SCHULTZ TM, 1995, AM J MENT RETARD, V99, P376; Shattuck PT, 2007, J AUTISM DEV DISORD, V37, P1735, DOI 10.1007/s10803-006-0307-7; Soorya L, 2008, CHILD ADOL PSYCH CL, V17, P753, DOI 10.1016/j.chc.2008.06.003; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; Szatmari P, 2006, J CHILD PSYCHOL PSYC, V47, P582, DOI 10.1111/j.1469-7610.2005.01537.x; Ventola P, 2015, BRAIN IMAGING BEHAV, V9, P74, DOI 10.1007/s11682-014-9331-y; Ventola P, 2014, J AUTISM DEV DISORD, V44, P2862, DOI 10.1007/s10803-014-2145-3; Werner E, 2005, ARCH GEN PSYCHIAT, V62, P889, DOI 10.1001/archpsyc.62.8.889; Wiig E.H., 2004, CELF PRESCHOOL 2; Wiig E.H., 2006, Clinical evaluation of language fundamentals - preschool: Australian standardised edition, V2nd";47;18;22;3;51;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;AUG;2016;46;8;;;;;2813;2820;;10.1007/s10803-016-2813-6;http://dx.doi.org/10.1007/s10803-016-2813-6;;;8;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;DQ9SC;27230762;Green Accepted;;;24/11/2024;WOS:000379548600024;View Full Record in Web of Science
J;"Meints, K; Brelsford, VL; Dimolareva, M; Maréchal, L; Pennington, K; Rowan, E; Gee, NR";;;;"Meints, Kerstin; Brelsford, Victoria L.; Dimolareva, Mirena; Marechal, Laetitia; Pennington, Kyla; Rowan, Elise; Gee, Nancy R.";;;Can dogs reduce stress levels in school children? effects of dog-assisted interventions on salivary cortisol in children with and without special educational needs using randomized controlled trials;PLOS ONE;;;English;Article;;;;;;;"AUTISM SPECTRUM DISORDERS; MENTAL-HEALTH; ACADEMIC-PERFORMANCE; PERCEIVED STRESS; WORKING-MEMORY; THERAPY; ADOLESCENTS; BEHAVIOR; PROGRAM; TASK";Prolonged or excessive stress negatively affects learning, behavior and health across the life-span. To alleviate adverse effects of stress in school children, stressors should be reduced, and support and effective interventions provided. Animal-assisted interventions (AAI) have shown beneficial effects on health and wellbeing, however, robust knowledge on stress mediation in children is lacking. Despite this, AAIs are increasingly employed in settings world-wide, including schools, to reduce stress and support learning and wellbeing. This study is the first randomized controlled trial to investigate dog-assisted interventions as a mediator of stress in school children with and without special educational needs (SEN) over the school term. Interventions were carried out individually and in small groups twice a week for 20 minutes over the course of 4 weeks. We compared physiological changes in salivary cortisol in a dog intervention group with a relaxation intervention group and a no treatment control group. We compared cortisol level means before and after the 4 weeks of interventions in all children as well as acute cortisol in mainstream school children. Dog interventions lead to significantly lower stress in children with and without special educational needs compared to their peers in relaxation or no treatment control groups. In neurotypical children, those in the dog interventions showed no baseline stress level increases over the school term. In addition, acute cortisol levels evidenced significant stress reduction following the interventions. In contrast, the no treatment control group showed significant rises in baseline cortisol levels from beginning to end of school term. Increases also occurred in the relaxation intervention group. Children with SEN showed significantly decreased cortisol levels after dog group interventions. No changes occurred in the relaxation or no treatment control groups. These findings provide crucial evidence that dog interventions can successfully attenuate stress levels in school children with important implications for AAI implementation, learning and wellbeing.;"[Meints, Kerstin; Brelsford, Victoria L.; Marechal, Laetitia; Pennington, Kyla; Rowan, Elise] Univ Lincoln, Sch Psychol, Lincoln, Lincs, England; [Dimolareva, Mirena] Bath Spa Univ, Sch Sci, Dept Psychol, Bath, Somerset, England; [Gee, Nancy R.] Virginia Commonwealth Univ, Ctr Human Anim Interact, Sch Med, Richmond, VA USA";"University of Lincoln; Bath Spa University; Virginia Commonwealth University";Meints, K (corresponding author), Univ Lincoln, Sch Psychol, Lincoln, Lincs, England.;kmeints@lincoln.ac.uk;Marechal, Laetitia/U-8364-2019;"Gee, Nancy/0000-0003-2890-9884; Meints, Kerstin/0000-0003-1048-5091";WALTHAMT Centre for Pet Nutrition, Leicestershire, UK;WALTHAMT Centre for Pet Nutrition, Leicestershire, UK;The author KM received funding from 2015-2018 for this project from WALTHAMT Centre for Pet Nutrition, Leicestershire, UK. https://www.waltham.com/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.;"[Anonymous], 1991, AUDACITY 2 1 2 COPYR; [Anonymous], 2017, SALIMETRICS; Autistica [Internet, SCI STRAT C2022; Barker SB, 2005, PSYCHOL REP, V96, P713; Beetz A, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00352; Beetz A, 2011, ANTHROZOOS, V24, P349, DOI 10.2752/175303711X13159027359746; Beetz AM, 2017, APPL DEV SCI, V21, P139, DOI 10.1080/10888691.2016.1262263; Bellini S., 2006, Focus on Autism and Other Developmental Disorders, V21, P138, DOI DOI 10.1177/10883576060210030201; Berry A, 2013, J ALTERN COMPLEM MED, V19, P73, DOI 10.1089/acm.2011.0835; Bert F, 2016, EUR J INTEGR MED, V8, P695, DOI 10.1016/j.eujim.2016.05.005; Biggs K, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3807-4; Brännlund A, 2017, J MENT HEALTH, V26, P318, DOI 10.1080/09638237.2017.1294739; Brelsford VL, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10060974; Brelsford VL, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14070669; Bunterm T, 2012, PROCD SOC BEHV, V46, P5387, DOI 10.1016/j.sbspro.2012.06.444; Butzer B, 2015, J EVID-BASED INTEGR, V20, P41, DOI 10.1177/2156587214557695; Cacioppo JT, 2016, HDB PSYCHOPHYSIOBIOL; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; Clarke AM., 2015, WHAT WORKS ENHANCING; Deighton J, 2018, BRIT J DEV PSYCHOL, V36, P110, DOI 10.1111/bjdp.12218; Diamond A, 2011, SCIENCE, V333, P959, DOI 10.1126/science.1204529; Dimolareva M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051025; Duckworth AL, 2005, PSYCHOL SCI, V16, P939, DOI 10.1111/j.1467-9280.2005.01641.x; ENGEL GL, 1981, J MED PHILOS, V6, P101, DOI 10.1093/jmp/6.2.101; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fine AH, 2019, ANIMAL ASSISTED THER, V5 th ed; Freund L.S., 2016, The Social Neuroscience of HumanAnimal Interaction; Friedmann E., 2017, COMPANION ANIMALS MO, P98; Friedmann E, 2013, ANTHROZOOS, V26, P535, DOI 10.2752/175303713X13795775536138; Gee N.R., 2017, How animals help students learn: Research and practice for educators and mental-health professionals; Gee NR, 2017, AERA OPEN, V3, DOI 10.1177/2332858417724346; Gee NR, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01416; Gee NR, 2012, ANTHROZOOS, V25, P187, DOI 10.2752/175303712X13316289505387; Gee NR, 2010, ANTHROZOOS, V23, P223, DOI 10.2752/175303710X12750451258896; Gee NR, 2010, ANTHROZOOS, V23, P173, DOI 10.2752/175303710X12682332910051; Handlin L, 2012, ANTHROZOOS, V25, P215, DOI 10.2752/175303712X13316289505468; Hanrahan K, 2006, APPL NURS RES, V19, P95, DOI 10.1016/j.apnr.2006.02.001; Hergovich A, 2002, ANTHROZOOS, V15, P37, DOI 10.2752/089279302786992775; Herzog H, 2011, CURR DIR PSYCHOL SCI, V20, P236, DOI 10.1177/0963721411415220; Hoagwood KE, 2017, APPL DEV SCI, V21, P1, DOI 10.1080/10888691.2015.1134267; Jäger K, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01473; Julius H., 2013, ATTACHMENT PETS INTE; Kazdin AE, 2010, METHODOLOGICAL STAND, P519; Kelly SJ, 2008, PSYCHONEUROENDOCRINO, V33, P1257, DOI 10.1016/j.psyneuen.2008.06.010; Keperling J.P., 2017, Group interventions in schools: a guide for practitioners; Kerr C., 2005, ENCHANTED MED KIDS C; Kertes DA, 2017, SOC DEV, V26, P382, DOI 10.1111/sode.12203; KIRSCHBAUM C, 1989, NEUROPSYCHOBIOLOGY, V22, P150, DOI 10.1159/000118611; Kirschbaum C., 2000, Encyclopedia of Stress, P424; Knott F, 2006, AUTISM, V10, P609, DOI 10.1177/1362361306068510; Kotrschal K, 2003, ANTHROZOOS, V16, P147, DOI 10.2752/089279303786992170; Kudielka BM, 2009, PSYCHONEUROENDOCRINO, V34, P2, DOI 10.1016/j.psyneuen.2008.10.004; Lehman BJ, 2017, SOC PERSONAL PSYCHOL, V11, DOI 10.1111/spc3.12328; Liston C, 2009, P NATL ACAD SCI USA, V106, P912, DOI 10.1073/pnas.0807041106; Lupien SJ, 2007, BRAIN COGNITION, V65, P209, DOI 10.1016/j.bandc.2007.02.007; Lupien SJ, 2013, NEUROSCIENCE, V249, P74, DOI 10.1016/j.neuroscience.2013.01.057; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Manikandan S, 2010, J PHARMACOL PHARMACO, V1, P126, DOI 10.4103/0976-500X.72373; McCardle P, 2011, ANIMALS AFFECT US EX; McNicholas J, 2000, BRIT J PSYCHOL, V91, P61, DOI 10.1348/000712600161673; Meints K., 2017, How Animals Help Students Learn, P12; Meints K, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00257; Mowbray T, 2012, EDUC DEV PSYCHOL, V29, P141, DOI 10.1017/edp.2012.16; Lasa SM, 2015, NEUROLOGIA, V30, P1, DOI 10.1016/j.nrl.2013.01.012; Murphy M., 2012, Annual report of the chief medical officer, P1; National Scientific Council on the Developing Child, 2014, 3 NSCDC; Nicolson N, 2012, INTRO HYPOTHALAMIC P; O'Haire ME, 2014, J ALTERN COMPLEM MED, V20, P162, DOI 10.1089/acm.2013.0165; Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X; Odendaal JSJ, 2000, J PSYCHOSOM RES, V49, P275, DOI 10.1016/S0022-3999(00)00183-5; Ozbay Fatih, 2007, Psychiatry (Edgmont), V4, P35; Pascoe MC, 2020, INT J ADOLESC YOUTH, V25, P104, DOI 10.1080/02673843.2019.1596823; Pendry P, 2019, AERA OPEN, V5, DOI 10.1177/2332858419852592; Petersson M, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01796; Putnam SK, 2015, J DEV PHYS DISABIL, V27, P453, DOI 10.1007/s10882-015-9428-2; Putnam SK, 2012, CHILD PSYCHIAT HUM D, V43, P560, DOI 10.1007/s10578-012-0284-3; Reilly KM, 2020, ANTHROZOOS, V33, P339, DOI 10.1080/08927936.2020.1746523; RICHDALE AL, 1992, J AUTISM DEV DISORD, V22, P433, DOI 10.1007/BF01048245; Schonert-Reichl KA, 2015, DEV PSYCHOL, V51, P52, DOI 10.1037/a0038454; Schretzmayer L, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00090; Schupp CW, 2013, J AUTISM DEV DISORD, V43, P2405, DOI 10.1007/s10803-013-1790-2; Serpell JA, 2010, ANIMAL ASSISTED INTE, V4th ed., P11; Serpell J, 2017, APPL DEV SCI, V21, P223, DOI 10.1080/10888691.2016.1262775; Shiloh S, 2003, ANXIETY STRESS COPIN, V16, P387, DOI 10.1080/1061580031000091582; Sigfusdottir ID, 2017, HEALTH PROMOT INT, V32, P1081, DOI 10.1093/heapro/daw038; Sjörs A, 2014, BIOL PSYCHOL, V99, P193, DOI 10.1016/j.biopsycho.2014.04.002; Smyth N, 2013, SOC PERSONAL PSYCHOL, V7, P605, DOI 10.1111/spc3.12057; Souter MA, 2007, ANTHROZOOS, V20, P167, DOI 10.2752/175303707X207954; Spratt EG, 2012, J AUTISM DEV DISORD, V42, P75, DOI 10.1007/s10803-011-1214-0; Stefanini MC, 2015, COMPLEMENT THER CLIN, V21, P42, DOI 10.1016/j.ctcp.2015.01.001; Tachibana Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196272; The Key, 2017, STAT ED SURV REP 201; Viau R, 2010, PSYCHONEUROENDOCRINO, V35, P1187, DOI 10.1016/j.psyneuen.2010.02.004; Yalom I., 2020, Existential Psychotherapy, V6th; Yoo YG, 2016, J PEDIATR NURS, V31, pE185, DOI 10.1016/j.pedn.2015.12.001";95;7;8;2;22;PUBLIC LIBRARY SCIENCE;SAN FRANCISCO;1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA;1932-6203;;;PLOS ONE;PLoS One;;2022;17;6;;;;;;;e0269333;10.1371/journal.pone.0269333;http://dx.doi.org/10.1371/journal.pone.0269333;;;26;Multidisciplinary Sciences;Science Citation Index Expanded (SCI-EXPANDED);Science & Technology - Other Topics;3Y2OK;35704561;gold, Green Published;;;24/11/2024;WOS:000843567600052;View Full Record in Web of Science
J;"Capone, GT; Brecher, L; Bay, M";;;;"Capone, George T.; Brecher, Liza; Bay, Mihee";;;Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors;JOURNAL OF CHILD NEUROLOGY;;;English;Article;;;;;;"Down syndrome; intellectual disability; attention-deficit hyperactivity disorder (ADHD); disruptive behavior; aggression; guanfacine; Alpha(2a)-adrenergic agonist";"AUTISTIC-SPECTRUM DISORDERS; DEFICIT/HYPERACTIVITY DISORDER; OPEN TRIAL; NEUROBIOLOGY; CLONIDINE; SCALE; SLEEP";The purpose of this study was to characterize children with Down syndrome and attention-deficit hyperactivity disorder (ADHD) with disruptive behaviors using the Aberrant Behavior Checklist (ABC), and to measure the treatment effects of guanfacine on maladaptive behaviors. Subjects were enrolled from a group of outpatients who visited our clinic between 2002 and 2007. Subjects (N = 23) were children with Down syndrome ages 4 to 12 years (mean 7.4 +/- 4.1), who met criteria for ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. The Aberrant Behavior Checklist Irritability and Hyperactivity subscales each showed a significant decrease (P < .0001) at follow-up. The mean decline on Hyperactivity was 25% (-7.8 points), and for Irritability, 25% (-3.5 points). The mean composite score also declined by 24% (-12 points). Effect size differences on Irritability were moderate, whereas differences on Hyperactivity and composite score appeared large. Clinically important target behaviors were reduced. Medication was generally well tolerated and the incidence of treatment emergent side effects remained low.;"[Capone, George T.; Bay, Mihee] Kennedy Krieger Inst, Div Neurodev Med, 707 N Broadway, Baltimore, MD 21205 USA; [Capone, George T.; Bay, Mihee] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Brecher, Liza] Tufts Univ, Sch Med, Publ Hlth Program, Boston, MA 02111 USA; [Brecher, Liza] Tufts Univ, Sch Med, Profess Degree Program, Boston, MA 02111 USA";"Kennedy Krieger Institute; Johns Hopkins University; Tufts University; Tufts University";Capone, GT (corresponding author), Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.;capone@kennedykrieger.org;;;;;;"Aman MG, 2003, J CHILD ADOL PSYCHOP, V13, P29, DOI 10.1089/104454603321666171; AMAN MG, 1985, AM J MENT DEF, V89, P492; AMAN MG, 1985, AM J MENT DEF, V89, P485; American Psychological Association, 2013, DIAGN STAT MAN MENT, V5th, DOI 10.1176/appi.books.9780890425596; Arnsten AFT, 2011, PHARMACOL BIOCHEM BE, V99, P211, DOI 10.1016/j.pbb.2011.01.020; Borella E, 2013, RES DEV DISABIL, V34, P65, DOI 10.1016/j.ridd.2012.07.017; Capone G, 2006, AM J MED GENET C, V142C, P158, DOI 10.1002/ajmg.c.30097; Capone GT, 2008, J DEV BEHAV PEDIATR, V29, P106, DOI 10.1097/DBP.0b013e318165c100; Capone GT, 2005, AM J MED GENET A, V134A, P373, DOI 10.1002/ajmg.a.30622; Carter JC, 2007, AM J MED GENET B, V144B, P87, DOI 10.1002/ajmg.b.30407; Coe DA, 1999, J AUTISM DEV DISORD, V29, P149, DOI 10.1023/A:1023044711293; Cohen J., 1988, Statistical Power Analysis for the Behavioral Sciences; Conners K., 1990, CONNERS ABBREVIATED; Cortese S, 2012, EXPERT REV NEUROTHER, V12, P461, DOI [10.1586/ERN.12.23, 10.1586/ern.12.23]; Crosbie J, 2008, NEUROSCI BIOBEHAV R, V32, P40, DOI 10.1016/j.neubiorev.2007.05.002; Daunhauer LA, 2014, AJIDD-AM J INTELLECT, V119, P303, DOI 10.1352/1944-7558-119.4.303; Ekstein S, 2011, J CHILD NEUROL, V26, P1290, DOI 10.1177/0883073811405201; Feeley Kathleen M, 2006, Downs Syndr Res Pract, V11, P64, DOI 10.3104/perspectives.316; GREEN JM, 1989, J MENT DEFIC RES, V33, P105; HUNT RD, 1995, J AM ACAD CHILD PSY, V34, P50, DOI 10.1097/00004583-199501000-00013; Lalonde J, 1998, CAN J PSYCHIAT, V43, P623, DOI 10.1177/070674379804300612; Ma CL, 2005, BIOL PSYCHIAT, V57, P192, DOI 10.1016/j.biopsych.2004.11.004; Matthys W, 2013, DEV PSYCHOPATHOL, V25, P193, DOI 10.1017/S0954579412000272; Matthys W, 2012, CLIN CHILD FAM PSYCH, V15, P234, DOI 10.1007/s10567-012-0118-7; Owens JA, 2009, CHILD ADOL PSYCH CL, V18, P1001, DOI 10.1016/j.chc.2009.04.009; Poissant H, 2008, ENCEPHALE, V34, P161, DOI 10.1016/j.encep.2007.01.007; Prince J, 2008, J CLIN PSYCHOPHARM, V28, pS39, DOI 10.1097/JCP.0b013e318174f92a; PUESCHEL SM, 1991, J MENT DEFIC RES, V35, P502; Ramos BP, 2007, PHARMACOL THERAPEUT, V113, P523, DOI 10.1016/j.pharmthera.2006.11.006; Scahill L, 2001, AM J PSYCHIAT, V158, P1067, DOI 10.1176/appi.ajp.158.7.1067; Scahill L, 2006, J CHILD ADOL PSYCHOP, V16, P589, DOI 10.1089/cap.2006.16.589; Schnoes CJ, 2006, CLIN PEDIATR, V45, P229, DOI 10.1177/000992280604500304; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; SPIEGEL R, 1980, BRIT J CLIN PHARMACO, V10, pS165, DOI 10.1111/j.1365-2125.1980.tb04925.x; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; ZAMETKIN AJ, 1987, J AM ACAD CHILD PSY, V26, P676, DOI 10.1097/00004583-198709000-00011";36;17;18;0;5;SAGE PUBLICATIONS INC;THOUSAND OAKS;2455 TELLER RD, THOUSAND OAKS, CA 91320 USA;0883-0738;1708-8283;;J CHILD NEUROL;J. Child Neurol.;JUL;2016;31;8;;;;;957;964;;10.1177/0883073816634854;http://dx.doi.org/10.1177/0883073816634854;;;8;"Clinical Neurology; Pediatrics";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pediatrics";DQ0GL;26936058;;;;24/11/2024;WOS:000378876900001;View Full Record in Web of Science
J;"Park, M; Hanley, GE; Guhn, M; Oberlander, TF";;;;"Park, Mina; Hanley, Gillian E.; Guhn, Martin; Oberlander, Tim F.";;;Prenatal antidepressant exposure and child development at kindergarten age: a population-based study;PEDIATRIC RESEARCH;;;English;Article;;;;;;;"AUTISM SPECTRUM DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SEROTONIN REUPTAKE INHIBITORS; PREGNANCY; OUTCOMES; DEPRESSION; WOMEN; RISK; DISCONTINUATION; BEHAVIOR";"Background Though prenatal antidepressant exposure has been associated with adverse developmental outcomes, the extent to which the effects are due to prenatal drug exposure or underlying maternal mood disturbances is unclear. Methods This was a population-based retrospective cohort study using administrative data from British Columbia, Canada (n = 94,712). Analyses were designed to remove confounding effects of prenatal antidepressant exposure from maternal mood. First, children prenatally exposed to antidepressants were matched to unexposed children using high-dimensional propensity scores (HDPS). Second, children whose mothers had used antidepressants throughout pregnancy were compared against those whose mothers discontinued treatment. Results In all, 3.87% (n = 3661) of children in the overall study population were prenatally exposed to antidepressants. In both analyses, we report increased odds for lower levels of physical independence (HDPS: OR, 1.14; 95% CI, 1.00-1.30; continuers/discontinuers: OR, 1.14; 95% CI, 0.99-1.32), and higher levels of anxious behaviors (HDPS: OR, 1.30; 95% CI, 1.01-1.66; continuers/discontinuers: OR, 1.32; 95% CI, 1.01-1.72) associated with antidepressant use in pregnancy. All other relationships were not significant using these methods. Conclusions Prenatal antidepressant exposure was selectively associated with worse anxious behaviors and physical independence at kindergarten age, with no effects on other developmental domains. Effects are also likely attributable to maternal mental illness severity or other unmeasured confounding factors. Impact Selective associations between prenatal antidepressant exposure and children's anxiety and physical independence at kindergarten were identified, with no impact on other developmental domains. Contradictory reports have emerged regarding the association of adverse child outcomes with prenatal antidepressant exposure. These inconsistencies may be due to differences in control for confounding. Effects of prenatal antidepressant exposure on anxious behaviors and physical independence are likely also attributable to severity of underlying maternal mood disorders, highlighting the importance of maternal mental health for developmental health.";"[Park, Mina; Guhn, Martin; Oberlander, Tim F.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Park, Mina; Hanley, Gillian E.; Oberlander, Tim F.] British Columbia Childrens Hosp, Res Inst, Vancouver, BC, Canada; [Hanley, Gillian E.] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC, Canada; [Oberlander, Tim F.] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada";"University of British Columbia; University of British Columbia; BC Childrens Hospital; University of British Columbia; University of British Columbia";"Oberlander, TF (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.;Oberlander, TF (corresponding author), British Columbia Childrens Hosp, Res Inst, Vancouver, BC, Canada.;Oberlander, TF (corresponding author), Univ British Columbia, Dept Pediat, Vancouver, BC, Canada.";toberlander@bcchr.ca;;"Oberlander, Tim/0000-0003-4781-6579; Hanley, Gillian/0000-0001-9594-0545";"Canadian Institutes of Health Research (CIHR) [117135]; CIHR Doctoral Research Award; Canadian Institutes for Health Research New Investigator Award";"Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR Doctoral Research Award(Canadian Institutes of Health Research (CIHR)); Canadian Institutes for Health Research New Investigator Award(Canadian Institutes of Health Research (CIHR))";This research was funded by the Canadian Institutes of Health Research (CIHR) Grant 117135. M.P. was supported by a CIHR Doctoral Research Award. G.E.H. is supported by a Canadian Institutes for Health Research New Investigator Award. T.F.O. is the R. Howard Webster Professor in Brain Imaging and Child Development. The authors also thank Ursula Brain for her careful review of the manuscript.;"[Anonymous], 2014, SAS SYST WIND 9 4; Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bennett IM, 2010, PSYCHIAT SERV, V61, P386, DOI 10.1176/ps.2010.61.4.386; Bonari L, 2004, CAN J PSYCHIAT, V49, P726, DOI 10.1177/070674370404901103; Boukhris T, 2016, JAMA PEDIATR, V170, P117, DOI 10.1001/jamapediatrics.2015.3356; Brandlistuen RE, 2015, INT J EPIDEMIOL, V44, P1397, DOI 10.1093/ije/dyv030; Brinkman S, 2013, CHILD INDIC RES, V6, P695, DOI 10.1007/s12187-013-9189-3; Brown HK, 2017, JAMA-J AM MED ASSOC, V317, P1544, DOI 10.1001/jama.2017.3415; Brown Hilary K, 2017, J Clin Psychiatry, V78, pe48, DOI 10.4088/JCP.15r10194; Brummelte S, 2017, NEUROSCIENCE, V342, P212, DOI 10.1016/j.neuroscience.2016.02.037; Cheng TL, 2015, PEDIATRICS, V135, pE225, DOI 10.1542/peds.2014-3109; Cohen LS, 2006, JAMA-J AM MED ASSOC, V295, P499, DOI 10.1001/jama.295.5.499; Forer B, 2011, SOC INDIC RES, V103, P231, DOI 10.1007/s11205-011-9844-3; Galbally M, 2015, AUST NZ J PSYCHIAT, V49, P642, DOI 10.1177/0004867415569800; Grzeskowiak LE, 2016, BJOG-INT J OBSTET GY, V123, P1919, DOI 10.1111/1471-0528.13611; Guhn M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012020; Handal M, 2016, BJOG-INT J OBSTET GY, V123, P1908, DOI 10.1111/1471-0528.13582; Hanley GE, 2020, ARCH WOMEN MENT HLTH, V23, P689, DOI 10.1007/s00737-020-01034-y; Hanley GE, 2015, PEDIATR RES, V78, P174, DOI 10.1038/pr.2015.77; Hanley GE, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-242; Hanley GE, 2013, EARLY HUM DEV, V89, P519, DOI 10.1016/j.earlhumdev.2012.12.012; Hurault-Delarue C, 2016, FUND CLIN PHARMACOL, V30, P476, DOI 10.1111/fcp.12209; Hviid A, 2013, NEW ENGL J MED, V369, P2406, DOI 10.1056/NEJMoa1301449; Janus M., 2005, Early Development Instrument guide; Janus M, 2007, CAN J BEHAV SCI, V39, P1, DOI 10.1037/cjbs2007001; Jarde A, 2016, JAMA PSYCHIAT, V73, P826, DOI 10.1001/jamapsychiatry.2016.0934; Liu XQ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3668; Man KKC, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2350; Roca A, 2013, J AFFECT DISORDERS, V150, P807, DOI 10.1016/j.jad.2013.02.040; Rommel AS, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19r12965; Rotem-Kohavi N, 2017, BIRTH DEFECTS RES, V109, P909, DOI 10.1002/bdr2.1076; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Skurtveit S, 2014, BJOG-INT J OBSTET GY, V121, P1621, DOI 10.1111/1471-0528.12821; Smolina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128312; Sujan AC, 2017, JAMA-J AM MED ASSOC, V317, P1553, DOI 10.1001/jama.2017.3413; Underwood L, 2016, ARCH WOMEN MENT HLTH, V19, P711, DOI 10.1007/s00737-016-0629-1; Viktorin A, 2017, PSYCHOL MED, V47, P2787, DOI 10.1017/S0033291717001301; Viktorin A, 2017, JAMA PSYCHIAT, V74, P1031, DOI 10.1001/jamapsychiatry.2017.1727";40;3;3;2;3;SPRINGERNATURE;LONDON;CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND;0031-3998;1530-0447;;PEDIATR RES;Pediatr. Res.;MAY;2021;89;6;;;;;1515;1522;;10.1038/s41390-020-01269-6;http://dx.doi.org/10.1038/s41390-020-01269-6;;DEC 2020;8;Pediatrics;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";Pediatrics;SJ9VT;33299120;;;;24/11/2024;WOS:000599028600002;View Full Record in Web of Science
J;"Weerkamp, PMM; Geuens, S; Collin, P; Goemans, N; Vermeulen, RJ; De Waele, L; Hendriksen, JGM; Klinkenberg, S";;;;"Weerkamp, Pien M. M.; Geuens, Sam; Collin, Philippe; Goemans, Nathalie; Vermeulen, R. Jeroen; De Waele, Liesbeth; Hendriksen, Jos G. M.; Klinkenberg, Sylvia";;;Psychopharmaceutical treatment for neurobehavioral problems in Duchenne muscular dystrophy: a descriptive study using real-world data;NEUROMUSCULAR DISORDERS;;;English;Article;;;;;;;"AUTISM SPECTRUM DISORDER; DEFICIT HYPERACTIVITY DISORDER; ADOLESCENTS; CHILDREN; ADHD; METHYLPHENIDATE; METAANALYSIS; MEDICATION; MALES";"Patients with Duchenne muscular dystrophy (DMD) are at risk to develop neurobehavioral problems. Evidence on how to treat these difficulties is scarce. This descriptive study reports the clinical experience with psychopharmaceutical treatment in 52 patients with DMD.Electronic patient files were searched for patients with DMD that had been treated with psychopharmaceuticals between 2008 and 2022. Information about neurobehavioral symptoms, type of medication, side effects, and behavioral changes were collected. Two independent clinicians used the clinical global impression scale (CGI) to assess severity of the neurobehavioral problems before and the change in symptoms after treatment. Descriptive statistics were used.Our results include 52 males with DMD (mean age 11 years) treated with psychopharmaceuticals of which 55.8% had four or more comorbid neurobehavioral symptoms. The clinical condition was much improved on the GCI in 54.2% treated with methylphenidate, in 38.9% of the patients treated with fluoxetine, and in 22.2% treated with risperidone. Minimal effects and side effects were also reported.In conclusion, patients with DMD may experience severe neurobehavioral symptoms interfering with learning and/or development. Treatment with psychopharmaceuticals can improve these neurobehavioral symptoms, but further research is needed to gain better insights in psychopharmaceutical treatment in patients with DMD.& COPY; 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )";"[Weerkamp, Pien M. M.; Collin, Philippe; Hendriksen, Jos G. M.; Klinkenberg, Sylvia] Kempenhaege, Ctr Neurol Learning Disabil, Heeze, Netherlands; [Weerkamp, Pien M. M.; Hendriksen, Jos G. M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Maastricht, Netherlands; [Geuens, Sam; Goemans, Nathalie; De Waele, Liesbeth] Univ Hosp Leuven, Dept Child Neurol, Leuven, Belgium; [Geuens, Sam; De Waele, Liesbeth] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium; [Collin, Philippe] Koraal, Dept Child & Adolescent Psychiat, Sittard, Netherlands; [Vermeulen, R. Jeroen; Hendriksen, Jos G. M.; Klinkenberg, Sylvia] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands; [Weerkamp, Pien M. M.] Ctr Neurol Learning Disabil, Sterkselseweg 65, NL-5591 VE Heeze, Netherlands";"Maastricht University; KU Leuven; University Hospital Leuven; KU Leuven; Maastricht University";Weerkamp, PMM (corresponding author), Ctr Neurol Learning Disabil, Sterkselseweg 65, NL-5591 VE Heeze, Netherlands.;weerkampp@kempenhaeghe.nl;Vermeulen, Roel/F-8037-2011;Weerkamp, Pien/0000-0002-1703-486X;"Duchenne Parent Project Netherlands; Kan-Go! Fund; European Union [847826]";"Duchenne Parent Project Netherlands(Netherlands Government); Kan-Go! Fund; European Union(European Union (EU))";This work is generated within the European Reference Network for Neuromuscular Diseases. We genuinely thank Duchenne Parent Project Netherlands for their support to J.H. and S.G. and the Kan-Go! Fund for their financial support to S.G. during this research project. Also, we gratefully acknowledge support to P.W. and J.H. from the European Union Horizon 2020 Framework Programme research and innovation program Brain Involvement iN Dystrophinopathies' (grant agreement, 847826) .;"Andrews JG, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4006; Banihani R, 2015, J CHILD NEUROL, V30, P1472, DOI 10.1177/0883073815570154; Biggar WD, 2022, J NEUROMUSCULAR DIS, V9, P463, DOI 10.3233/JND-210776; Birnkrant DJ, 2018, LANCET NEUROL, V17, P445, DOI 10.1016/S1474-4422(18)30026-7; Brusa C, 2022, BRAIN SCI, V12, DOI 10.3390/brainsci12020176; Busner Joan, 2007, Psychiatry (Edgmont), V4, P28; Carucci S, 2021, NEUROSCI BIOBEHAV R, V120, P509, DOI 10.1016/j.neubiorev.2020.09.031; Chieffo D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133214; Coghill DR, 2017, EUR CHILD ADOLES PSY, V26, P1283, DOI 10.1007/s00787-017-0986-y; Cortese S, 2018, LANCET PSYCHIAT, V5, P727, DOI 10.1016/S2215-0366(18)30269-4; Cotton S, 2001, DEV MED CHILD NEUROL, V43, P497, DOI 10.1017/S0012162201000913; Darmahkasih AJ, 2020, MUSCLE NERVE, V61, P466, DOI 10.1002/mus.26803; Doorenweerd N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12981-5; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; FISCHHOFF B, 1975, J EXP PSYCHOL HUMAN, V1, P288, DOI 10.1037/0096-1523.1.3.288; Forkmann T, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-83; Fujino H, 2018, NEUROL SCI, V39, P1279, DOI 10.1007/s10072-018-3341-2; Hendriksen JGM, 2016, NEUROMUSCULAR DISORD, V26, P659, DOI 10.1016/j.nmd.2016.08.003; Hendriksen JGM, 2008, J CHILD NEUROL, V23, P477, DOI 10.1177/0883073807309775; Hennissen L, 2017, CNS DRUGS, V31, P199, DOI 10.1007/s40263-017-0410-7; Jakubovski E, 2016, AM J PSYCHIAT, V173, P174, DOI 10.1176/appi.ajp.2015.15030331; Lager C, 2015, EUR J PAEDIATR NEURO, V19, P537, DOI 10.1016/j.ejpn.2015.04.005; Latimer R, 2017, J CHILD NEUROL, V32, P663, DOI 10.1177/0883073817701368; Liang EF, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081789; Lionarons JM, 2019, EUR J PAEDIATR NEURO, V23, P152, DOI 10.1016/j.ejpn.2018.09.005; MacQueen GM, 2016, CAN J PSYCHIAT, V61, P588, DOI 10.1177/0706743716659276; Maneeton N, 2018, NEUROPSYCH DIS TREAT, V14, P1811, DOI 10.2147/NDT.S151802; Mattison RE, 2014, J CHILD ADOL PSYCHOP, V24, P347, DOI 10.1089/cap.2013.0073; Moizard MP, 2000, EUR J HUM GENET, V8, P552, DOI 10.1038/sj.ejhg.5200488; Noda S, 2021, INTERNAL MED, V60, P3983, DOI 10.2169/internalmedicine.7248-21; Olfson M, 2015, NEW ENGL J MED, V372, P2029, DOI 10.1056/NEJMsa1413512; Pane M, 2012, J PEDIATR-US, V161, P705, DOI 10.1016/j.jpeds.2012.03.020; Ricotti V, 2016, DEV MED CHILD NEUROL, V58, P77, DOI 10.1111/dmcn.12922; Rosenbaum JF., 2010, HDB PSYCHIAT DRUG TH; Scheifes A, 2013, RES DEV DISABIL, V34, P3159, DOI 10.1016/j.ridd.2013.06.009; Sienko Susan, 2016, PLoS Curr, V8, DOI 10.1371/currents.md.7628d9c014bfa29f821a5cd19723bbaa; Taylor E, 2004, EUR CHILD ADOLES PSY, V13, P7, DOI 10.1007/s00787-004-1002-x; Taylor PJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008803";39;2;2;0;0;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0960-8966;1873-2364;;NEUROMUSCULAR DISORD;Neuromusc. Disord.;JUL;2023;33;7;;;;;619;626;;10.1016/j.nmd.2023.05.011;http://dx.doi.org/10.1016/j.nmd.2023.05.011;;juil-23;8;"Clinical Neurology; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);Neurosciences & Neurology;O5FG4;37453172;hybrid, Green Published;;;24/11/2024;WOS:001044061300001;View Full Record in Web of Science
J;"Brouwer, ME; Williams, AD; van Grinsven, SE; Cuijpers, P; Lambregtse-van den Berg, MP; Burger, H; Bockting, CLH";;;;"Brouwer, Marlies E.; Williams, Alishia D.; van Grinsven, Sam E.; Cuijpers, Pim; Lambregtse-van den Berg, Mijke P.; Burger, Huibert; Bockting, Claudi L. H.";;;Offspring outcomes after prenatal interventions for common mental disorders: a meta-analysis;BMC MEDICINE;;;English;Article;;;;;;"Common mental disorders; Prenatal interventions; Offspring; Child; Pregnancy; Antidepressant; Psychotherapy; Depression; Anxiety";"STRESS-MANAGEMENT INTERVENTION; COGNITIVE-BEHAVIOR THERAPY; AUTISM SPECTRUM DISORDER; FOR-GESTATIONAL-AGE; LOW-BIRTH-WEIGHT; ANTIDEPRESSANT USE; PREGNANT-WOMEN; PRETERM BIRTH; DEPRESSION INTERVENTION; MATERNAL DEPRESSION";BackgroundIt is presumed that pharmacological and non-pharmacological treatment of prenatal common mental disorders can mitigate associated adverse effects in offspring, yet strong evidence for the prophylactic benefits of treatment is lacking. We therefore examined the effect of prenatal treatments for common mental disorders on offspring outcomes.MethodsFor this meta-analysis, articles published up to August 31, 2017, were obtained from PubMed, PsycInfo, Embase, and Cochrane databases. Included studies needed to be randomized controlled trials (RCTs) on the effect of treatment of prenatal common mental disorders comparing an intervention to a control condition, including offspring outcome(s). Random effects models were used to calculate Hedges' g in the program Comprehensive Meta-Analysis((c)) (version 3.0).ResultsSixteen randomized controlled trials among 2778 pregnant women compared offspring outcomes between prenatal interventions and control groups. There were zero pharmacological, 13 psychological, and three other interventions (homeopathy, relaxation interventions, and short psycho-education). Birth weight (mean difference 42.88g, g=0.08, 95% CI -0.06 to 0.22, p=0.27, n=11), Apgar scores (g=0.13, 95% CI -0.28 to 0.54, p=0.53, n=4), and gestational age (g=0.03, 95% CI -0.06 to 0.54, p=0.49, n=10) were not significantly affected. Other offspring outcomes could not be meta-analyzed due to the inconsistent reporting of offspring outcomes and an insufficient number of studies.ConclusionsNon-pharmacological interventions had no significant effect on birth outcomes, although this outcome should be considered with caution due to the risk of biases. No randomized controlled trial examined the effects of prenatal pharmacological treatments as compared to treatment as usual for common mental disorders on offspring outcomes. Present clinical guidelines may require more research evidence on offspring outcomes, including child development, in order to warrant the current recommendation to routinely screen and subsequently treat prenatal common mental disorders.Trial registrationPROSPERO CRD42016047190;"[Brouwer, Marlies E.; Williams, Alishia D.; van Grinsven, Sam E.] Univ Utrecht, Dept Clin Psychol, Heidelberglaan 1, NL-3584 CS Utrecht, Netherlands; [Brouwer, Marlies E.; Bockting, Claudi L. H.] Univ Amsterdam, Amsterdam Univ Med Ctr, Locat AMC, Dept Psychiat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Cuijpers, Pim] Vrije Univ Amsterdam, Dept Clin Neuro & Dev Psychol, Boechorststr 1, NL-1081 BT Amsterdam, Netherlands; [Lambregtse-van den Berg, Mijke P.] Erasmus MC, Dept Psychiat & Child & Adolescent Psychiat Psych, POB 2060, NL-3000 CB Rotterdam, Netherlands; [Burger, Huibert] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands; [Williams, Alishia D.] Univ New South Wales, Fac Sci, Sch Psychol, Sydney, NSW 2052, Australia";"Utrecht University; University of Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; University of Groningen; University of New South Wales Sydney";Bockting, CLH (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr, Locat AMC, Dept Psychiat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.;c.l.bockting@amc.uva.nl;Bockting, Claudi/K-3768-2019;"Brouwer, Marlies/0000-0002-9972-9058; Lambregtse-van den Berg, Mijke/0000-0003-1764-5940; Burger, Huibert/0000-0001-6484-0349; Bockting, Claudi L.H./0000-0002-9220-9244";;;;"Alder J, 2007, J MATERN-FETAL NEO M, V20, P189, DOI 10.1080/14767050701209560; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, DOI 10.1176/dsm10.1176/appi.books.9780890420249.dsm-iv-tr; [Anonymous], 2014, Antenatal and postnatal mental health: clinical management and service guidance; [Anonymous], 2004, Low birthweight: Country, regional and global estimates; BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111; Bastani F, 2006, J PERINAT NEONAT NUR, V20, P138, DOI 10.1097/00005237-200604000-00007; Bayley N., 2006, BAYLEY SCALES INFANT; Belbasis L, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0692-5; Bennett HA, 2004, OBSTET GYNECOL, V103, P698, DOI 10.1097/01.AOG.0000116689.75396.5f; Bockting CL, 2015, CLIN PSYCHOL REV, V41, P16, DOI 10.1016/j.cpr.2015.02.003; Borenstein M., 2021, INTRO META ANAL; Brazelton T B, 1978, Monogr Soc Res Child Dev, V43, P1, DOI 10.2307/1165847; Brown HK, 2017, JAMA-J AM MED ASSOC, V317, P1544, DOI 10.1001/jama.2017.3415; Cappon R., 2015, Anxious Origins: Attenuating Maternal and Fetal Anxiety with Acoustically Modified Music; Chambers AS, 2009, RELAXATION PREGNANCY; Charlton RA, 2015, BJOG-INT J OBSTET GY, V122, P1010, DOI 10.1111/1471-0528.13143; Cuijpers P, 2015, EUR CHILD ADOLES PSY, V24, P237, DOI 10.1007/s00787-014-0660-6; de Mola CL, 2014, BRIT J PSYCHIAT, V205, P340, DOI 10.1192/bjp.bp.113.139014; de Vilhena EC, 2016, ALTERN THER HEALTH M, V22, P14; Dennis CL, 2017, BRIT J PSYCHIAT, V210, P315, DOI 10.1192/bjp.bp.116.187179; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Fenwick J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0721-y; Field T, 2009, INFANT BEHAV DEV, V32, P454, DOI 10.1016/j.infbeh.2009.07.001; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman SH, 2018, DEV PSYCHOPATHOL, V30, P1179, DOI 10.1017/S0954579418000536; Grigoriadis S, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f6932; Grigoriadis S, 2013, J CLIN PSYCHIAT, V74, pE293, DOI 10.4088/JCP.12r07966; Grigoriadis S, 2013, J CLIN PSYCHIAT, V74, pE309, DOI 10.4088/JCP.12r07967; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Huybrechts KF, 2015, JAMA-J AM MED ASSOC, V313, P2142, DOI 10.1001/jama.2015.5605; Huybrechts KF, 2014, NEW ENGL J MED, V370, P2397, DOI 10.1056/NEJMoa1312828; Ioannidis JPA, 2007, BMJ-BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; Karamoozian M, 2015, IRAN J NEONATOL, V6, P14; Ko JY, 2012, J WOMENS HEALTH, V21, P830, DOI 10.1089/jwh.2011.3466; Lahti M, 2017, J AM ACAD CHILD PSY, V56, P30, DOI 10.1016/j.jaac.2016.10.007; Lewis AJ, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-33; Madigan S, 2015, ATTACH HUM DEV, V17, P175, DOI 10.1080/14616734.2015.1006386; Man KKC, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2350; Maselko J, 2015, LANCET PSYCHIAT, V2, P609, DOI 10.1016/S2215-0366(15)00109-1; Milgrom J, 2015, ARCH WOMEN MENT HLTH, V18, P717, DOI 10.1007/s00737-015-0512-5; Netsi E, 2015, J AFFECT DISORDERS, V188, P252, DOI 10.1016/j.jad.2015.08.055; Newman L, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0982-7; O'Connor E, 2016, JAMA-J AM MED ASSOC, V315, P388, DOI 10.1001/jama.2015.18948; O'Donnell KJ, 2014, DEV PSYCHOPATHOL, V26, P393, DOI 10.1017/S0954579414000029; Orsini N., 2006, Statistical Software Components; Pearson RM, 2013, JAMA PSYCHIAT, V70, P1312, DOI 10.1001/jamapsychiatry.2013.2163; Rahman A, 2008, LANCET, V372, P902, DOI 10.1016/S0140-6736(08)61400-2; Rahman A, 2013, B WORLD HEALTH ORGAN, V91, P593, DOI 10.2471/BLT.12.109819; Rai D, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2811; Rescorla LA, 2005, MENT RETARD DEV D R, V11, P226, DOI 10.1002/mrdd.20071; Ross LE, 2013, JAMA PSYCHIAT, V70, P436, DOI 10.1001/jamapsychiatry.2013.684; ROTHBERG AD, 1991, AM J OBSTET GYNECOL, V165, P403, DOI 10.1016/0002-9378(91)90103-X; Rouhe H, 2013, BJOG-INT J OBSTET GY, V120, P75, DOI 10.1111/1471-0528.12011; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Sujan AC, 2017, JAMA-J AM MED ASSOC, V317, P1553, DOI 10.1001/jama.2017.3413; Talge NM, 2007, J CHILD PSYCHOL PSYC, V48, P245, DOI 10.1111/j.1469-7610.2006.01714.x; Urizar GG, 2011, PSYCHONEUROENDOCRINO, V36, P1480, DOI 10.1016/j.psyneuen.2011.04.002; Van den Bergh BRH, 2020, NEUROSCI BIOBEHAV R, V117, P26, DOI 10.1016/j.neubiorev.2017.07.003; Van den Bergh BRH, 2018, DEV PSYCHOPATHOL, V30, P743, DOI 10.1017/S0954579418000342; van Grinsven S, 2016, OFFSPRING OUTCOMES P; van Ravesteyn LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173397; Verbeek T, 2016, PREGNANCY PSYCHOPATH; Zhao Y, 2017, ARCH WOMEN MENT HLTH, V20, P333, DOI 10.1007/s00737-016-0712-7";65;9;9;1;9;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;1741-7015;;;BMC MED;BMC Med.;nov-15;2018;16;;;;;;;;208;10.1186/s12916-018-1192-6;http://dx.doi.org/10.1186/s12916-018-1192-6;;;13;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;HA7MJ;30428883;Green Published, gold;;;24/11/2024;WOS:000450465700001;View Full Record in Web of Science
J;"Heinonen, E; Szymanska-von Schultz, B; Kaldo, V; Nasiell, J; Andersson, E; Bergmark, M; Blomdahl-Wetterholm, M; Forsberg, L; Forsell, E; Forsgren, A; Frööjd, S; Goldman, A; Nordenadler, EM; Sklivanioti, M; Blennow, M; Wide, K; Gustafsson, LL";;;;"Heinonen, Essi; Szymanska-von Schultz, Barbara; Kaldo, Viktor; Nasiell, Josefine; Andersson, Ewa; Bergmark, Mikaela; Blomdahl-Wetterholm, Margareta; Forsberg, Lisa; Forsell, Erik; Forsgren, Anna; Froojd, Sandra; Goldman, Amy; Nordenadler, Eva-Mari; Sklivanioti, Myrto; Blennow, Mats; Wide, Katarina; Gustafsson, Lars L.";;;MAGDALENA: study protocol of a randomised, placebo-controlled trial on cognitive development at 2 years of age in children exposed to SSRI in utero;BMJ OPEN;;;English;Article;;;;;;"antenatal depression; internet-based cognitive behaviour therapy; serotonin reuptake inhibitors; neurodevelopment; pregnancy; drug metabolism";"SEROTONIN REUPTAKE INHIBITORS; BEHAVIORAL ACTIVATION-TREATMENT; MATERNAL ANTIDEPRESSANT USE; AUTISM SPECTRUM DISORDER; ANXIETY DISORDERS; PRENATAL EXPOSURE; POSTPARTUM WOMEN; PRETERM BIRTH; DEPRESSION; PREGNANCY";"Introduction Ten per cent of all pregnant women are depressed. Standard therapy of pregnant women with moderate depression is selective serotonin reuptakeinhibitors (SSRI). Observational studies on neurodevelopment after fetal SSRI exposure show conflicting results. Our primary objective is to compare the cognitive development in children exposed to sertraline and maternal depression with those exposed to maternal depression and placebo in utero. We hypothesise that there is a significant neurodevelopmental difference between the groups. As a secondary objective, we study the add-on effect of sertraline to internet-based cognitive behavioural therapy (ICBT) to treat moderate depression during pregnancy. Methods and analysis MAGDALENA is a randomised, placebo-controlled, double-blinded trial in Stockholm Healthcare Region with 2.3 million inhabitants. The women are recruited in weeks 9-21 of pregnancy either through Antenatal Health Clinics or through social media. They are to be diagnosed with moderate depression without ongoing antidepressive therapy or any serious comorbidity. The women in the intervention arm receive sertraline combined with a 12-week period of ICBT; the control arm is treated with placebo and ICBT. We assess the cognitive development in the offspring at the age of 2 years using Bayley Scales of Infant and Toddler Development, third edition (BSID-III). We aim at recruiting 200 women, 100 women in each treatment arm, to ensure statistical power to detect a clinically relevant difference between the groups. Ethics and dissemination This randomised trial will provide long-sought evidence about the effects of SSRI and maternal depression during pregnancy on the neurodevelopment in the offspring. The study is approved by the Regional Ethical Review Board at Karolinska Institutet in Stockholm and the Swedish Medical Products Agency. It is registered with the European Clinical Trials Database (EudraCT), Number: 2013-004444-31. Results will be disseminated at scientific conferences, published in peer-reviewed journals and made available to the public.";"[Heinonen, Essi; Forsgren, Anna; Blennow, Mats; Wide, Katarina] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Paediat, Stockholm, Sweden; [Heinonen, Essi; Blennow, Mats; Wide, Katarina] Karolinska Univ Hosp, Dept Paediat, Stockholm, Sweden; [Szymanska-von Schultz, Barbara; Nasiell, Josefine] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Obstet & Gynaecol, Stockholm, Sweden; [Szymanska-von Schultz, Barbara; Nasiell, Josefine] Karolinska Univ Hosp, Dept Obstet & Gynaecol, Stockholm, Sweden; [Kaldo, Viktor; Forsell, Erik] Karolinska Inst, Dept Clin Neurosci, Ctr Psychiat Res, Stockholm, Sweden; [Kaldo, Viktor; Bergmark, Mikaela; Blomdahl-Wetterholm, Margareta; Forsell, Erik; Froojd, Sandra; Goldman, Amy; Nordenadler, Eva-Mari; Sklivanioti, Myrto] Stockholm Hlth Care Reg, Psychiat South West, Stockholm, Sweden; [Kaldo, Viktor] Linnaeus Univ, Fac Hlth & Life Sci, Dept Psychol, Stockholm, Vaxjo, Sweden; [Andersson, Ewa] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Gustafsson, Lars L.] Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, Stockholm, Sweden; [Gustafsson, Lars L.] Karolinska Univ Hosp, Dept Clin Pharmacol, Stockholm, Sweden";"Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Linnaeus University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital";"Heinonen, E (corresponding author), Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Div Paediat, Stockholm, Sweden.;Heinonen, E (corresponding author), Karolinska Univ Hosp, Dept Paediat, Stockholm, Sweden.";essi.heinonen@ki.se;"Blennow, Mats/AAX-6202-2021; Kaldo, Viktor/J-2915-2012; Gustafsson, Lars/G-3902-2010; Heinonen, Essi/AFJ-9874-2022; Forsell, Erik/HOH-9081-2023; Andersson, Ewa/O-7297-2015";"Blennow, Mats/0000-0001-9517-0261; Andersson, Ewa/0000-0001-8453-2079; Forsell, Erik/0000-0001-8236-4323; Sklivanioti Greenfield, Myrto/0000-0002-4742-9395; Heinonen, Essi/0000-0003-2107-0561";"Vetenskapsradet [521-2012-3466]; Stockholms Lans Landsting [533069, 571301]; Lilla Barnets Fond";"Vetenskapsradet(Swedish Research Council); Stockholms Lans Landsting; Lilla Barnets Fond";The study was funded by Vetenskapsradet (521-2012-3466), Stockholms Lans Landsting (533069, 571301), Lilla Barnets Fond.;"Albers CA, 2007, J PSYCHOEDUC ASSESS, V25, P180, DOI 10.1177/0734282906297199; Andrade SE, 2016, ARCH WOMEN MENT HLTH, V19, P969, DOI 10.1007/s00737-016-0637-1; Andrews G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013196; [Anonymous], 2017, NATL RIKTLINJER VARD; Basterzi AD, 2005, HUM PSYCHOPHARM CLIN, V20, P473, DOI 10.1002/hup.717; Bode MM, 2014, J DEV BEHAV PEDIATR, V35, P570, DOI 10.1097/DBP.0000000000000110; Brown HK, 2017, JAMA-J AM MED ASSOC, V317, P1544, DOI 10.1001/jama.2017.3415; Cardonick EH, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.11.032; Casper RC, 2003, J PEDIATR-US, V142, P402, DOI 10.1067/mpd.2003.139; Charlton RA, 2015, BJOG-INT J OBSTET GY, V122, P1010, DOI 10.1111/1471-0528.13143; Cleare A, 2015, J PSYCHOPHARMACOL, V29, P459, DOI 10.1177/0269881115581093; Coverdale JH, 2008, OBSTET GYNECOL, V112, P1361, DOI 10.1097/AOG.0b013e31818c2a27; Croen LA, 2011, ARCH GEN PSYCHIAT, V68, P1104, DOI 10.1001/archgenpsychiatry.2011.73; Cuijpers P, 2010, PSYCHOL MED, V40, P1943, DOI 10.1017/S0033291710000772; Cuijpers P, 2014, WORLD PSYCHIATRY, V13, P56, DOI 10.1002/wps.20089; Danaher BG, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2876; Dubowitz L, 2005, MENT RETARD DEV D R, V11, P52, DOI 10.1002/mrdd.20048; El Marroun H, 2014, BRIT J PSYCHIAT, V205, P95, DOI 10.1192/bjp.bp.113.127746; Eriksen J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014345; Field T, 2006, INFANT BEHAV DEV, V29, P445, DOI 10.1016/j.infbeh.2006.03.003; First MB, 2016, SCID-5-CV: structured clinical interview for DSM-5 disorders: clinician version; Forsberg L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111327; Forsell E, 2017, J AFFECT DISORDERS, V221, P56, DOI 10.1016/j.jad.2017.06.013; Foukakis T, 2016, JAMA-J AM MED ASSOC, V316, P1888, DOI 10.1001/jama.2016.15865; Freeman MP, 2008, J CLIN PSYCHOPHARM, V28, P646, DOI 10.1097/JCP.0b013e31818d2048; Friedman DD, 2010, CLIN SOC WORK J, V38, P8, DOI 10.1007/s10615-010-0261-x; Furu K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1798; Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db; Gentile S, 2017, NEUROSCIENCE, V342, P154, DOI 10.1016/j.neuroscience.2015.09.001; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Gustafsson LL, 2011, BASIC CLIN PHARMACOL, V108, P224, DOI 10.1111/j.1742-7843.2011.00682.x; Hedman E, 2014, J AFFECT DISORDERS, V155, P49, DOI 10.1016/j.jad.2013.10.023; Helldén A, 2013, PHARMACOGENOMICS, V14, P1779, DOI 10.2217/pgs.13.176; Le Strat Y, 2011, J AFFECT DISORDERS, V135, P128, DOI 10.1016/j.jad.2011.07.004; Lindqvist PG, 2014, J THROMB HAEMOST, V12, P1986, DOI 10.1111/jth.12757; Lupton D, 2016, WOMEN BIRTH, V29, P368, DOI 10.1016/j.wombi.2016.01.008; Molenaar NM, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0752-6; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Morales DR, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0993-3; Moses-Kolko EL, 2005, JAMA-J AM MED ASSOC, V293, P2372, DOI 10.1001/jama.293.19.2372; Nonnenmacher N, 2016, ARCH WOMEN MENT HLTH, V19, P927, DOI 10.1007/s00737-016-0648-y; Nörby U, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0181; O'Mahen HA, 2014, PSYCHOL MED, V44, P1675, DOI 10.1017/S0033291713002092; O'Mahen HA, 2013, J AFFECT DISORDERS, V150, P814, DOI 10.1016/j.jad.2013.03.005; Oberlander TF, 2009, CLIN PHARMACOL THER, V86, P672, DOI 10.1038/clpt.2009.201; Oberlander TF, 2016, J AM ACAD CHILD PSY, V55, P351, DOI 10.1016/j.jaac.2016.02.012; Osma J, 2016, CYBERPSYCH BEH SOC N, V19, P412, DOI 10.1089/cyber.2015.0549; Park YM, 2017, PSYCHIAT INVEST, V14, P368, DOI 10.4306/pi.2017.14.3.368; Pugh NE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149186; Qiu CF, 2009, AM J HYPERTENS, V22, P397, DOI 10.1038/ajh.2008.366; Rai D, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2811; Rai D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2059; Romeo DMM, 2013, EUR J PAEDIATR NEURO, V17, P192, DOI 10.1016/j.ejpn.2012.09.006; Rubertsson C, 2011, NORD J PSYCHIAT, V65, P414, DOI 10.3109/08039488.2011.590606; Saiz-Rodriguez M, BASIC CLIN PHARM TOX; Santucci AK, 2014, J CLIN PSYCHIAT, V75, P1088, DOI 10.4088/JCP.13m08902; Serenius F, 2013, JAMA-J AM MED ASSOC, V309, P1810, DOI 10.1001/jama.2013.3786; SLL, 2014, REG VARDPR PSYK SJUK, P20; Sujan AC, 2017, JAMA-J AM MED ASSOC, V317, P1553, DOI 10.1001/jama.2017.3413; Susser LC, 2016, AM J OBSTET GYNECOL, V215, P722, DOI 10.1016/j.ajog.2016.07.011; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Tamayo-Sarver JH, 2003, ACAD EMERG MED, V10, P1239, DOI 10.1197/S1069-6563903)00494-9; Viuff ACF, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0262-x; Wouldes TA, 2014, NEUROTOXICOL TERATOL, V42, P77, DOI 10.1016/j.ntt.2014.02.004; Zoega H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144474";65;7;8;5;10;BMJ PUBLISHING GROUP;LONDON;BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND;2044-6055;;;BMJ OPEN;BMJ Open;AUG;2018;8;8;;;;;;;e023281;10.1136/bmjopen-2018-023281;http://dx.doi.org/10.1136/bmjopen-2018-023281;;;11;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;GV9IO;30082365;Green Published, gold;;;24/11/2024;WOS:000446470200178;View Full Record in Web of Science
J;"Salari, AA; Fatehi-Gharehlar, L; Motayagheni, N; Homberg, JR";;;;"Salari, Ali-Akbar; Fatehi-Gharehlar, Laleh; Motayagheni, Negar; Homberg, Judith R.";;;Fluoxetine normalizes the effects of prenatal maternal stress on depression- and anxiety-like behaviors in mouse dams and male offspring;BEHAVIOURAL BRAIN RESEARCH;;;English;Article;;;;;;"Prenatal stress; HPA axis; Pregnancy; Antidepressant; Postpartum; Corticosterone";"SEROTONIN REUPTAKE INHIBITORS; NEONATAL IMMUNE ACTIVATION; AUTISM SPECTRUM DISORDER; HPA AXIS FUNCTION; GESTATIONAL STRESS; POSTPARTUM DEPRESSION; ADULT MALE; ANTIDEPRESSANT EXPOSURE; PERINATAL OUTCOMES; DEPENDENT MANNER";Maternal depression during pregnancy and the postpartum period (lactation) is a common debilitating condition affecting mother-fetus/-infant interactions, which can be a risk factor for cognitive and affective disorders in mothers and their children. Selective-serotonin-reuptake-inhibitor-(SSRI) pharmacotherapy is known as the first-line treatment of maternal depression. However, its use during pregnancy and lactation is a topic of concern. The present study aimed to investigate the effects of prenatal stress alone or in combination with fluoxetine (FLX) on hypothalamic pituitary adrenal axis (HPA) activity, anxiety-/depression-like behaviors in dams and in offspring. To do this, gestationally-stressed and non-stressed mouse dams were orally treated with FLX-(8/mg/kg/day) from gestational day 10 to lactation day 20. The behavioral outcomes of prenatal stress and FLX treatment in dams and male offspring were assessed using the sucrose preference, forced swim, zero maze, and light-dark box tests. Stress-induced corticosterone levels were also evaluated as indicative of abnormal HPA-axis function. Our findings indicated that maternal stress resulted in increased depression-like behavior and HPA axis hyperactivity in dams during pregnancy and lactation which were reversed by FLX. Furthermore, prenatal stress increased anxiety/depression-like behaviors and HPA-axis reactivity in male offspring. These effects were reversed by maternal FLX treatment. Developmental FLX exposure, without prenatal stress, did not have any adverse effects on the above measured parameters. Our results suggest that prenatal stress induces maternal depression-like behavior which affects the development of affective symptoms in male offspring, and that remediation of maternal depression-like behavior coincidences with the normalization of anxiety- and depression-like symptoms in male offspring. (C) 2016 Elsevier B.V. All rights reserved.;"[Salari, Ali-Akbar; Fatehi-Gharehlar, Laleh] Tabriz Univ Med Sci, Drug Appl Res Ctr, POB 51656-65811, Tabriz, Iran; [Salari, Ali-Akbar] Univ Tabriz, Hayyan Res Inst, Lab Neuropsychopharmacol & Psychoneuroimmunol, Tabriz, Iran; [Motayagheni, Negar] Univ Calif Los Angeles, Dept Anesthesiol, Div Mol Med, Cardiovasc Res Labs, Los Angeles, CA 90024 USA; [Homberg, Judith R.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, Med Ctr,Ctr Neurosci, Nijmegen, Netherlands";"Tabriz University of Medical Science; University of Tabriz; University of California System; University of California Los Angeles; Radboud University Nijmegen";Salari, AA (corresponding author), Tabriz Univ Med Sci, Drug Appl Res Ctr, POB 51656-65811, Tabriz, Iran.;aa.salari@yahoo.com;"Homberg, J.R./N-4172-2019; Salari, Ali-Akbar/I-7843-2013";"Salari, Ali-Akbar/0000-0002-4970-0337; Homberg, Judith/0000-0002-7621-1010";Hayyan Research Institute (GN) [92-12.4];Hayyan Research Institute (GN);This study was supported in part by the Hayyan Research Institute (GN: 92-12.4).;"ALONSO SJ, 1991, PHYSIOL BEHAV, V50, P511, DOI 10.1016/0031-9384(91)90538-Y; Altieri SC, 2015, NEUROPSYCHOPHARMACOL, V40, P1456, DOI 10.1038/npp.2014.331; Amani M, 2013, NEUROPHARMACOLOGY, V73, P87, DOI 10.1016/j.neuropharm.2013.04.056; [Anonymous], 2005, EVID REP TECHNOL ASS, DOI DOI 10.1037/E439372005-001; Babri S, 2014, BRAIN BEHAV IMMUN, V37, P164, DOI 10.1016/j.bbi.2013.12.003; Babri S, 2014, BEHAV BRAIN RES, V261, P305, DOI 10.1016/j.bbr.2013.12.037; Bairy KL, 2007, PHARMACOLOGY, V79, P1, DOI 10.1159/000096645; Barha CK, 2007, PHYSIOL BEHAV, V92, P939, DOI 10.1016/j.physbeh.2007.06.022; Bitanihirwe BKY, 2010, NEUROPSYCHOPHARMACOL, V35, P2462, DOI 10.1038/npp.2010.129; Bourke CH, 2013, NEUROTOXICOL TERATOL, V39, P100, DOI 10.1016/j.ntt.2013.07.008; Brummelte S, 2012, NEUROPHARMACOLOGY, V62, P406, DOI 10.1016/j.neuropharm.2011.08.017; Brummelte S, 2010, HORM BEHAV, V58, P769, DOI 10.1016/j.yhbeh.2010.07.012; Casper RC, 2015, J NERV MENT DIS, V203, P167, DOI 10.1097/NMD.0000000000000258; Champagne F, 2001, Prog Brain Res, V133, P287; Choi SK, 2014, J RES MED SCI, V19, P807; Christian LM, 2014, AM J OBSTET GYNECOL, V211, P275, DOI 10.1016/j.ajog.2014.06.042; Clements CC, 2015, MOL PSYCHIATR, V20, P727, DOI 10.1038/mp.2014.90; Croen LA, 2011, ARCH GEN PSYCHIAT, V68, P1104, DOI 10.1001/archgenpsychiatry.2011.73; Davis EP, 2012, PSYCHONEUROENDOCRINO, V37, P1224, DOI 10.1016/j.psyneuen.2011.12.016; Deave T, 2008, BJOG-INT J OBSTET GY, V115, P1043, DOI 10.1111/j.1471-0528.2008.01752.x; Dedovic K, 2015, NEUROPSYCH DIS TREAT, V11, P1181, DOI 10.2147/NDT.S62289; Doosti MH, 2013, PROG NEURO-PSYCHOPH, V43, P55, DOI 10.1016/j.pnpbp.2012.12.003; Duthie L, 2013, NEUROENDOCRINOLOGY, V98, P106, DOI 10.1159/000354702; El Marroun H, 2012, ARCH GEN PSYCHIAT, V69, P706, DOI 10.1001/archgenpsychiatry.2011.2333; Enayati M, 2012, BRAIN RES BULL, V87, P295, DOI 10.1016/j.brainresbull.2011.08.015; Engelstad HJ, 2014, NEONATOLOGY, V105, P149, DOI 10.1159/000356774; Figueroa R, 2010, J DEV BEHAV PEDIATR, V31, P641, DOI 10.1097/DBP.0b013e3181e5ac93; Francis-Oliveira J, 2013, BEHAV BRAIN RES, V252, P195, DOI 10.1016/j.bbr.2013.05.064; Grigoriadis S, 2014, BMJ-BRIT MED J, V14, P348; Haim A, 2016, HORM BEHAV, V77, P124, DOI 10.1016/j.yhbeh.2015.05.005; Haim A, 2014, EUR J NEUROSCI, V40, P3766, DOI 10.1111/ejn.12752; Halligan SL, 2007, BIOL PSYCHIAT, V62, P40, DOI 10.1016/j.biopsych.2006.09.011; Hanley GE, 2013, EARLY HUM DEV, V89, P519, DOI 10.1016/j.earlhumdev.2012.12.012; Harrington RA, 2014, PEDIATRICS, V133, pE1241, DOI 10.1542/peds.2013-3406; Harvey L, 2012, DEV NEUROBIOL, V72, P1335, DOI 10.1002/dneu.22043; Hay DF, 2008, J CHILD PSYCHOL PSYC, V49, P1079, DOI 10.1111/j.1469-7610.2008.01959.x; Heikkinen T, 2003, CLIN PHARMACOL THER, V73, P330, DOI 10.1016/S0009-9236(02)17634-X; Henrichs J, 2010, PSYCHOL MED, V40, P633, DOI 10.1017/S0033291709990894; Hillerer KM, 2011, ENDOCRINOLOGY, V152, P3930, DOI 10.1210/en.2011-1091; Horwitz SM, 2007, J WOMENS HEALTH, V16, P678, DOI 10.1089/jwh.2006.0185; Huang H, 2014, GEN HOSP PSYCHIAT, V36, P13, DOI 10.1016/j.genhosppsych.2013.08.002; Kapoor A, 2008, BRAIN RES REV, V57, P586, DOI 10.1016/j.brainresrev.2007.06.013; Kiryanova V, 2016, NEUROSCIENCE, V320, P281, DOI 10.1016/j.neuroscience.2016.01.064; Kiryanova V, 2014, DEV NEUROSCI-BASEL, V36, P396, DOI 10.1159/000363102; Knaepen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057608; Laloux C, 2012, PSYCHONEUROENDOCRINO, V37, P1646, DOI 10.1016/j.psyneuen.2012.02.010; Lerch S, 2015, BEHAV BRAIN RES, V279, P155, DOI 10.1016/j.bbr.2014.11.007; Leuner B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089912; Lin YL, 2014, BEHAV BRAIN RES, V259, P24, DOI 10.1016/j.bbr.2013.10.034; Lin YL, 2012, BRAIN BEHAV IMMUN, V26, P459, DOI 10.1016/j.bbi.2011.12.003; Lisboa SFS, 2007, PHARMACOLOGY, V80, P49, DOI 10.1159/000103097; Lucassen PJ, 2009, EUR J NEUROSCI, V29, P97, DOI 10.1111/j.1460-9568.2008.06543.x; Mairesse J., 2015, SLEEP PRENATALLY RES, P27; Majidi-Zolbanin J, 2015, NEUROSCIENCE, V294, P69, DOI 10.1016/j.neuroscience.2015.03.016; Majidi-Zolbanin J., 2014, NEUROIMMUNOL NEUROIN, V1, P35, DOI [10.4103/2347-8659.135575, DOI 10.4103/2347-8659.135575]; Majidi-Zolbanin J, 2013, BEHAV BRAIN RES, V250, P123, DOI 10.1016/j.bbr.2013.05.003; McAllister BB, 2012, NEUROSCIENCE, V226, P356, DOI 10.1016/j.neuroscience.2012.09.024; Miyagawa K, 2011, NEUROSCI RES, V70, P111, DOI 10.1016/j.neures.2011.02.002; Monteggia LM, 2007, BIOL PSYCHIAT, V61, P187, DOI 10.1016/j.biopsych.2006.03.021; Nephew B, 2013, NEUROPEPTIDES, V47, P371, DOI 10.1016/j.npep.2013.10.013; Noorlander CW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002782; O'Connor TG, 2002, BRIT J PSYCHIAT, V180, P502, DOI 10.1192/bjp.180.6.502; O'Hara MW, 2013, ANNU REV CLIN PSYCHO, V9, P379, DOI 10.1146/annurev-clinpsy-050212-185612; O'Mahony SM, 2006, NEUROIMMUNOMODULAT, V13, P82, DOI 10.1159/000096090; Oberlander TF, 2008, EARLY HUM DEV, V84, P689, DOI 10.1016/j.earlhumdev.2008.06.008; Olivier J. D., 2013, FRONT CELL NEUROSCI, P7; Olivier JDA, 2011, PSYCHOPHARMACOLOGY, V217, P419, DOI 10.1007/s00213-011-2299-z; Pallarés ME, 2007, PHYSIOL BEHAV, V92, P951, DOI 10.1016/j.physbeh.2007.06.021; Pawluski JL, 2012, NEUROSCIENCE, V220, P131, DOI 10.1016/j.neuroscience.2012.06.034; Pawluski JL, 2016, HORM BEHAV, V77, P86, DOI 10.1016/j.yhbeh.2015.06.004; Pawluski JL, 2012, PSYCHONEUROENDOCRINO, V37, P1019, DOI 10.1016/j.psyneuen.2011.11.011; Rampono J, 2006, BRIT J CLIN PHARMACO, V62, P316, DOI 10.1111/j.1365-2125.2006.02659.x; Rayen I, 2013, PSYCHONEUROENDOCRINO, V38, P1618, DOI 10.1016/j.psyneuen.2013.01.007; Rayen I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024003; Rebello TJ, 2014, J NEUROSCI, V34, P12379, DOI 10.1523/JNEUROSCI.1020-13.2014; Salari AA, 2015, EUR NEUROPSYCHOPHARM, V25, P1260, DOI 10.1016/j.euroneuro.2015.04.022; Santucci AK, 2014, J CLIN PSYCHIAT, V75, P1088, DOI 10.4088/JCP.13m08902; Simpson KL, 2011, P NATL ACAD SCI USA, V108, P18465, DOI 10.1073/pnas.1109353108; Smith JW, 2004, PSYCHONEUROENDOCRINO, V29, P227, DOI 10.1016/S0306-4530(03)00025-8; Smith MV, 2013, EARLY HUM DEV, V89, P81, DOI 10.1016/j.earlhumdev.2012.08.001; Vitalis T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00093; Wachs TD, 2009, CHILD DEV PERSPECT, V3, P51, DOI 10.1111/j.1750-8606.2008.00077.x; Walf AA, 2007, STRESS, V10, P251, DOI 10.1080/00958970701220416; Weinstock Marta, 2015, Adv Neurobiol, V10, P3, DOI 10.1007/978-1-4939-1372-5_1; Wisner KL, 2013, AM J PSYCHIAT, V170, P485, DOI 10.1176/appi.ajp.2012.11121873; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Yu Q, 2014, MOL PSYCHIATR, V19, P688, DOI 10.1038/mp.2014.10; Zaretsky MV, 2004, OBSTET GYNECOL, V103, P546, DOI 10.1097/01.AOG.0000114980.40445.83; Zimmerberg B, 2015, DEV PSYCHOBIOL, V57, P141, DOI 10.1002/dev.21264";89;72;82;0;42;ELSEVIER;AMSTERDAM;RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS;0166-4328;1872-7549;;BEHAV BRAIN RES;Behav. Brain Res.;sept-15;2016;311;;;;;;354;367;;10.1016/j.bbr.2016.05.062;http://dx.doi.org/10.1016/j.bbr.2016.05.062;;;14;"Behavioral Sciences; Neurosciences";Science Citation Index Expanded (SCI-EXPANDED);"Behavioral Sciences; Neurosciences & Neurology";DS1XJ;27263073;;;;24/11/2024;WOS:000380418200037;View Full Record in Web of Science
J;"Chen, DN; Strang, JF; Kolbuck, VD; Rosenthal, SM; Wallen, K; Waber, DP; Steinberg, L; Sisk, CL; Ross, J; Paus, T; Mueller, SC; McCarthy, MM; Micevych, PE; Martin, CL; Kreukels, BPC; Kenworthy, L; Herting, MM; Herlitz, A; Haraldsen, IRJH; Dahl, R; Crone, EA; Chelune, GJ; Burke, SM; Berenbaum, SA; Beltz, AM; Bakker, J; Eliot, L; Vilain, E; Wallace, GL; Nelson, EE; Garofalo, R";;;;"Chen, Diane; Strang, John F.; Kolbuck, Victoria D.; Rosenthal, Stephen M.; Wallen, Kim; Waber, Deborah P.; Steinberg, Laurence; Sisk, Cheryl L.; Ross, Judith; Paus, Tomas; Mueller, Sven C.; McCarthy, Margaret M.; Micevych, Paul E.; Martin, Carol L.; Kreukels, Baudewijntje P. C.; Kenworthy, Lauren; Herting, Megan M.; Herlitz, Agneta; Haraldsen, Ira R. J. Hebold; Dahl, Ronald; Crone, Eveline A.; Chelune, Gordon J.; Burke, Sarah M.; Berenbaum, Sheri A.; Beltz, Adriene M.; Bakker, Julie; Eliot, Lise; Vilain, Eric; Wallace, Gregory L.; Nelson, Eric E.; Garofalo, Robert";;;Consensus Parameter: Research Methodologies to Evaluate Neurodevelopmental Effects of Pubertal Suppression in Transgender Youth;TRANSGENDER HEALTH;;;English;Article;;;;;;"expert consensus; Delphi; puberty blockers; GnRHa; transgender; adolescents";"AUTISM SPECTRUM DISORDERS; GENDER IDENTITY DISORDER; ADOLESCENT BRAIN; MESSENGER-RNA; RISK-TAKING; CHILDREN; CHILDHOOD; HORMONES; PERIOD; AGE";Purpose: Pubertal suppression is standard of care for early pubertal transgender youth to prevent the development of undesired and distressing secondary sex characteristics incongruent with gender identity. Preliminary evidence suggests pubertal suppression improves mental health functioning. Given the widespread changes in brain and cognition that occur during puberty, a critical question is whether this treatment impacts neurodevelopment. Methods: A Delphi consensus procedure engaged 24 international experts in neurodevelopment, gender development, puberty/adolescence, neuroendocrinology, and statistics/psychometrics to identify priority research methodologies to address the empirical question: is pubertal suppression treatment associated with real-world neurocognitive sequelae? Recommended study approaches reaching 80% consensus were included in the consensus parameter. Results: The Delphi procedure identified 160 initial expert recommendations, 44 of which ultimately achieved consensus. Consensus study design elements include the following: a minimum of three measurement time points, pubertal staging at baseline, statistical modeling of sex in analyses, use of analytic approaches that account for heterogeneity, and use of multiple comparison groups to minimize the limitations of any one group. Consensus study comparison groups include untreated transgender youth matched on pubertal stage, cisgender (i.e., gender congruent) youth matched on pubertal stage, and an independent sample from a large-scale youth development database. The consensus domains for assessment includes: mental health, executive function/cognitive control, and social awareness/functioning. Conclusion: An international interdisciplinary team of experts achieved consensus around primary methods and domains for assessing neurodevelopmental effects (i.e., benefits and/or difficulties) of pubertal suppression treatment in transgender youth.;"[Chen, Diane; Kolbuck, Victoria D.; Garofalo, Robert] Ann & Robert H Lurie Childrens Hosp Chicago, Potocsnak Family Div Adolescent & Young Adult Med, 225 East Chicago Ave,Box 161B, Chicago, IL 60611 USA; [Chen, Diane] Ann & Robert H Lurie Childrens Hosp Chicago, Pritzker Dept Psychiat & Behav Hlth, Chicago, IL 60611 USA; [Chen, Diane] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [Chen, Diane; Garofalo, Robert] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Strang, John F.; Kenworthy, Lauren] Childrens Natl Med Ctr, Div Neuropsychol, Washington, DC 20010 USA; [Strang, John F.; Kenworthy, Lauren] Childrens Natl Med Ctr, Ctr Neurosci, Childrens Res Inst, Washington, DC 20010 USA; [Strang, John F.; Kenworthy, Lauren] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; [Strang, John F.; Kenworthy, Lauren] George Washington Univ, Sch Med, Dept Neurol, Washington, DC USA; [Strang, John F.; Kenworthy, Lauren] George Washington Univ, Dept Psychiat, Sch Med, Washington, DC USA; [Rosenthal, Stephen M.] Univ Calif San Francisco, Benioff Childrens Hosp, Div Endocrinol, San Francisco, CA 94143 USA; [Wallen, Kim] Emory Univ, Dept Psychol, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA; [Waber, Deborah P.] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA; [Waber, Deborah P.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [Steinberg, Laurence] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA; [Sisk, Cheryl L.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; [Ross, Judith] Nemours duPont Hosp Children, Delaware, OH USA; [Ross, Judith] Thomas Jefferson Univ, Dept Pediat, Philadelphia, PA 19107 USA; [Paus, Tomas] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Paus, Tomas] Univ Toronto, Dept Psychol, Toronto, ON, Canada; [Paus, Tomas] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Mueller, Sven C.] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium; [Mueller, Sven C.] Univ Deusto, Dept Personal Psychol Assessment & Treatment, Bilbao, Spain; [McCarthy, Margaret M.] Univ Maryland, Sch Med, Dept Pharmacol, Program Neurosci, Baltimore, MD 21201 USA; [Micevych, Paul E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Martin, Carol L.] Arizona State Univ, Sch Social & Family Dynam, Tempe, AZ USA; [Kreukels, Baudewijntje P. C.] Amsterdam UMC, Locat VUmc, Dept Med Psychol, Amsterdam, Netherlands; [Kreukels, Baudewijntje P. C.] Ctr Expertise Gender Dysphoria, Amsterdam, Netherlands; [Herting, Megan M.] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA; [Herting, Megan M.] Univ Southern Calif, Dept Pediat, Los Angeles, CA 90007 USA; [Herlitz, Agneta] Karolinska Inst, Dept Clin Neurosci, Sect Psychol, Stockholm, Sweden; [Haraldsen, Ira R. J. Hebold] Oslo Univ Hosp, Ctr Cognit Hlth Brain Dis, Oslo, Norway; [Dahl, Ronald] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Crone, Eveline A.; Burke, Sarah M.] Leiden Univ, Brain & Dev Res Ctr, Dept Dev & Educ Psychol, Leiden, Netherlands; [Chelune, Gordon J.] Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT USA; [Berenbaum, Sheri A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Berenbaum, Sheri A.] Penn State Univ, Dept Pediat, University Pk, PA 16802 USA; [Beltz, Adriene M.] Univ Michigan, Dept Psychol, Ann Arbor, MI USA; [Bakker, Julie] Univ Liege, GIGA Neurosci, Liege, Belgium; [Eliot, Lise] Rosalind Franklin Univ Med & Sci, Dept Neurosci, Chicago, IL USA; [Vilain, Eric] Childrens Natl Med Ctr, Ctr Genet Med Res, Washington, DC 20010 USA; [Vilain, Eric] George Washington Univ, Dept Genom & Precis Med, Washington, DC USA; [Vilain, Eric] CNRS, Epigenet Data & Polit, Paris, France; [Wallace, Gregory L.] George Washington Univ, Dept Speech Language & Hearing Sci, Washington, DC USA; [Nelson, Eric E.] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Nelson, Eric E.] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA";"Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Children's National Health System; Children's National Health System; George Washington University; George Washington University; George Washington University; University of California System; University of California San Francisco; Emory University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Michigan State University; Jefferson University; University of Toronto; Holland Bloorview Kids Rehabilitation Hospital; University of Toronto; University of Toronto; Ghent University; University of Deusto; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Arizona State University; Arizona State University-Tempe; University of Amsterdam; Vrije Universiteit Amsterdam; University of Southern California; University of Southern California; Karolinska Institutet; University of Oslo; University of California System; University of California Berkeley; Leiden University - Excl LUMC; Leiden University; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Michigan System; University of Michigan; University of Liege; Chicago Medical School; Rosalind Franklin University of Medicine & Science; Children's National Health System; George Washington University; Centre National de la Recherche Scientifique (CNRS); George Washington University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University";Chen, DN (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, Potocsnak Family Div Adolescent & Young Adult Med, 225 East Chicago Ave,Box 161B, Chicago, IL 60611 USA.;dichen@luriechildrens.org;"Wallace, Gregory/H-2158-2018; Sisk, Cheryl/C-1199-2012; Kenworthy, Lauren/AAI-7572-2020; Martin, Carol/AAS-8916-2020; Nelson, Eric/B-8980-2008; Strang, John/H-5460-2011; Burke, Sarah/J-6635-2019; McCarthy, Margaret/O-2059-2017";"Burke, Sarah/0000-0001-7172-491X; Nelson, Eric/0000-0002-3376-2453; Herlitz, Agneta/0000-0002-9313-4192; Ross, Judith/0000-0002-8613-2498; Kreukels, Baudewijntje/0000-0002-9713-4835";Ann & Robert H. Lurie Children's Hospital of Chicago Foundation;Ann & Robert H. Lurie Children's Hospital of Chicago Foundation;This work was supported by a grant from the Ann & Robert H. Lurie Children's Hospital of Chicago Foundation funded by a grateful family that has chosen to remain anonymous. Study sponsors had no role in (1) study design, (2) collection, analysis, and interpretation of data, (3) writing of the report, or (4) the decision to submit the article for publication.;"Akgül GY, 2018, J SEX MARITAL THER, V44, P619, DOI 10.1080/0092623X.2018.1437489; Akins Ralitsa B, 2005, BMC Med Res Methodol, V5, P37, DOI 10.1186/1471-2288-5-37; Albert D, 2013, CURR DIR PSYCHOL SCI, V22, P114, DOI 10.1177/0963721412471347; Amir D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155883; [Anonymous], 2010, DELPHI TECHNIQUE NUR; [Anonymous], 2007, PRACT ASSESS RES EVA, DOI DOI 10.7275/PDZ9-TH90; Blakemore SJ, 2014, ANNU REV PSYCHOL, V65, P187, DOI 10.1146/annurev-psych-010213-115202; Braams BR, 2015, J NEUROSCI, V35, P7226, DOI 10.1523/JNEUROSCI.4764-14.2015; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; CLARK AS, 1988, ENDOCRINOLOGY, V123, P932, DOI 10.1210/endo-123-2-932; Coleman E, 2012, INT J TRANSGENDERISM, V13, P165, DOI 10.1080/15532739.2011.700873; Costa R, 2016, NAT REV UROL, V13, P456, DOI 10.1038/nrurol.2016.128; Costa R, 2015, J SEX MED, V12, P2206, DOI 10.1111/jsm.13034; Crone EA, 2017, TRENDS COGN SCI, V21, P205, DOI 10.1016/j.tics.2017.01.003; Crone EA, 2012, NAT REV NEUROSCI, V13, P636, DOI 10.1038/nrn3313; Cservenka A, 2015, BRAIN COGNITION, V99, P135, DOI 10.1016/j.bandc.2015.06.002; Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001; de Vries ALC, 2014, PEDIATRICS, V134, P696, DOI 10.1542/peds.2013-2958; de Vries ALC, 2012, J HOMOSEXUAL, V59, P301, DOI 10.1080/00918369.2012.653300; de Vries ALC, 2011, J SEX MED, V8, P2276, DOI 10.1111/j.1743-6109.2010.01943.x; de Vries ALC, 2010, J AUTISM DEV DISORD, V40, P930, DOI 10.1007/s10803-010-0935-9; Dumontheil I, 2014, DEV COGN NEUROS-NETH, V10, P57, DOI 10.1016/j.dcn.2014.07.009; Ernst M, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0433-6; Gennatas ED, 2017, J NEUROSCI, V37, P5065, DOI 10.1523/JNEUROSCI.3550-16.2017; Goddings AL, 2019, J RES ADOLESCENCE, V29, P32, DOI 10.1111/jora.12408; Graber JA, 2013, HORM BEHAV, V64, P262, DOI 10.1016/j.yhbeh.2013.04.003; Hembree WC, 2018, J CLIN ENDOCR METAB, V103, P699, DOI [10.1210/jc.2017-02548, 10.1210/jc.2017-01658]; Hisle-Gorman E, 2019, LGBT HEALTH, V6, P95, DOI 10.1089/lgbt.2018.0252; Kilford EJ, 2016, NEUROSCI BIOBEHAV R, V70, P106, DOI 10.1016/j.neubiorev.2016.08.016; Koerselman K, 2018, LABOUR ECON, V54, P1, DOI 10.1016/j.labeco.2018.05.001; Kolskar K. K., 2018, eNeuro, V5, DOI DOI 10.1523/ENEURO.0092-18.2018; Kreukels BPC, 2011, NAT REV ENDOCRINOL, V7, P466, DOI 10.1038/nrendo.2011.78; Ladouceur CD, 2012, DEV COGN NEUROS-NETH, V2, P36, DOI 10.1016/j.dcn.2011.06.002; Lin HY, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0418-5; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; McCormick EM, 2017, J COGNITIVE NEUROSCI, V29, P413, DOI 10.1162/jocn_a_01061; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Pfeifer JH, 2013, J NEUROSCI, V33, P7415, DOI 10.1523/JNEUROSCI.4074-12.2013; Piekarski DJ, 2017, BRAIN RES, V1654, P123, DOI 10.1016/j.brainres.2016.08.042; Pugliese CE, 2016, J AUTISM DEV DISORD, V46, P467, DOI 10.1007/s10803-015-2584-5; Rey-Casserly C, 2019, CURR OPIN PEDIATR, V31, P789, DOI 10.1097/MOP.0000000000000837; Rowe G, 1999, INT J FORECASTING, V15, P353, DOI 10.1016/S0169-2070(99)00018-7; Sadjadi S, 2013, J MED HUMANIT, V34, P255, DOI 10.1007/s10912-013-9228-6; Scherf KS, 2013, HORM BEHAV, V64, P298, DOI 10.1016/j.yhbeh.2013.05.011; Schneider MA, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00528; Schulz KM, 2006, MOL CELL ENDOCRINOL, V254, P120, DOI 10.1016/j.mce.2006.04.025; Schulz KM, 2016, NEUROSCI BIOBEHAV R, V70, P148, DOI 10.1016/j.neubiorev.2016.07.036; Selemon LD, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.7; Shaw P, 2012, BIOL PSYCHIAT, V72, P191, DOI 10.1016/j.biopsych.2012.01.031; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; Somerville LH, 2017, J EXP PSYCHOL GEN, V146, P155, DOI 10.1037/xge0000250; Spielberg JM, 2014, DEV COGN NEUROS-NETH, V8, P86, DOI 10.1016/j.dcn.2014.01.004; Staphorsius AS, 2015, PSYCHONEUROENDOCRINO, V56, P190, DOI 10.1016/j.psyneuen.2015.03.007; Steinberg L, 2005, TRENDS COGN SCI, V9, P69, DOI 10.1016/j.tics.2004.12.005; Steinberg L, 2004, ANN NY ACAD SCI, V1021, P51, DOI 10.1196/annals.1308.005; Strang JF, 2018, J CLIN CHILD ADOLESC, V47, P105, DOI 10.1080/15374416.2016.1228462; Strauss P., 2017, Trans Pathways the Mental Health Experiences and Care Pathways of Trans Young People; Taylor A, 2020, COGN BEHAV THERAPY, V49, P242, DOI 10.1080/16506073.2019.1641146; Turban JL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1725; van den Bos W, 2011, PSYCHOL SCI, V22, P60, DOI 10.1177/0956797610391102; van der Miesen AIR, 2020, J ADOLESCENT HEALTH, V66, P699, DOI 10.1016/j.jadohealth.2019.12.018; Vijayakumar N, 2018, NEUROSCI BIOBEHAV R, V92, P417, DOI 10.1016/j.neubiorev.2018.06.004; Vogel C, 2019, INT J OBESITY, V43, P2573, DOI 10.1038/s41366-018-0313-9; Vrouenraets LJJJ, 2015, J ADOLESCENT HEALTH, V57, P367, DOI 10.1016/j.jadohealth.2015.04.004; Wong APY, 2018, CEREB CORTEX, V28, P1272, DOI 10.1093/cercor/bhx040; Yousuf M.I., 2007, Practical Assessment, Research, and Evaluation, V12, P4, DOI [DOI 10.7275/RRPH-T210, 10.7275/rrph-t210]";69;26;26;2;20;MARY ANN LIEBERT, INC;NEW ROCHELLE;140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA;2688-4887;2380-193X;;TRANSGENDER HEALTH;Transgender Health;DEC 1;2020;5;4;;;;;246;257;;10.1089/trgh.2020.0006;http://dx.doi.org/10.1089/trgh.2020.0006;;;12;"Psychology, Clinical; Public, Environmental & Occupational Health; Social Sciences, Biomedical";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Psychology; Public, Environmental & Occupational Health; Biomedical Social Sciences";UT5KS;33376803;hybrid, Green Submitted, Green Published;;;24/11/2024;WOS:000698156200007;View Full Record in Web of Science
J;"Singal, D; Brownell, M; Chateau, D; Ruth, C; Katz, LY";;;;"Singal, Deepa; Brownell, Marni; Chateau, Dan; Ruth, Chelsea; Katz, Laurence Y.";;;Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data;BMJ OPEN;;;English;Article;;;;;;;"SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; AUTISM SPECTRUM DISORDER; DEFICIT HYPERACTIVITY DISORDER; PRENATAL DEPRESSION; MENTAL-DISORDERS; MEDICATION USE; UNITED-STATES; DRUG-USE; RISK";"Introduction: Antidepressants are commonly prescribed during pregnancy; however, there are inconsistent data on the safety of these medications during the prenatal period. To address this gap, this study will investigate short-term and long-term neurodevelopmental, physical and mental health, and educational outcomes of children who have been exposed to selective serotonin reuptake inhibitors (SSRIs) or selective serotonin norepinephrine reuptake inhibitors (SNRIs) and/or maternal depression during pregnancy. Methods and analysis: Administrative data will be linked to generate 4 population-based exposed groups from all children born in Manitoba between 1996 and 2014 whose mother had at least 2 prescriptions for either an SSRI or SNRI: (1) throughout the prenatal period (beginning of pregnancy until birth); (2) in the first trimester (<= 14 weeks gestation); (3) in the second trimester (15-26 weeks gestation); (4) in the third trimester (>= 27 weeks gestation) and 1 populationbased unexposed group consisting of children whose mothers had a diagnosis of mood or anxiety disorder during pregnancy but did not use antidepressants. Propensity scores and inverse probability treatment weights will be used to adjust for confounding. Multivariate regression modelling will determine whether, compared with untreated mood/anxiety disorder, prenatal exposure to antidepressant medications is associated with: (1) adverse birth and neonatal outcomes, including: preterm birth, low birth weight, low Apgar scores, respiratory distress, congenital malformations and persistent pulmonary hypertension; (2) adverse early childhood outcomes, including: early childhood education challenges, diagnosis of neurodevelopmental disorders and diagnosis of mental disorders. We will determine if exposure effects differ between SSRIs and SRNIs, and determine if exposure effects differ between gestation timing of exposure to antidepressants. Ethics and dissemination: Ethical approval was obtained from the University of Manitoba Health Research Ethics Board. Dissemination of results will include engagement of stakeholders and patients, writing of reports for policymakers and patients, and publication of scientific papers.";"[Singal, Deepa; Brownell, Marni; Chateau, Dan] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Brownell, Marni; Chateau, Dan] Univ Manitoba, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; [Ruth, Chelsea] Univ Manitoba, Dept Paediat & Child Hlth, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; [Katz, Laurence Y.] Univ Manitoba, Dept Psychiat Child & Adolescent Mental Psychiat, Winnipeg, MB, Canada";"University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba";Singal, D (corresponding author), Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada.;deepakapoorsingal@gmail.com;"Katz, Laurence/N-6698-2019; Ruth, Chelsea/AAP-9657-2021";"chateau, Dan/0000-0002-2215-820X; Brownell, Marni/0000-0001-7673-4404; Ruth, Chelsea/0000-0002-7097-0542";Canadian Institutes of Health Research [142356];Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR));This work is supported by an operating grant from the Canadian Institutes of Health Research (number 142356).;"Alwan S, 2007, NEW ENGL J MED, V356, P2684, DOI 10.1056/NEJMoa066584; Alwan S, 2011, J CLIN PHARMACOL, V51, P264, DOI 10.1177/0091270010373928; Andrade SE, 2009, PHARMACOEPIDEM DR S, V18, P246, DOI 10.1002/pds.1710; [Anonymous], NEUROSCIENCE; [Anonymous], 2013, BMJ, DOI DOI 10.1136/BMJ.F2059; [Anonymous], CHILD NEUROPSYCHOL; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bakker MK, 2010, BIRTH DEFECTS RES A, V88, P94, DOI 10.1002/bdra.20641; Bérard A, 2007, BIRTH DEFECTS RES B, V80, P18, DOI 10.1002/bdrb.20099; Brandlistuen RE, 2015, INT J EPIDEMIOL, V44, P1397, DOI 10.1093/ije/dyv030; Brownell M., 2012, How Are Manitoba's Children Doing?; Brownell MD, 2001, SOC SCI MED, V52, P657, DOI 10.1016/S0277-9536(00)00168-4; Byatt N, 2013, ACTA PSYCHIAT SCAND, V127, P94, DOI 10.1111/acps.12042; Casper RC, 2003, J PEDIATR-US, V142, P402, DOI 10.1067/mpd.2003.139; Castro VM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.190; Chambers CD, 2006, NEW ENGL J MED, V354, P579, DOI 10.1056/NEJMoa052744; Chateau D, 2012, CAN J PUBLIC HEALTH, V103, pS23, DOI 10.1007/BF03403825; Clements CC, 2015, MOL PSYCHIATR, V20, P727, DOI 10.1038/mp.2014.90; Cole JA, 2007, PHARMACOEPIDEM DR S, V16, P1075, DOI 10.1002/pds.1463; Cooper WO, 2007, AM J OBSTET GYNECOL, V196, P544, DOI 10.1016/j.ajog.2007.01.033; Croen LA, 2011, ARCH GEN PSYCHIAT, V68, P1104, DOI 10.1001/archgenpsychiatry.2011.73; Curtis LH, 2007, MED CARE, V45, pS103, DOI 10.1097/MLR.0b013e31806518ac; Daw J. R., 2011, DRUG SAFETY, V20; Daw JR, 2012, CLIN THER, V34, P239, DOI 10.1016/j.clinthera.2011.11.025; Diav-Citrin O, 2008, BRIT J CLIN PHARMACO, V66, P695, DOI 10.1111/j.1365-2125.2008.03261.x; Field T, 2011, INFANT BEHAV DEV, V34, P1, DOI 10.1016/j.infbeh.2010.09.008; Field T, 2010, INT J NEUROSCI, V120, P163, DOI 10.3109/00207450802338697; Furu K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1798; Gentile S, 2016, J MATERN-FETAL NEO M, P1; Gentile S, 2015, J AFFECT DISORDERS, V182, P132, DOI 10.1016/j.jad.2015.04.048; Gentile S, 2010, CNS SPECTRUMS, V15, P167, DOI 10.1017/S1092852900027449; Glynn RJ, 2006, BASIC CLIN PHARMACOL, V98, P253, DOI 10.1111/j.1742-7843.2006.pto_293.x; Grigoriadis S, 2013, J CLIN PSYCHIAT, V74, pE321, DOI 10.4088/JCP.12r07968; Grote NK, 2010, ARCH GEN PSYCHIAT, V67, P1012, DOI 10.1001/archgenpsychiatry.2010.111; Handal M, 2016, BJOG; Hanley GE, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-242; Hanley GE, 2014, BEST PRACT RES CL OB, V28, P37, DOI 10.1016/j.bpobgyn.2013.09.001; Hanley GE, 2012, BIRTH DEFECTS RES A, V94, P651, DOI 10.1002/bdra.23032; Harrington RA, 2014, PEDIATRICS, V133, pE1241, DOI 10.1542/peds.2013-3406; Heaman M., 2012, PERINATAL SERVICES O; Hoffman S, 2000, HEALTH PSYCHOL, V19, P535, DOI 10.1037/0278-6133.19.6.535; Howard LM, 2014, LANCET, V384, P1775, DOI 10.1016/S0140-6736(14)61276-9; Howland RH, 2013, J PSYCHOSOC NURS MEN, V51, P11, DOI 10.3928/02793695-20121219-01; Huybrechts KF, 2015, JAMA-J AM MED ASSOC, V313, P2142, DOI 10.1001/jama.2015.5605; Huybrechts KF, 2014, NEW ENGL J MED, V371, P1168, DOI 10.1056/NEJMc1409203; Hviid A, 2013, NEW ENGL J MED, V369, P2406, DOI 10.1056/NEJMoa1301449; Jimenez-Solem E., 2012, BMJ Open, V2; Joffe MM, 1999, AM J EPIDEMIOL, V150, P327; Jutte DP, 2011, ANNU REV PUBL HEALTH, V32, P91, DOI 10.1146/annurev-publhealth-031210-100700; Källén B, 2008, PHARMACOEPIDEM DR S, V17, P801, DOI 10.1002/pds.1570; Källén BAJ, 2007, BIRTH DEFECTS RES A, V79, P301, DOI 10.1002/bdra.20327; Kaplan YC, 2016, REPROD TOXICOL, V66, P31, DOI 10.1016/j.reprotox.2016.09.013; Kieler H., 2012, BMJ, V344, pd8012, DOI DOI 10.1136/BMJ.D8012; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; Malm H, 2016, J AM ACAD CHILD PSY, V55, P359, DOI 10.1016/j.jaac.2016.02.013; Malm H, 2011, OBSTET GYNECOL, V118, P111, DOI 10.1097/AOG.0b013e318220edcc; Marcus Sheila M, 2009, Can J Clin Pharmacol, V16, pe15; Margulis AV, 2014, MATERN CHILD HLTH J, V18, P1742, DOI 10.1007/s10995-013-1419-2; McDonagh MS, 2014, OBSTET GYNECOL, V124, P526, DOI 10.1097/AOG.0000000000000410; Oberlander TF, 2006, ARCH GEN PSYCHIAT, V63, P898, DOI 10.1001/archpsyc.63.8.898; Rampono J, 2009, PHARMACOPSYCHIATRY, V42, P95, DOI 10.1055/s-0028-1103296; Ray S, 2014, BEST PRACT RES CL OB, V28, P71, DOI 10.1016/j.bpobgyn.2013.09.005; Reis M, 2010, PSYCHOL MED, V40, P1723, DOI 10.1017/S0033291709992194; Robinson GE, 2015, J NERV MENT DIS, V203, P159, DOI 10.1097/NMD.0000000000000256; Robinson JR, 1997, MED CARE, V35, P932, DOI 10.1097/00005650-199709000-00006; Roos LL, 1999, J CLIN EPIDEMIOL, V52, P39, DOI 10.1016/S0895-4356(98)00126-7; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; Roos LL, 2005, CAN J AGING, V24, P153, DOI 10.1353/cja.2005.0055; Roos LL, 2004, SOC SCI MED, V58, P2231, DOI 10.1016/j.socscimed.2003.08.008; Rosenbaum P.R., 2010, Observational studies, V2nd; Ross LE, 2013, JAMA PSYCHIAT, V70, P436, DOI 10.1001/jamapsychiatry.2013.684; Sabahi Abdolreza, 2014, Sultan Qaboos Univ Med J, V14, pe382; Skurtveit S, 2014, BJOG-INT J OBSTET GY, V121, P1621, DOI 10.1111/1471-0528.12821; Sorensen Merete Juul, 2013, Clin Epidemiol, V5, P449, DOI 10.2147/CLEP.S53009; STEER RA, 1992, J CLIN EPIDEMIOL, V45, P1093, DOI 10.1016/0895-4356(92)90149-H; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Suri R, 2014, J CLIN PSYCHIAT, V75, pE1142, DOI 10.4088/JCP.13r08926; Ververs T, 2006, EUR J CLIN PHARMACOL, V62, P863, DOI 10.1007/s00228-006-0177-0; Vigod SN, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1547; Weisskopf E, 2015, EXPERT OPIN DRUG SAF, V14, P413, DOI 10.1517/14740338.2015.997708; Wichman CL, 2009, MAYO CLIN PROC, V84, P23, DOI 10.4065/84.1.23; Yonkers KA, 2014, ANNU REV CLIN PSYCHO, V10, P369, DOI 10.1146/annurev-clinpsy-032813-153626; Yonkers KA, 2009, GEN HOSP PSYCHIAT, V31, P403, DOI [10.1016/j.genhosppsych.2009.04.003, 10.1097/AOG.0b013e3181ba0632]";83;8;8;3;11;BMJ PUBLISHING GROUP;LONDON;BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND;2044-6055;;;BMJ OPEN;BMJ Open;;2016;6;11;;;;;;;e013293;10.1136/bmjopen-2016-013293;http://dx.doi.org/10.1136/bmjopen-2016-013293;;;11;Medicine, General & Internal;"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";General & Internal Medicine;EG8JQ;27899401;Green Published, gold;;;24/11/2024;WOS:000391303400177;View Full Record in Web of Science
J;"Blum, NJ; Shults, J; Harstad, E; Wiley, S; Augustyn, M; Meinzen-Derr, JK; Wolraich, ML; Barbaresi, WJ";;;;"Blum, Nathan J.; Shults, Justine; Harstad, Elizabeth; Wiley, Susan; Augustyn, Marilyn; Meinzen-Derr, Jareen K.; Wolraich, Mark L.; Barbaresi, William J.";;;Common Use of Stimulants and Alpha-2 Agonists to Treat Preschool Attention-Deficit Hyperactivity Disorder: A DBPNet Study;JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS;;;English;Article;;;;;;"ADHD; preschool; stimulants; alpha-2 agonists; developmental-behavioral pediatrics";"DEVELOPMENTAL-BEHAVIORAL PEDIATRICIANS; AUTISM SPECTRUM DISORDER; DEFICIT/HYPERACTIVITY-DISORDER; ACADEMIC CENTERS; YOUNG-CHILDREN; DIAGNOSIS; METHYLPHENIDATE; MEDICATION; EFFICACY; SAFETY";Objective: To describe the use of stimulants and alpha-2 agonists (A2As) for the treatment of preschool-aged children with attention-deficit hyperactivity disorder (ADHD) at 2 Developmental-Behavioral Pediatrics Research Network sites. Methods: Demographic information, diagnoses, and medications prescribed by developmental-behavioral pediatricians (DBPs) were extracted from the electronic health record for all outpatient visits from January 1, 2010, to December 31, 2011. The subset of visits for children aged 2 to 5 years who had a diagnosis of ADHD was included in this analysis. Multivariable models were constructed to identify factors associated with prescribing stimulants and A2As. Results: Over the 2-year period, 984 children with a diagnosis of ADHD were seen at 1779 visits. Of the 984 children, 342 (34.8%) were prescribed a stimulant, and 243 (24.7%) were prescribed an A2A. Both medications were prescribed at the same visit at least once during the 2-year period for 97 children (9.9%). Alpha-2 agonists were prescribed more often at site 2 than site 1 (OR [odds ratio] = 1.62, p = 0.015). Stimulants were more likely to be prescribed for older preschool-aged children (OR = 1.66, p < 0.001), and A2As were more likely to be prescribed for younger children (OR 5 0.82, p = 0.02). Both stimulants and A2As were more likely to be prescribed to children with ADHD and comorbid conditions. Conclusion: Alpha-2 agonists are commonly used by some DBPs for preschool ADHD. Variation in the use of A2As across sites may indicate a lack of consensus on when to use these medications and suggests a need for comparative effectiveness research to better define the relative benefits and side effects of A2As and stimulants for the treatment of preschool ADHD.;"[Blum, Nathan J.] Childrens Hosp Philadelphia, Dept Pediat, 3550 Market St, Philadelphia, PA 19104 USA; [Shults, Justine] Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA USA; [Harstad, Elizabeth; Barbaresi, William J.] Boston Childrens Hosp, Div Dev Med, Boston, MA USA; [Wiley, Susan] Cincinnati Childrens Hosp & Med Ctr, Dept Pediat, Cincinnati, OH USA; [Augustyn, Marilyn] Boston Med Ctr, Dept Pediat, Boston, MA USA; [Meinzen-Derr, Jareen K.] Cincinnati Childrens Hosp Med Ctr, Dept Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Wolraich, Mark L.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA";"University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Boston Children's Hospital; Cincinnati Children's Hospital Medical Center; Boston Medical Center; Cincinnati Children's Hospital Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center";Blum, NJ (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, 3550 Market St, Philadelphia, PA 19104 USA.;blum@email.chop.edu;;;"Maternal and Child Health Bureau, Health Resources and Services Administration [UA3MC20218, T77MC00012, T77MC00011]; U.S. Department of Health and Human Services";"Maternal and Child Health Bureau, Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); U.S. Department of Health and Human Services";Supported by cooperative agreement UA3MC20218 and by projects T77MC00012 and T77MC00011 from the Maternal and Child Health Bureau, Health Resources and Services Administration and the U.S. Department of Health and Human Services. This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the US government.;"Agency for Healthcare Research and Quality Rockville MD, 2013, NAT HEALTHC QUAL REP; Anderson LE, 2015, PEDIATRICS, V136, pE1178, DOI 10.1542/peds.2015-0807; [Anonymous], 2013, DIAGNOSTIC STAT MANU, VFifth, P1000, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], FOLL CAR CHILDR PRES; Comer JS, 2010, J AM ACAD CHILD PSY, V49, P1001, DOI 10.1016/j.jaac.2010.07.007; Feldman HM, 2015, ACAD PEDIATR, V15, P282, DOI 10.1016/j.acap.2014.09.004; Fierro JL, 2014, INFECT CONT HOSP EP, V35, pS79, DOI 10.1086/677820; Fiks AG, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2025; Ghuman JK, 2007, J CHILD ADOL PSYCHOP, V17, P563, DOI 10.1089/cap.2007.0071; Gilliam W.S., 2005, Prekindergarteners left behind: Expulsion rates in state prekindergarten systems; Gleason MM, 2007, J AM ACAD CHILD PSY, V46, P1532, DOI 10.1097/chi.0b013e3181570d9e; Greenhill L, 2006, J AM ACAD CHILD PSY, V45, P1284, DOI 10.1097/01.chi.0000235077.32661.61; Hansen RL, 2016, PEDIATRICS, V137, pS79, DOI 10.1542/peds.2015-2851F; Harstad E, 2016, J DEV BEHAV PEDIATR, V37, P541, DOI 10.1097/DBP.0000000000000329; Hirota T, 2014, J AM ACAD CHILD PSY, V53, P153, DOI 10.1016/j.jaac.2013.11.009; HUNT RD, 1995, J AM ACAD CHILD PSY, V34, P50, DOI 10.1097/00004583-199501000-00013; Jackel C, 2017, J DEV BEHAV PEDIATR, V38, P584, DOI 10.1097/DBP.0000000000000488; Kratochvil CJ, 2011, PEDIATRICS, V127, pE862, DOI 10.1542/peds.2010-0825; Nair V, 2009, J TROP PEDIATRICS, V55, P116, DOI 10.1093/tropej/fmn117; Posner K, 2007, J CHILD ADOL PSYCHOP, V17, P547, DOI 10.1089/cap.2007.0075; Spira EG, 2005, J CHILD PSYCHOL PSYC, V46, P755, DOI 10.1111/j.1469-7610.2005.01466.x; Visser SN, 2016, MMWR-MORBID MORTAL W, V65, P443; Wigal T, 2006, J AM ACAD CHILD PSY, V45, P1294, DOI 10.1097/01.chi.0000235082.63156.27; Winterstein AG, 2017, J CLIN PSYCHIAT, V78, pE774, DOI 10.4088/JCP.16m10884; Wolraich M, 2011, PEDIATRICS, V128, P1007, DOI 10.1542/peds.2011-2654; Zito JM, 2007, J CHILD ADOL PSYCHOP, V17, P195, DOI 10.1089/cap.2007.0006";26;20;20;1;4;LIPPINCOTT WILLIAMS & WILKINS;PHILADELPHIA;TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA;0196-206X;1536-7312;;J DEV BEHAV PEDIATR;J. Dev. Behav. Pediatr.;SEP;2018;39;7;;;;;531;537;;10.1097/DBP.0000000000000585;http://dx.doi.org/10.1097/DBP.0000000000000585;;;7;"Behavioral Sciences; Psychology, Developmental; Pediatrics";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Behavioral Sciences; Psychology; Pediatrics";HD5IQ;29851669;;;;24/11/2024;WOS:000452562800001;View Full Record in Web of Science
J;"He, Y; Hogrefe, CE; Grapov, D; Palazoglu, M; Fiehn, O; Turck, CW; Golub, MS";;;;"He, Y.; Hogrefe, C. E.; Grapov, D.; Palazoglu, M.; Fiehn, O.; Turck, C. W.; Golub, M. S.";;;Identifying individual differences of fluoxetine response in juvenile rhesus monkeys by metabolite profiling;TRANSLATIONAL PSYCHIATRY;;;English;Article;;;;;;;"OBSESSIVE-COMPULSIVE DISORDER; AUTISM SPECTRUM DISORDERS; SUICIDAL IDEATION; ANTIDEPRESSANT TREATMENT; CLINICAL-TRIAL; SELF-CONTROL; ADULT MICE; CHILDREN; ADOLESCENTS; DEPRESSION";Fluoxetine is the only psychopharmacological agent approved for depression by the US Food and Drug Administration for children and is commonly used therapeutically in a variety of neurodevelopmental disorders. Therapeutic response shows high individual variability, and severe side effects have been observed. In the current study we set out to identify biomarkers of response to fluoxetine as well as biomarkers that correlate with impulsivity, a measure of reward delay behavior and potential side effect of the drug, in juvenile male rhesus monkeys. The study group was also genotyped for polymorphisms of monoamine oxidase A (MAOA), a gene that has been associated with psychiatric disorders. We used peripheral metabolite profiling of blood and cerebrospinal fluid (CSF) from animals treated daily with fluoxetine or vehicle for one year. Fluoxetine response metabolite profiles and metabolite/reward delay behavior associations were evaluated using multivariate analysis. Our analyses identified a set of plasma and CSF metabolites that distinguish fluoxetine-from vehicle-treated animals and metabolites that correlate with impulsivity. Some metabolites displayed an interaction between fluoxetine and MAOA genotype. The identified metabolite biomarkers belong to pathways that have important functions in central nervous system physiology. Biomarkers of response to fluoxetine in the normally functioning brain of juvenile nonhuman primates may aid in finding predictors of response to treatment in young psychiatric populations and in progress toward the realization of a precision medicine approach in the area of neurodevelopmental disorders.;"[He, Y.; Turck, C. W.] Max Planck Inst Psychiat, Dept Translat Res Psychiat, D-80804 Munich, Germany; [Hogrefe, C. E.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Grapov, D.; Palazoglu, M.; Fiehn, O.] Univ Calif Davis, NIH West Coast Metabol Ctr, Davis, CA 95616 USA; [Golub, M. S.] Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA";"Max Planck Society; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis";Turck, CW (corresponding author), Max Planck Inst Psychiat, Dept Translat Res Psychiat, Kraepelinstr 2, D-80804 Munich, Germany.;"turck@psych.mpg.de; msgolub@ucdavis.edu";Fiehn, Oliver/AFO-9881-2022;Grapov, Dmitry/0000-0002-7204-3128;"NIH [HD065826, OD011107]; WCMC [U24 DK097154]; Max Planck Society";"NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); WCMC; Max Planck Society(Max Planck Society)";Supported by NIH grants HD065826, HD065826 (supplement) (MSG PI), OD011107 (Harris Lewin, PI), WCMC funding U24 DK097154 (OF PI) and the Max Planck Society (CWT PI).;"Ansorge MS, 2008, J NEUROSCI, V28, P199, DOI 10.1523/JNEUROSCI.3973-07.2008; Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678; Berman MG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2374; Berman RM, 2000, BIOL PSYCHIAT, V47, P351, DOI 10.1016/S0006-3223(99)00230-9; Berton O, 2006, NAT REV NEUROSCI, V7, P137, DOI 10.1038/nrn1846; CALLERY PS, 1985, J NEUROCHEM, V45, P946, DOI 10.1111/j.1471-4159.1985.tb04085.x; Carpenter DJ, 2011, J CLIN PSYCHIAT, V72, P1503, DOI 10.4088/JCP.08m04927blu; Casey BJ, 2011, P NATL ACAD SCI USA, V108, P14998, DOI 10.1073/pnas.1108561108; Dai YT, 2010, J ETHNOPHARMACOL, V128, P482, DOI 10.1016/j.jep.2010.01.016; Delgado PL, 2004, J CLIN PSYCHIAT, V65, P25; Deupree JD, 2007, J PHARMACOL EXP THER, V321, P770, DOI 10.1124/jpet.106.118935; Duckworth AL, 2013, PERS SOC PSYCHOL B, V39, P843, DOI 10.1177/0146167213482589; Emslie GJ, 2002, J AM ACAD CHILD PSY, V41, P1205, DOI 10.1097/00004583-200210000-00010; Geller DA, 2001, J AM ACAD CHILD PSY, V40, P773, DOI 10.1097/00004583-200107000-00011; Golub MS, 2007, J NUTR, V137, P979, DOI 10.1093/jn/137.4.979; Golub MS, 2014, PSYCHOPHARMACOLOGY, V231, P4041, DOI 10.1007/s00213-014-3537-y; Golub MS, 2005, NEUROTOXICOL TERATOL, V27, P615, DOI 10.1016/j.ntt.2005.04.003; Hare TA, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00050; Iñiguez SD, 2014, J NEUROSCI, V34, P1007, DOI 10.1523/JNEUROSCI.5725-12.2014; Ji Y, 2011, CLIN PHARMACOL THER, V89, P97, DOI 10.1038/clpt.2010.250; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Jun Chansoo, 2014, Exp Neurobiol, V23, P28, DOI 10.5607/en.2014.23.1.28; Kaddurah-Daouk R, 2007, MOL PSYCHIATR, V12, P934, DOI 10.1038/sj.mp.4002000; Karpova NN, 2009, EUR NEUROPSYCHOPHARM, V19, P97, DOI 10.1016/j.euroneuro.2008.09.002; Kohlstadt I, 2010, AM FAM PHYSICIAN, V81, P585; Leskovec TJ, 2008, HARVARD REV PSYCHIAT, V16, P97, DOI 10.1080/10673220802075852; Licinio J, 2005, NAT REV DRUG DISCOV, V4, P165, DOI 10.1038/nrd1634; Liebowitz MR, 2002, J AM ACAD CHILD PSY, V41, P1431, DOI 10.1097/00004583-200212000-00014; Marshall E, 2004, SCIENCE, V304, P1576, DOI 10.1126/science.304.5677.1576; MASAND P, 1991, NEW ENGL J MED, V324, P420; McClure J, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00003; McDougle CJ, 2003, J CLIN PSYCHIAT, V64, P16; Menke A, 2012, NEUROPSYCHOPHARMACOL, V37, P797, DOI 10.1038/npp.2011.257; Miller BH, 2008, NEUROPSYCHOPHARMACOL, V33, P1312, DOI 10.1038/sj.npp.1301497; MIRMIRAN M, 1981, BRAIN RES, V204, P129, DOI 10.1016/0006-8993(81)90657-0; MISCHEL W, 1988, J PERS SOC PSYCHOL, V54, P687, DOI 10.1037/0022-3514.54.4.687; Moretti A, 2003, MOL PSYCHIATR, V8, P773, DOI 10.1038/sj.mp.4001353; Mulder RT, 2008, ACTA PSYCHIAT SCAND, V118, P116, DOI 10.1111/j.1600-0447.2008.01179.x; Newman TK, 2005, BIOL PSYCHIAT, V57, P167, DOI 10.1016/j.biopsych.2004.10.012; Oh JE, 2009, NEUROPSYCHOPHARMACOL, V34, P2197, DOI 10.1038/npp.2009.47; Paige LA, 2007, INT J GERIATR PSYCH, V22, P418, DOI 10.1002/gps.1690; PAUL S M, 1982, Encephale, V8, P131; Perlis RH, 2007, PSYCHOTHER PSYCHOSOM, V76, P40, DOI 10.1159/000096363; Posey DJ, 2006, J CHILD ADOL PSYCHOP, V16, P181, DOI 10.1089/cap.2006.16.181; RICKETTS RW, 1993, J AM ACAD CHILD PSY, V32, P865, DOI 10.1097/00004583-199307000-00024; RIDDLE MA, 1992, J AM ACAD CHILD PSY, V31, P1062, DOI 10.1097/00004583-199211000-00011; Seemüller F, 2009, INT J NEUROPSYCHOPH, V12, P181, DOI 10.1017/S1461145708009139; Shrestha SS, 2014, AM J PSYCHIAT, V171, P323, DOI 10.1176/appi.ajp.2013.13020183; Soorya L, 2008, CHILD ADOL PSYCH CL, V17, P753, DOI 10.1016/j.chc.2008.06.003; Su ZH, 2011, J PHARMACEUT BIOMED, V55, P533, DOI 10.1016/j.jpba.2011.02.013; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; VOGEL G, 1990, NEUROSCI BIOBEHAV R, V14, P85, DOI 10.1016/S0149-7634(05)80164-2; Walkup J, 2002, J CHILD ADOL PSYCHOP, V12, P175; Webhofer C, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.56; WIRSHING WC, 1992, ARCH GEN PSYCHIAT, V49, P580";55;15;16;0;15;NATURE PUBLISHING GROUP;NEW YORK;75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA;2158-3188;;;TRANSL PSYCHIAT;Transl. Psychiatr.;NOV;2014;4;;;;;;;;e478;10.1038/tp.2014.116;http://dx.doi.org/10.1038/tp.2014.116;;;9;Psychiatry;Science Citation Index Expanded (SCI-EXPANDED);Psychiatry;CB7RU;25369145;Green Published, gold;;;24/11/2024;WOS:000349825900002;View Full Record in Web of Science
J;"Kishimoto, M; Yamaguchi, A; Niimura, M; Mizumoto, M; Hikitsuchi, T; Ogawa, K; Ozawa, N; Tachibana, Y";;;;"Kishimoto, Makiko; Yamaguchi, Arisa; Niimura, Marina; Mizumoto, Miki; Hikitsuchi, Tatsuo; Ogawa, Kohei; Ozawa, Nobuaki; Tachibana, Yoshiyuki";;;Factors affecting the grieving process after perinatal loss;BMC WOMENS HEALTH;;;English;Article;;;;;;"Perinatal loss; Complicated grief; Personality trait; Developmental trait; Coping style; Attachment style";"DEFICIT HYPERACTIVITY DISORDER; ADVERSE CHILDHOOD EXPERIENCES; AUTISM SPECTRUM DISORDERS; ATTACHMENT";"Background Factors associated with the grief process in response to perinatal loss have been investigated. However, few studies focused on the intrapersonal factors, such as developmental and personality traits. Hence, this study aimed to investigate medical and psychosocial risk factors, including inter- and intrapersonal factors for the development of complicated grief following perinatal loss, while considering emotional support. Methods A total of 50 patients who were treated for grief due to perinatal loss at the National Center for Child Health and Development were divided into two groups according to the treatment period (< 6 months: n = 28; >= 6 months: n = 22). We compared medical and psychosocial variables between the two groups using the chi(2) test and t test. All data were further analyzed using a logistic regression model to adjust for confounding effects. Results Patients who had traits of developmental/personality disorders (adjusted odds ratio [OR]: 7.21, 95% confidence interval (CI): 1.21-42.9, P = .030), and those treated with psychoactive drugs (adjusted OR: 5.77, 95% CI 1.09-30.5, P = .039) required a longer treatment period (>= 6 months). Conclusions Patients with personality/developmental traits and those with active psychiatric symptoms required a more extended treatment period in response to loss, suggesting the accumulation of negative factors in these patients; thus, more intensive and specialized care is necessary for these patients. Precise analysis of the coping style, attachment style, communication skills, and life history including relationship with the original family of the patients may have implications on the approach toward patients with complicated grief after perinatal loss. Studies with larger sample size are required to increase the reliability of the present findings, and future research should address the effects of the differential attachment and coping styles of patients with developmental/personality traits on the grief process.";"[Kishimoto, Makiko; Hikitsuchi, Tatsuo; Tachibana, Yoshiyuki] Natl Ctr Child Hlth & Dev, Dept Psychosocial Med, Div Early Childhood Mental Hlth, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan; [Yamaguchi, Arisa; Niimura, Marina] Natl Ctr Child Hlth & Dev, Dept Psychosocial Med, Tokyo, Japan; [Mizumoto, Miki] Shoin Univ, Fac Commun & Culture, Atsugi, Kanagawa, Japan; [Ogawa, Kohei] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Div Obstet, Tokyo, Japan; [Ozawa, Nobuaki] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Div Obstet, Neonatal & Reprod Med, Tokyo, Japan";"National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan";Kishimoto, M (corresponding author), Natl Ctr Child Hlth & Dev, Dept Psychosocial Med, Div Early Childhood Mental Hlth, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.;kishimoto-m@ncchd.go.jp;Ogawa, Kohei/ABQ-5991-2022;Yamaguchi, Arisa/0000-0003-4105-5166;;;;"APA, 2013, DIAGNOSTIC STAT MANU, VFifth; Bertollo JR, 2020, J AUTISM DEV DISORD, V50, P42, DOI 10.1007/s10803-019-04220-9; Bhat A, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0663-8; Brown NM, 2017, ACAD PEDIATR, V17, P349, DOI 10.1016/j.acap.2016.08.013; Buchheim A, 2018, PSYCHIAT CLIN N AM, V41, P651, DOI 10.1016/j.psc.2018.07.010; Burden C, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0800-8; Cummings EM, 2015, J ABNORM CHILD PSYCH, V43, P503, DOI 10.1007/s10802-014-9926-1; Gold KJ, 2016, J WOMENS HEALTH, V25, P263, DOI 10.1089/jwh.2015.5284; Hoover DW, 2018, CURR OPIN PSYCHIATR, V31, P128, DOI 10.1097/YCO.0000000000000390; Hutti MH, 2015, JOGNN-J OBST GYN NEO, V44, P42, DOI 10.1111/1552-6909.12539; Jaaniste T, 2017, CHILDREN-BASEL, V4, DOI 10.3390/children4110096; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Karst JS, 2012, CLIN CHILD FAM PSYCH, V15, P247, DOI 10.1007/s10567-012-0119-6; Kearney JA, 2015, PALLIAT SUPPORT CARE, V13, P1559, DOI 10.1017/S147895151300134X; Kersting Anette, 2012, Dialogues Clin Neurosci, V14, P187; Klier C M, 2002, Arch Womens Ment Health, V5, P129, DOI 10.1007/s00737-002-0146-2; Kulathilaka S, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0812-y; Levi-Belz Y, 2019, J NERV MENT DIS, V207, P131, DOI 10.1097/NMD.0000000000000940; Lugnegård T, 2012, COMPR PSYCHIAT, V53, P333, DOI 10.1016/j.comppsych.2011.05.014; Matthies S, 2016, CURR PSYCHIAT REP, V18, DOI 10.1007/s11920-016-0675-4; Miklósi M, 2016, J NERV MENT DIS, V204, P364, DOI 10.1097/NMD.0000000000000472; Nakajima S, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0273; Philipsen A, 2008, BRIT J PSYCHIAT, V192, P118, DOI 10.1192/bjp.bp.107.035782; Pisula E, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0370-x; Stroebe M, 2017, OMEGA-J DEATH DYING, V74, P455, DOI 10.1177/0030222817691870; Strunz S, 2015, J AUTISM DEV DISORD, V45, P4026, DOI 10.1007/s10803-014-2183-x; Tseng YF, 2017, J CLIN NURS, V26, P5133, DOI 10.1111/jocn.14059; van Wijk-Herbrink M, 2011, J PERS DISORD, V25, P634, DOI 10.1521/pedi.2011.25.5.634; Vegsund HK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214138";29;10;12;6;18;BMC;LONDON;CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND;;1472-6874;;BMC WOMENS HEALTH;BMC Womens Health;AUG 26;2021;21;1;;;;;;;313;10.1186/s12905-021-01457-4;http://dx.doi.org/10.1186/s12905-021-01457-4;;;6;"Public, Environmental & Occupational Health; Obstetrics & Gynecology";"Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)";"Public, Environmental & Occupational Health; Obstetrics & Gynecology";UJ0BB;34446003;gold, Green Published;;;24/11/2024;WOS:000690959500001;View Full Record in Web of Science
J;"Eckert, EM; Dominick, KC; Pedapati, EV; Wink, LK; Shaffer, RC; Andrews, H; Choo, TH; Chen, C; Kaufmann, WE; Tartaglia, N; Berry-Kravis, EM; Erickson, CA";;;;"Eckert, Eleanor M.; Dominick, Kelli C.; Pedapati, Ernest V.; Wink, Logan K.; Shaffer, Rebecca C.; Andrews, Howard; Choo, Tse-Hwei; Chen, Chen; Kaufmann, Walter E.; Tartaglia, Nicole; Berry-Kravis, Elizabeth M.; Erickson, Craig A.";;;Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis;JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS;;;English;Article;;;;;;"Fragile X syndrome; Irritability; Pharmacotherapy";"AUTISM SPECTRUM DISORDER; QUALITY-OF-LIFE; YOUNG BOYS; COOCCURRING CONDITIONS; CHECKLIST; CHILDREN; HEALTH; ANTIPSYCHOTICS; SYMPTOMS; SCALE";Using a dataset involving 415 individuals with irritability, aggression, agitation and self-injury (IAAS) behaviors from the fragile X syndrome (FXS) FORWARD database, we describe the psychopharmacologic management of IAAS and features of the population of persons with FXS treated with drug therapy for IAAS. Among those with FXS exhibiting IAAS, individuals with FXS receiving drug treatment of IAAS were older, more predominantly male, have more significant intellectual disability, more like to have comorbid autism, hyperarousal, and social impairments. The most commonly utilized medications for IAAS in FXS are antipsychotic medications, specifically aripiprazole and risperidone (37% and 27%, respectively). The majority of subjects (63%) experienced no side effects noted from the use of their psychopharmacologic medications.;"[Eckert, Eleanor M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Dominick, Kelli C.; Pedapati, Ernest V.; Wink, Logan K.; Erickson, Craig A.] Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat, Cincinnati, OH 45229 USA; [Dominick, Kelli C.; Pedapati, Ernest V.; Wink, Logan K.; Erickson, Craig A.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH 45221 USA; [Shaffer, Rebecca C.; Erickson, Craig A.] Cincinnati Childrens Hosp Med Ctr, Div Dev & Behav Pediat, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA; [Shaffer, Rebecca C.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Andrews, Howard] Columbia Univ Irving, Med Ctr, Dept Psychiat, New York, NY USA; [Andrews, Howard] Columbia Univ Irving, Med Ctr, Dept Biostat, New York, NY USA; [Choo, Tse-Hwei; Chen, Chen] New York State Psychiat Inst & Hosp, Div Mental Hlth Data Sci, New York, NY 10032 USA; [Kaufmann, Walter E.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA; [Kaufmann, Walter E.] Univ Calif Davis, Sch Med, MIND Inst, Dept Neurol, Sacramento, CA USA; [Tartaglia, Nicole] Univ Colorado, Sch Med, Dev Pediat, Aurora, CO USA; [Berry-Kravis, Elizabeth M.] Rush Univ, Med Ctr, Dept Pediat, Chicago, IL USA; [Berry-Kravis, Elizabeth M.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL USA; [Berry-Kravis, Elizabeth M.] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL USA";"University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; New York State Psychiatry Institute; Emory University; University of California System; University of California Davis; University of Colorado System; University of Colorado Anschutz Medical Campus; Rush University; Rush University; Rush University";"Erickson, CA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Child & Adolescent Psychiat, Cincinnati, OH 45229 USA.;Erickson, CA (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH 45221 USA.;Erickson, CA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Dev & Behav Pediat, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.";craig.erickson@cchmc.org;"Erickson, Craig/M-8933-2017; pedapati, ernest/GPT-0086-2022; Dominick, Kelli/AAK-3798-2020";"Tartaglia, Nicole/0000-0002-8529-6722; Dominick, Kelli/0000-0003-3775-2479";Centers for Disease Control and Prevention [5U01DD000231, 5U19DD000753, 1U01DD001189];Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA);The FORWARD project is supported by the Cooperative Agreement Numbers 5U01DD000231, 5U19DD000753, and 1U01DD001189 funded by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. No authors have a conflict financially or otherwise related to the content of this manuscript. The FORWARD database project was local IRB approved at all participating sites. The data reviewed in preparation of this manuscript was deidentified data.;"AMAN MG, 1985, AM J MENT DEF, V89, P485; [Anonymous], 1976, ECDEU ASSESSMENT MAN; Bailey DB, 1998, J AUTISM DEV DISORD, V28, P499; Bailey DB, 2001, AM J MENT RETARD, V106, P16, DOI 10.1352/0895-8017(2001)106<0016:VIFAED>2.0.CO;2; Bailey DB, 2001, J AUTISM DEV DISORD, V31, P165; Bailey DB, 2008, AM J MED GENET A, V146A, P2060, DOI 10.1002/ajmg.a.32439; Bailey DB, 2012, J DEV BEHAV PEDIATR, V33, P705, DOI 10.1097/DBP.0b013e318272dcbc; Bailey DB, 2012, J DEV BEHAV PEDIATR, V33, P62, DOI 10.1097/DBP.0b013e318236c0e1; Berry-Kravis E, 2004, MENT RETARD DEV D R, V10, P42, DOI 10.1002/mrdd.20007; Berry-Kravis E, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/843016; Budimirovic DB, 2011, DEV NEUROSCI-BASEL, V33, P379, DOI 10.1159/000330213; Chevreul K, 2015, J INTELL DISABIL RES, V59, P1108, DOI 10.1111/jir.12215; Chevreul K, 2016, EUR J HEALTH ECON, V17, P43, DOI 10.1007/s10198-016-0784-3; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Cordeiro L, 2011, J NEURODEV DISORD, V3, P57, DOI 10.1007/s11689-010-9067-y; Erickson Craig A, 2005, Expert Rev Neurother, V5, P713, DOI 10.1586/14737175.5.6.713; Erickson CA, 2017, J NEURODEV DISORD, V9, DOI 10.1186/s11689-017-9186-9; Erickson CA, 2011, PSYCHOPHARMACOLOGY, V216, P85, DOI 10.1007/s00213-011-2194-7; Erickson CA, 2010, NEUROTHERAPEUTICS, V7, P258, DOI 10.1016/j.nurt.2010.04.001; Haessler F, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1020-5; Hagerman RJ, 2008, JAMA-J AM MED ASSOC, V300, P2419, DOI 10.1001/jama.2008.684; Hagerman RJ, 2015, CURR OPIN PSYCHIATR, V28, P107, DOI 10.1097/YCO.0000000000000131; Hatton DD, 1999, DEV MED CHILD NEUROL, V41, P625, DOI 10.1017/S0012162299001280; Hatton DD, 2003, AM J MENT RETARD, V108, P373, DOI 10.1352/0895-8017(2003)108<373:ABICWF>2.0.CO;2; Hernandez RN, 2009, AM J MED GENET A, V149A, P1125, DOI 10.1002/ajmg.a.32848; Kaufmann WE, 2017, PEDIATRICS, V139, pS194, DOI [10.1542/peds.2016-159F, 10.1542/peds.2016-1159F]; Kaufmann WE, 1999, AM J MED GENET, V83, P286, DOI 10.1002/(SICI)1096-8628(19990402)83:4<286::AID-AJMG10>3.0.CO;2-H; Lewis P, 2006, J INTELL DISABIL RES, V50, P532, DOI 10.1111/j.1365-2788.2006.00803.x; Loesch DZ, 2004, MENT RETARD DEV D R, V10, P31, DOI 10.1002/mrdd.20006; MCCLELLAN L, 2016, CURRENT TREATMENT OP, V3, P161; McDougle CJ, 2008, J CLIN PSYCHIAT, V69, P15; Posey DJ, 2008, J CLIN INVEST, V118, P6, DOI 10.1172/JCI32483; Sansone SM, 2012, J AUTISM DEV DISORD, V42, P1377, DOI 10.1007/s10803-011-1370-2; Sherman SL, 2017, PEDIATRICS, V139, pS183, DOI 10.1542/peds.2016-1159E; Symons FJ, 2003, AM J MED GENET A, V118A, P115, DOI 10.1002/ajmg.a.10078; Symons FJ, 2010, AJIDD-AM J INTELLECT, V115, P473, DOI 10.1352/1944-7558-115.6.473; Tsiouris JA, 2004, CNS DRUGS, V18, P687, DOI 10.2165/00023210-200418110-00001; Wheeler AC, 2016, J INTELL DISABIL RES, V60, P113, DOI 10.1111/jir.12238; Williams K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004677.pub3, 10.1002/14651858.CD007407.pub3]; Witwer AN, 2007, J INTELLECT DEV DIS, V32, P179, DOI 10.1080/13668250701604776";40;19;20;1;15;SPRINGER/PLENUM PUBLISHERS;NEW YORK;233 SPRING ST, NEW YORK, NY 10013 USA;0162-3257;1573-3432;;J AUTISM DEV DISORD;J. Autism Dev. Disord.;NOV;2019;49;11;;;;;4595;4602;;10.1007/s10803-019-04173-z;http://dx.doi.org/10.1007/s10803-019-04173-z;;;8;Psychology, Developmental;Social Science Citation Index (SSCI);Psychology;JG9TP;31468273;Green Accepted;;;24/11/2024;WOS:000492419200022;View Full Record in Web of Science
J;"Breda, V; Cerqueira, RO; Ceolin, G; Koning, E; Fabe, J; McDonald, A; Gomes, FA; Brietzke, E";;;;"Breda, Vitor; Cerqueira, Raphael O.; Ceolin, Gilciane; Koning, Elena; Fabe, Jennifer; McDonald, Alexandra; Gomes, Fabiano A.; Brietzke, Elisa";;;Is there a place for dietetic interventions in adult ADHD?;PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY;;;English;Article;;;;;;"ADHD; Adult ADHD; Cognition; Nutrition; Diet; Lifestyle";"ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDERS; QUALITY-OF-LIFE; STIMULANT TREATMENT; MEDITERRANEAN DIET; LOW-CARBOHYDRATE; CHILDREN; METAANALYSIS; ADOLESCENTS";"Current treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults are limited by lack of response and side effects in about one third of the individuals. Changes towards a healthier lifestyle could have a positive impact beyond the relief of specific symptoms. However, it is not clear if nutritional interventions influence mental health and cognition. The objective of this study was to summarize the available literature addressing the impact of different diets in ADHD. The most promising dietetic approaches in ADHD are diets considered to be healthy (Mediterranean-type; DASH) and the Few-Foods Diet for children. Studies should take into account the presence of multiple confounders, biases associated with difficulties in blinding participants and researchers, and search for possible mechanisms of action, so we can have better evidence to guide clinical mental care of adults with ADHD.";"[Breda, Vitor; Koning, Elena; Gomes, Fabiano A.; Brietzke, Elisa] Queens Univ, Dept Psychiat, Sch Med, 752 King St West, Kingston, ON K7L 7X3, Canada; [Breda, Vitor; Koning, Elena; Gomes, Fabiano A.; Brietzke, Elisa] Queens Univ, Ctr Neurosci Studies CNS, 18 Stuart St, Kingston, ON K7L 3N6, Canada; [Cerqueira, Raphael O.] Univ Fed Sao Paulo, Dept Psychiat, Rua Major Maragliano 241, BR-04017030 Sao Paulo, SP, Brazil; [Ceolin, Gilciane] Univ Fed Santa Catarina, Postgrad Program Nutr, Rua Dellno Conti,Campus Trindade, BR-88040970 Florianopolis, SC, Brazil; [Fabe, Jennifer] McMasters Childrens Hosp, Hamilton Hlth Sci, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada; [McDonald, Alexandra] Carleton Univ, 1125 Colonel Dr, Ottawa, ON K1S 5B6, Canada; [Brietzke, Elisa] 752 King St West, Kingston, ON K7L 7X3, Canada";"Queens University - Canada; Queens University - Canada; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Santa Catarina (UFSC); McMaster University; Carleton University";Brietzke, E (corresponding author), 752 King St West, Kingston, ON K7L 7X3, Canada.;"vitor.breda@queensu.ca; elena.koning@queensu.ca; fabe@hhsc.ca; alexandrajmcdonald@cmail.carleton.ca; fabiano.alvesgomes@queensu.ca; elisa.brietzke@queensu.ca";"Ceolin, Gilciane/AAB-5642-2021; Breda, Vitor/U-2199-2019";"Cerqueira, Raphael/0000-0002-9219-2534; Breda, Vitor/0000-0002-1349-5220; McDonald, Alexandra/0009-0009-6856-9627";;;;"Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; Alkhayyat M, 2021, J GASTROEN HEPATOL, V36, P2165, DOI 10.1111/jgh.15437; Altun H, 2018, PSYCHIAT DANUB, V30, P310, DOI 10.24869/psyd.2018.310; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI DOI 10.1176/APPI.BOOKS.9780890425596.744053; Bala KA, 2016, J PEDIATR ENDOCR MET, V29, P1077, DOI 10.1515/jpem-2015-0473; Barrio C, 2022, PSYCHONEUROENDOCRINO, V137, DOI 10.1016/j.psyneuen.2021.105640; Becker SP, 2019, J AM ACAD CHILD PSY, V58, P433, DOI 10.1016/j.jaac.2018.09.439; Beheshti A, 2020, BMC PSYCHIATRY, V20, DOI 10.1186/s12888-020-2442-7; Benton D, 2008, CRIT REV FOOD SCI, V48, P385, DOI 10.1080/10408390701407316; Biederman Joseph, 2006, MedGenMed, V8, P12; Breslau J, 2011, J PSYCHIATR RES, V45, P295, DOI 10.1016/j.jpsychires.2010.06.014; Brietzke E, 2018, NEUROSCI BIOBEHAV R, V84, P368, DOI 10.1016/j.neubiorev.2017.08.009; Brinkworth GD, 2009, ARCH INTERN MED, V169, P1873, DOI 10.1001/archinternmed.2009.329; Ceolin Gilciane, 2022, Curr Treat Options Psychiatry, V9, P151, DOI 10.1007/s40501-022-00259-1; Chang JPC, 2018, NEUROPSYCHOPHARMACOL, V43, P534, DOI 10.1038/npp.2017.160; Charach A, 2004, J AM ACAD CHILD PSY, V43, P559, DOI 10.1097/00004583-200405000-00009; Chen CCH, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8714; Dalsgaard S, 2015, LANCET, V385, P2190, DOI 10.1016/S0140-6736(14)61684-6; Danckaerts M, 2010, EUR CHILD ADOLES PSY, V19, P83, DOI 10.1007/s00787-009-0046-3; Darabi Z, 2022, CLIN NUTR ESPEN, V47, P346, DOI 10.1016/j.clnesp.2021.11.014; Den Heijer AE, 2017, J NEURAL TRANSM, V124, pS3, DOI 10.1007/s00702-016-1593-7; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Faraone SV, 2010, J CLIN PSYCHIAT, V71, P754, DOI 10.4088/JCP.08m04902pur; Faraone SV, 2010, EUR CHILD ADOLES PSY, V19, P353, DOI 10.1007/s00787-009-0054-3; Farsad-Naeimi A, 2020, COMPLEMENT THER MED, V53, DOI 10.1016/j.ctim.2020.102512; Fayyad J, 2017, ADHD-ATTEND DEFICIT, V9, P47, DOI 10.1007/s12402-016-0208-3; Feingold B F, 1975, Am J Nurs, V75, P797, DOI 10.2307/3423460; Filippou CD, 2020, ADV NUTR, V11, P1150, DOI 10.1093/advances/nmaa041; Garipardic M, 2017, MED SCI MONITOR, V23, P1378, DOI 10.12659/MSM.899976; Grigolon RB, 2020, PROG NEURO-PSYCHOPH, V102, DOI 10.1016/j.pnpbp.2020.109947; Halyburton AK, 2007, AM J CLIN NUTR, V86, P580, DOI 10.1093/ajcn/86.3.580; Hawkey E, 2014, CLIN PSYCHOL REV, V34, P496, DOI 10.1016/j.cpr.2014.05.005; Hennissen L, 2017, CNS DRUGS, V31, P199, DOI 10.1007/s40263-017-0410-7; Hill P, 2001, ARCH DIS CHILD, V84, P404, DOI 10.1136/adc.84.5.404; Hontelez S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-01684-7; Hurt EA, 2014, CHILD ADOL PSYCH CL, V23, P955, DOI 10.1016/j.chc.2014.06.002; Colho HJ, 2021, AGEING RES REV, V70, DOI 10.1016/j.arr.2021.101395; Kalenik A, 2021, PROG NEURO-PSYCHOPH, V110, DOI 10.1016/j.pnpbp.2021.110277; Karababa IF, 2017, J ATTEN DISORD, V21, P487, DOI 10.1177/1087054714538657; Khoshbakht Y, 2021, EUR J NUTR, V60, P3647, DOI 10.1007/s00394-021-02527-x; Korrel H, 2017, J CHILD PSYCHOL PSYC, V58, P640, DOI 10.1111/jcpp.12688; Kristensen VA, 2019, SCAND J GASTROENTERO, V54, P571, DOI 10.1080/00365521.2019.1608467; Landaas ET, 2016, BJPSYCH OPEN, V2, P377, DOI 10.1192/bjpo.bp.116.003491; Lapage CP, 1934, BRIT MED J, V1934, P985, DOI 10.1136/bmj.2.3856.985; Lebwohl B, 2021, CLIN GASTROENTEROL H, V19, P2093, DOI 10.1016/j.cgh.2020.08.018; Lee SS, 2011, CLIN PSYCHOL REV, V31, P328, DOI 10.1016/j.cpr.2011.01.006; Lee YC, 2016, RES DEV DISABIL, V51-52, P160, DOI 10.1016/j.ridd.2015.11.009; Li L, 2020, AM J MED GENET B, V183, P475, DOI 10.1002/ajmg.b.32825; Liang EF, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081789; Lien L, 2006, AM J PUBLIC HEALTH, V96, P1815, DOI 10.2105/AJPH.2004.059477; Lugo J, 2020, EUR NEUROPSYCHOPHARM, V38, P1, DOI 10.1016/j.euroneuro.2020.07.004; Lyons L, 2020, EPILEPSIA, V61, P1261, DOI 10.1111/epi.16543; Mick E, 2013, EUR NEUROPSYCHOPHARM, V23, P534, DOI 10.1016/j.euroneuro.2012.06.011; Mohr-Jensen C, 2019, J AM ACAD CHILD PSY, V58, P443, DOI 10.1016/j.jaac.2018.11.016; NICE, 2018, ATTENTION DEFICIT HY; Niederhofer Helmut, 2011, Prim Care Companion CNS Disord, V13, DOI 10.4088/PCC.10br01104; Niederhofer Helmut, 2006, J Atten Disord, V10, P200, DOI 10.1177/1087054706292109; Nigg JT, 2014, CHILD ADOL PSYCH CL, V23, P937, DOI 10.1016/j.chc.2014.05.010; Nigg JT, 2012, J AM ACAD CHILD PSY, V51, P86, DOI 10.1016/j.jaac.2011.10.015; O'Neill T, 2022, ARCH DIS CHILD, V107, P377, DOI 10.1136/archdischild-2021-321770; Pärtty A, 2015, PEDIATR RES, V77, P823, DOI 10.1038/pr.2015.51; Pelsser L, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00096; Pelsser LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169277; Philipsen A, 2015, JAMA PSYCHIAT, V72, P1199, DOI 10.1001/jamapsychiatry.2015.2146; Pievsky MA, 2018, ARCH CLIN NEUROPSYCH, V33, P143, DOI 10.1093/arclin/acx055; Pliszka SR, 2007, NEUROPSYCHOL REV, V17, P61, DOI 10.1007/s11065-006-9017-3; Rimestad ML, 2019, J ATTEN DISORD, V23, P423, DOI 10.1177/1087054716648775; Ríos-Hernández A, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2027; Ros R, 2018, J CLIN CHILD ADOLESC, V47, P213, DOI 10.1080/15374416.2016.1266644; Ruiz-Goikoetxea M, 2018, NEUROSCI BIOBEHAV R, V84, P63, DOI 10.1016/j.neubiorev.2017.11.007; Sacks Frank M., 1995, Annals of Epidemiology, V5, P108, DOI 10.1016/1047-2797(94)00055-X; Martín IS, 2018, NUTR NEUROSCI, V21, P641, DOI 10.1080/1028415X.2017.1331952; Scassellati C, 2012, J AM ACAD CHILD PSY, V51, P1003, DOI 10.1016/j.jaac.2012.08.015; Sedky K, 2014, SLEEP MED REV, V18, P349, DOI 10.1016/j.smrv.2013.12.003; Septier M, 2019, NEUROSCI BIOBEHAV R, V103, P109, DOI 10.1016/j.neubiorev.2019.05.022; Serra-Majem L, 2006, NUTR REV, V64, pS27, DOI [10.1111/j.1753-4887.2006.tb00232.x, 10.1301/nr.2006.feb.S27-S47]; Shareghfarid E, 2020, CLIN NUTR ESPEN, V36, P28, DOI 10.1016/j.clnesp.2019.10.013; Skott E, 2020, BRAIN BEHAV IMMUN, V89, P9, DOI 10.1016/j.bbi.2020.05.056; Sonuga-Barke EJS, 2013, AM J PSYCHIAT, V170, P275, DOI 10.1176/appi.ajp.2012.12070991; Strine Tara W, 2006, Prev Chronic Dis, V3, pA52; Sun SH, 2019, JAMA PSYCHIAT, V76, P1141, DOI 10.1001/jamapsychiatry.2019.1944; Szopinska-Tokov J, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030406; Thapar A, 2017, LANCET PSYCHIAT, V4, P339, DOI 10.1016/S2215-0366(16)30376-5; Tseng PT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19096-x; Tsujii N, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.19r13015; Vaa T, 2014, ACCIDENT ANAL PREV, V62, P415, DOI 10.1016/j.aap.2013.10.003; Van Horn L, 2016, CIRCULATION, V134, pE505, DOI 10.1161/CIR.0000000000000462; Victor MM, 2018, AUST NZ J PSYCHIAT, V52, P509, DOI 10.1177/0004867418769743; Vysniauske R, 2020, J ATTEN DISORD, V24, P644, DOI 10.1177/1087054715627489; Wang LJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050709; Wang Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169145; Willcutt E, 2012, NEUROTHERAPEUTICS, V9, P490, DOI 10.1007/s13311-012-0135-8; Willett Walter C., 1995, American Journal of Clinical Nutrition, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; WOLRAICH ML, 1995, JAMA-J AM MED ASSOC, V274, P1617, DOI 10.1001/jama.274.20.1617; Yazici KU, 2019, CLIN PSYCHOPHARM NEU, V17, P105, DOI 10.9758/cpn.2019.17.1.105; Yektas Ç, 2019, NEUROPSYCH DIS TREAT, V15, P2213, DOI 10.2147/NDT.S212361; Young Z, 2020, J ATTEN DISORD, V24, P875, DOI 10.1177/1087054716664413; Zhou LQ, 2019, BEHAV BRAIN RES, V364, P374, DOI 10.1016/j.bbr.2018.01.011";98;11;12;3;45;PERGAMON-ELSEVIER SCIENCE LTD;OXFORD;THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND;0278-5846;1878-4216;;PROG NEURO-PSYCHOPH;Prog. Neuro-Psychopharmacol. Biol. Psychiatry;DEC 20;2022;119;;;;;;;;110613;10.1016/j.pnpbp.2022.110613;http://dx.doi.org/10.1016/j.pnpbp.2022.110613;;AUG 2022;7;"Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry";Science Citation Index Expanded (SCI-EXPANDED);"Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry";4W9HA;35964708;;;;24/11/2024;WOS:000860464600003;View Full Record in Web of Science
